PMID-sentid Pub_year Sent_text comp_official_name comp_offset protein_name organism prot_offset 33278579-7 2021 Moreover, qRT-PCR findings showed that the wounds treated with SMV alone had the highest expression levels of CD31, VEGF, Akt, mTOR, and p70S6K after 7 and 14 days of burn model (p < 0.001). Simvastatin 63-66 vascular endothelial growth factor A Rattus norvegicus 116-120 33581257-10 2021 Through molecular docking, it was found that the four hub targets (TP53, IL6, VEGFA, and AKT1) binds luteolin and quercetin more tightly. Luteolin 101-109 vascular endothelial growth factor A Rattus norvegicus 78-83 33905820-0 2021 Quyu Shengxin capsule (QSC) inhibits Ang-II-induced abnormal proliferation of VSMCs by down-regulating TGF-beta, VEGF, mTOR and JAK-STAT pathways. quyu shengxin capsule 0-21 vascular endothelial growth factor A Rattus norvegicus 113-117 33905820-0 2021 Quyu Shengxin capsule (QSC) inhibits Ang-II-induced abnormal proliferation of VSMCs by down-regulating TGF-beta, VEGF, mTOR and JAK-STAT pathways. (R)-(+)-1-Phenylethylamine 23-26 vascular endothelial growth factor A Rattus norvegicus 113-117 33581257-10 2021 Through molecular docking, it was found that the four hub targets (TP53, IL6, VEGFA, and AKT1) binds luteolin and quercetin more tightly. Quercetin 114-123 vascular endothelial growth factor A Rattus norvegicus 78-83 33631172-9 2021 After Dex treatment, the expressions of miR-361-5p, VEGFA, BMD related indexes were increased in OP rats. Dexmedetomidine 6-9 vascular endothelial growth factor A Rattus norvegicus 52-57 33631172-12 2021 After miR-361-5p overexpression + Dex treatment, the indexes related to osteogenesis and angiogenesis in OP rats and BMSCs were decreased, which were reversed after further overexpressing VEGFA. Dexmedetomidine 34-37 vascular endothelial growth factor A Rattus norvegicus 188-193 33631172-13 2021 SIGNIFICANCE: Dex can enhance VEGFA by inhibiting miR-361-5p, and then promote osteogenesis-angiogenesis, thus providing potential targets for PMOP treatment. Dexmedetomidine 14-17 vascular endothelial growth factor A Rattus norvegicus 30-35 33753107-8 2021 Saroglitazar also reduced VEGF-induced angiogenesis in CAM assay. saroglitazar 0-12 vascular endothelial growth factor A Rattus norvegicus 26-30 33704910-0 2021 Trimetazidine improved adriamycin-induced cardiomyopathy by downregulating TNF-alpha, BAX, and VEGF immunoexpression via an antioxidant mechanism. Trimetazidine 0-13 vascular endothelial growth factor A Rattus norvegicus 95-99 33704910-0 2021 Trimetazidine improved adriamycin-induced cardiomyopathy by downregulating TNF-alpha, BAX, and VEGF immunoexpression via an antioxidant mechanism. Doxorubicin 23-33 vascular endothelial growth factor A Rattus norvegicus 95-99 34056691-9 2021 TGF-beta and VEGF were found to be down-regulated after treatment with efonidipine in gene expression study. efonidipine 71-82 vascular endothelial growth factor A Rattus norvegicus 13-17 34015278-11 2021 Treatment with free ATRA and the selected formulations led to a significant amelioration of DN by reducing of creatinine, urea, TNF-alpha, ICAM-1, GM-CSF, VEGF levels as well as elevating AMPK and LKB1 levels. Tretinoin 20-24 vascular endothelial growth factor A Rattus norvegicus 155-159 33727052-4 2021 In the present study we investigated a new therapeutic approach by exploring the potential role of a specific microRNA, miR-126, in regulating VEGFA expression and retinal neovascularization in a rat oxygen-induced retinopathy (OIR) model. Oxygen 200-206 vascular endothelial growth factor A Rattus norvegicus 143-148 34054520-15 2021 LEV treatment resulted in a significant increase in HIF-1alpha, VEGF, and HSP70 levels in extracts from the ischemic cerebral cortex. Levetiracetam 0-3 vascular endothelial growth factor A Rattus norvegicus 64-68 33460758-14 2021 Notably, treatment with EOBT for 14 days increased the expression of VEGF compared to that using an anti-ulcer drug (lansoprazole). Lansoprazole 117-129 vascular endothelial growth factor A Rattus norvegicus 69-73 33992625-13 2021 Expression of TGF-beta, IL-1beta and VEGF was significantly lower in the citicoline/UVB group compared to the UVB group (p < 0.05). Cytidine Diphosphate Choline 73-83 vascular endothelial growth factor A Rattus norvegicus 37-41 34054531-12 2021 GHI administration attenuated the pathological change and morphology of the cerebral microvasculature, and immunohistochemical staining indicated that the expressions of BFGF, VEGF, and TGF-beta1 were significantly increased. ghi 0-3 vascular endothelial growth factor A Rattus norvegicus 176-180 33789142-12 2021 In streptozotocin-induced diabetic rat model, astaxanthin reduced the expression of HIF1alpha, XBP1, and VEGF as well as protected the abnormalities in the retinal layers induced by diabetes condition. astaxanthine 46-57 vascular endothelial growth factor A Rattus norvegicus 105-109 33964948-5 2021 In vitro studies showed that the 3D short fiber sponge provided an oxygen-rich environment for cell growth, which was conducive to the 3D proliferation and growth of HUVECs, stimulated the expression of VEGF, and well promoted the vascularization of HUVECs. Oxygen 67-73 vascular endothelial growth factor A Rattus norvegicus 203-207 33516071-15 2021 With regard to the pharmacological mechanism, the network analysis indicated that 12 targets might be the therapeutic targets of TP and Levofloxacin on HPS, namely ET-1, NOs3, VEGFa, CCl2, TNF, Ptgs2, Hmox1, Alb, Ace, Cav1, and Mmp9. tp 129-131 vascular endothelial growth factor A Rattus norvegicus 176-181 33516071-15 2021 With regard to the pharmacological mechanism, the network analysis indicated that 12 targets might be the therapeutic targets of TP and Levofloxacin on HPS, namely ET-1, NOs3, VEGFa, CCl2, TNF, Ptgs2, Hmox1, Alb, Ace, Cav1, and Mmp9. Levofloxacin 136-148 vascular endothelial growth factor A Rattus norvegicus 176-181 33913864-12 2021 Conclusion: The study demonstrated that carvacrol significantly reduced retinal pathological angiogenesis, NV, VEC nuclei count, VEGF, and TNF-alpha levels. carvacrol 40-49 vascular endothelial growth factor A Rattus norvegicus 129-133 33878208-9 2021 In addition, treatment with vitamin D3 attenuated alveolar simplification, increased VEGF and VEGFR2, and protected alveolar simplification induced by hyperoxia. Cholecalciferol 28-38 vascular endothelial growth factor A Rattus norvegicus 85-89 33508487-18 2021 CONCLUSIONS: Less expression of VEGF in the ozone receiving group may cause less edema in the surrounding tissue as a result of less degradation vascular permeability in rat brain tissue. Ozone 44-49 vascular endothelial growth factor A Rattus norvegicus 32-36 33908150-0 2021 Hesperidin protects against the chlorpyrifos-induced chronic hepato-renal toxicity in rats associated with oxidative stress, inflammation, apoptosis, autophagy, and up-regulation of PARP-1/VEGF. Hesperidin 0-10 vascular endothelial growth factor A Rattus norvegicus 189-193 33908150-0 2021 Hesperidin protects against the chlorpyrifos-induced chronic hepato-renal toxicity in rats associated with oxidative stress, inflammation, apoptosis, autophagy, and up-regulation of PARP-1/VEGF. Chlorpyrifos 32-44 vascular endothelial growth factor A Rattus norvegicus 189-193 33913581-3 2021 We have previously reported that the expression of the angiogenic cytokines vascular endothelial growth factor A (VEGFA) and IL-6 is strongly upregulated in EpiSC by adenosine acting via the A2B receptor (A2B R). Adenosine 166-175 vascular endothelial growth factor A Rattus norvegicus 76-112 33913581-3 2021 We have previously reported that the expression of the angiogenic cytokines vascular endothelial growth factor A (VEGFA) and IL-6 is strongly upregulated in EpiSC by adenosine acting via the A2B receptor (A2B R). Adenosine 166-175 vascular endothelial growth factor A Rattus norvegicus 114-119 33851708-8 2021 Besides, GSEA demonstrated that ADAMTS6 might be involved in multiple biological processes and pathways, such as the vascular endothelial growth factor A (VEGFA), kirsten rat sarcoma viral oncogene (KRAS), tumor protein P53, c-Jun N-terminal kinase (JNK), cadherin (CDH1) or tumor necrosis factor (TNF) pathways. gsea 9-13 vascular endothelial growth factor A Rattus norvegicus 117-153 33851708-8 2021 Besides, GSEA demonstrated that ADAMTS6 might be involved in multiple biological processes and pathways, such as the vascular endothelial growth factor A (VEGFA), kirsten rat sarcoma viral oncogene (KRAS), tumor protein P53, c-Jun N-terminal kinase (JNK), cadherin (CDH1) or tumor necrosis factor (TNF) pathways. gsea 9-13 vascular endothelial growth factor A Rattus norvegicus 155-160 33740374-6 2021 Endothelial migration through porous insert and VEGF induction were obtained in vitro in response to GS4012 as well as the upregulation of ALP, Runx2, Col I, and OC gene expressions. GS4012 101-107 vascular endothelial growth factor A Rattus norvegicus 48-52 33662819-2 2021 Reinforced hydrogels containing both Vascular Endothelial Growth Factor (VEGF) and Platelet-derived Growth Factor (PDGF) were prepared by crosslinking chemically modified hyaluronic acid and heparin with poly(ethylene glycol)-diacrylate around a reinforcing silk mesh. Heparin 191-198 vascular endothelial growth factor A Rattus norvegicus 73-77 32959702-0 2021 Sildenafil ameliorates Alzheimer disease via the modulation of vascular endothelial growth factor and vascular cell adhesion molecule-1 in rats. Sildenafil Citrate 0-10 vascular endothelial growth factor A Rattus norvegicus 63-97 33140116-0 2021 Oxytocin and cabergoline alleviate ovarian hyperstimulation syndrome (OHSS) by suppressing vascular endothelial growth factor (VEGF) in an experimental model. Oxytocin 0-8 vascular endothelial growth factor A Rattus norvegicus 91-125 33140116-0 2021 Oxytocin and cabergoline alleviate ovarian hyperstimulation syndrome (OHSS) by suppressing vascular endothelial growth factor (VEGF) in an experimental model. Oxytocin 0-8 vascular endothelial growth factor A Rattus norvegicus 127-131 33140116-0 2021 Oxytocin and cabergoline alleviate ovarian hyperstimulation syndrome (OHSS) by suppressing vascular endothelial growth factor (VEGF) in an experimental model. Cabergoline 13-24 vascular endothelial growth factor A Rattus norvegicus 91-125 33140116-0 2021 Oxytocin and cabergoline alleviate ovarian hyperstimulation syndrome (OHSS) by suppressing vascular endothelial growth factor (VEGF) in an experimental model. Cabergoline 13-24 vascular endothelial growth factor A Rattus norvegicus 127-131 33140116-12 2021 VEGF expressions in ovaries and peritoneal VEGF levels were decreased in cabergoline and OT groups compared to that of the OHSS groups (p < 0.001 for cabergoline and OT-80 mug/kg; p < 0.00001 for OT-160 mug/kg). Cabergoline 73-84 vascular endothelial growth factor A Rattus norvegicus 0-4 33140116-12 2021 VEGF expressions in ovaries and peritoneal VEGF levels were decreased in cabergoline and OT groups compared to that of the OHSS groups (p < 0.001 for cabergoline and OT-80 mug/kg; p < 0.00001 for OT-160 mug/kg). Cabergoline 73-84 vascular endothelial growth factor A Rattus norvegicus 43-47 33140116-12 2021 VEGF expressions in ovaries and peritoneal VEGF levels were decreased in cabergoline and OT groups compared to that of the OHSS groups (p < 0.001 for cabergoline and OT-80 mug/kg; p < 0.00001 for OT-160 mug/kg). Cabergoline 150-161 vascular endothelial growth factor A Rattus norvegicus 0-4 33140116-14 2021 CONCLUSION: Both OT and cabergoline were active in the alleviation of OHSS through suppression of VEGF and VP. Oxytocin 17-19 vascular endothelial growth factor A Rattus norvegicus 98-102 33140116-14 2021 CONCLUSION: Both OT and cabergoline were active in the alleviation of OHSS through suppression of VEGF and VP. Cabergoline 24-35 vascular endothelial growth factor A Rattus norvegicus 98-102 32822562-0 2021 Nicorandil prevents the nephrotoxic effect of cyclosporine-A in albino rats through modulation of HIF-1alpha/VEGF /eNOS signaling. Nicorandil 0-10 vascular endothelial growth factor A Rattus norvegicus 109-113 32822562-0 2021 Nicorandil prevents the nephrotoxic effect of cyclosporine-A in albino rats through modulation of HIF-1alpha/VEGF /eNOS signaling. Cyclosporine 46-60 vascular endothelial growth factor A Rattus norvegicus 109-113 32822562-9 2021 Cyclosporine decreased the renal expression levels (P<0.001) of HIF-1alpha, eNOS, and VEGF inducing endothelial dysfunction and the triggered inflammation, and upregulated the pro-fibrotic marker transforming growth factor (TGF-beta). Cyclosporine 0-12 vascular endothelial growth factor A Rattus norvegicus 86-90 32822562-10 2021 Nicorandil fixed the disturbed HIF-1alpha/VEGF/eNOS signaling. Nicorandil 0-10 vascular endothelial growth factor A Rattus norvegicus 42-46 32822562-13 2021 Nicorandil reversed the disturbed HIF-1alpha/VEGF/eNOS pathway created by cyclosporine. Nicorandil 0-10 vascular endothelial growth factor A Rattus norvegicus 45-49 32822562-13 2021 Nicorandil reversed the disturbed HIF-1alpha/VEGF/eNOS pathway created by cyclosporine. Cyclosporine 74-86 vascular endothelial growth factor A Rattus norvegicus 45-49 33609510-7 2021 Serum VEGF-A was upregulated in the PGE2-treated diabetic rats vs non-treated diabetic rats and significantly downregulated in AH23848-treated diabetic rats. Dinoprostone 36-40 vascular endothelial growth factor A Rattus norvegicus 6-12 33609510-7 2021 Serum VEGF-A was upregulated in the PGE2-treated diabetic rats vs non-treated diabetic rats and significantly downregulated in AH23848-treated diabetic rats. AH 23848 127-134 vascular endothelial growth factor A Rattus norvegicus 6-12 32959702-16 2021 These findings suggested a protective effect of sildenafil via modulation of VEGF-A, and VCAM-1. Sildenafil Citrate 48-58 vascular endothelial growth factor A Rattus norvegicus 77-83 33223333-9 2021 Since HIF-1alpha and VEGFA are critical factors promoting alveolar development and pulmonary angiogenesis, these results suggested that PFOS may also affect lung development by inhibiting HIF-1alpha and VEGFA expression. perfluorooctane sulfonic acid 136-140 vascular endothelial growth factor A Rattus norvegicus 21-26 33609067-9 2021 Intrahepatic neovascularization was ameliorated with reduced hepatic expressions of Vegf1, Vegf2 and Vegfa in lenvatinib-treated rats. lenvatinib 110-120 vascular endothelial growth factor A Rattus norvegicus 101-106 33842738-3 2021 VEGF-A overexpressing Schwann cells were established and loaded into the inner wall of hydroxyethyl cellulose/soy protein isolate/polyaniline sponge (HSPS) conduits. hydroxyethylcellulose 87-109 vascular endothelial growth factor A Rattus norvegicus 0-6 33455449-0 2021 The impact of ellagic acid on some apoptotic gene expressions: a new perspective for the regulation of pancreatic Nrf-2/NF-kappaB and Akt/VEGF signaling in CCl4-induced pancreas damage in rats. Ellagic Acid 14-26 vascular endothelial growth factor A Rattus norvegicus 138-142 33940981-4 2021 The 2-NP injection upregulated serum AST and ALT activities, as well as hepatic TNF- alpha, IL-6, and MDA levels and the expression of vascular endothelial growth factor (VEGF) and caspase-3, whereas GSH contents and SOD activity were decreased. 2-nitropropane 4-8 vascular endothelial growth factor A Rattus norvegicus 135-169 33940981-4 2021 The 2-NP injection upregulated serum AST and ALT activities, as well as hepatic TNF- alpha, IL-6, and MDA levels and the expression of vascular endothelial growth factor (VEGF) and caspase-3, whereas GSH contents and SOD activity were decreased. 2-nitropropane 4-8 vascular endothelial growth factor A Rattus norvegicus 171-175 33898027-8 2021 Results: In a rats model of deep dermal wound healing, topical Vaseline significantly increased serum VEGF compared to control. Petrolatum 63-71 vascular endothelial growth factor A Rattus norvegicus 102-106 33746762-0 2021 l-Borneol Exerted the Neuroprotective Effect by Promoting Angiogenesis Coupled With Neurogenesis via Ang1-VEGF-BDNF Pathway. isoborneol 0-9 vascular endothelial growth factor A Rattus norvegicus 106-110 33746762-10 2021 In addition, l-borneol can significantly promote the expression level of VEGF, BDNF and inhibit the expression levels of TGF-beta1 and MMP9 to promote neurogenesis. isoborneol 13-22 vascular endothelial growth factor A Rattus norvegicus 73-77 33746762-11 2021 The above suggests that l-borneol can promote angiogenesis coupled neurogenesis by regulating Ang1-VEGF-BDNF to play a neuroprotective effect. isoborneol 24-33 vascular endothelial growth factor A Rattus norvegicus 99-103 33345997-10 2021 In cultured DRG neurons, phosphatidylinositol 3 (PI3K)/Akt, extracellular signal-regulated protein kinase (ERK) and p38 inhibitors significantly attenuated VEGF-induced neurite elongation. Phosphatidylinositols 25-45 vascular endothelial growth factor A Rattus norvegicus 156-160 33223333-9 2021 Since HIF-1alpha and VEGFA are critical factors promoting alveolar development and pulmonary angiogenesis, these results suggested that PFOS may also affect lung development by inhibiting HIF-1alpha and VEGFA expression. perfluorooctane sulfonic acid 136-140 vascular endothelial growth factor A Rattus norvegicus 203-208 33068653-0 2021 Chinese medicine GeGen-DanShen extract protects from myocardial ischemic injury through promoting angiogenesis via up-regulation of VEGF/VEGFR2 signaling pathway. gegen-danshen 17-30 vascular endothelial growth factor A Rattus norvegicus 132-136 32767051-7 2021 There were no blood pressure changes and VEGF-A level in renal medulla was significantly higher only for PTAI-10-14-based formulation. ptai-10-14 105-115 vascular endothelial growth factor A Rattus norvegicus 41-47 33535016-1 2021 Purpose: Propranolol, a nonselective B1/B2 adrenoceptor antagonist, promotes the regression of infantile hemangiomas likely through suppression of vascular endothelial growth factor (VEGF), which prompted its use for the prevention of retinopathy of prematurity. Propranolol 9-20 vascular endothelial growth factor A Rattus norvegicus 147-181 33535016-1 2021 Purpose: Propranolol, a nonselective B1/B2 adrenoceptor antagonist, promotes the regression of infantile hemangiomas likely through suppression of vascular endothelial growth factor (VEGF), which prompted its use for the prevention of retinopathy of prematurity. Propranolol 9-20 vascular endothelial growth factor A Rattus norvegicus 183-187 33535016-7 2021 The beneficial effects of propranolol were associated with reduced ocular VEGF and increased endogenous soluble inhibitor, sVEGFR-1, when administered topically. Propranolol 26-37 vascular endothelial growth factor A Rattus norvegicus 74-78 33503445-1 2021 As a VEGF-targeting agent, sorafenib has been used to treat a number of solid tumors but can easily lead to adverse vascular effects. Sorafenib 27-36 vascular endothelial growth factor A Rattus norvegicus 5-9 33671638-11 2021 For the first time, we could show that miR204-5p has a negative effect on VEGF sensitivity in juvenile PC, resulting in a significant decrease of dendritic growth compared to untreated juvenile PC. mir204-5p 39-48 vascular endothelial growth factor A Rattus norvegicus 74-78 33628394-10 2021 Results: Resveratrol can significantly decrease the expression of lipase, amylase, acetyl-FOXO1, VEGF, Ang II, ET, NO, TXB2, and 6-keto-PGF1alpha and the ratio of wet/dry weight, ET/NO, and TXB2/6-keto-PGF1alpha by improving microcirculatory dysfunction and blood viscosity in SAP. Resveratrol 9-20 vascular endothelial growth factor A Rattus norvegicus 97-101 33480300-9 2021 HDAC9 inhibition or miR-92a elevation improved pathological changes and repressed apoptosis and expression of MMP-2, MMP-9, VEGF and inflammatory factors in vascular tissues from IA rats. mir-92a 20-27 vascular endothelial growth factor A Rattus norvegicus 124-128 33047165-10 2021 Metformin significantly attenuated diabetes-related histopathological ocular deteriorations in the cornea, lens, sclera, ciliary body, iris, conjunctiva, retina, and optic nerve partly by restoring serum TNF-alpha, VEGF, claudin-1, and glutathione/malondialdehyde ratios without significantly affecting the fasting blood glucose levels or body weight in these hyperglycemic rats. Metformin 0-9 vascular endothelial growth factor A Rattus norvegicus 215-219 33829697-15 2021 Conclusion: Dingkun Dan combined with estradiol valerateon can increase the thicken of the endometrium by up-regulation of VEGF, while down-regulate of beta-catenin, E-cadherin and MMP-9 in rats with Shen-Yang deficiency and thin endometrium. Estradiol 38-47 vascular endothelial growth factor A Rattus norvegicus 123-127 33635529-0 2021 Suramin enhances the urinary excretion of VEGF-A in normoglycemic and streptozotocin-induced diabetic rats. Suramin 0-7 vascular endothelial growth factor A Rattus norvegicus 42-48 33635529-0 2021 Suramin enhances the urinary excretion of VEGF-A in normoglycemic and streptozotocin-induced diabetic rats. Streptozocin 70-84 vascular endothelial growth factor A Rattus norvegicus 42-48 33635529-3 2021 Since the ATP-induced release of MMP-9 is mediated by P2Rs, we investigated the effect of suramin on VEGF-A excretion in urine and the urinary activity of total MMP and MMP-9. Suramin 90-97 vascular endothelial growth factor A Rattus norvegicus 101-107 33635529-4 2021 METHODS: The effect of suramin (10 mg/kg, ip) on VEGF-A concentration in serum and its excretion in urine was investigated in streptozotocin (STZ)-induced diabetic rats over a 21-day period. Suramin 23-30 vascular endothelial growth factor A Rattus norvegicus 49-55 33635529-9 2021 Suramin potentiates VEGF-A urinary excretion by 36% (p = 0.046) in non-diabetic and by 75% (p = 0.0322) in diabetic rats but it did not affect VEGF-A concentration in the serum of non-diabetic and diabetic rats. Suramin 0-7 vascular endothelial growth factor A Rattus norvegicus 20-26 33635529-11 2021 CONCLUSION: Suramin increases the urinary excretion of VEGF-A in normoglycemia and hyperglycaemia, possibly without the involvement of MMP-9. Suramin 12-19 vascular endothelial growth factor A Rattus norvegicus 55-61 33635529-12 2021 Suramin may be used as a pharmacological tool enhancing VEGF-A urinary secretion. Suramin 0-7 vascular endothelial growth factor A Rattus norvegicus 56-62 33716750-12 2021 Rats in the high-dose Api group exhibited higher average flap survival area, microcirculatory flow, increased SOD activity, and higher VEGF expression levels compared with the other two groups. Apigenin 22-25 vascular endothelial growth factor A Rattus norvegicus 135-139 32935224-6 2021 Stabilization of the DHFR(DD)-Flt23k fusion protein by TMP was able to inhibit intracellular VEGF in hypoxic cells. Trimethoprim 55-58 vascular endothelial growth factor A Rattus norvegicus 93-97 32935224-12 2021 c In the presence of the ligand TMP, DHFR(DD)-Flt23k is stabilized and sequestered in the ER, thereby conditionally inhibiting VEGF. Trimethoprim 32-35 vascular endothelial growth factor A Rattus norvegicus 127-131 33515165-14 2021 Western blot and qRT-PCR analysis revealed high expression levels of COL I, VEGF, eNOS, and FGF in the verapamil. Verapamil 103-112 vascular endothelial growth factor A Rattus norvegicus 76-80 33415607-0 2021 Knockdown of miR-203a-3p alleviates the development of bronchopulmonary dysplasia partly via the up-regulation of vascular endothelial growth factor A. mir-203a-3p 13-24 vascular endothelial growth factor A Rattus norvegicus 114-150 33415607-8 2021 VEGFA treatment significantly attenuated the increase in the RLE-6TN cell apoptotic rates induced by miR-203a-3p overexpression; while VEGFA knockdown significantly increased the cell apoptotic rates of RLE-6TN cells, which was partially reversed by the treatment with miR-203a-3p inhibitor. mir-203a 101-109 vascular endothelial growth factor A Rattus norvegicus 0-5 33415607-8 2021 VEGFA treatment significantly attenuated the increase in the RLE-6TN cell apoptotic rates induced by miR-203a-3p overexpression; while VEGFA knockdown significantly increased the cell apoptotic rates of RLE-6TN cells, which was partially reversed by the treatment with miR-203a-3p inhibitor. p-Bis(2-chloroethyl)amino-o-methoxyphenylalanine 110-112 vascular endothelial growth factor A Rattus norvegicus 0-5 33415607-8 2021 VEGFA treatment significantly attenuated the increase in the RLE-6TN cell apoptotic rates induced by miR-203a-3p overexpression; while VEGFA knockdown significantly increased the cell apoptotic rates of RLE-6TN cells, which was partially reversed by the treatment with miR-203a-3p inhibitor. mir-203a 269-277 vascular endothelial growth factor A Rattus norvegicus 0-5 33415607-10 2021 In summary, the findings of our study indicate that miR-203a-3p knockdown alleviates hyperoxia-induced lung tissue damage in the BPD rat model, and its effect may be associated with the up-regulation of VEGF. mir-203a-3p 52-63 vascular endothelial growth factor A Rattus norvegicus 203-207 32790879-8 2021 The expression levels of proliferating cell nuclear antigen (PCNA), vascular endothelial growth factor (VEGF), and osteopontin (OPN) in the DPSC + THSG group were significantly greater than those in other groups. dpsc 140-144 vascular endothelial growth factor A Rattus norvegicus 68-102 33484396-12 2021 Furthermore, administration of umbelliferone significantly (P < 0.001) suppressed the NF-kappaB and VEGF. 7-hydroxycoumarin 31-44 vascular endothelial growth factor A Rattus norvegicus 100-104 33645090-15 2021 The compounds in Danggui Sini Decoction can play a therapeutic role in the treatment of PD by acting on VEGFA, IL-6, PTGS2, TNF and other targets to regulate arachidonic acid and inflammatory signaling pathways. Arachidonic Acid 158-174 vascular endothelial growth factor A Rattus norvegicus 104-109 33413359-9 2021 Norwogonin also acted as an antioxidant by scavenging ROS, reducing MDA production, maintaining the activities of superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx), and decreasing the expression levels of HIF-1alpha and VEGF. norwogonin 0-10 vascular endothelial growth factor A Rattus norvegicus 246-250 33479328-0 2021 Hyperglycemia-induced VEGF and ROS production in retinal cells is inhibited by the mTOR inhibitor, rapamycin. Sirolimus 99-108 vascular endothelial growth factor A Rattus norvegicus 22-26 33479328-1 2021 Determine the impact of the mTOR inhibitor, rapamycin, on the hyperglycemia-induced expression of vascular endothelial growth factor (VEGF) and the production of reactive oxygen species (ROS) in retinal cells. Sirolimus 44-53 vascular endothelial growth factor A Rattus norvegicus 98-132 33479328-1 2021 Determine the impact of the mTOR inhibitor, rapamycin, on the hyperglycemia-induced expression of vascular endothelial growth factor (VEGF) and the production of reactive oxygen species (ROS) in retinal cells. Sirolimus 44-53 vascular endothelial growth factor A Rattus norvegicus 134-138 33479328-8 2021 In rat retina, rapamycin attenuates the diabetes-induced VEGF overexpression, and in cultured Muller cells and HRMECs, inhibits the hyperglycemia-induced boost ROS. Sirolimus 15-24 vascular endothelial growth factor A Rattus norvegicus 57-61 33409912-8 2021 Mg supplementation significantly decreased the expression levels of NF-kappaB, INOS, ICAM, and VEGF in HFD rats while increasing the level of Nrf2 (p < 0.001). Magnesium 0-2 vascular endothelial growth factor A Rattus norvegicus 95-99 33409912-9 2021 Mg supplementation significantly decreased the levels of NF-kappaB, INOS, ICAM, and VEGF and increased Nrf2 level in HFD rats (p < 0.001), with stronger effects seen from MgPic. Magnesium 0-2 vascular endothelial growth factor A Rattus norvegicus 84-88 33197564-10 2021 Treatment with Val-SLN for 12 days revealed enhanced healing characteristics through cyclooxygenase-2 (COX-2), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB), nitric oxide (NO), transforming growth factor-beta (TGF-beta), matrix metalloproteinase (MMPs) and vascular endothelial growth factor (VEGF) pathways. val-sln 15-22 vascular endothelial growth factor A Rattus norvegicus 286-320 33197564-10 2021 Treatment with Val-SLN for 12 days revealed enhanced healing characteristics through cyclooxygenase-2 (COX-2), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB), nitric oxide (NO), transforming growth factor-beta (TGF-beta), matrix metalloproteinase (MMPs) and vascular endothelial growth factor (VEGF) pathways. val-sln 15-22 vascular endothelial growth factor A Rattus norvegicus 322-326 33573585-10 2021 RESULTS: Dantrolene exhibited synergistic effect when used in combination with sorafenib compared to either drug alone (p <0.05) through decreasing p53, VEGF, MMP-9, Cyclin D1, and Ki-67. Dantrolene 9-19 vascular endothelial growth factor A Rattus norvegicus 153-157 33573585-10 2021 RESULTS: Dantrolene exhibited synergistic effect when used in combination with sorafenib compared to either drug alone (p <0.05) through decreasing p53, VEGF, MMP-9, Cyclin D1, and Ki-67. Sorafenib 79-88 vascular endothelial growth factor A Rattus norvegicus 153-157 33220275-0 2021 Metformin reduces proteinuria in spontaneously hypertensive rats by activating the HIF-2alpha-VEGF-A pathway. Metformin 0-9 vascular endothelial growth factor A Rattus norvegicus 94-100 33220275-8 2021 Metformin increased the production of vascular endothelial growth factor (VEGF)-A in rat kidneys and cultured rat podocytes. Metformin 0-9 vascular endothelial growth factor A Rattus norvegicus 74-78 33220275-9 2021 Metformin activated hypoxia-inducible factor-2alpha (Hif-2alpha) in response to VEGF but did not affect Hif-1alpha in rat kidneys and cultured rat podocytes. Metformin 0-9 vascular endothelial growth factor A Rattus norvegicus 80-84 33220275-10 2021 Metformin reduced the proteinuria induced by long-term high blood pressure in vivo and increased the VEGF-A production in rat kidneys and cultured rat podocytes, probably by activating the Hif-2alpha-VEGF signaling pathway. Metformin 0-9 vascular endothelial growth factor A Rattus norvegicus 101-107 33220275-10 2021 Metformin reduced the proteinuria induced by long-term high blood pressure in vivo and increased the VEGF-A production in rat kidneys and cultured rat podocytes, probably by activating the Hif-2alpha-VEGF signaling pathway. Metformin 0-9 vascular endothelial growth factor A Rattus norvegicus 101-105 33407988-5 2021 Ovaries from Delta9-THC-exposed offspring had reduced blood vessel density in association with decreased expression of the pro-angiogenic factor VEGF and its receptor VEGFR-2, as well as an increase in the anti-angiogenic factor thrombospondin 1 (TSP-1). Dronabinol 20-23 vascular endothelial growth factor A Rattus norvegicus 145-149 33180154-7 2021 Finally, we found that L-NBP significantly increased the protein and mRNA expression levels of Nrf2, HIF-1alpha, and VEGF in the brain of MACO/R rats. l-nbp 23-28 vascular endothelial growth factor A Rattus norvegicus 117-121 33346402-10 2021 In vitro, VT treatment significantly decreases endothelial cell death and decreases MCP-1, endothelin-1, and VEGF expression under high glucose (HG) and ischemic conditions and significantly increases capillary tube formation under HG conditions when compared to non-treated control group. Vasculotide 10-12 vascular endothelial growth factor A Rattus norvegicus 109-113 33199100-6 2021 Our results showed that vortioxetine significantly increased the number of ramified (resting) microglia and astrocytes accompanied by VEGF level elevation, whereas fluoxetine had no effect after 7 days treatment on these measures. Vortioxetine 24-36 vascular endothelial growth factor A Rattus norvegicus 134-138 32290677-9 2021 Correlation analysis between immunohistochemistry and quantitative parameters of spectral CT showed that the single energy CT value of 70 keV, slope of the energy spectrum curve, and concentration of iodine were positively correlated with VEGF and HIF-1alpha at different time points in the experimental group and the control group. Iodine 200-206 vascular endothelial growth factor A Rattus norvegicus 239-243 33180154-8 2021 In conclusion, our results demonstrated that L-NBP exerted significant beneficial effects on cerebral I/R injury in rats through promoting angiogenesis, which may be associated with the activation of Nrf2/HIF-1alpha/VEGF signaling pathway. l-nbp 45-50 vascular endothelial growth factor A Rattus norvegicus 216-220 33301773-13 2021 Upon pre-incubation of these cell lines with high glucose (HG) media, [3H]paeonol uptake decreased and mRNA expression levels of angiogenetic factors, such as hypoxia inducible factor-1 (HIF-1) and vascular endothelial growth factor (VEGF) increased. Glucose 50-57 vascular endothelial growth factor A Rattus norvegicus 198-232 32959172-9 2021 In conclusion, the mechanism for morphological and functional neuroprotection by UA in ischemic stroke is multifaceted, since it is associated to activation of the IL-6/STAT3 pathway, attenuation of edematogenic VEGF-A/MMP-9 signaling, and modulation of relevant mediators of oxidative stress, neuroinflammation, and apoptotic cell death. Uric Acid 81-83 vascular endothelial growth factor A Rattus norvegicus 212-218 33301773-13 2021 Upon pre-incubation of these cell lines with high glucose (HG) media, [3H]paeonol uptake decreased and mRNA expression levels of angiogenetic factors, such as hypoxia inducible factor-1 (HIF-1) and vascular endothelial growth factor (VEGF) increased. Glucose 50-57 vascular endothelial growth factor A Rattus norvegicus 234-238 33301773-14 2021 However, after the pretreatment of unlabeled paeonol in HG conditions, the mRNA levels of VEGF and HIF-1 were comparatively reduced, and the [3H]paeonol uptake rate was restored. paeonol 45-52 vascular endothelial growth factor A Rattus norvegicus 90-94 33214096-12 2021 Exenatide also enhanced the expression of VEGF and reduced the expression of inflammatory cytokines (IL-6, IL-1beta, NF-kappaB, TLR4, and TNF-alpha), thereby promoting angiogenesis and inhibiting inflammation. Exenatide 0-9 vascular endothelial growth factor A Rattus norvegicus 42-46 33396450-6 2020 PEDF-R- and LR-knocked-down cells demonstrated a markedly attenuated expression of anti-apoptotic Bcl-2 family members (Bcl-2, Bcl-xL) and neuroprotective mediators (PEDF, VEGF, BDNF) suggesting that both PEDF-R and LR mediate pro-survival effects of PEDF on RGC. Arginine 5-6 vascular endothelial growth factor A Rattus norvegicus 172-176 33179107-16 2021 Caspase-3 and PPARgamma expression increased and expression of VEGF and MAT2A decreased in RSG-treated groups. rsg 91-94 vascular endothelial growth factor A Rattus norvegicus 63-67 33396450-6 2020 PEDF-R- and LR-knocked-down cells demonstrated a markedly attenuated expression of anti-apoptotic Bcl-2 family members (Bcl-2, Bcl-xL) and neuroprotective mediators (PEDF, VEGF, BDNF) suggesting that both PEDF-R and LR mediate pro-survival effects of PEDF on RGC. Arginine 13-14 vascular endothelial growth factor A Rattus norvegicus 172-176 33392182-4 2020 The results of MTT combined with Elisa reagent showed that with the prolonged period of hypoxia, the secretion of VEGF protein increased, and that the proliferation of target cells and neural stem cells was better promoted (p < 0.05). monooxyethylene trimethylolpropane tristearate 15-18 vascular endothelial growth factor A Rattus norvegicus 114-118 33376304-13 2020 Conclusion: In conclusion, these results suggest that BPC 157 inhibited Clopidogrel-induced gastric mucosa injury partially by inhibition of gastric mucosa cell ER stress-mediated apoptosis and inflammation, and promoting gastric mucosa angiogenesis via VEGF-A/VEGFR1 mediated-AKT/p38/MAPK signaling pathways. S-(4-bromophenyl)cysteine sulfoxide 54-57 vascular endothelial growth factor A Rattus norvegicus 254-260 32871518-9 2020 Importantly, the anti-apoptotic property of NAC could be attributed to inactivation of MAPK signaling molecules; p38 and JNK, and enhancement of the ovarian vascular endothelial growth factor (VEGF) expression. Acetylcysteine 44-47 vascular endothelial growth factor A Rattus norvegicus 157-191 32871518-9 2020 Importantly, the anti-apoptotic property of NAC could be attributed to inactivation of MAPK signaling molecules; p38 and JNK, and enhancement of the ovarian vascular endothelial growth factor (VEGF) expression. Acetylcysteine 44-47 vascular endothelial growth factor A Rattus norvegicus 193-197 32871518-10 2020 Taken together, our results suggest that NAC can inhibit radiotherapy-induced POF while preserving ovarian function and structure through upregulating VEGF expression and suppressing NOX4/MAPK/p53 apoptotic signaling. Acetylcysteine 41-44 vascular endothelial growth factor A Rattus norvegicus 151-155 33270292-3 2021 Phosphodiesterase-5 inhibitors act by inhibiting the degradation of guanosine 3",5"-cyclic monophosphate in the nitric oxide pathway, increasing its bioavailability and promoting vascular endothelial growth factor (VEGF)-mediated neovascular recruitment and the induction of tissue regeneration in traumatized bone. guanosine 3",5"-cyclic monophosphate 68-104 vascular endothelial growth factor A Rattus norvegicus 215-219 33270292-3 2021 Phosphodiesterase-5 inhibitors act by inhibiting the degradation of guanosine 3",5"-cyclic monophosphate in the nitric oxide pathway, increasing its bioavailability and promoting vascular endothelial growth factor (VEGF)-mediated neovascular recruitment and the induction of tissue regeneration in traumatized bone. Nitric Oxide 112-124 vascular endothelial growth factor A Rattus norvegicus 215-219 33270292-8 2021 CONCLUSION: The present study demonstrated that sildenafil optimized bone tissue regeneration by increasing VEGF signaling and osteopontin expression, with increased bone formation (osteoid and carbohydrate macromolecule deposition) in the early stages following traumatic ischemic insult. Sildenafil Citrate 48-58 vascular endothelial growth factor A Rattus norvegicus 108-112 33389832-7 2020 RESULTS: Both applications of VEGF caused decreases in plasma levels of interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-alpha), intestinal malondialdehyde (MDA), oxidized glutathione, protein carbonyl levels, and increases in intestinal total glutathione and superoxide dismutase (SOD) levels. Malondialdehyde 146-161 vascular endothelial growth factor A Rattus norvegicus 30-34 33389832-7 2020 RESULTS: Both applications of VEGF caused decreases in plasma levels of interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-alpha), intestinal malondialdehyde (MDA), oxidized glutathione, protein carbonyl levels, and increases in intestinal total glutathione and superoxide dismutase (SOD) levels. Malondialdehyde 163-166 vascular endothelial growth factor A Rattus norvegicus 30-34 33389832-7 2020 RESULTS: Both applications of VEGF caused decreases in plasma levels of interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-alpha), intestinal malondialdehyde (MDA), oxidized glutathione, protein carbonyl levels, and increases in intestinal total glutathione and superoxide dismutase (SOD) levels. Glutathione 178-189 vascular endothelial growth factor A Rattus norvegicus 30-34 33389832-7 2020 RESULTS: Both applications of VEGF caused decreases in plasma levels of interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-alpha), intestinal malondialdehyde (MDA), oxidized glutathione, protein carbonyl levels, and increases in intestinal total glutathione and superoxide dismutase (SOD) levels. Glutathione 250-261 vascular endothelial growth factor A Rattus norvegicus 30-34 33389832-7 2020 RESULTS: Both applications of VEGF caused decreases in plasma levels of interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-alpha), intestinal malondialdehyde (MDA), oxidized glutathione, protein carbonyl levels, and increases in intestinal total glutathione and superoxide dismutase (SOD) levels. Superoxides 266-276 vascular endothelial growth factor A Rattus norvegicus 30-34 33166863-6 2020 Our results showed that the STZ-induced diabetic rats had delayed wound healing compared with the normal rats, exhibited by intense oxidative DNA damage, low vascular endothelial growth factor (VEGF) and transforming growth factor beta1 (TGF-beta1) expression, as well as increased apoptosis. Streptozocin 28-31 vascular endothelial growth factor A Rattus norvegicus 158-192 33166863-6 2020 Our results showed that the STZ-induced diabetic rats had delayed wound healing compared with the normal rats, exhibited by intense oxidative DNA damage, low vascular endothelial growth factor (VEGF) and transforming growth factor beta1 (TGF-beta1) expression, as well as increased apoptosis. Streptozocin 28-31 vascular endothelial growth factor A Rattus norvegicus 194-198 33045614-8 2020 Higher expression of EGF, VEGF, bFGF, and TGF-beta were observed in HFBSC-injected rats. hfbsc 68-73 vascular endothelial growth factor A Rattus norvegicus 26-30 32437020-8 2020 Our in vivo study revealed that DFO increased HIF-1alpha/VEGF expression and promoted angiogenesis and osteogenesis in GIOFH. dfo 32-35 vascular endothelial growth factor A Rattus norvegicus 57-61 33315517-0 2020 MiR-17-5p promotes the endothelialization of endothelial progenitor cells to facilitate the vascular repair of aneurysm by regulating PTEN-mediated PI3K/AKT/VEGFA pathway. mir-17-5p 0-9 vascular endothelial growth factor A Rattus norvegicus 157-162 33315517-7 2020 In vitro study: miR-17-5p overexpression promoted the viability, migration, and tube formation of EPCs, up-regulated the expressions of VEGFA, p-PI3K, and p-AKT, and down-regulated the PTEN expression in EPCs; miR-17-5p silencing did the opposite; PTEN was targeted by miR-17-3p and further abrogated the effects of miR-17-5p overexpression on EPCs. mir-17-5p 16-25 vascular endothelial growth factor A Rattus norvegicus 136-141 33315517-8 2020 MiR-17-5p promoted the endothelialization of EPCs to facilitate the vascular repair of aneurysm by regulating PTEN-mediated PI3K/AKT/VEGFA pathway. mir-17-5p 0-9 vascular endothelial growth factor A Rattus norvegicus 133-138 33113423-12 2020 In the urothelium the RA induced the elevation of ATP, CGRP, substance P, VEGF-A, OTC3, and ERK1/2. retinol acetate 22-24 vascular endothelial growth factor A Rattus norvegicus 74-80 32945205-9 2020 beta-sitosterol-SLN significantly (p < .001) reduced the level of cyclooxygenase-2 (COX-2), prostaglandin E2 (PGE2), vascular Endothelial Growth Factor (VEGF) and NF-kappaB. gamma-sitosterol 0-15 vascular endothelial growth factor A Rattus norvegicus 117-151 32945205-9 2020 beta-sitosterol-SLN significantly (p < .001) reduced the level of cyclooxygenase-2 (COX-2), prostaglandin E2 (PGE2), vascular Endothelial Growth Factor (VEGF) and NF-kappaB. gamma-sitosterol 0-15 vascular endothelial growth factor A Rattus norvegicus 153-157 32437020-2 2020 By chelating Fe2+ , desferoxamine (DFO) was reported to be able to activate the HIF-1alpha/VEGF pathway and promote angiogenesis. ammonium ferrous sulfate 13-17 vascular endothelial growth factor A Rattus norvegicus 91-95 33258351-13 2020 The administration of fasudil and high-dose MXXTM significantly reduced the contents of HIF-1alpha, VEGF, PRA, ANG-II and ALD. fasudil 22-29 vascular endothelial growth factor A Rattus norvegicus 100-104 32437020-2 2020 By chelating Fe2+ , desferoxamine (DFO) was reported to be able to activate the HIF-1alpha/VEGF pathway and promote angiogenesis. desferoxamine 20-33 vascular endothelial growth factor A Rattus norvegicus 91-95 32437020-2 2020 By chelating Fe2+ , desferoxamine (DFO) was reported to be able to activate the HIF-1alpha/VEGF pathway and promote angiogenesis. dfo 35-38 vascular endothelial growth factor A Rattus norvegicus 91-95 33258351-13 2020 The administration of fasudil and high-dose MXXTM significantly reduced the contents of HIF-1alpha, VEGF, PRA, ANG-II and ALD. mxxtm 44-49 vascular endothelial growth factor A Rattus norvegicus 100-104 32791190-11 2020 Blocking the melatonin system by administrating MT2 receptor antagonist, 4-P-PDOT, alleviates OHSS symptoms by decreasing the expression of VEGF. Melatonin 13-22 vascular endothelial growth factor A Rattus norvegicus 140-144 32791190-11 2020 Blocking the melatonin system by administrating MT2 receptor antagonist, 4-P-PDOT, alleviates OHSS symptoms by decreasing the expression of VEGF. 4-phenyl-2-propionamidotetraline 73-81 vascular endothelial growth factor A Rattus norvegicus 140-144 32931799-0 2020 Neuroprotection of benzoinum in cerebral ischemia model rats via the ACE-AngI-VEGF pathway. benzoinum 19-28 vascular endothelial growth factor A Rattus norvegicus 78-82 33328980-0 2020 Total Flavonoids of Rhizoma Drynariae Enhances Angiogenic-Osteogenic Coupling During Distraction Osteogenesis by Promoting Type H Vessel Formation Through PDGF-BB/PDGFR-beta Instead of HIF-1alpha/ VEGF Axis. Flavonoids 6-16 vascular endothelial growth factor A Rattus norvegicus 197-201 33282174-5 2020 The inclusion of TA on HA brought the composites with enhanced osteogenesis and angiogenesis, evidenced by osteocalcin (OCN) and vascular endothelial growth factor (VEGF) immunohistochemical staining. Tannins 17-19 vascular endothelial growth factor A Rattus norvegicus 129-163 33282174-5 2020 The inclusion of TA on HA brought the composites with enhanced osteogenesis and angiogenesis, evidenced by osteocalcin (OCN) and vascular endothelial growth factor (VEGF) immunohistochemical staining. Tannins 17-19 vascular endothelial growth factor A Rattus norvegicus 165-169 33203103-8 2020 Allicin increased Nrf2 expression and decreased SBP, Keap1, HIF-1alpha, and VEGF expression. allicin 0-7 vascular endothelial growth factor A Rattus norvegicus 76-80 33273907-2 2020 Whether EEs also promote VEGF-mediated neuroprotection and angiogenesis in the contralateral hemisphere remains unclear. ees 8-11 vascular endothelial growth factor A Rattus norvegicus 25-29 33273907-3 2020 Here, we explored the effect of EEs on VEGF expression and angiogenesis within the contralateral cerebral cortex in a rat middle cerebral artery occlusion/reperfusion (MCAO/r) model. ees 32-35 vascular endothelial growth factor A Rattus norvegicus 39-43 33219891-6 2021 In a rat model of chemically induced RCC, squalene displayed chemopreventive capabilities by substantial reversal of lipid peroxidation, mitochondrial redox regulation, maintaining psim, inflammation [Akt, nuclear factor kappaB (NF-kappaB)], angiogenesis (VEGFalpha), metastasis [matrix metalloproteinase 2 (MMP-2)], and survival (Bax/Bcl2, cytochrome-c, Casp3). Squalene 42-50 vascular endothelial growth factor A Rattus norvegicus 257-266 33219891-8 2021 The correlation of thiobarbituric acid reactive substance with VEGF/NF-kappaB and negative association of GSH with Casp3 show that squalene employs reduction in ROS regulation. thiobarbituric acid 19-38 vascular endothelial growth factor A Rattus norvegicus 63-67 33219891-8 2021 The correlation of thiobarbituric acid reactive substance with VEGF/NF-kappaB and negative association of GSH with Casp3 show that squalene employs reduction in ROS regulation. Squalene 131-139 vascular endothelial growth factor A Rattus norvegicus 63-67 33202817-8 2020 The immunoblotting data indicated that rutin promotes production of antioxidant enzymes induced by nuclear factor erythroid 2-related factor 2 (NRF2), inhibits the expression of matrix metalloproteinases (MMPs) regulated by NF-kappaB, and decreases the expression of vascular endothelial growth factor (VEGF). Rutin 39-44 vascular endothelial growth factor A Rattus norvegicus 267-301 33202817-8 2020 The immunoblotting data indicated that rutin promotes production of antioxidant enzymes induced by nuclear factor erythroid 2-related factor 2 (NRF2), inhibits the expression of matrix metalloproteinases (MMPs) regulated by NF-kappaB, and decreases the expression of vascular endothelial growth factor (VEGF). Rutin 39-44 vascular endothelial growth factor A Rattus norvegicus 303-307 33184252-10 2020 Treatment of rats with curcumin significantly (P<0.05) promoted expression of PCNA and VEGF. Curcumin 23-31 vascular endothelial growth factor A Rattus norvegicus 87-91 33179297-3 2021 The goal of this study was to investigate whether the local delivery of anti-VEGF antibody (alpha-VEGF; 7.5mug) from alginate:chitosan hydrogels to the tibial physeal injury site in rats prevents bony bar formation. Alginates 117-125 vascular endothelial growth factor A Rattus norvegicus 77-81 33179297-3 2021 The goal of this study was to investigate whether the local delivery of anti-VEGF antibody (alpha-VEGF; 7.5mug) from alginate:chitosan hydrogels to the tibial physeal injury site in rats prevents bony bar formation. Chitosan 126-134 vascular endothelial growth factor A Rattus norvegicus 77-81 33273907-6 2020 Further experiments showed that EEs increased neuronal VEGF expression surrounding the cingulum in MCAO/r rats and robustly upregulated eNOS expression. ees 32-35 vascular endothelial growth factor A Rattus norvegicus 55-59 33273907-7 2020 These results revealed that EEs enhanced angiogenesis, VEGF expression, and activation of the VEGF-eNOS pathway in and/or around the cingulum in MCAO/r rats, which were involved in the functional recovery of MCAO/r rats. ees 28-31 vascular endothelial growth factor A Rattus norvegicus 55-59 33273907-7 2020 These results revealed that EEs enhanced angiogenesis, VEGF expression, and activation of the VEGF-eNOS pathway in and/or around the cingulum in MCAO/r rats, which were involved in the functional recovery of MCAO/r rats. ees 28-31 vascular endothelial growth factor A Rattus norvegicus 94-98 33167932-14 2020 CONCLUSIONS: The present results suggest that emodin might protect against retinal ischemia insulted neurons such as RGCs by significantly downregulating the upregulation of beta-catenin/VEGF protein that occurs during ischemia. Emodin 46-52 vascular endothelial growth factor A Rattus norvegicus 187-191 32620992-7 2020 CONCLUSION: Our results demonstrate that bioreducible lipidoid nanoparticles conveying VEGF siRNA can effectively inhibit retinal neovascularization in a rodent model of OIR, and reduce the expression of VEGF mRNA and protein. lipidoid 54-62 vascular endothelial growth factor A Rattus norvegicus 87-91 32620992-7 2020 CONCLUSION: Our results demonstrate that bioreducible lipidoid nanoparticles conveying VEGF siRNA can effectively inhibit retinal neovascularization in a rodent model of OIR, and reduce the expression of VEGF mRNA and protein. lipidoid 54-62 vascular endothelial growth factor A Rattus norvegicus 204-208 32950574-10 2020 Moreover, G-CSF treatment stimulated the expression of VEGF and LIF in the 95% ethanol-induced thin-endometrium rat model. Ethanol 79-86 vascular endothelial growth factor A Rattus norvegicus 55-59 32673612-3 2020 We propose the concept of capillary network unit and show that the concentration and gradient of oxygen/hypoxia-induced VEGF around straight segments are lower/higher than that around vascular bifurcations; sprouting mainly occurs at straight segments and intussusception at vascular bifurcations. Oxygen 97-103 vascular endothelial growth factor A Rattus norvegicus 120-124 32673612-4 2020 The results indicate that the locations susceptible to sprouting and intussusception are determined by the distribution characteristics of oxygen/hypoxia-induced VEGF in the capillary network unit. Oxygen 139-145 vascular endothelial growth factor A Rattus norvegicus 162-166 32931799-10 2020 At an optimal dose, benzoinum could significantly up-regulate VEGF, SHH and ANG-1, yet down-regulate ACE expression in MCAO model rats. benzoinum 20-29 vascular endothelial growth factor A Rattus norvegicus 62-66 32931799-11 2020 SIGNIFICANCE: Balsamic acid is the active ingredient of benzoinum that protects against ischemic stroke and the possible mechanism is related to the promotion of angiogenesis via regulating ACE-AngI-VEGF pathway. balsamic acid 14-27 vascular endothelial growth factor A Rattus norvegicus 199-203 32931799-11 2020 SIGNIFICANCE: Balsamic acid is the active ingredient of benzoinum that protects against ischemic stroke and the possible mechanism is related to the promotion of angiogenesis via regulating ACE-AngI-VEGF pathway. benzoinum 56-65 vascular endothelial growth factor A Rattus norvegicus 199-203 33029500-7 2020 Meanwhile, the alendronate group had more OCs, but less OCN and VEGF levels along with decreased p-AKT, HIF-1alpha, RANKL, and NFATc1 expressions than the control group. Alendronate 15-26 vascular endothelial growth factor A Rattus norvegicus 64-68 33068355-0 2020 [Effect of acupuncture technique of Tiaoxin Tongdu on learning-memory ability and expressions of hippocampal VEGF and Ang-1 in rats with vascular dementia]. tiaoxin 36-43 vascular endothelial growth factor A Rattus norvegicus 109-113 33011733-15 2020 Furthermore, Z-LIG inhibited expression of vascular endothelial growth factor-alpha (VEGF-alpha) at the mRNA and protein levels. z-lig 13-18 vascular endothelial growth factor A Rattus norvegicus 43-83 33011733-16 2020 CONCLUSIONS Z-LIG can inhibit inflammatory response and cell apoptosis in retinas of diabetic rats by repressing the VEGF-alpha pathway. z-lig 12-17 vascular endothelial growth factor A Rattus norvegicus 117-127 33081553-9 2020 CONCLUSION: Baicalin reversed vascular endothelial cell injury in pregnant hypertensive rats by promoting VEGF, eNOS, PGI-2, and estrogen expression. baicalin 12-20 vascular endothelial growth factor A Rattus norvegicus 106-110 32972407-10 2020 Furthermore, TCG exhibited marked upregulation in the VEGF, bFGF, and alpha-SMA genes expression. TMG-chitotriomycin 13-16 vascular endothelial growth factor A Rattus norvegicus 54-58 32866905-9 2020 The HIF-1alpha (hypoxia-inducible factor 1alpha)/VEGF (vascular endothelial growth factor) pathway was activated by catalpol both in the brains of cerebral ischemic rats and in primary brain microvascular endothelial cells, and the activating effects of catalpol were inhibited by SU1498. SU 1498 281-287 vascular endothelial growth factor A Rattus norvegicus 49-53 32909490-0 2020 miR-15a-5p suppresses peritoneal fibrosis induced by peritoneal dialysis via targeting VEGF in rats. mir-15a-5p 0-10 vascular endothelial growth factor A Rattus norvegicus 87-91 32909490-17 2020 CONCLUSION: miR-15a-5p may participate in the endothelial to mesenchymal transition of PF caused by PD through VEGF. mir-15a-5p 12-22 vascular endothelial growth factor A Rattus norvegicus 111-115 33116264-3 2020 We aimed to design a new bioactive surface of titanium implants with a synergetic PEG biopolymer-based composition for gradual delivery of growth factors (FGF2, VEGF, and BMP4) during bone healing. peg biopolymer 82-96 vascular endothelial growth factor A Rattus norvegicus 161-165 33100111-9 2022 Moreover, formononetin could increase the content of vascular endothelial growth factor (VEGF), nitric oxide (NO) and the levels of CD34, tight junction proteins (ZO-1 and occludin) and p-IkappaBalpha in a dose-dependent manner. formononetin 10-22 vascular endothelial growth factor A Rattus norvegicus 53-87 33100111-9 2022 Moreover, formononetin could increase the content of vascular endothelial growth factor (VEGF), nitric oxide (NO) and the levels of CD34, tight junction proteins (ZO-1 and occludin) and p-IkappaBalpha in a dose-dependent manner. formononetin 10-22 vascular endothelial growth factor A Rattus norvegicus 89-93 32551816-9 2020 Antenatal administration of PHi markedly up-regulates lung HIF-1a, HIF-2a, VEGF and eNOS expression after ETX exposure. 2-ethoxyethanol 106-109 vascular endothelial growth factor A Rattus norvegicus 75-79 32649934-4 2020 By blocking VEGF/VEGFR-2 binding via pre-treatment with itraconazole we demonstrated that animals" condition was deteriorated soon at 1-2 h post-PNV exposure concurrently with decreased expression of VEGF, BBB-associated proteins, ZO-1, beta-catenin, laminin, P-gp (P-glycoprotein), Neu-N (neuron"s viability marker) and MAPKphosphorylated-p38, while phosphorylated-ERK and Src pathways were increased. Itraconazole 56-68 vascular endothelial growth factor A Rattus norvegicus 12-16 32649934-4 2020 By blocking VEGF/VEGFR-2 binding via pre-treatment with itraconazole we demonstrated that animals" condition was deteriorated soon at 1-2 h post-PNV exposure concurrently with decreased expression of VEGF, BBB-associated proteins, ZO-1, beta-catenin, laminin, P-gp (P-glycoprotein), Neu-N (neuron"s viability marker) and MAPKphosphorylated-p38, while phosphorylated-ERK and Src pathways were increased. Itraconazole 56-68 vascular endothelial growth factor A Rattus norvegicus 17-21 33068355-1 2020 OBJECTIVE: To observe the effect of acupuncture technique of Tiaoxin Tongdu on learning-memory ability and expressions of hippocampal vascular endothelial growth factor (VEGF) and angiogenin-1 (Ang-1) in rats with vascular dementia (VD), and to explore the mechanism of acupuncture technique of Tiaoxin Tongdu for VD. tiaoxin 61-68 vascular endothelial growth factor A Rattus norvegicus 170-174 33068355-11 2020 CONCLUSION: The acupuncture technique of Tiaoxin Tongdu can significantly improve the learning and memory ability of VD rats, and its mechanism may be related to up-regulating the expressions of VEGF and Ang-1 protein in hippocampus and inducing angiogenesis. tiaoxin 41-48 vascular endothelial growth factor A Rattus norvegicus 195-199 32351125-0 2020 Prophylactic low-molecular-weight heparin administration protected against severe acute pancreatitis partially by VEGF/Flt-1 signaling in a rat model. Heparin 34-41 vascular endothelial growth factor A Rattus norvegicus 114-118 32351125-9 2020 Prophylactic LMWH administration reduced the inflammatory and oxidative response markers expression and decreased the expression of VEGF and Flt-1. Heparin, Low-Molecular-Weight 13-17 vascular endothelial growth factor A Rattus norvegicus 132-136 32351125-11 2020 The underlying mechanism may result from downregulating VEGF/Flt-1 signaling of LMWH in SAP rat model. Heparin, Low-Molecular-Weight 80-84 vascular endothelial growth factor A Rattus norvegicus 56-60 33029500-8 2020 For comparison, alendronate combined with DFO further improved the bone volume, trabecular number, trabecular separation, and trabecular thickness with lower ratio of osteocyte lacunae and OC number, higher expression of OCN and VEGF and upregulated signal factors of HIF-1alpha and beta-catenin, and decreased RANKL and NFATc1. Alendronate 16-27 vascular endothelial growth factor A Rattus norvegicus 229-233 33029500-8 2020 For comparison, alendronate combined with DFO further improved the bone volume, trabecular number, trabecular separation, and trabecular thickness with lower ratio of osteocyte lacunae and OC number, higher expression of OCN and VEGF and upregulated signal factors of HIF-1alpha and beta-catenin, and decreased RANKL and NFATc1. Deferoxamine 42-45 vascular endothelial growth factor A Rattus norvegicus 229-233 32585450-9 2020 The present study demonstrated that 1,25-(OH)2D3 intervention had a partially protective effect on peritoneum fibrosis, which might inhibit CTGF/HSP47 and CD34/VEGF in the peritoneum tissues. Calcitriol 36-48 vascular endothelial growth factor A Rattus norvegicus 160-164 33062917-4 2020 Objective: To assess the endometrial expression changes of vascular endothelial growth factor A (VEGFA) and leukemia inhibitory factor (LIF), at the time of implantation in diabetic rats following treatment with Metformin and Pioglitazone. Metformin 212-221 vascular endothelial growth factor A Rattus norvegicus 59-95 33062917-4 2020 Objective: To assess the endometrial expression changes of vascular endothelial growth factor A (VEGFA) and leukemia inhibitory factor (LIF), at the time of implantation in diabetic rats following treatment with Metformin and Pioglitazone. Metformin 212-221 vascular endothelial growth factor A Rattus norvegicus 97-102 33062917-4 2020 Objective: To assess the endometrial expression changes of vascular endothelial growth factor A (VEGFA) and leukemia inhibitory factor (LIF), at the time of implantation in diabetic rats following treatment with Metformin and Pioglitazone. Pioglitazone 226-238 vascular endothelial growth factor A Rattus norvegicus 59-95 33062917-8 2020 Results: The relative expression of VEGFA transcript was higher in the diabetic (p = 0.02) and Metformin-treated (p = 0.04) rats compared to the control group. Metformin 95-104 vascular endothelial growth factor A Rattus norvegicus 36-41 33062917-9 2020 Furthermore, the VEGFA transcript level significantly reduced in Pioglitazone-treated diabetic rats (p = 0.03). Pioglitazone 65-77 vascular endothelial growth factor A Rattus norvegicus 17-22 33062917-13 2020 Pioglitazone is able to restore the VEGFA and LIF expressions to their baseline levels more efficiently than Metformin. Pioglitazone 0-12 vascular endothelial growth factor A Rattus norvegicus 36-41 32585450-8 2020 Furthermore, calcitriol prevented angiogenic mediators of fibrosis by reduced the expression of CD34 and vascular endothelial growth factor (VEGF). Calcitriol 13-23 vascular endothelial growth factor A Rattus norvegicus 105-139 32585450-8 2020 Furthermore, calcitriol prevented angiogenic mediators of fibrosis by reduced the expression of CD34 and vascular endothelial growth factor (VEGF). Calcitriol 13-23 vascular endothelial growth factor A Rattus norvegicus 141-145 32768933-0 2020 Ziziphora clinopodioides flavonoids based on network pharmacology attenuates atherosclerosis in rats induced by high-fat emulsion combined with vitamin D3 by down-regulating VEGF/AKT/NF-kappaB signaling pathway. Flavonoids 25-35 vascular endothelial growth factor A Rattus norvegicus 174-178 32768933-0 2020 Ziziphora clinopodioides flavonoids based on network pharmacology attenuates atherosclerosis in rats induced by high-fat emulsion combined with vitamin D3 by down-regulating VEGF/AKT/NF-kappaB signaling pathway. Cholecalciferol 144-154 vascular endothelial growth factor A Rattus norvegicus 174-178 32967512-7 2020 The Hes1 and Vegf mRNA levels and NICD and HIF-1alpha protein expression levels were all down-regulated by Fli-06 treatment. cyclohexyl 2,7,7-trimethyl-4-(4-nitrophenyl)-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate 107-113 vascular endothelial growth factor A Rattus norvegicus 13-17 32228192-0 2020 PTEN/PI3K/VEGF signaling pathway involved in the protective effect of xanthine oxidase inhibitor febuxostat against endometrial hyperplasia in rats. Febuxostat 97-107 vascular endothelial growth factor A Rattus norvegicus 10-14 32228192-11 2020 Uteri of the EV group showed a significant drop in GSH content and SOD activity and rise in the expressions of PI3K, Akt, VEGF, and IL-6. Estradiol 13-15 vascular endothelial growth factor A Rattus norvegicus 122-126 32554039-0 2020 Melatonin regulates the expression of inflammatory cytokines, VEGF and apoptosis in diabetic retinopathy in rats. Melatonin 0-9 vascular endothelial growth factor A Rattus norvegicus 62-66 32428522-7 2020 Low level of H2O2 significantly promoted endothelial cell (EC) proliferation, migration and tube formation and upregulated levels of VEGF, BDNF, MMP-9 and phos-JNK. Hydrogen Peroxide 13-17 vascular endothelial growth factor A Rattus norvegicus 133-137 32789575-9 2020 The expression of VEGF but not HO-1 was induced by Iso. Isoflurane 51-54 vascular endothelial growth factor A Rattus norvegicus 18-22 32922227-0 2020 Manipulation of Quercetin and Melatonin in the Down-Regulation of HIF-1alpha, HSP-70 and VEGF Pathways in Rat"s Kidneys Induced by Hypoxic Stress. Quercetin 16-25 vascular endothelial growth factor A Rattus norvegicus 89-93 32922227-0 2020 Manipulation of Quercetin and Melatonin in the Down-Regulation of HIF-1alpha, HSP-70 and VEGF Pathways in Rat"s Kidneys Induced by Hypoxic Stress. Melatonin 30-39 vascular endothelial growth factor A Rattus norvegicus 89-93 32383023-3 2020 Using an SCI model of moderate compression, rats were intraperitoneally injected with 30 mg/kg or 100 mg/kg DFO for 1-2 weeks, and significant neovascularization was found in the injured spinal cord, showing overexpression of hypoxia inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF), and an increase in the number of new blood vessels. Deferoxamine 108-111 vascular endothelial growth factor A Rattus norvegicus 275-309 32383023-3 2020 Using an SCI model of moderate compression, rats were intraperitoneally injected with 30 mg/kg or 100 mg/kg DFO for 1-2 weeks, and significant neovascularization was found in the injured spinal cord, showing overexpression of hypoxia inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF), and an increase in the number of new blood vessels. Deferoxamine 108-111 vascular endothelial growth factor A Rattus norvegicus 311-315 32830149-6 2020 In addition, IGF-1 treatment rescued the curcumin-induced down-regulated expression of p- PI3K, p-Akt, and VEGF, and VEGF overexpression counteracted the inhibitory effect of curcumin on brain HI damage. Curcumin 41-49 vascular endothelial growth factor A Rattus norvegicus 107-111 32830149-6 2020 In addition, IGF-1 treatment rescued the curcumin-induced down-regulated expression of p- PI3K, p-Akt, and VEGF, and VEGF overexpression counteracted the inhibitory effect of curcumin on brain HI damage. Curcumin 41-49 vascular endothelial growth factor A Rattus norvegicus 117-121 32830149-6 2020 In addition, IGF-1 treatment rescued the curcumin-induced down-regulated expression of p- PI3K, p-Akt, and VEGF, and VEGF overexpression counteracted the inhibitory effect of curcumin on brain HI damage. Curcumin 175-183 vascular endothelial growth factor A Rattus norvegicus 117-121 32830149-7 2020 Overall, pretreatment with curcumin protected against brain HI damage by targeting VEGF via the PI3K/Akt signaling pathway in neonatal rats. Curcumin 27-35 vascular endothelial growth factor A Rattus norvegicus 83-87 32772683-2 2020 Heparan sulfate (HS) sugars play important roles in regulating VEGF bioactivity in the pericellular compartment. Heparitin Sulfate 0-15 vascular endothelial growth factor A Rattus norvegicus 63-67 32772683-2 2020 Heparan sulfate (HS) sugars play important roles in regulating VEGF bioactivity in the pericellular compartment. Heparitin Sulfate 17-19 vascular endothelial growth factor A Rattus norvegicus 63-67 32772683-2 2020 Heparan sulfate (HS) sugars play important roles in regulating VEGF bioactivity in the pericellular compartment. Sugars 21-27 vascular endothelial growth factor A Rattus norvegicus 63-67 32772683-10 2020 CONCLUSIONS: A VEGF-activating glycosaminoglycan sugar, by itself, is able to enhance endogenous VEGF165 activity during the post-ischemic recovery phase of stroke. glycosaminoglycan sugar 31-54 vascular endothelial growth factor A Rattus norvegicus 15-19 32904641-7 2020 Results: NLRP3-targeted shRNA given by intravitreal injection effectively alleviated the retinal histopathological changes in STZ-induced diabetic rats, which reduced the activation of the NLRP3 inflammasome and suppressed the expressions of hypoxia-inducible factor-1alpha (HIF-1alpha), vascular endothelial growth factor (VEGF), and inflammatory cytokines in diabetic rats" retinas. Streptozocin 126-129 vascular endothelial growth factor A Rattus norvegicus 288-322 32904641-7 2020 Results: NLRP3-targeted shRNA given by intravitreal injection effectively alleviated the retinal histopathological changes in STZ-induced diabetic rats, which reduced the activation of the NLRP3 inflammasome and suppressed the expressions of hypoxia-inducible factor-1alpha (HIF-1alpha), vascular endothelial growth factor (VEGF), and inflammatory cytokines in diabetic rats" retinas. Streptozocin 126-129 vascular endothelial growth factor A Rattus norvegicus 324-328 32554039-1 2020 The present study analyzed whether melatonin could mediate the expression of VEGF, IL-6 and TNF-alpha, as well as the apoptotic index in rats with diabetic retinopathy. Melatonin 35-44 vascular endothelial growth factor A Rattus norvegicus 77-81 32554039-5 2020 The results showed that the groups that were treated with melatonin decreased the expression of cytokines and VEGF, in addition to apoptosis. Melatonin 58-67 vascular endothelial growth factor A Rattus norvegicus 110-114 32372246-10 2020 The expression levels of HIF-1alpha, stromal cell-derived factor-1alpha (SDF-1alpha) and vascular endothelial growth factor (VEGF) in MSCs were significantly regulated by DMOG (P < 0.05). oxalylglycine 171-175 vascular endothelial growth factor A Rattus norvegicus 89-123 32417374-8 2020 In vitro, we found that high glucose could promote the migration and angiogensis of GEC, and significantly increased the expression of VEGF and Ang protein, but significantly decreased the expression of THBS1 and Arg1 protein. Glucose 29-36 vascular endothelial growth factor A Rattus norvegicus 135-139 32787917-11 2020 Meanwhile, ATV-Exos promoted the proliferation, migration, tube formation, and VEGF level of endothelial cells in vitro. Atorvastatin 11-14 vascular endothelial growth factor A Rattus norvegicus 79-83 32758232-9 2020 RESULTS: In RUPP induced rats, quercetin treatment decreased SBP and DBP, fetal resorptions percentage, plasma ET-1 and sFlt-1 concentrations, ET-1 and ETAR levels, but increased fetal body weight and VEGF expression. Quercetin 31-40 vascular endothelial growth factor A Rattus norvegicus 201-205 32743958-4 2020 To this end, a porous polycaprolactone/hydroxyapatite (PCL/HA) scaffold is prepared via the SLS technique, which is further modified with vascular endothelial growth factor (VEGF) by coprecipitation with apatite. polycaprolactone 22-38 vascular endothelial growth factor A Rattus norvegicus 138-172 32743958-4 2020 To this end, a porous polycaprolactone/hydroxyapatite (PCL/HA) scaffold is prepared via the SLS technique, which is further modified with vascular endothelial growth factor (VEGF) by coprecipitation with apatite. polycaprolactone 22-38 vascular endothelial growth factor A Rattus norvegicus 174-178 32743958-4 2020 To this end, a porous polycaprolactone/hydroxyapatite (PCL/HA) scaffold is prepared via the SLS technique, which is further modified with vascular endothelial growth factor (VEGF) by coprecipitation with apatite. Durapatite 39-53 vascular endothelial growth factor A Rattus norvegicus 174-178 31701462-0 2020 The Chronic Use of Magnesium Decreases VEGF Levels in the Uterine Tissue in Rats. Magnesium 19-28 vascular endothelial growth factor A Rattus norvegicus 39-43 31701462-5 2020 Redox status, which can be regulated by magnesium, was shown to affect VEGF expression. Magnesium 40-49 vascular endothelial growth factor A Rattus norvegicus 71-75 31701462-6 2020 The aim of this study was to evaluate the effects of chronic magnesium use on VEGF and oxidative status in the uterus. Magnesium 61-70 vascular endothelial growth factor A Rattus norvegicus 78-82 31701462-9 2020 In the uterine tissue of Mg-treated subjects, magnesium levels increased while VEGF, SOD, GPx, and MDA levels decreased without histological changes. Magnesium 25-27 vascular endothelial growth factor A Rattus norvegicus 79-83 31701462-10 2020 There was a negative correlation between uterine tissue magnesium levels and VEGF, SOD, GPx, and MDA levels. Magnesium 56-65 vascular endothelial growth factor A Rattus norvegicus 77-81 31701462-11 2020 Consequently, the results of this study demonstrated that regular magnesium use decreased VEGF levels in uterus. Magnesium 66-75 vascular endothelial growth factor A Rattus norvegicus 90-94 32162354-8 2020 Preliminary results serve to illustrate that TN-T, VEGF and HIF-1alpha might be valuable molecular markers in cantharidin-induced myocardial injury and that diagnostic accuracy needs to be studied further. Cantharidin 110-121 vascular endothelial growth factor A Rattus norvegicus 51-55 32446114-13 2020 In addition, DEX upregulated VEGF expression, promoted angiogenesis, and increased blood perfusion. Dexmedetomidine 13-16 vascular endothelial growth factor A Rattus norvegicus 29-33 32351022-9 2020 The therapeutic mechanism for dBECM+MSCs-PGA+HA were highly associated with the enhanced angiogenesis, as indicated by VEGF and CD31 staining. Prostaglandins A 41-44 vascular endothelial growth factor A Rattus norvegicus 119-123 32460592-0 2020 High-purity magnesium pin enhances bone consolidation in distraction osteogenesis model through activation of the VHL/HIF-1alpha/VEGF signaling. Magnesium 12-21 vascular endothelial growth factor A Rattus norvegicus 129-133 32792836-11 2020 On the other hand, TMP enhanced both COX-1 and PGE2 and encouraged angiogenesis via increasing VEGF expression. tetramethylpyrazine 19-22 vascular endothelial growth factor A Rattus norvegicus 95-99 32372246-10 2020 The expression levels of HIF-1alpha, stromal cell-derived factor-1alpha (SDF-1alpha) and vascular endothelial growth factor (VEGF) in MSCs were significantly regulated by DMOG (P < 0.05). oxalylglycine 171-175 vascular endothelial growth factor A Rattus norvegicus 125-129 32372246-11 2020 The number of bone marrow microvessels decreased after the VEGF/VEGFR signaling pathway was blocked by SU5416 (P < 0.05). Semaxinib 103-109 vascular endothelial growth factor A Rattus norvegicus 59-63 32958128-11 2020 Expression levels of beta-catenin, VEGF, AngII protein were obviously up-regulated in Naoluoxintong high- and middle-dose groups. naoluoxintong 86-99 vascular endothelial growth factor A Rattus norvegicus 35-39 32694590-3 2020 Based on the evidence, we aimed to explore the biomarkers which may be used for the postmortem diagnosis of cantharidin-induced myocardial injury and PMI estimation using the study of the proteins expression of TN-T, VEGF and HIF-1alpha by ELISA. Cantharidin 108-119 vascular endothelial growth factor A Rattus norvegicus 217-221 32722564-5 2020 On the other hand, GW501516 promoted infiltration of M2 macrophages, infiltration of vascular endothelial cells associated with neovascularization in the wounded area, and expression of vascular endothelial growth factor A mRNA. GW 501516 19-27 vascular endothelial growth factor A Rattus norvegicus 186-222 32801741-0 2020 Resveratrol Suppresses Tumor Progression via Inhibiting STAT3/HIF-1alpha/VEGF Pathway in an Orthotopic Rat Model of Non-Small-Cell Lung Cancer (NSCLC). Resveratrol 0-11 vascular endothelial growth factor A Rattus norvegicus 73-77 32801741-2 2020 The aim of the present study was to investigate whether resveratrol (RES) could suppress NSCLC progression via inhibiting the expressions of STAT3, HIF-1alpha, and VEGF in a nude rat model. Resveratrol 56-67 vascular endothelial growth factor A Rattus norvegicus 164-168 32801741-2 2020 The aim of the present study was to investigate whether resveratrol (RES) could suppress NSCLC progression via inhibiting the expressions of STAT3, HIF-1alpha, and VEGF in a nude rat model. Resveratrol 69-72 vascular endothelial growth factor A Rattus norvegicus 164-168 32668794-9 2020 Lupeol treatment showed involvement in the proliferative phase by stimulating the formation of new blood vessels, increasing the immunostaining of Ki-67 and gene expression, and immunolabeling of vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF), and increasing gene expression of transforming growth factor beta-1 (TGF-beta1) after seven days of treatment. lupeol 0-6 vascular endothelial growth factor A Rattus norvegicus 196-230 32668794-9 2020 Lupeol treatment showed involvement in the proliferative phase by stimulating the formation of new blood vessels, increasing the immunostaining of Ki-67 and gene expression, and immunolabeling of vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF), and increasing gene expression of transforming growth factor beta-1 (TGF-beta1) after seven days of treatment. lupeol 0-6 vascular endothelial growth factor A Rattus norvegicus 232-236 32644942-5 2020 CIBs from the agomir group exhibited significantly higher p-Akt, VEGF, CD31 and eNOS expression compared with the control CIBs. cibs 0-4 vascular endothelial growth factor A Rattus norvegicus 65-69 32802174-8 2020 Results: PFTBA core-shell fibers provided high levels of oxygen to SCs in vitro, enhancing their survival, and increasing NGF, BDNF, and VEGF expression in 2D and 3D culture systems under hypoxic condition. perfluorotributylamine 9-14 vascular endothelial growth factor A Rattus norvegicus 137-141 32627090-10 2021 MiR-130a-5p was found to be a target of MEG8, and VEGFA was predicted to be a potential target of miR-130a-5p. mir-130a-5p 98-109 vascular endothelial growth factor A Rattus norvegicus 50-55 32714394-13 2020 More 5-ethynyl-2"-deoxyuridine- (EdU-) positive EPCs could be found lining in the cavernous endothelial layer in the ADSC/EPC group than the EPC group, which was attributed to the paracrine of vascular endothelial growth factor (VEGF) and stromal-derived factor-1 (SDF-1) by ADSCs. 5-ethynyl-2'-deoxyuridine 5-30 vascular endothelial growth factor A Rattus norvegicus 193-227 32714394-13 2020 More 5-ethynyl-2"-deoxyuridine- (EdU-) positive EPCs could be found lining in the cavernous endothelial layer in the ADSC/EPC group than the EPC group, which was attributed to the paracrine of vascular endothelial growth factor (VEGF) and stromal-derived factor-1 (SDF-1) by ADSCs. 5-ethynyl-2'-deoxyuridine 5-30 vascular endothelial growth factor A Rattus norvegicus 229-233 31872938-6 2020 Dexamethasone led to a reduction in VEGF levels in ASCs derived from rats, mice, and humans, while this reduction was absent in rabbit ASCs (rbASCs). Dexamethasone 0-13 vascular endothelial growth factor A Rattus norvegicus 36-40 32294470-2 2020 This in vivo study investigated the hypothesis that fluoxetine may affect HIF-1alpha-Netrin/VEGF cascade, angiogenesis and neuroprotection using a rat model of transient middle cerebral artery occlusion (tMCAO). Fluoxetine 52-62 vascular endothelial growth factor A Rattus norvegicus 92-96 32294470-8 2020 Similarly, fluoxetine increased protein expression of Netrin and its receptor DCC, VEGF and its receptor VEGFR. Fluoxetine 11-21 vascular endothelial growth factor A Rattus norvegicus 83-87 32294470-12 2020 Our results indicated that fluoxetine could upregulate protein expression of HIF-1alpha-Netrin/VEGF cascade, promote angiogenesis, and improve long-term functional recovery after ischemic stroke. Fluoxetine 27-37 vascular endothelial growth factor A Rattus norvegicus 95-99 32574829-0 2020 The NO-donor MPC-1011 stimulates angiogenesis and arteriogenesis and improves hindlimb ischemia via a cGMP-dependent pathway involving VEGF and SDF-1alpha. mpc-1011 13-21 vascular endothelial growth factor A Rattus norvegicus 135-139 32574829-0 2020 The NO-donor MPC-1011 stimulates angiogenesis and arteriogenesis and improves hindlimb ischemia via a cGMP-dependent pathway involving VEGF and SDF-1alpha. Cyclic GMP 102-106 vascular endothelial growth factor A Rattus norvegicus 135-139 32574829-9 2020 Moreover, MPC-1011 stimulated the release of proangiogenic cytokines, including VEGF, SDF1alpha and increased tissue cGMP levels, reduced platelet activation and aggregation, potentiated proliferation and migration of endothelial cells which was blunted in the presence of soluble guanylyl cyclase inhibitor LY83583. mpc-1011 10-18 vascular endothelial growth factor A Rattus norvegicus 80-84 32574829-11 2020 CONCLUSIONS: Here we show that the NO donor, MPC-1011, is a specific promoter of angiogenesis and arteriogenesis in a hindlimb ischemia model in an NO-cGMP-VEGF- dependent manner. Cyclic GMP 151-155 vascular endothelial growth factor A Rattus norvegicus 156-160 32655820-12 2020 And in the histological result, the mean vessel density and VEGF level were statistically higher when treated with crocin. crocin 115-121 vascular endothelial growth factor A Rattus norvegicus 60-64 32045685-3 2020 AIM OF THE STUDY: The present study was designed to examine the anti-angiogenic effects of cultivated Orostachys japonicus 70% ethanol extract (CE) in vascular endothelial growth factor (VEGF)-stimulated human umbilical vein endothelial cells (HUVECs). Ethanol 127-134 vascular endothelial growth factor A Rattus norvegicus 187-191 32590679-0 2020 Recipient-Site Preconditioning with Deferoxamine Increases Fat Graft Survival by Inducing VEGF and Neovascularization in a Rat Model. Deferoxamine 36-48 vascular endothelial growth factor A Rattus norvegicus 90-94 32590680-0 2020 Reply: Recipient-Site Preconditioning with Deferoxamine Increases Fat Graft Survival by Inducing VEGF and Neovascularization in a Rat Model. Deferoxamine 43-55 vascular endothelial growth factor A Rattus norvegicus 97-101 32590681-0 2020 Recipient-Site Preconditioning with Deferoxamine Increases Fat Graft Survival by Inducing VEGF and Neovascularization in a Rat Model. Deferoxamine 36-48 vascular endothelial growth factor A Rattus norvegicus 90-94 32590682-0 2020 Reply: Recipient-Site Preconditioning with Deferoxamine Increases Fat Graft Survival by Inducing VEGF and Neovascularization in a Rat Model. Deferoxamine 43-55 vascular endothelial growth factor A Rattus norvegicus 97-101 32600401-16 2020 Timed-pregnant rats given a continuous infusion of unfractionated heparin exhibited an increased mean arterial pressure as well as decreased bioavailable VEGF compared to vehicle-treated animals. Heparin 66-73 vascular endothelial growth factor A Rattus norvegicus 154-158 32199990-10 2020 Pathological changes to retinal tissues and the expression of vascular endothelial growth factor (VEGF) and protein kinase C (PKC) in the retina were detected after TLFA treatment. tlfa 165-169 vascular endothelial growth factor A Rattus norvegicus 62-96 32199990-10 2020 Pathological changes to retinal tissues and the expression of vascular endothelial growth factor (VEGF) and protein kinase C (PKC) in the retina were detected after TLFA treatment. tlfa 165-169 vascular endothelial growth factor A Rattus norvegicus 98-102 32199990-17 2020 For DR treatment, after 3 months of administration, the amount of dye leakage in the TLFA-administered groups was reduced by more than 50% compared with that in the model group, which indicated that TLFA has a therapeutic effect on middle and late DR. Messenger RNA (mRNA) expression of VEGF and PKCbeta2 in the retina detected by real-time fluorescent quantitative reverse transcription-polymerase chain reaction (FQ-RT-PCR) showed that TLFA could inhibit the expression of them, which was consistent with the results of immunohistochemistry (IHC). tlfa 85-89 vascular endothelial growth factor A Rattus norvegicus 287-291 32199990-17 2020 For DR treatment, after 3 months of administration, the amount of dye leakage in the TLFA-administered groups was reduced by more than 50% compared with that in the model group, which indicated that TLFA has a therapeutic effect on middle and late DR. Messenger RNA (mRNA) expression of VEGF and PKCbeta2 in the retina detected by real-time fluorescent quantitative reverse transcription-polymerase chain reaction (FQ-RT-PCR) showed that TLFA could inhibit the expression of them, which was consistent with the results of immunohistochemistry (IHC). tlfa 199-203 vascular endothelial growth factor A Rattus norvegicus 287-291 31055753-4 2020 The co-administration of carnosine or melatonin to rats intoxicated with TDO-ns significantly attenuated the increases in serum tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), C-reactive protein (CRP), immunoglobulin G (IgG), vascular endothelial growth factor (VEGF), nitric oxide (NO), and alanine aminotransferase (ALT) levels. Melatonin 38-47 vascular endothelial growth factor A Rattus norvegicus 277-281 32581722-8 2020 Gene expression analysis demonstrated significant increases in iNOS, MMP9, and VEGF in the eyes of PA animals, which were prevented by MB treatment. Methylene Blue 135-137 vascular endothelial growth factor A Rattus norvegicus 79-83 32347012-7 2020 The expression of SPP1, VEGF, TGF-beta, and Claudin in brain tissue was significantly downregulated after lorlatinib administration, and the expression level of early growth transcription factor 1 (Egr-1) was significantly increased. lorlatinib 106-116 vascular endothelial growth factor A Rattus norvegicus 24-28 31055753-4 2020 The co-administration of carnosine or melatonin to rats intoxicated with TDO-ns significantly attenuated the increases in serum tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), C-reactive protein (CRP), immunoglobulin G (IgG), vascular endothelial growth factor (VEGF), nitric oxide (NO), and alanine aminotransferase (ALT) levels. Melatonin 38-47 vascular endothelial growth factor A Rattus norvegicus 241-275 32167672-2 2020 In order to overcome the gastrointestinal digestion and bioaccessibility, VEGF was encapsulated with poly-lactic-co-glycolic acid (PLGA) nanospheres (NS) in order to prevent the VEGF degradation until its release. Polylactic Acid-Polyglycolic Acid Copolymer 101-129 vascular endothelial growth factor A Rattus norvegicus 74-78 32149562-1 2020 Dexamethasone (Dex) is one of the most commonly used anti-vascular endothelial growth factor (anti-VEGF) drugs being used in ocular diseases whether it is associated with anterior segment or posterior segment. Dexamethasone 0-13 vascular endothelial growth factor A Rattus norvegicus 99-103 32399705-0 2020 Histomorphological, VEGF and TGF-beta immunoexpression changes in the diabetic rats" ovary and the potential amelioration following treatment with metformin and insulin. Metformin 147-156 vascular endothelial growth factor A Rattus norvegicus 20-24 32336028-0 2020 Repairing peripheral nerve defects with revascularized tissue-engineered nerve based on a VEGF-heparin sustained release system. Heparin 95-102 vascular endothelial growth factor A Rattus norvegicus 90-94 32336028-1 2020 To enhance the angiogenic capacity of tissue-engineered peripheral nerves, we have constructed revascularized tissue-engineered nerves based on a Vascular endothelial growth factor (VEGF)-heparin sustained release system. Heparin 188-195 vascular endothelial growth factor A Rattus norvegicus 146-180 32336028-1 2020 To enhance the angiogenic capacity of tissue-engineered peripheral nerves, we have constructed revascularized tissue-engineered nerves based on a Vascular endothelial growth factor (VEGF)-heparin sustained release system. Heparin 188-195 vascular endothelial growth factor A Rattus norvegicus 182-186 32336028-5 2020 The results showed that the tissue-engineered peripheral nerve based on a VEGF-heparin sustained release system can achieve early vascularization and restore blood supply in the nerve graft area. Heparin 79-86 vascular endothelial growth factor A Rattus norvegicus 74-78 32399705-14 2020 Furthermore, insulin showed more beneficial effects than metformin in hindering these complications by modifying the expression of VEGF and TGF-beta. Metformin 57-66 vascular endothelial growth factor A Rattus norvegicus 131-135 32149562-1 2020 Dexamethasone (Dex) is one of the most commonly used anti-vascular endothelial growth factor (anti-VEGF) drugs being used in ocular diseases whether it is associated with anterior segment or posterior segment. Dexamethasone 0-3 vascular endothelial growth factor A Rattus norvegicus 99-103 32473710-0 2020 beta-hydroxybutyrate antagonizes aortic endothelial injury by promoting generation of VEGF in diabetic rats. 3-Hydroxybutyric Acid 0-20 vascular endothelial growth factor A Rattus norvegicus 86-90 32473710-3 2020 beta-hydroxybutyrate reportedly causes histone H3K9 beta-hydroxybutyrylation (H3K9bhb), which activates gene expression; however, there has been no report regarding the role of H3K9bhb in up-regulation of vascular endothelial growth factor (VEGF), a crucial factor in endothelial integrity and function. 3-Hydroxybutyric Acid 0-20 vascular endothelial growth factor A Rattus norvegicus 205-239 32473710-3 2020 beta-hydroxybutyrate reportedly causes histone H3K9 beta-hydroxybutyrylation (H3K9bhb), which activates gene expression; however, there has been no report regarding the role of H3K9bhb in up-regulation of vascular endothelial growth factor (VEGF), a crucial factor in endothelial integrity and function. 3-Hydroxybutyric Acid 0-20 vascular endothelial growth factor A Rattus norvegicus 241-245 32473710-8 2020 However, beta-hydroxybutyrate treatment attenuated diabetic injury of the endothelium and up-regulated the generation of VEGF. 3-Hydroxybutyric Acid 9-29 vascular endothelial growth factor A Rattus norvegicus 121-125 32473710-11 2020 In conclusion, moderately elevated beta-hydroxybutyrate could antagonize aortic endothelial injury, potentially by causing H3K9bhb to promote generation of VEGF in diabetic rats. 3-Hydroxybutyric Acid 35-55 vascular endothelial growth factor A Rattus norvegicus 156-160 32596375-12 2020 Furthermore, the expression of VEGF-alpha in the UVB+VitC group was dramatically decreased compared with that in the UVB group (p < 0.05), and the expression of SOD2 in the UVB+VitC group was dramatically increased compared with that in the UVB group at 7 d post-UVB exposure (p < 0.05). Ascorbic Acid 53-57 vascular endothelial growth factor A Rattus norvegicus 31-41 32565857-17 2020 Treatment with LHF upregulated eNOS expression in heart tissue and downregulated Col1a1, Col3a1, TGF-beta1, caspase-3, VEGF, and VEGFR2 expression. 5-[[2-[(2~{r},3~{s},4~{r},5~{r})-5-(6-Aminopurin-9-Yl)-3,4-Bis(Oxidanyl)oxolan-2-Yl]ethylamino]methyl]-4-Azanyl-1-[2-(4-Bromanylphenoxy)ethyl]pyrimidin-2-One 15-18 vascular endothelial growth factor A Rattus norvegicus 119-123 32565857-19 2020 Upregulated eNOS expression and downregulated Col1a1, Col3a1, TGF-beta1, caspase-3, VEGF, and VEGFR2 expression may play a role in the observed LHF cardioprotective effect. 5-[[2-[(2~{r},3~{s},4~{r},5~{r})-5-(6-Aminopurin-9-Yl)-3,4-Bis(Oxidanyl)oxolan-2-Yl]ethylamino]methyl]-4-Azanyl-1-[2-(4-Bromanylphenoxy)ethyl]pyrimidin-2-One 144-147 vascular endothelial growth factor A Rattus norvegicus 84-88 32596375-12 2020 Furthermore, the expression of VEGF-alpha in the UVB+VitC group was dramatically decreased compared with that in the UVB group (p < 0.05), and the expression of SOD2 in the UVB+VitC group was dramatically increased compared with that in the UVB group at 7 d post-UVB exposure (p < 0.05). Ascorbic Acid 177-181 vascular endothelial growth factor A Rattus norvegicus 31-41 32596375-13 2020 Conclusion: Vitamin C could protect infant rats from corneal injury induced by UVB via alleviating corneal edema, improving corneal inflammatory reaction, and decreasing VEGF-alpha expression. Ascorbic Acid 12-21 vascular endothelial growth factor A Rattus norvegicus 170-180 32421396-0 2020 Zaprinast and avanafil increase the vascular endothelial growth factor, vitamin D3, bone morphogenic proteins 4 and 7 levels in the kidney tissue of male rats applied the glucocorticoid. zaprinast 0-9 vascular endothelial growth factor A Rattus norvegicus 36-70 31978540-10 2020 Moreover, Dex had no effect on bradykinin- or shear-stress-stimulated NO production, indicating that VEGF-stimulated eNOS phosphorylation is a target of Dex"s effects. Dexamethasone 153-156 vascular endothelial growth factor A Rattus norvegicus 101-105 32421396-0 2020 Zaprinast and avanafil increase the vascular endothelial growth factor, vitamin D3, bone morphogenic proteins 4 and 7 levels in the kidney tissue of male rats applied the glucocorticoid. avanafil 14-22 vascular endothelial growth factor A Rattus norvegicus 36-70 31338802-9 2020 A significant increase of serum MDA, NO and VEGF in NiSO4 treatment with a concomitant decrease of serum ascorbic acid and alpha-tocopherol as compared to their respective controls were also observed. nickel sulfate 52-57 vascular endothelial growth factor A Rattus norvegicus 44-48 32412057-7 2020 CONCLUSIONS: Over-expressing miR-375 can inhibit the expression of VEGF, thus slow down the invasion and proliferation of TCS in PE rats, which is realized by regulating SHH signal pathway. Technetium 122-125 vascular endothelial growth factor A Rattus norvegicus 67-71 32412861-9 2020 In conclusion, miR-155 signal in the parietal cortex and hippocampus is engaged in the processes of neural injury during ICH and blocking central miR-155 pathway plays a beneficial role in regulating neurological function via reduction in PICs and products of oxidative stress; and enhancement of VEGF. mir-155 15-22 vascular endothelial growth factor A Rattus norvegicus 297-301 32412861-9 2020 In conclusion, miR-155 signal in the parietal cortex and hippocampus is engaged in the processes of neural injury during ICH and blocking central miR-155 pathway plays a beneficial role in regulating neurological function via reduction in PICs and products of oxidative stress; and enhancement of VEGF. mir-155 146-153 vascular endothelial growth factor A Rattus norvegicus 297-301 32436127-0 2020 Empagliflozin alleviates neuronal apoptosis induced by cerebral ischemia/reperfusion injury through HIF-1alpha/VEGF signaling pathway. empagliflozin 0-13 vascular endothelial growth factor A Rattus norvegicus 111-115 32436127-3 2020 Thereby, this study was designed to investigate the ameliorative effect of empagliflozin on the neuronal apoptosis exhibited in cerebral ischemia/reperfusion (I/R) in a rat model targeting HIF-1alpha/VEGF signaling which is involved in this insult. empagliflozin 75-88 vascular endothelial growth factor A Rattus norvegicus 200-204 32436127-8 2020 In parallel, protein expressions of HIF-1alpha and its downstream mediator VEGF were upregulated in the ischemic brain following empagliflozin treatment. empagliflozin 129-142 vascular endothelial growth factor A Rattus norvegicus 75-79 32436127-9 2020 The results indicated that empagliflozin attenuates cerebral I/R-induced neuronal death via the HIF-1alpha/VEGF cascade. empagliflozin 27-40 vascular endothelial growth factor A Rattus norvegicus 107-111 31488552-7 2020 Retroviral expression of VP16-HIF-1alpha in SCs increased HIF-alpha by 5.9-fold and its target genes implicated in oxygen transport and delivery (VEGF, 2.2-fold) and cellular metabolism (enolase, 1.7-fold). Oxygen 115-121 vascular endothelial growth factor A Rattus norvegicus 146-150 32119963-13 2020 SIGNIFICANCE: APG can ameliorate CCl4-induced liver fibrosis via VEGF-mediated FAK phosphorylation through the MAPKs, PI3K/Akt, HIF-1, ROS, and eNOS pathways, which may hopefully become the anti-liver fibrosis activity of natural product. ros 135-138 vascular endothelial growth factor A Rattus norvegicus 65-69 32107104-5 2020 DHC-induced angiogenesis significantly increased the expression of angiogenic factor proteins, such as hypoxia inducible factor 1alpha (HIF-1alpha), vascular endothelial growth factor (VEGF), and matrix metalloprotease 9 (MMP-9), at 3 d and 14 d following I/R and also increased the expression of angiogenic inhibitors, such as angiopoietin 1 (Ang-1) and its receptor tyrosine kinase (Tie-2), at 14 d following reperfusion. dihydrocapsaicin 0-3 vascular endothelial growth factor A Rattus norvegicus 149-183 32107104-5 2020 DHC-induced angiogenesis significantly increased the expression of angiogenic factor proteins, such as hypoxia inducible factor 1alpha (HIF-1alpha), vascular endothelial growth factor (VEGF), and matrix metalloprotease 9 (MMP-9), at 3 d and 14 d following I/R and also increased the expression of angiogenic inhibitors, such as angiopoietin 1 (Ang-1) and its receptor tyrosine kinase (Tie-2), at 14 d following reperfusion. dihydrocapsaicin 0-3 vascular endothelial growth factor A Rattus norvegicus 185-189 32410995-3 2020 Here, kaempferol was shown to bind with vascular endothelial growth factor (VEGF), probably in the heparin binding domain of VEGF: this binding potentiated the angiogenic functions of VEGF in various culture models. Heparin 99-106 vascular endothelial growth factor A Rattus norvegicus 125-129 32067150-6 2020 After miR-126-3p inhibition, the levels of SPRED1 and VEGFA expression were increased, and p-Raf-1 expression was decreased after OGD/R. mir-126-3p 6-16 vascular endothelial growth factor A Rattus norvegicus 54-59 32028820-6 2020 Angiogenic growth factors viz., VEGF, PDGF and bFGF are also shown to be increased in the DMH alone administered tumor bearing rats as compared to control. Dimethylhydrazines 90-93 vascular endothelial growth factor A Rattus norvegicus 32-36 32733674-7 2020 Results: The group treated with a combination of propolis and Ca(OH)2 for 7 days showed that the expression of IL-10, IL-8, TLR-2, VEGF, TGF-beta increased significantly compared to the treatment group treated with only Ca(OH)2. Calcium Hydroxide 62-69 vascular endothelial growth factor A Rattus norvegicus 131-135 32733674-8 2020 The expression of IL-10, TLR-2, TGF-beta, VEGF increased in the treatment group treated with propolis and Ca(OH)2 for 14 days, while the expression of IL-8 in the decreased significantly. Calcium Hydroxide 106-113 vascular endothelial growth factor A Rattus norvegicus 42-46 32410995-3 2020 Here, kaempferol was shown to bind with vascular endothelial growth factor (VEGF), probably in the heparin binding domain of VEGF: this binding potentiated the angiogenic functions of VEGF in various culture models. kaempferol 6-16 vascular endothelial growth factor A Rattus norvegicus 76-80 32410995-3 2020 Here, kaempferol was shown to bind with vascular endothelial growth factor (VEGF), probably in the heparin binding domain of VEGF: this binding potentiated the angiogenic functions of VEGF in various culture models. Heparin 99-106 vascular endothelial growth factor A Rattus norvegicus 125-129 32410995-3 2020 Here, kaempferol was shown to bind with vascular endothelial growth factor (VEGF), probably in the heparin binding domain of VEGF: this binding potentiated the angiogenic functions of VEGF in various culture models. kaempferol 6-16 vascular endothelial growth factor A Rattus norvegicus 125-129 32410995-3 2020 Here, kaempferol was shown to bind with vascular endothelial growth factor (VEGF), probably in the heparin binding domain of VEGF: this binding potentiated the angiogenic functions of VEGF in various culture models. kaempferol 6-16 vascular endothelial growth factor A Rattus norvegicus 125-129 32410995-5 2020 In cultured HUVECs, application of kaempferol strongly potentiated the VEGF-induced phosphorylations of VEGFR2, endothelial nitric oxide synthase (eNOS) and extracellular signal-regulated kinase (Erk) in time-dependent and concentration-dependent manners, and in parallel the VEGF-mediated expressions of matrix metalloproteinases (MMPs), MMP-2 and MMP-9, were significantly enhanced. kaempferol 35-45 vascular endothelial growth factor A Rattus norvegicus 71-75 32410995-3 2020 Here, kaempferol was shown to bind with vascular endothelial growth factor (VEGF), probably in the heparin binding domain of VEGF: this binding potentiated the angiogenic functions of VEGF in various culture models. Heparin 99-106 vascular endothelial growth factor A Rattus norvegicus 76-80 32410995-5 2020 In cultured HUVECs, application of kaempferol strongly potentiated the VEGF-induced phosphorylations of VEGFR2, endothelial nitric oxide synthase (eNOS) and extracellular signal-regulated kinase (Erk) in time-dependent and concentration-dependent manners, and in parallel the VEGF-mediated expressions of matrix metalloproteinases (MMPs), MMP-2 and MMP-9, were significantly enhanced. kaempferol 35-45 vascular endothelial growth factor A Rattus norvegicus 104-108 32410995-5 2020 In cultured HUVECs, application of kaempferol strongly potentiated the VEGF-induced phosphorylations of VEGFR2, endothelial nitric oxide synthase (eNOS) and extracellular signal-regulated kinase (Erk) in time-dependent and concentration-dependent manners, and in parallel the VEGF-mediated expressions of matrix metalloproteinases (MMPs), MMP-2 and MMP-9, were significantly enhanced. Nitric Oxide 124-136 vascular endothelial growth factor A Rattus norvegicus 71-75 32410995-6 2020 In addition, the potentiation effect of kaempferol was revealed in VEGF-induced migration of skin cell and monocyte. kaempferol 40-50 vascular endothelial growth factor A Rattus norvegicus 67-71 32410995-7 2020 Taken together, our results suggested the pharmacological roles of kaempferol in potentiating VEGF-mediated functions should be considered. kaempferol 67-77 vascular endothelial growth factor A Rattus norvegicus 94-98 32325771-9 2020 The mean CNV grade was significantly lower in chrysin-treated vs. control eyes (2.34 +- 1.14 vs. 2.97 +- 1.05, p < 0.001), as was the mean CNV thickness (33.90 +- 4.89 vs. 38.50 +- 5.43 mum, p < 0.001) and mean HIF-1alpha and VEGF levels (both p < 0.001). chrysin 46-53 vascular endothelial growth factor A Rattus norvegicus 226-230 32355441-13 2020 Conclusions: Vitamin B12 supplementation of diabetic rats appeared to be beneficial by circumventing retinal hypoxia, VEGF overexpression, and ER stress-mediated cell death in the retina. Vitamin B 12 13-24 vascular endothelial growth factor A Rattus norvegicus 118-122 32314927-6 2020 However, BMP4 levels were only high in the OVX + tadalafil group (p < .05).Conclusion: The results indicated that vardenafil, udenafil, and especially tadalafil increased VEGF, BMP2, and VitaminD3 levels. Vardenafil Dihydrochloride 114-124 vascular endothelial growth factor A Rattus norvegicus 171-175 32314927-6 2020 However, BMP4 levels were only high in the OVX + tadalafil group (p < .05).Conclusion: The results indicated that vardenafil, udenafil, and especially tadalafil increased VEGF, BMP2, and VitaminD3 levels. udenafil 126-134 vascular endothelial growth factor A Rattus norvegicus 171-175 32314927-6 2020 However, BMP4 levels were only high in the OVX + tadalafil group (p < .05).Conclusion: The results indicated that vardenafil, udenafil, and especially tadalafil increased VEGF, BMP2, and VitaminD3 levels. Tadalafil 151-160 vascular endothelial growth factor A Rattus norvegicus 171-175 32050083-12 2020 Collectively, DS can augment the anti-angiogenic activity of Sild and PTX during HPS through regulation of TNF-alpha/VEGF, IGF-1/PI3K/AKT, and FGF-1/ANG-2 signaling pathways. Pentoxifylline 70-73 vascular endothelial growth factor A Rattus norvegicus 117-121 31991140-8 2020 The proangiogenic effect of morroniside might be mediated by the VEGFA/VEGF receptor 2 signaling pathway. morroniside 28-39 vascular endothelial growth factor A Rattus norvegicus 65-70 32050083-0 2020 Diosmin enhances the anti-angiogenic activity of sildenafil and pentoxifylline against hepatopulmonary syndrome via regulation of TNF-alpha/VEGF, IGF-1/PI3K/AKT, and FGF-1/ANG-2 signaling pathways. sildenafil 49-59 vascular endothelial growth factor A Rattus norvegicus 140-144 32050083-0 2020 Diosmin enhances the anti-angiogenic activity of sildenafil and pentoxifylline against hepatopulmonary syndrome via regulation of TNF-alpha/VEGF, IGF-1/PI3K/AKT, and FGF-1/ANG-2 signaling pathways. Pentoxifylline 64-78 vascular endothelial growth factor A Rattus norvegicus 140-144 32050083-12 2020 Collectively, DS can augment the anti-angiogenic activity of Sild and PTX during HPS through regulation of TNF-alpha/VEGF, IGF-1/PI3K/AKT, and FGF-1/ANG-2 signaling pathways. Diosmin 14-16 vascular endothelial growth factor A Rattus norvegicus 117-121 32050083-12 2020 Collectively, DS can augment the anti-angiogenic activity of Sild and PTX during HPS through regulation of TNF-alpha/VEGF, IGF-1/PI3K/AKT, and FGF-1/ANG-2 signaling pathways. sildenafil 61-65 vascular endothelial growth factor A Rattus norvegicus 117-121 32864011-11 2020 Cordyceps polysaccharide can effectively suppress the protein expression of caspase-1, IL-18, and IL-10, while simultaneously increasing the protein expression of VEGF and SDF-1alpha, as well as the mRNA expression of PCNA and SIRPalpha1. cordyceps polysaccharide 0-24 vascular endothelial growth factor A Rattus norvegicus 163-167 31991160-6 2020 DEX induced hypertension concomitantly with capillary density loss (CD, -23.9%) and decrease of VEGF (-43.0%), p-AKT/AKT (-39.6%) and Bcl-2 (-23.0%) and an increase in caspase-3-cleaved protein level (+34.0%) in TA muscle. Dexamethasone 0-3 vascular endothelial growth factor A Rattus norvegicus 96-100 31980236-0 2020 Low expression of vascular endothelial growth factor and high serum level of cyclic guanine monophosphate as the risk factors of femoral head osteonecrosis in alcohol-exposed Wistar rat. Ethanol 159-166 vascular endothelial growth factor A Rattus norvegicus 18-52 32260544-11 2020 In conclusion, oral TRF supplementation protects against retinal degenerative changes and an increase in VEGF expression in rats with streptozotocin-induced diabetic retinopathy. Streptozocin 134-148 vascular endothelial growth factor A Rattus norvegicus 105-109 32086377-4 2020 Intravitreal co-injection of norrin with VEGF completely ablated VEGF-induced BRB permeability to Evans blue-albumin. Evans Blue 98-108 vascular endothelial growth factor A Rattus norvegicus 41-45 32086377-4 2020 Intravitreal co-injection of norrin with VEGF completely ablated VEGF-induced BRB permeability to Evans blue-albumin. Evans Blue 98-108 vascular endothelial growth factor A Rattus norvegicus 65-69 32372953-11 2020 The experimental validation results demonstrated that NE-THCQ might inhibit the inflammatory processes, reduce ECM deposition and reverse EMT via PI3K/AKT/mTOR and HIF-1alpha/VEGF signaling pathways to exert its effect against renal fibrosis. thcq 57-61 vascular endothelial growth factor A Rattus norvegicus 175-179 31980236-3 2020 This study aimed to explore the expression of vascular endothelial growth factor (VEGF) and cyclic guanine monophosphate (cGMP) serum level as the risk factors of femoral head osteonecrosis in alcohol-exposed Wistar rats. Ethanol 193-200 vascular endothelial growth factor A Rattus norvegicus 46-80 31980236-3 2020 This study aimed to explore the expression of vascular endothelial growth factor (VEGF) and cyclic guanine monophosphate (cGMP) serum level as the risk factors of femoral head osteonecrosis in alcohol-exposed Wistar rats. Ethanol 193-200 vascular endothelial growth factor A Rattus norvegicus 82-86 31980236-8 2020 RESULTS: VEGF expression in the femoral head of alcohol-exposed Wistar rats was lower than those not exposed to alcohol (p < 0.005). Ethanol 48-55 vascular endothelial growth factor A Rattus norvegicus 9-13 31980236-12 2020 CONCLUSIONS: Based on the result of this study, VEGF and cGMP may be considered as diagnostic biomarkers for alcohol-induced femoral head osteonecrosis. Ethanol 109-116 vascular endothelial growth factor A Rattus norvegicus 48-52 32097704-10 2020 Sulforaphane also inhibited ectopic endometrial tissue growth in sciatic endometriosis rat, shown as the shrinkage of lesion size and decreased VEGF levels. sulforaphane 0-12 vascular endothelial growth factor A Rattus norvegicus 144-148 32078859-6 2020 Here, we found that GA could reduce OGD/R-induced inflammation and oxidative stress by inhibiting the expression of TNF-alpha, IL-6, ICAM-1, and VEGF, and suppressing the production of ROS via reduced NADPH oxidase 1 (NOX1) expression. Glatiramer Acetate 20-22 vascular endothelial growth factor A Rattus norvegicus 145-149 32078859-8 2020 Using siRNA for Egr-1, we found that GA could reduce the expression of ICAM-1 and VEGF by inhibiting Egr-1 expression. Glatiramer Acetate 37-39 vascular endothelial growth factor A Rattus norvegicus 82-86 32130427-0 2020 Emodin alleviated pulmonary inflammation in rats with LPS-induced acute lung injury through inhibiting the mTOR/HIF-1alpha/VEGF signaling pathway. Emodin 0-6 vascular endothelial growth factor A Rattus norvegicus 123-127 32144772-10 2020 Furthermore, in the experimental groups at low isoflavone concentrations, the concentrations of OPG, TGF, and VEGF were increased and positively correlated with OB proliferation. Isoflavones 47-57 vascular endothelial growth factor A Rattus norvegicus 110-114 32144772-12 2020 Soybean isoflavone could promote the growth and proliferation of rat OB, it might act as the stimulator of OPG, TGF, and VEGF pathway, and the inhibitor of IL-1, GM-CSF pathway as well. Isoflavones 8-18 vascular endothelial growth factor A Rattus norvegicus 121-125 32207349-6 2020 However, only VEGF and BMP2 levels in OVX + zaprinast group were significant according to sham (p < .05). zaprinast 44-53 vascular endothelial growth factor A Rattus norvegicus 14-18 32230876-1 2020 PURPOSE: To investigate the effect of a selective aquaporin 4 (AQP4) inhibitor, 2-(nicotinamide)-1,3,4-thiadiazole (TGN-020), on the expression of vascular endothelial growth factor (VEGF) and reactive oxygen species (ROS) production, as well as on the retinal edema in diabetic retina. 2-(nicotinamide)-1,3,4-thiadiazole 80-114 vascular endothelial growth factor A Rattus norvegicus 147-181 32230876-1 2020 PURPOSE: To investigate the effect of a selective aquaporin 4 (AQP4) inhibitor, 2-(nicotinamide)-1,3,4-thiadiazole (TGN-020), on the expression of vascular endothelial growth factor (VEGF) and reactive oxygen species (ROS) production, as well as on the retinal edema in diabetic retina. 2-(nicotinamide)-1,3,4-thiadiazole 80-114 vascular endothelial growth factor A Rattus norvegicus 183-187 32230876-1 2020 PURPOSE: To investigate the effect of a selective aquaporin 4 (AQP4) inhibitor, 2-(nicotinamide)-1,3,4-thiadiazole (TGN-020), on the expression of vascular endothelial growth factor (VEGF) and reactive oxygen species (ROS) production, as well as on the retinal edema in diabetic retina. Reactive Oxygen Species 193-216 vascular endothelial growth factor A Rattus norvegicus 147-181 32230876-1 2020 PURPOSE: To investigate the effect of a selective aquaporin 4 (AQP4) inhibitor, 2-(nicotinamide)-1,3,4-thiadiazole (TGN-020), on the expression of vascular endothelial growth factor (VEGF) and reactive oxygen species (ROS) production, as well as on the retinal edema in diabetic retina. Reactive Oxygen Species 218-221 vascular endothelial growth factor A Rattus norvegicus 147-181 31927699-6 2020 In the condition of short-term or long-term hypoxia and serum deprivation, the apoptotic cells in rapamycin-pretreated cells were less, and secretion of HGF, IGF-1, SCF, SDF-1 and VEGF was increased. Sirolimus 98-107 vascular endothelial growth factor A Rattus norvegicus 180-184 32207349-7 2020 Also, angiogenesis in OVX + zaprinast and OVX + avanafil groups was dominant according to sham and OVX (p < .05).Conclusions: Zaprinast and avanafil induced BMP2, 4 and 7 levels synergistically with increased VEGF and angiogenesis in renal tissue. zaprinast 126-135 vascular endothelial growth factor A Rattus norvegicus 209-213 32104265-1 2020 Effect of atorvastatin combined with routine therapy on the expression of hypoxia inducible factor (HIF-1) and vascular endothelial growth factor (VEGF) in rats with acute myocardial infarction (AMI) and its therapeutic effect were investigated. Atorvastatin 10-22 vascular endothelial growth factor A Rattus norvegicus 147-151 32214801-8 2020 Western blotting and gelatin zymography were used to detect the expression and activities of VEGF, MMP-2 and MMP-9 secreted by MSCs under the influence of 1,25(OH)2D3. Calcitriol 155-166 vascular endothelial growth factor A Rattus norvegicus 93-97 31773790-0 2020 Sitagliptin protects male albino rats with testicular ischaemia/reperfusion damage: Modulation of VCAM-1 and VEGF-A. Sitagliptin Phosphate 0-11 vascular endothelial growth factor A Rattus norvegicus 109-115 32214801-12 2020 There was a significant increase in the expression of VEGF, MMP-2 and MMP-9 secreted by MSCs treated with 1,25(OH)2D3, as well as in the activity of MMP-2 and MMP-9. Calcitriol 106-117 vascular endothelial growth factor A Rattus norvegicus 54-58 31761520-6 2020 Further molecular mechanism research revealed that BNH could inhibit the expression of NF-kappaB, TNF-a and IL-6, but increase the expression of F VEGF, CD 31 and SMA by activating Sirt 1 which were benefit for wound healing of diabetic rats. BNH 51-54 vascular endothelial growth factor A Rattus norvegicus 147-151 32104265-0 2020 Atorvastatin combined with routine therapy on HIF-1, VEGF concentration and cardiac function in rats with acute myocardial infarction. Atorvastatin 0-12 vascular endothelial growth factor A Rattus norvegicus 53-57 32104265-10 2020 In conclusion, atorvastatin combined with routine therapy can better reduce serum HIF-1 and VEGF levels and improve the left ventricular function in rats than routine therapy. Atorvastatin 15-27 vascular endothelial growth factor A Rattus norvegicus 92-96 32104265-1 2020 Effect of atorvastatin combined with routine therapy on the expression of hypoxia inducible factor (HIF-1) and vascular endothelial growth factor (VEGF) in rats with acute myocardial infarction (AMI) and its therapeutic effect were investigated. Atorvastatin 10-22 vascular endothelial growth factor A Rattus norvegicus 111-145 31985021-0 2020 Ginsenoside protects against AKI via activation of HIF-1alpha and VEGF-A in the kidney-brain axis. Ginsenosides 0-11 vascular endothelial growth factor A Rattus norvegicus 66-72 31788758-3 2020 Neonatal rats were treated subcutaneously with the vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor KRN633 (10 mg/kg) on postnatal day (P) 7 and P8 to induce ROP. Tyrosine 102-110 vascular endothelial growth factor A Rattus norvegicus 87-91 31788758-3 2020 Neonatal rats were treated subcutaneously with the vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor KRN633 (10 mg/kg) on postnatal day (P) 7 and P8 to induce ROP. N-(2-chloro-4-((6,7-dimethoxy-4-quinazolinyl)oxy)phenyl)-N'-propylurea 128-134 vascular endothelial growth factor A Rattus norvegicus 51-85 31788758-3 2020 Neonatal rats were treated subcutaneously with the vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor KRN633 (10 mg/kg) on postnatal day (P) 7 and P8 to induce ROP. N-(2-chloro-4-((6,7-dimethoxy-4-quinazolinyl)oxy)phenyl)-N'-propylurea 128-134 vascular endothelial growth factor A Rattus norvegicus 87-91 31985021-9 2020 Furthermore, GS improved the activation of hypoxia-inducible factor 1alpha (HIF-1alpha) and vascular endothelial growth factor A (VEGF-A) in the hypothalamus response to AKI, and in the kidney tissues. Ginsenosides 13-15 vascular endothelial growth factor A Rattus norvegicus 92-128 31985021-9 2020 Furthermore, GS improved the activation of hypoxia-inducible factor 1alpha (HIF-1alpha) and vascular endothelial growth factor A (VEGF-A) in the hypothalamus response to AKI, and in the kidney tissues. Ginsenosides 13-15 vascular endothelial growth factor A Rattus norvegicus 130-136 31985021-11 2020 Taken together, these results suggested that GS was involved in the protective effects against AKI by decreasing oxidative damage to the kidney and brain, and by upregulating HIF-1alpha and VEGF-A levels in the kidney-brain axis. Ginsenosides 45-47 vascular endothelial growth factor A Rattus norvegicus 190-196 31633245-11 2020 Therefore, verteporfin can inhibit VEGF-induced YAP pathway activation by inhibiting YAP activity. verteporfin 11-22 vascular endothelial growth factor A Rattus norvegicus 35-39 32016634-0 2020 Combretastatin A-4 disodium phosphate and low dose gamma irradiation suppress hepatocellular carcinoma by downregulating ROCK1 and VEGF gene expression. fosbretabulin 0-37 vascular endothelial growth factor A Rattus norvegicus 131-135 32863837-6 2020 After EVOO administration, sFlt-1 level was lower in dose 1 and 2 groups but higher in dose 3 group in accordance with VEGF and eNOS levels that were increasing both in dose 1 and dose 2 groups but decreasing in dose 3. evoo 6-10 vascular endothelial growth factor A Rattus norvegicus 119-123 32863837-10 2020 Conclusion: Administration of EVOO modulates eNOS as vasodilator enzyme by repairing the angiogenic function indicated by decreased sFlt-1 level and increased VEGF in rat model of preeclampsia. evoo 30-34 vascular endothelial growth factor A Rattus norvegicus 159-163 32016634-8 2020 Our results showed that expression of CD31 and gene expression of ROCK1 and VEGF was significantly repressed at all-time intervals by combination therapy ofLDR and CA-4DP as compared with untreated NDEA/HCC group and NDEA/HCC groups treated with either LDR or CA-4DP alone, (P < 0.05). fosbretabulin 164-170 vascular endothelial growth factor A Rattus norvegicus 76-80 32016634-8 2020 Our results showed that expression of CD31 and gene expression of ROCK1 and VEGF was significantly repressed at all-time intervals by combination therapy ofLDR and CA-4DP as compared with untreated NDEA/HCC group and NDEA/HCC groups treated with either LDR or CA-4DP alone, (P < 0.05). Diethylnitrosamine 198-202 vascular endothelial growth factor A Rattus norvegicus 76-80 32016634-8 2020 Our results showed that expression of CD31 and gene expression of ROCK1 and VEGF was significantly repressed at all-time intervals by combination therapy ofLDR and CA-4DP as compared with untreated NDEA/HCC group and NDEA/HCC groups treated with either LDR or CA-4DP alone, (P < 0.05). Diethylnitrosamine 217-221 vascular endothelial growth factor A Rattus norvegicus 76-80 32016634-8 2020 Our results showed that expression of CD31 and gene expression of ROCK1 and VEGF was significantly repressed at all-time intervals by combination therapy ofLDR and CA-4DP as compared with untreated NDEA/HCC group and NDEA/HCC groups treated with either LDR or CA-4DP alone, (P < 0.05). fosbretabulin 260-266 vascular endothelial growth factor A Rattus norvegicus 76-80 32180818-10 2020 Conclusion and implications: The findings of the current study revealed that bee pollen methanolic extract has an anti-inflammatory and anti-angiogenesis effect, which could be attributed to the inhibition of VEGF and TNF-alpha production in the inflammatory exudates. methanolic 88-98 vascular endothelial growth factor A Rattus norvegicus 209-213 32149087-0 2020 Polydeoxyribonucleotide Exerts Therapeutic Effect by Increasing VEGF and Inhibiting Inflammatory Cytokines in Ischemic Colitis Rats. Polydeoxyribonucleotides 0-23 vascular endothelial growth factor A Rattus norvegicus 64-68 32016463-12 2020 In addition, IPO/DPO could increase the mRNA expression of HIF-1alpha and the downstream factors of the HIF-1/HRE pathway (the mRNA and protein expression of HO-1, iNOS and VEGF; P<0.05). dpo 17-20 vascular endothelial growth factor A Rattus norvegicus 173-177 32066777-0 2020 VEGF and bFGF induction by nitric oxide is associated with hyperbaric oxygen-induced angiogenesis and muscle regeneration. Nitric Oxide 27-39 vascular endothelial growth factor A Rattus norvegicus 0-4 32066777-0 2020 VEGF and bFGF induction by nitric oxide is associated with hyperbaric oxygen-induced angiogenesis and muscle regeneration. Oxygen 70-76 vascular endothelial growth factor A Rattus norvegicus 0-4 32066777-3 2020 Nitric oxide (NO), a type of ROS, generally stabilizes hypoxia-inducible factor (HIF) 1alpha and stimulates secretion of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) from endothelial cells and macrophages, which then induces angiogenesis. Nitric Oxide 0-12 vascular endothelial growth factor A Rattus norvegicus 121-155 32066777-3 2020 Nitric oxide (NO), a type of ROS, generally stabilizes hypoxia-inducible factor (HIF) 1alpha and stimulates secretion of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) from endothelial cells and macrophages, which then induces angiogenesis. Nitric Oxide 0-12 vascular endothelial growth factor A Rattus norvegicus 157-161 32024231-11 2020 In this model, early systemic bumetanide administration reduces severe OIR, the benefits of which appear to be mediated via suppression of AQP-4 and VEGF. Bumetanide 30-40 vascular endothelial growth factor A Rattus norvegicus 149-153 31769639-11 2020 VEGF protein levels were elevated in the 21-d CAPE group and 7-d ABS group. caffeic acid phenethyl ester 46-50 vascular endothelial growth factor A Rattus norvegicus 0-4 32141587-0 2020 MiR-20a ameliorates diabetic angiopathy in streptozotocin-induced diabetic rats by regulating intracellular antioxidant enzymes and VEGF. Streptozocin 43-57 vascular endothelial growth factor A Rattus norvegicus 132-136 32957814-5 2020 Quercetin treatment increased the expressions of IL-10, VEGF, TGF-beta1, CD31, alpha-SMA, PCNA, and GAP-43, and decreased the expressions of TNF-alpha. Quercetin 0-9 vascular endothelial growth factor A Rattus norvegicus 56-60 31894295-8 2020 The inhibition of VEGF attenuated the effects of the overexpression of miR-15a-5p on the inhibition of cell proliferation, apoptotic rate, caspase-3/9 activity and protein expression of Bax, and it attenuated the increased inflammation, as indicated by the protein expression of p38 and MMP-2 in the PASMCs. mir-15a-5p 71-81 vascular endothelial growth factor A Rattus norvegicus 18-22 31894295-9 2020 In conclusion, the data of the present study demonstrated that miR-15a-5p induced the apoptosis of PASMCs in an animal model of PAH via the VEGF/p38/MMP-2 signaling pathway. mir-15a-5p 63-73 vascular endothelial growth factor A Rattus norvegicus 140-144 29869899-10 2020 Flap perfusion and the level of vascular endothelial growth factor were significantly elevated in the morroniside-treated group. morroniside 102-113 vascular endothelial growth factor A Rattus norvegicus 32-66 31608617-11 2020 The group co-administered with DHEA and aspirin showed significant increases in SOD, GST, CAT, GSH, Progesterone, Ca2+ ATPase, Na+ ATPase, H+ ATPase and significant reduction (p<0.05) in malondialdehyde, VEGF, TNF-alpha and estrogen as compared with the DHEA group. Dehydroepiandrosterone 31-35 vascular endothelial growth factor A Rattus norvegicus 204-208 31630885-0 2020 HIF-1alpha and VEGF Are Involved in Deferoxamine-Ameliorated Traumatic Brain Injury. Deferoxamine 36-48 vascular endothelial growth factor A Rattus norvegicus 15-19 31630885-2 2020 This study aimed to investigate the neuroprotective effect of DFX and its effect on hypoxia-inducible factor 1 alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) in rats after traumatic brain injury (TBI). Deferoxamine 62-65 vascular endothelial growth factor A Rattus norvegicus 134-168 31630885-2 2020 This study aimed to investigate the neuroprotective effect of DFX and its effect on hypoxia-inducible factor 1 alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) in rats after traumatic brain injury (TBI). Deferoxamine 62-65 vascular endothelial growth factor A Rattus norvegicus 170-174 31630885-9 2020 RESULTS: DFX treatment upregulated the expression of HIF-1alpha and VEGF after TBI. Deferoxamine 9-12 vascular endothelial growth factor A Rattus norvegicus 68-72 31630885-13 2020 The protective effect of DFX may, at least in part, be through upregulating the expression of HIF-1alpha and its downstream target gene VEGF. Deferoxamine 25-28 vascular endothelial growth factor A Rattus norvegicus 136-140 31608617-11 2020 The group co-administered with DHEA and aspirin showed significant increases in SOD, GST, CAT, GSH, Progesterone, Ca2+ ATPase, Na+ ATPase, H+ ATPase and significant reduction (p<0.05) in malondialdehyde, VEGF, TNF-alpha and estrogen as compared with the DHEA group. Aspirin 40-47 vascular endothelial growth factor A Rattus norvegicus 204-208 31729495-0 2020 Bioengineering a pre-vascularized pouch for subsequent islet transplantation using VEGF-loaded polylactide capsules. polylactide-polyethylene glycol-polylactide 95-106 vascular endothelial growth factor A Rattus norvegicus 83-87 31991809-1 2020 SH-1242, a novel inhibitor of heat shock protein 90 (HSP90), is a synthetic analog of deguelin: It was previously reported that the treatment of SH-1242 led to a strong suppression of hypoxia-mediated retinal neovascularization and vascular leakage in diabetic retinas by inhibiting the hypoxia-induced upregulation of expression in hypoxia-inducible factor 1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF). 2-(3,4-dimethoxyphenyl)-1-(5-methoxy-2,2-dimethyl-2H-chromen-6-yl)ethanone 0-7 vascular endothelial growth factor A Rattus norvegicus 382-416 31991809-1 2020 SH-1242, a novel inhibitor of heat shock protein 90 (HSP90), is a synthetic analog of deguelin: It was previously reported that the treatment of SH-1242 led to a strong suppression of hypoxia-mediated retinal neovascularization and vascular leakage in diabetic retinas by inhibiting the hypoxia-induced upregulation of expression in hypoxia-inducible factor 1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF). 2-(3,4-dimethoxyphenyl)-1-(5-methoxy-2,2-dimethyl-2H-chromen-6-yl)ethanone 0-7 vascular endothelial growth factor A Rattus norvegicus 418-422 31991809-1 2020 SH-1242, a novel inhibitor of heat shock protein 90 (HSP90), is a synthetic analog of deguelin: It was previously reported that the treatment of SH-1242 led to a strong suppression of hypoxia-mediated retinal neovascularization and vascular leakage in diabetic retinas by inhibiting the hypoxia-induced upregulation of expression in hypoxia-inducible factor 1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF). 2-(3,4-dimethoxyphenyl)-1-(5-methoxy-2,2-dimethyl-2H-chromen-6-yl)ethanone 145-152 vascular endothelial growth factor A Rattus norvegicus 382-416 31991809-1 2020 SH-1242, a novel inhibitor of heat shock protein 90 (HSP90), is a synthetic analog of deguelin: It was previously reported that the treatment of SH-1242 led to a strong suppression of hypoxia-mediated retinal neovascularization and vascular leakage in diabetic retinas by inhibiting the hypoxia-induced upregulation of expression in hypoxia-inducible factor 1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF). 2-(3,4-dimethoxyphenyl)-1-(5-methoxy-2,2-dimethyl-2H-chromen-6-yl)ethanone 145-152 vascular endothelial growth factor A Rattus norvegicus 418-422 33585719-8 2020 The increase in blood glucose levels resulted in a statistically significant increase in tissue level of fibrosis, CD34 and VEGF. Glucose 22-29 vascular endothelial growth factor A Rattus norvegicus 124-128 31729495-4 2020 In our study, we tested surface-modified poly(lactide-co-caprolactone) (PLCL) capsular scaffolds containing the pro-angiogenic factor VEGF. poly(epsilon-caprolactone-co-lactide)-poly(ethylene glycol) 41-70 vascular endothelial growth factor A Rattus norvegicus 134-138 31729495-4 2020 In our study, we tested surface-modified poly(lactide-co-caprolactone) (PLCL) capsular scaffolds containing the pro-angiogenic factor VEGF. poly(epsilon-caprolactone-co-lactide)-poly(ethylene glycol) 72-76 vascular endothelial growth factor A Rattus norvegicus 134-138 31729495-8 2020 The heparin layer served as a VEGF reservoir with an in vitro VEGF release for at least four weeks. Heparin 4-11 vascular endothelial growth factor A Rattus norvegicus 30-34 31729495-8 2020 The heparin layer served as a VEGF reservoir with an in vitro VEGF release for at least four weeks. Heparin 4-11 vascular endothelial growth factor A Rattus norvegicus 62-66 31729495-9 2020 In vivo studies revealed that to obtain highly vascularized PLCL capsules (a) the optimal VEGF dose for the capsule was 50 mug and (b) the implantation time was four weeks when implanted into the greater omentum of Lewis rats; dense fibrous tissue accompanied by vessels completely infiltrated the scaffold and created sparse granulation tissue within the internal cavity of the capsule. poly(epsilon-caprolactone-co-lactide)-poly(ethylene glycol) 60-64 vascular endothelial growth factor A Rattus norvegicus 90-94 31678498-6 2020 Meanwhile, our in vitro study found that 17beta-estradiol stimulation resulted in the loss of extracellular matrix, increased expression of TNF-alpha, IL-1, HIF2alpha and its" down-stream OA-related cytokines (MMP-13, VEGF and Col X) in primary condylar chondrocytes via oestrogen receptor beta (ERbeta), which could be reversed by ER antagonist, selective estrogen receptor modulators (SERMs) and HIF2alpha translation inhibitor. Estradiol 41-57 vascular endothelial growth factor A Rattus norvegicus 218-222 31836883-6 2020 CIH may up-regulate VEGF expression and simultaneously increase TSP-1 production. cih 0-3 vascular endothelial growth factor A Rattus norvegicus 20-24 31408201-0 2020 MiR-203a-3p inhibits retinal angiogenesis and alleviates proliferative diabetic retinopathy in oxygen-induced retinopathy (OIR) rat model via targeting VEGFA and HIF-1alpha. Oxygen 95-101 vascular endothelial growth factor A Rattus norvegicus 152-157 31656158-7 2020 The treatment of TXF also improved the status of oxidative stress and inhibited the levels of p38MAPK, VEGF and ERK1/2. taxifolin 17-20 vascular endothelial growth factor A Rattus norvegicus 103-107 31656158-9 2020 The results suggest that the protective effect of TXF against cataract and retinopathy may be due to the anti-oxidative potential of TXF and its inhibiting effect on VEGF, ERK1/2, p38MAPK and aldose reductase. taxifolin 50-53 vascular endothelial growth factor A Rattus norvegicus 166-170 31533469-8 2020 Significant improvement in VEGF and CD31 expression after warfarin injection was associated with increased capillary density, neovascularization, and decreased myocardial fibrosis together with the reestablishment of myocardial structural and ultrastructural patterns. Warfarin 58-66 vascular endothelial growth factor A Rattus norvegicus 27-31 32116075-12 2020 The reduced miR-142-5p level enhanced HRECs proliferation via activating IGF/IGF1R-mediated signaling pathway including p-PI3K, p-ERK, p-AKT, and VEGF activation, ultimately giving rise to cell proliferation. mir-142-5p 12-22 vascular endothelial growth factor A Rattus norvegicus 146-150 32368225-13 2020 Conclusion: Implantation losses caused by soy isoflavones seemed to be due to the down regulation of PR that failed to down regulate ER-alpha action and decreased VEGF production. Isoflavones 46-57 vascular endothelial growth factor A Rattus norvegicus 163-167 32863302-8 2020 In the ATRA-experiment, ATRA suppressed the secretion of IL-6 and NO, downregulated the NF-kappaB P65 and Bcl-2, increased levels of autophagy marker protein LC3, but different doses of ATRA showed inconsistent regulatory effects on VEGF and MMP-9. Tretinoin 24-28 vascular endothelial growth factor A Rattus norvegicus 233-237 31806568-8 2020 The NOB-treated group mitigated oxidative stress via augmented SOD, reduced MDA, and enhanced vascular endothelial growth factor (VEGF) expression. nobiletin 4-7 vascular endothelial growth factor A Rattus norvegicus 94-128 31806568-8 2020 The NOB-treated group mitigated oxidative stress via augmented SOD, reduced MDA, and enhanced vascular endothelial growth factor (VEGF) expression. nobiletin 4-7 vascular endothelial growth factor A Rattus norvegicus 130-134 32718263-10 2020 BA also downregulated the transcription of vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF-beta) and decreased the expression of the NF-kB pathway proteins (NF-kB-P65, IkBalpha, and IKKalpha/beta) in the TNF-alpha-stimulated RA-FLS. betulinic acid 0-2 vascular endothelial growth factor A Rattus norvegicus 43-77 32718263-10 2020 BA also downregulated the transcription of vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF-beta) and decreased the expression of the NF-kB pathway proteins (NF-kB-P65, IkBalpha, and IKKalpha/beta) in the TNF-alpha-stimulated RA-FLS. betulinic acid 0-2 vascular endothelial growth factor A Rattus norvegicus 79-83 32718263-11 2020 These results indicate that BA alleviated the symptoms of CIA by inhibiting synoviocyte proliferation, modifying TNF-alpha- and NF-kB-related inflammatory pathways, and downregulating inflammatory mediators and growth factors including IL-1beta, IL-6, VEGF, and TGF-beta. betulinic acid 28-30 vascular endothelial growth factor A Rattus norvegicus 252-256 32863302-8 2020 In the ATRA-experiment, ATRA suppressed the secretion of IL-6 and NO, downregulated the NF-kappaB P65 and Bcl-2, increased levels of autophagy marker protein LC3, but different doses of ATRA showed inconsistent regulatory effects on VEGF and MMP-9. Tretinoin 24-28 vascular endothelial growth factor A Rattus norvegicus 233-237 31976335-10 2019 Conclusions: These results suggested that SCU can be an oral drug to alleviate microvascular dysfunction of DR and exerts its antiangiogenic effects by inhibiting the expression of the crosstalk of VEGF, p-ERK, p-FAK, and p-Src. scutellarin 42-45 vascular endothelial growth factor A Rattus norvegicus 198-202 33251532-3 2020 Sorafenib is a tyrosine kinase inhibitor that acts via the vascular endothelial growth factor (VEGF) signaling pathway and is widely used to treat a variety of cancers. Sorafenib 0-9 vascular endothelial growth factor A Rattus norvegicus 59-93 33251532-3 2020 Sorafenib is a tyrosine kinase inhibitor that acts via the vascular endothelial growth factor (VEGF) signaling pathway and is widely used to treat a variety of cancers. Sorafenib 0-9 vascular endothelial growth factor A Rattus norvegicus 95-99 31658444-9 2019 Upon incorporation of the DMOG-loaded CMPs (DCMPs) within the mesenspheres, a similar osteogenic differentiation and an upregulation in angiogenic gense (VEGF; 5-fold, KDR; 2-fold) were obsereved after the 14-day culture. dimethyloxallyl glycine 26-30 vascular endothelial growth factor A Rattus norvegicus 154-158 31930126-0 2019 Caffeic Acid Phenethyl Ester (CAPE) Induces VEGF Expression and Production in Rat Odontoblastic Cells. caffeic acid phenethyl ester 0-28 vascular endothelial growth factor A Rattus norvegicus 44-48 31930126-0 2019 Caffeic Acid Phenethyl Ester (CAPE) Induces VEGF Expression and Production in Rat Odontoblastic Cells. caffeic acid phenethyl ester 30-34 vascular endothelial growth factor A Rattus norvegicus 44-48 31930126-4 2019 CAPE significantly induced mRNA expression and production of VEGF in rat clonal odontoblast-like KN-3 cells cultured in normal medium or osteogenic induction medium. caffeic acid phenethyl ester 0-4 vascular endothelial growth factor A Rattus norvegicus 61-65 31712059-11 2019 Isoquercitrin also attenuated the increased HIF-1alpha expression while increased that of the VEGF and beta-catenin. isoquercitrin 0-13 vascular endothelial growth factor A Rattus norvegicus 94-98 31842985-0 2019 The combinatory effect of sinusoidal electromagnetic field and VEGF promotes osteogenesis and angiogenesis of mesenchymal stem cell-laden PCL/HA implants in a rat subcritical cranial defect. Hydroxyapatites 138-144 vascular endothelial growth factor A Rattus norvegicus 63-67 31608754-8 2019 Treatment with KSE (20 microg/mL) significantly suppressed VEGF-induced migration, invasion and capillary-like structure formation of HUVECs and microvessel sprouting from rat aortic rings. KSE 15-18 vascular endothelial growth factor A Rattus norvegicus 59-63 31885614-11 2019 In addition, the analysis of CM-DiI-labeled BMSCs showed that the BMSC+VEGF group exhibited better cell engraftment and that the engrafted cells were mainly distributed in the hepatic parenchyma. 3,3'-dioctadecylindocarbocyanine 32-35 vascular endothelial growth factor A Rattus norvegicus 71-75 31317786-3 2019 Methods: ROP was induced in rats by the subcutaneous injection of the vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor KRN633 (10 mg/kg) on postnatal day (P) 7 and P8. N-(2-chloro-4-((6,7-dimethoxy-4-quinazolinyl)oxy)phenyl)-N'-propylurea 147-153 vascular endothelial growth factor A Rattus norvegicus 70-104 31317786-3 2019 Methods: ROP was induced in rats by the subcutaneous injection of the vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor KRN633 (10 mg/kg) on postnatal day (P) 7 and P8. N-(2-chloro-4-((6,7-dimethoxy-4-quinazolinyl)oxy)phenyl)-N'-propylurea 147-153 vascular endothelial growth factor A Rattus norvegicus 106-110 31850806-15 2019 In comparison with the control cells, exposure to 10muM MeHg for 0.5h significantly inhibited the expression of astrocytic HIF-1alpha, and the downstream genes GLUT-1, EPO, and VEGF-A (p<0.05), in the absence of a significant decrease in HIF-1alpha mRNA levels. Mercury 56-60 vascular endothelial growth factor A Rattus norvegicus 177-183 31841190-5 2019 Also, the roles of the inhibitor PX-478 and miR-199a mimics in the expressions of miR-199a, HIF-1alpha, and VEGF proteins, as well as their influences on cell proliferation ability were detected. 2-amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide 34-40 vascular endothelial growth factor A Rattus norvegicus 109-113 31841190-9 2019 Both HIF-1alpha/VEGF signaling pathway inhibitor PX-478 and miR-199a mimics significantly reduced the expressions of HIF-1alpha and VEGF proteins (p<0.01) and suppressed the cell proliferation activity. 2-amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide 49-55 vascular endothelial growth factor A Rattus norvegicus 16-20 31841190-9 2019 Both HIF-1alpha/VEGF signaling pathway inhibitor PX-478 and miR-199a mimics significantly reduced the expressions of HIF-1alpha and VEGF proteins (p<0.01) and suppressed the cell proliferation activity. 2-amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide 49-55 vascular endothelial growth factor A Rattus norvegicus 132-136 30905241-11 2019 ASI promoted angiogenesis, with increased vascular density (2.08-fold) and induced mRNA expression of CD31 (1.81-fold) and VEGF (2.70-fold) in the ischemic heart. astragaloside A 0-3 vascular endothelial growth factor A Rattus norvegicus 123-127 30905241-12 2019 Furthermore, ASI induced the phosphorylation of JAK (1.89-fold) and STAT3 (2.95-fold), as well as the activity of VEGF promoter which was regulated by STAT3. astragaloside A 13-16 vascular endothelial growth factor A Rattus norvegicus 114-118 31697035-3 2019 An NIR-II fluorescent molecular probe, indocyanine green (ICG) conjugated bevacizumab (Bev-ICG) that targets vascular endothelial growth factor (VEGF), is successfully synthesized and evaluated along with the NIR-II endoscopy imaging system. Indocyanine Green 39-56 vascular endothelial growth factor A Rattus norvegicus 109-143 31697035-3 2019 An NIR-II fluorescent molecular probe, indocyanine green (ICG) conjugated bevacizumab (Bev-ICG) that targets vascular endothelial growth factor (VEGF), is successfully synthesized and evaluated along with the NIR-II endoscopy imaging system. Indocyanine Green 39-56 vascular endothelial growth factor A Rattus norvegicus 145-149 31697035-3 2019 An NIR-II fluorescent molecular probe, indocyanine green (ICG) conjugated bevacizumab (Bev-ICG) that targets vascular endothelial growth factor (VEGF), is successfully synthesized and evaluated along with the NIR-II endoscopy imaging system. Indocyanine Green 58-61 vascular endothelial growth factor A Rattus norvegicus 109-143 31697035-3 2019 An NIR-II fluorescent molecular probe, indocyanine green (ICG) conjugated bevacizumab (Bev-ICG) that targets vascular endothelial growth factor (VEGF), is successfully synthesized and evaluated along with the NIR-II endoscopy imaging system. Indocyanine Green 58-61 vascular endothelial growth factor A Rattus norvegicus 145-149 31697035-3 2019 An NIR-II fluorescent molecular probe, indocyanine green (ICG) conjugated bevacizumab (Bev-ICG) that targets vascular endothelial growth factor (VEGF), is successfully synthesized and evaluated along with the NIR-II endoscopy imaging system. Indocyanine Green 91-94 vascular endothelial growth factor A Rattus norvegicus 109-143 31697035-3 2019 An NIR-II fluorescent molecular probe, indocyanine green (ICG) conjugated bevacizumab (Bev-ICG) that targets vascular endothelial growth factor (VEGF), is successfully synthesized and evaluated along with the NIR-II endoscopy imaging system. Indocyanine Green 91-94 vascular endothelial growth factor A Rattus norvegicus 145-149 31625080-7 2019 RESULTS: Cilostazol promoted angiogenesis by increasing the number of new blood vessels and up-regulating the expression of VEGF, HGF, bFGF and PDGF-B in myocardial I/R-injury rat model. cilostazol 9-19 vascular endothelial growth factor A Rattus norvegicus 124-128 31625080-9 2019 Furthermore, after 8-Br-cAMP treatment, VEGF, HGF, bFGF, PDGF-B, p-AKT and p-eNOS expression were up-regulated, while cleaved-caspase 3 and cleaved-PARP expression were down-regulated. 8-Bromo Cyclic Adenosine Monophosphate 19-28 vascular endothelial growth factor A Rattus norvegicus 40-44 31486114-10 2019 In short, the present study suggests that the inhibition of placental TFPI-2 and HIF-1alpha/VEGF might be one of the potential mechanisms underlying the protective effects of VI to experimental PE induced by l-NAME. NG-Nitroarginine Methyl Ester 208-214 vascular endothelial growth factor A Rattus norvegicus 92-96 32133066-10 2019 Simvastatin could promote expressions of aggrecan, collagen type II, HIF-1alpha, VEGF and GLUT-1, while 0.1 mumol/l concentration reached the maximum effect. Simvastatin 0-11 vascular endothelial growth factor A Rattus norvegicus 81-85 31778078-3 2022 ISO injection significantly (p < 0.05) increased the activities of cardiac marker enzymes (CK-MB, LDH, ALT, and AST), cardiac troponin-I, levels of lipid peroxides (MDA), nitric oxide (NO), and vascular endothelial growth factor (VEGF), serum angiotensin-converting enzyme (ACE) activity and neutrophil infiltration marker; myeloperoxidase (MPO) in the cardiac tissues. Isoproterenol 0-3 vascular endothelial growth factor A Rattus norvegicus 197-231 31841472-1 2019 OBJECTIVE: The objective of this work was to study the effect of the combined action of X-radiation and the cyclooxygenase-2 (COX-2) inhibitor on the level of vascular endothelial growth factor (VEGF) and prostaglandin E2 (PGE-2) in blood serum of rat-tumor carriers at irradiation in different doses. Dinoprostone 205-221 vascular endothelial growth factor A Rattus norvegicus 195-199 31841472-1 2019 OBJECTIVE: The objective of this work was to study the effect of the combined action of X-radiation and the cyclooxygenase-2 (COX-2) inhibitor on the level of vascular endothelial growth factor (VEGF) and prostaglandin E2 (PGE-2) in blood serum of rat-tumor carriers at irradiation in different doses. Dinoprostone 223-228 vascular endothelial growth factor A Rattus norvegicus 159-193 31841472-1 2019 OBJECTIVE: The objective of this work was to study the effect of the combined action of X-radiation and the cyclooxygenase-2 (COX-2) inhibitor on the level of vascular endothelial growth factor (VEGF) and prostaglandin E2 (PGE-2) in blood serum of rat-tumor carriers at irradiation in different doses. Dinoprostone 223-228 vascular endothelial growth factor A Rattus norvegicus 195-199 31841472-8 2019 In the case of combined exposure to radiation (10 Gy) and the COX-2 inhibitor, meloxivet, the potential decrease in VEGF levels was 3.49 times compared to con- trol and 1.8 times with isolated exposure. Meloxicam 79-88 vascular endothelial growth factor A Rattus norvegicus 116-120 31841472-14 2019 The combined effect of ionizing radiation and the COX-2 inhibitor (meloxivet) affects the level of PGE-2, VEGF, ie, the slowing of angiogenesis. Meloxicam 67-76 vascular endothelial growth factor A Rattus norvegicus 106-110 31778078-3 2022 ISO injection significantly (p < 0.05) increased the activities of cardiac marker enzymes (CK-MB, LDH, ALT, and AST), cardiac troponin-I, levels of lipid peroxides (MDA), nitric oxide (NO), and vascular endothelial growth factor (VEGF), serum angiotensin-converting enzyme (ACE) activity and neutrophil infiltration marker; myeloperoxidase (MPO) in the cardiac tissues. Isoproterenol 0-3 vascular endothelial growth factor A Rattus norvegicus 233-237 31778078-4 2022 Pretreatment with chloroform or petroleum ether extracts significantly (p < 0.05) prevented the ISO-induced alteration; they upregulated VEGF expression. Chloroform 18-28 vascular endothelial growth factor A Rattus norvegicus 140-144 31778078-4 2022 Pretreatment with chloroform or petroleum ether extracts significantly (p < 0.05) prevented the ISO-induced alteration; they upregulated VEGF expression. naphtha 32-47 vascular endothelial growth factor A Rattus norvegicus 140-144 31778078-4 2022 Pretreatment with chloroform or petroleum ether extracts significantly (p < 0.05) prevented the ISO-induced alteration; they upregulated VEGF expression. Isoproterenol 99-102 vascular endothelial growth factor A Rattus norvegicus 140-144 31758020-0 2019 VEGF/Flk1 Mechanism is Involved in Roxarsone Promotion of Rat Endothelial Cell Growth and B16F10 Xenograft Tumor Angiogenesis. Roxarsone 35-44 vascular endothelial growth factor A Rattus norvegicus 0-4 32038475-10 2019 The in vivo results indicated that sitagliptin promoted endothelialization of the aneurysm neck and increased circulating EPCs and expression levels of SDF-1 and VEGF in peripheral blood. sitagliptin 35-46 vascular endothelial growth factor A Rattus norvegicus 162-166 32038475-12 2019 Western blot analysis and ELISA showed that sitagliptin promoted the expression of SDF-1 and VEGF in progenitor endothelial cells. sitagliptin 44-55 vascular endothelial growth factor A Rattus norvegicus 93-97 31766610-9 2019 This showed that the release of DMOG was sustained over 48 h. The release of DMOG was enough to cause a significant increase in HIF-1alpha levels in the bioassay, and when incubated with rat aortic endothelial cells (RAECs) for 2 h resulted in transcriptional activation of a HIF-1alpha target gene (VEGF). dimethyloxallyl glycine 32-36 vascular endothelial growth factor A Rattus norvegicus 300-304 31766610-9 2019 This showed that the release of DMOG was sustained over 48 h. The release of DMOG was enough to cause a significant increase in HIF-1alpha levels in the bioassay, and when incubated with rat aortic endothelial cells (RAECs) for 2 h resulted in transcriptional activation of a HIF-1alpha target gene (VEGF). dimethyloxallyl glycine 77-81 vascular endothelial growth factor A Rattus norvegicus 300-304 31588098-7 2019 Gingival VEGF levels increased in all groups that created experimental periodontitis and the greatest increase seen in the Pae group. peoniflorin 123-126 vascular endothelial growth factor A Rattus norvegicus 9-13 31758020-6 2019 Cell viability and VEGF expression following roxarsone treatment were significantly higher than that of the control (P < 0.05), peaking following treatment with 1.0 muM roxarsone. Roxarsone 45-54 vascular endothelial growth factor A Rattus norvegicus 19-23 31758020-6 2019 Cell viability and VEGF expression following roxarsone treatment were significantly higher than that of the control (P < 0.05), peaking following treatment with 1.0 muM roxarsone. Roxarsone 172-181 vascular endothelial growth factor A Rattus norvegicus 19-23 31758020-2 2019 We explored the mechanism of vascular endothelial growth factor (VEGF) and its receptor (VEGFR) in roxarsone promotion of rat vascular endothelial cells (ECs) and B16F10 mouse xenografts. Roxarsone 99-108 vascular endothelial growth factor A Rattus norvegicus 29-63 31758020-7 2019 Compared to roxarsone alone, the VEGF antibody decreased cell promotion by roxarsone (P < 0.05), and the Flk1 antibody greatly reduced cell viability compared to the Flt1 antibody (P < 0.01). Roxarsone 75-84 vascular endothelial growth factor A Rattus norvegicus 33-37 31758020-8 2019 Roxarsone and Flk1 antibody co-treatment increased supernatant VEGF significantly, while cellular VEGF was obviously decreased (P < 0.01), whereas there was no significant difference following Flt1 antibody blockade. Roxarsone 0-9 vascular endothelial growth factor A Rattus norvegicus 63-67 31758020-2 2019 We explored the mechanism of vascular endothelial growth factor (VEGF) and its receptor (VEGFR) in roxarsone promotion of rat vascular endothelial cells (ECs) and B16F10 mouse xenografts. Roxarsone 99-108 vascular endothelial growth factor A Rattus norvegicus 65-69 31758020-9 2019 The siRNA against Vegf or Flk1 significantly attenuated the roxarsone promotion effects on EC proliferation, migration, and tube-like formation (P < 0.01), whereas the siRNA against Flt1 effected no obvious differences. Roxarsone 60-69 vascular endothelial growth factor A Rattus norvegicus 18-22 31436780-5 2019 By changing the hydrophilic-hydrophobic balance in the copolymer, anti-VEGF release rates can be modulated. copolymer 55-64 vascular endothelial growth factor A Rattus norvegicus 71-75 31758020-10 2019 Furthermore, the RNA interference significantly weakened the roxarsone-induced increase in xenograft weight and volume, and VEGF and Flk1 expression. Roxarsone 61-70 vascular endothelial growth factor A Rattus norvegicus 124-128 31597821-7 2019 STZ treatment led to an increase in expression of Matrix metalloproteinases-9 (MMP-9), Tumour necrosis factor-alpha (Tnf-alpha), Hypoxia inducible factor-alpha (HIF-1alpha), Vascular endothelial growth factor (VEGF), Interleukin-6 (IL-6), Protein kinase C-epsilon (PKC-epsilon), Nuclear factor kappa-light-chain-enhancer of activated B-cells (NFkB), and Caspase-3. Streptozocin 0-3 vascular endothelial growth factor A Rattus norvegicus 174-208 31597821-7 2019 STZ treatment led to an increase in expression of Matrix metalloproteinases-9 (MMP-9), Tumour necrosis factor-alpha (Tnf-alpha), Hypoxia inducible factor-alpha (HIF-1alpha), Vascular endothelial growth factor (VEGF), Interleukin-6 (IL-6), Protein kinase C-epsilon (PKC-epsilon), Nuclear factor kappa-light-chain-enhancer of activated B-cells (NFkB), and Caspase-3. Streptozocin 0-3 vascular endothelial growth factor A Rattus norvegicus 210-214 31699972-6 2019 As expected, in renal tubular epithelial NRK-52E cells, high glucose (HG)-induced overexpression of TGF-beta1, ACE/AT1, and VEGF were abrogated by S3I-201 pretreatment, as well as by genetic knockdown of STAT3 using specific siRNA sequence. Glucose 61-68 vascular endothelial growth factor A Rattus norvegicus 124-128 31567367-12 2019 Moreover, spinal blocking vascular endothelial growth factor A/vascular endothelial growth factor receptor 2 pathways suppressed protein kinase C-mediated N-methyl-D-aspartate receptor activation and Src family kinase-mediated proinflammatory cytokine production. N-Methylaspartate 155-175 vascular endothelial growth factor A Rattus norvegicus 26-62 31741856-0 2019 Inhibition of beta-elemene on the expressions of HIF-lalpha, VEGF and iNOS in diabetic rats model. beta-elemene 14-26 vascular endothelial growth factor A Rattus norvegicus 61-65 31741856-1 2019 AIM: To evaluate the effect of beta-elemene on the expressions of hypoxia-inducible factor (HIF)-lalpha, vascular endothelial growth factor (VEGF) and inducible nitric oxide synthase (iNOS) in a streptozotocin (STZ) induced diabetic Sprague-Dawley (SD) rat model. beta-elemene 31-43 vascular endothelial growth factor A Rattus norvegicus 105-139 31741856-1 2019 AIM: To evaluate the effect of beta-elemene on the expressions of hypoxia-inducible factor (HIF)-lalpha, vascular endothelial growth factor (VEGF) and inducible nitric oxide synthase (iNOS) in a streptozotocin (STZ) induced diabetic Sprague-Dawley (SD) rat model. beta-elemene 31-43 vascular endothelial growth factor A Rattus norvegicus 141-145 31741856-6 2019 RESULTS: The results indicated that the protein and mRNA expressions of HIF-1alpha, VEGF and iNOS after treated by beta-elemene periocularly and intravitreally injections were all found to be reduced compared with the levels in the diabetic rats group (P<0.05). beta-elemene 115-127 vascular endothelial growth factor A Rattus norvegicus 84-88 31741856-8 2019 CONCLUSION: The results show beta-elemene protect the retina of diabetic rats from high glucose damage by downregulating the expression of HIF-1alpha, VEGF and iNOS. beta-elemene 29-41 vascular endothelial growth factor A Rattus norvegicus 151-155 31521813-14 2019 The results showed that the addition of octyl glucoside (OG) could change the water channel size of LLC, which enabled the LLC system to release VEGF in a sustained manner and to possess a suitable modulus to favor angiogenesis simultaneously. octyl-beta-D-glucoside 40-55 vascular endothelial growth factor A Rattus norvegicus 145-149 31521813-14 2019 The results showed that the addition of octyl glucoside (OG) could change the water channel size of LLC, which enabled the LLC system to release VEGF in a sustained manner and to possess a suitable modulus to favor angiogenesis simultaneously. octyl-beta-D-glucoside 57-59 vascular endothelial growth factor A Rattus norvegicus 145-149 31521813-14 2019 The results showed that the addition of octyl glucoside (OG) could change the water channel size of LLC, which enabled the LLC system to release VEGF in a sustained manner and to possess a suitable modulus to favor angiogenesis simultaneously. Water 78-83 vascular endothelial growth factor A Rattus norvegicus 145-149 31256287-10 2019 In DM1, we found disturbance of VEGF-transporting vesicular PTCs system, which was substantially worsened in STZ + DHA and STZ + N6. Streptozocin 109-112 vascular endothelial growth factor A Rattus norvegicus 32-36 31116952-0 2019 Sitagliptin protects diabetic rats with acute myocardial infarction through induction of angiogenesis: role of IGF-1 and VEGF. Sitagliptin Phosphate 0-11 vascular endothelial growth factor A Rattus norvegicus 121-125 31116952-5 2019 Treatment with sitagliptin improved the electrocardiogram and histopathological sections, upregulated vascular endothelial growth factor (VEGF) and transmembrane phosphoglycoprotein protein (CD34) in cardiac tissues, and increased serum insulin-like growth factor 1 (IGF-1) and decreased cardiac tissue homogenate for interleukin 6 (IL-6) and cyclooxygenase 2 (COX-2). Sitagliptin Phosphate 15-26 vascular endothelial growth factor A Rattus norvegicus 102-136 31116952-5 2019 Treatment with sitagliptin improved the electrocardiogram and histopathological sections, upregulated vascular endothelial growth factor (VEGF) and transmembrane phosphoglycoprotein protein (CD34) in cardiac tissues, and increased serum insulin-like growth factor 1 (IGF-1) and decreased cardiac tissue homogenate for interleukin 6 (IL-6) and cyclooxygenase 2 (COX-2). Sitagliptin Phosphate 15-26 vascular endothelial growth factor A Rattus norvegicus 138-142 31256287-10 2019 In DM1, we found disturbance of VEGF-transporting vesicular PTCs system, which was substantially worsened in STZ + DHA and STZ + N6. dehydroacetic acid 115-118 vascular endothelial growth factor A Rattus norvegicus 32-36 31256287-10 2019 In DM1, we found disturbance of VEGF-transporting vesicular PTCs system, which was substantially worsened in STZ + DHA and STZ + N6. Streptozocin 123-126 vascular endothelial growth factor A Rattus norvegicus 32-36 31256287-10 2019 In DM1, we found disturbance of VEGF-transporting vesicular PTCs system, which was substantially worsened in STZ + DHA and STZ + N6. n6 129-131 vascular endothelial growth factor A Rattus norvegicus 32-36 31578682-0 2019 Nicotine increased VEGF and MMP2 levels in the rat eye and kidney. Nicotine 0-8 vascular endothelial growth factor A Rattus norvegicus 19-23 31578682-12 2019 According to our findings, it can be suggested that nicotine has negative effects on microvascular circulation by increasing VEGF and MMP2 levels. Nicotine 52-60 vascular endothelial growth factor A Rattus norvegicus 125-129 31578682-4 2019 The aim of this study was to investigate the effect of nicotine on VEGF and MMP2 levels in kidney and eyes, where microcirculation is very important for their function. Nicotine 55-63 vascular endothelial growth factor A Rattus norvegicus 67-71 31578682-7 2019 The VEGF and MMP2 levels were increased in kidney tissue of both genders as a result of given nicotine. Nicotine 94-102 vascular endothelial growth factor A Rattus norvegicus 4-8 31578682-9 2019 However, VEGF levels increased in the eye tissue with nicotine in males, whereas it did not change in females. Nicotine 54-62 vascular endothelial growth factor A Rattus norvegicus 9-13 31578682-10 2019 The use of nicotine made VEGF and MMP2 levels increase in kidney tissue in both genders of rats. Nicotine 11-19 vascular endothelial growth factor A Rattus norvegicus 25-29 31799638-9 2019 The expression level of VEGF in bone tissues at fracture ends of rats in the experimental group A, experimental group B and control group was observed through the hematoxylin-eosin (HE) staining. Hematoxylin 163-174 vascular endothelial growth factor A Rattus norvegicus 24-28 31799638-9 2019 The expression level of VEGF in bone tissues at fracture ends of rats in the experimental group A, experimental group B and control group was observed through the hematoxylin-eosin (HE) staining. Eosine Yellowish-(YS) 175-180 vascular endothelial growth factor A Rattus norvegicus 24-28 31322979-9 2019 What"s more, the synergism of the Sr2+ and CaP from the Sr-CaP/PCL/CS membrane enhanced BMSCs angiogenic differentiation, herein resulting in the largest VEGF secretion amount. strontium cation 34-38 vascular endothelial growth factor A Rattus norvegicus 154-158 31322979-9 2019 What"s more, the synergism of the Sr2+ and CaP from the Sr-CaP/PCL/CS membrane enhanced BMSCs angiogenic differentiation, herein resulting in the largest VEGF secretion amount. Cesium 67-69 vascular endothelial growth factor A Rattus norvegicus 154-158 31555994-9 2019 However, Pirfenidone, a TGF-beta2 inhibitor, decreased the expression levels of TGF-beta2, p-Smad3, VEGF, and CD34 (P < 0.05). pirfenidone 9-20 vascular endothelial growth factor A Rattus norvegicus 100-104 31420792-9 2019 Supplementation of omega-3 fatty acids and vitamin E to LOP improved the levels of VEGF and VEGF receptor-1 only in the LOP but not in the EOP group. Fatty Acids, Omega-3 19-38 vascular endothelial growth factor A Rattus norvegicus 83-87 31420792-9 2019 Supplementation of omega-3 fatty acids and vitamin E to LOP improved the levels of VEGF and VEGF receptor-1 only in the LOP but not in the EOP group. Vitamin E 43-52 vascular endothelial growth factor A Rattus norvegicus 83-87 31527337-6 2019 Norepinephrine further increased VEGF mRNA; this effect was unaffected by carvedilol. Norepinephrine 0-14 vascular endothelial growth factor A Rattus norvegicus 33-37 31494238-7 2019 During the in-vivo studies, both the selected PG-loaded SC and the unmedicated SC showed a significant improvement in the healing process compared to the untreated group, this was evidenced by the measurement of wound contraction % [627% and 467%, respectively, p < 0.05], as well as the level of some biomarkers (TNF-alpha, VEGF and MMP-9). Pioglitazone 46-48 vascular endothelial growth factor A Rattus norvegicus 325-329 31527337-7 2019 VEGF promoted VEGF receptor phosphorylation and tube formation of human umbilical vein endothelial cells, which were inhibited by carvedilol. Carvedilol 130-140 vascular endothelial growth factor A Rattus norvegicus 14-18 31527337-12 2019 Inhibition of VEGF effects by carvedilol abolished their beneficial effects. Carvedilol 30-40 vascular endothelial growth factor A Rattus norvegicus 14-18 31437429-8 2019 In addition to inhibiting DPP-4, saxagliptin increased the renal kidney injury molecule-1/pY705-STAT3/hypoxia-inducible factor-1alpha/VEGF pathway to enhance angiogenesis. saxagliptin 33-44 vascular endothelial growth factor A Rattus norvegicus 134-138 31401155-10 2019 In addition, ICA treatment was associated with decreases in the tissue MDA level, proinflammatory cytokine production, and the level of PDE5, but increases in SOD activity, blood flow volume, and the level of VEGF expression. icariin 13-16 vascular endothelial growth factor A Rattus norvegicus 209-213 31437429-0 2019 Novel repair mechanisms in a renal ischaemia/reperfusion model: Subsequent saxagliptin treatment modulates the pro-angiogenic GLP-1/cAMP/VEGF, ANP/eNOS/NO, SDF-1alpha/CXCR4, and Kim-1/STAT3/HIF-1alpha/VEGF/eNOS pathways. saxagliptin 75-86 vascular endothelial growth factor A Rattus norvegicus 137-141 31437429-0 2019 Novel repair mechanisms in a renal ischaemia/reperfusion model: Subsequent saxagliptin treatment modulates the pro-angiogenic GLP-1/cAMP/VEGF, ANP/eNOS/NO, SDF-1alpha/CXCR4, and Kim-1/STAT3/HIF-1alpha/VEGF/eNOS pathways. saxagliptin 75-86 vascular endothelial growth factor A Rattus norvegicus 201-205 31090463-4 2019 Furthermore, melatonin can relatively modulate genes in the HIF1 family, TNF-alpha and VEGF, thus acting as a direct anti-angiogenic molecule. Melatonin 13-22 vascular endothelial growth factor A Rattus norvegicus 87-91 30853494-7 2019 Ketotifen reduces the degree of hepatic insufficiency and the splanchnic inflammatory mediators, as well as VEGF and TGF-ss1 levels. Ketotifen 0-9 vascular endothelial growth factor A Rattus norvegicus 108-112 31432121-0 2019 Ginsenoside Rb1 prevents steroid-induced avascular necrosis of the femoral head through the bone morphogenetic protein-2 and vascular endothelial growth factor pathway. Steroids 25-32 vascular endothelial growth factor A Rattus norvegicus 125-159 31632529-7 2019 The high glucose culture resulted in a significant decrease in VEGF and BDNF levels in culture medium and cells of NSCs. Glucose 9-16 vascular endothelial growth factor A Rattus norvegicus 63-67 31250275-0 2019 Isoflurane-Induced Postoperative Neurovascular and Cognitive Dysfunction Is Associated with VEGF Overexpression in Aged Rats. Isoflurane 0-10 vascular endothelial growth factor A Rattus norvegicus 92-96 31250275-4 2019 VEGF protein expression was increased in the hippocampus after isoflurane exposure, suggesting that inhalation anaesthesia induces hippocampal VEGF protein overexpression in aged rats. Isoflurane 63-73 vascular endothelial growth factor A Rattus norvegicus 0-4 31250275-4 2019 VEGF protein expression was increased in the hippocampus after isoflurane exposure, suggesting that inhalation anaesthesia induces hippocampal VEGF protein overexpression in aged rats. Isoflurane 63-73 vascular endothelial growth factor A Rattus norvegicus 143-147 31250275-5 2019 Pretreatment with 2 mg/kg RB-222, an anti-VEGF neutralizing antibody, may partially abolish the degradation of occludin protein in cerebral capillaries, thereby maintaining the ultrastructural and functional integrity of the hippocampal BBB. rb-222 26-32 vascular endothelial growth factor A Rattus norvegicus 42-46 31250275-6 2019 Inhibition of VEGF also significantly attenuated the isoflurane-induced cognitive deficits in the Morris water maze task. Isoflurane 53-63 vascular endothelial growth factor A Rattus norvegicus 14-18 31250275-7 2019 Together, our findings show, for the first time, that elevated expression of brain VEGF after isoflurane exposure contributes to POCD in aged rats. Isoflurane 94-104 vascular endothelial growth factor A Rattus norvegicus 83-87 30887626-9 2019 Injection of macrophage clean reagent and omega-3PUFA significantly inhibited M2 activation, and decreased Masson staining, alpha-SMA, TGF-beta1, VEGF and ALK5 protein expression in peritoneal tissues in PD treated rats. Fatty Acids, Omega-3 42-53 vascular endothelial growth factor A Rattus norvegicus 146-150 31351970-12 2019 The plasma and testicular microvasculature VEGF levels were increased in the CIH group. cih 77-80 vascular endothelial growth factor A Rattus norvegicus 43-47 31349469-8 2019 Gene expression study demonstrated that the presence of Y2O3 in the scaffolds can upregulate the expression of cell proliferation and angiogenesis related biomolecules such as VEGF and EGFR. y2o3 56-60 vascular endothelial growth factor A Rattus norvegicus 176-180 31568298-0 2019 Recipient-Site Preconditioning with Deferoxamine Increases Fat Graft Survival by Inducing VEGF and Neovascularization in a Rat Model. Deferoxamine 36-48 vascular endothelial growth factor A Rattus norvegicus 90-94 31568299-0 2019 Discussion: Recipient-Site Preconditioning with Deferoxamine Increases Fat-Graft Survival by Inducing VEGF and Neovascularization in a Rat Model. Deferoxamine 48-60 vascular endothelial growth factor A Rattus norvegicus 102-106 31582019-0 2019 Nicotine-induced oxidative stress alters sciatic nerve barriers in rat through modulation of ZO-1 & VEGF expression. Nicotine 0-8 vascular endothelial growth factor A Rattus norvegicus 104-108 31582019-12 2019 A dose-dependent nicotine-induced oxidative stress on the sciatic nerve occurred via disruption of nerve barriers, altered VEGF and ZO-1 levels. Nicotine 17-25 vascular endothelial growth factor A Rattus norvegicus 123-127 31594182-36 2019 The expression level of vascular endothelial growth factor (VEGF) in hASCs of protein-high osmotic pressure combination group decreased gradually with the prolongation of culture time, while that in hASCs of AGEs-high glucose combination group on PCD 4 decreased significantly as compared with that on PCD 2 (P<0.05). Glucose 218-225 vascular endothelial growth factor A Rattus norvegicus 24-58 31594182-36 2019 The expression level of vascular endothelial growth factor (VEGF) in hASCs of protein-high osmotic pressure combination group decreased gradually with the prolongation of culture time, while that in hASCs of AGEs-high glucose combination group on PCD 4 decreased significantly as compared with that on PCD 2 (P<0.05). Glucose 218-225 vascular endothelial growth factor A Rattus norvegicus 60-64 31571883-14 2019 Finally, Galuteolin markedly inhibited the expression of VEGF in cerebral infarction tissues. luteolin-7-glucoside 9-19 vascular endothelial growth factor A Rattus norvegicus 57-61 31583245-7 2019 At 37 C, LSECs efficiently took up and degraded [125I]-VEGF-A for at least 2 hours. 2-iodotyrosine 49-53 vascular endothelial growth factor A Rattus norvegicus 55-61 31583245-8 2019 Uptake of [125I]-VEGF-A by LSECs was blocked by dynasore that inhibits dynamin-dependent internalization, whereas inhibition of cysteine proteases by leupeptin inhibited degradation without affecting the uptake of [125I]-VEGF-A, suggesting that it is degraded following transport to lysosomes. 2-iodotyrosine 10-16 vascular endothelial growth factor A Rattus norvegicus 17-23 31583245-8 2019 Uptake of [125I]-VEGF-A by LSECs was blocked by dynasore that inhibits dynamin-dependent internalization, whereas inhibition of cysteine proteases by leupeptin inhibited degradation without affecting the uptake of [125I]-VEGF-A, suggesting that it is degraded following transport to lysosomes. 2-iodotyrosine 10-16 vascular endothelial growth factor A Rattus norvegicus 221-227 31583245-8 2019 Uptake of [125I]-VEGF-A by LSECs was blocked by dynasore that inhibits dynamin-dependent internalization, whereas inhibition of cysteine proteases by leupeptin inhibited degradation without affecting the uptake of [125I]-VEGF-A, suggesting that it is degraded following transport to lysosomes. 2-iodotyrosine 214-220 vascular endothelial growth factor A Rattus norvegicus 17-23 31583245-10 2019 This possibility was supported by the observation that a hexapeptide that specifically blocks VEGF-A binding to VEGFR1 caused a marked reduction in the uptake of [125I]-VEGF-A, whereas a control peptide had no effect. phenylalanyl-glycyl-histidyl-statyl-alanyl-phenylalanine methyl ester 57-68 vascular endothelial growth factor A Rattus norvegicus 94-100 31583245-10 2019 This possibility was supported by the observation that a hexapeptide that specifically blocks VEGF-A binding to VEGFR1 caused a marked reduction in the uptake of [125I]-VEGF-A, whereas a control peptide had no effect. phenylalanyl-glycyl-histidyl-statyl-alanyl-phenylalanine methyl ester 57-68 vascular endothelial growth factor A Rattus norvegicus 169-175 31583245-10 2019 This possibility was supported by the observation that a hexapeptide that specifically blocks VEGF-A binding to VEGFR1 caused a marked reduction in the uptake of [125I]-VEGF-A, whereas a control peptide had no effect. 2-iodotyrosine 162-168 vascular endothelial growth factor A Rattus norvegicus 94-100 31583245-10 2019 This possibility was supported by the observation that a hexapeptide that specifically blocks VEGF-A binding to VEGFR1 caused a marked reduction in the uptake of [125I]-VEGF-A, whereas a control peptide had no effect. 2-iodotyrosine 162-168 vascular endothelial growth factor A Rattus norvegicus 169-175 31126777-12 2019 CONCLUSION: This study demonstrated that beeswax-olive oil-butter mixture impregnated bandage treatment in a second-degree burn rat model improved burn wound healing and encouraged skin renewal via modulating tissue TGF-beta1 and VEGF-alpha. Butter 59-65 vascular endothelial growth factor A Rattus norvegicus 230-240 30982154-6 2019 METHODS: Streptozotocin (STZ)-treated rats were intraperitoneally inoculated with either of two small molecule P2X7R receptor inhibitors, A740003 and AZ10606120, and after blood glucose levels increased to above 400 mg/dL, retinae were analyzed for P2X7R expression, vascular permeability, VEGF, and IL-6 expression. Streptozocin 9-23 vascular endothelial growth factor A Rattus norvegicus 290-294 30982154-7 2019 RESULTS: STZ administration caused a near fourfold increase in blood glucose, a large increase in retinal microvasculature permeability, as well as in retinal P2X7R, VEGF, and IL-6 expression. Streptozocin 9-12 vascular endothelial growth factor A Rattus norvegicus 166-170 31406128-11 2019 In this study, we found that animal oil-induced FE significantly increased pulmonary VEGF expression and MAPK phosphorylation. Oils 36-39 vascular endothelial growth factor A Rattus norvegicus 85-89 31034915-0 2019 Bis(propyl)-cognitin potentiates rehabilitation of treadmill exercise after a transient focal cerebral ischemia, possibly via inhibiting NMDA receptor and regulating VEGF expression. bis(propyl)cognitin 0-20 vascular endothelial growth factor A Rattus norvegicus 166-170 31034915-7 2019 Both bis(propyl)-cognitin and treadmill exercise significantly elevated brain VEGF expression and decreased brain infarct volume at 14 day post-ischemia. bis(propyl)cognitin 5-25 vascular endothelial growth factor A Rattus norvegicus 78-82 31034915-8 2019 Our study reveals that bis(propyl)-cognitin potentiated rehabilitation of treadmill exercise after ischemic stroke, possibly via regulating brain VEGF expression, indicating that the combination of NMDA receptor antagonists and exercise might be useful for stroke rehabilitation. bis(propyl)cognitin 23-43 vascular endothelial growth factor A Rattus norvegicus 146-150 31434198-10 2019 Linagliptin prevented abnormal proliferation and migration of rat brain microvascular endothelial cells in a state of hypoperfusion via SIRT1/HIF-1alpha/VEGF pathway. Linagliptin 0-11 vascular endothelial growth factor A Rattus norvegicus 153-157 31462015-9 2019 Anti-rat VEGF and CD31 antibody activity were the highest in the FxCL+lidocaine group. fxcl 65-69 vascular endothelial growth factor A Rattus norvegicus 9-13 31462015-9 2019 Anti-rat VEGF and CD31 antibody activity were the highest in the FxCL+lidocaine group. Lidocaine 70-79 vascular endothelial growth factor A Rattus norvegicus 9-13 31103824-9 2019 In the uterus, quercetin supplement to aspirin prevented the expression of VEGF and sFlt-1 mRNA. Quercetin 15-24 vascular endothelial growth factor A Rattus norvegicus 75-79 31103824-9 2019 In the uterus, quercetin supplement to aspirin prevented the expression of VEGF and sFlt-1 mRNA. Aspirin 39-46 vascular endothelial growth factor A Rattus norvegicus 75-79 31209145-9 2019 Pretreatment with nicotine reversed LPS-induced high levels of placental inflammatory cytokines, low levels of placental VEGF and placental pathological damage, then rescued the number and weights of live fetuses. Nicotine 18-26 vascular endothelial growth factor A Rattus norvegicus 121-125 30974486-1 2019 INTRODUCTION: Arteriolargenesis can be induced by concomitant stimulation of nitric Oxide (NO)-Angiopoietin receptor (Tie)-Vascular Endothelial Growth Factor (VEGF) signaling in the rat mesentery angiogenesis assay. Nitric Oxide 77-89 vascular endothelial growth factor A Rattus norvegicus 159-163 30701536-10 2019 Additionally, the treatment with Hcy in CMECs led to reduced viability, migration ability, tube formation, VEGF expression, SOD activity as well as increased cell apoptosis, MDA and ROS levels. Homocysteine 33-36 vascular endothelial growth factor A Rattus norvegicus 107-111 30701536-11 2019 The experimental results demonstrated that miR-128 mimics and IRS1 siRNA in rat CMECs promoted viability, migration ability, tube formation, VEGF expression, SOD activity, while repressing cell apoptosis, MDA and ROS levels. mir-128 43-50 vascular endothelial growth factor A Rattus norvegicus 141-145 31252288-6 2019 Naringenin ameliorated the expression of prognostic markers (TAK1, PAK1, VEGF and PCNA) involved in development and progression of endometriotic cells. naringenin 0-10 vascular endothelial growth factor A Rattus norvegicus 73-77 31006100-9 2019 The therapeutic effect of YYTNG may be due to the promotion of neurogenesis in the peri-infarct area and the upregulation of neuroprotective factors BDNF and VEGF in MCAO rats. yytng 26-31 vascular endothelial growth factor A Rattus norvegicus 158-162 30995434-3 2019 The principal objective of this study was to interrogate whether Substance P (SP), a constitutive neurotransmitter of amacrine and ganglion cells, may protect against N-methyl-d-aspartate (NMDA)-induced excitotoxic apoptosis of ganglion cells and VEGF-induced vessel leakage in the retina. N-Methylaspartate 189-193 vascular endothelial growth factor A Rattus norvegicus 247-251 30995112-0 2019 Functional effects of blocking VEGF/VEGFR2 signaling in the rat urinary bladder in acute and chronic CYP-induced cystitis. Cyclophosphamide 101-104 vascular endothelial growth factor A Rattus norvegicus 31-35 30970221-11 2019 Moreover, DSAP-MSC transplantation down-regulated the expression of IL-6 and IL-1beta and up-regulated the level of VEGF and HGF. dsap 10-14 vascular endothelial growth factor A Rattus norvegicus 116-120 31142603-9 2019 In cocultures, metformin-stimulated Ad-hMSCs inhibited the mRNA expression of RUNX2, COL X, VEGF, MMP1, MMP3, and MMP13 in IL-1beta-stimulated OA chondrocytes and increased the expression of TIMP1 and TIMP3. Metformin 15-24 vascular endothelial growth factor A Rattus norvegicus 92-96 30974023-0 2019 Chrysin ameliorates ANTU-induced pulmonary edema and pulmonary arterial hypertension via modulation of VEGF and eNOs. alpha-naphthyl thiourea 20-24 vascular endothelial growth factor A Rattus norvegicus 103-107 31280210-11 2019 The VEGF expression of TMZ+FIR group was significantly higher compared to the control group and the TMZ group at Day 28. Temozolomide 23-26 vascular endothelial growth factor A Rattus norvegicus 4-8 31280210-11 2019 The VEGF expression of TMZ+FIR group was significantly higher compared to the control group and the TMZ group at Day 28. Temozolomide 100-103 vascular endothelial growth factor A Rattus norvegicus 4-8 31280210-12 2019 CONCLUSION: FIR might increase the growth of glioma under TMZ treatment in rats possibly via increasing VEGF expression, but not HIF-1alpha expression. Temozolomide 58-61 vascular endothelial growth factor A Rattus norvegicus 104-108 30565680-7 2019 In control rats, genistein significantly enhanced expression of vascular endothelial growth factor (VEGF; p < 0.01), particularly in osteoblasts, and angiogenesis marker CD31 ( p < 0.001) in bone. Genistein 17-26 vascular endothelial growth factor A Rattus norvegicus 64-98 30565680-7 2019 In control rats, genistein significantly enhanced expression of vascular endothelial growth factor (VEGF; p < 0.01), particularly in osteoblasts, and angiogenesis marker CD31 ( p < 0.001) in bone. Genistein 17-26 vascular endothelial growth factor A Rattus norvegicus 100-104 30565680-8 2019 In MTX-treated rats, genistein suppressed MTX-induced apoptosis of BM SECs ( p < 0.001 vs MTX alone group) and tended to increase expression of CD31 and VEGF ( p < 0.05). Methotrexate 3-6 vascular endothelial growth factor A Rattus norvegicus 156-160 30565680-8 2019 In MTX-treated rats, genistein suppressed MTX-induced apoptosis of BM SECs ( p < 0.001 vs MTX alone group) and tended to increase expression of CD31 and VEGF ( p < 0.05). Genistein 21-30 vascular endothelial growth factor A Rattus norvegicus 156-160 30565680-11 2019 These data suggest that genistein can protect BM sinusoids during MTX therapy, which is associated, at least partially, with its indirect effect of promoting VEGF expression in osteoblasts and its direct effect of enhancing nitric oxide production in SECs. Genistein 24-33 vascular endothelial growth factor A Rattus norvegicus 158-162 31121197-12 2019 Islets from INGAP-PP-treated rats significantly increased GSIS, beta-cell mass, and mRNA levels of Bcl-2, Ngn-3, VEGF-A, VEGF-R2, CD31, Ang1 and Ang2, Laminin beta-1, and Integrin beta-1, and decreased mRNA levels of Caspase-8, Bad, and Bax. Ingap (104-118) 12-20 vascular endothelial growth factor A Rattus norvegicus 113-119 31121197-14 2019 CONCLUSION: Our results reinforce the concept that INGAP-PP enhances insulin secretion and beta-cell mass, acting through PI3K/Akt/mTOR pathways and simultaneously activating angiogenesis through HIF-1alpha-mediated VEGF-A secretion. Ingap (104-118) 51-59 vascular endothelial growth factor A Rattus norvegicus 216-222 30892121-4 2019 Cabergoline and clarithromycin significantly lowered VEGF-2 levels. Cabergoline 0-11 vascular endothelial growth factor A Rattus norvegicus 53-57 30892121-4 2019 Cabergoline and clarithromycin significantly lowered VEGF-2 levels. Clarithromycin 16-30 vascular endothelial growth factor A Rattus norvegicus 53-57 30892121-10 2019 Clarithromycin is known to suppress the production of some pro-inflammatory molecules such as VEGF, IL-8, IL-1, IL-6 and TNF-a. Clarithromycin 0-14 vascular endothelial growth factor A Rattus norvegicus 94-98 31251771-8 2019 Further, hypoxia mediated increase in HIF-1alpha was stabilized and VEGF levels in lungs were significantly down regulated by quercetin supplementation, leading to reduction in vascular leakage in lungs of rats under hypoxia. Quercetin 126-135 vascular endothelial growth factor A Rattus norvegicus 68-72 30817065-0 2019 Roxadustat promotes angiogenesis through HIF-1alpha/VEGF/VEGFR2 signaling and accelerates cutaneous wound healing in diabetic rats. roxadustat 0-10 vascular endothelial growth factor A Rattus norvegicus 52-56 30817065-8 2019 In conclusion, roxadustat promotes angiogenesis via activation of the HIF-1alpha/VEGF/VEGFR2 pathway and exhibits therapeutic effects on diabetic wound healing by increasing angiogenesis. roxadustat 15-25 vascular endothelial growth factor A Rattus norvegicus 81-85 31528026-8 2019 Conclusion: The findings showed that EBN could ameliorate the detrimental effects of LA toxicity on the uterus possibly by enhancing enzymatic antioxidant (SOD) activity as well as expressions of EGF, VEGF, and PCNA with cell proliferation roles. CHEMBL3344321 37-40 vascular endothelial growth factor A Rattus norvegicus 201-205 31308854-10 2019 RT-PCR and Western Blotting results showed that the mRNA and protein levels of VEGF, VEGFR-2, PI3K, and AKT in the model group were significantly decreased compared with the control group, while ligustrazine restored the changes. tetramethylpyrazine 195-207 vascular endothelial growth factor A Rattus norvegicus 79-83 31217757-11 2019 Additionally, posttreatment of sulforaphane inhibited levels of IL-6, IL-10, TNF-alpha, IFN-gamma, and VEGF in peritoneal fluid and plasma. sulforaphane 31-43 vascular endothelial growth factor A Rattus norvegicus 103-107 31217757-12 2019 Posttreatment of sulforaphane regulated the expressions of VEGF, bcl-2, Bax, and cleaved Caspase-3 in EM model. sulforaphane 17-29 vascular endothelial growth factor A Rattus norvegicus 59-63 30954486-0 2019 Uric acid treatment after stroke modulates the Kruppel-like factor 2-VEGF-A axis to protect brain endothelial cell functions: Impact of hypertension. Uric Acid 0-9 vascular endothelial growth factor A Rattus norvegicus 69-73 30968117-3 2019 We have isolated fully modified 2"-O-methyl-ribose-1,5-anhydrohexitol nucleic acid (MeORNA-HNA) aptamers targeting the rat vascular endothelial growth factor 164 (rVEGF164). 2"-o-methyl-ribose-1,5-anhydrohexitol nucleic acid 32-82 vascular endothelial growth factor A Rattus norvegicus 163-171 30968117-3 2019 We have isolated fully modified 2"-O-methyl-ribose-1,5-anhydrohexitol nucleic acid (MeORNA-HNA) aptamers targeting the rat vascular endothelial growth factor 164 (rVEGF164). meorna-hna 84-94 vascular endothelial growth factor A Rattus norvegicus 163-171 30943774-2 2019 Approach and Results- Pulmonary vascular disease was induced in Sprague-Dawley rats by exposure to a single injection of VEGFRII (vascular endothelial growth factor receptor II) antagonist SU5416 (Su) followed by hypoxia (Hx) plus normoxia (4 weeks each-HxSu model) and in WT (wild type; Tie2.Cre-; Cav1 lox/lox) and EC- Cav1-/- (Tie2.Cre+; Cav1 fl/fl) mice (Hx: 4 weeks). Semaxinib 189-195 vascular endothelial growth factor A Rattus norvegicus 121-128 30954486-2 2019 High concentrations of UA inhibit angiogenesis of cultured endothelial cells via Kruppel-like factor 2 (KLF)-induced downregulation of vascular endothelial growth factor (VEGF), a pro-angiogenic mediator that is able to increase blood-brain barrier (BBB) permeability in acute stroke. Uric Acid 23-25 vascular endothelial growth factor A Rattus norvegicus 135-169 30954486-2 2019 High concentrations of UA inhibit angiogenesis of cultured endothelial cells via Kruppel-like factor 2 (KLF)-induced downregulation of vascular endothelial growth factor (VEGF), a pro-angiogenic mediator that is able to increase blood-brain barrier (BBB) permeability in acute stroke. Uric Acid 23-25 vascular endothelial growth factor A Rattus norvegicus 171-175 30954486-3 2019 Here, we investigated whether UA treatment after ischaemic stroke protects brain endothelial cell functions and modulates the KLF2-VEGF-A axis. Uric Acid 30-32 vascular endothelial growth factor A Rattus norvegicus 131-137 30954486-11 2019 UA treatment reduced infarct volume and Evans blue leakage in both rat strains, improved endothelial cell barrier integrity and KLF2 expression, and lowered VEGF-A levels in SHR rats. Uric Acid 0-2 vascular endothelial growth factor A Rattus norvegicus 157-163 30918132-0 2019 Curcumin Ameliorates Chronic Renal Failure in 5/6 Nephrectomized Rats by Regulation of the mTOR/HIF-1alpha/VEGF Signaling Pathway. Curcumin 0-8 vascular endothelial growth factor A Rattus norvegicus 107-111 30954486-14 2019 We conclude that UA treatment after ischaemic stroke upregulates KLF2, reduces VEGF-A signalling, and attenuates brain endothelial cell dysfunctions leading to neuroprotection. Uric Acid 17-19 vascular endothelial growth factor A Rattus norvegicus 79-85 30918132-2 2019 Therefore, the aim of the present study was to investigate the therapeutic effects of curcumin against chronic renal failure (CRF) in a rat model induced by 5/6 nephrectomy through inhibition of mTOR/HIF-1alpha/VEGF signaling. Curcumin 86-94 vascular endothelial growth factor A Rattus norvegicus 211-215 30413372-8 2019 GKT137831 reduced the production of H2O2, down regulated mesenteric angiogenesis markers (CD31, vascular endothelial growth factor (VEGF) and VEGFR-2 expression. setanaxib 0-9 vascular endothelial growth factor A Rattus norvegicus 96-130 30413372-8 2019 GKT137831 reduced the production of H2O2, down regulated mesenteric angiogenesis markers (CD31, vascular endothelial growth factor (VEGF) and VEGFR-2 expression. setanaxib 0-9 vascular endothelial growth factor A Rattus norvegicus 132-136 33330199-8 2019 Results: The TAS, TOS, OSI, iNOS, and VEGF values were significantly lower than the pre-treatment levels in rats receiving exogenous melatonin treatment (3 or 6 weeks) (p<0.05). Melatonin 133-142 vascular endothelial growth factor A Rattus norvegicus 38-42 31126077-0 2019 Differential Expression of CD3, TNF-alpha, and VEGF Induced by Olanzapine on the Spleen of Adult Male Albino Rats and the Possible Protective Role of Vitamin C. Olanzapine 63-73 vascular endothelial growth factor A Rattus norvegicus 47-51 31164986-1 2019 Vandetanib and pazopanib are clinically available, multi-targeted inhibitors of vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor tyrosine kinases. vandetanib 0-10 vascular endothelial growth factor A Rattus norvegicus 80-114 31164986-1 2019 Vandetanib and pazopanib are clinically available, multi-targeted inhibitors of vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor tyrosine kinases. vandetanib 0-10 vascular endothelial growth factor A Rattus norvegicus 116-120 31164986-1 2019 Vandetanib and pazopanib are clinically available, multi-targeted inhibitors of vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor tyrosine kinases. pazopanib 15-24 vascular endothelial growth factor A Rattus norvegicus 80-114 31164986-1 2019 Vandetanib and pazopanib are clinically available, multi-targeted inhibitors of vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor tyrosine kinases. pazopanib 15-24 vascular endothelial growth factor A Rattus norvegicus 116-120 31178701-8 2019 In addition, it increased p38 MAPK phosphorylation and expressions of vascular endothelial growth factor (VEGF), laminin and endothelial nitric oxide synthase (eNOS), which were abrogated by SB202190, a p38 MAPK inhibitor. 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole 191-199 vascular endothelial growth factor A Rattus norvegicus 70-104 31178701-8 2019 In addition, it increased p38 MAPK phosphorylation and expressions of vascular endothelial growth factor (VEGF), laminin and endothelial nitric oxide synthase (eNOS), which were abrogated by SB202190, a p38 MAPK inhibitor. 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole 191-199 vascular endothelial growth factor A Rattus norvegicus 106-110 31126077-8 2019 The administration of vitamin C repaired structural and immunohistochemical changes via increased CD3 and decreased TNF-alpha and VEGF. Ascorbic Acid 22-31 vascular endothelial growth factor A Rattus norvegicus 130-134 31137143-8 2019 Conclusion: Androgen replacement therapy with testosterone undecanoate can improve the erectile function of castrated rats by protecting the integrity of endothelial cells through AR/VEGF pathway. testosterone undecanoate 46-70 vascular endothelial growth factor A Rattus norvegicus 183-187 31193586-5 2019 We hypothesized that astrocytes conditioned in high glucose media would produce and secrete decreased VEGF which would lead to impaired proliferation, migration, and tube formation of CMEC in vitro. Glucose 52-59 vascular endothelial growth factor A Rattus norvegicus 102-106 31156438-5 2019 We found that long-term DCA administration improved cognitive function in VD rats, reduced brain infarct size and brain atrophy, increased VEGF and bFGF levels in vivo, promoted angiogenesis in damaged areas, and significantly improved EPC function in VD rats. Dichloroacetic Acid 24-27 vascular endothelial growth factor A Rattus norvegicus 139-143 31096936-0 2019 Protective effects of hydrogen gas in a rat model of branch retinal vein occlusion via decreasing VEGF-alpha expression. Hydrogen 22-30 vascular endothelial growth factor A Rattus norvegicus 98-108 31096936-14 2019 CONCLUSIONS: Our findings demonstrate that inhalation of hydrogen gas could alleviate retinal oedema, shorten reopen time and improve retinal function, and the potential mechanism might be related to a decrease in VEGF-alpha expression. Hydrogen 57-65 vascular endothelial growth factor A Rattus norvegicus 214-224 30912953-9 2019 In diabetic rats, Feno-NP ameliorated retinal dysfunctions, reduced retinal vascular leakage, inhibited retinal leukostasis, and downregulated the overexpression of VEGF and ICAM-1 at 8 weeks after one IVT injection. feno-np 18-25 vascular endothelial growth factor A Rattus norvegicus 165-169 30945836-6 2019 Additionally, the secretion of angiogenic VEGF and osteogenic BMP-2 proteins is increased, which may be attributed to the synergistic effects of GO and Sr on the activation of the MAPK signaling pathway. Strontium 152-154 vascular endothelial growth factor A Rattus norvegicus 42-46 30910851-6 2019 To further explore the pharmacological activities of harmine, we tested harmine"s influence on blood vessel formation and found that harmine effectively blocked the microvessel sprouting in rat aortic ring assay when stimulated by vascular endothelial growth factor (VEGF). Harmine 53-60 vascular endothelial growth factor A Rattus norvegicus 231-265 30910851-6 2019 To further explore the pharmacological activities of harmine, we tested harmine"s influence on blood vessel formation and found that harmine effectively blocked the microvessel sprouting in rat aortic ring assay when stimulated by vascular endothelial growth factor (VEGF). Harmine 72-79 vascular endothelial growth factor A Rattus norvegicus 231-265 30910851-6 2019 To further explore the pharmacological activities of harmine, we tested harmine"s influence on blood vessel formation and found that harmine effectively blocked the microvessel sprouting in rat aortic ring assay when stimulated by vascular endothelial growth factor (VEGF). Harmine 72-79 vascular endothelial growth factor A Rattus norvegicus 231-265 30988781-10 2019 In conclusion, triptolide may exert its effects against RA via the PI3K/AKT pathway and has an inhibitory effect on the expression of VEGFA and C1QTNF3, thus are potentially associated with the occurrence and development of RA. triptolide 15-25 vascular endothelial growth factor A Rattus norvegicus 134-139 30897537-8 2019 Moreover, the expression of VEGF and CD34 in the earlier stage of CCH and the diameters of bilateral vertebral arteries (VAs), were significantly enlarged by DNB treatment. 1-acetyl-2-(coumariniminecarboxamide-3-yl)hydrazine 66-69 vascular endothelial growth factor A Rattus norvegicus 28-32 30897537-8 2019 Moreover, the expression of VEGF and CD34 in the earlier stage of CCH and the diameters of bilateral vertebral arteries (VAs), were significantly enlarged by DNB treatment. 3-n-butylphthalide 158-161 vascular endothelial growth factor A Rattus norvegicus 28-32 31173327-11 2019 The relative expression of Vascular Endothelial Growth Factor (VEGF) in the propranolol group was significantly higher than that in the control group on the 2nd day (p<0.05), while the relative expression of VEGF in the propranolol group was significantly increased on the 11th day after modeling (p<0.05). Propranolol 76-87 vascular endothelial growth factor A Rattus norvegicus 27-61 31173327-11 2019 The relative expression of Vascular Endothelial Growth Factor (VEGF) in the propranolol group was significantly higher than that in the control group on the 2nd day (p<0.05), while the relative expression of VEGF in the propranolol group was significantly increased on the 11th day after modeling (p<0.05). Propranolol 76-87 vascular endothelial growth factor A Rattus norvegicus 63-67 31173327-11 2019 The relative expression of Vascular Endothelial Growth Factor (VEGF) in the propranolol group was significantly higher than that in the control group on the 2nd day (p<0.05), while the relative expression of VEGF in the propranolol group was significantly increased on the 11th day after modeling (p<0.05). Propranolol 76-87 vascular endothelial growth factor A Rattus norvegicus 208-212 31173327-11 2019 The relative expression of Vascular Endothelial Growth Factor (VEGF) in the propranolol group was significantly higher than that in the control group on the 2nd day (p<0.05), while the relative expression of VEGF in the propranolol group was significantly increased on the 11th day after modeling (p<0.05). Propranolol 220-231 vascular endothelial growth factor A Rattus norvegicus 27-61 31173327-11 2019 The relative expression of Vascular Endothelial Growth Factor (VEGF) in the propranolol group was significantly higher than that in the control group on the 2nd day (p<0.05), while the relative expression of VEGF in the propranolol group was significantly increased on the 11th day after modeling (p<0.05). Propranolol 220-231 vascular endothelial growth factor A Rattus norvegicus 208-212 31173327-14 2019 CONCLUSIONS: The results indicated that propranolol can accelerate the healing of diabetic wounds by regulating the expression of VEGF by phosphorylation of ERK1/2 protein, thus promoting chronic wound healing in diabetes. Propranolol 40-51 vascular endothelial growth factor A Rattus norvegicus 130-134 31118578-8 2019 The expressions of angiogenesis-related protein VEGF increased in the TMP treatment group than in the control group. tetramethylpyrazine 70-73 vascular endothelial growth factor A Rattus norvegicus 48-52 31068814-0 2019 Controlled in vivo Bone Formation and Vascularization Using Ultrasound-Triggered Release of Recombinant Vascular Endothelial Growth Factor From Poly(D,L-lactic-co-glycolicacid) Microbubbles. Polylactic Acid-Polyglycolic Acid Copolymer 144-175 vascular endothelial growth factor A Rattus norvegicus 104-138 30855407-0 2019 Ligustilide Ameliorates the Permeability of the Blood-Brain Barrier Model In Vitro During Oxygen-Glucose Deprivation Injury Through HIF/VEGF Pathway. ligustilide 0-11 vascular endothelial growth factor A Rattus norvegicus 136-140 31055890-9 2019 Plasma VEGF level was significantly higher in the physiological saline treatment group compared to the OT treatment group. Sodium Chloride 64-70 vascular endothelial growth factor A Rattus norvegicus 7-11 31028241-0 2019 Effects of Sevoflurane Pretreatment on Myocardial Ischemia-Reperfusion Injury Through the Akt/Hypoxia-Inducible Factor 1-alpha (HIF-1alpha)/Vascular Endothelial Growth Factor (VEGF) Signaling Pathway. Sevoflurane 11-22 vascular endothelial growth factor A Rattus norvegicus 176-180 31060148-3 2019 The mechanism of mucosal injury included free radical injury induced by aspirin and decreased synthesis of vascular endothelial growth factor (VEGF) by clopidogrel. Clopidogrel 152-163 vascular endothelial growth factor A Rattus norvegicus 107-141 31060148-3 2019 The mechanism of mucosal injury included free radical injury induced by aspirin and decreased synthesis of vascular endothelial growth factor (VEGF) by clopidogrel. Clopidogrel 152-163 vascular endothelial growth factor A Rattus norvegicus 143-147 31060148-4 2019 Teprenone may repair intestinal mucosa via boosting VEGF level. geranylgeranylacetone 0-9 vascular endothelial growth factor A Rattus norvegicus 52-56 31068814-7 2019 The results demonstrated that the expression of osteogenesis-related genes and calcium deposits were increased by VEGF MBs in combination of UTMD. Calcium 79-86 vascular endothelial growth factor A Rattus norvegicus 114-118 31193299-5 2019 Both mono delivery of BMP2 and the combined delivery of a lower ratio of VEGFA and BMP2 (1:4) led to up-regulation of osteogenic genes (Alpl and Runx2) and increased calcium deposition in vitro, compared with the GFP control. Calcium 166-173 vascular endothelial growth factor A Rattus norvegicus 73-78 30503749-5 2019 In an in vivo study, resveratrol significantly recovered the insulin level and PON1 expression and activity, as well as clearly reduced the retinal vascular permeability, retinal AGEs, LDL, Ox-LDL, caspase3 activity, retinal damage, IL-1beta, IL-6, TNFalpha, VEGF, IFNgamma and MCP-1 in STZ-diabetic rats. Resveratrol 21-32 vascular endothelial growth factor A Rattus norvegicus 259-263 31024240-10 2019 However, cyclopamine, the specific inhibitor of the Sonic hedgehog (Shh) signaling pathway, decreased the expression levels of VEGF and CD34, and counteracted the protective effects of ISO post-conditioning against I/R injury in rats. cyclopamine 9-20 vascular endothelial growth factor A Rattus norvegicus 127-131 31040646-11 2019 Conclusion: According to these results, celecoxib significantly decreased VEGF, IL-2, and ET-1 levels as much as cabergoline and could reduce the extent of OHSS development. Celecoxib 40-49 vascular endothelial growth factor A Rattus norvegicus 74-78 30936964-4 2019 In the present study, a streptozotocin (STZ)-induced diabetic rat model was constructed and the expression of microRNA (miR)-204-5p and vascular endothelial growth factor (VEGF) were determined. Streptozocin 40-43 vascular endothelial growth factor A Rattus norvegicus 136-170 30906439-0 2019 Angiogenic function of astragaloside IV in rats with myocardial infarction occurs via the PKD1-HDAC5-VEGF pathway. astragaloside 23-36 vascular endothelial growth factor A Rattus norvegicus 101-105 30906439-9 2019 The expression of PKD1, HDAC5 and VEGF mRNA and protein in myocardial tissue of model group and CID755673 inhibitor group were significantly lower than the other four groups (P<0.05), whereas these levels in the AS-IV group were significantly higher than those in the other five groups (P<0.01). CID755673 96-105 vascular endothelial growth factor A Rattus norvegicus 34-38 30936964-4 2019 In the present study, a streptozotocin (STZ)-induced diabetic rat model was constructed and the expression of microRNA (miR)-204-5p and vascular endothelial growth factor (VEGF) were determined. Streptozocin 40-43 vascular endothelial growth factor A Rattus norvegicus 172-176 30676864-0 2019 Modulation of cardiac vascular endothelial growth factor and PGC-1alpha with regular postexercise cold-water immersion of rats. Water 103-108 vascular endothelial growth factor A Rattus norvegicus 22-56 30973576-8 2019 In addition, H/R-induced hypoxia-inducible factor 1alpha (HIF1alpha) levels were decreased by olaparib, which possibly contributed to reduced VEGF expression. r 15-16 vascular endothelial growth factor A Rattus norvegicus 142-146 30973576-8 2019 In addition, H/R-induced hypoxia-inducible factor 1alpha (HIF1alpha) levels were decreased by olaparib, which possibly contributed to reduced VEGF expression. olaparib 94-102 vascular endothelial growth factor A Rattus norvegicus 142-146 30973576-12 2019 The protective mechanisms of olaparib most probably involved Nrf2 activation and ROS reduction, as well as normalization of HIF1alpha and related VEGF expression. olaparib 29-37 vascular endothelial growth factor A Rattus norvegicus 146-150 30676864-14 2019 NEW & NOTEWORTHY A regular postexercise cold-water immersion for 10 wk of endurance training augmented the myocardial mitochondrial biogenesis and vascular angiogenesis coactivators peroxisome proliferator-activated receptor gamma coactivator-1alpha and vascular endothelial growth factor, respectively. Water 49-54 vascular endothelial growth factor A Rattus norvegicus 258-292 30678950-3 2019 In this work, we encapsulated vascular endothelial growth factor (VEGF) into polycaprolactone (PCL) nanoparticles. polycaprolactone 77-93 vascular endothelial growth factor A Rattus norvegicus 30-64 30678950-3 2019 In this work, we encapsulated vascular endothelial growth factor (VEGF) into polycaprolactone (PCL) nanoparticles. polycaprolactone 77-93 vascular endothelial growth factor A Rattus norvegicus 66-70 30678950-3 2019 In this work, we encapsulated vascular endothelial growth factor (VEGF) into polycaprolactone (PCL) nanoparticles. polycaprolactone 95-98 vascular endothelial growth factor A Rattus norvegicus 30-64 30678950-3 2019 In this work, we encapsulated vascular endothelial growth factor (VEGF) into polycaprolactone (PCL) nanoparticles. polycaprolactone 95-98 vascular endothelial growth factor A Rattus norvegicus 66-70 30678950-5 2019 The encapsulation efficiency of the PCL nanoparticles for VEGF was up to 82%, and the in vitro accumulated release rate was slow without an evident initial burst release. polycaprolactone 36-39 vascular endothelial growth factor A Rattus norvegicus 58-62 31090331-4 2019 Through the study of network pharmacology,12 components of aspirin and Trichosanthis Fructus,including hydroxygenkwanin,quercetin and adenosine,were found to show the anti-platelet aggregation and anti-thrombosis mechanisms through9 common protein targets,such as SRC,RAC1,MAPK14,MAPK1,AKT1,and 14 common signaling pathways,such as VEGF signaling pathway. Aspirin 59-66 vascular endothelial growth factor A Rattus norvegicus 332-336 30759452-9 2019 Expression of MIF was unaffected by ISO-92; however, ISO-92 increased p-eNOS and VEGF activities and reduced arginase 1, 2 and Sflt-1. iso 53-56 vascular endothelial growth factor A Rattus norvegicus 81-85 31090331-4 2019 Through the study of network pharmacology,12 components of aspirin and Trichosanthis Fructus,including hydroxygenkwanin,quercetin and adenosine,were found to show the anti-platelet aggregation and anti-thrombosis mechanisms through9 common protein targets,such as SRC,RAC1,MAPK14,MAPK1,AKT1,and 14 common signaling pathways,such as VEGF signaling pathway. Quercetin 120-129 vascular endothelial growth factor A Rattus norvegicus 332-336 31090331-4 2019 Through the study of network pharmacology,12 components of aspirin and Trichosanthis Fructus,including hydroxygenkwanin,quercetin and adenosine,were found to show the anti-platelet aggregation and anti-thrombosis mechanisms through9 common protein targets,such as SRC,RAC1,MAPK14,MAPK1,AKT1,and 14 common signaling pathways,such as VEGF signaling pathway. Adenosine 134-143 vascular endothelial growth factor A Rattus norvegicus 332-336 31090331-5 2019 After the intervention with Trichosanthis Fructus pellets combined with aspirin pellets,the vascular endothslia growth factor(VEGF) signaling pathway can be activated to inhibit platelet aggregation and improve vascular endothelial function,and show the anti-platelet aggregation and anti-thrombosis mechanisms,which verify the results of the network pharmacology,and explain the anti-platelet aggregation and anti-thrombotic mechanisms of the combination of Trichosanthis Fructus pellets with aspirin pellets. Aspirin 72-79 vascular endothelial growth factor A Rattus norvegicus 126-130 31090331-5 2019 After the intervention with Trichosanthis Fructus pellets combined with aspirin pellets,the vascular endothslia growth factor(VEGF) signaling pathway can be activated to inhibit platelet aggregation and improve vascular endothelial function,and show the anti-platelet aggregation and anti-thrombosis mechanisms,which verify the results of the network pharmacology,and explain the anti-platelet aggregation and anti-thrombotic mechanisms of the combination of Trichosanthis Fructus pellets with aspirin pellets. Aspirin 494-501 vascular endothelial growth factor A Rattus norvegicus 126-130 30864638-0 2019 Is the effect of melatonin on vascular endothelial growth factor receptor-2 associated with angiogenesis in the rat ovary? Melatonin 17-26 vascular endothelial growth factor A Rattus norvegicus 30-64 30760661-8 2019 VEGF expression was significantly increased in the iloprost/PLGA microsphere group relative to the other groups. Iloprost 51-59 vascular endothelial growth factor A Rattus norvegicus 0-4 30864638-6 2019 The effects of melatonin on the expression of VEGF, VEGFR1 and VEGFR2 were established by immunohistochemistry analysis. Melatonin 15-24 vascular endothelial growth factor A Rattus norvegicus 46-50 30864638-9 2019 Our data indicate that melatonin treatment can significantly increase VEGF and VEGFR1 expression in the ovary ( p <0.05). Melatonin 23-32 vascular endothelial growth factor A Rattus norvegicus 70-74 30942155-3 2019 However, the expression of VEGF is inhibited by decreases in oxygen content, which is different from what obtains in Sprague Dawley (SD)rats. Oxygen 61-67 vascular endothelial growth factor A Rattus norvegicus 27-31 30864638-3 2019 We investigated the influence of melatonin on the expression of VEGF, vascular endothelial growth factor receptor-1 (VEGFR1) and vascular endothelial growth factor receptor-2 (VEGFR2), as well as on changes in oxidative stress markers and follicle numbers in rat ovaries. Melatonin 33-42 vascular endothelial growth factor A Rattus norvegicus 64-68 30837602-0 2019 4-Hexylresorcinol and silk sericin increase the expression of vascular endothelial growth factor via different pathways. Hexylresorcinol 0-17 vascular endothelial growth factor A Rattus norvegicus 62-96 30136405-9 2019 Treatment with DPP-4 inhibitors counteracted the attenuating effects of hypoxic/high-glucose conditions on the expression of VEGF, eNOS, HIF-1alpha, and SIRT1, which can be completely eliminated by the inhibition of SIRT1 with 1 mmol/L nicotinamide. Glucose 85-92 vascular endothelial growth factor A Rattus norvegicus 125-129 30136405-9 2019 Treatment with DPP-4 inhibitors counteracted the attenuating effects of hypoxic/high-glucose conditions on the expression of VEGF, eNOS, HIF-1alpha, and SIRT1, which can be completely eliminated by the inhibition of SIRT1 with 1 mmol/L nicotinamide. Niacinamide 236-248 vascular endothelial growth factor A Rattus norvegicus 125-129 30136405-10 2019 CONCLUSIONS: The protection of rBMVECs from hypoxia/high-glucose induced impairment by DPP-4 inhibitors may be mediated by the SIRT1/HIF-1alpha/VEGF pathway. Glucose 57-64 vascular endothelial growth factor A Rattus norvegicus 144-148 30964182-0 2019 MiRNA-210 induces the apoptosis of neuronal cells of rats with cerebral ischemia through activating HIF-1alpha-VEGF pathway. mirna-210 0-9 vascular endothelial growth factor A Rattus norvegicus 111-115 30520953-3 2019 Objective: To assess whether polysaccharide-based scaffold (PS) constructs that are cross-linked with smoothened agonist (SAG), vascular endothelial growth factor (VEGF), and bone morphogenetic protein 6 (BMP-6) would substantially increase bone regeneration. Polysaccharides 29-43 vascular endothelial growth factor A Rattus norvegicus 128-162 30553875-8 2019 After four weeks, cytokines associated with chronic intestinal inflammation (fractalkine, IP-10, leptin, LIX, MIP-2, RANTES and VEGF) were increased in rats fed with HM-SM compared to C-SM. hm-sm 166-171 vascular endothelial growth factor A Rattus norvegicus 128-132 30478742-4 2019 In addition, the transcutaneous CO2 attenuated a decrease in capillary and the expression level of eNOS and VEGF protein, and an increase in the expression level of MDM-2 and TSP-1 protein of soleus muscle due to STZ-induced hyperglycemia. Carbon Dioxide 32-35 vascular endothelial growth factor A Rattus norvegicus 108-112 30653813-9 2019 Results Control-Dabi rats showed significantly higher high-sensitivity C-reactive protein, von Willebrand factor (VWF), vascular endothelial growth factor (VEGF) and fibronectin levels, and significantly lower PAR4 agonist-induced aggregation, than Control rats. DABI 16-20 vascular endothelial growth factor A Rattus norvegicus 120-154 30653813-9 2019 Results Control-Dabi rats showed significantly higher high-sensitivity C-reactive protein, von Willebrand factor (VWF), vascular endothelial growth factor (VEGF) and fibronectin levels, and significantly lower PAR4 agonist-induced aggregation, than Control rats. DABI 16-20 vascular endothelial growth factor A Rattus norvegicus 156-160 30653813-11 2019 Diabetes-Dabi rats showed significantly higher VWF, VEGF and fibronectin levels than Diabetes rats, and similar PAR4 agonist-induced aggregation as Diabetes rats, and significantly higher ADP-induced aggregation than Diabetes rats. DABI 9-13 vascular endothelial growth factor A Rattus norvegicus 52-56 30844729-7 2019 Upregualtion of VEGF expression and secretion by C1q was also observed in RBMECs, HBMECs and in IBZ in pMCAO rats. Procarbazine 96-99 vascular endothelial growth factor A Rattus norvegicus 16-20 30605790-11 2019 In conclusion, findings of this study revealed that EBN enhances fertility and embryo implantation rate via promoting proliferation and differentiation of uterine structures as evidenced by the upregulation of the expressions of steroid receptors, EGF, EGFR, VEGF, and PCNA in the uterus. CHEMBL3344321 52-55 vascular endothelial growth factor A Rattus norvegicus 259-263 30662833-8 2019 VEGF, ICAM-1 and MMP2 induced by HG were also suppressed by 5-aza-dC treatment. Azacitidine 60-65 vascular endothelial growth factor A Rattus norvegicus 0-4 30530044-10 2019 In the MCAO + ISO group, the neurological deficit score, infarct volumes and neuron apoptosis reduced significantly, the expression levels of Wnt3a, beta-catenin, VEGF and Cyclin D1 increased, while the expression level of GSK-3beta and Caspase 3 decreased relative to MCAO group. Isoproterenol 14-17 vascular endothelial growth factor A Rattus norvegicus 163-167 29621956-5 2019 Our ovariectomy studies show that Vegf164, Vegf188, and Vegf120 are significantly decreased by estrogen, and, to a lesser extent progesterone, when compared to control animals. Progesterone 129-141 vascular endothelial growth factor A Rattus norvegicus 34-41 30547177-6 2019 Furthermore, the expression levels of VEGF and inflammation-related iNOS, IL-6, IL-1beta, and TNF-alpha were significantly down-regulated in the ginsenoside Rf groups in a dose-dependent manner. ginsenoside Rf 145-159 vascular endothelial growth factor A Rattus norvegicus 38-42 30683144-16 2019 hAD-MSC-CM injection improved the local microenvironment of POI ovaries, leading to a decrease in Bax expression and an increase in Bcl-2 and endogenous VEGF expression in ovarian cells, which inhibited chemotherapy-induced GC apoptosis, promoted angiogenesis and regulated follicular development, thus partly reducing ovarian injury and improving ovarian function in rats with POI. Curium 8-10 vascular endothelial growth factor A Rattus norvegicus 153-157 30705637-12 2018 VA increased the concentration of CEPCs and VEGF in serum, CD133 content and microvessel density (MVD), and protected the morphology of microvascular endothelial cells in the marginal area of MI at 7 days post-MI surgery. Vanillic Acid 0-2 vascular endothelial growth factor A Rattus norvegicus 44-48 30652694-8 2019 RESULTS The rat model of ROP showed increased serum levels of VEGF, VEGFR-1, and VEGFR-2 compared with the control group, which were decreased in the DAPT group. dapt 150-154 vascular endothelial growth factor A Rattus norvegicus 62-66 30652694-11 2019 CONCLUSIONS In a rat model, treatment with DAPT reduced the retinal changes associated with ROP with a mechanism that involved VEGF and its receptors through the DLL4/Notch-1 pathway. dapt 43-47 vascular endothelial growth factor A Rattus norvegicus 127-131 30787995-6 2019 In addition, Rev upregulated the expression of MMP9, VEGF, and Cadherin5, indicating that Rev promotes angiogenesis in ischemic flaps. Resveratrol 13-16 vascular endothelial growth factor A Rattus norvegicus 53-57 30625210-11 2019 At week 8, a general reduction of VEGF expression was noted, remaining higher in F1 (Med:35.1; Q1.30.6; Q3.39.6%area) and LLLT&F1 (Med:18.5; Q1:16; Q3:25%area). Adenosine Monophosphate 127-130 vascular endothelial growth factor A Rattus norvegicus 34-38 30687018-7 2018 Pharmacological inhibition of VEGF signaling by oral application of a tyrosine kinase inhibitor (Vandetanib) prevented the recovery of spatial and visual memory in animals housed in EE, along with an increase in apoptosis and a reduction in neurogenesis. vandetanib 97-107 vascular endothelial growth factor A Rattus norvegicus 30-34 31078441-12 2019 CONCLUSION: Folic acid ameliorated the adverse effects of homocysteine in the cirrhotic rats, which may be related to down-regulation of the VEGF-NO signaling pathway. Folic Acid 12-22 vascular endothelial growth factor A Rattus norvegicus 141-145 31078441-12 2019 CONCLUSION: Folic acid ameliorated the adverse effects of homocysteine in the cirrhotic rats, which may be related to down-regulation of the VEGF-NO signaling pathway. Homocysteine 58-70 vascular endothelial growth factor A Rattus norvegicus 141-145 30342306-8 2019 Compared to other groups, the phenytoin group demonstrated increased expression of COL-1, VEGF-A, osteoblast and osteoclast markers (BMP-2, TGF-beta1, OCN and TRAP staining), as well as decreased expression of MMP-8. Phenytoin 30-39 vascular endothelial growth factor A Rattus norvegicus 90-96 30782069-5 2019 VEGF stimulation significantly promoted cell proliferation and migration of HUVECs, knockdown of MIAT dramatically reversed the effects of VEGF, while cells co-transfected with miR-1246 inhibitor obviously abolished the effect of VEGF+si-MIAT, however, enalaprilat abolished the effects of VEGF+si-MIAT+miR-1246 inhibitor. mir-1246 177-185 vascular endothelial growth factor A Rattus norvegicus 0-4 30399593-10 2019 Immunohistochemical assay supported the findings that Cinnamaldehyde+beta-TCP enhanced expression of OCN, VEGF and CD31. cinnamaldehyde 54-68 vascular endothelial growth factor A Rattus norvegicus 106-110 30399593-10 2019 Immunohistochemical assay supported the findings that Cinnamaldehyde+beta-TCP enhanced expression of OCN, VEGF and CD31. beta-tricalcium phosphate 69-77 vascular endothelial growth factor A Rattus norvegicus 106-110 29931049-0 2019 Vascular endothelial growth factor regulation of endothelial nitric oxide synthase phosphorylation is involved in isoflurane cardiac preconditioning. Isoflurane 114-124 vascular endothelial growth factor A Rattus norvegicus 0-34 29931049-3 2019 Therefore, this study examined the role of vascular endothelial growth factor (VEGF) in isoflurane cardiac preconditioning. Isoflurane 88-98 vascular endothelial growth factor A Rattus norvegicus 43-77 29931049-3 2019 Therefore, this study examined the role of vascular endothelial growth factor (VEGF) in isoflurane cardiac preconditioning. Isoflurane 88-98 vascular endothelial growth factor A Rattus norvegicus 79-83 29931049-6 2019 The beneficial effects of isoflurane were blocked by neutralizing antibody against VEGF (nVEGF). Isoflurane 26-36 vascular endothelial growth factor A Rattus norvegicus 83-87 29931049-10 2019 The protective effect of isoflurane on CMs was compromised by nVEGF and after VEGF in ECs was inhibited with hypoxia inducible factor-1alpha short hairpin RNA (shRNA). Isoflurane 25-35 vascular endothelial growth factor A Rattus norvegicus 63-67 29931049-12 2019 Conclusion: Isoflurane cardiac preconditioning is associated with VEGF regulation of phosphorylation of eNOS and nitric oxide production. Isoflurane 12-22 vascular endothelial growth factor A Rattus norvegicus 66-70 29931049-12 2019 Conclusion: Isoflurane cardiac preconditioning is associated with VEGF regulation of phosphorylation of eNOS and nitric oxide production. Nitric Oxide 113-125 vascular endothelial growth factor A Rattus norvegicus 66-70 30782069-5 2019 VEGF stimulation significantly promoted cell proliferation and migration of HUVECs, knockdown of MIAT dramatically reversed the effects of VEGF, while cells co-transfected with miR-1246 inhibitor obviously abolished the effect of VEGF+si-MIAT, however, enalaprilat abolished the effects of VEGF+si-MIAT+miR-1246 inhibitor. Enalaprilat 253-264 vascular endothelial growth factor A Rattus norvegicus 0-4 30782069-5 2019 VEGF stimulation significantly promoted cell proliferation and migration of HUVECs, knockdown of MIAT dramatically reversed the effects of VEGF, while cells co-transfected with miR-1246 inhibitor obviously abolished the effect of VEGF+si-MIAT, however, enalaprilat abolished the effects of VEGF+si-MIAT+miR-1246 inhibitor. mir-1246 303-311 vascular endothelial growth factor A Rattus norvegicus 0-4 30291853-13 2019 Co-culture increased VEGF mRNA in both B10 and HMO6. hmo6 47-51 vascular endothelial growth factor A Rattus norvegicus 21-25 30423403-6 2019 DEN-induced rats exhibited increased gene expression of NF-kappaB, COX-2, CYP2E1, VEGF, Bcl-2, PI3K/AKT/mTOR and significantly decreased the gene expression of p53, Bax, caspase-9 and caspase-3. Diethylnitrosamine 0-3 vascular endothelial growth factor A Rattus norvegicus 82-86 30483728-5 2019 Furthermore, significant stimulation in the expression level of collagen-1 and the signaling pathway of VEGF after topical application of BSLB was indicated. bslb 138-142 vascular endothelial growth factor A Rattus norvegicus 104-108 30536359-2 2019 The negative effects of formaldehyde were described using vascular endothelial growth factor (VEGF), matrix metallopeptidase 2 (MMP-2) and osteonectin antibodies involved in the extracellular matrix and angiogenetic development. Formaldehyde 24-36 vascular endothelial growth factor A Rattus norvegicus 58-92 30536359-10 2019 Interestingly, VEGF expression in the formaldehyde group was the most significant finding between the two groups (p < 0.001). Formaldehyde 38-50 vascular endothelial growth factor A Rattus norvegicus 15-19 30835336-0 2019 Expression of VEGF and GFAP in a rat model of traumatic brain injury treated with Honokiol: a biochemical and immunohistochemical study. honokiol 82-90 vascular endothelial growth factor A Rattus norvegicus 14-18 30835336-9 2019 In TBI + Honokiol group, vascular endothelial growth factor (VEGF) expression was positive in the endothelial and few inflammatory cells of the mildly dilated blood vessels. honokiol 9-17 vascular endothelial growth factor A Rattus norvegicus 25-59 30835336-9 2019 In TBI + Honokiol group, vascular endothelial growth factor (VEGF) expression was positive in the endothelial and few inflammatory cells of the mildly dilated blood vessels. honokiol 9-17 vascular endothelial growth factor A Rattus norvegicus 61-65 30043157-0 2019 Sustained delivery of vascular endothelial growth factor using a dextran/poly(lactic-co-glycolic acid)-combined microsphere system for therapeutic neovascularization. Dextrans 65-72 vascular endothelial growth factor A Rattus norvegicus 22-56 30043157-0 2019 Sustained delivery of vascular endothelial growth factor using a dextran/poly(lactic-co-glycolic acid)-combined microsphere system for therapeutic neovascularization. Polylactic Acid-Polyglycolic Acid Copolymer 73-102 vascular endothelial growth factor A Rattus norvegicus 22-56 30043157-2 2019 VEGF-loaded dextran microparticles were fabricated and then encapsulated into poly(lactic-co-glycolic acid) (PLGA) microspheres to prepare VEGF-dextran-PLGA microspheres. Dextrans 12-19 vascular endothelial growth factor A Rattus norvegicus 0-4 30043157-2 2019 VEGF-loaded dextran microparticles were fabricated and then encapsulated into poly(lactic-co-glycolic acid) (PLGA) microspheres to prepare VEGF-dextran-PLGA microspheres. Polylactic Acid-Polyglycolic Acid Copolymer 78-107 vascular endothelial growth factor A Rattus norvegicus 0-4 30662514-10 2018 GZFLC treatment significantly decreased the GLUT-4 and VEGF mRNA expression levels in the endometriotic tissues of the endometriosis rats (P < 0.05). gzflc 0-5 vascular endothelial growth factor A Rattus norvegicus 55-59 30142307-7 2019 Simultaneous inhibition of VEGF, PDGF, and FGF receptor signaling by BIBF1000 prevents and reverses the progression of severe pulmonary arterial hypertension and vascular remodeling in this experimental model. BIBF 1000 69-77 vascular endothelial growth factor A Rattus norvegicus 27-31 30474364-3 2018 Serum lycopene concentration was negatively correlated with the levels of serum TC, TG, LDL-C, as well as the cerebral LDL-C, VEGF, and VCAM-1. Lycopene 6-14 vascular endothelial growth factor A Rattus norvegicus 126-130 30687543-8 2018 Moreover expressions of inducible nitric oxide synthtase (iNOS), vascular endothelial growth factor (VEGF), p53 and nuclear receptor factor-2 (Nrf2) in the brain tissue attenuated by fangchinoline treated group. fangchinoline 183-196 vascular endothelial growth factor A Rattus norvegicus 65-99 30687543-8 2018 Moreover expressions of inducible nitric oxide synthtase (iNOS), vascular endothelial growth factor (VEGF), p53 and nuclear receptor factor-2 (Nrf2) in the brain tissue attenuated by fangchinoline treated group. fangchinoline 183-196 vascular endothelial growth factor A Rattus norvegicus 101-105 30539852-0 2018 Evaluation of the effect of hesperidin on vascular endothelial growth factor gene expression in rat skin animal models following cobalt-60 gamma irradiation. Hesperidin 28-38 vascular endothelial growth factor A Rattus norvegicus 42-76 30618728-12 2018 Crocetin treatment increased the level of red blood cells (RBC), hemoglobin (Hb) and decreased level of white blood cells (WBC), erythrocyte sedimentation rate (ESR), alkaline phosphatase (ALP), serum glutamic pyruvic transaminase (SGPT), and serum glutamic-oxaloacetic transaminase (SGOT) parameters, with reduction of TNF-alpha, IL-6, and IL-1beta.The protective effect of crocetin was substantiated with a reduction in expression of IL-6, IL-1beta, VEGF, and TNF-R1, respectively. crocetin 0-8 vascular endothelial growth factor A Rattus norvegicus 452-456 30997021-7 2019 Both maternal caffeine doses caused a marked attenuation in the values of fetal serum GH, IGF-II, VEGF, TGF-beta, TNF-alpha, IL-1beta, IL-6, leptin and MCP-1, and a noticeable elevation in the value of fetal serum adiponectin at ED 20. Caffeine 14-22 vascular endothelial growth factor A Rattus norvegicus 98-102 30255981-9 2018 RESULTS: Glycyrrhizic acid treatment reduced the expression of Ki-67, proliferating cell nuclear antigen (PCNA), nuclear factor-kappa B (NF-kB), cyclooxygenase-2 (COX-2), induced nitric oxide synthase (iNOS), and vascular endothelial growth factor (VEGF) while enhanced the expression of p53, connexin-43, b-cell lymphoma-2 (Bcl-2), survivin, and cleaved caspase-3. Glycyrrhizic Acid 9-26 vascular endothelial growth factor A Rattus norvegicus 213-247 30255981-9 2018 RESULTS: Glycyrrhizic acid treatment reduced the expression of Ki-67, proliferating cell nuclear antigen (PCNA), nuclear factor-kappa B (NF-kB), cyclooxygenase-2 (COX-2), induced nitric oxide synthase (iNOS), and vascular endothelial growth factor (VEGF) while enhanced the expression of p53, connexin-43, b-cell lymphoma-2 (Bcl-2), survivin, and cleaved caspase-3. Glycyrrhizic Acid 9-26 vascular endothelial growth factor A Rattus norvegicus 249-253 30539852-6 2018 The aim of this study is to investigate whether hesperidin can affect the VEGF gene expression in rat skin following gamma irradiation or not. Hesperidin 48-58 vascular endothelial growth factor A Rattus norvegicus 74-78 30539852-14 2018 Results: VEGF gene in the radiation + hesperidin group overexpressed 25-fold relative to the control group. Hesperidin 38-48 vascular endothelial growth factor A Rattus norvegicus 9-13 30539852-20 2018 Hesperidin as a radioprotector can initiate angiogenesis by VEGF gene induction. Hesperidin 0-10 vascular endothelial growth factor A Rattus norvegicus 60-64 29462373-10 2018 Doxycycline decreased MVD, suppressed MMP-3 overexpression, and reduced VEGF, TGF-beta, and TIMP-1 levels compared with the controls (P < .05). Doxycycline 0-11 vascular endothelial growth factor A Rattus norvegicus 72-76 30119970-10 2018 VEGF and PIGF levels were decreased in the L-NAME administered rats, while this levels were increased in the L-NAME + L-Arg group and L-Arg group when compared with the L-NAME alone group (p < 0.05). NG-Nitroarginine Methyl Ester 43-49 vascular endothelial growth factor A Rattus norvegicus 0-4 30193865-3 2018 Our previous in vitro study identified that salvianolic acid B (Sal-B), a polyphenol of traditional Chinese herbal danshen, stimulated lung cell proliferation and migration, and protected against induced lung cell death, by virtue of signal transducer and activator of transcription 3 (STAT3) activation and VEGF stimulation/elevation. salvianolic acid B 44-62 vascular endothelial growth factor A Rattus norvegicus 308-312 30193865-3 2018 Our previous in vitro study identified that salvianolic acid B (Sal-B), a polyphenol of traditional Chinese herbal danshen, stimulated lung cell proliferation and migration, and protected against induced lung cell death, by virtue of signal transducer and activator of transcription 3 (STAT3) activation and VEGF stimulation/elevation. salvianolic acid B 64-69 vascular endothelial growth factor A Rattus norvegicus 308-312 30193865-10 2018 In the PPE-induced model, Sal-B reduced induction of lung"s matrix metalloproteinase (MMP)-9 and MMP-2 activities by 59 and 94%, respectively, and restored pSTAT3 and VEGF expressions to the healthy lung levels, while leaving neutrophil accumulation unchecked [myeloperoxidase (MPO) activity]. ppe 7-10 vascular endothelial growth factor A Rattus norvegicus 167-171 30268739-9 2018 Further curcumin significantly enhanced the levels of antioxidant enzymes in BALF along with stabilized expression of hypoxia inducible factor 1(HIF-1alpha) followed by reduced expression of vascular endothelial growth factor (VEGF) in lungs of rats. Curcumin 8-16 vascular endothelial growth factor A Rattus norvegicus 191-225 30268739-9 2018 Further curcumin significantly enhanced the levels of antioxidant enzymes in BALF along with stabilized expression of hypoxia inducible factor 1(HIF-1alpha) followed by reduced expression of vascular endothelial growth factor (VEGF) in lungs of rats. Curcumin 8-16 vascular endothelial growth factor A Rattus norvegicus 227-231 30291890-0 2018 Salvianolic acid B as an anti-emphysema agent I: In vitro stimulation of lung cell proliferation and migration, and protection against lung cell death, and in vivo lung STAT3 activation and VEGF elevation. salvianolic acid B 0-18 vascular endothelial growth factor A Rattus norvegicus 190-194 30193865-10 2018 In the PPE-induced model, Sal-B reduced induction of lung"s matrix metalloproteinase (MMP)-9 and MMP-2 activities by 59 and 94%, respectively, and restored pSTAT3 and VEGF expressions to the healthy lung levels, while leaving neutrophil accumulation unchecked [myeloperoxidase (MPO) activity]. salvianolic acid B 26-31 vascular endothelial growth factor A Rattus norvegicus 167-171 30291890-3 2018 Thus, we hypothesized that salvianolic acid B (Sal-B), a polyphenol in traditional Chinese herbal danshen, is an alveolar structural recovery agent for emphysema by virtue of VEGF stimulation/elevation via activation of Janus kinase 2 (JAK2) and signal transducer and activator of transcription 3 (STAT3), as stimulating lung cell proliferation and migration, and protecting against lung cell death. salvianolic acid B 27-45 vascular endothelial growth factor A Rattus norvegicus 175-179 30291890-3 2018 Thus, we hypothesized that salvianolic acid B (Sal-B), a polyphenol in traditional Chinese herbal danshen, is an alveolar structural recovery agent for emphysema by virtue of VEGF stimulation/elevation via activation of Janus kinase 2 (JAK2) and signal transducer and activator of transcription 3 (STAT3), as stimulating lung cell proliferation and migration, and protecting against lung cell death. salvianolic acid B 47-52 vascular endothelial growth factor A Rattus norvegicus 175-179 30291890-9 2018 In rats, Sal-B at 0.2 mg/kg enabled 1.9 and 1.5-fold increased STAT3 phosphorylation and VEGF elevation in the lungs, respectively, while causing no functional and morphological abnormalities. salvianolic acid B 9-14 vascular endothelial growth factor A Rattus norvegicus 89-93 30291890-10 2018 Hence, Sal-B was projected to be a new class of anti-emphysema agent capable of reversing alveolar structural destruction/loss via JAK2/STAT3/VEGF-dependent stimulation of lung cell proliferation and migration, and inhibition of induced lung cell death. salvianolic acid B 7-12 vascular endothelial growth factor A Rattus norvegicus 142-146 30193865-12 2018 These results provide an in vivo proof-of-concept for Sal-B as one of the first anti-emphysema agents enabling reversal of alveolar structural destruction and loss via local lung treatment by virtue of its STAT3 activation and VEGF stimulation. salvianolic acid B 54-59 vascular endothelial growth factor A Rattus norvegicus 227-231 30240794-0 2018 Role of Oleanolic acid in maintaining BBB integrity by targeting p38MAPK/VEGF/Src signaling pathway in rat model of subarachnoid hemorrhage. Oleanolic Acid 8-22 vascular endothelial growth factor A Rattus norvegicus 73-77 30622953-0 2018 Corrigendum #2 to "Effects of Chronic Exposure to Sodium Arsenite on Expressions of VEGF and VEGFR2 Proteins in the Epididymis of Rats". sodium arsenite 50-65 vascular endothelial growth factor A Rattus norvegicus 84-88 30584457-7 2018 Furthermore, our in vivo experimental results show that in sodium iodate-induced retinal degeneration rat model, kaempferol could protect sodium iodate-induced pathological changes of retina tissue and retinal cells apoptosis as well as the upregulated VEGF protein expression in RPE cells. kaempferol 113-123 vascular endothelial growth factor A Rattus norvegicus 253-257 30511620-0 2018 Melatonin protects against streptozotocin-induced diabetic cardiomyopathy by the phosphorylation of vascular endothelial growth factor-A (VEGF-A). Melatonin 0-9 vascular endothelial growth factor A Rattus norvegicus 100-136 30511620-0 2018 Melatonin protects against streptozotocin-induced diabetic cardiomyopathy by the phosphorylation of vascular endothelial growth factor-A (VEGF-A). Melatonin 0-9 vascular endothelial growth factor A Rattus norvegicus 138-144 30511620-0 2018 Melatonin protects against streptozotocin-induced diabetic cardiomyopathy by the phosphorylation of vascular endothelial growth factor-A (VEGF-A). Streptozocin 27-41 vascular endothelial growth factor A Rattus norvegicus 100-136 30511620-0 2018 Melatonin protects against streptozotocin-induced diabetic cardiomyopathy by the phosphorylation of vascular endothelial growth factor-A (VEGF-A). Streptozocin 27-41 vascular endothelial growth factor A Rattus norvegicus 138-144 30511620-1 2018 The aim of the present study is to investigate if the melatonin has any protective effect on diabetic cardiomyopathy and antioxidant enzymes via phosphorylation of vascular endothelial growth factor-A (VEGF-A). Melatonin 54-63 vascular endothelial growth factor A Rattus norvegicus 164-200 30511620-1 2018 The aim of the present study is to investigate if the melatonin has any protective effect on diabetic cardiomyopathy and antioxidant enzymes via phosphorylation of vascular endothelial growth factor-A (VEGF-A). Melatonin 54-63 vascular endothelial growth factor A Rattus norvegicus 202-208 30511620-7 2018 In comparison to the group 1, DM induced a decrease in p-VEGF-A in coronary vessels of group 2. dm 30-32 vascular endothelial growth factor A Rattus norvegicus 57-63 30511620-8 2018 The lower constitutive phosphorylation of VEGF-A in the group 2 was also increased in coronary vessels after melatonin treatment (p&lt;0.05). Melatonin 109-118 vascular endothelial growth factor A Rattus norvegicus 42-48 30511620-8 2018 The lower constitutive phosphorylation of VEGF-A in the group 2 was also increased in coronary vessels after melatonin treatment (p&lt;0.05). Phosphorus 23-24 vascular endothelial growth factor A Rattus norvegicus 42-48 30511620-8 2018 The lower constitutive phosphorylation of VEGF-A in the group 2 was also increased in coronary vessels after melatonin treatment (p&lt;0.05). Adenosine Monophosphate 132-135 vascular endothelial growth factor A Rattus norvegicus 42-48 30511620-10 2018 Cardio-protective effect of melatonin may reduce the damages of diabetes mellitus on the heart muscle fibers and coronary vessels via the phosphorylation of VEGF-A. Melatonin 28-37 vascular endothelial growth factor A Rattus norvegicus 157-163 30511620-11 2018 Melatonin-dependent phosphorylation of VEGF-A in coronary angiogenesis may be associated with the physiological as well as with the pathological cardiac hypertrophy. Melatonin 0-9 vascular endothelial growth factor A Rattus norvegicus 39-45 30439990-12 2018 EMD-mediated Vegf upregulation was suppressed by the Akt inhibitor wortmannin, although the effect was significantly lower in HG medium (p<0.01). Wortmannin 67-77 vascular endothelial growth factor A Rattus norvegicus 13-17 29689297-4 2018 The levels of the angiogenic markers VEGF and VEGFR-2 were significantly decreased in CTZ group. Clotrimazole 86-89 vascular endothelial growth factor A Rattus norvegicus 37-41 30536336-0 2018 MiR-940 regulates angiogenesis after cerebral infarction through VEGF. mir-940 0-7 vascular endothelial growth factor A Rattus norvegicus 65-69 30413178-12 2018 CONCLUSIONS: Early combination therapy of hBM-MSCs with minocycline in an ischemic stroke model may enhance neurological recovery, reduce the volume of the infarcted area, and promote the expression of NeuN and VEGF in ischemic boundary cells. Minocycline 56-67 vascular endothelial growth factor A Rattus norvegicus 211-215 29513041-0 2018 VEGF-mediated angiogenesis and vascularization of a fumarate-crosslinked polycaprolactone (PCLF) scaffold. polycaprolactone 73-89 vascular endothelial growth factor A Rattus norvegicus 0-4 29513041-0 2018 VEGF-mediated angiogenesis and vascularization of a fumarate-crosslinked polycaprolactone (PCLF) scaffold. poly(caprolactone fumarate) 91-95 vascular endothelial growth factor A Rattus norvegicus 0-4 30536336-8 2018 Finally, recovery experiment was used to determine whether miR-940 affected angiogenesis and proliferation of BMECs by regulating VEGF expression. mir-940 59-66 vascular endothelial growth factor A Rattus norvegicus 130-134 30536336-15 2018 Further studies revealed that VEGF could reverse the inhibitory effect of miR-940 on lumen formation and cell proliferation in BMECs. mir-940 74-81 vascular endothelial growth factor A Rattus norvegicus 30-34 30536336-17 2018 The low expression of miR-940 could promote the angiogenesis ability of cerebral microvascular endothelial cells after cerebral infarction, which might be resulted from the inhibitory effect of miR-940 on VEGF. mir-940 22-29 vascular endothelial growth factor A Rattus norvegicus 205-209 30536336-17 2018 The low expression of miR-940 could promote the angiogenesis ability of cerebral microvascular endothelial cells after cerebral infarction, which might be resulted from the inhibitory effect of miR-940 on VEGF. mir-940 194-201 vascular endothelial growth factor A Rattus norvegicus 205-209 31949615-13 2018 On the other hand, GAS can up-regulate the expression of VEGF, thusly promoting micro-vacsular regeneration. gastrodin 19-22 vascular endothelial growth factor A Rattus norvegicus 57-61 30160015-4 2018 Morin inhibits HUVECs migration and tube formation induced by VEGF, which is reversed by PPARgamma antagonist GW9662 or siPPARgamma. 2-chloro-5-nitrobenzanilide 110-116 vascular endothelial growth factor A Rattus norvegicus 62-66 30031765-14 2018 Furthermore, the expression of VEGF and bFGF was significantly higher and that of HIF-1alpha was significantly lower in the CO2 than in the control group (p < 0.05). Carbon Dioxide 124-127 vascular endothelial growth factor A Rattus norvegicus 31-35 30075232-3 2018 We investigated whether VEGF has a neuroprotective role by inhibiting its binding to receptor Flk-1 by itraconazole (ITZ). Itraconazole 103-115 vascular endothelial growth factor A Rattus norvegicus 24-28 30075232-3 2018 We investigated whether VEGF has a neuroprotective role by inhibiting its binding to receptor Flk-1 by itraconazole (ITZ). Itraconazole 117-120 vascular endothelial growth factor A Rattus norvegicus 24-28 29802904-8 2018 RESULTS: In streptozotocin (STZ)-induced DR rats, TPP (0.4 g/kg) treatment restored electrophysiology indexes and retinal ultrastructures, reduced serum IL-6 and TNF-alpha levels, decreased VEGF and bFGF expression in retinal tissues, and improved haemorheology indexes. tpp 50-53 vascular endothelial growth factor A Rattus norvegicus 190-194 30071297-7 2018 Further, the inhibition on vascular endothelial growth factor (VEGF) signaling was stronger in sorafenib than in toceranib. Sorafenib 95-104 vascular endothelial growth factor A Rattus norvegicus 27-61 30071297-7 2018 Further, the inhibition on vascular endothelial growth factor (VEGF) signaling was stronger in sorafenib than in toceranib. Sorafenib 95-104 vascular endothelial growth factor A Rattus norvegicus 63-67 30518184-1 2018 The nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK; nicotine derived nitrosamine ketone) is one of the strongest carcinogens in tobacco which is involved in induction of lung cancer by changing the stimulation of vascular endothelial growth factor (VEGF) and annexin A2 expression. SCHEMBL420028 4-62 vascular endothelial growth factor A Rattus norvegicus 266-270 30518184-1 2018 The nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK; nicotine derived nitrosamine ketone) is one of the strongest carcinogens in tobacco which is involved in induction of lung cancer by changing the stimulation of vascular endothelial growth factor (VEGF) and annexin A2 expression. Nicotine 69-77 vascular endothelial growth factor A Rattus norvegicus 266-270 30508994-18 2018 Sumatriptan treatment significantly reduced the mechanical hypersensitivity induced by IS stimulations and decreased the BBB disruption and VEGF expression. Sumatriptan 0-11 vascular endothelial growth factor A Rattus norvegicus 140-144 30508994-20 2018 CONCLUSIONS: The present study showed that repeated IS stimulations induced long-lasting allodynia, increased BBB permeability, and upregulated VEGF expression, all of which could be attenuated by early sumatriptan treatment. Sumatriptan 203-214 vascular endothelial growth factor A Rattus norvegicus 144-148 30071297-7 2018 Further, the inhibition on vascular endothelial growth factor (VEGF) signaling was stronger in sorafenib than in toceranib. Toceranib 113-122 vascular endothelial growth factor A Rattus norvegicus 27-61 30071297-7 2018 Further, the inhibition on vascular endothelial growth factor (VEGF) signaling was stronger in sorafenib than in toceranib. Toceranib 113-122 vascular endothelial growth factor A Rattus norvegicus 63-67 30307983-5 2018 Palmitoleic acid modified TNF-alpha, IL-1beta, IL-6, CINC-2alpha/beta, MIP-3alpha and VEGF-alpha profiles at the wound site 24, 48, 120, 216 and 288 hours post-wounding. palmitoleic acid 0-16 vascular endothelial growth factor A Rattus norvegicus 86-96 30353332-0 2018 Expression of Hif-1alpha, Nf-kappab, and Vegf Genes in the Liver and Blood Serum Levels of HIF-1alpha, Erythropoietin, VEGF, TGF-beta, 8-Isoprostane, and Corticosterone in Wistar Rats with High and Low Resistance to Hypoxia. Corticosterone 154-168 vascular endothelial growth factor A Rattus norvegicus 26-45 30518184-1 2018 The nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK; nicotine derived nitrosamine ketone) is one of the strongest carcinogens in tobacco which is involved in induction of lung cancer by changing the stimulation of vascular endothelial growth factor (VEGF) and annexin A2 expression. nitrosamine ketone 86-104 vascular endothelial growth factor A Rattus norvegicus 266-270 30515035-0 2018 Effect of Melatonin on the Expression of VEGF-A and on the Degeneration of Follicle Reserve in Rat Ovary. Melatonin 10-19 vascular endothelial growth factor A Rattus norvegicus 41-47 29951700-9 2018 Gene expression analysis of vitamin E-treated pASCs showed down-regulated expression for the genes associated with oxidative stress and apoptosis, viz., NOS2, Casp3, p53, BAX, MDM2, NFkappaB, HIF1alpha and VEGF-A genes. Vitamin E 28-37 vascular endothelial growth factor A Rattus norvegicus 206-212 30098279-9 2018 The chemopreventive effect of hesperidin was assessed in terms of antioxidant activities, renal function, PGE2 level, and the expressions of COX-2 and VEGF. Hesperidin 30-40 vascular endothelial growth factor A Rattus norvegicus 151-155 30098279-11 2018 Hesperidin was also found to decrease the level of PGE2 and downregulate the expressions of COX-2 and VEGF. Hesperidin 0-10 vascular endothelial growth factor A Rattus norvegicus 102-106 29752623-3 2018 The aim of this study was to investigate the effect of catalpol pre-treatment on the survival and vascular endothelial growth factor (VEGF) secretion of BMSCs under oxygen glucose deprivation (OGD) condition and their role in myocardial repair in a rat model of MI. catalpol 55-63 vascular endothelial growth factor A Rattus norvegicus 98-132 29752623-3 2018 The aim of this study was to investigate the effect of catalpol pre-treatment on the survival and vascular endothelial growth factor (VEGF) secretion of BMSCs under oxygen glucose deprivation (OGD) condition and their role in myocardial repair in a rat model of MI. catalpol 55-63 vascular endothelial growth factor A Rattus norvegicus 134-138 29752623-9 2018 Finally, angiogenesis and VEGF expression in the ischemic myocardium were significantly promoted in catalpol pre-treated BMSCs group. catalpol 100-108 vascular endothelial growth factor A Rattus norvegicus 26-30 29804263-6 2018 TEM findings revealed an initial presence of VEGF in the vesicular transport apparatus of PTCs in healthy rats and its gradual translocation to the apical membrane of PTCs after renal damage caused by high sucrose treatment. Sucrose 206-213 vascular endothelial growth factor A Rattus norvegicus 45-49 30515035-1 2018 Objective: To analyze the effects of melatonin on vascular endothelial growth factor A (VEGF-A) expression and follicle reserve in rat ovary. Melatonin 37-46 vascular endothelial growth factor A Rattus norvegicus 50-86 30515035-1 2018 Objective: To analyze the effects of melatonin on vascular endothelial growth factor A (VEGF-A) expression and follicle reserve in rat ovary. Melatonin 37-46 vascular endothelial growth factor A Rattus norvegicus 88-94 30515035-8 2018 Additionally, we observed a weak immunoblot stain in the melatonin group for VEGF-A protein. Melatonin 57-66 vascular endothelial growth factor A Rattus norvegicus 77-83 30515035-9 2018 Interestingly, melatonin treatment induced a significant decrease in VEGF-A expression in the ovary of group 3 rats (p<0.05), whereas no such difference was observed between group 1 and group 2 rats (p>0.05). Melatonin 15-24 vascular endothelial growth factor A Rattus norvegicus 69-75 30233664-0 2018 Effect of simvastatin on expression of VEGF and TGF-beta1 in atherosclerotic animal model of type 2 diabetes mellitus. Simvastatin 10-21 vascular endothelial growth factor A Rattus norvegicus 39-43 30515035-10 2018 Conclusion: The present study demonstrates that the protective effect of melatonin on the degeneration of follicles in rat ovary is reduced by decreasing the VEGF-A expression. Melatonin 73-82 vascular endothelial growth factor A Rattus norvegicus 158-164 29982962-9 2018 Moreover, POLY and MTX downregulated gene expressions of receptor activator of nuclear factor kappa-B ligand (RANKL) as well as signal transducer and activator of transcription-3 (STAT3) besides hampering immunohistochemical staining of vascular endothelial growth factor (VEGF) and nuclear factor kappa-B (NF-kappaB). Methotrexate 19-22 vascular endothelial growth factor A Rattus norvegicus 237-271 30233664-1 2018 Expression of vascular endothelial growth factor (VEGF) and transforming growth factor-beta1 (TGF-beta1) in atherosclerosis animal model of type 2 diabetes mellitus treated with simvastatin was investigated. Simvastatin 178-189 vascular endothelial growth factor A Rattus norvegicus 14-48 30233664-1 2018 Expression of vascular endothelial growth factor (VEGF) and transforming growth factor-beta1 (TGF-beta1) in atherosclerosis animal model of type 2 diabetes mellitus treated with simvastatin was investigated. Simvastatin 178-189 vascular endothelial growth factor A Rattus norvegicus 50-54 30233664-14 2018 Simvastatin may play a therapeutic role in T2MD AS by downregulating VEGF and upregulating the expression of TGF-beta1. Simvastatin 0-11 vascular endothelial growth factor A Rattus norvegicus 69-73 30030103-0 2018 Succinate induces synovial angiogenesis in rheumatoid arthritis through metabolic remodeling and HIF-1alpha/VEGF axis. Succinic Acid 0-9 vascular endothelial growth factor A Rattus norvegicus 108-112 30030103-3 2018 EXPERIMENTAL APPROACH: The interaction between elevated succinate and VEGF production was examined in endothelial cells. Succinic Acid 56-65 vascular endothelial growth factor A Rattus norvegicus 70-74 30030103-5 2018 KEY RESULTS: Intracellular succinate promoted VEGF production and induced angiogenic response dependent on HIF-1alpha induction in endothelial cells. Succinic Acid 27-36 vascular endothelial growth factor A Rattus norvegicus 46-50 30030103-6 2018 Luciferase reporter assay showed that succinate increased VEGF expression through gene promoter activation dependent on HIF-1alpha induction. Succinic Acid 38-47 vascular endothelial growth factor A Rattus norvegicus 58-62 30030103-7 2018 Intracellular succinate released into intercellular space, where extracellular succinate activated succinate receptor G-protein-coupled receptor 91 (GPR91) and induced VEGF production, further exacerbating angiogenesis. Succinic Acid 14-23 vascular endothelial growth factor A Rattus norvegicus 168-172 29982962-9 2018 Moreover, POLY and MTX downregulated gene expressions of receptor activator of nuclear factor kappa-B ligand (RANKL) as well as signal transducer and activator of transcription-3 (STAT3) besides hampering immunohistochemical staining of vascular endothelial growth factor (VEGF) and nuclear factor kappa-B (NF-kappaB). polydatin 10-14 vascular endothelial growth factor A Rattus norvegicus 237-271 29982962-9 2018 Moreover, POLY and MTX downregulated gene expressions of receptor activator of nuclear factor kappa-B ligand (RANKL) as well as signal transducer and activator of transcription-3 (STAT3) besides hampering immunohistochemical staining of vascular endothelial growth factor (VEGF) and nuclear factor kappa-B (NF-kappaB). polydatin 10-14 vascular endothelial growth factor A Rattus norvegicus 273-277 29982962-9 2018 Moreover, POLY and MTX downregulated gene expressions of receptor activator of nuclear factor kappa-B ligand (RANKL) as well as signal transducer and activator of transcription-3 (STAT3) besides hampering immunohistochemical staining of vascular endothelial growth factor (VEGF) and nuclear factor kappa-B (NF-kappaB). Methotrexate 19-22 vascular endothelial growth factor A Rattus norvegicus 273-277 29857294-12 2018 The higher expression of VEGFA in aspirin + PNS group verified the predicted potential protective targets of PNS. Aspirin 34-41 vascular endothelial growth factor A Rattus norvegicus 25-30 30525078-12 2018 Under normoxia, angiotensin II increased the level of VEGF mRNA in ASCs, which was abolished by irbesartan. Irbesartan 96-106 vascular endothelial growth factor A Rattus norvegicus 54-58 30525078-13 2018 Under hypoxia, irbesartan reduced the level of VEGF mRNA in ASCs regardless of whether angiotensin II was present or not. Irbesartan 15-25 vascular endothelial growth factor A Rattus norvegicus 47-51 30525078-16 2018 Conclusions: ASC sheets ameliorated cardiac dysfunctions and remodeling after MI via increasing VEGF expression, which was abolished by pretreatment with irbesartan before the creation of MI and transplantation. Irbesartan 154-164 vascular endothelial growth factor A Rattus norvegicus 96-100 30177602-7 2018 Results show that Cd exposure had no effect on HIF-1alpha and prolyl hydroxylase 2 protein levels, but it reduced HIF-1 DNA-binding ability, which was confirmed by a decrease in vascular endothelial growth factor (VEGF) mRNA levels. Cadmium 18-20 vascular endothelial growth factor A Rattus norvegicus 178-212 30177602-7 2018 Results show that Cd exposure had no effect on HIF-1alpha and prolyl hydroxylase 2 protein levels, but it reduced HIF-1 DNA-binding ability, which was confirmed by a decrease in vascular endothelial growth factor (VEGF) mRNA levels. Cadmium 18-20 vascular endothelial growth factor A Rattus norvegicus 214-218 30354256-3 2018 Here, we asked whether a salt accumulation shown to result in VEGF (vascular endothelial growth factor)-C secretion and lymphangiogenesis had any influence on lymphatic function. Salts 25-29 vascular endothelial growth factor A Rattus norvegicus 62-66 30354256-3 2018 Here, we asked whether a salt accumulation shown to result in VEGF (vascular endothelial growth factor)-C secretion and lymphangiogenesis had any influence on lymphatic function. Salts 25-29 vascular endothelial growth factor A Rattus norvegicus 68-102 30266118-1 2018 OBJECTIVE: To investigate the effect of berberine on angiogenesis and signal transduction pathway of hypoxia-inducible growth factor-1&alpha; (HIF-1&alpha;) / vascular endothelial growth factor (VEGF) in rats with cerebral ischemia-reperfusion injury. Berberine 40-49 vascular endothelial growth factor A Rattus norvegicus 167-201 30266118-11 2018 After 7 days of administration, neurological score of berberine group was lower than that of model group (p <0.001), MVD, HIF-1&alpha; mRNA and VEGF mRNA expression. Berberine 54-63 vascular endothelial growth factor A Rattus norvegicus 151-155 30266118-12 2018 HIF-1&alpha; and VEGF protein expression levels were lower in model group than berberine group (all p <0.001). Berberine 83-92 vascular endothelial growth factor A Rattus norvegicus 21-25 30266118-14 2018 Its mechanism may be activation of HIF-1&alpha; / VEGF signal transduction pathway. Adenosine Monophosphate 41-44 vascular endothelial growth factor A Rattus norvegicus 54-58 30219518-10 2018 Additionally, in vitro study demonstrated that 11, 12-epoxyeicosatrienoic acid (11, 12-EET) induced more robust tube formation and markedly increased VEGF-A and bFGF expression in hypoxia and normoxia. 11,12-epoxy-5,8,14-eicosatrienoic acid 47-78 vascular endothelial growth factor A Rattus norvegicus 150-156 30219518-10 2018 Additionally, in vitro study demonstrated that 11, 12-epoxyeicosatrienoic acid (11, 12-EET) induced more robust tube formation and markedly increased VEGF-A and bFGF expression in hypoxia and normoxia. 11,12-epoxy-5,8,14-eicosatrienoic acid 80-90 vascular endothelial growth factor A Rattus norvegicus 150-156 29453608-7 2018 The study revealed that the expression of VEGF, MMP-2, MMP-9, and the chemokine MCP-1 to be very high in DMBA and DMBA + LPS groups, while Bcl-2 also shows an elevated expression. 9,10-Dimethyl-1,2-benzanthracene 105-109 vascular endothelial growth factor A Rattus norvegicus 42-46 29453608-7 2018 The study revealed that the expression of VEGF, MMP-2, MMP-9, and the chemokine MCP-1 to be very high in DMBA and DMBA + LPS groups, while Bcl-2 also shows an elevated expression. 9,10-Dimethyl-1,2-benzanthracene 114-118 vascular endothelial growth factor A Rattus norvegicus 42-46 30281683-10 2018 Finally, the osteopontin (OPN) and vascular endothelial growth factor (VEGF) levels were higher in the melatonin groups than in the CNT group, and the MLT-D2 had higher OPN and VEGF levels than the MLT-D1 (p < 0.05). Melatonin 103-112 vascular endothelial growth factor A Rattus norvegicus 71-75 30254425-6 2018 Furthermore, both tacrolimus and anti-VEGF significantly decreased the VEGF-A expression on Days 7 and 14, with no significant difference between the two groups. Tacrolimus 18-28 vascular endothelial growth factor A Rattus norvegicus 71-77 29857294-13 2018 CONCLUSIONS: PNS may have protective function for aspirin-induced gastrointestinal injury through increasing VEGFA expression. Aspirin 50-57 vascular endothelial growth factor A Rattus norvegicus 109-114 30127118-13 2018 Together, our findings indicate that exposure to a high concentration of sevoflurane (3.5%) in mid-gestation decreases VEGF, PI3K and p-AKT protein levels and induces neural stem cell apoptosis, thereby causing learning and memory dysfunction in the offspring. Sevoflurane 73-84 vascular endothelial growth factor A Rattus norvegicus 119-123 30056191-6 2018 Simvastatin increased some factors attenuated by glucose fluctuations: mRNA VEGF expression and mRNA VEGFR-1 expression in the myocardium and in the aorta. Simvastatin 0-11 vascular endothelial growth factor A Rattus norvegicus 76-80 30056191-6 2018 Simvastatin increased some factors attenuated by glucose fluctuations: mRNA VEGF expression and mRNA VEGFR-1 expression in the myocardium and in the aorta. Glucose 49-56 vascular endothelial growth factor A Rattus norvegicus 76-80 30354753-7 2018 Expression levels of VEGF (vascular endothelial growth factor), S1PR1, and S1PR3 in renal arteriole endothelial cells were significantly greater in the DOCA+FTY720 and DOCA groups compared with the control group, with levels being similar between the 2 groups. Desoxycorticosterone Acetate 152-156 vascular endothelial growth factor A Rattus norvegicus 21-25 30354753-7 2018 Expression levels of VEGF (vascular endothelial growth factor), S1PR1, and S1PR3 in renal arteriole endothelial cells were significantly greater in the DOCA+FTY720 and DOCA groups compared with the control group, with levels being similar between the 2 groups. Desoxycorticosterone Acetate 152-156 vascular endothelial growth factor A Rattus norvegicus 27-61 30354753-7 2018 Expression levels of VEGF (vascular endothelial growth factor), S1PR1, and S1PR3 in renal arteriole endothelial cells were significantly greater in the DOCA+FTY720 and DOCA groups compared with the control group, with levels being similar between the 2 groups. Desoxycorticosterone Acetate 168-172 vascular endothelial growth factor A Rattus norvegicus 21-25 30354753-7 2018 Expression levels of VEGF (vascular endothelial growth factor), S1PR1, and S1PR3 in renal arteriole endothelial cells were significantly greater in the DOCA+FTY720 and DOCA groups compared with the control group, with levels being similar between the 2 groups. Desoxycorticosterone Acetate 168-172 vascular endothelial growth factor A Rattus norvegicus 27-61 29409374-6 2018 Furthermore, the SeSCTF treated group showed complete recovery of key protein expressions of the downstream signaling pathway of vascular endothelial growth factor (VEGF), angiopoietin-2/1 (Ang-2/1), the signaling pathway of insulin receptors and anti-oxidative status. sesctf 17-23 vascular endothelial growth factor A Rattus norvegicus 129-163 29409374-6 2018 Furthermore, the SeSCTF treated group showed complete recovery of key protein expressions of the downstream signaling pathway of vascular endothelial growth factor (VEGF), angiopoietin-2/1 (Ang-2/1), the signaling pathway of insulin receptors and anti-oxidative status. sesctf 17-23 vascular endothelial growth factor A Rattus norvegicus 165-169 29981346-11 2018 The NAA, IGF-1, and VEGF levels in the brain were improved after treatment with WL and GA. wedelolactone 80-82 vascular endothelial growth factor A Rattus norvegicus 20-24 29981346-11 2018 The NAA, IGF-1, and VEGF levels in the brain were improved after treatment with WL and GA. Gallic Acid 87-89 vascular endothelial growth factor A Rattus norvegicus 20-24 30056191-5 2018 RESULTS: Simvastatin decreased several factors enhanced by glucose excursions: circulating VEGF, mRNA TGF-beta expression in the myocardium and mRNA VEGFR-2 expression in the aorta. Simvastatin 9-20 vascular endothelial growth factor A Rattus norvegicus 91-95 30056191-5 2018 RESULTS: Simvastatin decreased several factors enhanced by glucose excursions: circulating VEGF, mRNA TGF-beta expression in the myocardium and mRNA VEGFR-2 expression in the aorta. Glucose 59-66 vascular endothelial growth factor A Rattus norvegicus 91-95 29955127-6 2018 The aim of this study was to explore whether the engineered VEGF-A and PDGF-B based plasmid-loaded nanospheres could be upregulated in streptozotocin-induced diabetic rats and improve the wound healing. Streptozocin 135-149 vascular endothelial growth factor A Rattus norvegicus 60-66 30228820-11 2018 ESWT increased the quantity of MSCs in the corpus cavernosum and also induced MSCs to express more VEGF in vitro and vivo (P < 0.05) which activated the PI3K/AKT/mTOR and NO/cGMP signaling pathways in the corpus cavernosum. Cyclic GMP 177-181 vascular endothelial growth factor A Rattus norvegicus 99-103 30029933-15 2018 CONCLUSIONS: Thalidomide, which is a specific VEGF inhibitor, significantly inhibited neointimal hyperplasia and vascular restenosis after balloon injury to the carotid artery in rats, thus potentially providing a novel method for the prevention and treatment of restenosis, especially in-stent restenosis. Thalidomide 13-24 vascular endothelial growth factor A Rattus norvegicus 46-50 30210447-3 2018 Materials and Methods: The expression pattern of imatinib"s targets (c-kit, VEGF, and PDGFR-alpha/beta) was studied using immunohistochemistry and immunoblotting 157 giant (>=4 cm) pituitary adenomas (121 non-functioning pituitary adenomas, 32 somatotropinomas, and four prolactinomas) and compared to normal pituitary (n = 4) obtained at autopsy. Imatinib Mesylate 49-57 vascular endothelial growth factor A Rattus norvegicus 76-80 30224933-13 2018 LWDH administration decreased the expression of serum levels of IL-1beta (p>0.05), while it increased VEGF (p>0.05) expression. lwdh 0-4 vascular endothelial growth factor A Rattus norvegicus 105-109 29904189-10 2018 VEGF expression was increased in the irradiated spinal cord, and the number of VEGF-positive cells was significantly decreased by Ramipril treatment (P < 0.001). Ramipril 130-138 vascular endothelial growth factor A Rattus norvegicus 0-4 29890158-0 2018 Oral supplementation with melatonin reduces oxidative damage and concentrations of inducible nitric oxide synthase, VEGF and matrix metalloproteinase 9 in the retina of rats with streptozotocin/nicotinamide induced pre-diabetes. Melatonin 26-35 vascular endothelial growth factor A Rattus norvegicus 116-120 30056863-6 2018 KEY FINDINGS: Olopatadine, in the present work, effectively and dose-dependently enhanced the corneal healing after alkali application, with significant reduction of the corneal opacity and neovascularization scores, besides, it suppressed the augmented corneal IL-1beta, VEGF, caspase-3 levels, and nuclear NF-kappaB immunohistochemical expression, meanwhile it abrogated the corneal histopathological changes, induced by alkali application. Olopatadine Hydrochloride 14-25 vascular endothelial growth factor A Rattus norvegicus 272-276 29936250-11 2018 The expression of ANG2 and VEGF was increased in diabetic flap tissues under ATRA administration. Tretinoin 77-81 vascular endothelial growth factor A Rattus norvegicus 27-31 29750888-6 2018 Moreover, APN changed-proliferation, apoptosis and VEGF expression of VEPCs were partially suppressed after blocking the mTOR-STAT3 signaling pathway by the mTOR inhibitor XL388. XL388 172-177 vascular endothelial growth factor A Rattus norvegicus 51-55 29890158-9 2018 Finally, supplementation with melatonin reduced concentrations of TBARS, AOPP, iNOS, VEGF, and MMP9 in significant level, thereby exerting an overall positive effect on oxidative stress and pro-angiogenic signaling in the pre-diabetic retina. Melatonin 30-39 vascular endothelial growth factor A Rattus norvegicus 85-89 30186572-11 2018 Furthermore, in comparison with the control group, the number of blood vessels and VEGF-positive cells in treated groups with GLN and Ala-GLN were significantly higher. Glutamine 126-129 vascular endothelial growth factor A Rattus norvegicus 83-87 30186572-11 2018 Furthermore, in comparison with the control group, the number of blood vessels and VEGF-positive cells in treated groups with GLN and Ala-GLN were significantly higher. alanylglutamine 134-141 vascular endothelial growth factor A Rattus norvegicus 83-87 29752091-6 2018 The results also demonstrated that the releasing profile of vancomycin was pH-dependent and the VEGF"s profile was adjustable by changing the pore sizes of PLGA microspheres. Vancomycin 60-70 vascular endothelial growth factor A Rattus norvegicus 96-100 29904189-10 2018 VEGF expression was increased in the irradiated spinal cord, and the number of VEGF-positive cells was significantly decreased by Ramipril treatment (P < 0.001). Ramipril 130-138 vascular endothelial growth factor A Rattus norvegicus 79-83 30025088-5 2018 Primary human fetal RPE cells and RPE-J cells were used to verify the effect of ascorbate on VEGF expression. Ascorbic Acid 80-89 vascular endothelial growth factor A Rattus norvegicus 93-97 29980670-11 2018 In addition, lactate facilitated NF-kappaB translocation to induce increased transcription of VEGF and bFGF. Lactic Acid 13-20 vascular endothelial growth factor A Rattus norvegicus 94-98 30112400-3 2018 This study investigates the effect of reduced beta2GPI on glomerular mesangial cells VEGF-NO axis uncoupling induced by high glucose. Glucose 125-132 vascular endothelial growth factor A Rattus norvegicus 85-89 30112400-4 2018 Compared to control group, glomerular mesangial cell line HBZY-1 cells treated with high glucose expressed higher levels of VEGF mRNA and protein and produced more ROS but less NO. Glucose 89-96 vascular endothelial growth factor A Rattus norvegicus 124-128 29146554-0 2018 INGAP-PP effects on beta-cell mass and function are related to its positive effect on islet angiogenesis and VEGFA production. Ingap (104-118) 0-8 vascular endothelial growth factor A Rattus norvegicus 109-114 29146554-1 2018 Our aim was to determine whether islet angiogenesis and VEGFA production/release participate in the mechanism by which INGAP-PP enhances beta-cell function and mass. Ingap (104-118) 119-127 vascular endothelial growth factor A Rattus norvegicus 56-61 29146554-4 2018 Normal islets cultured with INGAP-PP and VEGFA increased insulin and VEGFA secretion while apoptosis decreased. Ingap (104-118) 28-36 vascular endothelial growth factor A Rattus norvegicus 69-74 29146554-6 2018 INGAP-PP effects on beta-cell mass and function were significantly associated with a positive effect on islet angiogenesis and VEGFA production/release. Ingap (104-118) 0-8 vascular endothelial growth factor A Rattus norvegicus 127-132 29146554-7 2018 VEGF-A possibly potentiates INGAP-PP effect through mTORC pathway. Ingap (104-118) 28-36 vascular endothelial growth factor A Rattus norvegicus 0-6 30029250-7 2018 Results: Thalidomide and three novel analogs all showed inhibitory effects on endothelial cell proliferation and VEGF expression in vitro. Thalidomide 9-20 vascular endothelial growth factor A Rattus norvegicus 113-117 30029250-13 2018 Conclusions: DAID is a novel phenylphthalimide analog with potent effects on NV and retinal vascular leakage through downregulation of VEGF and inflammatory factors and has therapeutic potential. phenylphthalimide 29-46 vascular endothelial growth factor A Rattus norvegicus 135-139 29597832-8 2018 PUFA omega-3 supplementation produced a higher level of total omega-3 in lung tissue and breast milk and was found to reverse the reduced levels of VEGFA, VEGF receptor 2, angiopoietin-1 (ANGPT1), endothelial TEK tyrosine kinase, endothelial nitric oxide synthase, and nitric oxide concentrations in lung tissue and the increased ANGPT2 levels in hyperoxia-exposed rats. omega-3 5-12 vascular endothelial growth factor A Rattus norvegicus 148-153 30057668-4 2018 After 24 h, post I/R treatment with trimetazidine significantly reduced serum blood urea nitrogen and creatinine levels and tubular injury accompanied with upregulation of hypoxia-inducible factor- (HIF-) 1alpha, vascular endothelial growth factor (VEGF), and Bcl-2 expression. Trimetazidine 36-49 vascular endothelial growth factor A Rattus norvegicus 213-247 30057668-4 2018 After 24 h, post I/R treatment with trimetazidine significantly reduced serum blood urea nitrogen and creatinine levels and tubular injury accompanied with upregulation of hypoxia-inducible factor- (HIF-) 1alpha, vascular endothelial growth factor (VEGF), and Bcl-2 expression. Trimetazidine 36-49 vascular endothelial growth factor A Rattus norvegicus 249-253 30057668-5 2018 After 5 d, post I/R treatment with trimetazidine reduced renal tubular cell necrosis and apoptosis with upregulation of HIF-1alpha-VEGF and tissue inhibitors of metalloproteinase activities, attenuation of matrix metalloproteinase activities, and alteration of the ratio of Bax to Bcl-2 levels. Trimetazidine 35-48 vascular endothelial growth factor A Rattus norvegicus 131-135 29570780-10 2018 In vitro, postconditoning after oxygen-glucose deprivation up-regulated VEGF release in primary neuron cultures, and adding VEGF to microglial cultures partly shifted their M2-like markers. oxygen-glucose 32-46 vascular endothelial growth factor A Rattus norvegicus 72-76 29693137-0 2018 Mesenchymal stem cells attenuate doxorubicin-induced cellular senescence through the VEGF/Notch/TGF-beta signaling pathway in H9c2 cardiomyocytes. Doxorubicin 33-44 vascular endothelial growth factor A Rattus norvegicus 85-89 29693137-10 2018 The results revealed that MSCs rescued H9c2 cells from Dox-induced senescence through the release of VEGF, which activated the Jagged-1/Notch-1 signaling pathway, leading to the inhibition of TGF-beta1 release. Doxorubicin 55-58 vascular endothelial growth factor A Rattus norvegicus 101-105 29620141-10 2018 In addition, expression levels of its downstream effectors IL-1beta, TNF-alpha and VEGF were attenuated by intrathecal treatment with LV-JMJD6, compared with those in the NS- and NC-treated CCI rats. CCI 190-193 vascular endothelial growth factor A Rattus norvegicus 83-87 29947531-6 2018 IRL-1620 improved learning and memory, reduced oxidative stress and increased VEGF and NGF in Abeta treated rats. UNII-042A8N37WH 94-99 vascular endothelial growth factor A Rattus norvegicus 78-90 29204817-12 2018 Administration of combination therapy harmonized the DENA-induced elevation of serum biochemical parameters, including but not limited to, alpha-fetoprotein (AFP), alanine- and aspartate-aminotransferase, alkaline phosphatase, vascular endothelial growth factor (VEGF), and antioxidant enzymes like superoxide dismutase (SOD), catalase (CAT), and lipid per oxidation (LPO). Diethylnitrosamine 53-57 vascular endothelial growth factor A Rattus norvegicus 227-261 29204817-12 2018 Administration of combination therapy harmonized the DENA-induced elevation of serum biochemical parameters, including but not limited to, alpha-fetoprotein (AFP), alanine- and aspartate-aminotransferase, alkaline phosphatase, vascular endothelial growth factor (VEGF), and antioxidant enzymes like superoxide dismutase (SOD), catalase (CAT), and lipid per oxidation (LPO). Diethylnitrosamine 53-57 vascular endothelial growth factor A Rattus norvegicus 263-267 30091538-12 2018 The levels of CIRI-induced increase of mNSS and CIRI-induced decrease of the number of Nissl bodies in the EA+VEGF group were respectively remarkably lower or higher than those of the simple EA and simple VEGF groups (P<0.05). ciri 14-18 vascular endothelial growth factor A Rattus norvegicus 110-114 30046341-8 2018 Besides, BDNF, GDNF, VEGF, bFGF, and CD34 levels were significantly increased by XDD, suggesting that the protective effects of XDD may also be associated with the promotion of neurogenesis and angiogenesis. xdd 81-84 vascular endothelial growth factor A Rattus norvegicus 21-25 30091538-12 2018 The levels of CIRI-induced increase of mNSS and CIRI-induced decrease of the number of Nissl bodies in the EA+VEGF group were respectively remarkably lower or higher than those of the simple EA and simple VEGF groups (P<0.05). ciri 14-18 vascular endothelial growth factor A Rattus norvegicus 205-209 30091538-12 2018 The levels of CIRI-induced increase of mNSS and CIRI-induced decrease of the number of Nissl bodies in the EA+VEGF group were respectively remarkably lower or higher than those of the simple EA and simple VEGF groups (P<0.05). ciri 48-52 vascular endothelial growth factor A Rattus norvegicus 110-114 29787262-1 2018 Herein a novel series of pazopanib hybrids as polypharmacological antitumor agents were developed based on the crosstalk between histone deacetylases (HDACs) and vascular endothelial growth factor (VEGF) pathway. pazopanib 25-34 vascular endothelial growth factor A Rattus norvegicus 162-196 30091538-12 2018 The levels of CIRI-induced increase of mNSS and CIRI-induced decrease of the number of Nissl bodies in the EA+VEGF group were respectively remarkably lower or higher than those of the simple EA and simple VEGF groups (P<0.05). ciri 48-52 vascular endothelial growth factor A Rattus norvegicus 205-209 30003121-6 2018 Studies in rats showed increased plasma and tissue Vegfa concentrations and signs of bone marrow microhemorrhage on the first day of excess dietary vitamin A intake. Vitamin A 148-157 vascular endothelial growth factor A Rattus norvegicus 51-56 29787262-1 2018 Herein a novel series of pazopanib hybrids as polypharmacological antitumor agents were developed based on the crosstalk between histone deacetylases (HDACs) and vascular endothelial growth factor (VEGF) pathway. pazopanib 25-34 vascular endothelial growth factor A Rattus norvegicus 198-202 28874077-9 2018 Also, in comparison with the control group; VEGF-A expression was downregulated by nearly 0.75 times in sunitinib group and nearly 0.52 times in bevacizumab group. Sunitinib 104-113 vascular endothelial growth factor A Rattus norvegicus 44-50 29977804-0 2018 Protective effects of a novel drug RC28-E blocking both VEGF and FGF2 on early diabetic rat retina. rc28-e 35-41 vascular endothelial growth factor A Rattus norvegicus 56-60 29977804-17 2018 CONCLUSION: Dual blockade of VEGF and FGF2 by RC28-E generates remarkable protective effects, including anti-apoptosis, anti-gliosis, anti-leakage, and improving ultrastructures and proinflammatory microenvironment, in early diabetic retina, thereby supporting further development of RC28-E into a novel and effective drug to diabetic retinopathy (DR). rc28-e 46-52 vascular endothelial growth factor A Rattus norvegicus 29-33 29977804-17 2018 CONCLUSION: Dual blockade of VEGF and FGF2 by RC28-E generates remarkable protective effects, including anti-apoptosis, anti-gliosis, anti-leakage, and improving ultrastructures and proinflammatory microenvironment, in early diabetic retina, thereby supporting further development of RC28-E into a novel and effective drug to diabetic retinopathy (DR). rc28-e 284-290 vascular endothelial growth factor A Rattus norvegicus 29-33 29551453-2 2018 Modern theories of acute coronary syndrome mainly focus on rupture of thin-cap fibroatheromas (TCFAs), which is closely related to the release of vascular endothelial growth factor and its receptor (VEGF/VEGFR). tcfas 95-100 vascular endothelial growth factor A Rattus norvegicus 199-203 29551453-15 2018 CONCLUSIONS: WHJF inhibits TCFA formation by influencing the VEGF/VEGFR signaling pathway. whjf 13-17 vascular endothelial growth factor A Rattus norvegicus 61-65 29551453-15 2018 CONCLUSIONS: WHJF inhibits TCFA formation by influencing the VEGF/VEGFR signaling pathway. tcfa 27-31 vascular endothelial growth factor A Rattus norvegicus 61-65 29896433-5 2018 Compared to PBS treatment, APX3330 treatment of stroke in T1DM rats significantly improves neurological functional outcome, decreases lesion volume, and improves BBB integrity as well as decreases total vessel density and VEGF expression, while significantly increases arterial density in the ischemic border zone (IBZ). E 3330 27-34 vascular endothelial growth factor A Rattus norvegicus 222-226 29926276-0 2018 Endothelialization of Polycaprolactone Vascular Graft under the Action of Locally Applied Vascular Endothelial Growth Factor. polycaprolactone 22-38 vascular endothelial growth factor A Rattus norvegicus 90-124 29926276-1 2018 We have previously developed a polycaprolactone (PCL) vascular graft with incorporated vascular endothelial growth factor (VEGF). polycaprolactone 31-47 vascular endothelial growth factor A Rattus norvegicus 87-121 29926276-1 2018 We have previously developed a polycaprolactone (PCL) vascular graft with incorporated vascular endothelial growth factor (VEGF). polycaprolactone 31-47 vascular endothelial growth factor A Rattus norvegicus 123-127 29926276-1 2018 We have previously developed a polycaprolactone (PCL) vascular graft with incorporated vascular endothelial growth factor (VEGF). polycaprolactone 49-52 vascular endothelial growth factor A Rattus norvegicus 87-121 29926276-1 2018 We have previously developed a polycaprolactone (PCL) vascular graft with incorporated vascular endothelial growth factor (VEGF). polycaprolactone 49-52 vascular endothelial growth factor A Rattus norvegicus 123-127 28874077-0 2018 Effects of sunitinib and bevacizumab on VEGF and miRNA levels on corneal neovascularization. Sunitinib 11-20 vascular endothelial growth factor A Rattus norvegicus 40-44 28874077-14 2018 CONCLUSION: Topical application of bevacizumab (5 mg/ml) and sunitinib (0.5 mg/ml) decreases the levels of VEGFR-2 and VEGF-A in CNV. Sunitinib 61-70 vascular endothelial growth factor A Rattus norvegicus 119-125 29471105-9 2018 KEY FINDINGS: VEGF protein expression was significantly increased after icariin treatment with the highest expression in the 10-7 M icariin group. icariin 72-79 vascular endothelial growth factor A Rattus norvegicus 14-18 29193246-10 2018 The mRNA expression of Atrogin-1 and MuRF-1 was lower, mRNA expression of VEGF and myogenin and MyoD was higher in CO2 group at postoperative week 2 compared to the control group. Carbon Dioxide 115-118 vascular endothelial growth factor A Rattus norvegicus 74-78 29631143-3 2018 Supplementation with GPE (300 mg/kg body weight/day) reduced adipocyte diameter and increased levels of proteins that participate in adipogenesis and angiogenesis, i.e., peroxisome-proliferator activated receptor gamma (PPARgamma), vascular endothelial grow factor-A (VEGF-A) and its receptor 2 (VEGF-R2), and partially increased the uncoupling protein 1 (UCP-1) in WKY. gpe 21-24 vascular endothelial growth factor A Rattus norvegicus 232-266 29631143-3 2018 Supplementation with GPE (300 mg/kg body weight/day) reduced adipocyte diameter and increased levels of proteins that participate in adipogenesis and angiogenesis, i.e., peroxisome-proliferator activated receptor gamma (PPARgamma), vascular endothelial grow factor-A (VEGF-A) and its receptor 2 (VEGF-R2), and partially increased the uncoupling protein 1 (UCP-1) in WKY. gpe 21-24 vascular endothelial growth factor A Rattus norvegicus 268-274 29471105-9 2018 KEY FINDINGS: VEGF protein expression was significantly increased after icariin treatment with the highest expression in the 10-7 M icariin group. icariin 132-139 vascular endothelial growth factor A Rattus norvegicus 14-18 29880170-6 2018 Peritoneal fluid VEGF levels were lower for RSV group compared to group 2 and 3. Resveratrol 44-47 vascular endothelial growth factor A Rattus norvegicus 17-21 29486300-8 2018 Minocycline-treated rats showed increased VEGF-A protein, TJP formation, and oligodendrocyte proliferation. Minocycline 0-11 vascular endothelial growth factor A Rattus norvegicus 42-48 29880170-8 2018 CONCLUSION: These results indicate that RSV is beneficial for prevention of OHSS by reducing the increases in body and ovarian weight and VEGF activity. Resveratrol 40-43 vascular endothelial growth factor A Rattus norvegicus 138-142 29332242-6 2018 In HUVEC, the IMD0354 treatment caused a dose-dependent reduction in VEGF-A expression, suppressed TNFalpha-stimulated expression of chemokines CCL2 and CXCL5, and diminished actin filament fibers and cell filopodia formation. N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide 14-21 vascular endothelial growth factor A Rattus norvegicus 69-75 29875625-0 2018 Resveratrol Promotes Nerve Regeneration via Activation of p300 Acetyltransferase-Mediated VEGF Signaling in a Rat Model of Sciatic Nerve Crush Injury. Resveratrol 0-11 vascular endothelial growth factor A Rattus norvegicus 90-94 29875625-9 2018 Resveratrol activated p300 acetyltransferase-mediated VEGF signaling in the affected ventral spinal cord, which may have thus contributed to the acceleration of nerve regeneration and motor repair. Resveratrol 0-11 vascular endothelial growth factor A Rattus norvegicus 54-58 29454091-3 2018 In this research, we demonstrated that anlotinib, a potent multi-tyrosine kinases inhibitor (TKI), showed a significant inhibitory effect on VEGF/PDGF-BB/FGF-2-induced angiogenesis in vitro and in vivo. anlotinib 39-48 vascular endothelial growth factor A Rattus norvegicus 141-145 29454091-4 2018 Wound healing assay, chamber directional migration assay and tube formation assay indicated that anlotinib inhibited VEGF/PDGF-BB/FGF-2-induced cell migration and formation of capillary-like tubes in endothelial cells. anlotinib 97-106 vascular endothelial growth factor A Rattus norvegicus 117-121 29427700-8 2018 RESULTS: ALA induced pro-angiogenic effect in the myocardium of rats with diabetes increasing mRNA VEGF expression and decreasing mRNA VEGFR-1 expression, while in the aortal wall ALA increased mRNA VEGFR-2 and VEGFR-1 expression. Thioctic Acid 9-12 vascular endothelial growth factor A Rattus norvegicus 99-103 29875657-9 2018 TSP treatment markedly suppressed mammary phosphorylation levels of ERK1/2, as well as reduced the mRNA and protein overexpression of VEGF and bFGF in mammary of rats. tsp 0-3 vascular endothelial growth factor A Rattus norvegicus 134-138 29568939-9 2018 Furthermore, puerarin activated the protein expression levels of VEGFA and Ang-I, and increased nitric oxide production, phosphorylated-endothelial nitric oxide synthase protein expression and caspase-3 activity. puerarin 13-21 vascular endothelial growth factor A Rattus norvegicus 65-70 29518435-6 2018 Furthermore, ZFE effectively modulated the mRNA expression of redox-sensitive transcription factors, such as nuclear factor (erythroid-derived 2)-like 2 and heme oxygenase-1, downregulated the expression of p38 mitogen-activated protein kinase, and upregulated that of vascular endothelial growth factor A and interleukin-1beta in AcOH-induced colitis in rats. zfe 13-16 vascular endothelial growth factor A Rattus norvegicus 269-305 29568939-10 2018 These results demonstrated that the myocardial protective effect of puerarin serves to reduce myocardial I/R injury, via upregulation of VEGFA/Ang-1 and suppression of apoptosis, in diabetic rats with myocardial I/R. puerarin 68-76 vascular endothelial growth factor A Rattus norvegicus 137-142 30171751-0 2018 [Finasteride inhibits microvascular density and VEGF expression in the seminal vesicle of rats]. Finasteride 1-12 vascular endothelial growth factor A Rattus norvegicus 48-52 30171751-6 2018 CONCLUSIONS: Finasteride can inhibit the expression of VEGF in the seminal vesicle tissue of the rat and hence suppress the angiogenesis of microvessels of the seminal vesicle. Finasteride 13-24 vascular endothelial growth factor A Rattus norvegicus 55-59 29888571-1 2018 OBJECTIVE: To observe the effect of different frequencies of electroacupuncture (EA) stimulation on pain threshold (PT) and expression of vascular endothelial growth factor (VEGF) in dorsal horns (DHs) of the lumbar spinal cord in resiniferatoxin (RTX)-induced post-herpetic neuralgia (PHN) rats, so as to reveal its mechanism in alleviating PHN. resiniferatoxin 231-246 vascular endothelial growth factor A Rattus norvegicus 138-172 29888571-10 2018 RTX administration increased the mRNA and protein expression of VEGF in the lumbar spinal cord compared with the control group (P<0. resiniferatoxin 0-3 vascular endothelial growth factor A Rattus norvegicus 64-68 29446853-5 2018 Concordant with this activity, anlotinib inhibited VEGF-induced signaling and cell proliferation in HUVEC with picomolar IC50 values. anlotinib 31-40 vascular endothelial growth factor A Rattus norvegicus 51-55 29684003-10 2018 17beta-E2 treatment significantly promoted the proliferation, migration, tubular structure formation, and VEGF secretion in CMECs. 17beta-e2 0-9 vascular endothelial growth factor A Rattus norvegicus 106-110 29615543-9 2018 CONCLUSION: Overall, we presented how IH application has a beneficial cardiovascular remodeling effect in left ventricular function of diabetic rats, at most, via affecting increased oxidative stress and HIF-VEGF related angiogenesis, providing information on hyperglycemia associated new targets and therapeutic strategies. Ile-His 38-40 vascular endothelial growth factor A Rattus norvegicus 208-212 29501817-3 2018 Here, we describe a synthetic 2-N, 6-O-sulfated chitosan (26SCS) with a high affinity to VEGF promoting the binding of the signaling protein to its VEGF receptor 2 (VEGFR2), activating receptor phosphorylation and pro-angiogenic related genes expression, and further stimulating downstream VEGF-dependent endothelial cell viability, migration, tube formation and rat aortic rings outgrowth. 2-n, 6-o 30-38 vascular endothelial growth factor A Rattus norvegicus 89-93 29501817-3 2018 Here, we describe a synthetic 2-N, 6-O-sulfated chitosan (26SCS) with a high affinity to VEGF promoting the binding of the signaling protein to its VEGF receptor 2 (VEGFR2), activating receptor phosphorylation and pro-angiogenic related genes expression, and further stimulating downstream VEGF-dependent endothelial cell viability, migration, tube formation and rat aortic rings outgrowth. 2-n, 6-o 30-38 vascular endothelial growth factor A Rattus norvegicus 148-152 29164711-0 2018 Vitamin E improves testicular damage in streptozocin-induced diabetic rats, via increasing vascular endothelial growth factor and poly(ADP-ribose) polymerase-1. Vitamin E 0-9 vascular endothelial growth factor A Rattus norvegicus 91-125 29164711-7 2018 Vitamin E administration was protective against oxidative stress-associated damage evidenced by lower MDA levels, improved testicular weight, spermatogenesis and higher immunostaining for VEGF and PARP-1. Vitamin E 0-9 vascular endothelial growth factor A Rattus norvegicus 188-192 28393322-1 2018 AIM: This study was to investigate the anti-angiogenic effect of hexahydrocurcumin (HHC) to evaluate gene (p-basic fibroblast growth factor (bFGF)-SAINT-18 & p-vascular endothelial growth factor (VEGF)-SAINT-18 complex)-induced corneal neovascularization (CorNV) in rats. hexahydrocurcumin 65-82 vascular endothelial growth factor A Rattus norvegicus 162-198 28393322-1 2018 AIM: This study was to investigate the anti-angiogenic effect of hexahydrocurcumin (HHC) to evaluate gene (p-basic fibroblast growth factor (bFGF)-SAINT-18 & p-vascular endothelial growth factor (VEGF)-SAINT-18 complex)-induced corneal neovascularization (CorNV) in rats. hexahydrocurcumin 65-82 vascular endothelial growth factor A Rattus norvegicus 200-204 29219948-7 2018 In summary, ASA VI promotes angiogenesis of HUVECs in vitro via up-regulating the HIF-1alpha/VEGF pathway, and efficiently enhances the vascularization in regenerated tissue and facilitates wound healing in vivo. Aspirin 12-15 vascular endothelial growth factor A Rattus norvegicus 93-97 29687856-10 2018 LY294002 significantly decreased p-AKT, Bcl-2, and VEGF expressions, and alleviated the cell apoptosis protective and angiogenesis effect induced by G-CSF. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 vascular endothelial growth factor A Rattus norvegicus 51-55 29683499-12 2018 Testosterone supplementation significantly increased the inflammatory cell count, decreased the levels of IL-4, IL-10, IL-1beta, IL-6, and TNF-alpha; and increased VEGF and EGF. Testosterone 0-12 vascular endothelial growth factor A Rattus norvegicus 164-168 29436655-0 2018 Effects of dexmedetomidine post-treatment on BDNF and VEGF expression following cerebral ischemia/reperfusion injury in rats. Dexmedetomidine 11-26 vascular endothelial growth factor A Rattus norvegicus 54-58 29436655-1 2018 Brain-derived neurotrophic factor (BDNF) and vascular endothelial growth factor (VEGF) serves a significant role in neural protection by activating the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway, which also was associated with the neuroprotective the treatment with dexmedetomidine (DEX). Dexmedetomidine 282-297 vascular endothelial growth factor A Rattus norvegicus 45-79 29436655-1 2018 Brain-derived neurotrophic factor (BDNF) and vascular endothelial growth factor (VEGF) serves a significant role in neural protection by activating the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway, which also was associated with the neuroprotective the treatment with dexmedetomidine (DEX). Dexmedetomidine 282-297 vascular endothelial growth factor A Rattus norvegicus 81-85 29436655-1 2018 Brain-derived neurotrophic factor (BDNF) and vascular endothelial growth factor (VEGF) serves a significant role in neural protection by activating the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway, which also was associated with the neuroprotective the treatment with dexmedetomidine (DEX). Dexmedetomidine 299-302 vascular endothelial growth factor A Rattus norvegicus 45-79 29436655-1 2018 Brain-derived neurotrophic factor (BDNF) and vascular endothelial growth factor (VEGF) serves a significant role in neural protection by activating the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway, which also was associated with the neuroprotective the treatment with dexmedetomidine (DEX). Dexmedetomidine 299-302 vascular endothelial growth factor A Rattus norvegicus 81-85 29436655-2 2018 The present study aimed to further explore whether treatment with DEX post-IR increased the expression level of BDNF and VEGF in the rat brain. Dexmedetomidine 66-69 vascular endothelial growth factor A Rattus norvegicus 121-125 29436655-5 2018 The results indicated that the mRNA expression levels of BDNF and VEGF were higher in the I/R and DEX groups compared with expression levels in the Control group at 6 h and 1 day post-treatment; the levels of BNDF mRNA expression were higher in the DEX group compared with the I/R group. Dexmedetomidine 98-101 vascular endothelial growth factor A Rattus norvegicus 66-70 29436655-5 2018 The results indicated that the mRNA expression levels of BDNF and VEGF were higher in the I/R and DEX groups compared with expression levels in the Control group at 6 h and 1 day post-treatment; the levels of BNDF mRNA expression were higher in the DEX group compared with the I/R group. Dexmedetomidine 249-252 vascular endothelial growth factor A Rattus norvegicus 66-70 29436655-6 2018 The levels of BDNF and VEGF protein expression in the I/R and DEX groups were also significantly higher compared with those in the Control group. Dexmedetomidine 62-65 vascular endothelial growth factor A Rattus norvegicus 23-27 29436655-8 2018 Results from the present study indicated that post-surgical treatment with DEX may increase the expression of BDNF and VEGF following I/R, which may serve a role in nerve protection. Dexmedetomidine 75-78 vascular endothelial growth factor A Rattus norvegicus 119-123 29584740-10 2018 Expression of PGE2, 6-keto-PGF1alpha, COX-2, and VEGF in the gastric mucosa was upregulated in the PQS+DAPT group compared with the standard DAPT group. dapt 103-107 vascular endothelial growth factor A Rattus norvegicus 49-53 29806274-1 2018 Objective: To explore the effect of vascular endothelial growth factor 165 (VEGF 165)-loaded porous poly (epsilon-caprolactone) (PCL) scaffolds on the osteogenic differentiation of adipose-derived stem cells (ADSCs). polycaprolactone 100-127 vascular endothelial growth factor A Rattus norvegicus 76-80 29806274-15 2018 The results of Micro-CT and HE staining also confirmed the promotion effect of Sf-g/VEGF scaffolds. Helium 28-30 vascular endothelial growth factor A Rattus norvegicus 84-88 29643035-7 2018 Compared with the untreated diabetic rats, the rats with SU5416 treatment showed increased 24-h urinary protein, urea nitrogen, and nephrin expression and decreased TRPC6 expression without significant changes in fasting blood glucose, serum creatinine, or VEGF expression. Semaxinib 57-63 vascular endothelial growth factor A Rattus norvegicus 257-261 29643035-8 2018 The rats treated with LY294002 showed decreased 24-h urinary protein and TRPC6 expression without significant changes in fasting blood glucose, serum creatinine, urea nitrogen, or expressions of nephrin and VEGF. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 22-30 vascular endothelial growth factor A Rattus norvegicus 207-211 29241656-9 2018 In oxaliplatin-treated rats, the plasma concentration of vascular endothelial growth factor (pan VEGF-A) was increased while the isoform VEGF165b was upregulated in the spinal cord. Oxaliplatin 3-14 vascular endothelial growth factor A Rattus norvegicus 97-103 29241656-11 2018 The anti-VEGF-A monoclonal antibody bevacizumab (intraperitoneally) reduced oxaliplatin-dependent pain. Oxaliplatin 76-87 vascular endothelial growth factor A Rattus norvegicus 9-15 29367090-10 2018 Inhibition of NF-kappaB induced by MG was indicated by reduced the expression of p-p65 and VEGF in synovium. mangostin 35-37 vascular endothelial growth factor A Rattus norvegicus 91-95 29285756-6 2018 KEY RESULTS: mRNA levels of the kinin and VEGF systems were significantly enhanced at 2 weeks in streptozotocin (STZ)-retina compared to control-retina and were further increased at 6 weeks. Streptozocin 97-111 vascular endothelial growth factor A Rattus norvegicus 42-46 29285756-6 2018 KEY RESULTS: mRNA levels of the kinin and VEGF systems were significantly enhanced at 2 weeks in streptozotocin (STZ)-retina compared to control-retina and were further increased at 6 weeks. Streptozocin 113-116 vascular endothelial growth factor A Rattus norvegicus 42-46 29285756-11 2018 Intravitreal B1 receptor siRNA inhibited gene expression of kinin and VEGF systems in STZ-retina. Streptozocin 86-89 vascular endothelial growth factor A Rattus norvegicus 70-74 29203367-11 2018 NaHS increased Nrf-2, EGFr, VEGFA and decreased pro-inflammatory markers expression and IL-1beta, IL-2, IL-13, TNF-alpha, GM-CSF plasma concentration. sodium bisulfide 0-4 vascular endothelial growth factor A Rattus norvegicus 28-33 29203367-13 2018 We conclude that NaHS accelerates gastric ulcer healing increasing microcirculation and Nrf-2, EGFr, VEGFA expression. sodium bisulfide 17-21 vascular endothelial growth factor A Rattus norvegicus 101-106 29456715-0 2018 Protective effect of vitexin reduces sevoflurane-induced neuronal apoptosis through HIF-1alpha, VEGF and p38 MAPK signaling pathway in vitro and in newborn rats. vitexin 21-28 vascular endothelial growth factor A Rattus norvegicus 96-100 29456715-0 2018 Protective effect of vitexin reduces sevoflurane-induced neuronal apoptosis through HIF-1alpha, VEGF and p38 MAPK signaling pathway in vitro and in newborn rats. Sevoflurane 37-48 vascular endothelial growth factor A Rattus norvegicus 96-100 29456715-5 2018 Furthermore, it was revealed that treatment with vitexin induced hypoxia inducible factor 1alpha subunit (HIF-1alpha) and vascular endothelial growth factor (VEGF) protein expression, and suppressed phosphorylated-p38 MAP kinase (p38) protein expression in sevoflurane-induced newborn rat. vitexin 49-56 vascular endothelial growth factor A Rattus norvegicus 122-156 29456715-5 2018 Furthermore, it was revealed that treatment with vitexin induced hypoxia inducible factor 1alpha subunit (HIF-1alpha) and vascular endothelial growth factor (VEGF) protein expression, and suppressed phosphorylated-p38 MAP kinase (p38) protein expression in sevoflurane-induced newborn rat. vitexin 49-56 vascular endothelial growth factor A Rattus norvegicus 158-162 29456715-6 2018 Together, the results of the current study suggest that the protective effect of vitexin reduces sevoflurane-induced neuronal apoptosis through HIF-1alpha-, VEGF- and p38-associated signaling pathways in newborn rats. Sevoflurane 97-108 vascular endothelial growth factor A Rattus norvegicus 157-161 29077517-15 2018 HIF-1alpha and VEGF both increased substantially after long-term hypoxia and decreased in the kidney after methazolamide treatment. Methazolamide 107-120 vascular endothelial growth factor A Rattus norvegicus 15-19 29644165-9 2018 The rats treated with Li-ESWT also had increased vascularity, which was confirmed by immunohistochemistry of rat endothelial cell antigen, while reverse-transcriptase polymerase chain reaction (RT-PCR) showed VEGF expression was significantly enhanced. li-eswt 22-29 vascular endothelial growth factor A Rattus norvegicus 209-213 29628979-10 2018 A rat aortic ring assay revealed that isomangiferin significantly inhibited blood vessel formation during VEGF-induced microvessel sprouting. isomangiferin 38-51 vascular endothelial growth factor A Rattus norvegicus 106-110 28786500-8 2018 The results indicated that the implantation of CS/CBD-VEGF into the model rats improved the survival rate and exerted beneficial effect on functional recovery. Cesium 47-49 vascular endothelial growth factor A Rattus norvegicus 54-58 29511499-0 2018 MiR-103 regulates the angiogenesis of ischemic stroke rats by targeting vascular endothelial growth factor (VEGF). mir-103 0-7 vascular endothelial growth factor A Rattus norvegicus 72-106 29511499-0 2018 MiR-103 regulates the angiogenesis of ischemic stroke rats by targeting vascular endothelial growth factor (VEGF). mir-103 0-7 vascular endothelial growth factor A Rattus norvegicus 108-112 29511499-1 2018 Objectives: To investigate the effect of miR-103 on the angiogenesis of ischemic stroke rats via targeting vascular endothelial growth factor (VEGF) at the molecular level. mir-103 41-48 vascular endothelial growth factor A Rattus norvegicus 107-141 29511499-1 2018 Objectives: To investigate the effect of miR-103 on the angiogenesis of ischemic stroke rats via targeting vascular endothelial growth factor (VEGF) at the molecular level. mir-103 41-48 vascular endothelial growth factor A Rattus norvegicus 143-147 29511499-5 2018 Dual-luciferase assay was used for analyzing the targeting relationship between miR-103 and VEGF. mir-103 80-87 vascular endothelial growth factor A Rattus norvegicus 92-96 29511499-7 2018 Down-regulating miR-103 with the miR-103 inhibitor enhanced VEGF, ameliorated the neurological scores, decreased infarct volume, and increased vascular density in rats after MCAO. mir-103 16-23 vascular endothelial growth factor A Rattus norvegicus 60-64 29511499-7 2018 Down-regulating miR-103 with the miR-103 inhibitor enhanced VEGF, ameliorated the neurological scores, decreased infarct volume, and increased vascular density in rats after MCAO. mir-103 33-40 vascular endothelial growth factor A Rattus norvegicus 60-64 29511499-9 2018 Additionally, we found that miR-103 could directly target VEGF and thereby lead to the down-expression of VEGF. mir-103 28-35 vascular endothelial growth factor A Rattus norvegicus 58-62 29511499-9 2018 Additionally, we found that miR-103 could directly target VEGF and thereby lead to the down-expression of VEGF. mir-103 28-35 vascular endothelial growth factor A Rattus norvegicus 106-110 29511499-10 2018 Meanwhile, si-VEGF could reverse the effect of miR-103 inhibitor on angiogenesis in rats subjected to MCAO. mir-103 47-54 vascular endothelial growth factor A Rattus norvegicus 14-18 29511499-11 2018 Conclusion: Inhibition of miR-103 could promote ischemic stroke angiogenesis and reduce infarction volume via enhancing VEGF, which provides a new target for the clinical treatment of ischemic stroke. mir-103 26-33 vascular endothelial growth factor A Rattus norvegicus 120-124 29490689-10 2018 RESULTS: The comparison of the GA and GAmet animals revealed that metformin decreased the weight as well as the glucose and insulin levels, slowed the proliferation of the theca interna and interstitial cells, as evidenced by Ki-67 and VEGF-A expression, and diminished CYP17 expression in the analyzed ovarian structures. Metformin 66-75 vascular endothelial growth factor A Rattus norvegicus 236-242 28887194-8 2018 Overall, our results demonstrate that hippocampal HIF-1alpha/VEGF signaling seems to be the upstream mechanism of isoflurane-induced cognitive impairment, and provides apotential preventive and therapeutic target for POCD. Isoflurane 114-124 vascular endothelial growth factor A Rattus norvegicus 61-65 28992645-9 2018 RESULTS: Compared with controls, the tirofiban-treated groups exhibited significantly larger mean areas of flap survival, significantly increased SOD activity, and vascular endothelial growth factor (VEGF) expression, and significantly reduced MDA level. Tirofiban 38-47 vascular endothelial growth factor A Rattus norvegicus 165-199 29479987-6 2018 Additionally, the HCC group declared mild positive immunoreaction for VEGF inhepatocytes while treatment with doxorubicin or ellagic acid was associated with a negative immunoreaction for VEGF.These results were supported by histological examination of liver tissue. Doxorubicin 110-121 vascular endothelial growth factor A Rattus norvegicus 188-192 29479987-6 2018 Additionally, the HCC group declared mild positive immunoreaction for VEGF inhepatocytes while treatment with doxorubicin or ellagic acid was associated with a negative immunoreaction for VEGF.These results were supported by histological examination of liver tissue. Ellagic Acid 125-137 vascular endothelial growth factor A Rattus norvegicus 188-192 29287196-11 2018 MEMC treatment significantly decreased Cox-2, VEGF, HDAC and MMP-2,-9 and increased Casp-3,-8 as compared to DENAgroup,which demonstrated that the anticancer effect of MEMC may be through the inhibition of angiogenesis, proliferation and metastasis and the activation of apoptosis. Mercury, chloro(2-methoxyethyl)- 0-4 vascular endothelial growth factor A Rattus norvegicus 46-50 29287196-11 2018 MEMC treatment significantly decreased Cox-2, VEGF, HDAC and MMP-2,-9 and increased Casp-3,-8 as compared to DENAgroup,which demonstrated that the anticancer effect of MEMC may be through the inhibition of angiogenesis, proliferation and metastasis and the activation of apoptosis. Mercury, chloro(2-methoxyethyl)- 168-172 vascular endothelial growth factor A Rattus norvegicus 46-50 28954306-7 2018 The serum VEGF level was negatively correlated with the sciatic NCV (r=-0.932, P<0.01) and positively correlated with the tail flick threshold temperature (r=0.835, P<0.01) as well as the water content of the sciatic nerve (r=0.901, P<0.01). Water 194-199 vascular endothelial growth factor A Rattus norvegicus 10-14 28954306-8 2018 CONCLUSION: Prostaglandin E1 could protect the peripheral nerve by improving sciatic nerve function, reducing the VEGF level, and decreasing the vascular permeability. Alprostadil 12-28 vascular endothelial growth factor A Rattus norvegicus 114-118 29434758-8 2018 Resveratrol significantly increased the expression of eNOS (P<0.01) and suppressed the expression of VEGF and p-p38 (both P<0.01) in rats with DRMI. Resveratrol 0-11 vascular endothelial growth factor A Rattus norvegicus 104-108 29434758-9 2018 These results suggest that treatment with resveratrol is able to improve cardiovascular function via inhibition of eNOS and VEGF, and suppression of p38 phosphorylation in rats with DRMI. Resveratrol 42-53 vascular endothelial growth factor A Rattus norvegicus 124-128 29411009-5 2018 Results: In diabetes, dh404 prevented vascular leakage into the retina and vitreous cavity as well as upregulation of the vascular permeability and angiogenic factors, VEGF, and angiopoietin-2, and inflammatory mediators, including TNF-alpha and IL-6. dh404 22-27 vascular endothelial growth factor A Rattus norvegicus 168-172 29130610-7 2018 Groups injected with zoledronic and dexamethasone had higher C-terminal cross-linked telopeptide of type 1 collagen (CTX-1), tartrate-resistant acid phosphatase 5b (TRACP 5b), and the number of osteoclast cells, with less vascular endothelial growth factor (VEGF) and osteocalcin (OCN). Zoledronic Acid 21-31 vascular endothelial growth factor A Rattus norvegicus 222-256 29130610-7 2018 Groups injected with zoledronic and dexamethasone had higher C-terminal cross-linked telopeptide of type 1 collagen (CTX-1), tartrate-resistant acid phosphatase 5b (TRACP 5b), and the number of osteoclast cells, with less vascular endothelial growth factor (VEGF) and osteocalcin (OCN). Zoledronic Acid 21-31 vascular endothelial growth factor A Rattus norvegicus 258-262 29130610-7 2018 Groups injected with zoledronic and dexamethasone had higher C-terminal cross-linked telopeptide of type 1 collagen (CTX-1), tartrate-resistant acid phosphatase 5b (TRACP 5b), and the number of osteoclast cells, with less vascular endothelial growth factor (VEGF) and osteocalcin (OCN). Dexamethasone 36-49 vascular endothelial growth factor A Rattus norvegicus 222-256 29130610-7 2018 Groups injected with zoledronic and dexamethasone had higher C-terminal cross-linked telopeptide of type 1 collagen (CTX-1), tartrate-resistant acid phosphatase 5b (TRACP 5b), and the number of osteoclast cells, with less vascular endothelial growth factor (VEGF) and osteocalcin (OCN). Dexamethasone 36-49 vascular endothelial growth factor A Rattus norvegicus 258-262 29130610-9 2018 CONCLUSION: Concurrent use of zoledronic and dexamethasone inhibits the expression of VEGF, OCN, and wound healing and increases the number of osteoclast cells, serum CTX-1, and TRACP-5b after discontinuation for 10 weeks. Zoledronic Acid 30-40 vascular endothelial growth factor A Rattus norvegicus 86-90 29130610-9 2018 CONCLUSION: Concurrent use of zoledronic and dexamethasone inhibits the expression of VEGF, OCN, and wound healing and increases the number of osteoclast cells, serum CTX-1, and TRACP-5b after discontinuation for 10 weeks. Dexamethasone 45-58 vascular endothelial growth factor A Rattus norvegicus 86-90 28887194-6 2018 Increases in HIF-1alpha and VEGF proteins and activation of MMP-2 in the hippocampus were also observed in the hippocamp of isoflurane-exposed rats compared with control rats. Isoflurane 124-134 vascular endothelial growth factor A Rattus norvegicus 28-32 28887194-7 2018 Pharmacological inhibition of HIF-1alpha activation by 3-(5"-hydroxymethyl-2"-furyl)-1-benzylindazole (YC-1) markedly suppressed the expression of HIF-1alpha, VEGF and MMP-2, and mitigated the severity of BBB disruption.YC-1 pretreatment also significantly attenuated isoflurane-induced cognitive deficits in the Morris water maze task. 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole 55-101 vascular endothelial growth factor A Rattus norvegicus 159-163 30108955-8 2018 Compound 9d interacts with rVEGF through hydrogen bonds in silico, thereby down-regulating the expression of VEGF in angiogenesis. Hydrogen 41-49 vascular endothelial growth factor A Rattus norvegicus 27-32 29289839-9 2018 Furthermore, ZJPE also alleviated the retinal electrophysiology changes and impaired morphology of the retina and lowered the high levels of TNF-alpha, IL-1beta, ICAM-1, VEGF, AGEs, and AR in the retina. zjpe 13-17 vascular endothelial growth factor A Rattus norvegicus 170-174 29248560-4 2018 The results showed that intranasal administration of VEGF (72h post-ischemia for 6 successive days) caused a significant improvement in the cognitive deficits induced by 2-VO, accompanied by a reversal of oxidative stress and VEGF depletion in the hippocampus. 2-vo 170-174 vascular endothelial growth factor A Rattus norvegicus 53-57 28992645-9 2018 RESULTS: Compared with controls, the tirofiban-treated groups exhibited significantly larger mean areas of flap survival, significantly increased SOD activity, and vascular endothelial growth factor (VEGF) expression, and significantly reduced MDA level. Tirofiban 38-47 vascular endothelial growth factor A Rattus norvegicus 201-205 29386650-1 2018 Oxygen-induced retinopathy (OIR) upregulates Muller cell vascular endothelial growth factor A (VEGFA) that causes intravitreal neovascularization similar to severe retinopathy of prematurity (ROP). Oxygen 0-6 vascular endothelial growth factor A Rattus norvegicus 57-93 29257241-0 2018 Salvianolic acid B recovers cognitive deficits and angiogenesis in a cerebral small vessel disease rat model via the STAT3/VEGF signaling pathway. salvianolic acid B 0-18 vascular endothelial growth factor A Rattus norvegicus 123-127 29257241-5 2018 In addition, salvianolic acid B upregulated signal transducer and activator of transcription 3 (STAT3) phosphorylation protein expression, and induced vascular endothelial growth factor (VEGF) and VEGF receptor 2 protein expression in cerebral small vessel disease rats. salvianolic acid B 13-31 vascular endothelial growth factor A Rattus norvegicus 151-185 29257241-5 2018 In addition, salvianolic acid B upregulated signal transducer and activator of transcription 3 (STAT3) phosphorylation protein expression, and induced vascular endothelial growth factor (VEGF) and VEGF receptor 2 protein expression in cerebral small vessel disease rats. salvianolic acid B 13-31 vascular endothelial growth factor A Rattus norvegicus 187-191 29257241-5 2018 In addition, salvianolic acid B upregulated signal transducer and activator of transcription 3 (STAT3) phosphorylation protein expression, and induced vascular endothelial growth factor (VEGF) and VEGF receptor 2 protein expression in cerebral small vessel disease rats. salvianolic acid B 13-31 vascular endothelial growth factor A Rattus norvegicus 197-201 29257241-6 2018 In conclusion, the results demonstrated that salvianolic acid B recovers cognitive deficits and angiogenesis in the cerebral small vessel disease rat model via STAT3/VEGF signaling pathway. salvianolic acid 45-61 vascular endothelial growth factor A Rattus norvegicus 166-170 29386650-1 2018 Oxygen-induced retinopathy (OIR) upregulates Muller cell vascular endothelial growth factor A (VEGFA) that causes intravitreal neovascularization similar to severe retinopathy of prematurity (ROP). Oxygen 0-6 vascular endothelial growth factor A Rattus norvegicus 95-100 29387016-7 2017 We found that, compared with the AMI model rats, in rats treated by TPAE, the CEPC counts, the expression of VEGF, eNOS, NO, and MMP-9 in myocardial tissue and their plasma content all increased more rapidly 7 days after AMI and remained at higher level (P < 0.05 or P < 0.01). tpae 68-72 vascular endothelial growth factor A Rattus norvegicus 109-113 29387016-8 2017 Our results showed that, in AMI rats, the TPAE could significantly promote the mobilization of EPC and up-regulate the expression level of VEGF, eNOS, NO, and MMP-9 in myocardium and their plasma content. tpae 42-46 vascular endothelial growth factor A Rattus norvegicus 139-143 29330453-6 2018 Levels of VEGF, BMP-2 and TGF-beta1 in CS-induced membrane were insignificantly higher than those in PMMA-induced membrane at different time points. Cesium 39-41 vascular endothelial growth factor A Rattus norvegicus 10-14 29565168-8 2018 Induction of Vegfa, Igf1and Ctgfgene expressions might indicate a favorable influence of teduglutide on the intestinal anastomotic healing. teduglutide 89-100 vascular endothelial growth factor A Rattus norvegicus 13-18 29169872-6 2018 Moreover, quercetin administration progressively increased the expression of vascular endothelial growth factor (VEGF) and its receptor, VEGFR2 in diabetes rats. Quercetin 10-19 vascular endothelial growth factor A Rattus norvegicus 77-111 29169872-6 2018 Moreover, quercetin administration progressively increased the expression of vascular endothelial growth factor (VEGF) and its receptor, VEGFR2 in diabetes rats. Quercetin 10-19 vascular endothelial growth factor A Rattus norvegicus 113-117 29330453-10 2018 CS-induced membrane has a better capacity of generating VEGF, BMP-2 and TGF-beta1.osteogenic and neovascular activities achieve highest level at 6 week. Cesium 0-2 vascular endothelial growth factor A Rattus norvegicus 56-60 29893708-6 2018 In addition, compared with rats in the Rapamycin + TAE group, N-cadherin, Vimentin, HIF-1alpha, VEGF, and MVD-CD34 were obviously enhanced, while E-cadherin was lowered in those TAE group, which were the complete opposite to the Rapamycin group. Sirolimus 39-48 vascular endothelial growth factor A Rattus norvegicus 96-100 29101801-10 2018 Furthermore, the levels of VEGF were significantly higher at day 1 post-wounding in those treated with sodium usnic acid. sodium usnic acid 103-120 vascular endothelial growth factor A Rattus norvegicus 27-31 29435181-6 2018 Serum glucose in diabetes group and diabetes + VEGF group obviously exceeded 13mmol/L after STZ injection. Streptozocin 92-95 vascular endothelial growth factor A Rattus norvegicus 47-51 29219024-8 2018 Furthermore, excess maternal thyroxine reduced cell proliferation and vascular endothelial growth factor (VEGF) expression in the growth cartilage of newborn and 20-day-old rats ( P < 0.05). Thyroxine 29-38 vascular endothelial growth factor A Rattus norvegicus 70-104 29196964-0 2018 The earlier, the better: the effects of different administration timepoints of sorafenib in suppressing the carcinogenesis of VEGF in rats. Sorafenib 79-88 vascular endothelial growth factor A Rattus norvegicus 126-130 29196964-1 2018 PURPOSE: To investigate the optimal starting time point of sorafenib therapy in suppressing the tumor-promoting effects of VEGF up-regulation, which is frequently found after local therapy in clinical practice. Sorafenib 59-68 vascular endothelial growth factor A Rattus norvegicus 123-127 29196964-11 2018 CONCLUSIONS: According to our results, the most suitable regimen for the administration of sorafenib is before the increased expression of VEGF, which showed a potential advantage for controlling the tumor growth and prolonging the survival time of test animal via inhibiting VEGF-receptor expression through the bifunction of VEGF, and the reduction of tumor angiogenesis. Sorafenib 91-100 vascular endothelial growth factor A Rattus norvegicus 139-143 29196964-11 2018 CONCLUSIONS: According to our results, the most suitable regimen for the administration of sorafenib is before the increased expression of VEGF, which showed a potential advantage for controlling the tumor growth and prolonging the survival time of test animal via inhibiting VEGF-receptor expression through the bifunction of VEGF, and the reduction of tumor angiogenesis. Sorafenib 91-100 vascular endothelial growth factor A Rattus norvegicus 276-280 29196964-11 2018 CONCLUSIONS: According to our results, the most suitable regimen for the administration of sorafenib is before the increased expression of VEGF, which showed a potential advantage for controlling the tumor growth and prolonging the survival time of test animal via inhibiting VEGF-receptor expression through the bifunction of VEGF, and the reduction of tumor angiogenesis. Sorafenib 91-100 vascular endothelial growth factor A Rattus norvegicus 276-280 29219024-8 2018 Furthermore, excess maternal thyroxine reduced cell proliferation and vascular endothelial growth factor (VEGF) expression in the growth cartilage of newborn and 20-day-old rats ( P < 0.05). Thyroxine 29-38 vascular endothelial growth factor A Rattus norvegicus 106-110 29345720-0 2018 Effects of nicotine administration in rats on MMP2 and VEGF levels in periodontal membrane. Nicotine 11-19 vascular endothelial growth factor A Rattus norvegicus 55-59 30016789-10 2018 The VNS-induced VEGF-A/B expressions and angiogenesis were abolished by m-AChR inhibitor atropine and alpha7-nAChR blocker mecamylamine in vivo. Atropine 89-97 vascular endothelial growth factor A Rattus norvegicus 16-22 30016789-10 2018 The VNS-induced VEGF-A/B expressions and angiogenesis were abolished by m-AChR inhibitor atropine and alpha7-nAChR blocker mecamylamine in vivo. Mecamylamine 123-135 vascular endothelial growth factor A Rattus norvegicus 16-22 30016789-15 2018 Mechanistically, vagal neurotransmitter acetylcholine stimulated VEGF-A/B expressions through m/nACh-R/PI3K/Akt/Sp1 pathway in EC. Acetylcholine 40-53 vascular endothelial growth factor A Rattus norvegicus 65-71 30394217-8 2018 Employing darapladib as an agent of Lp-PLA2 selective inhibitors, this study aimed to find out the effect of darapladib as an Lp- PLA2 selective inhibitor agent on the formation of vasa vasorum angiogenesis and the decrease of HIF-1alpha and VEGF expression in aortic tissue of rats with dyslipidemia. darapladib 109-119 vascular endothelial growth factor A Rattus norvegicus 242-246 30394217-12 2018 RESULTS: The study results which were analyzed using NOVA test showed that with darapladib administration, there was a significant decrease in vasa vasorum angiogenesis (p=0.000), HIF-1alpha (p=0.005) and VEGF (p=0.009) expression in each time series. darapladib 80-90 vascular endothelial growth factor A Rattus norvegicus 205-209 30394217-14 2018 CONCLUSION: Darapladib injection as an Lp-PLA2 selective inhibitor correlates with the decreasing vasa vasorum angiogenesis through alteration in HIF-1alpha and VEGF expressions in the aorta of high fat diet rats. darapladib 12-22 vascular endothelial growth factor A Rattus norvegicus 161-165 30198795-9 2018 Arginine and ADMA rose at P7 in the L-Cit group whose members also showed higher VEGF levels with respect to the Controls. Arginine 0-8 vascular endothelial growth factor A Rattus norvegicus 81-85 30198795-9 2018 Arginine and ADMA rose at P7 in the L-Cit group whose members also showed higher VEGF levels with respect to the Controls. Citrulline 36-41 vascular endothelial growth factor A Rattus norvegicus 81-85 29345720-2 2018 This article aimed at identifying the expression of matrix metalloproteinases 2 (MMPs2) and vascular endothelial growth factor (VEGF) proteins on extracellular matrix, fibrous distribution and angiogenetic development in periodontitis caused by nicotine effects on periodontal membrane. Nicotine 245-253 vascular endothelial growth factor A Rattus norvegicus 92-126 30509036-9 2018 The expression of ICAM-1 and VEGF in rat brain tissue was rare in the sham group, but was significantly elevated in the CIR group (p < 0.05) and even higher in the CIH group, compared to the CIR group. cih 167-170 vascular endothelial growth factor A Rattus norvegicus 29-33 29345720-2 2018 This article aimed at identifying the expression of matrix metalloproteinases 2 (MMPs2) and vascular endothelial growth factor (VEGF) proteins on extracellular matrix, fibrous distribution and angiogenetic development in periodontitis caused by nicotine effects on periodontal membrane. Nicotine 245-253 vascular endothelial growth factor A Rattus norvegicus 128-132 30509036-10 2018 Hence, the brain injury in ischemia-reperfusion rat models following CIH intervention may be related to the increased expression of ICAM-1 and VEGF. cih 69-72 vascular endothelial growth factor A Rattus norvegicus 143-147 29138802-10 2018 Ginsenoside may initiate the expression of downstream VEGF, which is involved in promoting the survival, self-renewal and differentiation of NSCs. Ginsenosides 0-11 vascular endothelial growth factor A Rattus norvegicus 54-58 29229114-11 2018 In addition, 17beta-estradiol significantly prevented the ex-vivo release of IL-1beta and VEGF from lung tissue. Estradiol 13-29 vascular endothelial growth factor A Rattus norvegicus 90-94 29257210-6 2018 Tanshinone IIA effectively suppressed the protein expression of inducible nitric oxide synthase (NOS), phosphorylated (p-) nuclear factor (NF)-kappaB, p-p38MAPK and VEGF, and activated the phosphorylation of inhibitor of NF-kappaB and the protein expression of neuronal NOS in the SCP rat model. tanshinone 0-14 vascular endothelial growth factor A Rattus norvegicus 165-169 29071768-10 2018 Furthermore, SAA inhibited platelet activation, elevated Klotho protein expression and up-regulated vascular endothelial growth factor A expression. salvianolic acid A 13-16 vascular endothelial growth factor A Rattus norvegicus 100-136 29111778-0 2018 Multi-Carotenoids at Physiological Levels Inhibit VEGF-Induced Tube Formation of Endothelial Cells and the Possible Mechanisms of Action Both In Vitro and Ex Vivo. multi-carotenoids 0-17 vascular endothelial growth factor A Rattus norvegicus 50-54 29597206-15 2018 It was observed that curcumin attenuated the expression of VEGF in the retina of diabetic rats. Curcumin 21-29 vascular endothelial growth factor A Rattus norvegicus 59-63 29597206-17 2018 CONCLUSIONS: Taken together, these results suggest that curcumin may have great therapeutic potential in the treatment of diabetic retinopathy which could be attributed to the hypoglycemic, antioxidant, VEGF-downregulating and neuroprotection properties of curcumin. Curcumin 56-64 vascular endothelial growth factor A Rattus norvegicus 203-207 29597206-17 2018 CONCLUSIONS: Taken together, these results suggest that curcumin may have great therapeutic potential in the treatment of diabetic retinopathy which could be attributed to the hypoglycemic, antioxidant, VEGF-downregulating and neuroprotection properties of curcumin. Curcumin 257-265 vascular endothelial growth factor A Rattus norvegicus 203-207 29485632-8 2017 Decreased fetal weight was also observed in HS + lip group accompanied with an increase in PIGF, and VEGF levels with no change in blood pressure, protein and liver enzymes. hs + lip 44-52 vascular endothelial growth factor A Rattus norvegicus 101-105 29479160-9 2018 Conclusion: Findings of this study revealed that EBN promotes proliferation of the uterine structures as evidenced by the upregulation of the expressions of steroid receptors, EGF, REGF, VEGF, and PCNA in the uterus and increased in the plasma concentrations of AO and reduced levels of OS. CHEMBL3344321 49-52 vascular endothelial growth factor A Rattus norvegicus 187-191 29259285-4 2017 Fenofibrate reduced not only mRNA expression of vascular endothelial growth factor-A but also angiopoietin-1 and angiopoietin-2. Fenofibrate 0-11 vascular endothelial growth factor A Rattus norvegicus 48-84 29162665-18 2017 Curcumin also attenuated splanchnic hyperdynamic circulation by inducing vasoconstriction through inhibition of eNOS activation and by decreasing mesenteric angiogenesis via VEGF pathway blockade. Curcumin 0-8 vascular endothelial growth factor A Rattus norvegicus 174-178 29306257-6 2017 A significant difference was noted between the sham and LMSC groups concerning VEGF staining intensity (P = 0.017). lmsc 56-60 vascular endothelial growth factor A Rattus norvegicus 79-83 29285153-0 2017 Effects of quercetin on the expression of MCP-1, MMP-9 and VEGF in rats with diabetic retinopathy. Quercetin 11-20 vascular endothelial growth factor A Rattus norvegicus 59-63 29321959-11 2018 Voluntary exercise promoted pilocarpine-induced saliva secretion, probably via an increase in the expression level of AQP1 due to VEGF-induced CD31-positive angiogenesis in the SMG. Pilocarpine 28-39 vascular endothelial growth factor A Rattus norvegicus 130-134 29399548-11 2017 Conclusion: Verapamil has significant anti-inflammatory and anti-angiogenesis effects in the air pouch model probably due to attenuation effects of verapamil on IL-1beta and VEGF. Verapamil 12-21 vascular endothelial growth factor A Rattus norvegicus 174-178 29399548-11 2017 Conclusion: Verapamil has significant anti-inflammatory and anti-angiogenesis effects in the air pouch model probably due to attenuation effects of verapamil on IL-1beta and VEGF. Verapamil 148-157 vascular endothelial growth factor A Rattus norvegicus 174-178 29399553-7 2017 Results: Our results showed significant down-regulation of Syp, Mapk3 and Tnfalpha and up-regulation of Vegf in rat"s hippocampus after treatment with ectoine comparing to the STZ-induced group. ectoine 151-158 vascular endothelial growth factor A Rattus norvegicus 104-108 28953090-0 2017 Hyperbaric oxygen promotes neural stem cell proliferation by activating vascular endothelial growth factor/extracellular signal-regulated kinase signaling after traumatic brain injury. Oxygen 11-17 vascular endothelial growth factor A Rattus norvegicus 72-106 29629873-8 2017 ELP-VEGF infusion increased total plasma soluble fms-like tyrosine kinase-1 levels but dramatically reduced free plasma soluble fms-like tyrosine kinase-1 and induced urinary excretion of nitrate/nitrite, indicating enhanced renal nitric oxide signaling. Nitrates 188-195 vascular endothelial growth factor A Rattus norvegicus 4-8 29629873-8 2017 ELP-VEGF infusion increased total plasma soluble fms-like tyrosine kinase-1 levels but dramatically reduced free plasma soluble fms-like tyrosine kinase-1 and induced urinary excretion of nitrate/nitrite, indicating enhanced renal nitric oxide signaling. Nitrites 196-203 vascular endothelial growth factor A Rattus norvegicus 4-8 29629873-8 2017 ELP-VEGF infusion increased total plasma soluble fms-like tyrosine kinase-1 levels but dramatically reduced free plasma soluble fms-like tyrosine kinase-1 and induced urinary excretion of nitrate/nitrite, indicating enhanced renal nitric oxide signaling. Nitric Oxide 231-243 vascular endothelial growth factor A Rattus norvegicus 4-8 29285153-10 2017 No significant difference in serum MCP-1 content was found between the model group and the quercetin group, but levels of MMP-9 and VEGF were significantly decreased in the quercetin group (P<0.01). Quercetin 173-182 vascular endothelial growth factor A Rattus norvegicus 132-136 29285153-12 2017 No significant differences in expression levels of MCP-1 mRNA and protein were found between the model group and the quercetin group, but levels of MMP-9 and VEGF mRNA and protein were significantly decreased in the quercetin group (P<0.01). Quercetin 216-225 vascular endothelial growth factor A Rattus norvegicus 158-162 29285153-13 2017 Quercetin has a certain therapeutic effect on rats with diabetic retinopathy and its effect may be achieved by reducing the expression of MMP-9 and VEGF, but not the inflammatory mediator, MCP-1. Quercetin 0-9 vascular endothelial growth factor A Rattus norvegicus 148-152 27844282-4 2017 Administration of 6-OHDA into MFB in addition to a remarkable depletion of dopamine in the nigrostriatal system induced an increase of glial fibrillary acidic protein (GFAP)-positive cells in SN and an intense immunoreactivity for OX-42, vascular endothelial growth factor (VEGF), and Lycopersycum esculentum agglutinin (LEA) in striatum and SN. Dopamine 75-83 vascular endothelial growth factor A Rattus norvegicus 238-272 28277073-0 2017 Enhancement of vascular endothelial growth factor"s angiogenic capacity by the therapeutic modulation of notch signalling improves tram flap survival in rats submitted to nicotine. Nicotine 171-179 vascular endothelial growth factor A Rattus norvegicus 15-49 28277073-2 2017 Considering that Notch signalling through its ligand Delta-like 4 (Dll4) functions as anti-angiogenic factor by inhibiting the pro-angiogenic effects of vascular endothelial growth factor (VEGF), it is hypothesised that inhibition of the Notch would promote angiogenesis and increase TRAM flap survival in rats submitted to nicotine. Nicotine 324-332 vascular endothelial growth factor A Rattus norvegicus 189-193 28277073-15 2017 CONCLUSION: Notch inhibition significantly improved TRAM flap survival in animals exposed to nicotine by promoting VEGF-induced angiogenesis. Nicotine 93-101 vascular endothelial growth factor A Rattus norvegicus 115-119 27844282-4 2017 Administration of 6-OHDA into MFB in addition to a remarkable depletion of dopamine in the nigrostriatal system induced an increase of glial fibrillary acidic protein (GFAP)-positive cells in SN and an intense immunoreactivity for OX-42, vascular endothelial growth factor (VEGF), and Lycopersycum esculentum agglutinin (LEA) in striatum and SN. Dopamine 75-83 vascular endothelial growth factor A Rattus norvegicus 274-278 27844282-4 2017 Administration of 6-OHDA into MFB in addition to a remarkable depletion of dopamine in the nigrostriatal system induced an increase of glial fibrillary acidic protein (GFAP)-positive cells in SN and an intense immunoreactivity for OX-42, vascular endothelial growth factor (VEGF), and Lycopersycum esculentum agglutinin (LEA) in striatum and SN. Oxidopamine 18-24 vascular endothelial growth factor A Rattus norvegicus 238-272 27844282-4 2017 Administration of 6-OHDA into MFB in addition to a remarkable depletion of dopamine in the nigrostriatal system induced an increase of glial fibrillary acidic protein (GFAP)-positive cells in SN and an intense immunoreactivity for OX-42, vascular endothelial growth factor (VEGF), and Lycopersycum esculentum agglutinin (LEA) in striatum and SN. Oxidopamine 18-24 vascular endothelial growth factor A Rattus norvegicus 274-278 30632530-11 2018 Sorafenib and etanercept decreased tissue VEGF and VEGF receptor levels, perisynovial inflammation, damage of cartilage/bone. Sorafenib 0-9 vascular endothelial growth factor A Rattus norvegicus 42-46 29211249-0 2017 Effects of bone morphogenetic protein-2 (BMP-2) and vascular endothelial growth factor (VEGF) release from polylactide-poly (ethylene glycol)-polylactide (PELA) microcapsule-based scaffolds on bone. polylactide-polyethylene glycol-polylactide 107-153 vascular endothelial growth factor A Rattus norvegicus 52-86 29211249-0 2017 Effects of bone morphogenetic protein-2 (BMP-2) and vascular endothelial growth factor (VEGF) release from polylactide-poly (ethylene glycol)-polylactide (PELA) microcapsule-based scaffolds on bone. polylactide-polyethylene glycol-polylactide 107-153 vascular endothelial growth factor A Rattus norvegicus 88-92 29211249-0 2017 Effects of bone morphogenetic protein-2 (BMP-2) and vascular endothelial growth factor (VEGF) release from polylactide-poly (ethylene glycol)-polylactide (PELA) microcapsule-based scaffolds on bone. polylactide-polyethylene glycol-polylactide 155-159 vascular endothelial growth factor A Rattus norvegicus 52-86 29211249-0 2017 Effects of bone morphogenetic protein-2 (BMP-2) and vascular endothelial growth factor (VEGF) release from polylactide-poly (ethylene glycol)-polylactide (PELA) microcapsule-based scaffolds on bone. polylactide-polyethylene glycol-polylactide 155-159 vascular endothelial growth factor A Rattus norvegicus 88-92 29211249-2 2017 We investigated the effects of sequential release of bone morphogenetic protein-2 (BMP-2) and vascular endothelial growth factor (VEGF) from polylactide-poly (ethylene glycol)-polylactide (PELA) microcapsule-based scaffolds on bone regeneration. poly(lactide) 141-152 vascular endothelial growth factor A Rattus norvegicus 94-128 29211249-2 2017 We investigated the effects of sequential release of bone morphogenetic protein-2 (BMP-2) and vascular endothelial growth factor (VEGF) from polylactide-poly (ethylene glycol)-polylactide (PELA) microcapsule-based scaffolds on bone regeneration. poly(lactide) 141-152 vascular endothelial growth factor A Rattus norvegicus 130-134 29211249-2 2017 We investigated the effects of sequential release of bone morphogenetic protein-2 (BMP-2) and vascular endothelial growth factor (VEGF) from polylactide-poly (ethylene glycol)-polylactide (PELA) microcapsule-based scaffolds on bone regeneration. poly(lactide) 176-187 vascular endothelial growth factor A Rattus norvegicus 130-134 30632530-11 2018 Sorafenib and etanercept decreased tissue VEGF and VEGF receptor levels, perisynovial inflammation, damage of cartilage/bone. Sorafenib 0-9 vascular endothelial growth factor A Rattus norvegicus 51-55 30632530-12 2018 Conclusion: Our findings indicate that sorafenib treatment ameliorates collagen-induced arthritis with anti-VEGF effectiveness. Sorafenib 39-48 vascular endothelial growth factor A Rattus norvegicus 108-112 28844859-7 2017 Both the stimulation of VEGF and the inhibition of HGF could be partly prevented by 4-PBA or Salubrinal. 4-phenylbutyric acid 84-89 vascular endothelial growth factor A Rattus norvegicus 24-28 29218089-4 2017 Moreover, sildenafil dramatically decreased the expression of transforming growth factor-beta1 (TGF-beta1), vascular endothelial growth factor (VEGF), and alpha-smooth muscle actin (alpha-SMA) in the grafted aortas and increased the concentrations of cyclic guanosine monophosphate (cGMP) and endothelial nitric oxide synthase (eNOS) in serum. Sildenafil Citrate 10-20 vascular endothelial growth factor A Rattus norvegicus 108-142 29218089-4 2017 Moreover, sildenafil dramatically decreased the expression of transforming growth factor-beta1 (TGF-beta1), vascular endothelial growth factor (VEGF), and alpha-smooth muscle actin (alpha-SMA) in the grafted aortas and increased the concentrations of cyclic guanosine monophosphate (cGMP) and endothelial nitric oxide synthase (eNOS) in serum. Sildenafil Citrate 10-20 vascular endothelial growth factor A Rattus norvegicus 144-148 29140979-11 2017 Immunohistochemical and Western Blotting assays confirmed that the expression of VEGF, p-Akt, and p-mTOR was down-regulated in ginsenoside Rg3 -treated lesions. Ginsenosides 127-138 vascular endothelial growth factor A Rattus norvegicus 81-85 28844859-7 2017 Both the stimulation of VEGF and the inhibition of HGF could be partly prevented by 4-PBA or Salubrinal. salubrinal 93-103 vascular endothelial growth factor A Rattus norvegicus 24-28 28969989-12 2017 Pioglitazone did not influence the hemodynamic parameters, glucose and liver biochemistry levels, oxygen saturation and alveolar arterial gradient, but significantly down-regulated pulmonary VEGF protein expression, endothelial NO synthase (eNOS) activation, and decreased intrapulmonary shunts. Pioglitazone 0-12 vascular endothelial growth factor A Rattus norvegicus 191-195 28969989-14 2017 CONCLUSION: Pioglitazone down-regulated VEGF, eNOS and decreased intrapulmonary shunts without improving oxygenation. Pioglitazone 12-24 vascular endothelial growth factor A Rattus norvegicus 40-44 28666582-11 2017 CONCLUSIONS: Clonidine increased VEGF and VEGF-receptor expression, decreased HMGB1 expression, decreased lung inflammation, and improved lung tissue repair. Clonidine 13-22 vascular endothelial growth factor A Rattus norvegicus 42-46 29383122-5 2017 Meanwhile, posttreatment with corilagin in MCAO rats significantly decreased malondialdehyde levels, restored the superoxide dismutase and glutathione activity, elevating the Nrf2, heme oxygenase-1, the vascular endothelial growth factor (VEGF) and VEGF receptor 2 (VEGFR2) expression. corilagin 30-39 vascular endothelial growth factor A Rattus norvegicus 203-237 29383122-5 2017 Meanwhile, posttreatment with corilagin in MCAO rats significantly decreased malondialdehyde levels, restored the superoxide dismutase and glutathione activity, elevating the Nrf2, heme oxygenase-1, the vascular endothelial growth factor (VEGF) and VEGF receptor 2 (VEGFR2) expression. corilagin 30-39 vascular endothelial growth factor A Rattus norvegicus 239-243 28807800-4 2017 The results showed that SMS bioceramics could enhance ALP activity and expression of Col 1, OCN, Runx2, and angiogenic factors including VEGF and Ang-1. sms 24-27 vascular endothelial growth factor A Rattus norvegicus 137-141 28807800-13 2017 The results showed that SMS bioceramics could enhance ALP activity and expression of Col 1, OCN, Runx2 and angiogenic factors including VEGF and Ang-1. sms 24-27 vascular endothelial growth factor A Rattus norvegicus 136-140 28944889-9 2017 Furthermore, MAE-P6 increased the expression levels of VEGFA and reduced NF-kappaB expression through Akt, which was verified by treatment with the Akt-specific inhibitor, LY294002. mae-p6 13-19 vascular endothelial growth factor A Rattus norvegicus 55-60 28944889-9 2017 Furthermore, MAE-P6 increased the expression levels of VEGFA and reduced NF-kappaB expression through Akt, which was verified by treatment with the Akt-specific inhibitor, LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 172-180 vascular endothelial growth factor A Rattus norvegicus 55-60 28899730-11 2017 A significant increase in the gene expression of growth factors (FGF2 and VEGF), was noted in the spinal cord of EGCG-treated rats. epigallocatechin gallate 113-117 vascular endothelial growth factor A Rattus norvegicus 74-78 28964802-9 2017 In particular, PACAP treatment downregulates VEGF and VEGFRs that are increasingly expressed in STZ-treated animals as compared to controls. Streptozocin 96-99 vascular endothelial growth factor A Rattus norvegicus 45-49 30294225-10 2017 In addition, immunohistochemistry (IHC) also revealed that the protein expressions of growth factors [transforming growth factor beta1 (TGF-beta1) and vascular endothelial growth factor (VEGF)] in prostate tissue were decreased in the KH053 group. kh053 235-240 vascular endothelial growth factor A Rattus norvegicus 151-185 30294225-10 2017 In addition, immunohistochemistry (IHC) also revealed that the protein expressions of growth factors [transforming growth factor beta1 (TGF-beta1) and vascular endothelial growth factor (VEGF)] in prostate tissue were decreased in the KH053 group. kh053 235-240 vascular endothelial growth factor A Rattus norvegicus 187-191 29023577-8 2017 At the same time, it was evaluated if sevoflurane effects are mediated through VEGF. Sevoflurane 38-49 vascular endothelial growth factor A Rattus norvegicus 79-83 29023577-13 2017 Increased expression of VEGF after H/R was attenuated by sevoflurane by 34% (p = 0.004). Sevoflurane 57-68 vascular endothelial growth factor A Rattus norvegicus 24-28 29023577-15 2017 Furthermore, the protective effect of sevoflurane was abolished in the presence of recombinant VEGF. Sevoflurane 38-49 vascular endothelial growth factor A Rattus norvegicus 95-99 29023577-16 2017 CONCLUSIONS: In H/R-induced rat brain endothelial cell injury sevoflurane maintains endothelial barrier function through downregulation of VEGF, which is a key player not only in mediating injury, but also with regard to the protective effect of sevoflurane. r 18-19 vascular endothelial growth factor A Rattus norvegicus 139-143 29023577-16 2017 CONCLUSIONS: In H/R-induced rat brain endothelial cell injury sevoflurane maintains endothelial barrier function through downregulation of VEGF, which is a key player not only in mediating injury, but also with regard to the protective effect of sevoflurane. Sevoflurane 62-73 vascular endothelial growth factor A Rattus norvegicus 139-143 29023577-16 2017 CONCLUSIONS: In H/R-induced rat brain endothelial cell injury sevoflurane maintains endothelial barrier function through downregulation of VEGF, which is a key player not only in mediating injury, but also with regard to the protective effect of sevoflurane. Sevoflurane 246-257 vascular endothelial growth factor A Rattus norvegicus 139-143 29212216-3 2017 Naringin accelerates angiogenesis by activating the expression of vascular endothelial growth factor (VEGF). naringin 0-8 vascular endothelial growth factor A Rattus norvegicus 66-100 29212216-3 2017 Naringin accelerates angiogenesis by activating the expression of vascular endothelial growth factor (VEGF). naringin 0-8 vascular endothelial growth factor A Rattus norvegicus 102-106 28666582-1 2017 BACKGROUND: We hypothesized that clonidine and propranolol would increase VEGF and VEGF-receptor expression and promote lung healing following severe trauma and chronic stress. Clonidine 33-42 vascular endothelial growth factor A Rattus norvegicus 74-78 28666582-1 2017 BACKGROUND: We hypothesized that clonidine and propranolol would increase VEGF and VEGF-receptor expression and promote lung healing following severe trauma and chronic stress. Clonidine 33-42 vascular endothelial growth factor A Rattus norvegicus 83-87 28666582-1 2017 BACKGROUND: We hypothesized that clonidine and propranolol would increase VEGF and VEGF-receptor expression and promote lung healing following severe trauma and chronic stress. Propranolol 47-58 vascular endothelial growth factor A Rattus norvegicus 74-78 28666582-1 2017 BACKGROUND: We hypothesized that clonidine and propranolol would increase VEGF and VEGF-receptor expression and promote lung healing following severe trauma and chronic stress. Propranolol 47-58 vascular endothelial growth factor A Rattus norvegicus 83-87 28666582-6 2017 RESULTS: Clonidine increased VEGF expression following LCHS (43%*) and LCHS/CS (46%*). Clonidine 9-18 vascular endothelial growth factor A Rattus norvegicus 29-33 28666582-10 2017 Propranolol minimally affected VEGF and did not improve lung healing. Propranolol 0-11 vascular endothelial growth factor A Rattus norvegicus 31-35 28666582-11 2017 CONCLUSIONS: Clonidine increased VEGF and VEGF-receptor expression, decreased HMGB1 expression, decreased lung inflammation, and improved lung tissue repair. Clonidine 13-22 vascular endothelial growth factor A Rattus norvegicus 33-37 29042978-7 2017 In addition, ticagrelor significantly decreased the ulcer-stimulated expression levels of EGF, VEGF, phosphorylated extracellular signal-regulated kinase (ERK), phosphorylated P38 mitogen-activated protein kinase and nuclear factor-kappaB P65 at the ulcer margin (P<0.05). Ticagrelor 13-23 vascular endothelial growth factor A Rattus norvegicus 95-99 28836407-0 2017 Administration of Selenium Decreases Lipid Peroxidation and Increases Vascular Endothelial Growth Factor in Streptozotocin Induced Diabetes Mellitus. Selenium 18-26 vascular endothelial growth factor A Rattus norvegicus 70-104 28836407-0 2017 Administration of Selenium Decreases Lipid Peroxidation and Increases Vascular Endothelial Growth Factor in Streptozotocin Induced Diabetes Mellitus. Streptozocin 108-122 vascular endothelial growth factor A Rattus norvegicus 70-104 28836407-3 2017 Se treatment induces angiogenesis and improves endothelial function through increased expression of vascular endothelial growth factor (VEGF). Selenium 0-2 vascular endothelial growth factor A Rattus norvegicus 100-134 28836407-3 2017 Se treatment induces angiogenesis and improves endothelial function through increased expression of vascular endothelial growth factor (VEGF). Selenium 0-2 vascular endothelial growth factor A Rattus norvegicus 136-140 28836407-4 2017 The aim of this study is to investigate the effect of selenium on oxidative stress, VEGF, and endothelin 1 (ET1) in a DM rat model. Selenium 54-62 vascular endothelial growth factor A Rattus norvegicus 84-88 28836407-16 2017 Se administration reversed the increased MDA and decreased VEGF levels, and lowered plasma glucose levels in the DM+Se7 and DM+Se21 diabetic groups compared with diabetic rats (DM7, DM21). Selenium 0-2 vascular endothelial growth factor A Rattus norvegicus 59-63 28640960-0 2017 Ferulic acid alleviates symptoms of preeclampsia in rats by upregulating vascular endothelial growth factor. ferulic acid 0-12 vascular endothelial growth factor A Rattus norvegicus 73-107 28764936-5 2017 Inhibition of SE-induced VEGF over-expression by leptomycin B also abrogated PI3K and AKT phosphorylations, but not TRPC3 expression. leptomycin B 49-61 vascular endothelial growth factor A Rattus norvegicus 25-29 28791491-0 2017 Retinal VEGF levels correlate with ocular circulation measured by a laser speckle-micro system in an oxygen-induced retinopathy rat model. Oxygen 101-107 vascular endothelial growth factor A Rattus norvegicus 8-12 28791491-1 2017 PURPOSE: We used a Laser speckle flowgraphy (LSFG)-micro system to examine the relationship between ocular blood flow and retinal vascular endothelial growth factor (VEGF) at retinopathy onset in oxygen-induced ischemic retinopathy (OIR) model rats. Oxygen 196-202 vascular endothelial growth factor A Rattus norvegicus 130-164 28791491-1 2017 PURPOSE: We used a Laser speckle flowgraphy (LSFG)-micro system to examine the relationship between ocular blood flow and retinal vascular endothelial growth factor (VEGF) at retinopathy onset in oxygen-induced ischemic retinopathy (OIR) model rats. Oxygen 196-202 vascular endothelial growth factor A Rattus norvegicus 166-170 28980001-9 2017 In addition, Feno-FA downregulated the expression of inflammatory factors, including VEGF, TNF-alpha, and intercellular cell adhesion molecule-1 (ICAM-1), in the eyecups of CNV rats and decreased adherent retinal leukocytes in Vldlr-/- mice. fenofibric acid 13-20 vascular endothelial growth factor A Rattus norvegicus 85-89 29062662-0 2017 Hyperbaric Oxygen Inhibits Reperfusion-Induced Neutrophil Polarization and Adhesion Via Plasmin-Mediated VEGF Release. Oxygen 11-17 vascular endothelial growth factor A Rattus norvegicus 105-109 28974974-8 2017 In addition, salbutamol decreased the production of VEGF and IL-1beta. Albuterol 13-23 vascular endothelial growth factor A Rattus norvegicus 52-56 28974974-13 2017 The observed IL-1beta and VEGF inhibitory properties of salbutamol may be responsible for anti-inflammatory and anti-angiogenic effect of the agent. Albuterol 56-66 vascular endothelial growth factor A Rattus norvegicus 26-30 28454492-1 2017 The aim of this study was to evaluate the morphometry and the gene expression of Ki-67, VEGF and caspase 3 and the stress oxidative in the adrenal gland of ovariectomized rats treated with estrogen or isoflavones. Isoflavones 201-212 vascular endothelial growth factor A Rattus norvegicus 88-92 28454492-5 2017 These hypertrofic effects agree with higher expression elevation of Ki67 and VEGF, which did not occur with the caspase 3, indicating that isoflavones have great proliferative effect on the adrenal gland. Isoflavones 139-150 vascular endothelial growth factor A Rattus norvegicus 77-81 28791384-0 2017 Curcumin attenuates the development of thoracic aortic aneurysm by inhibiting VEGF expression and inflammation. Curcumin 0-8 vascular endothelial growth factor A Rattus norvegicus 78-82 28791384-9 2017 In addition, curcumin decreased neovascularization and the expression of VEGF. Curcumin 13-21 vascular endothelial growth factor A Rattus norvegicus 73-77 28791384-13 2017 Treatment with curcumin inhibited TAA development in rats, which was associated with suppression of VEGF expression. Curcumin 15-23 vascular endothelial growth factor A Rattus norvegicus 100-104 29037554-8 2017 RESULTS: Histological evaluation and immunohistochemical evaluations showed that treatment with a resveratrol significantly increased the thickness of the uterine wall and VEGF expression and decreased expression PDGF during wound healing. Resveratrol 98-109 vascular endothelial growth factor A Rattus norvegicus 172-176 28950890-4 2017 DCE-MRI parameters were correlated with histological grade, microvascular density (MVD), vascular endothelial growth factor (VEGF) and fraction of Ki67-positive cells and the serum level of cancer antigen 125 (CA125). ethylene dichloride 0-3 vascular endothelial growth factor A Rattus norvegicus 89-123 28894635-9 2017 Topical NTX accelerated DNA synthesis, as measured by BrdU incorporation, increased mast cells, and enhanced expression of platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF), a marker for angiogenesis. Naltrexone 8-11 vascular endothelial growth factor A Rattus norvegicus 165-199 28880966-11 2017 GSK360A provided rapid exposure in plasma (7734 ng/ml), kidney (45-52% of plasma level) and brain (1-4% of plasma level), and increased kidney EPO mRNA (80-fold) and brain VEGF mRNA (2-fold). N-((1-(cyclopropylethyl)-6-fluoro-4-hydroxy-2-oxo-1,2-dihydro-3-quinolinyl)carbonyl)glycine 0-7 vascular endothelial growth factor A Rattus norvegicus 172-176 28880966-12 2017 We also observed that GSK360A increased plasma EPO (300-fold) and VEGF (2-fold). N-((1-(cyclopropylethyl)-6-fluoro-4-hydroxy-2-oxo-1,2-dihydro-3-quinolinyl)carbonyl)glycine 22-29 vascular endothelial growth factor A Rattus norvegicus 66-70 28906472-7 2017 In addition, the level of vascular endothelial growth factor (VEGF) in the retinas of STZ rats was 9.26-fold higher than in in normal rats, with this increase also prevented by the instillation of CLZnano Thus, we have found that a-wave and b-wave levels in addition to OP amplitude are decreased in rats following the injection of excessive streptozotocin. Streptozocin 86-89 vascular endothelial growth factor A Rattus norvegicus 26-60 28906472-7 2017 In addition, the level of vascular endothelial growth factor (VEGF) in the retinas of STZ rats was 9.26-fold higher than in in normal rats, with this increase also prevented by the instillation of CLZnano Thus, we have found that a-wave and b-wave levels in addition to OP amplitude are decreased in rats following the injection of excessive streptozotocin. Streptozocin 86-89 vascular endothelial growth factor A Rattus norvegicus 62-66 28906472-7 2017 In addition, the level of vascular endothelial growth factor (VEGF) in the retinas of STZ rats was 9.26-fold higher than in in normal rats, with this increase also prevented by the instillation of CLZnano Thus, we have found that a-wave and b-wave levels in addition to OP amplitude are decreased in rats following the injection of excessive streptozotocin. Streptozocin 342-356 vascular endothelial growth factor A Rattus norvegicus 26-60 28906472-7 2017 In addition, the level of vascular endothelial growth factor (VEGF) in the retinas of STZ rats was 9.26-fold higher than in in normal rats, with this increase also prevented by the instillation of CLZnano Thus, we have found that a-wave and b-wave levels in addition to OP amplitude are decreased in rats following the injection of excessive streptozotocin. Streptozocin 342-356 vascular endothelial growth factor A Rattus norvegicus 62-66 28894635-9 2017 Topical NTX accelerated DNA synthesis, as measured by BrdU incorporation, increased mast cells, and enhanced expression of platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF), a marker for angiogenesis. Naltrexone 8-11 vascular endothelial growth factor A Rattus norvegicus 201-205 28645008-10 2017 In comparison to the ICH group, the miR-129-5p, EP, FPS-ZM1 groups had a decline in the VEGF protein expression and MVD. mir-129-5p 36-46 vascular endothelial growth factor A Rattus norvegicus 88-92 28557571-2 2017 METHODS: Anti-VEGF (ranibizumab or aflibercept) was loaded into poly(lactic-co-glycolic acid) microspheres that were then suspended within an injectable poly(N-isopropylacrylamide)-based thermo-responsive hydrogel DDS.The DDS was shown previously to release bioactive anti-VEGF for ~200 days. Polylactic Acid-Polyglycolic Acid Copolymer 64-93 vascular endothelial growth factor A Rattus norvegicus 14-18 28557571-2 2017 METHODS: Anti-VEGF (ranibizumab or aflibercept) was loaded into poly(lactic-co-glycolic acid) microspheres that were then suspended within an injectable poly(N-isopropylacrylamide)-based thermo-responsive hydrogel DDS.The DDS was shown previously to release bioactive anti-VEGF for ~200 days. poly-N-isopropylacrylamide 153-180 vascular endothelial growth factor A Rattus norvegicus 14-18 28648975-3 2017 In the present study, we investigated the effect of Pueraria tuberosa extract (PTY-2r) on the expression of HIF-1alpha, VEGF and nephrin in streptozotocin (STZ) induced diabetic nephropathy (DN). Streptozocin 156-159 vascular endothelial growth factor A Rattus norvegicus 120-124 28684188-9 2017 In three series of paralleled groups, rats treated with 28-day ascorbate or vehicle received hemodynamic measurements, hepatic and collateral vasoresponsiveness perfusion experiments, mesenteric CD31 immunofluorescence staining, and Western blot analyses of mesenteric VEGF, VEGFR2, pVEGFR2, PDGF, PDGFbeta, COX1, COX2, eNOS, p-eNOS-Thr495, p-eNOS-Ser1177 protein expressions. Ascorbic Acid 63-72 vascular endothelial growth factor A Rattus norvegicus 269-273 28397013-5 2017 Treatment of DEK effectively suppressed the NDEA-initiated hepatocarcinogenesis by modulation of XMEs, inducing of apoptosis via the mitochondrial pathway as revealed by modulating the Bcl-2 family proteins, cytochrome C, caspases, and inhibiting invasion, and angiogenesis as evidenced by changes in the activities of MMPs (MMP2/9) and the expression of VEGF. Diethylnitrosamine 44-48 vascular endothelial growth factor A Rattus norvegicus 355-359 28755050-3 2017 The aim of this work was to establish the changes in immunoreactivity to VEGF-A, VEGF-B, VEGFR-1 and VEGFR-2 proteins induced by neonatal MSG treatment (4 g/kg, subcutaneous, at PD1, 3, 5 and 7) in the cerebral motor cortex (CMC) and Hp. Sodium Glutamate 138-141 vascular endothelial growth factor A Rattus norvegicus 73-79 28755050-2 2017 Neonatal monosodium glutamate (MSG) treatment triggers an excitotoxic degenerative process associated with several neuropathological conditions, and VEGF messenger RNA (mRNA) expression is increased at postnatal day (PD) 14 in rat hippocampus (Hp) following the treatment. Sodium Glutamate 9-29 vascular endothelial growth factor A Rattus norvegicus 149-153 28713958-0 2017 Lipo-prostaglandin E1 modifies cognitive impairment in rats with vascular cognitive impairment by promoting angiogenesis via the VEGF/VEGFR pathway. lipo-prostaglandin e1 0-21 vascular endothelial growth factor A Rattus norvegicus 129-133 28460604-2 2017 15(S)-hydroxyeicosatetraenoic acid (15-HETE) is one of the major metabolites of arachidonic acid by 15-lipoxygenase (15-LO) and stimulates the production of vascular endothelial growth factor (VEGF), thus, inducing autocrine-mediated angiogenesis. 15-hydroxy-5,8,11,13-eicosatetraenoic acid 0-34 vascular endothelial growth factor A Rattus norvegicus 157-191 28460604-2 2017 15(S)-hydroxyeicosatetraenoic acid (15-HETE) is one of the major metabolites of arachidonic acid by 15-lipoxygenase (15-LO) and stimulates the production of vascular endothelial growth factor (VEGF), thus, inducing autocrine-mediated angiogenesis. 15-hydroxy-5,8,11,13-eicosatetraenoic acid 0-34 vascular endothelial growth factor A Rattus norvegicus 193-197 28460604-2 2017 15(S)-hydroxyeicosatetraenoic acid (15-HETE) is one of the major metabolites of arachidonic acid by 15-lipoxygenase (15-LO) and stimulates the production of vascular endothelial growth factor (VEGF), thus, inducing autocrine-mediated angiogenesis. 15-hydroxy-5,8,11,13-eicosatetraenoic acid 36-43 vascular endothelial growth factor A Rattus norvegicus 157-191 28460604-2 2017 15(S)-hydroxyeicosatetraenoic acid (15-HETE) is one of the major metabolites of arachidonic acid by 15-lipoxygenase (15-LO) and stimulates the production of vascular endothelial growth factor (VEGF), thus, inducing autocrine-mediated angiogenesis. 15-hydroxy-5,8,11,13-eicosatetraenoic acid 36-43 vascular endothelial growth factor A Rattus norvegicus 193-197 28460604-2 2017 15(S)-hydroxyeicosatetraenoic acid (15-HETE) is one of the major metabolites of arachidonic acid by 15-lipoxygenase (15-LO) and stimulates the production of vascular endothelial growth factor (VEGF), thus, inducing autocrine-mediated angiogenesis. Arachidonic Acid 80-96 vascular endothelial growth factor A Rattus norvegicus 157-191 28460604-2 2017 15(S)-hydroxyeicosatetraenoic acid (15-HETE) is one of the major metabolites of arachidonic acid by 15-lipoxygenase (15-LO) and stimulates the production of vascular endothelial growth factor (VEGF), thus, inducing autocrine-mediated angiogenesis. Arachidonic Acid 80-96 vascular endothelial growth factor A Rattus norvegicus 193-197 28460604-6 2017 RESULTS: Oxygen-glucose deprivation increased cellular expression of 15-LO-1 and VEGF. oxygen-glucose 9-23 vascular endothelial growth factor A Rattus norvegicus 81-85 28766254-10 2017 Furthermore, our results demonstrated that CCH could induce excessive autophagy which could be inhibited by VEGF. 1-acetyl-2-(coumariniminecarboxamide-3-yl)hydrazine 43-46 vascular endothelial growth factor A Rattus norvegicus 108-112 28766254-11 2017 Thus, we speculated that VEGF could ameliorate impaired synaptic function induced by CCH because of its ability to inhibit excessive autophagy, and eventually improve spatial learning and memory function. 1-acetyl-2-(coumariniminecarboxamide-3-yl)hydrazine 85-88 vascular endothelial growth factor A Rattus norvegicus 25-29 28713958-2 2017 Prostaglandin E1 (PGE1) serves roles in the promotion of vascular endothelial growth factor (VEGF) expression, angiogenesis and enhances blood flow to ischemic regions. Alprostadil 0-16 vascular endothelial growth factor A Rattus norvegicus 57-91 28713958-2 2017 Prostaglandin E1 (PGE1) serves roles in the promotion of vascular endothelial growth factor (VEGF) expression, angiogenesis and enhances blood flow to ischemic regions. Alprostadil 0-16 vascular endothelial growth factor A Rattus norvegicus 93-97 28713958-2 2017 Prostaglandin E1 (PGE1) serves roles in the promotion of vascular endothelial growth factor (VEGF) expression, angiogenesis and enhances blood flow to ischemic regions. Alprostadil 18-22 vascular endothelial growth factor A Rattus norvegicus 57-91 28733472-10 2017 In the VEGF shRNA-2, PD2 + Endostar, VEGF shRNA-4, and in PD4 + Endostar group increased UFV, reduced MTG and expression of VEGF, and decreased number of new blood capillaries were detected. 3-Bromo-4,5-diaminobenzotrifluoride 89-92 vascular endothelial growth factor A Rattus norvegicus 7-11 28713958-2 2017 Prostaglandin E1 (PGE1) serves roles in the promotion of vascular endothelial growth factor (VEGF) expression, angiogenesis and enhances blood flow to ischemic regions. Alprostadil 18-22 vascular endothelial growth factor A Rattus norvegicus 93-97 28733472-10 2017 In the VEGF shRNA-2, PD2 + Endostar, VEGF shRNA-4, and in PD4 + Endostar group increased UFV, reduced MTG and expression of VEGF, and decreased number of new blood capillaries were detected. 3-Bromo-4,5-diaminobenzotrifluoride 89-92 vascular endothelial growth factor A Rattus norvegicus 37-41 28713958-6 2017 The results confirmed that VCI rats treated with lipo-PGE1 presented improved cognitive function, less neuronal cell loss, a greater number of blood vessels in the hippocampal region and higher VEGF protein and mRNA expression. Alprostadil 54-58 vascular endothelial growth factor A Rattus norvegicus 194-198 28733472-10 2017 In the VEGF shRNA-2, PD2 + Endostar, VEGF shRNA-4, and in PD4 + Endostar group increased UFV, reduced MTG and expression of VEGF, and decreased number of new blood capillaries were detected. 3-Bromo-4,5-diaminobenzotrifluoride 89-92 vascular endothelial growth factor A Rattus norvegicus 37-41 28713958-9 2017 The underlying mechanism may be associated with angiogenesis promoted by lipo-PGE1, which may involve the VEGF/VEGFR pathway. Alprostadil 78-82 vascular endothelial growth factor A Rattus norvegicus 106-110 28769047-8 2017 Iodoacetamide-induced rise in the colonic levels of TNF-alpha, VEGF, angiostatin and endostatin was reversed by niacin. Iodoacetamide 0-13 vascular endothelial growth factor A Rattus norvegicus 63-67 28733472-10 2017 In the VEGF shRNA-2, PD2 + Endostar, VEGF shRNA-4, and in PD4 + Endostar group increased UFV, reduced MTG and expression of VEGF, and decreased number of new blood capillaries were detected. (Methylthio)acetic acid 102-105 vascular endothelial growth factor A Rattus norvegicus 37-41 28733472-10 2017 In the VEGF shRNA-2, PD2 + Endostar, VEGF shRNA-4, and in PD4 + Endostar group increased UFV, reduced MTG and expression of VEGF, and decreased number of new blood capillaries were detected. (Methylthio)acetic acid 102-105 vascular endothelial growth factor A Rattus norvegicus 37-41 28733472-12 2017 VEGF expression was negatively correlated with UFV, but positively correlated with MTG. 3-Bromo-4,5-diaminobenzotrifluoride 47-50 vascular endothelial growth factor A Rattus norvegicus 0-4 28733472-12 2017 VEGF expression was negatively correlated with UFV, but positively correlated with MTG. (Methylthio)acetic acid 83-86 vascular endothelial growth factor A Rattus norvegicus 0-4 28932080-8 2017 Although both treatment agents exerted similar ulcer reducing ability, only treatment with tocotrienol led to increased expression of VEGF (P = 0.008), bFGF (P = 0.001) and TGF-alpha (P = 0.002) mRNA. Tocotrienols 91-102 vascular endothelial growth factor A Rattus norvegicus 134-138 28817384-5 2017 LMW elastic polymer improved the elasticity of the scaffolds, and significantly increased the amount of heparin conjugated to the micro/nanofibrous scaffolds, which in turn increased the loading capacity of vascular endothelial growth factor (VEGF) and prolonged the release of VEGF. Heparin 104-111 vascular endothelial growth factor A Rattus norvegicus 207-241 28817384-5 2017 LMW elastic polymer improved the elasticity of the scaffolds, and significantly increased the amount of heparin conjugated to the micro/nanofibrous scaffolds, which in turn increased the loading capacity of vascular endothelial growth factor (VEGF) and prolonged the release of VEGF. Heparin 104-111 vascular endothelial growth factor A Rattus norvegicus 243-247 28817384-5 2017 LMW elastic polymer improved the elasticity of the scaffolds, and significantly increased the amount of heparin conjugated to the micro/nanofibrous scaffolds, which in turn increased the loading capacity of vascular endothelial growth factor (VEGF) and prolonged the release of VEGF. Heparin 104-111 vascular endothelial growth factor A Rattus norvegicus 278-282 28600129-5 2017 When the GAG mimetic nanofiber gels were injected in the infarct site of rodent myocardial infarct model, increased VEGF-A expression and recruitment of vascular cells was observed. Glycosaminoglycans 9-12 vascular endothelial growth factor A Rattus norvegicus 116-122 28861155-10 2017 Compared with the calcitriol group, the calcitriol+3MA group showed a smaller mean flap survival area and greater tissue edema, had a markedly decreased level of VEGF mRNA/protein and SOD activity, and a significantly higher level of MDA and GSH. Calcitriol 40-50 vascular endothelial growth factor A Rattus norvegicus 162-166 28811496-7 2017 Strong suppression of Reg3g and the inflammatory chemokines Ccl2 and Cxcl5 and activation of classical complement pathway factors C1r, C1s, C2, and C3 occurred with dexamethasone treatment, effects absent with anti-Vegf treatment. Dexamethasone 165-178 vascular endothelial growth factor A Rattus norvegicus 215-219 27875022-11 2017 ERK inhibitor (PD98059, 50 mumol L-1 ) significantly attenuated collagen production and increased VEGF production in RA fibroblasts but not in LA fibroblasts. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 15-22 vascular endothelial growth factor A Rattus norvegicus 98-102 28769047-8 2017 Iodoacetamide-induced rise in the colonic levels of TNF-alpha, VEGF, angiostatin and endostatin was reversed by niacin. Niacin 112-118 vascular endothelial growth factor A Rattus norvegicus 63-67 28769047-10 2017 Mepenzolate bromide, a GPR109A receptor blocker, abolished the beneficial effects of niacin on body weight, colon wet weight as well as colonic levels of MPO and VEGF. mepenzolic acid 0-19 vascular endothelial growth factor A Rattus norvegicus 162-166 28547766-3 2017 Poly(vinyl alcohol) fiber mats bearing poly(lactic-co-glycolic acid) nanoparticles that incorporate VEGF are fabricated using electrospinning and electrospray methods. Polyvinyl Alcohol 0-19 vascular endothelial growth factor A Rattus norvegicus 100-104 28648907-2 2017 We hypothesized that our sulfated dehydropolymer of caffeic acid, CDSO3, exerts anti-cell death activities and therapeutic interventions in emphysema by virtue of Fe2+ chelation-based HIF-1alpha/VEGF stabilization and elevation. caffeic acid 52-64 vascular endothelial growth factor A Rattus norvegicus 195-199 28648907-2 2017 We hypothesized that our sulfated dehydropolymer of caffeic acid, CDSO3, exerts anti-cell death activities and therapeutic interventions in emphysema by virtue of Fe2+ chelation-based HIF-1alpha/VEGF stabilization and elevation. cdso3 66-71 vascular endothelial growth factor A Rattus norvegicus 195-199 28648907-5 2017 CDSO3 was spray-dosed to the lung for three weeks (day 1-21) in an in vivo rat model of apoptotic emphysema induced with a VEGF receptor antagonist SU5416. cdso3 0-5 vascular endothelial growth factor A Rattus norvegicus 123-127 28648907-8 2017 At 10 muM, CDSO3 inhibited HMVEC-L and A549 cell death induced by histone deacetylase inhibition with trichostatin A, VEGF receptor blockade with SU5416, and cigarette smoke extract by 65-99%, which were all significantly opposed by addition of excess Fe2+ or HIF-1alpha inhibitors. cdso3 11-16 vascular endothelial growth factor A Rattus norvegicus 118-122 28648907-11 2017 All of these were consistent with CDSO3"s Fe2+ chelation-based HIF-1alpha/VEGF stabilization and elevation against their pathobiologic deficiency, inhibiting lung cell death and development of apoptotic emphysema. cdso3 34-39 vascular endothelial growth factor A Rattus norvegicus 74-78 28648907-11 2017 All of these were consistent with CDSO3"s Fe2+ chelation-based HIF-1alpha/VEGF stabilization and elevation against their pathobiologic deficiency, inhibiting lung cell death and development of apoptotic emphysema. ammonium ferrous sulfate 42-46 vascular endothelial growth factor A Rattus norvegicus 74-78 28505603-9 2017 The antiangiogenic activity of ICA was evidenced by lowered levels of mRNA of Ang-1 and protein expression of VEGF, PDGF-beta, and CTGF immunohistochemically. icariin 31-34 vascular endothelial growth factor A Rattus norvegicus 110-114 28648907-0 2017 Sulfated dehydropolymer of caffeic acid: In vitro anti-lung cell death activity and in vivo intervention in emphysema induced by VEGF receptor blockade. dehydropolymer 9-23 vascular endothelial growth factor A Rattus norvegicus 129-133 28648907-0 2017 Sulfated dehydropolymer of caffeic acid: In vitro anti-lung cell death activity and in vivo intervention in emphysema induced by VEGF receptor blockade. caffeic acid 27-39 vascular endothelial growth factor A Rattus norvegicus 129-133 28648907-2 2017 We hypothesized that our sulfated dehydropolymer of caffeic acid, CDSO3, exerts anti-cell death activities and therapeutic interventions in emphysema by virtue of Fe2+ chelation-based HIF-1alpha/VEGF stabilization and elevation. dehydropolymer 34-48 vascular endothelial growth factor A Rattus norvegicus 195-199 28547766-3 2017 Poly(vinyl alcohol) fiber mats bearing poly(lactic-co-glycolic acid) nanoparticles that incorporate VEGF are fabricated using electrospinning and electrospray methods. Polylactic Acid-Polyglycolic Acid Copolymer 39-68 vascular endothelial growth factor A Rattus norvegicus 100-104 28547766-6 2017 Thus, local VEGF release near the transplanted cardiomyocytes induces vascularization, which supplies sufficient oxygen and nutrients to prevent necrosis. Oxygen 113-119 vascular endothelial growth factor A Rattus norvegicus 12-16 28755734-5 2017 RESULTS: It was found that epigallocatechin-3-gallate exhibited significant chemopreventive effects and anti-cancer stem cell activity through several pathways, including a significant decrease in the size and number of tumors per rat, significant amelioration of the oxidative stress markers" alterations and significant inhibition of CD44, VEGF, Ki-67 and MMP-2 expression associated with a significantly increased expression of caspase-3. epigallocatechin gallate 27-53 vascular endothelial growth factor A Rattus norvegicus 342-346 28810822-7 2017 The transcript levels of vascular endothelial growth factor A and inducible nitric oxide synthase genes were significantly higher in the diethylnitrosamine-treated group in comparison with controls. Diethylnitrosamine 137-155 vascular endothelial growth factor A Rattus norvegicus 25-61 28810822-11 2017 In conclusion, irradiated beta-glucan modulated signal growth factors, vascular endothelial growth factor A, extracellular signal-regulated kinase 1, and phosphatidylinositol-3-kinase, which contributed to experimental hepatocarcinogenesis. beta-Glucans 26-37 vascular endothelial growth factor A Rattus norvegicus 71-107 28672973-0 2017 Compound anisodine affects the proliferation and calcium overload of hypoxia-induced rat retinal progenitor cells and brain neural stem cells via the p-ERK1/2/HIF-1alpha/VEGF pathway. anisodine 9-18 vascular endothelial growth factor A Rattus norvegicus 170-174 28706608-0 2017 The Effects of Melilotus officinalis Extract on Expression of Daxx, Nfkb and Vegf Genes in the Streptozotocin-Induced Rat Model of Sporadic Alzheimer"s Disease. Streptozocin 95-109 vascular endothelial growth factor A Rattus norvegicus 77-81 28233432-0 2017 Triptolide Suppresses Alkali Burn-Induced Corneal Angiogenesis Along with a Downregulation of VEGFA and VEGFC Expression. triptolide 0-10 vascular endothelial growth factor A Rattus norvegicus 94-99 27856999-5 2017 In addition, dams from the l-NAME group showed lower vascular endothelial growth factor (VEGF) and interleukin (IL) 10 levels and higher plasma-soluble FMS-like tyrosine kinase 1 (sFlt-1), tumor necrosis factor alpha (TNF-alpha), and oxidative stress marker malondialdehyde (MDA) levels as compared to control dams ( P < .01, for all). NG-Nitroarginine Methyl Ester 27-33 vascular endothelial growth factor A Rattus norvegicus 53-87 28740299-12 2017 Dietary supplementation of EA to diabetic rats resulted in: (1) inhibition of accumulation of CML and activation of RAGE in retina, (2) attenuation of expression of GFAP, VEGF, and HIF-1alpha in retina, (3) attenuation of cell death by reducing proapoptic mediator Bax and (4) amelioration of retinal thickness and function. Ellagic Acid 27-29 vascular endothelial growth factor A Rattus norvegicus 171-175 27856999-5 2017 In addition, dams from the l-NAME group showed lower vascular endothelial growth factor (VEGF) and interleukin (IL) 10 levels and higher plasma-soluble FMS-like tyrosine kinase 1 (sFlt-1), tumor necrosis factor alpha (TNF-alpha), and oxidative stress marker malondialdehyde (MDA) levels as compared to control dams ( P < .01, for all). NG-Nitroarginine Methyl Ester 27-33 vascular endothelial growth factor A Rattus norvegicus 89-93 27856999-6 2017 Interestingly, simvastatin treatment significantly increased VEGF and IL-10 levels while decreased sFlt-1, TNF-alpha, and MDA levels compared to the untreated l-NAME group. Simvastatin 15-26 vascular endothelial growth factor A Rattus norvegicus 61-65 28569795-8 2017 In vitro, we observed that CYS C-induced VEGF, a secreted protein, attenuated 6-OHDA-lesioned DAergic PC12 cell degeneration by regulating p-PKC-alpha/p-ERK1/2-Nurr1 signaling and inducing autophagy. Oxidopamine 78-84 vascular endothelial growth factor A Rattus norvegicus 41-45 28457180-6 2017 EDC cross-linking could thereby help to improve decellularized tissue without the toxicity of GA. MATERIAL AND METHODS: Porcine aortic wall tissue specimens (TS) were decellularized, treated with EDC, and coated with fibroblast growth factor (FGF) or vascular endothelial growth factor (VEGF). ethylene dichloride 0-3 vascular endothelial growth factor A Rattus norvegicus 251-285 28457180-6 2017 EDC cross-linking could thereby help to improve decellularized tissue without the toxicity of GA. MATERIAL AND METHODS: Porcine aortic wall tissue specimens (TS) were decellularized, treated with EDC, and coated with fibroblast growth factor (FGF) or vascular endothelial growth factor (VEGF). ethylene dichloride 0-3 vascular endothelial growth factor A Rattus norvegicus 287-291 28457180-10 2017 RESULTS: Quantification of vital cells showed reduced reseeding of EDC-treated TS compared to noncross-linked TS after 2 (p < 0.05) and 4 weeks (p < 0.05), while after 6 weeks only EDC+VEGF showed fewer viable cells (p < 0.01). ethylene dichloride 67-70 vascular endothelial growth factor A Rattus norvegicus 191-195 28632747-12 2017 In addition, SC-560 decreased intrapulmonary shunts, attenuated pulmonary inflammation and angiogenesis through down-regulating COX-, NFkappaB- and VEGF-mediated pathways. SC 560 13-19 vascular endothelial growth factor A Rattus norvegicus 148-152 28666022-12 2017 ELISA showed a significant difference in VEGF level between itraconazole-injected and BSS-injected eyes on days 7 and 14 (p = 0.04 and p = 0.001). Itraconazole 60-72 vascular endothelial growth factor A Rattus norvegicus 41-45 28666022-12 2017 ELISA showed a significant difference in VEGF level between itraconazole-injected and BSS-injected eyes on days 7 and 14 (p = 0.04 and p = 0.001). bss 86-89 vascular endothelial growth factor A Rattus norvegicus 41-45 28666022-14 2017 Itraconazole had anti-angiogenic activity along with the reduction of VEGFR2 and VEGF levels. Itraconazole 0-12 vascular endothelial growth factor A Rattus norvegicus 70-74 28659817-10 2017 After treating the diabetic rats with CoCl2, SPC significantly upregulated the expression of HIF-1alpha, VEGF and eNOS, which markedly improved cardiac function, NO, mitochondrial respiratory function, and enzyme activity and decreased the infarction areas and ROS. cobaltous chloride 38-43 vascular endothelial growth factor A Rattus norvegicus 105-109 28569795-9 2017 VEGF-mediated angiogenesis was markedly enhanced in the conditioned media of 6-OHDA-lesioned PC12 cells with CYS C-overexpression, whereas blockage of autophagy in CYS C-overexpressing PC12 cells significantly downregulated VEGF expression and the associated angiogenesis. Oxidopamine 77-83 vascular endothelial growth factor A Rattus norvegicus 0-4 28569795-9 2017 VEGF-mediated angiogenesis was markedly enhanced in the conditioned media of 6-OHDA-lesioned PC12 cells with CYS C-overexpression, whereas blockage of autophagy in CYS C-overexpressing PC12 cells significantly downregulated VEGF expression and the associated angiogenesis. Oxidopamine 77-83 vascular endothelial growth factor A Rattus norvegicus 224-228 28025049-0 2017 Polylysine-modified polyethylenimine (PEI-PLL) mediated VEGF gene delivery protects dopaminergic neurons in cell culture and in rat models of Parkinson"s Disease (PD). Polylysine 0-10 vascular endothelial growth factor A Rattus norvegicus 56-60 29658670-10 2017 The immunohistochemistry and Western blot showed that the expression of VEGF in choke zone II of L-Arg group was significantly higher than that in control group (<i>t</i>=9.428 and -3.054,<i>P</i><0.05 or <i>P</i><0.01). Arginine 97-102 vascular endothelial growth factor A Rattus norvegicus 72-76 28553113-13 2017 LDE-MTX increased the expression of myocardial vascular endothelium growth factor (VEGF) associated with adenosine release; this correlated not only with an increase in angiogenesis, but also with other parameters improved by LDE-MTX, suggesting that VEGF increase played an important role in the beneficial effects of LDE-MTX. lde-mtx 0-7 vascular endothelial growth factor A Rattus norvegicus 47-81 28553113-13 2017 LDE-MTX increased the expression of myocardial vascular endothelium growth factor (VEGF) associated with adenosine release; this correlated not only with an increase in angiogenesis, but also with other parameters improved by LDE-MTX, suggesting that VEGF increase played an important role in the beneficial effects of LDE-MTX. lde-mtx 0-7 vascular endothelial growth factor A Rattus norvegicus 83-87 28553113-13 2017 LDE-MTX increased the expression of myocardial vascular endothelium growth factor (VEGF) associated with adenosine release; this correlated not only with an increase in angiogenesis, but also with other parameters improved by LDE-MTX, suggesting that VEGF increase played an important role in the beneficial effects of LDE-MTX. lde-mtx 0-7 vascular endothelial growth factor A Rattus norvegicus 251-255 28553113-13 2017 LDE-MTX increased the expression of myocardial vascular endothelium growth factor (VEGF) associated with adenosine release; this correlated not only with an increase in angiogenesis, but also with other parameters improved by LDE-MTX, suggesting that VEGF increase played an important role in the beneficial effects of LDE-MTX. Adenosine 105-114 vascular endothelial growth factor A Rattus norvegicus 47-81 28553113-13 2017 LDE-MTX increased the expression of myocardial vascular endothelium growth factor (VEGF) associated with adenosine release; this correlated not only with an increase in angiogenesis, but also with other parameters improved by LDE-MTX, suggesting that VEGF increase played an important role in the beneficial effects of LDE-MTX. Adenosine 105-114 vascular endothelial growth factor A Rattus norvegicus 83-87 28553113-13 2017 LDE-MTX increased the expression of myocardial vascular endothelium growth factor (VEGF) associated with adenosine release; this correlated not only with an increase in angiogenesis, but also with other parameters improved by LDE-MTX, suggesting that VEGF increase played an important role in the beneficial effects of LDE-MTX. lde-mtx 226-233 vascular endothelial growth factor A Rattus norvegicus 47-81 28553113-13 2017 LDE-MTX increased the expression of myocardial vascular endothelium growth factor (VEGF) associated with adenosine release; this correlated not only with an increase in angiogenesis, but also with other parameters improved by LDE-MTX, suggesting that VEGF increase played an important role in the beneficial effects of LDE-MTX. lde-mtx 226-233 vascular endothelial growth factor A Rattus norvegicus 83-87 28553113-13 2017 LDE-MTX increased the expression of myocardial vascular endothelium growth factor (VEGF) associated with adenosine release; this correlated not only with an increase in angiogenesis, but also with other parameters improved by LDE-MTX, suggesting that VEGF increase played an important role in the beneficial effects of LDE-MTX. lde-mtx 226-233 vascular endothelial growth factor A Rattus norvegicus 47-81 28553113-13 2017 LDE-MTX increased the expression of myocardial vascular endothelium growth factor (VEGF) associated with adenosine release; this correlated not only with an increase in angiogenesis, but also with other parameters improved by LDE-MTX, suggesting that VEGF increase played an important role in the beneficial effects of LDE-MTX. lde-mtx 226-233 vascular endothelial growth factor A Rattus norvegicus 83-87 28717534-10 2017 Similarly, in the diabetic control group STZ treatment decreased VEGF levels, while in the LESWT+DM group VEGF nearly approached to baseline levels. Streptozocin 41-44 vascular endothelial growth factor A Rattus norvegicus 65-69 28481082-6 2017 The HANW@MS/CS porous scaffold not only promotes the attachment and growth of rat bone marrow derived mesenchymal stem cells (rBMSCs), but also induces the expression of osteogenic differentiation related genes and the vascular endothelial growth factor (VEGF) gene of rBMSCs. Chitosan 12-14 vascular endothelial growth factor A Rattus norvegicus 219-253 28481082-6 2017 The HANW@MS/CS porous scaffold not only promotes the attachment and growth of rat bone marrow derived mesenchymal stem cells (rBMSCs), but also induces the expression of osteogenic differentiation related genes and the vascular endothelial growth factor (VEGF) gene of rBMSCs. Chitosan 12-14 vascular endothelial growth factor A Rattus norvegicus 255-259 28492549-3 2017 To optimize the neuroprotective efficacy of BMMSCs further, in this study we have derived BMMSCs, which co-overexpress both BDNF and VEGF, and tested them for the treatment of CA-GCII in a rat model. ca-gcii 176-183 vascular endothelial growth factor A Rattus norvegicus 133-137 28025049-0 2017 Polylysine-modified polyethylenimine (PEI-PLL) mediated VEGF gene delivery protects dopaminergic neurons in cell culture and in rat models of Parkinson"s Disease (PD). modified polyethylenimine 11-36 vascular endothelial growth factor A Rattus norvegicus 56-60 28025049-0 2017 Polylysine-modified polyethylenimine (PEI-PLL) mediated VEGF gene delivery protects dopaminergic neurons in cell culture and in rat models of Parkinson"s Disease (PD). pei-pll 38-45 vascular endothelial growth factor A Rattus norvegicus 56-60 28025049-3 2017 In this study, we utilized a novel non-viral gene carrier designated as PEI-PLL synthesized by our laboratory to deliver VEGF gene to study its effect by using both cell culture as well as animal models of PD. pei-pll 72-79 vascular endothelial growth factor A Rattus norvegicus 121-125 28025049-7 2017 VEGF administration prevented the loss of motor functions induced by 6-OHDA as determined by behavior analysis. Oxidopamine 69-75 vascular endothelial growth factor A Rattus norvegicus 0-4 28025049-8 2017 Similarly, VEGF inhibited the 6-OHDA mediated loss of DA neurons in Substantia Nigra Pars Compacta (SNPc) as well as DA nerve fibers in striatum as determined by TH immunostaining. Oxidopamine 30-36 vascular endothelial growth factor A Rattus norvegicus 11-15 28025049-12 2017 To the best of our knowledge, this is the first report describing the use of novel polymeric gene carriers for the delivery of VEGF gene to DA neurons with improved transfection efficiency. amsonic acid 140-142 vascular endothelial growth factor A Rattus norvegicus 127-131 28284729-6 2017 Expression of beta-catenin, COX-2, VEGF, and cyclin D1 was significantly higher in the combined DMH and DEHP-treated rats by comparison to that of the DMH group. 1,2-Dimethylhydrazine 96-99 vascular endothelial growth factor A Rattus norvegicus 35-39 28410463-1 2017 Vascular endothelial growth factor (VEGF) treatment during pilocarpine-induced status epilepticus (SE) causes sustained preservation of behavioral function in rats in the absence of enduring neuroprotection (Nicoletti et al., 2010), suggesting the possibility that other cells or mechanisms could be involved in the beneficial effects of VEGF during SE. Pilocarpine 59-70 vascular endothelial growth factor A Rattus norvegicus 0-34 28410463-1 2017 Vascular endothelial growth factor (VEGF) treatment during pilocarpine-induced status epilepticus (SE) causes sustained preservation of behavioral function in rats in the absence of enduring neuroprotection (Nicoletti et al., 2010), suggesting the possibility that other cells or mechanisms could be involved in the beneficial effects of VEGF during SE. Pilocarpine 59-70 vascular endothelial growth factor A Rattus norvegicus 36-40 27426446-9 2017 Transfection of cultured rat NP cells with STAT1 or STAT3 lentiviral short hairpin RNAs or treatment with the JAK2 inhibitor AG490 significantly reduced IL-17-stimulated VEGF expression. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 125-130 vascular endothelial growth factor A Rattus norvegicus 170-174 28284729-6 2017 Expression of beta-catenin, COX-2, VEGF, and cyclin D1 was significantly higher in the combined DMH and DEHP-treated rats by comparison to that of the DMH group. Diethylhexyl Phthalate 104-108 vascular endothelial growth factor A Rattus norvegicus 35-39 28729914-5 2017 Blocking mTOR using rapamycin attenuated upregulation of pro-inflammatory cytokines (namely IL-1beta, IL-6 and TNF-alpha), and Caspase-3, indicating cell apoptosis and also promoting the levels of vascular endothelial growth factor (VEGF) and its subtype receptor VEGFR-2 in the hippocampus. Sirolimus 20-29 vascular endothelial growth factor A Rattus norvegicus 197-231 28729914-5 2017 Blocking mTOR using rapamycin attenuated upregulation of pro-inflammatory cytokines (namely IL-1beta, IL-6 and TNF-alpha), and Caspase-3, indicating cell apoptosis and also promoting the levels of vascular endothelial growth factor (VEGF) and its subtype receptor VEGFR-2 in the hippocampus. Sirolimus 20-29 vascular endothelial growth factor A Rattus norvegicus 233-237 28116460-13 2017 Inhibition of VEGF signalling using SKLB1002 increased ROBO4 expression (p < 0.05) and reduced neovascularisation indices (p < 0.05). SKLB1002 36-44 vascular endothelial growth factor A Rattus norvegicus 14-18 28448515-0 2017 Chronic cocaine induces HIF-VEGF pathway activation along with angiogenesis in the brain. Cocaine 8-15 vascular endothelial growth factor A Rattus norvegicus 28-32 28448515-6 2017 We showed that chronic cocaine significantly affected NOS1, HIF-1alpha and VEGF expression, in a region- and cocaine treatment-time- dependent manner. Cocaine 23-30 vascular endothelial growth factor A Rattus norvegicus 75-79 28448515-9 2017 These results suggest that following chronic cocaine use, as cerebral ischemia developed, NOS1, the regulatory protein to counteract blood vessel constriction, was upregulated; meanwhile, the HIF-VEGF pathway was activated to increase microvascular density (i.e., angiogenesis) and thus restore local blood flow and oxygen supply. Cocaine 45-52 vascular endothelial growth factor A Rattus norvegicus 196-200 28398226-9 2017 Importantly, vascular endothelial growth factor (VEGF) was severely reduced after melatonin therapy in animals given or not given ethanol. Melatonin 82-91 vascular endothelial growth factor A Rattus norvegicus 13-47 28398226-9 2017 Importantly, vascular endothelial growth factor (VEGF) was severely reduced after melatonin therapy in animals given or not given ethanol. Melatonin 82-91 vascular endothelial growth factor A Rattus norvegicus 49-53 28376733-11 2017 RESULTS: Intravitreal injection of 2-ME (in the two concentrations) caused marked regression of the new vascular tufts on the vitreal side with normal organization and thickness of the retina especially in study group II, which also show negative VEGF immunoreaction. 2-Methoxyestradiol 35-39 vascular endothelial growth factor A Rattus norvegicus 247-251 28374767-5 2017 Western blot and qRT-PCR demonstrated that CoCl2 exposure promoted VEGF expression and secretion, activated the ERK1/2 signaling pathways and upregulated C/EBP and AP-1. cobaltous chloride 43-48 vascular endothelial growth factor A Rattus norvegicus 67-71 28418864-10 2017 Moreover, the pLVX-miR-21-BMSC group showed enhanced expression of Bcl-2, VEGF and Cx43 and reduced expression of Bax, BNP and troponin T. CONCLUSION: These findings suggest miR-21 overexpression enhanced the proliferation, invasiveness and differentiation of BMSCs as well as expression of key factors (Bcl-2, VEGF and Bax) essential for repairing the cardiac damage induced by anthracyclines and restoring heart function. Anthracyclines 379-393 vascular endothelial growth factor A Rattus norvegicus 311-315 27939902-8 2017 Our results suggest that cilostazol could potentially improve autoregulatory responses in the small cerebral arteries by increasing eNOS phosphorylation and VEGF expression in DM, and thus, may act as a neurovascular protectant. Cilostazol 25-35 vascular endothelial growth factor A Rattus norvegicus 157-161 25783558-0 2017 Controlled release of vascular endothelial growth factor from spray-dried alginate microparticles in collagen-hydroxyapatite scaffolds for promoting vascularization and bone repair. Alginates 74-82 vascular endothelial growth factor A Rattus norvegicus 22-56 25783558-0 2017 Controlled release of vascular endothelial growth factor from spray-dried alginate microparticles in collagen-hydroxyapatite scaffolds for promoting vascularization and bone repair. collagen-hydroxyapatite 101-124 vascular endothelial growth factor A Rattus norvegicus 22-56 25783558-3 2017 A collagen-hydroxyapatite (CHA) scaffold, previously optimized for bone regeneration, was functionalized for the sustained delivery of an angiogenic growth factor, vascular endothelial growth factor (VEGF), with the aim of facilitating angiogenesis and enhancing bone regeneration. collagen-hydroxyapatite 2-25 vascular endothelial growth factor A Rattus norvegicus 164-198 25783558-3 2017 A collagen-hydroxyapatite (CHA) scaffold, previously optimized for bone regeneration, was functionalized for the sustained delivery of an angiogenic growth factor, vascular endothelial growth factor (VEGF), with the aim of facilitating angiogenesis and enhancing bone regeneration. collagen-hydroxyapatite 2-25 vascular endothelial growth factor A Rattus norvegicus 200-204 25783558-4 2017 VEGF was initially encapsulated in alginate MPs by spray-drying, producing particles of < 10 microm in diameter. Alginates 35-43 vascular endothelial growth factor A Rattus norvegicus 0-4 28122882-0 2017 Effects of miRNA-200b on the development of diabetic retinopathy by targeting VEGFA gene. mirna-200b 11-21 vascular endothelial growth factor A Rattus norvegicus 78-83 28340277-8 2017 The GMSC also showed higher expression of IL-10 24 h after injury, GDNF at 48 h and 8 days, and VEGF at 21 days. gmsc 4-8 vascular endothelial growth factor A Rattus norvegicus 96-100 28361415-1 2017 The study established enhanced expression of vascular endothelial growth factor (VEGF) in the subpopulation of osteoblasts located in the regeneration region of femoral bone fracture near the titanium implants with bioactive calcium phosphate and hydroxyapatite coatings and suppressed activity of transforming growth factor-beta2 (TGF-beta2) in chondroblasts during the two weeks after surgery. calcium phosphate 225-242 vascular endothelial growth factor A Rattus norvegicus 45-79 28403346-12 2017 Decreased levels of VEGF due to infection reversed by ozone therapy in control and vancomycin groups. Vancomycin 83-93 vascular endothelial growth factor A Rattus norvegicus 20-24 28361415-1 2017 The study established enhanced expression of vascular endothelial growth factor (VEGF) in the subpopulation of osteoblasts located in the regeneration region of femoral bone fracture near the titanium implants with bioactive calcium phosphate and hydroxyapatite coatings and suppressed activity of transforming growth factor-beta2 (TGF-beta2) in chondroblasts during the two weeks after surgery. calcium phosphate 225-242 vascular endothelial growth factor A Rattus norvegicus 81-85 28361415-1 2017 The study established enhanced expression of vascular endothelial growth factor (VEGF) in the subpopulation of osteoblasts located in the regeneration region of femoral bone fracture near the titanium implants with bioactive calcium phosphate and hydroxyapatite coatings and suppressed activity of transforming growth factor-beta2 (TGF-beta2) in chondroblasts during the two weeks after surgery. Durapatite 247-261 vascular endothelial growth factor A Rattus norvegicus 45-79 28361415-1 2017 The study established enhanced expression of vascular endothelial growth factor (VEGF) in the subpopulation of osteoblasts located in the regeneration region of femoral bone fracture near the titanium implants with bioactive calcium phosphate and hydroxyapatite coatings and suppressed activity of transforming growth factor-beta2 (TGF-beta2) in chondroblasts during the two weeks after surgery. Durapatite 247-261 vascular endothelial growth factor A Rattus norvegicus 81-85 27868196-11 2017 Endogenous VEGF signalling prevents excess neovessel pericyte coverage, and is required for VSMC recruitment during increased nitric oxide-mediated vasodilatation and angiopoietin signalling (NO-Tie-mediated arteriogenesis). vsmc 92-96 vascular endothelial growth factor A Rattus norvegicus 11-15 28052321-6 2017 The SMO inhibitor cyclopamine and Gli1 inhibitor GANT-58 reduced expression of VEGF and angiopoietin 1 in HSCs and suppressed HSC tubulogenesis capacity. cyclopamine 18-29 vascular endothelial growth factor A Rattus norvegicus 79-83 28017765-7 2017 RESULTS: The results of this study showed that treatment with tamoxifen-loaded SLN significantly reduced the mRNA levels of ERalpha and VEGF-A gene and the total oxidant status compared to the ovariectomized control group. Tamoxifen 62-71 vascular endothelial growth factor A Rattus norvegicus 136-142 27287478-7 2017 Celecoxib also reduced RFA-associated a) increased c-Met expression at 24 h, b) HGF and VEGF levels at 72 h, c) periablational macrophage and stellate cells at 3d, and d) hepatocyte proliferation at 7d. Celecoxib 0-9 vascular endothelial growth factor A Rattus norvegicus 88-92 28450910-10 2017 Therefore, the results of the current study suggest that ML228 may effectively activate the HIF-1alpha/VEGF signaling pathway to promote the expression of HIF-1alpha and VEGF proteins within the injured segment of the spinal cord, which promotes neural functional recovery following SCI in rats. ML228 57-62 vascular endothelial growth factor A Rattus norvegicus 103-107 28450910-10 2017 Therefore, the results of the current study suggest that ML228 may effectively activate the HIF-1alpha/VEGF signaling pathway to promote the expression of HIF-1alpha and VEGF proteins within the injured segment of the spinal cord, which promotes neural functional recovery following SCI in rats. ML228 57-62 vascular endothelial growth factor A Rattus norvegicus 170-174 28017765-0 2017 Effects of tamoxifen-loaded solid lipid nanoparticles on the estrogen receptor-alpha (ER-alpha) and vascular endothelial growth factor-A (VEGF-A) genes expression in the endometrial tissue of ovariectomized female Sprague-Dawley rats. Tamoxifen 11-20 vascular endothelial growth factor A Rattus norvegicus 100-136 28017765-0 2017 Effects of tamoxifen-loaded solid lipid nanoparticles on the estrogen receptor-alpha (ER-alpha) and vascular endothelial growth factor-A (VEGF-A) genes expression in the endometrial tissue of ovariectomized female Sprague-Dawley rats. Tamoxifen 11-20 vascular endothelial growth factor A Rattus norvegicus 138-144 28017765-2 2017 An in vivo study was carried out to compare the effect of tamoxifen-loaded solid lipid nanoparticles and free drug on the ER-alpha and VEGF-A genes expression. Tamoxifen 58-67 vascular endothelial growth factor A Rattus norvegicus 135-141 27868196-11 2017 Endogenous VEGF signalling prevents excess neovessel pericyte coverage, and is required for VSMC recruitment during increased nitric oxide-mediated vasodilatation and angiopoietin signalling (NO-Tie-mediated arteriogenesis). Nitric Oxide 126-138 vascular endothelial growth factor A Rattus norvegicus 11-15 28098876-10 2017 PD98059, an antagonist of ERK1/2, elicited the same effects on VEGF from the BDNF-stimulated osteoblasts, however, it did not affect the phosphorylation of TrkB. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 0-7 vascular endothelial growth factor A Rattus norvegicus 63-67 28024287-6 2017 In addition, TMP attenuated angiogenesis by downregulation of vascular endothelial growth factor-A (VEGF-A), vascular endothelial growth factor receptor 2 (VEGF-R2), platelet-derived growth factor-BB (PDGF-BB), and platelet-derived growth factor-beta receptor (PDGF-betaR), four important factors transmitting pro-angiogenic pathways. tetramethylpyrazine 13-16 vascular endothelial growth factor A Rattus norvegicus 62-98 28167795-5 2017 Moreover, cage-like structures were patterned within the scaffolds and accommodated poly(lactic-co-glycolic acid) (PLGA) microparticulate systems that controlled the release of VEGF, which promotes vascularization, or dexamethasone, an anti-inflammatory agent. Polylactic Acid-Polyglycolic Acid Copolymer 84-113 vascular endothelial growth factor A Rattus norvegicus 177-181 27622962-6 2017 RESULTS: Exposure to 5 mug BPA/kg bodyweight/day plus fructose increased mRNA expression of Vegf, Vegfr2, eNos, and Ace1 in rat heart. Fructose 54-62 vascular endothelial growth factor A Rattus norvegicus 92-96 28024287-6 2017 In addition, TMP attenuated angiogenesis by downregulation of vascular endothelial growth factor-A (VEGF-A), vascular endothelial growth factor receptor 2 (VEGF-R2), platelet-derived growth factor-BB (PDGF-BB), and platelet-derived growth factor-beta receptor (PDGF-betaR), four important factors transmitting pro-angiogenic pathways. tetramethylpyrazine 13-16 vascular endothelial growth factor A Rattus norvegicus 100-106 28352358-5 2017 Then, the effect of 28-day daily treatment with desipramine (DMI; 10 mg/kg), fluoxetine (5 mg/kg) or tianeptine (10 mg/kg) on the number of copies of VEGF mRNA in the amygdala, hippocampus and hypothalamus, and on serum VEGF protein levels, of rats subjected to chronic stress was determined. Desipramine 48-59 vascular endothelial growth factor A Rattus norvegicus 150-154 27862498-8 2017 RESULTS: In ATRA-treated MSCs, expressions of COX-2, HIF-1, CXCR4, CCR2, VEGF, Ang-2 and Ang-4 increased compared to control groups. Tretinoin 12-16 vascular endothelial growth factor A Rattus norvegicus 73-77 28352358-5 2017 Then, the effect of 28-day daily treatment with desipramine (DMI; 10 mg/kg), fluoxetine (5 mg/kg) or tianeptine (10 mg/kg) on the number of copies of VEGF mRNA in the amygdala, hippocampus and hypothalamus, and on serum VEGF protein levels, of rats subjected to chronic stress was determined. Fluoxetine 77-87 vascular endothelial growth factor A Rattus norvegicus 150-154 28352358-5 2017 Then, the effect of 28-day daily treatment with desipramine (DMI; 10 mg/kg), fluoxetine (5 mg/kg) or tianeptine (10 mg/kg) on the number of copies of VEGF mRNA in the amygdala, hippocampus and hypothalamus, and on serum VEGF protein levels, of rats subjected to chronic stress was determined. tianeptine 101-111 vascular endothelial growth factor A Rattus norvegicus 150-154 28352358-11 2017 Furthermore, the results identified that the stress-induced increase in VEGF mRNA expression in the amygdala and hypothalamus was attenuated by long-term administration of DMI. Desipramine 172-175 vascular endothelial growth factor A Rattus norvegicus 72-76 28352358-13 2017 In conclusion, the current study suggests that under conditions of stress, VEGF serves a role in the mechanism of action of DMI, through modulating activity of the norepinephrine system. Desipramine 124-127 vascular endothelial growth factor A Rattus norvegicus 75-79 28352358-13 2017 In conclusion, the current study suggests that under conditions of stress, VEGF serves a role in the mechanism of action of DMI, through modulating activity of the norepinephrine system. Norepinephrine 164-178 vascular endothelial growth factor A Rattus norvegicus 75-79 27747480-6 2017 We found that the total protein expression of both caveolin-1 and VEGF was increased by exercise and consistent with the improved neurological recovery, decreased infarct volumes and increased 5-bromo-2"-deoxyuridine (BrdU) in the ipsilateral Subventricular zone (SVZ), as well as increased numbers of BrdU/DCX and BrdU/Neun-positive cells in the peri-infarct region. Bromodeoxyuridine 193-216 vascular endothelial growth factor A Rattus norvegicus 66-70 27638772-11 2017 CONCLUSION: This animal study showed TAE combined with HIF-1alpha-RNAi could significantly improve efficacy of TAE in treating HCC by inhibiting expressions of HIF-1alpha and VEGF after TAE treatment. tae 37-40 vascular endothelial growth factor A Rattus norvegicus 175-179 27638772-11 2017 CONCLUSION: This animal study showed TAE combined with HIF-1alpha-RNAi could significantly improve efficacy of TAE in treating HCC by inhibiting expressions of HIF-1alpha and VEGF after TAE treatment. tae 111-114 vascular endothelial growth factor A Rattus norvegicus 175-179 27638772-11 2017 CONCLUSION: This animal study showed TAE combined with HIF-1alpha-RNAi could significantly improve efficacy of TAE in treating HCC by inhibiting expressions of HIF-1alpha and VEGF after TAE treatment. tae 111-114 vascular endothelial growth factor A Rattus norvegicus 175-179 27913969-7 2017 PBM with a wavelength of 830 nm increased the viability of the TRAM flap, with a smaller area of necrosis, increased number of mast cells, and higher expression of VEGF and CD34. pbm 0-3 vascular endothelial growth factor A Rattus norvegicus 164-168 27747480-6 2017 We found that the total protein expression of both caveolin-1 and VEGF was increased by exercise and consistent with the improved neurological recovery, decreased infarct volumes and increased 5-bromo-2"-deoxyuridine (BrdU) in the ipsilateral Subventricular zone (SVZ), as well as increased numbers of BrdU/DCX and BrdU/Neun-positive cells in the peri-infarct region. Bromodeoxyuridine 218-222 vascular endothelial growth factor A Rattus norvegicus 66-70 27747480-6 2017 We found that the total protein expression of both caveolin-1 and VEGF was increased by exercise and consistent with the improved neurological recovery, decreased infarct volumes and increased 5-bromo-2"-deoxyuridine (BrdU) in the ipsilateral Subventricular zone (SVZ), as well as increased numbers of BrdU/DCX and BrdU/Neun-positive cells in the peri-infarct region. Bromodeoxyuridine 302-306 vascular endothelial growth factor A Rattus norvegicus 66-70 27747480-6 2017 We found that the total protein expression of both caveolin-1 and VEGF was increased by exercise and consistent with the improved neurological recovery, decreased infarct volumes and increased 5-bromo-2"-deoxyuridine (BrdU) in the ipsilateral Subventricular zone (SVZ), as well as increased numbers of BrdU/DCX and BrdU/Neun-positive cells in the peri-infarct region. Bromodeoxyuridine 302-306 vascular endothelial growth factor A Rattus norvegicus 66-70 28117425-2 2017 The endothelial cell-specific mitogen vascular endothelial growth factor (VEGF), as well as its receptors, VEGFR1, VEGFR2, are thought to be the major mediators of pathological angiogenesis, and sunitinib exhibits anti-angiogenesis property through VEGF blockage and has been widely used to treat various cancers. Sunitinib 195-204 vascular endothelial growth factor A Rattus norvegicus 38-72 28138126-0 2017 Curcumol Promotes Vascular Endothelial Growth Factor (VEGF)-Mediated Diabetic Wound Healing in Streptozotocin-Induced Hyperglycemic Rats. curcumol 0-8 vascular endothelial growth factor A Rattus norvegicus 18-52 28138126-0 2017 Curcumol Promotes Vascular Endothelial Growth Factor (VEGF)-Mediated Diabetic Wound Healing in Streptozotocin-Induced Hyperglycemic Rats. curcumol 0-8 vascular endothelial growth factor A Rattus norvegicus 54-58 28138126-0 2017 Curcumol Promotes Vascular Endothelial Growth Factor (VEGF)-Mediated Diabetic Wound Healing in Streptozotocin-Induced Hyperglycemic Rats. Streptozocin 95-109 vascular endothelial growth factor A Rattus norvegicus 18-52 28138126-0 2017 Curcumol Promotes Vascular Endothelial Growth Factor (VEGF)-Mediated Diabetic Wound Healing in Streptozotocin-Induced Hyperglycemic Rats. Streptozocin 95-109 vascular endothelial growth factor A Rattus norvegicus 54-58 28138126-13 2017 CONCLUSIONS Our analyses clearly suggested that the observed enhancement in wound healing as a result of curcumol administration was attributable to VEGF-mediated angiogenesis. curcumol 105-113 vascular endothelial growth factor A Rattus norvegicus 149-153 28128406-8 2017 However, high dose ICA-treated group exhibited significantly higher expression of CD31, factor VIII, and VEGF compared to that in the low dose and vehicle-treated groups. icariin 19-22 vascular endothelial growth factor A Rattus norvegicus 105-109 28128406-10 2017 This study demonstrated that ICA increases thickness of the endometrium, and it may modulate expression of VEGF, CD31, and factor VIII. icariin 29-32 vascular endothelial growth factor A Rattus norvegicus 107-111 28117425-2 2017 The endothelial cell-specific mitogen vascular endothelial growth factor (VEGF), as well as its receptors, VEGFR1, VEGFR2, are thought to be the major mediators of pathological angiogenesis, and sunitinib exhibits anti-angiogenesis property through VEGF blockage and has been widely used to treat various cancers. Sunitinib 195-204 vascular endothelial growth factor A Rattus norvegicus 74-78 28117425-2 2017 The endothelial cell-specific mitogen vascular endothelial growth factor (VEGF), as well as its receptors, VEGFR1, VEGFR2, are thought to be the major mediators of pathological angiogenesis, and sunitinib exhibits anti-angiogenesis property through VEGF blockage and has been widely used to treat various cancers. Sunitinib 195-204 vascular endothelial growth factor A Rattus norvegicus 107-111 28117425-5 2017 Sunitinib treatment was associated with less angiogenesis in small-airway remodelling with a slightly disordered lung architecture, and lower expression level of VEGF, VEGFR1, VEGFR2. Sunitinib 0-9 vascular endothelial growth factor A Rattus norvegicus 162-166 28117425-6 2017 Overall, our results indicate that VEGF is a vital important factor that contributes to the small-airway remodelling in a rat model of COPD through promoting angiogenesis, which mainly depend on the specific binding between VEGF and VEGFR1 and can be effectively attenuated by sunitinib. Sunitinib 277-286 vascular endothelial growth factor A Rattus norvegicus 35-39 28117425-6 2017 Overall, our results indicate that VEGF is a vital important factor that contributes to the small-airway remodelling in a rat model of COPD through promoting angiogenesis, which mainly depend on the specific binding between VEGF and VEGFR1 and can be effectively attenuated by sunitinib. Sunitinib 277-286 vascular endothelial growth factor A Rattus norvegicus 224-228 27866977-7 2017 It showed that QYD and swertiamarin ameliorated the testosterone-induced prostatic hyperplasia and collagen deposition, attenuated the over-expressions of HIF-1alpha, VEGF, EGF, betaFGF, PCNA, AR and ER-alpha, reduced the ratio of Bcl-2/Bax, enhanced the expression of ER-beta, inhibited the oxidative stress and local inflammation, as well as relieved prostatic EMT. swertiamarin 23-35 vascular endothelial growth factor A Rattus norvegicus 167-171 27833010-0 2017 Naringin promotes fracture healing through stimulation of angiogenesis by regulating the VEGF/VEGFR-2 signaling pathway in osteoporotic rats. naringin 0-8 vascular endothelial growth factor A Rattus norvegicus 89-93 29121798-5 2017 Pretreatment with SB203580, a p38 MAPK inhibitor, dramatically abrogated the upregulating effects of DG-1g on p-p38 MAPK/p38 MAPK, p-CREB/CREB, and p-Bad/Bad ratios and HIF-1[Formula: see text], VEGF-A, and vWF expression and the downregulating effects of DG-1g on GFAP, cytochrome c, cleaved caspase-3, and cerebral infarction. SB 203580 18-26 vascular endothelial growth factor A Rattus norvegicus 195-201 27384939-5 2017 As hydrogel component, alginate and an alginate-gellan gum blend were evaluated; the blend exhibited a more favourable VEGF release profile and was chosen for biphasic scaffold fabrication. Alginates 39-47 vascular endothelial growth factor A Rattus norvegicus 119-123 28791301-0 2017 Effects of Chronic Exposure to Sodium Arsenite on Expressions of VEGF and VEGFR2 Proteins in the Epididymis of Rats. sodium arsenite 31-46 vascular endothelial growth factor A Rattus norvegicus 65-69 28814094-3 2017 Pegaptanib sodium is an antiangiogenetic drug that prevents the development of new vessels and thus adhesion by inhibiting the effect of VEGF. pegaptanib 0-17 vascular endothelial growth factor A Rattus norvegicus 137-141 29061060-10 2017 Cordyceps polysaccharide can alleviate the immune inflammatory response in acute liver failure, and may be specifically homing to the damaged liver, thus promoting the secretion of VEGF, proliferation of hepatocyte, regeneration of liver vessels, and repair of liver tissues. cordyceps polysaccharide 0-24 vascular endothelial growth factor A Rattus norvegicus 181-185 29209629-0 2017 Corrigendum to "Effects of Chronic Exposure to Sodium Arsenite on Expressions of VEGF and VEGFR2 Proteins in the Epididymis of Rats". sodium arsenite 47-62 vascular endothelial growth factor A Rattus norvegicus 81-85 28814094-11 2017 RESULTS: The epidural fibrosis grade in the pegaptanib sodium was significantly lower than in the control group c2 = 11,65; (p = 0.004)CONCLUSION: Pegaptanib sodium blocked the VEGF through its anti-VEGF effect and decreased spinal epidural fibrosis in rats that had undergone laminectomy (Tab. pegaptanib 147-164 vascular endothelial growth factor A Rattus norvegicus 177-181 28814094-11 2017 RESULTS: The epidural fibrosis grade in the pegaptanib sodium was significantly lower than in the control group c2 = 11,65; (p = 0.004)CONCLUSION: Pegaptanib sodium blocked the VEGF through its anti-VEGF effect and decreased spinal epidural fibrosis in rats that had undergone laminectomy (Tab. pegaptanib 147-164 vascular endothelial growth factor A Rattus norvegicus 199-203 28478450-4 2017 RESULTS: The results revealed that both the PDGF receptor-tyrosine kinase inhibitor imatinib and the multi-targeted VEGF and PDGF receptor inhibit or sunitinib malate reversed hypoxia-induced increases in right ventricular systolic pressure (RVSP), right ventricular function and thickening of the medial walls. Sunitinib 150-166 vascular endothelial growth factor A Rattus norvegicus 116-120 28721809-10 2017 RESULTS: VEGF&lt;sub&gt;165&lt;/sub&gt; was entrapped with high efficiency (90.8+-3.1) %. Adenosine Monophosphate 25-28 vascular endothelial growth factor A Rattus norvegicus 9-13 26917494-8 2017 In the OTM + MC group on day 7 of tooth movement, the expression of TGF-beta1 and VEGF was significantly reduced whereas the expression of bFGF was increased in PL. Methylcholanthrene 13-15 vascular endothelial growth factor A Rattus norvegicus 82-86 28721809-10 2017 RESULTS: VEGF&lt;sub&gt;165&lt;/sub&gt; was entrapped with high efficiency (90.8+-3.1) %. Adenosine Monophosphate 14-17 vascular endothelial growth factor A Rattus norvegicus 9-13 28721809-10 2017 RESULTS: VEGF&lt;sub&gt;165&lt;/sub&gt; was entrapped with high efficiency (90.8+-3.1) %. Adenosine Monophosphate 25-28 vascular endothelial growth factor A Rattus norvegicus 9-13 28721809-11 2017 In vitro VEGF&lt;sub&gt;165&lt;/sub&gt; release kinetics study showed an initial burst of 1.966 mug mg NPs-1 and 1.045mug mg V-ASCS-1 respectively in the first 24 hours. Adenosine Monophosphate 14-17 vascular endothelial growth factor A Rattus norvegicus 9-13 28721809-11 2017 In vitro VEGF&lt;sub&gt;165&lt;/sub&gt; release kinetics study showed an initial burst of 1.966 mug mg NPs-1 and 1.045mug mg V-ASCS-1 respectively in the first 24 hours. Adenosine Monophosphate 25-28 vascular endothelial growth factor A Rattus norvegicus 9-13 29189156-14 2017 CONCLUSION: CIMT-induced neuroprotection and functional recovery following cerebral ischemia were possibly mediated by an increase in endogenous HIF-1alpha and VEGF expression with subsequent neurogenesis and angiogenesis. cimt 12-16 vascular endothelial growth factor A Rattus norvegicus 160-164 28721809-11 2017 In vitro VEGF&lt;sub&gt;165&lt;/sub&gt; release kinetics study showed an initial burst of 1.966 mug mg NPs-1 and 1.045mug mg V-ASCS-1 respectively in the first 24 hours. Adenosine Monophosphate 25-28 vascular endothelial growth factor A Rattus norvegicus 9-13 28721809-11 2017 In vitro VEGF&lt;sub&gt;165&lt;/sub&gt; release kinetics study showed an initial burst of 1.966 mug mg NPs-1 and 1.045mug mg V-ASCS-1 respectively in the first 24 hours. Adenosine Monophosphate 25-28 vascular endothelial growth factor A Rattus norvegicus 9-13 29333188-8 2017 Western blot revealed that DP could also facilitate the expression of EGF and VEGF proteins. dracorhodin 27-29 vascular endothelial growth factor A Rattus norvegicus 78-82 28460626-1 2017 BACKGROUND: Sugen5416 (semaxinib) is an inhibitor of the vascular endothelial growth factor (VEGF) receptor. Semaxinib 12-21 vascular endothelial growth factor A Rattus norvegicus 93-97 28460626-1 2017 BACKGROUND: Sugen5416 (semaxinib) is an inhibitor of the vascular endothelial growth factor (VEGF) receptor. Semaxinib 23-32 vascular endothelial growth factor A Rattus norvegicus 93-97 27940247-3 2017 In this study, we tested whether olaptesed pegol (OLA-PEG, NOX-A12), a novel SDF-1alpha inhibitor, could reverse the recruitment of macrophages and potentiate the antitumor effect of anti-vascular endothelial growth factor (VEGF) therapy. pegol 43-48 vascular endothelial growth factor A Rattus norvegicus 183-222 29158916-0 2017 The Involvement of beta-Catenin/COX-2/VEGF Axis in NMDA-Caused Retinopathy. N-Methylaspartate 51-55 vascular endothelial growth factor A Rattus norvegicus 38-42 27909732-9 2017 RB-222 significantly repressed VEGF expression as well as decreased MMP-2 and MMP-9 expression. rb-222 0-6 vascular endothelial growth factor A Rattus norvegicus 31-35 29035589-8 2017 RESULTS: Immunohistologic analysis showed a decrease in growth factors/receptors on POD 60 (nintedanib-treated vs. nontreated controls: platelet-derived growth factor (PDGF) A: [P <= 0.001]; PDGF receptor-alpha: [P <= 0.001]; vascular endothelial growth factor (VEGF) A: [P <= 0.001]; VEGF receptor-2: [P <= 0.001]). nintedanib 92-102 vascular endothelial growth factor A Rattus norvegicus 232-266 29035589-8 2017 RESULTS: Immunohistologic analysis showed a decrease in growth factors/receptors on POD 60 (nintedanib-treated vs. nontreated controls: platelet-derived growth factor (PDGF) A: [P <= 0.001]; PDGF receptor-alpha: [P <= 0.001]; vascular endothelial growth factor (VEGF) A: [P <= 0.001]; VEGF receptor-2: [P <= 0.001]). nintedanib 92-102 vascular endothelial growth factor A Rattus norvegicus 268-272 29035589-8 2017 RESULTS: Immunohistologic analysis showed a decrease in growth factors/receptors on POD 60 (nintedanib-treated vs. nontreated controls: platelet-derived growth factor (PDGF) A: [P <= 0.001]; PDGF receptor-alpha: [P <= 0.001]; vascular endothelial growth factor (VEGF) A: [P <= 0.001]; VEGF receptor-2: [P <= 0.001]). nintedanib 92-102 vascular endothelial growth factor A Rattus norvegicus 294-298 27883998-9 2017 There were significant decreases in interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF) levels in peritoneal fluid samples in quinagolide-treated rats when compared to pre-treatment levels (p = 0.03 and p < 0.01). quinagolide 141-152 vascular endothelial growth factor A Rattus norvegicus 61-95 27883998-9 2017 There were significant decreases in interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF) levels in peritoneal fluid samples in quinagolide-treated rats when compared to pre-treatment levels (p = 0.03 and p < 0.01). quinagolide 141-152 vascular endothelial growth factor A Rattus norvegicus 97-101 27883998-11 2017 CONCLUSIONS: Quinagolide caused a significant regression in endometriotic implants and it also significantly reduced the levels of IL-6 and VEGF in peritoneal fluid. quinagolide 13-24 vascular endothelial growth factor A Rattus norvegicus 140-144 27862673-7 2017 The vitamin D treatment group had significantly increased VEGF, and reduced sFlt-1 and TNF-alpha compared with the untreated PE group. Vitamin D 4-13 vascular endothelial growth factor A Rattus norvegicus 58-62 27940247-11 2017 MRI with ferumoxytol as a contrast agent noninvasively demonstrated macrophage reduction in OLA-PEG + anti-VEGF-treated rats compared with VEGF blockade alone. Ferrosoferric Oxide 9-20 vascular endothelial growth factor A Rattus norvegicus 107-111 27940247-3 2017 In this study, we tested whether olaptesed pegol (OLA-PEG, NOX-A12), a novel SDF-1alpha inhibitor, could reverse the recruitment of macrophages and potentiate the antitumor effect of anti-vascular endothelial growth factor (VEGF) therapy. pegol 43-48 vascular endothelial growth factor A Rattus norvegicus 224-228 27940247-12 2017 In conclusion, inhibition of SDF-1 with OLA-PEG inhibited the recruitment of TAMs by VEGF blockage and potentiated its antitumor efficacy in GBM. ola-peg 40-47 vascular endothelial growth factor A Rattus norvegicus 85-89 27940247-3 2017 In this study, we tested whether olaptesed pegol (OLA-PEG, NOX-A12), a novel SDF-1alpha inhibitor, could reverse the recruitment of macrophages and potentiate the antitumor effect of anti-vascular endothelial growth factor (VEGF) therapy. ola-peg 50-57 vascular endothelial growth factor A Rattus norvegicus 183-222 27940247-10 2017 Intratumoral CD68+ tumor associated macrophages (TAMs) were increased by VEGF blockade, but the combination of OLA-PEG + VEGF blockade markedly lowered TAM levels compared with VEGF blockade alone. tam 49-52 vascular endothelial growth factor A Rattus norvegicus 73-77 27743986-0 2016 A combined supplementation of vitamin B12 and n-3 polyunsaturated fatty acids across two generations improves nerve growth factor and vascular endothelial growth factor levels in the rat hippocampus. Vitamin B 12 30-41 vascular endothelial growth factor A Rattus norvegicus 134-168 27729285-9 2016 Moreover, DHI improved the mRNA expression of VEGF and increased the blood vessel density of myocardial infarct border zone. dehydrosoyasaponin I 10-13 vascular endothelial growth factor A Rattus norvegicus 46-50 28095381-0 2017 A Single Oral Dose of Geranylgeranylacetone Upregulates Vascular Endothelial Growth Factor and Protects against Kainic Acid-Induced Neuronal Cell Death: Involvement of the Phosphatidylinositol-3 Kinase/Akt Pathway. geranylgeranylacetone 22-43 vascular endothelial growth factor A Rattus norvegicus 56-90 27743986-0 2016 A combined supplementation of vitamin B12 and n-3 polyunsaturated fatty acids across two generations improves nerve growth factor and vascular endothelial growth factor levels in the rat hippocampus. Fatty Acids, Omega-3 46-77 vascular endothelial growth factor A Rattus norvegicus 134-168 27743986-8 2016 Our results indicate that the combined supplementation of vitamin B12 and n-3 PUFA improves NGF and maintains VEGF levels in the brain which may improve neurovascular function. zwittergent 3-12 66-69 vascular endothelial growth factor A Rattus norvegicus 110-114 28078001-8 2016 Following the L-ARG treatment, the expression of the pro-angiogenic factors (VEGF and FGF-2) was higher and the expression of anti-angiogenic factors (endostatin) was lower than the vehicle-treated animals. Arginine 14-19 vascular endothelial growth factor A Rattus norvegicus 77-81 28078001-9 2016 In contrast, the L-NAME treatment reduced the expression of VEGF and increased the expression of endostatin. NG-Nitroarginine Methyl Ester 17-23 vascular endothelial growth factor A Rattus norvegicus 60-64 27647013-15 2016 Both EtOAc and MeOH extract-administered groups displayed significant remission in the levels of TNF-alpha, VEGF and IL-6. ethyl acetate 5-10 vascular endothelial growth factor A Rattus norvegicus 108-112 27647013-15 2016 Both EtOAc and MeOH extract-administered groups displayed significant remission in the levels of TNF-alpha, VEGF and IL-6. Methanol 15-19 vascular endothelial growth factor A Rattus norvegicus 108-112 27955748-6 2016 These polysaccharide extracts of JCEM, PCEM and EHEM produced significant decrease in serum AFP, CEA, GPC-3, HGF and VEGF compared with untreated HCC group. Polysaccharides 6-20 vascular endothelial growth factor A Rattus norvegicus 117-121 27620880-0 2016 Sodium hydrosulfide prevents hypertension and increases in vascular endothelial growth factor and soluble fms-like tyrosine kinase-1 in hypertensive pregnant rats. sodium bisulfide 0-19 vascular endothelial growth factor A Rattus norvegicus 59-93 27620880-14 2016 Treatment with NaHS prevents hypertension in pregnancy and concomitantly reduces circulating plasma sFlt-1 and VEGF levels; this correlates with improved litter size with more viable fetuses and increase in NO levels. sodium bisulfide 15-19 vascular endothelial growth factor A Rattus norvegicus 111-115 27904705-11 2016 In addition, the levels of anti-CII antibodies as well as serum tumor necrosis factor (TNF)-alpha and vascular endothelial growth factor (VEGF) levels were remarkably lower in PTX group than those in 5% GS controls (p<0.05). Paclitaxel 176-179 vascular endothelial growth factor A Rattus norvegicus 102-136 27686964-9 2016 Either RS-102221 or terguride reduced the increments in lung water contents, grading of lung fibrosis, lung tumor necrosis factor-alpha (TNF-alpha), transforming growth factor-beta1 (TGF-beta1) and vascular endothelial growth factor (VEGF) levels in lung injury and fibrosis-induced by bleomycin. 8-(5-(5-amino-2,4-dimethoxyphenyl)-5-oxopentyl)-1,3,8-triazaspiro(4.5)decane-2,4-dione 7-16 vascular endothelial growth factor A Rattus norvegicus 198-232 27686964-9 2016 Either RS-102221 or terguride reduced the increments in lung water contents, grading of lung fibrosis, lung tumor necrosis factor-alpha (TNF-alpha), transforming growth factor-beta1 (TGF-beta1) and vascular endothelial growth factor (VEGF) levels in lung injury and fibrosis-induced by bleomycin. 8-(5-(5-amino-2,4-dimethoxyphenyl)-5-oxopentyl)-1,3,8-triazaspiro(4.5)decane-2,4-dione 7-16 vascular endothelial growth factor A Rattus norvegicus 234-238 27686964-9 2016 Either RS-102221 or terguride reduced the increments in lung water contents, grading of lung fibrosis, lung tumor necrosis factor-alpha (TNF-alpha), transforming growth factor-beta1 (TGF-beta1) and vascular endothelial growth factor (VEGF) levels in lung injury and fibrosis-induced by bleomycin. dironyl 20-29 vascular endothelial growth factor A Rattus norvegicus 198-232 27686964-9 2016 Either RS-102221 or terguride reduced the increments in lung water contents, grading of lung fibrosis, lung tumor necrosis factor-alpha (TNF-alpha), transforming growth factor-beta1 (TGF-beta1) and vascular endothelial growth factor (VEGF) levels in lung injury and fibrosis-induced by bleomycin. dironyl 20-29 vascular endothelial growth factor A Rattus norvegicus 234-238 27861620-7 2016 In 2W CORT animals, prazosin treatment elicited a significant increase in vascular endothelial growth factor-A (VEGF-A) mRNA and protein. Prazosin 20-28 vascular endothelial growth factor A Rattus norvegicus 74-110 27861620-7 2016 In 2W CORT animals, prazosin treatment elicited a significant increase in vascular endothelial growth factor-A (VEGF-A) mRNA and protein. Prazosin 20-28 vascular endothelial growth factor A Rattus norvegicus 112-118 27861620-11 2016 This study demonstrates that GC-mediated capillary rarefaction is associated with a reduction in Ang-1 mRNA within the skeletal muscle microenvironment and that concurrent prazosin treatment effectively increases VEGF-A levels and prevents capillary loss. Prazosin 172-180 vascular endothelial growth factor A Rattus norvegicus 213-219 27852325-8 2016 The extent of the epidural scar, the regeneration of the vasculature and the expression levels of VEGF suggested better outcomes in the Sal B-treated groups. salvianolic acid B 136-141 vascular endothelial growth factor A Rattus norvegicus 98-102 27904676-6 2016 In astrocytes co-cultured with primary rat BMEC under mild hypoxia, NO was released by the BMECs and prevented the degradation of HIF-1alpha in astrocytes, leading to the up-regulated mRNA expression of VEGF and LDHA, elevated VEGF protein expression and increased production of lactic acid. Lactic Acid 279-290 vascular endothelial growth factor A Rattus norvegicus 203-207 27904705-11 2016 In addition, the levels of anti-CII antibodies as well as serum tumor necrosis factor (TNF)-alpha and vascular endothelial growth factor (VEGF) levels were remarkably lower in PTX group than those in 5% GS controls (p<0.05). Paclitaxel 176-179 vascular endothelial growth factor A Rattus norvegicus 138-142 27619839-4 2016 METHODS: We combined these approaches and produced a compacted calcium-alginate microsphere patch, restrained by a chitosan sheet, to deliver vascular endothelial growth factor (VEGF) to the heart after myocardial injury in rats. Calcium 63-70 vascular endothelial growth factor A Rattus norvegicus 142-176 27659963-0 2016 Leptomycin B ameliorates vasogenic edema formation induced by status epilepticus via inhibiting p38 MAPK/VEGF pathway. leptomycin B 0-12 vascular endothelial growth factor A Rattus norvegicus 105-109 27659963-5 2016 This anti-edema effect of LMB was relevant to inhibitions of VEGF over-expression as well as p38 mitogen-activated protein kinase (MAPK) phosphorylation. leptomycin B 26-29 vascular endothelial growth factor A Rattus norvegicus 61-65 27659963-6 2016 Furthermore, SB202190 (a p38 MAPK inhibitor) ameliorated vasogenic edema and VEGF over-expression induced by SE. 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole 13-21 vascular endothelial growth factor A Rattus norvegicus 77-81 27619839-4 2016 METHODS: We combined these approaches and produced a compacted calcium-alginate microsphere patch, restrained by a chitosan sheet, to deliver vascular endothelial growth factor (VEGF) to the heart after myocardial injury in rats. Calcium 63-70 vascular endothelial growth factor A Rattus norvegicus 178-182 27619839-4 2016 METHODS: We combined these approaches and produced a compacted calcium-alginate microsphere patch, restrained by a chitosan sheet, to deliver vascular endothelial growth factor (VEGF) to the heart after myocardial injury in rats. Alginates 71-79 vascular endothelial growth factor A Rattus norvegicus 142-176 27619839-4 2016 METHODS: We combined these approaches and produced a compacted calcium-alginate microsphere patch, restrained by a chitosan sheet, to deliver vascular endothelial growth factor (VEGF) to the heart after myocardial injury in rats. Alginates 71-79 vascular endothelial growth factor A Rattus norvegicus 178-182 27742705-6 2016 Treatment of GMECs with NGF significantly increased in vitro angiogenesis similar to that seen in GMECs treated with VEGF. gmecs 98-103 vascular endothelial growth factor A Rattus norvegicus 117-121 27638877-4 2016 In isolated rat mesenteric resistance arteries precontracted with the thromboxane analog U46619 to 80-90% of maximum contraction, VEGFA (25 ng/ml) caused a small and gradual relaxation (28.9 +- 3.9%). Thromboxanes 70-81 vascular endothelial growth factor A Rattus norvegicus 130-135 27638877-6 2016 VEGFA-induced relaxations were also inhibited in endothelial-denuded arteries and in arteries pretreated with the nitric oxide synthase (NOS) inhibitor, Nomega-nitro-l-arginine methyl ester (100 muM). NG-Nitroarginine Methyl Ester 153-189 vascular endothelial growth factor A Rattus norvegicus 0-5 26530694-9 2016 VEGF + BMMNC-treated rats had more BMMNC migration in the ischemic brain, better learning and memory, greater proliferation of vessels, and fewer degenerating neurons than did BMMNC-treated rats. bmmnc 7-12 vascular endothelial growth factor A Rattus norvegicus 0-4 26530694-10 2016 Pretreatment with VEGF receptor inhibitor SU5416 significantly decreased BMMNC migration and abolished the therapeutic effect of BMMNC transplantation. Semaxinib 42-48 vascular endothelial growth factor A Rattus norvegicus 18-22 27748921-7 2016 The present study determined that GSS treatment effectively decreased the levels of blood glucose, TC, TG, Lp-a, VEGF, IL-6, phosphorylated (p)-p38, p-ERK1/2 and p-JNK; however, treatment with GSS increased insulin and HDL levels. Ginsenosides 34-37 vascular endothelial growth factor A Rattus norvegicus 113-117 26621244-11 2016 After R-phenibut treatment at a dose of 50mg/kg statistically significant increase of BDNF and VEGF gene expression was found in damaged brain hemisphere. r-phenibut 6-16 vascular endothelial growth factor A Rattus norvegicus 95-99 27380212-6 2016 Celecoxib and octreotide exerted their anti-angiogenesis effect via an axis of cyclooxygenase-2/prostaglandin E2/EP-2/somatostatin receptor-2, which consequently down-regulated phosphorylation of extracellular signal-regulated kinase (p-ERK)-hypoxia-inducible factor-1alpha (HIF-1alpha)-vascular endothelial growth factor (VEGF) integrated signaling pathways. Celecoxib 0-9 vascular endothelial growth factor A Rattus norvegicus 323-327 29786208-9 2016 The clearer skin flaps structure, lighter inflammation reaction and inflammation cell infiltration, and higher VEGF staining intensity were observed in the Tempol group than the control group after 7 days. tempol 156-162 vascular endothelial growth factor A Rattus norvegicus 111-115 27792147-5 2016 More Col1-, Col2-, CD31-, and VEGF-positive cells, together with a greater degree of osteogenesis, were detected in the ICA group compared with the control group. icariin 120-123 vascular endothelial growth factor A Rattus norvegicus 30-34 27733124-14 2016 CONCLUSIONS: The results suggest that 10 % HS could alleviate cerebral oedema possibly through reducing the ischemia induced BBB permeability as a consequence of inhibiting VEGF-VEGFR2-mediated down-regulation of ZO-1, claudin-5. Hydrogen 43-45 vascular endothelial growth factor A Rattus norvegicus 173-177 27380212-6 2016 Celecoxib and octreotide exerted their anti-angiogenesis effect via an axis of cyclooxygenase-2/prostaglandin E2/EP-2/somatostatin receptor-2, which consequently down-regulated phosphorylation of extracellular signal-regulated kinase (p-ERK)-hypoxia-inducible factor-1alpha (HIF-1alpha)-vascular endothelial growth factor (VEGF) integrated signaling pathways. Octreotide 14-24 vascular endothelial growth factor A Rattus norvegicus 323-327 27492847-0 2016 Nanocrystalline calcium sulfate/hydroxyapatite biphasic compound as a TGF-beta1/VEGF reservoir for vital pulp therapy. Calcium Sulfate 16-31 vascular endothelial growth factor A Rattus norvegicus 80-84 27444229-7 2016 Furthermore, simultaneous treatment of castrated rats with diabetes with testosterone and exercise had a synergistic effect on capillary density, VEGF-A and SDF-1a levels in the heart. Testosterone 73-85 vascular endothelial growth factor A Rattus norvegicus 146-152 27444229-8 2016 In the group with diabetes, either testosterone or exercise increased capillary density, VEGF-A and SDF-1a protein levels in heart tissue. Testosterone 35-47 vascular endothelial growth factor A Rattus norvegicus 89-95 27444229-9 2016 However, the effects of combination therapy in rats with diabetes with testosterone and exercise on capillary density, VEGF-A and SDF-1a levels in the heart was synergistic. Testosterone 71-83 vascular endothelial growth factor A Rattus norvegicus 119-125 27444229-11 2016 The proangiogenesis effect of testosterone and exercise is associated with the enhanced expression of VEGF-A and SDF-1a in heart tissue. Testosterone 30-42 vascular endothelial growth factor A Rattus norvegicus 102-108 27297262-4 2016 The in vivo anti-angiogenic potential of DAP was evaluated by vascular endothelial growth factor (VEGF)-induced rat aortic ring (RAR) assay and chick chorioallantoic membrane (CAM) assay. daphnetin 41-44 vascular endothelial growth factor A Rattus norvegicus 62-96 27297262-4 2016 The in vivo anti-angiogenic potential of DAP was evaluated by vascular endothelial growth factor (VEGF)-induced rat aortic ring (RAR) assay and chick chorioallantoic membrane (CAM) assay. daphnetin 41-44 vascular endothelial growth factor A Rattus norvegicus 98-102 27562627-6 2016 The VEGF-R inhibitor tivozanib was used to analyze the paracrine role of VEGF, and the osteogenesis-promoting effects of 6% tensile strain were abrogated in the co-cultured cells treated with tivozanib. tivozanib 192-201 vascular endothelial growth factor A Rattus norvegicus 4-8 27562627-6 2016 The VEGF-R inhibitor tivozanib was used to analyze the paracrine role of VEGF, and the osteogenesis-promoting effects of 6% tensile strain were abrogated in the co-cultured cells treated with tivozanib. tivozanib 192-201 vascular endothelial growth factor A Rattus norvegicus 73-77 27492847-0 2016 Nanocrystalline calcium sulfate/hydroxyapatite biphasic compound as a TGF-beta1/VEGF reservoir for vital pulp therapy. Durapatite 32-46 vascular endothelial growth factor A Rattus norvegicus 80-84 27301615-0 2016 Catalpol stimulates VEGF production via the JAK2/STAT3 pathway to improve angiogenesis in rats" stroke model. catalpol 0-8 vascular endothelial growth factor A Rattus norvegicus 20-24 27208621-8 2016 EA in testosterone exposed dams compared with controls increased systolic pressure by 30%, decreased circulating norepinephrine and corticosterone, fetal and placental weight and placental VEGFR1 and proNGF protein expression, and increased the VEGFA/VEGFR1 ratio, mature NGF (mNGF) and the mNGF/proNGF ratio. Testosterone 6-18 vascular endothelial growth factor A Rattus norvegicus 245-250 27652091-6 2016 RESULTS: DHA reduced the apoptosis rate (P = 0.026) and decreased the secretion of Ang-2, VEGF, PGE2, and PGI2 (P = 0.006, P = 0.000, P = 0.002, P = 0.004 respectively). Docosahexaenoic Acids 9-12 vascular endothelial growth factor A Rattus norvegicus 90-94 27652091-11 2016 CONCLUSION: DHA reduced apoptosis induced by an OGD environment, thus decreasing Ang-2 and VEGF synthesis. Docosahexaenoic Acids 12-15 vascular endothelial growth factor A Rattus norvegicus 91-95 27497919-0 2016 Salvianolic acid B improves the disruption of high glucose-mediated brain microvascular endothelial cells via the ROS/HIF-1alpha/VEGF and miR-200b/VEGF signaling pathways. salvianolic acid B 0-18 vascular endothelial growth factor A Rattus norvegicus 129-133 27089240-8 2016 Treatment with ATN-161 combined with anti-VEGF antibody showed joint effects in attenuating angiogenesis. acetyl-prolyl-histidyl-seryl-cysteinyl-asparaginamide 15-22 vascular endothelial growth factor A Rattus norvegicus 42-46 27497919-0 2016 Salvianolic acid B improves the disruption of high glucose-mediated brain microvascular endothelial cells via the ROS/HIF-1alpha/VEGF and miR-200b/VEGF signaling pathways. salvianolic acid B 0-18 vascular endothelial growth factor A Rattus norvegicus 147-151 27497919-0 2016 Salvianolic acid B improves the disruption of high glucose-mediated brain microvascular endothelial cells via the ROS/HIF-1alpha/VEGF and miR-200b/VEGF signaling pathways. Glucose 51-58 vascular endothelial growth factor A Rattus norvegicus 129-133 27497919-0 2016 Salvianolic acid B improves the disruption of high glucose-mediated brain microvascular endothelial cells via the ROS/HIF-1alpha/VEGF and miR-200b/VEGF signaling pathways. Glucose 51-58 vascular endothelial growth factor A Rattus norvegicus 147-151 27497919-3 2016 And the increase of reactive oxidative species (ROS) production, the upregulation of hypoxia-inducible factor-1 alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) protein induced by high glucose were antagonized by Sal B. species 39-46 vascular endothelial growth factor A Rattus norvegicus 135-169 27497919-3 2016 And the increase of reactive oxidative species (ROS) production, the upregulation of hypoxia-inducible factor-1 alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) protein induced by high glucose were antagonized by Sal B. ros 48-51 vascular endothelial growth factor A Rattus norvegicus 135-169 27497919-3 2016 And the increase of reactive oxidative species (ROS) production, the upregulation of hypoxia-inducible factor-1 alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) protein induced by high glucose were antagonized by Sal B. Glucose 201-208 vascular endothelial growth factor A Rattus norvegicus 135-169 27497919-3 2016 And the increase of reactive oxidative species (ROS) production, the upregulation of hypoxia-inducible factor-1 alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) protein induced by high glucose were antagonized by Sal B. Glucose 201-208 vascular endothelial growth factor A Rattus norvegicus 171-175 27497919-3 2016 And the increase of reactive oxidative species (ROS) production, the upregulation of hypoxia-inducible factor-1 alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) protein induced by high glucose were antagonized by Sal B. salvianolic acid B 229-234 vascular endothelial growth factor A Rattus norvegicus 135-169 27497919-3 2016 And the increase of reactive oxidative species (ROS) production, the upregulation of hypoxia-inducible factor-1 alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) protein induced by high glucose were antagonized by Sal B. salvianolic acid B 229-234 vascular endothelial growth factor A Rattus norvegicus 171-175 27497919-6 2016 This led to the conclusion that Sal B-mediated improvement of blood-brain barrier dysfunction induced by high-glucose is related to the ROS/HIF-1alpha/VEGF and miR-200b/VEGF signaling pathways. salvianolic acid B 32-37 vascular endothelial growth factor A Rattus norvegicus 151-155 27497919-6 2016 This led to the conclusion that Sal B-mediated improvement of blood-brain barrier dysfunction induced by high-glucose is related to the ROS/HIF-1alpha/VEGF and miR-200b/VEGF signaling pathways. salvianolic acid B 32-37 vascular endothelial growth factor A Rattus norvegicus 169-173 27565753-7 2016 The results revealed that low ethanol consumption promoted angiogenesis in association with higher VEGF and lower endostatin. Ethanol 30-37 vascular endothelial growth factor A Rattus norvegicus 99-103 27539446-11 2016 VEGF and TNF-alpha concentrations in pulmonary tissues were significantly increased in both the TNBS colitis and DSS colitis groups compared to their own control groups (p = 0.002 and p = 0.004, respectively; and p = 0.002 and p = 0.002, respectively). dss 113-116 vascular endothelial growth factor A Rattus norvegicus 0-4 27558909-10 2016 Additionally, SAL administration partially ameliorated this hypoxia via the HIF-1alpha-VEGF signalling pathway. rhodioloside 14-17 vascular endothelial growth factor A Rattus norvegicus 87-91 27565753-10 2016 This study highlights that low ethanol consumption obviously promotes angiogenesis in myocardial-infarction rats while increasing the expression of VEGF, whereas high ethanol consumption inhibits ischemia-induced angiogenesis. Ethanol 31-38 vascular endothelial growth factor A Rattus norvegicus 148-152 26603138-8 2016 Fluorocitrate, an astrocytic inhibitor, significantly decreased GFAP and nestin expression in ischemic brains, and also reduced VEGF-enhanced neurogenic effects. fluorocitrate 0-13 vascular endothelial growth factor A Rattus norvegicus 128-132 27475885-8 2016 The results demonstrated that retinal HuR and VEGF are significantly increased in STZ-rats and are blunted by HuR siRNA treatment. Streptozocin 82-85 vascular endothelial growth factor A Rattus norvegicus 46-50 27565753-8 2016 High ethanol intake suppressed angiogenesis with unchanged VEGF and elevated endostatin. Ethanol 5-12 vascular endothelial growth factor A Rattus norvegicus 59-63 27565753-9 2016 Treatment with rosuvastatin preserved angiogenesis following high ethanol intake, with an upregulation of VEGF. Rosuvastatin Calcium 15-27 vascular endothelial growth factor A Rattus norvegicus 106-110 27362476-0 2016 Restoration of ovarian tissue function and estrous cycle in rat after autotransplantation using hyaluronic acid hydrogel scaffold containing VEGF and bFGF. Hyaluronic Acid 96-111 vascular endothelial growth factor A Rattus norvegicus 141-145 27564518-9 2016 Rapamycin improves lysosomal proteolytic activity by improving cathepsin L activity restoring autophagic cargo degradation, and preventing increased VEGF release (P < 0.0001). Sirolimus 0-9 vascular endothelial growth factor A Rattus norvegicus 149-153 26939766-7 2016 But vascular permeability, VEGF, and COX-2 expressions were reduced in animals treated with the resveratrol group compared with the cabergoline group (group 5) and the severe OHSS (group 3) group. Resveratrol 96-107 vascular endothelial growth factor A Rattus norvegicus 27-31 26939766-9 2016 CONCLUSION(S): Our results in a rat model suggest that resveratrol has a beneficial effect on OHSS by reducing the increases in ovarian daimeter, VP, and VEGF expression associated with OHSS. Resveratrol 55-66 vascular endothelial growth factor A Rattus norvegicus 154-158 27441774-13 2016 LIPUS is thought to exert humoral effects by recruiting bone marrow cells into the healing socket along with VEGF/angiogenesis induced by PGE2. Dinoprostone 138-142 vascular endothelial growth factor A Rattus norvegicus 109-113 27287221-8 2016 8-pCPT induced the development of hypersensitivity and increased pERK and VEGF expression in normal rats, whereas siRNA decreased the expression of pERK and VEGF. 8-pcpt 0-6 vascular endothelial growth factor A Rattus norvegicus 74-78 27564518-11 2016 CONCLUSIONS: High glucose upregulates autophagy but accumulates p62/SQTSM1 cargo due to lysosomal dysfunction, leading to massive VEGF release and cell death of rMCs. Glucose 18-25 vascular endothelial growth factor A Rattus norvegicus 130-134 27016022-5 2016 Rotenone-treated rats showed motor dysfunction, lower striatal dopamine, lower staining for nigral tyrosine hydroxylase but higher level of striatal cyclooxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) compared to vehicle-treated rats (P < 0.05). Rotenone 0-8 vascular endothelial growth factor A Rattus norvegicus 178-212 27016022-5 2016 Rotenone-treated rats showed motor dysfunction, lower striatal dopamine, lower staining for nigral tyrosine hydroxylase but higher level of striatal cyclooxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) compared to vehicle-treated rats (P < 0.05). Rotenone 0-8 vascular endothelial growth factor A Rattus norvegicus 214-218 27016022-6 2016 Treatment with l-dopa showed wearing-off over the course of the experiment in addition to development of abnormal involuntary movements and upregulated striatal VEGF level. Levodopa 15-21 vascular endothelial growth factor A Rattus norvegicus 161-165 27016022-7 2016 Treatment with ibuprofen or piroxicam in combination with l-dopa preserved the effect of l-dopa at the end of week 10, delayed the development of dyskinesia and decreased striatal COX-2 and VEGF levels. Ibuprofen 15-24 vascular endothelial growth factor A Rattus norvegicus 190-194 27016022-7 2016 Treatment with ibuprofen or piroxicam in combination with l-dopa preserved the effect of l-dopa at the end of week 10, delayed the development of dyskinesia and decreased striatal COX-2 and VEGF levels. Piroxicam 28-37 vascular endothelial growth factor A Rattus norvegicus 190-194 27016022-7 2016 Treatment with ibuprofen or piroxicam in combination with l-dopa preserved the effect of l-dopa at the end of week 10, delayed the development of dyskinesia and decreased striatal COX-2 and VEGF levels. Levodopa 58-64 vascular endothelial growth factor A Rattus norvegicus 190-194 27524968-0 2016 Vascular Endothelial Growth Factor Improves Physico-Mechanical Properties and Enhances Endothelialization of Poly(3-hydroxybutyrate-co-3-hydroxyvalerate)/Poly(epsilon-caprolactone) Small-Diameter Vascular Grafts In vivo. poly(3-hydroxybutyrate)-co-(3-hydroxyvalerate) 109-153 vascular endothelial growth factor A Rattus norvegicus 0-34 27524968-0 2016 Vascular Endothelial Growth Factor Improves Physico-Mechanical Properties and Enhances Endothelialization of Poly(3-hydroxybutyrate-co-3-hydroxyvalerate)/Poly(epsilon-caprolactone) Small-Diameter Vascular Grafts In vivo. polycaprolactone 154-179 vascular endothelial growth factor A Rattus norvegicus 0-34 27447611-10 2016 The findings provide the first evidence of argon-induced effects on the survival of cardiomyocytes during the second window of preconditioning, which may be mediated through the induction of HSP27, SOD2, VEGF and iNOS. Argon 43-48 vascular endothelial growth factor A Rattus norvegicus 204-208 27468656-9 2016 The present result demonstrated that leptin combined with CoCl2 significantly increased the mRNA expression levels of HIF1A, Vegfa, Runx2, Bmp2, Bglap and Alpl. cobaltous chloride 58-63 vascular endothelial growth factor A Rattus norvegicus 125-130 27464629-19 2016 (4) On POD 7, the expressions of VEGF in CZ 2 of flaps in rats of group DMOG detected by immunohistochemistry and Western blotting were 5 060+-432 and 0.48+-0.04 respectively, which were significantly higher than those of group NS (2 811+-382 and 0.26+-0.06, with t values respectively 9.54 and 5.67, P values below 0.01). oxalylglycine 72-76 vascular endothelial growth factor A Rattus norvegicus 33-37 26852735-10 2016 Removal of copper by a copper chelator, tetraethylenepentamine, from primary cultures of neonatal rat cardiomyocytes also suppressed the expression of HIF-1 regulated VEGF and BNIP3, but not IGF-2. Copper 11-17 vascular endothelial growth factor A Rattus norvegicus 167-171 27468227-9 2016 Mechanistically, 5-FU and TQ remarkably cooperated to repress the expression of procancerous Wnt, beta-catenin, NF-kappaB, COX-2, iNOS, VEGF, and TBRAS and upregulate the expression of anti-tumorigenesis DKK-1, CDNK-1A, TGF-beta1, TGF-betaRII, Smad4, and GPx. Fluorouracil 17-21 vascular endothelial growth factor A Rattus norvegicus 136-140 33465876-2 2016 Heparin mimetic peptide nanofibers can bind to and enhance production and activity of major angiogenic growth factors, including VEGF. Heparin 0-7 vascular endothelial growth factor A Rattus norvegicus 129-133 26852735-10 2016 Removal of copper by a copper chelator, tetraethylenepentamine, from primary cultures of neonatal rat cardiomyocytes also suppressed the expression of HIF-1 regulated VEGF and BNIP3, but not IGF-2. Copper 23-29 vascular endothelial growth factor A Rattus norvegicus 167-171 26852735-10 2016 Removal of copper by a copper chelator, tetraethylenepentamine, from primary cultures of neonatal rat cardiomyocytes also suppressed the expression of HIF-1 regulated VEGF and BNIP3, but not IGF-2. tetraethylenepentamine 40-62 vascular endothelial growth factor A Rattus norvegicus 167-171 27383124-10 2016 Treatment with quercetin did not significantly alter HIF-1alpha levels, but did reduce AaPO2 as well as lung tissue NF-kappaB activity, VEGFA gene and protein levels, Akt activity, and angiogenesis. Quercetin 15-24 vascular endothelial growth factor A Rattus norvegicus 136-141 27383124-12 2016 Interestingly, quercetin inhibited pulmonary vascular angiogenesis in rats with HPS, with involvement of Akt/NF-kappaB and VEGFA/VEGFR-2 pathways. Quercetin 15-24 vascular endothelial growth factor A Rattus norvegicus 123-128 27139338-9 2016 Sal B inhibited the expression of Bax, cleaved caspase-9 and cleaved PARP, while promoted the expression of Bcl-2, LC3-II, Beclin1 and VEGF. salvianolic acid B 0-5 vascular endothelial growth factor A Rattus norvegicus 135-139 27379578-0 2016 Different Ipsi- and Contralateral Glial Responses to Anti-VEGF and Triamcinolone Intravitreal Injections in Rats. ipsi 10-14 vascular endothelial growth factor A Rattus norvegicus 58-62 27063455-4 2016 Viral-mediated hippocampal knockdown of vascular endothelial growth factor (VEGF) produced depressive-like behaviors in the FST and NSFT, which were partially recovered by ketamine to the level observed in the control group. Ketamine 172-180 vascular endothelial growth factor A Rattus norvegicus 40-74 27063455-4 2016 Viral-mediated hippocampal knockdown of vascular endothelial growth factor (VEGF) produced depressive-like behaviors in the FST and NSFT, which were partially recovered by ketamine to the level observed in the control group. Ketamine 172-180 vascular endothelial growth factor A Rattus norvegicus 76-80 27063455-5 2016 The behavioral effects of VEGF knock down were accompanied by a decrease in hippocampal neurogenesis, which was also partially recovered by ketamine. Ketamine 140-148 vascular endothelial growth factor A Rattus norvegicus 26-30 27063455-6 2016 Our results suggest that basal hippocampal VEGF expression is necessary for ketamine-induced antidepressant-like behaviors in rats, but ketamine-induced VEGF expression only partially contributes to hippocampal neurogenesis and the antidepressant-like effects of ketamine. Ketamine 136-144 vascular endothelial growth factor A Rattus norvegicus 153-157 27063455-6 2016 Our results suggest that basal hippocampal VEGF expression is necessary for ketamine-induced antidepressant-like behaviors in rats, but ketamine-induced VEGF expression only partially contributes to hippocampal neurogenesis and the antidepressant-like effects of ketamine. Ketamine 136-144 vascular endothelial growth factor A Rattus norvegicus 153-157 27435772-0 2016 [Media of rat macrophage NR8383 cells with prostaglandins E2-induced VEGF over-expression promotes migration and tube formation of human umbilical vein endothelial cells]. Dinoprostone 43-60 vascular endothelial growth factor A Rattus norvegicus 69-73 26649730-10 2016 There was significant downregulation of permeability factor VEGF by EDHB with concomitant increment in hypoxia inducible factor (HIF1alpha) and anti-inflammatory proteins HO-1 and MT-1 compared to HH control thus accentuating the potential of EDHB as effective hypoxic preconditioning agent in ameliorating HH mediated injury in brain. ethyl protocatechuate 68-72 vascular endothelial growth factor A Rattus norvegicus 60-64 26649730-10 2016 There was significant downregulation of permeability factor VEGF by EDHB with concomitant increment in hypoxia inducible factor (HIF1alpha) and anti-inflammatory proteins HO-1 and MT-1 compared to HH control thus accentuating the potential of EDHB as effective hypoxic preconditioning agent in ameliorating HH mediated injury in brain. ethyl protocatechuate 243-247 vascular endothelial growth factor A Rattus norvegicus 60-64 27435772-1 2016 OBJECTIVE: To investigate the effect of prostaglandins E2 (PGE2) in enhancing vascular endothelial growth factor (VEGF) expression in a rat macrophage cell line and the effect of the media from PGE2-inuced rat macrophages on angiogenetic ability of human umbilical vein endothelial cells (HUVECs) in vitro. Dinoprostone 40-57 vascular endothelial growth factor A Rattus norvegicus 78-112 27435772-1 2016 OBJECTIVE: To investigate the effect of prostaglandins E2 (PGE2) in enhancing vascular endothelial growth factor (VEGF) expression in a rat macrophage cell line and the effect of the media from PGE2-inuced rat macrophages on angiogenetic ability of human umbilical vein endothelial cells (HUVECs) in vitro. Dinoprostone 40-57 vascular endothelial growth factor A Rattus norvegicus 114-118 27435772-1 2016 OBJECTIVE: To investigate the effect of prostaglandins E2 (PGE2) in enhancing vascular endothelial growth factor (VEGF) expression in a rat macrophage cell line and the effect of the media from PGE2-inuced rat macrophages on angiogenetic ability of human umbilical vein endothelial cells (HUVECs) in vitro. Dinoprostone 59-63 vascular endothelial growth factor A Rattus norvegicus 78-112 27435772-1 2016 OBJECTIVE: To investigate the effect of prostaglandins E2 (PGE2) in enhancing vascular endothelial growth factor (VEGF) expression in a rat macrophage cell line and the effect of the media from PGE2-inuced rat macrophages on angiogenetic ability of human umbilical vein endothelial cells (HUVECs) in vitro. Dinoprostone 59-63 vascular endothelial growth factor A Rattus norvegicus 114-118 27435772-2 2016 METHODS: Western blotting and qPCR were employed to investigate the expressions of VEGF protein and mRNAs in rat macrophage cell line NR8383 stimulated by PGE2 in the presence or absence of EP2 receptor inhibitor (AH6809) and EP4 receptor inhibitor (AH23848). Dinoprostone 155-159 vascular endothelial growth factor A Rattus norvegicus 83-87 27435772-4 2016 RESULTS: PGE2 stimulation significantly enhanced the expression of VEGF protein and mRNAs in NR8383 cells in a dose-dependent manner. Dinoprostone 9-13 vascular endothelial growth factor A Rattus norvegicus 67-71 27435772-7 2016 CONCLUSION: PGE2 can dose-dependently increase VEGF expression in NR8383 cells, and the supernatants derived from PGE2-stimulated NR8383 cells can induce HUVEC migration and accelerate the growth of tube like structures. Dinoprostone 12-16 vascular endothelial growth factor A Rattus norvegicus 47-51 27435772-7 2016 CONCLUSION: PGE2 can dose-dependently increase VEGF expression in NR8383 cells, and the supernatants derived from PGE2-stimulated NR8383 cells can induce HUVEC migration and accelerate the growth of tube like structures. Dinoprostone 114-118 vascular endothelial growth factor A Rattus norvegicus 47-51 26988565-9 2016 Furthermore, western blot analysis was carried out to examine the protein expression of ICAM-1, NOS, NF-kappaB p65 and VEGF in high glucose-induced HRMECs. Glucose 132-139 vascular endothelial growth factor A Rattus norvegicus 119-123 27032713-5 2016 In OHSS model rats, TUDCA administration prevented the OHSS development, reducing ovarian VEGFA production. ursodoxicoltaurine 20-25 vascular endothelial growth factor A Rattus norvegicus 90-95 26988565-14 2016 CONCLUSION: The data indicated that TUDCA could ameliorate DR by decreasing NO content and down-regulating the protein expression of ICAM-1, NOS, NF-kappaB p65 and VEGF. ursodoxicoltaurine 36-41 vascular endothelial growth factor A Rattus norvegicus 164-168 27020656-9 2016 Mechanistically, paricalcitol and 5-FU had cooperated together to repress the expression of procancerous Wnt, beta-catenin, NF-kappaB, COX-2, iNOS, VEGF, and HSP-90 more, and to upregulate the expression of antitumorigenesis DKK-1 and CDNK-1A, compared with their monotherapies. paricalcitol 17-29 vascular endothelial growth factor A Rattus norvegicus 148-152 27055905-2 2016 We hypothesized that retinoic acid-related orphan nuclear receptor gamma (RORgamma) and its downstream effector, interleukin (IL)-17A, upregulate VEGF and hence are important treatment targets for neovascular retinopathies. Tretinoin 21-34 vascular endothelial growth factor A Rattus norvegicus 146-150 26875015-8 2016 Pretreatment with imatinib, a PDGF receptor activity blocker, in HT rats reduced the alphaSMA-positive cell proliferation and fibrosis in the PVs and also induced a significant reduction in VEGF expression. Imatinib Mesylate 18-26 vascular endothelial growth factor A Rattus norvegicus 190-194 27020656-9 2016 Mechanistically, paricalcitol and 5-FU had cooperated together to repress the expression of procancerous Wnt, beta-catenin, NF-kappaB, COX-2, iNOS, VEGF, and HSP-90 more, and to upregulate the expression of antitumorigenesis DKK-1 and CDNK-1A, compared with their monotherapies. Fluorouracil 34-38 vascular endothelial growth factor A Rattus norvegicus 148-152 27338064-15 2016 BMSC therapy with rosuvastatin (instead of BMSC therapy alone) upregulated the VEGF and bFGF expression, increased the capillary density and improved the cardiac function. Rosuvastatin Calcium 18-30 vascular endothelial growth factor A Rattus norvegicus 79-83 27105936-9 2016 Moreover, the secretion of VEGF by BM-MSCs increased after treatment with CBDL rat serum. cbdl 74-78 vascular endothelial growth factor A Rattus norvegicus 27-31 26681729-0 2016 Effect of high salt diet on blood pressure and renal damage during vascular endothelial growth factor inhibition with sunitinib. Salts 15-19 vascular endothelial growth factor A Rattus norvegicus 67-101 26681729-0 2016 Effect of high salt diet on blood pressure and renal damage during vascular endothelial growth factor inhibition with sunitinib. Sunitinib 118-127 vascular endothelial growth factor A Rattus norvegicus 67-101 26681729-1 2016 BACKGROUND: Antiangiogenic treatment with the multitargeted vascular endothelial growth factor (VEGF) receptor inhibitor sunitinib associates with a blood pressure (BP) rise and glomerular renal injury. Sunitinib 121-130 vascular endothelial growth factor A Rattus norvegicus 60-94 26681729-1 2016 BACKGROUND: Antiangiogenic treatment with the multitargeted vascular endothelial growth factor (VEGF) receptor inhibitor sunitinib associates with a blood pressure (BP) rise and glomerular renal injury. Sunitinib 121-130 vascular endothelial growth factor A Rattus norvegicus 96-100 27225425-7 2016 Niaspan treatment significantly improved clinical and histopathological outcomes; decreased the expressions of VEGF/VEGFR, VCAM-1/CD45, apoptosis and BRB breakdown, significantly increased tight junction proteins and Ang-1/Tie-2 expressions, as well as increased retinal miR-126 expression compared to non-treatment diabetic rats. Niacin 0-7 vascular endothelial growth factor A Rattus norvegicus 111-115 27212231-0 2016 Regenerative repair of Pifithrin-alpha in cerebral ischemia via VEGF dependent manner. pifithrin 23-38 vascular endothelial growth factor A Rattus norvegicus 64-68 26276507-8 2016 eNOS and VEGF immune expressions diminished in penile corpora of STZ-DM rats and improved with VPA treatment. Streptozocin 65-68 vascular endothelial growth factor A Rattus norvegicus 9-13 26276507-8 2016 eNOS and VEGF immune expressions diminished in penile corpora of STZ-DM rats and improved with VPA treatment. Valproic Acid 95-98 vascular endothelial growth factor A Rattus norvegicus 9-13 27220712-1 2016 OBJECTIVE: To observe the effect of tert-butylhydroquinone (tBHQ) on the islets function and expression of HO-1 and VEGF in retina of type 2 diabetic rats. 2-tert-butylhydroquinone 36-58 vascular endothelial growth factor A Rattus norvegicus 116-120 26690356-9 2016 CONCLUSIONS: Letrozole and cabergoline were equally effective to prevent OHSS, reducing the ovarian diameter, VP, and PEDF and VEGF levels to similar extents. Letrozole 13-22 vascular endothelial growth factor A Rattus norvegicus 127-131 26690356-9 2016 CONCLUSIONS: Letrozole and cabergoline were equally effective to prevent OHSS, reducing the ovarian diameter, VP, and PEDF and VEGF levels to similar extents. Cabergoline 27-38 vascular endothelial growth factor A Rattus norvegicus 127-131 26458922-8 2016 The lithium group showed preventive effects against steroid-related vessel loss by micro-CT-based angiography and VEGF staining. Lithium 4-11 vascular endothelial growth factor A Rattus norvegicus 114-118 27168839-0 2016 Effects of carvedilol reduce conjunctivitis through changes in inflammation, NGF and VEGF levels in a rat model. Carvedilol 11-21 vascular endothelial growth factor A Rattus norvegicus 85-89 27168839-10 2016 Carvedilol was also able to significantly reduce the protein expression levels of NF-kappaB, and induce the protein expression levels of NGF and VEGF in the LPS-induced rat model of conjunctivitis (P<0.01). Carvedilol 0-10 vascular endothelial growth factor A Rattus norvegicus 145-149 27168839-11 2016 In conclusion, the effects of carvedilol may reduce conjunctivitis clinical scores through inflammation, NGF and VEGF in LPS-induced rat models. Carvedilol 30-40 vascular endothelial growth factor A Rattus norvegicus 113-117 26947206-0 2016 Effects of total saponins from Rhizoma Dioscoreae Nipponicae on expression of vascular endothelial growth factor and angiopoietin-2 and Tie-2 receptors in the synovium of rats with rheumatoid arthritis. Saponins 17-25 vascular endothelial growth factor A Rattus norvegicus 78-112 26947206-1 2016 BACKGROUND: This study aimed to determine the effects of total saponins from Rhizoma Dioscoreae Nipponicae (TS-RDN) on the expression of vascular endothelial growth factor (VEGF) and angiopoietin (Ang)-2 and Tie-2 (endothelial tyrosine kinase receptor) receptors in the synovium of rats with rheumatoid arthritis (RA) (collagen-induced arthritis; CIA), and to examine the mechanisms of TS-RDN in alleviating RA. Saponins 63-71 vascular endothelial growth factor A Rattus norvegicus 137-171 26947206-1 2016 BACKGROUND: This study aimed to determine the effects of total saponins from Rhizoma Dioscoreae Nipponicae (TS-RDN) on the expression of vascular endothelial growth factor (VEGF) and angiopoietin (Ang)-2 and Tie-2 (endothelial tyrosine kinase receptor) receptors in the synovium of rats with rheumatoid arthritis (RA) (collagen-induced arthritis; CIA), and to examine the mechanisms of TS-RDN in alleviating RA. Saponins 63-71 vascular endothelial growth factor A Rattus norvegicus 173-177 27220712-0 2016 [Influence of tert-butylhydroquinone on the islets function and expression of HO-1 and VEGF in retina of type 2 diabetic rats]. 2-tert-butylhydroquinone 14-36 vascular endothelial growth factor A Rattus norvegicus 87-91 27220712-1 2016 OBJECTIVE: To observe the effect of tert-butylhydroquinone (tBHQ) on the islets function and expression of HO-1 and VEGF in retina of type 2 diabetic rats. 2-tert-butylhydroquinone 60-64 vascular endothelial growth factor A Rattus norvegicus 116-120 27220712-17 2016 The expression of VEGF mRNA increased significantly in diabetic group(t4w=11.92, t12w=29.27)and tBHQ intervention group(t4w=12.50, t12w= 11.24)than that in normal group(P<0.05). 2-tert-butylhydroquinone 96-100 vascular endothelial growth factor A Rattus norvegicus 18-22 27220712-18 2016 The expression of VEGF mRNA increased significantly in tBHQ intervention group(t4w=-6.36, t12w=-20.22)than that in diabetic group(P<0.05). 2-tert-butylhydroquinone 55-59 vascular endothelial growth factor A Rattus norvegicus 18-22 27220712-19 2016 CONCLUSION: tBHQ can promote the secretion of insulin in diabetic rats, lowered glucose levels, also induce the expression of HO-1 and suppress the expression of VEGF in retina to confer protection to islets function and retina of type 2 diabtic rats. 2-tert-butylhydroquinone 12-16 vascular endothelial growth factor A Rattus norvegicus 162-166 26935971-10 2016 The present study demonstrated that SENP-1 was able to enhance the proliferative ability of PASMCs by initiating deSUMOylation of HIF-1alpha and increasing the expression of its downstream responsive gene, VEGF. pasmcs 92-98 vascular endothelial growth factor A Rattus norvegicus 206-210 26933083-9 2016 Intramyocardial-targeted delivery of the vascular endothelial growth factor receptor 3-selective designer protein VEGF-CC152S, using albumin-alginate microparticles, accelerated cardiac lymphangiogenesis in a dose-dependent manner and limited precollector remodeling post-MI. Alginates 141-149 vascular endothelial growth factor A Rattus norvegicus 114-118 26936330-7 2016 The expression levels of VEGF, Flk-1 and Nestin were significantly increased in the rats treated with Ilexonin A, compared with the rats administered with saline. ilexonin A 102-112 vascular endothelial growth factor A Rattus norvegicus 25-29 26500193-8 2016 Expressions of VEGF and VEGFR-2 were enhanced on P14 in KRN633-treated rat retinas. N-(2-chloro-4-((6,7-dimethoxy-4-quinazolinyl)oxy)phenyl)-N'-propylurea 56-62 vascular endothelial growth factor A Rattus norvegicus 15-19 26989466-1 2016 AIM: To investigate the dynamic expression of p-signal transducer and activator of transcription 3 (STAT3) and vascular endothelial growth factor (VEGF) in the formation of gastric tumors induced by drinking water containing N-methyl-N"-nitro-N-nitrosoguanidine (MNNG) in Wistar rats. Water 208-213 vascular endothelial growth factor A Rattus norvegicus 111-145 26989466-1 2016 AIM: To investigate the dynamic expression of p-signal transducer and activator of transcription 3 (STAT3) and vascular endothelial growth factor (VEGF) in the formation of gastric tumors induced by drinking water containing N-methyl-N"-nitro-N-nitrosoguanidine (MNNG) in Wistar rats. Water 208-213 vascular endothelial growth factor A Rattus norvegicus 147-151 26989466-1 2016 AIM: To investigate the dynamic expression of p-signal transducer and activator of transcription 3 (STAT3) and vascular endothelial growth factor (VEGF) in the formation of gastric tumors induced by drinking water containing N-methyl-N"-nitro-N-nitrosoguanidine (MNNG) in Wistar rats. Methylnitronitrosoguanidine 225-261 vascular endothelial growth factor A Rattus norvegicus 147-151 27363062-11 2016 CONCLUSION: The increased level of VEGF expression in the nicotine-treated group may have affected endothelial cell apoptosis. Nicotine 58-66 vascular endothelial growth factor A Rattus norvegicus 35-39 27323438-9 2016 The effects of EA+ PGB were evidently superior to those of simple EA and simple PBG in up-regulating BDNF and VEGF IR-positive neuron numbers and expression levels in the PVN ( P<0.05). ea+ pgb 15-22 vascular endothelial growth factor A Rattus norvegicus 110-114 27323438-9 2016 The effects of EA+ PGB were evidently superior to those of simple EA and simple PBG in up-regulating BDNF and VEGF IR-positive neuron numbers and expression levels in the PVN ( P<0.05). pbg 80-83 vascular endothelial growth factor A Rattus norvegicus 110-114 27323438-10 2016 CONCLUSION: EA combined with PGB can up-regulate the expression of BDNF and VEGF in the PVN of hypothalamus in cerebral ischemia rats, which might contribute to its effect in improving cerebral ischemia. Prostaglandins B 29-32 vascular endothelial growth factor A Rattus norvegicus 76-80 26872098-0 2016 Normobaric oxygen therapy inhibits HIF-1alpha and VEGF expression in perihematoma and reduces neurological function defects. Oxygen 11-17 vascular endothelial growth factor A Rattus norvegicus 50-54 26872098-10 2016 These results suggest that NBO therapy with oxygen delivered at 90% conferred best neuroprotection to ICH rats, potentially through amelioration of brain edema by suppressing HIF-1alpha and VEGF expression in the perihematoma. Oxygen 44-50 vascular endothelial growth factor A Rattus norvegicus 190-194 26944125-7 2016 Consistent with these outcome measures, the low dose atorvastatin increased the expression of angiopoient-1 and VEGF and reduced MMP9 expression in the connective tissue of the SDH wall, resulting in an increased vascular density and enhanced vascular maturation. Atorvastatin 53-65 vascular endothelial growth factor A Rattus norvegicus 112-116 26806300-9 2016 DW10075 (1-100 nmol/L) dose-dependently inhibited VEGF-induced HUVEC migration and tube formation and suppressed angiogenesis in both the rat aortic ring model and the chicken chorioallantoic membrane model. dw10075 0-7 vascular endothelial growth factor A Rattus norvegicus 50-54 27145632-0 2016 Quercetin accelerated cutaneous wound healing in rats by increasing levels of VEGF and TGF-beta1. Quercetin 0-9 vascular endothelial growth factor A Rattus norvegicus 78-82 26518179-0 2016 The effect of intravitreal vascular endothelial growth factor on inner retinal oxygen delivery and metabolism in rats. Oxygen 79-85 vascular endothelial growth factor A Rattus norvegicus 27-61 26518179-2 2016 Increased VEGF may affect inner retinal oxygen delivery (DO2) and oxygen metabolism (MO2), however, quantitative information is lacking. Oxygen 40-46 vascular endothelial growth factor A Rattus norvegicus 10-14 26518179-2 2016 Increased VEGF may affect inner retinal oxygen delivery (DO2) and oxygen metabolism (MO2), however, quantitative information is lacking. do2 57-60 vascular endothelial growth factor A Rattus norvegicus 10-14 26518179-2 2016 Increased VEGF may affect inner retinal oxygen delivery (DO2) and oxygen metabolism (MO2), however, quantitative information is lacking. Oxygen 66-72 vascular endothelial growth factor A Rattus norvegicus 10-14 26518179-11 2016 DO2 was 950 +- 340 and 1380 +- 650 nL O2/min in control and VEGF-injected eyes, respectively (P = 0.005). Oxygen 1-3 vascular endothelial growth factor A Rattus norvegicus 60-64 27689093-3 2016 Vascular endothelial growth factor (VEGF) was loaded on mesoporous silica nanoparticle (MSN), which was then incorporated within a type I collagen sponge, to produce collagen/MSN/VEGF (CMV) scaffold. Silicon Dioxide 67-73 vascular endothelial growth factor A Rattus norvegicus 0-34 26746666-3 2016 Rats underwent permanent middle cerebral artery occlusion (pMCAO) and then received intraperitoneal injections of progesterone (15 mg/kg) or vehicle at 1 h followed by subcutaneous injections at 6, 24, and 48 h. We examined VEGF and BDNF expression by Western blotting and/or immunostaining and microvessel density by lectin immunostaining. Progesterone 114-126 vascular endothelial growth factor A Rattus norvegicus 224-228 27997905-5 2016 RESULTS: Our results show that HIF-1alpha and VEGF as well as VEGF receptor subtype 2 (VEGFR-2) were increased in STZ rats. Streptozocin 114-117 vascular endothelial growth factor A Rattus norvegicus 46-50 27997905-7 2016 Blocking mTOR by using rapamycin significantly attenuated activities of HIF-1alpha and VEGF signaling pathways. Sirolimus 23-32 vascular endothelial growth factor A Rattus norvegicus 87-91 26783748-0 2016 All-Trans Retinoic Acid Attenuates Hypoxia-Induced Injury in NRK52E Cells via Inhibiting NF-x03BA;B/VEGF and TGF-beta2/VEGF Pathway. Tretinoin 10-23 vascular endothelial growth factor A Rattus norvegicus 100-104 26783748-0 2016 All-Trans Retinoic Acid Attenuates Hypoxia-Induced Injury in NRK52E Cells via Inhibiting NF-x03BA;B/VEGF and TGF-beta2/VEGF Pathway. Tretinoin 10-23 vascular endothelial growth factor A Rattus norvegicus 119-123 26783748-14 2016 CONCLUSIONS: This study indicated that ATRA may attenuate hypoxia-induced injury in NRK52E cells via inhibiting NF-x03BA;B/VEGF and TGF-beta2/VEGF pathway. Tretinoin 39-43 vascular endothelial growth factor A Rattus norvegicus 123-127 26783748-14 2016 CONCLUSIONS: This study indicated that ATRA may attenuate hypoxia-induced injury in NRK52E cells via inhibiting NF-x03BA;B/VEGF and TGF-beta2/VEGF pathway. Tretinoin 39-43 vascular endothelial growth factor A Rattus norvegicus 142-146 27595397-10 2016 RESULTS: Curcumin and KN93 significantly inhibited the activation of CaMKII/NF-kappaB signaling induced by diabetes or elevated glucose, and subsequently decreased the expression of VEGF, iNOS and ICAM-1. Curcumin 9-17 vascular endothelial growth factor A Rattus norvegicus 182-186 27595397-10 2016 RESULTS: Curcumin and KN93 significantly inhibited the activation of CaMKII/NF-kappaB signaling induced by diabetes or elevated glucose, and subsequently decreased the expression of VEGF, iNOS and ICAM-1. KN 93 22-26 vascular endothelial growth factor A Rattus norvegicus 182-186 27347496-7 2016 Compared to 5.5mM, MIO-M1 and rMC-1 in 30mM glucose had increased levels of VEGF in cell medium (pg/ml by 24% and 20%) and also VEGF concentration in cells held in 0mM increased by 47% and 10% respectively. Glucose 44-51 vascular endothelial growth factor A Rattus norvegicus 76-80 27347496-7 2016 Compared to 5.5mM, MIO-M1 and rMC-1 in 30mM glucose had increased levels of VEGF in cell medium (pg/ml by 24% and 20%) and also VEGF concentration in cells held in 0mM increased by 47% and 10% respectively. Glucose 44-51 vascular endothelial growth factor A Rattus norvegicus 128-132 27347496-8 2016 In both MIO-M1 and rMC-1, the amount of VEGF secreted per cell increased by about 100% when glucose was changed from 5.5 to 0mM but decreased slightly (17% in MIO-M1 and 11% in rMC-1) when glucose was increased from 5.5 to 30mM. Glucose 92-99 vascular endothelial growth factor A Rattus norvegicus 40-44 27347496-8 2016 In both MIO-M1 and rMC-1, the amount of VEGF secreted per cell increased by about 100% when glucose was changed from 5.5 to 0mM but decreased slightly (17% in MIO-M1 and 11% in rMC-1) when glucose was increased from 5.5 to 30mM. Glucose 189-196 vascular endothelial growth factor A Rattus norvegicus 40-44 26751458-0 2016 Inhibition of Ultraviolet B-Induced Expression of the Proinflammatory Cytokines TNF-alpha and VEGF in the Cornea by Fucoxanthin Treatment in a Rat Model. fucoxanthin 116-127 vascular endothelial growth factor A Rattus norvegicus 94-98 26751458-8 2016 Pretreatment with fucoxanthin may protect against UVB radiation-induced corneal disorders by inhibiting expression of proinflammatory factors, TNF-alpha, and VEGF and by blocking polymorphonuclear leukocyte infiltration. fucoxanthin 18-29 vascular endothelial growth factor A Rattus norvegicus 158-162 26586663-7 2016 Incubation of EC with high glucose or latent heparanase resulted in secretion of vascular endothelial growth factor (VEGF). Glucose 27-34 vascular endothelial growth factor A Rattus norvegicus 81-115 26586663-7 2016 Incubation of EC with high glucose or latent heparanase resulted in secretion of vascular endothelial growth factor (VEGF). Glucose 27-34 vascular endothelial growth factor A Rattus norvegicus 117-121 27243031-11 2016 Amlodipine treatment also increased cardiac SDF-1/CXCR4 expression and gave rise to activation of VEGF/Akt/eNOS signaling in bone marrow. Amlodipine 0-10 vascular endothelial growth factor A Rattus norvegicus 98-102 26773175-1 2016 This study investigates the impacts of n-butylphthalide (NBP) on the expression of vascular endothelial growth factor (VEGF) and transforming growth factor-beta1 (TGF-beta1) in rats with focal cerebral ischemia. 3-n-butylphthalide 39-55 vascular endothelial growth factor A Rattus norvegicus 83-117 26773175-1 2016 This study investigates the impacts of n-butylphthalide (NBP) on the expression of vascular endothelial growth factor (VEGF) and transforming growth factor-beta1 (TGF-beta1) in rats with focal cerebral ischemia. 3-n-butylphthalide 39-55 vascular endothelial growth factor A Rattus norvegicus 119-123 26606166-9 2016 In both epithelial and stromal regions, the immunoreactivity of VEGF-A and the percentage of Ki-67-positive cells were significantly higher in the groups treated with estradiol, while they were similar in the early/late isoflavone groups and control groups. Estradiol 167-176 vascular endothelial growth factor A Rattus norvegicus 64-70 27689093-3 2016 Vascular endothelial growth factor (VEGF) was loaded on mesoporous silica nanoparticle (MSN), which was then incorporated within a type I collagen sponge, to produce collagen/MSN/VEGF (CMV) scaffold. Silicon Dioxide 67-73 vascular endothelial growth factor A Rattus norvegicus 36-40 26893598-8 2016 In the enalapril-treated group, intrarenal VEGF-A protein expression was significantly higher, whereas VEGFR1 protein expression was lower than that in the control group (P<0.05). Enalapril 7-16 vascular endothelial growth factor A Rattus norvegicus 43-49 27525002-13 2016 PDGF, TGF-beta, and VEGF levels and neomucosa formation were higher in glutamine group (p = 0.003, p = 0.003, and p = 0.025). Glutamine 71-80 vascular endothelial growth factor A Rattus norvegicus 20-24 25565380-12 2016 Dexmedetomidine preconditioning also elevated HIF-1alpha and VEGF expression after global cerebral ischemia following asphyxial CA. Dexmedetomidine 0-15 vascular endothelial growth factor A Rattus norvegicus 61-65 25565380-13 2016 CONCLUSION: Dexmedetomidine preconditioning protected against cerebral ischemic injury and was associated with upregulation of HIF-1alpha and VEGF expression. Dexmedetomidine 12-27 vascular endothelial growth factor A Rattus norvegicus 142-146 26386269-2 2016 In this study, we evaluated the release kinetics and delivery efficacies of vascular endothelial growth factor (VEGF), a potent angiogenic growth factor, incorporated into calcium phosphate bone grafts (BGs). calcium phosphate 172-189 vascular endothelial growth factor A Rattus norvegicus 76-110 26386269-2 2016 In this study, we evaluated the release kinetics and delivery efficacies of vascular endothelial growth factor (VEGF), a potent angiogenic growth factor, incorporated into calcium phosphate bone grafts (BGs). calcium phosphate 172-189 vascular endothelial growth factor A Rattus norvegicus 112-116 27910782-7 2016 Analysis by immunofluorescence and western blotting shows that the expression of VEGF, MMP-2, and MMP-9 was found to be significantly elevated in the DMH- treated group and notably lowered by NSAID coadministration. 1,2-Dimethylhydrazine 150-153 vascular endothelial growth factor A Rattus norvegicus 81-85 26679676-11 2016 HIF-1alpha, VEGF, SDF-1alpha, TGF-beta1, IL-10 mRNA and protein levels were significantly higher on days 3, 7 and 14 in bilirubin-treated rats. Bilirubin 120-129 vascular endothelial growth factor A Rattus norvegicus 12-16 27910782-10 2016 Results from the present study indicate the potential role of these chemokines along with VEGF and MMPs against angiogenesis in DMH-induced cancer. 1,2-Dimethylhydrazine 128-131 vascular endothelial growth factor A Rattus norvegicus 90-94 26518240-4 2016 Here we defined the mechanism by which VEGF antagonized neuron-like PC12 cells apoptosis induced by hypoxia mimetic agent cobalt chloride (CoCl2) is through restoration of NF-kappaB activity. cobaltous chloride 122-137 vascular endothelial growth factor A Rattus norvegicus 39-43 27565331-1 2016 Hypoxia-inducible factor-1alpha (HIF-1alpha) is a key transcription factor to initiate the expressions of distinct pro-angiogenic growth genes, particularly the expression of vascular endothelial growth factor (VEGF).CoCl2 was used in rat liver tumor cell line McA RH-7777 to stimulate hypoxia to mimic the hypoxic conditions induced by transcatheter arterial chemoembolization (TACE). cobaltous chloride 217-222 vascular endothelial growth factor A Rattus norvegicus 175-209 27565331-1 2016 Hypoxia-inducible factor-1alpha (HIF-1alpha) is a key transcription factor to initiate the expressions of distinct pro-angiogenic growth genes, particularly the expression of vascular endothelial growth factor (VEGF).CoCl2 was used in rat liver tumor cell line McA RH-7777 to stimulate hypoxia to mimic the hypoxic conditions induced by transcatheter arterial chemoembolization (TACE). cobaltous chloride 217-222 vascular endothelial growth factor A Rattus norvegicus 211-215 27057362-9 2016 Fluoxetine administration ameliorated behavioral abnormalities and damage to hippocampal neurons caused by anger emotional stress, as well as abnormal expression of some proteins in VEGF/VEGFR2 and its induced PI3K/AKT/mTOR signal pathway. Fluoxetine 0-10 vascular endothelial growth factor A Rattus norvegicus 182-186 26518240-4 2016 Here we defined the mechanism by which VEGF antagonized neuron-like PC12 cells apoptosis induced by hypoxia mimetic agent cobalt chloride (CoCl2) is through restoration of NF-kappaB activity. cobaltous chloride 139-144 vascular endothelial growth factor A Rattus norvegicus 39-43 26518240-5 2016 Depletion of VEGF with small interfering RNA (siRNA) in PC12 cells conferred CoCl2-induced cytotoxicity which was mitigated by VEGF administration. cobaltous chloride 77-82 vascular endothelial growth factor A Rattus norvegicus 13-17 26518240-5 2016 Depletion of VEGF with small interfering RNA (siRNA) in PC12 cells conferred CoCl2-induced cytotoxicity which was mitigated by VEGF administration. cobaltous chloride 77-82 vascular endothelial growth factor A Rattus norvegicus 127-131 26518240-6 2016 Treatment of PC12 cells with VEGF attenuated the CoCl2-induced cytotoxicity in both dose- and time-dependent manner. cobaltous chloride 49-54 vascular endothelial growth factor A Rattus norvegicus 29-33 26518240-8 2016 Meanwhile, VEGF administration reversed the dysregulation of IkappaBalpha phosphorylation and ubiquitination, P65 nuclear translocation as well as XIAP and CCND1 expression induced by CoCl2. cobaltous chloride 184-189 vascular endothelial growth factor A Rattus norvegicus 11-15 26518240-9 2016 Notably, the VEGF-dependent cytoprotection was abolished by pretreatment with BAY 11-7085, a specific inhibitor of NF-kappaB. BAY 11-7085 78-89 vascular endothelial growth factor A Rattus norvegicus 13-17 26802939-0 2016 Supplementation of maternal omega-3 fatty acids to pregnancy induced hypertension Wistar rats improves IL10 and VEGF levels. Fatty Acids, Omega-3 28-47 vascular endothelial growth factor A Rattus norvegicus 112-116 26802939-10 2016 In contrast individual omega-3 fatty acid as well as combined micronutrient supplementation showed IL-10 and VEGF levels comparable to that of control. Fatty Acids, Omega-3 23-41 vascular endothelial growth factor A Rattus norvegicus 109-113 26607470-6 2015 Immunohistochemical analysis confirmed the presence of VEGF, ICAM-1, nitrotyrosine (a marker of peroxynitrite), and tight junctions in the retina of STZ-treated rats. Streptozocin 149-152 vascular endothelial growth factor A Rattus norvegicus 55-59 27062778-8 2016 The addition of VEGF to the high-glucose media significantly reduced the release of insulin at the concentration of 40 ng/mL. Glucose 33-40 vascular endothelial growth factor A Rattus norvegicus 16-20 27062778-13 2016 CONCLUSION; VEGF inhibited the secretion of insulin from INS-1 cells in the high-glucose condition. Glucose 81-88 vascular endothelial growth factor A Rattus norvegicus 12-16 27062778-14 2016 Our study provides new clues to the function of VEGF on the glucose metabolism. Glucose 60-67 vascular endothelial growth factor A Rattus norvegicus 48-52 26262503-0 2016 Oral Platelet-Derived Growth Factor and Vascular Endothelial Growth Factor Inhibitor Sunitinib Prevents Chronic Allograft Injury in Experimental Kidney Transplantation Model. Sunitinib 85-94 vascular endothelial growth factor A Rattus norvegicus 40-74 26262503-2 2016 Sunitinib is a tyrosine kinase inhibitor which inhibits both VEGF and PDGF receptors. Sunitinib 0-9 vascular endothelial growth factor A Rattus norvegicus 61-65 26262503-12 2016 Sunitinib also inhibited chronic PDGF-A and -B and VEGF-A and -B expressions. Sunitinib 0-9 vascular endothelial growth factor A Rattus norvegicus 51-64 26262503-13 2016 CONCLUSIONS: These results demonstrate that combined inhibition of PGDF and VEGF with sunitinib prevents chronic rejection changes in experimental kidney transplantation which indicates that sunitinib could be a potential intervention also in clinical kidney transplantation. Sunitinib 191-200 vascular endothelial growth factor A Rattus norvegicus 76-80 26567726-8 2015 Moreover, oral administration of choline significantly augmented pMCAO-induced increases in the expression levels of alpha7 nAChR, HIF-1alpha and VEGF in the ischemic cerebral cortices as well as in the serum levels of VEGF. Choline 33-40 vascular endothelial growth factor A Rattus norvegicus 146-150 26662426-9 2015 rCBV was positively correlated with VEGF (r = 0.94, P < 0.05). rcbv 0-4 vascular endothelial growth factor A Rattus norvegicus 36-40 26567726-8 2015 Moreover, oral administration of choline significantly augmented pMCAO-induced increases in the expression levels of alpha7 nAChR, HIF-1alpha and VEGF in the ischemic cerebral cortices as well as in the serum levels of VEGF. Choline 33-40 vascular endothelial growth factor A Rattus norvegicus 219-223 26567726-10 2015 Treatment of rBMECs cultured under hypoxic conditions in vitro with choline (1, 10 and 100 mumol/L) dose-dependently promoted the endothelial-cell proliferation, migration and tube formation, as well as VEGF secretion, which were prevented by co-treatment with MLA (1 mumol/L) or by transfection with HIF-1alpha siRNA. Choline 68-75 vascular endothelial growth factor A Rattus norvegicus 203-207 26567726-11 2015 CONCLUSION: Choline effectively attenuates brain ischemic injury in pMCAO rats, possibly by facilitating pial arteriogenesis and cerebral-cortical capillary angiogenesis via upregulating alpha7 nAChR levels and inducing the expression of HIF-1alpha and VEGF. Choline 12-19 vascular endothelial growth factor A Rattus norvegicus 253-257 26610445-9 2015 Additionally, butylidenephthalide also inhibited the laser-induced CNV formation and macrophage infiltration and down-regulated the expression of IGFBP-1, MCP-1 and VEGF. butylidenephthalide 14-33 vascular endothelial growth factor A Rattus norvegicus 165-169 25367879-7 2015 Besides, BAY 43-9006 inhibited the phosphorylation of Raf-1 and ERK1/2; decreased the protein levels of COX-2, VEGF, and MMP-9; and reversed the activation of NF-kappaB induced by SAH. Sorafenib 9-20 vascular endothelial growth factor A Rattus norvegicus 111-115 26548348-7 2015 Pristimerin also decreased the expression of VEGF and p-VEGFR2 in the synovial membrane, whereas the total amount of VEGFR2 remained unchanged. pristimerin 0-11 vascular endothelial growth factor A Rattus norvegicus 45-49 26548348-8 2015 Pristimerin suppressed the sprouting vessels of the aortic ring and inhibited VEGF-induced HFLS-RA migration in vitro. pristimerin 0-11 vascular endothelial growth factor A Rattus norvegicus 78-82 26548348-9 2015 Pristimerin also inhibited VEGF-induced proliferation, migration and tube formation by HUVECs, blocked the autophosphorylation of VEGF-induced VEGFR2 and consequently downregulated the signaling pathways of activated PI3K, AKT, mTOR, ERK1/2, JNK, and p38 in VEGF-induced HUVECs. pristimerin 0-11 vascular endothelial growth factor A Rattus norvegicus 27-31 26548348-9 2015 Pristimerin also inhibited VEGF-induced proliferation, migration and tube formation by HUVECs, blocked the autophosphorylation of VEGF-induced VEGFR2 and consequently downregulated the signaling pathways of activated PI3K, AKT, mTOR, ERK1/2, JNK, and p38 in VEGF-induced HUVECs. pristimerin 0-11 vascular endothelial growth factor A Rattus norvegicus 130-134 26548348-9 2015 Pristimerin also inhibited VEGF-induced proliferation, migration and tube formation by HUVECs, blocked the autophosphorylation of VEGF-induced VEGFR2 and consequently downregulated the signaling pathways of activated PI3K, AKT, mTOR, ERK1/2, JNK, and p38 in VEGF-induced HUVECs. pristimerin 0-11 vascular endothelial growth factor A Rattus norvegicus 130-134 26359087-10 2015 Furthermore, DZ preconditioned DM-EPCs exhibited up-regulated expression of prosurvival genes (VEGF, SDF-1alpha, HGF, bFGF, and Bcl2) on exposure to H2O2, and VEGF and Bcl2 on exposure to hyperglycemia while down regulation of Caspase-3 gene. Hydrogen Peroxide 149-153 vascular endothelial growth factor A Rattus norvegicus 95-99 26359087-10 2015 Furthermore, DZ preconditioned DM-EPCs exhibited up-regulated expression of prosurvival genes (VEGF, SDF-1alpha, HGF, bFGF, and Bcl2) on exposure to H2O2, and VEGF and Bcl2 on exposure to hyperglycemia while down regulation of Caspase-3 gene. Hydrogen Peroxide 149-153 vascular endothelial growth factor A Rattus norvegicus 159-163 25990477-5 2015 RESULTS: Vascular permeability, VEGF and COX-2 expressions were reduced in animals treated with MI and/or metformin. Inositol 96-98 vascular endothelial growth factor A Rattus norvegicus 32-36 26885006-0 2015 Puerarin accelerate scardiac angiogenesis and improves cardiac function of myocardial infarction by upregulating VEGFA, Ang-1 and Ang-2 in rats. puerarin 0-8 vascular endothelial growth factor A Rattus norvegicus 113-118 26885006-8 2015 Impaired angiogenesis and cardiac function were remarkably improved in puerarin treatment rats with great increase of VEGFA, Ang-1 and Ang-2. puerarin 71-79 vascular endothelial growth factor A Rattus norvegicus 118-123 26885006-9 2015 CONCLUSION: The above results demonstrated that puerarin could accelerate cardiac angiogenesis and improve cardiac function of myocardial infarction rats by upregulating VEGFA, Ang-1 and Ang-2. puerarin 48-56 vascular endothelial growth factor A Rattus norvegicus 170-175 25990477-5 2015 RESULTS: Vascular permeability, VEGF and COX-2 expressions were reduced in animals treated with MI and/or metformin. Metformin 106-115 vascular endothelial growth factor A Rattus norvegicus 32-36 26323652-8 2015 Further analysis of the expression levels of HIF-1alpha and VEGF revealed that their changes were consistent with the changes in serum levels of progesterone, which occurred in the development of the corpus luteum in the ovaries of pregnant rats. Progesterone 145-157 vascular endothelial growth factor A Rattus norvegicus 60-64 24584757-8 2015 RESULTS: Compared with the CIA model group, a remarkable reduction in various angiogenic (VEGF and IL-8) and inflammatory mediators (TNF-alpha, IL-4 and COX-2) after treatment with DDB either alone or combined with MTX P<0.05 or P<0.01). ddb 181-184 vascular endothelial growth factor A Rattus norvegicus 90-94 26101070-10 2015 HIF-1alpha, VEGF, SDF-1alpha, TGF-beta1, IL-10 mRNA and their protein levels were significantly higher on days 3, 7 and 14 in deferoxamine-treated rats. Deferoxamine 126-138 vascular endothelial growth factor A Rattus norvegicus 12-16 26352430-0 2015 Astragalosides promote angiogenesis via vascular endothelial growth factor and basic fibroblast growth factor in a rat model of myocardial infarction. astragalosides 0-14 vascular endothelial growth factor A Rattus norvegicus 40-74 26283324-11 2015 These data suggest that Curculigoside A induces cell proliferation and angiogenesis through the Wnt5a/beta-catenin and VEGF/CREB/Egr-3/VCAM-1 signaling axis and promotes maturation and stability of new blood vessels via increasing Ang1 and Tie-2 expression. curculigoside 24-39 vascular endothelial growth factor A Rattus norvegicus 119-123 26490686-9 2015 Results of immunohistochemistry and western-blot showed decreased expressions of VEGF, TGF-ss1, and IGF1 were also decreased in the curcumin group. Curcumin 132-140 vascular endothelial growth factor A Rattus norvegicus 81-85 26770424-0 2015 Effect of simvastatin on the expression of nephrin, podocin, and vascular endothelial growth factor (VEGF) in podocytes of diabetic rat. Simvastatin 10-21 vascular endothelial growth factor A Rattus norvegicus 65-99 26770424-0 2015 Effect of simvastatin on the expression of nephrin, podocin, and vascular endothelial growth factor (VEGF) in podocytes of diabetic rat. Simvastatin 10-21 vascular endothelial growth factor A Rattus norvegicus 101-105 26770424-9 2015 Simvastatin (SVT) could reduce serum creatinine levels and the UAER, maintain the expression of nephrin and podocin, reduce the expression of VEGF, and improve the pathological changes of podocytes, which were much more pronounced at 8 weeks (P < 0.01). Simvastatin 0-11 vascular endothelial growth factor A Rattus norvegicus 142-146 26770424-10 2015 Simvastatin could maintain the distribution of nephrin and podocin in podocytes, inhibit VEGF expression, and thus improve podocyte injuries and protect kidney functions in diabetic rats. Simvastatin 0-11 vascular endothelial growth factor A Rattus norvegicus 89-93 25963915-8 2015 The VEGF score was significantly decreased similarly by pazopanib, sunitinib, and sorafenib compared to normal saline (P < .05). pazopanib 56-65 vascular endothelial growth factor A Rattus norvegicus 4-8 25963915-8 2015 The VEGF score was significantly decreased similarly by pazopanib, sunitinib, and sorafenib compared to normal saline (P < .05). Sunitinib 67-76 vascular endothelial growth factor A Rattus norvegicus 4-8 25963915-8 2015 The VEGF score was significantly decreased similarly by pazopanib, sunitinib, and sorafenib compared to normal saline (P < .05). Sorafenib 82-91 vascular endothelial growth factor A Rattus norvegicus 4-8 25963915-13 2015 This effect may be related to the suppressive effect of pazopanib on the endometriotic tissue expressions of VEGF and CD117 but not Bax. pazopanib 56-65 vascular endothelial growth factor A Rattus norvegicus 109-113 26869868-13 2015 L-arginine supplementation causes additional effects on exercise-induced angiogenesis by preventing more reduction of VEGF gene expression in response to exercise. Arginine 0-10 vascular endothelial growth factor A Rattus norvegicus 118-122 26266428-7 2015 RESULTS: Topical application of H-KI20 significantly inhibited corneal NV induced by vascular endothelial growth factor (VEGF), and intrastromal suture (P < 0.01 vs. the PBS group), and the area of corneal NV was suppressed by 80.3% and 83.6%, respectively (PBS group as 100%). h-ki20 32-38 vascular endothelial growth factor A Rattus norvegicus 85-119 26266428-7 2015 RESULTS: Topical application of H-KI20 significantly inhibited corneal NV induced by vascular endothelial growth factor (VEGF), and intrastromal suture (P < 0.01 vs. the PBS group), and the area of corneal NV was suppressed by 80.3% and 83.6%, respectively (PBS group as 100%). h-ki20 32-38 vascular endothelial growth factor A Rattus norvegicus 121-125 26260462-8 2015 Plasma vascular endothelial growth factor (VEGF) levels and the mesenteric protein expression of VEGF and phosphor-vascular endothelial growth factor receptor 2 (VEGFR-2) decreased in the spironolactone group. Spironolactone 188-202 vascular endothelial growth factor A Rattus norvegicus 7-41 25972152-2 2015 Dopamine through D2 receptor (D2R) inhibits VEGF/VPF-mediated vascular permeability and angiogenesis in tumor models. Dopamine 0-8 vascular endothelial growth factor A Rattus norvegicus 44-48 25972152-2 2015 Dopamine through D2 receptor (D2R) inhibits VEGF/VPF-mediated vascular permeability and angiogenesis in tumor models. Dopamine 0-8 vascular endothelial growth factor A Rattus norvegicus 49-52 25979073-6 2015 DME vitreous containing relatively high levels of PKal and low VEGF induced RVP when injected into the vitreous of diabetic rats, a response blocked by bradykinin receptor antagonism but not by bevacizumab. dme 0-3 vascular endothelial growth factor A Rattus norvegicus 63-67 25728412-7 2015 One millimolar NaW alone reduced secretion of both TGFbeta-1 and -2, and stimulated secretion of VEGF-A after 48 h. However, these patterns of secretion were not observed after diabetic rat serum treatment, suggesting that protection from E-cadherin loss by serum from NaW-treated diabetic rats originates from an indirect rather than a direct effect of this salt on HK-2 cells, via a mechanism independent of TGFbeta and VEGF-A functions. naw 15-18 vascular endothelial growth factor A Rattus norvegicus 97-103 25728412-7 2015 One millimolar NaW alone reduced secretion of both TGFbeta-1 and -2, and stimulated secretion of VEGF-A after 48 h. However, these patterns of secretion were not observed after diabetic rat serum treatment, suggesting that protection from E-cadherin loss by serum from NaW-treated diabetic rats originates from an indirect rather than a direct effect of this salt on HK-2 cells, via a mechanism independent of TGFbeta and VEGF-A functions. naw 15-18 vascular endothelial growth factor A Rattus norvegicus 422-428 26260462-8 2015 Plasma vascular endothelial growth factor (VEGF) levels and the mesenteric protein expression of VEGF and phosphor-vascular endothelial growth factor receptor 2 (VEGFR-2) decreased in the spironolactone group. Spironolactone 188-202 vascular endothelial growth factor A Rattus norvegicus 43-47 26260462-8 2015 Plasma vascular endothelial growth factor (VEGF) levels and the mesenteric protein expression of VEGF and phosphor-vascular endothelial growth factor receptor 2 (VEGFR-2) decreased in the spironolactone group. Spironolactone 188-202 vascular endothelial growth factor A Rattus norvegicus 97-101 26260462-10 2015 The down-regulation of VEGF pathway participates, albeit partly, in the antiangiogenic effect of spironolactone. Spironolactone 97-111 vascular endothelial growth factor A Rattus norvegicus 23-27 26239701-10 2015 The expression of VEGF in the alveolar and bronchial epithelial cells of the SmSt group was similar to that in the CtL group, and significantly higher compared with that of the Sm group. Samarium 77-79 vascular endothelial growth factor A Rattus norvegicus 18-22 26239701-12 2015 Simvastatin exerted a significant impact on the expression of VEGF and attenuated cigarette smoke-induced emphysema in rats. Simvastatin 0-11 vascular endothelial growth factor A Rattus norvegicus 62-66 26239779-8 2015 The present study demonstrated that in rats treated with CoCl2, the expression of HIF-1alpha, VEGF, Runx2, ALP and OC was significantly increased at mRNA and protein levels, and that CoCl2 treatment enhances fracture repair in vivo. cobaltous chloride 57-62 vascular endothelial growth factor A Rattus norvegicus 94-98 26239779-8 2015 The present study demonstrated that in rats treated with CoCl2, the expression of HIF-1alpha, VEGF, Runx2, ALP and OC was significantly increased at mRNA and protein levels, and that CoCl2 treatment enhances fracture repair in vivo. cobaltous chloride 183-188 vascular endothelial growth factor A Rattus norvegicus 94-98 26398373-10 2015 Increased gene expressions of VEGF (p<0.05) and VCAM-1 (p<0.01) in hypercholesterolemia were regressed in captopril treated rats (p<0.01 and p<0.05, respectively). Captopril 112-121 vascular endothelial growth factor A Rattus norvegicus 30-34 26398373-11 2015 CONCLUSION: Captopril, an ACE inhibitor, improves hyperlipidemia and prevents from overexpression of genes for VEGF and VCAM-1, that are implicated in the inflammation and angiogenesis. Captopril 12-21 vascular endothelial growth factor A Rattus norvegicus 111-115 26092525-6 2015 These results indicate OVX may induce 3-D capillary regression in soleus muscle through an imbalance between VEGF-A and TSP-1 expression, possibly associated with decreased exercise tolerance in ovariectomized rats. ovx 23-26 vascular endothelial growth factor A Rattus norvegicus 109-115 26211444-10 2015 Minocycline administration significantly reduced HIF-1alpha expression, protein and mRNA expression of MMP-2, MMP-9 and Vascular Endothelial Growth Factor (VEGF) (P<0.05), and increased TJs (ZO-1, claudin-5 and occluding) (P<0.05) in HBMECs after hypoxia. Minocycline 0-11 vascular endothelial growth factor A Rattus norvegicus 120-154 26211444-10 2015 Minocycline administration significantly reduced HIF-1alpha expression, protein and mRNA expression of MMP-2, MMP-9 and Vascular Endothelial Growth Factor (VEGF) (P<0.05), and increased TJs (ZO-1, claudin-5 and occluding) (P<0.05) in HBMECs after hypoxia. Minocycline 0-11 vascular endothelial growth factor A Rattus norvegicus 156-160 26386664-0 2015 Glutamate promotes neural stem cell proliferation by increasing the expression of vascular endothelial growth factor of astrocytes in vitro. Glutamic Acid 0-9 vascular endothelial growth factor A Rattus norvegicus 82-116 26138344-3 2015 While bone morphogenetic protein (BMP)-2 is encapsulated in the PLGA NPs, vascular endothelial growth factor (VEGF) is included in the alginate MCs, where BMP-2-loaded PLGA NPs are entrapped together in the fabrication process. alginate mcs 135-147 vascular endothelial growth factor A Rattus norvegicus 74-108 26386664-3 2015 In this study, we investigated the effect of glutamate on the proliferation of rat embryonic neural stem/progenitor cells (NSCs) through regulating the vascular endothelial growth factor (VEGF) expression of astrocytes (ASTs) in vitro, and the cyclin D1 expression of NSCs. Glutamic Acid 45-54 vascular endothelial growth factor A Rattus norvegicus 152-186 26386664-3 2015 In this study, we investigated the effect of glutamate on the proliferation of rat embryonic neural stem/progenitor cells (NSCs) through regulating the vascular endothelial growth factor (VEGF) expression of astrocytes (ASTs) in vitro, and the cyclin D1 expression of NSCs. Glutamic Acid 45-54 vascular endothelial growth factor A Rattus norvegicus 188-192 26386664-4 2015 The results showed that glutamate promoted the expression and secretion of VEGF of rat astrocytes by activating group I mGluRs. Glutamic Acid 24-33 vascular endothelial growth factor A Rattus norvegicus 75-79 26386664-7 2015 ACM (30%)+VEGF NAb (15 mug/ml) decreased the expressions of cyclin D1 and increased cell death compared with ACM (30%). nab 15-18 vascular endothelial growth factor A Rattus norvegicus 10-14 26386664-8 2015 These results demonstrated that glutamate could also indirectly promote the proliferation of rat embryonic NSCs through inducing the VEGF expression of ASTs in vitro, and VEGF may increase the expression of cyclin D1. Glutamic Acid 32-41 vascular endothelial growth factor A Rattus norvegicus 133-137 26270628-4 2015 For the first time, bioactive PGS-PCL fibers functionalized with vascular endothelial growth factor (VEGF) are developed, the approach used being chemical modification of the PGS-PCL fibers followed by subsequent binding of VEGF via amide bonding. Amides 233-238 vascular endothelial growth factor A Rattus norvegicus 65-99 26270628-4 2015 For the first time, bioactive PGS-PCL fibers functionalized with vascular endothelial growth factor (VEGF) are developed, the approach used being chemical modification of the PGS-PCL fibers followed by subsequent binding of VEGF via amide bonding. Amides 233-238 vascular endothelial growth factor A Rattus norvegicus 101-105 26270628-4 2015 For the first time, bioactive PGS-PCL fibers functionalized with vascular endothelial growth factor (VEGF) are developed, the approach used being chemical modification of the PGS-PCL fibers followed by subsequent binding of VEGF via amide bonding. Amides 233-238 vascular endothelial growth factor A Rattus norvegicus 224-228 26270628-5 2015 The approach results in uniform immobilization of VEGF on the fibers; the concentrations are 1.0 mug cm(-2) for the PGS-PCL (H) and 0.60 mug cm(-2) for the PGS-PCL (L) samples. pgs-pcl 116-123 vascular endothelial growth factor A Rattus norvegicus 50-54 26270628-5 2015 The approach results in uniform immobilization of VEGF on the fibers; the concentrations are 1.0 mug cm(-2) for the PGS-PCL (H) and 0.60 mug cm(-2) for the PGS-PCL (L) samples. pgs-pcl 156-163 vascular endothelial growth factor A Rattus norvegicus 50-54 25940601-12 2015 In addition, rosuvastatin treatment reduced intrapulmonary shunts and plasma levels of VEGF and TNF-alpha. Rosuvastatin Calcium 13-25 vascular endothelial growth factor A Rattus norvegicus 87-91 26464259-4 2015 In the present study, the rat model of chronic alcoholic encephalopathy was established by the gavage administration of alcohol; the learning and memory ability was tested by Morris water maze; the expression of VEGF was measured by RT-PCR and Western blot; and the serum levels of ET-1 was measured by radioimmunoassay. Alcohols 47-54 vascular endothelial growth factor A Rattus norvegicus 212-216 26464259-6 2015 TMP intervention improved learning abilities, increased the VEGF expression and reduced ET-1 level. tetramethylpyrazine 0-3 vascular endothelial growth factor A Rattus norvegicus 60-64 25850685-0 2015 Effect of oxygen and glucose deprivation on VEGF and its receptors in microvascular endothelial cells co-cultured with mast cells. Oxygen 10-16 vascular endothelial growth factor A Rattus norvegicus 44-48 25850685-1 2015 The aim of this study was to determine the correlation between angiogenesis and the differential expression of vascular endothelial growth factor (VEGF) and its receptors in myocardial microvascular endothelial cells (MMVECs) co-cultured with mast cells (MCs) or mast cell granules (MCGs) under oxygen and glucose deprivation (OGD). Oxygen 295-301 vascular endothelial growth factor A Rattus norvegicus 111-145 25850685-1 2015 The aim of this study was to determine the correlation between angiogenesis and the differential expression of vascular endothelial growth factor (VEGF) and its receptors in myocardial microvascular endothelial cells (MMVECs) co-cultured with mast cells (MCs) or mast cell granules (MCGs) under oxygen and glucose deprivation (OGD). Oxygen 295-301 vascular endothelial growth factor A Rattus norvegicus 147-151 25850685-6 2015 Expression of VEGF, Flt-1, and Flk-1 increased significantly when MMVECs were co-cultured with MCGs or active MCs, but MCs had only a limited ability to induce angiogenesis in OGD. mcgs 95-99 vascular endothelial growth factor A Rattus norvegicus 14-18 25940601-14 2015 We concluded that rosuvastatin alleviates experimental HPS through blockade of pulmonary inflammatory angiogenesis via TNF-alpha/NF-kappaB and VEGF/Rho-associated A kinase pathways down-regulation. Rosuvastatin Calcium 18-30 vascular endothelial growth factor A Rattus norvegicus 143-147 26099282-10 2015 Finally, the regulation of VEGF was inhibited by LY294002 and PD98059, and their combination exhibited a synergistic effect. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 49-57 vascular endothelial growth factor A Rattus norvegicus 27-31 26150384-10 2015 Increased expression of VEGF may have a crucial role in changes in microvessel permeability and DPN. dpn 96-99 vascular endothelial growth factor A Rattus norvegicus 24-28 26617877-0 2015 Effect of fosinopril on chemerin and VEGF expression in diabetic nephropathy rats. Fosinopril 10-20 vascular endothelial growth factor A Rattus norvegicus 37-41 26617877-2 2015 This study analyzed the effect of ACEI analog-fosinopril-on the expression of chemerin and vascular epithelial growth factor (VEGF), in an attempt to reveal the mechanism of ACEI analog on renal protection. Fosinopril 46-56 vascular endothelial growth factor A Rattus norvegicus 91-124 26617877-2 2015 This study analyzed the effect of ACEI analog-fosinopril-on the expression of chemerin and vascular epithelial growth factor (VEGF), in an attempt to reveal the mechanism of ACEI analog on renal protection. Fosinopril 46-56 vascular endothelial growth factor A Rattus norvegicus 126-130 26617877-6 2015 After fosinopril treatment, blood creatinine, urea nitrogen, 24-hour urinary protein, Chemerin and VEGF protein concentrations were significantly depressed (P<0.05 compared to model group). Fosinopril 6-16 vascular endothelial growth factor A Rattus norvegicus 99-103 26617877-7 2015 Positive relationships existed between renal chemerin, VEGF and urea protein levels. Urea 64-68 vascular endothelial growth factor A Rattus norvegicus 55-59 26617877-8 2015 Fosinopril may protect renal tissues in diabetes by suppressing chemerin and VEGF protein expression. Fosinopril 0-10 vascular endothelial growth factor A Rattus norvegicus 77-81 26154398-4 2015 The results of this study show structural changes in the eye and mandible as well as biochemical changes including the up-regulation of VEGF in response to the bisphosphonate-associated ischemia. Diphosphonates 160-174 vascular endothelial growth factor A Rattus norvegicus 136-140 26099282-10 2015 Finally, the regulation of VEGF was inhibited by LY294002 and PD98059, and their combination exhibited a synergistic effect. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 62-69 vascular endothelial growth factor A Rattus norvegicus 27-31 26182882-6 2015 Most interestingly, GFAP and VEGF expression was suppressed by DAPT pretreatment in hypoxic astrocytes and further confirmed in neonatal rats following hypoxic brain injury. dapt 63-67 vascular endothelial growth factor A Rattus norvegicus 29-33 28913056-10 2015 CONCLUSION: Thalidomide provides volumetric and histopathologic recovery in implants particularly because the VEGF inhibition and anti-angiogenic effect, which suggests that it could be effective in the treatment of endometriosis. Thalidomide 12-23 vascular endothelial growth factor A Rattus norvegicus 110-114 26262605-8 2015 Tumor necrosis factor alpha (TNF-alpha), interleukin (IL-1beta) and vascular endothelial growth factor (VEGF) were significantly reduced in diabetic rats treated with EAE, compared with untreated diabetic rats. EAE 167-170 vascular endothelial growth factor A Rattus norvegicus 68-102 26262605-7 2015 EAE treatment produced a reduction in blood glucose levels, HbA1c, malondialdehyde and vascular endothelial growth factor (VEGF) in diabetic retina (p < 0.001), as well as an enhancement in antioxidant capacity against streptozocine-induced oxidative stress. EAE 0-3 vascular endothelial growth factor A Rattus norvegicus 87-121 25960165-7 2015 The abundance of AEA in the uterine lumen disrupted the decidualization process accompanied by a decreased expression of COX-2 and VEGF. anandamide 17-20 vascular endothelial growth factor A Rattus norvegicus 131-135 26262605-8 2015 Tumor necrosis factor alpha (TNF-alpha), interleukin (IL-1beta) and vascular endothelial growth factor (VEGF) were significantly reduced in diabetic rats treated with EAE, compared with untreated diabetic rats. EAE 167-170 vascular endothelial growth factor A Rattus norvegicus 104-108 26262605-7 2015 EAE treatment produced a reduction in blood glucose levels, HbA1c, malondialdehyde and vascular endothelial growth factor (VEGF) in diabetic retina (p < 0.001), as well as an enhancement in antioxidant capacity against streptozocine-induced oxidative stress. EAE 0-3 vascular endothelial growth factor A Rattus norvegicus 123-127 26345811-6 2015 Additionally, echinomycin blocked luteal development by inhibiting VEGF expression mediated by HIF-1a and following luteal function by detecting the progesterone changes at day 7. Echinomycin 14-25 vascular endothelial growth factor A Rattus norvegicus 67-71 25618750-4 2015 RESULTS: VEGF expression in the vitamin D group was similar to that in the OHSS group. Vitamin D 32-41 vascular endothelial growth factor A Rattus norvegicus 9-13 26345811-0 2015 Effect of HIF-1a/VEGF signaling pathway on plasma progesterone and ovarian prostaglandin F2a secretion during luteal development of pseudopregnant rats. Progesterone 50-62 vascular endothelial growth factor A Rattus norvegicus 17-21 26345811-0 2015 Effect of HIF-1a/VEGF signaling pathway on plasma progesterone and ovarian prostaglandin F2a secretion during luteal development of pseudopregnant rats. Dinoprost 75-92 vascular endothelial growth factor A Rattus norvegicus 17-21 25618750-7 2015 Vitamin D effectively increases PEDF, which has an opposing effect on VEGF, which plays a key role in OHSS. Vitamin D 0-9 vascular endothelial growth factor A Rattus norvegicus 70-74 25917462-5 2015 KEY RESULTS: The imidazole-based alkaloid derivative LCB54-0009 inhibited capillary-like tube formation in VEGF-induced HUVECs without inducing cytotoxic effects. imidazole 17-26 vascular endothelial growth factor A Rattus norvegicus 107-111 26026876-0 2015 Dietary glycotoxins induce RAGE and VEGF up-regulation in the retina of normal rats. glycotoxins 8-19 vascular endothelial growth factor A Rattus norvegicus 36-40 26321522-12 2015 CONCLUSIONS: Endostar injection combined with intraperitoneal injection of cisplatin is effective in reducing tumor VEGF score and MVD of transplanted tumor tissues in rats with Lewis lung cancer to obstruct the nutrient supply of tumor cells and kill tumor cells, so that the inhibition of tumor cell proliferation and metastasis can be achieved with a remarkable effect. Cisplatin 75-84 vascular endothelial growth factor A Rattus norvegicus 116-120 25917462-5 2015 KEY RESULTS: The imidazole-based alkaloid derivative LCB54-0009 inhibited capillary-like tube formation in VEGF-induced HUVECs without inducing cytotoxic effects. Alkaloids 33-41 vascular endothelial growth factor A Rattus norvegicus 107-111 25917462-5 2015 KEY RESULTS: The imidazole-based alkaloid derivative LCB54-0009 inhibited capillary-like tube formation in VEGF-induced HUVECs without inducing cytotoxic effects. 3-(2-((3,4-dihydroxyphenyl)-(4-(2-dimethylaminoethyl)imidazol-1-yl)methyl)benzo(1,3)dioxol-5-yl)propionic acid 53-63 vascular endothelial growth factor A Rattus norvegicus 107-111 25917462-9 2015 LCB54-0009 also inhibited the hypoxia-induced expression of angiopoietin-2, and VEGF-induced VEGFR-2 activation and downstream signalling, resulting in the down-regulation of the expression of pro-angiogenic factors and pro-inflammatory mediators and an up-regulation of the expression of anti-angiogenic factors. 3-(2-((3,4-dihydroxyphenyl)-(4-(2-dimethylaminoethyl)imidazol-1-yl)methyl)benzo(1,3)dioxol-5-yl)propionic acid 0-10 vascular endothelial growth factor A Rattus norvegicus 80-84 25937636-0 2015 Blocking VEGF/Caveolin-1 signaling contributes to renal protection of fasudil in streptozotocin-induced diabetic rats. fasudil 70-77 vascular endothelial growth factor A Rattus norvegicus 9-13 26492704-6 2015 RESULTS: Ovarian diameter and VEGF expression were significantly lower in the montelukast and cabergoline groups than in the severe OHSS group. montelukast 78-89 vascular endothelial growth factor A Rattus norvegicus 30-34 26492704-6 2015 RESULTS: Ovarian diameter and VEGF expression were significantly lower in the montelukast and cabergoline groups than in the severe OHSS group. Cabergoline 94-105 vascular endothelial growth factor A Rattus norvegicus 30-34 26492704-9 2015 Montelukast limits VEGF expression, and cabergoline reduces both VEGF and VEGFR-2 expressions; they are both effective therapies for the prevention of severe OHSS. montelukast 0-11 vascular endothelial growth factor A Rattus norvegicus 19-23 26492704-9 2015 Montelukast limits VEGF expression, and cabergoline reduces both VEGF and VEGFR-2 expressions; they are both effective therapies for the prevention of severe OHSS. Cabergoline 40-51 vascular endothelial growth factor A Rattus norvegicus 65-69 26223919-9 2015 It was concluded that escitalopram oxalate could significantly improve the learning and memory ability of the rats with chronic cerebral ischemia probably by the VEGF-mediated angiogenesis. Citalopram 22-42 vascular endothelial growth factor A Rattus norvegicus 162-166 25891515-5 2015 Betaine treatment attenuated this increase in VEGF and HIF-1alpha expression via suppression of diabetes-induced Akt activation in the retinas of the diabetic rats. Betaine 0-7 vascular endothelial growth factor A Rattus norvegicus 46-50 25891515-3 2015 In the present study, the effects of betaine on the expression levels of vascular endothelial growth factor (VEGF) and hypoxia-inducible factor (HIF)-1alpha in association with the Akt pathway were investigated in the retinas of streptozotocin (STZ)-induced diabetic rats using western blot and immunohistochemical analyses. Betaine 37-44 vascular endothelial growth factor A Rattus norvegicus 73-107 25891515-3 2015 In the present study, the effects of betaine on the expression levels of vascular endothelial growth factor (VEGF) and hypoxia-inducible factor (HIF)-1alpha in association with the Akt pathway were investigated in the retinas of streptozotocin (STZ)-induced diabetic rats using western blot and immunohistochemical analyses. Betaine 37-44 vascular endothelial growth factor A Rattus norvegicus 109-113 25891515-3 2015 In the present study, the effects of betaine on the expression levels of vascular endothelial growth factor (VEGF) and hypoxia-inducible factor (HIF)-1alpha in association with the Akt pathway were investigated in the retinas of streptozotocin (STZ)-induced diabetic rats using western blot and immunohistochemical analyses. Streptozocin 229-243 vascular endothelial growth factor A Rattus norvegicus 73-107 25891515-4 2015 The results of the present study revealed that the expression levels of VEGF, HIF-1alpha, and Akt were increased in the retinas of the STZ-induced diabetic rats. Streptozocin 135-138 vascular endothelial growth factor A Rattus norvegicus 72-76 25872187-0 2015 VEGF attenuated increase of outward delayed-rectifier potassium currents in hippocampal neurons induced by focal ischemia via PI3-K pathway. Potassium 54-63 vascular endothelial growth factor A Rattus norvegicus 0-4 25872187-1 2015 We recently indicated that the vascular endothelial growth factor (VEGF) protects neurons against hypoxic death via enhancement of tyrosine phosphorylation of Kv1.2, an isoform of the delayed-rectifier potassium channels through activation of the phosphatidylinositol 3-kinase (PI3-K) signaling pathway. Tyrosine 131-139 vascular endothelial growth factor A Rattus norvegicus 31-65 25872187-1 2015 We recently indicated that the vascular endothelial growth factor (VEGF) protects neurons against hypoxic death via enhancement of tyrosine phosphorylation of Kv1.2, an isoform of the delayed-rectifier potassium channels through activation of the phosphatidylinositol 3-kinase (PI3-K) signaling pathway. Tyrosine 131-139 vascular endothelial growth factor A Rattus norvegicus 67-71 25872187-2 2015 The present study investigated whether VEGF could attenuate ischemia-induced increase of the potassium currents in the hippocampal pyramidal neurons of rats after ischemic injury. Potassium 93-102 vascular endothelial growth factor A Rattus norvegicus 39-43 25872187-7 2015 This inhibitory effect of VEGF could be completely abolished by wortmannin, an inhibitor of PI3-K. Our data indicate that VEGF attenuates the ischemia-induced increase of IK via activation of the PI3-K signaling pathway. Wortmannin 64-74 vascular endothelial growth factor A Rattus norvegicus 26-30 25872187-7 2015 This inhibitory effect of VEGF could be completely abolished by wortmannin, an inhibitor of PI3-K. Our data indicate that VEGF attenuates the ischemia-induced increase of IK via activation of the PI3-K signaling pathway. Wortmannin 64-74 vascular endothelial growth factor A Rattus norvegicus 122-126 25937636-0 2015 Blocking VEGF/Caveolin-1 signaling contributes to renal protection of fasudil in streptozotocin-induced diabetic rats. Streptozocin 81-95 vascular endothelial growth factor A Rattus norvegicus 9-13 25937636-9 2015 Furthermore, fasudil treatment prevented the upregulation of VEGF, VEGFR1, VEGFR2 and fibronectin, and the increased association between VEGFR2 and caveolin-1 in the renal cortices, and partially blocked Src activation and caveolin-1 phosphorylation on tyrosine 14 in the kidneys, whereas enalapril treatment had no effects on the VEGFR2/Src/caveolin-1 signaling pathway. fasudil 13-20 vascular endothelial growth factor A Rattus norvegicus 61-65 25954843-1 2015 Polydeoxyribonucleotide (PDRN) has multiple vascular actions such as angiogenesis and production of a vascular endothelial growth factor (VEGF) through the adenosine A2 receptor stimulation. Polydeoxyribonucleotides 0-23 vascular endothelial growth factor A Rattus norvegicus 138-142 25936351-2 2015 In our previous study, we demonstrated that succinate levels were elevated in the retinas of diabetic rats and that the knockdown of the succinate receptor, G-protein-coupled receptor 91 (GPR91), inhibited the release of VEGF and attenuated retinal vascular disorder in the early stages of DR. Succinic Acid 44-53 vascular endothelial growth factor A Rattus norvegicus 221-225 25524539-6 2015 Activity of SOD and TIMP-2 staining in melatonin group was significantly higher (both P < 0.01) while there were significant reductions in implant levels of VEGF and MMP-9 in melatonin group (both P < 0.01) than controls. Melatonin 178-187 vascular endothelial growth factor A Rattus norvegicus 160-164 25524539-7 2015 CONCLUSIONS: Melatonin induces the regression of endometriotic implants in rats by modulating implant levels of SOD, MDA, VEGF, MMP-9 and TIMP-2. Melatonin 13-22 vascular endothelial growth factor A Rattus norvegicus 122-126 25959017-2 2015 This study aimed to investigate whether induction of haem oxygenase-1 (HO-1) can protect the kidneys of obese rats by regulating the glomerular vascular endothelial growth factor-nitric oxide (VEGF-NO) axis by increasing the adiponectin concentrations. Nitric Oxide 179-191 vascular endothelial growth factor A Rattus norvegicus 193-197 25959017-6 2015 The glomerular vascular endothelial growth factor-nitric oxide (VEGF-NO) axis plays a critical role in maintenance of normal kidney function in obesity. Nitric Oxide 50-62 vascular endothelial growth factor A Rattus norvegicus 64-68 25954843-1 2015 Polydeoxyribonucleotide (PDRN) has multiple vascular actions such as angiogenesis and production of a vascular endothelial growth factor (VEGF) through the adenosine A2 receptor stimulation. Polydeoxyribonucleotides 0-23 vascular endothelial growth factor A Rattus norvegicus 102-136 25959017-19 2015 These results indicate that induction of HO-1 with cobalt protoporphyrin reduces the degree of microalbuminuria and has renal protective effects by improving endothelial dysfunction and regulating the glomerular VEGF-NO axis in diet-induced obese rats by increasing adiponectin levels. cobaltiprotoporphyrin 51-72 vascular endothelial growth factor A Rattus norvegicus 212-216 25715026-11 2015 HIF2alpha protein expression was increased in megakaryocytes from iron-deficient rats, and VEGF-A concentration was higher in iron-deficient culture supernatants. Iron 126-130 vascular endothelial growth factor A Rattus norvegicus 91-97 26653647-9 2015 Compared with the control group, VEGF was increased of all phases, especially in beryllium oxide exposure 40d and 80 groups, LBP treatment groups and beryllium oxide exposure 60 d (P < 0.05 or P < 0.01). beryllium oxide 81-96 vascular endothelial growth factor A Rattus norvegicus 33-37 26653647-9 2015 Compared with the control group, VEGF was increased of all phases, especially in beryllium oxide exposure 40d and 80 groups, LBP treatment groups and beryllium oxide exposure 60 d (P < 0.05 or P < 0.01). beryllium oxide 150-165 vascular endothelial growth factor A Rattus norvegicus 33-37 26653647-12 2015 The content of VEGF of beryllium oxide exposure group was higher than LBP treatment for 40 d group and high dose of LBP treatment for 60 d (P < 0.05 or P < 0.01). beryllium oxide 23-38 vascular endothelial growth factor A Rattus norvegicus 15-19 26048285-6 2015 Curcumin stabilized the brain HIF-1alpha levels followed by maintaining VEGF levels along with upregulated Na(+)/K(+)-ATPase and ENaC levels (p < 0.001) under hypoxia. Curcumin 0-8 vascular endothelial growth factor A Rattus norvegicus 72-76 26202747-6 2015 Consequently, VEGF secretion from tumor cells was reduced, which could potentiate the direct inhibition of tanshinone-1 on endothelial cells. tanshinone-1 107-119 vascular endothelial growth factor A Rattus norvegicus 14-18 25789687-0 2015 Finasteride reduces microvessel density and expression of vascular endothelial growth factor in renal tissue of diabetic rats. Finasteride 0-11 vascular endothelial growth factor A Rattus norvegicus 58-92 25789687-9 2015 When compared with diabetic rats, the glomerular tuft area, glomerular volume, MVD, VEGF protein expression in glomeruli and VEGF mRNA expression in the renal cortex tissue of finasteride-treated rats were significantly decreased (P < 0.05, P < 0.01). Finasteride 176-187 vascular endothelial growth factor A Rattus norvegicus 125-129 25789687-10 2015 CONCLUSIONS: Finasteride reduces the VEGF expression and decreases the MVD in the renal tissue of diabetic rats, suggesting the therapeutic potential of finasteride on diabetic microvascular complications. Finasteride 13-24 vascular endothelial growth factor A Rattus norvegicus 37-41 25808925-0 2015 Effect of Local Sustainable Release of BMP2-VEGF from Nano-Cellulose Loaded in Sponge Biphasic Calcium Phosphate on Bone Regeneration. calcium phosphate 95-112 vascular endothelial growth factor A Rattus norvegicus 44-48 25981588-6 2015 Furthermore, mRNA and protein expression of vascular endothelial growth factor (VEGF) were analyzed in DMOG-treated RP cells. oxalylglycine 103-107 vascular endothelial growth factor A Rattus norvegicus 44-78 25808925-4 2015 A biphasic calcium phosphate (BCP)-NC-BMP2-VEGF (BNBV) scaffold was fabricated for this purpose. calcium phosphate 11-28 vascular endothelial growth factor A Rattus norvegicus 43-47 25808925-4 2015 A biphasic calcium phosphate (BCP)-NC-BMP2-VEGF (BNBV) scaffold was fabricated for this purpose. hydroxyapatite-beta tricalcium phosphate 30-33 vascular endothelial growth factor A Rattus norvegicus 43-47 26242129-6 2015 RESULTS: Compared with the normal control group, expressions of VEGF and VEGF mRNA were significantly increased in the high glucose group, the low dose AGEs group and the high dose AGEs group (all P < 0.01). Glucose 124-131 vascular endothelial growth factor A Rattus norvegicus 64-68 26242129-6 2015 RESULTS: Compared with the normal control group, expressions of VEGF and VEGF mRNA were significantly increased in the high glucose group, the low dose AGEs group and the high dose AGEs group (all P < 0.01). Glucose 124-131 vascular endothelial growth factor A Rattus norvegicus 73-77 26242129-8 2015 The LDH leakage, expressions of VEGF and VEGF mRNA were obviously decreased by BHC-containing serum both in high glucose and AGEs conditions (P < 0.05, P < 0.01). Glucose 113-120 vascular endothelial growth factor A Rattus norvegicus 41-45 26242129-11 2015 Up-regulated expressions of VEGF and VEGF mRNA in cultured Muller cells could be induced by AGEs or high glucose. Glucose 105-112 vascular endothelial growth factor A Rattus norvegicus 28-32 26242129-11 2015 Up-regulated expressions of VEGF and VEGF mRNA in cultured Muller cells could be induced by AGEs or high glucose. Glucose 105-112 vascular endothelial growth factor A Rattus norvegicus 37-41 26029348-16 2015 In addition, kidneys of fKSC treated rats had an up-regulation of angiogenic proteins hypoxia-inducible factor-1alpha, VEGF and eNOS on day 3 (P < 0.05). fksc 24-28 vascular endothelial growth factor A Rattus norvegicus 119-123 25981588-6 2015 Furthermore, mRNA and protein expression of vascular endothelial growth factor (VEGF) were analyzed in DMOG-treated RP cells. oxalylglycine 103-107 vascular endothelial growth factor A Rattus norvegicus 80-84 25981588-13 2015 mRNA and protein expression of VEGF were significantly stimulated by DMOG treatment. oxalylglycine 69-73 vascular endothelial growth factor A Rattus norvegicus 31-35 25752672-7 2015 Vascular endothelial growth factor-A blocker 1 was found most effective in increasing cellular viability and maintaining normal VEGF levels under hypoxia (0.5% oxygen) in N2a cells. Oxygen 160-166 vascular endothelial growth factor A Rattus norvegicus 0-34 24862689-10 2015 Real-time RT-PCR analyses showed significantly lower expressions of Alpl, Col1a1 and VEGFA in cranium defects after treatment with PHB patches compared to untreated bony defects of the same cranium. poly-beta-hydroxybutyrate 131-134 vascular endothelial growth factor A Rattus norvegicus 85-90 25752672-8 2015 Vascular endothelial growth factor-A blocker 1 effectively restored VEGF levels, decreased cerebral oedema, and reduced vascular leakage under hypobaric hypoxia when compared to sunitinib-treated rats. Sunitinib 178-187 vascular endothelial growth factor A Rattus norvegicus 0-36 25599748-10 2015 Body weight, ovarian weight, VP, peritoneal fluid VEGF values and VEGF expression were significantly lower in both cabergoline- and montelukast-treated rats than in those not treated OHSS group. Cabergoline 115-126 vascular endothelial growth factor A Rattus norvegicus 50-54 25599748-10 2015 Body weight, ovarian weight, VP, peritoneal fluid VEGF values and VEGF expression were significantly lower in both cabergoline- and montelukast-treated rats than in those not treated OHSS group. Cabergoline 115-126 vascular endothelial growth factor A Rattus norvegicus 66-70 25599748-10 2015 Body weight, ovarian weight, VP, peritoneal fluid VEGF values and VEGF expression were significantly lower in both cabergoline- and montelukast-treated rats than in those not treated OHSS group. montelukast 132-143 vascular endothelial growth factor A Rattus norvegicus 50-54 25599748-10 2015 Body weight, ovarian weight, VP, peritoneal fluid VEGF values and VEGF expression were significantly lower in both cabergoline- and montelukast-treated rats than in those not treated OHSS group. montelukast 132-143 vascular endothelial growth factor A Rattus norvegicus 66-70 25557829-9 2015 Caffeine down-regulated endothelial nitric oxide synthase, vascular endothelial growth factor (VEGF), phospho-VEGFR2, and phospho-Akt mesenteric protein expression. Caffeine 0-8 vascular endothelial growth factor A Rattus norvegicus 59-93 24961937-6 2015 In vivo studies revealed that acute co-incubation of N-acetylcysteine or hydrogen-rich saline with VEGF effectively suppressed VEGF-induced angiogenesis and migration of HUVEC accompanied by decreasing of oxidative stress and inflammatory cytokines. Acetylcysteine 53-69 vascular endothelial growth factor A Rattus norvegicus 99-103 24961937-6 2015 In vivo studies revealed that acute co-incubation of N-acetylcysteine or hydrogen-rich saline with VEGF effectively suppressed VEGF-induced angiogenesis and migration of HUVEC accompanied by decreasing of oxidative stress and inflammatory cytokines. Acetylcysteine 53-69 vascular endothelial growth factor A Rattus norvegicus 127-131 24961937-6 2015 In vivo studies revealed that acute co-incubation of N-acetylcysteine or hydrogen-rich saline with VEGF effectively suppressed VEGF-induced angiogenesis and migration of HUVEC accompanied by decreasing of oxidative stress and inflammatory cytokines. Hydrogen 73-81 vascular endothelial growth factor A Rattus norvegicus 99-103 24961937-6 2015 In vivo studies revealed that acute co-incubation of N-acetylcysteine or hydrogen-rich saline with VEGF effectively suppressed VEGF-induced angiogenesis and migration of HUVEC accompanied by decreasing of oxidative stress and inflammatory cytokines. Hydrogen 73-81 vascular endothelial growth factor A Rattus norvegicus 127-131 24961937-6 2015 In vivo studies revealed that acute co-incubation of N-acetylcysteine or hydrogen-rich saline with VEGF effectively suppressed VEGF-induced angiogenesis and migration of HUVEC accompanied by decreasing of oxidative stress and inflammatory cytokines. Sodium Chloride 87-93 vascular endothelial growth factor A Rattus norvegicus 99-103 24961937-6 2015 In vivo studies revealed that acute co-incubation of N-acetylcysteine or hydrogen-rich saline with VEGF effectively suppressed VEGF-induced angiogenesis and migration of HUVEC accompanied by decreasing of oxidative stress and inflammatory cytokines. Sodium Chloride 87-93 vascular endothelial growth factor A Rattus norvegicus 127-131 24961937-5 2015 RESULTS: The data indicate that 1-month treatment of N-acetylcysteine or hydrogen-rich saline significantly ameliorated systemic and splanchnic hyperdynamic circulation, corrected hepatic endothelial dysfunction, and decreased intrahepatic resistance and mesenteric angiogenesis by inhibiting inflammatory cytokines, nitric oxide, VEGF and reducing mesenteric oxidative stress in cirrhotic rats. Acetylcysteine 53-69 vascular endothelial growth factor A Rattus norvegicus 331-335 24961937-5 2015 RESULTS: The data indicate that 1-month treatment of N-acetylcysteine or hydrogen-rich saline significantly ameliorated systemic and splanchnic hyperdynamic circulation, corrected hepatic endothelial dysfunction, and decreased intrahepatic resistance and mesenteric angiogenesis by inhibiting inflammatory cytokines, nitric oxide, VEGF and reducing mesenteric oxidative stress in cirrhotic rats. Hydrogen 73-81 vascular endothelial growth factor A Rattus norvegicus 331-335 24961937-5 2015 RESULTS: The data indicate that 1-month treatment of N-acetylcysteine or hydrogen-rich saline significantly ameliorated systemic and splanchnic hyperdynamic circulation, corrected hepatic endothelial dysfunction, and decreased intrahepatic resistance and mesenteric angiogenesis by inhibiting inflammatory cytokines, nitric oxide, VEGF and reducing mesenteric oxidative stress in cirrhotic rats. Sodium Chloride 87-93 vascular endothelial growth factor A Rattus norvegicus 331-335 25709009-0 2015 Bone formation of a porous Gelatin-Pectin-biphasic calcium phosphate composite in presence of BMP-2 and VEGF. calcium phosphate 51-68 vascular endothelial growth factor A Rattus norvegicus 104-108 25557829-9 2015 Caffeine down-regulated endothelial nitric oxide synthase, vascular endothelial growth factor (VEGF), phospho-VEGFR2, and phospho-Akt mesenteric protein expression. Caffeine 0-8 vascular endothelial growth factor A Rattus norvegicus 95-99 26191204-8 2015 RESULTS: The study indicated a significant increase in levels of VEGF and ICAM-1 and a decline in activity of coagulation in diabetic rats treated with sodium bisulfide. sodium bisulfide 152-168 vascular endothelial growth factor A Rattus norvegicus 65-69 25641377-8 2015 Hepatic artery ligation significantly promoted carbon tetrachloride-induced rat liver fibrosis progression as indicated by Sirius Red and alpha-SMA staining, as well as increased expression of hypoxia-inducible factor (HIF)-1alpha, transforming growth factor (TGF)-beta1, and vascular endothelial growth factor (VEGF). Carbon Tetrachloride 47-67 vascular endothelial growth factor A Rattus norvegicus 276-310 26191204-11 2015 The beneficial effect of H2S may be associated with formation of granulation, anti-inflammation, antioxidant, and the increased level of vascular endothelial growth factor (VEGF). Hydrogen Sulfide 25-28 vascular endothelial growth factor A Rattus norvegicus 137-171 26191204-11 2015 The beneficial effect of H2S may be associated with formation of granulation, anti-inflammation, antioxidant, and the increased level of vascular endothelial growth factor (VEGF). Hydrogen Sulfide 25-28 vascular endothelial growth factor A Rattus norvegicus 173-177 25641377-8 2015 Hepatic artery ligation significantly promoted carbon tetrachloride-induced rat liver fibrosis progression as indicated by Sirius Red and alpha-SMA staining, as well as increased expression of hypoxia-inducible factor (HIF)-1alpha, transforming growth factor (TGF)-beta1, and vascular endothelial growth factor (VEGF). Carbon Tetrachloride 47-67 vascular endothelial growth factor A Rattus norvegicus 312-316 25910559-0 2015 Buffered l-ascorbic acid, alone or bound to KMUP-1 or sildenafil, reduces vascular endothelium growth factor and restores endothelium nitric oxide synthase in hypoxic pulmonary artery. Ascorbic Acid 9-24 vascular endothelial growth factor A Rattus norvegicus 74-108 25897495-6 2015 Moreover, FGF-2 and Vegfa increased as a consequence of onapristone treatment. onapristone 56-67 vascular endothelial growth factor A Rattus norvegicus 20-25 25933224-8 2015 oATP down-regulated eNOS, inducible NOS (iNOS), VEGF, Akt, p-Akt, and nuclear factor-kappa B (NF-kappaB) expressions in splenorenal shunt, the most prominent intra-abdominal collateral vessel in rodents. 2',3'-dialdehyde ATP 0-4 vascular endothelial growth factor A Rattus norvegicus 48-52 25910559-1 2015 Ascorbic acid bound to KMUP-1 and sildenafil were examined for their antioxidant effects on vascular endothelium growth factor (VEGF) and endothelium nitric oxide synthase (eNOS) in hypoxic pulmonary artery (PA). Ascorbic Acid 0-13 vascular endothelial growth factor A Rattus norvegicus 92-126 25910559-8 2015 Oral KMUP-1A or sildenafil-A for 21 days in hypoxia prevented the rarefaction of eNOS in immunohistochemistry (IHC), reduced the IHC of VEGF in PAs, restored eNOS/protein kinase G/phosphodiesterase 5A; unaffected sGC-alpha and inactivated ROCK II expression were also found in lung tissues. 1a 10-12 vascular endothelial growth factor A Rattus norvegicus 136-140 25910559-8 2015 Oral KMUP-1A or sildenafil-A for 21 days in hypoxia prevented the rarefaction of eNOS in immunohistochemistry (IHC), reduced the IHC of VEGF in PAs, restored eNOS/protein kinase G/phosphodiesterase 5A; unaffected sGC-alpha and inactivated ROCK II expression were also found in lung tissues. sildenafil-a 16-28 vascular endothelial growth factor A Rattus norvegicus 136-140 25910559-12 2015 l-Ascorbic acid + l-sodium ascorbate (40, 80muM) buffer alone directly inhibited the IHC of VEGF in hypoxic PA. Ascorbic Acid 0-15 vascular endothelial growth factor A Rattus norvegicus 92-96 25910559-12 2015 l-Ascorbic acid + l-sodium ascorbate (40, 80muM) buffer alone directly inhibited the IHC of VEGF in hypoxic PA. l-sodium ascorbate 18-36 vascular endothelial growth factor A Rattus norvegicus 92-96 25945035-7 2015 Brain capillary endothelial cells were used to show that GSNO promotes angiogenesis and that GSNO-mediated induction of VEGF and the stimulation of angiogenesis are dependent on HIF-1alpha activity. S-Nitrosoglutathione 93-97 vascular endothelial growth factor A Rattus norvegicus 120-124 25945035-9 2015 GSNO treatment of IR not only remarkably enhanced further the expression of HIF-1alpha, VEGF, and PECAM-1 but also improved functioning compared with IR. S-Nitrosoglutathione 0-4 vascular endothelial growth factor A Rattus norvegicus 88-92 25945035-0 2015 Promoting endothelial function by S-nitrosoglutathione through the HIF-1alpha/VEGF pathway stimulates neurorepair and functional recovery following experimental stroke in rats. S-Nitrosoglutathione 34-54 vascular endothelial growth factor A Rattus norvegicus 78-82 25945035-11 2015 Increased expression of VEGF and the degree of tube formation (angiogenesis) by GSNO were reduced after the inhibition of HIF-1alpha by 2-ME in an endothelial cell culture model. S-Nitrosoglutathione 80-84 vascular endothelial growth factor A Rattus norvegicus 24-28 25945035-3 2015 Using a rat model of cerebral ischemia and reperfusion (IR) in this study, we tested the hypothesis that GSNO invokes the neurorepair process and improves neurobehavioral functions through the angiogenic HIF-1alpha/VEGF pathway. S-Nitrosoglutathione 105-109 vascular endothelial growth factor A Rattus norvegicus 215-219 25945035-11 2015 Increased expression of VEGF and the degree of tube formation (angiogenesis) by GSNO were reduced after the inhibition of HIF-1alpha by 2-ME in an endothelial cell culture model. 2-Methoxyestradiol 136-140 vascular endothelial growth factor A Rattus norvegicus 24-28 25787738-0 2015 Engineered VEGF-releasing PEG-MAL hydrogel for pancreatic islet vascularization. Polyethylene Glycols 26-29 vascular endothelial growth factor A Rattus norvegicus 11-15 26131126-8 2015 CONCLUSIONS: Dexamethasone gelatin sponge could significantly reduce the occurrence of epidural scar tissue hyperplasia and adhesion after laminectomy in rats, and its mechanism may be related to the decreased expression of VEGF and VEGFR2. Dexamethasone 13-26 vascular endothelial growth factor A Rattus norvegicus 224-228 25302540-7 2015 RESULTS: Mean surface endometriotic area, histological score of implants, adhesion formation, plasma VEGF, TNF, PTX-3 and CRP levels were significantly lower in the losartan group compared with control (P < 0.05). Losartan 165-173 vascular endothelial growth factor A Rattus norvegicus 101-105 25975048-8 2015 The expression of VEGF and CD31 showed a dose-dependent manner when calycosin was administrated. 7,3'-dihydroxy-4'-methoxyisoflavone 68-77 vascular endothelial growth factor A Rattus norvegicus 18-22 25975048-9 2015 The calycosin-treated (4 mg/kg) group displayed a two-fold increase in VEGF expression at both the mRNA and protein levels compared with the DMSO group. 7,3'-dihydroxy-4'-methoxyisoflavone 4-13 vascular endothelial growth factor A Rattus norvegicus 71-75 25975048-11 2015 CONCLUSION: Calycosin improved left ventricular ejection fraction in the MI rat models, induced VEGF expression in the ischaemic myocardium, increased CD31 expression and promoted angiogenesis. 7,3'-dihydroxy-4'-methoxyisoflavone 12-21 vascular endothelial growth factor A Rattus norvegicus 96-100 25907949-7 2015 The level of sFlt-1 was significantly higher and VEGF level significantly lower in the model group than in the other two groups (P<0.05); sFlt-1 level remained higher and VEGF lower in hemin group than in the control group (P<0.05). Hemin 188-193 vascular endothelial growth factor A Rattus norvegicus 174-178 25302540-8 2015 Furthermore, the peritoneal VEGF level was lower in the losartan group than in the control group (P < 0.001), but peritoneal TNF-alpha was similar in both groups (P > 0.05). Losartan 56-64 vascular endothelial growth factor A Rattus norvegicus 28-32 25302540-9 2015 CONCLUSION: Losartan suppressed the implant surface area of experimental endometriosis in rats and reduced the levels of plasma VEGF, TNF-alpha, PTX-3 and CRP. Losartan 12-20 vascular endothelial growth factor A Rattus norvegicus 128-132 25848212-13 2015 CONCLUSION: Tamoxifen 1 g and 3 g resulted in a dose-dependent increase in VEGF and endothelin 1 levels, and ovarian follicle reserves were significantly reduced in our experimental model. Tamoxifen 12-21 vascular endothelial growth factor A Rattus norvegicus 75-79 25789487-8 2015 Polysaccharide and MSCs acted additively to increase the expression of anti-inflammatory cytokine (TGF-beta), antiangiogenic cytokine (TSP-1) and decrease those promoting inflammation (TNF-alpha), chemotaxis (MIP-1alpha and MCP-1) and angiogenesis (VEGF and MMP-2). Polysaccharides 0-14 vascular endothelial growth factor A Rattus norvegicus 249-253 25223860-11 2015 Higher doses of melatonin treatment might be more effective in the regression of implants and improvement of histologic scores as well as in the precise evaluation of SOD, MDA and VEGF distributions in the rat experimental models. Melatonin 16-25 vascular endothelial growth factor A Rattus norvegicus 180-184 25479925-7 2015 According to our results Dexamethasone, a synthetic glucocorticoid, administration led to a decrease in VEGF, PIGF expression during pregnancy. Dexamethasone 25-38 vascular endothelial growth factor A Rattus norvegicus 104-108 25373440-5 2015 Serum VEGF (p = 0.05) and MCP-1 (p = 0.01) levels after treatment were also significantly lower in the resveratrol and leuprolide acetate groups. Resveratrol 103-114 vascular endothelial growth factor A Rattus norvegicus 6-10 25479925-10 2015 Dexamethasone injection also resulted in a reduction of VEGF, VEGFR1, and VEGFR2 mRNA expression at gestational days 14 and 20, but PIGF mRNA expression was not altered. Dexamethasone 0-13 vascular endothelial growth factor A Rattus norvegicus 56-60 25778658-0 2015 Expression of vascular endothelial growth factor (VEGF-A) in rat mandibular salivary gland during paraneoplastic process and treatment with cyclophosphamide and melatonin. Cyclophosphamide 140-156 vascular endothelial growth factor A Rattus norvegicus 14-48 25778658-0 2015 Expression of vascular endothelial growth factor (VEGF-A) in rat mandibular salivary gland during paraneoplastic process and treatment with cyclophosphamide and melatonin. Cyclophosphamide 140-156 vascular endothelial growth factor A Rattus norvegicus 50-56 25778658-0 2015 Expression of vascular endothelial growth factor (VEGF-A) in rat mandibular salivary gland during paraneoplastic process and treatment with cyclophosphamide and melatonin. Melatonin 161-170 vascular endothelial growth factor A Rattus norvegicus 14-48 25778658-0 2015 Expression of vascular endothelial growth factor (VEGF-A) in rat mandibular salivary gland during paraneoplastic process and treatment with cyclophosphamide and melatonin. Melatonin 161-170 vascular endothelial growth factor A Rattus norvegicus 50-56 25778658-1 2015 Expression of VEGF-A in Walker 256 carcinosarcoma and mandibular salivary gland of rats during paraneoplastic process and various regimens of chemotherapy with melatonin and cyclophosphamide were studied by immunohistochemical methods. Melatonin 160-169 vascular endothelial growth factor A Rattus norvegicus 14-20 25778658-1 2015 Expression of VEGF-A in Walker 256 carcinosarcoma and mandibular salivary gland of rats during paraneoplastic process and various regimens of chemotherapy with melatonin and cyclophosphamide were studied by immunohistochemical methods. Cyclophosphamide 174-190 vascular endothelial growth factor A Rattus norvegicus 14-20 25778658-2 2015 VEGF-A expression increased in the tumor node and salivary gland after monotherapy with melatonin and cyclophosphamide during progression of tumor growth and paraneoplastic syndrome. Melatonin 88-97 vascular endothelial growth factor A Rattus norvegicus 0-6 25778658-2 2015 VEGF-A expression increased in the tumor node and salivary gland after monotherapy with melatonin and cyclophosphamide during progression of tumor growth and paraneoplastic syndrome. Cyclophosphamide 102-118 vascular endothelial growth factor A Rattus norvegicus 0-6 25778658-3 2015 A decrease in VEGF-A expression in the tumor node and salivary gland was found after monotherapy with melatonin and cyclophosphamide and, especially, after combined treatment, which proves maximum therapeutic efficiency of combined administration of chemical agents with various mechanisms of action. Melatonin 102-111 vascular endothelial growth factor A Rattus norvegicus 14-20 25778658-3 2015 A decrease in VEGF-A expression in the tumor node and salivary gland was found after monotherapy with melatonin and cyclophosphamide and, especially, after combined treatment, which proves maximum therapeutic efficiency of combined administration of chemical agents with various mechanisms of action. Cyclophosphamide 116-132 vascular endothelial growth factor A Rattus norvegicus 14-20 24924353-9 2015 All atorvastatin-treated groups showed higher expression of IRS-1, PI3K, Akt, GSK-3, IL-10, eNOS, VEGF, and ERK on Day 7. Atorvastatin 4-16 vascular endothelial growth factor A Rattus norvegicus 98-102 25667627-12 2015 Conversely, ZDY reversed the changes in endometrial MVD, VEGF and OPN, and was indicated to improve uterine receptivity and pregnancy outcome. zdy 12-15 vascular endothelial growth factor A Rattus norvegicus 57-61 25524396-8 2015 In addition, the expression levels of VEGF, and Akt and eNOS phosphorylation were significantly higher in the group exposed to the combination treatment than in the group treated with rosuvastatin alone. Rosuvastatin Calcium 184-196 vascular endothelial growth factor A Rattus norvegicus 38-42 25499719-9 2015 At day 14, PTU-treated rats showed reduced VEGF, PGF, and rPlf gene expression. Propylthiouracil 11-14 vascular endothelial growth factor A Rattus norvegicus 43-47 25492119-8 2015 Hydrogen sulfide also attenuated CA and CPR-induced increases of matrix metalloproteinase-9 (MMP-9) activity and vascular endothelial growth factor (VEGF) expression, and increased the expression of angiogenin-1 (Ang-1). Hydrogen Sulfide 0-16 vascular endothelial growth factor A Rattus norvegicus 113-147 25492119-8 2015 Hydrogen sulfide also attenuated CA and CPR-induced increases of matrix metalloproteinase-9 (MMP-9) activity and vascular endothelial growth factor (VEGF) expression, and increased the expression of angiogenin-1 (Ang-1). Hydrogen Sulfide 0-16 vascular endothelial growth factor A Rattus norvegicus 149-153 25492119-11 2015 The therapeutic benefits of H2S could be associated with suppression of MMP-9 and VEGF expression and increased expression of Ang-1. Hydrogen Sulfide 28-31 vascular endothelial growth factor A Rattus norvegicus 82-86 25640057-0 2015 Functionalization of titanium implants using a modular system for binding and release of VEGF enhances bone-implant contact in a rodent model. Titanium 21-29 vascular endothelial growth factor A Rattus norvegicus 89-93 25546615-9 2015 VEGF-alpha concentrations and SOD activity increased by 179% and 22%, respectively, in the melatonin-treated group compared with the control group. Melatonin 91-100 vascular endothelial growth factor A Rattus norvegicus 0-10 26109968-3 2015 The purpose of this study was to compare the topical versus systemic L-arginine treatment on total nitrite (NOx) and vascular endothelial growth factor (VEGF) concentrations in wound fluid and rate of wound healing in an acute incisional diabetic wound model. Arginine 69-79 vascular endothelial growth factor A Rattus norvegicus 117-151 26109968-3 2015 The purpose of this study was to compare the topical versus systemic L-arginine treatment on total nitrite (NOx) and vascular endothelial growth factor (VEGF) concentrations in wound fluid and rate of wound healing in an acute incisional diabetic wound model. Arginine 69-79 vascular endothelial growth factor A Rattus norvegicus 153-157 26109968-15 2015 VEGF content in L-arginine treated groups were significantly more than controls (P < 0.05). Arginine 16-26 vascular endothelial growth factor A Rattus norvegicus 0-4 25499719-10 2015 PTU-treated group showed reduced VEGF immunostaining in the placental labyrinth at 14 and 19 days of gestation but it showed increased VEGF immunostaining in the spongiotrophoblast layer at day 14. Propylthiouracil 0-3 vascular endothelial growth factor A Rattus norvegicus 33-37 25499719-10 2015 PTU-treated group showed reduced VEGF immunostaining in the placental labyrinth at 14 and 19 days of gestation but it showed increased VEGF immunostaining in the spongiotrophoblast layer at day 14. Propylthiouracil 0-3 vascular endothelial growth factor A Rattus norvegicus 135-139 25723475-10 2015 The protein and mRNA levels of HIF-1alpha, VEGF and TGF-beta1 increased significantly in group GLU, and decreased significantly after administration of LMWH in a dose-dependent manner. Glutamic Acid 95-98 vascular endothelial growth factor A Rattus norvegicus 43-47 25992275-3 2015 Here we address, at first glance, the confusing and paradoxical aspect of the model, namely, that treatment of rats with the antiangiogenic vascular endothelial growth factor (VEGF) receptor 1 and 2 kinase inhibitor, Sugen 5416, when combined with chronic hypoxia, causes angioproliferative pulmonary vascular disease. sugen 217-222 vascular endothelial growth factor A Rattus norvegicus 176-180 25992275-5 2015 We also considered that Sugen 5416-induced VEGFR1 and VEGFR2 blockade could alter the expression pattern of VEGF isoform proteins. sugen 24-29 vascular endothelial growth factor A Rattus norvegicus 43-47 25723475-10 2015 The protein and mRNA levels of HIF-1alpha, VEGF and TGF-beta1 increased significantly in group GLU, and decreased significantly after administration of LMWH in a dose-dependent manner. Heparin, Low-Molecular-Weight 152-156 vascular endothelial growth factor A Rattus norvegicus 43-47 25723475-0 2015 Low molecular weight heparin (LMWH) improves peritoneal function and inhibits peritoneal fibrosis possibly through suppression of HIF-1alpha, VEGF and TGF-beta1. Heparin 21-28 vascular endothelial growth factor A Rattus norvegicus 142-146 25723475-11 2015 CONCLUSIONS: LMWH ameliorates peritoneal function and inhibits peritoneal fibrosis, possibly through suppression of HIF-1alpha, VEGF and TGF-beta1. Heparin, Low-Molecular-Weight 13-17 vascular endothelial growth factor A Rattus norvegicus 128-132 25723475-0 2015 Low molecular weight heparin (LMWH) improves peritoneal function and inhibits peritoneal fibrosis possibly through suppression of HIF-1alpha, VEGF and TGF-beta1. Heparin, Low-Molecular-Weight 30-34 vascular endothelial growth factor A Rattus norvegicus 142-146 25668036-5 2015 The effect of WA-25 on the endothelial vascular endothelial growth factor (VEGF) signaling pathway was elucidated using qRT-PCR, immunoblot analysis, immunofluorescence and flow cytometric analyses. wa-25 14-19 vascular endothelial growth factor A Rattus norvegicus 39-73 25668036-5 2015 The effect of WA-25 on the endothelial vascular endothelial growth factor (VEGF) signaling pathway was elucidated using qRT-PCR, immunoblot analysis, immunofluorescence and flow cytometric analyses. wa-25 14-19 vascular endothelial growth factor A Rattus norvegicus 75-79 25668036-12 2015 CONCLUSIONS: WA-25 is a potent angiogenesis inhibitor that acts through the down-regulation of VEGF and VEGFR2 in endothelial cells. wa-25 13-18 vascular endothelial growth factor A Rattus norvegicus 95-99 25284371-8 2015 These results indicate that neuronal cell loss in the retina precedes retinal capillary degeneration following NMDA treatment, and VEGF-dependent immature capillaries might be more susceptible to NMDA-induced neuronal damage. N-Methylaspartate 196-200 vascular endothelial growth factor A Rattus norvegicus 131-135 25973002-2 2015 Cediranib is a protein tyrosine kinase inhibitor that potently inhibits VEGF receptor-2, but there is no study about its effects on the endometriosis. cediranib 0-9 vascular endothelial growth factor A Rattus norvegicus 72-76 25673207-0 2015 Time-dependent expression of PEDF and VEGF in blood serum and retina of rats with oxygen-induced retinopathy. Oxygen 82-88 vascular endothelial growth factor A Rattus norvegicus 38-42 25255906-8 2015 Genistein significantly potentiated the vasodilatory effect by the VEGF. Genistein 0-9 vascular endothelial growth factor A Rattus norvegicus 67-71 25474224-7 2015 Taken together, CB1 transgenic mice and rats treated with CB1 agonist WIN55212-2 induced proteinuria with upregulation of CB1 resulting in impaired nephrin expression, by inducing excess VEGF reaction in the renal glomeruli. (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone 70-78 vascular endothelial growth factor A Rattus norvegicus 187-191 24888239-0 2015 Vascular endothelial growth factor mRNA levels as a biomarker for short-term N-butyl-N-(4-hydroxybutyl) nitrosamine-induced rat bladder carcinogenesis bioassay. Butylhydroxybutylnitrosamine 77-115 vascular endothelial growth factor A Rattus norvegicus 0-34 24888239-8 2015 However, VEGF mRNA levels of rat bladders at 10 weeks" BBN treatment revealed a strong significant correlation with the incidence of bladder lesions at 26 weeks" treatment. Butylhydroxybutylnitrosamine 55-58 vascular endothelial growth factor A Rattus norvegicus 9-13 24888239-9 2015 Here, we suggest that quantitative VEGF mRNA levels are a good biomarker for a short-term BBN-induced bioassay for rat bladder carcinogenesis. Butylhydroxybutylnitrosamine 90-93 vascular endothelial growth factor A Rattus norvegicus 35-39 25075768-8 2015 Large-dose treatment was superior to valsartan in reducing oxidative stress and inhibiting TGFbeta1/Smad3- and VEGF-mediated pathways. Valsartan 37-46 vascular endothelial growth factor A Rattus norvegicus 111-115 25560253-0 2015 Water extract of Cinnamomum cassia suppresses angiogenesis through inhibition of VEGF receptor 2 phosphorylation. Water 0-5 vascular endothelial growth factor A Rattus norvegicus 81-85 25602014-5 2015 In apparent paradox, but confirming observations made separately in other models, high glucose but also low glucose increased mRNA level of vascular endothelial growth factor A (VEGFA). Glucose 87-94 vascular endothelial growth factor A Rattus norvegicus 140-176 25602014-5 2015 In apparent paradox, but confirming observations made separately in other models, high glucose but also low glucose increased mRNA level of vascular endothelial growth factor A (VEGFA). Glucose 87-94 vascular endothelial growth factor A Rattus norvegicus 178-183 25602014-5 2015 In apparent paradox, but confirming observations made separately in other models, high glucose but also low glucose increased mRNA level of vascular endothelial growth factor A (VEGFA). Glucose 108-115 vascular endothelial growth factor A Rattus norvegicus 140-176 25602014-5 2015 In apparent paradox, but confirming observations made separately in other models, high glucose but also low glucose increased mRNA level of vascular endothelial growth factor A (VEGFA). Glucose 108-115 vascular endothelial growth factor A Rattus norvegicus 178-183 25759816-7 2015 Moreover, TMP significantly increased the vessel volume, vessel surface, percentage of vessel volume, and vessel thickness of the femoral heads by micro-CT. Interestingly, the downregulation of VEGF and FLK1 proteins in the sera and necrotic femoral heads could be reversed by TMP treatment, and this was true for their mRNA expressions in femoral heads. tetramethylpyrazine 10-13 vascular endothelial growth factor A Rattus norvegicus 194-198 25759816-7 2015 Moreover, TMP significantly increased the vessel volume, vessel surface, percentage of vessel volume, and vessel thickness of the femoral heads by micro-CT. Interestingly, the downregulation of VEGF and FLK1 proteins in the sera and necrotic femoral heads could be reversed by TMP treatment, and this was true for their mRNA expressions in femoral heads. tetramethylpyrazine 277-280 vascular endothelial growth factor A Rattus norvegicus 194-198 25759816-8 2015 In conclusion, these findings suggest for the first time that TMP may prevent steroid-induced ONFH and also enhance femoral head vascularization by inhibiting the effect of steroid on VEGF/FLK1 signal pathway. tetramethylpyrazine 62-65 vascular endothelial growth factor A Rattus norvegicus 184-188 25759816-8 2015 In conclusion, these findings suggest for the first time that TMP may prevent steroid-induced ONFH and also enhance femoral head vascularization by inhibiting the effect of steroid on VEGF/FLK1 signal pathway. Steroids 173-180 vascular endothelial growth factor A Rattus norvegicus 184-188 25845219-0 2015 [The impact of different duration of EA-pretreatment on expression of MMP-9 and VEGF in blood-brain barrier in rats with cerebral ischemia-reperfusion injury]. ea 37-39 vascular endothelial growth factor A Rattus norvegicus 80-84 25179820-1 2015 The aim of this study was to elucidate whether metformin can regulate the expression of vascular endothelial growth factor (VEGF) in rat-derived uterine leiomyoma cells (ELT-3 cells). Metformin 47-56 vascular endothelial growth factor A Rattus norvegicus 88-122 25179820-1 2015 The aim of this study was to elucidate whether metformin can regulate the expression of vascular endothelial growth factor (VEGF) in rat-derived uterine leiomyoma cells (ELT-3 cells). Metformin 47-56 vascular endothelial growth factor A Rattus norvegicus 124-128 25179820-3 2015 Under normoxic conditions, metformin suppressed VEGF protein levels in the supernatant and cells in a dose-dependent manner. Metformin 27-36 vascular endothelial growth factor A Rattus norvegicus 48-52 25179820-4 2015 In hypoxia-mimicking conditions, VEGF and hypoxia-inducible factor-1alpha (HIF-1alpha) proteins were both highly expressed and were suppressed by the metformin treatment. Metformin 150-159 vascular endothelial growth factor A Rattus norvegicus 33-37 25179820-7 2015 This study revealed the anti-angiogenic activity of metformin in ELT-3 cells by suppressing the expression of VEGF via the mTORC1/HIF-1alpha pathway. Metformin 52-61 vascular endothelial growth factor A Rattus norvegicus 110-114 25560253-5 2015 Furthermore, CCWE inhibited VEGF-induced vessel sprouting of rat aorta ex vivo. ccwe 13-17 vascular endothelial growth factor A Rattus norvegicus 28-32 25934975-0 2015 A Pilot Study Evaluating Combinatorial and Simultaneous Delivery of Polyethylenimine-Plasmid DNA Complexes Encoding for VEGF and PDGF for Bone Regeneration in Calvarial Bone Defects. Polyethyleneimine 68-84 vascular endothelial growth factor A Rattus norvegicus 120-124 25008404-4 2015 Thus, we thought to investigate the effect of SES on VEGF regulation in cultured neonatal rat ventricular myocytes (NRVMs), in the aim to reveal new techniques for therapeutic angiogenesis in ischemic heart disease. ses 46-49 vascular endothelial growth factor A Rattus norvegicus 53-57 25327303-0 2015 Meloxicam temporally inhibits the expression of vascular endothelial growth factor receptor (VEGFR)-1 and VEGFR-2 during alveolar bone repair in rats. Meloxicam 0-9 vascular endothelial growth factor A Rattus norvegicus 48-82 25628749-15 2015 In addition, DWYG gradually restored IL-1, GRO/KC, and VEGF levels to those of the normal group. dwyg 13-17 vascular endothelial growth factor A Rattus norvegicus 55-59 26369707-12 2015 For the TL, ranibizumab, and cabergoline groups VEGF intensity was similar. Cabergoline 29-40 vascular endothelial growth factor A Rattus norvegicus 48-52 25327303-2 2015 This study investigated whether the use of meloxicam alters bone repair via downregulation of VEGF and receptor expression. Meloxicam 43-52 vascular endothelial growth factor A Rattus norvegicus 94-98 25435978-9 2015 Curcumin and the VEGF blocker are each capable of inhibiting hepatocellular carcinoma progression by regulating the VEGF/VEGFR/K-ras pathway. Curcumin 0-8 vascular endothelial growth factor A Rattus norvegicus 116-120 25435978-1 2015 The aim of the present study was to explore the effects of curcumin in combination with bevacizumab on the vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR)/K-ras pathway in hepatocellular carcinoma. Curcumin 59-67 vascular endothelial growth factor A Rattus norvegicus 107-141 25084762-9 2015 The expression of vascular endothelial growth factor (VEGF) and brain-derived neurotrophic factor (BDNF) and its receptor was significantly increased in the animals treated with candesartan. candesartan 178-189 vascular endothelial growth factor A Rattus norvegicus 18-52 25084762-9 2015 The expression of vascular endothelial growth factor (VEGF) and brain-derived neurotrophic factor (BDNF) and its receptor was significantly increased in the animals treated with candesartan. candesartan 178-189 vascular endothelial growth factor A Rattus norvegicus 54-58 25435978-1 2015 The aim of the present study was to explore the effects of curcumin in combination with bevacizumab on the vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR)/K-ras pathway in hepatocellular carcinoma. Curcumin 59-67 vascular endothelial growth factor A Rattus norvegicus 143-147 25179655-0 2015 Bosentan protects the spinal cord from ischemia reperfusion injury in rats through vascular endothelial growth factor receptors. Bosentan 0-8 vascular endothelial growth factor A Rattus norvegicus 83-117 25435978-1 2015 The aim of the present study was to explore the effects of curcumin in combination with bevacizumab on the vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR)/K-ras pathway in hepatocellular carcinoma. Curcumin 59-67 vascular endothelial growth factor A Rattus norvegicus 149-153 25435978-4 2015 Compared with the control group, the mRNA levels of VEGF and VEGFR were revealed to be significantly increased in the model, curcumin and VEGF blocker groups. Curcumin 125-133 vascular endothelial growth factor A Rattus norvegicus 52-56 25435978-4 2015 Compared with the control group, the mRNA levels of VEGF and VEGFR were revealed to be significantly increased in the model, curcumin and VEGF blocker groups. Curcumin 125-133 vascular endothelial growth factor A Rattus norvegicus 61-65 25435978-5 2015 The VEGF mRNA levels in the curcumin, VEGF blocker and curcumin + VEGF blocker groups were all decreased when compared with the model group. Curcumin 28-36 vascular endothelial growth factor A Rattus norvegicus 4-8 25435978-5 2015 The VEGF mRNA levels in the curcumin, VEGF blocker and curcumin + VEGF blocker groups were all decreased when compared with the model group. Curcumin 55-63 vascular endothelial growth factor A Rattus norvegicus 4-8 25435978-6 2015 In addition, the VEGF mRNA levels in the curcumin + VEGF blocker group were significantly lower compared with the curcumin group (P<0.05). Curcumin 41-49 vascular endothelial growth factor A Rattus norvegicus 17-21 25435978-6 2015 In addition, the VEGF mRNA levels in the curcumin + VEGF blocker group were significantly lower compared with the curcumin group (P<0.05). Curcumin 41-49 vascular endothelial growth factor A Rattus norvegicus 52-56 25435978-6 2015 In addition, the VEGF mRNA levels in the curcumin + VEGF blocker group were significantly lower compared with the curcumin group (P<0.05). Curcumin 114-122 vascular endothelial growth factor A Rattus norvegicus 17-21 25435978-7 2015 The VEGF mRNA levels in the curcumin, VEGF blocker and curcumin + VEGF blocker groups were decreased when compared with the model group (P=0.0001). Curcumin 28-36 vascular endothelial growth factor A Rattus norvegicus 4-8 25435978-7 2015 The VEGF mRNA levels in the curcumin, VEGF blocker and curcumin + VEGF blocker groups were decreased when compared with the model group (P=0.0001). Curcumin 55-63 vascular endothelial growth factor A Rattus norvegicus 4-8 25249648-10 2015 As confirmed by western blotting, the levels of VEGF in lung homogenates were higher in the Azm-treated group than in the COPD, saline-treated, and Lev-treated groups. Azithromycin 92-95 vascular endothelial growth factor A Rattus norvegicus 48-52 25249648-10 2015 As confirmed by western blotting, the levels of VEGF in lung homogenates were higher in the Azm-treated group than in the COPD, saline-treated, and Lev-treated groups. lenvatinib 148-151 vascular endothelial growth factor A Rattus norvegicus 48-52 25249648-12 2015 CONCLUSIONS: Azm attenuates pulmonary emphysema by partly reversing the decrease in the numbers of inflammatory cells (neutrophil and macrophage) and VEGF secretion and VEGFR2 protein expression in smoking-induced COPD in rats. Azithromycin 13-16 vascular endothelial growth factor A Rattus norvegicus 150-154 26074974-7 2015 Curcumin pretreatment significantly increased cell viability and VEGF secretion, and decreased cell injury and apoptosis via regulation of PTEN/Akt/p53 and HO-1 signal proteins expression. Curcumin 0-8 vascular endothelial growth factor A Rattus norvegicus 65-69 26028413-6 2015 The healing-impairment action of loxoprofen was accompanied by the down-regulation of vascular endothelium-derived growth factor (VEGF) expression and an angiogenic response. loxoprofen 33-43 vascular endothelial growth factor A Rattus norvegicus 86-128 26074974-9 2015 Transplantation of curcumin pretreated ADSCs not only resulted in better heart function, higher cells retention, and smaller infarct size, but also decreased myocardial apoptosis, promoted neovascularization, and increased VEGF level in ischemic myocardium. Curcumin 19-27 vascular endothelial growth factor A Rattus norvegicus 223-227 26281317-8 2015 CONCLUSION: Quercetin exhibited an effective inhibition of VEGF mRNA expression, while a lower inhibition of the VEGF mRNA level was observed in the hydroxy citric acid- and the pioglitazone-treated rats. Quercetin 12-21 vascular endothelial growth factor A Rattus norvegicus 59-63 26281317-8 2015 CONCLUSION: Quercetin exhibited an effective inhibition of VEGF mRNA expression, while a lower inhibition of the VEGF mRNA level was observed in the hydroxy citric acid- and the pioglitazone-treated rats. hydroxycitric acid 149-168 vascular endothelial growth factor A Rattus norvegicus 113-117 26281317-8 2015 CONCLUSION: Quercetin exhibited an effective inhibition of VEGF mRNA expression, while a lower inhibition of the VEGF mRNA level was observed in the hydroxy citric acid- and the pioglitazone-treated rats. Pioglitazone 178-190 vascular endothelial growth factor A Rattus norvegicus 113-117 26281317-0 2015 Effect of pioglitazone, quercetin, and hydroxy citric acid on vascular endothelial growth factor messenger RNA (VEGF mRNA) expression in experimentally induced nonalcoholic steatohepatitis (NASH). hydroxycitric acid 39-58 vascular endothelial growth factor A Rattus norvegicus 62-96 26281317-2 2015 In this study, the comparative effect of pioglitazone, quercetin, and hydroxy citric acid on VEGF mRNA in experimentally induced NASH was investigated. Pioglitazone 41-53 vascular endothelial growth factor A Rattus norvegicus 93-97 26281317-2 2015 In this study, the comparative effect of pioglitazone, quercetin, and hydroxy citric acid on VEGF mRNA in experimentally induced NASH was investigated. Quercetin 55-64 vascular endothelial growth factor A Rattus norvegicus 93-97 26281317-2 2015 In this study, the comparative effect of pioglitazone, quercetin, and hydroxy citric acid on VEGF mRNA in experimentally induced NASH was investigated. hydroxycitric acid 70-89 vascular endothelial growth factor A Rattus norvegicus 93-97 26281317-6 2015 A very mild increase in VEGF mRNA expression was observed in the rats treated with quercetin. Quercetin 83-92 vascular endothelial growth factor A Rattus norvegicus 24-28 26281317-7 2015 In contrast, a mild increase in the expression of VEGF mRNA was observed in the rats treated with pioglitazone and hydroxy citric acid. Pioglitazone 98-110 vascular endothelial growth factor A Rattus norvegicus 50-54 26281317-7 2015 In contrast, a mild increase in the expression of VEGF mRNA was observed in the rats treated with pioglitazone and hydroxy citric acid. hydroxycitric acid 115-134 vascular endothelial growth factor A Rattus norvegicus 50-54 26028413-6 2015 The healing-impairment action of loxoprofen was accompanied by the down-regulation of vascular endothelium-derived growth factor (VEGF) expression and an angiogenic response. loxoprofen 33-43 vascular endothelial growth factor A Rattus norvegicus 130-134 26028413-7 2015 The impaired healing caused by loxoprofen was significantly restored by co-treatment with a diet containing 5% MSG for 5 d, accompanied by the enhancement of VEGF expression and angiogenesis. loxoprofen 31-41 vascular endothelial growth factor A Rattus norvegicus 158-162 25663994-8 2014 Compared to sole drug, VEGF and BDNF expression were significantly up-regulated in atorvastatin combination with BMSC group (P < 0.05). Atorvastatin 83-95 vascular endothelial growth factor A Rattus norvegicus 23-27 24814385-4 2014 In this study, we used a fluid percussion injury (FPI) model in rats to determine the effects of acute ethanol intake on the expression levels of HIF-1alpha, AQP4, and VEGF prior to FPI. Ethanol 103-110 vascular endothelial growth factor A Rattus norvegicus 168-172 25514418-5 2014 Meanwhile, NaHS administration significantly increased cystathionine gamma-lyase (CSE), HO-1, alpha-SMA, and VEGF expression. sodium bisulfide 11-15 vascular endothelial growth factor A Rattus norvegicus 109-113 25107896-8 2014 This study thus demonstrates that VEGF recovers PE-suppressed COX activity by restoring Cu availability and VEGF suppression of ROS accumulation and homocysteine elevation would contribute to the increased Cu availability. Reactive Oxygen Species 128-131 vascular endothelial growth factor A Rattus norvegicus 108-112 25107896-0 2014 Vascular endothelial growth factor recovers suppressed cytochrome c oxidase activity by restoring copper availability in hypertrophic cardiomyocytes. Copper 98-104 vascular endothelial growth factor A Rattus norvegicus 0-34 25107896-5 2014 The hypertrophic cardiomyocytes were exposed to VEGF at a final concentration of 20 ng/mL in cultures for 24 h. Atomic absorption spectrometry analysis revealed that VEGF restored PE-depleted Cu concentrations in hypertrophic cardiomyocytes along with the recovery of COX activity. Copper 192-194 vascular endothelial growth factor A Rattus norvegicus 166-170 25107896-8 2014 This study thus demonstrates that VEGF recovers PE-suppressed COX activity by restoring Cu availability and VEGF suppression of ROS accumulation and homocysteine elevation would contribute to the increased Cu availability. Homocysteine 149-161 vascular endothelial growth factor A Rattus norvegicus 34-38 25107896-6 2014 Western blot analysis showed that protein contents of COX subunit COX-IV and Cu chaperones for COX (COX17, COX11, and SCO2) were decreased in response to PE treatment, and recovered after VEGF treatment. pe 154-156 vascular endothelial growth factor A Rattus norvegicus 188-192 25269821-3 2014 The Src protein tyrosine kinase (PTK) inhibitor, PP2, protects the rat brain against ischemic injury, possibly through the reduction of vascular endothelial growth factor A (VEGFA) expression and the upregulation of claudin-5 expression, which preserves the integrity of the BBB. pp2 49-52 vascular endothelial growth factor A Rattus norvegicus 136-172 25107896-7 2014 In addition, VEGF treatment suppressed PE-induced accumulation of reactive oxygen species (ROS) and the relevant elevation of homocysteine, which has been shown to form complexes with Cu to restrict Cu availability. Reactive Oxygen Species 66-89 vascular endothelial growth factor A Rattus norvegicus 13-17 25107896-7 2014 In addition, VEGF treatment suppressed PE-induced accumulation of reactive oxygen species (ROS) and the relevant elevation of homocysteine, which has been shown to form complexes with Cu to restrict Cu availability. Reactive Oxygen Species 91-94 vascular endothelial growth factor A Rattus norvegicus 13-17 25107896-7 2014 In addition, VEGF treatment suppressed PE-induced accumulation of reactive oxygen species (ROS) and the relevant elevation of homocysteine, which has been shown to form complexes with Cu to restrict Cu availability. Homocysteine 126-138 vascular endothelial growth factor A Rattus norvegicus 13-17 25107896-7 2014 In addition, VEGF treatment suppressed PE-induced accumulation of reactive oxygen species (ROS) and the relevant elevation of homocysteine, which has been shown to form complexes with Cu to restrict Cu availability. Copper 184-186 vascular endothelial growth factor A Rattus norvegicus 13-17 25107896-8 2014 This study thus demonstrates that VEGF recovers PE-suppressed COX activity by restoring Cu availability and VEGF suppression of ROS accumulation and homocysteine elevation would contribute to the increased Cu availability. Reactive Oxygen Species 128-131 vascular endothelial growth factor A Rattus norvegicus 34-38 25269821-10 2014 These findings suggested that PP2 treatment attenuated the disruption of the BBB following ischemia and minimized the neurological deficit; these effects were associated with a decreased VEGFA expression and an increased claudin-5 expression. pp2 30-33 vascular endothelial growth factor A Rattus norvegicus 187-192 25269821-3 2014 The Src protein tyrosine kinase (PTK) inhibitor, PP2, protects the rat brain against ischemic injury, possibly through the reduction of vascular endothelial growth factor A (VEGFA) expression and the upregulation of claudin-5 expression, which preserves the integrity of the BBB. pp2 49-52 vascular endothelial growth factor A Rattus norvegicus 174-179 25160895-10 2014 Interestingly, animals treated with both candesartan and l-dopa displayed significantly lower levels of VEGF, IL-1beta and dyskinesia than those treated with l-dopa alone. candesartan 41-52 vascular endothelial growth factor A Rattus norvegicus 104-108 25066133-6 2014 Exposure to 1 nM VEGF transiently increased P to 2.2, 10.5, 9.8, and 12.8 times control values, for fluorescein, Dex-20k, Dex-70k, and IgG, respectively, within 30 sec, and all returned to control levels within 2 min. Fluorescein 100-111 vascular endothelial growth factor A Rattus norvegicus 17-21 25066133-7 2014 After 20 min of pretreatment with 2 mM of the cAMP analog 8-bromo-cAMP, the initial increase by 1 nM VEGF was completely abolished in P of all solutes. Cyclic AMP 46-50 vascular endothelial growth factor A Rattus norvegicus 101-105 25066133-7 2014 After 20 min of pretreatment with 2 mM of the cAMP analog 8-bromo-cAMP, the initial increase by 1 nM VEGF was completely abolished in P of all solutes. 8-Bromo Cyclic Adenosine Monophosphate 58-70 vascular endothelial growth factor A Rattus norvegicus 101-105 25283081-6 2014 On the other hand, Pcox administered before irradiation showed a significant increase in both vascular endothelial growth factor (VEGF) and COX-2 levels (p < 0.05) and in nitric oxide production (p < 0.01), when compared with the control group. parecoxib 19-23 vascular endothelial growth factor A Rattus norvegicus 94-128 25283081-6 2014 On the other hand, Pcox administered before irradiation showed a significant increase in both vascular endothelial growth factor (VEGF) and COX-2 levels (p < 0.05) and in nitric oxide production (p < 0.01), when compared with the control group. parecoxib 19-23 vascular endothelial growth factor A Rattus norvegicus 130-134 25316436-9 2014 In the immunohistochemistry, VEGF decreased more in CDHDV group (p < 0.05). cdhdv 52-57 vascular endothelial growth factor A Rattus norvegicus 29-33 25316436-12 2014 CONCLUSION: The use of prenatal dexamethasone added to ventilation alters the VEGF and NO pathways. Dexamethasone 32-45 vascular endothelial growth factor A Rattus norvegicus 78-82 24499803-2 2014 Using lenvatinib, a VEGF RTK inhibitor, we characterized the histologic time course of this duodenal change in rats. lenvatinib 6-16 vascular endothelial growth factor A Rattus norvegicus 20-24 24548632-9 2014 ETDB at 6 h further increased the elevated levels of VEGF angiogenic signaling in endotoxemic heart. etdb 0-4 vascular endothelial growth factor A Rattus norvegicus 53-57 25160895-10 2014 Interestingly, animals treated with both candesartan and l-dopa displayed significantly lower levels of VEGF, IL-1beta and dyskinesia than those treated with l-dopa alone. Levodopa 57-63 vascular endothelial growth factor A Rattus norvegicus 104-108 24989632-7 2014 The endometrial gland degeneration scores, stromal fibrosis scores and VEGF immunoexpression was significantly lower, and the EGFR immunoexpression was significantly higher in the atorvastatin-treated diabetic rats when compared to the non-treated diabetic group, suggesting that atorvastatin ameliorates the uterine microenvironment in diabetes mellitus. Atorvastatin 180-192 vascular endothelial growth factor A Rattus norvegicus 71-75 25217874-10 2014 The effects of this D2-ag on VP and VEGF protein levels were partially reversed by concomitant administration of a D2-ant. d2-ant 115-121 vascular endothelial growth factor A Rattus norvegicus 36-40 25275248-1 2014 OBJECTIVES: The therapeutic use of the vascular endothelial growth factor (VEGF) antagonist sunitinib is limited by sunitinib-induced hypertension. Sunitinib 92-101 vascular endothelial growth factor A Rattus norvegicus 39-73 26000399-3 2014 Here we report a new approach to locally deliver recombinant VEGF from an electrospun poly-epsilon-caprolactone nanofiber mesh and its effect on improving rat liver regeneration after 70% hepatectomy. polycaprolactone 86-111 vascular endothelial growth factor A Rattus norvegicus 61-65 25275248-1 2014 OBJECTIVES: The therapeutic use of the vascular endothelial growth factor (VEGF) antagonist sunitinib is limited by sunitinib-induced hypertension. Sunitinib 92-101 vascular endothelial growth factor A Rattus norvegicus 75-79 25275248-1 2014 OBJECTIVES: The therapeutic use of the vascular endothelial growth factor (VEGF) antagonist sunitinib is limited by sunitinib-induced hypertension. Sunitinib 116-125 vascular endothelial growth factor A Rattus norvegicus 39-73 25275248-1 2014 OBJECTIVES: The therapeutic use of the vascular endothelial growth factor (VEGF) antagonist sunitinib is limited by sunitinib-induced hypertension. Sunitinib 116-125 vascular endothelial growth factor A Rattus norvegicus 75-79 25275248-8 2014 CONCLUSION: Our data indicate that early sunitinib-induced hypertension is associated with modest alterations in renal vascular function, but markedly increased renal sodium reabsorption, probably due to direct actions of the VEGF antagonist on the collecting duct, suggesting that VEGF receptors regulate renal Na+ absorption. Sunitinib 41-50 vascular endothelial growth factor A Rattus norvegicus 226-230 25275248-8 2014 CONCLUSION: Our data indicate that early sunitinib-induced hypertension is associated with modest alterations in renal vascular function, but markedly increased renal sodium reabsorption, probably due to direct actions of the VEGF antagonist on the collecting duct, suggesting that VEGF receptors regulate renal Na+ absorption. Sunitinib 41-50 vascular endothelial growth factor A Rattus norvegicus 282-286 25473215-9 2014 This endogenous neovascularization induced by AMD-3100 may be a result of the increase in both the area and number of vessels, as well as paracrine augmentation of the expression of VEGF and EPCs. plerixafor 46-54 vascular endothelial growth factor A Rattus norvegicus 182-186 25300058-10 2014 There were also significant reductions in VEGF immunoreactivity scores and both stroma and epithelium MMP-2 and MMP-9 immunoreactivity scores in the propranolol-treated group compared with the control group (p<0.005 for all scores). Propranolol 149-160 vascular endothelial growth factor A Rattus norvegicus 42-46 25300058-11 2014 CONCLUSIONS: Propranolol may suppress endometrial tissue by its antiangiogenic activity through inhibitory actions on VEGF, MMP-2, and MMP-9. Propranolol 13-24 vascular endothelial growth factor A Rattus norvegicus 118-122 25450902-10 2014 Compared to control carcinoma cells, Pitavastatin alone increased VEGF expression by 41%, however melatonin totally reversed its undesirable effect. pitavastatin 37-49 vascular endothelial growth factor A Rattus norvegicus 66-70 25364265-0 2014 Ginsenoside Rg3 attenuates hepatoma VEGF overexpression after hepatic artery embolization in an orthotopic transplantation hepatocellular carcinoma rat model. Ginsenosides 0-11 vascular endothelial growth factor A Rattus norvegicus 36-40 25364265-1 2014 BACKGROUND: Hypoxia-induced vascular endothelial growth factor (VEGF) upregulation and angiogenesis following treatment of hepatocellular carcinoma (HCC) with transarterial embolization (TAE) or transarterial chemoembolization (TACE) may be mediated by ginsenoside Rg3, an anti-angiogenic saponin extracted from ginseng. Ginsenosides 253-264 vascular endothelial growth factor A Rattus norvegicus 64-68 25364265-1 2014 BACKGROUND: Hypoxia-induced vascular endothelial growth factor (VEGF) upregulation and angiogenesis following treatment of hepatocellular carcinoma (HCC) with transarterial embolization (TAE) or transarterial chemoembolization (TACE) may be mediated by ginsenoside Rg3, an anti-angiogenic saponin extracted from ginseng. Saponins 289-296 vascular endothelial growth factor A Rattus norvegicus 64-68 25148708-9 2014 Furthermore, the induction of VEGF protein, microvessel density, decrease of infarct volumes and neurological recovery was significantly inhibited by daidzein. daidzein 150-158 vascular endothelial growth factor A Rattus norvegicus 30-34 24939171-5 2014 H2 S promotes the phosphorylation of AKT and ERK and increases the expression of vascular endothelial growth factor (VEGF) and angiopoietin-1 (Ang-1). Hydrogen 0-2 vascular endothelial growth factor A Rattus norvegicus 81-115 24939171-5 2014 H2 S promotes the phosphorylation of AKT and ERK and increases the expression of vascular endothelial growth factor (VEGF) and angiopoietin-1 (Ang-1). Hydrogen 0-2 vascular endothelial growth factor A Rattus norvegicus 117-121 24939171-7 2014 H2 S-treated astrocytes increased VEGF and Ang-1 expression, and the inhibition of phosphatidylinositide 3-kinase (PI3K)/AKT signaling by LY294002 significantly reduced H2 S-induced VEGF and Ang-1 expression in astrocytes. Hydrogen 0-2 vascular endothelial growth factor A Rattus norvegicus 34-38 24939171-7 2014 H2 S-treated astrocytes increased VEGF and Ang-1 expression, and the inhibition of phosphatidylinositide 3-kinase (PI3K)/AKT signaling by LY294002 significantly reduced H2 S-induced VEGF and Ang-1 expression in astrocytes. Hydrogen 0-2 vascular endothelial growth factor A Rattus norvegicus 182-186 24939171-7 2014 H2 S-treated astrocytes increased VEGF and Ang-1 expression, and the inhibition of phosphatidylinositide 3-kinase (PI3K)/AKT signaling by LY294002 significantly reduced H2 S-induced VEGF and Ang-1 expression in astrocytes. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 138-146 vascular endothelial growth factor A Rattus norvegicus 182-186 24939171-7 2014 H2 S-treated astrocytes increased VEGF and Ang-1 expression, and the inhibition of phosphatidylinositide 3-kinase (PI3K)/AKT signaling by LY294002 significantly reduced H2 S-induced VEGF and Ang-1 expression in astrocytes. Hydrogen Sulfide 0-4 vascular endothelial growth factor A Rattus norvegicus 34-38 24939171-7 2014 H2 S-treated astrocytes increased VEGF and Ang-1 expression, and the inhibition of phosphatidylinositide 3-kinase (PI3K)/AKT signaling by LY294002 significantly reduced H2 S-induced VEGF and Ang-1 expression in astrocytes. Hydrogen Sulfide 0-4 vascular endothelial growth factor A Rattus norvegicus 182-186 25280703-5 2014 In addition, boron containing scaffold application resulted in increased bone regeneration by enhancing osteocalcin, VEGF and collagen type I protein levels in a femur defect model. Boron 13-18 vascular endothelial growth factor A Rattus norvegicus 117-121 25201493-3 2014 The present study investigated the effects of ATRA on the expression of vascular endothelial growth factor (VEGF) and hypoxia-inducible factor-1alpha (HIF-1alpha) in various glioma cell lines under normoxia and hypoxia. Tretinoin 46-50 vascular endothelial growth factor A Rattus norvegicus 72-106 25201493-3 2014 The present study investigated the effects of ATRA on the expression of vascular endothelial growth factor (VEGF) and hypoxia-inducible factor-1alpha (HIF-1alpha) in various glioma cell lines under normoxia and hypoxia. Tretinoin 46-50 vascular endothelial growth factor A Rattus norvegicus 108-112 25201493-9 2014 Following ATRA treatment, the expression of VEGF and HIF-1alpha was found to vary among the different concentration groups. Tretinoin 10-14 vascular endothelial growth factor A Rattus norvegicus 44-48 25201493-10 2014 In the glioma cells in the lower concentration groups (5 and 10 micromol/l ATRA), a significant increase in VEGF and HIF-1alpha expression was observed. Tretinoin 75-79 vascular endothelial growth factor A Rattus norvegicus 108-112 25201493-11 2014 Conversely, a significant decrease in VEGF and HIF-1alpha expression was found in the glioma cells in the high ATRA concentration group (40 micromol/l), compared with that in the cells in the control group. Tretinoin 111-115 vascular endothelial growth factor A Rattus norvegicus 38-42 32261870-6 2014 Furthermore, the addition of the copper element could stimulate the expression of angiogenic genes, including the hypoxia-inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) in rat bone marrow stem cells (BMSCs). Copper 33-39 vascular endothelial growth factor A Rattus norvegicus 163-197 32261870-6 2014 Furthermore, the addition of the copper element could stimulate the expression of angiogenic genes, including the hypoxia-inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) in rat bone marrow stem cells (BMSCs). Copper 33-39 vascular endothelial growth factor A Rattus norvegicus 199-203 25331352-0 2014 Gelatin-chondroitin-6-sulfate-hyaluronic acid scaffold seeded with vascular endothelial growth factor 165 modified hair follicle stem cells as a three-dimensional skin substitute. Chondroitin Sulfates 8-29 vascular endothelial growth factor A Rattus norvegicus 67-101 25331352-0 2014 Gelatin-chondroitin-6-sulfate-hyaluronic acid scaffold seeded with vascular endothelial growth factor 165 modified hair follicle stem cells as a three-dimensional skin substitute. Hyaluronic Acid 30-45 vascular endothelial growth factor A Rattus norvegicus 67-101 25294002-12 2014 The expression of VEGF and inflammatory factors in operative sites also suggested better results in the Sal B group than the other two groups. salvianolic acid B 104-109 vascular endothelial growth factor A Rattus norvegicus 18-22 25295523-0 2014 The suppressive effect of resveratrol on HIF-1alpha and VEGF expression after warm ischemia and reperfusion in rat liver. Resveratrol 26-37 vascular endothelial growth factor A Rattus norvegicus 56-60 25295523-2 2014 The aim of the present study was to investigate the effect of resveratrol (RES) on the expression of ischemic-induced HIF-1alpha and vascular endothelial growth factor (VEGF) in rat liver. Resveratrol 62-73 vascular endothelial growth factor A Rattus norvegicus 133-167 25295523-2 2014 The aim of the present study was to investigate the effect of resveratrol (RES) on the expression of ischemic-induced HIF-1alpha and vascular endothelial growth factor (VEGF) in rat liver. Resveratrol 62-73 vascular endothelial growth factor A Rattus norvegicus 169-173 25118612-1 2014 PURPOSE: To determine whether adiponectin could reduce microalbuminuria and provide renal protective effects by improving endothelial dysfunction and uncoupling of the glomerular vascular endothelial growth factor (VEGF)-nitric oxide (NO) axis in streptozotocin-induced type 2 diabetic rats. Nitric Oxide 221-233 vascular endothelial growth factor A Rattus norvegicus 215-219 25591158-13 2014 Nw-Nitro-L-arginine methyl ester hydrochloride blockade during reactivated colitis restored HIF-1alpha, VEGF and apelin expression. nw-nitro-l-arginine methyl ester hydrochloride 0-46 vascular endothelial growth factor A Rattus norvegicus 104-108 25016027-8 2014 We also found that several signaling pathways, including calcium-PLC-PKC-PKD1 pathway, NF-kappaB pathway, and MAP kinase (ERK, p38, and JNK) pathways are important for VEGF-A-induced TR3-TV2 and TR3-TV3 mRNA induction. Calcium 57-64 vascular endothelial growth factor A Rattus norvegicus 168-174 24803296-5 2014 The expression levels of tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6, IL-17 and vascular endothelial growth factor (VEGF) were obviously reduced in the sera of berberine-treated rats (all P<0.05). Berberine 180-189 vascular endothelial growth factor A Rattus norvegicus 100-134 24803296-5 2014 The expression levels of tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6, IL-17 and vascular endothelial growth factor (VEGF) were obviously reduced in the sera of berberine-treated rats (all P<0.05). Berberine 180-189 vascular endothelial growth factor A Rattus norvegicus 136-140 24803296-6 2014 Moreover, berberine showed marked inhibition of the expression of VEGF and CD34 (all P<0.05). Berberine 10-19 vascular endothelial growth factor A Rattus norvegicus 66-70 25118612-1 2014 PURPOSE: To determine whether adiponectin could reduce microalbuminuria and provide renal protective effects by improving endothelial dysfunction and uncoupling of the glomerular vascular endothelial growth factor (VEGF)-nitric oxide (NO) axis in streptozotocin-induced type 2 diabetic rats. Streptozocin 247-261 vascular endothelial growth factor A Rattus norvegicus 215-219 24889188-10 2014 PGE1 significantly decreased nerve growth factor (NGF) mRNA and increased vascular endothelial growth factor (VEGF) mRNA in the tibial nerve (both P < 0.01). Alprostadil 0-4 vascular endothelial growth factor A Rattus norvegicus 74-108 25192050-7 2014 LY294002 and SB203580 decreased the expression of HIF-1alpha and VEGF after HPC, whereas U0126 increased HIF-1alpha and VEGF after tGCI. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 vascular endothelial growth factor A Rattus norvegicus 65-69 25192050-7 2014 LY294002 and SB203580 decreased the expression of HIF-1alpha and VEGF after HPC, whereas U0126 increased HIF-1alpha and VEGF after tGCI. SB 203580 13-21 vascular endothelial growth factor A Rattus norvegicus 65-69 25192050-7 2014 LY294002 and SB203580 decreased the expression of HIF-1alpha and VEGF after HPC, whereas U0126 increased HIF-1alpha and VEGF after tGCI. U 0126 89-94 vascular endothelial growth factor A Rattus norvegicus 120-124 25151950-3 2014 The VEGF inhibitor used (VEGF receptor-1 (FLT-1)/Fc chimera, TRAP) decreased the concentrations of progesterone and estradiol as well as the percentage of CL and cystic structures in OHSS rats, and increased apoptosis in CL. Progesterone 99-111 vascular endothelial growth factor A Rattus norvegicus 4-8 25151950-3 2014 The VEGF inhibitor used (VEGF receptor-1 (FLT-1)/Fc chimera, TRAP) decreased the concentrations of progesterone and estradiol as well as the percentage of CL and cystic structures in OHSS rats, and increased apoptosis in CL. Progesterone 99-111 vascular endothelial growth factor A Rattus norvegicus 25-29 25151950-3 2014 The VEGF inhibitor used (VEGF receptor-1 (FLT-1)/Fc chimera, TRAP) decreased the concentrations of progesterone and estradiol as well as the percentage of CL and cystic structures in OHSS rats, and increased apoptosis in CL. Estradiol 116-125 vascular endothelial growth factor A Rattus norvegicus 4-8 25151950-3 2014 The VEGF inhibitor used (VEGF receptor-1 (FLT-1)/Fc chimera, TRAP) decreased the concentrations of progesterone and estradiol as well as the percentage of CL and cystic structures in OHSS rats, and increased apoptosis in CL. Estradiol 116-125 vascular endothelial growth factor A Rattus norvegicus 25-29 24889188-10 2014 PGE1 significantly decreased nerve growth factor (NGF) mRNA and increased vascular endothelial growth factor (VEGF) mRNA in the tibial nerve (both P < 0.01). Alprostadil 0-4 vascular endothelial growth factor A Rattus norvegicus 110-114 24889188-11 2014 In conclusion, neurological deteriorations of diabetic rats were alleviated with PGE1, which is associated with inhibition of NGF and enhancement of VEGF at the entrapment site. Alprostadil 81-85 vascular endothelial growth factor A Rattus norvegicus 149-153 24929859-8 2014 Furthermore, in MCT-treated rats, oral administration of MAG-DPA decreased NF-kappaB and p38 MAPK activation, leading to a reduction in MMP-2, MMP-9, and VEGF expression levels in lung tissue homogenates. 1-O-docosapentaenoylglycerol 57-64 vascular endothelial growth factor A Rattus norvegicus 154-158 25059824-4 2014 Treatment of rats with misoprostol, a PGE1 analog capable of activating EP receptors, enhanced phosphorylation of CREB, stimulated VEGF expression and angiogenesis, and accelerated esophageal ulcer healing. Misoprostol 23-34 vascular endothelial growth factor A Rattus norvegicus 131-135 25090631-11 2014 Peritoneal fluids VEGF level in the captopril and leuprolide acetate groups was lower than that in the control group. Captopril 36-45 vascular endothelial growth factor A Rattus norvegicus 18-22 25090631-13 2014 The serum VEGF and MCP-1 levels post treatment were significantly lower in the captopril and leuprolide acetate groups than in the control group. Captopril 79-88 vascular endothelial growth factor A Rattus norvegicus 10-14 24953608-6 2014 SB209670 treatment was more effective in reversing decreased expressions of KDR and phosphorylated AKT, downstream of VEGF angiogenic signaling, than TA-0201 treatment. 1H-Indene-2-carboxylic acid, 1-(1,3-benzodioxol-5-yl)-3-(2- (carboxymethoxy)-4-methoxyphenyl)-2,3-dihydro-5-propoxy-, (1S,2R,3S)- 0-8 vascular endothelial growth factor A Rattus norvegicus 118-122 25541842-8 2014 RESULTS: Sildenafil increased levels of Gpx, and Flt-1, and decreased MDA and VEGF levels in tissues. Sildenafil Citrate 9-19 vascular endothelial growth factor A Rattus norvegicus 78-82 25541842-9 2014 Sildenafil also increased serum levels of TAC and Flt-1 and decreased TOS, OSI, and VEGF. Sildenafil Citrate 0-10 vascular endothelial growth factor A Rattus norvegicus 84-88 28962276-3 2014 Administration of bromobenzene (10 mmol/kg body weight) to rats resulted in increased levels of liver marker enzymes, lipid peroxidation, TNF-alpha, IL-1beta and VEGF. bromobenzene 18-30 vascular endothelial growth factor A Rattus norvegicus 162-166 24933712-14 2014 Despite differential suppression of vessel dilation, macrophage recruitment, and vascular invasion, anti-VEGF and dexamethasone both down-regulated VEGF-A and IL-6 expression at 24 h with sustained effect to 7 d. They also both down regulated FGF-2 and TNF-alpha at 24 h and CCL2 at 7 d. In conclusion, anti-angiogenic treatments influence early, pre-angiogenic tissue activity such as limbal vessel dilation, inflammatory cell infiltration of the stroma, and macrophage recruitment. Dexamethasone 114-127 vascular endothelial growth factor A Rattus norvegicus 148-152 24819316-9 2014 CONCLUSIONS: Studying the different check points of the VEGF pathway, we conclude that targeting calcium pathways could be beneficial for the vascular permeability control in an OHSS animal model. Calcium 97-104 vascular endothelial growth factor A Rattus norvegicus 56-60 24945939-0 2014 Acceleration of aneurysm healing by P(DLLA-co-TMC)-coated coils enabling the controlled release of vascular endothelial growth factor. dlla-co-tmc 38-49 vascular endothelial growth factor A Rattus norvegicus 99-133 24945939-3 2014 We prepared a bioactive coil coated with poly(d,l-lactide)-7co-(1,3-trimethylene carbonate) (P(DLLA-co-TMC)), a novel copolymer for controlling the release of vascular endothelial growth factor (VEGF). poly(d,l-lactide)-7co-(1,3-trimethylene carbonate) 41-91 vascular endothelial growth factor A Rattus norvegicus 159-193 24945939-3 2014 We prepared a bioactive coil coated with poly(d,l-lactide)-7co-(1,3-trimethylene carbonate) (P(DLLA-co-TMC)), a novel copolymer for controlling the release of vascular endothelial growth factor (VEGF). poly(d,l-lactide)-7co-(1,3-trimethylene carbonate) 41-91 vascular endothelial growth factor A Rattus norvegicus 195-199 24945939-3 2014 We prepared a bioactive coil coated with poly(d,l-lactide)-7co-(1,3-trimethylene carbonate) (P(DLLA-co-TMC)), a novel copolymer for controlling the release of vascular endothelial growth factor (VEGF). dlla-co-tmc 95-106 vascular endothelial growth factor A Rattus norvegicus 159-193 24945939-3 2014 We prepared a bioactive coil coated with poly(d,l-lactide)-7co-(1,3-trimethylene carbonate) (P(DLLA-co-TMC)), a novel copolymer for controlling the release of vascular endothelial growth factor (VEGF). copolymer 118-127 vascular endothelial growth factor A Rattus norvegicus 159-193 24945939-3 2014 We prepared a bioactive coil coated with poly(d,l-lactide)-7co-(1,3-trimethylene carbonate) (P(DLLA-co-TMC)), a novel copolymer for controlling the release of vascular endothelial growth factor (VEGF). copolymer 118-127 vascular endothelial growth factor A Rattus norvegicus 195-199 24945939-5 2014 Then, recombinant human VEGF-165 (rhVEGF) was immobilized by affinity binding to heparin. Heparin 81-88 vascular endothelial growth factor A Rattus norvegicus 24-28 24945939-14 2014 Furthermore, Western blotting analysis confirmed that the major released VEGF in the aneurysm sac was from the P(DLLA-co-TMC)/VEGF-coated coil. dlla-co-tmc 113-124 vascular endothelial growth factor A Rattus norvegicus 73-77 24819316-7 2014 The Verapamil group showed the lowest corpus luteum formation, while the Parecoxib (COX-2 inhibition), the Parecoxib + Verapamil (COX-2 + Calcium inhibition), the Bevacizumab + Parecoxib (VEGF + COX-2 inhibition) and the Bevacizumab + Verapamil (VEGF + Calcium inhibition) groups were also characterized by lower corpus luteum numbers compared to the OHSS group. Verapamil 4-13 vascular endothelial growth factor A Rattus norvegicus 188-192 24819316-7 2014 The Verapamil group showed the lowest corpus luteum formation, while the Parecoxib (COX-2 inhibition), the Parecoxib + Verapamil (COX-2 + Calcium inhibition), the Bevacizumab + Parecoxib (VEGF + COX-2 inhibition) and the Bevacizumab + Verapamil (VEGF + Calcium inhibition) groups were also characterized by lower corpus luteum numbers compared to the OHSS group. Verapamil 4-13 vascular endothelial growth factor A Rattus norvegicus 246-250 24696420-11 2014 High-glucose PD fluid and uraemic circumstance resulted in the abnormal expression of TTP and the VEGF family in a PD time-dependent manner; this may lead to UFF through angiogenesis and lymphangiogenesis. Glucose 5-12 vascular endothelial growth factor A Rattus norvegicus 98-102 24482159-1 2014 This study aimed to evaluate morphometrically the bone formation and immunohistochemically the expression of vascular endothelial growth factor (VEGF) and metalloproteinase (MMP)-2 and -9 during the healing of critical-size defects treated with sintered anorganic bone (sAB). sab 270-273 vascular endothelial growth factor A Rattus norvegicus 109-143 25009646-6 2014 During DEN-induced rat liver carcinogenesis, STAT-3 protein continually activated MMP-10, VEGF, KDR, HIF-1alpha, bFGF and IL-10, and its expression was found to positively correlate with the expression of these proteins. Diethylnitrosamine 7-10 vascular endothelial growth factor A Rattus norvegicus 90-94 25130830-3 2014 The inhibitor DAPT was used to block Notch signaling pathway, and the effect of the pathway on VEGF promoting proliferation of MSC was observed. dapt 14-18 vascular endothelial growth factor A Rattus norvegicus 95-99 25130830-6 2014 The results indicated that the cells survival rate MSC in DAPT group and VEGF+DAPT group was low in each time point (24 h, 48 h, 72 h), the cell number decreased, and the cells became rounded. dapt 78-82 vascular endothelial growth factor A Rattus norvegicus 73-77 25130830-8 2014 Flk-1 mRNA level in DAPT group and VEGF+DAPT group was slightly lower, but the difference was not statistically significant (P > 0.05). dapt 40-44 vascular endothelial growth factor A Rattus norvegicus 35-39 25130830-9 2014 It is concluded that Notch signaling pathway plays an important role in promoting the proliferation of rat MSC, treated with VEGF, however, the DAPT can weaken this effect. dapt 144-148 vascular endothelial growth factor A Rattus norvegicus 125-129 25324681-0 2014 ERK1/2/COX-2/PGE2 signaling pathway mediates GPR91-dependent VEGF release in streptozotocin-induced diabetes. Dinoprostone 13-17 vascular endothelial growth factor A Rattus norvegicus 61-65 25324681-0 2014 ERK1/2/COX-2/PGE2 signaling pathway mediates GPR91-dependent VEGF release in streptozotocin-induced diabetes. Streptozocin 77-91 vascular endothelial growth factor A Rattus norvegicus 61-65 25324681-3 2014 In this study, we examined the signaling pathways involved in GPR91-dependent VEGF release during the early stages of retinal vascular change in streptozotocin-induced diabetes. Streptozocin 145-159 vascular endothelial growth factor A Rattus norvegicus 78-82 24744011-6 2014 RESULTS: Expressions of NT-3, brain-derived neurotrophic factor (BDNF), and vascular endothelial growth factor (VEGF) proteins increased significantly in the NT-3-BMSC group, and hind-limb locomotor functions improved significantly in the NT-3-BMSC group compared with the other two groups. nt-3-bmsc 158-167 vascular endothelial growth factor A Rattus norvegicus 76-110 24744011-6 2014 RESULTS: Expressions of NT-3, brain-derived neurotrophic factor (BDNF), and vascular endothelial growth factor (VEGF) proteins increased significantly in the NT-3-BMSC group, and hind-limb locomotor functions improved significantly in the NT-3-BMSC group compared with the other two groups. nt-3-bmsc 158-167 vascular endothelial growth factor A Rattus norvegicus 112-116 24744011-6 2014 RESULTS: Expressions of NT-3, brain-derived neurotrophic factor (BDNF), and vascular endothelial growth factor (VEGF) proteins increased significantly in the NT-3-BMSC group, and hind-limb locomotor functions improved significantly in the NT-3-BMSC group compared with the other two groups. nt-3-bmsc 239-248 vascular endothelial growth factor A Rattus norvegicus 112-116 23946111-8 2014 The local delivery of VEGF by injectable alginate:fibrinogen-based hydrogel induced some plasticity in the injured spinal cord involving fiber growth into the lesion site. Alginates 41-49 vascular endothelial growth factor A Rattus norvegicus 22-26 24779927-7 2014 Further investigations showed that curcumin inhibited VEGF expression in HSCs associated with disrupting platelet-derived growth factor-beta receptor (PDGF-betaR)/ERK and mTOR pathways. Curcumin 35-43 vascular endothelial growth factor A Rattus norvegicus 54-58 24610727-16 2014 VEGF analysis trended toward increased VEGF for all sildenafil-treated groups (P > 0.05). Sildenafil Citrate 52-62 vascular endothelial growth factor A Rattus norvegicus 0-4 24610727-16 2014 VEGF analysis trended toward increased VEGF for all sildenafil-treated groups (P > 0.05). Sildenafil Citrate 52-62 vascular endothelial growth factor A Rattus norvegicus 39-43 24482159-10 2014 The physical and chemical properties of sAB allow increased autocrine expression of VEGF, MMP-2 and MMP-9, favoring bone formation/remodeling with very good healing of cranial defects when compared to natural repair in the CSD-control. sab 40-43 vascular endothelial growth factor A Rattus norvegicus 84-88 25324681-13 2014 Meanwhile, COX-2, PGE2, and VEGF expression was inhibited by ERK1/2 inhibitor U0126 and COX-2 inhibitor NS-398. U 0126 78-83 vascular endothelial growth factor A Rattus norvegicus 28-32 25324681-13 2014 Meanwhile, COX-2, PGE2, and VEGF expression was inhibited by ERK1/2 inhibitor U0126 and COX-2 inhibitor NS-398. N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide 104-110 vascular endothelial growth factor A Rattus norvegicus 28-32 25324681-14 2014 CONCLUSIONS: Our data suggest that hyperglycemia causes succinate accumulation and GPR91 activity in retinal ganglion cells, which mediate VEGF-induced retinal vascular change via the ERK1/2/COX-2/PGE2 pathway. Succinic Acid 56-65 vascular endothelial growth factor A Rattus norvegicus 139-143 25324681-14 2014 CONCLUSIONS: Our data suggest that hyperglycemia causes succinate accumulation and GPR91 activity in retinal ganglion cells, which mediate VEGF-induced retinal vascular change via the ERK1/2/COX-2/PGE2 pathway. Dinoprostone 197-201 vascular endothelial growth factor A Rattus norvegicus 139-143 25050781-9 2014 Moreover, 4-HPA decreased monolayer permeability through suppressing hypertonicity and hypoxia-induced HIF-1alpha, which was mediated by inhibiting vascular endothelial growth factor (VEGF) in rat lung microvascular endothelial cell line (RLMVEC). 4-hydroxyphenylacetic acid 10-15 vascular endothelial growth factor A Rattus norvegicus 148-182 25050781-9 2014 Moreover, 4-HPA decreased monolayer permeability through suppressing hypertonicity and hypoxia-induced HIF-1alpha, which was mediated by inhibiting vascular endothelial growth factor (VEGF) in rat lung microvascular endothelial cell line (RLMVEC). 4-hydroxyphenylacetic acid 10-15 vascular endothelial growth factor A Rattus norvegicus 184-188 25075254-7 2014 We found that the expression of HIF-1alpha, VEGF, and p-Erk1/2 was significantly upregulated and peaked at 4 h after HI in DFO treated group, with higher level and earlier peak time than control group. Deferoxamine 123-126 vascular endothelial growth factor A Rattus norvegicus 44-48 25075254-9 2014 Our findings suggest that DFO might up-regulate HIF-1alpha and its target gene VEGF through Erk1/2 MAPK pathway in the developing rat brain after HI. Deferoxamine 26-29 vascular endothelial growth factor A Rattus norvegicus 79-83 24625878-5 2014 However, opposing expression patterns were observed for VEGF receptors (an increase and a decrease for VEGFR1 and VEGFR2, respectively) in FRUCT animals, with these patterns being strengthened by mineral-rich water ingestion. Water 209-214 vascular endothelial growth factor A Rattus norvegicus 56-60 24976917-3 2014 Several mechanisms have been proposed to explain the cardioprotective action of high glucose exposure, namely, up-regulation of anti-apoptotic factor Bcl-2, inactivation of pro-apoptotic factor bad, and activation of pro-survival factors such as protein kinase B (Akt), vascular endothelial growth factor (VEGF), hypoxia inducible factor-1alpha and protein kinase C-epsilon. Glucose 85-92 vascular endothelial growth factor A Rattus norvegicus 270-304 24976917-3 2014 Several mechanisms have been proposed to explain the cardioprotective action of high glucose exposure, namely, up-regulation of anti-apoptotic factor Bcl-2, inactivation of pro-apoptotic factor bad, and activation of pro-survival factors such as protein kinase B (Akt), vascular endothelial growth factor (VEGF), hypoxia inducible factor-1alpha and protein kinase C-epsilon. Glucose 85-92 vascular endothelial growth factor A Rattus norvegicus 306-310 24774750-13 2014 In comparison with saline treatment, the atorvastatin treatment did not change IL-10 expression and secretion, but it significantly decreased TNF-alpha and IL-6 level as well as VEGF gene expression. Atorvastatin 41-53 vascular endothelial growth factor A Rattus norvegicus 178-182 24680619-3 2014 Indomethacin down regulated PGE2, anti-inflammatory cytokines (IL-4, IL-10) and pro-angiogenic factors (VEGF and EGF). Indomethacin 0-12 vascular endothelial growth factor A Rattus norvegicus 80-116 24861078-11 2014 Piroxicam docked in VEGF-A binding site of VEGF-A receptors i.e., VEGFR1 and VEGFR2, while phycocyanobilin (a chromophore of C-phycocyanin) docked with VEGFR1 alone. Piroxicam 0-9 vascular endothelial growth factor A Rattus norvegicus 20-26 24917142-14 2014 SKF-525a inhibited retinal NV and reduced retinal VEGF levels in OIR rats. Proadifen 0-8 vascular endothelial growth factor A Rattus norvegicus 50-54 24709590-3 2014 We aimed to evaluate the effect of VEGF inhibition on neuronal cells in a streptozotocin-induced diabetic rat retina. Streptozocin 74-88 vascular endothelial growth factor A Rattus norvegicus 35-39 24861078-11 2014 Piroxicam docked in VEGF-A binding site of VEGF-A receptors i.e., VEGFR1 and VEGFR2, while phycocyanobilin (a chromophore of C-phycocyanin) docked with VEGFR1 alone. Piroxicam 0-9 vascular endothelial growth factor A Rattus norvegicus 43-49 24214898-7 2014 ITPP treatment restored tumor normoxia and caused a reduction in hypoxia inducible factor-1alpha levels, with subsequent VEGF and Lox downregulation, resulting in improved vessel structure and decreased desmoplasia. inositol trispyrophosphate 0-4 vascular endothelial growth factor A Rattus norvegicus 121-125 24895989-6 2014 RESULTS: UUO induced an elevation in Scr, renal hypoxia, inflammation, interstitial fibrosis, TGF-beta1, VEGF, Flk-1, and Flt-1 mRNA and protein expression levels (P < 0.05). uuo 9-12 vascular endothelial growth factor A Rattus norvegicus 105-109 24681872-0 2014 Candesartan induces a prolonged proangiogenic effect and augments endothelium-mediated neuroprotection after oxygen and glucose deprivation: role of vascular endothelial growth factors A and B. candesartan 0-11 vascular endothelial growth factor A Rattus norvegicus 149-192 24087846-11 2014 VEGF levels from the anastomotic tissue were also found lower in the celecoxib group. Celecoxib 69-78 vascular endothelial growth factor A Rattus norvegicus 0-4 24523141-2 2014 In the rat C6 glioma model, the extravasation of Evans blue (EB) through the BTB was increased significantly by VEGF and PA. Evans Blue 49-59 vascular endothelial growth factor A Rattus norvegicus 112-116 24523141-2 2014 In the rat C6 glioma model, the extravasation of Evans blue (EB) through the BTB was increased significantly by VEGF and PA. Evans Blue 61-63 vascular endothelial growth factor A Rattus norvegicus 112-116 24523141-2 2014 In the rat C6 glioma model, the extravasation of Evans blue (EB) through the BTB was increased significantly by VEGF and PA. btb 77-80 vascular endothelial growth factor A Rattus norvegicus 112-116 24523141-3 2014 VEGF-induced and PA-induced increase of EB extravasation was further increased after combining VEGF with PA infusion. Papaverine 17-19 vascular endothelial growth factor A Rattus norvegicus 95-99 24523141-3 2014 VEGF-induced and PA-induced increase of EB extravasation was further increased after combining VEGF with PA infusion. Papaverine 105-107 vascular endothelial growth factor A Rattus norvegicus 0-4 24523141-6 2014 In addition, after VEGF and PA infusion, the results of radioimmunoassay, Western blot, and enzyme-linked immunosorbent assay (ELISA) revealed a significant increase in expression levels of cGMP and protein kinase G-1 (PKG-1) and the activation of nuclear factor-kappaB (NF-kappaB) p65. Cyclic GMP 190-194 vascular endothelial growth factor A Rattus norvegicus 19-23 24523141-7 2014 This study demonstrates that combination of VEGF and PA can increase the permeability of the BTB by a paracellular pathway (downregulation of occludin and claudin-5) and a transcellular pathway (upregulation of caveolin-1 and caveolin-2) and that the cGMP/PKG/NF-kappaB signal pathway might be involved in the modulation process. btb 93-96 vascular endothelial growth factor A Rattus norvegicus 44-48 24523141-7 2014 This study demonstrates that combination of VEGF and PA can increase the permeability of the BTB by a paracellular pathway (downregulation of occludin and claudin-5) and a transcellular pathway (upregulation of caveolin-1 and caveolin-2) and that the cGMP/PKG/NF-kappaB signal pathway might be involved in the modulation process. Cyclic GMP 251-255 vascular endothelial growth factor A Rattus norvegicus 44-48 24574139-7 2014 Cell proliferation and growth factors, VEGF and IGF-I, within fracture calluses treated with local ZnCl2 were increased at day 7. zinc chloride 99-104 vascular endothelial growth factor A Rattus norvegicus 39-43 24681872-7 2014 A single candesartan dose induced a prolonged proangiogenic effect and a prolonged upregulation of VEGF-A and VEGF-B in vivo. candesartan 9-20 vascular endothelial growth factor A Rattus norvegicus 99-105 24936215-5 2014 SB also strongly upregulated vascular endothelial growth factor (VEGF), which plays a major role in neurogenesis, angiogenesis, and functional recovery after stroke. Butyric Acid 0-2 vascular endothelial growth factor A Rattus norvegicus 29-63 24920904-2 2014 Continuing a previous work published by our research group, and with the aim to overcome different limitations related to growth factor administration, VEGF and GDNF were encapsulated in poly(lactic-co-glycolic acid) nanospheres (NS). Polylactic Acid-Polyglycolic Acid Copolymer 187-216 vascular endothelial growth factor A Rattus norvegicus 152-156 24920904-3 2014 This strategy facilitates the combined administration of the VEGF and GDNF into the brain of 6-hydroxydopamine (6-OHDA) partially lesioned rats, resulting in a continuous and simultaneous drug release. Oxidopamine 93-110 vascular endothelial growth factor A Rattus norvegicus 61-65 24920904-3 2014 This strategy facilitates the combined administration of the VEGF and GDNF into the brain of 6-hydroxydopamine (6-OHDA) partially lesioned rats, resulting in a continuous and simultaneous drug release. Oxidopamine 112-118 vascular endothelial growth factor A Rattus norvegicus 61-65 24589546-10 2014 Protein expression of VEGF and phosphorylated Raf1 and ERK1/2 was also significantly increased by BMMNC treatment, but this upregulation was reversed by SU5416. Semaxinib 153-159 vascular endothelial growth factor A Rattus norvegicus 22-26 23979688-0 2014 Hydroxysafflor yellow A improves learning and memory in a rat model of vascular dementia by increasing VEGF and NR1 in the hippocampus. hydroxysafflor yellow A 0-23 vascular endothelial growth factor A Rattus norvegicus 103-107 24589546-6 2014 Contribution of the VEGF-VEGFR2 signaling pathway was confirmed by using VEGFR2 inhibitor SU5416. Semaxinib 90-96 vascular endothelial growth factor A Rattus norvegicus 20-24 24936215-5 2014 SB also strongly upregulated vascular endothelial growth factor (VEGF), which plays a major role in neurogenesis, angiogenesis, and functional recovery after stroke. Butyric Acid 0-2 vascular endothelial growth factor A Rattus norvegicus 65-69 24325631-6 2014 In in vitro study, acute brivanib alaninate incubation inhibited the transforming growth factor-beta1-induced HSCs contraction/migration and VEGF-induced LECs angiogenesis. brivanib 25-33 vascular endothelial growth factor A Rattus norvegicus 141-145 24559584-14 2014 CONCLUSIONS: COX-2 could increase VEGF-A and VEGF-C expressions in peritoneal tissue, resulting in increased formation of peritoneal microvessels and lymphatic microvessels, playing pivotal roles in the development of UFF. uff 218-221 vascular endothelial growth factor A Rattus norvegicus 34-40 24329544-0 2014 The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation. fostamatinib 39-51 vascular endothelial growth factor A Rattus norvegicus 20-24 24329544-4 2014 Here, we have assessed the mechanistic link between fostamatinib-induced BP elevation and inhibition of VEGF signalling. fostamatinib 52-64 vascular endothelial growth factor A Rattus norvegicus 104-108 24329544-15 2014 CONCLUSIONS AND IMPLICATIONS: Increased vascular resistance, secondary to reduced VEGF-induced NO release from endothelium, may contribute to BP increases observed with fostamatanib. Benzo(a)pyrene 142-144 vascular endothelial growth factor A Rattus norvegicus 82-86 24329544-15 2014 CONCLUSIONS AND IMPLICATIONS: Increased vascular resistance, secondary to reduced VEGF-induced NO release from endothelium, may contribute to BP increases observed with fostamatanib. fostamatanib 169-181 vascular endothelial growth factor A Rattus norvegicus 82-86 24820655-9 2014 Moreover, nicotinic receptor blocker inhibited VEGF expression and VEGF receptor 2 phosphorylation (p-VEGFR2) induced by ACh analog. Acetylcholine 121-124 vascular endothelial growth factor A Rattus norvegicus 47-51 24820655-9 2014 Moreover, nicotinic receptor blocker inhibited VEGF expression and VEGF receptor 2 phosphorylation (p-VEGFR2) induced by ACh analog. Acetylcholine 121-124 vascular endothelial growth factor A Rattus norvegicus 67-71 24063570-7 2014 Compared with the DW group, GTP significantly decreased portosystemic shunting, liver fibrosis, intrahepatic angiogenesis, mesenteric window vascular density, VEGF concentration and down-regulated the mesenteric HIF (hypoxia-inducible factor)-1alpha, VEGF and phospho-Akt expression. Guanosine Triphosphate 28-31 vascular endothelial growth factor A Rattus norvegicus 159-163 24063570-7 2014 Compared with the DW group, GTP significantly decreased portosystemic shunting, liver fibrosis, intrahepatic angiogenesis, mesenteric window vascular density, VEGF concentration and down-regulated the mesenteric HIF (hypoxia-inducible factor)-1alpha, VEGF and phospho-Akt expression. Guanosine Triphosphate 28-31 vascular endothelial growth factor A Rattus norvegicus 251-255 24063570-8 2014 In conclusion, GTP ameliorates the severity of portosystemic shunting and mesenteric angiogenesis via the suppression of HIF-1alpha, Akt activation and VEGF. Guanosine Triphosphate 15-18 vascular endothelial growth factor A Rattus norvegicus 152-156 24408111-5 2014 HIF-1alpha and vascular endothelial growth factor (VEGF) expression in ischemic muscle were also reduced by pioglitazone. Pioglitazone 108-120 vascular endothelial growth factor A Rattus norvegicus 15-49 24408111-5 2014 HIF-1alpha and vascular endothelial growth factor (VEGF) expression in ischemic muscle were also reduced by pioglitazone. Pioglitazone 108-120 vascular endothelial growth factor A Rattus norvegicus 51-55 24708217-7 2014 Atorvastatin treatment significantly increased VEGF-induced angiogenic responsiveness and the NO-releasing properties of cECs from all of the subgroups, compared with their respective non-treated subgroups except for the late-phase diabetic rat hearts that underwent ischemia-reperfusion, and the high dose of atorvastatin treatment groups. Atorvastatin 0-12 vascular endothelial growth factor A Rattus norvegicus 47-51 24308702-4 2014 In CMECs, extracellular Ub increased protein levels of VEGF-A and MMP-2, known angiogenesis regulators. BM 24-26 vascular endothelial growth factor A Rattus norvegicus 55-61 24765139-5 2014 Furthermore, it was found that MFH treatment downregulated the protein expression of vascular endothelial growth factor (VEGF) in the tumor tissue, as observed by immunohistochemistry. N-methyl-N-formylhydrazine 31-34 vascular endothelial growth factor A Rattus norvegicus 85-119 24765139-5 2014 Furthermore, it was found that MFH treatment downregulated the protein expression of vascular endothelial growth factor (VEGF) in the tumor tissue, as observed by immunohistochemistry. N-methyl-N-formylhydrazine 31-34 vascular endothelial growth factor A Rattus norvegicus 121-125 24759991-3 2014 In vitro, VEGF-A small interfering RNA (siRNA) and AKT inhibitor MK-2206 were employed to podocytes and NRK-52 cells cultured in high glucose (30 mM). Glucose 134-141 vascular endothelial growth factor A Rattus norvegicus 10-16 24759991-9 2014 MK-2206 enhanced VEGF-A expression in both podocytes and NRK-52E cells by inhibiting AKT activities. MK 2206 0-7 vascular endothelial growth factor A Rattus norvegicus 17-23 24694757-11 2014 The increased VEGF and TGF-b expression following PHT and HP treatment strongly indicate that PHT and HP treatment promotes VEGF and TGF-b production and action in the burn wound area. Phenytoin 50-53 vascular endothelial growth factor A Rattus norvegicus 14-18 24694757-11 2014 The increased VEGF and TGF-b expression following PHT and HP treatment strongly indicate that PHT and HP treatment promotes VEGF and TGF-b production and action in the burn wound area. Phenytoin 50-53 vascular endothelial growth factor A Rattus norvegicus 124-128 24694757-11 2014 The increased VEGF and TGF-b expression following PHT and HP treatment strongly indicate that PHT and HP treatment promotes VEGF and TGF-b production and action in the burn wound area. hypericin 58-60 vascular endothelial growth factor A Rattus norvegicus 14-18 24694757-11 2014 The increased VEGF and TGF-b expression following PHT and HP treatment strongly indicate that PHT and HP treatment promotes VEGF and TGF-b production and action in the burn wound area. hypericin 58-60 vascular endothelial growth factor A Rattus norvegicus 124-128 24694757-11 2014 The increased VEGF and TGF-b expression following PHT and HP treatment strongly indicate that PHT and HP treatment promotes VEGF and TGF-b production and action in the burn wound area. Phenytoin 94-97 vascular endothelial growth factor A Rattus norvegicus 14-18 24694757-11 2014 The increased VEGF and TGF-b expression following PHT and HP treatment strongly indicate that PHT and HP treatment promotes VEGF and TGF-b production and action in the burn wound area. Phenytoin 94-97 vascular endothelial growth factor A Rattus norvegicus 124-128 24708217-9 2014 Thus, treatment with a low dose of atorvastatin improves the angiogenic responsiveness of the cECs from normal and diabetic rats, in the presence of VEGF, via activation of eNOS-NO release. Atorvastatin 35-47 vascular endothelial growth factor A Rattus norvegicus 149-153 24480752-8 2014 Pretreatment with DMOG, a specific competitive PHD inhibitor, upregulated HIF-1alpha and VEGF expression and significantly reversed Nox4 knockdown-induced injury. dimethyloxallyl glycine 18-22 vascular endothelial growth factor A Rattus norvegicus 89-93 24507756-0 2014 Atorvastatin for ovarian torsion: effects on follicle counts, AMH, and VEGF expression. Atorvastatin 0-12 vascular endothelial growth factor A Rattus norvegicus 71-75 24507756-11 2014 RESULTS: Primordial follicles (p=0.001), VEGF-A expression (p=0.018) and vascularization (p=0.02) were significantly higher in the atorvastatin group compared to controls. Atorvastatin 131-143 vascular endothelial growth factor A Rattus norvegicus 41-47 24507756-13 2014 Primordial follicles (p=0.001), AMH (p=0.001) and VEGFA expression (p=0.001), and vascularization (p=0.001) were significantly higher in the atorvastatin+torsion group compared to the torsion group. Atorvastatin 141-153 vascular endothelial growth factor A Rattus norvegicus 50-55 24480752-10 2014 In conclusion, this study demonstrated a previously unrecognized protective role of Nox4, a ROS-generating enzyme and the major Nox isoform in CMECs, against H/R injury by inhibiting apoptosis and promoting migration and angiogenesis via a PHD2-dependent upregulation of HIF-1/VEGF proangiogenic signaling. nicotine 1-N-oxide 84-87 vascular endothelial growth factor A Rattus norvegicus 277-281 24650557-7 2014 Sitagliptin-treated diabetic rats presented a reduced pancreas Bax/Bcl2 ratio, suggestive of an antiapoptotic effect; in addition, sitagliptin was able to completely reduce (p < 0.001) the pancreas overexpression of IL-1beta and TRIB3 found in the untreated diabetic animals; and promoted a significant (p < 0.001) overexpression of VEGF and PCNA. Sitagliptin Phosphate 0-11 vascular endothelial growth factor A Rattus norvegicus 339-343 24335973-0 2014 Hydrogen sulfide attenuates sFlt1-induced hypertension and renal damage by upregulating vascular endothelial growth factor. Hydrogen Sulfide 0-16 vascular endothelial growth factor A Rattus norvegicus 88-122 24335973-6 2014 Measurement of plasma protein concentrations with ELISA revealed a reduction of free plasma sFlt1 and an increase of free plasma vascular endothelial growth factor (VEGF) after treatment with NaHS. sodium bisulfide 192-196 vascular endothelial growth factor A Rattus norvegicus 129-163 24335973-6 2014 Measurement of plasma protein concentrations with ELISA revealed a reduction of free plasma sFlt1 and an increase of free plasma vascular endothelial growth factor (VEGF) after treatment with NaHS. sodium bisulfide 192-196 vascular endothelial growth factor A Rattus norvegicus 165-169 24335973-7 2014 Renal VEGF-A mRNA expression increased significantly with NaHS treatment. sodium bisulfide 58-62 vascular endothelial growth factor A Rattus norvegicus 6-12 24335973-9 2014 Stimulation of podocytes with NaHS resulted in both short-term VEGF release (120 minutes) and upregulation of VEGF-A mRNA levels (24 hours). sodium bisulfide 30-34 vascular endothelial growth factor A Rattus norvegicus 63-67 24335973-9 2014 Stimulation of podocytes with NaHS resulted in both short-term VEGF release (120 minutes) and upregulation of VEGF-A mRNA levels (24 hours). sodium bisulfide 30-34 vascular endothelial growth factor A Rattus norvegicus 110-116 24335973-10 2014 Furthermore, pretreatment of mesenteric vessels with a VEGF receptor 2-neutralizing antibody significantly attenuated NaHS-induced vasodilation. sodium bisulfide 118-122 vascular endothelial growth factor A Rattus norvegicus 55-59 24335973-11 2014 These results suggest that hydrogen sulfide ameliorates sFlt1-induced hypertension, proteinuria, and glomerular endotheliosis in rats by increasing VEGF expression. Hydrogen Sulfide 27-43 vascular endothelial growth factor A Rattus norvegicus 148-152 24650557-7 2014 Sitagliptin-treated diabetic rats presented a reduced pancreas Bax/Bcl2 ratio, suggestive of an antiapoptotic effect; in addition, sitagliptin was able to completely reduce (p < 0.001) the pancreas overexpression of IL-1beta and TRIB3 found in the untreated diabetic animals; and promoted a significant (p < 0.001) overexpression of VEGF and PCNA. Sitagliptin Phosphate 131-142 vascular endothelial growth factor A Rattus norvegicus 339-343 24648727-0 2014 Carbon nanotubes as VEGF carriers to improve the early vascularization of porcine small intestinal submucosa in abdominal wall defect repair. Carbon 0-6 vascular endothelial growth factor A Rattus norvegicus 20-24 24623966-10 2014 In hRMVECs transfected with NOX4 siRNA and treated with VEGF or control, 1) ROS generation was measured using the 5-(and-6)-chloromethyl-2",7"-dichlorodihydrofluorescein diacetate, acetyl ester fluorescence assay and 2) phosphorylated VEGF receptor 2 and STAT3, and total VEGFR2 and STAT3 were measured in western blot analyses. Reactive Oxygen Species 76-79 vascular endothelial growth factor A Rattus norvegicus 56-60 24491567-4 2014 Thus, we investigated the pathogenic mechanism of this abnormal bone metabolism, which is included in the regulation of VEGF and MCP-1 secretions from osteoblasts, by using UMR-106 osteosarcoma cells as an osteoblast cell model and treating them with palmitate in order to mimic a state of hyperlipidemia. Palmitates 251-260 vascular endothelial growth factor A Rattus norvegicus 120-124 24491567-6 2014 Moreover, the treatment with palmitate significantly increased VEGF-A mRNA with the maximal 2.5-fold upregulation at 12h after the treatment (p<0.01). Palmitates 29-38 vascular endothelial growth factor A Rattus norvegicus 63-69 24623966-16 2014 In cultured hRMVECs, knockdown of NOX4 by siRNA transfection inhibited VEGF-induced ROS generation. Reactive Oxygen Species 84-87 vascular endothelial growth factor A Rattus norvegicus 71-75 23742256-6 2014 Anticarcinogenic potential of N2GB was reflected by its ability in the management of DEN-induced reactive oxygen species generation, mitochondrial dysfunction, p53, NF-kappaB, inducible nitric oxide synthase, COX-2 and VEGF expressions, and induction of apoptosis in cancer cells in the rat liver. ginkgolide B 32-34 vascular endothelial growth factor A Rattus norvegicus 219-223 24405730-0 2014 A potential novel strategy, inhibition of vasopressin-induced VEGF secretion by relcovaptan, for decreasing the incidence of ovarian hyperstimulation syndrome in the hyperstimulated rat model. relcovaptan 80-91 vascular endothelial growth factor A Rattus norvegicus 62-66 24405730-14 2014 CONCLUSION: Relcovaptan may be a novel strategy for decreasing risk of OHSS by inhibition of vasopressin-induced VEGF secretion through V1A receptor antagonist. relcovaptan 12-23 vascular endothelial growth factor A Rattus norvegicus 113-117 24507647-10 2014 Retinal oxygen can induce over-expression of HIF-1alpha and VEGF. Oxygen 8-14 vascular endothelial growth factor A Rattus norvegicus 60-64 24351506-10 2014 Xenon-preconditioned cells showed a significantly elevated content of VEGF (0.025 +- 0.010 IDV [integrated density values when compared with GAPDH] vs 0.003 +- 0.006 IDV in controls; P = 0.0003). Xenon 0-5 vascular endothelial growth factor A Rattus norvegicus 70-74 24351506-16 2014 In contrast to isoflurane treatment, xenon-induced preconditioning does not lead to an increase in COX-2 gene transcription but to a significant increase in HIF-1alpha and subsequently VEGF. Xenon 37-42 vascular endothelial growth factor A Rattus norvegicus 185-189 24380924-7 2014 RESULTS: In the NEC+VEGF group, tissue malondialdehyde, nitric oxide, interleukin-6, tumor necrosis factor alpha levels and caspase-3 activity were significantly decreased. Malondialdehyde 39-54 vascular endothelial growth factor A Rattus norvegicus 20-24 24380924-7 2014 RESULTS: In the NEC+VEGF group, tissue malondialdehyde, nitric oxide, interleukin-6, tumor necrosis factor alpha levels and caspase-3 activity were significantly decreased. Nitric Oxide 56-68 vascular endothelial growth factor A Rattus norvegicus 20-24 24519134-0 2014 VEGF receptor expression decreases during lung development in congenital diaphragmatic hernia induced by nitrofen. nitrofen 105-113 vascular endothelial growth factor A Rattus norvegicus 0-4 32261312-7 2014 The in vivo experiments confirmed that PEG-HM-3 decreased the number of blood vessels in rheumatic synovium, reduced the level of serum anti-CII autoantibodies, and decreased the levels of synovial TNF-alpha and VEGF in a collagen-induced arthritis (CIA) model. peg-hm-3 39-47 vascular endothelial growth factor A Rattus norvegicus 212-216 32261312-10 2014 PEG-HM-3 could significantly inhibit the TNF-alpha and VEGF levels in the LPS-stimulated macrophage and the latter effect was stronger than that seen with HM-3. peg-hm-3 0-8 vascular endothelial growth factor A Rattus norvegicus 55-59 32261312-10 2014 PEG-HM-3 could significantly inhibit the TNF-alpha and VEGF levels in the LPS-stimulated macrophage and the latter effect was stronger than that seen with HM-3. hm-3 4-8 vascular endothelial growth factor A Rattus norvegicus 55-59 24551170-13 2014 Cell loss was inhibited by TCA-induced vascular endothelial cell migration, which was mediated by TGF-beta1 and VEGF-A released from ESCC cells. Taurocholic Acid 27-30 vascular endothelial growth factor A Rattus norvegicus 112-118 24280192-0 2014 MSC-based VEGF gene therapy in rat myocardial infarction model using facial amphipathic bile acid-conjugated polyethyleneimine. Bile Acids and Salts 88-97 vascular endothelial growth factor A Rattus norvegicus 10-14 24280192-0 2014 MSC-based VEGF gene therapy in rat myocardial infarction model using facial amphipathic bile acid-conjugated polyethyleneimine. aziridine 109-126 vascular endothelial growth factor A Rattus norvegicus 10-14 24280192-4 2014 Herein, facially amphipathic bile acid-modified polyethyleneimine (BA-PEI) conjugates were synthesized and used to transfer hypoxia-inducible vascular endothelial growth factor gene (pHI-VEGF) in MSCs for the treatment of rat myocardial infarction. Bile Acids and Salts 29-38 vascular endothelial growth factor A Rattus norvegicus 187-191 24280192-4 2014 Herein, facially amphipathic bile acid-modified polyethyleneimine (BA-PEI) conjugates were synthesized and used to transfer hypoxia-inducible vascular endothelial growth factor gene (pHI-VEGF) in MSCs for the treatment of rat myocardial infarction. aziridine 48-65 vascular endothelial growth factor A Rattus norvegicus 187-191 24280192-4 2014 Herein, facially amphipathic bile acid-modified polyethyleneimine (BA-PEI) conjugates were synthesized and used to transfer hypoxia-inducible vascular endothelial growth factor gene (pHI-VEGF) in MSCs for the treatment of rat myocardial infarction. ba-pei 67-73 vascular endothelial growth factor A Rattus norvegicus 187-191 24280192-7 2014 The transplantation of MSCs genetically modified to overexpress VEGF by BA-PEI enhanced the capillary formation in the infarction region and eventually attenuated left ventricular remodeling after myocardial infarction in rats. ba-pei 72-78 vascular endothelial growth factor A Rattus norvegicus 64-68 24905317-6 2014 Finally, the influence of fluvastatin on cell migration and production of MMP-9 and VEGF was determined using a wound-healing assay and ELISA test, respectively. Fluvastatin 26-37 vascular endothelial growth factor A Rattus norvegicus 84-88 24385009-6 2014 Cysteamine enhanced the binding of STAT3 to its DNA consensus sequences at 6, 12, and 24 h after cysteamine by 1.5-, 1.8-, and 3.5-fold, respectively, and activated the expression of STAT3 target genes such as VEGF, Bcl-xL, Ref-1, and STAT3-induced feedback inhibitor, a suppressor of cytokine signaling 3. Cysteamine 0-10 vascular endothelial growth factor A Rattus norvegicus 210-214 24905317-9 2014 CONCLUSION: The inhibitory effects of fluvastatin on cell proliferation seemed to be associated with decreased p-ERK1/2 expression, upregulation of p-JNK1/2, and reduction in the MMP-9 and VEGF concentrations in culture media. Fluvastatin 38-49 vascular endothelial growth factor A Rattus norvegicus 189-193 23962064-3 2014 Vascular endothelial growth factor (VEGF) preserves lung angiogenesis and alveolarization in experimental O2-induced arrested alveolar growth in newborn rats, but combined VEGF+angiopoietin 1 treatment is necessary to correct VEGF-induced vessel leakiness. Oxygen 106-108 vascular endothelial growth factor A Rattus norvegicus 0-34 24416421-10 2014 Surprisingly, increased levels of VEGF protein were detected in overloaded muscle from losartan-treated rats. Losartan 87-95 vascular endothelial growth factor A Rattus norvegicus 34-38 23962064-3 2014 Vascular endothelial growth factor (VEGF) preserves lung angiogenesis and alveolarization in experimental O2-induced arrested alveolar growth in newborn rats, but combined VEGF+angiopoietin 1 treatment is necessary to correct VEGF-induced vessel leakiness. Oxygen 106-108 vascular endothelial growth factor A Rattus norvegicus 36-40 25572464-9 2014 Silencing VEGF-A decreased the level of c-fos and c-jun and bevacizumab and SP600125 treatment attenuated podocyte apoptosis. pyrazolanthrone 76-84 vascular endothelial growth factor A Rattus norvegicus 10-16 24200956-9 2014 Sorafenib inhibited VEGF-A-mediated signaling and angiogenesis in vivo and in vitro and improved arterial gas exchange and intrapulmonary shunting. Sorafenib 0-9 vascular endothelial growth factor A Rattus norvegicus 20-26 25572464-12 2014 With bevacizumab and SP600125 treatment, the level of VEGF-A and AP-1 decreased while bcl-2 increased. pyrazolanthrone 21-29 vascular endothelial growth factor A Rattus norvegicus 54-60 24795889-9 2014 Furthermore, naringenin and its beta-CD complex significantly inhibited the mRNA and protein expression of VEGF, COX-2, PI3K, p38MAPK, MMP-2, and MMP-9 in retina and choroid tissues. naringenin 13-23 vascular endothelial growth factor A Rattus norvegicus 107-111 25165710-11 2014 Enhanced hepatic vascular endothelial growth factor (VEGF) expression and reduced CD68 expression were found in dexmedetomidine group compared with the group 3. Dexmedetomidine 112-127 vascular endothelial growth factor A Rattus norvegicus 17-51 25165710-11 2014 Enhanced hepatic vascular endothelial growth factor (VEGF) expression and reduced CD68 expression were found in dexmedetomidine group compared with the group 3. Dexmedetomidine 112-127 vascular endothelial growth factor A Rattus norvegicus 53-57 24795889-10 2014 Naringenin/beta-CD complex showed more significant inhibitory effect on VEGF and COX-2 expression than naringenin. betadex 11-18 vascular endothelial growth factor A Rattus norvegicus 72-76 25309917-6 2014 In addition, tissue concentrations of angiogenic growth factors (such as VEGF, FGF2, and PDGF) significantly increased in L + CG group. l + cg 122-128 vascular endothelial growth factor A Rattus norvegicus 73-77 24795889-9 2014 Furthermore, naringenin and its beta-CD complex significantly inhibited the mRNA and protein expression of VEGF, COX-2, PI3K, p38MAPK, MMP-2, and MMP-9 in retina and choroid tissues. betadex 32-39 vascular endothelial growth factor A Rattus norvegicus 107-111 24795889-10 2014 Naringenin/beta-CD complex showed more significant inhibitory effect on VEGF and COX-2 expression than naringenin. naringenin 0-10 vascular endothelial growth factor A Rattus norvegicus 72-76 24490705-10 2014 Telmisartan treatment showed significant increase in VEGF-induced angiogenic responsiveness and nitric oxide releasing properties of cECs of all subgroups as compared to their respective non-treated subgroups. Telmisartan 0-11 vascular endothelial growth factor A Rattus norvegicus 53-57 24490705-12 2014 Our data suggest that telmisartan improves VEGF-induced coronary angiogenic activity in normal and diabetic rats via stimulation of PI3K/eNOS/NO pathway. Telmisartan 22-33 vascular endothelial growth factor A Rattus norvegicus 43-47 24867508-0 2014 Effect of pioglitazone on expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in ischemic hindlimb of diabetic rats. Pioglitazone 10-22 vascular endothelial growth factor A Rattus norvegicus 76-110 23886378-6 2014 The healing-impairment effect of loxoprofen was accompanied by the down-regulation of vascular endothelium- derived growth factor (VEGF) expression and angiogenic response, and these responses were all antagonized by feeding diet containing 5% MSG for 5 days after ulceration. loxoprofen 33-43 vascular endothelial growth factor A Rattus norvegicus 86-129 23886378-6 2014 The healing-impairment effect of loxoprofen was accompanied by the down-regulation of vascular endothelium- derived growth factor (VEGF) expression and angiogenic response, and these responses were all antagonized by feeding diet containing 5% MSG for 5 days after ulceration. loxoprofen 33-43 vascular endothelial growth factor A Rattus norvegicus 131-135 23886378-7 2014 It is suggested that MSG exhibits a prophylactic effect against loxoprofen-induced small intestinal lesions, this effect is functionally associated with the up-regulation of Muc2 expression/mucus secretion, resulting in suppression of enterobacterial invasion and iNOS expression, the major pathogenic events in NSAID-induced enteropathy, and MSG also has the healing promoting effect on these lesions through enhancement of VEGF expression and angiogenesis. loxoprofen 64-74 vascular endothelial growth factor A Rattus norvegicus 425-429 24867508-1 2014 OBJECTIVE: To observe effects of the drug pioglitazone on expression of hypoxia inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) in diabetic rats with hindlimb ischemia, and explore the role of pioglitazone in angiogenesis after ischemia and its possible mechanism. Pioglitazone 42-54 vascular endothelial growth factor A Rattus norvegicus 121-155 24867508-1 2014 OBJECTIVE: To observe effects of the drug pioglitazone on expression of hypoxia inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) in diabetic rats with hindlimb ischemia, and explore the role of pioglitazone in angiogenesis after ischemia and its possible mechanism. Pioglitazone 42-54 vascular endothelial growth factor A Rattus norvegicus 157-161 24867508-7 2014 The above indicators in pioglitazone-treated diabetic rats were significantly decreased (p < 0.01) with decreased expression of HIF-1alpha and VEGF (p < 0.01), while the microvessel density (MVD) of the ischemic limb was increased (p < 0.01) and blood perfusion was also increased (p < 0.01). Pioglitazone 24-36 vascular endothelial growth factor A Rattus norvegicus 146-150 24867508-11 2014 It suggested that pioglitazone may improve ischemic limb angiogenesis mechanisms correlated with regulating the HIF-1alpha/VEGF hypoxia response pathway. Pioglitazone 18-30 vascular endothelial growth factor A Rattus norvegicus 123-127 24173596-3 2014 We found that chronic alcohol consumption induced a variety of behavioral abnormalities, accompanied by severe pathological changes in cerebral arterioles, prefrontal cortex and cerebellar tissue, as well as an upregulation of vascular endothelial growth factor (VEGF), leptin receptor (ob-R) and endothelin-1 (ET-1). Alcohols 22-29 vascular endothelial growth factor A Rattus norvegicus 227-261 24963322-0 2014 Yi qi qing re gao attenuates podocyte injury and inhibits vascular endothelial growth factor overexpression in puromycin aminonucleoside rat model. Puromycin Aminonucleoside 111-136 vascular endothelial growth factor A Rattus norvegicus 58-92 24173596-3 2014 We found that chronic alcohol consumption induced a variety of behavioral abnormalities, accompanied by severe pathological changes in cerebral arterioles, prefrontal cortex and cerebellar tissue, as well as an upregulation of vascular endothelial growth factor (VEGF), leptin receptor (ob-R) and endothelin-1 (ET-1). Alcohols 22-29 vascular endothelial growth factor A Rattus norvegicus 263-267 24173596-4 2014 Treatment with mimodipine for 15 days significantly improved behavioral abnormalities, alleviated the pathological changes in blood vessels and brain tissues, increased VEGF expression, decreased ob-R expression, reduced plasma ET-1 leakage and protected vascular and neuronal functions. mimodipine 15-25 vascular endothelial growth factor A Rattus norvegicus 169-173 23646851-0 2014 Assessment of vascular endothelial growth factor and matrix metalloproteinase-9 in the periodontium of rats treated with atorvastatin. Atorvastatin 121-133 vascular endothelial growth factor A Rattus norvegicus 14-48 24314864-0 2014 Copper promotion of angiogenesis in isolated rat aortic ring: role of vascular endothelial growth factor. Copper 0-6 vascular endothelial growth factor A Rattus norvegicus 70-104 24314864-1 2014 Copper stimulation of angiogenesis at the organ system level is vascular endothelial growth factor (VEGF) dependent, but copper stimulation of vascular endothelial cell proliferation in cultures is VEGF independent. Copper 0-6 vascular endothelial growth factor A Rattus norvegicus 64-98 24314864-1 2014 Copper stimulation of angiogenesis at the organ system level is vascular endothelial growth factor (VEGF) dependent, but copper stimulation of vascular endothelial cell proliferation in cultures is VEGF independent. Copper 0-6 vascular endothelial growth factor A Rattus norvegicus 100-104 24314864-10 2014 On the other hand, the treatment with anti-VEGF antibody completely blocked the proangiogenesis effect of 5-muM copper. Copper 112-118 vascular endothelial growth factor A Rattus norvegicus 43-47 24126783-5 2014 Overexpression of IGF-1 prevented MDSCs from H2O2-induced caspase-dependent apoptotic cell death by upregulating the PI3K/AKT pathway, accompanied with an increase of NF-kappaB, p-NF-kappaB, Bcl-2, and VEGF, as well as a decrease of Bax. Hydrogen Peroxide 45-49 vascular endothelial growth factor A Rattus norvegicus 202-206 25212428-6 2014 Furthermore, IGFBP7 attenuated VEGFA-enhanced cyclooxygenase (COX)-2 mRNA expression and prostaglandin E2 secretion. Dinoprostone 89-105 vascular endothelial growth factor A Rattus norvegicus 31-36 25535647-2 2014 With hypoxic stress, vascular endothelial growth factor (VEGF) is a signal protein produced by cells and further contributes to improvement of vascular functions and restoring the oxygen supply to tissues. Oxygen 180-186 vascular endothelial growth factor A Rattus norvegicus 21-55 24239160-9 2014 Labyrinth mRNA levels of Slc38a2 were decreased and Vegfa were increased in placentas following PC EtOH-exposure but only placentas from female fetuses exhibited increased Kdr expression. Ethanol 99-103 vascular endothelial growth factor A Rattus norvegicus 52-57 25535647-2 2014 With hypoxic stress, vascular endothelial growth factor (VEGF) is a signal protein produced by cells and further contributes to improvement of vascular functions and restoring the oxygen supply to tissues. Oxygen 180-186 vascular endothelial growth factor A Rattus norvegicus 57-61 25535647-6 2014 Our results demonstrated that hypoxic stress induced by exposure of lower O(2) (6 h) significantly increased the levels of HIF-1alpha and VEGF in the oxidative and glycolytic muscles of SD rats and pikas (P<0.05 vs. normoxic conditions). Oxygen 74-78 vascular endothelial growth factor A Rattus norvegicus 138-142 24527576-18 2014 This imbalance of VEGF/NO was partly improved by rosiglitazone intervention (P < 0.05). Rosiglitazone 49-62 vascular endothelial growth factor A Rattus norvegicus 18-22 24527576-19 2014 CONCLUSION: Rosiglitazone reduces urinary albumin excretion and has renal protective effects by improving the imbalance of VEGF/NO and endothelial dysfunction in diet-induced obese rats. Rosiglitazone 12-25 vascular endothelial growth factor A Rattus norvegicus 123-127 24312656-11 2013 Increased permeability and cellular junction disruption of cultured endothelial cells caused by VEGF were also inhibited by resveratrol pretreatment. Resveratrol 124-135 vascular endothelial growth factor A Rattus norvegicus 96-100 24183749-0 2014 Effect of VEGF and CX43 on the promotion of neurological recovery by hyperbaric oxygen treatment in spinal cord-injured rats. Oxygen 80-86 vascular endothelial growth factor A Rattus norvegicus 10-14 24095833-0 2013 The herbal formula CGX ameliorates the expression of vascular endothelial growth factor in alcoholic liver fibrosis. N4-cyclopropyl-5-ethyl-6-piperidin-1-yl-pyrimidine-2,4-diamine 19-22 vascular endothelial growth factor A Rattus norvegicus 53-87 24095833-4 2013 The mRNA and protein expression levels of vascular endothelial growth factor (VEGF), one of the candidate genes selected in this study, in alcohol-induced rat livers were measured by real-time PCR and enzyme-linked immunosorbent assays, respectively. Alcohols 139-146 vascular endothelial growth factor A Rattus norvegicus 42-76 24095833-4 2013 The mRNA and protein expression levels of vascular endothelial growth factor (VEGF), one of the candidate genes selected in this study, in alcohol-induced rat livers were measured by real-time PCR and enzyme-linked immunosorbent assays, respectively. Alcohols 139-146 vascular endothelial growth factor A Rattus norvegicus 78-82 24095833-7 2013 Especially, Vegf was decreased in CGX 200 mg/kg/day-fed rat livers at all time points evaluated, and mRNA and protein levels at the 4-week time point were validated. N4-cyclopropyl-5-ethyl-6-piperidin-1-yl-pyrimidine-2,4-diamine 34-37 vascular endothelial growth factor A Rattus norvegicus 12-16 24095833-9 2013 Suppression of VEGF may play a critical role in anti-fibrotic action of CGX in alcoholic liver injury. N4-cyclopropyl-5-ethyl-6-piperidin-1-yl-pyrimidine-2,4-diamine 72-75 vascular endothelial growth factor A Rattus norvegicus 15-19 24204046-0 2013 Combination of targeted PDT and anti-VEGF therapy for rat CNV by RGD-modified liposomal photocyanine and sorafenib. photocyanine 88-100 vascular endothelial growth factor A Rattus norvegicus 37-41 24204046-0 2013 Combination of targeted PDT and anti-VEGF therapy for rat CNV by RGD-modified liposomal photocyanine and sorafenib. Sorafenib 105-114 vascular endothelial growth factor A Rattus norvegicus 37-41 24791504-9 2013 RESULT: Sophoridine could significantly increase the mechanical withdrawal threshold and the thermal withdrawal latency (P < 0.05, P < 0.01), significantly relief the bone injury caused by W256 tumor cells (P < 0.05), and notably down-regulate the COX-2 and VEGF expressions in tumor tissues (P < 0.05). matrine 8-19 vascular endothelial growth factor A Rattus norvegicus 267-271 23873112-1 2013 This study aims to investigate whether the expression of heat shock protein 90 (HSP90) is associated with the malignant pheochromocytoma (PHEO) and the effects of 17-allylamino-17-demethoxygeldanamcyin (17-AAG) on the expression of vascular endothelial growth factor (VEGF) in PHEO cell line PC12. 17-allylamino-17-demethoxygeldanamcyin 163-201 vascular endothelial growth factor A Rattus norvegicus 232-266 23873112-10 2013 17-AAG significantly downregulated VEGF-165 protein level in PC12 cells. tanespimycin 0-6 vascular endothelial growth factor A Rattus norvegicus 35-39 24076420-6 2013 High or fluctuating glucose induced BRB breakdown, and increased PLA2 activity, PGE2 and VEGF in EC/PC co-cultures; inhibition of PLA2 in mono- or co-cultures treated with high or fluctuating glucose dampened PGE2 and VEGF production down to the levels of controls. Glucose 20-27 vascular endothelial growth factor A Rattus norvegicus 89-93 24076420-6 2013 High or fluctuating glucose induced BRB breakdown, and increased PLA2 activity, PGE2 and VEGF in EC/PC co-cultures; inhibition of PLA2 in mono- or co-cultures treated with high or fluctuating glucose dampened PGE2 and VEGF production down to the levels of controls. Glucose 20-27 vascular endothelial growth factor A Rattus norvegicus 218-222 24076420-10 2013 In conclusion, the present findings indicate that PLA2 upregulation represents an early step in glucose-induced alteration of BRB, possibly upstream of VEGF; thus, PLA2 may be an interesting target in managing diabetic retinopathy. Glucose 96-103 vascular endothelial growth factor A Rattus norvegicus 152-156 24002353-9 2013 We also observed a significant increase of VEGF expression in myocardium measured by immunostaining in MI and LY333 groups compared to sham group. ruboxistaurin 110-115 vascular endothelial growth factor A Rattus norvegicus 43-47 24278109-8 2013 In the L-NAME model, several factors involved in alveolarization, VEGF, VEGF-R1 and -R2, MMP14, MMP16, FGFR3 and 4, FGF18 and 7, were significantly decreased at day 4 and/or day 10, while the various factors studied were not modified in the LPD group. NG-Nitroarginine Methyl Ester 7-13 vascular endothelial growth factor A Rattus norvegicus 66-70 24260208-5 2013 We have also shown that amitriptyline (AMI), a tricyclic antidepressant, induces the expressions of GDNF, BDNF, FGF2 and VEGF, common neurogenic factors, in primary cultured astrocytes (PCA). Amitriptyline 24-37 vascular endothelial growth factor A Rattus norvegicus 121-125 24260208-5 2013 We have also shown that amitriptyline (AMI), a tricyclic antidepressant, induces the expressions of GDNF, BDNF, FGF2 and VEGF, common neurogenic factors, in primary cultured astrocytes (PCA). Amitriptyline 39-42 vascular endothelial growth factor A Rattus norvegicus 121-125 24345508-9 2013 Compared with the control group, the anastrozole group, loureirin A group, ginsenoside Re group, and SJZTC treated group showed smaller implant volumes, as well as lower levels of VEGF and TNF-alpha in the peritoneal focus (P < 0.01 for all comparisons). Anastrozole 37-48 vascular endothelial growth factor A Rattus norvegicus 180-184 24345508-9 2013 Compared with the control group, the anastrozole group, loureirin A group, ginsenoside Re group, and SJZTC treated group showed smaller implant volumes, as well as lower levels of VEGF and TNF-alpha in the peritoneal focus (P < 0.01 for all comparisons). loureirin A 56-67 vascular endothelial growth factor A Rattus norvegicus 180-184 24345508-9 2013 Compared with the control group, the anastrozole group, loureirin A group, ginsenoside Re group, and SJZTC treated group showed smaller implant volumes, as well as lower levels of VEGF and TNF-alpha in the peritoneal focus (P < 0.01 for all comparisons). Ginsenosides 75-86 vascular endothelial growth factor A Rattus norvegicus 180-184 24345508-9 2013 Compared with the control group, the anastrozole group, loureirin A group, ginsenoside Re group, and SJZTC treated group showed smaller implant volumes, as well as lower levels of VEGF and TNF-alpha in the peritoneal focus (P < 0.01 for all comparisons). sjztc 101-106 vascular endothelial growth factor A Rattus norvegicus 180-184 23639739-5 2013 The treatment of 6-OHDA-lesioned rats with GDNF microspheres and with both VEGF and GDNF microspheres resulted in improved results in the rotation behaviour test. Oxidopamine 17-23 vascular endothelial growth factor A Rattus norvegicus 75-79 23639739-7 2013 These results were confirmed by the pronounced TH+neuron recovery in the group receiving VEGF+GDNF-MS, demonstrating regenerative effects. Thorium 47-50 vascular endothelial growth factor A Rattus norvegicus 89-101 24029661-11 2013 CONCLUSIONS: beta-Blockade promotes cardiac angiogenesis in heart failure via activation of VEGF signaling pathway. beta-blockade 13-26 vascular endothelial growth factor A Rattus norvegicus 92-96 23928877-0 2013 Elevated cell proliferation and VEGF production by high-glucose conditions in Muller cells involve XIAP. Glucose 56-63 vascular endothelial growth factor A Rattus norvegicus 32-36 23928877-2 2013 The objective of this study was to determine the potential mechanism of Muller cell proliferation and VEGF production due to high-glucose conditions. Glucose 130-137 vascular endothelial growth factor A Rattus norvegicus 102-106 23928877-5 2013 RESULTS: High concentrations of glucose-induced Muller cell proliferation and altered expression and/or phosphorylation of 47 proteins that have been identified to have key roles in several important signaling pathways (XIAP, VEGF, HIF1alpha, NFkappaB, etc) and are involved in the regulation of cell survival, proliferation, or apoptosis. Glucose 32-39 vascular endothelial growth factor A Rattus norvegicus 226-230 23543392-0 2013 Simvastatin reduces VEGF and NO levels in acute stages of experimental traumatic brain injury. Simvastatin 0-11 vascular endothelial growth factor A Rattus norvegicus 20-24 23543392-7 2013 In the T group, significant increases of VEGF levels in serum and brain tissues were noted, which were prevented with simvastatin treatment in the T + S group. Simvastatin 118-129 vascular endothelial growth factor A Rattus norvegicus 41-45 24195027-0 2013 Streptozotocin induced diabetic retinopathy in rat and the expression of vascular endothelial growth factor and its receptor. Streptozocin 0-14 vascular endothelial growth factor A Rattus norvegicus 73-107 23816753-7 2013 NP-1 augmented the inhibitory effect of VEGF/VEGFR-2 interaction on apoptosis induced by adhesion inhibition through the alphaV-integrin inhibitor cRGDfV. cyclo(arginyl-glycyl-aspartyl-phenylalanyl-valyl) 147-153 vascular endothelial growth factor A Rattus norvegicus 40-44 24022223-3 2013 Hypoxia is known to produce an enhanced angiogenic response and heightened levels of VEGF-A have been seen in oxygen deprived epithelial and endothelial cells, yet the pathways for VEGF-A signaling in BM-EPCs have not been described. Oxygen 110-116 vascular endothelial growth factor A Rattus norvegicus 85-91 24022223-5 2013 VEGF-A signaling network analysis following liquid chromatographic separation and tandem mass spectrometry revealed proteins related to inositol/calcium signaling, nitric oxide signaling, cell survival, cell migration, and inflammatory responses. Inositol 136-144 vascular endothelial growth factor A Rattus norvegicus 0-6 24022223-5 2013 VEGF-A signaling network analysis following liquid chromatographic separation and tandem mass spectrometry revealed proteins related to inositol/calcium signaling, nitric oxide signaling, cell survival, cell migration, and inflammatory responses. Calcium 145-152 vascular endothelial growth factor A Rattus norvegicus 0-6 24022223-5 2013 VEGF-A signaling network analysis following liquid chromatographic separation and tandem mass spectrometry revealed proteins related to inositol/calcium signaling, nitric oxide signaling, cell survival, cell migration, and inflammatory responses. Nitric Oxide 164-176 vascular endothelial growth factor A Rattus norvegicus 0-6 23816242-14 2013 Terminal deoxynucleotidyl transferase mediated dUPT nick end labeling (TUNEL)-positive cell count was significantly lower in groups I/R + AM and I/R + VEGF than Group I/R (P < 0.0001, P < 0.0001, respectively). dupt 47-51 vascular endothelial growth factor A Rattus norvegicus 151-155 24204851-12 2013 Furthermore, triptolide significantly reduced the expression of angiogenic activators including TNF-alpha, IL-17, VEGF, VEGFR, Ang-1, Ang-2 and Tie2, as well as suppressed the IL1-beta-induced phosphorylated of ERK, p38 and JNK at protein levels. triptolide 13-23 vascular endothelial growth factor A Rattus norvegicus 114-118 24114697-0 2013 In vivo study on the effects of curcumin on the expression profiles of anti-tumour genes (VEGF, CyclinD1 and CDK4) in liver of rats injected with DEN. Curcumin 32-40 vascular endothelial growth factor A Rattus norvegicus 90-94 23590933-9 2013 VEGF measurement by ELISA after 4d post-MI showed increased expression in DSMI group compared to DMI group. dsmi 74-78 vascular endothelial growth factor A Rattus norvegicus 0-4 23590933-9 2013 VEGF measurement by ELISA after 4d post-MI showed increased expression in DSMI group compared to DMI group. dmi 97-100 vascular endothelial growth factor A Rattus norvegicus 0-4 24157153-0 2013 Hyperbaric oxygen intervention on expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in spinal cord injury models in rats. Oxygen 11-17 vascular endothelial growth factor A Rattus norvegicus 84-118 23783073-7 2013 Inhibition of VEGF receptor tyrosine kinase (axitinib, 4 mg/kg/d, 14 d) had no effect on increased distensibility with relaxin, but caused outward hypertrophic remodeling of PAs from SHRs. Axitinib 45-53 vascular endothelial growth factor A Rattus norvegicus 14-18 23783073-9 2013 VEGF appears to be involved in remodeling of PAs, but not relaxin-induced increased distensibility. Aminosalicylic Acid 45-48 vascular endothelial growth factor A Rattus norvegicus 0-4 23900029-8 2013 Repeated administration of low-dose indomethacin impaired the ulcer healing with a decrease of VEGF expression and a further increase of endostatin expression, resulting in a marked decrease in the ratio of VEGF/endostatin expression. Indomethacin 36-48 vascular endothelial growth factor A Rattus norvegicus 95-99 23900029-8 2013 Repeated administration of low-dose indomethacin impaired the ulcer healing with a decrease of VEGF expression and a further increase of endostatin expression, resulting in a marked decrease in the ratio of VEGF/endostatin expression. Indomethacin 36-48 vascular endothelial growth factor A Rattus norvegicus 207-211 24120388-3 2013 Hence, the effect of alpha-linolenic acid (ALA), an essential fatty acid, on oxidative stress, inflammatory indices and production of vascular endothelial growth factor (VEGF) in streptozotocin-induced diabetic retinopathy indices in vivo was studied. alpha-Linolenic Acid 43-46 vascular endothelial growth factor A Rattus norvegicus 134-168 24120388-3 2013 Hence, the effect of alpha-linolenic acid (ALA), an essential fatty acid, on oxidative stress, inflammatory indices and production of vascular endothelial growth factor (VEGF) in streptozotocin-induced diabetic retinopathy indices in vivo was studied. Streptozocin 179-193 vascular endothelial growth factor A Rattus norvegicus 170-174 24120388-5 2013 RESULTS: STZ-induced diabetic rats had significantly higher levels of VEGF in the serum and retina and IL-6 in the serum, whereas BDNF was lower in the serum, all of which reverted to near normal in ALA-treated diabetic animals. Streptozocin 9-12 vascular endothelial growth factor A Rattus norvegicus 70-74 24120388-7 2013 CONCLUSIONS: STZ-induced changes in serum glutathione peroxidase, BDNF, VEGF and IL-6 that reverted to near control by ALA treatment, especially in ALA + STZ group, lending support to the concept that both oxidative stress and inflammation participate in DR and ALA treatment is of benefit in its prevention. Streptozocin 13-16 vascular endothelial growth factor A Rattus norvegicus 72-76 24120388-7 2013 CONCLUSIONS: STZ-induced changes in serum glutathione peroxidase, BDNF, VEGF and IL-6 that reverted to near control by ALA treatment, especially in ALA + STZ group, lending support to the concept that both oxidative stress and inflammation participate in DR and ALA treatment is of benefit in its prevention. alpha-Linolenic Acid 119-122 vascular endothelial growth factor A Rattus norvegicus 72-76 24114697-0 2013 In vivo study on the effects of curcumin on the expression profiles of anti-tumour genes (VEGF, CyclinD1 and CDK4) in liver of rats injected with DEN. Diethylnitrosamine 146-149 vascular endothelial growth factor A Rattus norvegicus 90-94 24114697-4 2013 Moreover, RT-PCR and Western blot analysis results showed that curcumin treatment significantly decreased liver vascular endothelial growth factor (VEGF), CyclinD1 and CDK4 mRNA expression levels and CyclinD1 and CDK4 proteins levels in liver cancer rats. Curcumin 63-71 vascular endothelial growth factor A Rattus norvegicus 112-146 24114697-4 2013 Moreover, RT-PCR and Western blot analysis results showed that curcumin treatment significantly decreased liver vascular endothelial growth factor (VEGF), CyclinD1 and CDK4 mRNA expression levels and CyclinD1 and CDK4 proteins levels in liver cancer rats. Curcumin 63-71 vascular endothelial growth factor A Rattus norvegicus 148-152 23887803-6 2013 RESULTS: A novel disubstituted furan inhibitor was selective for the SRPK family of kinases and reduced expression of pro-angiogenic but not antiangiogenic VEGF isoforms. furan 31-36 vascular endothelial growth factor A Rattus norvegicus 156-160 24065093-0 2013 Oleic acid increases synthesis and secretion of VEGF in rat vascular smooth muscle cells: role of oxidative stress and impairment in obesity. Oleic Acid 0-10 vascular endothelial growth factor A Rattus norvegicus 48-52 24065093-2 2013 Free fatty acids are involved in the pathogenesis of obesity vascular complications, and we have aimed to clarify whether oleic acid (OA) enhances VEGF synthesis/secretion in VSMC, and whether this effect is impaired in obesity. Oleic Acid 122-132 vascular endothelial growth factor A Rattus norvegicus 147-151 23714244-4 2013 To address these requirements, we developed a new post-translationally regulated hypoxia-responsible VEGF plasmid, pbeta-SP-ODD-VEGF, and a dendrimer-type bio-reducible polymer, PAM-ABP. pbeta-sp 115-123 vascular endothelial growth factor A Rattus norvegicus 128-132 23764464-4 2013 In this study, we used AG490, a specific inhibitor of the signaling pathway involving the Janus Kinase 2 (JAK2)/Signal Transducers and Activators of Transcription 3 (STAT3) signaling molecules and suramin, a potent inhibitor of vascular endothelial growth factor (VEGF), to investigate the mechanisms of SMND-309. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 23-28 vascular endothelial growth factor A Rattus norvegicus 228-262 23764464-4 2013 In this study, we used AG490, a specific inhibitor of the signaling pathway involving the Janus Kinase 2 (JAK2)/Signal Transducers and Activators of Transcription 3 (STAT3) signaling molecules and suramin, a potent inhibitor of vascular endothelial growth factor (VEGF), to investigate the mechanisms of SMND-309. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 23-28 vascular endothelial growth factor A Rattus norvegicus 264-268 23764464-6 2013 SMND-309 mitigated the effects of ischemia and reperfusion injury on brain by decreasing the infract volume, improving neurological function, increasing the survival of neurons and promoting angiogenesis by increasing the levels of erythropoietin (EPO), erythropoietin receptor (EPOR), phosphorylated JAK2 (P-JAK2), phosphorylated STAT3 (P-STAT3), VEGF and VEGF receptor 2 (Flk-1) in the brain. 2-(6-(2-carboxyvinyl)-2,3-dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)acrylic acid 0-8 vascular endothelial growth factor A Rattus norvegicus 348-352 23764464-6 2013 SMND-309 mitigated the effects of ischemia and reperfusion injury on brain by decreasing the infract volume, improving neurological function, increasing the survival of neurons and promoting angiogenesis by increasing the levels of erythropoietin (EPO), erythropoietin receptor (EPOR), phosphorylated JAK2 (P-JAK2), phosphorylated STAT3 (P-STAT3), VEGF and VEGF receptor 2 (Flk-1) in the brain. 2-(6-(2-carboxyvinyl)-2,3-dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)acrylic acid 0-8 vascular endothelial growth factor A Rattus norvegicus 357-361 23707263-10 2013 In addition, l-Glutamate and NH4Cl significantly reduced VEGF secretion. Glutamic Acid 13-24 vascular endothelial growth factor A Rattus norvegicus 57-61 23707263-10 2013 In addition, l-Glutamate and NH4Cl significantly reduced VEGF secretion. Ammonium Chloride 29-34 vascular endothelial growth factor A Rattus norvegicus 57-61 23707263-11 2013 Furthermore, inhibition of two major subtypes of LPA receptors by Ki16425 and specific siRNA for LPA receptors prevented LPA-induced VEGF secretion and ORP150 expression. 3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid 66-73 vascular endothelial growth factor A Rattus norvegicus 133-137 23707263-11 2013 Furthermore, inhibition of two major subtypes of LPA receptors by Ki16425 and specific siRNA for LPA receptors prevented LPA-induced VEGF secretion and ORP150 expression. lysophosphatidic acid 49-52 vascular endothelial growth factor A Rattus norvegicus 133-137 23707263-14 2013 Both LPA1 and LPA3 are involved in the LPA-induced VEGF secretion that is independent of Gi protein coupling but associated with the inactivation of KATP channels and inhibition of Na(+)/K(+)-ATPase activity. lysophosphatidic acid 5-8 vascular endothelial growth factor A Rattus norvegicus 51-55 23714244-5 2013 The efficacy of VEGF gene therapy with the PAM-ABP/pbeta-SP-ODD-VEGF was evaluated and compared to the RTP-VEGF plasmid, a previously constructed hypoxia-inducible plasmid, in an ischemia/reperfusion (I/R) rat model. pbeta-sp 51-59 vascular endothelial growth factor A Rattus norvegicus 16-20 23714244-5 2013 The efficacy of VEGF gene therapy with the PAM-ABP/pbeta-SP-ODD-VEGF was evaluated and compared to the RTP-VEGF plasmid, a previously constructed hypoxia-inducible plasmid, in an ischemia/reperfusion (I/R) rat model. pbeta-sp 51-59 vascular endothelial growth factor A Rattus norvegicus 64-68 23714244-5 2013 The efficacy of VEGF gene therapy with the PAM-ABP/pbeta-SP-ODD-VEGF was evaluated and compared to the RTP-VEGF plasmid, a previously constructed hypoxia-inducible plasmid, in an ischemia/reperfusion (I/R) rat model. pbeta-sp 51-59 vascular endothelial growth factor A Rattus norvegicus 64-68 23714244-7 2013 The PAM-ABP/pbeta-SP-ODD-VEGF treatment more effectively protected cardiomyocytes against apoptosis, preserved left ventricular (LV) function, and prevented LV remodeling compared to the PAM-ABP/RTP-VEGF-treated rats. pbeta-sp 12-20 vascular endothelial growth factor A Rattus norvegicus 25-29 23714244-7 2013 The PAM-ABP/pbeta-SP-ODD-VEGF treatment more effectively protected cardiomyocytes against apoptosis, preserved left ventricular (LV) function, and prevented LV remodeling compared to the PAM-ABP/RTP-VEGF-treated rats. pbeta-sp 12-20 vascular endothelial growth factor A Rattus norvegicus 199-203 23714244-8 2013 These results suggest that the pbeta-SP-ODD-VEGF with PAM-ABP may be efficacious in the treatment of acute ischemic heart disease. pbeta-sp 31-39 vascular endothelial growth factor A Rattus norvegicus 44-48 23972394-3 2013 By using a relevant ROP model, the 50/10 oxygen-induced retinopathy (OIR) model, we previously found that broad inhibition of VEGFA bioactivity using a neutralizing antibody to rat VEGF significantly reduced IVNV area compared with control IgG but also significantly reduced body weight gain in the pups, suggesting an adverse effect. Oxygen 41-47 vascular endothelial growth factor A Rattus norvegicus 126-131 23972394-3 2013 By using a relevant ROP model, the 50/10 oxygen-induced retinopathy (OIR) model, we previously found that broad inhibition of VEGFA bioactivity using a neutralizing antibody to rat VEGF significantly reduced IVNV area compared with control IgG but also significantly reduced body weight gain in the pups, suggesting an adverse effect. Oxygen 41-47 vascular endothelial growth factor A Rattus norvegicus 126-130 23951261-0 2013 Diabetes-induced superoxide anion and breakdown of the blood-retinal barrier: role of the VEGF/uPAR pathway. Superoxides 17-33 vascular endothelial growth factor A Rattus norvegicus 90-94 23951261-3 2013 The purpose of this study was to define the role of superoxide anion in VEGF/uPAR expression and BRB breakdown in diabetes. Superoxides 52-68 vascular endothelial growth factor A Rattus norvegicus 72-76 23707263-0 2013 Lysophosphatidic acid promotes secretion of VEGF by increasing expression of 150-kD Oxygen-regulated protein (ORP150) in mesenchymal stem cells. lysophosphatidic acid 0-21 vascular endothelial growth factor A Rattus norvegicus 44-48 23707263-3 2013 In this study, we examined the pharmacological and molecular regulation of VEGF secretion induced by LPA in rat MSCs. lysophosphatidic acid 101-104 vascular endothelial growth factor A Rattus norvegicus 75-79 23707263-4 2013 We showed that LPA stimulated VEGF secretion in MSCs but not in cardiomyocytes or cardiac fibroblasts. lysophosphatidic acid 15-18 vascular endothelial growth factor A Rattus norvegicus 30-34 23707263-7 2013 Inhibition of ORP150 upregulation by siRNA knockdown attenuated LPA-induced VEGF secretion. lysophosphatidic acid 64-67 vascular endothelial growth factor A Rattus norvegicus 76-80 23707263-8 2013 On the other hand, diazoxide, an activator of KATP channel, markedly inhibited LPA-induced ORP150 expression and VEGF secretion. Diazoxide 19-28 vascular endothelial growth factor A Rattus norvegicus 113-117 23707263-8 2013 On the other hand, diazoxide, an activator of KATP channel, markedly inhibited LPA-induced ORP150 expression and VEGF secretion. lysophosphatidic acid 79-82 vascular endothelial growth factor A Rattus norvegicus 113-117 23707263-9 2013 Meanwhile, ATP concentration dependently increased VEGF secretion. Adenosine Triphosphate 11-14 vascular endothelial growth factor A Rattus norvegicus 51-55 21849351-7 2013 Ketanserin (0.6 mg/kg/day) enhanced BRS, and increased capillary density, regional blood flow, and VEGF. Ketanserin 0-10 vascular endothelial growth factor A Rattus norvegicus 99-103 23172681-4 2013 In this study, we examined the molecular mechanisms by which naringenin inhibited NDEA-induced hepatocellular carcinoma in rats by analysing the expression patterns of proliferating cell nuclear antigen, Bcl-2, NF-kappaB, VEGF and MMP-2/9. naringenin 61-71 vascular endothelial growth factor A Rattus norvegicus 222-226 23172681-8 2013 Downregulation of NF-kappaB, VEGF and MMPs by naringenin seen in the present study were correlated with the inhibition of liver tumour induced by NDEA. naringenin 46-56 vascular endothelial growth factor A Rattus norvegicus 29-33 21849351-11 2013 In cultured cardiac microvascular endothelial cells, ACh stimulated the expression of VEGF, phosphorylation of VEGF receptor 2, and tube formation in a manner dependent upon alpha7-nAChR. Acetylcholine 53-56 vascular endothelial growth factor A Rattus norvegicus 86-90 21849351-11 2013 In cultured cardiac microvascular endothelial cells, ACh stimulated the expression of VEGF, phosphorylation of VEGF receptor 2, and tube formation in a manner dependent upon alpha7-nAChR. Acetylcholine 53-56 vascular endothelial growth factor A Rattus norvegicus 111-115 23859538-8 2013 Compared with PD group, the mRNA and protein expressions of TGF-beta1, alphaSMA and Collagen I were significantly downregulated in fasudil treatment groups in a dose-dependent manner, and the expression of VEGF and peritoneal MVD was also significantly downregulated in fasudil treatment groups in a dose-dependent manner. fasudil 131-138 vascular endothelial growth factor A Rattus norvegicus 206-210 23665315-8 2013 Significant amelioration of aortic and coronary wall changes, along with the restoration of elevated level of IL6, CRP, and the decreased level of VEGF compared to that of the controls were found in vitamin E-treated animals. Vitamin E 199-208 vascular endothelial growth factor A Rattus norvegicus 147-151 23563804-13 2013 This uncoupling of VEGF-NO axis was partially improved by fenofibrate. Fenofibrate 58-69 vascular endothelial growth factor A Rattus norvegicus 19-23 23563804-15 2013 The mechanism may be related to FFA-induced uncoupling of VEGF-NO axis and endothelial dysfunction. Fatty Acids, Nonesterified 32-35 vascular endothelial growth factor A Rattus norvegicus 58-62 24223382-6 2013 L-arginine significantly increased serum vascular endothelial growth factor (VEGF) concentration (353.01 +- 7.03 vs. 100.5 +- 6.61 pg/ml; P < 0.05), however, did not change myocardial capillary density. Arginine 0-10 vascular endothelial growth factor A Rattus norvegicus 41-75 24223382-6 2013 L-arginine significantly increased serum vascular endothelial growth factor (VEGF) concentration (353.01 +- 7.03 vs. 100.5 +- 6.61 pg/ml; P < 0.05), however, did not change myocardial capillary density. Arginine 0-10 vascular endothelial growth factor A Rattus norvegicus 77-81 23904909-0 2013 Cell type-specific dependency on the PI3K/Akt signaling pathway for the endogenous Epo and VEGF induction by baicalein in neurons versus astrocytes. baicalein 109-118 vascular endothelial growth factor A Rattus norvegicus 91-95 24917971-7 2013 RESULTS: In the orthotopic HCC model, GDC-0449 significantly decreased tumoral VEGF expression which was accompanied by a significant reduction of microvessel density and tumour growth. HhAntag691 38-46 vascular endothelial growth factor A Rattus norvegicus 79-83 24917971-9 2013 CONCLUSIONS: Hh inhibition with GDC-0449 downregulates tumoral VEGF production in vitro and reduces tumoral VEGF expression, angiogenesis, and tumour growth in an orthotopic HCC model. HhAntag691 32-40 vascular endothelial growth factor A Rattus norvegicus 63-67 24917971-9 2013 CONCLUSIONS: Hh inhibition with GDC-0449 downregulates tumoral VEGF production in vitro and reduces tumoral VEGF expression, angiogenesis, and tumour growth in an orthotopic HCC model. HhAntag691 32-40 vascular endothelial growth factor A Rattus norvegicus 108-112 23904909-8 2013 These results suggest distinct mechanisms of baicalein-mediated Epo/VEGF production in neurons and astrocytes for neuroprotection, and provide new insights into the mechanisms and potential of baicalein in treating brain injury in vivo. baicalein 45-54 vascular endothelial growth factor A Rattus norvegicus 68-72 23922700-13 2013 Furthermore, the up-regulation of hepatic mRNA and protein levels of VEGF, VEGFR-2 and COX-2 induced by TAA was significantly inhibited after celecoxib treatment. Celecoxib 142-151 vascular endothelial growth factor A Rattus norvegicus 69-73 23922700-16 2013 The anti-angiogenesis effect afforded by celecoxib may attribute to its modulation on VEGF/VEGFR-2 through the down-regulation of integrated signal pathways involving PGE2- HIF-1alpha- VEGF and p-ERK- c-fos- VEGFR-2. Celecoxib 41-50 vascular endothelial growth factor A Rattus norvegicus 86-90 23922700-16 2013 The anti-angiogenesis effect afforded by celecoxib may attribute to its modulation on VEGF/VEGFR-2 through the down-regulation of integrated signal pathways involving PGE2- HIF-1alpha- VEGF and p-ERK- c-fos- VEGFR-2. Celecoxib 41-50 vascular endothelial growth factor A Rattus norvegicus 91-95 23904909-2 2013 Yet, the significance and regulation of prosurvival cytokines erythropoietin (Epo) and vascular endothelial growth factor (VEGF), two transcriptional targets of HIF1alpha, in baicalein-mediated neuroprotection in neurons and astrocytes remains unknown. baicalein 175-184 vascular endothelial growth factor A Rattus norvegicus 87-121 23904909-2 2013 Yet, the significance and regulation of prosurvival cytokines erythropoietin (Epo) and vascular endothelial growth factor (VEGF), two transcriptional targets of HIF1alpha, in baicalein-mediated neuroprotection in neurons and astrocytes remains unknown. baicalein 175-184 vascular endothelial growth factor A Rattus norvegicus 123-127 23904909-4 2013 Our results show that baicalein induced Epo and VEGF expression in a HIF1alpha- and PI3K/Akt-dependent manner in neurons. baicalein 22-31 vascular endothelial growth factor A Rattus norvegicus 48-52 23904909-5 2013 Baicalein also protected neurons against excitotoxicity in a PI3K- and Epo/VEGF-dependent manner without affecting neuronal excitability. baicalein 0-9 vascular endothelial growth factor A Rattus norvegicus 75-79 23904909-6 2013 In contrast, at least a 10-fold higher concentration of baicalein was needed to induce Epo/VEGF production and PI3K/Akt activity in astrocytes for protection of neurons. baicalein 56-65 vascular endothelial growth factor A Rattus norvegicus 91-95 23904909-7 2013 Moreover, only baicalein-induced astrocytic VEGF, but not Epo expression requires HIF1alpha, while PI3K/Akt signaling had little role in baicalein-induced astrocytic Epo/VEGF expression. baicalein 15-24 vascular endothelial growth factor A Rattus norvegicus 44-48 23846802-8 2013 Ginsenoside Rg1 administration enhanced angiogenesis by increasing the expression of HIF-1 and VEGF. Ginsenosides 0-11 vascular endothelial growth factor A Rattus norvegicus 95-99 23726275-7 2013 Compared to the vehicle or VEGF treatment, DFO significantly increased neovascularization through up-regulation of HIF-1alpha and target genes including VEGF and stromal cell-derived factor-1alpha (SDF-1alpha). Deferoxamine 43-46 vascular endothelial growth factor A Rattus norvegicus 27-31 23726275-7 2013 Compared to the vehicle or VEGF treatment, DFO significantly increased neovascularization through up-regulation of HIF-1alpha and target genes including VEGF and stromal cell-derived factor-1alpha (SDF-1alpha). Deferoxamine 43-46 vascular endothelial growth factor A Rattus norvegicus 153-157 24278883-3 2013 In the present study, we investigated the effects of treadmill exercise on vascular endothelial growth factor (VEGF) expression and apoptotic cell death in the retinas of streptozotocin (STZ)-induced diabetic rats. Streptozocin 187-190 vascular endothelial growth factor A Rattus norvegicus 111-115 23867845-3 2013 To stimulate this process, heparin, a glycosaminoglycan involved in growth factor binding, was covalently bound to porous collagenous scaffolds (14%), with or without vascular endothelial growth factor (VEGF; 0.4 microg/mg scaffold), hepatocyte growth factor (HGF; 0.5 microg/mg scaffold) or a combination of VEGF + HGF (0.2 + 0.5 microg/mg scaffold). Heparin 27-34 vascular endothelial growth factor A Rattus norvegicus 203-207 23867845-3 2013 To stimulate this process, heparin, a glycosaminoglycan involved in growth factor binding, was covalently bound to porous collagenous scaffolds (14%), with or without vascular endothelial growth factor (VEGF; 0.4 microg/mg scaffold), hepatocyte growth factor (HGF; 0.5 microg/mg scaffold) or a combination of VEGF + HGF (0.2 + 0.5 microg/mg scaffold). Heparin 27-34 vascular endothelial growth factor A Rattus norvegicus 309-313 23588551-9 2013 This experimental study demonstrates that vinpocetine improves survival of random skin flaps, promotes neovascularization, and increases VEGF expression. vinpocetine 42-53 vascular endothelial growth factor A Rattus norvegicus 137-141 24344561-9 2013 Premedication with ZM323881 or L-NAME decreased the dilatory effects of VEGF. ZM323881 19-27 vascular endothelial growth factor A Rattus norvegicus 72-76 23545307-8 2013 Levels of HIF target genes (PHD2 and 3, VEGF, and PGK1) were 2-4 fold higher in hypoxic o-AQP-c than in wt-PC12 cells, and morphological changes in colony shape together with higher cell proliferation rates were observed in all o-AQP-c. Interestingly, analysis of PHD levels under normoxia revealed lower (50%) PHD3 expression in o-AQP-c than in controls. o-aqp 88-93 vascular endothelial growth factor A Rattus norvegicus 40-44 23643633-8 2013 Interestingly, urinary VEGF levels were also significantly decreased in the sulodexide-treated group. glucuronyl glucosamine glycan sulfate 76-86 vascular endothelial growth factor A Rattus norvegicus 23-27 23643633-9 2013 In accordance with UAE and urinary VEGF changes, the renal expression of profibrotic molecules was significantly decreased after sulodexide treatment. glucuronyl glucosamine glycan sulfate 129-139 vascular endothelial growth factor A Rattus norvegicus 35-39 23643633-11 2013 In cultured podocytes, sulodexide treatment significantly decreased high glucose-induced p38 MAPK activation and VEGF synthesis. glucuronyl glucosamine glycan sulfate 23-33 vascular endothelial growth factor A Rattus norvegicus 113-117 23643633-12 2013 SIGNIFICANCE: Sulodexide directly suppresses VEGF synthesis through the p38 MAPK pathway in podocytes, and these results suggest that sulodexide may provide renoprotection via suppression of renal VEGF synthesis independently of glomerular basement membrane ionic permselectivity in type 2 diabetic rats. glucuronyl glucosamine glycan sulfate 14-24 vascular endothelial growth factor A Rattus norvegicus 45-49 23643633-12 2013 SIGNIFICANCE: Sulodexide directly suppresses VEGF synthesis through the p38 MAPK pathway in podocytes, and these results suggest that sulodexide may provide renoprotection via suppression of renal VEGF synthesis independently of glomerular basement membrane ionic permselectivity in type 2 diabetic rats. glucuronyl glucosamine glycan sulfate 134-144 vascular endothelial growth factor A Rattus norvegicus 197-201 24344561-9 2013 Premedication with ZM323881 or L-NAME decreased the dilatory effects of VEGF. NG-Nitroarginine Methyl Ester 31-37 vascular endothelial growth factor A Rattus norvegicus 72-76 23411112-0 2013 Inhibition of vascular endothelial growth factor-mediated angiogenesis involved in reproductive toxicity induced by sesquiterpenoids of Curcuma zedoaria in rats. sesquiterpenoids 116-132 vascular endothelial growth factor A Rattus norvegicus 14-48 23252598-7 2013 Treatment for 30 days with (-)-epicatechin increased capillarity (P<0.001) and was associated with increases in protein expression of VEGF (vascular endothelial growth factor)-A with a concomitant decrease in TSP-1 (thrombospondin-1) and its receptor, which remained after 15 days of (-)-epicatechin cessation. Catechin 27-42 vascular endothelial growth factor A Rattus norvegicus 137-141 23252598-7 2013 Treatment for 30 days with (-)-epicatechin increased capillarity (P<0.001) and was associated with increases in protein expression of VEGF (vascular endothelial growth factor)-A with a concomitant decrease in TSP-1 (thrombospondin-1) and its receptor, which remained after 15 days of (-)-epicatechin cessation. Catechin 27-42 vascular endothelial growth factor A Rattus norvegicus 143-180 23252598-7 2013 Treatment for 30 days with (-)-epicatechin increased capillarity (P<0.001) and was associated with increases in protein expression of VEGF (vascular endothelial growth factor)-A with a concomitant decrease in TSP-1 (thrombospondin-1) and its receptor, which remained after 15 days of (-)-epicatechin cessation. Catechin 287-302 vascular endothelial growth factor A Rattus norvegicus 137-141 23536314-6 2013 Immunofluorescence staining and Western blotting demonstrated that cilostazol treatment reduced GFAP and VEGF expression in the retinas of OLETF rats. Cilostazol 67-77 vascular endothelial growth factor A Rattus norvegicus 105-109 23444047-9 2013 Up-regulation of VEGF and osteoprotegerin gene expression as well as the pro-survival effect induced by osteostatin treatment were all prevented by both SU1498 and SU6656 in these osteoblastic cells. SU 1498 153-159 vascular endothelial growth factor A Rattus norvegicus 17-21 23444047-9 2013 Up-regulation of VEGF and osteoprotegerin gene expression as well as the pro-survival effect induced by osteostatin treatment were all prevented by both SU1498 and SU6656 in these osteoblastic cells. SU 6656 164-170 vascular endothelial growth factor A Rattus norvegicus 17-21 23371355-6 2013 The percentage of VEGF positive area in US15d + ALA group was significantly higher than US15d group and US30d + ALA group was significantly higher than US30d group. Thioctic Acid 48-51 vascular endothelial growth factor A Rattus norvegicus 18-22 23371355-6 2013 The percentage of VEGF positive area in US15d + ALA group was significantly higher than US15d group and US30d + ALA group was significantly higher than US30d group. Thioctic Acid 112-115 vascular endothelial growth factor A Rattus norvegicus 18-22 23371355-8 2013 VEGF was significantly higher in US15d + ALA and US30d + ALA groups when compared to US15 and US30d groups. Thioctic Acid 41-44 vascular endothelial growth factor A Rattus norvegicus 0-4 23371355-8 2013 VEGF was significantly higher in US15d + ALA and US30d + ALA groups when compared to US15 and US30d groups. Thioctic Acid 57-60 vascular endothelial growth factor A Rattus norvegicus 0-4 23411112-7 2013 Our results suggest that the reproductive toxicity of C. zedoaria may be caused by sesquiterpenoids in the essential oil blocking VEGF-mediated angiogenesis. sesquiterpenoids 83-99 vascular endothelial growth factor A Rattus norvegicus 130-134 23350662-10 2013 Dex increased mRNA levels for hypertrophic factors (BMP-2, FGF-18) and decreased angiogenic factor secretion (VEGF-A). Dexamethasone 0-3 vascular endothelial growth factor A Rattus norvegicus 110-116 23411112-7 2013 Our results suggest that the reproductive toxicity of C. zedoaria may be caused by sesquiterpenoids in the essential oil blocking VEGF-mediated angiogenesis. Oils, Volatile 107-120 vascular endothelial growth factor A Rattus norvegicus 130-134 23460276-10 2013 In rats, overexpression of soluble fms-like tyrosine kinase-1, an endogenous VEGF inhibitor, led to adrenocortical capillary rarefaction and fall in aldosterone concentrations that correlated inversely with soluble fms-like tyrosine kinase-1 levels. Aldosterone 149-160 vascular endothelial growth factor A Rattus norvegicus 77-81 23980365-0 2013 [Effects of dioscornin tablet containing serum on NF-kappaB p65, STAT3, and VEGF mRNA expressions in rats" synovial cell strain RSC-364 induced by IL-17 and TNF-alpha]. dioscornin 12-22 vascular endothelial growth factor A Rattus norvegicus 76-80 23980365-10 2013 Compared with the model group, the NF-kappaB p65 activity, the expressions of STAT3 and VEGF mRNA decreased significantly in the DT containing serum group and the positive control group (P < 0.01, P < 0.05). Thymidine 129-131 vascular endothelial growth factor A Rattus norvegicus 88-92 23980365-12 2013 CONCLUSION: DT inhibited the VEGF mRNA expression through inhibiting the NF-kappaB p65 activity and the STAT3 protein expression in the Janus kinase (JAK)-signal transducer and activating transcription factor pathway, thus inhibiting the angiogenesis of RA. Thymidine 12-14 vascular endothelial growth factor A Rattus norvegicus 29-33 23717603-0 2013 Repair of abdominal wall defects in vitro and in vivo using VEGF sustained-release multi-walled carbon nanotubes (MWNT) composite scaffolds. Carbon 96-102 vascular endothelial growth factor A Rattus norvegicus 60-64 23717603-3 2013 Multi-walled carbon nanotubes (MWNTs) can more effectively transport VEGF to cells or tissues because of their large specific surface area and interior cavity. Carbon 13-19 vascular endothelial growth factor A Rattus norvegicus 69-73 23532625-7 2013 Moreover, either of the 2 used agents successfully alleviated the alteration in nitric oxide (NO) and vascular endothelial growth factor (VEGF) in ZnO-NPs in sera of intoxicated group. Zinc Oxide 147-150 vascular endothelial growth factor A Rattus norvegicus 102-136 23532625-7 2013 Moreover, either of the 2 used agents successfully alleviated the alteration in nitric oxide (NO) and vascular endothelial growth factor (VEGF) in ZnO-NPs in sera of intoxicated group. Zinc Oxide 147-150 vascular endothelial growth factor A Rattus norvegicus 138-142 23114998-0 2013 Mineralized poly(lactic acid) scaffolds loading vascular endothelial growth factor and the in vivo performance in rat subcutaneous model. poly(lactide) 12-29 vascular endothelial growth factor A Rattus norvegicus 48-82 23385964-0 2013 Response of vascular endothelial growth factor and angiogenesis-related genes to stepwise increases in inspired oxygen in neonatal rat lungs. Oxygen 112-118 vascular endothelial growth factor A Rattus norvegicus 12-46 23888777-5 2013 Here we have analyzed the effects of semax and its C-terminal Pro-Gly-Pro tripeptide upon Vegfa mRNA expression in different rat brain regions after common carotid artery occlusion. pro-gly-pro tripeptide 62-84 vascular endothelial growth factor A Rattus norvegicus 90-95 22213124-12 2013 5-LOX plays an important role in DMBA-induced inflammation associated carcinogenesis via activation of MMP-2 and VEGF. 6,11-dimethylbenzo(b)naphtho(2,3-d)thiophene 33-37 vascular endothelial growth factor A Rattus norvegicus 113-117 23471892-8 2013 In addition, VEGF expression was immunolocalized in cells of the ganglion cell layer of the IR and this expression significantly increased in the PA group from PND15 on. Protactinium 146-148 vascular endothelial growth factor A Rattus norvegicus 13-17 23522997-7 2013 Udenafil had no statistical significance on increasing nNOS expression, but enhanced VEGF expression. udenafil 0-8 vascular endothelial growth factor A Rattus norvegicus 85-89 23522997-9 2013 AB/udenafil treatment significantly increased nNOS expression, VEGF expression, and elevated cGMP level, compared with the udenafil group and AB group. udenafil 3-11 vascular endothelial growth factor A Rattus norvegicus 63-67 23719521-9 2013 Compared with the DN group, the pathological changes were relieved, the 24 h urinary protein excretion, urine NAGase and serum creatinine level were decreased, and the expressions of HIF-1alpha and VEGF decreased in the CS group (all P<0.05), but they were still higher than those in the normal contral group (P<0.05). dn 18-20 vascular endothelial growth factor A Rattus norvegicus 198-202 23719521-9 2013 Compared with the DN group, the pathological changes were relieved, the 24 h urinary protein excretion, urine NAGase and serum creatinine level were decreased, and the expressions of HIF-1alpha and VEGF decreased in the CS group (all P<0.05), but they were still higher than those in the normal contral group (P<0.05). Cesium 220-222 vascular endothelial growth factor A Rattus norvegicus 198-202 23637830-7 2013 However, PEMF stimulation attenuated the development of the abnormalities observed in STZ-treated rats with DPN, which were demonstrated by increased hind paw withdrawal threshold to mechanical and thermal stimuli, slighter demyelination and axon enlargement and less VEGF immunostaining of sciatic nerve compared to those of the DM group. Streptozocin 86-89 vascular endothelial growth factor A Rattus norvegicus 268-272 23637907-10 2013 All of these effects of diosmin were associated with increased zonular occluden-1 (ZO-1) and occludin protein expression and decreased VEGF/PEDF ratio. Diosmin 24-31 vascular endothelial growth factor A Rattus norvegicus 135-139 23637830-7 2013 However, PEMF stimulation attenuated the development of the abnormalities observed in STZ-treated rats with DPN, which were demonstrated by increased hind paw withdrawal threshold to mechanical and thermal stimuli, slighter demyelination and axon enlargement and less VEGF immunostaining of sciatic nerve compared to those of the DM group. dpn 108-111 vascular endothelial growth factor A Rattus norvegicus 268-272 23066786-6 2013 Uric acid (UA), a PN scavenger, and 5,10,15,20-Tetrakis (4-sulfonatophenyl) porphyrinato Iron III Chloride (FeTPPS), a PN decomposition catalyst, suppressed Wnt signaling and ICAM-1 and VEGF overexpression induced by PN, HNE, and HG. 5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrinato iron(III) chloride 36-106 vascular endothelial growth factor A Rattus norvegicus 186-190 23417865-4 2013 Therefore, the purpose of this study was to determine whether AICAR (5-aminoimidazole-4-carboxamide-3-ribonucleoside), a potent AMPK stimulator, would increase circulating VEGF, improve angiogenic potential, decrease oxidative stress, and abrogate placental ischemia-induced hypertension. acadesine 62-67 vascular endothelial growth factor A Rattus norvegicus 172-176 23417865-4 2013 Therefore, the purpose of this study was to determine whether AICAR (5-aminoimidazole-4-carboxamide-3-ribonucleoside), a potent AMPK stimulator, would increase circulating VEGF, improve angiogenic potential, decrease oxidative stress, and abrogate placental ischemia-induced hypertension. 5-aminoimidazole-4-carboxamide-3-ribonucleoside 69-116 vascular endothelial growth factor A Rattus norvegicus 172-176 23066786-8 2013 In streptozotocin-induced diabetic rats, retinal levels of 3-NT, beta-catenin, nuclear beta-catenin, pLRP6, VEGF, and ICAM-1 were markedly increased. Streptozocin 3-17 vascular endothelial growth factor A Rattus norvegicus 108-112 23043394-9 2013 The AaPO2 (alveolar-arterial O2 gradient) and plasma VEGF levels were reduced after sorafenib treatment [AaPO2, 7.2+-3.4 mmHg in sorafenib-treated rats compared with 15.3+-4.2 mmHg in controls (P=0.004); VEGF, 45.3+-2.7 pg/ml in sorafenib-treated rats compared with 54.4+-7.7 pg/ml in controls (P=0.021)]. Sorafenib 84-93 vascular endothelial growth factor A Rattus norvegicus 204-208 23043394-10 2013 Sorafenib attenuated pulmonary VEGF mRNA and VEGF, VEGFR-2 (VEGF receptor 2), phospho-VEGFR-2 and Akt protein expression. Sorafenib 0-9 vascular endothelial growth factor A Rattus norvegicus 31-35 23043394-9 2013 The AaPO2 (alveolar-arterial O2 gradient) and plasma VEGF levels were reduced after sorafenib treatment [AaPO2, 7.2+-3.4 mmHg in sorafenib-treated rats compared with 15.3+-4.2 mmHg in controls (P=0.004); VEGF, 45.3+-2.7 pg/ml in sorafenib-treated rats compared with 54.4+-7.7 pg/ml in controls (P=0.021)]. Sorafenib 84-93 vascular endothelial growth factor A Rattus norvegicus 53-57 23043394-10 2013 Sorafenib attenuated pulmonary VEGF mRNA and VEGF, VEGFR-2 (VEGF receptor 2), phospho-VEGFR-2 and Akt protein expression. Sorafenib 0-9 vascular endothelial growth factor A Rattus norvegicus 45-49 23379999-1 2013 Recent research using a rat oxygen-induced retinopathy model has demonstrated that the G protein-coupled receptor 91 (GPR91) of retinal ganglion neurons is the principal respondent to succinate and consequently induces the release of angiogenic factor vascular endothelial growth factor (VEGF). Oxygen 28-34 vascular endothelial growth factor A Rattus norvegicus 288-292 23456363-2 2013 Because these isoflavones have estrogenic properties, we hypothesized that, like estrogens, they would inhibit acute vascular injury and the detrimental acute increase in hypoxia-induced vascular endothelial growth factor (VEGF) that leads to cerebral edema after stroke. Isoflavones 14-25 vascular endothelial growth factor A Rattus norvegicus 187-221 23456363-2 2013 Because these isoflavones have estrogenic properties, we hypothesized that, like estrogens, they would inhibit acute vascular injury and the detrimental acute increase in hypoxia-induced vascular endothelial growth factor (VEGF) that leads to cerebral edema after stroke. Isoflavones 14-25 vascular endothelial growth factor A Rattus norvegicus 223-227 23379999-1 2013 Recent research using a rat oxygen-induced retinopathy model has demonstrated that the G protein-coupled receptor 91 (GPR91) of retinal ganglion neurons is the principal respondent to succinate and consequently induces the release of angiogenic factor vascular endothelial growth factor (VEGF). Succinic Acid 184-193 vascular endothelial growth factor A Rattus norvegicus 288-292 23590952-3 2013 The aims of this study were to examine the effects of maternal retinoic acid treatment on lung VEGF expression and angiogenesis in oligohydramnios-exposed fetal rats. Tretinoin 63-76 vascular endothelial growth factor A Rattus norvegicus 95-99 23541263-14 2013 Compared with the control group, atorvastatin treatment improved skin flap blood perfusion, vascular density, and necrotic area dependent on VEGF mRNA expression. Atorvastatin 33-45 vascular endothelial growth factor A Rattus norvegicus 141-145 23340020-0 2013 Vasoactive intestinal peptide increases VEGF expression to promote proliferation of brain vascular endothelial cells via the cAMP/PKA pathway after ischemic insult in vitro. Cyclic AMP 125-129 vascular endothelial growth factor A Rattus norvegicus 40-44 23340020-10 2013 These data suggest that treatment with VIP promotes VEGF-mediated endothelial cell proliferation after ischemic insult in vitro, and this effect appears to be initiated by the VPAC receptors leading to activation of the cAMP/PKA pathway. Cyclic AMP 220-224 vascular endothelial growth factor A Rattus norvegicus 52-56 22886508-6 2013 The 48-week CDAA diet exacerbated liver cirrhosis, and developed hepatocellular carcinoma (HCC) in 54.6 % of the rats concurrently with increases of hypoxia-inducible factor-1alpha (HIF-1alpha) protein and vascular endothelial growth factor (VEGF) mRNA, which are potent angiogenic factors in the liver. CDAA 12-16 vascular endothelial growth factor A Rattus norvegicus 206-240 22886508-6 2013 The 48-week CDAA diet exacerbated liver cirrhosis, and developed hepatocellular carcinoma (HCC) in 54.6 % of the rats concurrently with increases of hypoxia-inducible factor-1alpha (HIF-1alpha) protein and vascular endothelial growth factor (VEGF) mRNA, which are potent angiogenic factors in the liver. CDAA 12-16 vascular endothelial growth factor A Rattus norvegicus 242-246 22886508-7 2013 Telmisartan inhibited hepatic fibrosis and preneoplastic lesions and prevented the development of HCC along with inducing decreases in HIF-1alpha protein and VEGF mRNA. Telmisartan 0-11 vascular endothelial growth factor A Rattus norvegicus 158-162 23590952-1 2013 BACKGROUND: All-trans retinoic acid (ATRA) induces in vitro angiogenesis and vascular endothelial growth factor (VEGF) secretion. Tretinoin 12-35 vascular endothelial growth factor A Rattus norvegicus 77-111 23590952-1 2013 BACKGROUND: All-trans retinoic acid (ATRA) induces in vitro angiogenesis and vascular endothelial growth factor (VEGF) secretion. Tretinoin 12-35 vascular endothelial growth factor A Rattus norvegicus 113-117 23590952-1 2013 BACKGROUND: All-trans retinoic acid (ATRA) induces in vitro angiogenesis and vascular endothelial growth factor (VEGF) secretion. Tretinoin 37-41 vascular endothelial growth factor A Rattus norvegicus 77-111 23590952-1 2013 BACKGROUND: All-trans retinoic acid (ATRA) induces in vitro angiogenesis and vascular endothelial growth factor (VEGF) secretion. Tretinoin 37-41 vascular endothelial growth factor A Rattus norvegicus 113-117 23253439-7 2013 More recent studies have found a central role for VEGF in vascular lesion formation in DR and proposed blockage of VEGF as an effective approach to manage DR. Atorvastatin, a 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitor, has been proven to decrease VEGF production of MSCs under hypoxic conditions. Atorvastatin 159-171 vascular endothelial growth factor A Rattus norvegicus 115-119 23253439-7 2013 More recent studies have found a central role for VEGF in vascular lesion formation in DR and proposed blockage of VEGF as an effective approach to manage DR. Atorvastatin, a 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitor, has been proven to decrease VEGF production of MSCs under hypoxic conditions. Atorvastatin 159-171 vascular endothelial growth factor A Rattus norvegicus 50-54 23253439-7 2013 More recent studies have found a central role for VEGF in vascular lesion formation in DR and proposed blockage of VEGF as an effective approach to manage DR. Atorvastatin, a 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitor, has been proven to decrease VEGF production of MSCs under hypoxic conditions. Atorvastatin 159-171 vascular endothelial growth factor A Rattus norvegicus 115-119 23926451-8 2013 Based on Nissl and iron staining, a single VEGF injection reduced the injury score, compared to the animals that underwent MCAO and PBS injection. Iron 19-23 vascular endothelial growth factor A Rattus norvegicus 43-47 23847952-6 2013 RESULT: Sapindus saponins reduced LVMI, and blocked the expression level of Ang II, AT1R, p-p38MAPK, VEGF and hs-CRP in myocardial tissue. Saponins 17-25 vascular endothelial growth factor A Rattus norvegicus 101-105 23269647-7 2013 VEGF-induced RhoA activation was prevented by disrupting caveolae with cholesterol depletion and rescued by cholesterol repletion. Cholesterol 71-82 vascular endothelial growth factor A Rattus norvegicus 0-4 23269647-7 2013 VEGF-induced RhoA activation was prevented by disrupting caveolae with cholesterol depletion and rescued by cholesterol repletion. Cholesterol 108-119 vascular endothelial growth factor A Rattus norvegicus 0-4 23253439-10 2013 It could be hypothesized that co-administration of MSCs with atorvastatin may be a significant step forward in development of an efficient MSC therapy of DR through preventing excess VEGF production by MSCs under hypoxic conditions as well as increasing the viability and homing of transplanted MSCs. Atorvastatin 61-73 vascular endothelial growth factor A Rattus norvegicus 183-187 23139358-7 2013 RESULTS: Western blot analysis showed that rosuvastatin could change the cytokine expressions in the peri-infarction region by upregulating the SDF-1 expression and downregulating the expressions of CXCR-4, ICAM-1, and VEGF in 4 to 14 days after AMI. Rosuvastatin Calcium 43-55 vascular endothelial growth factor A Rattus norvegicus 219-223 23426508-5 2013 Hematoxylin-eosin staining revealed a marked increase in uterine eosinophilic infiltrations in ovariectomized rats treated with E2, E2+P4 or P4, which was associated with increased expression of vascular endothelial growth factor (VEGF), nuclear factor-kappaB (NF-kappaB), and tumor necrosis factor-alpha (TNF-alpha) proteins as determined by immunohistochemical and Western blot analysis. Eosine Yellowish-(YS) 12-17 vascular endothelial growth factor A Rattus norvegicus 195-229 23426142-0 2013 Effect of thalidomide on the expression of vascular endothelial growth factor in a rat model of liver regeneration. Thalidomide 10-21 vascular endothelial growth factor A Rattus norvegicus 43-77 23426142-2 2013 The present study investigated the influence of thalidomide, an antiangiogenic agent, on vascular endothelial growth factor (VEGF) expression and liver regeneration after 70% partial hepatectomy (PH) in rats. Thalidomide 48-59 vascular endothelial growth factor A Rattus norvegicus 89-123 23426142-2 2013 The present study investigated the influence of thalidomide, an antiangiogenic agent, on vascular endothelial growth factor (VEGF) expression and liver regeneration after 70% partial hepatectomy (PH) in rats. Thalidomide 48-59 vascular endothelial growth factor A Rattus norvegicus 125-129 23426142-10 2013 The immunohistochemical staining revealed a waved pattern of VEGF expression which advanced from the periportal to pericentral area in both groups, but a slower advancement was detected in thalidomide-treated rats. Thalidomide 189-200 vascular endothelial growth factor A Rattus norvegicus 61-65 22791702-6 2013 Aliskiren treatment also improved albumin levels in plasma, suppressed profibrotic and proinflammatory cytokine synthesis viz TNF-alpha and TGF-beta and angiogenesis by a decrease in VEGF. aliskiren 0-9 vascular endothelial growth factor A Rattus norvegicus 183-187 23267795-10 2013 Under CoCl(2)-mimicking hypoxic conditions, the expression of VEGF and p65 increased. cobaltous chloride 6-13 vascular endothelial growth factor A Rattus norvegicus 62-66 23267795-14 2013 CONCLUSION: The protective effects of atRA against hypoxia-induced injury might be involved in suppression of VEGF expression via stimulating Scpep1 distinct pathways and inhibiting the NFkappaB pathway. Tretinoin 38-42 vascular endothelial growth factor A Rattus norvegicus 110-114 23426508-5 2013 Hematoxylin-eosin staining revealed a marked increase in uterine eosinophilic infiltrations in ovariectomized rats treated with E2, E2+P4 or P4, which was associated with increased expression of vascular endothelial growth factor (VEGF), nuclear factor-kappaB (NF-kappaB), and tumor necrosis factor-alpha (TNF-alpha) proteins as determined by immunohistochemical and Western blot analysis. Hematoxylin 0-11 vascular endothelial growth factor A Rattus norvegicus 195-229 23426508-5 2013 Hematoxylin-eosin staining revealed a marked increase in uterine eosinophilic infiltrations in ovariectomized rats treated with E2, E2+P4 or P4, which was associated with increased expression of vascular endothelial growth factor (VEGF), nuclear factor-kappaB (NF-kappaB), and tumor necrosis factor-alpha (TNF-alpha) proteins as determined by immunohistochemical and Western blot analysis. Hematoxylin 0-11 vascular endothelial growth factor A Rattus norvegicus 231-235 21704393-2 2013 This study tested the hypothesis that norepinephrine (NE) induces CTGF and VEGF gene and protein expression in cardiac fibroblasts (CF) and the CTGF/VEGF complex will have an effect on angiogenesis. Norepinephrine 38-52 vascular endothelial growth factor A Rattus norvegicus 75-79 23211559-10 2013 Treatment with estradiol also increased HIF-1alpha and VEGF protein levels in the ischemic ipsilateral SVZ at all time points examined (P<0.05). Estradiol 15-24 vascular endothelial growth factor A Rattus norvegicus 55-59 23211559-11 2013 These findings indicate that post-stroke estradiol administration promotes SVZ neurogenesis in rats, probably by increasing HIF-1alpha and VEGF protein expression. Estradiol 41-50 vascular endothelial growth factor A Rattus norvegicus 139-143 23088455-6 2013 The accumulation of reactive oxygen species and the over-expression of superoxide dismutase (SOD-1), a decrease in the levels of vascular endothelial growth factor (VEGF) and its receptors, an inhibition of the angiopoietin pathway and an increase of thrombospondin-1 (TSP-1), as an anti-angiogenic factor were showed. Reactive Oxygen Species 20-43 vascular endothelial growth factor A Rattus norvegicus 165-169 23088455-7 2013 Administration of astaxanthin attenuated the changes in SOD-1 and VEGF, up-regulated the angiogenic factors and reduced the capillary regression in the soleus of hindlimb unloaded rats. astaxanthine 18-29 vascular endothelial growth factor A Rattus norvegicus 66-70 23088455-8 2013 In addition, the VEGF-to-TSP1 ratio was higher in the astaxanthin treated groups than in the control and HU groups. astaxanthine 54-65 vascular endothelial growth factor A Rattus norvegicus 17-21 23004355-0 2013 Silibinin inhibits VEGF secretion and age-related macular degeneration in a hypoxia-dependent manner through the PI-3 kinase/Akt/mTOR pathway. Silybin 0-9 vascular endothelial growth factor A Rattus norvegicus 19-23 23229928-0 2013 Sirolimus reduces vasculopathy but exacerbates proteinuria in association with inhibition of VEGF and VEGFR in a rat kidney model of chronic allograft dysfunction. Sirolimus 0-9 vascular endothelial growth factor A Rattus norvegicus 93-97 23004355-7 2013 KEY RESULTS: Silibinin pretreatment of RPE cells increased proline hydroxylase-2 expression, inhibited HIF-1alpha subunit accumulation, and inhibited VEGF secretion. Silybin 13-22 vascular endothelial growth factor A Rattus norvegicus 150-154 23004355-9 2013 In the rat model of AMD, silibinin administration prevented VEGF- and VEGF plus hypoxia-induced retinal oedema and neovascularization. Silybin 25-34 vascular endothelial growth factor A Rattus norvegicus 60-64 23004355-9 2013 In the rat model of AMD, silibinin administration prevented VEGF- and VEGF plus hypoxia-induced retinal oedema and neovascularization. Silybin 25-34 vascular endothelial growth factor A Rattus norvegicus 70-74 22772900-0 2013 Effect of semax and its C-terminal fragment Pro-Gly-Pro on the expression of VEGF family genes and their receptors in experimental focal ischemia of the rat brain. Proline 44-48 vascular endothelial growth factor A Rattus norvegicus 77-81 22772900-0 2013 Effect of semax and its C-terminal fragment Pro-Gly-Pro on the expression of VEGF family genes and their receptors in experimental focal ischemia of the rat brain. glycylproline 48-55 vascular endothelial growth factor A Rattus norvegicus 77-81 22772900-3 2013 We studied the action of Semax and its C-terminal tripeptide Pro-Gly-Pro on the expression of the VEGF gene family (Vegf-a, Vegf-b, Vegf-c, Vegf-d, and Plgf) and their receptors (Vegfr-1, Vegfr-2, and Vegfr-3) in the frontoparietal cortex region of the rat brain at 3, 24, and 72 h after permanent left middle cerebral artery occlusion (pMCAO). prolyl-glycyl-proline 61-72 vascular endothelial growth factor A Rattus norvegicus 98-102 23229928-10 2013 Significantly diminished expression of VEGF and VEGFR mRNA and protein was evident in the sirolimus group. Sirolimus 90-99 vascular endothelial growth factor A Rattus norvegicus 39-43 23229928-11 2013 In vitro, sirolimus reduced VEGF production by podocytes (P < 0.05) and inhibited VEGF-induced proliferation of podocytes, endothelial and mesangial cells. Sirolimus 10-19 vascular endothelial growth factor A Rattus norvegicus 28-32 23229928-11 2013 In vitro, sirolimus reduced VEGF production by podocytes (P < 0.05) and inhibited VEGF-induced proliferation of podocytes, endothelial and mesangial cells. Sirolimus 10-19 vascular endothelial growth factor A Rattus norvegicus 85-89 23229928-13 2013 Sirolimus exhibits greater protection against vasculopathy but induces proteinuria; effects are likely to be related to inhibition of VEGF signalling. Sirolimus 0-9 vascular endothelial growth factor A Rattus norvegicus 134-138 23137544-5 2013 Daily administration of ethyl pyruvate, which inhibited HMGB1 expression, reduced the recovery of neurological function, decreased vascular endothelial growth factor (VEGF) and nerve growth factor (NGF) levels in the ipsilateral striatum, and decreased the numbers of 5-bromo-2-deoxyuridine (BrdU)- and doublecortin (DCX)-positive cells around the hematoma. ethyl pyruvate 24-38 vascular endothelial growth factor A Rattus norvegicus 131-165 23137544-5 2013 Daily administration of ethyl pyruvate, which inhibited HMGB1 expression, reduced the recovery of neurological function, decreased vascular endothelial growth factor (VEGF) and nerve growth factor (NGF) levels in the ipsilateral striatum, and decreased the numbers of 5-bromo-2-deoxyuridine (BrdU)- and doublecortin (DCX)-positive cells around the hematoma. ethyl pyruvate 24-38 vascular endothelial growth factor A Rattus norvegicus 167-171 22814223-1 2013 The potential of poly(lactic-co-glycolic) acid (PLGA) microparticles as carriers for vascular endothelial growth factor (VEGF) has been demonstrated in a previous study by our group, where we found improved angiogenesis and heart remodeling in a rat myocardial infarction model (Formiga et al., 2010). Polylactic Acid-Polyglycolic Acid Copolymer 17-46 vascular endothelial growth factor A Rattus norvegicus 85-119 22814223-1 2013 The potential of poly(lactic-co-glycolic) acid (PLGA) microparticles as carriers for vascular endothelial growth factor (VEGF) has been demonstrated in a previous study by our group, where we found improved angiogenesis and heart remodeling in a rat myocardial infarction model (Formiga et al., 2010). Polylactic Acid-Polyglycolic Acid Copolymer 17-46 vascular endothelial growth factor A Rattus norvegicus 121-125 23065129-8 2013 Furthermore, the oxygen sensor hypoxia-inducible factor (HIF)-1/2alpha and the angiogenic factor vascular endothelial growth factor (VEGF) were highly expressed in the lungs of sildenafil-treated rats. Sildenafil Citrate 177-187 vascular endothelial growth factor A Rattus norvegicus 133-137 24457640-2 2013 Oxygen-glucose deprivation (OGD) can induce astrocyte proliferation by increasing hypoxia-inducible factor alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF). oxygen-glucose 0-14 vascular endothelial growth factor A Rattus norvegicus 130-164 24457640-2 2013 Oxygen-glucose deprivation (OGD) can induce astrocyte proliferation by increasing hypoxia-inducible factor alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF). oxygen-glucose 0-14 vascular endothelial growth factor A Rattus norvegicus 166-170 23317887-0 2013 Effect of endostar combined with cisplatin on expression of VEGF and Sema3A of Lewis lung cancer rats. Cisplatin 33-42 vascular endothelial growth factor A Rattus norvegicus 60-64 23577303-2 2013 This study assesses the radioprotective effects of N-acetyl-5-methoxytryptamine (melatonin) through its modulation of VEGF expression after localized irradiation of the cervical spinal cord. Melatonin 51-79 vascular endothelial growth factor A Rattus norvegicus 118-122 23649256-0 2013 Nitric oxide induces vascular endothelial growth factor expression in the rat placenta in vivo and in vitro. Nitric Oxide 0-12 vascular endothelial growth factor A Rattus norvegicus 21-55 23649256-1 2013 We investigated the role of nitric oxide (NO) in vascular endothelial growth factor (VEGF) expression in the rat placenta. Nitric Oxide 28-40 vascular endothelial growth factor A Rattus norvegicus 49-83 23649256-1 2013 We investigated the role of nitric oxide (NO) in vascular endothelial growth factor (VEGF) expression in the rat placenta. Nitric Oxide 28-40 vascular endothelial growth factor A Rattus norvegicus 85-89 23649256-4 2013 VEGF mRNA expression was temporally decreased by L-NAME, but recovered to normal levels after 24 h of treatment, whereas hypoxia inducible factor (HIF)-1alpha and induced NOS (iNOS) expression increased. NG-Nitroarginine Methyl Ester 49-55 vascular endothelial growth factor A Rattus norvegicus 0-4 23649256-5 2013 VEGF expression decreased significantly in placental explants after 6 h of co-treatment with L-NAME and lipopolysaccharide, an iNOS inducer. NG-Nitroarginine Methyl Ester 93-99 vascular endothelial growth factor A Rattus norvegicus 0-4 24236430-12 2013 RESULTS: TOS levels were significantly higher in Group I/R, when compared with groups S, AM and VEGF (p=0.004, p=0.011, p=0.017, respectively) and significantly lower in groups I/R+AM and I/R+VEGF, when compared with Group I/R (p=0.018, p=0.006, respectively). tos 9-12 vascular endothelial growth factor A Rattus norvegicus 192-196 23577303-2 2013 This study assesses the radioprotective effects of N-acetyl-5-methoxytryptamine (melatonin) through its modulation of VEGF expression after localized irradiation of the cervical spinal cord. Melatonin 81-90 vascular endothelial growth factor A Rattus norvegicus 118-122 23577303-9 2013 VEGF expression in the melatonin pre-treatment group significantly down-regulated in the 20(th) and 22(nd) weeks after irradiation compared to the radiation-only group. Melatonin 23-32 vascular endothelial growth factor A Rattus norvegicus 0-4 23577303-10 2013 CONCLUSION: The results support the hypothesis that modulation of VEGF expression by melatonin administration may increase the survival rate of irradiated animals. Melatonin 85-94 vascular endothelial growth factor A Rattus norvegicus 66-70 24295576-9 2013 In immunohistochemical assessment, reactions to S-100 in VEGF group were more positive than that in silicone group. s-100 48-53 vascular endothelial growth factor A Rattus norvegicus 57-61 23635649-7 2013 RESULTS: Isoflurane exposure induced expression of HIF-1alpha protein, HO-1 and VEGF mRNA and proteins in a time-dependent manner. Isoflurane 9-19 vascular endothelial growth factor A Rattus norvegicus 80-84 23050982-19 2013 The levels of FGF-10 and VEGFalpha were increased in nitrofen+AFS cell explants, while the levels of TGF-beta1 were similar to controls. nitrofen 53-61 vascular endothelial growth factor A Rattus norvegicus 25-34 24393559-7 2013 Pretreatment with Se normalized the cardiac enzymes, lipid peroxidation, GSH, SOD, CAT, GPx, TNF-alpha and VEGF (P<0.001) and reduced the immunostaining of p47 phox subunit. Selenium 18-20 vascular endothelial growth factor A Rattus norvegicus 107-111 24186594-6 2013 Rapamycin in a wide range of concentrations (10(-5) to 10(-8) M) induced a slight inhibitory effect on PC12 viability and decreased cell proliferation at the concentration of 10(-5) M. VEGF, endostatin and JV1-36 did not influence the growth of PC12. Sirolimus 0-9 vascular endothelial growth factor A Rattus norvegicus 185-189 24281241-9 2013 After surgery, blood glucose levels of VEGF but not EPO- or NaCl-treated animals remained normal. Blood Glucose 15-28 vascular endothelial growth factor A Rattus norvegicus 39-43 24348555-12 2013 Estrogen replacement was protective for ovariectomized rats from DMH-induced carcinogenesis, and one of the mechanisms for this was due to estrogen"s inhibitive effects on blood vessel formation by downregulating VEGF and HIF-1 alpha expressions. Dimethylhydrazines 65-68 vascular endothelial growth factor A Rattus norvegicus 213-217 23524495-5 2013 The present study investigated the therapeutic time window during which inhibition of VEGF can reduce CVI in a rat two-vein occlusion (2-VO) model. 2-vo 135-139 vascular endothelial growth factor A Rattus norvegicus 86-90 24060905-7 2013 VEGF protein levels were decreased in both the IC (-9.5%) and the contralateral cortex (CC; -10.2%) with PX-12 treatment. 1-methylpropyl-2-imidazolyl disulfide 105-110 vascular endothelial growth factor A Rattus norvegicus 0-4 23069939-4 2013 We determined that the adenosine A(2B) receptor (A(2B)AR) mediates VEGF overproduction in ex vivo glomeruli exposed to high glucose concentration, requiring PKCalpha and Erk1/2 activation. Glucose 124-131 vascular endothelial growth factor A Rattus norvegicus 67-71 23069939-5 2013 The glomerular content of A(2B)AR was concomitantly increased with VEGF at early stages of renal disease in streptozotocin-induced diabetic rats. Streptozocin 108-122 vascular endothelial growth factor A Rattus norvegicus 67-71 23069939-9 2013 In conclusion, we evidenced that adenosine signaling at the onset of diabetic kidney disease is a pathogenic event that promotes VEGF induction. Adenosine 33-42 vascular endothelial growth factor A Rattus norvegicus 129-133 23428587-7 2013 Fasudil and sildenafil given alone or in combination caused a significant increase in plasma VEGF-A level as compared to rats exposed to MCT. fasudil 0-7 vascular endothelial growth factor A Rattus norvegicus 93-99 23428587-7 2013 Fasudil and sildenafil given alone or in combination caused a significant increase in plasma VEGF-A level as compared to rats exposed to MCT. Sildenafil Citrate 12-22 vascular endothelial growth factor A Rattus norvegicus 93-99 24060905-8 2013 In the VEGF-treated rats, PX-12 also attenuated (-41%) the Ki of the IC. 1-methylpropyl-2-imidazolyl disulfide 26-31 vascular endothelial growth factor A Rattus norvegicus 7-11 23226762-5 2012 The data also revealed that LY294002, an inhibitor of phosphoinositide-3-kinase (PI3K), decreased the VEGF-induced migration and VCAM-1 expression of BMSCs. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 28-36 vascular endothelial growth factor A Rattus norvegicus 102-106 23457494-8 2013 RESULTS: GA supplementation suppressed the development of precancerous lesions and it also reduced the infiltration of mast cells, suppressed the immunostaining of Ki-67, NF-kB-p65, COX-2, iNOS and VEGF while enhanced the immunostaining of p53, connexin-43, caspase-9 and cleaved caspase-3. Glycyrrhizic Acid 9-11 vascular endothelial growth factor A Rattus norvegicus 198-202 23546895-6 2013 RESULTS: Combined therapy with progesterone and magnesium sulfate significantly attenuated trauma-induced neuronal death, increased brain VEGF levels and improved spatial memory deficits that appear later in life. Progesterone 31-43 vascular endothelial growth factor A Rattus norvegicus 138-142 23546895-6 2013 RESULTS: Combined therapy with progesterone and magnesium sulfate significantly attenuated trauma-induced neuronal death, increased brain VEGF levels and improved spatial memory deficits that appear later in life. Magnesium Sulfate 48-65 vascular endothelial growth factor A Rattus norvegicus 138-142 23295601-0 2012 Effects of the administration of pentoxifylline and prednisolone on the evolution of portal fibrogenesis secondary to biliary obstruction in growing animals: immunohistochemical analysis of the expression of TGF-beta and VEGF. Pentoxifylline 33-47 vascular endothelial growth factor A Rattus norvegicus 221-225 23089551-0 2012 The impact of 1,25-dihydroxy vitamin D3 on the expressions of vascular endothelial growth factor and transforming growth factor-beta1 in the retinas of rats with diabetes. Calcitriol 14-39 vascular endothelial growth factor A Rattus norvegicus 62-96 23089551-1 2012 AIMS: To define whether 1,25-dihydroxy vitamin D3 (1,25-(OH)2 D3) can protect diabetic retinopathy and to investigate its impact on the expressions of vascular endothelial growth factor (VEGF) and transforming growth factor-beta1 (TGF-beta1) in the retinas of rats with diabetes. Calcitriol 24-49 vascular endothelial growth factor A Rattus norvegicus 151-185 23089551-1 2012 AIMS: To define whether 1,25-dihydroxy vitamin D3 (1,25-(OH)2 D3) can protect diabetic retinopathy and to investigate its impact on the expressions of vascular endothelial growth factor (VEGF) and transforming growth factor-beta1 (TGF-beta1) in the retinas of rats with diabetes. Calcitriol 24-49 vascular endothelial growth factor A Rattus norvegicus 187-191 22959450-10 2012 However, resveratrol decreased aromatization and VEGF expression, whereas AMH expression remained unaltered. Resveratrol 9-20 vascular endothelial growth factor A Rattus norvegicus 49-53 23326540-9 2013 Fenretinide also suppressed HIF-1alpha and VEGF protein expression in rat lungs. Fenretinide 0-11 vascular endothelial growth factor A Rattus norvegicus 43-47 25215095-9 2013 Protein and mRNA levels of HIF-1alpha, VEGF and EPO were significantly increased in the SA group (P<0.05). sa 88-90 vascular endothelial growth factor A Rattus norvegicus 39-43 23197686-6 2012 RESULTS: Retinal VEGF mRNA and protein expression increased in Zucker diabetic fatty (ZDF(fa/fa)) rats and streptozotosin (STZ) induced diabetic Sprague-Dawley rats, after two months of disease, but not in Zucker fatty (ZF) rats. zdf 86-89 vascular endothelial growth factor A Rattus norvegicus 17-21 23197686-6 2012 RESULTS: Retinal VEGF mRNA and protein expression increased in Zucker diabetic fatty (ZDF(fa/fa)) rats and streptozotosin (STZ) induced diabetic Sprague-Dawley rats, after two months of disease, but not in Zucker fatty (ZF) rats. Streptozocin 123-126 vascular endothelial growth factor A Rattus norvegicus 17-21 22927341-14 2012 ET-induced BrdU incorporation and cyclin D1 expression were reduced by a neutralizing antibody against VEGF-A. Bromodeoxyuridine 11-15 vascular endothelial growth factor A Rattus norvegicus 103-109 22902870-9 2012 Expression of hepatic VEGF messenger RNA and protein increased 5-fold by 24 hours after dimethylnitrosamine injection. Dimethylnitrosamine 88-107 vascular endothelial growth factor A Rattus norvegicus 22-26 22902870-10 2012 Knockdown of hepatic VEGF with antisense oligonucleotides completely prevented dimethylnitrosamine-induced proliferation of BM SPCs and their mobilization to the circulation, reduced their engraftment by 46%, completely prevented formation of fenestration after engraftment as LSECs, and exacerbated dimethylnitrosamine injury. Oligonucleotides 41-57 vascular endothelial growth factor A Rattus norvegicus 21-25 23316332-11 2012 CONCLUSIONS: VEGF administration to infarcted myocardium enhances the efficacy of GMT-mediated cellular reprogramming in improving myocardial function and reducing the extent of myocardial fibrosis compared with the use of GMT or VEGF alone. GlcNAc-Mal 82-85 vascular endothelial growth factor A Rattus norvegicus 13-17 22902870-10 2012 Knockdown of hepatic VEGF with antisense oligonucleotides completely prevented dimethylnitrosamine-induced proliferation of BM SPCs and their mobilization to the circulation, reduced their engraftment by 46%, completely prevented formation of fenestration after engraftment as LSECs, and exacerbated dimethylnitrosamine injury. Dimethylnitrosamine 79-98 vascular endothelial growth factor A Rattus norvegicus 21-25 22902870-10 2012 Knockdown of hepatic VEGF with antisense oligonucleotides completely prevented dimethylnitrosamine-induced proliferation of BM SPCs and their mobilization to the circulation, reduced their engraftment by 46%, completely prevented formation of fenestration after engraftment as LSECs, and exacerbated dimethylnitrosamine injury. Dimethylnitrosamine 300-319 vascular endothelial growth factor A Rattus norvegicus 21-25 22927341-9 2012 Exogenous ET-1 (100 nM) and VEGF(165) (100 ng/mL), an isopeptide of VEGF-A, stimulated bromodeoxyuridine (BrdU) incorporation into cultured astrocytes. Bromodeoxyuridine 87-104 vascular endothelial growth factor A Rattus norvegicus 28-32 22927341-9 2012 Exogenous ET-1 (100 nM) and VEGF(165) (100 ng/mL), an isopeptide of VEGF-A, stimulated bromodeoxyuridine (BrdU) incorporation into cultured astrocytes. Bromodeoxyuridine 87-104 vascular endothelial growth factor A Rattus norvegicus 68-74 22927341-9 2012 Exogenous ET-1 (100 nM) and VEGF(165) (100 ng/mL), an isopeptide of VEGF-A, stimulated bromodeoxyuridine (BrdU) incorporation into cultured astrocytes. Bromodeoxyuridine 106-110 vascular endothelial growth factor A Rattus norvegicus 28-32 22927341-9 2012 Exogenous ET-1 (100 nM) and VEGF(165) (100 ng/mL), an isopeptide of VEGF-A, stimulated bromodeoxyuridine (BrdU) incorporation into cultured astrocytes. Bromodeoxyuridine 106-110 vascular endothelial growth factor A Rattus norvegicus 68-74 22927341-13 2012 In 60-70% confluent cultures, SU4312 (10 muM), a VEGF receptor tyrosine kinase inhibitor, partially reduced the effects of ET-1 on BrdU incorporation and cyclin D1 expression. 3-(4-dimethylaminobenzylidene)-1,3-dihydroindol-2-one 30-36 vascular endothelial growth factor A Rattus norvegicus 49-53 23316332-11 2012 CONCLUSIONS: VEGF administration to infarcted myocardium enhances the efficacy of GMT-mediated cellular reprogramming in improving myocardial function and reducing the extent of myocardial fibrosis compared with the use of GMT or VEGF alone. GlcNAc-Mal 82-85 vascular endothelial growth factor A Rattus norvegicus 230-234 22986296-16 2012 CONCLUSION: Injection of ds miR-210 was effective in promoting the healing of partially torn ACLs through enhancement of angiogenesis via upregulation of VEGF and FGF2. ds 25-27 vascular endothelial growth factor A Rattus norvegicus 154-158 22960289-7 2012 RT-PCR and western-blot analyses showed that ghrelin significantly increased vascular endothelial growth factor (VEGF) expression in the peri-infarct zone compared with the control group. Ghrelin 45-52 vascular endothelial growth factor A Rattus norvegicus 77-111 22960289-7 2012 RT-PCR and western-blot analyses showed that ghrelin significantly increased vascular endothelial growth factor (VEGF) expression in the peri-infarct zone compared with the control group. Ghrelin 45-52 vascular endothelial growth factor A Rattus norvegicus 113-117 22960289-9 2012 Taken together, ghrelin could induce angiogenesis in rats after MI, the process that may be associated with the enhancement of VEGF and an anti-apoptosis effect. Ghrelin 16-23 vascular endothelial growth factor A Rattus norvegicus 127-131 23106861-9 2012 Similarly, thrombospondin 2 immunofluorescent staining was stronger, whereas VEGF-A, MMP 9 and TGF-beta staining were weaker in the vitamin A group (p < 0.05). Vitamin A 132-141 vascular endothelial growth factor A Rattus norvegicus 77-83 23106861-10 2012 In addition, thrombospondin 2 mRNA levels were higher, whereas VEGF-A, MMP 9 and TGF-beta mRNA levels were lower in the vitamin A group (p < 0.05). Vitamin A 120-129 vascular endothelial growth factor A Rattus norvegicus 63-69 23106861-11 2012 CONCLUSIONS: Retinyl palmitate eye drops can inhibit VEGF-A and activate thrombospondin 2 and improve conjunctival impression cytologic findings. retinol palmitate 13-30 vascular endothelial growth factor A Rattus norvegicus 53-59 22842496-1 2012 The combination of chronic hypoxia and treatment of rats with the vascular endothelial growth factor (VEGF) receptor blocker, SU5416, induces pulmonary angio-obliteration, resulting in severe pulmonary arterial hypertension (PAH). Semaxinib 126-132 vascular endothelial growth factor A Rattus norvegicus 66-100 22842496-1 2012 The combination of chronic hypoxia and treatment of rats with the vascular endothelial growth factor (VEGF) receptor blocker, SU5416, induces pulmonary angio-obliteration, resulting in severe pulmonary arterial hypertension (PAH). Semaxinib 126-132 vascular endothelial growth factor A Rattus norvegicus 102-106 22906018-0 2012 Influence of lactic acid on differential expression of vascular endothelial growth factor and pigment epithelium-derived factor in explants of rat retina. Lactic Acid 13-24 vascular endothelial growth factor A Rattus norvegicus 55-89 23006058-10 2012 In LPK rats, tempol treatment reduced immunofluorescence for 3-nitrotyrosine and HIF1A mRNA while upregulating VEGF and p47phox mRNA expression, but otherwise had little impact on disease progression, renal tissue hypoxia or hypertension. tempol 13-19 vascular endothelial growth factor A Rattus norvegicus 111-115 23146804-0 2012 Puerarin enhances superoxide dismutase activity and inhibits RAGE and VEGF expression in retinas of STZ-induced early diabetic rats. puerarin 0-8 vascular endothelial growth factor A Rattus norvegicus 70-74 23146804-8 2012 mRNA and protein expression levels of RAGE and VEGF in the DM group were significantly higher than those of the other groups (P<0.05), and decreased after puerarin treatment (P<0.05). puerarin 158-166 vascular endothelial growth factor A Rattus norvegicus 47-51 23146804-9 2012 CONCLUSIONS: Puerarin is able to enhance SOD activity, and inhibit RAGE and VEGF expressions in retinas of STZ-induced early diabetic rats. puerarin 13-21 vascular endothelial growth factor A Rattus norvegicus 76-80 23146804-9 2012 CONCLUSIONS: Puerarin is able to enhance SOD activity, and inhibit RAGE and VEGF expressions in retinas of STZ-induced early diabetic rats. Streptozocin 107-110 vascular endothelial growth factor A Rattus norvegicus 76-80 22906018-1 2012 PURPOSE: To investigate the influence of lactate on expression of vascular endothelial growth factor (VEGF) and pigment epithelium-derived factor (PEDF) in rat retina. Lactic Acid 41-48 vascular endothelial growth factor A Rattus norvegicus 66-100 22906018-1 2012 PURPOSE: To investigate the influence of lactate on expression of vascular endothelial growth factor (VEGF) and pigment epithelium-derived factor (PEDF) in rat retina. Lactic Acid 41-48 vascular endothelial growth factor A Rattus norvegicus 102-106 22906018-6 2012 Compared with control, both RT-PCR and Western blot analysis showed that 30 mM of lactic acid significantly increased the levels of VEGF, but not PEDF. Lactic Acid 82-93 vascular endothelial growth factor A Rattus norvegicus 132-136 22906018-7 2012 CONCLUSIONS: Stimulation of production of retinal VEGF by lactate is dependent on the concentration of lactate. Lactic Acid 58-65 vascular endothelial growth factor A Rattus norvegicus 50-54 22906018-7 2012 CONCLUSIONS: Stimulation of production of retinal VEGF by lactate is dependent on the concentration of lactate. Lactic Acid 103-110 vascular endothelial growth factor A Rattus norvegicus 50-54 23066659-7 2012 The expression of HO-1 induced by pantoprazole was significantly associated with the increased in vitro tube formation (P < 0.05) and angiogenic factors including VEGF, bFGF, and HIF-1alpha. Pantoprazole 34-46 vascular endothelial growth factor A Rattus norvegicus 166-170 23373220-12 2012 Compared with the normal group, the expression of VEGF in the iodine group significantly decreased after treatment. Iodine 62-68 vascular endothelial growth factor A Rattus norvegicus 50-54 23373220-13 2012 Compared with the iodine group, the expression of VEGF in the phlegm group and the L-T4 group significantly reduced. Iodine 18-24 vascular endothelial growth factor A Rattus norvegicus 50-54 22894831-8 2012 An additional group of rats inhaling 270 ppm 2,3-pentanedione for 6 hours 41 minutes showed increased expression of IL-6 and nitric oxide synthase-2 and decreased expression of vascular endothelial growth factor A in the OB, striatum, hippocampus, and cerebellum using real-time PCR. 2,3-pentanedione 45-61 vascular endothelial growth factor A Rattus norvegicus 177-213 23442644-5 2012 Reduced dihydrotestosterone, VEGF, bFGF, EGF, and KGF levels were observed both in TFA- and AHT-treated rats. Trifluoroacetic Acid 83-86 vascular endothelial growth factor A Rattus norvegicus 29-33 23442644-5 2012 Reduced dihydrotestosterone, VEGF, bFGF, EGF, and KGF levels were observed both in TFA- and AHT-treated rats. Anhydrothymidine 92-95 vascular endothelial growth factor A Rattus norvegicus 29-33 22963465-5 2012 Heparin mimetic nanofibers were shown to bind to vascular endothelial growth factor (VEGF) and direct endothelial cells to angiogenesis. Heparin 0-7 vascular endothelial growth factor A Rattus norvegicus 49-83 22963465-5 2012 Heparin mimetic nanofibers were shown to bind to vascular endothelial growth factor (VEGF) and direct endothelial cells to angiogenesis. Heparin 0-7 vascular endothelial growth factor A Rattus norvegicus 85-89 22963465-8 2012 We observed that heparin mimetic peptide nanofibers demonstrate better binding profiles to VEGF, hepatocyte growth factor (HGF), and fibroblast growth factor-2 (FGF-2) than control peptide nanofibers. Heparin 17-24 vascular endothelial growth factor A Rattus norvegicus 91-95 22963465-9 2012 We also identified that the heparin-binding domain of VEGF is critical for its interaction with these nanofibers. Heparin 28-35 vascular endothelial growth factor A Rattus norvegicus 54-58 22579736-9 2012 In addition, LCP still significantly affect VEGF and Cyclin D1 proteins expression in liver cancer rats. Perchloric Acid 13-16 vascular endothelial growth factor A Rattus norvegicus 44-48 23997981-9 2012 GSNO also increased the expression of VEGF, reduced cellular infiltration (H&E staining) and apoptotic cell death (TUNEL assay), and hampered demyelination (LFB staining and g-ratio). S-Nitrosoglutathione 0-4 vascular endothelial growth factor A Rattus norvegicus 38-42 22290271-3 2012 CUSPIO imaging was performed in subcutaneous rat C6 gliomas before and 2 days after treatment with the potent VEGF-signaling inhibitor cediranib (n = 12), or vehicle (n = 12). cediranib 135-144 vascular endothelial growth factor A Rattus norvegicus 110-114 22797318-2 2012 We examined the influence of the tyrosine 321 site of G protein-coupled receptor kinase interacting protein 1 (GIT1) on platelet-derived growth factor (PDGF)-induced VEGF synthesis in vitro and on bone healing in vivo. Tyrosine 33-41 vascular endothelial growth factor A Rattus norvegicus 166-170 22797318-12 2012 In conclusion, tyrosine 321 of GIT1 is a critical phosphorylation site for GIT1 interaction with ERK1/2, regulation of ERK1/2 activation, VEGF expression and angiogenesis at the fracture site. Tyrosine 15-23 vascular endothelial growth factor A Rattus norvegicus 138-142 22732653-0 2012 Rosuvastatin promotes angiogenesis and reverses isoproterenol-induced acute myocardial infarction in rats: role of iNOS and VEGF. Rosuvastatin Calcium 0-12 vascular endothelial growth factor A Rattus norvegicus 124-128 22732653-6 2012 Treatment with rosuvastatin (5 or 10 mg/kg) for 8 weeks in myocardial-infarct rats enhanced the electrocardiographic pattern, reduced serum cardiac biomarkers, reduced tissue tumor necrosis factor-alpha (TNF-alpha) and upregulated vascular endothelial growth factor (VEGF) level. Rosuvastatin Calcium 15-27 vascular endothelial growth factor A Rattus norvegicus 231-265 22732653-6 2012 Treatment with rosuvastatin (5 or 10 mg/kg) for 8 weeks in myocardial-infarct rats enhanced the electrocardiographic pattern, reduced serum cardiac biomarkers, reduced tissue tumor necrosis factor-alpha (TNF-alpha) and upregulated vascular endothelial growth factor (VEGF) level. Rosuvastatin Calcium 15-27 vascular endothelial growth factor A Rattus norvegicus 267-271 22732653-7 2012 In addition, immunohistochemical staining revealed higher expression of inducible nitric oxide synthase (iNOS), VEGF and CD(34) (a marker for microvessel density) in the cardiac tissues after treatment with rosuvastatin compared to control group. Rosuvastatin Calcium 207-219 vascular endothelial growth factor A Rattus norvegicus 112-116 22884646-9 2012 Our study indicated that atorvastatin can improve the discrimination ability of whisker stimulation in rats and amplify post-ischemic angiogenesis induced by whisker stimulation, potentially via enhanced expression of VEGF and BDNF in the peri-infarct region. Atorvastatin 25-37 vascular endothelial growth factor A Rattus norvegicus 218-222 22561107-0 2012 Role of nitric oxide and vascular endothelial growth factor in fluoride-induced goitrogenesis in rats. Fluorides 63-71 vascular endothelial growth factor A Rattus norvegicus 25-59 22677637-8 2012 However, mRNA expression of MMP-9 and VEGF differed significantly only in the cornea between the A-Mphi group and phosphate-buffered saline group 5 days after the implantation. Phosphate-Buffered Saline 114-139 vascular endothelial growth factor A Rattus norvegicus 38-42 22561107-4 2012 The principle objective of this study was to investigate the possible roles of nitric oxide (NO) and vascular endothelial growth factor (VEGF) in the genesis of fluoride-induced nodular goiters. Fluorides 161-169 vascular endothelial growth factor A Rattus norvegicus 101-135 22561107-4 2012 The principle objective of this study was to investigate the possible roles of nitric oxide (NO) and vascular endothelial growth factor (VEGF) in the genesis of fluoride-induced nodular goiters. Fluorides 161-169 vascular endothelial growth factor A Rattus norvegicus 137-141 22561107-16 2012 Compared to the control group, the expression of VEGF mRNA in the thyroid gland and the serum NO levels in the fluoride-treated groups were significantly increased (p<0.05). Fluorides 111-119 vascular endothelial growth factor A Rattus norvegicus 49-53 22561107-17 2012 Furthermore, the deposition of VEGF in epithelial and follicular cells of the thyroid gland was significantly higher in fluoride-treated groups than in the control group. Fluorides 120-128 vascular endothelial growth factor A Rattus norvegicus 31-35 22561107-18 2012 These results suggested that abnormal expression of VEGF induced by fluoride can lead to the proliferation of vascular endothelial cells in the thyroid gland. Fluorides 68-76 vascular endothelial growth factor A Rattus norvegicus 52-56 22561107-20 2012 Furthermore, we proposed that there might be a positive feedback mechanism between NO and VEGF expression in fluoride-induced goiter formation. Fluorides 109-117 vascular endothelial growth factor A Rattus norvegicus 90-94 22561107-21 2012 It was concluded that angiogenic and vasodilative factors such as VEGF and NO must be involved in fluoride-induced thyroid goitrogenesis. Fluorides 98-106 vascular endothelial growth factor A Rattus norvegicus 66-70 23450373-0 2012 Prefabrication of vascularized bone graft using an interconnected porous calcium hydroxyapatite ceramic in presence of vascular endothelial growth factor and bone marrow mesenchymal stem cells: Experimental study in rats. Durapatite 73-95 vascular endothelial growth factor A Rattus norvegicus 119-153 22580375-6 2012 This effect was blocked with the VEGF/Flk-1 inhibitor SU5416. Semaxinib 54-60 vascular endothelial growth factor A Rattus norvegicus 33-37 22634341-9 2012 Of note, erlotinib treatment resulted in endothelial cell migration and vascular sprouting of aortic rings through induction of VEGF mRNA and protein levels in endothelial and tumor cells, which was blocked by sorafenib. Erlotinib Hydrochloride 9-18 vascular endothelial growth factor A Rattus norvegicus 128-132 22634341-9 2012 Of note, erlotinib treatment resulted in endothelial cell migration and vascular sprouting of aortic rings through induction of VEGF mRNA and protein levels in endothelial and tumor cells, which was blocked by sorafenib. Sorafenib 210-219 vascular endothelial growth factor A Rattus norvegicus 128-132 22634341-10 2012 In vivo, erlotinib had no single agent antitumor activity, raised serum-VEGF levels, and lacked a synergistic effect in combination with sorafenib. Erlotinib Hydrochloride 9-18 vascular endothelial growth factor A Rattus norvegicus 72-76 22634341-11 2012 CONCLUSIONS: Erlotinib had no antitumor effect on HCC in vitro nor in vivo, but induced VEGF, which may reflect a resistance mechanism to erlotinib monotherapy. Erlotinib Hydrochloride 13-22 vascular endothelial growth factor A Rattus norvegicus 88-92 22580375-9 2012 Interestingly, treatment with the SSRI fluoxetine, which is well known to stimulate neurogenesis and VEGF-signaling, also produced a similar expression pattern of Erk1/2 and Akt in proliferating cells. Fluoxetine 39-49 vascular endothelial growth factor A Rattus norvegicus 101-105 22739211-5 2012 Curcumin also blocked hypoxia-induced mRNA synthesis and secretion of VEGFA in GH3 cells and in all human pituitary adenoma cell cultures investigated (n=18). Curcumin 0-8 vascular endothelial growth factor A Rattus norvegicus 70-75 22560293-11 2012 CONCLUSION: Experimental ethanol ingestion rapidly increases VEGF production, significantly increasing the capillary bed in the heart, brain, and skeletal muscle. Ethanol 25-32 vascular endothelial growth factor A Rattus norvegicus 61-65 22796763-0 2012 Calcium mediates high glucose-induced HIF-1alpha and VEGF expression in cultured rat retinal Muller cells through CaMKII-CREB pathway. Calcium 0-7 vascular endothelial growth factor A Rattus norvegicus 53-57 22796763-0 2012 Calcium mediates high glucose-induced HIF-1alpha and VEGF expression in cultured rat retinal Muller cells through CaMKII-CREB pathway. Glucose 22-29 vascular endothelial growth factor A Rattus norvegicus 53-57 22796763-1 2012 AIM: To investigate the effects of high glucose (HG) medium on expression of hypoxia-inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) in cultured rat retinal Muller cells and to determine the signaling pathways mediating the effects. Glucose 40-47 vascular endothelial growth factor A Rattus norvegicus 126-160 22796763-1 2012 AIM: To investigate the effects of high glucose (HG) medium on expression of hypoxia-inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) in cultured rat retinal Muller cells and to determine the signaling pathways mediating the effects. Glucose 40-47 vascular endothelial growth factor A Rattus norvegicus 162-166 22796763-7 2012 Transfection of the cultured retinal Muller cells with antisense CREB oligonucleotide (300 nmol/L) was similarly effective in blocking the HG-induced increase of HIF-1alpha and VEGF. Oligonucleotides 70-85 vascular endothelial growth factor A Rattus norvegicus 177-181 22441658-7 2012 (3) The expression of CD44v6, ICAM-1, MMP-2 and VEGF of tissue in CO(2) and N(2) group after 1, 2 and 4 weeks of pneumoperitoneum were lower than air group, TIMP-2 and ENS were higher than air group. Carbon Dioxide 66-71 vascular endothelial growth factor A Rattus norvegicus 48-52 22441658-7 2012 (3) The expression of CD44v6, ICAM-1, MMP-2 and VEGF of tissue in CO(2) and N(2) group after 1, 2 and 4 weeks of pneumoperitoneum were lower than air group, TIMP-2 and ENS were higher than air group. Nitrogen 76-80 vascular endothelial growth factor A Rattus norvegicus 48-52 22580375-10 2012 Finally, pharmacological experiments showed that administration of inhibitors of either MAPK/ERK (U0126) or PI3K (LY294002) blocked VEGF-stimulation of hippocampal cell proliferation in vivo and in vitro. U 0126 98-103 vascular endothelial growth factor A Rattus norvegicus 132-136 22580375-10 2012 Finally, pharmacological experiments showed that administration of inhibitors of either MAPK/ERK (U0126) or PI3K (LY294002) blocked VEGF-stimulation of hippocampal cell proliferation in vivo and in vitro. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 114-122 vascular endothelial growth factor A Rattus norvegicus 132-136 23227543-2 2012 After 48 h, sodium nitrite enhanced cell viability and vascular endothelial growth factor (VEGF) secretion. Sodium Nitrite 12-26 vascular endothelial growth factor A Rattus norvegicus 55-89 23227543-2 2012 After 48 h, sodium nitrite enhanced cell viability and vascular endothelial growth factor (VEGF) secretion. Sodium Nitrite 12-26 vascular endothelial growth factor A Rattus norvegicus 91-95 23227543-4 2012 Compared with the negative control, sodium nitrite (1.4 mmol x L(-1)) also upregulated the expression of VEGF mRNA (P < 0.05) and hypoxia inducible factor 1 alpha (HIF-1 alpha) or VEGF protein expression (P < 0.05) in cultures of PC12 cells. Sodium Nitrite 36-50 vascular endothelial growth factor A Rattus norvegicus 105-109 23227543-4 2012 Compared with the negative control, sodium nitrite (1.4 mmol x L(-1)) also upregulated the expression of VEGF mRNA (P < 0.05) and hypoxia inducible factor 1 alpha (HIF-1 alpha) or VEGF protein expression (P < 0.05) in cultures of PC12 cells. Sodium Nitrite 36-50 vascular endothelial growth factor A Rattus norvegicus 183-187 23227543-6 2012 Taken together, these results suggest that low doses of sodium nitrite could induce neurite outgrowth in PC12 cells by activating the HIF-1alpha-VEGF pathway. Sodium Nitrite 56-70 vascular endothelial growth factor A Rattus norvegicus 145-149 22560293-0 2012 Ethanol protects from injury due to ischemia and reperfusion by increasing vascularity via vascular endothelial growth factor. Ethanol 0-7 vascular endothelial growth factor A Rattus norvegicus 91-125 22560293-8 2012 A neutralizing VEGF antibody, bevacizumab, inhibited new blood vessel formation induced by moderate doses of ethanol. Ethanol 109-116 vascular endothelial growth factor A Rattus norvegicus 15-19 22579701-0 2012 Podocyte injury and overexpression of vascular endothelial growth factor and transforming growth factor-beta 1 in adriamycin-induced nephropathy in rats. Doxorubicin 114-124 vascular endothelial growth factor A Rattus norvegicus 38-72 22430123-12 2012 Lung VEGF and eNOS increased in the L-citrulline-treated rats, though this treatment did not change MMP2 gene expression but regulated the MMP2 active protein, which rose in BALF (p = 0.003). Citrulline 36-48 vascular endothelial growth factor A Rattus norvegicus 5-9 22931606-6 2012 Real-time PCR and immunohistochemistry showed that compared with BDL group, spironolactone treatment significantly inhibited the expression of VEGF-A mRNA (0.71-+0.12 vs 1.75-+0.15, P=0.00) and vWF (1.15-+0.09 vs 3.08-+0.17, P=0.00) in the liver. Spironolactone 76-90 vascular endothelial growth factor A Rattus norvegicus 143-149 22695743-5 2012 Oral administration with OLA decreased the production of IL-1beta, IL-6 and CINC-2alphabeta by resident macrophages and LNA decreased the production of IL-1beta, IL-6 and VEGF in the absence of lipopolysaccharide (LPS), although it accelerated IL-1beta release and decreased IL-10 synthesis when cells were stimulated with LPS. ola 25-28 vascular endothelial growth factor A Rattus norvegicus 171-175 22931606-8 2012 CONCLUSION: Spironolactone can inhibit hepatic sinusoid angiogenesis in rats with BDL-induced hepatic fibrosis by inhibiting the expression of VEGF-A. Spironolactone 12-26 vascular endothelial growth factor A Rattus norvegicus 143-149 22621815-0 2012 Prenatal retinoic acid improves lung vascularization and VEGF expression in CDH rat. Tretinoin 9-22 vascular endothelial growth factor A Rattus norvegicus 57-61 22453521-0 2012 Naringin treatment improves functional recovery by increasing BDNF and VEGF expression, inhibiting neuronal apoptosis after spinal cord injury. naringin 0-8 vascular endothelial growth factor A Rattus norvegicus 71-75 22453521-11 2012 These findings suggest that naringin treatment starting 1 day after SCI can significantly improve locomotor recovery, and this neuroprotective effect may be related to the upregulation of BDNF and VEGF and the inhibition of neural apoptosis. naringin 28-36 vascular endothelial growth factor A Rattus norvegicus 197-201 22683506-12 2012 Western blot and immunohistochemistry showed higher expression of BDNF and VEGF in the simvastatin treated group than the control group. Simvastatin 87-98 vascular endothelial growth factor A Rattus norvegicus 75-79 22683506-13 2012 In conclusion, simvastatin can help to repair spinal cord injury in rat, where the underlying mechanism appears to involve the mobilization of bone marrow stromal cells to the injured area and higher expression of BNDF and VEGF. Simvastatin 15-26 vascular endothelial growth factor A Rattus norvegicus 223-227 22731844-0 2012 Cycloartane-type triterpenes from the leaves of Homonoia riparia with VEGF-induced angiogenesis inhibitory activity. cycloartane 0-11 vascular endothelial growth factor A Rattus norvegicus 70-74 22731844-0 2012 Cycloartane-type triterpenes from the leaves of Homonoia riparia with VEGF-induced angiogenesis inhibitory activity. Triterpenes 17-28 vascular endothelial growth factor A Rattus norvegicus 70-74 22621815-1 2012 OBJECTIVE: We sought to investigate the effects of antenatal retinoic acid on the pulmonary vasculature and vascular endothelial growth factor (VEGF) and VEGF receptors (VEGFR) expression in a nitrofen-induced congenital diaphragmatic hernia (CDH) model. nitrofen 193-201 vascular endothelial growth factor A Rattus norvegicus 108-142 22621815-1 2012 OBJECTIVE: We sought to investigate the effects of antenatal retinoic acid on the pulmonary vasculature and vascular endothelial growth factor (VEGF) and VEGF receptors (VEGFR) expression in a nitrofen-induced congenital diaphragmatic hernia (CDH) model. nitrofen 193-201 vascular endothelial growth factor A Rattus norvegicus 144-148 22621815-1 2012 OBJECTIVE: We sought to investigate the effects of antenatal retinoic acid on the pulmonary vasculature and vascular endothelial growth factor (VEGF) and VEGF receptors (VEGFR) expression in a nitrofen-induced congenital diaphragmatic hernia (CDH) model. nitrofen 193-201 vascular endothelial growth factor A Rattus norvegicus 154-158 22621815-9 2012 ATRA recovered expression of VEGF and receptors, which were reduced in CDH. Tretinoin 0-4 vascular endothelial growth factor A Rattus norvegicus 29-33 22245234-0 2012 Maternal nicotine effects on vascular endothelial growth factor expression and morphometry in rat lungs. Nicotine 9-17 vascular endothelial growth factor A Rattus norvegicus 29-63 22351845-1 2012 OBJECTIVE: To increase the viability of fat grafts using vascular endothelial growth factor (VEGF) in a calcium alginate microsphere controlled release system. Alginates 104-120 vascular endothelial growth factor A Rattus norvegicus 57-91 22351845-1 2012 OBJECTIVE: To increase the viability of fat grafts using vascular endothelial growth factor (VEGF) in a calcium alginate microsphere controlled release system. Alginates 104-120 vascular endothelial growth factor A Rattus norvegicus 93-97 22484312-6 2012 Eriodictyol treatment significantly lowered retinal TNF-alpha, ICAM-1, VEGF, and eNOS in a dose-dependent manner. eriodictyol 0-11 vascular endothelial growth factor A Rattus norvegicus 71-75 22245234-2 2012 We evaluated the effects of maternal nicotine exposure on lung VEGF expression and morphometry during the postnatal period in rats. Nicotine 37-45 vascular endothelial growth factor A Rattus norvegicus 63-67 22245234-7 2012 Nicotine exposure caused a significant decrease in vascular endothelial growth factor receptor (VEGFR)-2 mRNA expression, compared with the level of the control rats on Postnatal Day 1. Nicotine 0-8 vascular endothelial growth factor A Rattus norvegicus 51-85 22577112-11 2012 In summary, this study describes an alteration not only in the VEGF/fetal liver kinase-1 system but also in the ANGPT/TIE2 system in a dehydroepiandrosterone-induced PCOS rat model. Dehydroepiandrosterone 135-157 vascular endothelial growth factor A Rattus norvegicus 63-67 22245234-9 2012 CONCLUSIONS: Maternal nicotine exposure during pregnancy decreases VEGF and VEGFR-2 mRNA expression and alters lung structure in the lungs of postnatal rats. Nicotine 22-30 vascular endothelial growth factor A Rattus norvegicus 67-71 22245234-10 2012 Because angiogenesis is vital for alveolarization during normal lung development, these results suggest that decreased VEGF expression might be involved in the structural alterations of the developing lung after exposure to antenatal nicotine. Nicotine 234-242 vascular endothelial growth factor A Rattus norvegicus 119-123 22148982-0 2012 Effect of resveratrol on Bcl-2 and VEGF expression in oxygen-induced retinopathy of prematurity. Resveratrol 10-21 vascular endothelial growth factor A Rattus norvegicus 35-39 23087509-0 2012 Vasoactive agent buflomedil up-regulated expression of vascular endothelial growth factor in a rat model of sciatic nerve crush injury. buflomedil 17-27 vascular endothelial growth factor A Rattus norvegicus 55-89 23087509-5 2012 The effects of Buflomedil on expression of VEGF and repair of neural pathology were also evaluated. buflomedil 15-25 vascular endothelial growth factor A Rattus norvegicus 43-47 23087509-6 2012 RESULTS: VEGF mRNA was significantly increased in Buflomedil and Buflomedil + VEGF-antibody groups, compared with other groups. buflomedil 50-60 vascular endothelial growth factor A Rattus norvegicus 9-13 23087509-6 2012 RESULTS: VEGF mRNA was significantly increased in Buflomedil and Buflomedil + VEGF-antibody groups, compared with other groups. buflomedil 65-75 vascular endothelial growth factor A Rattus norvegicus 9-13 23087509-7 2012 The number of VEGF-positive neurons was significantly increased in the Buflomedil and the saline groups. buflomedil 71-81 vascular endothelial growth factor A Rattus norvegicus 14-18 23087509-7 2012 The number of VEGF-positive neurons was significantly increased in the Buflomedil and the saline groups. Sodium Chloride 90-96 vascular endothelial growth factor A Rattus norvegicus 14-18 23087509-9 2012 CONCLUSIONS: The vasoactive agent Buflomedil may decrease the pathological lesion and improve the functional rehabilitation of peripheral nerves, which may correlate to upregulation of the expression of VEGF, following crush injury to the peripheral nerves. buflomedil 34-44 vascular endothelial growth factor A Rattus norvegicus 203-207 22148982-0 2012 Effect of resveratrol on Bcl-2 and VEGF expression in oxygen-induced retinopathy of prematurity. Oxygen 54-60 vascular endothelial growth factor A Rattus norvegicus 35-39 22148982-9 2012 Significant differences in expression of Bcl-2 and VEGF were also noted among the three treatment groups with resveratrol (P < .01). Resveratrol 110-121 vascular endothelial growth factor A Rattus norvegicus 51-55 22148982-10 2012 After treatment with resveratrol at 10, 30, and 60 mg/kg/d, the inhibition rate of Bcl-2 expression was 11.1%, 38.1%, and 69.8% and that of VEGF expression was 3.4%, 23.0%, and 43.7%, respectively. Resveratrol 21-32 vascular endothelial growth factor A Rattus norvegicus 140-144 22148982-11 2012 CONCLUSION: Resveratrol can significantly inhibit expression of Bcl-2 and VEGF in the retina of neonatal rats with oxygen-induced ROP. Resveratrol 12-23 vascular endothelial growth factor A Rattus norvegicus 74-78 22148982-11 2012 CONCLUSION: Resveratrol can significantly inhibit expression of Bcl-2 and VEGF in the retina of neonatal rats with oxygen-induced ROP. Oxygen 115-121 vascular endothelial growth factor A Rattus norvegicus 74-78 22488214-10 2012 The vessel density and VEGF level in the infarcted zone was significantly increased with MC-SC+MSC transplantation (P < 0.05). mc-sc 89-94 vascular endothelial growth factor A Rattus norvegicus 23-27 22374305-6 2012 Selective stimulation of the AT(1)R by Ang II in the presence of PD123,319 revealed a pro-angiogenic activity which further increased VEGF-driven EC sprouting and migration. pd123 65-70 vascular endothelial growth factor A Rattus norvegicus 134-138 22140134-7 2012 Valsartan administration promoted regeneration of the glomerular tuft, lowered proteinuria and resulted in enhanced vascular endothelial growth factor (VEGF) expression in the cortex and glomerular tuft. Valsartan 0-9 vascular endothelial growth factor A Rattus norvegicus 116-150 22140134-7 2012 Valsartan administration promoted regeneration of the glomerular tuft, lowered proteinuria and resulted in enhanced vascular endothelial growth factor (VEGF) expression in the cortex and glomerular tuft. Valsartan 0-9 vascular endothelial growth factor A Rattus norvegicus 152-156 22140134-8 2012 In addition, valsartan promoted increased recruitment of BM-derived cells (BMDCs) many of which expressed VEGF and likely contributed directly to glomerular repair. Valsartan 13-22 vascular endothelial growth factor A Rattus norvegicus 106-110 22140134-10 2012 CONCLUSIONS: In conclusion, the data shows that ARB by valsartan prevents glomerulosclerosis progression by enhancing glomerular capillary repair which is associated with the recruitment of VEGF producing "reparative" monocytes and macrophages from the BM. Valsartan 55-64 vascular endothelial growth factor A Rattus norvegicus 190-194 22572614-7 2012 The administration of L-Arg promoted the synthesis of NO and significantly elevated the expressions of VEGF, eNOS and PTC density with the conspicuous loss of HIF-1alpha and TGF-beta1 expressions and ultimately ameliorated renal fibrosis, which was markedly aggravated by L-NAME administration. Arginine 22-27 vascular endothelial growth factor A Rattus norvegicus 103-107 22511624-10 2012 Inhibition of ERK1/2 phosphorylation with U0126 was observed for changes in VEGF secretion. U 0126 42-47 vascular endothelial growth factor A Rattus norvegicus 76-80 22511624-12 2012 In vitro high glucose stimulation of Muller cells increased VEGF secretion with a peak at 24 hours. Glucose 14-21 vascular endothelial growth factor A Rattus norvegicus 60-64 22511624-13 2012 An ERK1/2 specific inhibitor, U0126, stopped the phosphorylation of ERK1/2, lowered AP-1 DNA binding activity, and reduced Muller cells secretion of VEGF under high glucose conditions. U 0126 30-35 vascular endothelial growth factor A Rattus norvegicus 149-153 22511624-13 2012 An ERK1/2 specific inhibitor, U0126, stopped the phosphorylation of ERK1/2, lowered AP-1 DNA binding activity, and reduced Muller cells secretion of VEGF under high glucose conditions. Glucose 165-172 vascular endothelial growth factor A Rattus norvegicus 149-153 22484505-0 2012 Testosterone replacement therapy promotes angiogenesis after acute myocardial infarction by enhancing expression of cytokines HIF-1a, SDF-1a and VEGF. Testosterone 0-12 vascular endothelial growth factor A Rattus norvegicus 145-149 22484505-9 2012 The pro-angiogenesis effect of testosterone-replacement therapy is associated with the enhanced expression of HIF-1a, SDF-1a and VEGF in myocardium after myocardial infarction. Testosterone 31-43 vascular endothelial growth factor A Rattus norvegicus 129-133 22374305-7 2012 In contrast, selective stimulation of the AT(2)R by either CGP42112A or Ang II in the presence of telmisartan inhibited the VEGF-driven angiogenic response. Telmisartan 98-109 vascular endothelial growth factor A Rattus norvegicus 124-128 23482588-8 2012 Simvastatin and atorvastatin treatment increased the expression of BDNF, VEGF and NGF in both low- and high-dose groups at 7 days after ICH (p < 0.05). Simvastatin 0-11 vascular endothelial growth factor A Rattus norvegicus 73-77 21898269-7 2012 Pretreatment with CSEX also inhibited TNF-alpha, IL-1beta, VEGF-alpha, and IL-17A and blocked inflammation-related events (ICAM-1 and iNOS) by activation of NF-kappaB. csex 18-22 vascular endothelial growth factor A Rattus norvegicus 59-69 22403298-2 2012 This study tested the hypotheses that 1) cerebral but not peripheral angiogenesis is increased in a spatial manner and 2) peroxynitrite orchestrates vascular endothelial growth factor (VEGF)-mediated brain angiogenesis in diabetes. Peroxynitrous Acid 122-135 vascular endothelial growth factor A Rattus norvegicus 149-183 22403298-2 2012 This study tested the hypotheses that 1) cerebral but not peripheral angiogenesis is increased in a spatial manner and 2) peroxynitrite orchestrates vascular endothelial growth factor (VEGF)-mediated brain angiogenesis in diabetes. Peroxynitrous Acid 122-135 vascular endothelial growth factor A Rattus norvegicus 185-189 22403298-12 2012 Increased VEGF-dependent angiogenic function in BMECs is mediated by peroxynitrite and involves c-src and MT1-MMP activation. Peroxynitrous Acid 69-82 vascular endothelial growth factor A Rattus norvegicus 10-14 21448670-8 2012 Vegfr expression was inhibited significantly by SB-T-12851 and SB-T-12854, but effect of SB-T-12851 was compromised by induced Vegf expression. (2R,3S)-2-Hydroxy-3-(tert-butoxycarbonylamino)-5,5-difluoro-4-pentenoic acid 1,7beta-dihydroxy-2alpha-(benzoyloxy)-4,10beta-diacetoxy-9-oxo-5beta,20-epoxytaxa-11-ene-13alpha-yl ester 48-58 vascular endothelial growth factor A Rattus norvegicus 0-4 21448670-9 2012 The very effective SB-T-1214 decreased the expression of Vegf, Egf and all receptors most prominently indicating the possible supporting role of these genes in anti-lymphoma effects. SB T-1214 19-28 vascular endothelial growth factor A Rattus norvegicus 57-61 22707888-10 2012 PTX significantly decreased mRNA expression of HIF-1alpha and VEGF at 4 and 8 weeks, and decreased HO-1 and GLUT-1 at 4 weeks. Pentoxifylline 0-3 vascular endothelial growth factor A Rattus norvegicus 62-66 23482588-8 2012 Simvastatin and atorvastatin treatment increased the expression of BDNF, VEGF and NGF in both low- and high-dose groups at 7 days after ICH (p < 0.05). Atorvastatin 16-28 vascular endothelial growth factor A Rattus norvegicus 73-77 22281060-6 2012 RESULTS: Immunohistochemical HSCORE decreased for VEGF and TGF-beta1 staining and increased for iNOS staining in rats treated with VPA compared with the control group. Valproic Acid 131-134 vascular endothelial growth factor A Rattus norvegicus 50-54 22450230-9 2012 Hyaluronan tetrasaccharide (HA(4)) induced NF-kappaB and c-IAP(2) to suppress the H(2)O(2)-induced apoptosis in primary neuronal cultures and increased BDNF and VEGF expression in astrocytic cultures in vitro. hyaluronan tetrasaccharide 0-26 vascular endothelial growth factor A Rattus norvegicus 161-165 22450230-9 2012 Hyaluronan tetrasaccharide (HA(4)) induced NF-kappaB and c-IAP(2) to suppress the H(2)O(2)-induced apoptosis in primary neuronal cultures and increased BDNF and VEGF expression in astrocytic cultures in vitro. ha(4) 28-33 vascular endothelial growth factor A Rattus norvegicus 161-165 22403787-5 2012 Moreover, a common HIF target, VEGF mRNA, was also upregulated after chronic nicotine. Nicotine 77-85 vascular endothelial growth factor A Rattus norvegicus 31-35 22041019-8 2012 CONCLUSIONS: Our results showed that DHDM increases the expression of VEGF and accelerates the healing process in rats tooth sockets, by stimulating bone deposition and also vessels formation. dhdm 37-41 vascular endothelial growth factor A Rattus norvegicus 70-74 22647483-12 2012 In addition, nor-NOHA decreased IL-6 and VEGF plasma levels in AIA rats. norLeu3-A(1-7) 13-21 vascular endothelial growth factor A Rattus norvegicus 41-45 22361062-14 2012 VEGF enhanced the amplitude of ATP and alpha,beta-meATP -activated currents of both sham and CCI rats. Adenosine Triphosphate 31-34 vascular endothelial growth factor A Rattus norvegicus 0-4 21801303-10 2012 Plasma VEGF levels were significantly elevated in those rats exposed to 12 weeks of CCl(4) inhalation (63.7 pg/ml, P < 0.01), compared to the controls (8.5 pg/ml). Cefaclor 84-87 vascular endothelial growth factor A Rattus norvegicus 7-11 22326847-2 2012 We tested, if the cytotoxic cancer therapy doxorubicin (Doxo) or the anti-angiogenic therapy sunitinib alters viability and VEGF signaling in primary cardiac microvascular endothelial cells (CMEC) and adult rat ventricular myocytes (ARVM). Doxorubicin 43-54 vascular endothelial growth factor A Rattus norvegicus 124-128 22326847-2 2012 We tested, if the cytotoxic cancer therapy doxorubicin (Doxo) or the anti-angiogenic therapy sunitinib alters viability and VEGF signaling in primary cardiac microvascular endothelial cells (CMEC) and adult rat ventricular myocytes (ARVM). Sunitinib 93-102 vascular endothelial growth factor A Rattus norvegicus 124-128 22326847-10 2012 Endothelial cells up-regulated VEGF-A release after peroxide or Doxo treatment. Peroxides 52-60 vascular endothelial growth factor A Rattus norvegicus 31-37 22326847-10 2012 Endothelial cells up-regulated VEGF-A release after peroxide or Doxo treatment. Doxorubicin 64-68 vascular endothelial growth factor A Rattus norvegicus 31-37 22326847-14 2012 VEGF receptor 2 amounts were reduced by Doxo and by sunitinib in a dose-dependent manner in both CMEC and ARVM. Doxorubicin 40-44 vascular endothelial growth factor A Rattus norvegicus 0-4 22326847-14 2012 VEGF receptor 2 amounts were reduced by Doxo and by sunitinib in a dose-dependent manner in both CMEC and ARVM. Sunitinib 52-61 vascular endothelial growth factor A Rattus norvegicus 0-4 22326847-15 2012 In conclusion, these data suggest that cancer therapy with anthracyclines modulates VEGF-A release and its cellular receptors in CMEC and ARVM, and therefore alters paracrine signaling in the myocardium. Anthracyclines 59-73 vascular endothelial growth factor A Rattus norvegicus 84-90 22361062-16 2012 Both ATP (100 muM) and alpha,beta-meATP (10 muM)- activated currents enhanced by VEGF ( 1nM) were significantly blocked by Vatalanib (1 muM, an inhibitor of VEGF receptors). Adenosine Triphosphate 5-8 vascular endothelial growth factor A Rattus norvegicus 81-85 22361062-16 2012 Both ATP (100 muM) and alpha,beta-meATP (10 muM)- activated currents enhanced by VEGF ( 1nM) were significantly blocked by Vatalanib (1 muM, an inhibitor of VEGF receptors). Adenosine Triphosphate 5-8 vascular endothelial growth factor A Rattus norvegicus 157-161 22361062-16 2012 Both ATP (100 muM) and alpha,beta-meATP (10 muM)- activated currents enhanced by VEGF ( 1nM) were significantly blocked by Vatalanib (1 muM, an inhibitor of VEGF receptors). alpha,beta-methyleneadenosine 5'-triphosphate 23-39 vascular endothelial growth factor A Rattus norvegicus 81-85 22361062-16 2012 Both ATP (100 muM) and alpha,beta-meATP (10 muM)- activated currents enhanced by VEGF ( 1nM) were significantly blocked by Vatalanib (1 muM, an inhibitor of VEGF receptors). alpha,beta-methyleneadenosine 5'-triphosphate 23-39 vascular endothelial growth factor A Rattus norvegicus 157-161 22361062-16 2012 Both ATP (100 muM) and alpha,beta-meATP (10 muM)- activated currents enhanced by VEGF ( 1nM) were significantly blocked by Vatalanib (1 muM, an inhibitor of VEGF receptors). vatalanib 123-132 vascular endothelial growth factor A Rattus norvegicus 81-85 22361062-16 2012 Both ATP (100 muM) and alpha,beta-meATP (10 muM)- activated currents enhanced by VEGF ( 1nM) were significantly blocked by Vatalanib (1 muM, an inhibitor of VEGF receptors). vatalanib 123-132 vascular endothelial growth factor A Rattus norvegicus 157-161 22361062-14 2012 VEGF enhanced the amplitude of ATP and alpha,beta-meATP -activated currents of both sham and CCI rats. beta-meatp 45-55 vascular endothelial growth factor A Rattus norvegicus 0-4 22361062-18 2012 Vatalanib can alleviate chronic neuropathic pain by decreasing the activation of VEGF on VEGFR-2 and the positive interaction between the up-regulated VEGFR-2 and P2X(2/3) receptors in the neuropathic pain signaling. vatalanib 0-9 vascular endothelial growth factor A Rattus norvegicus 81-85 22361062-15 2012 Increment effects of VEGF on ATP and alpha,beta-meATP -activated currents in CCI rats were higher than those in sham rats. Adenosine Triphosphate 29-32 vascular endothelial growth factor A Rattus norvegicus 21-25 22322387-10 2012 Furthermore, PTX treatment also increased the gene expression of VEGF189 and VEGF165, increased VEGF protein expression, and improved pulmonary vascularization. Pentoxifylline 13-16 vascular endothelial growth factor A Rattus norvegicus 65-69 22812226-7 2012 CsA inhibited the expression of VEGF and the complement inhibitor DAF and increased the expression of CRP of vascular endothelial cells. Cyclosporine 0-3 vascular endothelial growth factor A Rattus norvegicus 32-36 22812226-10 2012 CONCLUSION: CsA can damage vascular endothelium of hyperlipidemic rats by activating the complement system induced by VEGF/DAF and ROS/CRP pathway. Cyclosporine 12-15 vascular endothelial growth factor A Rattus norvegicus 118-122 22265022-0 2012 The effect of formoterol on peritoneal VEGF levels in rats with endometriosis. Formoterol Fumarate 14-24 vascular endothelial growth factor A Rattus norvegicus 39-43 22265022-1 2012 AIM: The aim of this study is to investigate the effect of formoterol (beta2 adrenergic receptor agonist) on peritoneal VEGF levels in rats with endometriosis. Formoterol Fumarate 59-69 vascular endothelial growth factor A Rattus norvegicus 120-124 22265022-10 2012 On the other hand, based on the group 2(F) and 4"s (FF) VEGF levels after the treatment, low dose or high dose formoterol may be effective with long term therapy. Formoterol Fumarate 111-121 vascular endothelial growth factor A Rattus norvegicus 56-60 22191573-2 2012 The present study investigated the effects of resveratrol (RSV) treatment on the mRNA expression profile of VEGF, ACE, MMP-9, and eNOS, which are associated with vascular neovascularization, and glutathione, protein carbonyl, and nitrite-nitrate levels, which are markers of oxidative stress in eyes of diabetic rats. Resveratrol 46-57 vascular endothelial growth factor A Rattus norvegicus 108-112 22448962-2 2012 To investigate the possible role of hypoxia-inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) in mediating this protective effect, MCT-treated rats were administered fluoxetine by gavage, at doses of 2 mg/kg body mass or 10 mg/kg once daily for 3 weeks. Monocrotaline 164-167 vascular endothelial growth factor A Rattus norvegicus 121-125 22448962-5 2012 In addition, 10 mg/kg fluoxetine mitigated the MCT-induced up-regulation of HIF-1alpha and VEGF protein and reactive oxygen species (ROS) in the lungs. Fluoxetine 22-32 vascular endothelial growth factor A Rattus norvegicus 91-95 22448962-7 2012 In conclusion, fluoxetine can protect against MCT-induced pulmonary arterial remodeling, which linked to reduced ROS generation and decreased HIF-1alpha and VEGF protein levels via the ERK1/2 phosphorylation pathway. Fluoxetine 15-25 vascular endothelial growth factor A Rattus norvegicus 157-161 22448962-0 2012 Fluoxetine protects against monocrotaline-induced pulmonary arterial remodeling by inhibition of hypoxia-inducible factor-1alpha and vascular endothelial growth factor. Fluoxetine 0-10 vascular endothelial growth factor A Rattus norvegicus 133-167 22191573-2 2012 The present study investigated the effects of resveratrol (RSV) treatment on the mRNA expression profile of VEGF, ACE, MMP-9, and eNOS, which are associated with vascular neovascularization, and glutathione, protein carbonyl, and nitrite-nitrate levels, which are markers of oxidative stress in eyes of diabetic rats. Resveratrol 59-62 vascular endothelial growth factor A Rattus norvegicus 108-112 21500193-8 2012 Furthermore, VEGF and GLUT1, downstream targets of HIF-1alpha, were also reduced in prostate cancer cells after MSeA treatment. methylselenic acid 112-116 vascular endothelial growth factor A Rattus norvegicus 13-17 21952821-9 2012 VEGF and ICAM-1 expressions were significantly up-regulated in retinal blood vessels from diabetic rats, and such up-regulation was attenuated by N-acetylcysteine treatment. Acetylcysteine 146-162 vascular endothelial growth factor A Rattus norvegicus 0-4 21952821-11 2012 Long-term N-acetylcysteine treatment exerts protective effects on the diabetic retinas, possibly through its down-regulation of the expression of VEGF and ICAM-1, and reduction of reactive oxygen species content in retinal vascular tissues in diabetic rats. Acetylcysteine 10-26 vascular endothelial growth factor A Rattus norvegicus 146-150 22230249-5 2012 Here, we show that STAT3 was activated by increased retinal VEGF in the rat 50/10 oxygen-induced retinopathy model. Oxygen 82-88 vascular endothelial growth factor A Rattus norvegicus 60-64 22256989-1 2012 Transscleral retinal delivery of celecoxib, an anti-inflammatory and anti-VEGF agent, is restricted by its poor solubility and binding to the melanin pigment in choroid-RPE. Celecoxib 33-42 vascular endothelial growth factor A Rattus norvegicus 74-78 22229270-0 2012 Low-dosage metronomic chemotherapy and angiogenesis: topoisomerase inhibitors irinotecan and mitoxantrone stimulate VEGF-A-mediated angiogenesis. Irinotecan 78-88 vascular endothelial growth factor A Rattus norvegicus 116-122 22464549-7 2012 RESULTS: GW0742 significantly increased serum nitrite and VEGFR-2 concentrations and VEGF-to-VEGFR-2 ratio in control and diabetic rats. GW0742 9-15 vascular endothelial growth factor A Rattus norvegicus 58-62 22192876-10 2012 Anti-rVEGF treatment in CCI rats reduced the expression of VEGFR-2 and P2X(2/3) receptors in L4/5 SDH compared with those in CCI+PBS group. CCI 24-27 vascular endothelial growth factor A Rattus norvegicus 5-10 22192876-10 2012 Anti-rVEGF treatment in CCI rats reduced the expression of VEGFR-2 and P2X(2/3) receptors in L4/5 SDH compared with those in CCI+PBS group. Lead 129-132 vascular endothelial growth factor A Rattus norvegicus 5-10 22192876-12 2012 Anti-rVEGF treatment in CCI rats reduced the expression of VEGFR-2 and inhibited the transmission of neuropathic pain in L4/5 SDH via decreasing the expression of P2X(2/3). sdh 126-129 vascular endothelial growth factor A Rattus norvegicus 5-10 22229270-0 2012 Low-dosage metronomic chemotherapy and angiogenesis: topoisomerase inhibitors irinotecan and mitoxantrone stimulate VEGF-A-mediated angiogenesis. Mitoxantrone 93-105 vascular endothelial growth factor A Rattus norvegicus 116-122 22229270-4 2012 The aim of the present study was to assess the systemic effect of low-dosage metronomic treatment with either irinotecan or mitoxantrone on angiogenesis induced by VEGF-A. Irinotecan 110-120 vascular endothelial growth factor A Rattus norvegicus 164-170 22229270-4 2012 The aim of the present study was to assess the systemic effect of low-dosage metronomic treatment with either irinotecan or mitoxantrone on angiogenesis induced by VEGF-A. Mitoxantrone 124-136 vascular endothelial growth factor A Rattus norvegicus 164-170 21889514-4 2012 Pre-treatment of RAGE overexpressing myocytes with the NF-kappaB inhibitor caffeic acid phenethyl ester inhibited increases in VEGF mRNA, VEGF protein and VEGF in the medium by S100B. caffeic acid phenethyl ester 75-103 vascular endothelial growth factor A Rattus norvegicus 127-131 21889514-4 2012 Pre-treatment of RAGE overexpressing myocytes with the NF-kappaB inhibitor caffeic acid phenethyl ester inhibited increases in VEGF mRNA, VEGF protein and VEGF in the medium by S100B. caffeic acid phenethyl ester 75-103 vascular endothelial growth factor A Rattus norvegicus 138-142 21889514-4 2012 Pre-treatment of RAGE overexpressing myocytes with the NF-kappaB inhibitor caffeic acid phenethyl ester inhibited increases in VEGF mRNA, VEGF protein and VEGF in the medium by S100B. caffeic acid phenethyl ester 75-103 vascular endothelial growth factor A Rattus norvegicus 138-142 21976136-5 2012 (125) I-VEGF was colyophilized with trehalose and serum albumin and distributed as particles throughout a photo-cross-linked elastomer composed of trimethylene carbonate, epsilon-caprolactone, and d,l-lactide. Trehalose 36-45 vascular endothelial growth factor A Rattus norvegicus 8-12 21692632-0 2012 Immunohistochemical analysis of CD45RO+ T cells and vascular endothelial growth factor expression in cyclosporin A-induced rat gingival tissue. Cyclosporine 101-114 vascular endothelial growth factor A Rattus norvegicus 52-86 21976136-5 2012 (125) I-VEGF was colyophilized with trehalose and serum albumin and distributed as particles throughout a photo-cross-linked elastomer composed of trimethylene carbonate, epsilon-caprolactone, and d,l-lactide. trimethylene carbonate 147-169 vascular endothelial growth factor A Rattus norvegicus 8-12 21692632-1 2012 BACKGROUND: The aim of this study is to evaluate CD4(+), CD8(+), and CD45RO(+) T cells, and vascular endothelial growth factor (VEGF) expression in cyclosporin A (CsA)-induced rat overgrown gingival tissue during an 8-week period. Cyclosporine 148-161 vascular endothelial growth factor A Rattus norvegicus 92-126 21692632-1 2012 BACKGROUND: The aim of this study is to evaluate CD4(+), CD8(+), and CD45RO(+) T cells, and vascular endothelial growth factor (VEGF) expression in cyclosporin A (CsA)-induced rat overgrown gingival tissue during an 8-week period. Cyclosporine 148-161 vascular endothelial growth factor A Rattus norvegicus 128-132 21976136-5 2012 (125) I-VEGF was colyophilized with trehalose and serum albumin and distributed as particles throughout a photo-cross-linked elastomer composed of trimethylene carbonate, epsilon-caprolactone, and d,l-lactide. caprolactone 171-191 vascular endothelial growth factor A Rattus norvegicus 8-12 21692632-1 2012 BACKGROUND: The aim of this study is to evaluate CD4(+), CD8(+), and CD45RO(+) T cells, and vascular endothelial growth factor (VEGF) expression in cyclosporin A (CsA)-induced rat overgrown gingival tissue during an 8-week period. Cyclosporine 163-166 vascular endothelial growth factor A Rattus norvegicus 92-126 21692632-7 2012 RESULTS: CD4(+), CD8(+), and CD45RO(+) T cells, and VEGF expression were more prevalent in the CsA-treated group than in the control group (P <0.05). Cyclosporine 95-98 vascular endothelial growth factor A Rattus norvegicus 52-56 21976136-5 2012 (125) I-VEGF was colyophilized with trehalose and serum albumin and distributed as particles throughout a photo-cross-linked elastomer composed of trimethylene carbonate, epsilon-caprolactone, and d,l-lactide. d,l-lactide 197-208 vascular endothelial growth factor A Rattus norvegicus 8-12 21692632-9 2012 CONCLUSION: Based on our findings, we conclude that VEGF, a major regulator of angiogenesis, and CD4(+), CD8(+), and CD45RO(+) memory T cells play a key role in CsA-induced gingival overgrowth. Cyclosporine 161-164 vascular endothelial growth factor A Rattus norvegicus 52-56 21750165-16 2012 As there was no difference in VEGF at the protein level in the dialysate, we hypothesize that oral sulodexide inhibits VEGF locally by binding. glucuronyl glucosamine glycan sulfate 99-109 vascular endothelial growth factor A Rattus norvegicus 119-123 22153287-9 2012 CS also blocked the compensatory increases of HIF-1alpha, VEGF, and TGF-beta in the VO-stressed heart. Cesium 0-2 vascular endothelial growth factor A Rattus norvegicus 58-62 22214372-1 2012 OBJECTIVE: The aims of this study were to examine the effects of prophylactic heparin treatment during taurocholate-induced pancreatitis in rats and its impact on serum VEGF levels and local VEGF contents within the pancreas. Heparin 78-85 vascular endothelial growth factor A Rattus norvegicus 169-173 21938552-4 2012 VEGF was shown to inhibit hypoosmotic swelling of rat Muller cells by inducing the release of glutamate (Wurm et al. Glutamic Acid 94-103 vascular endothelial growth factor A Rattus norvegicus 0-4 22214372-1 2012 OBJECTIVE: The aims of this study were to examine the effects of prophylactic heparin treatment during taurocholate-induced pancreatitis in rats and its impact on serum VEGF levels and local VEGF contents within the pancreas. Heparin 78-85 vascular endothelial growth factor A Rattus norvegicus 191-195 23157042-2 2012 In this study, we aimed to observe the effects of sorafenib in postoperative adhesions and, to examine the effects of sorafenib on tissue levels of vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF). Sorafenib 118-127 vascular endothelial growth factor A Rattus norvegicus 148-182 22178140-9 2012 Furthermore, pretreatment with rapamycin, a mTOR specific inhibitor, significantly inhibited HIF-1alpha and VEGF protein after HI. Sirolimus 31-40 vascular endothelial growth factor A Rattus norvegicus 108-112 22116052-11 2012 Additionally, edaravone reduced effectively ROS generation and HIF-1alpha as well as VEGF protein levels in the ischemic ipsilateral SVZ (P<0.05). Edaravone 14-23 vascular endothelial growth factor A Rattus norvegicus 85-89 22281871-5 2012 We recently observed that the phosphorylated form of alphaT, alpha-tocopheryl phosphate (alphaTP), increases the expression of VEGF. alpha-tocopherol phosphate 61-87 vascular endothelial growth factor A Rattus norvegicus 127-131 22281871-5 2012 We recently observed that the phosphorylated form of alphaT, alpha-tocopheryl phosphate (alphaTP), increases the expression of VEGF. alpha-tocopherol phosphate 89-96 vascular endothelial growth factor A Rattus norvegicus 127-131 22281871-6 2012 We propose that the stimulatory effect of alphaT on angiogenesis and vasculogenesis is potentiated by phosphorylation to alphaTP, which may act as a cofactor or active lipid mediator increasing VEGF expression. alpha-tocopherol phosphate 121-128 vascular endothelial growth factor A Rattus norvegicus 194-198 22281871-7 2012 Increased VEGF expression and consequent enhanced angiogenesis and vasculogenesis induced by alphaTP may explain not only the essential roles of vitamin E on reproduction, but also its beneficial effects against pre-eclampsia, ischemia/reperfusion injury, and during wound healing. alpha-tocopherol phosphate 93-100 vascular endothelial growth factor A Rattus norvegicus 10-14 21944582-9 2012 PFOB emulsions preserved viability and functionality of RINm5F cells with a decrease of HIF-1alpha and VEGF expression. perflubron 0-4 vascular endothelial growth factor A Rattus norvegicus 103-107 22472890-5 2012 An increased hypoxia inducible factor-1alpha (HIF-1alpha) translocation and vascular endothelial growth factor (VEGF) expression has been found upon 95% oxygen exposure to induce morphological modifications. Oxygen 153-159 vascular endothelial growth factor A Rattus norvegicus 76-110 22472890-5 2012 An increased hypoxia inducible factor-1alpha (HIF-1alpha) translocation and vascular endothelial growth factor (VEGF) expression has been found upon 95% oxygen exposure to induce morphological modifications. Oxygen 153-159 vascular endothelial growth factor A Rattus norvegicus 112-116 22094066-1 2012 ONO-1301, a synthetic prostacyclin agonist with thromboxane synthase inhibitory activity, promotes the production of hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF) by various cell types. ONO 1301 0-8 vascular endothelial growth factor A Rattus norvegicus 152-186 22094066-1 2012 ONO-1301, a synthetic prostacyclin agonist with thromboxane synthase inhibitory activity, promotes the production of hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF) by various cell types. ONO 1301 0-8 vascular endothelial growth factor A Rattus norvegicus 188-192 22094066-1 2012 ONO-1301, a synthetic prostacyclin agonist with thromboxane synthase inhibitory activity, promotes the production of hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF) by various cell types. Epoprostenol 22-34 vascular endothelial growth factor A Rattus norvegicus 188-192 22281871-7 2012 Increased VEGF expression and consequent enhanced angiogenesis and vasculogenesis induced by alphaTP may explain not only the essential roles of vitamin E on reproduction, but also its beneficial effects against pre-eclampsia, ischemia/reperfusion injury, and during wound healing. Vitamin E 145-154 vascular endothelial growth factor A Rattus norvegicus 10-14 22468718-2 2012 In the present study, the vascular endothelial growth factor (VEGF) levels in serum and pulmonary artery samples of rats have been analyzed with monocrotaline (MCT)-induced PH after treatments with iloprost, bosentan, and sildenafil. Monocrotaline 160-163 vascular endothelial growth factor A Rattus norvegicus 62-66 23157042-2 2012 In this study, we aimed to observe the effects of sorafenib in postoperative adhesions and, to examine the effects of sorafenib on tissue levels of vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF). Sorafenib 118-127 vascular endothelial growth factor A Rattus norvegicus 184-188 23157042-6 2012 RESULTS: The sorafenib group had lower scores of total adhesions [1 (0-2.5) vs 1.5 (1-4); p: 0.037], staining of VEGF [1 (0-1) vs 1 (1-3); p: 0.029] and PDGF [1 (0-2) vs 2 (1-3); p: 0.006], and vascular proliferation [1 (0-2) vs 2 (1-3); p: 0.038] than the control group. Sorafenib 13-22 vascular endothelial growth factor A Rattus norvegicus 113-117 22888345-1 2012 We aimed to investigate whether oral administration of captopril modulate wound healing, nitric oxide (NO), and vascular endothelial growth factor (VEGF) concentration in wound fluid of diabetic rats. Captopril 55-64 vascular endothelial growth factor A Rattus norvegicus 112-146 22927877-5 2012 DBT decreased the expression of VEGF, Ang1 and TGF-beta1 and their signaling mediators, whereas NAC had no effect on VEGF and VEGFR2 expression. di-n-butyltin 0-3 vascular endothelial growth factor A Rattus norvegicus 32-36 22121831-10 2012 CONCLUSION: The long form of Flk-1 is the predominant mediator of VEGF-A in the pathogenesis of diabetic retinopathy (DR) and can be significantly inhibited by the IVTA treatment. ivta 164-168 vascular endothelial growth factor A Rattus norvegicus 66-72 21911594-6 2012 Results showed that VEGF significantly increased permeability (x10(7) mum(3)/min) from 9.7 +- 3.5 to 21.0 +- 1.5 (P<0.05) in NP veins exposed to NP plasma, that was prevented when LP veins were exposed to LP plasma; (9.7+-3.8; P>0.05). leucylproline 183-185 vascular endothelial growth factor A Rattus norvegicus 20-24 21911594-6 2012 Results showed that VEGF significantly increased permeability (x10(7) mum(3)/min) from 9.7 +- 3.5 to 21.0 +- 1.5 (P<0.05) in NP veins exposed to NP plasma, that was prevented when LP veins were exposed to LP plasma; (9.7+-3.8; P>0.05). leucylproline 208-210 vascular endothelial growth factor A Rattus norvegicus 20-24 21911594-7 2012 Both LP plasma and soluble FMS-like tyrosine-kinase 1 (sFlt1) in NP plasma abolished VEGF-induced BBB permeability in NP veins (9.5+-2.9 and 12+-2.6; P>0.05). leucylproline 5-7 vascular endothelial growth factor A Rattus norvegicus 85-89 22888345-1 2012 We aimed to investigate whether oral administration of captopril modulate wound healing, nitric oxide (NO), and vascular endothelial growth factor (VEGF) concentration in wound fluid of diabetic rats. Captopril 55-64 vascular endothelial growth factor A Rattus norvegicus 148-152 22888345-12 2012 VEGF concentration was significantly higher in both captopril-treated groups versus DM-control group (P < .05). Captopril 52-61 vascular endothelial growth factor A Rattus norvegicus 0-4 22949809-0 2012 Effects of high glucose on vascular endothelial growth factor synthesis and secretion in aortic vascular smooth muscle cells from obese and lean Zucker rats. Glucose 16-23 vascular endothelial growth factor A Rattus norvegicus 27-61 22507334-11 2012 Atorvastatin was also found to increase neuroprotection factors pAkt/Akt, eNOS and VEGF. Atorvastatin 0-12 vascular endothelial growth factor A Rattus norvegicus 83-87 22949809-6 2012 Thus, glucose increases via an osmotic mechanism VEGF synthesis and secretion in VSMC, an effect attenuated in the presence of insulin resistance. Glucose 6-13 vascular endothelial growth factor A Rattus norvegicus 49-53 22293291-6 2012 These intestinal lesions healed spontaneously within 6 days, but the process was impaired by the repeated administration of low-dose loxoprofen (30 mg/kg) for 5 days after the ulceration, with the decrease of vascular endothelial derived growth factor (VEGF) expression and angiogenesis. loxoprofen 133-143 vascular endothelial growth factor A Rattus norvegicus 209-251 21311050-9 2012 There was a significant improvement of erectile function, the content of smooth muscle and endothelium, and the VEGF concentration in the corpus cavernosum in the DM+VMSC group compared with the DM+MSC group. vmsc 169-173 vascular endothelial growth factor A Rattus norvegicus 114-118 21898537-8 2012 Consumption of Suppl SB resulted in decreased serum VEGF levels (18.42%), N-acetylglucosaminidase activity (27.77%), IL1beta concentration (9.07%), and NO released (77.06%), accompanied by a reduced redox state as observed by increased GSH/GSSG ratio (to 198.80%). suppl sb 15-23 vascular endothelial growth factor A Rattus norvegicus 52-56 22150679-9 2012 The proteins of HIF-1alpha, VEGF and RTP801 were significantly increased by dexmedetomidine treatment. Dexmedetomidine 76-91 vascular endothelial growth factor A Rattus norvegicus 28-32 22150679-10 2012 CONCLUSIONS: Dexmedetomidine activated the I2 imidazoline receptor-PI3K/AKT pathway, and up-regulated HIF-1alpha, VEGF and RTP801 expression to protect against OGD-induced injury in rat C6 cells. Dexmedetomidine 13-28 vascular endothelial growth factor A Rattus norvegicus 114-118 22293291-6 2012 These intestinal lesions healed spontaneously within 6 days, but the process was impaired by the repeated administration of low-dose loxoprofen (30 mg/kg) for 5 days after the ulceration, with the decrease of vascular endothelial derived growth factor (VEGF) expression and angiogenesis. loxoprofen 133-143 vascular endothelial growth factor A Rattus norvegicus 253-257 21777345-7 2012 L-mimosine administered from week 5 to week 12 led to accumulation of HIF-1alpha and HIF-2alpha proteins, increased expression of VEGF, HO-1 and GLUT-1, and improved renal function. Mimosine 0-10 vascular endothelial growth factor A Rattus norvegicus 130-134 22355244-13 2012 In diabetes conditions, K5R expression levels are decreased in the retina, which could contribute to the VEGF overexpression in diabetic retinopathy. k5r 24-27 vascular endothelial growth factor A Rattus norvegicus 105-109 21863308-9 2012 Pretreatment with PD98059 significantly inhibited COX-2 expression and VEGF production within the PDGF-activated HSCs, but the effect was nullified by exogenous prostaglandin E2. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 18-25 vascular endothelial growth factor A Rattus norvegicus 71-75 21863308-9 2012 Pretreatment with PD98059 significantly inhibited COX-2 expression and VEGF production within the PDGF-activated HSCs, but the effect was nullified by exogenous prostaglandin E2. Dinoprostone 161-177 vascular endothelial growth factor A Rattus norvegicus 71-75 21863308-11 2012 VEGF production in PDGF-stimulated HSCs is dependent on the overexpression of COX-2 protein via the phospho-p42/44 MAP kinase activation, based on PD98059 inhibition. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 147-154 vascular endothelial growth factor A Rattus norvegicus 0-4 22511847-8 2012 Blocking with GZ, NAC, and JNK significantly suppressed AGE-induced VEGF-A production. Glycyrrhizic Acid 14-16 vascular endothelial growth factor A Rattus norvegicus 68-74 22511847-8 2012 Blocking with GZ, NAC, and JNK significantly suppressed AGE-induced VEGF-A production. Acetylcysteine 18-21 vascular endothelial growth factor A Rattus norvegicus 68-74 22511847-10 2012 Blocking HMGB1, ROS, or the JNK pathway may attenuate VEGF-A production, suggesting HMGB1 and related signaling molecules play a role in diabetic retinopathy. ros 16-19 vascular endothelial growth factor A Rattus norvegicus 54-60 22126908-7 2012 RESULTS: CsA-treated rats developed mild hyperuricemia with arteriolar hyalinosis, tubular atrophy, striped interstitial fibrosis, increased cell proliferation and decreased VEGF expression. Cyclosporine 9-12 vascular endothelial growth factor A Rattus norvegicus 174-178 22126908-8 2012 Treatment with allopurinol or benzbromarone limited renal disease, with reduced interstitial fibrosis, cell proliferation, macrophage infiltration, osteopontin expression and arteriolar hyalinosis, in association with restoration of VEGF expression. Allopurinol 15-26 vascular endothelial growth factor A Rattus norvegicus 233-237 22126908-8 2012 Treatment with allopurinol or benzbromarone limited renal disease, with reduced interstitial fibrosis, cell proliferation, macrophage infiltration, osteopontin expression and arteriolar hyalinosis, in association with restoration of VEGF expression. Benzbromarone 30-43 vascular endothelial growth factor A Rattus norvegicus 233-237 21807004-8 2012 VEGF receptor (FLK-1) inhibition was achieved by i.c.v administration of the antagonist SU5416 during the period of EE/VE. Semaxinib 88-94 vascular endothelial growth factor A Rattus norvegicus 0-4 22675432-8 2012 RESULTS: Acute administration of acrolein caused a significant elevation of activated caspase 3, upregulation of VEGF expression and induced ER stress proteins in the lung tissue. Acrolein 33-41 vascular endothelial growth factor A Rattus norvegicus 113-117 23226440-4 2012 We have previously engineered poly(ethylene glycol) (PEG)-based hydrogels to present cell adhesive motifs and deliver VEGF to promote vascularization in vivo. Polyethylene Glycols 30-51 vascular endothelial growth factor A Rattus norvegicus 118-122 23226440-4 2012 We have previously engineered poly(ethylene glycol) (PEG)-based hydrogels to present cell adhesive motifs and deliver VEGF to promote vascularization in vivo. Polyethylene Glycols 53-56 vascular endothelial growth factor A Rattus norvegicus 118-122 23056375-7 2012 Endothelial cell proliferation was reduced in corticosterone treated cells, coinciding with elevated FoxO1 and reduced VEGF production. Corticosterone 46-60 vascular endothelial growth factor A Rattus norvegicus 119-123 22745791-3 2012 We investigated the renal effects of the administration, during 45 days, of sunitinib (Su), a VEGF receptor inhibitor, to rats with 5/6 renal ablation (Nx). Sunitinib 76-85 vascular endothelial growth factor A Rattus norvegicus 94-98 22715398-18 2012 Thus, we show that l-THP activates the PI3K/Akt/eNOS/NO pathway and increases expression of HIF-1alpha and VEGF, whilst depressing iNOS-derived NO production in myocardium. tetrahydropalmatine 19-24 vascular endothelial growth factor A Rattus norvegicus 107-111 22276220-5 2012 PRINCIPAL FINDINGS: Copper depletion caused emphysematous changes, decreased HIF-1alpha activity, and downregulated VEGF expression in the rat lungs. Copper 20-26 vascular endothelial growth factor A Rattus norvegicus 116-120 22715398-13 2012 However, the expression of HIF-1alpha and VEGF were increased in I(30 min)R(6 h), but decreased to normal level in I(30 min)R(24 h), while treatment with l-THP (20 mg/kg b.w.) tetrahydropalmatine 154-159 vascular endothelial growth factor A Rattus norvegicus 42-46 22645419-5 2012 Stimulatory effect of estrogen on cell proliferation and VEGF expression in blood vessels was attenuated by losartan, PD123319, and captopril. Losartan 108-116 vascular endothelial growth factor A Rattus norvegicus 57-61 22276220-1 2012 BACKGROUND: Copper is an important regulator of hypoxia inducible factor 1 alpha (HIF-1alpha) dependent vascular endothelial growth factor (VEGF) expression, and is also required for the activity of lysyl oxidase (LOX) to effect matrix protein cross-linking. Copper 12-18 vascular endothelial growth factor A Rattus norvegicus 104-138 22276220-1 2012 BACKGROUND: Copper is an important regulator of hypoxia inducible factor 1 alpha (HIF-1alpha) dependent vascular endothelial growth factor (VEGF) expression, and is also required for the activity of lysyl oxidase (LOX) to effect matrix protein cross-linking. Copper 12-18 vascular endothelial growth factor A Rattus norvegicus 140-144 22645419-5 2012 Stimulatory effect of estrogen on cell proliferation and VEGF expression in blood vessels was attenuated by losartan, PD123319, and captopril. PD 123319 118-126 vascular endothelial growth factor A Rattus norvegicus 57-61 22645419-5 2012 Stimulatory effect of estrogen on cell proliferation and VEGF expression in blood vessels was attenuated by losartan, PD123319, and captopril. Captopril 132-141 vascular endothelial growth factor A Rattus norvegicus 57-61 21895488-2 2012 We have employed a freely interconnecting porous scaffold developed by us to determine the utility of a covalently bound heparin surface coating for the delivery of vascular endothelial growth factor (VEGF) and platelet-derived growth factor BB (PDGF-BB) in vivo. Heparin 121-128 vascular endothelial growth factor A Rattus norvegicus 165-199 21895488-2 2012 We have employed a freely interconnecting porous scaffold developed by us to determine the utility of a covalently bound heparin surface coating for the delivery of vascular endothelial growth factor (VEGF) and platelet-derived growth factor BB (PDGF-BB) in vivo. Heparin 121-128 vascular endothelial growth factor A Rattus norvegicus 201-205 21895488-3 2012 The heparin surface was shown to release VEGF far more rapidly than PDGF-BB in vitro (VEGF: 75 ng/h for 24 h; PDGF-BB: 86 pg/h for >7 days). Heparin 4-11 vascular endothelial growth factor A Rattus norvegicus 41-45 21895488-3 2012 The heparin surface was shown to release VEGF far more rapidly than PDGF-BB in vitro (VEGF: 75 ng/h for 24 h; PDGF-BB: 86 pg/h for >7 days). Heparin 4-11 vascular endothelial growth factor A Rattus norvegicus 86-90 21895488-9 2012 Thus, the covalent modification of a porous scaffold with heparin allows for the differential release of VEGF and PDGF-BB that results in both a rapid and sustained increase in scaffold vascularization. Heparin 58-65 vascular endothelial growth factor A Rattus norvegicus 105-109 23983337-6 2012 Moreover, QDTM increased the serum VEGF-A level (P < 0.05) in rats treated with hypoxia for 7 days but suppressed the upregulation of serum VEGF-A in rats treated with hypoxia for 14 days. qdtm 10-14 vascular endothelial growth factor A Rattus norvegicus 35-41 22332532-13 2012 CONCLUSION: rShh-N treatment can enhance the expression and secretion of VEGF and bFGF in BMSCs, which could provide the experimental evidence for the further application of Shh-MSCs in the treatment of ischemia-related diseases and bone repair. rshh-n 12-18 vascular endothelial growth factor A Rattus norvegicus 73-77 23983337-6 2012 Moreover, QDTM increased the serum VEGF-A level (P < 0.05) in rats treated with hypoxia for 7 days but suppressed the upregulation of serum VEGF-A in rats treated with hypoxia for 14 days. qdtm 10-14 vascular endothelial growth factor A Rattus norvegicus 143-149 22340244-4 2011 LY294002 and AMD3100 were used to interfere with the signaling of VEGF and SDF-1alpha/CXCR4 axis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 vascular endothelial growth factor A Rattus norvegicus 66-70 21925572-0 2011 Phosphatidylcholine hydroperoxide promotes VEGF-induced angiogenesis in endothelial cells and rat aorta ring cultures. phosphatidylcholine hydroperoxide 0-33 vascular endothelial growth factor A Rattus norvegicus 43-47 21964460-8 2011 Concomitant up regulation of ERalpha, VEGF, cyclin D1, CDK4 and Ki-67 was also observed to be more prominent for ATRA-treated rats as compared to the rats that were allowed to recover naturally for 56 days. Tretinoin 113-117 vascular endothelial growth factor A Rattus norvegicus 38-42 21801813-7 2011 VEGF up-regulates the activity of ERK (extracellular signal-regulated kinase) in cultured cortical neurons and U0126 (a mitogen activated protein kinase kinase (MEK) inhibitor) suppressed VEGF induced activity of ERK. U 0126 111-116 vascular endothelial growth factor A Rattus norvegicus 188-192 21801813-8 2011 Furthermore, incubation of cells with U0126 attenuated the ability of VEGF to protect neurons against mechanical trauma-induced apoptosis. U 0126 38-43 vascular endothelial growth factor A Rattus norvegicus 70-74 21821731-3 2011 We found that CIH did not modify the CB volume or the number of glomus cells but increased VEGF-ir and enlarged the vascular area by increasing the size of the blood vessels, whereas the number of the vessels was unchanged. cih 14-17 vascular endothelial growth factor A Rattus norvegicus 91-95 21821731-4 2011 Because oxidative stress plays an essential role in the CIH-induced carotid chemosensory potentiation, we tested whether antioxidant treatment with ascorbic acid may impede the vascular enlargement and the VEGF upregulation. Ascorbic Acid 148-161 vascular endothelial growth factor A Rattus norvegicus 206-210 21969195-9 2011 The eNOS protein expression and NO production were significantly increased from 72 to 168 h. The expression of VEGF protein was significantly increased at 72 h. L-NAME significantly inhibited the increases in the liver mass and decreased the PCNA labeling index of hepatocytes at 24 h. L-NAME also inhibited the induction of VEGF protein at 72 h. CONCLUSIONS: Endothelial NOS and VEGF coordinately regulate SEC proliferation during liver regeneration. NG-Nitroarginine Methyl Ester 161-167 vascular endothelial growth factor A Rattus norvegicus 111-115 21969195-9 2011 The eNOS protein expression and NO production were significantly increased from 72 to 168 h. The expression of VEGF protein was significantly increased at 72 h. L-NAME significantly inhibited the increases in the liver mass and decreased the PCNA labeling index of hepatocytes at 24 h. L-NAME also inhibited the induction of VEGF protein at 72 h. CONCLUSIONS: Endothelial NOS and VEGF coordinately regulate SEC proliferation during liver regeneration. NG-Nitroarginine Methyl Ester 161-167 vascular endothelial growth factor A Rattus norvegicus 325-329 21969195-9 2011 The eNOS protein expression and NO production were significantly increased from 72 to 168 h. The expression of VEGF protein was significantly increased at 72 h. L-NAME significantly inhibited the increases in the liver mass and decreased the PCNA labeling index of hepatocytes at 24 h. L-NAME also inhibited the induction of VEGF protein at 72 h. CONCLUSIONS: Endothelial NOS and VEGF coordinately regulate SEC proliferation during liver regeneration. NG-Nitroarginine Methyl Ester 161-167 vascular endothelial growth factor A Rattus norvegicus 325-329 21969195-9 2011 The eNOS protein expression and NO production were significantly increased from 72 to 168 h. The expression of VEGF protein was significantly increased at 72 h. L-NAME significantly inhibited the increases in the liver mass and decreased the PCNA labeling index of hepatocytes at 24 h. L-NAME also inhibited the induction of VEGF protein at 72 h. CONCLUSIONS: Endothelial NOS and VEGF coordinately regulate SEC proliferation during liver regeneration. NG-Nitroarginine Methyl Ester 286-292 vascular endothelial growth factor A Rattus norvegicus 111-115 22039247-10 2011 With DTSH treatment, doxycycline inhibited the activity and expression of MMPs, the expression of VEGF and of phosphorylated VEGFR1 and VEGFR2, and the production of iNOS and IL-1beta in local cornea. dtsh 5-9 vascular endothelial growth factor A Rattus norvegicus 98-102 22039247-10 2011 With DTSH treatment, doxycycline inhibited the activity and expression of MMPs, the expression of VEGF and of phosphorylated VEGFR1 and VEGFR2, and the production of iNOS and IL-1beta in local cornea. Doxycycline 21-32 vascular endothelial growth factor A Rattus norvegicus 98-102 22039247-11 2011 CONCLUSIONS: Doxycycline enhances the inhibitory effects of bevacizumab on CNV and prevents its side effects on CWH, possibly by inhibiting the expression and activity of MMPs, the expression of VEGF and of phosphorylated VEGFR1 and VEGFR2, and the production of iNOS and IL-1beta. Doxycycline 13-24 vascular endothelial growth factor A Rattus norvegicus 195-199 21821731-1 2011 Chronic intermittent hypoxia (CIH), a characteristic of sleep obstructive apnea, enhances carotid body (CB) chemosensory responses to hypoxia, but its consequences on CB vascular area and VEGF expression are unknown. cih 30-33 vascular endothelial growth factor A Rattus norvegicus 188-192 21785345-18 2011 Moderate-intensity and high-intensity running upregulated the expression of VEGF protein and increased microvessels, which may have partly improved cardiac function after MI in this study. 2-methyl-4-isothiazolin-3-one 171-173 vascular endothelial growth factor A Rattus norvegicus 76-80 22340244-7 2011 VEGF attenuated H2O2 induced cardiac myocyte death. Hydrogen Peroxide 16-20 vascular endothelial growth factor A Rattus norvegicus 0-4 22340244-8 2011 The phosphoinositol-3-kinase (PI3K) inhibitor, LY294002 and Flk-1 antibody abolished the beneficial effects of VEGF on H2O2 induced cell death. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 47-55 vascular endothelial growth factor A Rattus norvegicus 111-115 22340244-8 2011 The phosphoinositol-3-kinase (PI3K) inhibitor, LY294002 and Flk-1 antibody abolished the beneficial effects of VEGF on H2O2 induced cell death. Hydrogen Peroxide 119-123 vascular endothelial growth factor A Rattus norvegicus 111-115 22340244-9 2011 In the mean time SDF-1alpha-CXCR4 axis was up-regulated by VEGF through PI3K-Akt signaling and contributed to the protective effects of VEGF on H2O2 induced cell death. Hydrogen Peroxide 144-148 vascular endothelial growth factor A Rattus norvegicus 136-140 22340244-10 2011 Interestingly, SDF-1alpha also promoted production of VEGF in cultured cardiac myocytes and LY294002 reversed the up-regulation of VEGF induced by SDF-1alpha. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 92-100 vascular endothelial growth factor A Rattus norvegicus 131-135 22045654-8 2011 The high-glucose-induced expression of VEGF and its receptor VEGF receptor II (flk-1) was also ameliorated by curcumin. Glucose 9-16 vascular endothelial growth factor A Rattus norvegicus 39-43 20462597-15 2011 The expression of VEGF, VEGFR-2, VEGFR-3, GHR, and IGF-1R was significantly lower in HAL group than in CON group (P < 0.05). hal 85-88 vascular endothelial growth factor A Rattus norvegicus 18-22 20462597-16 2011 Following administration of rhGH to HAL rats, the expression of VEGF, VEGFR-2, VEGFR-3, IGF-1R, and GHR was significantly higher (P < 0.05). rhgh 28-32 vascular endothelial growth factor A Rattus norvegicus 64-68 20462597-16 2011 Following administration of rhGH to HAL rats, the expression of VEGF, VEGFR-2, VEGFR-3, IGF-1R, and GHR was significantly higher (P < 0.05). hal 36-39 vascular endothelial growth factor A Rattus norvegicus 64-68 22045654-8 2011 The high-glucose-induced expression of VEGF and its receptor VEGF receptor II (flk-1) was also ameliorated by curcumin. Glucose 9-16 vascular endothelial growth factor A Rattus norvegicus 61-65 22045654-8 2011 The high-glucose-induced expression of VEGF and its receptor VEGF receptor II (flk-1) was also ameliorated by curcumin. Curcumin 110-118 vascular endothelial growth factor A Rattus norvegicus 39-43 22045654-8 2011 The high-glucose-induced expression of VEGF and its receptor VEGF receptor II (flk-1) was also ameliorated by curcumin. Curcumin 110-118 vascular endothelial growth factor A Rattus norvegicus 61-65 22040519-13 2011 Silymarin and EGb also beneficially down-regulated the increase in serum ALT, AST, GGT activities and VEGF level induced by NDEA. Silymarin 0-9 vascular endothelial growth factor A Rattus norvegicus 102-106 22092841-9 2011 CD31-positive vessels and VEGF protein expression were significantly greater in the RLX group. Relaxin 84-87 vascular endothelial growth factor A Rattus norvegicus 26-30 22092841-10 2011 Thus, administration of RLX-expressing adenovirus into elevated skin flaps increased VEGF expression, the number of capillaries, and blood flow to the flap, thereby improving skin flap survival. Relaxin 24-27 vascular endothelial growth factor A Rattus norvegicus 85-89 22053310-13 2011 These results suggest that the suppression of the increased NGF and VEGF levels might partially be involved in the improvement of allergy-like behavior (sneezing and nasal skin temperature rise) by the treatment of olopatadine. Olopatadine Hydrochloride 215-226 vascular endothelial growth factor A Rattus norvegicus 68-72 22229198-10 2011 Immunocytochemistry results showed positive DAB staining for VEGF at 5 and 7 days in experimental group. diazobenzenesulfonic acid 44-47 vascular endothelial growth factor A Rattus norvegicus 61-65 21703259-0 2011 Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial proliferation, arterial relaxation, vascular permeability and angiogenesis by dobesilate. 2,5-Dihydroxybenzenesulfonic Acid 154-164 vascular endothelial growth factor A Rattus norvegicus 14-48 21190420-2 2011 The authors aimed to investigate the effect of sildenafil citrate (Sc) on expressions of beta(3) integrin and vascular endothelial growth factor (VEGF), which is taking part in endometrium receptivity in implantation window period in controlled ovarian hyperstimulation (COH) performed rats. Sildenafil Citrate 47-65 vascular endothelial growth factor A Rattus norvegicus 110-144 21190420-2 2011 The authors aimed to investigate the effect of sildenafil citrate (Sc) on expressions of beta(3) integrin and vascular endothelial growth factor (VEGF), which is taking part in endometrium receptivity in implantation window period in controlled ovarian hyperstimulation (COH) performed rats. Sildenafil Citrate 47-65 vascular endothelial growth factor A Rattus norvegicus 146-150 21513798-10 2011 At PND 50, an increased vascular area associated with higher VEGF expression was observed in the 250 BPA-treated rats. bisphenol A 101-104 vascular endothelial growth factor A Rattus norvegicus 61-65 21703259-0 2011 Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial proliferation, arterial relaxation, vascular permeability and angiogenesis by dobesilate. 2,5-Dihydroxybenzenesulfonic Acid 154-164 vascular endothelial growth factor A Rattus norvegicus 50-54 21703259-3 2011 The aim of the present study was to evaluate the effects of DHBS on VEGF-induced actions. dihydrodibutylstilbestrol 60-64 vascular endothelial growth factor A Rattus norvegicus 68-72 21703259-5 2011 DHBS at 50 and 100 muM concentration significantly inhibited the proliferation of HUVEC induced by VEGF (10 ng/ml), without significantly affecting HUVEC proliferation in the absence of VEGF. dihydrodibutylstilbestrol 0-4 vascular endothelial growth factor A Rattus norvegicus 99-103 21703259-6 2011 Rapid VEGF-induced activation of Akt in HUVEC was also prevented by DHBS (100 muM). dihydrodibutylstilbestrol 68-72 vascular endothelial growth factor A Rattus norvegicus 6-10 21703259-7 2011 Additionally, DHBS (2 muM) specifically inhibited the relaxation of rat aorta induced by VEGF (0.1 to 30 ng/ml), but not endothelium-dependent relaxation to acetylcholine (1 nM to 10 muM). dihydrodibutylstilbestrol 14-18 vascular endothelial growth factor A Rattus norvegicus 89-93 21703259-8 2011 The in vivo enhancement of vascular permeability caused by VEGF injection (50 mul at 10 ng/ml) in rat skin was also inhibited by DHBS co-administration (200 muM) (74.8+-3.8% inhibition of dye extravasation). dihydrodibutylstilbestrol 129-133 vascular endothelial growth factor A Rattus norvegicus 59-63 21664951-4 2011 administration of 500 pmol/d Ala(1,3,11,15)-ET-1, an ET(B) receptor agonist, increased the level of VEGF-A mRNA in the rat cerebrum, whereas those of VEGF-B, placental growth factor (PLGF), angiopoietin (ANG)-1, and ANG-2 mRNAs were not largely affected by Ala(1,3,11,15)-ET. ala(1,3,11,15)-et-1 29-48 vascular endothelial growth factor A Rattus norvegicus 100-106 21703259-11 2011 DHBS inhibits main responses elicited in vitro and in vivo by VEGF. dihydrodibutylstilbestrol 0-4 vascular endothelial growth factor A Rattus norvegicus 62-66 21664951-4 2011 administration of 500 pmol/d Ala(1,3,11,15)-ET-1, an ET(B) receptor agonist, increased the level of VEGF-A mRNA in the rat cerebrum, whereas those of VEGF-B, placental growth factor (PLGF), angiopoietin (ANG)-1, and ANG-2 mRNAs were not largely affected by Ala(1,3,11,15)-ET. Alanine 29-32 vascular endothelial growth factor A Rattus norvegicus 100-106 21703259-12 2011 As a dual antagonist of VEGF and FGF activities, DHBS could be of therapeutic interest in the treatment of diseases related to VEGF/FGF overproduction and excessive angiogenesis. dihydrodibutylstilbestrol 49-53 vascular endothelial growth factor A Rattus norvegicus 24-28 21664951-5 2011 The ET-induced increases in cerebrum VEGF-A mRNA were reduced by coadministration of 1 nmol/d BQ788, an ET(B) antagonist. BQ 788 94-99 vascular endothelial growth factor A Rattus norvegicus 37-43 21664951-6 2011 Ala(1,3,11,15)-ET-1 also stimulated the production of VEGF-A proteins in the cerebrum. ala(1,3,11,15)-et-1 0-19 vascular endothelial growth factor A Rattus norvegicus 54-60 21703259-12 2011 As a dual antagonist of VEGF and FGF activities, DHBS could be of therapeutic interest in the treatment of diseases related to VEGF/FGF overproduction and excessive angiogenesis. dihydrodibutylstilbestrol 49-53 vascular endothelial growth factor A Rattus norvegicus 127-131 21977870-9 2011 RESULTS: Compared with the model group, the expression of VEGF and TGF-beta1, and the density of small arteries and the number of VEGF-positive blood vessels in the AI group and the MI group significantly increased (both P < 0.01). 2-methyl-4-isothiazolin-3-one 182-184 vascular endothelial growth factor A Rattus norvegicus 58-62 21807419-3 2011 In addition, VEGF expression was increased in neurons and over-expressed in glial cells in a model of neuroexcitotoxicity in the hippocampus, in which rats were neonatally exposed to high glutamate concentrations. Glutamic Acid 188-197 vascular endothelial growth factor A Rattus norvegicus 13-17 21276205-0 2011 Vascular endothelial growth factor protects post-ganglionic sympathetic neurones from the detrimental effects of hydrogen peroxide by increasing catalase. Hydrogen Peroxide 113-130 vascular endothelial growth factor A Rattus norvegicus 0-34 21276205-3 2011 Vascular cells also produce vascular endothelial growth factor (VEGF), which could protect perivascular nerves from the detrimental effects of H(2)O(2) . Hydrogen Peroxide 143-151 vascular endothelial growth factor A Rattus norvegicus 28-62 21276205-3 2011 Vascular cells also produce vascular endothelial growth factor (VEGF), which could protect perivascular nerves from the detrimental effects of H(2)O(2) . Hydrogen Peroxide 143-151 vascular endothelial growth factor A Rattus norvegicus 64-68 21276205-10 2011 VEGF increased catalase, a primary determinant of intracellular concentrations of H(2)O(2) , and decreased H(2)O(2) -induced increases in ROS. Reactive Oxygen Species 138-141 vascular endothelial growth factor A Rattus norvegicus 0-4 21620822-2 2011 The present study was undertaken to determine mechanisms through which pazopanib, a drug that targets multiple receptor tyrosine kinases such as VEGF receptors, inhibits angiogenesis and experimental choroidal neovascularization (CNV). pazopanib 71-80 vascular endothelial growth factor A Rattus norvegicus 145-149 21620822-3 2011 Pazopanib inhibited VEGF expression by retinal pigment epithelium (RPE) cells and choroidal endothelial cells (CEC), decreased VEGF-induced cellular migration in a dose-dependent manner and suppressed extracellular signal-regulated kinase (ERK)-1/-2 phosphorylation. pazopanib 0-9 vascular endothelial growth factor A Rattus norvegicus 20-24 21620822-3 2011 Pazopanib inhibited VEGF expression by retinal pigment epithelium (RPE) cells and choroidal endothelial cells (CEC), decreased VEGF-induced cellular migration in a dose-dependent manner and suppressed extracellular signal-regulated kinase (ERK)-1/-2 phosphorylation. pazopanib 0-9 vascular endothelial growth factor A Rattus norvegicus 127-131 21620822-6 2011 Furthermore, the thickness of the developed CNV lesions was significantly inhibited by 71.7% (P<0.001) in pazopanib-treated eyes, and immunoreactivity of VEGF was lower than in control eyes. pazopanib 109-118 vascular endothelial growth factor A Rattus norvegicus 157-161 21640648-8 2011 In summary, after PH pretreatment, transplantation of fetal hepatocyte-embedded, heparin-immobilized, collagen-gel-filled PUF scaffold into a VEGF-induced prevascularized cavity appears to be a promising strategy for future liver tissue engineering. Heparin 81-88 vascular endothelial growth factor A Rattus norvegicus 142-146 21804442-11 2011 VEGF protein levels in the allograft epithelium of the BMSCs injection group were higher than the levels in the phosphate-buffered saline injection group. Phosphate-Buffered Saline 112-137 vascular endothelial growth factor A Rattus norvegicus 0-4 21766270-0 2011 Effect of systemic piracetam treatment on flap survival and vascular endothelial growth factor expression after ischemia-reperfusion injury. Piracetam 19-28 vascular endothelial growth factor A Rattus norvegicus 60-94 21766270-12 2011 VEGF expression was significantly increased in piracetam-treated Group 4 compared with Group 3 ( P = 0.005). Piracetam 47-56 vascular endothelial growth factor A Rattus norvegicus 0-4 21766270-13 2011 This experimental study demonstrates that systemic piracetam treatment improves survival of pedicled flaps, reduces necrosis amounts, and increases VEGF expression in I/R induced flaps. Piracetam 51-60 vascular endothelial growth factor A Rattus norvegicus 148-152 21977870-9 2011 RESULTS: Compared with the model group, the expression of VEGF and TGF-beta1, and the density of small arteries and the number of VEGF-positive blood vessels in the AI group and the MI group significantly increased (both P < 0.01). 2-methyl-4-isothiazolin-3-one 182-184 vascular endothelial growth factor A Rattus norvegicus 130-134 21977870-10 2011 Compared with the MI group, the density of small arteries and the number of VEGF-positive blood vessels in the AI group significantly increased (both P < 0.01); Compared with the model group and the normal control group, the serum expression quantity of NO and VEGF in the AI group and the MI group were significantly increased (P < 0.01). 2-methyl-4-isothiazolin-3-one 18-20 vascular endothelial growth factor A Rattus norvegicus 76-80 21268133-0 2011 Diclofenac, a selective COX-2 inhibitor, inhibits DMH-induced colon tumorigenesis through suppression of MCP-1, MIP-1alpha and VEGF. Diclofenac 0-10 vascular endothelial growth factor A Rattus norvegicus 127-131 21709668-15 2011 VEGF increased in the ocular fluid after laser treatment and was inhibited by bromfenac and SnMP canceling these effects. bromfenac 78-87 vascular endothelial growth factor A Rattus norvegicus 0-4 21709668-15 2011 VEGF increased in the ocular fluid after laser treatment and was inhibited by bromfenac and SnMP canceling these effects. tin mesoporphyrin 92-96 vascular endothelial growth factor A Rattus norvegicus 0-4 21268133-0 2011 Diclofenac, a selective COX-2 inhibitor, inhibits DMH-induced colon tumorigenesis through suppression of MCP-1, MIP-1alpha and VEGF. Dimenhydrinate 50-53 vascular endothelial growth factor A Rattus norvegicus 127-131 21268133-7 2011 Expression of COX-2 and VEGF was found to be significantly elevated in the DMH-treated group as compared to the control, which was lowered notably by Diclofenac co-administration with DMH. Dimenhydrinate 75-78 vascular endothelial growth factor A Rattus norvegicus 24-28 21268133-7 2011 Expression of COX-2 and VEGF was found to be significantly elevated in the DMH-treated group as compared to the control, which was lowered notably by Diclofenac co-administration with DMH. Diclofenac 150-160 vascular endothelial growth factor A Rattus norvegicus 24-28 21268133-7 2011 Expression of COX-2 and VEGF was found to be significantly elevated in the DMH-treated group as compared to the control, which was lowered notably by Diclofenac co-administration with DMH. Dimenhydrinate 184-187 vascular endothelial growth factor A Rattus norvegicus 24-28 21268133-10 2011 Our results indicate potential role of chemokines alongwith VEGF in angiogenesis in DMH-induced cancer and its chemoprevention with diclofenac. Dimenhydrinate 84-87 vascular endothelial growth factor A Rattus norvegicus 60-64 21906476-1 2011 AIM: To explore the effect of VEGF inhibitor SU5416 on podocytopathy of rats with type I diabetic nephropathy. Semaxinib 45-51 vascular endothelial growth factor A Rattus norvegicus 30-34 21906476-13 2011 CONCLUSION: VEGF-R inhibitor SU5416 can obviously ameliorate albuminuria and histologic changes, and restore the expression of podocyte-specific genes nephrin and podocin in DN rats, suggesting that VEGF-R inhibitor is beneficial for the repair of podocytes in DN, which might be an important adjunct for podocytopathy therapy. Semaxinib 29-35 vascular endothelial growth factor A Rattus norvegicus 12-16 21906476-13 2011 CONCLUSION: VEGF-R inhibitor SU5416 can obviously ameliorate albuminuria and histologic changes, and restore the expression of podocyte-specific genes nephrin and podocin in DN rats, suggesting that VEGF-R inhibitor is beneficial for the repair of podocytes in DN, which might be an important adjunct for podocytopathy therapy. Semaxinib 29-35 vascular endothelial growth factor A Rattus norvegicus 199-203 21575684-2 2011 It has been shown that vascular endothelial growth factor (VEGF) induces a Ca2+-dependent release of glutamate from the cells [Wurm et al. Glutamic Acid 101-110 vascular endothelial growth factor A Rattus norvegicus 23-57 22129820-9 2011 High dose of enalapril decreased the serum and dialysate TGF-beta1 levels, decreased the thickness of the liver peritoneum, and decreased the expression of TGF-beta1, alpha-SMA, fibronectin, collagen and VEGF-positive cells in the liver peritoneum. Enalapril 13-22 vascular endothelial growth factor A Rattus norvegicus 204-208 21575684-2 2011 It has been shown that vascular endothelial growth factor (VEGF) induces a Ca2+-dependent release of glutamate from the cells [Wurm et al. Glutamic Acid 101-110 vascular endothelial growth factor A Rattus norvegicus 59-63 21575684-5 2011 We found that the inhibitory effect of VEGF on the osmotic swelling of retinal glial cells, used as an indicator of glutamate release, is prevented in the presence of selective blockers of T-type VGCCs (kurtoxin, mibefradil, Ni2+) and Na(v) channels (TTX, saxitoxin, phenytoin). Glutamic Acid 116-125 vascular endothelial growth factor A Rattus norvegicus 39-43 21575684-5 2011 We found that the inhibitory effect of VEGF on the osmotic swelling of retinal glial cells, used as an indicator of glutamate release, is prevented in the presence of selective blockers of T-type VGCCs (kurtoxin, mibefradil, Ni2+) and Na(v) channels (TTX, saxitoxin, phenytoin). Mibefradil 213-223 vascular endothelial growth factor A Rattus norvegicus 39-43 21575684-5 2011 We found that the inhibitory effect of VEGF on the osmotic swelling of retinal glial cells, used as an indicator of glutamate release, is prevented in the presence of selective blockers of T-type VGCCs (kurtoxin, mibefradil, Ni2+) and Na(v) channels (TTX, saxitoxin, phenytoin). Nickel(2+) 225-229 vascular endothelial growth factor A Rattus norvegicus 39-43 21575684-5 2011 We found that the inhibitory effect of VEGF on the osmotic swelling of retinal glial cells, used as an indicator of glutamate release, is prevented in the presence of selective blockers of T-type VGCCs (kurtoxin, mibefradil, Ni2+) and Na(v) channels (TTX, saxitoxin, phenytoin). Tetrodotoxin 251-254 vascular endothelial growth factor A Rattus norvegicus 39-43 21575684-5 2011 We found that the inhibitory effect of VEGF on the osmotic swelling of retinal glial cells, used as an indicator of glutamate release, is prevented in the presence of selective blockers of T-type VGCCs (kurtoxin, mibefradil, Ni2+) and Na(v) channels (TTX, saxitoxin, phenytoin). Phenytoin 267-276 vascular endothelial growth factor A Rattus norvegicus 39-43 21584441-12 2011 The tissue expression of VEGF was elevated in the animals that received methylprednisolone both 48 and 72 h after surgery (P = 0.0243). Methylprednisolone 72-90 vascular endothelial growth factor A Rattus norvegicus 25-29 21823056-2 2011 The aim of this study was to investigate the effect of 17beta-estradiol on the blood-retina barrier (BRB) breakdown induced by intravitreous injection of vascular endothelial growth factor (VEGF), a significant mediator of vascular permeability. Estradiol 55-71 vascular endothelial growth factor A Rattus norvegicus 154-188 21823056-2 2011 The aim of this study was to investigate the effect of 17beta-estradiol on the blood-retina barrier (BRB) breakdown induced by intravitreous injection of vascular endothelial growth factor (VEGF), a significant mediator of vascular permeability. Estradiol 55-71 vascular endothelial growth factor A Rattus norvegicus 190-194 21823056-9 2011 These results suggest that 17beta-estradiol attenuates BRB breakdown induced by VEGF in male rats, which may provide a new role of 17beta-estradiol in ocular diseases. Estradiol 27-43 vascular endothelial growth factor A Rattus norvegicus 80-84 21823056-9 2011 These results suggest that 17beta-estradiol attenuates BRB breakdown induced by VEGF in male rats, which may provide a new role of 17beta-estradiol in ocular diseases. Estradiol 131-147 vascular endothelial growth factor A Rattus norvegicus 80-84 21788833-10 2011 CONCLUSION: Dimethyloxalylglycine treatment significantly increases VEGF and HIF-1alpha expression in endothelial cell cultures and enhances skin flap survival in vivo in a rat model. oxalylglycine 12-33 vascular endothelial growth factor A Rattus norvegicus 68-72 21505181-2 2011 We have previously shown that medroxyprogesterone acetate (MPA), a commonly administered synthetic progestin, increases production of the potent angiogenic factor vascular endothelial growth factor (VEGF) by tumor cells, leading to the development of new blood vessels and tumor growth. Medroxyprogesterone Acetate 30-57 vascular endothelial growth factor A Rattus norvegicus 199-203 21574020-5 2011 Resveratrol (10 nM) or N-acetylcysteine (NAC, 20 mM) diminished the transcriptional activity of hypoxiainducible factor-1 and hypoxia-induced expression of VEGF. Resveratrol 0-11 vascular endothelial growth factor A Rattus norvegicus 156-160 21574020-5 2011 Resveratrol (10 nM) or N-acetylcysteine (NAC, 20 mM) diminished the transcriptional activity of hypoxiainducible factor-1 and hypoxia-induced expression of VEGF. Acetylcysteine 23-39 vascular endothelial growth factor A Rattus norvegicus 156-160 21574020-5 2011 Resveratrol (10 nM) or N-acetylcysteine (NAC, 20 mM) diminished the transcriptional activity of hypoxiainducible factor-1 and hypoxia-induced expression of VEGF. Acetylcysteine 41-44 vascular endothelial growth factor A Rattus norvegicus 156-160 21801958-3 2011 The prolyl hydroxylase inhibitor mimosine can increase VEGF production through the HIF-1 pathway. Mimosine 33-41 vascular endothelial growth factor A Rattus norvegicus 55-59 21801965-0 2011 Systemic pretreatment with dimethyloxalylglycine increases myocardial HIF-1alpha and VEGF production and improves functional recovery after acute ischemia/reperfusion. oxalylglycine 27-48 vascular endothelial growth factor A Rattus norvegicus 85-89 21801965-3 2011 Dimethyloxalylglycine (DMOG) prevents the deactivation of HIF-1alpha and increases VEGF production. oxalylglycine 0-21 vascular endothelial growth factor A Rattus norvegicus 83-87 21801965-3 2011 Dimethyloxalylglycine (DMOG) prevents the deactivation of HIF-1alpha and increases VEGF production. oxalylglycine 23-27 vascular endothelial growth factor A Rattus norvegicus 83-87 21801965-11 2011 Myocardial HIF-1alpha and VEGF levels were increased by DMOG therapy. oxalylglycine 56-60 vascular endothelial growth factor A Rattus norvegicus 26-30 21801965-12 2011 CONCLUSION: In conclusion, systemic pretreatment with DMOG augments post-ischemic myocardial functional recovery through increased HIF-1alpha levels and greater VEGF production. oxalylglycine 54-58 vascular endothelial growth factor A Rattus norvegicus 161-165 21775609-9 2011 The FAK inhibitor PF573228 reduced VEGF-A-induced OPC migration. 6-(4-(3-(methylsulfonyl)benzylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-3,4-dihydroquinolin-2(1H)-one 18-26 vascular endothelial growth factor A Rattus norvegicus 35-41 21775609-10 2011 VEGF-A signaling also evoked a transient rise in reactive oxygen species (ROS), and OPC migration was increased when antioxidants were removed from the culture media. Reactive Oxygen Species 49-72 vascular endothelial growth factor A Rattus norvegicus 0-6 21775609-10 2011 VEGF-A signaling also evoked a transient rise in reactive oxygen species (ROS), and OPC migration was increased when antioxidants were removed from the culture media. Reactive Oxygen Species 74-77 vascular endothelial growth factor A Rattus norvegicus 0-6 21775609-11 2011 Our findings demonstrate that VEGF-A can induce OPC migration via an ROS- and FAK-dependent mechanism, and suggest a novel role for VEGF-A in white-matter maintenance and homeostasis. Reactive Oxygen Species 69-72 vascular endothelial growth factor A Rattus norvegicus 30-36 21775611-4 2011 After kainate-induced seizure-like events (SLEs), we observed an overexpression of VEGF and VEGF receptor-2 (VEGFR-2) as well as receptor activation. Kainic Acid 6-13 vascular endothelial growth factor A Rattus norvegicus 83-87 21775611-8 2011 Recombinant VEGF reproduced the kainate-induced vascular changes. Kainic Acid 32-39 vascular endothelial growth factor A Rattus norvegicus 12-16 21584441-14 2011 However, the overexpression of VEGF in this group showed that methylprednisolone is related to this elevation. Methylprednisolone 62-80 vascular endothelial growth factor A Rattus norvegicus 31-35 21193965-2 2011 The second goal was to determine possible cellular mechanisms by which VEGF increases permeability of the BTB. btb 106-109 vascular endothelial growth factor A Rattus norvegicus 71-75 22041628-1 2011 OBJECTIVE: To investigate the effect of local application of zoledronic acid (ZA) on the expression of type I collagen and vascular endothelial growth factor (VEGF). Zoledronic Acid 61-76 vascular endothelial growth factor A Rattus norvegicus 159-163 21330654-0 2011 Nicotine increases the VEGF/PEDF ratio in retinal pigment epithelium: a possible mechanism for CNV in passive smokers with AMD. Nicotine 0-8 vascular endothelial growth factor A Rattus norvegicus 23-27 21425119-0 2011 Imbalance of glomerular VEGF-NO axis in diabetic rats: prevention by chronic therapy with propyl gallate. Propyl Gallate 90-104 vascular endothelial growth factor A Rattus norvegicus 24-28 21425119-1 2011 BACKGROUND: The uncoupling of the vascular endothelial growth factor-nitric oxide (VEGF-NO) axis may play a vital role in inducing glomerular endothelial dysfunction. Nitric Oxide 69-81 vascular endothelial growth factor A Rattus norvegicus 83-87 21425119-13 2011 Propyl gallate improved glomerular pathological changes in diabetic rats, possibly through oxidative stress reduction and VEGF-NO axis recovery. Propyl Gallate 0-14 vascular endothelial growth factor A Rattus norvegicus 122-126 22041628-1 2011 OBJECTIVE: To investigate the effect of local application of zoledronic acid (ZA) on the expression of type I collagen and vascular endothelial growth factor (VEGF). Zoledronic Acid 78-80 vascular endothelial growth factor A Rattus norvegicus 159-163 22041628-3 2011 The expression of type I collagen and VEGF were detected with SP immunohistochemistry method 1, 2 and 4 weeks after operation. TFF2 protein, human 62-64 vascular endothelial growth factor A Rattus norvegicus 18-42 21804622-8 2011 RESULTS: Enalapril significantly increased serum NO and VEGF concentrations and reduced serum sVEGF-R1 concentrations in diabetic sham and hind limb ischemic rats (p<0.05). Enalapril 9-18 vascular endothelial growth factor A Rattus norvegicus 56-60 21538185-9 2011 Endothelin-1 and VEGF expression were higher in HIF-CDCs exposed to hypoxia, compared with non-transduced CDCs. chenodeoxycholate sulfate conjugate 52-56 vascular endothelial growth factor A Rattus norvegicus 17-21 21193965-3 2011 In the rat C6 glioma model, the permeability of the BTB was significantly increased after VEGF injection at dose of 0.05 ng/g and reached its peak at 45 min. btb 52-55 vascular endothelial growth factor A Rattus norvegicus 90-94 21193965-7 2011 All of these results strongly indicated that VEGF increased permeability of the BTB caused by enhancement of the density of pinocytotic vesicles, and the molecular mechanism might be associated with upregulated expression of caveolin-1 and caveolin-2. btb 80-83 vascular endothelial growth factor A Rattus norvegicus 45-49 21693319-9 2011 Moreover, thalidomide significantly inhibited the production of VEGF and ICAM-1 in serum (P < .05). Thalidomide 10-21 vascular endothelial growth factor A Rattus norvegicus 64-68 22272053-2 2011 In the present study, expression of VEGF in the articular cartilage was determined in three different OA models: medial meniscectomy and monoiodoacetate (MIA) injection in rats and age-associated spontaneous joint cartilage destruction in guinea pigs. Iodoacetic Acid 137-152 vascular endothelial growth factor A Rattus norvegicus 36-40 21721350-0 2011 Immunohistochemical expression of apoptosis and VEGF expression on random skin flaps in rats treated with hyperbaric oxygen and N-acetylcysteine. Acetylcysteine 128-144 vascular endothelial growth factor A Rattus norvegicus 48-52 21240876-13 2011 SUT significantly improved overexpression of dialysate transforming growth factor-ss1, monocyte chemoattractant protein-1 and vascular endothelial growth factor (VEGF) levels as compared with resting group. Sunitinib 0-3 vascular endothelial growth factor A Rattus norvegicus 126-160 21240876-13 2011 SUT significantly improved overexpression of dialysate transforming growth factor-ss1, monocyte chemoattractant protein-1 and vascular endothelial growth factor (VEGF) levels as compared with resting group. Sunitinib 0-3 vascular endothelial growth factor A Rattus norvegicus 162-166 21277368-10 2011 tMCAO-mediated induction of the pro-inflammatory chemokines CCL2, CCL5 and interleukin 6 was attenuated by E and P, whereas the expression of vascular endothelial growth factor (VEGF) was fortified. tmcao 0-5 vascular endothelial growth factor A Rattus norvegicus 142-176 21277368-10 2011 tMCAO-mediated induction of the pro-inflammatory chemokines CCL2, CCL5 and interleukin 6 was attenuated by E and P, whereas the expression of vascular endothelial growth factor (VEGF) was fortified. tmcao 0-5 vascular endothelial growth factor A Rattus norvegicus 178-182 21343256-0 2011 17beta-estradiol increases astrocytic vascular endothelial growth factor (VEGF) in adult female rat hippocampus. Estradiol 0-16 vascular endothelial growth factor A Rattus norvegicus 38-72 21343256-0 2011 17beta-estradiol increases astrocytic vascular endothelial growth factor (VEGF) in adult female rat hippocampus. Estradiol 0-16 vascular endothelial growth factor A Rattus norvegicus 74-78 21343256-7 2011 The results demonstrated that VEGF immunoreactivity was increased when serum levels of 17beta-estradiol were elevated. Estradiol 87-103 vascular endothelial growth factor A Rattus norvegicus 30-34 21263376-0 2011 Spironolactone and enalapril differentially up-regulate the expression of VEGF and heme oxygenase-1 in the neonatal rat kidney. Spironolactone 0-14 vascular endothelial growth factor A Rattus norvegicus 74-78 21263376-0 2011 Spironolactone and enalapril differentially up-regulate the expression of VEGF and heme oxygenase-1 in the neonatal rat kidney. Enalapril 19-28 vascular endothelial growth factor A Rattus norvegicus 74-78 21263376-3 2011 The expression of VEGF and heme oxygenase (HO)-1 related with the oxygen was analyzed in the enalapril- or spironolactone-treated neonatal rat kidneys. Enalapril 93-102 vascular endothelial growth factor A Rattus norvegicus 18-22 21263376-3 2011 The expression of VEGF and heme oxygenase (HO)-1 related with the oxygen was analyzed in the enalapril- or spironolactone-treated neonatal rat kidneys. Spironolactone 107-121 vascular endothelial growth factor A Rattus norvegicus 18-22 21263376-6 2011 VEGF and HO-1 protein expression was significantly increased by immunoblots and immunohistochemistry in both the enalapril- and spironolactone-treated kidneys, compared with the controls (p < 0.05). Enalapril 113-122 vascular endothelial growth factor A Rattus norvegicus 0-4 21263376-6 2011 VEGF and HO-1 protein expression was significantly increased by immunoblots and immunohistochemistry in both the enalapril- and spironolactone-treated kidneys, compared with the controls (p < 0.05). Spironolactone 128-142 vascular endothelial growth factor A Rattus norvegicus 0-4 21505731-13 2011 The level of VEGF mRNA in the brain of plateau zokor is lower than that of SD rat, which may be as a result of inhibition by the higher concentration of carbon dioxide in the burrow. Carbon Dioxide 153-167 vascular endothelial growth factor A Rattus norvegicus 13-17 21277350-0 2011 Dexamethasone pre-treatment protects brain against hypoxic-ischemic injury partially through up-regulation of vascular endothelial growth factor A in neonatal rats. Dexamethasone 0-13 vascular endothelial growth factor A Rattus norvegicus 110-146 21277350-3 2011 The objective of this study was to evaluate the role of the VEGF signaling pathway in the Dex-induced neuroprotection in newborn rats. Dexamethasone 90-93 vascular endothelial growth factor A Rattus norvegicus 60-64 21277350-10 2011 Dex pre-treatment reduced brain injury and enhanced the HI-induced brain VEGF protein while a GR blocker inhibited these effects. Dexamethasone 0-3 vascular endothelial growth factor A Rattus norvegicus 73-77 21277350-10 2011 Dex pre-treatment reduced brain injury and enhanced the HI-induced brain VEGF protein while a GR blocker inhibited these effects. hi 56-58 vascular endothelial growth factor A Rattus norvegicus 73-77 21277350-12 2011 Dex pre-treatment enhanced the HI-induced increase in mRNA expression of VEGF splice variants and decreased the HI-induced reduction of Akt phosphorylation. Dexamethasone 0-3 vascular endothelial growth factor A Rattus norvegicus 73-77 21277350-12 2011 Dex pre-treatment enhanced the HI-induced increase in mRNA expression of VEGF splice variants and decreased the HI-induced reduction of Akt phosphorylation. hi 31-33 vascular endothelial growth factor A Rattus norvegicus 73-77 21277350-14 2011 We conclude that Dex provides robust neuroprotection against subsequent HI in newborn rats via GR likely with the partial involvement of VEGF signaling pathway. Dexamethasone 17-20 vascular endothelial growth factor A Rattus norvegicus 137-141 21382440-9 2011 Expression of VEGF, iNOS, MMP-2, and MMP-9 in aneurysmal walls was also increased by methionine treatment. Methionine 85-95 vascular endothelial growth factor A Rattus norvegicus 14-18 21111728-2 2011 We have previously shown that S-nitroso-N-acetyl-D,L-penicillamine (SNAP) increases the expression of several muscular markers and VEGF in mesenchymal stem cells, indicating that transplantation of SNAP-treated cells could provide better functional outcomes. snap 30-66 vascular endothelial growth factor A Rattus norvegicus 131-135 21256125-0 2011 Vernolide-A inhibits tumour specific angiogenesis by regulating proinflammatory cytokines, VEGF, MMPs and TIMP. vernolide-A 0-11 vascular endothelial growth factor A Rattus norvegicus 91-95 21256125-8 2011 Taken together, these results demonstrate that vernolide-A inhibits tumour-specific angiogenesis by downregulating the production of pro-angiogenic factors like pro-inflammatory cytokines, VEGF, and MMPs and also upregulating the anti-angiogenic factors such as IL-2 and TIMP-1. vernolide-A 47-58 vascular endothelial growth factor A Rattus norvegicus 189-193 20563582-7 2011 Both 20 and 50 muM beta-elemene in vitro inhibited VEGF-induced sprouting vessel of rat aortic ring and microvessel formation of chick embryo chorioallantoic membrane. beta-elemene 19-31 vascular endothelial growth factor A Rattus norvegicus 51-55 21738895-1 2011 BACKGROUND: While there is an evidence that the anti-inflammatory properties of spironolactone can attenuate proteinuria in type 2 diabetes, its effects on vascular endothelial growth factor (VEGF) expression in diabetic nephropathy have not been clearly defined. Spironolactone 80-94 vascular endothelial growth factor A Rattus norvegicus 192-196 21738895-6 2011 There was a significant reduction in renal VEGF, transforming growth factor (TGF)-beta, and type IV collagen mRNA levels in the spironolactone- and combination regimen-treated groups. Spironolactone 128-142 vascular endothelial growth factor A Rattus norvegicus 43-47 21738895-9 2011 CONCLUSION: These results suggest that losartan alone and a combined regimen of spironolactone and losartan could ameliorate albuninuria by reducing renal VEGF expression. Losartan 39-47 vascular endothelial growth factor A Rattus norvegicus 155-159 21738895-9 2011 CONCLUSION: These results suggest that losartan alone and a combined regimen of spironolactone and losartan could ameliorate albuninuria by reducing renal VEGF expression. Spironolactone 80-94 vascular endothelial growth factor A Rattus norvegicus 155-159 21738895-9 2011 CONCLUSION: These results suggest that losartan alone and a combined regimen of spironolactone and losartan could ameliorate albuninuria by reducing renal VEGF expression. Losartan 99-107 vascular endothelial growth factor A Rattus norvegicus 155-159 21111728-2 2011 We have previously shown that S-nitroso-N-acetyl-D,L-penicillamine (SNAP) increases the expression of several muscular markers and VEGF in mesenchymal stem cells, indicating that transplantation of SNAP-treated cells could provide better functional outcomes. snap 68-72 vascular endothelial growth factor A Rattus norvegicus 131-135 21107440-7 2011 HUMSC transplantation ameliorated apomorphine-evoked rotations and reduced the loss of dopaminergic neurons in the lesioned substantia nigra (SNc), which was enhanced significantly by VEGF expression in HUMSCs. Apomorphine 34-45 vascular endothelial growth factor A Rattus norvegicus 184-188 20735383-0 2011 Effect of mitomycin C on concentrations of vascular endothelial growth factor and its receptors in bladder cancer cells and in bladders of rats intravesically instilled with mitomycin C. Mitomycin 10-21 vascular endothelial growth factor A Rattus norvegicus 43-77 20735383-10 2011 VEGFR-2 mRNA and protein concentrations and urinary VEGF concentrations were increased in bladders of rats instilled with MMC. Mitomycin 122-125 vascular endothelial growth factor A Rattus norvegicus 0-4 20735383-11 2011 CONCLUSIONS: Intravesically instilled MMC increases urinary VEGF and bladder VEGFR-2 protein and mRNA in rats. Mitomycin 40-43 vascular endothelial growth factor A Rattus norvegicus 62-66 21327539-7 2011 PI3K inhibitor LY294002 significantly attenuated Rg1-enhanced VEGF expression and capillary density. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 15-23 vascular endothelial growth factor A Rattus norvegicus 62-66 21273371-5 2011 The antagonist against the PGE receptor type 2 (EP2 receptor), AH6809, completely inhibited PGE(2)-induced tube formation and partly suppressed the VEGF-induced tube formation but did not attenuate PGE(2)-induced phosphorylation of both AKT kinase and extracellular signal-regulated kinase 1/2. 6-isopropoxy-9-oxoxanthene-2-carboxylic acid 63-69 vascular endothelial growth factor A Rattus norvegicus 148-152 21273371-5 2011 The antagonist against the PGE receptor type 2 (EP2 receptor), AH6809, completely inhibited PGE(2)-induced tube formation and partly suppressed the VEGF-induced tube formation but did not attenuate PGE(2)-induced phosphorylation of both AKT kinase and extracellular signal-regulated kinase 1/2. Prostaglandins E 27-30 vascular endothelial growth factor A Rattus norvegicus 148-152 21273371-6 2011 VEGF significantly enhanced the expression of COX-2 mRNAs detected by real-time RT-PCR and PGE(2) secretion into the media measured by ELISA in luteal ECs. Dinoprostone 91-97 vascular endothelial growth factor A Rattus norvegicus 0-4 21273371-7 2011 In turn, PGE(2) stimulated VEGF expression. Dinoprostone 9-15 vascular endothelial growth factor A Rattus norvegicus 27-31 21226888-6 2011 Ki-67, alpha-SMA and VEGF were also overexpressed in squamous cell carcinomas induced after 20 weeks of treatment with 4NQO. 4-Nitroquinoline-1-oxide 119-123 vascular endothelial growth factor A Rattus norvegicus 21-25 20497492-3 2011 Vascular endothelial growth factor (VEGF) and VEGF receptors (VEGFRs) are the main regulatory systems in angiogenesis and have been used as hot targets for radionuclide-based molecular imaging. Radioisotopes 156-168 vascular endothelial growth factor A Rattus norvegicus 0-34 20497492-3 2011 Vascular endothelial growth factor (VEGF) and VEGF receptors (VEGFRs) are the main regulatory systems in angiogenesis and have been used as hot targets for radionuclide-based molecular imaging. Radioisotopes 156-168 vascular endothelial growth factor A Rattus norvegicus 36-40 20497492-3 2011 Vascular endothelial growth factor (VEGF) and VEGF receptors (VEGFRs) are the main regulatory systems in angiogenesis and have been used as hot targets for radionuclide-based molecular imaging. Radioisotopes 156-168 vascular endothelial growth factor A Rattus norvegicus 46-50 21370375-1 2011 Myo-inositol trispyrophosphate (ITPP), a synthetic allosteric effector of hemoglobin, increases the regulated oxygen-releasing capacity of red blood cells (RBCs), leading to suppression of hypoxia-inducible factor 1alpha (HIF-1alpha) and to down-regulation of hypoxia-inducible genes such as vascular endothelial growth factor (VEGF). inositol trispyrophosphate 0-30 vascular endothelial growth factor A Rattus norvegicus 292-326 21370375-1 2011 Myo-inositol trispyrophosphate (ITPP), a synthetic allosteric effector of hemoglobin, increases the regulated oxygen-releasing capacity of red blood cells (RBCs), leading to suppression of hypoxia-inducible factor 1alpha (HIF-1alpha) and to down-regulation of hypoxia-inducible genes such as vascular endothelial growth factor (VEGF). inositol trispyrophosphate 0-30 vascular endothelial growth factor A Rattus norvegicus 328-332 21370375-1 2011 Myo-inositol trispyrophosphate (ITPP), a synthetic allosteric effector of hemoglobin, increases the regulated oxygen-releasing capacity of red blood cells (RBCs), leading to suppression of hypoxia-inducible factor 1alpha (HIF-1alpha) and to down-regulation of hypoxia-inducible genes such as vascular endothelial growth factor (VEGF). inositol trispyrophosphate 32-36 vascular endothelial growth factor A Rattus norvegicus 292-326 21370375-1 2011 Myo-inositol trispyrophosphate (ITPP), a synthetic allosteric effector of hemoglobin, increases the regulated oxygen-releasing capacity of red blood cells (RBCs), leading to suppression of hypoxia-inducible factor 1alpha (HIF-1alpha) and to down-regulation of hypoxia-inducible genes such as vascular endothelial growth factor (VEGF). inositol trispyrophosphate 32-36 vascular endothelial growth factor A Rattus norvegicus 328-332 20797711-0 2011 Activation of adenosine A2A receptors by polydeoxyribonucleotide increases vascular endothelial growth factor and protects against testicular damage induced by experimental varicocele in rats. Polydeoxyribonucleotides 41-64 vascular endothelial growth factor A Rattus norvegicus 75-109 21362404-9 2011 Matrix metalloproteinase-2 (MMP-2) activity and vascular endothelial growth factor (VEGF) expression decreased in rats bearing W256 treated with 10 mg/kg quercetin when compared with CTR. Quercetin 154-163 vascular endothelial growth factor A Rattus norvegicus 48-82 21362404-9 2011 Matrix metalloproteinase-2 (MMP-2) activity and vascular endothelial growth factor (VEGF) expression decreased in rats bearing W256 treated with 10 mg/kg quercetin when compared with CTR. Quercetin 154-163 vascular endothelial growth factor A Rattus norvegicus 84-88 21362404-10 2011 Thus, the inhibition of tumor growth, survival increase, decrease of MMP-2 and VEGF levels and reduction of cachexia in animals treated with quercetin strongly support the anticancer function of this flavonoid. Quercetin 141-150 vascular endothelial growth factor A Rattus norvegicus 79-83 21362404-10 2011 Thus, the inhibition of tumor growth, survival increase, decrease of MMP-2 and VEGF levels and reduction of cachexia in animals treated with quercetin strongly support the anticancer function of this flavonoid. Flavonoids 200-209 vascular endothelial growth factor A Rattus norvegicus 79-83 20797711-1 2011 In rat experimental varicocele, polydeoxyribonucleotide (PDRN) induces vascular endothelial growth factor (VEGF) production, thereby enhancing testicular function. Polydeoxyribonucleotides 32-55 vascular endothelial growth factor A Rattus norvegicus 71-105 20797711-1 2011 In rat experimental varicocele, polydeoxyribonucleotide (PDRN) induces vascular endothelial growth factor (VEGF) production, thereby enhancing testicular function. Polydeoxyribonucleotides 32-55 vascular endothelial growth factor A Rattus norvegicus 107-111 20797711-1 2011 In rat experimental varicocele, polydeoxyribonucleotide (PDRN) induces vascular endothelial growth factor (VEGF) production, thereby enhancing testicular function. Polydeoxyribonucleotides 57-61 vascular endothelial growth factor A Rattus norvegicus 71-105 20797711-1 2011 In rat experimental varicocele, polydeoxyribonucleotide (PDRN) induces vascular endothelial growth factor (VEGF) production, thereby enhancing testicular function. Polydeoxyribonucleotides 57-61 vascular endothelial growth factor A Rattus norvegicus 107-111 20821229-2 2011 Increased amounts of reactive oxygen species (ROS) are also known to associated with diabetic retinopathy and VEGF expression. Reactive Oxygen Species 21-44 vascular endothelial growth factor A Rattus norvegicus 110-114 21563650-3 2011 Papaverine, a myorelaxant and vasodilatator, and pentoxiphylline, a hemorrheologic agent are used for microcirculation disorders and vascular endothelial growth factor (VEGF) is a stimulator of angiogenesis. Papaverine 0-10 vascular endothelial growth factor A Rattus norvegicus 133-167 21563650-3 2011 Papaverine, a myorelaxant and vasodilatator, and pentoxiphylline, a hemorrheologic agent are used for microcirculation disorders and vascular endothelial growth factor (VEGF) is a stimulator of angiogenesis. Papaverine 0-10 vascular endothelial growth factor A Rattus norvegicus 169-173 21563650-3 2011 Papaverine, a myorelaxant and vasodilatator, and pentoxiphylline, a hemorrheologic agent are used for microcirculation disorders and vascular endothelial growth factor (VEGF) is a stimulator of angiogenesis. Pentoxifylline 49-64 vascular endothelial growth factor A Rattus norvegicus 133-167 21563650-3 2011 Papaverine, a myorelaxant and vasodilatator, and pentoxiphylline, a hemorrheologic agent are used for microcirculation disorders and vascular endothelial growth factor (VEGF) is a stimulator of angiogenesis. Pentoxifylline 49-64 vascular endothelial growth factor A Rattus norvegicus 169-173 21563650-10 2011 In group 3, VEGF levels were significantly higher showing that the hypoxic stimulus continued without any treatment and in Group 4, significantly lower than Group 3 related to the inhibition of pentoxiphylline. Pentoxifylline 194-209 vascular endothelial growth factor A Rattus norvegicus 12-16 21563650-14 2011 Although the antioxidant effect of pentoxiphylline in ischemia reperfusion injury may be benefical in treatment, its inhibition of VEGF is a disadvantage in wound healing. Pentoxifylline 35-50 vascular endothelial growth factor A Rattus norvegicus 131-135 21224215-5 2011 TSA suppressed hypoxia-inducible factor-1alpha (HIF-1alpha), VEGF, and lysyl oxidase (LOX) and increased microtubule-associated protein-1 light chain 3 (LC3), p53, and miR34a microRNA expression in both rat lungs and cultured HPMVEC. trichostatin A 0-3 vascular endothelial growth factor A Rattus norvegicus 61-65 20821229-2 2011 Increased amounts of reactive oxygen species (ROS) are also known to associated with diabetic retinopathy and VEGF expression. Reactive Oxygen Species 46-49 vascular endothelial growth factor A Rattus norvegicus 110-114 20821229-11 2011 Simvastatin treatment blocked hyperglycemia-induced increases in VEGF, angiopoietin 2 and erythropoietin levels, as demonstrated by RT-PCR and Western blot analysis. Simvastatin 0-11 vascular endothelial growth factor A Rattus norvegicus 65-69 20821229-12 2011 CONCLUSIONS: Simvastatin treatment led to suppression of superoxide formation and decreased expression of VEGF, angiopoietin 2 and erythropoietin in diabetic rat retinas. Simvastatin 13-24 vascular endothelial growth factor A Rattus norvegicus 106-110 21378373-0 2011 Fetal and neonatal exposure to nicotine disrupts postnatal lung development in rats: role of VEGF and its receptors. Nicotine 31-39 vascular endothelial growth factor A Rattus norvegicus 93-97 21378373-8 2011 The current study suggests that perinatal exposure to nicotine alters lung development, an effect which may be mediated via decreased vascular endothelial growth factor (VEGF) signaling. Nicotine 54-62 vascular endothelial growth factor A Rattus norvegicus 134-168 21378373-8 2011 The current study suggests that perinatal exposure to nicotine alters lung development, an effect which may be mediated via decreased vascular endothelial growth factor (VEGF) signaling. Nicotine 54-62 vascular endothelial growth factor A Rattus norvegicus 170-174 21128742-10 2011 FITC-dextran marking showed increased vascular density in the penumbra of Tf-VEGF-PL-treated hemispheres (245,873.9, number of microvessels per field) compared with that in VEGF-PL-treated hemispheres (139,801.3) or saline-treated hemispheres (102,175.5) (p < 0.05). fluorescein isothiocyanate dextran 0-12 vascular endothelial growth factor A Rattus norvegicus 77-81 21287239-3 2011 This study was performed to determine the ability of strontium-doped calcium polyphosphate (SCPP) to induce angiogenesis via researching its effect on the mRNA expressions and protein secretion of VEGF and bFGF in/from cultured osteoblasts (ROS17/2.8 cells). Strontium 53-62 vascular endothelial growth factor A Rattus norvegicus 197-201 21287239-3 2011 This study was performed to determine the ability of strontium-doped calcium polyphosphate (SCPP) to induce angiogenesis via researching its effect on the mRNA expressions and protein secretion of VEGF and bFGF in/from cultured osteoblasts (ROS17/2.8 cells). doped 63-68 vascular endothelial growth factor A Rattus norvegicus 197-201 21287239-3 2011 This study was performed to determine the ability of strontium-doped calcium polyphosphate (SCPP) to induce angiogenesis via researching its effect on the mRNA expressions and protein secretion of VEGF and bFGF in/from cultured osteoblasts (ROS17/2.8 cells). calcium polyphosphate 69-90 vascular endothelial growth factor A Rattus norvegicus 197-201 21287239-3 2011 This study was performed to determine the ability of strontium-doped calcium polyphosphate (SCPP) to induce angiogenesis via researching its effect on the mRNA expressions and protein secretion of VEGF and bFGF in/from cultured osteoblasts (ROS17/2.8 cells). scpp 92-96 vascular endothelial growth factor A Rattus norvegicus 197-201 21287239-6 2011 The results of RT-PCR and ELISA indicated that, compared with those in CPP group, the mRNA expression as well as protein levels of VEGF and bFGF in/from cultured osteoblasts were dose-dependent increasing in response to increasing strontium before reaching the peak in SCPP groups, and 8% SCPP showed the optimal promoting role. scpp 269-273 vascular endothelial growth factor A Rattus norvegicus 131-135 21287239-6 2011 The results of RT-PCR and ELISA indicated that, compared with those in CPP group, the mRNA expression as well as protein levels of VEGF and bFGF in/from cultured osteoblasts were dose-dependent increasing in response to increasing strontium before reaching the peak in SCPP groups, and 8% SCPP showed the optimal promoting role. scpp 289-293 vascular endothelial growth factor A Rattus norvegicus 131-135 21293297-6 2011 These results suggest that increased VEGF and NO production in hypoxia resulted in increased vascular permeability, which, along with increased levels of glutamate, may have induced structural alterations of the neurons, dendrites, and axons. Glutamic Acid 154-163 vascular endothelial growth factor A Rattus norvegicus 37-41 21293297-7 2011 Administration of the antioxidant neurohormone melatonin (10mg/kg) before and after the hypoxia reduced VEGF, NO, and glutamate levels and improved ultrastructural abnormalities induced by hypoxia exposure, suggesting that it may have a therapeutic potential in reducing hypoxia-associated brainstem damage. Melatonin 47-56 vascular endothelial growth factor A Rattus norvegicus 104-108 21115498-8 2011 Overexpression of Sp1 protein with an alanine mutation at Thr-453 or Thr-739 suppressed CO-induced Sp1 binding to the VEGF promoter and its transcriptional activation. Threonine 58-61 vascular endothelial growth factor A Rattus norvegicus 118-122 21115498-9 2011 Collectively, these data suggest that p38-dependent phosphorylation of Sp1 at Thr-453/Thr-739 is crucial for HO-1/CO-induced VEGF expression in myocytes. Threonine 78-81 vascular endothelial growth factor A Rattus norvegicus 125-129 21115498-9 2011 Collectively, these data suggest that p38-dependent phosphorylation of Sp1 at Thr-453/Thr-739 is crucial for HO-1/CO-induced VEGF expression in myocytes. Threonine 86-89 vascular endothelial growth factor A Rattus norvegicus 125-129 21129996-9 2011 High dose of valsartan decreased the serum and dialysate TGF-beta1 level, decreased the thickness of the liver peritoneum, and decreased the expression of TGF-beta1, alpha-SMA, fibronectin, collagen, and VEGF-positive cells in liver peritoneum. Valsartan 13-22 vascular endothelial growth factor A Rattus norvegicus 204-208 20921951-8 2011 The expression of VEGF in proximal tubular epithelial cells in response to hypoxia was suppressed by the mitochondrial electron transfer inhibitor myxothiazol. myxothiazol 147-158 vascular endothelial growth factor A Rattus norvegicus 18-22 20887680-4 2011 Secondly, we attempted to restore brain tissue using a novel biomaterial, polydimethysiloxane-tetraethoxysilane (PDMS-TEOS) hybrid with or without vascular endothelial growth factor (VEGF), and we could show that implantation of a PDMS-TEOS scaffold with VEGF might be effective for treating old brain infarction or trauma. polydimethysiloxane-tetraethoxysilane 74-111 vascular endothelial growth factor A Rattus norvegicus 255-259 21288455-13 2011 The anti-angiogenic activity of genistein may correlate to its inhibitory effect on the expressions of VEGF and MMP-1, 2 and 9 in serum of CIA rats; genistein plus MTX are superior to single agents in treating rheumatoid arthritis. Genistein 32-41 vascular endothelial growth factor A Rattus norvegicus 103-107 21092735-2 2011 Using adult rat spinal cord injury model, it was found that up-regulation of hypoxia inducible factor-1alpha (HIF-1alpha), vascular endothelial growth factor (VEGF), AQP4, and AQP1 in response to spinal cord injury was greatly antagonized by 2-methoxyestradiol (2ME2), which can post-transcriptionally inhibit the expression of HIF-1alpha. 2-Methoxyestradiol 242-260 vascular endothelial growth factor A Rattus norvegicus 123-157 20933271-9 2011 Degrease with methanol/chloroform dramatically reduced the contents of VEGF, b-FGF, TGF-beta, and TNF-alpha within SISii, but further treatment could not significantly reduced the contents of growth factors. Methanol 14-22 vascular endothelial growth factor A Rattus norvegicus 71-75 20933271-9 2011 Degrease with methanol/chloroform dramatically reduced the contents of VEGF, b-FGF, TGF-beta, and TNF-alpha within SISii, but further treatment could not significantly reduced the contents of growth factors. Chloroform 23-33 vascular endothelial growth factor A Rattus norvegicus 71-75 21294962-3 2011 We aimed to develop pharmacological strategies for VEGF overexpression in pancreatic islets using the iron chelator deferoxamine (DFO), thus avoiding obstacles or safety risks associated with gene therapy. iron chelator deferoxamine 103-129 vascular endothelial growth factor A Rattus norvegicus 52-56 21125447-8 2011 The number of VEGF-positive cells in MC treatment group was less than the ICH group (P < 0.05), whereas the number of NGF- and HSP70-positive cells were more than the ICH group (P < 0.05). Minocycline 37-39 vascular endothelial growth factor A Rattus norvegicus 14-18 21125447-12 2011 Early intraperitoneal injection with MC could reduce the damage of BBB and increase the protective effect on nerve cells, the mechanism of which may be achieved by reducing VEGF expression and enhancing NGF and HSP70 expressions. Minocycline 37-39 vascular endothelial growth factor A Rattus norvegicus 173-177 21138364-0 2011 The impact of tacrolimus on vascular endothelial growth factor in experimental corneal neovascularization. Tacrolimus 14-24 vascular endothelial growth factor A Rattus norvegicus 28-62 21294962-3 2011 We aimed to develop pharmacological strategies for VEGF overexpression in pancreatic islets using the iron chelator deferoxamine (DFO), thus avoiding obstacles or safety risks associated with gene therapy. Deferoxamine 131-134 vascular endothelial growth factor A Rattus norvegicus 52-56 21294962-7 2011 DFO induced transient VEGF overexpression over 3 days, whereas infection with ADE resulted in prolonged VEGF overexpression lasting 14 days; however, this was toxic and decreased islet viability and functionality. Deferoxamine 0-3 vascular endothelial growth factor A Rattus norvegicus 22-26 21138364-1 2011 PURPOSE: To investigate the impact of tacrolimus on vascular endothelial growth factor (VEGF) in experimental corneal neovascularization (NV) immunohistochemically. Tacrolimus 38-48 vascular endothelial growth factor A Rattus norvegicus 52-86 21138364-1 2011 PURPOSE: To investigate the impact of tacrolimus on vascular endothelial growth factor (VEGF) in experimental corneal neovascularization (NV) immunohistochemically. Tacrolimus 38-48 vascular endothelial growth factor A Rattus norvegicus 88-92 21138364-11 2011 The mean intensity of the epithelial VEGF immunostaining of the intraperitoneally tacrolimus-treated group was less than that of its sham group (p = 0.002), while the mean intensity of the stromal VEGF staining of the topically tacrolimus-treated group was lesser than that of its sham group (p = 0.042). Tacrolimus 82-92 vascular endothelial growth factor A Rattus norvegicus 37-41 21138364-11 2011 The mean intensity of the epithelial VEGF immunostaining of the intraperitoneally tacrolimus-treated group was less than that of its sham group (p = 0.002), while the mean intensity of the stromal VEGF staining of the topically tacrolimus-treated group was lesser than that of its sham group (p = 0.042). Tacrolimus 82-92 vascular endothelial growth factor A Rattus norvegicus 197-201 21138364-12 2011 The intensities of the endothelial VEGF immunostaining of the intraperitoneally and topically tacrolimus-treated groups were less than those of the sham groups (p = 0.038, p = 0.032). Tacrolimus 94-104 vascular endothelial growth factor A Rattus norvegicus 35-39 21138364-13 2011 CONCLUSION: Systemic and topical administration of tacrolimus may be beneficial in the prevention of corneal NV because of its effect on VEGF. Tacrolimus 51-61 vascular endothelial growth factor A Rattus norvegicus 137-141 21069258-1 2011 The aim of this study was to observe the inhibitory effect of curcumin on endometriosis (EMS) and to determine its influence on vascular endothelial growth factor (VEGF) and microvessel density (MVD) in eutopic and ectopic endometrium of experimental rats, thus exploring the pathogenesis of EMS offering more experimental evidence for the clinical use of curcumin. Curcumin 62-70 vascular endothelial growth factor A Rattus norvegicus 164-168 21548866-6 2011 Indeed, daily treatment of rats with bFGF, PDGF or VEGF markedly improved the healing of cysteamine-induced chronic duodenal ulcers, without any reduction in gastric acid secretion. Cysteamine 89-99 vascular endothelial growth factor A Rattus norvegicus 51-55 21196299-3 2011 The expression levels of TNF-alpha, IL-1beta, IL-6 and VEGF in cultured rat Muller cells were enhanced by 1 mM glyoxal. Glyoxal 111-118 vascular endothelial growth factor A Rattus norvegicus 55-59 21069258-8 2011 There was an increase in MVD and VEGF in the ectopic endometrium, which was decreased significantly after treatment with curcumin (P<0.05); the effects being dose-dependent. Curcumin 121-129 vascular endothelial growth factor A Rattus norvegicus 33-37 21069258-11 2011 Curcumin decreased the quantity of microvessels and VEGF protein expression in the heterotopic endometrium of rats with EMS. Curcumin 0-8 vascular endothelial growth factor A Rattus norvegicus 52-56 22553631-8 2011 Western blot analyses revealed that 20mg/L DHA significantly inhibited the expressions of VEGF and phospho-VEGFR-2. artenimol 43-46 vascular endothelial growth factor A Rattus norvegicus 90-94 21035240-16 2011 Level of VEGF in peritoneal fluid did not change in any treatment group but post-treatment VEGF immunoreactivity was found significantly lower in the letrozole treated group. Letrozole 150-159 vascular endothelial growth factor A Rattus norvegicus 91-95 21949693-7 2011 Followed ILK alternation, vascular endothelial growth factor (VEGF) expression and phosphorylation of endothelial nitric oxide synthase (eNOS) was significantly decreased 8 weeks after MI. 2-methyl-4-isothiazolin-3-one 185-187 vascular endothelial growth factor A Rattus norvegicus 26-60 21035240-18 2011 The only group with decreased VEGF expression was letrozole. Letrozole 50-59 vascular endothelial growth factor A Rattus norvegicus 30-34 21672350-7 2011 In diabetic rats, minocycline treatment decreased AQP4, VEGF, Iba-1 and IL-1beta levels and retinal oedema, and increased Kir4.1 levels. Minocycline 18-29 vascular endothelial growth factor A Rattus norvegicus 56-60 20717888-4 2011 VEGF and Ang1 were covalently immobilized onto porous collagen scaffolds, using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) chemistry. 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 80-139 vascular endothelial growth factor A Rattus norvegicus 0-4 20717888-4 2011 VEGF and Ang1 were covalently immobilized onto porous collagen scaffolds, using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) chemistry. 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 141-144 vascular endothelial growth factor A Rattus norvegicus 0-4 20717888-7 2011 PBS as the reaction buffer resulted in higher amounts of VEGF and Ang1 immobilized (ELISA), higher cell proliferation rates (XTT) and increased lactate metabolism compared to water and MES as the reaction buffers. pbs 0-3 vascular endothelial growth factor A Rattus norvegicus 57-61 20717888-10 2011 Tube formation by CD31-positive cells was also observed in collagen scaffolds with immobilized VEGF or Ang1 using H5V and primary rat aortic endothelial cells but not on control scaffolds. 7-deaza-2'-C-methyladenosine 114-117 vascular endothelial growth factor A Rattus norvegicus 95-99 21738387-9 2011 Exposure to fluctuations of oxygen in the 50/10 oxygen-induced retinopathy model compared to RA was associated with increased PEDF mRNA (p=0.0185), PEDF protein (p<0.0001), or VEGF protein (p<0.0001). Oxygen 28-34 vascular endothelial growth factor A Rattus norvegicus 179-183 21738387-9 2011 Exposure to fluctuations of oxygen in the 50/10 oxygen-induced retinopathy model compared to RA was associated with increased PEDF mRNA (p=0.0185), PEDF protein (p<0.0001), or VEGF protein (p<0.0001). Oxygen 48-54 vascular endothelial growth factor A Rattus norvegicus 179-183 21738387-12 2011 CONCLUSIONS: Increased expression levels of VEGF and PEDF are associated with older postnatal day age or with exposure to fluctuations in oxygen in the 50/10 oxygen-induced retinopathy model compared to RA. Oxygen 138-144 vascular endothelial growth factor A Rattus norvegicus 44-48 21738387-12 2011 CONCLUSIONS: Increased expression levels of VEGF and PEDF are associated with older postnatal day age or with exposure to fluctuations in oxygen in the 50/10 oxygen-induced retinopathy model compared to RA. Oxygen 158-164 vascular endothelial growth factor A Rattus norvegicus 44-48 21269989-7 2011 Compared with the control group, the expressions of VEGF in the pancreatic tissues of SAP group were significantly up-regulated following the operation (P<0.05). BENSULIDE 86-89 vascular endothelial growth factor A Rattus norvegicus 52-56 21269989-8 2011 The vascular permeability of the pancreatic microcirculation significantly increased after the onset of SAP, and injection of recombinant rat VEGF significantly increased the leakage rate of Evans Blue. Evans Blue 191-201 vascular endothelial growth factor A Rattus norvegicus 142-146 21311201-0 2011 Dexamethasone and betamethasone for prenatal lung maturation: differences in vascular endothelial growth factor expression and alveolarization in rats. Dexamethasone 0-13 vascular endothelial growth factor A Rattus norvegicus 77-111 21311201-0 2011 Dexamethasone and betamethasone for prenatal lung maturation: differences in vascular endothelial growth factor expression and alveolarization in rats. Betamethasone 18-31 vascular endothelial growth factor A Rattus norvegicus 77-111 21311201-3 2011 OBJECTIVES: The purpose of this study was to compare pulmonary VEGF expression in newborn rats that were exposed to antenatal betamethasone versus dexamethasone and to evaluate its impact on the alveolarization period of rats (0-14 days of life). Betamethasone 126-139 vascular endothelial growth factor A Rattus norvegicus 63-67 21311201-6 2011 RESULTS: Betamethasone and dexamethasone were observed to have different actions on VEGF expression with a correlation with alveolarization on both days of study. Betamethasone 9-22 vascular endothelial growth factor A Rattus norvegicus 84-88 21311201-6 2011 RESULTS: Betamethasone and dexamethasone were observed to have different actions on VEGF expression with a correlation with alveolarization on both days of study. Dexamethasone 27-40 vascular endothelial growth factor A Rattus norvegicus 84-88 21311201-7 2011 Antenatal dexamethasone decreased VEGF expression, betamethasone tended to produce the induction of the expression of VEGF, and moreover, betamethasone did not produce a decrease in alveolarization as seen in the animals that received dexamethasone. Dexamethasone 10-23 vascular endothelial growth factor A Rattus norvegicus 34-38 21311201-7 2011 Antenatal dexamethasone decreased VEGF expression, betamethasone tended to produce the induction of the expression of VEGF, and moreover, betamethasone did not produce a decrease in alveolarization as seen in the animals that received dexamethasone. Betamethasone 51-64 vascular endothelial growth factor A Rattus norvegicus 118-122 21642023-8 2011 RESULTS: VEGF, FGF and combined therapy significantly accelerated many of the histological parameters of healing, including fibroblast activation, collagen deposition, and angiogenesis, and augmented the levels of hydroxyproline and bursting pressure. Hydroxyproline 214-228 vascular endothelial growth factor A Rattus norvegicus 9-13 20407463-10 2011 This effect was associated with an increase of VEGF and eNOS and was mediated by improved rCBF after DMOG treatment. oxalylglycine 101-105 vascular endothelial growth factor A Rattus norvegicus 47-51 21494058-0 2011 Tetramethylpyrazine inhibits hypoxia-induced pulmonary vascular leakage in rats via the ROS-HIF-VEGF pathway. tetramethylpyrazine 0-19 vascular endothelial growth factor A Rattus norvegicus 96-100 21494058-0 2011 Tetramethylpyrazine inhibits hypoxia-induced pulmonary vascular leakage in rats via the ROS-HIF-VEGF pathway. Reactive Oxygen Species 88-91 vascular endothelial growth factor A Rattus norvegicus 96-100 21494058-7 2011 Treatment with TMP decreased the hypoxia-induced RPMVEC monolayer permeability and attenuated the elevation of ROS, HIF-1alpha and VEGF protein levels. tetramethylpyrazine 15-18 vascular endothelial growth factor A Rattus norvegicus 131-135 21494058-8 2011 TMP-treated animals showed less pulmonary vascular leakage and HIF-1alpha and VEGF expression compared with those exposed to hypoxia alone. tetramethylpyrazine 0-3 vascular endothelial growth factor A Rattus norvegicus 78-82 21494058-10 2011 The underlying mechanisms may be related to the scavenging of intracellular ROS and the suppression of hypoxia-induced upregulation of HIF-1alpha and VEGF proteins. Reactive Oxygen Species 76-79 vascular endothelial growth factor A Rattus norvegicus 150-154 21931795-11 2011 In vitro, CLZ enhanced proliferation, adhesion and migration activity, and differentiation with mRNA upregulation of adhesion molecule integrin alphavbeta3, chemokine receptor CXCR4 and growth factor VEGF assessed by real-time RT-PCR in rat BM-derived cultured EPCs. chlorozotocin 10-13 vascular endothelial growth factor A Rattus norvegicus 200-204 21949693-7 2011 Followed ILK alternation, vascular endothelial growth factor (VEGF) expression and phosphorylation of endothelial nitric oxide synthase (eNOS) was significantly decreased 8 weeks after MI. 2-methyl-4-isothiazolin-3-one 185-187 vascular endothelial growth factor A Rattus norvegicus 62-66 21168749-0 2010 Effects of a cGMP-specific phosphodiesterase inhibitor on expression of endothelial nitric oxide synthase and vascular endothelial growth factor in rats with cyclosporine-induced nephrotoxicity. Cyclic GMP 13-17 vascular endothelial growth factor A Rattus norvegicus 110-144 21116108-2 2011 SU5416 is the first VEGF receptor 2 inhibitor to enter clinical development for cancer therapy. Semaxinib 0-6 vascular endothelial growth factor A Rattus norvegicus 20-24 21116108-4 2011 It has been shown that VEGF receptor blockade using SU5416 combined with chronic hypoxia results in severe angioproliferative pulmonary hypertension (PAH) with neointimal changes in adult rats. Semaxinib 52-58 vascular endothelial growth factor A Rattus norvegicus 23-27 21116108-9 2011 The aim of the present review is to provide information useful for understanding a potent inhibitor of VEGF receptor tyrosine kinase, SU5416, and to better understand its use for generating animal models of PAH. Semaxinib 134-140 vascular endothelial growth factor A Rattus norvegicus 103-107 20854808-10 2010 Furthermore, leonurine not only increased the expression of HIF-1alpha but also the expression of survivin and VEGF. leonurine 13-22 vascular endothelial growth factor A Rattus norvegicus 111-115 21437112-2 2010 Curcumin has been reviewed for its multiple molecular action on inhibiting tumor angiogenesis via its mechanisms of cyclooxygenase (COX)-2, and vascular endothelial growth factor (VEGF) inhibition. Curcumin 0-8 vascular endothelial growth factor A Rattus norvegicus 144-178 21437112-2 2010 Curcumin has been reviewed for its multiple molecular action on inhibiting tumor angiogenesis via its mechanisms of cyclooxygenase (COX)-2, and vascular endothelial growth factor (VEGF) inhibition. Curcumin 0-8 vascular endothelial growth factor A Rattus norvegicus 180-184 21123607-11 2010 Expression of TGF-beta and VEGF in the BMC group was significantly increased compared with that in the other groups at four days after incision (TGF-beta: 1.6 vs. 1.3 or 0.6, p < 0.01; VEGF: 1.7 vs. 1.1 or 0.9, p < 0.01). S-benzyl-N-malonylcysteine 39-42 vascular endothelial growth factor A Rattus norvegicus 27-31 21123607-11 2010 Expression of TGF-beta and VEGF in the BMC group was significantly increased compared with that in the other groups at four days after incision (TGF-beta: 1.6 vs. 1.3 or 0.6, p < 0.01; VEGF: 1.7 vs. 1.1 or 0.9, p < 0.01). S-benzyl-N-malonylcysteine 39-42 vascular endothelial growth factor A Rattus norvegicus 188-192 20487237-0 2010 Chronic administration of sildenafil modified the impaired VEGF system and improved the erectile function in rats with diabetic erectile dysfunction. Sildenafil Citrate 26-36 vascular endothelial growth factor A Rattus norvegicus 59-63 20487237-3 2010 AIM: To determine whether chronic sildenafil administration can modify the impaired vascular endothelial growth factor (VEGF) system and improve the erectile function in rats with diabetic erectile dysfunction. Sildenafil Citrate 34-44 vascular endothelial growth factor A Rattus norvegicus 84-118 20487237-3 2010 AIM: To determine whether chronic sildenafil administration can modify the impaired vascular endothelial growth factor (VEGF) system and improve the erectile function in rats with diabetic erectile dysfunction. Sildenafil Citrate 34-44 vascular endothelial growth factor A Rattus norvegicus 120-124 20487237-13 2010 CONCLUSION: We demonstrated that daily sildenafil administration can restore the impaired VEGF system in the penis of DMED rats and progressively improve both erectile function and endothelial function, suggesting a potential general mechanism of improved signaling through the VEGF/eNOS signaling cascade. Sildenafil Citrate 39-49 vascular endothelial growth factor A Rattus norvegicus 90-94 20487237-13 2010 CONCLUSION: We demonstrated that daily sildenafil administration can restore the impaired VEGF system in the penis of DMED rats and progressively improve both erectile function and endothelial function, suggesting a potential general mechanism of improved signaling through the VEGF/eNOS signaling cascade. Sildenafil Citrate 39-49 vascular endothelial growth factor A Rattus norvegicus 278-282 21124130-0 2010 Vascular endothelial growth factor overexpression positively modulates the characteristics of periprosthetic tissue of polyurethane-coated silicone breast implant in rats. Polyurethanes 119-131 vascular endothelial growth factor A Rattus norvegicus 0-34 21124130-0 2010 Vascular endothelial growth factor overexpression positively modulates the characteristics of periprosthetic tissue of polyurethane-coated silicone breast implant in rats. Silicones 139-147 vascular endothelial growth factor A Rattus norvegicus 0-34 21124130-3 2010 In this study, the authors evaluated the differences in morphologic and molecular characteristics of the capsule formed around polyurethane-coated versus textured-surface silicone implants in rats, mainly the modifications in angiogenesis and the expression of vascular endothelial growth factor (VEGF). Polyurethanes 127-139 vascular endothelial growth factor A Rattus norvegicus 261-295 21124130-10 2010 Immunohistochemical analysis revealed high levels of transforming growth factor-beta and VEGF in the capsules around the polyurethane-coated silicone implants when compared with the textured-surface silicone implants. Polyurethanes 121-133 vascular endothelial growth factor A Rattus norvegicus 89-93 21124130-10 2010 Immunohistochemical analysis revealed high levels of transforming growth factor-beta and VEGF in the capsules around the polyurethane-coated silicone implants when compared with the textured-surface silicone implants. Silicones 141-149 vascular endothelial growth factor A Rattus norvegicus 89-93 21124130-11 2010 CONCLUSION: These findings suggest that the intense VEGF expression in capsules around the polyurethane-coated silicone implant is able to improve the tissue vascularization, resulting in a softer capsule compared with the textured-surface silicone implant. Polyurethanes 91-103 vascular endothelial growth factor A Rattus norvegicus 52-56 21124130-11 2010 CONCLUSION: These findings suggest that the intense VEGF expression in capsules around the polyurethane-coated silicone implant is able to improve the tissue vascularization, resulting in a softer capsule compared with the textured-surface silicone implant. Silicones 111-119 vascular endothelial growth factor A Rattus norvegicus 52-56 21124130-11 2010 CONCLUSION: These findings suggest that the intense VEGF expression in capsules around the polyurethane-coated silicone implant is able to improve the tissue vascularization, resulting in a softer capsule compared with the textured-surface silicone implant. Silicones 240-248 vascular endothelial growth factor A Rattus norvegicus 52-56 20962204-0 2010 Regulation of sFlt-1 and VEGF secretion by adenosine under hypoxic conditions in rat placental villous explants. Adenosine 43-52 vascular endothelial growth factor A Rattus norvegicus 25-29 20962204-1 2010 The role of adenosine in the regulation of cardiovascular function has long been acknowledged, but only recently has its importance in angiogenesis been appreciated, most notably, through its direct regulation of the proangiogenic growth factor, VEGF. Adenosine 12-21 vascular endothelial growth factor A Rattus norvegicus 246-250 20962204-3 2010 While adenosine has been reported to be an important regulator of VEGF in vascular tissue, the importance of adenosine in regulating VEGF and sFlt-1 in placental tissue is unclear. Adenosine 6-15 vascular endothelial growth factor A Rattus norvegicus 66-70 20962204-4 2010 Here, we have investigated the role of adenosine in the secretion of VEGF and the antiangiogenic protein sFlt-1 in placental villous explants. Adenosine 39-48 vascular endothelial growth factor A Rattus norvegicus 69-73 20962204-7 2010 Exogenous and the adenosine transporter inhibitor dipyridamole (which increases extracellular levels of adenosine) showed differential effects under normoxic conditions: sFlt-1 levels in media increased significantly (P < 0.05), whereas VEGF was unaffected (P = 0.67 and P = 0.19, respectively). Dipyridamole 50-62 vascular endothelial growth factor A Rattus norvegicus 240-244 20962204-7 2010 Exogenous and the adenosine transporter inhibitor dipyridamole (which increases extracellular levels of adenosine) showed differential effects under normoxic conditions: sFlt-1 levels in media increased significantly (P < 0.05), whereas VEGF was unaffected (P = 0.67 and P = 0.19, respectively). Adenosine 18-27 vascular endothelial growth factor A Rattus norvegicus 240-244 20962204-8 2010 These data indicate that extracellular adenosine can regulate VEGF and sFlt-1 secretion in the hypoxic placenta and could, therefore, control the balance of these competing angiogenic factors in diseases characterized by placental ischemia. Adenosine 39-48 vascular endothelial growth factor A Rattus norvegicus 62-66 21168749-0 2010 Effects of a cGMP-specific phosphodiesterase inhibitor on expression of endothelial nitric oxide synthase and vascular endothelial growth factor in rats with cyclosporine-induced nephrotoxicity. Cyclosporine 158-170 vascular endothelial growth factor A Rattus norvegicus 110-144 21168749-1 2010 BACKGROUND: The mechanism of cyclosporine (CsA)-induced nephrotoxicity has been suggested to be vasoconstriction due to reduced nitric oxide (NO), providing tissue fibrosis by elevation of transforming growth factor beta and vascular endothelial growth factor (VEGF). Cyclosporine 29-41 vascular endothelial growth factor A Rattus norvegicus 225-259 21168749-1 2010 BACKGROUND: The mechanism of cyclosporine (CsA)-induced nephrotoxicity has been suggested to be vasoconstriction due to reduced nitric oxide (NO), providing tissue fibrosis by elevation of transforming growth factor beta and vascular endothelial growth factor (VEGF). Cyclosporine 29-41 vascular endothelial growth factor A Rattus norvegicus 261-265 21168749-1 2010 BACKGROUND: The mechanism of cyclosporine (CsA)-induced nephrotoxicity has been suggested to be vasoconstriction due to reduced nitric oxide (NO), providing tissue fibrosis by elevation of transforming growth factor beta and vascular endothelial growth factor (VEGF). Cyclosporine 43-46 vascular endothelial growth factor A Rattus norvegicus 225-259 21168749-1 2010 BACKGROUND: The mechanism of cyclosporine (CsA)-induced nephrotoxicity has been suggested to be vasoconstriction due to reduced nitric oxide (NO), providing tissue fibrosis by elevation of transforming growth factor beta and vascular endothelial growth factor (VEGF). Cyclosporine 43-46 vascular endothelial growth factor A Rattus norvegicus 261-265 21168749-2 2010 In this study using a rat model of CsA-induced nephrotoxicity, we administered a phosphodiesterase-5 inhibitor to ameliorate the renal injury and alter the expression of endothelial No synthase (eNOS) and VEGF. Cyclosporine 35-38 vascular endothelial growth factor A Rattus norvegicus 205-209 21168749-12 2010 Western blots for VEGF revealed reduced expression only in the CsA plus udenafil group. Cyclosporine 63-66 vascular endothelial growth factor A Rattus norvegicus 18-22 21168749-12 2010 Western blots for VEGF revealed reduced expression only in the CsA plus udenafil group. udenafil 72-80 vascular endothelial growth factor A Rattus norvegicus 18-22 21168749-14 2010 VEGF mRNA which was decreased in the CsA group (2.026 +- 1.109), showed greater tendency after administration of udenafil (0.440 +- 0.449) (P = .003). Cyclosporine 37-40 vascular endothelial growth factor A Rattus norvegicus 0-4 21168749-14 2010 VEGF mRNA which was decreased in the CsA group (2.026 +- 1.109), showed greater tendency after administration of udenafil (0.440 +- 0.449) (P = .003). udenafil 113-121 vascular endothelial growth factor A Rattus norvegicus 0-4 21168749-15 2010 CONCLUSION: The phosphodiesterase inhibitor ameliorated renal injury in a rat model of CsA-induced nephrotoxicity, possibly related to increased eNOS and reduced VEGF expression. Cyclosporine 87-90 vascular endothelial growth factor A Rattus norvegicus 162-166 20705122-10 2010 The expressions of VEGF, VEGFR2 and P2X2(/)3 in L4-6 DRG of CCI rats treated with anti-rVEGF antibody group were decreased compared with those in CCI group (p<0.05). CCI 60-63 vascular endothelial growth factor A Rattus norvegicus 19-23 21211317-1 2010 OBJECTIVE: To investigate the influences of VEGF expression through the intervention of thalidomide in malignant transformation of hepatocytes. Thalidomide 88-99 vascular endothelial growth factor A Rattus norvegicus 44-48 21211317-12 2010 And the VEGF level of thalidomide group was lower than those in 2-FAA group. Thalidomide 22-33 vascular endothelial growth factor A Rattus norvegicus 8-12 21211317-13 2010 CONCLUSION: Thalidomide can inhibit the hepatic VEGF expression and arrest the development of rat hepatoma. Thalidomide 12-23 vascular endothelial growth factor A Rattus norvegicus 48-52 20801723-2 2010 We previously reported that endogenous VEGF protein is dramatically upregulated after pilocarpine-induced status epilepticus in the rat, and that intra-hippocampal infusions of recombinant human VEGF significantly protected against the loss of hippocampal CA1 neurons in this model (Nicoletti JN, Shah SK, McCloskey DP, et al. Pilocarpine 86-97 vascular endothelial growth factor A Rattus norvegicus 39-43 21031612-0 2010 Ginsenoside Rg1 modulation on thrombospondin-1 and vascular endothelial growth factor expression in early renal fibrogenesis in unilateral obstruction. Ginsenosides 0-11 vascular endothelial growth factor A Rattus norvegicus 51-85 21031612-9 2010 Interestingly, ginsenoside Rg1 decreased the expression of TSP-1 and enhanced vascular endothelial growth factor (VEGF) expression. Ginsenosides 15-26 vascular endothelial growth factor A Rattus norvegicus 78-112 21031612-9 2010 Interestingly, ginsenoside Rg1 decreased the expression of TSP-1 and enhanced vascular endothelial growth factor (VEGF) expression. Ginsenosides 15-26 vascular endothelial growth factor A Rattus norvegicus 114-118 21211366-13 2010 CONCLUSIONS: simvastatin ameliorated the development of cigarette smoke-induced COPD in rats, partly by promoting alveolar epithelial cell proliferation and up-regulating the expression of VEGF. Simvastatin 13-24 vascular endothelial growth factor A Rattus norvegicus 189-193 21139695-9 2010 RESULTS: Retinal transfection with the hPEDF gene construct led to sustained hPEDF gene expression for 6 months, significantly suppressing VEGF mRNA expression in the retina after 1, 3, and 6 months of diabetes induced by STZ compared with paired controls. Streptozocin 222-225 vascular endothelial growth factor A Rattus norvegicus 139-143 20686183-7 2010 RU486 treatment also caused significant increases in myometrial Esr1 and Vegf and a decrease in Esr2. Mifepristone 0-5 vascular endothelial growth factor A Rattus norvegicus 73-77 20698860-19 2010 In conclusion, Hcy impaired endothelial function through compromised VEGF/Akt/endothelial nitric oxide synthase signalling. Homocysteine 15-18 vascular endothelial growth factor A Rattus norvegicus 69-73 20705122-10 2010 The expressions of VEGF, VEGFR2 and P2X2(/)3 in L4-6 DRG of CCI rats treated with anti-rVEGF antibody group were decreased compared with those in CCI group (p<0.05). rvegf 87-92 vascular endothelial growth factor A Rattus norvegicus 19-23 20303838-1 2010 BACKGROUND: Ischemic injury by hepatic artery ligation (HAL) during obstructive cholestasis induced by bile duct ligation (BDL) results in bile duct damage, which can be prevented by administration of VEGF-A. hal 56-59 vascular endothelial growth factor A Rattus norvegicus 201-207 20880454-8 2010 The effect of isoflurane on upregulating VEGF expression was blocked by PKC inhibitor calphostin C (P < 0.01), but calphostin C did not alter VEGF expression (P > 0.05). calphostin C 86-98 vascular endothelial growth factor A Rattus norvegicus 41-45 20880454-11 2010 CONCLUSION: Isoflurane induces myocardial cells to release VEGF through activating PKC-epsilon from the endochylema to the cytomembrane, suggesting a possible novel mechanism of isoflurane protecting myocardial cells. Isoflurane 12-22 vascular endothelial growth factor A Rattus norvegicus 59-63 20880454-11 2010 CONCLUSION: Isoflurane induces myocardial cells to release VEGF through activating PKC-epsilon from the endochylema to the cytomembrane, suggesting a possible novel mechanism of isoflurane protecting myocardial cells. cytomembrane 123-135 vascular endothelial growth factor A Rattus norvegicus 59-63 20880454-11 2010 CONCLUSION: Isoflurane induces myocardial cells to release VEGF through activating PKC-epsilon from the endochylema to the cytomembrane, suggesting a possible novel mechanism of isoflurane protecting myocardial cells. Isoflurane 178-188 vascular endothelial growth factor A Rattus norvegicus 59-63 20303838-7 2010 TC also prevented HAL-inhibited VEGF-A and VEGFR-2 expression in liver sections and HAL-induced circulating VEGF-A levels, which were blocked by wortmannin administration. Taurocholic Acid 0-2 vascular endothelial growth factor A Rattus norvegicus 32-38 20303838-7 2010 TC also prevented HAL-inhibited VEGF-A and VEGFR-2 expression in liver sections and HAL-induced circulating VEGF-A levels, which were blocked by wortmannin administration. Taurocholic Acid 0-2 vascular endothelial growth factor A Rattus norvegicus 108-114 20880454-0 2010 Isoflurane induces expression of vascular endothelial growth factor through activating protein kinase C in myocardial cells. Isoflurane 0-10 vascular endothelial growth factor A Rattus norvegicus 33-67 20880454-2 2010 This study aimed to investigate the effect of isoflurane on VEGF expression and the potential intracellular signal transduction pathway in cultured rat myocardial cells in order to further reveal the molecular mechanism of myocardial preservation of isoflurane. Isoflurane 46-56 vascular endothelial growth factor A Rattus norvegicus 60-64 20880454-2 2010 This study aimed to investigate the effect of isoflurane on VEGF expression and the potential intracellular signal transduction pathway in cultured rat myocardial cells in order to further reveal the molecular mechanism of myocardial preservation of isoflurane. Isoflurane 250-260 vascular endothelial growth factor A Rattus norvegicus 60-64 20880454-6 2010 RESULTS: Isoflurane increased the VEGF expression in myocardial cells in a dose-dependent way. Isoflurane 9-19 vascular endothelial growth factor A Rattus norvegicus 34-38 20880454-7 2010 VEGF levels were significantly higher in 1.0 and 1.5 MAC isoflurane groups than in the control group (both P < 0.01). Isoflurane 57-67 vascular endothelial growth factor A Rattus norvegicus 0-4 20880454-8 2010 The effect of isoflurane on upregulating VEGF expression was blocked by PKC inhibitor calphostin C (P < 0.01), but calphostin C did not alter VEGF expression (P > 0.05). Isoflurane 14-24 vascular endothelial growth factor A Rattus norvegicus 41-45 20303838-7 2010 TC also prevented HAL-inhibited VEGF-A and VEGFR-2 expression in liver sections and HAL-induced circulating VEGF-A levels, which were blocked by wortmannin administration. hal 18-21 vascular endothelial growth factor A Rattus norvegicus 32-38 20303838-7 2010 TC also prevented HAL-inhibited VEGF-A and VEGFR-2 expression in liver sections and HAL-induced circulating VEGF-A levels, which were blocked by wortmannin administration. hal 84-87 vascular endothelial growth factor A Rattus norvegicus 108-114 20303838-7 2010 TC also prevented HAL-inhibited VEGF-A and VEGFR-2 expression in liver sections and HAL-induced circulating VEGF-A levels, which were blocked by wortmannin administration. Wortmannin 145-155 vascular endothelial growth factor A Rattus norvegicus 32-38 20303838-7 2010 TC also prevented HAL-inhibited VEGF-A and VEGFR-2 expression in liver sections and HAL-induced circulating VEGF-A levels, which were blocked by wortmannin administration. Wortmannin 145-155 vascular endothelial growth factor A Rattus norvegicus 108-114 20303838-8 2010 In vitro, TC stimulated increased VEGF-A secretion by cholangiocytes, which was blocked by wortmannin and stimulated cholangiocyte proliferation that was blocked by VEGFR-2 kinase inhibitor. Taurocholic Acid 10-12 vascular endothelial growth factor A Rattus norvegicus 34-40 20303838-2 2010 The potential regulation of VEGF and VEGF receptor expression and secretion by bile acids in BDL with HAL is unknown. Bile Acids and Salts 79-89 vascular endothelial growth factor A Rattus norvegicus 28-32 20303838-8 2010 In vitro, TC stimulated increased VEGF-A secretion by cholangiocytes, which was blocked by wortmannin and stimulated cholangiocyte proliferation that was blocked by VEGFR-2 kinase inhibitor. Wortmannin 91-101 vascular endothelial growth factor A Rattus norvegicus 34-40 20303838-2 2010 The potential regulation of VEGF and VEGF receptor expression and secretion by bile acids in BDL with HAL is unknown. Bile Acids and Salts 79-89 vascular endothelial growth factor A Rattus norvegicus 37-41 20303838-9 2010 CONCLUSION: TC prevented HAL-induced biliary damage by upregulation of VEGF-A expression. Taurocholic Acid 12-14 vascular endothelial growth factor A Rattus norvegicus 71-77 20303838-9 2010 CONCLUSION: TC prevented HAL-induced biliary damage by upregulation of VEGF-A expression. hal 25-28 vascular endothelial growth factor A Rattus norvegicus 71-77 20303838-3 2010 AIMS: We evaluated whether taurocholic acid (TC) can prevent HAL-induced cholangiocyte damage via the alteration of VEGFR-2 and/or VEGF-A expression. Taurocholic Acid 45-47 vascular endothelial growth factor A Rattus norvegicus 131-137 20659449-0 2010 Ketorolac inhibits choroidal neovascularization by suppression of retinal VEGF. Ketorolac 0-9 vascular endothelial growth factor A Rattus norvegicus 74-78 20659449-10 2010 Topical ketorolac inhibited CNV and suppressed retinal PGE(2) and VEGF production. Ketorolac 8-17 vascular endothelial growth factor A Rattus norvegicus 66-70 20811710-3 2010 Vandetanib (ZD6474) is mainly a vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) receptor tyrosine kinase inhibitor. vandetanib 0-10 vascular endothelial growth factor A Rattus norvegicus 32-66 20811710-3 2010 Vandetanib (ZD6474) is mainly a vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) receptor tyrosine kinase inhibitor. vandetanib 0-10 vascular endothelial growth factor A Rattus norvegicus 68-72 20811710-3 2010 Vandetanib (ZD6474) is mainly a vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) receptor tyrosine kinase inhibitor. vandetanib 12-18 vascular endothelial growth factor A Rattus norvegicus 32-66 20811710-3 2010 Vandetanib (ZD6474) is mainly a vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) receptor tyrosine kinase inhibitor. vandetanib 12-18 vascular endothelial growth factor A Rattus norvegicus 68-72 21063852-13 2010 In the cyclopamine group, the mRNA and protein expression of Gli1, HIF-1(alpha), VEGF and DLL4 was significantly down-regulated (P<0.05 for each) while the expression of PTCH1 showed no significant changes at the mRNA (P=0.293) and protein level (P=0.304). cyclopamine 7-18 vascular endothelial growth factor A Rattus norvegicus 81-85 20445124-9 2010 U0126, an inhibitor of ERK1/2, also downregulated VEGF expression, in addition to ERK1/2 and AP-1 activity. U 0126 0-5 vascular endothelial growth factor A Rattus norvegicus 50-54 20492444-5 2010 Melatonin augmented angiogenesis that was associated with amelioration of MMP-2 expression and activity and, upregulation of vascular endothelial growth factor (VEGF) in rat cornea. Melatonin 0-9 vascular endothelial growth factor A Rattus norvegicus 125-159 20015768-9 2010 The VEGF was expressed to a lesser degree than bFGF in the dexamethasone-treated group. Dexamethasone 59-72 vascular endothelial growth factor A Rattus norvegicus 4-8 20582486-1 2010 Previous studies have shown that both copper (Cu) and vascular endothelial growth factor (VEGF) reduce the size of hypertrophic cardiomyocytes, but the Cu-induced regression is VEGF dependent. Copper 38-44 vascular endothelial growth factor A Rattus norvegicus 177-181 20539216-7 2010 VEGF and CD34 levels were significantly induced by chemical cauterization in the groups treated with chloramphenicol, chondroitin sulfate, and normal saline, demonstrating corneal NV. Chloramphenicol 101-116 vascular endothelial growth factor A Rattus norvegicus 0-4 20539216-7 2010 VEGF and CD34 levels were significantly induced by chemical cauterization in the groups treated with chloramphenicol, chondroitin sulfate, and normal saline, demonstrating corneal NV. Chondroitin Sulfates 118-137 vascular endothelial growth factor A Rattus norvegicus 0-4 21063852-16 2010 It was concluded that intravitreal administration of cyclopamine can effectively inhibit the formation of laser-induced experimental CNV by down-regulating the expression of the HIF-1(alpha)-VEGF-DLL4 cascade in CNV. cyclopamine 53-64 vascular endothelial growth factor A Rattus norvegicus 191-195 20631299-5 2010 Moreover, CDODA-Me abrogated VEGF-induced sprouting of microvessels from rat aortic rings ex vivo and inhibited the generation of new vasculature in the Matrigel plugs in vivo, where CDODA-Me significantly decreased the number of infiltrating von Willebrand factor-positive endothelial cells. methyl 2-cyano-3,11-dioxo-18beta-olean-1,12-dien-30-oate 10-18 vascular endothelial growth factor A Rattus norvegicus 29-33 20631299-5 2010 Moreover, CDODA-Me abrogated VEGF-induced sprouting of microvessels from rat aortic rings ex vivo and inhibited the generation of new vasculature in the Matrigel plugs in vivo, where CDODA-Me significantly decreased the number of infiltrating von Willebrand factor-positive endothelial cells. methyl 2-cyano-3,11-dioxo-18beta-olean-1,12-dien-30-oate 183-191 vascular endothelial growth factor A Rattus norvegicus 29-33 20554037-6 2010 The optimal dose of Niaspan treatment of stroke was chosen for immunostaining: deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL), cleaved caspase-3, tumor necrosis factor alpha (TNF-alpha), vascular endothelial growth factor (VEGF) and phosphorylated phosphatidylinositol 3-kinase (p-PI3K). Niacin 20-27 vascular endothelial growth factor A Rattus norvegicus 209-243 20554037-6 2010 The optimal dose of Niaspan treatment of stroke was chosen for immunostaining: deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL), cleaved caspase-3, tumor necrosis factor alpha (TNF-alpha), vascular endothelial growth factor (VEGF) and phosphorylated phosphatidylinositol 3-kinase (p-PI3K). Niacin 20-27 vascular endothelial growth factor A Rattus norvegicus 245-249 20554037-12 2010 Niaspan treatment also significantly increased the expression of VEGF (5.2+/-0.9%) and PI3K/Akt (0.381+/-0.04%) in the ischemic brain compared with non-treated MCAo control (2.6+/-0.4%; 0.24+/-0.03, respectively; p<or=0.05). Niacin 0-7 vascular endothelial growth factor A Rattus norvegicus 65-69 20554037-16 2010 VEGF and the PI3K/Akt pathway may contribute to the Niaspan-induced neuroprotection after stroke. Niacin 52-59 vascular endothelial growth factor A Rattus norvegicus 0-4 20607367-1 2010 PURPOSE: A hypoxia-inducible VEGF expression system with the oxygen-dependent degradation (ODD) domain was constructed and tested to be used in gene therapy for ischemic myocardial disease. Oxygen 61-67 vascular endothelial growth factor A Rattus norvegicus 29-33 20607367-8 2010 The enhancement of VEGF protein production was attributed to increased protein stability due to oxygen deficiency. Oxygen 96-102 vascular endothelial growth factor A Rattus norvegicus 19-23 21129279-3 2010 After 72 hours, the effect of PD98059 or SB203580 on MSC proliferation mediated by VEGF was measured by MTT assay. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 30-37 vascular endothelial growth factor A Rattus norvegicus 83-87 21129279-3 2010 After 72 hours, the effect of PD98059 or SB203580 on MSC proliferation mediated by VEGF was measured by MTT assay. SB 203580 41-49 vascular endothelial growth factor A Rattus norvegicus 83-87 21129279-3 2010 After 72 hours, the effect of PD98059 or SB203580 on MSC proliferation mediated by VEGF was measured by MTT assay. monooxyethylene trimethylolpropane tristearate 104-107 vascular endothelial growth factor A Rattus norvegicus 83-87 21129279-7 2010 The effect of VEGF on MSC proliferation was found to be abolished, even was under level of control group after treating with PD98059 or SB203580 for 30 minutes. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 125-132 vascular endothelial growth factor A Rattus norvegicus 14-18 21129279-7 2010 The effect of VEGF on MSC proliferation was found to be abolished, even was under level of control group after treating with PD98059 or SB203580 for 30 minutes. SB 203580 136-144 vascular endothelial growth factor A Rattus norvegicus 14-18 20431905-5 2010 In skin-tumor rats generated with carcinosarcoma-cells, vincristine, which suppressed the skin tumor and restored normal blood concentration of vascular endothelial growth factor (VEGF), reproduced neuropathic side-effects. Vincristine 56-67 vascular endothelial growth factor A Rattus norvegicus 144-178 20431905-5 2010 In skin-tumor rats generated with carcinosarcoma-cells, vincristine, which suppressed the skin tumor and restored normal blood concentration of vascular endothelial growth factor (VEGF), reproduced neuropathic side-effects. Vincristine 56-67 vascular endothelial growth factor A Rattus norvegicus 180-184 20566666-7 2010 RESULTS: Simvastatin significantly upregulated PGC-1alpha (P < 0.01), subsequently decreased Deltapsim (P < 0.05) and ROS generation (P < 0.01), inhibited PARP activation (P < 0.01), and further reduced VEGF expression (P < 0.01) and p38 MAPK activity (P < 0.01). Simvastatin 9-20 vascular endothelial growth factor A Rattus norvegicus 215-219 19716283-6 2010 Vascular endothelial growth factor (VEGF) promoter activity reporter assays and semi-quantitative RT-PCR revealed that vitamin C inhibited HIF-1-dependent VEGF expression. Ascorbic Acid 119-128 vascular endothelial growth factor A Rattus norvegicus 0-34 19716283-6 2010 Vascular endothelial growth factor (VEGF) promoter activity reporter assays and semi-quantitative RT-PCR revealed that vitamin C inhibited HIF-1-dependent VEGF expression. Ascorbic Acid 119-128 vascular endothelial growth factor A Rattus norvegicus 155-159 19716283-12 2010 In vitamin C-treated rats, however, most prostate hyperplasia parameters and prostrate HIF-1alpha/VEGF levels were markedly reduced. Ascorbic Acid 3-12 vascular endothelial growth factor A Rattus norvegicus 98-102 20492444-5 2010 Melatonin augmented angiogenesis that was associated with amelioration of MMP-2 expression and activity and, upregulation of vascular endothelial growth factor (VEGF) in rat cornea. Melatonin 0-9 vascular endothelial growth factor A Rattus norvegicus 161-165 20492444-6 2010 Melatonin prevented gastric lesions by promoting angiogenesis via upregulation of VEGF followed by over-expression of MMP-2. Melatonin 0-9 vascular endothelial growth factor A Rattus norvegicus 82-86 20492444-9 2010 Our data demonstrated that melatonin exerts angiogenesis through MMP-2 and VEGF over-expression during protection and healing of gastric ulcers. Melatonin 27-36 vascular endothelial growth factor A Rattus norvegicus 75-79 19660197-6 2010 RESULTS: Intraventricular application of rAAV-VEGF/rAAV-Ang1, 8 weeks before tMCAO, resulted in VEGF and Ang1 overexpression, and significantly decreased Evans blue permeability following ischemia (p<0.05). tmcao 77-82 vascular endothelial growth factor A Rattus norvegicus 46-50 20832524-11 2010 The expression of VEGF on cholangiocytes and the proliferation rate of cholangiocytes were higher in the HP group than in the AT group over the entire experiment (P < .05). Hematoporphyrins 105-107 vascular endothelial growth factor A Rattus norvegicus 18-22 20832524-13 2010 The mechanism may be related to HP-induced overexpression of VEGF on cholangiocytes. Hematoporphyrins 32-34 vascular endothelial growth factor A Rattus norvegicus 61-65 21063140-3 2010 We evaluated the effect of VGA1155 (5- [N-Methyl-N-(4-octadecyloxyphenyl)acetyl]amino-2- methylthiobenzoic acid), a novel binding antagonist of VEGF, on cerebral edema after transient focal cerebral ischemia. VGA1155 27-34 vascular endothelial growth factor A Rattus norvegicus 144-148 21063140-3 2010 We evaluated the effect of VGA1155 (5- [N-Methyl-N-(4-octadecyloxyphenyl)acetyl]amino-2- methylthiobenzoic acid), a novel binding antagonist of VEGF, on cerebral edema after transient focal cerebral ischemia. VGA1155 36-111 vascular endothelial growth factor A Rattus norvegicus 144-148 20333532-6 2010 LPZ administration also increased VEGF expression at the ulcer margin in a dose-dependent manner. Lansoprazole 0-3 vascular endothelial growth factor A Rattus norvegicus 34-38 20697002-1 2010 OBJECTIVE: To study the effects of oxygen fluctuations on rat vascular endothelial growth factor (VEGF), VEGF receptor 1(VEGFR1), and VEGFR2 in a model of retinopathy of prematurity (ROP). Oxygen 35-41 vascular endothelial growth factor A Rattus norvegicus 62-96 20673050-7 2010 RESULTS: In control (normoglycemic/normoxic) conditions, N-methyl-D-aspartate receptor (NMDA-R) antagonists MK801 and AP-5 increased secretion of VEGF from Muller cells, and this was not observed after AMPA/kainate receptor blockade. Dizocilpine Maleate 108-113 vascular endothelial growth factor A Rattus norvegicus 146-150 20673050-7 2010 RESULTS: In control (normoglycemic/normoxic) conditions, N-methyl-D-aspartate receptor (NMDA-R) antagonists MK801 and AP-5 increased secretion of VEGF from Muller cells, and this was not observed after AMPA/kainate receptor blockade. 2-amino-5-phosphopentanoic acid 118-122 vascular endothelial growth factor A Rattus norvegicus 146-150 20673050-8 2010 VEGF secretion after NMDA-R antagonists was independent of cell proliferation or cell lysis and it was maintained in cultures grown in hyperglycemia or hypoxia. N-Methylaspartate 21-25 vascular endothelial growth factor A Rattus norvegicus 0-4 20333532-0 2010 Effects of lansoprazole on the expression of VEGF and cellular proliferation in a rat model of acetic acid-induced gastric ulcer. Lansoprazole 11-23 vascular endothelial growth factor A Rattus norvegicus 45-49 20333532-0 2010 Effects of lansoprazole on the expression of VEGF and cellular proliferation in a rat model of acetic acid-induced gastric ulcer. Acetic Acid 95-106 vascular endothelial growth factor A Rattus norvegicus 45-49 20333532-10 2010 The effect of endogenous PG secretion may be related to the induction of VEGF expression. Prostaglandins 25-27 vascular endothelial growth factor A Rattus norvegicus 73-77 20333532-12 2010 The mechanisms of LPZ on ulcer healing may be involved by VEGF expression through endogenous PGs secretion. Lansoprazole 18-21 vascular endothelial growth factor A Rattus norvegicus 58-62 20333532-12 2010 The mechanisms of LPZ on ulcer healing may be involved by VEGF expression through endogenous PGs secretion. Phosphatidylglycerols 93-96 vascular endothelial growth factor A Rattus norvegicus 58-62 20599750-0 2010 Sofalcone, a gastric mucosa protective agent, increases vascular endothelial growth factor via the Nrf2-heme-oxygenase-1 dependent pathway in gastric epithelial cells. sofalcone 0-9 vascular endothelial growth factor A Rattus norvegicus 56-90 21180873-0 2010 [Melatonin action in apoptosis and vascular endothelial growth factor in adrenal cortex of pinealectomized female rats]. Melatonin 1-10 vascular endothelial growth factor A Rattus norvegicus 35-69 21180873-1 2010 PURPOSE: to evaluate the reactivity of VEGF-A and cleaved caspase-3 in the adrenal gland cortex of female pinealectomized rats treated with melatonin. Melatonin 140-149 vascular endothelial growth factor A Rattus norvegicus 39-45 20599750-7 2010 We also observed that sofalcone increased vascular endothelial growth factor (VEGF) production in the culture medium. sofalcone 22-31 vascular endothelial growth factor A Rattus norvegicus 42-76 20599750-7 2010 We also observed that sofalcone increased vascular endothelial growth factor (VEGF) production in the culture medium. sofalcone 22-31 vascular endothelial growth factor A Rattus norvegicus 78-82 20599750-8 2010 Treatment of RGM-1 cells with an HO-1 inhibitor (tin-protoporphyrin), or HO-1 siRNA inhibited sofalcone-induced VEGF production, suggesting that the effect of sofalcone on VEGF expression is mediated by the HO-1 pathway. tin protoporphyrin IX 49-67 vascular endothelial growth factor A Rattus norvegicus 112-116 20599750-8 2010 Treatment of RGM-1 cells with an HO-1 inhibitor (tin-protoporphyrin), or HO-1 siRNA inhibited sofalcone-induced VEGF production, suggesting that the effect of sofalcone on VEGF expression is mediated by the HO-1 pathway. sofalcone 94-103 vascular endothelial growth factor A Rattus norvegicus 112-116 20599750-8 2010 Treatment of RGM-1 cells with an HO-1 inhibitor (tin-protoporphyrin), or HO-1 siRNA inhibited sofalcone-induced VEGF production, suggesting that the effect of sofalcone on VEGF expression is mediated by the HO-1 pathway. sofalcone 94-103 vascular endothelial growth factor A Rattus norvegicus 172-176 20599750-8 2010 Treatment of RGM-1 cells with an HO-1 inhibitor (tin-protoporphyrin), or HO-1 siRNA inhibited sofalcone-induced VEGF production, suggesting that the effect of sofalcone on VEGF expression is mediated by the HO-1 pathway. sofalcone 159-168 vascular endothelial growth factor A Rattus norvegicus 112-116 20599750-8 2010 Treatment of RGM-1 cells with an HO-1 inhibitor (tin-protoporphyrin), or HO-1 siRNA inhibited sofalcone-induced VEGF production, suggesting that the effect of sofalcone on VEGF expression is mediated by the HO-1 pathway. sofalcone 159-168 vascular endothelial growth factor A Rattus norvegicus 172-176 20599750-9 2010 These results suggest that the gastroprotective effects of sofalcone are partly exerted via Nrf2-HO-1 activation followed by VEGF production. sofalcone 59-68 vascular endothelial growth factor A Rattus norvegicus 125-129 20106566-6 2010 The mRNA expression of collagen I, collagen III, bcl-2, vascular endothelial growth factor (VEGF) and transforming growth factor-beta1 (TGF-beta1) were markedly increased by CCl(4) treatment but suppressed by a coffee preparation treatment. Cefaclor 174-177 vascular endothelial growth factor A Rattus norvegicus 56-90 20621034-5 2010 Losartan treatment suppressed the excessive NO and lipid peroxidation production systemically without restoring them to that of healthy subjects and reduced VEGF levels while leaving sICAM-1 levels unchanged. Losartan 0-8 vascular endothelial growth factor A Rattus norvegicus 157-161 20434464-5 2010 Administration of eugenol induced apoptosis via the mitochondrial pathway by modulating the Bcl-2 family proteins, Apaf-1, cytochrome C, and caspases and inhibiting invasion, and angiogenesis as evidenced by changes in the activities of MMPs and the expression of MMP-2 and -9, VEGF, VEGFR1, TIMP-2 and RECK. Eugenol 18-25 vascular endothelial growth factor A Rattus norvegicus 278-282 20583517-13 2010 In addition, sildenafil increased the expression of VEGF-A, VEGF-B, and VEGF-C by 2.66-, 2.02-, and 2.00-fold, respectively. Sildenafil Citrate 13-23 vascular endothelial growth factor A Rattus norvegicus 52-58 20583517-15 2010 These data demonstrate that sildenafil altered the expression of FGF and VEGF. Sildenafil Citrate 28-38 vascular endothelial growth factor A Rattus norvegicus 73-77 20144589-1 2010 The aim of the present study was to assess the effect of drugs that increase gastric vascular endothelial growth factor (VEGF) and suppress gastric tumor necrosis factor-alpha (TNF-alpha) in gastric ulcer healing in streptozotocin-induced diabetic rats. Streptozocin 216-230 vascular endothelial growth factor A Rattus norvegicus 85-119 20144589-1 2010 The aim of the present study was to assess the effect of drugs that increase gastric vascular endothelial growth factor (VEGF) and suppress gastric tumor necrosis factor-alpha (TNF-alpha) in gastric ulcer healing in streptozotocin-induced diabetic rats. Streptozocin 216-230 vascular endothelial growth factor A Rattus norvegicus 121-125 20144589-7 2010 The use of insulin, combinations of insulin and pentoxifylline or simvastatin resulted in a significant decrease in gastric ulcer area, significant increase in epithelial regeneration assessed histologically, significant increase in gastric VEGF concentration, and gastric von Willebrand factor (vWF) as well as significant decrease in gastric TNF-alpha. Pentoxifylline 48-62 vascular endothelial growth factor A Rattus norvegicus 241-245 20144589-7 2010 The use of insulin, combinations of insulin and pentoxifylline or simvastatin resulted in a significant decrease in gastric ulcer area, significant increase in epithelial regeneration assessed histologically, significant increase in gastric VEGF concentration, and gastric von Willebrand factor (vWF) as well as significant decrease in gastric TNF-alpha. Simvastatin 66-77 vascular endothelial growth factor A Rattus norvegicus 241-245 20144589-8 2010 A significant difference in gastric ulcer area as well as in gastric TNF-alpha, VEGF and vWF levels could be observed between rats that received combinations of insulin and pentoxifylline or simvastatin compared to rats that received either drug alone. Pentoxifylline 173-187 vascular endothelial growth factor A Rattus norvegicus 80-84 20144589-8 2010 A significant difference in gastric ulcer area as well as in gastric TNF-alpha, VEGF and vWF levels could be observed between rats that received combinations of insulin and pentoxifylline or simvastatin compared to rats that received either drug alone. Simvastatin 191-202 vascular endothelial growth factor A Rattus norvegicus 80-84 20575564-2 2010 Optimal incorporation of VEGF was found at a VEGF/DS/CS ratio of 0.12:1:0.33, which resulted in nanoparticle complexes with diameters of 612+/-79 nm and zeta potentials of -31+/-1 mV. Dextran Sulfate 50-52 vascular endothelial growth factor A Rattus norvegicus 25-29 20575564-2 2010 Optimal incorporation of VEGF was found at a VEGF/DS/CS ratio of 0.12:1:0.33, which resulted in nanoparticle complexes with diameters of 612+/-79 nm and zeta potentials of -31+/-1 mV. Chitosan 53-55 vascular endothelial growth factor A Rattus norvegicus 25-29 20575564-5 2010 The extended VEGF retention was likely due to equilibrium binding of VEGF to DS and to endogenous glycosaminoglycans. Glycosaminoglycans 98-116 vascular endothelial growth factor A Rattus norvegicus 13-17 20106566-6 2010 The mRNA expression of collagen I, collagen III, bcl-2, vascular endothelial growth factor (VEGF) and transforming growth factor-beta1 (TGF-beta1) were markedly increased by CCl(4) treatment but suppressed by a coffee preparation treatment. Cefaclor 174-177 vascular endothelial growth factor A Rattus norvegicus 92-96 20514308-10 2010 These results suggest that SK-MS10 treatment accelerates the healing of gastric ulcers via upregulation of VEGF and angiogenesis in an acetic acid rat model. sk-ms10 27-34 vascular endothelial growth factor A Rattus norvegicus 107-111 20565307-8 2010 The VEGF level in the retina after laser treatment was lower in the TUDCA group than that in the control group (9.0 +/- 2.7 pg/mg vs. 29.4 +/- 8.2 pg/mg, P = 0.032), whereas the UDCA group showed no difference. ursodoxicoltaurine 68-73 vascular endothelial growth factor A Rattus norvegicus 4-8 20590386-6 2010 Compared to the control rats, intranasal administration of VEGF improved behavioral recovery, and increased the number of vWF(+), BrdU(+)/vWF(+) cells, and FITC-dextran perfused microvessels in ischemic boundary (p < .01). fluorescein isothiocyanate dextran 156-168 vascular endothelial growth factor A Rattus norvegicus 59-63 20435353-9 2010 In this group, the high cholesterol diet led to an increase in interleukin (IL)-4, IL-6, IL-12p70, IL-13, RANTES (Regulated on Activation, Normal T Expressed and Secreted) and VEGF (vascular endothelial growth factor). Cholesterol 24-35 vascular endothelial growth factor A Rattus norvegicus 176-180 20435353-9 2010 In this group, the high cholesterol diet led to an increase in interleukin (IL)-4, IL-6, IL-12p70, IL-13, RANTES (Regulated on Activation, Normal T Expressed and Secreted) and VEGF (vascular endothelial growth factor). Cholesterol 24-35 vascular endothelial growth factor A Rattus norvegicus 182-216 20432372-0 2010 Alendronate affects cartilage resorption by regulating vascular endothelial growth factor expression in rats. Alendronate 0-11 vascular endothelial growth factor A Rattus norvegicus 55-89 20423279-1 2010 OBJECTIVE: To compare the efficacy of cabergoline (Cb2) and meloxicam in curbing vascular endothelial growth factor (VEGF) expression and preventing ovarian hyperstimulation syndrome (OHSS). Cabergoline 38-49 vascular endothelial growth factor A Rattus norvegicus 81-115 20423279-1 2010 OBJECTIVE: To compare the efficacy of cabergoline (Cb2) and meloxicam in curbing vascular endothelial growth factor (VEGF) expression and preventing ovarian hyperstimulation syndrome (OHSS). Cabergoline 38-49 vascular endothelial growth factor A Rattus norvegicus 117-121 20423279-1 2010 OBJECTIVE: To compare the efficacy of cabergoline (Cb2) and meloxicam in curbing vascular endothelial growth factor (VEGF) expression and preventing ovarian hyperstimulation syndrome (OHSS). cb2 51-54 vascular endothelial growth factor A Rattus norvegicus 81-115 20423279-1 2010 OBJECTIVE: To compare the efficacy of cabergoline (Cb2) and meloxicam in curbing vascular endothelial growth factor (VEGF) expression and preventing ovarian hyperstimulation syndrome (OHSS). cb2 51-54 vascular endothelial growth factor A Rattus norvegicus 117-121 20423279-1 2010 OBJECTIVE: To compare the efficacy of cabergoline (Cb2) and meloxicam in curbing vascular endothelial growth factor (VEGF) expression and preventing ovarian hyperstimulation syndrome (OHSS). Meloxicam 60-69 vascular endothelial growth factor A Rattus norvegicus 81-115 20423279-1 2010 OBJECTIVE: To compare the efficacy of cabergoline (Cb2) and meloxicam in curbing vascular endothelial growth factor (VEGF) expression and preventing ovarian hyperstimulation syndrome (OHSS). Meloxicam 60-69 vascular endothelial growth factor A Rattus norvegicus 117-121 20432372-5 2010 Strong immunoreactivity to VEGF was observed in the hypertrophied chondrocytes and some proliferating chondrocytes in the epiphyseal cartilage at postnatal Day 5 and was decreased after the alendronate treatment for 5 days. Alendronate 190-201 vascular endothelial growth factor A Rattus norvegicus 27-31 20432372-8 2010 The level of VEGF expression was reduced by the alendronate treatment at both the transcription and translation levels. Alendronate 48-59 vascular endothelial growth factor A Rattus norvegicus 13-17 20432372-10 2010 These results suggest that VEGF expression is required for vascular invasion into the developing cartilage and alendronate can affect its resorption by downregulating VEGF expression. Alendronate 111-122 vascular endothelial growth factor A Rattus norvegicus 167-171 19888602-0 2010 Oroxylin A inhibits angiogenesis through blocking vascular endothelial growth factor-induced KDR/Flk-1 phosphorylation. 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one 0-10 vascular endothelial growth factor A Rattus norvegicus 50-84 19888602-2 2010 METHODS: Transwell assay and tube formation assay were used to evaluate the effects of oroxylin A on vascular endothelial growth factor (VEGF)-induced migration and tube formation of human umbilical vein endothelial cells (HUVECs). 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one 87-97 vascular endothelial growth factor A Rattus norvegicus 101-135 19888602-6 2010 RESULTS: Oroxylin A remarkably suppressed the VEGF-stimulated migration and tube formation of HUVECs. 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one 9-19 vascular endothelial growth factor A Rattus norvegicus 46-50 19888602-9 2010 Moreover, oroxylin A blocked VEGF-induced phosphorylation of KDR/Flk-1 and related downstream signaling molecules, including p38 mitogen-activated protein kinase, extracellular signal-regulated kinase and Akt. 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one 10-20 vascular endothelial growth factor A Rattus norvegicus 29-33 20586869-11 2010 Indomethacin (2 mg/kg) downregulated both VEGF expression and angiogenesis in the mucosa during the healing process, and these effects were significantly reversed by co-treatment with the EP4 agonist. Indomethacin 0-12 vascular endothelial growth factor A Rattus norvegicus 42-46 20586869-12 2010 CONCLUSION: The results suggest that endogenous PGE(2) promotes the healing of small intestinal lesions by stimulating angiogenesis through the upregulation of VEGF expression mediated by the activation of EP4 receptors. Prostaglandins E 48-51 vascular endothelial growth factor A Rattus norvegicus 160-164 20586869-0 2010 Endogenous prostaglandin E2 accelerates healing of indomethacin-induced small intestinal lesions through upregulation of vascular endothelial growth factor expression by activation of EP4 receptors. Dinoprostone 11-27 vascular endothelial growth factor A Rattus norvegicus 121-155 20586869-0 2010 Endogenous prostaglandin E2 accelerates healing of indomethacin-induced small intestinal lesions through upregulation of vascular endothelial growth factor expression by activation of EP4 receptors. Indomethacin 51-63 vascular endothelial growth factor A Rattus norvegicus 121-155 20207185-0 2010 Vascular endothelial growth factor in the early stage of skin incision wounds in cyclophosphamide-induced leukocytopenic rats. Cyclophosphamide 81-97 vascular endothelial growth factor A Rattus norvegicus 0-34 19759273-5 2010 RESULTS: Chronic high-glucose-based PDF exposure resulted in increased vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) expression, accumulation of advanced glycation end-products (AGEs), and up-regulation of the receptor for AGE (RAGE), which were ameliorated in the icodextrin-based PDF group. Glucose 22-29 vascular endothelial growth factor A Rattus norvegicus 71-105 19759273-5 2010 RESULTS: Chronic high-glucose-based PDF exposure resulted in increased vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) expression, accumulation of advanced glycation end-products (AGEs), and up-regulation of the receptor for AGE (RAGE), which were ameliorated in the icodextrin-based PDF group. Glucose 22-29 vascular endothelial growth factor A Rattus norvegicus 107-111 20483006-0 2010 3-n-Butylphthalide (NBP) reduces apoptosis and enhances vascular endothelial growth factor (VEGF) up-regulation in diabetic rats. 3-n-butylphthalide 0-18 vascular endothelial growth factor A Rattus norvegicus 56-90 20483006-0 2010 3-n-Butylphthalide (NBP) reduces apoptosis and enhances vascular endothelial growth factor (VEGF) up-regulation in diabetic rats. 3-n-butylphthalide 0-18 vascular endothelial growth factor A Rattus norvegicus 92-96 20629321-0 2010 [Podocyte injury and expression of nephrin and VEGF in rat nephrosis model induced by adriamycin]. Doxorubicin 86-96 vascular endothelial growth factor A Rattus norvegicus 47-51 20629321-1 2010 OBJECTIVE: To investigate podocyte injury and the expression of nephrin and VEGF in rat nephrosis model induced by adriamycin. Doxorubicin 115-125 vascular endothelial growth factor A Rattus norvegicus 76-80 20629321-4 2010 RESULTS: After second injected with adriamycin,the model group nephrin presented a weak signal in the end of the first week (P < 0.05), and the expression of VEGF started to increase at the end of the eighth week (P < 0.05). Doxorubicin 36-46 vascular endothelial growth factor A Rattus norvegicus 161-165 20629321-6 2010 The expression of nephrin and the number of podocyte were negatively correlated with the 24-hour urine protein, blood urea nitrogen and serum creatinine; while the expression of VEGF was positively correlated with the 24-hour urine protein, blood urea nitrogen and serum creatinine. Urea 247-251 vascular endothelial growth factor A Rattus norvegicus 178-182 20629321-6 2010 The expression of nephrin and the number of podocyte were negatively correlated with the 24-hour urine protein, blood urea nitrogen and serum creatinine; while the expression of VEGF was positively correlated with the 24-hour urine protein, blood urea nitrogen and serum creatinine. Nitrogen 252-260 vascular endothelial growth factor A Rattus norvegicus 178-182 20629321-6 2010 The expression of nephrin and the number of podocyte were negatively correlated with the 24-hour urine protein, blood urea nitrogen and serum creatinine; while the expression of VEGF was positively correlated with the 24-hour urine protein, blood urea nitrogen and serum creatinine. Creatinine 271-281 vascular endothelial growth factor A Rattus norvegicus 178-182 20629321-8 2010 VEGF participated in the process of proteinuria and glomerular sclerosis in the development of rat adriamycin nephrosis. Doxorubicin 99-109 vascular endothelial growth factor A Rattus norvegicus 0-4 20546541-8 2010 Rosiglitazone treatment prevented the hypoxia-induced reduction in PPARgamma expression, and restored ET-1 and VEGF expression almost to the levels of the normoxia group. Rosiglitazone 0-13 vascular endothelial growth factor A Rattus norvegicus 111-115 20546541-9 2010 CONCLUSIONS: Rosiglitazone inhibited the development of pulmonary hypertension induced by chronic hypoxia, perhaps by reversing the changes in PPARgamma, ET-1 and VEGF expression induced by hypoxia. Rosiglitazone 13-26 vascular endothelial growth factor A Rattus norvegicus 163-167 20207185-8 2010 Immunohistochemically, VEGF was positive in leukocytes and mesenchymal cells including fibroblasts and endothelial cells in the 3-day-old wound of saline-administered control rats, while a few fibroblasts and endothelial cells were positively stained in CPM-administered rats. Sodium Chloride 147-153 vascular endothelial growth factor A Rattus norvegicus 23-27 20153736-11 2010 We conclude that PC provides neuroprotection and augments and preserves the increase in VEGF following HI in the newborn rat brain which may play an important role in neuroprotection. pc 17-19 vascular endothelial growth factor A Rattus norvegicus 88-92 20376891-0 2010 Aldose reductase inhibitor ameliorates renal vascular endothelial growth factor expression in streptozotocin-induced diabetic rats. Streptozocin 94-108 vascular endothelial growth factor A Rattus norvegicus 45-79 20376891-7 2010 The renal VEGF messenger RNA (mRNA) and protein expression were significantly decreased in the fidarestat and losartan treated diabetic rat groups than in the diabetic control group. Losartan 110-118 vascular endothelial growth factor A Rattus norvegicus 10-14 20382589-8 2010 In the thalidomide-treated group, the morphologic changes generated only punctiform denaturation and necrosis at the early or middle stages, and nodular hyperplasia or a little atypical hyperplasia at the final stages, with the expression of NF-kappaB (X2=9.93, P<0.001) and VEGF (X2=8.024, P<0.001) lower than that in the 2-FAA group. Thalidomide 7-18 vascular endothelial growth factor A Rattus norvegicus 278-282 20210736-0 2010 The effects of radix curcumae extract on expressions of VEGF, COX-2 and PCNA in gastric mucosa of rats fed with MNNG. radix curcumae 15-29 vascular endothelial growth factor A Rattus norvegicus 56-60 20486991-9 2010 Aliskiren decreased the serum and dialysate TGF-beta1 level, decreased the thickness of the liver peritoneum, and decreased the expression of TGF-beta1, alpha-SMA, fibronectin, collagen, and VEGF-positive cells in liver peritoneum. aliskiren 0-9 vascular endothelial growth factor A Rattus norvegicus 191-195 20646347-9 2010 VEGF and eNOS were enhanced in glomeruli and the peritubular space with the EAA-supplemented diet. Amino Acids, Essential 76-79 vascular endothelial growth factor A Rattus norvegicus 0-4 20093283-6 2010 The expression of VEGF protein was down-regulated upon ovariectomy and was restored upon estradiol (E(2)) supplementation in rat growth plates. Estradiol 89-98 vascular endothelial growth factor A Rattus norvegicus 18-22 20093283-6 2010 The expression of VEGF protein was down-regulated upon ovariectomy and was restored upon estradiol (E(2)) supplementation in rat growth plates. Estradiol 100-105 vascular endothelial growth factor A Rattus norvegicus 18-22 20210736-5 2010 CONCLUSIONS: The distilled extract of curcumae can down-regulate the expressions of VEGF, COX-2 and PCNA in the gastric mucosa of rats during carcinogenesis induced MNNG and can reduce the incidence of gastric caner, suggesting it maybe as a potential chemopreventive agent for gastric cancer. curcumae 38-46 vascular endothelial growth factor A Rattus norvegicus 84-88 20368092-3 2010 METHODS: In a rat model of argon laser coagulation-induced CNV, the mRNA expressions of the annexins and VEGF protein expression in the retina were detected using fluorescent real-time polymerase chain reaction (PCR) and immunohistochemistry, respectively. Argon 27-32 vascular endothelial growth factor A Rattus norvegicus 105-109 20492297-0 2010 Effects of chronic red wine consumption on the expression of vascular endothelial growth factor, angiopoietin 1, angiopoietin 2, and its receptors in rat erectile tissue. red wine 19-27 vascular endothelial growth factor A Rattus norvegicus 61-95 20136703-8 2010 Hypoxic rats treated with melatonin showed reduced VEGF, NO and MDA concentrations, increased GSH content and reduced RhIC leakage in the PWM. Melatonin 26-35 vascular endothelial growth factor A Rattus norvegicus 51-55 20138968-10 2010 Strong up-regulation of VEGF immunoreactivity was noted in the saline group in the blood-brain barrier (BBB), and in neurons surrounding the peri-infarct area and periventricular area at 24 h after MCAO. Sodium Chloride 63-69 vascular endothelial growth factor A Rattus norvegicus 24-28 20138968-12 2010 Furthermore, there were high correlations between the brain water content with the serum albumin level, with serum VEGF protein level, and with brain VEGF mRNA expression at 24 h after MCAO. Water 60-65 vascular endothelial growth factor A Rattus norvegicus 115-119 20138968-12 2010 Furthermore, there were high correlations between the brain water content with the serum albumin level, with serum VEGF protein level, and with brain VEGF mRNA expression at 24 h after MCAO. Water 60-65 vascular endothelial growth factor A Rattus norvegicus 150-154 20107925-0 2010 Oxygen tension modulates neurite outgrowth in PC12 cells through a mechanism involving HIF and VEGF. Oxygen 0-6 vascular endothelial growth factor A Rattus norvegicus 95-99 20132794-0 2010 Excess iodide decreases transcription of NIS and VEGF genes in rat FRTL-5 thyroid cells. Iodides 7-13 vascular endothelial growth factor A Rattus norvegicus 49-53 20132794-4 2010 In this report, we show that excess iodide coordinately suppresses the expression of the NIS and VEGF genes in FRTL-5 thyroid cells. Iodides 36-42 vascular endothelial growth factor A Rattus norvegicus 97-101 19967395-10 2010 The VEGF protein expression decreased in the skeletal muscles of dexamethasone-treated rats and was unaltered by the exercise protocol. Dexamethasone 65-78 vascular endothelial growth factor A Rattus norvegicus 4-8 19945513-6 2010 The VEGF vector groups also had better brain functional performs than PBS group. Lead 70-73 vascular endothelial growth factor A Rattus norvegicus 4-8 19945513-7 2010 The better performs by the animals that received VEGF vectors may be directly linked to the inhibitory effect of VEGF on neuronal apoptosis because the animals had less neural loss in the cortex and hippocampal CA1 region as compared with PBS group. Lead 239-242 vascular endothelial growth factor A Rattus norvegicus 49-53 19945513-7 2010 The better performs by the animals that received VEGF vectors may be directly linked to the inhibitory effect of VEGF on neuronal apoptosis because the animals had less neural loss in the cortex and hippocampal CA1 region as compared with PBS group. Lead 239-242 vascular endothelial growth factor A Rattus norvegicus 113-117 19579000-9 2010 As RT-PCR and Western blot revealed that the treatment effects of risperidone and haloperidol seemed to be mediated through activation of VEGF and MMP2. Risperidone 66-77 vascular endothelial growth factor A Rattus norvegicus 138-142 19579000-9 2010 As RT-PCR and Western blot revealed that the treatment effects of risperidone and haloperidol seemed to be mediated through activation of VEGF and MMP2. Haloperidol 82-93 vascular endothelial growth factor A Rattus norvegicus 138-142 19579000-16 2010 The findings indicate a promoting effect of risperidone and haloperidol on survival of young neurons in the hippocampus by enhancing the expression of the anti-apoptotic protein BCL-2 and by activation of VEGF/MMP2, whereby an interference with ketamine and thus a priority role of the NMDA system was not evident. Risperidone 44-55 vascular endothelial growth factor A Rattus norvegicus 205-209 19579000-16 2010 The findings indicate a promoting effect of risperidone and haloperidol on survival of young neurons in the hippocampus by enhancing the expression of the anti-apoptotic protein BCL-2 and by activation of VEGF/MMP2, whereby an interference with ketamine and thus a priority role of the NMDA system was not evident. Haloperidol 60-71 vascular endothelial growth factor A Rattus norvegicus 205-209 19147132-1 2010 OBJECTIVE: To investigate the effects of pentoxifylline, on vascular endothelial growth factor (VEGF)-C and flk-1 expression in the rat endometriosis model. Pentoxifylline 41-55 vascular endothelial growth factor A Rattus norvegicus 60-94 19147132-1 2010 OBJECTIVE: To investigate the effects of pentoxifylline, on vascular endothelial growth factor (VEGF)-C and flk-1 expression in the rat endometriosis model. Pentoxifylline 41-55 vascular endothelial growth factor A Rattus norvegicus 96-100 20107925-6 2010 The hypoxic target gene Vegf was implicated as a neurotrophic factor, as neurite formation at 21% oxygen was mimicked with exogenous VEGF, and a VEGF-neutralizing antibody attenuated neurite formation under reduced oxygen conditions. Oxygen 98-104 vascular endothelial growth factor A Rattus norvegicus 24-28 20107925-6 2010 The hypoxic target gene Vegf was implicated as a neurotrophic factor, as neurite formation at 21% oxygen was mimicked with exogenous VEGF, and a VEGF-neutralizing antibody attenuated neurite formation under reduced oxygen conditions. Oxygen 215-221 vascular endothelial growth factor A Rattus norvegicus 24-28 20107925-6 2010 The hypoxic target gene Vegf was implicated as a neurotrophic factor, as neurite formation at 21% oxygen was mimicked with exogenous VEGF, and a VEGF-neutralizing antibody attenuated neurite formation under reduced oxygen conditions. Oxygen 215-221 vascular endothelial growth factor A Rattus norvegicus 145-149 20107925-7 2010 These findings demonstrate that behavior of neural-like cells is driven by the oxygen microenvironment via VEGF function, and suggest promising approaches for future applications in neural repair. Oxygen 79-85 vascular endothelial growth factor A Rattus norvegicus 107-111 19897019-9 2010 Amfenac treatment significantly inhibited VEGF-induced tube formation and proliferation by EC. amfenac 0-7 vascular endothelial growth factor A Rattus norvegicus 42-46 20335103-0 2010 [Effect of glutamate on vascular endothelial growth factor mRNA and protein expressions in hypoxic rat astrocytes in vitro]. Glutamic Acid 11-20 vascular endothelial growth factor A Rattus norvegicus 24-58 20335103-1 2010 OBJECTIVE: To study the effect of glutamate on the expression of vascular endothelial growth factor (VEGF) mRNA and protein in cultured rat astrocytes under hypoxia. Glutamic Acid 34-43 vascular endothelial growth factor A Rattus norvegicus 65-99 20335103-1 2010 OBJECTIVE: To study the effect of glutamate on the expression of vascular endothelial growth factor (VEGF) mRNA and protein in cultured rat astrocytes under hypoxia. Glutamic Acid 34-43 vascular endothelial growth factor A Rattus norvegicus 101-105 20335103-5 2010 RESULTS: The expressions of VEGF mRNA and protein underwent no significant changes in the control glutamate groups, but increased obviously in both hypoxia and hypoxia+glutamate groups at 2, 4, 6, 8 and 12 h of hypoxic exposure. Glutamic Acid 98-107 vascular endothelial growth factor A Rattus norvegicus 28-32 20335103-5 2010 RESULTS: The expressions of VEGF mRNA and protein underwent no significant changes in the control glutamate groups, but increased obviously in both hypoxia and hypoxia+glutamate groups at 2, 4, 6, 8 and 12 h of hypoxic exposure. Glutamic Acid 168-177 vascular endothelial growth factor A Rattus norvegicus 28-32 20335103-6 2010 At these time points, VEGF expressions at both the mRNA and protein levels were significantly higher in hypoxia+glutamate group than in hypoxia group. Glutamic Acid 112-121 vascular endothelial growth factor A Rattus norvegicus 22-26 20335103-7 2010 CONCLUSION: Glutamate at 1 micromol/L can further increase the expression of VEGF mRNA and protein in astrocytes exposed to hypoxia, which may result from the adaptive changes of glutamate receptors in hypoxic astrocytes. Glutamic Acid 12-21 vascular endothelial growth factor A Rattus norvegicus 77-81 19934008-2 2010 RESEARCH DESIGN AND METHODS: We compared the expression of VEGF-A in lumbar (L)4/5 dorsal root ganglia (DRG) of control rats and VZ+434-treated and untreated streptozotocin (STZ)-induced diabetic rats. Streptozocin 174-177 vascular endothelial growth factor A Rattus norvegicus 59-65 20130710-2 2010 The purpose of this study was to evaluate heparanase expression and its relationship with VEGF in streptozotocin (STZ)-induced diabetic rats" retinas. Streptozocin 98-112 vascular endothelial growth factor A Rattus norvegicus 90-94 20130710-13 2010 VEGF level was increased, as was heparanase expression, in high-glucose-treated HRECs and in the retinas of diabetic rats, and these increases were significantly decreased by phosphomannopentaose sulfate administration (p < 0.01). Glucose 64-71 vascular endothelial growth factor A Rattus norvegicus 0-4 20130710-13 2010 VEGF level was increased, as was heparanase expression, in high-glucose-treated HRECs and in the retinas of diabetic rats, and these increases were significantly decreased by phosphomannopentaose sulfate administration (p < 0.01). phosphomannopentaose sulfate 175-203 vascular endothelial growth factor A Rattus norvegicus 0-4 20130710-14 2010 CONCLUSIONS: Heparanase expression was upregulated and associated with an increase of VEGF expression in STZ-induced diabetic rat retinas. Streptozocin 105-108 vascular endothelial growth factor A Rattus norvegicus 86-90 20136425-2 2010 The aldose reductase inhibitor fidarestat was recently reported to prevent retinal oxidative stress and overexpression of vascular endothelial growth factor (VEGF) protein in diabetic rats. fidarestat 31-41 vascular endothelial growth factor A Rattus norvegicus 122-156 20136425-2 2010 The aldose reductase inhibitor fidarestat was recently reported to prevent retinal oxidative stress and overexpression of vascular endothelial growth factor (VEGF) protein in diabetic rats. fidarestat 31-41 vascular endothelial growth factor A Rattus norvegicus 158-162 19818372-11 2010 These data confirmed that poly(disulfide amine)s are the safe and feasible polymeric gene carriers to transfect VEGF(165) into primary myoblasts. poly(disulfide amine) 26-47 vascular endothelial growth factor A Rattus norvegicus 112-116 19934008-5 2010 Fewer VEGF-A-IR neurons were observed in DRG from STZ-induced diabetic rats; this decrease was confirmed and quantified by Western blotting. Streptozocin 50-53 vascular endothelial growth factor A Rattus norvegicus 6-12 19934008-6 2010 VZ+434 administration resulted in a significant increase in VEGF-A protein expression in ipsilateral DRG, 24 h after injection. vz+434 0-6 vascular endothelial growth factor A Rattus norvegicus 60-66 20026764-10 2010 Relaxation to acetylcholine was enhanced by the VEGF treatment (P<0.05). Acetylcholine 14-27 vascular endothelial growth factor A Rattus norvegicus 48-52 20107068-5 2010 This effect was blocked by inhibitors of the VEGF receptor flk-1 and Src kinase, but not by inhibitors of phosphatidylinositol-3-kinase or protein kinase C. VEGF also increased Tyr-14 phosphorylation of caveolin-1, and this was blocked by the Src inhibitor PP2. Tyrosine 177-180 vascular endothelial growth factor A Rattus norvegicus 45-49 20197608-7 2010 CONCLUSION: Butylphthalide may protect the neuron-vascular unit of the hippocampus of Alzheimer model rats by inhibiting the expression of GFAP and increasing the expression of VEGF. 3-n-butylphthalide 12-26 vascular endothelial growth factor A Rattus norvegicus 177-181 19661235-8 2010 The cPLA(2) inhibitor CAY10502 decreased hypoxia-induced PGE(2) and VEGF levels in Muller cell-conditioned medium by 68.6% (P < 0.001) and 46.6% (P < 0.001), respectively. CAY10502 22-30 vascular endothelial growth factor A Rattus norvegicus 68-72 19661235-10 2010 CAY10502 (250 nM) decreased OIR-induced retinal PGE(2) and VEGF levels by 69% (P < 0.001) and 40.2% (P < 0.01), respectively. CAY10502 0-8 vascular endothelial growth factor A Rattus norvegicus 59-63 19710406-0 2010 Inhibition of vitreoretinal VEGF elevation and blood-retinal barrier breakdown in streptozotocin-induced diabetic rats by brimonidine. Streptozocin 82-96 vascular endothelial growth factor A Rattus norvegicus 28-32 19710406-0 2010 Inhibition of vitreoretinal VEGF elevation and blood-retinal barrier breakdown in streptozotocin-induced diabetic rats by brimonidine. Brimonidine Tartrate 122-133 vascular endothelial growth factor A Rattus norvegicus 28-32 19710406-1 2010 PURPOSE: To determine whether long-term brimonidine (BRI) treatment prevents the hyperglycemia-induced increase in vitreoretinal vascular endothelial growth factor (VEGF) expression and breakdown of the blood-retinal barrier (BRB) in streptozotocin (STZ)-induced diabetic rats. Brimonidine Tartrate 40-51 vascular endothelial growth factor A Rattus norvegicus 129-163 19710406-1 2010 PURPOSE: To determine whether long-term brimonidine (BRI) treatment prevents the hyperglycemia-induced increase in vitreoretinal vascular endothelial growth factor (VEGF) expression and breakdown of the blood-retinal barrier (BRB) in streptozotocin (STZ)-induced diabetic rats. Brimonidine Tartrate 40-51 vascular endothelial growth factor A Rattus norvegicus 165-169 19710406-7 2010 RESULTS: At 5 weeks after STZ treatment, STZ-treated diabetic rats demonstrated significantly elevated vitreoretinal VEGF expression, vitreal glutamate concentrations, and BRB leakage compared with nondiabetic control rats. Streptozocin 41-44 vascular endothelial growth factor A Rattus norvegicus 117-121 20159699-7 2010 Simvastatin treatment also significantly increased VEGF and NO levels and a positive correlation was noted between their levels. Simvastatin 0-11 vascular endothelial growth factor A Rattus norvegicus 51-55 20159699-9 2010 Simvastatin increases VEGF and NO and promotes neogenesis of the vasa vasorum for the benefit of the aortic function. Simvastatin 0-11 vascular endothelial growth factor A Rattus norvegicus 22-26 20197608-0 2010 [Effect of butylphthalide on the expression of GFAP and VEGF in the hippocampus of rats with Alzheimer"s disease]. 3-n-butylphthalide 11-25 vascular endothelial growth factor A Rattus norvegicus 56-60 20107068-5 2010 This effect was blocked by inhibitors of the VEGF receptor flk-1 and Src kinase, but not by inhibitors of phosphatidylinositol-3-kinase or protein kinase C. VEGF also increased Tyr-14 phosphorylation of caveolin-1, and this was blocked by the Src inhibitor PP2. Tyrosine 177-180 vascular endothelial growth factor A Rattus norvegicus 157-161 20107068-6 2010 Pharmacological activation of Src kinase activity mimicked the effects of VEGF on P-glycoprotein activity and Tyr-14 phosphorylation of caveolin-1. Tyrosine 110-113 vascular endothelial growth factor A Rattus norvegicus 74-78 20107068-7 2010 In vivo, intracerebroventricular injection of VEGF increased brain distribution of P-glycoprotein substrates morphine and verapamil, but not the tight junction marker, sucrose; this effect was blocked by PP2. Morphine 109-117 vascular endothelial growth factor A Rattus norvegicus 46-50 20107068-7 2010 In vivo, intracerebroventricular injection of VEGF increased brain distribution of P-glycoprotein substrates morphine and verapamil, but not the tight junction marker, sucrose; this effect was blocked by PP2. Verapamil 122-131 vascular endothelial growth factor A Rattus norvegicus 46-50 20107068-7 2010 In vivo, intracerebroventricular injection of VEGF increased brain distribution of P-glycoprotein substrates morphine and verapamil, but not the tight junction marker, sucrose; this effect was blocked by PP2. Sucrose 168-175 vascular endothelial growth factor A Rattus norvegicus 46-50 20107068-7 2010 In vivo, intracerebroventricular injection of VEGF increased brain distribution of P-glycoprotein substrates morphine and verapamil, but not the tight junction marker, sucrose; this effect was blocked by PP2. pp2 204-207 vascular endothelial growth factor A Rattus norvegicus 46-50 20090952-9 2010 Expression of VEGFR2 detected by Tc-99m-HYNIC-VEGF SPECT also showed significantly increased activity in the treated tumors. Technetium 33-39 vascular endothelial growth factor A Rattus norvegicus 14-18 20476551-11 2010 The serumal H2S concentration decreased obviously, from (44.98 +/- 2.06) micromol/L of before feeding to (38.56 +/- 2.26), (32.96 +/- 2.38), (28.63 +/- 0.92), (23.55 +/- 0.92) nnol/L of after feeding 3, 6, 9, and 12 weeks, respectively, and lower than that of control at contemporaneity (44.72 +/- 0.85), (43.71 +/- 0.59), (41.96 +/- 0.97), (39.87 +/- 1.25) micromol/L, respectively ( P < 0.01), and VEGF expression of the vascular tissue also increased (P < 0.01). Hydrogen Sulfide 12-15 vascular endothelial growth factor A Rattus norvegicus 403-407 20476551-17 2010 The correlation analysis showed that H2S in serum had a negative correlation with both pathological damage scores (r = -0.917, P < 0.01) and the expression of VEGF (r = -0. Hydrogen Sulfide 37-40 vascular endothelial growth factor A Rattus norvegicus 162-166 20476551-21 2010 Administration of exogenous H2S could raise the H2S concentration of serum in artherosclerosis, which might improve the damage of vessels and inhibit the expression of VEGF. Hydrogen Sulfide 28-31 vascular endothelial growth factor A Rattus norvegicus 168-172 20476551-21 2010 Administration of exogenous H2S could raise the H2S concentration of serum in artherosclerosis, which might improve the damage of vessels and inhibit the expression of VEGF. Hydrogen Sulfide 48-51 vascular endothelial growth factor A Rattus norvegicus 168-172 20090952-13 2010 CONCLUSION: These findings indicate that PTK787 treatment induced over expression of VEGF as well as the Flk-1/VEGFR2 receptor tyrosine kinase, especially at the rim of the tumor, as proven by DCE-MRI, SPECT imaging, immunohistochemistry and western blot. vatalanib 41-47 vascular endothelial growth factor A Rattus norvegicus 85-89 19812964-2 2010 When induced by vascular endothelial growth factor (VEGF), eNOS synthesizes nitric oxide that increases vascular permeability. Nitric Oxide 76-88 vascular endothelial growth factor A Rattus norvegicus 16-50 19812964-2 2010 When induced by vascular endothelial growth factor (VEGF), eNOS synthesizes nitric oxide that increases vascular permeability. Nitric Oxide 76-88 vascular endothelial growth factor A Rattus norvegicus 52-56 20551625-9 2010 While renal TGF-beta1 activation was reduced by ramipril treatment but not by apocynin as a monotherapy, kidney cortical membranous VEGF was reduced by apocynin as monotherapy and dual therapy but not by ramipril alone. acetovanillone 152-160 vascular endothelial growth factor A Rattus norvegicus 132-136 21638970-0 2010 Evaluation of vascular endothelial growth factor (VEGF) in interradicular bone marrow in olpadronate treated animals. olpadronic acid 89-100 vascular endothelial growth factor A Rattus norvegicus 14-48 21638970-0 2010 Evaluation of vascular endothelial growth factor (VEGF) in interradicular bone marrow in olpadronate treated animals. olpadronic acid 89-100 vascular endothelial growth factor A Rattus norvegicus 50-54 21638970-5 2010 The aim of this study is to evaluate the expression of VEGF in bone marrow cells and the number of blood vessels and area occupied by them in animals treated with the BP sodium olpadronate (OPD). Diphosphonates 167-169 vascular endothelial growth factor A Rattus norvegicus 55-59 21638970-5 2010 The aim of this study is to evaluate the expression of VEGF in bone marrow cells and the number of blood vessels and area occupied by them in animals treated with the BP sodium olpadronate (OPD). UNII-G90M9V9GMQ 170-188 vascular endothelial growth factor A Rattus norvegicus 55-59 19696011-0 2010 Effects of neonatal exposure to bisphenol A on steroid regulation of vascular endothelial growth factor expression and endothelial cell proliferation in the adult rat uterus. bisphenol A 32-43 vascular endothelial growth factor A Rattus norvegicus 69-103 19493269-10 2010 VEGF appeared to favour NADPH diaphorase-positive neurites, whereas BDNF favoured TH-positive neurites. NADP 24-29 vascular endothelial growth factor A Rattus norvegicus 0-4 19696011-0 2010 Effects of neonatal exposure to bisphenol A on steroid regulation of vascular endothelial growth factor expression and endothelial cell proliferation in the adult rat uterus. Steroids 47-54 vascular endothelial growth factor A Rattus norvegicus 69-103 19696011-3 2010 Hormonal perturbations during neonatal development may alter sex steroid-dependent regulation of VEGF and may ultimately affect fertility later in life. Steroids 65-72 vascular endothelial growth factor A Rattus norvegicus 97-101 19696011-7 2010 Rats neonatally exposed to xenoestrogens showed a decreased induction of uterine endothelial proliferation and a decreased Vegf mRNA expression in response to ovarian steroid treatment. Steroids 167-174 vascular endothelial growth factor A Rattus norvegicus 123-127 19696011-10 2010 Because of the importance of VEGF in the implantation process, our data suggest that neonatal BPA exposure might have negative consequences on female fertility. bisphenol A 94-97 vascular endothelial growth factor A Rattus norvegicus 29-33 20675286-7 2010 We thus concluded that melatonin can modulate the effects of DES on the rat anterior pituitary by downregulating expression of VEGF and MMP-9 and suppressing the release of secretion granules, suggesting a therapeutic potential in estrogen-induced pituitary malfunctions. Melatonin 23-32 vascular endothelial growth factor A Rattus norvegicus 127-131 20412616-9 2010 Cerebral infarction analyzed using 2,3,5-triphenyl-tetrazolium chloride staining confirmed that the VEGF gels significantly and potently reduced the lesion volume. triphenyltetrazolium 35-71 vascular endothelial growth factor A Rattus norvegicus 100-104 20675286-5 2010 Administration of melatonin also reduced the expression of VEGF and MMP-9, although no changes were detected in AQP-1 expression. Melatonin 18-27 vascular endothelial growth factor A Rattus norvegicus 59-63 20675286-7 2010 We thus concluded that melatonin can modulate the effects of DES on the rat anterior pituitary by downregulating expression of VEGF and MMP-9 and suppressing the release of secretion granules, suggesting a therapeutic potential in estrogen-induced pituitary malfunctions. Diethylstilbestrol 61-64 vascular endothelial growth factor A Rattus norvegicus 127-131 20671964-3 2010 We investigated a novel pathway, namely extracellular signal regulated kinase 5 (ERK5) mediated signaling, in modulating glucose-induced vascular endothelial growth factor (VEGF) expression. Glucose 121-128 vascular endothelial growth factor A Rattus norvegicus 137-171 22553558-0 2010 Effect of ginsenoside-Rg3 on the expression of VEGF and TNF-alpha in retina with diabetic rats. Ginsenosides 10-21 vascular endothelial growth factor A Rattus norvegicus 47-51 22553558-1 2010 AIM: To investigate the effect of ginsenoside-Rg3 on the expression of vascular endothelial growth factor (VEGF) and tumor necrosis factor-alpha (TNF-alpha) in retina with diabetic rats and its roles in preventing neovascularization in diabetes. Ginsenosides 34-45 vascular endothelial growth factor A Rattus norvegicus 71-105 22553558-1 2010 AIM: To investigate the effect of ginsenoside-Rg3 on the expression of vascular endothelial growth factor (VEGF) and tumor necrosis factor-alpha (TNF-alpha) in retina with diabetic rats and its roles in preventing neovascularization in diabetes. Ginsenosides 34-45 vascular endothelial growth factor A Rattus norvegicus 107-111 22553558-4 2010 RESULTS: There were significant differences among negative control group, diabetic control group and ginsenoside-Rg3 treatment group in the expression of VEGF and TNF-alpha (F=129.363, 211.992; all the P<0.01). Ginsenosides 101-112 vascular endothelial growth factor A Rattus norvegicus 154-158 22553558-5 2010 VEGF and TNF-alpha expression were significantly higher in diabetic control group and ginsenoside-Rg3 treatment group than that in negative control group (P<0.01), with a significant reduction in ginsenoside-Rg3 treatment group than that in diabetic control group (P<0.01). Ginsenosides 86-97 vascular endothelial growth factor A Rattus norvegicus 0-4 22553558-5 2010 VEGF and TNF-alpha expression were significantly higher in diabetic control group and ginsenoside-Rg3 treatment group than that in negative control group (P<0.01), with a significant reduction in ginsenoside-Rg3 treatment group than that in diabetic control group (P<0.01). Ginsenosides 199-210 vascular endothelial growth factor A Rattus norvegicus 0-4 22553558-6 2010 CONCLUSION: Ginsenoside-Rg3 can down-regulate the expression of VEGF and TNF-alpha in retina, which may interfere in the development of diabetic retinopathy. Ginsenosides 12-23 vascular endothelial growth factor A Rattus norvegicus 64-68 20707649-9 2010 With the addition of U0126, further up- or down-regulation of Egfr, Ctgf, Tgif, Vegfa, Okl38 and Gdf15 in response to heat stress was observed. U 0126 21-26 vascular endothelial growth factor A Rattus norvegicus 80-85 20671964-9 2010 On the other hand, constitutively active MEK5, an activator of ERK5, increased ERK5 activation and ERK5 and KLF2 mRNA expression and attenuated basal- and glucose-induced VEGF mRNA expression. Glucose 155-162 vascular endothelial growth factor A Rattus norvegicus 171-175 20671964-11 2010 These results indicated that ERK5 depletion contributes to glucose induced increased VEGF production and angiogenesis. Glucose 59-66 vascular endothelial growth factor A Rattus norvegicus 85-89 20671964-3 2010 We investigated a novel pathway, namely extracellular signal regulated kinase 5 (ERK5) mediated signaling, in modulating glucose-induced vascular endothelial growth factor (VEGF) expression. Glucose 121-128 vascular endothelial growth factor A Rattus norvegicus 173-177 20571278-0 2010 Eplerenone suppresses salt-induced vascular endothelial growth factor expression in the kidney. Eplerenone 0-10 vascular endothelial growth factor A Rattus norvegicus 35-69 19889145-9 2010 Vardenafil treatment dramatically decreased hypoxyprobe staining, as well as VEGF and ETB expression in SHR bladder up to WKY level. Vardenafil Dihydrochloride 0-10 vascular endothelial growth factor A Rattus norvegicus 77-81 20122581-0 2010 Effect of selenium-enriched malt on VEGF and several relevant angiogenic cytokines in diethylnitrosamine-induced hepatocarcinoma rats. Selenium 10-18 vascular endothelial growth factor A Rattus norvegicus 36-40 20571278-0 2010 Eplerenone suppresses salt-induced vascular endothelial growth factor expression in the kidney. Salts 22-26 vascular endothelial growth factor A Rattus norvegicus 35-69 20571278-3 2010 In the present study, we investigated the role of eplerenone on vascular endothelial growth factor (VEGF) expression because we suspected that eplerenone treatment may trigger a unique mechanism that relies on the downregulation of VEGF. Eplerenone 50-60 vascular endothelial growth factor A Rattus norvegicus 64-98 20571278-3 2010 In the present study, we investigated the role of eplerenone on vascular endothelial growth factor (VEGF) expression because we suspected that eplerenone treatment may trigger a unique mechanism that relies on the downregulation of VEGF. Eplerenone 50-60 vascular endothelial growth factor A Rattus norvegicus 100-104 20571278-5 2010 RESULTS: In addition to reducing blood pressure, eplerenone inhibited glomeruli sclerosis and suppressed the expression of VEGF and endothelial nitric oxide synthase mRNA as well as protein levels. Eplerenone 49-59 vascular endothelial growth factor A Rattus norvegicus 123-127 20571278-6 2010 CONCLUSIONS: Based on these findings, we suggest that in part, VEGF stimulation of endothelial nitric oxide synthase plays a significant role in the eplerenone-induced reversal of the renal and vascular damage caused by high dietary salt intake. Eplerenone 149-159 vascular endothelial growth factor A Rattus norvegicus 63-67 20571278-6 2010 CONCLUSIONS: Based on these findings, we suggest that in part, VEGF stimulation of endothelial nitric oxide synthase plays a significant role in the eplerenone-induced reversal of the renal and vascular damage caused by high dietary salt intake. Salts 233-237 vascular endothelial growth factor A Rattus norvegicus 63-67 19629015-3 2010 We furthermore showed that curcumin, an Indian spice derived from the turmeric root, specifically inhibits MPA-induced VEGF secretion from breast cancer cells in vitro. Curcumin 27-35 vascular endothelial growth factor A Rattus norvegicus 119-123 19629015-10 2010 Immunohistochemical analyses of mammary tumors showed that curcumin decreased MPA-induced VEGF induction in hyperplastic lesions, although it did not affect the levels of estrogen and progesterone receptors. Curcumin 59-67 vascular endothelial growth factor A Rattus norvegicus 90-94 20453526-0 2010 Effects of antenatal betamethasone and dexamethasone on the lung expression of vascular endothelial growth factor and alveolarization in newborn rats exposed to acute hypoxia and recovered in normoxia or hyperoxia. Betamethasone 21-34 vascular endothelial growth factor A Rattus norvegicus 79-113 20453526-0 2010 Effects of antenatal betamethasone and dexamethasone on the lung expression of vascular endothelial growth factor and alveolarization in newborn rats exposed to acute hypoxia and recovered in normoxia or hyperoxia. Dexamethasone 39-52 vascular endothelial growth factor A Rattus norvegicus 79-113 20453526-2 2010 The purpose of this study was to compare pulmonary VEGF expression in newborn rats that were exposed to antenatal betamethasone versus dexamethasone under normoxia, hypoxia and oxidative stress, and to evaluate its impact on alveolarization. Betamethasone 114-127 vascular endothelial growth factor A Rattus norvegicus 51-55 20453526-6 2010 Betamethasone and dexamethasone were observed to have different actions on VEGF expression with a correlation with alveolarization. Betamethasone 0-13 vascular endothelial growth factor A Rattus norvegicus 75-79 20453526-6 2010 Betamethasone and dexamethasone were observed to have different actions on VEGF expression with a correlation with alveolarization. Dexamethasone 18-31 vascular endothelial growth factor A Rattus norvegicus 75-79 20453526-7 2010 Antenatal dexamethasone decreased VEGF expression, and dexamethasone and hyperoxia had an additive effect on the inhibition of VEGF with a reduction in alveolar development. Dexamethasone 10-23 vascular endothelial growth factor A Rattus norvegicus 34-38 20453526-7 2010 Antenatal dexamethasone decreased VEGF expression, and dexamethasone and hyperoxia had an additive effect on the inhibition of VEGF with a reduction in alveolar development. Dexamethasone 55-68 vascular endothelial growth factor A Rattus norvegicus 127-131 20160430-9 2010 The inhibitory action of curcumin on VEGF-A and IL-6 production was also found in primary rat pituitary cell cultures, in which FS cells are the only source of these proteins. Curcumin 25-33 vascular endothelial growth factor A Rattus norvegicus 37-43 20453526-8 2010 Betamethasone appeared to have an effect on the induction of the expression of VEGF, and it seemed to inhibit the negative action of hyperoxia on VEGF. Betamethasone 0-13 vascular endothelial growth factor A Rattus norvegicus 79-83 20389030-0 2010 VEGF secretion by neuroendocrine tumor cells is inhibited by octreotide and by inhibitors of the PI3K/AKT/mTOR pathway. Octreotide 61-71 vascular endothelial growth factor A Rattus norvegicus 0-4 20389030-6 2010 By Western blotting analysis, we observed decreased intracellular levels of VEGF and HIF-1alpha under octreotide, rapamycin and LY294002. Sirolimus 114-123 vascular endothelial growth factor A Rattus norvegicus 76-80 20389030-4 2010 Octreotide and rapamycin induced a significant decrease in VEGF production by all three cell lines; LY294002 significantly inhibited VEGF production by STC-1 and INS-r3 only. Octreotide 0-10 vascular endothelial growth factor A Rattus norvegicus 59-63 20453526-8 2010 Betamethasone appeared to have an effect on the induction of the expression of VEGF, and it seemed to inhibit the negative action of hyperoxia on VEGF. Betamethasone 0-13 vascular endothelial growth factor A Rattus norvegicus 146-150 20389030-4 2010 Octreotide and rapamycin induced a significant decrease in VEGF production by all three cell lines; LY294002 significantly inhibited VEGF production by STC-1 and INS-r3 only. Sirolimus 15-24 vascular endothelial growth factor A Rattus norvegicus 59-63 20389030-6 2010 By Western blotting analysis, we observed decreased intracellular levels of VEGF and HIF-1alpha under octreotide, rapamycin and LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 128-136 vascular endothelial growth factor A Rattus norvegicus 76-80 20389030-7 2010 For rapamycin and LY294002, this effect was likely mediated by the inhibition of the mTOR/HIF-1/VEGF pathway. Sirolimus 4-13 vascular endothelial growth factor A Rattus norvegicus 96-100 20389030-7 2010 For rapamycin and LY294002, this effect was likely mediated by the inhibition of the mTOR/HIF-1/VEGF pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 18-26 vascular endothelial growth factor A Rattus norvegicus 96-100 20389030-9 2010 In conclusion, our study points out to the complex regulation of VEGF synthesis and secretion in neoplastic GEP endocrine cells and suggests that the inhibition of VEGF production by octreotide and rapamycin may contribute to their therapeutic effects. Octreotide 183-193 vascular endothelial growth factor A Rattus norvegicus 65-69 20389030-9 2010 In conclusion, our study points out to the complex regulation of VEGF synthesis and secretion in neoplastic GEP endocrine cells and suggests that the inhibition of VEGF production by octreotide and rapamycin may contribute to their therapeutic effects. Octreotide 183-193 vascular endothelial growth factor A Rattus norvegicus 164-168 20389030-4 2010 Octreotide and rapamycin induced a significant decrease in VEGF production by all three cell lines; LY294002 significantly inhibited VEGF production by STC-1 and INS-r3 only. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 100-108 vascular endothelial growth factor A Rattus norvegicus 133-137 20389030-5 2010 We detected no effect of PD98059 whereas SB203850 significantly inhibited VEGF secretion in INS-r3 and INS-r9 cells only. sb203850 41-49 vascular endothelial growth factor A Rattus norvegicus 74-78 20389030-6 2010 By Western blotting analysis, we observed decreased intracellular levels of VEGF and HIF-1alpha under octreotide, rapamycin and LY294002. Octreotide 102-112 vascular endothelial growth factor A Rattus norvegicus 76-80 19703426-11 2009 In addition, ethanol exposure caused increased mRNA levels of Pax-3, p53, Vegf-A and decreased expression of Pax-6, Nfe2 in both cNCC and tNCC. Ethanol 13-20 vascular endothelial growth factor A Rattus norvegicus 74-80 20389030-9 2010 In conclusion, our study points out to the complex regulation of VEGF synthesis and secretion in neoplastic GEP endocrine cells and suggests that the inhibition of VEGF production by octreotide and rapamycin may contribute to their therapeutic effects. Sirolimus 198-207 vascular endothelial growth factor A Rattus norvegicus 164-168 19588214-10 2010 Stereological counts of NeuN-positive neurons throughout the striatum demonstrated that VEGF implants significantly protected against the loss of striatal neurons induced by QA. Quinolinic Acid 174-176 vascular endothelial growth factor A Rattus norvegicus 88-92 19762547-10 2009 This is the first demonstration that 5-ASA treatment reverses an imbalance between the angiogenic factor VEGF and antiangiogenic factors endostatin and angiostatin in experimental UC. Mesalamine 37-42 vascular endothelial growth factor A Rattus norvegicus 105-109 19666665-7 2009 RESULTS: PDF exposure induced an inflammatory condition evidenced by the increased leucocyte number and synthesis of MCP-1, VEGF and hyaluronic acid. pdf 9-12 vascular endothelial growth factor A Rattus norvegicus 124-128 20359129-8 2009 Quantitative proteomic analysis showed increased ratios of plasma proteins (such as albumin) and oxygen carriers (such as myoglobin) by Ad-VEGF and decreased ratios of proteins involved in glycolysis, calcium homeostasis and lipolysis by Ad-VEGF. Oxygen 97-103 vascular endothelial growth factor A Rattus norvegicus 139-143 20088419-10 2009 In contrast to the model group, the VEGF,bFGF levels in serum and the immunohistochemical expression quantity of VEGF and bFGF in the API and TMI groups were significantly increased (all P < 0.01). 4-tolyl isocyanate 142-145 vascular endothelial growth factor A Rattus norvegicus 113-117 20045921-12 2009 VEGF, SDF-1alpha, and CXCR-4 mRNA expression increased obviously after injecting STZ for 1 month and increased significantly after 5 months. Streptozocin 81-84 vascular endothelial growth factor A Rattus norvegicus 0-4 20359129-10 2009 Excessive amounts of VEGF by Ad-VEGF may offset Ad-LacZ-induced improvement in ventricular functions by interfering with calcium homeostasis and lipolysis in infarcted hearts. Calcium 121-128 vascular endothelial growth factor A Rattus norvegicus 21-25 20359129-10 2009 Excessive amounts of VEGF by Ad-VEGF may offset Ad-LacZ-induced improvement in ventricular functions by interfering with calcium homeostasis and lipolysis in infarcted hearts. Calcium 121-128 vascular endothelial growth factor A Rattus norvegicus 32-36 18815084-1 2009 BACKGROUND: The angiogenic potential of vascular endothelial growth factor (VEGF) and its oxygen pressure-dependent regulation suggest a strong connection between this growth factor and the "delay phenomenon". Oxygen 90-96 vascular endothelial growth factor A Rattus norvegicus 40-74 19131226-12 2009 Concomitant increase in vascular permeability caused by MIP-1, TNF-alpha and VEGF may lead to extravasation of chelated Gd or Gd-deposits. Gadolinium 120-122 vascular endothelial growth factor A Rattus norvegicus 77-81 19131226-12 2009 Concomitant increase in vascular permeability caused by MIP-1, TNF-alpha and VEGF may lead to extravasation of chelated Gd or Gd-deposits. Gadolinium 126-128 vascular endothelial growth factor A Rattus norvegicus 77-81 19695348-5 2009 The results showed that in the early stage of chondrogenesis (days 3), formononetin significantly increased the number of vessels, and expression of vascular endothelial growth factor (VEGF) and VEGF receptor 2 (VEGFR-2/flk-1) compared with control. formononetin 71-83 vascular endothelial growth factor A Rattus norvegicus 149-183 19695348-5 2009 The results showed that in the early stage of chondrogenesis (days 3), formononetin significantly increased the number of vessels, and expression of vascular endothelial growth factor (VEGF) and VEGF receptor 2 (VEGFR-2/flk-1) compared with control. formononetin 71-83 vascular endothelial growth factor A Rattus norvegicus 185-189 19695348-5 2009 The results showed that in the early stage of chondrogenesis (days 3), formononetin significantly increased the number of vessels, and expression of vascular endothelial growth factor (VEGF) and VEGF receptor 2 (VEGFR-2/flk-1) compared with control. formononetin 71-83 vascular endothelial growth factor A Rattus norvegicus 195-199 19830650-0 2009 Nandrolone inhibits VEGF mRNA in rat muscle. Nandrolone 0-10 vascular endothelial growth factor A Rattus norvegicus 20-24 19830650-2 2009 The aim of this study was to investigate the effect of androgenic-anabolic steroids (AAS) administration on VEGF mRNA expression in the rat soleus muscle after jumping training. Steroids 75-83 vascular endothelial growth factor A Rattus norvegicus 108-112 19830650-2 2009 The aim of this study was to investigate the effect of androgenic-anabolic steroids (AAS) administration on VEGF mRNA expression in the rat soleus muscle after jumping training. aas 85-88 vascular endothelial growth factor A Rattus norvegicus 108-112 19474404-9 2009 Melatonin administration reduced VEGF and NO production, diminished leakage of RhIC and HRP, and promoted cell proliferation, suggesting this as a potential therapeutic agent in reducing hypoxia-associated damage in the developing retina. Melatonin 0-9 vascular endothelial growth factor A Rattus norvegicus 33-37 18815084-1 2009 BACKGROUND: The angiogenic potential of vascular endothelial growth factor (VEGF) and its oxygen pressure-dependent regulation suggest a strong connection between this growth factor and the "delay phenomenon". Oxygen 90-96 vascular endothelial growth factor A Rattus norvegicus 76-80 19500802-0 2009 Cell-cell junctions and vascular endothelial growth factor in rat lung as affected by ischemia/reperfusion and preconditioning with inhaled nitric oxide. Nitric Oxide 140-152 vascular endothelial growth factor A Rattus norvegicus 24-58 19996486-0 2009 Changes in insulin like growth factors, myostatin and vascular endothelial growth factor in rat musculus latissimus dorsi by poly-3-hydroxybutyrate implants. poly-beta-hydroxybutyrate 125-147 vascular endothelial growth factor A Rattus norvegicus 54-88 19107574-0 2009 Effect of high glucose concentration on VEGF and PEDF expression in cultured retinal Muller cells. Glucose 15-22 vascular endothelial growth factor A Rattus norvegicus 40-44 19107574-1 2009 To explore the effect of high glucose concentration on the expression of vascular endothelial growth factor (VEGF) and pigment epithelium derived factor (PEDF) in the cultured rat retinal Muller cells. Glucose 30-37 vascular endothelial growth factor A Rattus norvegicus 73-107 19107574-1 2009 To explore the effect of high glucose concentration on the expression of vascular endothelial growth factor (VEGF) and pigment epithelium derived factor (PEDF) in the cultured rat retinal Muller cells. Glucose 30-37 vascular endothelial growth factor A Rattus norvegicus 109-113 19107574-3 2009 Under 10, 20, 30 mmol/L high glucose conditions, the levels of VEGF mRNA and protein increased and the levels of PEDF mRNA and protein decreased. Glucose 29-36 vascular endothelial growth factor A Rattus norvegicus 63-67 19107574-4 2009 These results suggest that the VEGF and PEDF expression in Muller cells are unbalance under high glucose concentration, which contribute to retinal neovascularization in diabetic retinopathy. Glucose 97-104 vascular endothelial growth factor A Rattus norvegicus 31-35 20209919-0 2009 [Relationship of tetramethylpyrazine on expression of vascular endothelial growth factor and development of adjuvant-induced arthritis in rats]. tetramethylpyrazine 17-36 vascular endothelial growth factor A Rattus norvegicus 54-88 20209919-1 2009 OBJECTIVE: To explore the effect of tetramethylpyrazine (TMP) on the expression of vascular endothelial growth factor (VEGF) in the synovium of adjuvant-induced arthritis (AIA) in rats. tetramethylpyrazine 36-55 vascular endothelial growth factor A Rattus norvegicus 83-117 20209919-1 2009 OBJECTIVE: To explore the effect of tetramethylpyrazine (TMP) on the expression of vascular endothelial growth factor (VEGF) in the synovium of adjuvant-induced arthritis (AIA) in rats. tetramethylpyrazine 36-55 vascular endothelial growth factor A Rattus norvegicus 119-123 20209919-1 2009 OBJECTIVE: To explore the effect of tetramethylpyrazine (TMP) on the expression of vascular endothelial growth factor (VEGF) in the synovium of adjuvant-induced arthritis (AIA) in rats. tetramethylpyrazine 57-60 vascular endothelial growth factor A Rattus norvegicus 83-117 20209919-1 2009 OBJECTIVE: To explore the effect of tetramethylpyrazine (TMP) on the expression of vascular endothelial growth factor (VEGF) in the synovium of adjuvant-induced arthritis (AIA) in rats. tetramethylpyrazine 57-60 vascular endothelial growth factor A Rattus norvegicus 119-123 20209919-4 2009 RESULT: Compared with arthritis model, 100 mg x kg(-1) TMP could remarkably reduce the footpad thickness, contents of TNF-alpha in serum and the expression of VEGF in the synovium. tetramethylpyrazine 55-58 vascular endothelial growth factor A Rattus norvegicus 159-163 20209919-5 2009 CONCLUSION: TMP can attenuate the degree of chronic inflammation in AIA rats, and its mechanism might be associated with inhibiting the expression of VEGF. tetramethylpyrazine 12-15 vascular endothelial growth factor A Rattus norvegicus 150-154 20209964-1 2009 OBJECTIVE: To investigate the effect of one kind of regulating-qi and Nourishing-yin Chinese herbs Zuoguiyin on the expression of rats ovarian vascular endothelial growth factor (VEGF) and secreted protein acidic rich in cysteine (SPARC) during the period of peri-menopause. Cysteine 221-229 vascular endothelial growth factor A Rattus norvegicus 179-183 19712927-0 2009 Up-regulation of vascular endothelial growth factor expression by adenosine through adenosine A2 receptors in the rat tongue treated with endotoxin. Adenosine 66-75 vascular endothelial growth factor A Rattus norvegicus 17-51 19712927-1 2009 The main focus of the present investigation is to evaluate a differential effect of adenosine on the up-regulation of vascular endothelial growth factor (VEGF) expression through adenosine A(2) receptors in the rat tongue treated with endotoxin (lipopolysaccharide: LPS). Adenosine 84-93 vascular endothelial growth factor A Rattus norvegicus 118-152 19712927-1 2009 The main focus of the present investigation is to evaluate a differential effect of adenosine on the up-regulation of vascular endothelial growth factor (VEGF) expression through adenosine A(2) receptors in the rat tongue treated with endotoxin (lipopolysaccharide: LPS). Adenosine 84-93 vascular endothelial growth factor A Rattus norvegicus 154-158 19542178-1 2009 AIMS: Vascular endothelial growth factor (VEGF) has been well documented to stimulate cell proliferation and differentiation; however, we have observed that copper (Cu)-induced regression of heart hypertrophy was VEGF-dependent. Copper 157-163 vascular endothelial growth factor A Rattus norvegicus 6-40 19542178-1 2009 AIMS: Vascular endothelial growth factor (VEGF) has been well documented to stimulate cell proliferation and differentiation; however, we have observed that copper (Cu)-induced regression of heart hypertrophy was VEGF-dependent. Copper 157-163 vascular endothelial growth factor A Rattus norvegicus 42-46 19542178-1 2009 AIMS: Vascular endothelial growth factor (VEGF) has been well documented to stimulate cell proliferation and differentiation; however, we have observed that copper (Cu)-induced regression of heart hypertrophy was VEGF-dependent. Copper 157-163 vascular endothelial growth factor A Rattus norvegicus 213-217 19542178-1 2009 AIMS: Vascular endothelial growth factor (VEGF) has been well documented to stimulate cell proliferation and differentiation; however, we have observed that copper (Cu)-induced regression of heart hypertrophy was VEGF-dependent. Copper 165-167 vascular endothelial growth factor A Rattus norvegicus 6-40 19542178-1 2009 AIMS: Vascular endothelial growth factor (VEGF) has been well documented to stimulate cell proliferation and differentiation; however, we have observed that copper (Cu)-induced regression of heart hypertrophy was VEGF-dependent. Copper 165-167 vascular endothelial growth factor A Rattus norvegicus 42-46 19542178-1 2009 AIMS: Vascular endothelial growth factor (VEGF) has been well documented to stimulate cell proliferation and differentiation; however, we have observed that copper (Cu)-induced regression of heart hypertrophy was VEGF-dependent. Copper 165-167 vascular endothelial growth factor A Rattus norvegicus 213-217 19542178-2 2009 The present study was undertaken to test the hypothesis that Cu causes alterations in the distribution of VEGF receptors (VEGFRs) in hypertrophic cardiomyocytes so that it switches the signalling pathway from stimulation of cell growth to reversal of cell hypertrophy. Copper 61-63 vascular endothelial growth factor A Rattus norvegicus 106-110 19726100-13 2009 The increased protein expression of CD31, alphaSMA, pERK, VEGF, PDGF, TNFalpha, and eNOS in rats with PHT was markedly decreased by sorafenib treatment. Sorafenib 132-141 vascular endothelial growth factor A Rattus norvegicus 58-62 19726100-14 2009 Sorafenib decreased mRNA levels of TNFalpha, VEGF receptor 2, VEGF receptor 1, transforming growth factor beta, cyclooxygenase 1, and expression of various genes that are involved in pathways of cellular proliferation, fibrogenesis, tissue remodeling, inflammation, and angiogenesis. Sorafenib 0-9 vascular endothelial growth factor A Rattus norvegicus 45-49 19726100-14 2009 Sorafenib decreased mRNA levels of TNFalpha, VEGF receptor 2, VEGF receptor 1, transforming growth factor beta, cyclooxygenase 1, and expression of various genes that are involved in pathways of cellular proliferation, fibrogenesis, tissue remodeling, inflammation, and angiogenesis. Sorafenib 0-9 vascular endothelial growth factor A Rattus norvegicus 62-66 20113663-0 2009 [Effects of prolonged exposure of high concentration of oxygen on expression of vascular endothelial growth factor and its receptors in neonatal rat lungs]. Oxygen 56-62 vascular endothelial growth factor A Rattus norvegicus 80-114 20113663-1 2009 OBJECTIVE: To study the effects of prolonged 75% oxygen exposure on the expression of vascular endothelial growth factor (VEGF) and its receptors (VEGFR1 and VEGFR2) in the neonatal rat lungs and to elucidate the effects of prolonged exposure of high concentration of oxygen on lung vascular development and its relationship with bronchopulmonary dysplasia (BPD). Oxygen 49-55 vascular endothelial growth factor A Rattus norvegicus 86-120 20113663-1 2009 OBJECTIVE: To study the effects of prolonged 75% oxygen exposure on the expression of vascular endothelial growth factor (VEGF) and its receptors (VEGFR1 and VEGFR2) in the neonatal rat lungs and to elucidate the effects of prolonged exposure of high concentration of oxygen on lung vascular development and its relationship with bronchopulmonary dysplasia (BPD). Oxygen 49-55 vascular endothelial growth factor A Rattus norvegicus 122-126 20113663-1 2009 OBJECTIVE: To study the effects of prolonged 75% oxygen exposure on the expression of vascular endothelial growth factor (VEGF) and its receptors (VEGFR1 and VEGFR2) in the neonatal rat lungs and to elucidate the effects of prolonged exposure of high concentration of oxygen on lung vascular development and its relationship with bronchopulmonary dysplasia (BPD). Oxygen 268-274 vascular endothelial growth factor A Rattus norvegicus 86-120 20113663-1 2009 OBJECTIVE: To study the effects of prolonged 75% oxygen exposure on the expression of vascular endothelial growth factor (VEGF) and its receptors (VEGFR1 and VEGFR2) in the neonatal rat lungs and to elucidate the effects of prolonged exposure of high concentration of oxygen on lung vascular development and its relationship with bronchopulmonary dysplasia (BPD). Oxygen 268-274 vascular endothelial growth factor A Rattus norvegicus 122-126 19712927-6 2009 The present results indicate that the LPS-induced adenosine might promote angiogenesis by the up-regulation of VEGF expression in macrophages/DCs through A(2) receptors. Adenosine 50-59 vascular endothelial growth factor A Rattus norvegicus 111-115 18798867-0 2009 High glucose attenuates VEGF expression in rat multipotent adult progenitor cells in association with inhibition of JAK2/STAT3 signalling. Glucose 5-12 vascular endothelial growth factor A Rattus norvegicus 24-28 19571795-5 2009 The influence of agomelatine on maturation and survival was accompanied by a selective increase in the levels of BDNF (brain-derived neurotrophic factor) vs those of VEGF (vascular endothelial factor) and IGF-1 (insulin-like growth factor 1), which were not affected. agomelatine 17-28 vascular endothelial growth factor A Rattus norvegicus 166-170 19664474-5 2009 In this study we show that synthetic benzophenone analogue, 2-benzoyl-phenoxy acetamide (BP-1) can act as a novel anti-arthritic agent in an experimental adjuvant induced arthritis (AIA) rat model by targeting VEGF and HIF-1alpha. benzophenone 37-49 vascular endothelial growth factor A Rattus norvegicus 210-214 19664474-5 2009 In this study we show that synthetic benzophenone analogue, 2-benzoyl-phenoxy acetamide (BP-1) can act as a novel anti-arthritic agent in an experimental adjuvant induced arthritis (AIA) rat model by targeting VEGF and HIF-1alpha. 2-benzoyl-phenoxy acetamide 60-87 vascular endothelial growth factor A Rattus norvegicus 210-214 19442724-0 2009 VEGF-controlled release within a bone defect from alginate/chitosan/PLA-H scaffolds. Alginates 50-58 vascular endothelial growth factor A Rattus norvegicus 0-4 19442724-2 2009 For this reason, we developed a composite (alginate/chitosan/PLA-H) system that controls the release kinetics of incorporated VEGF to enhance neovascularization in bone healing. Alginates 43-51 vascular endothelial growth factor A Rattus norvegicus 126-130 19442724-4 2009 VEGF was firstly encapsulated in alginate microspheres. Alginates 33-41 vascular endothelial growth factor A Rattus norvegicus 0-4 19553916-2 2009 First, by determining the requirement for VEGF in the actions of a 5-HT selective reuptake inhibitor (SSRI), fluoxetine in behavioral models of depression/antidepressant response; and second, by examining the role of the 5-HT1A receptor subtype in the regulation of VEGF, and the cellular localization of antidepressant regulation of VEGF expression. Fluoxetine 109-119 vascular endothelial growth factor A Rattus norvegicus 42-46 19553916-3 2009 The results show that pharmacological inhibition of VEGF receptor signaling blocks the behavioral actions of fluoxetine in rats subjected to chronic unpredictable stress. Fluoxetine 109-119 vascular endothelial growth factor A Rattus norvegicus 52-56 19553916-4 2009 Infusions of SU5416 or SU1498, two structurally dissimilar inhibitors of VEGF-Flk-1 receptor signaling, block the antidepressant effects of fluoxetine on sucrose preference, immobility in the forced swim test, and latency to feed in the novelty suppressed feeding paradigm. Semaxinib 13-19 vascular endothelial growth factor A Rattus norvegicus 73-77 19553916-4 2009 Infusions of SU5416 or SU1498, two structurally dissimilar inhibitors of VEGF-Flk-1 receptor signaling, block the antidepressant effects of fluoxetine on sucrose preference, immobility in the forced swim test, and latency to feed in the novelty suppressed feeding paradigm. SU 1498 23-29 vascular endothelial growth factor A Rattus norvegicus 73-77 19553916-4 2009 Infusions of SU5416 or SU1498, two structurally dissimilar inhibitors of VEGF-Flk-1 receptor signaling, block the antidepressant effects of fluoxetine on sucrose preference, immobility in the forced swim test, and latency to feed in the novelty suppressed feeding paradigm. Fluoxetine 140-150 vascular endothelial growth factor A Rattus norvegicus 73-77 19553916-5 2009 We also show that activation of 5-HT1A receptors is sufficient to induce VEGF expression and that a 5-HT1A antagonist blocks both the increase in VEGF and behavioral effects induced by fluoxetine. Fluoxetine 185-195 vascular endothelial growth factor A Rattus norvegicus 73-77 19553916-5 2009 We also show that activation of 5-HT1A receptors is sufficient to induce VEGF expression and that a 5-HT1A antagonist blocks both the increase in VEGF and behavioral effects induced by fluoxetine. Fluoxetine 185-195 vascular endothelial growth factor A Rattus norvegicus 146-150 19553916-6 2009 Finally, double labeling studies show that chronic fluoxetine administration increases VEGF expression in both neurons and endothelial cells in the hippocampus. Fluoxetine 51-61 vascular endothelial growth factor A Rattus norvegicus 87-91 19553916-7 2009 Taken together these studies show that VEGF is necessary for the behavioral effects of the SSRI fluoxetine, as well as norepinephrine selective reuptake inhibitor, and that these effects may be mediated by 5-HT1A receptors located on neurons and endothelial cells. Fluoxetine 96-106 vascular endothelial growth factor A Rattus norvegicus 39-43 19553916-7 2009 Taken together these studies show that VEGF is necessary for the behavioral effects of the SSRI fluoxetine, as well as norepinephrine selective reuptake inhibitor, and that these effects may be mediated by 5-HT1A receptors located on neurons and endothelial cells. Norepinephrine 119-133 vascular endothelial growth factor A Rattus norvegicus 39-43 19559076-10 2009 Compared to IN saline, middle and high doses of VEGF significantly increased the segment length, diameter and number of microvessels (P<0.01). Sodium Chloride 15-21 vascular endothelial growth factor A Rattus norvegicus 48-52 18798867-1 2009 This study was to investigate the effect of high glucose (HG) on vascular endothelial growth factor (VEGF) expression in bone marrow stem cells and JAK2/STAT-3 signalling. Glucose 49-56 vascular endothelial growth factor A Rattus norvegicus 101-105 19576905-6 2009 In SHRs, doxazosin and nifedipine caused a significant decrease in penile expression of Rock1 and Rock2, whereas the differential alterations in urogenital expression of Creb1, Vegfa, Kdr and Cav1 were attenuated by treatment with doxazosin, but not nifedipine. Doxazosin 9-18 vascular endothelial growth factor A Rattus norvegicus 177-182 19722804-9 2009 Premedication with ZM323881 or L-NAME decreased the dilatory effects of VEGF. ZM323881 19-27 vascular endothelial growth factor A Rattus norvegicus 72-76 19722804-9 2009 Premedication with ZM323881 or L-NAME decreased the dilatory effects of VEGF. NG-Nitroarginine Methyl Ester 31-37 vascular endothelial growth factor A Rattus norvegicus 72-76 19542903-3 2009 Exposure to 60% O2 for 14 d caused pulmonary neutrophil and macrophage influx, increased tissue fraction and tyrosine nitration, reduced VEGF-A and angiopoietin-1 expression, and reduced small vessel (20-65 microm) and alveolar numbers. Oxygen 16-18 vascular endothelial growth factor A Rattus norvegicus 137-143 19523924-3 2009 Ligustrazine inhibited VEGF-induced HUVECs migration and tube formation in a dose-dependent manner in vitro, and had limited cytotoxicity to HUVECs and normal fibroblasts even at a dose up to 100 microg/ml. tetramethylpyrazine 0-12 vascular endothelial growth factor A Rattus norvegicus 23-27 19523924-4 2009 Ligustrazine also suppressed VEGF-induced rat aortic ring sprouting dose-dependently. tetramethylpyrazine 0-12 vascular endothelial growth factor A Rattus norvegicus 29-33 19523924-6 2009 In addition, in a B16F10 spontaneous metastasis model, Ligustrazine decreased the expression of CD34 and VEGF in primary tumor tissue and reduced the number of metastasis nodi on the lung surface. tetramethylpyrazine 55-67 vascular endothelial growth factor A Rattus norvegicus 105-109 19779980-0 2009 Effects of melatonin and phospholipid on adhesion formation and correlation with vascular endothelial growth factor expression in rats. Phospholipids 25-37 vascular endothelial growth factor A Rattus norvegicus 81-115 19483477-3 2009 Additionally, VEGF-induced vessel sprouting of rat aortic ring was also inhibited by HS. Hydrogen 85-87 vascular endothelial growth factor A Rattus norvegicus 14-18 19420388-1 2009 We have previously shown that 17beta-estradiol (E(2)) increases vascular endothelial growth factor A (Vegfa) gene expression in the rat uterus, resulting in increased microvascular permeability, and that this involves the simultaneous recruitment of hypoxia-inducible factor 1 (HIF1) and estrogen receptor alpha (ESR1) to the Vegfa gene promoter. Estradiol 30-46 vascular endothelial growth factor A Rattus norvegicus 64-100 19420388-1 2009 We have previously shown that 17beta-estradiol (E(2)) increases vascular endothelial growth factor A (Vegfa) gene expression in the rat uterus, resulting in increased microvascular permeability, and that this involves the simultaneous recruitment of hypoxia-inducible factor 1 (HIF1) and estrogen receptor alpha (ESR1) to the Vegfa gene promoter. Estradiol 30-46 vascular endothelial growth factor A Rattus norvegicus 102-107 19420388-1 2009 We have previously shown that 17beta-estradiol (E(2)) increases vascular endothelial growth factor A (Vegfa) gene expression in the rat uterus, resulting in increased microvascular permeability, and that this involves the simultaneous recruitment of hypoxia-inducible factor 1 (HIF1) and estrogen receptor alpha (ESR1) to the Vegfa gene promoter. Estradiol 30-46 vascular endothelial growth factor A Rattus norvegicus 326-331 19420388-3 2009 However, those studies were carried out using whole uterine tissue, and while most evidence indicates that the likely site of E(2)-induced Vegfa expression is luminal epithelial (LE) cells, other studies have identified stromal cells as the site of that expression. Estradiol 126-130 vascular endothelial growth factor A Rattus norvegicus 139-144 19420388-8 2009 In summary, the rapid E(2)-induced signaling events that lead to the expression of Vegfa observed previously using the whole uterus occur in LE cells and appear to be initiated via a membrane form of ESR1. Estradiol 22-26 vascular endothelial growth factor A Rattus norvegicus 83-88 19672036-10 2009 Atorvastatin significantly increased the expressions of VEGF, IL-8, Ang-1, Ang-2, eNOS, and HO-1 proteins in ischemic hindlimbs. Atorvastatin 0-12 vascular endothelial growth factor A Rattus norvegicus 56-60 19712575-5 2009 Protein levels of Ang1, Ang2, eNOS, iNOS, HO1, and VEGF were increased 1 wk after monocrotaline treatment but Tie2 protein levels were decreased 2 wk afterward. Monocrotaline 82-95 vascular endothelial growth factor A Rattus norvegicus 51-55 19420288-8 2009 3H-thymidine incorporation assay showed that SU5416 blocked the actions of both exogenous and endogenous VEGF on the proliferation of HRPTEC. Tritium 0-2 vascular endothelial growth factor A Rattus norvegicus 105-109 19628068-12 2009 However, higher levels of myocardial VEGF were noted in the PPT-treated group compared with controls. 4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol 60-63 vascular endothelial growth factor A Rattus norvegicus 37-41 20021889-9 2009 qRT-PCR analysis was used to compare the changes shown by the SB225002-, DMSO- and non-laser-treated BN rats with regard to mRNA levels of CXCR2 and vascular endothelial growth factor (VEGF) in the RPE-choroidal complex. Dimethyl Sulfoxide 73-77 vascular endothelial growth factor A Rattus norvegicus 149-183 20021890-3 2009 Cultured rat corneal epithelial cells and keratocytes were transfected with synthesize VEGF siRNA by lipofectamine 2000. Lipofectamine 101-119 vascular endothelial growth factor A Rattus norvegicus 87-91 19420288-8 2009 3H-thymidine incorporation assay showed that SU5416 blocked the actions of both exogenous and endogenous VEGF on the proliferation of HRPTEC. Semaxinib 45-51 vascular endothelial growth factor A Rattus norvegicus 105-109 19420288-9 2009 VEGF (10 ng/ml) significantly increased eNOS protein levels by 29% in cultured HGMEC, but its action was completely abolished by SU5416. Semaxinib 129-135 vascular endothelial growth factor A Rattus norvegicus 0-4 19420288-10 2009 These results suggest that VEGF receptor inhibition enhances dietary salt-induced hypertension and kidney injury, possibly by direct damage on renal cells and decreasing NO production by eNOS. Salts 69-73 vascular endothelial growth factor A Rattus norvegicus 27-31 19327410-6 2009 Additionally, scopolin could reduce IL-6, VEGF and FGF-2 expressions in rat synovial tissues. scopolin 14-22 vascular endothelial growth factor A Rattus norvegicus 42-46 19466989-0 2009 Urocortin 1 improves renal function in rats with streptozotocin-induced diabetes by inhibiting overproduction of TGF-beta 1 and VEGF. Streptozocin 49-63 vascular endothelial growth factor A Rattus norvegicus 128-132 19466989-10 2009 The secretion of VEGF induced by TGF-beta1 in mesangial cells was inhibited by urocortin 1 pretreatment. Urocortins 79-90 vascular endothelial growth factor A Rattus norvegicus 17-21 19513500-10 2009 In conclusion, cimetidine may have an inhibitory effect on tumor growth in bladder carcinogenesis via reducing the expression of angiogenesis factors including VEGF and PDECGF. Cimetidine 15-25 vascular endothelial growth factor A Rattus norvegicus 160-164 20387635-1 2009 The main goal of this work was investigation of the effect of methyl tertbutyl ether, ecologically dangerous chemical compound, on the expression of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB-3) and vascular endothelial growth factor (VEGF) mRNA in different rat organs. methyl tert-butyl ether 62-84 vascular endothelial growth factor A Rattus norvegicus 218-252 19770537-0 2009 Expression of VEGF and neural repair after alprostadil treatment in a rat model of sciatic nerve crush injury. Alprostadil 43-54 vascular endothelial growth factor A Rattus norvegicus 14-18 19770537-11 2009 The number of VEGF-positive neurons was significantly increased in the alprostadil group, compared to the saline, saline+VEGF antibody, and alprostadil+VEGF antibody groups. Alprostadil 71-82 vascular endothelial growth factor A Rattus norvegicus 14-18 19770537-11 2009 The number of VEGF-positive neurons was significantly increased in the alprostadil group, compared to the saline, saline+VEGF antibody, and alprostadil+VEGF antibody groups. Sodium Chloride 106-112 vascular endothelial growth factor A Rattus norvegicus 14-18 19770537-13 2009 CONCLUSIONS: The vasoactive agent alprostadil may reduce the pathological lesion of peripheral nerves and improve the rehabilitation of the neural function, which may relate to upregulation of the expression of VEGF, following crush injury to the peripheral nerves. Alprostadil 34-45 vascular endothelial growth factor A Rattus norvegicus 211-215 20387635-6 2009 Results of this investigation clearly demonstrated that methyl tertbutyl ether affects the expression of PFKFB-3, a key regulatory enzyme of glycolysis, as well as VEGF, very important factor of angiogenesis, in an organ-specific and dose-dependent manner. methyl tert-butyl ether 56-78 vascular endothelial growth factor A Rattus norvegicus 164-168 20387635-1 2009 The main goal of this work was investigation of the effect of methyl tertbutyl ether, ecologically dangerous chemical compound, on the expression of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB-3) and vascular endothelial growth factor (VEGF) mRNA in different rat organs. methyl tert-butyl ether 62-84 vascular endothelial growth factor A Rattus norvegicus 254-258 20387635-3 2009 In this study we have shown that PFKFB-3 and VEGF mRNA expression in the liver, lung, and heart changes in rats, treated with methyl tertbutyl ether for two months, in organ-specific manner. methyl tert-butyl ether 126-148 vascular endothelial growth factor A Rattus norvegicus 45-49 20387635-4 2009 Expression of alternative splice variants of PFKFB-3 mRNA as well as VEGF mRNA also changes in organ-specific manner in rats, treated with methyl tertbutyl ether. methyl tert-butyl ether 139-161 vascular endothelial growth factor A Rattus norvegicus 69-73 20387635-5 2009 The effect of methyl tertbutyl ether on the expression of PFKFB-3 and VEGF mRNA and its alternative splice variants is dose-dependent. methyl tert-butyl ether 14-36 vascular endothelial growth factor A Rattus norvegicus 70-74 19376567-13 2009 CONCLUSIONS: Our findings suggest the importance of steroid hormones in maintaining the integrity of the bladder structure and regulating the expression of VEGF in the female urinary tract. Steroids 52-68 vascular endothelial growth factor A Rattus norvegicus 156-160 19332106-10 2009 The stimulatory effect of VIP on the proliferation of endothelial cells was significantly (P<0.01) inhibited by SU5416, a selective inhibitor of VEGF receptor tyrosine kinase. Semaxinib 115-121 vascular endothelial growth factor A Rattus norvegicus 148-152 18563306-4 2009 Simvastatin treatment significantly increased the number of peripheral blood CD34+ CD133+ cells, and serum concentration of vascular endothelial growth factor (VEGF) and AKT was markedly increased in vivo. Simvastatin 0-11 vascular endothelial growth factor A Rattus norvegicus 124-158 18563306-4 2009 Simvastatin treatment significantly increased the number of peripheral blood CD34+ CD133+ cells, and serum concentration of vascular endothelial growth factor (VEGF) and AKT was markedly increased in vivo. Simvastatin 0-11 vascular endothelial growth factor A Rattus norvegicus 160-164 18563306-5 2009 In cultured EPC, simvastatin increased the concentrations of VEGF, AKT and eNOS. Simvastatin 17-28 vascular endothelial growth factor A Rattus norvegicus 61-65 20687301-1 2009 AIM: To determine the effect of local simvastatin application on the mRNA expression level of transforming growth factor-beta1 (TGF-beta1), bone morphogenetic protein-2 (BMP-2) and vascular endothelial growth factor (VEGF) in the tooth sockets of rat. Simvastatin 38-49 vascular endothelial growth factor A Rattus norvegicus 181-215 19255283-1 2009 ABT-869 [N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N"-(2-fluoro-5-methylphenyl)urea] is a novel multitargeted inhibitor of the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor tyrosine kinase family members. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 vascular endothelial growth factor A Rattus norvegicus 123-157 19255283-1 2009 ABT-869 [N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N"-(2-fluoro-5-methylphenyl)urea] is a novel multitargeted inhibitor of the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor tyrosine kinase family members. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 vascular endothelial growth factor A Rattus norvegicus 159-163 19255283-1 2009 ABT-869 [N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N"-(2-fluoro-5-methylphenyl)urea] is a novel multitargeted inhibitor of the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor tyrosine kinase family members. N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N1-(2-fluoro-5-methylphenyl)urea 9-79 vascular endothelial growth factor A Rattus norvegicus 123-157 19255283-1 2009 ABT-869 [N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N"-(2-fluoro-5-methylphenyl)urea] is a novel multitargeted inhibitor of the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor tyrosine kinase family members. N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N1-(2-fluoro-5-methylphenyl)urea 9-79 vascular endothelial growth factor A Rattus norvegicus 159-163 19255283-7 2009 These studies demonstrate that the adverse cardiovascular effects of the VEGF/PDGF receptor tyrosine kinase inhibitor, ABT-869, are readily controlled by conventional antihypertensive therapy without affecting antitumor efficacy. N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N1-(2-fluoro-5-methylphenyl)urea 119-126 vascular endothelial growth factor A Rattus norvegicus 73-77 19194480-4 2009 We engineered transferrin, arginine-glycine-aspartic acid (RGD) peptide or dual-functionalized poly-(lactide-co-glycolide) nanoparticles to target delivery of anti-vascular endothelial growth factor (VEGF) intraceptor plasmid to CNV lesions. Polyglactin 910 95-122 vascular endothelial growth factor A Rattus norvegicus 159-198 19440904-0 2009 Vascular endothelial growth factor expression in the urethral epithelium of castrated adult female rats treated with tamoxifen. Tamoxifen 117-126 vascular endothelial growth factor A Rattus norvegicus 0-34 19440904-1 2009 OBJECTIVE: The aim of this study was to evaluate the effects of tamoxifen on vascular endothelial growth factor (VEGF) expression in the urethral epithelium of castrated rats. Tamoxifen 64-73 vascular endothelial growth factor A Rattus norvegicus 77-111 19440904-1 2009 OBJECTIVE: The aim of this study was to evaluate the effects of tamoxifen on vascular endothelial growth factor (VEGF) expression in the urethral epithelium of castrated rats. Tamoxifen 64-73 vascular endothelial growth factor A Rattus norvegicus 113-117 19440904-6 2009 CONCLUSIONS: Our results indicate that, at the dose and during the time of treatment used, tamoxifen increased VEGF expression in the urethral epithelium of castrated rats. Tamoxifen 91-100 vascular endothelial growth factor A Rattus norvegicus 111-115 18431788-0 2009 In vitro and in vivo evaluation of acellular diaphragmatic matrices seeded with muscle precursors cells and coated with VEGF silica gels to repair muscle defect of the diaphragm. Silicon Dioxide 125-131 vascular endothelial growth factor A Rattus norvegicus 120-124 18431788-1 2009 In this work, a bioartificial system consisting of VEGF-loaded porous silica gel and myoblasts cultured on acellular diaphragmatic matrix (ADM) has been implanted to repair a surgically created diaphragmatic defect in Lewis rats. Silica Gel 70-80 vascular endothelial growth factor A Rattus norvegicus 51-55 18431788-4 2009 Different grafts composed by ADMs with and without autologous male myoblasts or/and VEGF-loaded porous silica gel have been implanted to repair previously created diaphragmatic defects in female Lewis rats. Silica Gel 103-113 vascular endothelial growth factor A Rattus norvegicus 84-88 18431788-7 2009 The disappointing results obtained when VEGF was delivered by porous silica gel were probably due to an abnormal angiogenic response following an excess of local growth factor concentration. Silica Gel 69-79 vascular endothelial growth factor A Rattus norvegicus 40-44 19467946-2 2009 It has been shown that chronic thalidomide treatment decreases portal pressure, attenuates hyperdynamic circulation and inhibits vascular endothelial growth factor (VEGF) and tumor necrosis factor (TNF)-alpha in partially portal vein-ligated rats. Thalidomide 31-42 vascular endothelial growth factor A Rattus norvegicus 129-163 19467946-2 2009 It has been shown that chronic thalidomide treatment decreases portal pressure, attenuates hyperdynamic circulation and inhibits vascular endothelial growth factor (VEGF) and tumor necrosis factor (TNF)-alpha in partially portal vein-ligated rats. Thalidomide 31-42 vascular endothelial growth factor A Rattus norvegicus 165-169 19467946-11 2009 Compared with the control group, thalidomide-treated rats had significantly lower plasma VEGF levels (p < 0.001), accompanied by an insignificant reduction in plasma TNF-alpha levels (p > 0.05). Thalidomide 33-44 vascular endothelial growth factor A Rattus norvegicus 89-93 19467946-12 2009 The expressions of VEGF and TNF-alpha mRNA in the left adrenal veins of thalidomide-treated CBDL rats were not significantly changed compared with those of the control group. Thalidomide 72-83 vascular endothelial growth factor A Rattus norvegicus 19-23 19467946-14 2009 CONCLUSION: In cirrhotic rats, chronic thalidomide treatment improves the portal-systemic collateral vascular responsiveness to AVP, which was partly related to VEGF inhibition. Thalidomide 39-50 vascular endothelial growth factor A Rattus norvegicus 161-165 18587665-6 2009 Puerarin regulates expressions of VEGF and HIF-1alpha stimulated by STZ. Streptozocin 68-71 vascular endothelial growth factor A Rattus norvegicus 34-38 18937073-2 2009 Based on this hypothetical idea, the direct effect of hemin on the expression of genes encoding heme oxygenase-1 (HO-1), vascular endothelial growth factor (VEGF), and brain-derived neurotrophic factor (BDNF) in glial cells was examined using rat C6 glioma cells as an in vitro model system. Hemin 54-59 vascular endothelial growth factor A Rattus norvegicus 121-155 18937073-2 2009 Based on this hypothetical idea, the direct effect of hemin on the expression of genes encoding heme oxygenase-1 (HO-1), vascular endothelial growth factor (VEGF), and brain-derived neurotrophic factor (BDNF) in glial cells was examined using rat C6 glioma cells as an in vitro model system. Hemin 54-59 vascular endothelial growth factor A Rattus norvegicus 157-161 18937073-5 2009 These pharmacological studies indicate that hemin can induce the enhancement of VEGF and BDNF gene expression probably through the mechanism mediated by HO-1 activity in the glioma cells, proposing the possibility that glial cells are capable of contributing to the recovery of brain function from the damage caused by cerebral hemorrhage through the production of neurogenic and angiogenic factors. Hemin 44-49 vascular endothelial growth factor A Rattus norvegicus 80-84 18587665-6 2009 Puerarin regulates expressions of VEGF and HIF-1alpha stimulated by STZ. puerarin 0-8 vascular endothelial growth factor A Rattus norvegicus 34-38 19626991-0 2009 [Effects of dl-3n-butylphthalide on the expression of VEGF and bFGF in transient middle cerebral artery occlusion rats]. 3-n-butylphthalide 12-32 vascular endothelial growth factor A Rattus norvegicus 54-58 19233274-5 2009 Quantitative PCR revealed decreased FGF-2, NGF, Wnt3a, and VEGF-A hippocampal expression during PTU treatment, with recovery in adulthood. Propylthiouracil 96-99 vascular endothelial growth factor A Rattus norvegicus 59-65 19042927-0 2009 Administration of pigment epithelium-derived factor (PEDF) reduces proteinuria by suppressing decreased nephrin and increased VEGF expression in the glomeruli of adriamycin-injected rats. Doxorubicin 162-172 vascular endothelial growth factor A Rattus norvegicus 126-130 19626991-1 2009 OBJECTIVE: To investigate the effect of dl-3n-butylphthalide (NBP) on the expression of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in protein and mRNA levels in the treatment of cerebral infarction with transient middle cerebral artery occlusion (MCAO) in rats. 3-n-butylphthalide 40-60 vascular endothelial growth factor A Rattus norvegicus 88-122 19626991-1 2009 OBJECTIVE: To investigate the effect of dl-3n-butylphthalide (NBP) on the expression of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in protein and mRNA levels in the treatment of cerebral infarction with transient middle cerebral artery occlusion (MCAO) in rats. 3-n-butylphthalide 40-60 vascular endothelial growth factor A Rattus norvegicus 124-128 19150488-9 2009 CIG treatment obviously enhanced the mRNA expression of VEGF and its receptor Flk-1 and the protein expression of VEGF 7 and 28 days after ischemia. 2-AMINO-6-CHLOROPYRAZINE 0-3 vascular endothelial growth factor A Rattus norvegicus 56-60 19563735-5 2009 In this study, remnant kidney model was employed to investigate whether A & A affect the expression of VEGF, the density of the renal microvasculature and thus alleviate the renal injury. a & 72-78 vascular endothelial growth factor A Rattus norvegicus 107-111 19563735-22 2009 The renal level of VEGF was decreased in 5/6 Nx rats, but increased at the 8th and 12th week in A & A group (P < 0.05, vs. 5/6 Nx group). a & 96-102 vascular endothelial growth factor A Rattus norvegicus 19-23 19435557-9 2009 All the expression levels, including those of vWF, HIF-1alpha, HIF-1beta and VEGF, in the salidroside group were higher than those in the untreated group while lower than those in the Radix et Rhizoma Rhodiolae Kirilowii group. rhodioloside 90-101 vascular endothelial growth factor A Rattus norvegicus 77-81 19435557-11 2009 Salidroside may be one of the effective components in Radix et Rhizoma Rhodiolae Kirilowii, which increases the expressions of HIF-1alpha, HIF-1beta and VEGF during ischemia or hypoxia. rhodioloside 0-11 vascular endothelial growth factor A Rattus norvegicus 153-157 19357264-5 2009 VEGF-A, VEGFR-1, or VEGFR-2 was inhibited by antisense oligodeoxynucleotides (ODNs) in vivo and by a VEGF-A neutralizing antibody or VEGFR-2 inhibitor in vitro. Oligodeoxyribonucleotides 55-76 vascular endothelial growth factor A Rattus norvegicus 0-6 19357264-8 2009 Furthermore, oxygen-glucose deprivation (OGD) preconditioning upregulated VEGF-A, VEGFR-2, and pCREB levels and protected immortalized H19-7 neuronal cells and b.End3 vascular endothelial cells against 24 h OGD cell death. oxygen-glucose 13-27 vascular endothelial growth factor A Rattus norvegicus 74-80 19150488-9 2009 CIG treatment obviously enhanced the mRNA expression of VEGF and its receptor Flk-1 and the protein expression of VEGF 7 and 28 days after ischemia. 2-AMINO-6-CHLOROPYRAZINE 0-3 vascular endothelial growth factor A Rattus norvegicus 114-118 19150488-10 2009 The results indicated that CIG promoted neurogenesis and angiogenesis and improved neurological function after ischemia in rats, and the mechanism might be related to CIG"s increasing VEGF and Flk-1 in the brain. 2-AMINO-6-CHLOROPYRAZINE 27-30 vascular endothelial growth factor A Rattus norvegicus 184-188 19150488-10 2009 The results indicated that CIG promoted neurogenesis and angiogenesis and improved neurological function after ischemia in rats, and the mechanism might be related to CIG"s increasing VEGF and Flk-1 in the brain. 2-AMINO-6-CHLOROPYRAZINE 167-170 vascular endothelial growth factor A Rattus norvegicus 184-188 19622293-15 2009 CONCLUSION: The preventive and therapeutic effects of aloe gel on doxorubicin-induced extravasation injury are satisfactory, which may be in relation to the up-regulation of VEGF and EGFR. Doxorubicin 66-77 vascular endothelial growth factor A Rattus norvegicus 174-178 19188429-1 2009 OBJECTIVE: This study aimed to verify whether the decreased vascular endothelial growth factor (VEGF)-to-pigment epithelium-derived factor (PEDF) ratio can serve as an indicator for the protective effect of angiotensin-converting enzyme inhibitors (ACEIs) on diabetic retinopathy (DR) and to investigate the role of mitochondrial reactive oxygen species (ROS) in the downregulated VEGF-to-PEDF ratio. Reactive Oxygen Species 330-353 vascular endothelial growth factor A Rattus norvegicus 96-100 19414378-3 2009 Compound PMEG (an active metabolite of the prodrug GS-9219) down-regulates selected proangiogenic genes EGF, FGF, PDGF, VEGF, EGFR, FGFR, PDGFR and VEGFR much more efficiently. 9-((2-phosphonylmethoxy)ethyl)guanine 9-13 vascular endothelial growth factor A Rattus norvegicus 120-124 19188429-1 2009 OBJECTIVE: This study aimed to verify whether the decreased vascular endothelial growth factor (VEGF)-to-pigment epithelium-derived factor (PEDF) ratio can serve as an indicator for the protective effect of angiotensin-converting enzyme inhibitors (ACEIs) on diabetic retinopathy (DR) and to investigate the role of mitochondrial reactive oxygen species (ROS) in the downregulated VEGF-to-PEDF ratio. Reactive Oxygen Species 355-358 vascular endothelial growth factor A Rattus norvegicus 60-94 19188429-0 2009 Protective effect of perindopril on diabetic retinopathy is associated with decreased vascular endothelial growth factor-to-pigment epithelium-derived factor ratio: involvement of a mitochondria-reactive oxygen species pathway. Perindopril 21-32 vascular endothelial growth factor A Rattus norvegicus 86-120 19188429-1 2009 OBJECTIVE: This study aimed to verify whether the decreased vascular endothelial growth factor (VEGF)-to-pigment epithelium-derived factor (PEDF) ratio can serve as an indicator for the protective effect of angiotensin-converting enzyme inhibitors (ACEIs) on diabetic retinopathy (DR) and to investigate the role of mitochondrial reactive oxygen species (ROS) in the downregulated VEGF-to-PEDF ratio. Reactive Oxygen Species 355-358 vascular endothelial growth factor A Rattus norvegicus 96-100 19188429-1 2009 OBJECTIVE: This study aimed to verify whether the decreased vascular endothelial growth factor (VEGF)-to-pigment epithelium-derived factor (PEDF) ratio can serve as an indicator for the protective effect of angiotensin-converting enzyme inhibitors (ACEIs) on diabetic retinopathy (DR) and to investigate the role of mitochondrial reactive oxygen species (ROS) in the downregulated VEGF-to-PEDF ratio. Reactive Oxygen Species 330-353 vascular endothelial growth factor A Rattus norvegicus 60-94 19188429-6 2009 RESULTS: The VEGF-to-PEDF ratio was increased in the retina of diabetic rats; perindopril lowered the increased VEGF-to-PEDF ratio in diabetic rats and ameliorated the retinal damage. Perindopril 78-89 vascular endothelial growth factor A Rattus norvegicus 112-116 19188429-7 2009 In BRECs, perindopril lowered the hyperglycemia-induced elevation of VEGF-to-PEDF ratio by reducing mitochondrial ROS. Perindopril 10-21 vascular endothelial growth factor A Rattus norvegicus 69-73 19188429-7 2009 In BRECs, perindopril lowered the hyperglycemia-induced elevation of VEGF-to-PEDF ratio by reducing mitochondrial ROS. Reactive Oxygen Species 114-117 vascular endothelial growth factor A Rattus norvegicus 69-73 19188429-9 2009 CONCLUSIONS: It is concluded that the protective effect of ACEI on DR is associated with a decreased VEGF-to-PEDF ratio, which involves the mitochondria-ROS pathway through PPARgamma-mediated changes of UCP-2. Reactive Oxygen Species 153-156 vascular endothelial growth factor A Rattus norvegicus 101-105 19098317-8 2009 PI3K inhibitor (Ly294002) significantly decreased pAkt activity and HIF-1alpha and VEGF expression in vivo and in vitro, whereas MEK inhibitor (PD98059) reduced ERK phosphorylation and the expression of VEGF but had no effect on HIF-1alpha. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 16-24 vascular endothelial growth factor A Rattus norvegicus 83-87 19234059-0 2009 Taurocholate feeding to bile duct ligated rats prevents caffeic acid-induced bile duct damage by changes in cholangiocyte VEGF expression. Taurocholic Acid 0-12 vascular endothelial growth factor A Rattus norvegicus 122-126 19234059-5 2009 The aims of this study were to determine if: (i) CAPE induces bile duct damage; and (ii) TC prevents CAPE-induced bile duct damage by increasing cholangiocyte VEGF expression. Taurocholic Acid 89-91 vascular endothelial growth factor A Rattus norvegicus 159-163 19234059-12 2009 The protective effect of TC was associated with enhanced VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3. Taurocholic Acid 25-27 vascular endothelial growth factor A Rattus norvegicus 57-63 19234059-15 2009 CONCLUSION: Manipulation of cholangiocyte VEGF expression by bile acids may be important in preventing the impairment of cholangiocyte proliferation by exogenous agents. Bile Acids and Salts 61-71 vascular endothelial growth factor A Rattus norvegicus 42-46 19137587-4 2009 Sorafenib administered orally once a day for 2 weeks in experimental models of portal hypertension and cirrhosis effectively inhibited VEGF, PDGF, and Raf signaling pathways, and produced several protective effects by inducing an approximately 80% decrease in splanchnic neovascularization and a marked attenuation of hyperdynamic splanchnic and systemic circulations, as well as a significant 18% decrease in the extent of portosystemic collaterals. Sorafenib 0-9 vascular endothelial growth factor A Rattus norvegicus 135-139 19098317-8 2009 PI3K inhibitor (Ly294002) significantly decreased pAkt activity and HIF-1alpha and VEGF expression in vivo and in vitro, whereas MEK inhibitor (PD98059) reduced ERK phosphorylation and the expression of VEGF but had no effect on HIF-1alpha. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 16-24 vascular endothelial growth factor A Rattus norvegicus 203-207 19098317-8 2009 PI3K inhibitor (Ly294002) significantly decreased pAkt activity and HIF-1alpha and VEGF expression in vivo and in vitro, whereas MEK inhibitor (PD98059) reduced ERK phosphorylation and the expression of VEGF but had no effect on HIF-1alpha. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 144-151 vascular endothelial growth factor A Rattus norvegicus 203-207 19372635-0 2009 Acemannan stimulates gingival fibroblast proliferation; expressions of keratinocyte growth factor-1, vascular endothelial growth factor, and type I collagen; and wound healing. acemannan 0-9 vascular endothelial growth factor A Rattus norvegicus 101-135 19372635-9 2009 Acemannan concentrations between 2 - 16 mg/ml significantly stimulated KGF-1, VEGF, and type I collagen expressions (P<0.05). acemannan 0-9 vascular endothelial growth factor A Rattus norvegicus 78-82 19372635-11 2009 These findings suggest that acemannan plays a significant role in the oral wound healing process via the induction of fibroblast proliferation and stimulation of KGF-1, VEGF, and type I collagen expressions. acemannan 28-37 vascular endothelial growth factor A Rattus norvegicus 169-173 18814988-1 2009 Cediranib (RECENTIN, AZD2171) is a highly potent inhibitor of the tyrosine kinase activity associated with all three vascular endothelial growth factor (VEGF) receptors and is currently in Phase II/III clinical trials. cediranib 0-9 vascular endothelial growth factor A Rattus norvegicus 117-151 18814988-1 2009 Cediranib (RECENTIN, AZD2171) is a highly potent inhibitor of the tyrosine kinase activity associated with all three vascular endothelial growth factor (VEGF) receptors and is currently in Phase II/III clinical trials. cediranib 0-9 vascular endothelial growth factor A Rattus norvegicus 153-157 18814988-1 2009 Cediranib (RECENTIN, AZD2171) is a highly potent inhibitor of the tyrosine kinase activity associated with all three vascular endothelial growth factor (VEGF) receptors and is currently in Phase II/III clinical trials. cediranib 11-19 vascular endothelial growth factor A Rattus norvegicus 117-151 18814988-1 2009 Cediranib (RECENTIN, AZD2171) is a highly potent inhibitor of the tyrosine kinase activity associated with all three vascular endothelial growth factor (VEGF) receptors and is currently in Phase II/III clinical trials. cediranib 11-19 vascular endothelial growth factor A Rattus norvegicus 153-157 18814988-1 2009 Cediranib (RECENTIN, AZD2171) is a highly potent inhibitor of the tyrosine kinase activity associated with all three vascular endothelial growth factor (VEGF) receptors and is currently in Phase II/III clinical trials. cediranib 21-28 vascular endothelial growth factor A Rattus norvegicus 117-151 18814988-1 2009 Cediranib (RECENTIN, AZD2171) is a highly potent inhibitor of the tyrosine kinase activity associated with all three vascular endothelial growth factor (VEGF) receptors and is currently in Phase II/III clinical trials. cediranib 21-28 vascular endothelial growth factor A Rattus norvegicus 153-157 18814988-2 2009 Preclinically, cediranib inhibits VEGF signaling and angiogenesis in vivo and impedes solid tumor growth significantly. cediranib 15-24 vascular endothelial growth factor A Rattus norvegicus 34-38 19341424-9 2009 As confirmed by western blotting, the levels of VEGF in BAL fluid were higher in the NAC-treated group than in the COPD group. Acetylcysteine 85-88 vascular endothelial growth factor A Rattus norvegicus 48-52 19240696-5 2009 Treatment with pVEGFE+ significantly increased VEGF expression for 5 days after delivery compared to injection of pVEGF without EP (pVEGFE-). pvegfe 132-138 vascular endothelial growth factor A Rattus norvegicus 16-20 19341424-13 2009 CONCLUSIONS: NAC attenuates lung damage, pulmonary emphysema and alveolar septal cell apoptosis by partly reversing the decrease in VEGF secretion and VEGFR2 protein expression in smoking-induced COPD in rats. Acetylcysteine 13-16 vascular endothelial growth factor A Rattus norvegicus 132-136 19203849-1 2009 OBJECTIVE: The purpose of this study was to investigate Vascular Endothelial Growth Factor Expression (VEGF) gene regulation by isoflavone in urinary tract tissues of castrated adult rats. Isoflavones 128-138 vascular endothelial growth factor A Rattus norvegicus 103-107 30256863-0 2009 Induction stage-dependent expression of vascular endothelial growth factor and aquaporin-1 in diethylstilbestrol-treated rat pituitary. Diethylstilbestrol 94-112 vascular endothelial growth factor A Rattus norvegicus 40-74 30256863-7 2009 Our data indicated a dynamic scenario of biological alterations in DES-treated pituitary tissue, in which VEGF and AQP-1 exert their functions at different stages of induction, and we provide novel insights into understanding oestrogen-related tumourigenesis in the anterior pituitary gland. Diethylstilbestrol 67-70 vascular endothelial growth factor A Rattus norvegicus 106-110 19203849-5 2009 Determination of VEGF gene regulated by isoflavone was obtained using a semiquantitative RT-PCR and immunohistochemistry of total RNA isolated from bladder and urethra. Isoflavones 40-50 vascular endothelial growth factor A Rattus norvegicus 17-21 19203849-6 2009 RESULTS: Our results demonstrate that isoflavone was able to upregulate mRNA level of the VEGF gene in the lower urinary tract of rats in Group II, where isoflavone administration was started at an early phase of estrogen deprivation, while in Group III, where isoflavone administration was started in the late phase of hypoestrogenism, did not show alteration of bladder and urethra VEGF gene expression, compared to placebo, maintaining the same level of the castrated rats without treatment. Isoflavones 38-48 vascular endothelial growth factor A Rattus norvegicus 90-94 19203849-6 2009 RESULTS: Our results demonstrate that isoflavone was able to upregulate mRNA level of the VEGF gene in the lower urinary tract of rats in Group II, where isoflavone administration was started at an early phase of estrogen deprivation, while in Group III, where isoflavone administration was started in the late phase of hypoestrogenism, did not show alteration of bladder and urethra VEGF gene expression, compared to placebo, maintaining the same level of the castrated rats without treatment. Isoflavones 38-48 vascular endothelial growth factor A Rattus norvegicus 384-388 19203849-6 2009 RESULTS: Our results demonstrate that isoflavone was able to upregulate mRNA level of the VEGF gene in the lower urinary tract of rats in Group II, where isoflavone administration was started at an early phase of estrogen deprivation, while in Group III, where isoflavone administration was started in the late phase of hypoestrogenism, did not show alteration of bladder and urethra VEGF gene expression, compared to placebo, maintaining the same level of the castrated rats without treatment. Isoflavones 154-164 vascular endothelial growth factor A Rattus norvegicus 90-94 19203849-6 2009 RESULTS: Our results demonstrate that isoflavone was able to upregulate mRNA level of the VEGF gene in the lower urinary tract of rats in Group II, where isoflavone administration was started at an early phase of estrogen deprivation, while in Group III, where isoflavone administration was started in the late phase of hypoestrogenism, did not show alteration of bladder and urethra VEGF gene expression, compared to placebo, maintaining the same level of the castrated rats without treatment. Isoflavones 154-164 vascular endothelial growth factor A Rattus norvegicus 90-94 19203849-7 2009 CONCLUSIONS: The data indicate that VEGF expression in rats is also regulated by isoflavone in early phase of hypoestrogenism. Isoflavones 81-91 vascular endothelial growth factor A Rattus norvegicus 36-40 19292920-0 2009 Gamma-linolenic acid inhibits both tumour cell cycle progression and angiogenesis in the orthotopic C6 glioma model through changes in VEGF, Flt1, ERK1/2, MMP2, cyclin D1, pRb, p53 and p27 protein expression. gamma-Linolenic Acid 0-20 vascular endothelial growth factor A Rattus norvegicus 135-139 19109954-11 2009 PTX decreases the angiogenesis, reduces the symptoms of HPS, and downregulates VEGF-A mediated pathways. Pentoxifylline 0-3 vascular endothelial growth factor A Rattus norvegicus 79-83 19250642-13 2009 PI-88 significantly inhibited retinal leukostasis and reversed retinal dysfunction by a mechanism that may include decreased ICAM-1 and VEGF expression in diabetic rats. phosphomannopentaose sulfate 0-5 vascular endothelial growth factor A Rattus norvegicus 136-140 19041930-7 2009 These effects of VEGF were mediated through the phosphatidylinositol 3-kinase/Akt (PI3-K/Akt) signal transduction pathway, as they were blocked in the presence of the PI3-K inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 183-191 vascular endothelial growth factor A Rattus norvegicus 17-21 19060224-7 2009 Colonic VEGF mRNA and protein expressions increased as early as 0.5 h after iodoacetamide enema and remained elevated in the active phase of colitis. Iodoacetamide 76-89 vascular endothelial growth factor A Rattus norvegicus 8-12 19060224-9 2009 Colonic lesion area was significantly reduced from 370 +/- 140 or 311 +/- 170 mm(2) in saline- or IgG-treated groups to 122 +/- 57 mm(2) in the anti-VEGF-group (p < 0.05). Sodium Chloride 87-93 vascular endothelial growth factor A Rattus norvegicus 149-153 18829613-10 2009 Calcitriol left high VEGF unchanged, but upregulated VEGF receptor 2 (presumably reversing VEGF resistance). Calcitriol 0-10 vascular endothelial growth factor A Rattus norvegicus 21-25 18829613-10 2009 Calcitriol left high VEGF unchanged, but upregulated VEGF receptor 2 (presumably reversing VEGF resistance). Calcitriol 0-10 vascular endothelial growth factor A Rattus norvegicus 53-57 18829613-10 2009 Calcitriol left high VEGF unchanged, but upregulated VEGF receptor 2 (presumably reversing VEGF resistance). Calcitriol 0-10 vascular endothelial growth factor A Rattus norvegicus 53-57 19100245-0 2009 Intra-hippocampal administration of the VEGF receptor blocker PTK787/ZK222584 impairs long-term memory. vatalanib 62-68 vascular endothelial growth factor A Rattus norvegicus 40-44 19100245-0 2009 Intra-hippocampal administration of the VEGF receptor blocker PTK787/ZK222584 impairs long-term memory. vatalanib 69-77 vascular endothelial growth factor A Rattus norvegicus 40-44 19109983-10 2009 VEGF levels were 7.1+/-1.5, 7.3+/-1.9, 3.5+/-1.6 pg/mL in the control, ZDF and ZDF-ROSI groups, respectively (p=0.23). zdf 71-74 vascular endothelial growth factor A Rattus norvegicus 0-4 19109983-10 2009 VEGF levels were 7.1+/-1.5, 7.3+/-1.9, 3.5+/-1.6 pg/mL in the control, ZDF and ZDF-ROSI groups, respectively (p=0.23). zdf 79-82 vascular endothelial growth factor A Rattus norvegicus 0-4 19109983-10 2009 VEGF levels were 7.1+/-1.5, 7.3+/-1.9, 3.5+/-1.6 pg/mL in the control, ZDF and ZDF-ROSI groups, respectively (p=0.23). Rosiglitazone 83-87 vascular endothelial growth factor A Rattus norvegicus 0-4 19462895-5 2009 HSP70 and VEGF were both significantly reduced by quercetin or combination treatment, but no significant difference was seen between quercetin and combination treatment groups. Quercetin 50-59 vascular endothelial growth factor A Rattus norvegicus 10-14 19462895-6 2009 CONCLUSION: Quercetin inhibits surgically induced endometriosis in rats, and the possible mechanism is to inhibit the expression of HSP70 and VEGF. Quercetin 12-21 vascular endothelial growth factor A Rattus norvegicus 142-146 18996588-0 2009 Sequential delivery of dexamethasone and VEGF to control local tissue response for carbon nanotube fluorescence based micro-capillary implantable sensors. Carbon 83-89 vascular endothelial growth factor A Rattus norvegicus 41-45 19575935-14 2009 MK may be effective in reducing allergic airway inflammation and airway remodeling through VEGF and VEGFR. montelukast 0-2 vascular endothelial growth factor A Rattus norvegicus 91-95 18563560-5 2009 With supplementation of taurine in diet, lower expression of GFAP and VEGF while higher expression of GLAST, GS and GAD in retina of diabetic rats were determinated by RT-PCR, Western-blotting and immunofluorescence (P < 0.05). Taurine 24-31 vascular endothelial growth factor A Rattus norvegicus 70-74 18781316-2 2009 Bevacizumab (Avastin), ranibizumab (Lucentis) and pegaptanib sodium (Macugen) are anti-VEGF medications that have been used in the treatment of CNV. pegaptanib 50-67 vascular endothelial growth factor A Rattus norvegicus 87-91 18781316-2 2009 Bevacizumab (Avastin), ranibizumab (Lucentis) and pegaptanib sodium (Macugen) are anti-VEGF medications that have been used in the treatment of CNV. pegaptanib 69-76 vascular endothelial growth factor A Rattus norvegicus 87-91 18803284-0 2009 Vascular endothelial growth factor acutely reduces calcium influx via inhibition of the Ca2+ channels in rat hippocampal neurons. Calcium 51-58 vascular endothelial growth factor A Rattus norvegicus 0-34 18803284-6 2009 The results obtained from the Fluo-3 image experiments showed that VEGF pretreatment of cultured neurons at a final concentration of 50, 100, or 200 ng/ml acutely and dose dependently attenuated the Ca(2+) influx induced by application of KCl (60 mM) or glutamate (50 microM). Potassium Chloride 239-242 vascular endothelial growth factor A Rattus norvegicus 67-71 18803284-6 2009 The results obtained from the Fluo-3 image experiments showed that VEGF pretreatment of cultured neurons at a final concentration of 50, 100, or 200 ng/ml acutely and dose dependently attenuated the Ca(2+) influx induced by application of KCl (60 mM) or glutamate (50 microM). Glutamic Acid 254-263 vascular endothelial growth factor A Rattus norvegicus 67-71 18803284-7 2009 This effect was blocked by SU1498, an antagonist of Flk-1 VEGF receptor. SU 1498 27-33 vascular endothelial growth factor A Rattus norvegicus 58-62 19079293-0 2009 Inhibition of tubulointerstitial fibrosis by pentoxifylline is associated with improvement of vascular endothelial growth factor expression. Pentoxifylline 45-59 vascular endothelial growth factor A Rattus norvegicus 94-128 18974377-0 2009 Lithium upregulates vascular endothelial growth factor in brain endothelial cells and astrocytes. Lithium 0-7 vascular endothelial growth factor A Rattus norvegicus 20-54 18974377-9 2009 However, lithium (0.2 to 20 mmol/L) increased the phosphorylation of GSK-3beta and promoted VEGF secretion in a concentration-dependent manner in both endothelial and astrocyte cells. Lithium 9-16 vascular endothelial growth factor A Rattus norvegicus 92-96 18974377-10 2009 For endothelial cells, the potent GSK-3beta inhibitor SB-216763 upregulated VEGF, whereas inhibition of PI3-K with LY294002 suppressed lithium-induced responses in both phospho-GSK-3beta and VEGF. SB 216763 54-63 vascular endothelial growth factor A Rattus norvegicus 76-80 18974377-12 2009 CONCLUSIONS: Lithium promotes VEGF expression through PI3-K/GSK-3beta-dependent and -independent pathways in brain endothelium and astrocytes, respectively. Lithium 13-20 vascular endothelial growth factor A Rattus norvegicus 30-34 19007863-0 2009 Dexamethasone induces neurodegeneration but also up-regulates vascular endothelial growth factor A in neonatal rat brains. Dexamethasone 0-13 vascular endothelial growth factor A Rattus norvegicus 62-98 19007863-3 2009 Previous studies have demonstrated that Dex usually down-regulates VEGF. Dexamethasone 40-43 vascular endothelial growth factor A Rattus norvegicus 67-71 19007863-10 2009 The tapering and repeated doses of Dex significantly increased caspase-3 activity, VEGF protein and the expression of mRNA of VEGF(164) and VEGF(188) splice variants but the single dose did not. Dexamethasone 35-38 vascular endothelial growth factor A Rattus norvegicus 83-87 19007863-10 2009 The tapering and repeated doses of Dex significantly increased caspase-3 activity, VEGF protein and the expression of mRNA of VEGF(164) and VEGF(188) splice variants but the single dose did not. Dexamethasone 35-38 vascular endothelial growth factor A Rattus norvegicus 126-130 19007863-10 2009 The tapering and repeated doses of Dex significantly increased caspase-3 activity, VEGF protein and the expression of mRNA of VEGF(164) and VEGF(188) splice variants but the single dose did not. Dexamethasone 35-38 vascular endothelial growth factor A Rattus norvegicus 126-130 19007863-11 2009 We conclude that Dex is neurodegenerative in the developing brain but also increases VEGF which may play a neurotrophic and neuroprotective role. Dexamethasone 17-20 vascular endothelial growth factor A Rattus norvegicus 85-89 18932044-0 2009 Low-dose continuous 5-fluorouracil infusion stimulates VEGF-A-mediated angiogenesis. Fluorouracil 20-34 vascular endothelial growth factor A Rattus norvegicus 55-61 18819100-6 2009 RESULTS: We report an increase in infiltrating monocyte, iNOS, NF-kappaBp65, VEGF and TNF-alpha at the early and advanced stages of tumor growth in MNU plus testosterone treated rats. Methylnitrosourea 148-151 vascular endothelial growth factor A Rattus norvegicus 77-81 19537031-14 2009 The density of microvessel infused with FITC-dextran was (152,617 +/- 13,076) microm2/mm2 in the VEGF group, significantly higher than that of the control group [(91,658 +/- 6577) microm2/mm2 P < 0.05]. fluorescein isothiocyanate dextran 40-52 vascular endothelial growth factor A Rattus norvegicus 97-101 19079293-9 2009 Meanwhile, VEGF protein and mRNA in the kidney were increased in the PTX-treated group compared with the control group (P<0.01). Pentoxifylline 69-72 vascular endothelial growth factor A Rattus norvegicus 11-15 19079293-10 2009 PTX up-regulated expression of VEGF mRNA in a dose- and time-dependent manner in cultured HK-2 cells (P<0.01). Pentoxifylline 0-3 vascular endothelial growth factor A Rattus norvegicus 31-35 19079293-12 2009 PTX prolonged the half-life of VEGF mRNA by a 1.07-fold increase. Pentoxifylline 0-3 vascular endothelial growth factor A Rattus norvegicus 31-35 19079293-13 2009 CONCLUSIONS: PTX inhibited tubulointerstitial fibrosis in a rat model of obstructive nephropathy while preventing loss of VEGF. Pentoxifylline 13-16 vascular endothelial growth factor A Rattus norvegicus 122-126 19079293-14 2009 PTX up-regulated expression of VEGF mRNA through stabilization of its mRNA in cultured renal tubular epithelial cells. Pentoxifylline 0-3 vascular endothelial growth factor A Rattus norvegicus 31-35 19922391-11 2009 Positive immunoreactivity for vascular endothelial growth factor (VEGF) was observed in cholesterol and cholesterol plus L-NAME plus ANG II. Cholesterol 88-99 vascular endothelial growth factor A Rattus norvegicus 30-64 19546527-2 2009 The present study was designed to determine whether new peritoneal dialysis solutions (PDS), pyridoxamine (advanced glycation end products (AGE) inhibitor) or AT1 receptor blocker (ARB), affect the expression of VEGF and TGF-beta1 in rat peritoneal mesothelial cells (RPMC). Pyridoxamine 93-105 vascular endothelial growth factor A Rattus norvegicus 212-216 19546527-6 2009 RESULTS: Glucose-containing PDS, even N 2.5% diluted twofold with M199 (which contains 1.25% glucose), increased VEGF and TGF-beta1 expression in RPMC (p < 0.05). Glucose 9-16 vascular endothelial growth factor A Rattus norvegicus 113-117 19546527-6 2009 RESULTS: Glucose-containing PDS, even N 2.5% diluted twofold with M199 (which contains 1.25% glucose), increased VEGF and TGF-beta1 expression in RPMC (p < 0.05). 3-{1-[3-(Dimethylamino)propyl]-2-Methyl-1h-Indol-3-Yl}-4-(2-Methyl-1h-Indol-3-Yl)-1h-Pyrrole-2,5-Dione 28-31 vascular endothelial growth factor A Rattus norvegicus 113-117 19546527-8 2009 Pyridoxamine and ARB significantly reduced N 2.5%-induced VEGF and TGF-beta1 protein and mRNA expression in RPMC (p < 0.01). Pyridoxamine 0-12 vascular endothelial growth factor A Rattus norvegicus 58-62 19546527-8 2009 Pyridoxamine and ARB significantly reduced N 2.5%-induced VEGF and TGF-beta1 protein and mRNA expression in RPMC (p < 0.01). beta-L-Arabinose 17-20 vascular endothelial growth factor A Rattus norvegicus 58-62 19351613-0 2009 Induction stage-dependent expression of vascular endothelial growth factor and aquaporin-1 in diethylstilbestrol-treated rat pituitary. Diethylstilbestrol 94-112 vascular endothelial growth factor A Rattus norvegicus 40-74 19351613-7 2009 Our data indicated a dynamic scenario of biological alterations in DES-treated pituitary tissue, in which VEGF and AQP-1 exert their functions at different stages of induction, and we provide novel insights into understanding oestrogen-related tumourigenesis in the anterior pituitary gland. Diethylstilbestrol 67-70 vascular endothelial growth factor A Rattus norvegicus 106-110 19609456-0 2009 Rosiglitazone prevents high glucose-induced vascular endothelial growth factor and collagen IV expression in cultured mesangial cells. Rosiglitazone 0-13 vascular endothelial growth factor A Rattus norvegicus 44-78 19609456-0 2009 Rosiglitazone prevents high glucose-induced vascular endothelial growth factor and collagen IV expression in cultured mesangial cells. Glucose 28-35 vascular endothelial growth factor A Rattus norvegicus 44-78 19609456-2 2009 We postulated that rosiglitazone (RSG), an activator of PPARgamma prevents the upregulation of vascular endothelial growth factor (VEGF) and collagen IV by mesangial cells exposed to high glucose. Rosiglitazone 19-32 vascular endothelial growth factor A Rattus norvegicus 95-129 19609456-2 2009 We postulated that rosiglitazone (RSG), an activator of PPARgamma prevents the upregulation of vascular endothelial growth factor (VEGF) and collagen IV by mesangial cells exposed to high glucose. Rosiglitazone 19-32 vascular endothelial growth factor A Rattus norvegicus 131-135 19609456-2 2009 We postulated that rosiglitazone (RSG), an activator of PPARgamma prevents the upregulation of vascular endothelial growth factor (VEGF) and collagen IV by mesangial cells exposed to high glucose. Rosiglitazone 34-37 vascular endothelial growth factor A Rattus norvegicus 95-129 19609456-2 2009 We postulated that rosiglitazone (RSG), an activator of PPARgamma prevents the upregulation of vascular endothelial growth factor (VEGF) and collagen IV by mesangial cells exposed to high glucose. Rosiglitazone 34-37 vascular endothelial growth factor A Rattus norvegicus 131-135 19609456-2 2009 We postulated that rosiglitazone (RSG), an activator of PPARgamma prevents the upregulation of vascular endothelial growth factor (VEGF) and collagen IV by mesangial cells exposed to high glucose. Glucose 188-195 vascular endothelial growth factor A Rattus norvegicus 95-129 19609456-4 2009 In HG, PPARgamma mRNA and protein were reduced within 3 h, and enhanced ROS generation, expression of p22(phox), VEGF and collagen IV, and PKC-zeta membrane association were prevented by RSG. Rosiglitazone 187-190 vascular endothelial growth factor A Rattus norvegicus 113-117 19922391-11 2009 Positive immunoreactivity for vascular endothelial growth factor (VEGF) was observed in cholesterol and cholesterol plus L-NAME plus ANG II. Cholesterol 88-99 vascular endothelial growth factor A Rattus norvegicus 66-70 19922391-11 2009 Positive immunoreactivity for vascular endothelial growth factor (VEGF) was observed in cholesterol and cholesterol plus L-NAME plus ANG II. Cholesterol 104-115 vascular endothelial growth factor A Rattus norvegicus 30-64 19922391-11 2009 Positive immunoreactivity for vascular endothelial growth factor (VEGF) was observed in cholesterol and cholesterol plus L-NAME plus ANG II. Cholesterol 104-115 vascular endothelial growth factor A Rattus norvegicus 66-70 19922391-11 2009 Positive immunoreactivity for vascular endothelial growth factor (VEGF) was observed in cholesterol and cholesterol plus L-NAME plus ANG II. NG-Nitroarginine Methyl Ester 121-127 vascular endothelial growth factor A Rattus norvegicus 30-64 19922391-11 2009 Positive immunoreactivity for vascular endothelial growth factor (VEGF) was observed in cholesterol and cholesterol plus L-NAME plus ANG II. NG-Nitroarginine Methyl Ester 121-127 vascular endothelial growth factor A Rattus norvegicus 66-70 19491505-4 2009 RESULTS: The basal plasma values of VEGF were lower in the healthy control group than in rats with NMU-induced tumors ( P = 0.025). Methylnitrosourea 99-102 vascular endothelial growth factor A Rattus norvegicus 36-40 19491505-7 2009 Plasma EGFR expression was higher in rats with NMU-induced tumors than in healthy controls ( P Conclusions: The results allow us to conclude that goserelin may exert a short-term stimulatory effect on the release of VEGF, as well as a long-term inhibitory effect on VEGF but not EGFR expression. Methylnitrosourea 47-50 vascular endothelial growth factor A Rattus norvegicus 216-220 19293598-11 2009 CONCLUSION: The reduction in VEGF protein and nephrin phosphorylation was possibly involved in the proteinuria in Adriamycin rats, and there might be some relationship between VEGF and nephrin phosphorylation. Doxorubicin 114-124 vascular endothelial growth factor A Rattus norvegicus 29-33 19107668-0 2009 Delivery of hypoxia-inducible VEGF gene to rat islets using polyethylenimine. Polyethyleneimine 60-76 vascular endothelial growth factor A Rattus norvegicus 30-34 19319465-9 2009 CONCLUSIONS: In obese diabetic rats BCAAs exerted a chemopreventive effect against HCC, associated with the suppression of VEGF expression and hepatic neovascularization. Amino Acids, Branched-Chain 36-41 vascular endothelial growth factor A Rattus norvegicus 123-127 19521107-0 2009 Dehydroepiandrosterone pretreatment alters the ischaemia/reperfusion-induced VEGF, IL-1 and IL-6 gene expression in acute renal failure. Dehydroepiandrosterone 0-22 vascular endothelial growth factor A Rattus norvegicus 77-81 19521107-7 2009 VEGF protein levels were lower at T(2) and T(24 )in G(DHEA) than in G(PG). Dehydroepiandrosterone 54-58 vascular endothelial growth factor A Rattus norvegicus 0-4 19521107-8 2009 CONCLUSION: We found that DHEA pretreatment alters renal IL-1beta, IL-6 and VEGF synthesis. Dehydroepiandrosterone 26-30 vascular endothelial growth factor A Rattus norvegicus 76-80 19293598-0 2009 Reduction in VEGF protein and phosphorylated nephrin associated with proteinuria in adriamycin nephropathy rats. Doxorubicin 84-94 vascular endothelial growth factor A Rattus norvegicus 13-17 19293598-9 2009 The intervention of prednisone and lisinopril evidently reduced proteinuria, effectively attenuated the severe lesions of podocyte foot processes, and restored the reduction in VEGF and nephrin phosphorylation. Prednisone 20-30 vascular endothelial growth factor A Rattus norvegicus 177-181 19293598-12 2009 The antiproteinuric effects of lisinopril and prednisone were achieved at least partially by restoring VEGF protein and nephrin phosphorylation. Lisinopril 31-41 vascular endothelial growth factor A Rattus norvegicus 103-107 19293598-9 2009 The intervention of prednisone and lisinopril evidently reduced proteinuria, effectively attenuated the severe lesions of podocyte foot processes, and restored the reduction in VEGF and nephrin phosphorylation. Lisinopril 35-45 vascular endothelial growth factor A Rattus norvegicus 177-181 19293598-12 2009 The antiproteinuric effects of lisinopril and prednisone were achieved at least partially by restoring VEGF protein and nephrin phosphorylation. Prednisone 46-56 vascular endothelial growth factor A Rattus norvegicus 103-107 19478539-9 2009 The VEGF and IGF-1 mRNA levels were reduced following treatment with octreotide. Octreotide 69-79 vascular endothelial growth factor A Rattus norvegicus 4-8 19816088-7 2009 These results show that the suppression of the increase in NGF and VEGF might partially be involved in the improvement of nasal allergy signs by the treatment with olopatadine. Olopatadine Hydrochloride 164-175 vascular endothelial growth factor A Rattus norvegicus 67-71 19816088-4 2009 A single administration of olopatadine suppressed sneezing and the increases in histamine, nerve growth factor (NGF) and vascular endothelial growth factor (VEGF) production in nasal lavage fluid. Olopatadine Hydrochloride 27-38 vascular endothelial growth factor A Rattus norvegicus 121-155 19816088-4 2009 A single administration of olopatadine suppressed sneezing and the increases in histamine, nerve growth factor (NGF) and vascular endothelial growth factor (VEGF) production in nasal lavage fluid. Olopatadine Hydrochloride 27-38 vascular endothelial growth factor A Rattus norvegicus 157-161 18948613-4 2009 Several control experiments were performed to confirm the VEGFR specificity of (64)Cu-DOTA-VEGF(121) uptake in the stroke border zone. 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid 83-90 vascular endothelial growth factor A Rattus norvegicus 58-62 19968580-0 2009 Effect of dutasteride on the expression of hypoxia-inducible factor-1alpha, vascular endothelial growth factor and microvessel density in rat and human prostate tissue. Dutasteride 10-21 vascular endothelial growth factor A Rattus norvegicus 76-110 19968580-9 2009 CONCLUSIONS: The expression of HIF-1alpha and VEGF in rat prostates is suppressed by dutasteride. Dutasteride 85-96 vascular endothelial growth factor A Rattus norvegicus 46-50 18948613-8 2009 VEGFR specificity of (64)Cu-DOTA-VEGF(121) uptake was confirmed by significantly lower uptake of (64)Cu-DOTA-VEGF(mutant) in vivo and intense (125)I-VEGF(165) uptake ex vivo in the stroke border zone. Copper 25-27 vascular endothelial growth factor A Rattus norvegicus 0-4 18948613-8 2009 VEGFR specificity of (64)Cu-DOTA-VEGF(121) uptake was confirmed by significantly lower uptake of (64)Cu-DOTA-VEGF(mutant) in vivo and intense (125)I-VEGF(165) uptake ex vivo in the stroke border zone. Copper 25-27 vascular endothelial growth factor A Rattus norvegicus 33-37 18948613-8 2009 VEGFR specificity of (64)Cu-DOTA-VEGF(121) uptake was confirmed by significantly lower uptake of (64)Cu-DOTA-VEGF(mutant) in vivo and intense (125)I-VEGF(165) uptake ex vivo in the stroke border zone. Copper 25-27 vascular endothelial growth factor A Rattus norvegicus 33-37 18948613-8 2009 VEGFR specificity of (64)Cu-DOTA-VEGF(121) uptake was confirmed by significantly lower uptake of (64)Cu-DOTA-VEGF(mutant) in vivo and intense (125)I-VEGF(165) uptake ex vivo in the stroke border zone. 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid 28-32 vascular endothelial growth factor A Rattus norvegicus 0-4 18948613-8 2009 VEGFR specificity of (64)Cu-DOTA-VEGF(121) uptake was confirmed by significantly lower uptake of (64)Cu-DOTA-VEGF(mutant) in vivo and intense (125)I-VEGF(165) uptake ex vivo in the stroke border zone. 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid 28-32 vascular endothelial growth factor A Rattus norvegicus 33-37 18948613-8 2009 VEGFR specificity of (64)Cu-DOTA-VEGF(121) uptake was confirmed by significantly lower uptake of (64)Cu-DOTA-VEGF(mutant) in vivo and intense (125)I-VEGF(165) uptake ex vivo in the stroke border zone. 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid 28-32 vascular endothelial growth factor A Rattus norvegicus 33-37 18948613-8 2009 VEGFR specificity of (64)Cu-DOTA-VEGF(121) uptake was confirmed by significantly lower uptake of (64)Cu-DOTA-VEGF(mutant) in vivo and intense (125)I-VEGF(165) uptake ex vivo in the stroke border zone. Copper 101-103 vascular endothelial growth factor A Rattus norvegicus 0-4 18948613-8 2009 VEGFR specificity of (64)Cu-DOTA-VEGF(121) uptake was confirmed by significantly lower uptake of (64)Cu-DOTA-VEGF(mutant) in vivo and intense (125)I-VEGF(165) uptake ex vivo in the stroke border zone. Copper 101-103 vascular endothelial growth factor A Rattus norvegicus 33-37 18948613-8 2009 VEGFR specificity of (64)Cu-DOTA-VEGF(121) uptake was confirmed by significantly lower uptake of (64)Cu-DOTA-VEGF(mutant) in vivo and intense (125)I-VEGF(165) uptake ex vivo in the stroke border zone. Copper 101-103 vascular endothelial growth factor A Rattus norvegicus 33-37 18948613-8 2009 VEGFR specificity of (64)Cu-DOTA-VEGF(121) uptake was confirmed by significantly lower uptake of (64)Cu-DOTA-VEGF(mutant) in vivo and intense (125)I-VEGF(165) uptake ex vivo in the stroke border zone. 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid 104-108 vascular endothelial growth factor A Rattus norvegicus 0-4 18948613-8 2009 VEGFR specificity of (64)Cu-DOTA-VEGF(121) uptake was confirmed by significantly lower uptake of (64)Cu-DOTA-VEGF(mutant) in vivo and intense (125)I-VEGF(165) uptake ex vivo in the stroke border zone. 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid 104-108 vascular endothelial growth factor A Rattus norvegicus 33-37 18948613-8 2009 VEGFR specificity of (64)Cu-DOTA-VEGF(121) uptake was confirmed by significantly lower uptake of (64)Cu-DOTA-VEGF(mutant) in vivo and intense (125)I-VEGF(165) uptake ex vivo in the stroke border zone. 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid 104-108 vascular endothelial growth factor A Rattus norvegicus 33-37 18983856-8 2008 KEY FINDINGS: Our results showed cilostazol inhibited diabetes-induced hypertrophy of the glomeruli and infiltration of inflammatory cells, as well as the increase in the VCAM-1 and ICAM-1 mRNA and protein expression, and MCP-1 and VEGF contents in the kidneys. Cilostazol 33-43 vascular endothelial growth factor A Rattus norvegicus 232-236 18773975-3 2008 The reduction of growth factors such as transforming growth factor-alpha (TGF)-alpha and vascular endothelial cell growth factor (VEGF) by aspirin was determined by immunohistochemistry method. Aspirin 139-146 vascular endothelial growth factor A Rattus norvegicus 130-134 18773975-4 2008 Administration of CAA produced significant protection against aspirin induced gastric toxicity by showing significant increase in PGE2, TGF-alpha, VEGF expression and accompanied by a significant inhibition of nitric oxide and regulating the levels of cytokines in rats. caa 18-21 vascular endothelial growth factor A Rattus norvegicus 147-151 18773975-4 2008 Administration of CAA produced significant protection against aspirin induced gastric toxicity by showing significant increase in PGE2, TGF-alpha, VEGF expression and accompanied by a significant inhibition of nitric oxide and regulating the levels of cytokines in rats. Aspirin 62-69 vascular endothelial growth factor A Rattus norvegicus 147-151 18983856-10 2008 SIGNIFICANCE: These results demonstrate that the renoprotective effects of cilostazol may be mediated by its anti-inflammatory actions, including inhibition of NF-kappaB activation and the subsequent decrease in proinflammatory factors, such as VCAM-1, ICAM-1, MCP-1 and VEGF expression in kidneys of diabetic rats. Cilostazol 75-85 vascular endothelial growth factor A Rattus norvegicus 271-275 18799550-7 2008 Administration of VEGF-121 from day 0 to 14, day 0 to 35, or day 3 to 35 after I/R suppressed the effects of sodium diet on CKD development, while delayed administration of VEGF-121 from day 21 to 35 had no effect. Sodium 109-115 vascular endothelial growth factor A Rattus norvegicus 18-22 19102964-10 2008 However, GnRHanta treatment caused a greater reduction in serum estradiol concentrations, and in VEGF receptor mRNA expression than GnRHa. gnrhanta 9-17 vascular endothelial growth factor A Rattus norvegicus 97-101 18799550-10 2008 These data suggest that early, but not delayed, treatment with VEGF-121 can preserve vascular structure after ischemia and influence chronic renal function in response to elevated sodium intake. Sodium 180-186 vascular endothelial growth factor A Rattus norvegicus 63-67 19209768-8 2008 VEGF positive immuno-reaction was in the lining of multiple hepatic blood sinusoids on thyroxine therapy proved morphometrically by a significant increase in mean area % in G2 versus G1. Thyroxine 87-96 vascular endothelial growth factor A Rattus norvegicus 0-4 18835919-5 2008 NG-nitro-L-arginine methyl ester (L-NAME) (1x10(-5) M) eliminated vasodilation to flow, VEGF, and ACh, indicating dependence of these responses on NO. NG-Nitroarginine Methyl Ester 0-32 vascular endothelial growth factor A Rattus norvegicus 88-92 18835919-5 2008 NG-nitro-L-arginine methyl ester (L-NAME) (1x10(-5) M) eliminated vasodilation to flow, VEGF, and ACh, indicating dependence of these responses on NO. NG-Nitroarginine Methyl Ester 34-40 vascular endothelial growth factor A Rattus norvegicus 88-92 18835919-11 2008 Wortmannin, an inhibitor of phosphatidylinositol (PI) 3-kinase, eliminated age-related differences in both flow- and VEGF-induced vasodilation. Wortmannin 0-10 vascular endothelial growth factor A Rattus norvegicus 117-121 18835919-11 2008 Wortmannin, an inhibitor of phosphatidylinositol (PI) 3-kinase, eliminated age-related differences in both flow- and VEGF-induced vasodilation. Phosphatidylinositols 28-48 vascular endothelial growth factor A Rattus norvegicus 117-121 19209768-9 2008 The results showed a stimulating effect of thyroxine on liver regeneration following 2/3 partial hepatectomy evidenced by increased Cyclin D and sinusoidal endothelial VEGF expression. Thyroxine 43-52 vascular endothelial growth factor A Rattus norvegicus 168-172 18619619-12 2008 10x VEGF-treated hearts also exhibited significantly (P < 0.05, analysis of variance and Bonferroni"s) greater recovery of left ventricular developed pressure (69.97 +/- 9.69% versus 39.74 +/- 7.01% of equilibration), +dP/dt, and -dP/dt at end reperfusion. dp 222-224 vascular endothelial growth factor A Rattus norvegicus 4-8 18619619-12 2008 10x VEGF-treated hearts also exhibited significantly (P < 0.05, analysis of variance and Bonferroni"s) greater recovery of left ventricular developed pressure (69.97 +/- 9.69% versus 39.74 +/- 7.01% of equilibration), +dP/dt, and -dP/dt at end reperfusion. Thymidine 225-227 vascular endothelial growth factor A Rattus norvegicus 4-8 18619619-12 2008 10x VEGF-treated hearts also exhibited significantly (P < 0.05, analysis of variance and Bonferroni"s) greater recovery of left ventricular developed pressure (69.97 +/- 9.69% versus 39.74 +/- 7.01% of equilibration), +dP/dt, and -dP/dt at end reperfusion. dp 234-236 vascular endothelial growth factor A Rattus norvegicus 4-8 18619619-12 2008 10x VEGF-treated hearts also exhibited significantly (P < 0.05, analysis of variance and Bonferroni"s) greater recovery of left ventricular developed pressure (69.97 +/- 9.69% versus 39.74 +/- 7.01% of equilibration), +dP/dt, and -dP/dt at end reperfusion. Thymidine 237-239 vascular endothelial growth factor A Rattus norvegicus 4-8 18728233-5 2008 RESULTS: VEGF and bFGF mRNA expression were significantly increased in MSC-injected thigh muscles of STZ-induced diabetic rats. Streptozocin 101-104 vascular endothelial growth factor A Rattus norvegicus 9-13 18373738-0 2008 Sildenafil-mediated neovascularization and protection against myocardial ischaemia reperfusion injury in rats: role of VEGF/angiopoietin-1. Sildenafil Citrate 0-10 vascular endothelial growth factor A Rattus norvegicus 119-123 18373738-2 2008 Our study aimed to determine a novel role of sildenafil on cardioprotection through stimulating angiogenesis during ischaemia (I) reperfusion (R) at both capillary and arteriolar levels and to examine the role of vascular endothelial growth factor (VEGF) and angiopoietin-1 (Ang-1) in this mechanistic effect. Sildenafil Citrate 45-55 vascular endothelial growth factor A Rattus norvegicus 249-253 18373738-7 2008 Treatment with sildenafil demonstrated increased VEGF and Ang-1 mRNA after early reperfusion. Sildenafil Citrate 15-25 vascular endothelial growth factor A Rattus norvegicus 49-53 18373738-13 2008 Our study demonstrated for the first time a strong additional therapeutic potential of sildenafil by up-regulating VEGF and Ang-1 system, probably by stimulating a cascade of events leading to neovascularization and conferring myocardial protection in in vivo I/R rat model. Sildenafil Citrate 87-97 vascular endothelial growth factor A Rattus norvegicus 115-119 18954918-10 2008 Cobalt up-regulates the expression of a hypoxia-inducible factor (HIF) and its downstream genes (erythropoietin, VEGF, HO-1). Cobalt 0-6 vascular endothelial growth factor A Rattus norvegicus 113-117 19080171-12 2008 Moreover, administration of perindopril enhanced the mRNA expression of eNOS, VEGF, and bFGF by 1.45-, 1.44-, and 1.33-fold, increased the protein content of the above indices by 1.55-, 1.30- and 1.50-fold compared with the untreated diabetic rats respectively. Perindopril 28-39 vascular endothelial growth factor A Rattus norvegicus 78-82 18981453-0 2008 Nonclinical safety evaluation of sunitinib: a potent inhibitor of VEGF, PDGF, KIT, FLT3, and RET receptors. Sunitinib 33-42 vascular endothelial growth factor A Rattus norvegicus 66-70 18792999-0 2008 An angiogenesis inhibitor, 2-methoxyestradiol, involutes rat collagen-induced arthritis and suppresses gene expression of synovial vascular endothelial growth factor and basic fibroblast growth factor. 2-Methoxyestradiol 27-45 vascular endothelial growth factor A Rattus norvegicus 131-165 18761031-1 2008 This study evaluated the effects of alternagin-C (ALT-C) on mRNA levels of VEGF, MyoD and matrix metalloproteinase 2 (MMP-2) and on activity of MMPs in injured tibialis anterior (TA) muscle induced by cryolesioning in rats. alternagin-C 36-48 vascular endothelial growth factor A Rattus norvegicus 75-79 18981396-13 2008 TGF-beta1, VEGF, and alphaSMA were highly expressed in the peritoneum of the 10% CG group. chlorhexidine gluconate 81-83 vascular endothelial growth factor A Rattus norvegicus 11-15 18789935-3 2008 Immunohistochemical analysis revealed that alcohol and nicotine consumption increased MAC deposition and VEGF expression in laser spots. Alcohols 43-50 vascular endothelial growth factor A Rattus norvegicus 105-109 19080229-1 2008 OBJECTIVE: The aim of this study is to examine the effect of mycophenolate mofetil (MMF) on epithelial-myofibroblast translation (EMT) in adenine-induced chronic renal failure (CRF) rat model and the role of vascular endothelial growth factor(VEGF) and inhibitor of differentiation (Id2 and Id3) in EMT in the rat kidney. Mycophenolic Acid 84-87 vascular endothelial growth factor A Rattus norvegicus 243-247 19211999-5 2008 The addition of PEDF and VEGF together for 24 h preincubation, produced suppression of the PACAP- or VIP-evoked cAMP responses similar to that seen with PEDF alone. Cyclic AMP 112-116 vascular endothelial growth factor A Rattus norvegicus 25-29 18789935-3 2008 Immunohistochemical analysis revealed that alcohol and nicotine consumption increased MAC deposition and VEGF expression in laser spots. Nicotine 55-63 vascular endothelial growth factor A Rattus norvegicus 105-109 18422758-10 2008 Melatonin administration reduced VEGF and NO levels as well as leakage of RhIC, suggesting that it has a therapeutic potential in reducing hypoxia-associated damage in the developing hippocampus. Melatonin 0-9 vascular endothelial growth factor A Rattus norvegicus 33-37 18655767-6 2008 Thus our result strongly suggests that inhibition of angiogenesis by butyrate involves Sp1 dephosphorylation and down-regulation of VEGF gene expression. Butyrates 69-77 vascular endothelial growth factor A Rattus norvegicus 132-136 18855264-0 2008 Vascular endothelial growth factor attenuates Nomega-nitro-L-arginine methyl ester-induced preeclampsia-like manifestations in rats. NG-Nitroarginine Methyl Ester 46-82 vascular endothelial growth factor A Rattus norvegicus 0-34 18855264-1 2008 OBJECTIVES: To verify the hypothesis that vascular endothelial growth factor (VEGF) attenuates Nomega-Nitro-L-arginine Methyl Ester (L-NAME)-induced preeclampsia-like manifestations in rats. NG-Nitroarginine Methyl Ester 95-131 vascular endothelial growth factor A Rattus norvegicus 42-76 18855264-1 2008 OBJECTIVES: To verify the hypothesis that vascular endothelial growth factor (VEGF) attenuates Nomega-Nitro-L-arginine Methyl Ester (L-NAME)-induced preeclampsia-like manifestations in rats. NG-Nitroarginine Methyl Ester 95-131 vascular endothelial growth factor A Rattus norvegicus 78-82 18855264-1 2008 OBJECTIVES: To verify the hypothesis that vascular endothelial growth factor (VEGF) attenuates Nomega-Nitro-L-arginine Methyl Ester (L-NAME)-induced preeclampsia-like manifestations in rats. NG-Nitroarginine Methyl Ester 133-139 vascular endothelial growth factor A Rattus norvegicus 42-76 18855264-1 2008 OBJECTIVES: To verify the hypothesis that vascular endothelial growth factor (VEGF) attenuates Nomega-Nitro-L-arginine Methyl Ester (L-NAME)-induced preeclampsia-like manifestations in rats. NG-Nitroarginine Methyl Ester 133-139 vascular endothelial growth factor A Rattus norvegicus 78-82 18853323-4 2008 We also evaluated the effect of an ARB (2.5 mg/kg/day candesartan) or angiotensin II (500 ng/kg/min) on retinal gene expressions of VEGF and p22phox, a subunit of NADPH oxidase. candesartan 54-65 vascular endothelial growth factor A Rattus norvegicus 132-136 18855264-11 2008 CONCLUSION: VEGF attenuates L-NAME-induced preeclampsia-like manifestations in rats, suggesting the important role of VEGF in preeclampsia and providing a potential strategy for the prevention and treatment of preeclampsia. NG-Nitroarginine Methyl Ester 28-34 vascular endothelial growth factor A Rattus norvegicus 12-16 18853323-8 2008 At 50 weeks, significant increases in VEGF and p22phox, an NADPH oxidase subunit, were significantly reduced by candesartan. candesartan 112-123 vascular endothelial growth factor A Rattus norvegicus 38-42 18855264-11 2008 CONCLUSION: VEGF attenuates L-NAME-induced preeclampsia-like manifestations in rats, suggesting the important role of VEGF in preeclampsia and providing a potential strategy for the prevention and treatment of preeclampsia. NG-Nitroarginine Methyl Ester 28-34 vascular endothelial growth factor A Rattus norvegicus 118-122 18166186-12 2008 The ovaries from the meloxicam-treated group showed less immunoreactivity than the OHSS group, indicating diminished VEGF expression associated with meloxicam treatment. Meloxicam 21-30 vascular endothelial growth factor A Rattus norvegicus 117-121 18166186-12 2008 The ovaries from the meloxicam-treated group showed less immunoreactivity than the OHSS group, indicating diminished VEGF expression associated with meloxicam treatment. Meloxicam 149-158 vascular endothelial growth factor A Rattus norvegicus 117-121 18166186-15 2008 CONCLUSION(S): Our results in a rat model suggest that meloxicam has a beneficial effect on OHSS by reducing the increases in ovarian weight and VEGF expression associated with OHSS. Meloxicam 55-64 vascular endothelial growth factor A Rattus norvegicus 145-149 18388116-8 2008 In cDNA microarray analysis using renal cortical tissues, several inflammatory and profibrotic genes were significantly down-regulated by pioglitazone including NF-kappaB, CCL2, TGFbeta1, PAI-1 and VEGF. Pioglitazone 138-150 vascular endothelial growth factor A Rattus norvegicus 198-202 18534058-5 2008 RESULTS: Twenty-four hours following tMCAO, the rAAV-VEGF group, with VEGF overexpression in the rats brain, showed a significantly increase in ICP, brain water content and cerebral edema volume compared with two control groups (p<0.05). tmcao 37-42 vascular endothelial growth factor A Rattus norvegicus 53-57 18534058-5 2008 RESULTS: Twenty-four hours following tMCAO, the rAAV-VEGF group, with VEGF overexpression in the rats brain, showed a significantly increase in ICP, brain water content and cerebral edema volume compared with two control groups (p<0.05). Water 155-160 vascular endothelial growth factor A Rattus norvegicus 53-57 18534058-5 2008 RESULTS: Twenty-four hours following tMCAO, the rAAV-VEGF group, with VEGF overexpression in the rats brain, showed a significantly increase in ICP, brain water content and cerebral edema volume compared with two control groups (p<0.05). Water 155-160 vascular endothelial growth factor A Rattus norvegicus 70-74 18534058-7 2008 Forty-eight hours following tMCAO, a 1.3-fold larger infarct volume and 1.3-fold higher NSS were observed in the rAAV-VEGF group than both control groups (p<0.05). tmcao 28-33 vascular endothelial growth factor A Rattus norvegicus 118-122 18534058-8 2008 CONCLUSION: Our results indicate that intraventricular rAAV-VEGF pre-treatment can result in deleterious intracranial hypertension and augment secondary ischemic insults at the early stage of tMCAO, and pre-ischemic VEGF gene transfer via intraventricular approach may not be a favorable therapeutic strategy for tMCAO which should be adopted with caution or avoided in experimental stroke. tmcao 192-197 vascular endothelial growth factor A Rattus norvegicus 60-64 18534058-8 2008 CONCLUSION: Our results indicate that intraventricular rAAV-VEGF pre-treatment can result in deleterious intracranial hypertension and augment secondary ischemic insults at the early stage of tMCAO, and pre-ischemic VEGF gene transfer via intraventricular approach may not be a favorable therapeutic strategy for tMCAO which should be adopted with caution or avoided in experimental stroke. tmcao 313-318 vascular endothelial growth factor A Rattus norvegicus 60-64 18632792-0 2008 Upregulation of vascular endothelial growth factor isoform VEGF-164 and receptors (VEGFR-2, Npn-1, and Npn-2) in rats with cyclophosphamide-induced cystitis. Cyclophosphamide 123-139 vascular endothelial growth factor A Rattus norvegicus 59-67 18194463-8 2008 RESULTS: Octreotide treatment during 4 days markedly and significantly decreased splanchnic neovascularization, VEGF expression by 63% and portal pressure by 15%, whereas portosystemic collateralization and splanchnic blood flow were not modified. Octreotide 9-19 vascular endothelial growth factor A Rattus norvegicus 112-116 18846340-2 2008 pEGFP-C3-9HRE-CMV-VEGF vector was constructed with molecular biology technique and transfected to primary cultured rat skeletal myoblasts by lipofectamine in vitro. Lipofectamine 141-154 vascular endothelial growth factor A Rattus norvegicus 18-22 18846340-4 2008 The results showed that in hypoxia group, the VEGF gene bands were seen and with the decrease of oxygen concentrations and prolongation of hypoxia time, the expression of VEGF mRNA was obviously increased. Oxygen 97-103 vascular endothelial growth factor A Rattus norvegicus 171-175 18535483-4 2008 VEGF (5, 10, 20, or 40 ng) or vehicle was administered intracerebroventricularly 5 min after reoxygenation following HI. hi 117-119 vascular endothelial growth factor A Rattus norvegicus 0-4 18436858-9 2008 In summary, ASCs attached to polyurethane have a dramatically increased VEGF production compared with fibroblasts in vitro, and these cells also produce an increased microvessel density in the surrounding tissue when implanted subcutaneously in rats. Polyurethanes 29-41 vascular endothelial growth factor A Rattus norvegicus 72-76 18500511-7 2008 The additional beneficial effects of Sal B relative to benazpril, augmenting VEGF expression and promoting angiogenesis, may result in improved myocardial microcirculation. salvianolic acid B 37-42 vascular endothelial growth factor A Rattus norvegicus 77-81 18708542-14 2008 Effluent VEGF was higher in the pyruvate group. Pyruvic Acid 32-40 vascular endothelial growth factor A Rattus norvegicus 9-13 18720539-10 2008 The intensity of VEGF expression in capillaries was greater in the radiation group than in the control group and was also attenuated by thalidomide (P=0.003). Thalidomide 136-147 vascular endothelial growth factor A Rattus norvegicus 17-21 18579111-12 2008 CONCLUSIONS: The studies demonstrated that GX II exerted extensively beneficial cardioprotective effect on CAL rats, it might stimulate angiogenesis of ischemic region to compensate blood supply to the heart via upregulated VEGF expression. gx ii 43-48 vascular endothelial growth factor A Rattus norvegicus 224-228 18644387-1 2008 Hyperbaric oxygen preconditioning (HBO-PC) increases the level of HIF-1alpha (hypoxia inducible factor-1alpha) and its target gene VEGF (vascular endothelial growth factor) which is involved in angiogenesis. Oxygen 11-17 vascular endothelial growth factor A Rattus norvegicus 131-135 18644387-1 2008 Hyperbaric oxygen preconditioning (HBO-PC) increases the level of HIF-1alpha (hypoxia inducible factor-1alpha) and its target gene VEGF (vascular endothelial growth factor) which is involved in angiogenesis. Oxygen 11-17 vascular endothelial growth factor A Rattus norvegicus 137-171 18454179-2 2008 Here we describe that ablation of the Nox1 activity by Nox1 small-interference RNAs (siRNAs) or diphenylene iodonium (DPI) inhibited synthesis of both VEGF proteins and VEGF mRNAs in K-Ras transformed normal rat kidney (KNRK) cells. diphenyleneiodonium 96-116 vascular endothelial growth factor A Rattus norvegicus 151-155 18454179-2 2008 Here we describe that ablation of the Nox1 activity by Nox1 small-interference RNAs (siRNAs) or diphenylene iodonium (DPI) inhibited synthesis of both VEGF proteins and VEGF mRNAs in K-Ras transformed normal rat kidney (KNRK) cells. diphenyleneiodonium 96-116 vascular endothelial growth factor A Rattus norvegicus 169-173 18454179-2 2008 Here we describe that ablation of the Nox1 activity by Nox1 small-interference RNAs (siRNAs) or diphenylene iodonium (DPI) inhibited synthesis of both VEGF proteins and VEGF mRNAs in K-Ras transformed normal rat kidney (KNRK) cells. diphenyleneiodonium 118-121 vascular endothelial growth factor A Rattus norvegicus 151-155 18454179-2 2008 Here we describe that ablation of the Nox1 activity by Nox1 small-interference RNAs (siRNAs) or diphenylene iodonium (DPI) inhibited synthesis of both VEGF proteins and VEGF mRNAs in K-Ras transformed normal rat kidney (KNRK) cells. diphenyleneiodonium 118-121 vascular endothelial growth factor A Rattus norvegicus 169-173 18818569-0 2008 Increased superoxide radical with a decrease in vascular endothelial growth factor and inducible nitric oxide synthase level leads to the progression of left ventricular hypertrophy in a pressure-overload rat heart model. Superoxides 10-28 vascular endothelial growth factor A Rattus norvegicus 48-82 18586890-3 2008 Both CS and SS increased VEGF receptor (VEGF-R)2 protein levels and the extent of tube formation and branching. Cesium 5-7 vascular endothelial growth factor A Rattus norvegicus 25-29 18586890-4 2008 Moreover, both CS and SS enhanced VEGF-induced cell proliferation and tube formation, indicating that both types of stretch increase the sensitivity of ECs to VEGF. Cesium 15-17 vascular endothelial growth factor A Rattus norvegicus 34-38 18586890-4 2008 Moreover, both CS and SS enhanced VEGF-induced cell proliferation and tube formation, indicating that both types of stretch increase the sensitivity of ECs to VEGF. Cesium 15-17 vascular endothelial growth factor A Rattus norvegicus 159-163 18586890-4 2008 Moreover, both CS and SS enhanced VEGF-induced cell proliferation and tube formation, indicating that both types of stretch increase the sensitivity of ECs to VEGF. H-SER-SER-OH 22-24 vascular endothelial growth factor A Rattus norvegicus 34-38 18586890-4 2008 Moreover, both CS and SS enhanced VEGF-induced cell proliferation and tube formation, indicating that both types of stretch increase the sensitivity of ECs to VEGF. H-SER-SER-OH 22-24 vascular endothelial growth factor A Rattus norvegicus 159-163 18495151-0 2008 Copper reverses cardiomyocyte hypertrophy through vascular endothelial growth factor-mediated reduction in the cell size. Copper 0-6 vascular endothelial growth factor A Rattus norvegicus 50-84 18670086-0 2008 Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression. Dexamethasone 0-13 vascular endothelial growth factor A Rattus norvegicus 135-169 18670086-0 2008 Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression. Streptozocin 85-99 vascular endothelial growth factor A Rattus norvegicus 135-169 18670086-3 2008 After 2 d injection, we investigated the effect of dexamethasone on leukocyte accumulation, vascular permeability and the expression of vascular endothelial growth factor (VEGF) and intercellular adhesion molecule-1 (ICAM-1) in streptozotocin-diabetic rats. Streptozocin 228-242 vascular endothelial growth factor A Rattus norvegicus 136-170 18670086-3 2008 After 2 d injection, we investigated the effect of dexamethasone on leukocyte accumulation, vascular permeability and the expression of vascular endothelial growth factor (VEGF) and intercellular adhesion molecule-1 (ICAM-1) in streptozotocin-diabetic rats. Streptozocin 228-242 vascular endothelial growth factor A Rattus norvegicus 172-176 18670086-6 2008 Dexamethasone downregulated VEGF and ICAM-1 expression in diabetic rats which correlated with its effect on leukocytes accumulation and retinal vascular permeability. Dexamethasone 0-13 vascular endothelial growth factor A Rattus norvegicus 28-32 18670086-7 2008 The present data revealed that dexamethasone may inhibit retinal accumulation and leukostasis accumulation and vascular permeability through its blockage on VEGF and ICAM-1 expression. Dexamethasone 31-44 vascular endothelial growth factor A Rattus norvegicus 157-161 18443849-9 2008 The sildenafil-treated group showed a significant (p < 0.05) reduction in both areas at day 7 compared to the VEGF and control groups. Sildenafil Citrate 4-14 vascular endothelial growth factor A Rattus norvegicus 113-117 18772615-4 2008 We examined the therapeutic effect of VGA1155 (5- [N-Methyl-N- (4-octadecyloxyphenyl) acetyl] amino-2-methyl-thiobenzoic acid), a novel small molecule antagonist of VEGF, on rat permanent focal cerebral ischemia. VGA1155 38-45 vascular endothelial growth factor A Rattus norvegicus 165-169 18772615-4 2008 We examined the therapeutic effect of VGA1155 (5- [N-Methyl-N- (4-octadecyloxyphenyl) acetyl] amino-2-methyl-thiobenzoic acid), a novel small molecule antagonist of VEGF, on rat permanent focal cerebral ischemia. VGA1155 47-125 vascular endothelial growth factor A Rattus norvegicus 165-169 18396329-4 2008 Rat recombinant VEGF was encapsulated in poly(lactide-co-glycolide) microspheres by a double emulsion method. Polyglactin 910 41-67 vascular endothelial growth factor A Rattus norvegicus 16-20 18501894-9 2008 In common nerve grafts, minocycline, besides its direct anti-ischemic effect, hampered revascularization by down-regulation of MMP9 and VEGF prolonging ischemia and impeding macrophage recruitment. Minocycline 24-35 vascular endothelial growth factor A Rattus norvegicus 136-140 18495151-7 2008 Because copper stimulates vascular endothelial growth factor (VEGF) production through activation of hypoxia-inducible transcription factor, an anti-VEGF antibody at a final concentration of 2 ng/ml in cultures was used and shown to blunt copper-induced regression of cell hypertrophy. Copper 8-14 vascular endothelial growth factor A Rattus norvegicus 26-60 18495151-7 2008 Because copper stimulates vascular endothelial growth factor (VEGF) production through activation of hypoxia-inducible transcription factor, an anti-VEGF antibody at a final concentration of 2 ng/ml in cultures was used and shown to blunt copper-induced regression of cell hypertrophy. Copper 8-14 vascular endothelial growth factor A Rattus norvegicus 62-66 18495151-7 2008 Because copper stimulates vascular endothelial growth factor (VEGF) production through activation of hypoxia-inducible transcription factor, an anti-VEGF antibody at a final concentration of 2 ng/ml in cultures was used and shown to blunt copper-induced regression of cell hypertrophy. Copper 239-245 vascular endothelial growth factor A Rattus norvegicus 149-153 18495151-9 2008 This study demonstrates that both copper and VEGF reduce the size of hypertrophied cardiomyocytes, and copper regression of cardiac hypertrophy is VEGF-dependent. Copper 34-40 vascular endothelial growth factor A Rattus norvegicus 147-151 18495151-9 2008 This study demonstrates that both copper and VEGF reduce the size of hypertrophied cardiomyocytes, and copper regression of cardiac hypertrophy is VEGF-dependent. Copper 103-109 vascular endothelial growth factor A Rattus norvegicus 147-151 18562929-8 2008 SB203580, a p38 MAP kinase inhibitor, repressed LPS-induced VEGF mRNA expression. SB 203580 0-8 vascular endothelial growth factor A Rattus norvegicus 60-64 18413658-6 2008 In addition, topical LXA(4) (10 ng/eye) inhibited the LPS-induced production of IL-1beta, TNF-alpha, and PGE(2), and expression of COX-2 and VEGF. N-(1H-benzimidazol-2-ylmethyl)-2-methoxyacetamide 21-24 vascular endothelial growth factor A Rattus norvegicus 141-145 18580478-0 2008 Carbon monoxide ameliorates renal cold ischemia-reperfusion injury with an upregulation of vascular endothelial growth factor by activation of hypoxia-inducible factor. Carbon Monoxide 0-15 vascular endothelial growth factor A Rattus norvegicus 91-125 18562575-10 2008 (+)-Catechin also showed inhibitory effect on VEGF mRNA levels in B16F-10 melanoma cells. Catechin 0-12 vascular endothelial growth factor A Rattus norvegicus 46-50 18442798-7 2008 Olopatadine reduced nasal allergy signs and inhibited increases in NGF and VEGF. Olopatadine Hydrochloride 0-11 vascular endothelial growth factor A Rattus norvegicus 75-79 18442798-8 2008 These findings suggest that the increases in NGF and VEGF production are involved in the mechanism responsible for nasal allergy signs in TDI-challenged rats. Toluene 2,4-Diisocyanate 138-141 vascular endothelial growth factor A Rattus norvegicus 53-57 18533784-2 2008 The aims of this study were to investigate VEGF expression during the progression of periodontal disease and to evaluate the effect of a preferential cyclooxygenase (COX)-2 inhibitor meloxicam on VEGF expression and alveolar bone loss in experimentally induced periodontitis. Meloxicam 183-192 vascular endothelial growth factor A Rattus norvegicus 196-200 18533784-10 2008 Meloxicam significantly reduced the increased mRNA VEGF expression in diseased tissues after 14 days of treatment (P = 0.023). Meloxicam 0-9 vascular endothelial growth factor A Rattus norvegicus 51-55 18533784-13 2008 After 14 days of treatment with meloxicam, an important decrease in VEGF protein expression was detected in diseased tissues (P = 0.08). Meloxicam 32-41 vascular endothelial growth factor A Rattus norvegicus 68-72 18584585-11 2008 CONCLUSION: Systemic and local administration of irbesartan lowers glomerular expression of TGF-beta1, PDGF-B, VEGF and TNF-alpha. Irbesartan 49-59 vascular endothelial growth factor A Rattus norvegicus 111-115 18622048-11 2008 Likewise, the expression of VEGF was also up-regulated in the colon following DSS treatment, and this response was suppressed by both L-NAME and aminoguanidine. NG-Nitroarginine Methyl Ester 134-140 vascular endothelial growth factor A Rattus norvegicus 28-32 18533784-14 2008 Qualitative IHC analysis revealed that VEGF protein expression was higher in diseased tissues and decreased in tissues from rats treated with meloxicam. Meloxicam 142-151 vascular endothelial growth factor A Rattus norvegicus 39-43 18622048-11 2008 Likewise, the expression of VEGF was also up-regulated in the colon following DSS treatment, and this response was suppressed by both L-NAME and aminoguanidine. pimagedine 145-159 vascular endothelial growth factor A Rattus norvegicus 28-32 18533784-16 2008 Systemic therapy with meloxicam can modify the progression of experimentally induced periodontitis in rats by reducing VEGF expression and alveolar bone loss. Meloxicam 22-31 vascular endothelial growth factor A Rattus norvegicus 119-123 18483380-0 2008 Inhibition of vascular endothelial growth factor-a signaling induces hypertension: examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy. cediranib 107-116 vascular endothelial growth factor A Rattus norvegicus 14-50 18458672-3 2008 In this communication, we investigated the relationship between heparanase and VEGF in thioacetamide-induced liver fibrosis in rats. Thioacetamide 87-100 vascular endothelial growth factor A Rattus norvegicus 79-83 18458672-5 2008 We further demonstrated that treating fibrotic rat livers with halofuginone (HF), a multipotent antifibrogenic drug, and subsequently subjecting them to hydrodynamics-based transfection with human VEGF-165 resulted in elevated expression of heparanase mRNA. halofuginone 63-75 vascular endothelial growth factor A Rattus norvegicus 197-201 18182045-0 2008 Vascular endothelial growth factor protects spinal cord motoneurons against glutamate-induced excitotoxicity via phosphatidylinositol 3-kinase. Glutamic Acid 76-85 vascular endothelial growth factor A Rattus norvegicus 0-34 18337309-0 2008 Deleterious effects of endogenous and exogenous testosterone on mesenchymal stem cell VEGF production. Testosterone 48-60 vascular endothelial growth factor A Rattus norvegicus 86-90 18337309-9 2008 Exogenous testosterone significantly reduced VEGF production in BMSCs harvested from ovariectomized females in a dose-dependent manner. Testosterone 10-22 vascular endothelial growth factor A Rattus norvegicus 45-49 18247158-2 2008 Isoeugenodilol significantly inhibited 10% FBS, 20 ng/ml PDGF-BB, and 20 ng/ml vascular endothelial growth factor (VEGF)-induced proliferation. Isoeugenodilol 0-14 vascular endothelial growth factor A Rattus norvegicus 79-113 18247158-2 2008 Isoeugenodilol significantly inhibited 10% FBS, 20 ng/ml PDGF-BB, and 20 ng/ml vascular endothelial growth factor (VEGF)-induced proliferation. Isoeugenodilol 0-14 vascular endothelial growth factor A Rattus norvegicus 115-119 18182045-6 2008 Chronic (3 weeks) treatment with THA induced a significant loss of motoneurons that was inhibited by co-exposure to VEGF (50 ng/mL). tha 33-36 vascular endothelial growth factor A Rattus norvegicus 116-120 18182045-7 2008 VEGF activated the phosphatidylinositol 3-kinase/Akt (PI3-K/Akt) signal transduction pathway in the spinal cord cultures, and the effect on motoneuron survival was fully reversed by the specific PI3-K inhibitor, LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 212-220 vascular endothelial growth factor A Rattus norvegicus 0-4 18182045-8 2008 VEGF also prevented the down-regulation of Bcl-2 and survivin, two proteins implicated in anti-apoptotic and/or anti-excitotoxic effects, after THA exposure. tha 144-147 vascular endothelial growth factor A Rattus norvegicus 0-4 18182045-9 2008 Together, these findings indicate that VEGF has neuroprotective effects in rat spinal cord against chronic glutamate excitotoxicity by activating the PI3-K/Akt signal transduction pathway and also reinforce the hypothesis of the potential therapeutic effects of VEGF in the prevention of motoneuron degeneration in human ALS. Glutamic Acid 107-116 vascular endothelial growth factor A Rattus norvegicus 39-43 18622062-8 2008 However, Sal B enforced some different modality than benazepril, which might improve myocardial microcirculation by augmenting VEGF expression and promoting angiogenesis besides similar effects to benazepril. salvianolic acid B 9-14 vascular endothelial growth factor A Rattus norvegicus 127-131 18228115-2 2008 The effect of ZD6474, a potent inhibitor of VEGF-receptor-2, was evaluated in combination with either radiotherapy or temozolomide. vandetanib 14-20 vascular endothelial growth factor A Rattus norvegicus 44-48 18622062-8 2008 However, Sal B enforced some different modality than benazepril, which might improve myocardial microcirculation by augmenting VEGF expression and promoting angiogenesis besides similar effects to benazepril. benazepril 53-63 vascular endothelial growth factor A Rattus norvegicus 127-131 18416461-0 2008 Vascular endothelial growth factor attenuates hepatic sinusoidal capillarization in thioacetamide-induced cirrhotic rats. Thioacetamide 84-97 vascular endothelial growth factor A Rattus norvegicus 0-34 18174522-0 2008 Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas. Triamcinolone Acetonide 13-36 vascular endothelial growth factor A Rattus norvegicus 120-126 18174522-1 2008 OBJECTIVE: To elucidate the mechanism of the unique beneficial effect of intravitreal steroid therapy on diabetic macular edema, we investigated the effect of locally administered triamcinolone acetonide (TA) on the expression of vascular endothelial growth factor (VEGF)-A and its receptors in retinas of rats with streptozotocin (STZ)-induced diabetes. Triamcinolone Acetonide 180-203 vascular endothelial growth factor A Rattus norvegicus 230-264 17767813-1 2008 OBJECTIVE: Deferoxamine, an iron chelator, is reported to induce hypoxia-inducible factor 1 (HIF-1) that leads to transcriptional activation of numerous genes including vascular endothelial growth factor (VEGF) that is known to increase blood-brain barrier (BBB) permeability. Deferoxamine 11-23 vascular endothelial growth factor A Rattus norvegicus 169-203 17874466-2 2008 We evaluated the direct in vivo effects of both the GnRH-agonist Leuprolide acetate (LA) and the GnRH-antagonist Antide (Ant) on the expression of VEGF-A and ANPT-1 and their receptors in ovarian follicles from prepubertal eCG-treated rats. iturelix 113-116 vascular endothelial growth factor A Rattus norvegicus 147-153 18385086-9 2008 In the same rats, Zx also prevented diabetes-induced increases in retinal VEGF and ICAM-1. Zeaxanthins 18-20 vascular endothelial growth factor A Rattus norvegicus 74-78 18385086-12 2008 CONCLUSIONS: Zx significantly inhibits diabetes-induced retinal oxidative damage and elevation in VEGF and adhesion molecule, all abnormalities that are associated with the pathogenesis of diabetic retinopathy. Zeaxanthins 13-15 vascular endothelial growth factor A Rattus norvegicus 98-102 17960570-6 2008 Effect of curcuminoids in the absence of serum appears to depend on VEGF as (a) anti-VEGF antibody blocked the effect of curcuminoids (b) curcuminoids caused decrease in PAR modification of VEGF increasing its biological activity. curcuminoids 10-22 vascular endothelial growth factor A Rattus norvegicus 85-89 17960570-6 2008 Effect of curcuminoids in the absence of serum appears to depend on VEGF as (a) anti-VEGF antibody blocked the effect of curcuminoids (b) curcuminoids caused decrease in PAR modification of VEGF increasing its biological activity. curcuminoids 10-22 vascular endothelial growth factor A Rattus norvegicus 85-89 17960570-6 2008 Effect of curcuminoids in the absence of serum appears to depend on VEGF as (a) anti-VEGF antibody blocked the effect of curcuminoids (b) curcuminoids caused decrease in PAR modification of VEGF increasing its biological activity. curcuminoids 121-133 vascular endothelial growth factor A Rattus norvegicus 68-72 17960570-6 2008 Effect of curcuminoids in the absence of serum appears to depend on VEGF as (a) anti-VEGF antibody blocked the effect of curcuminoids (b) curcuminoids caused decrease in PAR modification of VEGF increasing its biological activity. curcuminoids 121-133 vascular endothelial growth factor A Rattus norvegicus 85-89 17960570-6 2008 Effect of curcuminoids in the absence of serum appears to depend on VEGF as (a) anti-VEGF antibody blocked the effect of curcuminoids (b) curcuminoids caused decrease in PAR modification of VEGF increasing its biological activity. curcuminoids 121-133 vascular endothelial growth factor A Rattus norvegicus 85-89 17960570-6 2008 Effect of curcuminoids in the absence of serum appears to depend on VEGF as (a) anti-VEGF antibody blocked the effect of curcuminoids (b) curcuminoids caused decrease in PAR modification of VEGF increasing its biological activity. curcuminoids 121-133 vascular endothelial growth factor A Rattus norvegicus 68-72 17960570-6 2008 Effect of curcuminoids in the absence of serum appears to depend on VEGF as (a) anti-VEGF antibody blocked the effect of curcuminoids (b) curcuminoids caused decrease in PAR modification of VEGF increasing its biological activity. curcuminoids 121-133 vascular endothelial growth factor A Rattus norvegicus 85-89 17960570-6 2008 Effect of curcuminoids in the absence of serum appears to depend on VEGF as (a) anti-VEGF antibody blocked the effect of curcuminoids (b) curcuminoids caused decrease in PAR modification of VEGF increasing its biological activity. curcuminoids 121-133 vascular endothelial growth factor A Rattus norvegicus 85-89 18375924-3 2008 We have developed a PET tracer (64Cu-DOTA-VEGF121 [DOTA is 1,4,7,10-tetraazadodecane-N,N",N"",N"""-tetraacetic acid]) to image VEGF receptor (VEGFR) expression after MI in the living subject. 64cu-dota 32-41 vascular endothelial growth factor A Rattus norvegicus 42-46 18375924-3 2008 We have developed a PET tracer (64Cu-DOTA-VEGF121 [DOTA is 1,4,7,10-tetraazadodecane-N,N",N"",N"""-tetraacetic acid]) to image VEGF receptor (VEGFR) expression after MI in the living subject. 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid 37-41 vascular endothelial growth factor A Rattus norvegicus 42-46 18375924-3 2008 We have developed a PET tracer (64Cu-DOTA-VEGF121 [DOTA is 1,4,7,10-tetraazadodecane-N,N",N"",N"""-tetraacetic acid]) to image VEGF receptor (VEGFR) expression after MI in the living subject. 1,4,7,10-tetraazadodecane-n,n",n"",n"""-tetraacetic acid 59-115 vascular endothelial growth factor A Rattus norvegicus 42-46 17767813-1 2008 OBJECTIVE: Deferoxamine, an iron chelator, is reported to induce hypoxia-inducible factor 1 (HIF-1) that leads to transcriptional activation of numerous genes including vascular endothelial growth factor (VEGF) that is known to increase blood-brain barrier (BBB) permeability. Deferoxamine 11-23 vascular endothelial growth factor A Rattus norvegicus 205-209 17767813-1 2008 OBJECTIVE: Deferoxamine, an iron chelator, is reported to induce hypoxia-inducible factor 1 (HIF-1) that leads to transcriptional activation of numerous genes including vascular endothelial growth factor (VEGF) that is known to increase blood-brain barrier (BBB) permeability. Iron 28-32 vascular endothelial growth factor A Rattus norvegicus 169-203 17767813-2 2008 This study was performed to test whether deferoxamine would disrupt BBB further in focal cerebral ischemia by altering the level of VEGF. Deferoxamine 41-53 vascular endothelial growth factor A Rattus norvegicus 132-136 17767813-10 2008 The number of areas that were stained with VEGF antibody in the deferoxamine 18 group (106 +/- 5/mm2) was significantly higher than that in the control group (54 +/- 2/mm2) or deferoxamine 48 group (58 +/- 1/mm2). Deferoxamine 64-76 vascular endothelial growth factor A Rattus norvegicus 43-47 17767813-11 2008 DISCUSSION: Our data suggest that deferoxamine induced an increase in VEGF but that its effect depends on the time of administration. Deferoxamine 34-46 vascular endothelial growth factor A Rattus norvegicus 70-74 17767813-12 2008 The increase in VEGF by deferoxamine could aggravate the disruption of BBB in focal cerebral ischemia. Deferoxamine 24-36 vascular endothelial growth factor A Rattus norvegicus 16-20 18324759-4 2008 Naphthamides 3, 20, and 22 exhibited good pharmacokinetics following oral dosing and showed potent inhibition of VEGF-induced angiogenesis in the rat corneal model. naphthamides 0-12 vascular endothelial growth factor A Rattus norvegicus 113-117 18385541-6 2008 Prednisolone induced gastric hemorrhagic lesions more readily in CSE rats than controls, with concomitant decrease in PaO(2) and increased levels of LPO, HIF-1alpha, and VEGF. Prednisolone 0-12 vascular endothelial growth factor A Rattus norvegicus 170-174 18405602-15 2008 CONCLUSION: BHQR is an effective recipe in promoting ovulation, and the effects of BHQR on balancing the internal environment of ovary may be due to the reduction of serum INS level and decrease in the expressions of ovarian INH, IGF-I and VEGF. bhqr 83-87 vascular endothelial growth factor A Rattus norvegicus 240-244 18022290-7 2008 Perfusion of the animals with FITC-albumin prior to sacrifice demonstrated localization of AQP4 protein in close proximity to the VEGF-induced new blood vessels. Fluorescein-5-isothiocyanate 30-34 vascular endothelial growth factor A Rattus norvegicus 130-134 17918246-8 2008 A dose-dependent increase in vascular endothelial growth factor-alpha (VEGF-alpha) and interleukin-1beta (IL-1beta) by neutrophils incubated in the presence of oleic and linoleic acid was observed. oleic 160-165 vascular endothelial growth factor A Rattus norvegicus 29-69 17918246-8 2008 A dose-dependent increase in vascular endothelial growth factor-alpha (VEGF-alpha) and interleukin-1beta (IL-1beta) by neutrophils incubated in the presence of oleic and linoleic acid was observed. Linoleic Acid 170-183 vascular endothelial growth factor A Rattus norvegicus 29-69 18241842-8 2008 Furthermore, we found that HIF-1alpha and VEGF protein were significantly inhibited after blocking the PI3K/Akt pathway using a specific inhibitor, wortmannin. Wortmannin 148-158 vascular endothelial growth factor A Rattus norvegicus 42-46 18374106-0 2008 Overexpression of vascular endothelial growth factor in vitro using deferoxamine: a new drug to increase islet vascularization during transplantation. Deferoxamine 68-80 vascular endothelial growth factor A Rattus norvegicus 18-52 18291259-16 2008 CONCLUSIONS: Using our rat cholangiocarcinoma model, we demonstrated that thalidomide inhibited tumor growth and was associated with a decrease in expression of reduced eIF4E and VEGF expression; in addition, thalidomide preserved fast-twitch skeletal muscle fibers and was associated with decreased expression of TNFalpha and TGFbeta1. Thalidomide 74-85 vascular endothelial growth factor A Rattus norvegicus 179-183 18630688-0 2008 [Effects of valsartan on the renal vascular endothelial growth factor and its receptor flk-1 of diabetic rats]. Valsartan 12-21 vascular endothelial growth factor A Rattus norvegicus 35-69 18630688-1 2008 OBJECTIVE: To explore effects of valsartan on expression changes of vascular endothelial growth factor (VEGF) and its receptor Flk-1 in diabetic rat kidney. Valsartan 33-42 vascular endothelial growth factor A Rattus norvegicus 68-102 18630688-1 2008 OBJECTIVE: To explore effects of valsartan on expression changes of vascular endothelial growth factor (VEGF) and its receptor Flk-1 in diabetic rat kidney. Valsartan 33-42 vascular endothelial growth factor A Rattus norvegicus 104-108 18630688-6 2008 The angiotensin II receptor antagonist--valsartan can protect kidney through the non-hemodynamic mechanism of inhibiting the abnormal expression of VEGF and Flk-1. Valsartan 40-49 vascular endothelial growth factor A Rattus norvegicus 148-152 18374106-2 2008 Deferoxamine (DFO), an iron chelator, increases vascular endothelial growth factor (VEGF) expression in cells. Deferoxamine 0-12 vascular endothelial growth factor A Rattus norvegicus 84-88 18374106-2 2008 Deferoxamine (DFO), an iron chelator, increases vascular endothelial growth factor (VEGF) expression in cells. Deferoxamine 0-12 vascular endothelial growth factor A Rattus norvegicus 48-82 18374106-2 2008 Deferoxamine (DFO), an iron chelator, increases vascular endothelial growth factor (VEGF) expression in cells. Deferoxamine 14-17 vascular endothelial growth factor A Rattus norvegicus 48-82 18039556-4 2008 Chronic exposure of C6 cells to BzATP enhanced the expression of pro-inflammatory factors including MCP-1, IL-8 and VEGF. BzATP 32-37 vascular endothelial growth factor A Rattus norvegicus 116-120 18374106-2 2008 Deferoxamine (DFO), an iron chelator, increases vascular endothelial growth factor (VEGF) expression in cells. Deferoxamine 14-17 vascular endothelial growth factor A Rattus norvegicus 84-88 18374106-11 2008 RT-PCR analysis showed stimulation of VEGF mRNA in the presence of 10 micromol/L of DFO in islets at 3 days after culture. Deferoxamine 84-87 vascular endothelial growth factor A Rattus norvegicus 38-42 18374106-12 2008 Finally, 10 micromol/L of DFO stimulated secretion of VEGF 7.95 +/- 0.84 versus 1.80 +/- 1.10 pg/microg total protein with 10 micromol/L of DFO in rat islets at 3 days after culture, n = 3; P < .001). Deferoxamine 26-29 vascular endothelial growth factor A Rattus norvegicus 54-58 18374106-12 2008 Finally, 10 micromol/L of DFO stimulated secretion of VEGF 7.95 +/- 0.84 versus 1.80 +/- 1.10 pg/microg total protein with 10 micromol/L of DFO in rat islets at 3 days after culture, n = 3; P < .001). Deferoxamine 140-143 vascular endothelial growth factor A Rattus norvegicus 54-58 18374106-13 2008 The use of DFO to stimulate VEGF expression and increase islet vascularization may be a realistic approach to improve islet viability during transplantation. Deferoxamine 11-14 vascular endothelial growth factor A Rattus norvegicus 28-32 18260796-0 2008 Simvastatin-mediated upregulation of VEGF and BDNF, activation of the PI3K/Akt pathway, and increase of neurogenesis are associated with therapeutic improvement after traumatic brain injury. Simvastatin 0-11 vascular endothelial growth factor A Rattus norvegicus 37-41 18060864-5 2008 The ex vivo treatment of kidney glomeruli with adenosine or a general AR agonist NECA, increases VEGF protein content. Adenosine 47-56 vascular endothelial growth factor A Rattus norvegicus 97-101 18060864-6 2008 In addition, NECA treatment elicits VEGF release. Adenosine-5'-(N-ethylcarboxamide) 13-17 vascular endothelial growth factor A Rattus norvegicus 36-40 18060864-8 2008 Furthermore, we showed that A(2B)AR activation was necessary to promote a higher expression of VEGF in kidney glomeruli upon exposure to high d-glucose concentration, a pathogenic condition like those observed in diabetic nephropathy. Glucose 142-151 vascular endothelial growth factor A Rattus norvegicus 95-99 17676396-4 2008 In comparison with ethanolamine, these 40 genes changed by cysteamine only may represent ulcer-associated genes, such as endothelin receptor B, endothelin 1, caspase 3, transcription factors egr-1, Sp1, the angiogenic growth factors vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF), and especially egr-1 and endothelin receptor B (ETRB) showed no changes in ileum and colon. Cysteamine 59-69 vascular endothelial growth factor A Rattus norvegicus 269-273 18065154-8 2008 Because a linear relationship does not always exist between expression of mRNA and protein, we investigated whether VEGF protein expression increased after pilocarpine-induced status epilepticus. Pilocarpine 156-167 vascular endothelial growth factor A Rattus norvegicus 116-120 17420770-0 2008 The correlation between nitric oxide and vascular endothelial growth factor in spinal cord injury. Nitric Oxide 24-36 vascular endothelial growth factor A Rattus norvegicus 41-75 17420770-5 2008 We aimed to determine the effects of L-arginine and NG-nitro-L-arginine methyl ester (L-NAME) on VEGF synthesis and free radicals in a rat model of spinal cord ischemia-reperfusion (IR) injury. Arginine 37-47 vascular endothelial growth factor A Rattus norvegicus 97-101 17420770-5 2008 We aimed to determine the effects of L-arginine and NG-nitro-L-arginine methyl ester (L-NAME) on VEGF synthesis and free radicals in a rat model of spinal cord ischemia-reperfusion (IR) injury. NG-Nitroarginine Methyl Ester 52-84 vascular endothelial growth factor A Rattus norvegicus 97-101 17420770-5 2008 We aimed to determine the effects of L-arginine and NG-nitro-L-arginine methyl ester (L-NAME) on VEGF synthesis and free radicals in a rat model of spinal cord ischemia-reperfusion (IR) injury. NG-Nitroarginine Methyl Ester 86-92 vascular endothelial growth factor A Rattus norvegicus 97-101 17420770-11 2008 RESULTS: L-Arginine treatment significantly increased MDA and NO, but decreased VEGF levels in spinal cord. Arginine 9-19 vascular endothelial growth factor A Rattus norvegicus 80-84 17420770-12 2008 However, nonselective inhibition of NOS with L-NAME significantly decreased MDA and NO, but increased VEGF levels. NG-Nitroarginine Methyl Ester 45-51 vascular endothelial growth factor A Rattus norvegicus 102-106 17420770-14 2008 CONCLUSION: Nonselective inhibition of NO synthase activity with L-NAME attenuated free radical formation and increased VEGF level when compared with NO precursor L-arginine in a rat model of spinal cord ischemia. NG-Nitroarginine Methyl Ester 65-71 vascular endothelial growth factor A Rattus norvegicus 120-124 19099959-7 2008 Treatment with SIN alone did not affect gene expressions of bFGF, VEGF, and ET-1 while expressions of bFGF, VEGF, and ET-1 were significantly reduced by combined treatment with SIN and CsA. Cyclosporine 185-188 vascular endothelial growth factor A Rattus norvegicus 108-112 17993583-1 2008 We hypothesized that abnormal fetal lung growth in experimental congenital diaphragmatic hernia after maternal nitrofen exposure alters lung structure due to impaired VEGF signaling, which can be reversed with VEGF or nitric oxide (NO) treatment. Nitric Oxide 218-230 vascular endothelial growth factor A Rattus norvegicus 167-171 18321563-14 2008 Moderately strong immunolabeling of VEGF and VEGFR-1 were observed in the dextran-70, gelatin and PS resuscitated groups, whereas only weak immunolabeling of VEGFR-2 was observed in these groups. Dextrans 74-84 vascular endothelial growth factor A Rattus norvegicus 36-40 17993583-0 2008 Impaired VEGF and nitric oxide signaling after nitrofen exposure in rat fetal lung explants. nitrofen 47-55 vascular endothelial growth factor A Rattus norvegicus 9-13 17993583-1 2008 We hypothesized that abnormal fetal lung growth in experimental congenital diaphragmatic hernia after maternal nitrofen exposure alters lung structure due to impaired VEGF signaling, which can be reversed with VEGF or nitric oxide (NO) treatment. nitrofen 111-119 vascular endothelial growth factor A Rattus norvegicus 167-171 17993583-6 2008 Nitrofen reduced lung VEGF but not endothelial NO synthase protein level. nitrofen 0-8 vascular endothelial growth factor A Rattus norvegicus 22-26 17993583-1 2008 We hypothesized that abnormal fetal lung growth in experimental congenital diaphragmatic hernia after maternal nitrofen exposure alters lung structure due to impaired VEGF signaling, which can be reversed with VEGF or nitric oxide (NO) treatment. nitrofen 111-119 vascular endothelial growth factor A Rattus norvegicus 210-214 17993583-11 2008 We conclude that nitrofen exposure increased apoptosis, decreased lung growth and reduced VEGF expression, and that exogenous NO but not VEGF treatment enhances lung growth. nitrofen 17-25 vascular endothelial growth factor A Rattus norvegicus 90-94 17924979-8 2008 Melatonin treatment reduced VEGF and NO levels as well as leakage of HRP suggesting its potential value in ameliorating damage in choroid plexus pathologies. Melatonin 0-9 vascular endothelial growth factor A Rattus norvegicus 28-32 18180313-6 2008 Treatment of 7-day castrated rats with testosterone resulted in increased epithelial hypoxyprobe staining and increased HIF-1alpha, VEGF, and CA-9 levels. Testosterone 39-51 vascular endothelial growth factor A Rattus norvegicus 132-136 18180313-11 2008 Transient epithelial cell hypoxia could by rapidly increasing HIF-1alpha and VEGF be an essential coordinator of testosterone-stimulated vascular and glandular growth. Testosterone 113-125 vascular endothelial growth factor A Rattus norvegicus 77-81 18270495-9 2008 Everolimus reduced the pro-angiogenic factor vascular endothelial growth factor (VEGF) and VEGF mRNA in glomeruli, while the transforming growth factor-beta signaling pathway was not affected. Everolimus 0-10 vascular endothelial growth factor A Rattus norvegicus 81-85 18001768-15 2008 The increased capillary and arteriolar density along with increased left ventricular functions on SDG treatment might be due to increased HO-1, VEGF and p-eNOS expression. secoisolariciresinol diglucoside 98-101 vascular endothelial growth factor A Rattus norvegicus 144-148 17942749-9 2008 Our results indicate that hypoxic brain glioma may secrete VEGF to increase glucose transport across blood-brain barrier. Glucose 76-83 vascular endothelial growth factor A Rattus norvegicus 59-63 18270495-9 2008 Everolimus reduced the pro-angiogenic factor vascular endothelial growth factor (VEGF) and VEGF mRNA in glomeruli, while the transforming growth factor-beta signaling pathway was not affected. Everolimus 0-10 vascular endothelial growth factor A Rattus norvegicus 91-95 18708733-9 2008 Even though the protein levels of VEGF were strongly increased with CPX pretreatment, this upregulation did not alter the hyperosmolar BBB disruption in the saline- or in the antibody-treated cortex. Ciclopirox 68-71 vascular endothelial growth factor A Rattus norvegicus 34-38 18497527-11 2008 The expression of VEGF in the corneal tissues was inhibited by curcumin on days 7 and 14 after alkaline burn. Curcumin 63-71 vascular endothelial growth factor A Rattus norvegicus 18-22 18043510-7 2008 mRNA for Vegf164 and Vegf188 was reduced during hyperoxia and addition of VEGF165, but not VEGF121, to explants grown in 50% O2 resulted in partial reversal of the decrease in lung branching, correlating with a decrease in cell apoptosis. Oxygen 125-127 vascular endothelial growth factor A Rattus norvegicus 9-16 18569938-10 2008 Exogenous simvastatin and manumycin A treatment alleviated urinary albumin secretion and attenuated Ras activation and VEGF protein expression in the kidneys of diabetic rats. Simvastatin 10-21 vascular endothelial growth factor A Rattus norvegicus 119-123 18569938-10 2008 Exogenous simvastatin and manumycin A treatment alleviated urinary albumin secretion and attenuated Ras activation and VEGF protein expression in the kidneys of diabetic rats. manumycin 26-37 vascular endothelial growth factor A Rattus norvegicus 119-123 18569938-0 2008 Simvastatin alleviates diabetes-induced VEGF-mediated nephropathy via the modulation of Ras signaling pathway. Simvastatin 0-11 vascular endothelial growth factor A Rattus norvegicus 40-44 18569938-2 2008 We examined the role of simvastatin in modulating Ras signaling and the expression of VEGF in mesangial cells stressed with high doses of glucose in vitro and in vivo. Simvastatin 24-35 vascular endothelial growth factor A Rattus norvegicus 86-90 18569938-2 2008 We examined the role of simvastatin in modulating Ras signaling and the expression of VEGF in mesangial cells stressed with high doses of glucose in vitro and in vivo. Glucose 138-145 vascular endothelial growth factor A Rattus norvegicus 86-90 18569938-5 2008 RESULTS: We showed that high glucose significantly increased VEGF gene expression and Ras activation. Glucose 29-36 vascular endothelial growth factor A Rattus norvegicus 61-65 18569938-6 2008 The pretreatment with 10 microM simvastatin and inhibition of Ras activity by manumycin A significantly reversed high glucose promotion of VEGF mRNA expression. Simvastatin 32-43 vascular endothelial growth factor A Rattus norvegicus 139-143 18569938-6 2008 The pretreatment with 10 microM simvastatin and inhibition of Ras activity by manumycin A significantly reversed high glucose promotion of VEGF mRNA expression. manumycin 78-89 vascular endothelial growth factor A Rattus norvegicus 139-143 18569938-12 2008 By inhibiting Ras activation, simvastatin modulates the high glucose-induced VEGF-mediated signaling pathway in vitro and in vivo. Simvastatin 30-41 vascular endothelial growth factor A Rattus norvegicus 77-81 18569938-6 2008 The pretreatment with 10 microM simvastatin and inhibition of Ras activity by manumycin A significantly reversed high glucose promotion of VEGF mRNA expression. Glucose 118-125 vascular endothelial growth factor A Rattus norvegicus 139-143 18569938-12 2008 By inhibiting Ras activation, simvastatin modulates the high glucose-induced VEGF-mediated signaling pathway in vitro and in vivo. Glucose 61-68 vascular endothelial growth factor A Rattus norvegicus 77-81 18245908-0 2008 [Effect of benazepril on the VEGF and MVD in the remnant kidney of 5/6 subtotal nephrectomized rats]. benazepril 11-21 vascular endothelial growth factor A Rattus norvegicus 29-33 18390208-0 2008 [Effects of dl-3-n-butylphthalide on expression of VEGF and bFGF in rat brain with permanent focal cerebral ischemia]. 3-n-butylphthalide 12-33 vascular endothelial growth factor A Rattus norvegicus 51-55 18390208-1 2008 OBJECTIVE: To study the effects of dl-3n-butylphthalide (NBP) on the protein and mRNA expression of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in rats brain with permanent middle cerebral artery occlusion (MCAO). 3-n-butylphthalide 35-55 vascular endothelial growth factor A Rattus norvegicus 100-134 18390208-1 2008 OBJECTIVE: To study the effects of dl-3n-butylphthalide (NBP) on the protein and mRNA expression of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in rats brain with permanent middle cerebral artery occlusion (MCAO). 3-n-butylphthalide 35-55 vascular endothelial growth factor A Rattus norvegicus 136-140 18085359-5 2008 L-Arginine further significantly increased MDA and NO, and decreased VEGF (P < 0.05 vs aortic IR). Arginine 0-10 vascular endothelial growth factor A Rattus norvegicus 69-73 18085359-6 2008 L-NAME significantly decreased MDA and NO (P < 0.05 vs L-arginine+aortic IR) and increased VEGF (P < 0.05 vs other groups). NG-Nitroarginine Methyl Ester 0-6 vascular endothelial growth factor A Rattus norvegicus 94-98 18245908-1 2008 OBJECTIVE: To explore the effect of benazepril (one of angiotesin converting enzymes) on the expression of vascular endothelial growth factor (VEGF) and the change of microvessel density (MVD) in the remnant kidney of rats that undergone 5/6 subtotal nephrectomy (STNx). benazepril 36-46 vascular endothelial growth factor A Rattus norvegicus 107-141 18245908-1 2008 OBJECTIVE: To explore the effect of benazepril (one of angiotesin converting enzymes) on the expression of vascular endothelial growth factor (VEGF) and the change of microvessel density (MVD) in the remnant kidney of rats that undergone 5/6 subtotal nephrectomy (STNx). benazepril 36-46 vascular endothelial growth factor A Rattus norvegicus 143-147 18245908-5 2008 RESULTS: UP, BUN, Cr, GSI, and TIS significantly decreased in the benazepirl group (P<0.05); and the expression of VEGF and MVD significant increased (P<0.05). benazepirl 66-76 vascular endothelial growth factor A Rattus norvegicus 118-122 18245908-8 2008 Benazepril can significantly relieve the remnant kidney fibrosis and protect the renal function by increasing the expression of VEGF and MVD in the remnant kidney. benazepril 0-10 vascular endothelial growth factor A Rattus norvegicus 128-132 18269875-0 2007 [Effects of vascular endothelial growth factor on apoptosis of sinusoidal endothelial cells caused by ethanol: experiment with rats]. Ethanol 102-109 vascular endothelial growth factor A Rattus norvegicus 12-46 17980489-3 2007 Lithium also results in increased levels of the angiogenic factor vascular endothelial growth factor (VEGF). Lithium 0-7 vascular endothelial growth factor A Rattus norvegicus 102-106 17980489-4 2007 Since VEGF was recently shown to have neurogenic properties, we were interested to examine whether lithium administration might also be accompanied by alterations in VEGF expression in the hippocampus of normal and stressed rats; the latter treatment was introduced to reproduce some of the psychopathological signs for which lithium is used therapeutically. Lithium 99-106 vascular endothelial growth factor A Rattus norvegicus 166-170 17980489-5 2007 The expression of VEGF in the hippocampus in stressed animals was lower than that in controls, but the effect of stress was significantly attenuated in animals concomitantly receiving lithium. Lithium 184-191 vascular endothelial growth factor A Rattus norvegicus 18-22 17980489-7 2007 Confirming the involvement of a known regulatory pathway in these actions of lithium, we demonstrated that lithium co-administration prevented the stress-induced upregulation of glycogen synthase kinase-3beta (GSK-3beta) and down-regulation of beta-catenin expression; GSK-3beta is a known primary lithium target and its inhibition by this mood stabilizer leads to an upregulation of beta-catenin and subsequently, an increase of VEGF. Lithium 77-84 vascular endothelial growth factor A Rattus norvegicus 430-434 17980489-7 2007 Confirming the involvement of a known regulatory pathway in these actions of lithium, we demonstrated that lithium co-administration prevented the stress-induced upregulation of glycogen synthase kinase-3beta (GSK-3beta) and down-regulation of beta-catenin expression; GSK-3beta is a known primary lithium target and its inhibition by this mood stabilizer leads to an upregulation of beta-catenin and subsequently, an increase of VEGF. Lithium 107-114 vascular endothelial growth factor A Rattus norvegicus 430-434 17980489-7 2007 Confirming the involvement of a known regulatory pathway in these actions of lithium, we demonstrated that lithium co-administration prevented the stress-induced upregulation of glycogen synthase kinase-3beta (GSK-3beta) and down-regulation of beta-catenin expression; GSK-3beta is a known primary lithium target and its inhibition by this mood stabilizer leads to an upregulation of beta-catenin and subsequently, an increase of VEGF. Lithium 107-114 vascular endothelial growth factor A Rattus norvegicus 430-434 17980489-8 2007 Our results suggest that the actions of lithium, and possibly its therapeutic efficacy as a mood stabilizer also, are mediated by VEGF. Lithium 40-47 vascular endothelial growth factor A Rattus norvegicus 130-134 18269875-11 2007 CONCLUSION: VEGF prevents the apoptosis of primary cultured SECs induced by ethanol, through at least in part, inhibition of ethanol-induced down-regulation of Ets-1 protein expression and ethanol-induced up-regulation of Casepase-8 activity in SECs. Ethanol 76-83 vascular endothelial growth factor A Rattus norvegicus 12-16 18269875-11 2007 CONCLUSION: VEGF prevents the apoptosis of primary cultured SECs induced by ethanol, through at least in part, inhibition of ethanol-induced down-regulation of Ets-1 protein expression and ethanol-induced up-regulation of Casepase-8 activity in SECs. Ethanol 125-132 vascular endothelial growth factor A Rattus norvegicus 12-16 18269875-11 2007 CONCLUSION: VEGF prevents the apoptosis of primary cultured SECs induced by ethanol, through at least in part, inhibition of ethanol-induced down-regulation of Ets-1 protein expression and ethanol-induced up-regulation of Casepase-8 activity in SECs. Ethanol 125-132 vascular endothelial growth factor A Rattus norvegicus 12-16 18269875-3 2007 VEGF (20 - 30 ng/ml) was added into the medium to be co-incubated for up to 6 h. Apoptosis was detected by terminal deoxynucleotidyl transferase (TdT)-mediated d-uridine triphosphate (dUTP)-biotin nick end labeling (TUNEL) technique. d-uridine triphosphate 160-182 vascular endothelial growth factor A Rattus norvegicus 0-4 18269875-3 2007 VEGF (20 - 30 ng/ml) was added into the medium to be co-incubated for up to 6 h. Apoptosis was detected by terminal deoxynucleotidyl transferase (TdT)-mediated d-uridine triphosphate (dUTP)-biotin nick end labeling (TUNEL) technique. deoxyuridine triphosphate 184-188 vascular endothelial growth factor A Rattus norvegicus 0-4 18269875-3 2007 VEGF (20 - 30 ng/ml) was added into the medium to be co-incubated for up to 6 h. Apoptosis was detected by terminal deoxynucleotidyl transferase (TdT)-mediated d-uridine triphosphate (dUTP)-biotin nick end labeling (TUNEL) technique. Biotin 190-196 vascular endothelial growth factor A Rattus norvegicus 0-4 18269875-8 2007 Six hours after VEGF (20 - 30 ng/ml) was added into the medium with ethanol (100 mmol/L) the percentage of TUNEL positive SECs decreased in a dose dependent manner (P < 0.05), the level of ethanol-induced apoptotic cells in the presence of VEGF (30 ng/ml) being around 71% 6 hours after ethanol incubation alone. Ethanol 68-75 vascular endothelial growth factor A Rattus norvegicus 16-20 18269875-8 2007 Six hours after VEGF (20 - 30 ng/ml) was added into the medium with ethanol (100 mmol/L) the percentage of TUNEL positive SECs decreased in a dose dependent manner (P < 0.05), the level of ethanol-induced apoptotic cells in the presence of VEGF (30 ng/ml) being around 71% 6 hours after ethanol incubation alone. Ethanol 68-75 vascular endothelial growth factor A Rattus norvegicus 243-247 18269875-8 2007 Six hours after VEGF (20 - 30 ng/ml) was added into the medium with ethanol (100 mmol/L) the percentage of TUNEL positive SECs decreased in a dose dependent manner (P < 0.05), the level of ethanol-induced apoptotic cells in the presence of VEGF (30 ng/ml) being around 71% 6 hours after ethanol incubation alone. Ethanol 192-199 vascular endothelial growth factor A Rattus norvegicus 16-20 18269875-8 2007 Six hours after VEGF (20 - 30 ng/ml) was added into the medium with ethanol (100 mmol/L) the percentage of TUNEL positive SECs decreased in a dose dependent manner (P < 0.05), the level of ethanol-induced apoptotic cells in the presence of VEGF (30 ng/ml) being around 71% 6 hours after ethanol incubation alone. Ethanol 192-199 vascular endothelial growth factor A Rattus norvegicus 16-20 17827251-0 2007 Early inhaled nitric oxide treatment decreases apoptosis of endothelial cells in neonatal rat lungs after vascular endothelial growth factor inhibition. Nitric Oxide 14-26 vascular endothelial growth factor A Rattus norvegicus 106-140 17711990-5 2007 Inhibition of protein kinase C (PKC)-beta(1) with the specific pharmacological inhibitor LY-333531 or inhibition of PKC-zeta with a cell permeable specific pseudosubstrate peptide also prevented enhanced VEGF expression in high glucose. ruboxistaurin 89-98 vascular endothelial growth factor A Rattus norvegicus 204-208 17711990-5 2007 Inhibition of protein kinase C (PKC)-beta(1) with the specific pharmacological inhibitor LY-333531 or inhibition of PKC-zeta with a cell permeable specific pseudosubstrate peptide also prevented enhanced VEGF expression in high glucose. Glucose 228-235 vascular endothelial growth factor A Rattus norvegicus 204-208 17711990-6 2007 Enhanced VEGF secretion in high glucose was prevented by Tempol, PKC-beta(1), or PKC-zeta inhibition. Glucose 32-39 vascular endothelial growth factor A Rattus norvegicus 9-13 17711990-8 2007 Hypoxia inducible factor-1alpha protein was significantly increased in high glucose only by 24 h, suggesting a possible contribution to high-glucose-stimulated VEGF expression at later time points. Glucose 76-83 vascular endothelial growth factor A Rattus norvegicus 160-164 17711990-8 2007 Hypoxia inducible factor-1alpha protein was significantly increased in high glucose only by 24 h, suggesting a possible contribution to high-glucose-stimulated VEGF expression at later time points. Glucose 141-148 vascular endothelial growth factor A Rattus norvegicus 160-164 17711990-9 2007 Thus reactive oxygen species generated by NADPH oxidase, and both PKC-beta(1) and -zeta, play important roles in high-glucose-stimulated VEGF expression and secretion by mesangial cells. Reactive Oxygen Species 5-28 vascular endothelial growth factor A Rattus norvegicus 137-141 17711990-0 2007 Reactive oxygen species, PKC-beta1, and PKC-zeta mediate high-glucose-induced vascular endothelial growth factor expression in mesangial cells. Reactive Oxygen Species 0-23 vascular endothelial growth factor A Rattus norvegicus 78-112 17711990-0 2007 Reactive oxygen species, PKC-beta1, and PKC-zeta mediate high-glucose-induced vascular endothelial growth factor expression in mesangial cells. Glucose 62-69 vascular endothelial growth factor A Rattus norvegicus 78-112 17711990-2 2007 High ambient glucose present in diabetes stimulates VEGF expression in several cell types, but the molecular mechanisms are incompletely understood. Glucose 13-20 vascular endothelial growth factor A Rattus norvegicus 52-56 17711990-3 2007 Here primary cultured rat mesangial cells served as a model to investigate the signal transduction pathways involved in high-glucose-induced VEGF expression. Glucose 125-132 vascular endothelial growth factor A Rattus norvegicus 141-145 17711990-4 2007 Exposure to high glucose (25 mM) significantly increased VEGF mRNA evaluated by real-time PCR by 3 h, VEGF cellular protein content assessed by immunoblotting or immunofluorescence within 24 h, and VEGF secretion by 24 h. High-glucose-induced VEGF expression was blocked by an antioxidant, Tempol, and antisense oligonucleotides directed against p22(phox), a NADPH oxidase subunit. Glucose 17-24 vascular endothelial growth factor A Rattus norvegicus 57-61 17711990-4 2007 Exposure to high glucose (25 mM) significantly increased VEGF mRNA evaluated by real-time PCR by 3 h, VEGF cellular protein content assessed by immunoblotting or immunofluorescence within 24 h, and VEGF secretion by 24 h. High-glucose-induced VEGF expression was blocked by an antioxidant, Tempol, and antisense oligonucleotides directed against p22(phox), a NADPH oxidase subunit. Glucose 17-24 vascular endothelial growth factor A Rattus norvegicus 102-106 17711990-4 2007 Exposure to high glucose (25 mM) significantly increased VEGF mRNA evaluated by real-time PCR by 3 h, VEGF cellular protein content assessed by immunoblotting or immunofluorescence within 24 h, and VEGF secretion by 24 h. High-glucose-induced VEGF expression was blocked by an antioxidant, Tempol, and antisense oligonucleotides directed against p22(phox), a NADPH oxidase subunit. Glucose 17-24 vascular endothelial growth factor A Rattus norvegicus 102-106 17711990-9 2007 Thus reactive oxygen species generated by NADPH oxidase, and both PKC-beta(1) and -zeta, play important roles in high-glucose-stimulated VEGF expression and secretion by mesangial cells. Glucose 118-125 vascular endothelial growth factor A Rattus norvegicus 137-141 17827251-1 2007 Vascular endothelial growth factor (VEGF) receptor blockade impairs lung growth and decreases nitric oxide (NO) production in neonatal rat lungs. Nitric Oxide 94-106 vascular endothelial growth factor A Rattus norvegicus 0-34 17711990-4 2007 Exposure to high glucose (25 mM) significantly increased VEGF mRNA evaluated by real-time PCR by 3 h, VEGF cellular protein content assessed by immunoblotting or immunofluorescence within 24 h, and VEGF secretion by 24 h. High-glucose-induced VEGF expression was blocked by an antioxidant, Tempol, and antisense oligonucleotides directed against p22(phox), a NADPH oxidase subunit. Glucose 17-24 vascular endothelial growth factor A Rattus norvegicus 102-106 17827251-1 2007 Vascular endothelial growth factor (VEGF) receptor blockade impairs lung growth and decreases nitric oxide (NO) production in neonatal rat lungs. Nitric Oxide 94-106 vascular endothelial growth factor A Rattus norvegicus 36-40 17534579-6 2007 Cisplatin combined with thalidomide caused a significant decrease in vascular endothelial growth factor (VEGF) levels by 73% in intracranial tumors (P < 0.05) and by 50% in subcutaneous tumors (P < 0.05) and caused the level of active hepatic growth factor (a-HGF) to double in both the subcutaneous and intracranial tumors (P < 0.05), suggesting this treatment altered the vasculature in these tumors. Cisplatin 0-9 vascular endothelial growth factor A Rattus norvegicus 69-103 17717296-6 2007 However, combination of atorvastatin and tPA significantly suppressed Egr-1 and VEGF mRNA levels in cerebral endothelial cells. Atorvastatin 24-36 vascular endothelial growth factor A Rattus norvegicus 80-84 17717296-7 2007 CONCLUSIONS: Activation of Akt and downregulation of cerebral endothelial Egr-1 and VEGF gene expression by atorvastatin contribute to the neuroprotective effect of combination treatment with atorvastatin and tPA. Atorvastatin 108-120 vascular endothelial growth factor A Rattus norvegicus 84-88 17717296-7 2007 CONCLUSIONS: Activation of Akt and downregulation of cerebral endothelial Egr-1 and VEGF gene expression by atorvastatin contribute to the neuroprotective effect of combination treatment with atorvastatin and tPA. Atorvastatin 192-204 vascular endothelial growth factor A Rattus norvegicus 84-88 18205103-5 2007 The aim of the study was to determine the in vitro effects of angiotensin peptides (Ang II, Ang III and Ang IV) on the secretion of VEGF in two anterior pituitary adenoma cell cultures: the culture of the rat pituitary lactosomatotrope tumour cell line (GH3) and the primary culture of rat PRL-secreting tumour induced by diethylstilbestrol (DES). Diethylstilbestrol 322-340 vascular endothelial growth factor A Rattus norvegicus 132-136 18205103-5 2007 The aim of the study was to determine the in vitro effects of angiotensin peptides (Ang II, Ang III and Ang IV) on the secretion of VEGF in two anterior pituitary adenoma cell cultures: the culture of the rat pituitary lactosomatotrope tumour cell line (GH3) and the primary culture of rat PRL-secreting tumour induced by diethylstilbestrol (DES). Diethylstilbestrol 342-345 vascular endothelial growth factor A Rattus norvegicus 132-136 18205103-13 2007 The stimulatory influence of Ang II on VEGF secretion in GH3 cell culture was negated by losartan or by PD123319 in both concentrations tested. Losartan 89-97 vascular endothelial growth factor A Rattus norvegicus 39-43 18205103-13 2007 The stimulatory influence of Ang II on VEGF secretion in GH3 cell culture was negated by losartan or by PD123319 in both concentrations tested. PD 123319 104-112 vascular endothelial growth factor A Rattus norvegicus 39-43 18225594-11 2007 RESULTS: Reduced O2 supply promoted expression of HIF-1alpha and VEGF. Oxygen 17-19 vascular endothelial growth factor A Rattus norvegicus 65-69 18084849-6 2007 These results demonstrated that PEDF could inhibit the VEGF-induced vascular hyperpermeability both in vitro and in vivo, and suggest that PEGF may be suitable to be considered as a novel therapeutic agent for various vasopermeable disorders in which VEGF is involved. pegf 139-143 vascular endothelial growth factor A Rattus norvegicus 55-59 18084849-6 2007 These results demonstrated that PEDF could inhibit the VEGF-induced vascular hyperpermeability both in vitro and in vivo, and suggest that PEGF may be suitable to be considered as a novel therapeutic agent for various vasopermeable disorders in which VEGF is involved. pegf 139-143 vascular endothelial growth factor A Rattus norvegicus 251-255 17534579-6 2007 Cisplatin combined with thalidomide caused a significant decrease in vascular endothelial growth factor (VEGF) levels by 73% in intracranial tumors (P < 0.05) and by 50% in subcutaneous tumors (P < 0.05) and caused the level of active hepatic growth factor (a-HGF) to double in both the subcutaneous and intracranial tumors (P < 0.05), suggesting this treatment altered the vasculature in these tumors. Cisplatin 0-9 vascular endothelial growth factor A Rattus norvegicus 105-109 17534579-6 2007 Cisplatin combined with thalidomide caused a significant decrease in vascular endothelial growth factor (VEGF) levels by 73% in intracranial tumors (P < 0.05) and by 50% in subcutaneous tumors (P < 0.05) and caused the level of active hepatic growth factor (a-HGF) to double in both the subcutaneous and intracranial tumors (P < 0.05), suggesting this treatment altered the vasculature in these tumors. Thalidomide 24-35 vascular endothelial growth factor A Rattus norvegicus 69-103 17534579-6 2007 Cisplatin combined with thalidomide caused a significant decrease in vascular endothelial growth factor (VEGF) levels by 73% in intracranial tumors (P < 0.05) and by 50% in subcutaneous tumors (P < 0.05) and caused the level of active hepatic growth factor (a-HGF) to double in both the subcutaneous and intracranial tumors (P < 0.05), suggesting this treatment altered the vasculature in these tumors. Thalidomide 24-35 vascular endothelial growth factor A Rattus norvegicus 105-109 17574386-7 2007 Similarly, acute administration of DDE resulted in a significant increase in immunoreactive VEGF, Flk-1 and IGF-1 in the rat ovary. Dichlorodiphenyl Dichloroethylene 35-38 vascular endothelial growth factor A Rattus norvegicus 92-96 17673547-10 2007 The expression of VEGF in primary rat gastric fibroblasts was increased by PGE2 or AE1-329 (EP4 agonist), and these responses were both attenuated by coadministration of CJ-42794. Dinoprostone 75-79 vascular endothelial growth factor A Rattus norvegicus 18-22 17673547-10 2007 The expression of VEGF in primary rat gastric fibroblasts was increased by PGE2 or AE1-329 (EP4 agonist), and these responses were both attenuated by coadministration of CJ-42794. ae1-329 83-90 vascular endothelial growth factor A Rattus norvegicus 18-22 17431590-0 2007 VEGF isoforms and receptors expression throughout acute acetaminophen-induced liver injury and regeneration. Acetaminophen 56-69 vascular endothelial growth factor A Rattus norvegicus 0-4 17804674-4 2007 Immunohistochemistry showed that sirolimus attenuated the increased expression of renal vascular endothelial growth factor (VEGF), as well as the expression of VEGF receptors 1 and 2. Sirolimus 33-42 vascular endothelial growth factor A Rattus norvegicus 160-164 17943254-0 2007 Prostaglandin E2 stimulates VEGF expression in primary rat gastric fibroblasts through EP4 receptors. Dinoprostone 0-16 vascular endothelial growth factor A Rattus norvegicus 28-32 17943254-2 2007 In addition, prostaglandin E2 (PGE2), derived from cyclooxygenase-2, stimulates VEGF release in gastric fibroblasts. Dinoprostone 13-29 vascular endothelial growth factor A Rattus norvegicus 80-84 17943254-2 2007 In addition, prostaglandin E2 (PGE2), derived from cyclooxygenase-2, stimulates VEGF release in gastric fibroblasts. Dinoprostone 31-35 vascular endothelial growth factor A Rattus norvegicus 80-84 17943254-4 2007 PGE2 stimulated VEGF protein expression in the fibroblasts in a time- and dose-dependent manner. Dinoprostone 0-4 vascular endothelial growth factor A Rattus norvegicus 16-20 17943254-5 2007 The up-regulation by PGE2 of VEGF expression was completely inhibited by a subtype selective EP4 receptor antagonist (AE3-208). Dinoprostone 21-25 vascular endothelial growth factor A Rattus norvegicus 29-33 17943254-7 2007 These results suggest that PGE2 stimulates VEGF expression in gastric fibroblasts through the activation of EP4 receptors, and this effect may be involved in the healing promoting action of PGE2 on gastric ulcers. Dinoprostone 27-31 vascular endothelial growth factor A Rattus norvegicus 43-47 17943254-7 2007 These results suggest that PGE2 stimulates VEGF expression in gastric fibroblasts through the activation of EP4 receptors, and this effect may be involved in the healing promoting action of PGE2 on gastric ulcers. Dinoprostone 190-194 vascular endothelial growth factor A Rattus norvegicus 43-47 17919370-0 2007 Effect of fluvastatin on vascular endothelial growth factor in rats with osteoporosis in process of fracture healing. Fluvastatin 10-21 vascular endothelial growth factor A Rattus norvegicus 25-59 17919370-1 2007 OBJECTIVE: To explore the effect of fluvastatin on vascular endothelial growth factor (VEGF) in rats with osteoporosis in the process of fracture healing. Fluvastatin 36-47 vascular endothelial growth factor A Rattus norvegicus 51-85 17919370-1 2007 OBJECTIVE: To explore the effect of fluvastatin on vascular endothelial growth factor (VEGF) in rats with osteoporosis in the process of fracture healing. Fluvastatin 36-47 vascular endothelial growth factor A Rattus norvegicus 87-91 17919370-7 2007 CONCLUSION: Fluvastatin can promote the VEGF level in rats with osteoporosis in process of fracture healing. Fluvastatin 12-23 vascular endothelial growth factor A Rattus norvegicus 40-44 17804674-5 2007 In conclusion, sirolimus halted the progression of proteinuria and structural damage in a rat model of reduced renal mass, possibly through a reduction in renal VEGF activity. Sirolimus 15-24 vascular endothelial growth factor A Rattus norvegicus 161-165 18396760-0 2007 [The influence of terbutaline on VEGF gene expression in rat astrocytes after norepinephrine and burn serum induction]. Terbutaline 18-29 vascular endothelial growth factor A Rattus norvegicus 33-37 18396760-0 2007 [The influence of terbutaline on VEGF gene expression in rat astrocytes after norepinephrine and burn serum induction]. Norepinephrine 78-92 vascular endothelial growth factor A Rattus norvegicus 33-37 18396760-1 2007 OBJECTIVE: To investigate the influence of adrenoreceptor beta-agonists terbutaline on gene expression of vascular endothelial growth factor (VEGF) in rat astrocyte after induction by norepinephrine (NE) and burn serum. Terbutaline 72-83 vascular endothelial growth factor A Rattus norvegicus 106-140 18396760-1 2007 OBJECTIVE: To investigate the influence of adrenoreceptor beta-agonists terbutaline on gene expression of vascular endothelial growth factor (VEGF) in rat astrocyte after induction by norepinephrine (NE) and burn serum. Terbutaline 72-83 vascular endothelial growth factor A Rattus norvegicus 142-146 18396760-1 2007 OBJECTIVE: To investigate the influence of adrenoreceptor beta-agonists terbutaline on gene expression of vascular endothelial growth factor (VEGF) in rat astrocyte after induction by norepinephrine (NE) and burn serum. Norepinephrine 184-198 vascular endothelial growth factor A Rattus norvegicus 106-140 18396760-1 2007 OBJECTIVE: To investigate the influence of adrenoreceptor beta-agonists terbutaline on gene expression of vascular endothelial growth factor (VEGF) in rat astrocyte after induction by norepinephrine (NE) and burn serum. Norepinephrine 184-198 vascular endothelial growth factor A Rattus norvegicus 142-146 18396760-10 2007 CONCLUSION: Terbutaline can increase gene expression of VEGF in rat astrocytes after induction by NE and burn serum. Terbutaline 12-23 vascular endothelial growth factor A Rattus norvegicus 56-60 17532791-1 2007 Despite 2-methoxyestradiol (2ME2) and tricyclodecan-9-yl-xanthogenate (D609) having multiple effects on cancer cells, mechanistically, both of them down-regulate hypoxia-inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF). 2-Methoxyestradiol 8-26 vascular endothelial growth factor A Rattus norvegicus 211-245 17662242-0 2007 Effect of curcumin on hyperglycemia-induced vascular endothelial growth factor expression in streptozotocin-induced diabetic rat retina. Curcumin 10-18 vascular endothelial growth factor A Rattus norvegicus 44-78 17662242-0 2007 Effect of curcumin on hyperglycemia-induced vascular endothelial growth factor expression in streptozotocin-induced diabetic rat retina. Streptozocin 93-107 vascular endothelial growth factor A Rattus norvegicus 44-78 17662242-4 2007 In this study, we evaluated whether curcumin and its dietary source turmeric can inhibit VEGF expression in strepotzotocin (STZ)-induced diabetic rat retina. Curcumin 36-44 vascular endothelial growth factor A Rattus norvegicus 89-93 17662242-4 2007 In this study, we evaluated whether curcumin and its dietary source turmeric can inhibit VEGF expression in strepotzotocin (STZ)-induced diabetic rat retina. strepotzotocin 108-122 vascular endothelial growth factor A Rattus norvegicus 89-93 17662242-4 2007 In this study, we evaluated whether curcumin and its dietary source turmeric can inhibit VEGF expression in strepotzotocin (STZ)-induced diabetic rat retina. Streptozocin 124-127 vascular endothelial growth factor A Rattus norvegicus 89-93 17662242-11 2007 Notably, feeding of curcumin and turmeric to diabetic rats inhibited expression of VEGF. Curcumin 20-28 vascular endothelial growth factor A Rattus norvegicus 83-87 17586065-5 2007 Here, we show that high VEGF mRNA and protein levels are concomitant with reparative angiogenesis that occurs dramatically during regeneration following acute involution induced by cyclophosphamide (CY) in the rat thymus. Cyclophosphamide 181-197 vascular endothelial growth factor A Rattus norvegicus 24-28 17586065-5 2007 Here, we show that high VEGF mRNA and protein levels are concomitant with reparative angiogenesis that occurs dramatically during regeneration following acute involution induced by cyclophosphamide (CY) in the rat thymus. Cyclophosphamide 199-201 vascular endothelial growth factor A Rattus norvegicus 24-28 17664136-9 2007 Resveratrol produced significant induction of p-AKT, p-eNOS, Trx-1, HO-1, and VEGF in addition to increased activation of MnSOD activity in diabetic animals compared to nondiabetic animals. Resveratrol 0-11 vascular endothelial growth factor A Rattus norvegicus 78-82 17664136-11 2007 In the present study we found that the mechanism(s) responsible for the cardioprotective effect of resveratrol in the diabetic myocardium include upregulation of Trx-1, NO/HO-1, and VEGF in addition to increased MnSOD activity and reduced blood glucose level. Resveratrol 99-110 vascular endothelial growth factor A Rattus norvegicus 182-186 17532791-1 2007 Despite 2-methoxyestradiol (2ME2) and tricyclodecan-9-yl-xanthogenate (D609) having multiple effects on cancer cells, mechanistically, both of them down-regulate hypoxia-inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF). 2-Methoxyestradiol 8-26 vascular endothelial growth factor A Rattus norvegicus 247-251 17532791-1 2007 Despite 2-methoxyestradiol (2ME2) and tricyclodecan-9-yl-xanthogenate (D609) having multiple effects on cancer cells, mechanistically, both of them down-regulate hypoxia-inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF). tricyclodecan-9-yl-xanthogenate 38-69 vascular endothelial growth factor A Rattus norvegicus 211-245 17532791-1 2007 Despite 2-methoxyestradiol (2ME2) and tricyclodecan-9-yl-xanthogenate (D609) having multiple effects on cancer cells, mechanistically, both of them down-regulate hypoxia-inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF). tricyclodecan-9-yl-xanthogenate 38-69 vascular endothelial growth factor A Rattus norvegicus 247-251 17586470-8 2007 HG suppressed CoCl(2)-induced VEGF expression in primary cultures of neonatal cardiomyocytes and MT overexpression suppressed the inhibition. cobaltous chloride 14-21 vascular endothelial growth factor A Rattus norvegicus 30-34 17522264-1 2007 Ruboxistaurin is an inhibitor of the beta isoform of protein kinase C (PKC-beta) that reduces the actions of vascular endothelial growth factor (VEGF) and attenuates the progression of diabetic retinopathy. ruboxistaurin 0-13 vascular endothelial growth factor A Rattus norvegicus 109-143 17706723-1 2007 In this work we investigated the role of nitric oxide (NO) in the angiogenesis mediated by vascular endothelial growth factor (VEGF) during rat liver regeneration after two-thirds partial hepatectomy. Nitric Oxide 41-53 vascular endothelial growth factor A Rattus norvegicus 91-125 17706723-1 2007 In this work we investigated the role of nitric oxide (NO) in the angiogenesis mediated by vascular endothelial growth factor (VEGF) during rat liver regeneration after two-thirds partial hepatectomy. Nitric Oxide 41-53 vascular endothelial growth factor A Rattus norvegicus 127-131 17706723-8 2007 On the other hand, aminoguanidine (AG) pre-treatment blocked the rise of inhibition of NO generation and decreased VEGF expression. pimagedine 19-33 vascular endothelial growth factor A Rattus norvegicus 115-119 17522264-1 2007 Ruboxistaurin is an inhibitor of the beta isoform of protein kinase C (PKC-beta) that reduces the actions of vascular endothelial growth factor (VEGF) and attenuates the progression of diabetic retinopathy. ruboxistaurin 0-13 vascular endothelial growth factor A Rattus norvegicus 145-149 17522264-8 2007 Both cell loss and VEGF overexpression were attenuated by the administration of either perindopril or ruboxistaurin, as single agent treatments with their combination providing additional, incremental improvements, reducing these manifestations of injury down to levels seen in nondiabetic, normotensive, nontransgenic animals. Perindopril 87-98 vascular endothelial growth factor A Rattus norvegicus 19-23 17522264-8 2007 Both cell loss and VEGF overexpression were attenuated by the administration of either perindopril or ruboxistaurin, as single agent treatments with their combination providing additional, incremental improvements, reducing these manifestations of injury down to levels seen in nondiabetic, normotensive, nontransgenic animals. ruboxistaurin 102-115 vascular endothelial growth factor A Rattus norvegicus 19-23 17655877-2 2007 Recently, exogenous administration of aldosterone significantly alleviated ischemic states in a model of femoral artery ligated rats, accompanied by an obvious enhancement of VEGF upregulation. Aldosterone 38-49 vascular endothelial growth factor A Rattus norvegicus 175-179 17410434-3 2007 Acetic acid-induced gastric ulcers healed spontaneously, with up-regulation of COX-2/prostaglandin E2 production as well as expression of vascular endothelium-derived growth factor (VEGF) and basic fibroblast growth factor (bFGF) in ulcerated mucosa. Acetic Acid 0-11 vascular endothelial growth factor A Rattus norvegicus 138-180 17410434-3 2007 Acetic acid-induced gastric ulcers healed spontaneously, with up-regulation of COX-2/prostaglandin E2 production as well as expression of vascular endothelium-derived growth factor (VEGF) and basic fibroblast growth factor (bFGF) in ulcerated mucosa. Acetic Acid 0-11 vascular endothelial growth factor A Rattus norvegicus 182-186 17410434-7 2007 Alendronate as well as indomethacin decreased the protein expression of both VEGF and bFGF in ulcerated mucosa, resulting in a reduction of angiogenesis in the ulcer base. Alendronate 0-11 vascular endothelial growth factor A Rattus norvegicus 77-81 17582234-6 2007 In this connection, administration of exogenous melatonin reduced the tissue concentration of vascular endothelial growth factor (VEGF) and nitric oxide (NO); both were elevated in hypoxic rats. Melatonin 48-57 vascular endothelial growth factor A Rattus norvegicus 94-128 17582234-6 2007 In this connection, administration of exogenous melatonin reduced the tissue concentration of vascular endothelial growth factor (VEGF) and nitric oxide (NO); both were elevated in hypoxic rats. Melatonin 48-57 vascular endothelial growth factor A Rattus norvegicus 130-134 17710629-1 2007 OBJECTIVE: The purpose of this study was to determine whether a high-salt diet modulates physiological angiogenesis in skeletal muscle by altering angiotensin II (ANGII) and vascular endothelial growth factor (VEGF) levels. Salts 69-73 vascular endothelial growth factor A Rattus norvegicus 174-208 17710629-1 2007 OBJECTIVE: The purpose of this study was to determine whether a high-salt diet modulates physiological angiogenesis in skeletal muscle by altering angiotensin II (ANGII) and vascular endothelial growth factor (VEGF) levels. Salts 69-73 vascular endothelial growth factor A Rattus norvegicus 210-214 17410434-7 2007 Alendronate as well as indomethacin decreased the protein expression of both VEGF and bFGF in ulcerated mucosa, resulting in a reduction of angiogenesis in the ulcer base. Indomethacin 23-35 vascular endothelial growth factor A Rattus norvegicus 77-81 17410434-11 2007 These results suggest that alendronate impairs the healing of gastric ulcers in rats, and this effect may be related to down-regulation of VEGF and bFGF, the important growth factors for vascularization/granulation, as well as suppression of the stimulatory action of EGF on epithelial proliferation/migration. Alendronate 27-38 vascular endothelial growth factor A Rattus norvegicus 139-143 17513385-7 2007 VEGF alone significantly increased FITC-dextran permeability and down-regulated mRNA and protein levels of ZO-1 in ARBECs. fluorescein isothiocyanate dextran 35-47 vascular endothelial growth factor A Rattus norvegicus 0-4 17481597-7 2007 RESULTS: Alginate gels were capable of delivering VEGF-A(165) and PDGF-BB in a sustainable manner, and PDGF-BB was released more slowly than VEGF-A(165). Alginates 9-17 vascular endothelial growth factor A Rattus norvegicus 50-56 17623304-9 2007 In CH, proteins of the nitric oxide (Hsc70; p = 0.002), carbon monoxide (biliverdin reductase; p = 0.005), and vascular endothelial growth factor (VEGF) pathway (annexin 3; p<0.001) were significantly increased. annexin 3 162-171 vascular endothelial growth factor A Rattus norvegicus 111-145 17400913-7 2007 17-AAG treatment significantly suppressed the LPS-induced increase in retinal leukocyte adhesion; vascular leakage; NF-kappaB, HIF-1alpha, p38, and PI-3K activity; and VEGF, TNF-alpha, and IL-1beta levels. tanespimycin 0-6 vascular endothelial growth factor A Rattus norvegicus 168-172 17884964-8 2007 NAC and vitamin E significantly reduced the increases in the local production of TNF-alpha and VEGF, and perivascular MPO activity. Acetylcysteine 0-3 vascular endothelial growth factor A Rattus norvegicus 95-99 17884964-8 2007 NAC and vitamin E significantly reduced the increases in the local production of TNF-alpha and VEGF, and perivascular MPO activity. Vitamin E 8-17 vascular endothelial growth factor A Rattus norvegicus 95-99 17369464-4 2007 Treatment with TA-0201 (10(-6) M), an ET(A)-selective blocker, eliminated ET-1-induced overexpression of VEGF and its receptors as well as cardiomyocyte hypertrophy. T 0201 15-22 vascular endothelial growth factor A Rattus norvegicus 105-109 17369464-4 2007 Treatment with TA-0201 (10(-6) M), an ET(A)-selective blocker, eliminated ET-1-induced overexpression of VEGF and its receptors as well as cardiomyocyte hypertrophy. et(a) 38-43 vascular endothelial growth factor A Rattus norvegicus 105-109 17623304-9 2007 In CH, proteins of the nitric oxide (Hsc70; p = 0.002), carbon monoxide (biliverdin reductase; p = 0.005), and vascular endothelial growth factor (VEGF) pathway (annexin 3; p<0.001) were significantly increased. annexin 3 162-171 vascular endothelial growth factor A Rattus norvegicus 147-151 17565644-11 2007 In addition, rofecoxib administration was found to reduce the number of activated HSCs and to downregulate hepatic protein levels of three detected types of collagen, laminin, VEGF and CTGF in CCl(4)-treated rats. rofecoxib 13-22 vascular endothelial growth factor A Rattus norvegicus 176-180 17413127-4 2007 METHODS: Athymic nude rats lacking T cells were treated with a single subcutaneous injection of vascular endothelial growth factor (VEGF) receptor blocker SU5416 (20 mg/kg) to induce pulmonary vascular endothelial cell apoptosis. Semaxinib 155-161 vascular endothelial growth factor A Rattus norvegicus 96-130 17413127-4 2007 METHODS: Athymic nude rats lacking T cells were treated with a single subcutaneous injection of vascular endothelial growth factor (VEGF) receptor blocker SU5416 (20 mg/kg) to induce pulmonary vascular endothelial cell apoptosis. Semaxinib 155-161 vascular endothelial growth factor A Rattus norvegicus 132-136 17418120-9 2007 Gene expression of VEGF, Ccl-2, and ICAM-1 were significantly decreased by pitavastatin administration in experimental CNV. pitavastatin 75-87 vascular endothelial growth factor A Rattus norvegicus 19-23 17953812-6 2007 The purpose of this study was to investigate the expression of VEGF and its receptors in premature lungs of rats with intra-amniotic endotoxin priming and/or exposed to 60% O2 and to elucidate the relationship between intrauterine inflammatory/chronic high O2 exposure and the pathogenesis of BPD. Oxygen 173-175 vascular endothelial growth factor A Rattus norvegicus 63-67 17953812-6 2007 The purpose of this study was to investigate the expression of VEGF and its receptors in premature lungs of rats with intra-amniotic endotoxin priming and/or exposed to 60% O2 and to elucidate the relationship between intrauterine inflammatory/chronic high O2 exposure and the pathogenesis of BPD. Oxygen 257-259 vascular endothelial growth factor A Rattus norvegicus 63-67 17953812-6 2007 The purpose of this study was to investigate the expression of VEGF and its receptors in premature lungs of rats with intra-amniotic endotoxin priming and/or exposed to 60% O2 and to elucidate the relationship between intrauterine inflammatory/chronic high O2 exposure and the pathogenesis of BPD. bpd 293-296 vascular endothelial growth factor A Rattus norvegicus 63-67 17434742-0 2007 Triamcinolone suppresses retinal vascular pathology via a potent interruption of proinflammatory signal-regulated activation of VEGF during a relative hypoxia. Triamcinolone 0-13 vascular endothelial growth factor A Rattus norvegicus 128-132 17434742-1 2007 We examined the effect of triamcinolone acetonide (TA), a corticosteroid, on the relationship between vascular pathophysiology and vascular endothelial growth factor (VEGF) activation in the retina of a rat model of oxygen-induced retinopathy (OIR). Triamcinolone Acetonide 26-49 vascular endothelial growth factor A Rattus norvegicus 131-165 17434742-1 2007 We examined the effect of triamcinolone acetonide (TA), a corticosteroid, on the relationship between vascular pathophysiology and vascular endothelial growth factor (VEGF) activation in the retina of a rat model of oxygen-induced retinopathy (OIR). Triamcinolone Acetonide 26-49 vascular endothelial growth factor A Rattus norvegicus 167-171 17434742-1 2007 We examined the effect of triamcinolone acetonide (TA), a corticosteroid, on the relationship between vascular pathophysiology and vascular endothelial growth factor (VEGF) activation in the retina of a rat model of oxygen-induced retinopathy (OIR). Triamcinolone Acetonide 51-53 vascular endothelial growth factor A Rattus norvegicus 131-165 17434742-1 2007 We examined the effect of triamcinolone acetonide (TA), a corticosteroid, on the relationship between vascular pathophysiology and vascular endothelial growth factor (VEGF) activation in the retina of a rat model of oxygen-induced retinopathy (OIR). Triamcinolone Acetonide 51-53 vascular endothelial growth factor A Rattus norvegicus 167-171 17434742-6 2007 These findings suggest a potential that TA suppresses retinal neovascular pathophysiology via proinflammation-mediated activation of VEGF during hypoxia. Triamcinolone Acetonide 40-42 vascular endothelial growth factor A Rattus norvegicus 133-137 17482424-0 2007 Folic acid supplementation affects ROS scavenging enzymes, enhances Vegf-A, and diminishes apoptotic state in yolk sacs of embryos of diabetic rats. Folic Acid 0-10 vascular endothelial growth factor A Rattus norvegicus 68-74 17285298-7 2007 Consistent with the latter finding, 4-OH TAM caused a dose-dependent suppression of vascular endothelial growth factor (VEGF)-stimulated (10(-9) mol/l) capillarity-like tubule formation by rat aortic endothelial cells in vitro via an estrogen receptor-independent mechanism. 4-oh tam 36-44 vascular endothelial growth factor A Rattus norvegicus 84-118 17285298-7 2007 Consistent with the latter finding, 4-OH TAM caused a dose-dependent suppression of vascular endothelial growth factor (VEGF)-stimulated (10(-9) mol/l) capillarity-like tubule formation by rat aortic endothelial cells in vitro via an estrogen receptor-independent mechanism. 4-oh tam 36-44 vascular endothelial growth factor A Rattus norvegicus 120-124 17623767-6 2007 The endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) expressions were down-regulated (50-55% of control) leading to depletion of aortic NO levels (69% of control) in ethanol treated rats compared to control. Ethanol 204-211 vascular endothelial growth factor A Rattus norvegicus 49-83 17569125-10 2007 RESULTS: Blood glucose and insulin levels in the VEGF group restored to normal 3 d after transplantation. Blood Glucose 9-22 vascular endothelial growth factor A Rattus norvegicus 49-53 17569125-12 2007 IVGTT showed that both the amplitude of blood glucose induction and the kinetics of blood glucose in the VEGF group restored to normal after transplantation. Glucose 90-97 vascular endothelial growth factor A Rattus norvegicus 105-109 17485853-5 2007 The rats fed the homocystine-diet showed an increase in vimentin, glial fibrillary acidic protein (GFAP), and VEGF immunoreactivity in the retina as compared to the controls. Homocystine 17-28 vascular endothelial growth factor A Rattus norvegicus 110-114 17399700-12 2007 These data show that two RTK inhibitors, AG013764 or AG013711, delivered intravitreally, significantly reduce blood vessel proliferation in this AAV-VEGF(165) model of CNV. AG013764 41-49 vascular endothelial growth factor A Rattus norvegicus 149-153 17399700-12 2007 These data show that two RTK inhibitors, AG013764 or AG013711, delivered intravitreally, significantly reduce blood vessel proliferation in this AAV-VEGF(165) model of CNV. AG013711 53-61 vascular endothelial growth factor A Rattus norvegicus 149-153 17623767-6 2007 The endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) expressions were down-regulated (50-55% of control) leading to depletion of aortic NO levels (69% of control) in ethanol treated rats compared to control. Ethanol 204-211 vascular endothelial growth factor A Rattus norvegicus 85-89 17461531-3 2007 We hypothesized that the vascular endothelial growth factor (VEGF) participates in the pathogenesis of diabetic nephropathy and that TZD may be beneficial for the treatment of diabetic nephropathy because of the effect it has on VEGF. 2,4-thiazolidinedione 133-136 vascular endothelial growth factor A Rattus norvegicus 229-233 17384960-12 2007 CONCLUSION: Experimentally, our data show that sirolimus impairs wound healing, and this is reflected by diminished expression of VEGF and nitric oxide in the wound. Sirolimus 47-56 vascular endothelial growth factor A Rattus norvegicus 130-134 17616733-9 2007 Animals treated with disodium cromoglycate showed a decrease in endothelial cell proliferation and in VEGF mRNA expression compared with controls. Cromolyn Sodium 21-42 vascular endothelial growth factor A Rattus norvegicus 102-106 17616733-12 2007 We suggest that cervical angiogenesis during pregnancy could be regulated by a mechanism which involves endogenous E(2) and chemical mediators stored in MC granules via a VEGF-dependent pathway. Estradiol 115-119 vascular endothelial growth factor A Rattus norvegicus 171-175 17537123-6 2007 Flaps treated with VEGF plasmids in the presence of uptake enhancing Lipofectamine transfection reagent increased flap survival 7 days postoperatively significantly associated with markedly elevated tissue perfusion and enhanced tissue VEGF-A protein expression. Lipofectamine 69-82 vascular endothelial growth factor A Rattus norvegicus 19-23 17537123-6 2007 Flaps treated with VEGF plasmids in the presence of uptake enhancing Lipofectamine transfection reagent increased flap survival 7 days postoperatively significantly associated with markedly elevated tissue perfusion and enhanced tissue VEGF-A protein expression. Lipofectamine 69-82 vascular endothelial growth factor A Rattus norvegicus 236-242 17461531-9 2007 CONCLUSION: These results suggest that TZD may have beneficial effects on diabetic nephropathy by reducing the VEGF expression. 2,4-thiazolidinedione 39-42 vascular endothelial growth factor A Rattus norvegicus 111-115 17461531-7 2007 However, there was a significant reduction in both the glomerular VEGF expression and the VEGF mRNA levels after treatment with pioglitazone and rosiglitazone. Pioglitazone 128-140 vascular endothelial growth factor A Rattus norvegicus 66-70 17461531-7 2007 However, there was a significant reduction in both the glomerular VEGF expression and the VEGF mRNA levels after treatment with pioglitazone and rosiglitazone. Pioglitazone 128-140 vascular endothelial growth factor A Rattus norvegicus 90-94 17461531-7 2007 However, there was a significant reduction in both the glomerular VEGF expression and the VEGF mRNA levels after treatment with pioglitazone and rosiglitazone. Rosiglitazone 145-158 vascular endothelial growth factor A Rattus norvegicus 66-70 17461531-7 2007 However, there was a significant reduction in both the glomerular VEGF expression and the VEGF mRNA levels after treatment with pioglitazone and rosiglitazone. Rosiglitazone 145-158 vascular endothelial growth factor A Rattus norvegicus 90-94 17437639-9 2007 Curcumin also inhibited diabetes-induced elevation in the levels of IL-1beta, VEGF and NF-kB. Curcumin 0-8 vascular endothelial growth factor A Rattus norvegicus 78-82 17440080-7 2007 Furthermore, blocking VEGF-mediated signaling by the Flk-1/KDR receptor kinase inhibitor SU5416 significantly inhibited the growth of VR tumors. Semaxinib 89-95 vascular endothelial growth factor A Rattus norvegicus 22-26 17276536-0 2007 Reducible poly(amido ethylenediamine) for hypoxia-inducible VEGF delivery. poly(amido ethylenediamine 10-36 vascular endothelial growth factor A Rattus norvegicus 60-64 17519114-7 2007 The endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) expressions were down-regulated leading to depletion of aortic NO levels in ethanol treated rats compared to control. Ethanol 167-174 vascular endothelial growth factor A Rattus norvegicus 49-83 17519114-7 2007 The endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) expressions were down-regulated leading to depletion of aortic NO levels in ethanol treated rats compared to control. Ethanol 167-174 vascular endothelial growth factor A Rattus norvegicus 85-89 17320132-8 2007 In addition, production of tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and vascular endothelial growth factor (VEGF) production induced by SCF was significantly inhibited by treatment with SC-236. 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide 204-210 vascular endothelial growth factor A Rattus norvegicus 90-124 17320132-8 2007 In addition, production of tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and vascular endothelial growth factor (VEGF) production induced by SCF was significantly inhibited by treatment with SC-236. 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide 204-210 vascular endothelial growth factor A Rattus norvegicus 126-130 17276536-1 2007 Delivery of the hypoxia-inducible vascular endothelial growth factor (RTP-VEGF) plasmid using a novel reducible disulfide poly(amido ethylenediamine) (SS-PAED) polymer carrier was studied in vitro and in vivo. Disulfides 112-121 vascular endothelial growth factor A Rattus norvegicus 74-78 17276536-1 2007 Delivery of the hypoxia-inducible vascular endothelial growth factor (RTP-VEGF) plasmid using a novel reducible disulfide poly(amido ethylenediamine) (SS-PAED) polymer carrier was studied in vitro and in vivo. disulfide poly(amido ethylenediamine) 151-158 vascular endothelial growth factor A Rattus norvegicus 74-78 17276536-8 2007 In conclusion, SS-PAED mediated therapeutic delivery improves the efficacy of ischemia-inducible VEGF gene therapy both in vitro and in vivo and therefore, has potential for the promotion of neo-vascular formation and improvement of tissue function in ischemic myocardium. disulfide poly(amido ethylenediamine) 15-22 vascular endothelial growth factor A Rattus norvegicus 97-101 17526173-0 2007 [Effect of panax quinquefolius saponin on angiogenesis and expressions of VEGF and bFGF in myocardium of rats with acute myocardial infarction]. Saponins 31-38 vascular endothelial growth factor A Rattus norvegicus 74-78 17320065-7 2007 RESULTS: The PPAR-gamma activators troglitazone (TZ) and 15-deoxy-prostaglandin J2 (15J2) induced the expression of VEGF and its receptors (Flt-1 and KDR) in myoFb. Troglitazone 35-47 vascular endothelial growth factor A Rattus norvegicus 116-120 17320065-7 2007 RESULTS: The PPAR-gamma activators troglitazone (TZ) and 15-deoxy-prostaglandin J2 (15J2) induced the expression of VEGF and its receptors (Flt-1 and KDR) in myoFb. Troglitazone 49-51 vascular endothelial growth factor A Rattus norvegicus 116-120 17320065-7 2007 RESULTS: The PPAR-gamma activators troglitazone (TZ) and 15-deoxy-prostaglandin J2 (15J2) induced the expression of VEGF and its receptors (Flt-1 and KDR) in myoFb. 15-deoxyprostaglandin J2 57-82 vascular endothelial growth factor A Rattus norvegicus 116-120 17303121-6 2007 Vitreous fluid and retinal VEGF protein and retinal VEGF mRNA expression were significantly higher in diabetic rats than in control rats, with a significant reduction in fosenopril sodium-treated diabetic rats (p<0.01). FOSINOPRIL SODIUM 170-187 vascular endothelial growth factor A Rattus norvegicus 27-31 17303121-7 2007 There was no significant difference in VEGF levels in diabetic rats and propranolol-treated diabetic rats (p>0.05), but there was a significant difference in VEGF protein and mRNA expression in propranolol-treated diabetic rats and fosenopril sodium-treated diabetic rats (p<0.01) without any significant difference in systolic blood pressure in the latter two groups (p>0.05). Propranolol 197-208 vascular endothelial growth factor A Rattus norvegicus 161-165 17303121-7 2007 There was no significant difference in VEGF levels in diabetic rats and propranolol-treated diabetic rats (p>0.05), but there was a significant difference in VEGF protein and mRNA expression in propranolol-treated diabetic rats and fosenopril sodium-treated diabetic rats (p<0.01) without any significant difference in systolic blood pressure in the latter two groups (p>0.05). FOSINOPRIL SODIUM 235-252 vascular endothelial growth factor A Rattus norvegicus 161-165 17439550-8 2007 Our findings indicate that excess production of VEGF and NO in pineal gland in response to hypoxia may be involved in increased vascular permeability as evidenced by an enhanced leakage of rhodamine isothiocyanate (RhIC). rhodamine isothiocyanate 189-213 vascular endothelial growth factor A Rattus norvegicus 48-52 17439550-10 2007 Administration of exogenous melatonin may be beneficial as it reduced VEGF concentration and NO production significantly in hypoxic rats, and leakage of RhIC was concomitantly reduced. Melatonin 28-37 vascular endothelial growth factor A Rattus norvegicus 70-74 17526173-1 2007 OBJECTIVE: To study the effect of Panax quinquefolius Saponin (PQS), an extraction from stem and leaf of American ginseng, on vascular regeneration in infarcted area, and expressions of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in myocardium of rats with acute myocardial infarction (AMI). Saponins 54-61 vascular endothelial growth factor A Rattus norvegicus 222-226 17292805-12 2007 VEGF and BDNF are proposed as key mediators of DES-induced NPC mitotic response. Diethylstilbestrol 47-50 vascular endothelial growth factor A Rattus norvegicus 0-4 17526173-1 2007 OBJECTIVE: To study the effect of Panax quinquefolius Saponin (PQS), an extraction from stem and leaf of American ginseng, on vascular regeneration in infarcted area, and expressions of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in myocardium of rats with acute myocardial infarction (AMI). Panax quinquefolium saponin 63-66 vascular endothelial growth factor A Rattus norvegicus 222-226 17526173-7 2007 RESULTS: The expressions of VEGF and MMVD were higher in the high and the middle dose PQS groups than those in the model group (P < 0.05) and the expression of bFGF was higher in the three PQS groups than that in the model group (P < 0.05). Panax quinquefolium saponin 86-89 vascular endothelial growth factor A Rattus norvegicus 28-32 17526173-8 2007 CONCLUSION: PQS can protect myocardium from ischemic injury in rats after AMI by way of promoting angiogenesis in the infarcted or ischemic area of myocardium and up-regulating expressions of VEGF and bFGF in myocardial cells. Panax quinquefolium saponin 12-15 vascular endothelial growth factor A Rattus norvegicus 192-196 17286987-0 2007 Nicotine-induced vascular endothelial growth factor release via the EGFR-ERK pathway in rat vascular smooth muscle cells. Nicotine 0-8 vascular endothelial growth factor A Rattus norvegicus 17-51 17286987-3 2007 In the present study, we investigated the effects of nicotine, which is one of the important constituents of cigarette smoke, on vascular endothelial growth factor (VEGF) release, in rat VSMC. Nicotine 53-61 vascular endothelial growth factor A Rattus norvegicus 129-163 17286987-3 2007 In the present study, we investigated the effects of nicotine, which is one of the important constituents of cigarette smoke, on vascular endothelial growth factor (VEGF) release, in rat VSMC. Nicotine 53-61 vascular endothelial growth factor A Rattus norvegicus 165-169 17286987-3 2007 In the present study, we investigated the effects of nicotine, which is one of the important constituents of cigarette smoke, on vascular endothelial growth factor (VEGF) release, in rat VSMC. vsmc 187-191 vascular endothelial growth factor A Rattus norvegicus 129-163 17286987-4 2007 The stimulation of cells with nicotine resulted in a time- and concentration-dependent release of VEGF. Nicotine 30-38 vascular endothelial growth factor A Rattus norvegicus 98-102 17286987-5 2007 Hexamethonium, an antagonist of nicotinic acetylcholine receptor (nAChR), inhibited nicotine-induced VEGF release. Hexamethonium 0-13 vascular endothelial growth factor A Rattus norvegicus 101-105 17286987-5 2007 Hexamethonium, an antagonist of nicotinic acetylcholine receptor (nAChR), inhibited nicotine-induced VEGF release. Nicotine 84-92 vascular endothelial growth factor A Rattus norvegicus 101-105 17286987-6 2007 We next investigated the mechanisms by which nicotine induces VEGF release in the cells. Nicotine 45-53 vascular endothelial growth factor A Rattus norvegicus 62-66 17286987-7 2007 The nicotine-induced VEGF release was inhibited by treatment with U0126, a selective inhibitor of MEK, which attenuated the nicotine-induced ERK phosphorylation. Nicotine 4-12 vascular endothelial growth factor A Rattus norvegicus 21-25 17286987-7 2007 The nicotine-induced VEGF release was inhibited by treatment with U0126, a selective inhibitor of MEK, which attenuated the nicotine-induced ERK phosphorylation. U 0126 66-71 vascular endothelial growth factor A Rattus norvegicus 21-25 17286987-7 2007 The nicotine-induced VEGF release was inhibited by treatment with U0126, a selective inhibitor of MEK, which attenuated the nicotine-induced ERK phosphorylation. Nicotine 124-132 vascular endothelial growth factor A Rattus norvegicus 21-25 17286987-9 2007 Furthermore, AG1478, a selective inhibitor of epidermal growth factor receptor (EGFR) kinase, inhibited nicotine-induced ERK phosphorylation and VEGF release. RTKI cpd 13-19 vascular endothelial growth factor A Rattus norvegicus 145-149 17286987-9 2007 Furthermore, AG1478, a selective inhibitor of epidermal growth factor receptor (EGFR) kinase, inhibited nicotine-induced ERK phosphorylation and VEGF release. Nicotine 104-112 vascular endothelial growth factor A Rattus norvegicus 145-149 17286987-10 2007 These data suggest that nicotine releases VEGF through nAChR in VSMC. Nicotine 24-32 vascular endothelial growth factor A Rattus norvegicus 42-46 17286987-11 2007 Moreover, VEGF release induced by nicotine is mediated by an EGFR-ERK pathway in VSMC. Nicotine 34-42 vascular endothelial growth factor A Rattus norvegicus 10-14 17440234-8 2007 We observed significantly higher mRNA levels for VEGF (1.73-fold), FGF-2 (5.6-fold) and TGFbeta receptor III (2.93-fold), PDGF receptor alpha (2.93-fold) and receptor beta (2.91-fold) in rats receiving indomethacin compared to rats given placebo (p < 0.05). Indomethacin 202-214 vascular endothelial growth factor A Rattus norvegicus 49-53 16725144-4 2007 In in vitro, the inhibition of SHP-1 by SHP-1 siRNA impaired the ability of TNF to block the tyrosine phosphorylation of KDR/flk-1 induced by VEGF and showed an increase in endothelial cell growth. Tyrosine 93-101 vascular endothelial growth factor A Rattus norvegicus 142-146 17327471-2 2007 Copper replenishment in the diet reverses cardiac hypertrophy and restores VEGF expression. Copper 0-6 vascular endothelial growth factor A Rattus norvegicus 75-79 17327471-3 2007 The present study was undertaken to specifically determine the role of VEGF in copper effect on cell hypertrophy. Copper 79-85 vascular endothelial growth factor A Rattus norvegicus 71-75 17327471-6 2007 In the presence of anti-VEGF antibody, copper inhibitory effect on cell hypertrophy was blunted, and VEGF alone mimicked the inhibitory effect of copper. Copper 39-45 vascular endothelial growth factor A Rattus norvegicus 24-28 17327471-6 2007 In the presence of anti-VEGF antibody, copper inhibitory effect on cell hypertrophy was blunted, and VEGF alone mimicked the inhibitory effect of copper. Copper 146-152 vascular endothelial growth factor A Rattus norvegicus 24-28 17327471-6 2007 In the presence of anti-VEGF antibody, copper inhibitory effect on cell hypertrophy was blunted, and VEGF alone mimicked the inhibitory effect of copper. Copper 146-152 vascular endothelial growth factor A Rattus norvegicus 101-105 17327471-7 2007 The results thus demonstrated that VEGF is critically involved in copper inhibition of cell hypertrophy induced by hydrogen peroxide in the H9c2 cells. Copper 66-72 vascular endothelial growth factor A Rattus norvegicus 35-39 17327471-7 2007 The results thus demonstrated that VEGF is critically involved in copper inhibition of cell hypertrophy induced by hydrogen peroxide in the H9c2 cells. Hydrogen Peroxide 115-132 vascular endothelial growth factor A Rattus norvegicus 35-39 17440234-10 2007 Our data indicates that indomethacin may regulate the expression of potent angiogenic factors VEGF and FGF-2. Indomethacin 24-36 vascular endothelial growth factor A Rattus norvegicus 94-98 17312485-0 2007 Rat epigastric flap survival and VEGF expression after local copper application. Copper 61-67 vascular endothelial growth factor A Rattus norvegicus 33-37 16947426-2 2007 It is shown that administration of cloprostenol (0.025 mg/rat) at mid-gestation (day 16) reduced EPU oxygenation, as detected by BOLD contrast MRI, in correlation with induction of vascular endothelial growth factor (VEGF) gene (Vegfa) expression in the corresponding placenta (r = 0.56, p = 0.03). Cloprostenol 35-47 vascular endothelial growth factor A Rattus norvegicus 181-215 17259381-6 2007 All of these abnormalities except NO and VEGF were significantly inhibited by Nepafenac. nepafenac 78-87 vascular endothelial growth factor A Rattus norvegicus 41-45 17038488-6 2007 VEGF secretion rate is determined from the predicted tissue oxygen level through its effect on the hypoxia inducible factor-1alpha transcription factor. Oxygen 60-66 vascular endothelial growth factor A Rattus norvegicus 0-4 16947426-2 2007 It is shown that administration of cloprostenol (0.025 mg/rat) at mid-gestation (day 16) reduced EPU oxygenation, as detected by BOLD contrast MRI, in correlation with induction of vascular endothelial growth factor (VEGF) gene (Vegfa) expression in the corresponding placenta (r = 0.56, p = 0.03). Cloprostenol 35-47 vascular endothelial growth factor A Rattus norvegicus 217-221 16947426-2 2007 It is shown that administration of cloprostenol (0.025 mg/rat) at mid-gestation (day 16) reduced EPU oxygenation, as detected by BOLD contrast MRI, in correlation with induction of vascular endothelial growth factor (VEGF) gene (Vegfa) expression in the corresponding placenta (r = 0.56, p = 0.03). Cloprostenol 35-47 vascular endothelial growth factor A Rattus norvegicus 229-234 16947426-3 2007 Elevated VEGF mRNA expression in response to cloprostenol treatment was also observed at early gestation (day 9) in the forming placenta (p = 0.04) and uterus (p = 0.03). Cloprostenol 45-57 vascular endothelial growth factor A Rattus norvegicus 9-13 17240241-1 2007 OBJECTIVE: We hypothesized that nitric oxide (NO) inhibition has synergistic effects with chronic hypoxia in altering maternal serum levels of soluble fms-like tyrosine kinase 1 (sFlt-1), vascular endothelial growth factor (VEGF), and placental growth factor (PlGF). Nitric Oxide 32-44 vascular endothelial growth factor A Rattus norvegicus 224-228 17257520-6 2007 Avidin-biotin complex immunohistochemistry revealed that GMG cells showed moderate staining for VEGF at the beginning of pregnancy and intense staining on Days 9 and 10 of pregnancy. avidin-biotin 0-13 vascular endothelial growth factor A Rattus norvegicus 96-100 17406120-0 2007 Dexamethasone treatment and ICAM-1 deficiency impair VEGF-induced angiogenesis in adult brain. Dexamethasone 0-13 vascular endothelial growth factor A Rattus norvegicus 53-57 17406120-6 2007 RESULTS: We demonstrate that inhibition of inflammation by treatment with dexamethasone significantly attenuated VEGF-induced pathological angiogenesis. Dexamethasone 74-87 vascular endothelial growth factor A Rattus norvegicus 113-117 17202673-6 2007 Both the aged explant and CML-HSA-treated explant significantly released vascular endothelial growth factor (VEGF), tumor necrosis factor (TNF) alpha and platelet-derived growth factor (PDGF)-B during the culture period. Altretamine 30-33 vascular endothelial growth factor A Rattus norvegicus 73-107 17202673-6 2007 Both the aged explant and CML-HSA-treated explant significantly released vascular endothelial growth factor (VEGF), tumor necrosis factor (TNF) alpha and platelet-derived growth factor (PDGF)-B during the culture period. Altretamine 30-33 vascular endothelial growth factor A Rattus norvegicus 109-113 17261964-11 2007 2-ME and 2-EE did not affect obesity or hypertension and had variable effects on glucose homeostasis, yet they attenuated proteinuria; increased renal blood flow and glomerular filtration; and reduced renal cortical expression of PCNA, NFkappaB, and VEGF. 2-Methoxyestradiol 0-4 vascular endothelial growth factor A Rattus norvegicus 250-254 17261964-11 2007 2-ME and 2-EE did not affect obesity or hypertension and had variable effects on glucose homeostasis, yet they attenuated proteinuria; increased renal blood flow and glomerular filtration; and reduced renal cortical expression of PCNA, NFkappaB, and VEGF. 2-ethoxyestradiol 9-13 vascular endothelial growth factor A Rattus norvegicus 250-254 18204296-3 2007 In the rat cold injury model, the VEGF receptor antagonist VGA1155 significantly reduced the brain water content and the maximum effect was obtained when given at 30 minutes after injury. Water 99-104 vascular endothelial growth factor A Rattus norvegicus 34-38 17257520-6 2007 Avidin-biotin complex immunohistochemistry revealed that GMG cells showed moderate staining for VEGF at the beginning of pregnancy and intense staining on Days 9 and 10 of pregnancy. glucose-mannose-glucose 57-60 vascular endothelial growth factor A Rattus norvegicus 96-100 17349140-16 2007 (2) The expression of VEGF and Flk-1 on the 14(th) day in the oxygen group was significantly stronger than that of the control group (P < 0.05). Oxygen 62-68 vascular endothelial growth factor A Rattus norvegicus 22-26 17622743-0 2007 Coordinated expression of Ets-1, pERK1/2, and VEGF in retina of streptozotocin-induced diabetic rats. Streptozocin 64-78 vascular endothelial growth factor A Rattus norvegicus 46-50 17622743-6 2007 RESULTS: The expression of Ets-1, pERK1/2, and VEGF in the retina increased in a time-dependent manner after STZ injection. Streptozocin 109-112 vascular endothelial growth factor A Rattus norvegicus 47-51 17622743-9 2007 CONCLUSIONS: These results indicate that in the retina of STZ-induced diabetic rats: (1) the alterations of Ets-1, pERK1/2, and VEGF are approximately synchronized; (2) the phosphorylation of ERK1/2 is regulated by the expression of Ets-1; (3) the production of Ets-1 protein is dependent on the ERK1/2 pathway, and (4) the protein level of VEGF is regulated by both Ets-1 expression and ERK1/2 phosphorylation. Streptozocin 58-61 vascular endothelial growth factor A Rattus norvegicus 128-132 17622743-9 2007 CONCLUSIONS: These results indicate that in the retina of STZ-induced diabetic rats: (1) the alterations of Ets-1, pERK1/2, and VEGF are approximately synchronized; (2) the phosphorylation of ERK1/2 is regulated by the expression of Ets-1; (3) the production of Ets-1 protein is dependent on the ERK1/2 pathway, and (4) the protein level of VEGF is regulated by both Ets-1 expression and ERK1/2 phosphorylation. Streptozocin 58-61 vascular endothelial growth factor A Rattus norvegicus 341-345 17349140-17 2007 In the oxygen group, VEGF and Flk-1 expression was the strongest in the retina on the 18(th) day, the result had significant difference as compared with the 14(th) and 25(th) day (P < 0.05), and they were also stronger than that of the control group (P < 0.05). Oxygen 7-13 vascular endothelial growth factor A Rattus norvegicus 21-25 17349140-22 2007 Increased expressions of VEGF and Flk-1 in the oxgen fluctuations-induced neovascularized retina suggested that VEGF and Flk-1 might play a critical role in the pathogenesis of ROP. oxgen 47-52 vascular endothelial growth factor A Rattus norvegicus 25-29 17349140-22 2007 Increased expressions of VEGF and Flk-1 in the oxgen fluctuations-induced neovascularized retina suggested that VEGF and Flk-1 might play a critical role in the pathogenesis of ROP. oxgen 47-52 vascular endothelial growth factor A Rattus norvegicus 112-116 16804104-2 2006 Therefore, we hypothesized that vascular endothelial growth factor (VEGF) administration would prevent the development of salt-sensitive hypertension induced by ANG II. Salts 122-126 vascular endothelial growth factor A Rattus norvegicus 32-66 17046137-10 2006 Posttreatment with erdosteine and NAC significantly reduced the increases in the local production of TNF-alpha and VEGF, and epithelial MPO activity. erdosteine 19-29 vascular endothelial growth factor A Rattus norvegicus 115-119 17046137-10 2006 Posttreatment with erdosteine and NAC significantly reduced the increases in the local production of TNF-alpha and VEGF, and epithelial MPO activity. Acetylcysteine 34-37 vascular endothelial growth factor A Rattus norvegicus 115-119 17046137-11 2006 The effects of NAC on apoptosis, the increases in the local production of TNF-alpha and VEGF, were weaker than the effects of erdosteine. Acetylcysteine 15-18 vascular endothelial growth factor A Rattus norvegicus 88-92 16804104-2 2006 Therefore, we hypothesized that vascular endothelial growth factor (VEGF) administration would prevent the development of salt-sensitive hypertension induced by ANG II. Salts 122-126 vascular endothelial growth factor A Rattus norvegicus 68-72 17016855-8 2006 Western blotting showed a reduction in phosphorylation of one subset of vascular endothelial growth factor (VEGF) receptors in the cRGDfV treatment group. cyclo(arginyl-glycyl-aspartyl-phenylalanyl-valyl) 131-137 vascular endothelial growth factor A Rattus norvegicus 72-106 16959835-9 2006 Overall, this study quantifies the labyrinth zone-specific increases in placental VEGF expression and vascular development during normal pregnancy, and shows that these increases are prevented by maternal dexamethasone treatment. Dexamethasone 205-218 vascular endothelial growth factor A Rattus norvegicus 82-86 16977604-6 2006 Increased VEGF tissue concentration and astrocytic swelling as observed in hypoxic rats were reduced after melatonin administration. Melatonin 107-116 vascular endothelial growth factor A Rattus norvegicus 10-14 16977604-10 2006 To this end, melatonin may be beneficial in reducing edema as it reduced VEGF concentration and, hence, vascular permeability. Melatonin 13-22 vascular endothelial growth factor A Rattus norvegicus 73-77 17016855-8 2006 Western blotting showed a reduction in phosphorylation of one subset of vascular endothelial growth factor (VEGF) receptors in the cRGDfV treatment group. cyclo(arginyl-glycyl-aspartyl-phenylalanyl-valyl) 131-137 vascular endothelial growth factor A Rattus norvegicus 108-112 17016855-10 2006 We conclude that poststroke treatment with cRGDfV reduces blood-brain barrier breakdown in focal ischemia, possibly through inhibition of VEGF-mediated vascular breakdown. cyclo(arginyl-glycyl-aspartyl-phenylalanyl-valyl) 43-49 vascular endothelial growth factor A Rattus norvegicus 138-142 17175256-8 2006 Moreover, genistein significantly inhibited the expression of VEGF and IFN-gamma production (P < .01). Genistein 10-19 vascular endothelial growth factor A Rattus norvegicus 62-66 17088081-9 2006 Western immunoblotting analysis indicated that 2-MeOHE(2) induces a concentration-dependent reduction in the expression of cyclin D1, Bcl-2, and VEGF proteins in both rat and human leiomyoma cell lines. 2-meohe 47-54 vascular endothelial growth factor A Rattus norvegicus 145-149 17175272-7 2006 Tyrosine phosphorylation of the VEGF receptor Flk-1 and the platelet-derived growth factor receptor (PDGF-R) was increased only at 1 hour after reperfusion, while c-Src tyrosine phosphorylation remained increased at 3 hours and remained up to 6 hours after reperfusion. Tyrosine 0-8 vascular endothelial growth factor A Rattus norvegicus 32-36 17175233-12 2006 In CsA-treated allografts moderate VEGF expression was seen already 5 days after transplantation; the expression increased at 90 days after transplantation. Cyclosporine 3-6 vascular endothelial growth factor A Rattus norvegicus 35-39 17175272-8 2006 In conclusion, 1-R led to alterations in protein tyrosine phosphorylation and increased expression of VEGF in rat liver. 1-r 15-18 vascular endothelial growth factor A Rattus norvegicus 102-106 17378159-9 2006 Angiostatin injection significantly reduced VEGF level in the retinas of STZ-diabetic rats but did not affect retinal VEGF level in normal rats. Streptozocin 73-76 vascular endothelial growth factor A Rattus norvegicus 44-48 17302218-1 2006 BACKGROUND: To investigate the long-term effect of insulin on vascular endothelial growth factor (VEGF) of streptozotocin (STZ)-induced diabetic rats. Streptozocin 107-121 vascular endothelial growth factor A Rattus norvegicus 62-96 16782844-3 2006 MCs were isolated from the adult rat uterus and cultured for three studies: 1) Intracellular VEGF levels were measured in MCs cultured with progesterone (10(-11), 10(-9), and 10(-7) M) (n = 6 tests per group). mcs 122-125 vascular endothelial growth factor A Rattus norvegicus 93-97 16782844-3 2006 MCs were isolated from the adult rat uterus and cultured for three studies: 1) Intracellular VEGF levels were measured in MCs cultured with progesterone (10(-11), 10(-9), and 10(-7) M) (n = 6 tests per group). Progesterone 140-152 vascular endothelial growth factor A Rattus norvegicus 93-97 16782844-6 2006 In study 1, cultured MCs expressed VEGF, with levels significantly (P < 0.05) upregulated by progesterone at an optimal dose of 10(-11) M. In study 2, MCs injected into the subcutaneous tissue with matrigel induced significantly more blood vessels, especially large-diameter vessels, than did SMCs or endothelial cells (P < 0.01 for all groups). mcs 21-24 vascular endothelial growth factor A Rattus norvegicus 35-39 16917119-3 2006 METHODS: In fully mismatched rat tracheal allografts, we used imatinib and PTK/ZK, either alone or in combination, to block PDGF and VEGF receptor protein tyrosine kinase (RTK) action, respectively. Imatinib Mesylate 62-70 vascular endothelial growth factor A Rattus norvegicus 133-137 17302218-1 2006 BACKGROUND: To investigate the long-term effect of insulin on vascular endothelial growth factor (VEGF) of streptozotocin (STZ)-induced diabetic rats. Streptozocin 107-121 vascular endothelial growth factor A Rattus norvegicus 98-102 17302218-1 2006 BACKGROUND: To investigate the long-term effect of insulin on vascular endothelial growth factor (VEGF) of streptozotocin (STZ)-induced diabetic rats. Streptozocin 123-126 vascular endothelial growth factor A Rattus norvegicus 62-96 17302218-1 2006 BACKGROUND: To investigate the long-term effect of insulin on vascular endothelial growth factor (VEGF) of streptozotocin (STZ)-induced diabetic rats. Streptozocin 123-126 vascular endothelial growth factor A Rattus norvegicus 98-102 16861242-0 2006 Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy. Everolimus 0-10 vascular endothelial growth factor A Rattus norvegicus 66-70 16901966-0 2006 Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Dopamine 9-17 vascular endothelial growth factor A Rattus norvegicus 48-82 16901966-0 2006 Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Dopamine 9-17 vascular endothelial growth factor A Rattus norvegicus 84-88 17113911-11 2006 Furthermore, upregulation of the ADM gene induced by DHT was inhibited by co-administration with a VEGF-neutralizing antibody. Dihydrotestosterone 53-56 vascular endothelial growth factor A Rattus norvegicus 99-103 17065408-5 2006 VEGFR-1 expressing somatotroph MtT-S cells were used as a model to study the role of VEGF on cell proliferation and to elucidate the underlying mechanism of action. monooxyethylene trimethylolpropane tristearate 31-34 vascular endothelial growth factor A Rattus norvegicus 0-4 17065332-6 2006 Islets from 7- and 12-week-old ZDF rats showed an approximate three- and twofold increase in vascular endothelial growth factor (VEGF)-A mRNA and VEGF protein secretion, respectively, compared with lean controls. zdf 31-34 vascular endothelial growth factor A Rattus norvegicus 93-127 17065332-6 2006 Islets from 7- and 12-week-old ZDF rats showed an approximate three- and twofold increase in vascular endothelial growth factor (VEGF)-A mRNA and VEGF protein secretion, respectively, compared with lean controls. zdf 31-34 vascular endothelial growth factor A Rattus norvegicus 129-133 17065332-6 2006 Islets from 7- and 12-week-old ZDF rats showed an approximate three- and twofold increase in vascular endothelial growth factor (VEGF)-A mRNA and VEGF protein secretion, respectively, compared with lean controls. zdf 31-34 vascular endothelial growth factor A Rattus norvegicus 146-150 17065532-10 2006 Chemical inhibitors of PKC activity blocked the VEGF-induced increase in occludin phosphorylation, as assessed by 2D gel and gel retardation in Western blot analysis, and blocked part of the VEGF-induced monolayer permeability to 70-kDa dextran. Dextrans 237-244 vascular endothelial growth factor A Rattus norvegicus 48-52 17065532-10 2006 Chemical inhibitors of PKC activity blocked the VEGF-induced increase in occludin phosphorylation, as assessed by 2D gel and gel retardation in Western blot analysis, and blocked part of the VEGF-induced monolayer permeability to 70-kDa dextran. Dextrans 237-244 vascular endothelial growth factor A Rattus norvegicus 191-195 17121709-3 2006 The occurrence rate of breast cancer was observed and the effect of celecoxib on COX-2 and vascular endothelial growth factor (VEGF) expressions assayed by immunohistochemical SP method. Celecoxib 68-77 vascular endothelial growth factor A Rattus norvegicus 91-125 17121709-3 2006 The occurrence rate of breast cancer was observed and the effect of celecoxib on COX-2 and vascular endothelial growth factor (VEGF) expressions assayed by immunohistochemical SP method. Celecoxib 68-77 vascular endothelial growth factor A Rattus norvegicus 127-131 17121709-6 2006 The positivity rate of VEGF expression in celecoxib group (42.86%) was significantly lower than that of control group (79.17%, P=0.023), but comparable with that in tamoxifen group (46.15%, P=0.863). Celecoxib 42-51 vascular endothelial growth factor A Rattus norvegicus 23-27 17121709-7 2006 CONCLUSION: Celecoxib can significantly suppress DMBA-induced breast cancer in female rats possibly through down-regulation of COX-2 and VEGF expressions. Celecoxib 12-21 vascular endothelial growth factor A Rattus norvegicus 137-141 17121709-7 2006 CONCLUSION: Celecoxib can significantly suppress DMBA-induced breast cancer in female rats possibly through down-regulation of COX-2 and VEGF expressions. 6,11-dimethylbenzo(b)naphtho(2,3-d)thiophene 49-53 vascular endothelial growth factor A Rattus norvegicus 137-141 17218962-7 2006 Moreover, Tet and silymarin treatments attenuated the mRNA expression levels of TGF-beta1,alpha-SMA, collagen 1alpha2, iNOS, ICAM-1, VEGF, and VEGFR2 genes, and induced the mRNA expression of the metallothionein gene. tetrandrine 10-13 vascular endothelial growth factor A Rattus norvegicus 133-137 17218962-7 2006 Moreover, Tet and silymarin treatments attenuated the mRNA expression levels of TGF-beta1,alpha-SMA, collagen 1alpha2, iNOS, ICAM-1, VEGF, and VEGFR2 genes, and induced the mRNA expression of the metallothionein gene. Silymarin 18-27 vascular endothelial growth factor A Rattus norvegicus 133-137 16859894-0 2006 Differential effects of haloperidol and olanzapine on levels of vascular endothelial growth factor and angiogenesis in rat hippocampus. Haloperidol 24-35 vascular endothelial growth factor A Rattus norvegicus 64-98 16859894-0 2006 Differential effects of haloperidol and olanzapine on levels of vascular endothelial growth factor and angiogenesis in rat hippocampus. Olanzapine 40-50 vascular endothelial growth factor A Rattus norvegicus 64-98 16859894-7 2006 After 14 days of treatment with both haloperidol and olanzapine, the levels of VEGF and angiogenesis were significantly increased (p<0.001 vs vehicle for both), but 45 days of treatment with haloperidol reduced their levels back to levels in vehicle-treated rats. Haloperidol 37-48 vascular endothelial growth factor A Rattus norvegicus 79-83 16859894-4 2006 Therefore, we studied the differential effects of time-dependent treatment (14 and 45 days) with haloperidol and olanzapine (2 and 10 mg/kg/day, respectively, in drinking water) on hippocampal levels of VEGF, its receptor Flk-1, and angiogenesis in adult rat. Haloperidol 97-108 vascular endothelial growth factor A Rattus norvegicus 203-207 16859894-7 2006 After 14 days of treatment with both haloperidol and olanzapine, the levels of VEGF and angiogenesis were significantly increased (p<0.001 vs vehicle for both), but 45 days of treatment with haloperidol reduced their levels back to levels in vehicle-treated rats. Olanzapine 53-63 vascular endothelial growth factor A Rattus norvegicus 79-83 16859894-4 2006 Therefore, we studied the differential effects of time-dependent treatment (14 and 45 days) with haloperidol and olanzapine (2 and 10 mg/kg/day, respectively, in drinking water) on hippocampal levels of VEGF, its receptor Flk-1, and angiogenesis in adult rat. Olanzapine 113-123 vascular endothelial growth factor A Rattus norvegicus 203-207 16859894-7 2006 After 14 days of treatment with both haloperidol and olanzapine, the levels of VEGF and angiogenesis were significantly increased (p<0.001 vs vehicle for both), but 45 days of treatment with haloperidol reduced their levels back to levels in vehicle-treated rats. Haloperidol 194-205 vascular endothelial growth factor A Rattus norvegicus 79-83 17165586-0 2006 [Effects of tetramethylpyrazine on expression of vascular endothelial growth factor and hypoxia-induced factor-1alpha by rat peritoneal macrophages]. tetramethylpyrazine 12-31 vascular endothelial growth factor A Rattus norvegicus 49-83 16859894-8 2006 However, olanzapine treatment further increased VEGF levels (p<0.05 vs levels after 14 days of treatment). Olanzapine 9-19 vascular endothelial growth factor A Rattus norvegicus 48-52 16859894-10 2006 Thus, the data indicate that haloperidol and olanzapine have distinct time-dependent patterns of regulation of VEGF and angiogenesis. Haloperidol 29-40 vascular endothelial growth factor A Rattus norvegicus 111-115 16859894-10 2006 Thus, the data indicate that haloperidol and olanzapine have distinct time-dependent patterns of regulation of VEGF and angiogenesis. Olanzapine 45-55 vascular endothelial growth factor A Rattus norvegicus 111-115 16846617-5 2006 On the other hand, simultaneous treatment of F344 rats with thalidomide for the last 15 days of the experiment attenuated the stimulatory effect of DES on PRL and VEGF secretion. Thalidomide 60-71 vascular endothelial growth factor A Rattus norvegicus 163-167 16846617-5 2006 On the other hand, simultaneous treatment of F344 rats with thalidomide for the last 15 days of the experiment attenuated the stimulatory effect of DES on PRL and VEGF secretion. desacetyluvaricin 148-151 vascular endothelial growth factor A Rattus norvegicus 163-167 16846617-8 2006 In addition, thalidomide (10(-4) to 10(-6) M) inhibited cell proliferation, prolactin and VEGF secretion from rat pituitary prolactinoma cells cultured in vitro. Thalidomide 13-24 vascular endothelial growth factor A Rattus norvegicus 90-94 17165586-1 2006 OBJECTIVE: To investigate the effects of tetramethylpyrazine on lipopolysaccharides (LPS)-induced expression of vascular endothelial growth factor (VEGF) and hypoxia-induced factor-1alpha (HIF-1alpha) in macrophages. tetramethylpyrazine 41-60 vascular endothelial growth factor A Rattus norvegicus 112-146 17165586-1 2006 OBJECTIVE: To investigate the effects of tetramethylpyrazine on lipopolysaccharides (LPS)-induced expression of vascular endothelial growth factor (VEGF) and hypoxia-induced factor-1alpha (HIF-1alpha) in macrophages. tetramethylpyrazine 41-60 vascular endothelial growth factor A Rattus norvegicus 148-152 17165586-5 2006 RESULT: 100 microg x mL(-1) and 10 microg x mL(-1) tetramethylpyrazine decreased the secretion of VEGF and also inhibited the expression of HIF-1alpha by LPS-induced macrophages. tetramethylpyrazine 51-70 vascular endothelial growth factor A Rattus norvegicus 98-102 17165586-7 2006 CONCLUSION: Tetramethylpyrazine could inhibit the secretion of VEGF by LPS-induced macrophages, and the mechanism must be associated with inhibiting the expression of HIF-1alpha. tetramethylpyrazine 12-31 vascular endothelial growth factor A Rattus norvegicus 63-67 17079204-8 2006 As compared with control animals at 9 days after ligation (with 10 rats for each group), rats treated with VEGF had significantly higher maximum rate of left ventricular pressure rise (+ dP/dtmax) or fall ( - dP/dtmax) and microvessel counts, and significantly lower left ventricular end-diastolic pressure (LVEDP) and infarct size. dp 187-189 vascular endothelial growth factor A Rattus norvegicus 107-111 18458396-5 2006 Release of protein trapped in the polymerized PEG was evaluated and VEGF-PEG surfaces were characterized for their ability to support cell growth. Polyethylene Glycols 73-76 vascular endothelial growth factor A Rattus norvegicus 68-72 17079204-8 2006 As compared with control animals at 9 days after ligation (with 10 rats for each group), rats treated with VEGF had significantly higher maximum rate of left ventricular pressure rise (+ dP/dtmax) or fall ( - dP/dtmax) and microvessel counts, and significantly lower left ventricular end-diastolic pressure (LVEDP) and infarct size. dtmax 190-195 vascular endothelial growth factor A Rattus norvegicus 107-111 17079204-8 2006 As compared with control animals at 9 days after ligation (with 10 rats for each group), rats treated with VEGF had significantly higher maximum rate of left ventricular pressure rise (+ dP/dtmax) or fall ( - dP/dtmax) and microvessel counts, and significantly lower left ventricular end-diastolic pressure (LVEDP) and infarct size. dp 209-211 vascular endothelial growth factor A Rattus norvegicus 107-111 17079204-8 2006 As compared with control animals at 9 days after ligation (with 10 rats for each group), rats treated with VEGF had significantly higher maximum rate of left ventricular pressure rise (+ dP/dtmax) or fall ( - dP/dtmax) and microvessel counts, and significantly lower left ventricular end-diastolic pressure (LVEDP) and infarct size. dtmax 212-217 vascular endothelial growth factor A Rattus norvegicus 107-111 17079204-9 2006 At 16 days after surgery (12, 7 and 9 rats in sham, control and treated groups; respectively), VEGF treatment significantly increased mean arterial pressure (MAP), left ventricular systolic pressure (LVSP), +/- dP/dtmax and microvessel counts, and significantly decreased LVEDP and infarct size. dp 211-213 vascular endothelial growth factor A Rattus norvegicus 95-99 17079204-9 2006 At 16 days after surgery (12, 7 and 9 rats in sham, control and treated groups; respectively), VEGF treatment significantly increased mean arterial pressure (MAP), left ventricular systolic pressure (LVSP), +/- dP/dtmax and microvessel counts, and significantly decreased LVEDP and infarct size. dtmax 214-219 vascular endothelial growth factor A Rattus norvegicus 95-99 16574985-7 2006 HAL induced in BDL rats 1) the disappearance of the PBP, 2) increased apoptosis and impaired cholangiocyte proliferation and secretin-stimulated ductal secretion, and 3) decreased cholangiocyte VEGF secretion. hal 0-3 vascular endothelial growth factor A Rattus norvegicus 194-198 16971894-6 2006 IPE cells grown on AMs had a greater upregulation in the expression of genes important for the function of differentiated RPE cells (e.g., pigment epithelium-derived factor [PEDF], RPE65, bestrophin, VEGF, and BDNF) than IPE cells grown on plastic plates. ipe 0-3 vascular endothelial growth factor A Rattus norvegicus 200-204 16574985-8 2006 The effects of HAL on the PBP and cholangiocyte functions were prevented by r-VEGF-A, which, by maintaining the integrity of the PBP and cholangiocyte proliferation, prevents damage of bile ducts following ischemic injury. hal 15-18 vascular endothelial growth factor A Rattus norvegicus 78-82 16574985-8 2006 The effects of HAL on the PBP and cholangiocyte functions were prevented by r-VEGF-A, which, by maintaining the integrity of the PBP and cholangiocyte proliferation, prevents damage of bile ducts following ischemic injury. Monobenzone 26-29 vascular endothelial growth factor A Rattus norvegicus 78-82 16707486-0 2006 Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. Reactive Oxygen Species 129-152 vascular endothelial growth factor A Rattus norvegicus 162-196 16861403-0 2006 Extracellular signal-regulated kinases trigger isoflurane preconditioning concomitant with upregulation of hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression in rats. Isoflurane 47-57 vascular endothelial growth factor A Rattus norvegicus 143-177 16861403-2 2006 We tested the hypothesis that isoflurane preconditioning is triggered by Erk1/2 concomitant with upregulation of hypoxia-inducible factor 1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) expression in rats instrumented for hemodynamic measurement and subjected to a 30-min coronary artery occlusion and 2-h reperfusion. Isoflurane 30-40 vascular endothelial growth factor A Rattus norvegicus 162-196 16861403-2 2006 We tested the hypothesis that isoflurane preconditioning is triggered by Erk1/2 concomitant with upregulation of hypoxia-inducible factor 1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) expression in rats instrumented for hemodynamic measurement and subjected to a 30-min coronary artery occlusion and 2-h reperfusion. Isoflurane 30-40 vascular endothelial growth factor A Rattus norvegicus 198-202 16861403-8 2006 Isoflurane-induced increases in phospho-Erk1/2, HIF-1alpha, and VEGF expression were also inhibited by PD 098059 pretreatment. Isoflurane 0-10 vascular endothelial growth factor A Rattus norvegicus 64-68 16861403-9 2006 CONCLUSIONS: The results indicate that Erk1/2 triggers isoflurane preconditioning concomitant with HIF-1alpha and VEGF upregulation in vivo. Isoflurane 55-65 vascular endothelial growth factor A Rattus norvegicus 114-118 16707486-5 2006 Simultaneous treatments with PEDF inhibited the AGE-elicited VEGF-mediated permeability by down-regulating mRNA levels of p22(phox) and gp91(phox), membrane components of NADPH oxidase, and subsequently decreasing retinal levels of an oxidative stress marker, 8-hydroxydeoxyguanosine. 8-ohdg 260-283 vascular endothelial growth factor A Rattus norvegicus 61-65 16712976-4 2006 This study was designed to study the effect of hypertension on serum Nitric Oxide (NO) and Vascular Endothelial Growth Factor (VEGF) concentrations in DOCA-Salt hypertensive ovariectomized rats. Salts 156-160 vascular endothelial growth factor A Rattus norvegicus 127-131 16461370-7 2006 Injection of the NOS inhibitor Nomega-nitro-L-arginine (15 mg/kg im), but not the cyclooxygenase inhibitor indomethacin (5 mg/kg im), 45 min preoperatively completely abolished the increase in skin flap blood flow and viability induced by Ad.VEGF-165 injected subdermally into the mapped skin flap 7 days preoperatively. Nitroarginine 31-54 vascular endothelial growth factor A Rattus norvegicus 242-246 16814127-7 2006 Immunoreactivity of VEGF and Ang1 in cortical tubules was increased by ang II and was attenuated by losartan or PD123319. Losartan 100-108 vascular endothelial growth factor A Rattus norvegicus 20-24 16814127-7 2006 Immunoreactivity of VEGF and Ang1 in cortical tubules was increased by ang II and was attenuated by losartan or PD123319. PD 123319 112-120 vascular endothelial growth factor A Rattus norvegicus 20-24 16814127-8 2006 The increase of VEGF induced by ang II was suppressed by losartan, and the increase of Ang1 induced by ang II was inhibited by PD123319 as detected by immunoblot. Losartan 57-65 vascular endothelial growth factor A Rattus norvegicus 16-20 16814127-9 2006 The increase of flk-1 and flt-1 (VEGF receptors) and tie-2 (Ang1 receptor) induced by ang II was significantly suppressed by PD123319. PD 123319 125-133 vascular endothelial growth factor A Rattus norvegicus 33-37 16799050-0 2006 Comparative effects of early postnatal ibuprofen and indomethacin on VEGF, IGF-I, and GH during rat ocular development. Indomethacin 53-65 vascular endothelial growth factor A Rattus norvegicus 69-73 16672722-8 2006 The VEGFA signaling inhibitors SU1498 (40 microM) and VEGFR-TKI (8 microM) inhibited cord formation in E13 testis cultures with 90% reduced vascular density (P<0.01) in VEGFR-TKI-treated organs. SU 1498 31-37 vascular endothelial growth factor A Rattus norvegicus 4-9 16672722-9 2006 Furthermore, Je-11 (10 microM), an antagonist to VEGFA, also perturbed cord formation and inhibited vascular density by more than 50% (P<0.01). je-11 13-18 vascular endothelial growth factor A Rattus norvegicus 49-54 16672722-10 2006 To determine signal transduction pathways involved in VEGFA"s regulation of testis morphogenesis, E13 testis were treated with LY 294002 (15 microM), a phosphoinositide 3-kinase (PI3K) pathway inhibitor, resulting in inhibition of both vascular density (46%) and cord formation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 127-136 vascular endothelial growth factor A Rattus norvegicus 54-59 16799050-9 2006 High-dose ibuprofen decreased retinal VEGF levels and retinal VEGF164, VEGF120, and VEGFR-2 transcripts, resulting in a significant increase in the cecal period in 87% of rats at P14. Ibuprofen 10-19 vascular endothelial growth factor A Rattus norvegicus 38-42 16799050-9 2006 High-dose ibuprofen decreased retinal VEGF levels and retinal VEGF164, VEGF120, and VEGFR-2 transcripts, resulting in a significant increase in the cecal period in 87% of rats at P14. Ibuprofen 10-19 vascular endothelial growth factor A Rattus norvegicus 62-69 16799050-10 2006 Both indomethacin doses suppressed retinal VEGF164 transcripts without affecting VEGF receptors. Indomethacin 5-17 vascular endothelial growth factor A Rattus norvegicus 43-50 16799050-10 2006 Both indomethacin doses suppressed retinal VEGF164 transcripts without affecting VEGF receptors. Indomethacin 5-17 vascular endothelial growth factor A Rattus norvegicus 43-47 16799050-11 2006 CONCLUSIONS: Ibuprofen may be more effective than indomethacin for suppression of retinal VEGF signaling, suggesting a possible therapy for retinal neovascularization. Ibuprofen 13-22 vascular endothelial growth factor A Rattus norvegicus 90-94 16799050-11 2006 CONCLUSIONS: Ibuprofen may be more effective than indomethacin for suppression of retinal VEGF signaling, suggesting a possible therapy for retinal neovascularization. Indomethacin 50-62 vascular endothelial growth factor A Rattus norvegicus 90-94 16513203-8 2006 The PCNA positive SEC, in contrast, was significantly increased in the hyperbaric oxygen group at 48h, furthermore, the hyperbaric oxygen treatment significantly increased the expression of VEGF protein in the regenerating liver at 24 and 48 h. CONCLUSIONS: Hyperbaric oxygen treatment can be considered as a therapeutic modality after massive PH. Oxygen 131-137 vascular endothelial growth factor A Rattus norvegicus 190-194 16909610-5 2006 The score of VEGF exhibited marked difference between Tamoxifen group and Alarelin (GnRHa) group, between Tamoxifen group and Tamoxifen plus Rhizoma curcumae oil group (P < 0.05). Tamoxifen 54-63 vascular endothelial growth factor A Rattus norvegicus 13-17 16513203-0 2006 Hyperbaric oxygen induces vascular endothelial growth factor and reduces liver injury in regenerating rat liver after partial hepatectomy. Oxygen 11-17 vascular endothelial growth factor A Rattus norvegicus 26-60 16513203-8 2006 The PCNA positive SEC, in contrast, was significantly increased in the hyperbaric oxygen group at 48h, furthermore, the hyperbaric oxygen treatment significantly increased the expression of VEGF protein in the regenerating liver at 24 and 48 h. CONCLUSIONS: Hyperbaric oxygen treatment can be considered as a therapeutic modality after massive PH. Oxygen 82-88 vascular endothelial growth factor A Rattus norvegicus 190-194 16513203-8 2006 The PCNA positive SEC, in contrast, was significantly increased in the hyperbaric oxygen group at 48h, furthermore, the hyperbaric oxygen treatment significantly increased the expression of VEGF protein in the regenerating liver at 24 and 48 h. CONCLUSIONS: Hyperbaric oxygen treatment can be considered as a therapeutic modality after massive PH. Oxygen 131-137 vascular endothelial growth factor A Rattus norvegicus 190-194 16909610-5 2006 The score of VEGF exhibited marked difference between Tamoxifen group and Alarelin (GnRHa) group, between Tamoxifen group and Tamoxifen plus Rhizoma curcumae oil group (P < 0.05). gnrha 84-89 vascular endothelial growth factor A Rattus norvegicus 13-17 16741177-7 2006 CONCLUSIONS: The selective integrin alphavbeta3 inhibitor cRGDfV improves outcomes in the MCAO model by preserving the blood-brain barrier, which mechanistically may occur in a VEGF- and VEGF-receptor-dependent manner. cyclo(arginyl-glycyl-aspartyl-phenylalanyl-valyl) 58-64 vascular endothelial growth factor A Rattus norvegicus 177-181 16741177-7 2006 CONCLUSIONS: The selective integrin alphavbeta3 inhibitor cRGDfV improves outcomes in the MCAO model by preserving the blood-brain barrier, which mechanistically may occur in a VEGF- and VEGF-receptor-dependent manner. cyclo(arginyl-glycyl-aspartyl-phenylalanyl-valyl) 58-64 vascular endothelial growth factor A Rattus norvegicus 187-191 16909610-5 2006 The score of VEGF exhibited marked difference between Tamoxifen group and Alarelin (GnRHa) group, between Tamoxifen group and Tamoxifen plus Rhizoma curcumae oil group (P < 0.05). Tamoxifen 106-115 vascular endothelial growth factor A Rattus norvegicus 13-17 16909610-5 2006 The score of VEGF exhibited marked difference between Tamoxifen group and Alarelin (GnRHa) group, between Tamoxifen group and Tamoxifen plus Rhizoma curcumae oil group (P < 0.05). rhizoma curcumae oil 141-161 vascular endothelial growth factor A Rattus norvegicus 13-17 16909610-6 2006 CONCLUSION: Tamoxifen in conjunction with Rhizoma curcumae oil could decrease markedly the volume and VEGF expression of ectopic implants. Tamoxifen 12-21 vascular endothelial growth factor A Rattus norvegicus 102-106 16484680-7 2006 Cysteamine induced phosphorylation of ERK1/2 and enhanced the synthesis of bFGF, PDGF, and VEGF in the preulcerogenic stages of duodenal ulceration, whereas egr-1 antisense oligonucleotide markedly decreased the expression of these growth factors in the duodenal mucosa. Cysteamine 0-10 vascular endothelial growth factor A Rattus norvegicus 91-95 16731852-5 2006 Importantly, single and repeat intramuscular injections of formulated plasmid DNA encoding the VEGF-A-activating ZFP-TF resulted in protection of both sensory and motor nerve conduction velocities in a streptozotocin-induced rat model of diabetes. Streptozocin 202-216 vascular endothelial growth factor A Rattus norvegicus 95-101 16734388-6 2006 The aim of this study was to determine if delivery of vascular endothelial growth factor (VEGF) from a biodegradable PLGA (copolymer of D,L-lactide and glycolide) scaffold could enhance neovascularization and bone regeneration in irradiated osseous defects. L-Lactide 138-147 vascular endothelial growth factor A Rattus norvegicus 54-88 16741055-0 2006 Effect of endothelin dual receptor antagonist on VEGF levels in streptozotocin-induced diabetic rat retina. Streptozocin 64-78 vascular endothelial growth factor A Rattus norvegicus 49-53 16741055-7 2006 The present study investigated the effect of ET(A/B) dual receptor antagonist (SB209670; 1 mg/rat/day) on the expression of VEGF and ICAM-1 in the diabetic rat retina. 1H-Indene-2-carboxylic acid, 1-(1,3-benzodioxol-5-yl)-3-(2- (carboxymethoxy)-4-methoxyphenyl)-2,3-dihydro-5-propoxy-, (1S,2R,3S)- 79-87 vascular endothelial growth factor A Rattus norvegicus 124-128 16741055-11 2006 In DM+vehicle group, the VEGF expression of the retinas was significantly increased (32.8 pg/mg) in comparison to that in the non-DM control group (26.2 pg/mg); this upregulation of VEGF was reversed in the DM+SB209670 group (28.6 pg/mg). 1H-Indene-2-carboxylic acid, 1-(1,3-benzodioxol-5-yl)-3-(2- (carboxymethoxy)-4-methoxyphenyl)-2,3-dihydro-5-propoxy-, (1S,2R,3S)- 210-218 vascular endothelial growth factor A Rattus norvegicus 25-29 16741055-11 2006 In DM+vehicle group, the VEGF expression of the retinas was significantly increased (32.8 pg/mg) in comparison to that in the non-DM control group (26.2 pg/mg); this upregulation of VEGF was reversed in the DM+SB209670 group (28.6 pg/mg). 1H-Indene-2-carboxylic acid, 1-(1,3-benzodioxol-5-yl)-3-(2- (carboxymethoxy)-4-methoxyphenyl)-2,3-dihydro-5-propoxy-, (1S,2R,3S)- 210-218 vascular endothelial growth factor A Rattus norvegicus 182-186 16763470-18 2006 The animals treated with TAE showed a statistically significant increase in VEGF levels compared with the control group. tae 25-28 vascular endothelial growth factor A Rattus norvegicus 76-80 16651724-10 2006 The mechanism may be that puerarin can induce VEGF and eNOS expression. puerarin 26-34 vascular endothelial growth factor A Rattus norvegicus 46-50 16734388-6 2006 The aim of this study was to determine if delivery of vascular endothelial growth factor (VEGF) from a biodegradable PLGA (copolymer of D,L-lactide and glycolide) scaffold could enhance neovascularization and bone regeneration in irradiated osseous defects. copolymer 123-132 vascular endothelial growth factor A Rattus norvegicus 54-88 16734388-6 2006 The aim of this study was to determine if delivery of vascular endothelial growth factor (VEGF) from a biodegradable PLGA (copolymer of D,L-lactide and glycolide) scaffold could enhance neovascularization and bone regeneration in irradiated osseous defects. copolymer 123-132 vascular endothelial growth factor A Rattus norvegicus 90-94 16734388-6 2006 The aim of this study was to determine if delivery of vascular endothelial growth factor (VEGF) from a biodegradable PLGA (copolymer of D,L-lactide and glycolide) scaffold could enhance neovascularization and bone regeneration in irradiated osseous defects. Deuterium 136-137 vascular endothelial growth factor A Rattus norvegicus 54-88 16734388-6 2006 The aim of this study was to determine if delivery of vascular endothelial growth factor (VEGF) from a biodegradable PLGA (copolymer of D,L-lactide and glycolide) scaffold could enhance neovascularization and bone regeneration in irradiated osseous defects. Deuterium 136-137 vascular endothelial growth factor A Rattus norvegicus 90-94 16741021-0 2006 Differential effects of selective endothelin type a receptor antagonist on the gene expression of vascular endothelial growth factor and its receptors in streptozotocin-induced diabetic heart. Streptozocin 154-168 vascular endothelial growth factor A Rattus norvegicus 98-132 16734388-6 2006 The aim of this study was to determine if delivery of vascular endothelial growth factor (VEGF) from a biodegradable PLGA (copolymer of D,L-lactide and glycolide) scaffold could enhance neovascularization and bone regeneration in irradiated osseous defects. L-Lactide 138-147 vascular endothelial growth factor A Rattus norvegicus 90-94 16734388-6 2006 The aim of this study was to determine if delivery of vascular endothelial growth factor (VEGF) from a biodegradable PLGA (copolymer of D,L-lactide and glycolide) scaffold could enhance neovascularization and bone regeneration in irradiated osseous defects. 1,4-Dioxane-2,5-dione 152-161 vascular endothelial growth factor A Rattus norvegicus 54-88 16734388-6 2006 The aim of this study was to determine if delivery of vascular endothelial growth factor (VEGF) from a biodegradable PLGA (copolymer of D,L-lactide and glycolide) scaffold could enhance neovascularization and bone regeneration in irradiated osseous defects. 1,4-Dioxane-2,5-dione 152-161 vascular endothelial growth factor A Rattus norvegicus 90-94 16735948-12 2006 The results suggest that there are quantitative differences in VEGF expression in these tissues depending on steroid hormone status. Steroids 109-124 vascular endothelial growth factor A Rattus norvegicus 63-67 16722033-12 2006 In the 20-mmol/L MGO-treated rats, loss of body weight, expression of VEGF, thickening of the peritoneum, and formation of abdominal cocoon were induced. Pyruvaldehyde 17-20 vascular endothelial growth factor A Rattus norvegicus 70-74 16597689-0 2006 High glucose blunts vascular endothelial growth factor response to hypoxia via the oxidative stress-regulated hypoxia-inducible factor/hypoxia-responsible element pathway. Glucose 5-12 vascular endothelial growth factor A Rattus norvegicus 20-54 16716015-9 2006 The amount of extravasated Evans blue in rat ligated hindlimb muscle (7 days after treatment) treated with both AngI and VEGF was significantly less compared with that in the rats transfected with VEGF alone (P < 0.01). Evans Blue 27-37 vascular endothelial growth factor A Rattus norvegicus 121-125 16597689-2 2006 High glucose regulates certain aspects of VEGF expression in various cell types, including proximal tubular cells. Glucose 5-12 vascular endothelial growth factor A Rattus norvegicus 42-46 16597689-8 2006 This response was significantly blunted by high d-glucose (1.98 +/- 0.11- versus 2.65 +/- 0.27-fold increase for VEGF mRNA expression, 252.8 +/- 14.7 versus 324.0 +/- 11.5 pg/10(5) cells for VEGF protein; P < 0.05 both) but not by high l-glucose. Glucose 48-57 vascular endothelial growth factor A Rattus norvegicus 113-117 16597689-8 2006 This response was significantly blunted by high d-glucose (1.98 +/- 0.11- versus 2.65 +/- 0.27-fold increase for VEGF mRNA expression, 252.8 +/- 14.7 versus 324.0 +/- 11.5 pg/10(5) cells for VEGF protein; P < 0.05 both) but not by high l-glucose. Glucose 48-57 vascular endothelial growth factor A Rattus norvegicus 191-195 16597689-8 2006 This response was significantly blunted by high d-glucose (1.98 +/- 0.11- versus 2.65 +/- 0.27-fold increase for VEGF mRNA expression, 252.8 +/- 14.7 versus 324.0 +/- 11.5 pg/10(5) cells for VEGF protein; P < 0.05 both) but not by high l-glucose. Glucose 239-248 vascular endothelial growth factor A Rattus norvegicus 113-117 16597689-9 2006 It is interesting that hydrogen peroxide also blunted this response, whereas alpha-tocopherol restored the VEGF response to hypoxia in the presence of high d-glucose. alpha-Tocopherol 77-93 vascular endothelial growth factor A Rattus norvegicus 107-111 16597689-9 2006 It is interesting that hydrogen peroxide also blunted this response, whereas alpha-tocopherol restored the VEGF response to hypoxia in the presence of high d-glucose. Glucose 156-165 vascular endothelial growth factor A Rattus norvegicus 107-111 16597689-14 2006 In conclusion, high glucose blunts VEGF response to hypoxia in IRPTC. Glucose 20-27 vascular endothelial growth factor A Rattus norvegicus 35-39 16757304-8 2006 CONCLUSION: Our results suggest that administration of exogenous VEGF protects the liver from CCl(4)-induced acute hepatic failure. Cefaclor 94-97 vascular endothelial growth factor A Rattus norvegicus 65-69 16762237-10 2006 Morphometric analysis and immunohistochemistry demonstrated rAAV-mediated antisense VEGF(165) significantly inhibited CNV. raav 60-64 vascular endothelial growth factor A Rattus norvegicus 84-88 16618418-1 2006 BACKGROUND & AIMS: Vascular endothelial growth factor (VEGF) is secreted by several epithelia and modulates cellular functions by autocrine and paracrine mechanisms. Adenosine Monophosphate 12-15 vascular endothelial growth factor A Rattus norvegicus 23-57 16539626-0 2006 Rapamycin attenuates liver graft injury in cirrhotic recipient--the significance of down-regulation of Rho-ROCK-VEGF pathway. Sirolimus 0-9 vascular endothelial growth factor A Rattus norvegicus 112-116 16539626-10 2006 In conclusion, rapamycin attenuated graft injury in a cirrhotic rat liver transplantation model by suppression of hepatic stellate cell activation, related to down-regulation of Rho-ROCK-VEGF pathway. Sirolimus 15-24 vascular endothelial growth factor A Rattus norvegicus 187-191 16411082-1 2006 Techniques involving fluorescein-5-isothiocyanate-conjugated gelatin injection, immunohistochemistry, and in situ reverse transcription/polymerase chain reaction (RT-PCR) revealed a close relationship between vascular endothelial growth factor (VEGF)-A-expressing cells and microvessels in the hypothalamic-pituitary axis of the rat. Fluorescein-5-isothiocyanate 21-49 vascular endothelial growth factor A Rattus norvegicus 209-243 16496123-10 2006 Both the reduction in plasma nitrate and nitrite and the elevation in aortic superoxide associated with STZ diabetes were normalised with VEGF treatment. Nitrates 29-36 vascular endothelial growth factor A Rattus norvegicus 138-142 16496123-10 2006 Both the reduction in plasma nitrate and nitrite and the elevation in aortic superoxide associated with STZ diabetes were normalised with VEGF treatment. Nitrites 41-48 vascular endothelial growth factor A Rattus norvegicus 138-142 16496123-10 2006 Both the reduction in plasma nitrate and nitrite and the elevation in aortic superoxide associated with STZ diabetes were normalised with VEGF treatment. Superoxides 77-87 vascular endothelial growth factor A Rattus norvegicus 138-142 16496123-10 2006 Both the reduction in plasma nitrate and nitrite and the elevation in aortic superoxide associated with STZ diabetes were normalised with VEGF treatment. Streptozocin 104-107 vascular endothelial growth factor A Rattus norvegicus 138-142 16496123-11 2006 VEGF also prevented the apparent paradoxical increased endothelial nitric oxide synthase expression seen in untreated STZ rats. Streptozocin 118-121 vascular endothelial growth factor A Rattus norvegicus 0-4 16496123-12 2006 CONCLUSIONS/INTERPRETATION: Chronic treatment with VEGF early in diabetes is able to prevent the attenuated agonist-evoked vascular responses in STZ rats and normalise the oxidative environment associated with the disease. Streptozocin 145-148 vascular endothelial growth factor A Rattus norvegicus 51-55 16496123-0 2006 Chronic treatment with vascular endothelial growth factor preserves agonist-evoked vascular responses in the streptozotocin-induced diabetic rat. Streptozocin 109-123 vascular endothelial growth factor A Rattus norvegicus 23-57 16496123-3 2006 We sought to determine whether vascular endothelial growth factor (VEGF) could prevent dysfunction from developing in the streptozotocin (STZ)-induced rat model of type 1 diabetes. Streptozocin 122-136 vascular endothelial growth factor A Rattus norvegicus 31-65 16496123-3 2006 We sought to determine whether vascular endothelial growth factor (VEGF) could prevent dysfunction from developing in the streptozotocin (STZ)-induced rat model of type 1 diabetes. Streptozocin 122-136 vascular endothelial growth factor A Rattus norvegicus 67-71 16496123-3 2006 We sought to determine whether vascular endothelial growth factor (VEGF) could prevent dysfunction from developing in the streptozotocin (STZ)-induced rat model of type 1 diabetes. Streptozocin 138-141 vascular endothelial growth factor A Rattus norvegicus 31-65 16496123-3 2006 We sought to determine whether vascular endothelial growth factor (VEGF) could prevent dysfunction from developing in the streptozotocin (STZ)-induced rat model of type 1 diabetes. Streptozocin 138-141 vascular endothelial growth factor A Rattus norvegicus 67-71 16618418-1 2006 BACKGROUND & AIMS: Vascular endothelial growth factor (VEGF) is secreted by several epithelia and modulates cellular functions by autocrine and paracrine mechanisms. Adenosine Monophosphate 12-15 vascular endothelial growth factor A Rattus norvegicus 59-63 16618418-9 2006 VEGF induces cholangiocyte proliferation by activation of inositol 1,4,5-triphosphate/[Ca2+]i/protein kinase C alpha and phosphorylation of Src/ERK1/2. Inositol 1,4,5-Trisphosphate 58-85 vascular endothelial growth factor A Rattus norvegicus 0-4 16567193-0 2006 Effect of VEGF on the branching morphogenesis of normal and nitrofen-induced hypoplastic fetal rat lung explants. nitrofen 60-68 vascular endothelial growth factor A Rattus norvegicus 10-14 16440199-0 2006 Early cardiac hypertrophy induced by thyroxine is accompanied by an increase in VEGF-A expression but not by an increase in capillary density. Thyroxine 37-46 vascular endothelial growth factor A Rattus norvegicus 80-86 16567193-2 2006 We hypothesized that VEGF may accelerate branching morphogenesis and thus may modulate lung growth in normal and nitrofen-induced pulmonary hypoplastic lungs. nitrofen 113-121 vascular endothelial growth factor A Rattus norvegicus 21-25 16567193-9 2006 CONCLUSION: These data suggest that VEGF plays an important role in lung morphogenesis and may accelerate lung growth in nitrofen-induced hypoplastic lung. nitrofen 121-129 vascular endothelial growth factor A Rattus norvegicus 36-40 16310882-6 2006 The serum ALT elevation, with a peak at 24 h after Gal-N+LPS intoxication, was markedly attenuated with VEGF treatment. Galactosamine 51-56 vascular endothelial growth factor A Rattus norvegicus 104-108 16413500-7 2006 Furthermore, TNP-470 blockage of VEGF production in activated HSCs could be nullified by exogenous inoculation with prostaglandin E(2). Prostaglandins E 116-131 vascular endothelial growth factor A Rattus norvegicus 33-37 16168402-0 2006 Serum level of vascular endothelial growth factor is increased by estrogen replacement therapy in normotensive and DOCA-Salt hypertensive ovariectomized rats. Desoxycorticosterone Acetate 115-119 vascular endothelial growth factor A Rattus norvegicus 15-49 16168402-0 2006 Serum level of vascular endothelial growth factor is increased by estrogen replacement therapy in normotensive and DOCA-Salt hypertensive ovariectomized rats. Salts 120-124 vascular endothelial growth factor A Rattus norvegicus 15-49 16310882-9 2006 Our in vitro study showed that VEGF significantly prevented the Gal-N+LPS-induced cytotoxicity and apoptosis of SEC. Galactosamine 64-69 vascular endothelial growth factor A Rattus norvegicus 31-35 16329123-4 2006 VEGF increased neurite outgrowth, measured using a colorimetric assay for cresyl violet staining of neuronal processes, with half-maximal enhancement at 10 ng/mL and maximal, approximately 60% enhancement at 30-100 ng/mL. cresyl violet 74-87 vascular endothelial growth factor A Rattus norvegicus 0-4 16329123-5 2006 The effect of VEGF was not reproduced by VEGF-B or placental growth factor, but was blocked by SU1498, consistent with a VEGFR2 receptor-mediated process. SU 1498 95-101 vascular endothelial growth factor A Rattus norvegicus 14-18 16329123-6 2006 VEGF-induced neurite outgrowth was also blocked by the ROK inhibitor Y27632 and the Rho inhibitors sulindac and Clostridium botulium exoenzyme C3, and was accompanied by Y27632-sensitive phosphorylation of cofilin, a downstream mediator of Rho/ROK signaling. Y 27632 69-75 vascular endothelial growth factor A Rattus norvegicus 0-4 16329123-6 2006 VEGF-induced neurite outgrowth was also blocked by the ROK inhibitor Y27632 and the Rho inhibitors sulindac and Clostridium botulium exoenzyme C3, and was accompanied by Y27632-sensitive phosphorylation of cofilin, a downstream mediator of Rho/ROK signaling. Sulindac 99-107 vascular endothelial growth factor A Rattus norvegicus 0-4 16329123-6 2006 VEGF-induced neurite outgrowth was also blocked by the ROK inhibitor Y27632 and the Rho inhibitors sulindac and Clostridium botulium exoenzyme C3, and was accompanied by Y27632-sensitive phosphorylation of cofilin, a downstream mediator of Rho/ROK signaling. Y 27632 170-176 vascular endothelial growth factor A Rattus norvegicus 0-4 16779912-0 2006 L-arginine supplementation causes additional effects on exercise-induced angiogenesis and VEGF expression in the heart and hind-leg muscles of middle-aged rats. Arginine 0-10 vascular endothelial growth factor A Rattus norvegicus 90-94 16049703-0 2006 Triamcinolone acetonide suppresses interleukin-1 beta-mediated increase in vascular endothelial growth factor expression in cultured rat Muller cells. Triamcinolone Acetonide 0-23 vascular endothelial growth factor A Rattus norvegicus 75-109 16049703-3 2006 We investigated the effect of TA on the expression of VEGF mRNA and protein induced by interleukin-1 beta (IL-1b) and hypoxia in cultured rat Muller cells. Triamcinolone Acetonide 30-32 vascular endothelial growth factor A Rattus norvegicus 54-58 16779912-7 2006 A Western blot analysis showed that training with L-arginine significantly increased VEGF protein expression by 2.9-fold in the soleus muscle and by 1.7-fold in the left ventricle, but the increase with training alone was insignificant. Arginine 50-60 vascular endothelial growth factor A Rattus norvegicus 85-89 16779912-10 2006 The present results suggest that in middle-aged rats, L-arginine administration caused additional effects on exercise-induced angiogenesis by presumably promoting VEGF expression in the hind-leg muscle as well as in the left ventricle. Arginine 54-64 vascular endothelial growth factor A Rattus norvegicus 163-167 17211973-0 2006 Effect of tibolone on cytochrome c oxidase I, beta-2-microglobulin and vascular endothelial growth factor gene expression in the lower urinary tract of castrated rats. tibolone 10-18 vascular endothelial growth factor A Rattus norvegicus 71-105 16249198-13 2006 CONCLUSIONS: Inhibition of VEGF prevented early glomerular hypertrophy in ZDF rats with established diabetes. zdf 74-77 vascular endothelial growth factor A Rattus norvegicus 27-31 16456233-0 2006 Resveratrol ameliorates myocardial damage by inducing vascular endothelial growth factor-angiogenesis and tyrosine kinase receptor Flk-1. Resveratrol 0-11 vascular endothelial growth factor A Rattus norvegicus 54-88 16456233-5 2006 We have successfully demonstrated in rat myocardial infarction (MI) model an effect of resveratrol on significant upregulation of the protein expression profiles of vascular endothelial growth factor (VEGF) and its tyrosine kinase receptor Flk-1, 3 wk after MI. Resveratrol 87-98 vascular endothelial growth factor A Rattus norvegicus 165-199 16456233-5 2006 We have successfully demonstrated in rat myocardial infarction (MI) model an effect of resveratrol on significant upregulation of the protein expression profiles of vascular endothelial growth factor (VEGF) and its tyrosine kinase receptor Flk-1, 3 wk after MI. Resveratrol 87-98 vascular endothelial growth factor A Rattus norvegicus 201-205 16499655-0 2006 Perinatal expression of HSP70 and VEGF in neonatal rat lung vessels exposed to nicotine during gestation. Nicotine 79-87 vascular endothelial growth factor A Rattus norvegicus 34-38 16499655-1 2006 We assessed the influence of maternal nicotine exposure during gestation on perinatal expression of HSP70 and VEGF in rat lung parenchyma and lung vessels. Nicotine 38-46 vascular endothelial growth factor A Rattus norvegicus 110-114 16499655-8 2006 In conclusion, gestational nicotine exposure increased the expression of VEGF and HSP70 in rat lung parenchyma, especially in the airway epithelium and vascular smooth muscle cells. Nicotine 27-35 vascular endothelial growth factor A Rattus norvegicus 73-77 17124426-7 2006 The expression of VEGF was inhibited by rosiglitazone while no apparent effect was found regarding TGF/Smad pathway. Rosiglitazone 40-53 vascular endothelial growth factor A Rattus norvegicus 18-22 17211973-7 2006 After RT-PCR (reverse transcriptase polymerase chain reaction), expression of COX I, B2M and VEGF genes was evaluated by agarose gel electrophoresis, visualized by UV illumination. Sepharose 121-128 vascular endothelial growth factor A Rattus norvegicus 93-97 17211973-9 2006 CONCLUSION: The use of tibolone increases the expression of COX, B2M and VEGF genes in the lower urinary tract as compared with that in castrated rats. tibolone 23-31 vascular endothelial growth factor A Rattus norvegicus 73-77 16239266-12 2006 The VEGF-induced elevation of LpA/Vi was blocked by the selective VEGF-R2 inhibitor ZM323881. ZM323881 84-92 vascular endothelial growth factor A Rattus norvegicus 4-8 16421022-0 2006 An endothelin type A receptor antagonist reverses upregulated VEGF and ICAM-1 levels in streptozotocin-induced diabetic rat retina. Streptozocin 88-102 vascular endothelial growth factor A Rattus norvegicus 62-66 16421022-7 2006 The current study investigated the effect of ET(A) receptor antagonist (TA-0201; 1 mg kg(-1) day(-1)) on the expressions of VEGF and ICAM-1 in rat diabetic retina. T 0201 72-79 vascular endothelial growth factor A Rattus norvegicus 124-128 16421022-11 2006 In DM+vehicle group, the VEGF expression of retina was significantly increased (33.5 pg/mg) in comparison with that in the Cont group (25.1 pg/mg), and the upregulation of VEGF was reversed in DM+TA-0201 group (26.9 pg/mg), a phenomenon consistent with the change in VEGF mRNA levels. dm 3-5 vascular endothelial growth factor A Rattus norvegicus 25-29 16421022-11 2006 In DM+vehicle group, the VEGF expression of retina was significantly increased (33.5 pg/mg) in comparison with that in the Cont group (25.1 pg/mg), and the upregulation of VEGF was reversed in DM+TA-0201 group (26.9 pg/mg), a phenomenon consistent with the change in VEGF mRNA levels. dm 3-5 vascular endothelial growth factor A Rattus norvegicus 172-176 16421022-11 2006 In DM+vehicle group, the VEGF expression of retina was significantly increased (33.5 pg/mg) in comparison with that in the Cont group (25.1 pg/mg), and the upregulation of VEGF was reversed in DM+TA-0201 group (26.9 pg/mg), a phenomenon consistent with the change in VEGF mRNA levels. dm 3-5 vascular endothelial growth factor A Rattus norvegicus 172-176 16421022-11 2006 In DM+vehicle group, the VEGF expression of retina was significantly increased (33.5 pg/mg) in comparison with that in the Cont group (25.1 pg/mg), and the upregulation of VEGF was reversed in DM+TA-0201 group (26.9 pg/mg), a phenomenon consistent with the change in VEGF mRNA levels. dm+ta 193-198 vascular endothelial growth factor A Rattus norvegicus 25-29 16421022-11 2006 In DM+vehicle group, the VEGF expression of retina was significantly increased (33.5 pg/mg) in comparison with that in the Cont group (25.1 pg/mg), and the upregulation of VEGF was reversed in DM+TA-0201 group (26.9 pg/mg), a phenomenon consistent with the change in VEGF mRNA levels. dm+ta 193-198 vascular endothelial growth factor A Rattus norvegicus 172-176 16421022-11 2006 In DM+vehicle group, the VEGF expression of retina was significantly increased (33.5 pg/mg) in comparison with that in the Cont group (25.1 pg/mg), and the upregulation of VEGF was reversed in DM+TA-0201 group (26.9 pg/mg), a phenomenon consistent with the change in VEGF mRNA levels. dm+ta 193-198 vascular endothelial growth factor A Rattus norvegicus 172-176 16420412-2 2006 We have previously shown expression of vascular endothelial growth factor (VEGF), a major regulator of endothelial cell proliferation, angiogenesis and vascular permeability, and VEGF receptors (VEGFR1 and 2) after TBI in rat. tbi 215-218 vascular endothelial growth factor A Rattus norvegicus 39-73 16420412-2 2006 We have previously shown expression of vascular endothelial growth factor (VEGF), a major regulator of endothelial cell proliferation, angiogenesis and vascular permeability, and VEGF receptors (VEGFR1 and 2) after TBI in rat. tbi 215-218 vascular endothelial growth factor A Rattus norvegicus 75-79 16420412-2 2006 We have previously shown expression of vascular endothelial growth factor (VEGF), a major regulator of endothelial cell proliferation, angiogenesis and vascular permeability, and VEGF receptors (VEGFR1 and 2) after TBI in rat. tbi 215-218 vascular endothelial growth factor A Rattus norvegicus 179-183 16420412-8 2006 Taken together, our findings point towards VEGF/VEGFR2 up-regulation after TBI as being an important endogenous cytoprotective mechanism in TBI. tbi 75-78 vascular endothelial growth factor A Rattus norvegicus 43-47 16420412-8 2006 Taken together, our findings point towards VEGF/VEGFR2 up-regulation after TBI as being an important endogenous cytoprotective mechanism in TBI. tbi 140-143 vascular endothelial growth factor A Rattus norvegicus 43-47 16327979-8 2006 We further demonstrated that the expression of angiogenic factors, such as vascular endothelial cell growth factor (VEGF) and basic fibroblastic growth factor (bFGF), were inhibited by THD. Thalidomide 185-188 vascular endothelial growth factor A Rattus norvegicus 116-120 16432165-0 2006 Improvement by solid dispersion of the bioavailability of KRN633, a selective inhibitor of VEGF receptor-2 tyrosine kinase, and identification of its potential therapeutic window. N-(2-chloro-4-((6,7-dimethoxy-4-quinazolinyl)oxy)phenyl)-N'-propylurea 58-64 vascular endothelial growth factor A Rattus norvegicus 91-95 16899993-8 2006 In contrast, VEGF expression and RhoA activity was increased in L-NAME-treated animals, and normalized with co-administration of ATO. NG-Nitroarginine Methyl Ester 64-70 vascular endothelial growth factor A Rattus norvegicus 13-17 16899993-8 2006 In contrast, VEGF expression and RhoA activity was increased in L-NAME-treated animals, and normalized with co-administration of ATO. Atorvastatin 129-132 vascular endothelial growth factor A Rattus norvegicus 13-17 16432165-1 2006 KRN633 is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases. N-(2-chloro-4-((6,7-dimethoxy-4-quinazolinyl)oxy)phenyl)-N'-propylurea 0-6 vascular endothelial growth factor A Rattus norvegicus 32-66 16432165-1 2006 KRN633 is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases. N-(2-chloro-4-((6,7-dimethoxy-4-quinazolinyl)oxy)phenyl)-N'-propylurea 0-6 vascular endothelial growth factor A Rattus norvegicus 68-72 16040626-9 2005 ET receptor blockade with bosentan prevented this increase in lung VEGF content, suggesting that ET promotes VEGF accumulation in the lung in this setting. Bosentan 26-34 vascular endothelial growth factor A Rattus norvegicus 67-71 16083310-0 2006 Inhibition of vascular endothelial growth factor-induced retinal neovascularization by retinoic acid in experimental retinopathy of prematurity. Tretinoin 87-100 vascular endothelial growth factor A Rattus norvegicus 14-48 16083310-2 2006 It is suggested that retinoids exert a highly potent antiangiogenic activity by inhibiting VEGF expression. Retinoids 21-30 vascular endothelial growth factor A Rattus norvegicus 91-95 16083310-3 2006 The aim of this study was to demonstrate the preventive effect of retinoic acid (RA) on the VEGF-induced retinal neovascularization in a rat model of ROP. Tretinoin 66-79 vascular endothelial growth factor A Rattus norvegicus 92-96 16083310-3 2006 The aim of this study was to demonstrate the preventive effect of retinoic acid (RA) on the VEGF-induced retinal neovascularization in a rat model of ROP. Tretinoin 81-83 vascular endothelial growth factor A Rattus norvegicus 92-96 16083310-13 2006 The VEGF immunostaining score significantly decreased in the RA-treated ROP group compared to that in the saline-administered ROP group. Tretinoin 61-63 vascular endothelial growth factor A Rattus norvegicus 4-8 16083310-14 2006 RA treatment might be beneficial in preventing neovascularization resulting from oxygen-induced retinopathy by downregulation of VEGF expression. Tretinoin 0-2 vascular endothelial growth factor A Rattus norvegicus 129-133 16083310-14 2006 RA treatment might be beneficial in preventing neovascularization resulting from oxygen-induced retinopathy by downregulation of VEGF expression. Oxygen 81-87 vascular endothelial growth factor A Rattus norvegicus 129-133 16579703-0 2006 Increased expression of vascular endothelial growth factor in cyclosporin A-induced gingival overgrowth in rats. Cyclosporine 62-75 vascular endothelial growth factor A Rattus norvegicus 24-58 16579703-3 2006 The aim of this experimental study was to examine the role of vascular endothelial growth factor (VEGF) in the pathogenesis of CsA-induced gingival overgrowth. Cyclosporine 127-130 vascular endothelial growth factor A Rattus norvegicus 62-96 16579703-3 2006 The aim of this experimental study was to examine the role of vascular endothelial growth factor (VEGF) in the pathogenesis of CsA-induced gingival overgrowth. Cyclosporine 127-130 vascular endothelial growth factor A Rattus norvegicus 98-102 16579703-10 2006 The biochemical findings showed that in vivo VEGF expression was higher in the CsA group compared to the control group (P <0.001). Cyclosporine 79-82 vascular endothelial growth factor A Rattus norvegicus 45-49 16579703-11 2006 CONCLUSION: The results of this study suggest that increased VEGF expression may be associated with the pathogenesis of CsA-induced gingival overgrowth. Cyclosporine 120-123 vascular endothelial growth factor A Rattus norvegicus 61-65 16297343-8 2005 When rats were pretreated with scutellarin (50 or 75 mg/kg), upregulation of eNOS expression and downregulation of VEGF, bFGF, and iNOS expression was observed, whereas scutellarin had no effect on nNOS expression. scutellarin 31-42 vascular endothelial growth factor A Rattus norvegicus 115-119 16040626-9 2005 ET receptor blockade with bosentan prevented this increase in lung VEGF content, suggesting that ET promotes VEGF accumulation in the lung in this setting. Bosentan 26-34 vascular endothelial growth factor A Rattus norvegicus 109-113 16303979-1 2005 PURPOSE: The present study examined the effects of riluzole, a Food and Drug Administration-approved drug for amyotrophic lateral sclerosis, on VEGF-stimulated endothelial cell proliferation in culture, and on neovascularization in a rat model of retinopathy of prematurity (ROP). Riluzole 51-59 vascular endothelial growth factor A Rattus norvegicus 144-148 16388451-5 2005 The important role of VEGF and its regulation depending on oxygen pressure suggest a strong connection between this growth factor and the delay phenomenon. Oxygen 59-65 vascular endothelial growth factor A Rattus norvegicus 22-26 16034458-0 2005 Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: a long-term study into inhibition of laser-induced CNV, distribution, uptake and toxicity. Oligonucleotides 35-50 vascular endothelial growth factor A Rattus norvegicus 30-34 16332239-0 2005 Upregulation of transforming growth factor-beta1 and vascular endothelial growth factor gene and protein expression in cyclosporin-induced overgrown edentulous gingiva in rats. Cyclosporine 119-130 vascular endothelial growth factor A Rattus norvegicus 53-87 16354548-13 2005 With L-NAME+ VEGF administration, the Ki of the IC became significantly lower than that of the VEGF alone (-38%, p<0.005). NG-Nitroarginine Methyl Ester 5-11 vascular endothelial growth factor A Rattus norvegicus 95-99 16354548-14 2005 Thus, L-NAME produced a much greater decrease in the Ki of the IC in the VEGF treated than the control animals (p<0.05). NG-Nitroarginine Methyl Ester 6-12 vascular endothelial growth factor A Rattus norvegicus 73-77 16353391-3 2005 MATERIAL AND METHODS: Qualitative immunohistochemical studies were performed by using specific antibodies to VEGF and its receptors on paraffin sections of the cochlea. Paraffin 135-143 vascular endothelial growth factor A Rattus norvegicus 109-113 16332239-7 2005 The mRNA expressions of TGF-beta1, IGF-1, and VEGF were higher in the gingivae of the CsA group than in the control group. Cyclosporine 86-89 vascular endothelial growth factor A Rattus norvegicus 46-50 16332239-8 2005 In addition, a greater mRNA expression (7.21-fold) of VEGF was demonstrated in the CsA group than in the control group by real-time polymerase chain reaction (PCR). Cyclosporine 83-86 vascular endothelial growth factor A Rattus norvegicus 54-58 16332239-10 2005 CONCLUSIONS: Greater mRNA expression and positive staining for TGF-beta1 and VEGF were observed in the edentulous gingivae of rats that received CsA. Cyclosporine 145-148 vascular endothelial growth factor A Rattus norvegicus 77-81 16332239-11 2005 Therefore, CsA may upregulate TGF-beta1 and VEGF gene expression and protein secretion in CsA-induced gingival overgrowth. Cyclosporine 11-14 vascular endothelial growth factor A Rattus norvegicus 44-48 16338311-8 2005 Vascular endothelial growth factor protein was detected in enterocytes from day 3 posttransplant in the SS group. H-SER-SER-OH 104-106 vascular endothelial growth factor A Rattus norvegicus 0-34 16338311-10 2005 CONCLUSIONS: Our results suggest that SS allows VEGF mRNA and, subsequently, VEGF protein in ASBG to be induced very soon after transplantation, which may contribute to the survival of ASBG transplanted without vascular reconstruction. asbg 93-97 vascular endothelial growth factor A Rattus norvegicus 77-81 16338311-10 2005 CONCLUSIONS: Our results suggest that SS allows VEGF mRNA and, subsequently, VEGF protein in ASBG to be induced very soon after transplantation, which may contribute to the survival of ASBG transplanted without vascular reconstruction. asbg 185-189 vascular endothelial growth factor A Rattus norvegicus 48-52 16338311-10 2005 CONCLUSIONS: Our results suggest that SS allows VEGF mRNA and, subsequently, VEGF protein in ASBG to be induced very soon after transplantation, which may contribute to the survival of ASBG transplanted without vascular reconstruction. asbg 185-189 vascular endothelial growth factor A Rattus norvegicus 77-81 16034458-1 2005 We have performed a long-term study into the use of a lipophilic amino-acid dendrimer to deliver an anti-vascular endothelial growth factor (VEGF) oligonucleotide (ODN-1) into the eyes of rats and inhibit laser-induced choroidal neovascularization (CNV). Oligonucleotides 147-162 vascular endothelial growth factor A Rattus norvegicus 100-139 16034458-1 2005 We have performed a long-term study into the use of a lipophilic amino-acid dendrimer to deliver an anti-vascular endothelial growth factor (VEGF) oligonucleotide (ODN-1) into the eyes of rats and inhibit laser-induced choroidal neovascularization (CNV). Oligonucleotides 147-162 vascular endothelial growth factor A Rattus norvegicus 141-145 16034458-1 2005 We have performed a long-term study into the use of a lipophilic amino-acid dendrimer to deliver an anti-vascular endothelial growth factor (VEGF) oligonucleotide (ODN-1) into the eyes of rats and inhibit laser-induced choroidal neovascularization (CNV). odn-1 164-169 vascular endothelial growth factor A Rattus norvegicus 100-139 16034458-1 2005 We have performed a long-term study into the use of a lipophilic amino-acid dendrimer to deliver an anti-vascular endothelial growth factor (VEGF) oligonucleotide (ODN-1) into the eyes of rats and inhibit laser-induced choroidal neovascularization (CNV). odn-1 164-169 vascular endothelial growth factor A Rattus norvegicus 141-145 16273603-11 2005 The expressions of VEGF and MVD in medium-dose (1 mg/kg) group were significantly lower than normal saline group (0.63+/-0.74 vs 2.44+/-0.88, P<0.05; 15.75+/-3.99 vs 47.44+/-13.41, t = 2.80, P<0.01). Sodium Chloride 100-106 vascular endothelial growth factor A Rattus norvegicus 19-23 16198371-0 2005 Resveratrol enhances neovascularization in the infarcted rat myocardium through the induction of thioredoxin-1, heme oxygenase-1 and vascular endothelial growth factor. Resveratrol 0-11 vascular endothelial growth factor A Rattus norvegicus 133-167 16198371-3 2005 Here we report resveratrol enhanced myocardial angiogenesis both in vivo and in vitro by induction of vascular endothelial growth factor (VEGF), which was regulated by thioredoxin-1 (Trx-1) and heme oxygenase-1 (HO-1). Resveratrol 15-26 vascular endothelial growth factor A Rattus norvegicus 102-136 16198371-3 2005 Here we report resveratrol enhanced myocardial angiogenesis both in vivo and in vitro by induction of vascular endothelial growth factor (VEGF), which was regulated by thioredoxin-1 (Trx-1) and heme oxygenase-1 (HO-1). Resveratrol 15-26 vascular endothelial growth factor A Rattus norvegicus 138-142 16198371-7 2005 Again, rat neonatal cardiomyocytes treated with resveratrol significantly expressed Trx-1, HO-1 as well as VEGF. Resveratrol 48-59 vascular endothelial growth factor A Rattus norvegicus 107-111 16198371-10 2005 Concomitantly, resveratrol-treated myocardium after MI significantly induced Trx-1, HO-1 and VEGF expression. Resveratrol 15-26 vascular endothelial growth factor A Rattus norvegicus 93-97 16198371-12 2005 Our findings suggest that resveratrol mediates cardioprotection and neovascularization through Trx-1-HO-1-VEGF pathway in rat ischemic myocardium. Resveratrol 26-37 vascular endothelial growth factor A Rattus norvegicus 106-110 16334555-12 2005 Howerver, 700 ng/ml SU1498 obviously inhibited the neuroprotective effect of VEGF on anoxic astrocytes. SU 1498 20-26 vascular endothelial growth factor A Rattus norvegicus 77-81 16232350-4 2005 METHODS: We employed primary cultures of embryonic rat spinal cord neurons, then administrated different concentrations of VEGF164 in the culture medium before hypoxia when the number of neurons was counted and the cell viability was detected by MTT. monooxyethylene trimethylolpropane tristearate 246-249 vascular endothelial growth factor A Rattus norvegicus 123-130 16232350-5 2005 The neuronal apoptosis and expression of VEGF and its receptor genes were evaluated by terminal deoxynucleotidyl transferase mediated dUTP nick-end labelling (TUNEL) and immunohistochemistry. deoxyuridine triphosphate 134-138 vascular endothelial growth factor A Rattus norvegicus 41-45 16232350-6 2005 The VEGFR2/FLK-1 inhibitor, SU1498, was used to confirm whether the neuroprotective effect of VEGF was mediated through VEGFR2/Flk-1 receptors. SU 1498 28-34 vascular endothelial growth factor A Rattus norvegicus 4-8 16232350-10 2005 The protective effect of VEGF was blocked by the VEGFR2/Flk-1 receptor tyrosine kinase inhibitor, SU1498. SU 1498 98-104 vascular endothelial growth factor A Rattus norvegicus 25-29 16385372-8 2005 Administration of HIF-1alpha antisense oligonucleotide before ligation of the LAD significantly inhibited VEGF protein expression induced by ischemia-reperfusion. Oligonucleotides 39-54 vascular endothelial growth factor A Rattus norvegicus 106-110 15946813-7 2005 In vivo studies using ovariectomized rats showed that 17beta-estradiol (20 mg/kg, s.c.) treatment restored VEGF expression in both uterus and brain, whereas RJ (1 g/kg, s.c.) restored it in uterus but not in brain. Estradiol 54-70 vascular endothelial growth factor A Rattus norvegicus 107-111 16105091-10 2005 The expression of vascular endothelial growth factor (VEGF) mRNA in the demineralized group with PGA at day 14 was the highest. propylene glycol alginate ester 97-100 vascular endothelial growth factor A Rattus norvegicus 18-52 16172417-9 2005 Treatment of DS rats with nicorandil greatly increased capillary and arteriolar densities and inhibited the downregulation of eNOS, VEGF, fms-like tyrosin kinase-1, and bFGF gene expression. Nicorandil 26-36 vascular endothelial growth factor A Rattus norvegicus 132-136 16105091-10 2005 The expression of vascular endothelial growth factor (VEGF) mRNA in the demineralized group with PGA at day 14 was the highest. propylene glycol alginate ester 97-100 vascular endothelial growth factor A Rattus norvegicus 54-58 16086057-0 2005 [Effects of low molecular weight heparin on vascular endothelial growth factor expression of early diabetic nephropathy]. Heparin 33-40 vascular endothelial growth factor A Rattus norvegicus 44-78 16222740-5 2005 The expression level of VEGF mRNA in gastric tissues during the healing process of JWYY treatment group rats significantly increased compared with other groups (normal group: 0.190+/-0.019, model group: 0.642+/-0.034, ranitidine group: 0.790+/-0.037, P<0.01). Ranitidine 218-228 vascular endothelial growth factor A Rattus norvegicus 24-28 16115043-0 2005 Oxygen: from the benefits of inducing VEGF expression to managing the risk of hyperbaric stress. Oxygen 0-6 vascular endothelial growth factor A Rattus norvegicus 38-42 16002497-1 2005 This study was designed to examine whether dietary L-arginine supplementation modulates exercise-induced angiogenesis and vascular endothelial growth factor (VEGF) expression in female Wistar rats. Arginine 51-61 vascular endothelial growth factor A Rattus norvegicus 122-156 16002497-7 2005 Western blot analysis showed that training with L-arginine significantly increased VEGF protein expression by 1.7-fold in the left ventricle, while the increase with training alone was insignificant. Arginine 48-58 vascular endothelial growth factor A Rattus norvegicus 83-87 16002497-10 2005 The present results suggest that L-arginine supplementation causes additional effects on exercise-induced angiogenesis in the rat heart by promoting VEGF expression. Arginine 33-43 vascular endothelial growth factor A Rattus norvegicus 149-153 15993383-2 2005 SD rats fed a high fat/sucrose diet showed increases in serum insulin and VEGF (both p < 0.01). Sucrose 23-30 vascular endothelial growth factor A Rattus norvegicus 74-78 15993383-3 2005 Treatment with a PPARgamma agonist GI262570 normalized the diet-elevated insulin and VEGF (both p < 0.01). farglitazar 35-43 vascular endothelial growth factor A Rattus norvegicus 85-89 15993383-5 2005 ZDF rats had higher serum glucose, insulin, and VEGF than Zucker lean rats (all p < 0.01). zdf 0-3 vascular endothelial growth factor A Rattus norvegicus 48-52 15993383-6 2005 Treatment of ZDF rats with PPARgamma agonist pioglitazone decreased serum glucose and VEGF (both p <0.01). zdf 13-16 vascular endothelial growth factor A Rattus norvegicus 86-90 15993383-6 2005 Treatment of ZDF rats with PPARgamma agonist pioglitazone decreased serum glucose and VEGF (both p <0.01). Pioglitazone 45-57 vascular endothelial growth factor A Rattus norvegicus 86-90 15993383-7 2005 There was a positive correlation between glucose and VEGF in ZDF rats (p < 0.05). Glucose 41-48 vascular endothelial growth factor A Rattus norvegicus 53-57 16045899-2 2005 Here, we investigated the neurorescue effects of VEGF on 6-hydroxydopamine (6-OHDA)-treated DA neurons in vitro and in vivo. Oxidopamine 57-74 vascular endothelial growth factor A Rattus norvegicus 49-53 16045899-2 2005 Here, we investigated the neurorescue effects of VEGF on 6-hydroxydopamine (6-OHDA)-treated DA neurons in vitro and in vivo. Oxidopamine 76-82 vascular endothelial growth factor A Rattus norvegicus 49-53 16045899-8 2005 Compared to lesioned rats that received BHK-Control capsules, lesioned rats transplanted with BHK-VEGF capsules showed a significant reduction in the number of amphetamine-induced rotations, a significant preservation of TH-positive neurons in the substantia nigra pars compacta, and a remarkable glial proliferation in the striatum, with the earlier transplantation exerting much more benefits than the delayed transplantation. Amphetamine 160-171 vascular endothelial growth factor A Rattus norvegicus 98-102 16086057-1 2005 OBJECTIVE: To investigate the effects of low molecular weight heparin (LMWH) on vascular endothelial growth factor (VEGF) expression of early diabetic nephropathy. Heparin 62-69 vascular endothelial growth factor A Rattus norvegicus 80-114 16086057-1 2005 OBJECTIVE: To investigate the effects of low molecular weight heparin (LMWH) on vascular endothelial growth factor (VEGF) expression of early diabetic nephropathy. Heparin 62-69 vascular endothelial growth factor A Rattus norvegicus 116-120 16086057-1 2005 OBJECTIVE: To investigate the effects of low molecular weight heparin (LMWH) on vascular endothelial growth factor (VEGF) expression of early diabetic nephropathy. Heparin, Low-Molecular-Weight 71-75 vascular endothelial growth factor A Rattus norvegicus 80-114 16086057-1 2005 OBJECTIVE: To investigate the effects of low molecular weight heparin (LMWH) on vascular endothelial growth factor (VEGF) expression of early diabetic nephropathy. Heparin, Low-Molecular-Weight 71-75 vascular endothelial growth factor A Rattus norvegicus 116-120 16086057-6 2005 CONCLUSION: The inhibition of VEGF expression may be one of the mechanisms of LMWH"s renal protective effects on early diabetic nephropathy. Heparin, Low-Molecular-Weight 78-82 vascular endothelial growth factor A Rattus norvegicus 30-34 15763267-6 2005 In our studies, we focussed on the modulation of the GAG-binding molecules macrophage chemoattractant protein-1 (MCP-1) and vascular endothelial growth factor-164 (VEGF164) in the inflammatory reaction against subcutaneously implanted degradable cross-linked dermal sheep collagen discs in AO rats. Glycosaminoglycans 53-56 vascular endothelial growth factor A Rattus norvegicus 164-171 16121981-8 2005 The encapsulated BHK-VEGF cell grafts significantly reduced the volume of the infarct and the number of apoptotic cells in the penumbral area when compared with the effect of the BHK-control cell capsule. (2R)-2-benzyl-5-hydroxy-4-oxopentanoic acid 17-20 vascular endothelial growth factor A Rattus norvegicus 21-25 15893841-2 2005 To determine whether this process is angiogenesis-dependent, we assessed the effects of SU5416, a specific inhibitor of VEGF receptor-2, in portal hypertensive rats. Semaxinib 88-94 vascular endothelial growth factor A Rattus norvegicus 120-124 16096950-4 2005 In part one of the study, VEGF plasmid DNA incorporated with lipofectamine was injected into the subcutaneous fascial layer of the upper abdominal walls of the rats. Lipofectamine 61-74 vascular endothelial growth factor A Rattus norvegicus 26-30 15774498-2 2005 Estrogen [17beta-estradiol (E2)], via its receptor (ER alpha), rapidly stimulates VEGF expression in the uterus at the transcriptional level. Estradiol 10-26 vascular endothelial growth factor A Rattus norvegicus 82-86 16135999-10 2005 Moreover, the concentration of VEGF in GH3 conditioned medium occurred to be 13 times higher than in the control medium. 3'-dGTP 39-42 vascular endothelial growth factor A Rattus norvegicus 31-35 15998812-9 2005 Blockage of VEGF-PLCgamma1 signaling decreases calcium transients in rat ventricular cardiomyocytes, whereas VEGF imposes a positive inotropic effect on cardiomyocytes by increasing calcium transients. Calcium 47-54 vascular endothelial growth factor A Rattus norvegicus 12-16 15998812-9 2005 Blockage of VEGF-PLCgamma1 signaling decreases calcium transients in rat ventricular cardiomyocytes, whereas VEGF imposes a positive inotropic effect on cardiomyocytes by increasing calcium transients. Calcium 182-189 vascular endothelial growth factor A Rattus norvegicus 109-113 16121981-9 2005 In addition, angiogenesis and gliogenesis significantly increased in the region around the capsule in animals that received BHK-VEGF cell capsules without an increase in focal cerebral blood flow; this did not occur in animals that received the BHK-control cell capsule. (2R)-2-benzyl-5-hydroxy-4-oxopentanoic acid 124-127 vascular endothelial growth factor A Rattus norvegicus 128-132 15852018-3 2005 Inhibition of enzymes controlling de novo ceramide synthesis prevented alveolar cell apoptosis, oxidative stress and emphysema caused by blockade of the vascular endothelial growth factor (VEGF) receptors in both rats and mice. Ceramides 42-50 vascular endothelial growth factor A Rattus norvegicus 153-187 15778488-6 2005 Simultaneous VEGF gene transfer and platelet-derived growth factor receptor inhibition with imatinib preserved respiratory epithelium and totally prevented luminal occlusion. Imatinib Mesylate 92-100 vascular endothelial growth factor A Rattus norvegicus 13-17 16025966-4 2005 RESULTS: The VEGF mRNA expression was significantly lower in nitric oxide synthesis inhibited model rats than that in rats non-modeled, or in model rats treated by ASC abstracts or nitroglycerin (P < 0.05, P < 0.01). Nitric Oxide 61-73 vascular endothelial growth factor A Rattus norvegicus 13-17 16025966-4 2005 RESULTS: The VEGF mRNA expression was significantly lower in nitric oxide synthesis inhibited model rats than that in rats non-modeled, or in model rats treated by ASC abstracts or nitroglycerin (P < 0.05, P < 0.01). Nitroglycerin 181-194 vascular endothelial growth factor A Rattus norvegicus 13-17 15879297-2 2005 Recent studies have shown that impaired angiogenesis due to inhibition of vascular endothelial growth factor (VEGF) signaling decreases alveolar and vessel growth in the developing lung, and that nitric oxide (NO) mediates VEGF-dependent angiogenesis. Nitric Oxide 196-208 vascular endothelial growth factor A Rattus norvegicus 223-227 15921676-6 2005 However, VEGF-induced angiogenesis was inhibited by NS-398 treatment. N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide 52-58 vascular endothelial growth factor A Rattus norvegicus 9-13 15921676-7 2005 These results suggest that PGE2 and TXA2 stimulate angiogenesis in the newly formed corpus luteum and that there is a possibility that these eicosanoids are involved in VEGF-induced progesterone production and the increase in luteal blood flow. Dinoprostone 27-31 vascular endothelial growth factor A Rattus norvegicus 169-173 15921676-7 2005 These results suggest that PGE2 and TXA2 stimulate angiogenesis in the newly formed corpus luteum and that there is a possibility that these eicosanoids are involved in VEGF-induced progesterone production and the increase in luteal blood flow. Eicosanoids 141-152 vascular endothelial growth factor A Rattus norvegicus 169-173 15921676-7 2005 These results suggest that PGE2 and TXA2 stimulate angiogenesis in the newly formed corpus luteum and that there is a possibility that these eicosanoids are involved in VEGF-induced progesterone production and the increase in luteal blood flow. Progesterone 182-194 vascular endothelial growth factor A Rattus norvegicus 169-173 15879344-8 2005 RESULTS: VEGF expression was observed in the cytoplasm of neurons exclusively in the area of vasogenic edema that was shown as a high-intensity area in the apparent diffusion coefficient of water map. Water 190-195 vascular endothelial growth factor A Rattus norvegicus 9-13 15862172-0 2005 Vascular endothelial growth factor expression and secretion by retinal pigment epithelial cells in high glucose and hypoxia is protein kinase C-dependent. Glucose 104-111 vascular endothelial growth factor A Rattus norvegicus 0-34 15862172-1 2005 Retinal pigment epithelial (RPE) cells express vascular endothelial growth factor (VEGF) in response to high glucose or hypoxia. Glucose 109-116 vascular endothelial growth factor A Rattus norvegicus 47-81 15862172-1 2005 Retinal pigment epithelial (RPE) cells express vascular endothelial growth factor (VEGF) in response to high glucose or hypoxia. Glucose 109-116 vascular endothelial growth factor A Rattus norvegicus 83-87 15862172-2 2005 We hypothesised that VEGF expression and secretion by RPE cells in high glucose and hypoxia are regulated by protein kinase C (PKC). Glucose 72-79 vascular endothelial growth factor A Rattus norvegicus 21-25 15862172-7 2005 In response to high glucose or acute phorbol myristate acetate (PMA) stimulation, VEGF mRNA analysed by RT-PCR was increased. Glucose 20-27 vascular endothelial growth factor A Rattus norvegicus 82-86 15862172-7 2005 In response to high glucose or acute phorbol myristate acetate (PMA) stimulation, VEGF mRNA analysed by RT-PCR was increased. Tetradecanoylphorbol Acetate 37-62 vascular endothelial growth factor A Rattus norvegicus 82-86 15862172-7 2005 In response to high glucose or acute phorbol myristate acetate (PMA) stimulation, VEGF mRNA analysed by RT-PCR was increased. Tetradecanoylphorbol Acetate 64-67 vascular endothelial growth factor A Rattus norvegicus 82-86 15862172-8 2005 Intracellular VEGF protein identified by immunoblotting and confocal immunofluorescence imaging was significantly increased by high glucose, hypoxia or acute PMA stimulation. Glucose 132-139 vascular endothelial growth factor A Rattus norvegicus 14-18 15862172-9 2005 Calphostin C or a specific inhibitor of PKC-zeta prevented high glucose-stimulated VEGF expression in high glucose. Glucose 64-71 vascular endothelial growth factor A Rattus norvegicus 83-87 15862172-9 2005 Calphostin C or a specific inhibitor of PKC-zeta prevented high glucose-stimulated VEGF expression in high glucose. Glucose 107-114 vascular endothelial growth factor A Rattus norvegicus 83-87 15862172-10 2005 VEGF secretion, as measured by ELISA in the culture medium, was enhanced in hypoxia but not in high glucose. Glucose 100-107 vascular endothelial growth factor A Rattus norvegicus 0-4 15862172-12 2005 Secretion of VEGF in normal or high glucose, or hypoxia was significantly reduced following treatment with PMA for 24 hr but not with the PKC-zeta inhibitor. Glucose 36-43 vascular endothelial growth factor A Rattus norvegicus 13-17 15862172-12 2005 Secretion of VEGF in normal or high glucose, or hypoxia was significantly reduced following treatment with PMA for 24 hr but not with the PKC-zeta inhibitor. Tetradecanoylphorbol Acetate 107-110 vascular endothelial growth factor A Rattus norvegicus 13-17 15862172-13 2005 We conclude that in high glucose and hypoxia PKC isozymes are activated and are necessary for VEGF expression. Glucose 25-32 vascular endothelial growth factor A Rattus norvegicus 94-98 15862172-15 2005 RPE cells may contribute to the pathogenesis of retinopathy caused by high glucose and hypoxia through the expression and secretion of VEGF that are regulated by PKC isozymes. Glucose 75-82 vascular endothelial growth factor A Rattus norvegicus 135-139 15852018-3 2005 Inhibition of enzymes controlling de novo ceramide synthesis prevented alveolar cell apoptosis, oxidative stress and emphysema caused by blockade of the vascular endothelial growth factor (VEGF) receptors in both rats and mice. Ceramides 42-50 vascular endothelial growth factor A Rattus norvegicus 189-193 15766573-5 2005 Moreover, 11,11"-dideoxyverticillin completely blocked VEGF-induced microvessel sprouting from Matrigel-embedded rat aortic rings and vessel growth in Matrigel plugs in mice. 11,11"-dideoxyverticillin 10-35 vascular endothelial growth factor A Rattus norvegicus 55-59 16167239-7 2005 Immunohistochemical staining was used to evaluate the effect of carraghenates suppository on expression of VEGF, iNOS, IL-8, MMP9, HIF-1 alpha and PCNA in the two groups. carraghenates 64-77 vascular endothelial growth factor A Rattus norvegicus 107-111 15687494-7 2005 This effect was paralleled by in vitro evidence that telomerase inhibition by 3"-azido-3"-deoxythymidine in VEGF-treated endothelial cells strongly reduced capillary density and promoted apoptosis in the absence of serum. Zidovudine 78-104 vascular endothelial growth factor A Rattus norvegicus 108-112 15687494-9 2005 Mechanistically, neo-angiogenesis in our system involved: (i) VEGF-dependent activation of telomerase through the nitric oxide pathway and (ii) telomerase-dependent activation of endothelial cell differentiation and protection from apoptosis. Nitric Oxide 114-126 vascular endothelial growth factor A Rattus norvegicus 62-66 15905131-0 2005 Coordinated induction of iNOS-VEGF-KDR-eNOS after resveratrol consumption: a potential mechanism for resveratrol preconditioning of the heart. Resveratrol 50-61 vascular endothelial growth factor A Rattus norvegicus 30-34 15832409-2 2005 METHODS: 5"-Isothiocyanate (FITC)-labeled vascular endothelial growth factor (VEGF) ASODN was added into Walker-256 cell culture media. 5"-isothiocyanate 9-26 vascular endothelial growth factor A Rattus norvegicus 42-76 15832409-2 2005 METHODS: 5"-Isothiocyanate (FITC)-labeled vascular endothelial growth factor (VEGF) ASODN was added into Walker-256 cell culture media. 5"-isothiocyanate 9-26 vascular endothelial growth factor A Rattus norvegicus 78-82 15832409-2 2005 METHODS: 5"-Isothiocyanate (FITC)-labeled vascular endothelial growth factor (VEGF) ASODN was added into Walker-256 cell culture media. Fluorescein-5-isothiocyanate 28-32 vascular endothelial growth factor A Rattus norvegicus 42-76 15832409-2 2005 METHODS: 5"-Isothiocyanate (FITC)-labeled vascular endothelial growth factor (VEGF) ASODN was added into Walker-256 cell culture media. Fluorescein-5-isothiocyanate 28-32 vascular endothelial growth factor A Rattus norvegicus 78-82 15832409-5 2005 5"-FITC-labeled VEGF ASODN mixed with (mixed group, n = 6) or without (TAI group, n = 6) ultra-fluid lipiodol was administrated via hepatic artery. Fluorescein-5-isothiocyanate 0-7 vascular endothelial growth factor A Rattus norvegicus 16-20 15832409-5 2005 5"-FITC-labeled VEGF ASODN mixed with (mixed group, n = 6) or without (TAI group, n = 6) ultra-fluid lipiodol was administrated via hepatic artery. asodn 21-26 vascular endothelial growth factor A Rattus norvegicus 16-20 15755557-4 2005 Treatment with antisense oligonucleotides (AS-ODNs) to flt-1 resulted in a dramatic decrease in GFAP and nestin immunoreactivity, which further confirmed the role of flt-1 in mediating VEGF"s gliotrophic effects, while AS-ODNs to flk-1 had no effect. Oligonucleotides 25-41 vascular endothelial growth factor A Rattus norvegicus 185-189 15755557-5 2005 VEGF-induced gliotrophic effects were found to be mediated by the MAPK/ERK and PI-3 kinase signaling pathways, since the both the MEK1 inhibitor, PD98059 and the PI-3 kinase inhibitor, Wortmannin abolished VEGF-induced astrocytic GFAP(+) expression. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 146-153 vascular endothelial growth factor A Rattus norvegicus 0-4 15755557-5 2005 VEGF-induced gliotrophic effects were found to be mediated by the MAPK/ERK and PI-3 kinase signaling pathways, since the both the MEK1 inhibitor, PD98059 and the PI-3 kinase inhibitor, Wortmannin abolished VEGF-induced astrocytic GFAP(+) expression. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 146-153 vascular endothelial growth factor A Rattus norvegicus 206-210 15755557-5 2005 VEGF-induced gliotrophic effects were found to be mediated by the MAPK/ERK and PI-3 kinase signaling pathways, since the both the MEK1 inhibitor, PD98059 and the PI-3 kinase inhibitor, Wortmannin abolished VEGF-induced astrocytic GFAP(+) expression. Wortmannin 185-195 vascular endothelial growth factor A Rattus norvegicus 0-4 15780112-7 2005 Crossover from standard PDF to low-GDP bicarbonate/lactate PDF resulted in a less impaired ultrafiltration (UF), less pronounced VEGF expression and neoangiogenesis, and less severe AGE accumulation, TGF-beta expression, and fibrosis compared to continuous standard PDF exposure for 20 weeks. Bicarbonates 39-50 vascular endothelial growth factor A Rattus norvegicus 129-133 15780112-7 2005 Crossover from standard PDF to low-GDP bicarbonate/lactate PDF resulted in a less impaired ultrafiltration (UF), less pronounced VEGF expression and neoangiogenesis, and less severe AGE accumulation, TGF-beta expression, and fibrosis compared to continuous standard PDF exposure for 20 weeks. Lactic Acid 51-58 vascular endothelial growth factor A Rattus norvegicus 129-133 15799775-0 2005 Effects of cold-water immersion on VEGF mRNA and protein expression in heart and skeletal muscles of rats. Water 16-21 vascular endothelial growth factor A Rattus norvegicus 35-39 15780228-8 2005 Compared with the two control groups, the flap treated with VEGF plasmid DNA showed a more significantly enhanced tissue viability: 87 +/- 5 versus 47 +/- 6% for the control plasmid DNA group and 46 +/- 5% for the saline group (P < 0.01). Sodium Chloride 214-220 vascular endothelial growth factor A Rattus norvegicus 60-64 15905131-0 2005 Coordinated induction of iNOS-VEGF-KDR-eNOS after resveratrol consumption: a potential mechanism for resveratrol preconditioning of the heart. Resveratrol 101-112 vascular endothelial growth factor A Rattus norvegicus 30-34 15905131-5 2005 Western blot detected an overexpression of iNOS and VEGF within 24 h of resveratrol treatment while the induction of KDR was not increased until after 3 days and eNOS expression after 5 days of resveratrol treatment. Resveratrol 72-83 vascular endothelial growth factor A Rattus norvegicus 52-56 15905131-9 2005 The hearts obtained from resveratrol-treated rats revealed enhanced expression for iNOS, eNOS and VEGF and KDR compared to control hearts at the end of reperfusion. Resveratrol 25-36 vascular endothelial growth factor A Rattus norvegicus 98-102 15905131-10 2005 The results of this study demonstrate that resveratrol leads to a coordinated upregulation of iNOS-VEGF-KDR-eNOS, which is likely to play a role in resveratrol-mediated cardioprotection. Resveratrol 43-54 vascular endothelial growth factor A Rattus norvegicus 99-103 15905131-10 2005 The results of this study demonstrate that resveratrol leads to a coordinated upregulation of iNOS-VEGF-KDR-eNOS, which is likely to play a role in resveratrol-mediated cardioprotection. Resveratrol 148-159 vascular endothelial growth factor A Rattus norvegicus 99-103 15498849-3 2005 Currently, we show that H-2g induces release of EC angiogenic basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF), an effect inhibited by decoy nuclear factor kappaB (NFkappaB) oligodeoxynucleotide (ODN). Oligodeoxyribonucleotides 209-229 vascular endothelial growth factor A Rattus norvegicus 104-138 15792788-1 2005 We have previously reported that repeated oral doses of celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, reduced diabetes-induced retinal vascular endothelial growth factor (VEGF) expression [Ayalasomayajula, S.P., Kompella, U.B., 2003. Celecoxib 56-65 vascular endothelial growth factor A Rattus norvegicus 148-182 15792788-1 2005 We have previously reported that repeated oral doses of celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, reduced diabetes-induced retinal vascular endothelial growth factor (VEGF) expression [Ayalasomayajula, S.P., Kompella, U.B., 2003. Celecoxib 56-65 vascular endothelial growth factor A Rattus norvegicus 184-188 15792788-2 2005 Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. Celecoxib 0-9 vascular endothelial growth factor A Rattus norvegicus 68-102 15790414-9 2005 When VEGF was inhibited by dexamethasone treatment or by the local application of a blocking antibody, the angiogenic response was strongly inhibited within the hypothalamic magnocellular nuclei of hyperosmotically stimulated rats. Dexamethasone 27-40 vascular endothelial growth factor A Rattus norvegicus 5-9 15498849-3 2005 Currently, we show that H-2g induces release of EC angiogenic basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF), an effect inhibited by decoy nuclear factor kappaB (NFkappaB) oligodeoxynucleotide (ODN). Oligodeoxyribonucleotides 209-229 vascular endothelial growth factor A Rattus norvegicus 140-144 15498849-3 2005 Currently, we show that H-2g induces release of EC angiogenic basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF), an effect inhibited by decoy nuclear factor kappaB (NFkappaB) oligodeoxynucleotide (ODN). Oligodeoxyribonucleotides 231-234 vascular endothelial growth factor A Rattus norvegicus 104-138 15498849-3 2005 Currently, we show that H-2g induces release of EC angiogenic basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF), an effect inhibited by decoy nuclear factor kappaB (NFkappaB) oligodeoxynucleotide (ODN). Oligodeoxyribonucleotides 231-234 vascular endothelial growth factor A Rattus norvegicus 140-144 15732037-0 2005 Carvedilol modulates the expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in a rat model of volume-overload heart failure. Carvedilol 0-10 vascular endothelial growth factor A Rattus norvegicus 75-109 15748867-4 2005 Furthermore, using 2 sizes of capsules (small/large) with different secreting quantities, 6-OHDA-treated rats receiving the small capsule filled with VEGF-secreting cells (BHK-VEGF) into the striatum showed a significant decrease in amphetamine-induced rotational behavior in number and a significant preservation of TH-positive fibers compared to those receiving the large BHK-VEGF capsule as well as those receiving BHK-Control capsule. Oxidopamine 90-96 vascular endothelial growth factor A Rattus norvegicus 150-154 15748867-4 2005 Furthermore, using 2 sizes of capsules (small/large) with different secreting quantities, 6-OHDA-treated rats receiving the small capsule filled with VEGF-secreting cells (BHK-VEGF) into the striatum showed a significant decrease in amphetamine-induced rotational behavior in number and a significant preservation of TH-positive fibers compared to those receiving the large BHK-VEGF capsule as well as those receiving BHK-Control capsule. Oxidopamine 90-96 vascular endothelial growth factor A Rattus norvegicus 176-180 15748867-4 2005 Furthermore, using 2 sizes of capsules (small/large) with different secreting quantities, 6-OHDA-treated rats receiving the small capsule filled with VEGF-secreting cells (BHK-VEGF) into the striatum showed a significant decrease in amphetamine-induced rotational behavior in number and a significant preservation of TH-positive fibers compared to those receiving the large BHK-VEGF capsule as well as those receiving BHK-Control capsule. Amphetamine 233-244 vascular endothelial growth factor A Rattus norvegicus 150-154 15748867-4 2005 Furthermore, using 2 sizes of capsules (small/large) with different secreting quantities, 6-OHDA-treated rats receiving the small capsule filled with VEGF-secreting cells (BHK-VEGF) into the striatum showed a significant decrease in amphetamine-induced rotational behavior in number and a significant preservation of TH-positive fibers compared to those receiving the large BHK-VEGF capsule as well as those receiving BHK-Control capsule. Amphetamine 233-244 vascular endothelial growth factor A Rattus norvegicus 176-180 15748867-6 2005 High-dose administration of VEGF might cause poor circulation related to brain edema, although low-dose administration of VEGF displays neuroprotective effects on DA neurons. Dopamine 163-165 vascular endothelial growth factor A Rattus norvegicus 122-126 15740736-1 2005 Calcium dobesilate reduces vascular endothelial growth factor (VEGF) over-expression in diabetic rat retina, but its effect on intraocular angiogenesis is unknown. Calcium Dobesilate 0-18 vascular endothelial growth factor A Rattus norvegicus 27-61 15740736-1 2005 Calcium dobesilate reduces vascular endothelial growth factor (VEGF) over-expression in diabetic rat retina, but its effect on intraocular angiogenesis is unknown. Calcium Dobesilate 0-18 vascular endothelial growth factor A Rattus norvegicus 63-67 15740736-6 2005 In vitro, calcium dobesilate dose- and time-dependently inhibited both microvessel formation and VEGF production, at concentrations >or=25 mug/ml (i.e. >or=60 microM), with complete inhibition at 100 microg/ml. Calcium Dobesilate 10-28 vascular endothelial growth factor A Rattus norvegicus 97-101 15721625-12 2005 CONCLUSIONS: Pioglitazone is effective in decreasing the density of angiogenesis in a VEGF-induced neovascular rat cornea model. Pioglitazone 13-25 vascular endothelial growth factor A Rattus norvegicus 86-90 15723445-6 2005 Administration of an adenovirus encoding CT-1 to NS-398-treated rats restituted normal levels of COX-1, prostaglandins, and VEGF in the liver after partial hepatectomy and restored normal liver regeneration. Nitrogen 49-51 vascular endothelial growth factor A Rattus norvegicus 124-128 15723445-9 2005 In conclusion, COX-2 activation and production of prostaglandins soon after partial hepatectomy are essential requirements for hepatocyte proliferation and for the correct induction of both CT-1 and VEGF. Prostaglandins 50-64 vascular endothelial growth factor A Rattus norvegicus 199-203 15732037-14 2005 Treatment with carvedilol is associated with a reversal of abnormal regulation of HIF-1alpha and VEGF in the failing ventricular myocardium. Carvedilol 15-25 vascular endothelial growth factor A Rattus norvegicus 97-101 15763178-0 2005 Vascular endothelial growth factor counteracts NMDA-induced cell death of adult cholinergic neurons in rat basal nucleus of Meynert. N-Methylaspartate 47-51 vascular endothelial growth factor A Rattus norvegicus 0-34 15763178-2 2005 The aim of the present study was to observe if VEGF can counteract the excitotoxic N-methyl-D-aspartate (NMDA)-induced cell death of cholinergic neurons of the basal nucleus of Meynert in vivo in adult rats. N-Methylaspartate 83-103 vascular endothelial growth factor A Rattus norvegicus 47-51 15763178-2 2005 The aim of the present study was to observe if VEGF can counteract the excitotoxic N-methyl-D-aspartate (NMDA)-induced cell death of cholinergic neurons of the basal nucleus of Meynert in vivo in adult rats. N-Methylaspartate 105-109 vascular endothelial growth factor A Rattus norvegicus 47-51 15966693-7 2005 RESULTS: Extravasation of Evans Blue dye was found in all specimens injected with rVEGF, and was quantified using a spectrophotometer. Evans Blue 26-36 vascular endothelial growth factor A Rattus norvegicus 82-87 15821839-2 2005 METHODS: Vascular endothelial growth factor (VEGF) (25 ng/mL) was added to cultured fetal cardiomyocytes labeled with bromodeoxyuridine (BrDU), which was injected into the border zones of myocardial infarction 4 weeks after coronary occlusion in rat hearts. Bromodeoxyuridine 118-135 vascular endothelial growth factor A Rattus norvegicus 9-43 15821839-2 2005 METHODS: Vascular endothelial growth factor (VEGF) (25 ng/mL) was added to cultured fetal cardiomyocytes labeled with bromodeoxyuridine (BrDU), which was injected into the border zones of myocardial infarction 4 weeks after coronary occlusion in rat hearts. Bromodeoxyuridine 118-135 vascular endothelial growth factor A Rattus norvegicus 45-49 15821839-2 2005 METHODS: Vascular endothelial growth factor (VEGF) (25 ng/mL) was added to cultured fetal cardiomyocytes labeled with bromodeoxyuridine (BrDU), which was injected into the border zones of myocardial infarction 4 weeks after coronary occlusion in rat hearts. Bromodeoxyuridine 137-141 vascular endothelial growth factor A Rattus norvegicus 9-43 15821839-2 2005 METHODS: Vascular endothelial growth factor (VEGF) (25 ng/mL) was added to cultured fetal cardiomyocytes labeled with bromodeoxyuridine (BrDU), which was injected into the border zones of myocardial infarction 4 weeks after coronary occlusion in rat hearts. Bromodeoxyuridine 137-141 vascular endothelial growth factor A Rattus norvegicus 45-49 15732037-11 2005 Treatment with carvedilol reversed both protein and mRNA of HIF-1alpha, VEGF, BNP, and NGF-beta to the baseline values. Carvedilol 15-25 vascular endothelial growth factor A Rattus norvegicus 72-76 16294503-8 2005 The VEGF protein concentration was higher in diabetic rats than in the nondiabetic rats (21.5 +/- 2.1 vs 27.7 +/- 5.8 pg/mg, p < 0.05), and this increase was attenuated by 10 mg/kg troxerutin (24.5 +/- 3.8 pg/mg, p < 0.05) and prevented by 50 mg/kg troxerutin (19.5 +/- 2.2 pg/mg, p < 0.05). troxerutin 184-194 vascular endothelial growth factor A Rattus norvegicus 4-8 28871857-0 2005 Encapsulation of Islets in Rough Surface, Hydroxymethylated Polysulfone Capillaries Stimulates VEGF Release and Promotes Vascularization after Transplantation. polysulfone P 1700 60-71 vascular endothelial growth factor A Rattus norvegicus 95-99 15708125-1 2005 Vascular endothelial-cadherin (VE-cadherin), a calcium-dependent homotypic adhesion molecule, contributes to endothelial assembly and VEGF-mediated survival during angiogenesis. Calcium 47-54 vascular endothelial growth factor A Rattus norvegicus 134-138 15708125-10 2005 L-NAME (a NOS inhibitor) reduced the VEGF-increased expression and L-arginine reversed the inhibitory effect of L-NAME. NG-Nitroarginine Methyl Ester 0-6 vascular endothelial growth factor A Rattus norvegicus 37-41 16294503-8 2005 The VEGF protein concentration was higher in diabetic rats than in the nondiabetic rats (21.5 +/- 2.1 vs 27.7 +/- 5.8 pg/mg, p < 0.05), and this increase was attenuated by 10 mg/kg troxerutin (24.5 +/- 3.8 pg/mg, p < 0.05) and prevented by 50 mg/kg troxerutin (19.5 +/- 2.2 pg/mg, p < 0.05). troxerutin 255-265 vascular endothelial growth factor A Rattus norvegicus 4-8 15643138-5 2005 AT1 receptor antagonism attenuated gene expression of these cytokines and receptors, yet PD123319, which had no effect on blood pressure, reduced VEGF-R2 and Ang-1 gene expression and decreased VEGF, Ang-1 and Ang-2 protein levels. PD 123319 89-97 vascular endothelial growth factor A Rattus norvegicus 146-150 15881419-0 2005 Encapsulation of islets in rough surface, hydroxymethylated polysulfone capillaries stimulates VEGF release and promotes vascularization after transplantation. polysulfone P 1700 60-71 vascular endothelial growth factor A Rattus norvegicus 95-99 16132581-13 2005 RESULTS: The VEGF and TNFalpha levels decreased rapidly after taurolidine therapy with low doses in vitro. taurolidine 62-73 vascular endothelial growth factor A Rattus norvegicus 13-17 15942707-0 2005 Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in pressure-overloaded rat heart. Carvedilol 0-10 vascular endothelial growth factor A Rattus norvegicus 98-132 15942707-14 2005 Treatment with carvedilol reversed both protein and mRNA of HIF-1alpha, VEGF, BNP, and NGF-beta to the baseline values. Carvedilol 15-25 vascular endothelial growth factor A Rattus norvegicus 72-76 15942707-17 2005 Treatment with carvedilol is associated with a reversal of abnormal regulation of HIF-1alpha, VEGF, BNP, and NGF-beta in the hypertrophic myocardium. Carvedilol 15-25 vascular endothelial growth factor A Rattus norvegicus 94-98 16032725-11 2005 There was a significant increase in survival of prefabricated flaps in the Ad-VEGF group compared to the control groups: Ad-VEGF, 88.9 +/- 6.1% vs. Ad-GFP, 65.6 +/- 9.4% (P < 0.05) and saline, 56.0 +/- 3.4% (P < 0.05). Sodium Chloride 188-194 vascular endothelial growth factor A Rattus norvegicus 78-82 15592104-5 2005 Intracavernous injection of VEGF was administered to randomly selected STZ diabetic rats 6 weeks after STZ injections. Streptozocin 71-74 vascular endothelial growth factor A Rattus norvegicus 28-32 16101023-4 2005 Taking in consideration the wide extension of PBP during BDL, aim of our study is to investigate the role of VEGF in stimulating angiogenesis and also in the modulation of epithelial cells proliferation. Monobenzone 46-49 vascular endothelial growth factor A Rattus norvegicus 109-113 15637440-5 2005 VEGF signaling was probed using NO synthase inhibition (L-NNA), calcium channel blockade (lanthanum chloride) and withdrawal (calcium-free solution), and inhibitors of the PLC-PKC cascade (U-73122 and chelerythrine chloride, respectively). Nitroarginine 56-61 vascular endothelial growth factor A Rattus norvegicus 0-4 15637440-5 2005 VEGF signaling was probed using NO synthase inhibition (L-NNA), calcium channel blockade (lanthanum chloride) and withdrawal (calcium-free solution), and inhibitors of the PLC-PKC cascade (U-73122 and chelerythrine chloride, respectively). lanthanum chloride 90-108 vascular endothelial growth factor A Rattus norvegicus 0-4 15637440-5 2005 VEGF signaling was probed using NO synthase inhibition (L-NNA), calcium channel blockade (lanthanum chloride) and withdrawal (calcium-free solution), and inhibitors of the PLC-PKC cascade (U-73122 and chelerythrine chloride, respectively). Calcium 64-71 vascular endothelial growth factor A Rattus norvegicus 0-4 15637440-5 2005 VEGF signaling was probed using NO synthase inhibition (L-NNA), calcium channel blockade (lanthanum chloride) and withdrawal (calcium-free solution), and inhibitors of the PLC-PKC cascade (U-73122 and chelerythrine chloride, respectively). 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione 189-196 vascular endothelial growth factor A Rattus norvegicus 0-4 15637440-5 2005 VEGF signaling was probed using NO synthase inhibition (L-NNA), calcium channel blockade (lanthanum chloride) and withdrawal (calcium-free solution), and inhibitors of the PLC-PKC cascade (U-73122 and chelerythrine chloride, respectively). chelerythrine 201-223 vascular endothelial growth factor A Rattus norvegicus 0-4 15637440-8 2005 Inhibition of PLC, PKC, and calcium signaling, but not NO, attenuated the response to VEGF. Calcium 28-35 vascular endothelial growth factor A Rattus norvegicus 86-90 15637440-10 2005 CONCLUSIONS: These results demonstrate uterine venous permeability to intermediate-sized solutes through a VEGF-sensitive pathway involving calcium and PLC-PKC, but not NO, and further substantiate a role for veno-arterial communication in uterine blood flow regulation during pregnancy. Calcium 140-147 vascular endothelial growth factor A Rattus norvegicus 107-111 15703462-9 2005 The effect of TGF-beta on PMC VEGF gene expression and protein synthesis was inhibited by PD98059 (a specific MAP kinase inhibitor) and chelerythrine (a specific protein kinase C inhibitor), but not cholera toxin (activator of cyclic AMP) or herbimycin A (inhibitor of protein tyrosine kinase). chelerythrine 136-149 vascular endothelial growth factor A Rattus norvegicus 30-34 15703462-9 2005 The effect of TGF-beta on PMC VEGF gene expression and protein synthesis was inhibited by PD98059 (a specific MAP kinase inhibitor) and chelerythrine (a specific protein kinase C inhibitor), but not cholera toxin (activator of cyclic AMP) or herbimycin A (inhibitor of protein tyrosine kinase). 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 90-97 vascular endothelial growth factor A Rattus norvegicus 30-34 15703462-9 2005 The effect of TGF-beta on PMC VEGF gene expression and protein synthesis was inhibited by PD98059 (a specific MAP kinase inhibitor) and chelerythrine (a specific protein kinase C inhibitor), but not cholera toxin (activator of cyclic AMP) or herbimycin A (inhibitor of protein tyrosine kinase). Cyclic AMP 227-237 vascular endothelial growth factor A Rattus norvegicus 30-34 15703462-9 2005 The effect of TGF-beta on PMC VEGF gene expression and protein synthesis was inhibited by PD98059 (a specific MAP kinase inhibitor) and chelerythrine (a specific protein kinase C inhibitor), but not cholera toxin (activator of cyclic AMP) or herbimycin A (inhibitor of protein tyrosine kinase). herbimycin 242-254 vascular endothelial growth factor A Rattus norvegicus 30-34 15590979-3 2004 Here we examined the relationship between VEGF and the expression of prostaglandin (PG)- metabolizing enzymes in rat ovarian luteal cells. Prostaglandins 69-82 vascular endothelial growth factor A Rattus norvegicus 42-46 15579770-0 2004 Thyrotropin (TSH)-induced production of vascular endothelial growth factor in thyroid cancer cells in vitro: evaluation of TSH signal transduction and of angiogenesis-stimulating growth factors. Thyrotropin 13-16 vascular endothelial growth factor A Rattus norvegicus 40-74 15579770-4 2004 Therefore, the aim of the current study was to 1) establish the effect of TSH on VEGF as well as 2) evaluate the TSH signal transduction of this effect, and 3) screen other growth factors for the ability to modulate VEGF in thyroid cancer cell lines. Thyrotropin 74-77 vascular endothelial growth factor A Rattus norvegicus 81-85 15579770-7 2004 TSHr signal transduction was evaluated by analyzing the effect of stimulators (cholera toxin, 8-bromo-cAMP, forskolin, and 12-O-tetradecanoyl-phorbol-13-acetate) and inhibitors (2",5"-dideoxyadenosine and staurosporine) on VEGF protein levels under basal and TSH-stimulated conditions. Thyrotropin 0-3 vascular endothelial growth factor A Rattus norvegicus 223-227 15579770-9 2004 The effects of TSH were mediated by protein kinase C (PKC), rather than protein kinase A (PKA), stimulation, because inhibition of PKC by staurosporine resulted in a decrease in VEGF production of up to 65%, whereas inhibition of the PKA signal transduction pathway (2",5"-dideoxyadenosine) resulted in only a minor decrease. Staurosporine 138-151 vascular endothelial growth factor A Rattus norvegicus 178-182 15569324-5 2004 Alterations of angiogenic competence in ZDF rats were associated with altered expression of vascular endothelial growth factor (VEGF), reduced expression of Flk-1, and neuropilin. zdf 40-43 vascular endothelial growth factor A Rattus norvegicus 92-126 15569324-5 2004 Alterations of angiogenic competence in ZDF rats were associated with altered expression of vascular endothelial growth factor (VEGF), reduced expression of Flk-1, and neuropilin. zdf 40-43 vascular endothelial growth factor A Rattus norvegicus 128-132 15780476-0 2005 Reduction of a vascular endothelial growth factor receptor, fetal liver kinase-1, by antisense oligonucleotides induces motor neuron death in rat spinal cord exposed to hypoxia. Oligonucleotides 95-111 vascular endothelial growth factor A Rattus norvegicus 15-49 15358675-1 2004 Activation of endothelial nitric oxide synthase (eNOS) and subsequent nitric oxide production (NO) are events that mediate the effect of important angiogenic, vasopermeability, and vasorelaxation factors, including vascular endothelial growth factor (VEGF), bradykinin (BK), and acetylcholine (ACh). nitric 26-32 vascular endothelial growth factor A Rattus norvegicus 215-249 15358675-1 2004 Activation of endothelial nitric oxide synthase (eNOS) and subsequent nitric oxide production (NO) are events that mediate the effect of important angiogenic, vasopermeability, and vasorelaxation factors, including vascular endothelial growth factor (VEGF), bradykinin (BK), and acetylcholine (ACh). nitric 26-32 vascular endothelial growth factor A Rattus norvegicus 251-255 15358675-1 2004 Activation of endothelial nitric oxide synthase (eNOS) and subsequent nitric oxide production (NO) are events that mediate the effect of important angiogenic, vasopermeability, and vasorelaxation factors, including vascular endothelial growth factor (VEGF), bradykinin (BK), and acetylcholine (ACh). Nitric Oxide 26-38 vascular endothelial growth factor A Rattus norvegicus 215-249 15358675-1 2004 Activation of endothelial nitric oxide synthase (eNOS) and subsequent nitric oxide production (NO) are events that mediate the effect of important angiogenic, vasopermeability, and vasorelaxation factors, including vascular endothelial growth factor (VEGF), bradykinin (BK), and acetylcholine (ACh). Nitric Oxide 26-38 vascular endothelial growth factor A Rattus norvegicus 251-255 15358675-1 2004 Activation of endothelial nitric oxide synthase (eNOS) and subsequent nitric oxide production (NO) are events that mediate the effect of important angiogenic, vasopermeability, and vasorelaxation factors, including vascular endothelial growth factor (VEGF), bradykinin (BK), and acetylcholine (ACh). Acetylcholine 279-292 vascular endothelial growth factor A Rattus norvegicus 215-249 15358675-1 2004 Activation of endothelial nitric oxide synthase (eNOS) and subsequent nitric oxide production (NO) are events that mediate the effect of important angiogenic, vasopermeability, and vasorelaxation factors, including vascular endothelial growth factor (VEGF), bradykinin (BK), and acetylcholine (ACh). Acetylcholine 294-297 vascular endothelial growth factor A Rattus norvegicus 215-249 15579770-13 2004 In thyroid cancer cell lines, TSH induces VEGF production involving the PKC, rather than the PKA, pathway. Thyrotropin 30-33 vascular endothelial growth factor A Rattus norvegicus 42-46 15590979-3 2004 Here we examined the relationship between VEGF and the expression of prostaglandin (PG)- metabolizing enzymes in rat ovarian luteal cells. Prostaglandins 84-86 vascular endothelial growth factor A Rattus norvegicus 42-46 15590979-5 2004 However, pretreatment of the luteal cells with a selective COX-II inhibitor, NS-398, abolished the VEGF-enhanced mPGES mRNA expression. N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide 77-83 vascular endothelial growth factor A Rattus norvegicus 99-103 15590979-6 2004 VEGF also increased PGE2 secretion. Dinoprostone 20-24 vascular endothelial growth factor A Rattus norvegicus 0-4 15590979-7 2004 Conversely, PGE2 dose-dependently stimulated VEGF mRNA expression. Dinoprostone 12-16 vascular endothelial growth factor A Rattus norvegicus 45-49 15590979-8 2004 Furthermore, VEGF induced VEGF mRNA expression, but this effect was abolished by NS-398 pretreatment. N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide 81-87 vascular endothelial growth factor A Rattus norvegicus 13-17 15590979-8 2004 Furthermore, VEGF induced VEGF mRNA expression, but this effect was abolished by NS-398 pretreatment. N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide 81-87 vascular endothelial growth factor A Rattus norvegicus 26-30 15590979-9 2004 These findings suggest that VEGF enhances PGE2 production by stimulating COX-II and mPGES expression in rat corpus luteum and that the effect of VEGF on luteal cells may be partially mediated by this stimulation of PGE2 production. Dinoprostone 42-46 vascular endothelial growth factor A Rattus norvegicus 28-32 15590979-9 2004 These findings suggest that VEGF enhances PGE2 production by stimulating COX-II and mPGES expression in rat corpus luteum and that the effect of VEGF on luteal cells may be partially mediated by this stimulation of PGE2 production. Dinoprostone 215-219 vascular endothelial growth factor A Rattus norvegicus 28-32 15590979-9 2004 These findings suggest that VEGF enhances PGE2 production by stimulating COX-II and mPGES expression in rat corpus luteum and that the effect of VEGF on luteal cells may be partially mediated by this stimulation of PGE2 production. Dinoprostone 215-219 vascular endothelial growth factor A Rattus norvegicus 145-149 15531137-8 2004 RESULTS: VEGF protein expression and MVD in the ischemic myocardium were higher in the rats receiving UMMD than in the group that did not receive UMMD. ummd 102-106 vascular endothelial growth factor A Rattus norvegicus 9-13 15521009-0 2004 Up-regulation of the enzymes involved in prostacyclin synthesis via Ras induces vascular endothelial growth factor. Epoprostenol 41-53 vascular endothelial growth factor A Rattus norvegicus 80-114 15500821-0 2004 Variable oxygen and retinal VEGF levels: correlation with incidence and severity of pathology in a rat model of oxygen-induced retinopathy. Oxygen 112-118 vascular endothelial growth factor A Rattus norvegicus 28-32 15500821-9 2004 However, VEGF levels were approximately 48 and 78% higher on post-oxygen exposure day 0 and 2, respectively, in the group treated with alternating periods of 45 and 12.5% oxygen compared to the group treated with alternating periods of 40 and 15% oxygen. Oxygen 66-72 vascular endothelial growth factor A Rattus norvegicus 9-13 15500821-9 2004 However, VEGF levels were approximately 48 and 78% higher on post-oxygen exposure day 0 and 2, respectively, in the group treated with alternating periods of 45 and 12.5% oxygen compared to the group treated with alternating periods of 40 and 15% oxygen. Oxygen 171-177 vascular endothelial growth factor A Rattus norvegicus 9-13 15500821-9 2004 However, VEGF levels were approximately 48 and 78% higher on post-oxygen exposure day 0 and 2, respectively, in the group treated with alternating periods of 45 and 12.5% oxygen compared to the group treated with alternating periods of 40 and 15% oxygen. Oxygen 171-177 vascular endothelial growth factor A Rattus norvegicus 9-13 15500821-12 2004 The results of this study suggest the existence of a threshold in the rat model of OIR, such that a small change in blood oxygen profile triggers a disproportionate increase in subsequent neovascularization, which is accompanied by more dramatic changes of retinal VEGF level than VEGFR2 or PEDF level. Oxygen 122-128 vascular endothelial growth factor A Rattus norvegicus 265-269 15521009-9 2004 The increase of VEGF was abolished after treatment with celecoxib, a selective COX-2 inhibitor. Celecoxib 56-65 vascular endothelial growth factor A Rattus norvegicus 16-20 15521009-10 2004 The addition of PGI 2 alone also induced the expression of VEGF. Epoprostenol 16-21 vascular endothelial growth factor A Rattus norvegicus 59-63 15521009-12 2004 The production of PGI(2) leads to an increase in the level of the pro-angiogenic factor VEGF, which is known to play a crucial role in the regulation of tumor-associated angiogenesis. Epoprostenol 18-24 vascular endothelial growth factor A Rattus norvegicus 88-92 15191879-9 2004 VEGF stimulates SEC production of nitric oxide. Nitric Oxide 34-46 vascular endothelial growth factor A Rattus norvegicus 0-4 15363662-0 2004 Nitric oxide-dependent synthesis of vascular endothelial growth factor is impaired by high glucose. Nitric Oxide 0-12 vascular endothelial growth factor A Rattus norvegicus 36-70 15363662-0 2004 Nitric oxide-dependent synthesis of vascular endothelial growth factor is impaired by high glucose. Glucose 91-98 vascular endothelial growth factor A Rattus norvegicus 36-70 15363662-1 2004 Synthesis of vascular endothelial growth factor (VEGF), the major angiogenic molecule, is induced by nitric oxide (NO) in various cell types, including vascular smooth muscle cells (VSMC). Nitric Oxide 101-113 vascular endothelial growth factor A Rattus norvegicus 13-47 15363662-1 2004 Synthesis of vascular endothelial growth factor (VEGF), the major angiogenic molecule, is induced by nitric oxide (NO) in various cell types, including vascular smooth muscle cells (VSMC). Nitric Oxide 101-113 vascular endothelial growth factor A Rattus norvegicus 49-53 15363662-3 2004 Here we investigated the effect of increased glucose concentration (25 mM vs. 5.5 mM) on cytokine-induced VEGF synthesis in rat VSMC. Glucose 45-52 vascular endothelial growth factor A Rattus norvegicus 106-110 15363662-8 2004 The results indicate that abnormally high concentrations of glucose can impair generation of NO and the NO-dependent VEGF synthesis. Glucose 60-67 vascular endothelial growth factor A Rattus norvegicus 117-121 15191879-10 2004 NG-nitro-L-arginine methyl ester blocked the paracrine effect of hepatocytes or stellate cells on SEC phenotype and blocked the ability of VEGF to preserve the phenotype of SEC cultured alone. NG-Nitroarginine Methyl Ester 0-32 vascular endothelial growth factor A Rattus norvegicus 139-143 15191879-12 2004 The VEGF-mediated paracrine effect of hepatocytes or stellate cells on maintenance of SEC phenotype requires autocrine production of nitric oxide by SEC. Nitric Oxide 133-145 vascular endothelial growth factor A Rattus norvegicus 4-8 15381036-0 2004 Inhibition of in vitro VEGF expression and choroidal neovascularization by synthetic dendrimer peptide mediated delivery of a sense oligonucleotide. Oligonucleotides 132-147 vascular endothelial growth factor A Rattus norvegicus 23-27 15231711-5 2004 We found that VEGF is involved in blood flow regulation with an activity equal to that of dihydrotestosterone (DHT). Dihydrotestosterone 90-109 vascular endothelial growth factor A Rattus norvegicus 14-18 15231711-5 2004 We found that VEGF is involved in blood flow regulation with an activity equal to that of dihydrotestosterone (DHT). Dihydrotestosterone 111-114 vascular endothelial growth factor A Rattus norvegicus 14-18 15231711-7 2004 The elevating effect of DHT on castrated rat prostate blood flow was abolished by coadministration of DHT with neutralizing anti-VEGF antibody. Dihydrotestosterone 24-27 vascular endothelial growth factor A Rattus norvegicus 129-133 15231711-7 2004 The elevating effect of DHT on castrated rat prostate blood flow was abolished by coadministration of DHT with neutralizing anti-VEGF antibody. Dihydrotestosterone 102-105 vascular endothelial growth factor A Rattus norvegicus 129-133 15381036-2 2004 We have previously described a sense oligonucleotide (ODN-1) that possesses anti-human and rat VEGF activity. Oligonucleotides 37-52 vascular endothelial growth factor A Rattus norvegicus 95-99 15474083-9 2004 Both rofecoxib and leuprolide statistically significantly decreased VEGF levels compared with controls. rofecoxib 5-14 vascular endothelial growth factor A Rattus norvegicus 68-72 15473891-6 2004 CONCLUSIONS: In VSMCs from humans and insulin-sensitive Zucker fa/+rats: (i) insulin increases VEGF protein expression and secretion via both PI3-K and MAPK; (ii) the insulin effects on VEGF are mediated by nitric oxide. Nitric Oxide 207-219 vascular endothelial growth factor A Rattus norvegicus 186-190 15473891-1 2004 BACKGROUND: We aimed to evaluate whether insulin influences vascular endothelial growth factor (VEGF) synthesis and secretion in cultured vascular smooth muscle cells (VSMCs) via nitric oxide (NO) and whether these putative effects are lost in insulin-resistant states. Nitric Oxide 179-191 vascular endothelial growth factor A Rattus norvegicus 60-94 15473891-1 2004 BACKGROUND: We aimed to evaluate whether insulin influences vascular endothelial growth factor (VEGF) synthesis and secretion in cultured vascular smooth muscle cells (VSMCs) via nitric oxide (NO) and whether these putative effects are lost in insulin-resistant states. Nitric Oxide 179-191 vascular endothelial growth factor A Rattus norvegicus 96-100 15473891-3 2004 RESULTS: We found that in VSMCs from humans and from insulin-sensitive Zucker fa/+rats, insulin increases VEGF protein expression and secretion, with mechanisms blunted by wortmannin and LY294002 (PI3-K inhibitors), PD98059 (MAPK inhibitor), L-NMMA (NOS inhibitor) and Rp-8pCT-cGMPs (PKG inhibitor). Wortmannin 172-182 vascular endothelial growth factor A Rattus norvegicus 106-110 15473891-3 2004 RESULTS: We found that in VSMCs from humans and from insulin-sensitive Zucker fa/+rats, insulin increases VEGF protein expression and secretion, with mechanisms blunted by wortmannin and LY294002 (PI3-K inhibitors), PD98059 (MAPK inhibitor), L-NMMA (NOS inhibitor) and Rp-8pCT-cGMPs (PKG inhibitor). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 187-195 vascular endothelial growth factor A Rattus norvegicus 106-110 15474083-10 2004 CONCLUSION(S): Rofecoxib causes regression and atrophy of the endometriotic lesions and is as effective as a GnRH agonist with an accompanying decrease in the VEGF levels. rofecoxib 15-24 vascular endothelial growth factor A Rattus norvegicus 159-163 15474085-9 2004 Although VEGF immunoreactivity was lower in the stimulation regimen plus enalapril group compared with the stimulation regimen-only group, the difference was insignificant. Enalapril 73-82 vascular endothelial growth factor A Rattus norvegicus 9-13 15553225-1 2004 PURPOSE: We have previously demonstrated that celecoxib, a selective COX-2 inhibitor, reaches the retina following repeated oral administrations and inhibits diabetes-induced vascular endothelial growth factor (VEGF) mRNA expression and vascular leakage in a rat model. Celecoxib 46-55 vascular endothelial growth factor A Rattus norvegicus 175-209 15454854-7 2004 The amount of VEGF increased in both the muscles injected with SOV and those injected with the saline but did not differ significantly. Sodium Chloride 95-101 vascular endothelial growth factor A Rattus norvegicus 14-18 15525586-8 2004 Urinary VEGF levels also showed a significant positive correlation with UAE (r=0.262, P=0.045) and serum creatinine (r=0.398, P=0.044), and were found to be independently correlated with UAE by Spearman"s rank correlation. Creatinine 105-115 vascular endothelial growth factor A Rattus norvegicus 8-12 15553225-1 2004 PURPOSE: We have previously demonstrated that celecoxib, a selective COX-2 inhibitor, reaches the retina following repeated oral administrations and inhibits diabetes-induced vascular endothelial growth factor (VEGF) mRNA expression and vascular leakage in a rat model. Celecoxib 46-55 vascular endothelial growth factor A Rattus norvegicus 211-215 15305185-2 2004 ZD6474 is a potent inhibitor of VEGF-R2 tyrosine kinase activity, but with additional inhibitory effects on other growth factors. vandetanib 0-6 vascular endothelial growth factor A Rattus norvegicus 32-36 15555311-7 2004 While in bleomycin treated groups, the expression of VEGF increased markedly. Bleomycin 9-18 vascular endothelial growth factor A Rattus norvegicus 53-57 15555311-10 2004 CONCLUSION: The high expression of VEGF is related to vascular endothelial cells injury which may be one of important factors in the formation of bleomycin-induced pulmonary fibrosis. Bleomycin 146-155 vascular endothelial growth factor A Rattus norvegicus 35-39 15313369-5 2004 Further studies on the mechanisms of DMCs to promote wound healing indicate that the supernatant of DMCs could promote the proliferation of fibroblasts and epidermal cells; DMCs expressed transcripts of a series of cytokines and extracellular matrix molecules, including VEGF, PDGF, HGF, TGF-beta, ICAM-1, VCAM-1, and Fibronectin, which were closely related to the wound healing by DNA microarray analysis. methyl carbonate 100-104 vascular endothelial growth factor A Rattus norvegicus 271-275 15331199-8 2004 SU5416 treatment corrected increased RI via increased iNOS in spite of increased ET-1, ET-3 and VEGF mRNA expression. Semaxinib 0-6 vascular endothelial growth factor A Rattus norvegicus 96-100 15339980-5 2004 Upregulation of glomerular VEGF mRNA and protein expression, in particular of the VEGF(164) splicing variant, occurred similarly in L-NIL-treated and untreated nephritic rats on days 2 and 7. L-NIL 132-137 vascular endothelial growth factor A Rattus norvegicus 27-31 15339980-6 2004 However, the upregulation of glomerular VEGF receptor 1 and 2 mRNA expression on day 2 was reduced by 77 and 67%, respectively, in L-NIL-treated nephritic rats as compared with untreated nephritic rats. L-NIL 131-136 vascular endothelial growth factor A Rattus norvegicus 40-44 15339980-7 2004 In parallel, glomerular VEGF(165) binding was reduced by 34% in L-NIL-treated nephritic rats on day 2. L-NIL 64-69 vascular endothelial growth factor A Rattus norvegicus 24-28 15339980-8 2004 Glomerular upregulation of the VEGF(164) co-receptor neuropilin-1 mRNA in nephritic rats was reduced by L-NIL treatment only on day 7. L-NIL 104-109 vascular endothelial growth factor A Rattus norvegicus 31-35 15364005-2 2004 Under these conditions, prostaglandin production is elevated, which in turn leads to an increased expression of vascular endothelial growth factor (VEGF)--a growth factor implicated in vascular leakage and neovascularization. Prostaglandins 24-37 vascular endothelial growth factor A Rattus norvegicus 112-146 15364005-2 2004 Under these conditions, prostaglandin production is elevated, which in turn leads to an increased expression of vascular endothelial growth factor (VEGF)--a growth factor implicated in vascular leakage and neovascularization. Prostaglandins 24-37 vascular endothelial growth factor A Rattus norvegicus 148-152 15178644-9 2004 We postulate that changes in androgen metabolism that tend to up-regulate local dihydrotestosterone concentration and diminish estrogen synthesis, in the frontal cortex of juvenile male SHRSP, may lower levels and/or activity of VEGF and its signaling cascade and, subsequently, reduce rCBF. Dihydrotestosterone 80-99 vascular endothelial growth factor A Rattus norvegicus 229-233 15339980-0 2004 Inducible nitric oxide synthase-derived nitric oxide promotes glomerular angiogenesis via upregulation of vascular endothelial growth factor receptors. Nitric Oxide 10-22 vascular endothelial growth factor A Rattus norvegicus 106-140 15339980-1 2004 The vascular endothelial growth factor (VEGF) system is of major importance for glomerular endothelial repair in glomerulonephritis (GN) and is significantly affected by nitric oxide (NO) release. Nitric Oxide 170-182 vascular endothelial growth factor A Rattus norvegicus 4-38 15339980-1 2004 The vascular endothelial growth factor (VEGF) system is of major importance for glomerular endothelial repair in glomerulonephritis (GN) and is significantly affected by nitric oxide (NO) release. Nitric Oxide 170-182 vascular endothelial growth factor A Rattus norvegicus 40-44 15313369-5 2004 Further studies on the mechanisms of DMCs to promote wound healing indicate that the supernatant of DMCs could promote the proliferation of fibroblasts and epidermal cells; DMCs expressed transcripts of a series of cytokines and extracellular matrix molecules, including VEGF, PDGF, HGF, TGF-beta, ICAM-1, VCAM-1, and Fibronectin, which were closely related to the wound healing by DNA microarray analysis. methyl carbonate 37-41 vascular endothelial growth factor A Rattus norvegicus 271-275 15313369-5 2004 Further studies on the mechanisms of DMCs to promote wound healing indicate that the supernatant of DMCs could promote the proliferation of fibroblasts and epidermal cells; DMCs expressed transcripts of a series of cytokines and extracellular matrix molecules, including VEGF, PDGF, HGF, TGF-beta, ICAM-1, VCAM-1, and Fibronectin, which were closely related to the wound healing by DNA microarray analysis. methyl carbonate 100-104 vascular endothelial growth factor A Rattus norvegicus 271-275 15588409-3 2004 Our aim is to achieve this goal by covalently incorporating heparin into collagen matrices and by physically immobilizing angiogenic vascular endothelial growth factor (VEGF) to the heparin. Heparin 182-189 vascular endothelial growth factor A Rattus norvegicus 133-167 15588409-3 2004 Our aim is to achieve this goal by covalently incorporating heparin into collagen matrices and by physically immobilizing angiogenic vascular endothelial growth factor (VEGF) to the heparin. Heparin 182-189 vascular endothelial growth factor A Rattus norvegicus 169-173 15588409-13 2004 It is apparent that the physical binding of VEGF to heparin allows for a release that is beneficial to angiogenesis. Heparin 52-59 vascular endothelial growth factor A Rattus norvegicus 44-48 15217908-0 2004 IQGAP1, a novel vascular endothelial growth factor receptor binding protein, is involved in reactive oxygen species--dependent endothelial migration and proliferation. Reactive Oxygen Species 92-115 vascular endothelial growth factor A Rattus norvegicus 16-50 15217908-2 2004 We have demonstrated that reactive oxygen species (ROS) derived from the small GTPase Rac1-dependent NAD(P)H oxidase are involved in vascular endothelial growth factor (VEGF)-mediated endothelial responses mainly through the VEGF type2 receptor (VEGFR2). Reactive Oxygen Species 26-49 vascular endothelial growth factor A Rattus norvegicus 133-167 15217908-11 2004 These results suggest that IQGAP1 functions as a VEGFR2-associated scaffold protein to organize ROS-dependent VEGF signaling, thereby promoting EC migration and proliferation, which may contribute to repair and maintenance of the functional integrity of established blood vessels. Reactive Oxygen Species 96-99 vascular endothelial growth factor A Rattus norvegicus 49-53 15217908-2 2004 We have demonstrated that reactive oxygen species (ROS) derived from the small GTPase Rac1-dependent NAD(P)H oxidase are involved in vascular endothelial growth factor (VEGF)-mediated endothelial responses mainly through the VEGF type2 receptor (VEGFR2). Reactive Oxygen Species 26-49 vascular endothelial growth factor A Rattus norvegicus 169-173 15249212-8 2004 Chronic L-NAME administration resulted in a depletion of cardiac NO level, NOS activity, and eNOS, nNOS, and iNOS protein expressions, as well as VEGF gene expression (2-fold increase in VEGF mRNA). NG-Nitroarginine Methyl Ester 8-14 vascular endothelial growth factor A Rattus norvegicus 146-150 15249212-8 2004 Chronic L-NAME administration resulted in a depletion of cardiac NO level, NOS activity, and eNOS, nNOS, and iNOS protein expressions, as well as VEGF gene expression (2-fold increase in VEGF mRNA). NG-Nitroarginine Methyl Ester 8-14 vascular endothelial growth factor A Rattus norvegicus 187-191 15217908-2 2004 We have demonstrated that reactive oxygen species (ROS) derived from the small GTPase Rac1-dependent NAD(P)H oxidase are involved in vascular endothelial growth factor (VEGF)-mediated endothelial responses mainly through the VEGF type2 receptor (VEGFR2). Reactive Oxygen Species 26-49 vascular endothelial growth factor A Rattus norvegicus 225-229 15217908-2 2004 We have demonstrated that reactive oxygen species (ROS) derived from the small GTPase Rac1-dependent NAD(P)H oxidase are involved in vascular endothelial growth factor (VEGF)-mediated endothelial responses mainly through the VEGF type2 receptor (VEGFR2). Reactive Oxygen Species 51-54 vascular endothelial growth factor A Rattus norvegicus 133-167 15217908-2 2004 We have demonstrated that reactive oxygen species (ROS) derived from the small GTPase Rac1-dependent NAD(P)H oxidase are involved in vascular endothelial growth factor (VEGF)-mediated endothelial responses mainly through the VEGF type2 receptor (VEGFR2). Reactive Oxygen Species 51-54 vascular endothelial growth factor A Rattus norvegicus 169-173 15217908-2 2004 We have demonstrated that reactive oxygen species (ROS) derived from the small GTPase Rac1-dependent NAD(P)H oxidase are involved in vascular endothelial growth factor (VEGF)-mediated endothelial responses mainly through the VEGF type2 receptor (VEGFR2). Reactive Oxygen Species 51-54 vascular endothelial growth factor A Rattus norvegicus 225-229 15217908-7 2004 In cultured ECs, VEGF stimulation rapidly promotes recruitment of Rac1 to IQGAP1, which inducibly binds to VEGFR2 and which, in turn, is associated with tyrosine phosphorylation of IQGAP1. Tyrosine 153-161 vascular endothelial growth factor A Rattus norvegicus 17-21 15217908-8 2004 Endogenous IQGAP1 knockdown by siRNA shows that IQGAP1 is involved in VEGF-stimulated ROS production, Akt phosphorylation, endothelial migration, and proliferation. Reactive Oxygen Species 86-89 vascular endothelial growth factor A Rattus norvegicus 70-74 15064225-0 2004 Inhaled nitric oxide attenuates pulmonary hypertension and improves lung growth in infant rats after neonatal treatment with a VEGF receptor inhibitor. Nitric Oxide 8-20 vascular endothelial growth factor A Rattus norvegicus 127-131 15064225-3 2004 Nitric oxide (NO) is a downstream mediator of VEGF, but whether the effects of impaired VEGF signaling are due to decreased NO production is unknown. Nitric Oxide 0-12 vascular endothelial growth factor A Rattus norvegicus 46-50 15064225-5 2004 Newborn rats received a single dose of SU-5416 (a VEGF receptor inhibitor) or vehicle by subcutaneous injection and were killed up to 3 wk of age for assessments of right ventricular hypertrophy (RVH), radial alveolar counts (RAC), lung eNOS protein, and NOx production in isolated perfused lungs (IPL). Semaxinib 39-46 vascular endothelial growth factor A Rattus norvegicus 50-54 15289360-6 2004 Up-regulation of hypoxia inducible factor 1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) at both mRNA and protein levels were detected in the groups receiving ligation and ligation with cisplatin, whereas a decreased level of von Hippel-Lindau tumor suppressor protein was identified in the group receiving ligation with cisplatin. Cisplatin 205-214 vascular endothelial growth factor A Rattus norvegicus 66-100 15289360-6 2004 Up-regulation of hypoxia inducible factor 1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) at both mRNA and protein levels were detected in the groups receiving ligation and ligation with cisplatin, whereas a decreased level of von Hippel-Lindau tumor suppressor protein was identified in the group receiving ligation with cisplatin. Cisplatin 205-214 vascular endothelial growth factor A Rattus norvegicus 102-106 15289360-6 2004 Up-regulation of hypoxia inducible factor 1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) at both mRNA and protein levels were detected in the groups receiving ligation and ligation with cisplatin, whereas a decreased level of von Hippel-Lindau tumor suppressor protein was identified in the group receiving ligation with cisplatin. Cisplatin 340-349 vascular endothelial growth factor A Rattus norvegicus 66-100 15289360-6 2004 Up-regulation of hypoxia inducible factor 1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) at both mRNA and protein levels were detected in the groups receiving ligation and ligation with cisplatin, whereas a decreased level of von Hippel-Lindau tumor suppressor protein was identified in the group receiving ligation with cisplatin. Cisplatin 340-349 vascular endothelial growth factor A Rattus norvegicus 102-106 15289360-7 2004 Sodium salicylate enhanced expression of von Hippel-Lindau tumor suppressor protein but down-regulated HIF-1alpha and VEGF levels after ligation with or without cisplatin. Sodium Salicylate 0-17 vascular endothelial growth factor A Rattus norvegicus 118-122 15447819-10 2004 CONCLUSION: L-arginine supplementation could be beneficial to the angiogenesis in the burn wound of the rats with diabetes, as well as to wound healing by increasing the synthesis and the release of VEGF, NO and TGF-beta1 from burn wound and by decreasing the glucose content in the cutaneous tissue of diabetic rats. Arginine 12-22 vascular endothelial growth factor A Rattus norvegicus 199-203 15325574-20 2004 In the cornea, VEGF protein is dramatically upregulated 24 and 48 hr after cautery, and both indomethacin and NS-398-but not SC-560-significantly inhibited this VEGF upregulation. Indomethacin 93-105 vascular endothelial growth factor A Rattus norvegicus 161-165 15325574-20 2004 In the cornea, VEGF protein is dramatically upregulated 24 and 48 hr after cautery, and both indomethacin and NS-398-but not SC-560-significantly inhibited this VEGF upregulation. N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide 110-116 vascular endothelial growth factor A Rattus norvegicus 15-19 15325574-20 2004 In the cornea, VEGF protein is dramatically upregulated 24 and 48 hr after cautery, and both indomethacin and NS-398-but not SC-560-significantly inhibited this VEGF upregulation. N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide 110-116 vascular endothelial growth factor A Rattus norvegicus 161-165 15325574-29 2004 Intravitreal VEGF-induced BRB breakdown--which was completely blocked by VEGF neutralizing s-Flt-1/Fc protein (intravitreal co-administration; p<0.001)--was not inhibited by indomethacin (20 mg kg(-1) day(-1), s.c.). Indomethacin 177-189 vascular endothelial growth factor A Rattus norvegicus 13-17 15325574-29 2004 Intravitreal VEGF-induced BRB breakdown--which was completely blocked by VEGF neutralizing s-Flt-1/Fc protein (intravitreal co-administration; p<0.001)--was not inhibited by indomethacin (20 mg kg(-1) day(-1), s.c.). Indomethacin 177-189 vascular endothelial growth factor A Rattus norvegicus 73-77 15325574-31 2004 These results suggest that eicosanoids produced by inducible COX-2 are among multiple mediators that modulate VEGF expression as a stimulus in inflammation-associated angiogenesis. Eicosanoids 27-38 vascular endothelial growth factor A Rattus norvegicus 110-114 15170218-4 2004 Here, we show that both VEGF and VEGFR2 expression increase with histological progression to invasive disease in the rat 7,12-dimethylbenz[a]anthracene (DMBA) model. 7,12-dimethylbenz[a 121-140 vascular endothelial growth factor A Rattus norvegicus 24-28 15170218-4 2004 Here, we show that both VEGF and VEGFR2 expression increase with histological progression to invasive disease in the rat 7,12-dimethylbenz[a]anthracene (DMBA) model. anthracene 141-151 vascular endothelial growth factor A Rattus norvegicus 24-28 15170218-4 2004 Here, we show that both VEGF and VEGFR2 expression increase with histological progression to invasive disease in the rat 7,12-dimethylbenz[a]anthracene (DMBA) model. 9,10-Dimethyl-1,2-benzanthracene 153-157 vascular endothelial growth factor A Rattus norvegicus 24-28 15170218-10 2004 These data support the hypothesis that progression of DMBA-induced preinvasive mammary pathologies to palpable disease requires angiogenesis via a VEGF-dependent mechanism. 9,10-Dimethyl-1,2-benzanthracene 54-58 vascular endothelial growth factor A Rattus norvegicus 147-151 15271251-0 2004 PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization. vatalanib 0-6 vascular endothelial growth factor A Rattus norvegicus 33-67 15271251-0 2004 PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization. vatalanib 7-15 vascular endothelial growth factor A Rattus norvegicus 33-67 15271251-1 2004 OBJECTIVE: The aim of this study was to test the efficacy of PTK787/ZK222584, an inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases, on VEGF-dependent glioma vascularization and growth. vatalanib 68-76 vascular endothelial growth factor A Rattus norvegicus 94-128 15271251-1 2004 OBJECTIVE: The aim of this study was to test the efficacy of PTK787/ZK222584, an inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases, on VEGF-dependent glioma vascularization and growth. vatalanib 68-76 vascular endothelial growth factor A Rattus norvegicus 130-134 15271251-1 2004 OBJECTIVE: The aim of this study was to test the efficacy of PTK787/ZK222584, an inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases, on VEGF-dependent glioma vascularization and growth. vatalanib 68-76 vascular endothelial growth factor A Rattus norvegicus 166-170 15319002-6 2004 The area of preserved spinal cord and the levels of COX-2 and VEGF staining were significantly higher in OEC- than in DMEM-injected rats. dmem 118-122 vascular endothelial growth factor A Rattus norvegicus 62-66 15447819-10 2004 CONCLUSION: L-arginine supplementation could be beneficial to the angiogenesis in the burn wound of the rats with diabetes, as well as to wound healing by increasing the synthesis and the release of VEGF, NO and TGF-beta1 from burn wound and by decreasing the glucose content in the cutaneous tissue of diabetic rats. Glucose 260-267 vascular endothelial growth factor A Rattus norvegicus 199-203 15249173-6 2004 Calcium dobesilate significantly reduced: (i) retinal albumin leakage (by 70%, P<0.008), (ii) retinal CML-AGEs contents (by 62%, P<0.008), and (iii) retinal VEGF expression (by 69.4%, P<0.008). Calcium Dobesilate 0-18 vascular endothelial growth factor A Rattus norvegicus 163-167 15249173-7 2004 In conclusion, calcium dobesilate orally given to diabetic rats markedly reduced retinal hyperpermeability, CML-AGE contents, and VEGF overexpression. Calcium Dobesilate 15-33 vascular endothelial growth factor A Rattus norvegicus 130-134 14975929-5 2004 The VEGF receptor-2 tyrosine kinase inhibitor tyrphostin SU-1498 and the protein kinase C inhibitor bis-indolylmaleimide I (GF-109203X) suppressed the VEGF-induced increase in monolayer permeability but not that caused by NPY. Tyrphostins 46-56 vascular endothelial growth factor A Rattus norvegicus 4-8 14975929-5 2004 The VEGF receptor-2 tyrosine kinase inhibitor tyrphostin SU-1498 and the protein kinase C inhibitor bis-indolylmaleimide I (GF-109203X) suppressed the VEGF-induced increase in monolayer permeability but not that caused by NPY. Tyrphostins 46-56 vascular endothelial growth factor A Rattus norvegicus 151-155 14975929-5 2004 The VEGF receptor-2 tyrosine kinase inhibitor tyrphostin SU-1498 and the protein kinase C inhibitor bis-indolylmaleimide I (GF-109203X) suppressed the VEGF-induced increase in monolayer permeability but not that caused by NPY. SU 1498 57-64 vascular endothelial growth factor A Rattus norvegicus 4-8 14975929-5 2004 The VEGF receptor-2 tyrosine kinase inhibitor tyrphostin SU-1498 and the protein kinase C inhibitor bis-indolylmaleimide I (GF-109203X) suppressed the VEGF-induced increase in monolayer permeability but not that caused by NPY. SU 1498 57-64 vascular endothelial growth factor A Rattus norvegicus 151-155 14975929-5 2004 The VEGF receptor-2 tyrosine kinase inhibitor tyrphostin SU-1498 and the protein kinase C inhibitor bis-indolylmaleimide I (GF-109203X) suppressed the VEGF-induced increase in monolayer permeability but not that caused by NPY. bisindolylmaleimide I 100-122 vascular endothelial growth factor A Rattus norvegicus 151-155 14975929-5 2004 The VEGF receptor-2 tyrosine kinase inhibitor tyrphostin SU-1498 and the protein kinase C inhibitor bis-indolylmaleimide I (GF-109203X) suppressed the VEGF-induced increase in monolayer permeability but not that caused by NPY. bisindolylmaleimide I 124-134 vascular endothelial growth factor A Rattus norvegicus 151-155 14975929-7 2004 However, the effects of both NPY and VEGF on the permeability of the RAEC monolayer were blocked with equal concentration dependence by STI571 (imatinib mesylate), which is an inhibitor of Abl tyrosine kinase in the nucleus and/or cytoplasm. Imatinib Mesylate 136-142 vascular endothelial growth factor A Rattus norvegicus 37-41 14975929-7 2004 However, the effects of both NPY and VEGF on the permeability of the RAEC monolayer were blocked with equal concentration dependence by STI571 (imatinib mesylate), which is an inhibitor of Abl tyrosine kinase in the nucleus and/or cytoplasm. Imatinib Mesylate 144-161 vascular endothelial growth factor A Rattus norvegicus 37-41 14975929-8 2004 The myosin light-chain kinase inhibitor 1-(5-chloronaphthalene-1-sulfonyl)-1H-hexahydro-1,4-diazepine HCl (ML-9) suppressed both NPY- and VEGF-induced increment in permeability by approximately 70%, whereas the calmodulin-dependent kinase inhibitor DY-9760e could decrease to below the baseline. ML 9 40-105 vascular endothelial growth factor A Rattus norvegicus 138-142 15305228-2 2004 The aim of this study was to determine the effects of an angiotensin II type I (AT-1) receptor antagonist and an ACE inhibitor on the pathogenesis of VEGF and ET-1-mediated kidney disease in STZ-induced diabetic rats. Streptozocin 191-194 vascular endothelial growth factor A Rattus norvegicus 150-154 15384251-0 2004 Analysis of vascular endothelial growth factor (VEGF) and a receptor subtype (KDR/flk-1) in the liver of rats exposed to riddelliine: a potential role in the development of hemangiosarcoma. riddelliine 121-132 vascular endothelial growth factor A Rattus norvegicus 12-46 15384251-1 2004 Riddelliine alters hepatocellular and endothelial cell kinetics and function including stimulating an increase in hepatocytic vascular endothelial growth factor (VEGF) in the absence of increased serological levels of VEGF (NYSKA et al. riddelliine 0-11 vascular endothelial growth factor A Rattus norvegicus 126-160 15384251-1 2004 Riddelliine alters hepatocellular and endothelial cell kinetics and function including stimulating an increase in hepatocytic vascular endothelial growth factor (VEGF) in the absence of increased serological levels of VEGF (NYSKA et al. riddelliine 0-11 vascular endothelial growth factor A Rattus norvegicus 162-166 15384251-3 2004 The objective of this study was to further assess hepatic VEGF and KDR/flk-1 synthesis and expression by hepatic cells under riddelliine treatment conditions. riddelliine 125-136 vascular endothelial growth factor A Rattus norvegicus 58-62 15305228-6 2004 Administration of enalapril maleate also suppressed the elevated renal VEGF protein content in these animals while candesartan cilexetil treatment had no effect. Enalapril 18-35 vascular endothelial growth factor A Rattus norvegicus 71-75 15087306-4 2004 Moreover, we showed that intravenous injection of PEth incorporated into HDL particles increased plasma concentration of VEGF by 2.4-fold in rats in vivo. phosphatidylethanol 50-54 vascular endothelial growth factor A Rattus norvegicus 121-125 15201557-0 2004 Betaxolol stimulates eNOS production associated with LOX-1 and VEGF in Dahl salt-sensitive rats. Betaxolol 0-9 vascular endothelial growth factor A Rattus norvegicus 63-67 15201557-1 2004 OBJECTIVE: Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) and vascular endothelial growth factor (VEGF) may play key roles in atherosclerosis, and have been shown to regulate nitric oxide (NO) production. Nitric Oxide 192-204 vascular endothelial growth factor A Rattus norvegicus 79-113 15201557-1 2004 OBJECTIVE: Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) and vascular endothelial growth factor (VEGF) may play key roles in atherosclerosis, and have been shown to regulate nitric oxide (NO) production. Nitric Oxide 192-204 vascular endothelial growth factor A Rattus norvegicus 115-119 15201557-2 2004 However, the molecular mechanisms by which betaxolol, a specific beta 1-antagonist, stimulates endothelial NO synthase (eNOS) expression associated with LOX-1 and VEGF are unclear. Betaxolol 43-52 vascular endothelial growth factor A Rattus norvegicus 163-167 15201557-3 2004 We hypothesized that in the left ventricle of Dahl salt-sensitive (DS) rats, betaxolol reduces production of LOX-1 by suppressing NAD(P)H oxidase p47phox expression; betaxolol stimulates eNOS production associated with expression of VEGF and LOX-1; and betaxolol inhibits adhesion molecule and signal transduction, which may be involved in cardiovascular remodeling. Betaxolol 77-86 vascular endothelial growth factor A Rattus norvegicus 233-237 15201557-3 2004 We hypothesized that in the left ventricle of Dahl salt-sensitive (DS) rats, betaxolol reduces production of LOX-1 by suppressing NAD(P)H oxidase p47phox expression; betaxolol stimulates eNOS production associated with expression of VEGF and LOX-1; and betaxolol inhibits adhesion molecule and signal transduction, which may be involved in cardiovascular remodeling. Betaxolol 166-175 vascular endothelial growth factor A Rattus norvegicus 233-237 15201557-3 2004 We hypothesized that in the left ventricle of Dahl salt-sensitive (DS) rats, betaxolol reduces production of LOX-1 by suppressing NAD(P)H oxidase p47phox expression; betaxolol stimulates eNOS production associated with expression of VEGF and LOX-1; and betaxolol inhibits adhesion molecule and signal transduction, which may be involved in cardiovascular remodeling. Betaxolol 166-175 vascular endothelial growth factor A Rattus norvegicus 233-237 15201557-6 2004 RESULTS: Decreased expression of eNOS and VEGF in DS rats was increased by betaxolol. Betaxolol 75-84 vascular endothelial growth factor A Rattus norvegicus 42-46 15201557-9 2004 CONCLUSIONS: These results suggest that cardioprotective effects of betaxolol may stimulate eNOS production associated with VEGF and LOX-1, and inhibit adhesion molecule and signal transduction in DS rats. Betaxolol 68-77 vascular endothelial growth factor A Rattus norvegicus 124-128 15178821-10 2004 In vitro, rhEPO enhanced capillary tube formation of cerebral endothelial cells, which was inhibited by a specific VEGF receptor 2 antagonist (SU1498). SU 1498 143-149 vascular endothelial growth factor A Rattus norvegicus 115-119 15180795-2 2004 This study was designed to examine the time-course changes in vascular endothelial growth factor (VEGF) expression and capillary geometry in skeletal muscles during endurance training with CoCl(2) administration in female Wistar rats. cobaltous chloride 189-196 vascular endothelial growth factor A Rattus norvegicus 62-96 15087306-0 2004 Lipoprotein-associated phosphatidylethanol increases the plasma concentration of vascular endothelial growth factor. lipoprotein-associated phosphatidylethanol 0-42 vascular endothelial growth factor A Rattus norvegicus 81-115 15202016-2 2004 In the experiments reported here, we evaluated if: a) PARP activation is present in the retina in short-term diabetes; and b) PARP inhibitors, 3-aminobenzamide and 1,5-isoquinolinediol, counteract diabetes- and hypoxia-induced retinal VEGF formation. 1,5-dihydroxyisoquinoline 164-184 vascular endothelial growth factor A Rattus norvegicus 235-239 15202016-5 2004 Retinal VEGF protein (ELISA, immunohistochemistry), but not mRNA (ribonuclease protection assay) abundance, was increased in diabetic rats, and this increase was corrected by both 3-aminobenzamide and 1,5-isoquinolinediol. 3-aminobenzamide 180-196 vascular endothelial growth factor A Rattus norvegicus 8-12 15202016-5 2004 Retinal VEGF protein (ELISA, immunohistochemistry), but not mRNA (ribonuclease protection assay) abundance, was increased in diabetic rats, and this increase was corrected by both 3-aminobenzamide and 1,5-isoquinolinediol. 1,5-dihydroxyisoquinoline 201-221 vascular endothelial growth factor A Rattus norvegicus 8-12 15202016-9 2004 In conclusion, PARP is involved in diabetes- and hypoxia-induced VEGF production at post-transcriptional level, downstream from the sorbitol pathway activation and oxidative stress. Sorbitol 132-140 vascular endothelial growth factor A Rattus norvegicus 65-69 15180795-2 2004 This study was designed to examine the time-course changes in vascular endothelial growth factor (VEGF) expression and capillary geometry in skeletal muscles during endurance training with CoCl(2) administration in female Wistar rats. cobaltous chloride 189-196 vascular endothelial growth factor A Rattus norvegicus 98-102 15180795-6 2004 RESULTS: In the soleus muscle, the density of VEGF-positive capillaries (VEGF-cap) was significantly increased after 6 and 10 days of the Co(2+) administration (by 27 and 65% respectively) while the capillary-to-fibre ratio (C : F) first increased after 10 days. Cobalt(2+) 138-144 vascular endothelial growth factor A Rattus norvegicus 46-50 15180795-6 2004 RESULTS: In the soleus muscle, the density of VEGF-positive capillaries (VEGF-cap) was significantly increased after 6 and 10 days of the Co(2+) administration (by 27 and 65% respectively) while the capillary-to-fibre ratio (C : F) first increased after 10 days. Cobalt(2+) 138-144 vascular endothelial growth factor A Rattus norvegicus 73-77 15180795-7 2004 The training with Co(2+) significantly increased VEGF-cap by 69, 44 and 60%, respectively, after 3, 6 and 10 days. Cobalt(2+) 18-24 vascular endothelial growth factor A Rattus norvegicus 49-53 15180795-10 2004 CONCLUSIONS: The present results suggest that activation of the cellular oxygen-sensing mechanism induced by Co(2+) administration slightly facilitates an expression of VEGF but does not facilitate exercise-induced microvascular remodelling in hind-leg muscles. Oxygen 73-79 vascular endothelial growth factor A Rattus norvegicus 169-173 15180795-10 2004 CONCLUSIONS: The present results suggest that activation of the cellular oxygen-sensing mechanism induced by Co(2+) administration slightly facilitates an expression of VEGF but does not facilitate exercise-induced microvascular remodelling in hind-leg muscles. Cobalt(2+) 109-115 vascular endothelial growth factor A Rattus norvegicus 169-173 15087306-7 2004 This may mediate the effects of ethanol on the arterial wall by increasing VEGF secretion from endothelial vascular cells. Ethanol 32-39 vascular endothelial growth factor A Rattus norvegicus 75-79 15145734-10 2004 In the VEGF group, total and regional flap perfusion did not change after pedicle ligation, but perfusion decreased significantly in zones B through D in the L-arginine treated rats. Arginine 158-168 vascular endothelial growth factor A Rattus norvegicus 7-11 15047143-0 2004 Rapid change of glucose concentration promotes mesangial cell proliferation via VEGF: inhibitory effects of thiazolidinedione. Glucose 16-23 vascular endothelial growth factor A Rattus norvegicus 80-84 15130775-5 2004 Plasma VEGF concentrations were significantly lower in the rosiglitazone-treated animals compared to the control animals (32.7 +/- 0.8 pg ml(-1) versus 46.1 +/- 1.2 pg ml(-1), P < 0.001). Rosiglitazone 59-72 vascular endothelial growth factor A Rattus norvegicus 7-11 14693680-8 2004 Because we have previously demonstrated that hypoxia (3% O2) can enhance VSMC proliferation induced by VEGF-A through Flt-1 receptor upregulation, the effects of hypoxia on the response of VSMCs to MCP-1 were investigated. Oxygen 57-59 vascular endothelial growth factor A Rattus norvegicus 103-109 15194408-9 2004 VEGF enhanced oxygen levels at the transplant site. Oxygen 14-20 vascular endothelial growth factor A Rattus norvegicus 0-4 15253542-2 2004 Platinum coils were prepared by successive deposition of cationic polyethyleneimine and anionic heparin, and VEGF was immobilized through affinity interaction with heparin. Heparin 164-171 vascular endothelial growth factor A Rattus norvegicus 109-113 15156404-0 2004 17beta-estradiol prevents blood-brain barrier disruption induced by VEGF. Estradiol 0-16 vascular endothelial growth factor A Rattus norvegicus 68-72 15156404-1 2004 We performed this study to determine how pretreatment of the ovariectomized rats with 17beta-estradiol could affect blood-brain barrier disruption caused by the vascular endothelial growth factor (VEGF), an important mediator of vascular permeability. Estradiol 86-102 vascular endothelial growth factor A Rattus norvegicus 161-195 15156404-1 2004 We performed this study to determine how pretreatment of the ovariectomized rats with 17beta-estradiol could affect blood-brain barrier disruption caused by the vascular endothelial growth factor (VEGF), an important mediator of vascular permeability. Estradiol 86-102 vascular endothelial growth factor A Rattus norvegicus 197-201 15156404-9 2004 The volume of dextran distribution in the control group increased by 47 % with VEGF 10 (- 9)M (p < 0.05), whereas there was no significant change in the volume of dextran distribution with VEGF application in the 17beta-estradiol group and the volume was lower than the corresponding volume of the vehicle-treated control group (10 (- 10)M: - 34 %, 10 (- 9)M: -32 %, p < 0.05). Dextrans 14-21 vascular endothelial growth factor A Rattus norvegicus 79-83 15156404-10 2004 In conclusion, our study demonstrated that chronic 17beta-estradiol treatment prevented BBB disruption induced by the VEGF in the ovariectomized rats. Estradiol 51-67 vascular endothelial growth factor A Rattus norvegicus 118-122 15063765-4 2004 As a result, expression of VEGF in HSCs was markedly elevated; and pretreatment with COX-2 inhibitors (nimesulide or indomethacin) could significantly ameliorate the angiogenic event. nimesulide 103-113 vascular endothelial growth factor A Rattus norvegicus 27-31 15063765-4 2004 As a result, expression of VEGF in HSCs was markedly elevated; and pretreatment with COX-2 inhibitors (nimesulide or indomethacin) could significantly ameliorate the angiogenic event. Indomethacin 117-129 vascular endothelial growth factor A Rattus norvegicus 27-31 15312628-1 2004 OBJECTIVE: To study the therapeutic effect of the calcium channel antagonist nimodipine on the proliferative retinopathy and it"s interaction with vascular endothelial growth factor (VEGF). Nimodipine 77-87 vascular endothelial growth factor A Rattus norvegicus 147-181 15312628-1 2004 OBJECTIVE: To study the therapeutic effect of the calcium channel antagonist nimodipine on the proliferative retinopathy and it"s interaction with vascular endothelial growth factor (VEGF). Nimodipine 77-87 vascular endothelial growth factor A Rattus norvegicus 183-187 15312628-8 2004 CONCLUSION: VEGF can induce cell proliferation by activating the calcium channel in cell membrane through which the influx of calcium is increased. Calcium 65-72 vascular endothelial growth factor A Rattus norvegicus 12-16 15312628-10 2004 Nimodipine can inhibit the expression of VEGF at certain degrees. Nimodipine 0-10 vascular endothelial growth factor A Rattus norvegicus 41-45 15047143-0 2004 Rapid change of glucose concentration promotes mesangial cell proliferation via VEGF: inhibitory effects of thiazolidinedione. 2,4-thiazolidinedione 108-125 vascular endothelial growth factor A Rattus norvegicus 80-84 15047143-3 2004 We hypothesized that VEGF participates in the pathogenesis of diabetic nephropathy and that TZD may be beneficial for the treatment of diabetic nephropathy through its effect on VEGF. 2,4-thiazolidinedione 92-95 vascular endothelial growth factor A Rattus norvegicus 178-182 15047143-4 2004 Increased VEGF expression was demonstrated in the glomeruli of DM rats and rat mesangial cells (RMC) incubated with high medium glucose. Glucose 128-135 vascular endothelial growth factor A Rattus norvegicus 10-14 15047143-5 2004 It was also demonstrated that VEGF promoted mesangial cell proliferation, which was inhibited by TZD. 2,4-thiazolidinedione 97-100 vascular endothelial growth factor A Rattus norvegicus 30-34 15047143-6 2004 It was shown that a rapid fall and rise of ambient glucose concentration induces more VEGF production and cell proliferation in RMC than in cells with continuously high glucose medium, which was also inhibited by TZD. Glucose 51-58 vascular endothelial growth factor A Rattus norvegicus 86-90 15047143-6 2004 It was shown that a rapid fall and rise of ambient glucose concentration induces more VEGF production and cell proliferation in RMC than in cells with continuously high glucose medium, which was also inhibited by TZD. 2,4-thiazolidinedione 213-216 vascular endothelial growth factor A Rattus norvegicus 86-90 15047143-7 2004 Prostaglandin J2 and protein C kinase inhibitors significantly inhibited [3H]thymidine incorporation in RMC incubated with VEGF, which was inhibited by TZD. 9-deoxy-delta-9-prostaglandin D2 0-16 vascular endothelial growth factor A Rattus norvegicus 123-127 15047143-7 2004 Prostaglandin J2 and protein C kinase inhibitors significantly inhibited [3H]thymidine incorporation in RMC incubated with VEGF, which was inhibited by TZD. Tritium 74-76 vascular endothelial growth factor A Rattus norvegicus 123-127 15047143-7 2004 Prostaglandin J2 and protein C kinase inhibitors significantly inhibited [3H]thymidine incorporation in RMC incubated with VEGF, which was inhibited by TZD. Thymidine 77-86 vascular endothelial growth factor A Rattus norvegicus 123-127 15047143-7 2004 Prostaglandin J2 and protein C kinase inhibitors significantly inhibited [3H]thymidine incorporation in RMC incubated with VEGF, which was inhibited by TZD. 2,4-thiazolidinedione 152-155 vascular endothelial growth factor A Rattus norvegicus 123-127 15047143-8 2004 These findings indicate that a rapid change of glucose concentration promotes RMC proliferation by the increased production of VEGF. Glucose 47-54 vascular endothelial growth factor A Rattus norvegicus 127-131 15259294-0 2004 Blood-retinal barrier breakdown induced by activation of protein kinase C via vascular endothelial growth factor in streptozotocin-induced diabetic rats. Streptozocin 116-130 vascular endothelial growth factor A Rattus norvegicus 78-112 15259294-1 2004 PURPOSE: To investigate (1) the mechanism of blood-retinal barrier breakdown induced by protein kinase C (PKC) activation (2) the relationship between PKC activation and vascular endothelial growth factor (VEGF) in 2-week streptozotocin-induced diabetes. Streptozocin 222-236 vascular endothelial growth factor A Rattus norvegicus 170-204 15259294-1 2004 PURPOSE: To investigate (1) the mechanism of blood-retinal barrier breakdown induced by protein kinase C (PKC) activation (2) the relationship between PKC activation and vascular endothelial growth factor (VEGF) in 2-week streptozotocin-induced diabetes. Streptozocin 222-236 vascular endothelial growth factor A Rattus norvegicus 206-210 15259294-5 2004 Alteration of retinal VEGF and blood-retinal barrier were observed after intravitreal injection of PKC inhibitor, GF109203X, in 2-week diabetic rats. bisindolylmaleimide I 114-123 vascular endothelial growth factor A Rattus norvegicus 22-26 15259294-7 2004 Retinal VEGF and retinal vascular permeability were decreased after intravitreal injection of GF109203X (10(-5), 10(-6) mol/L) in a dose-dependent manner. bisindolylmaleimide I 94-103 vascular endothelial growth factor A Rattus norvegicus 8-12 15117580-0 2004 The effect of local subcutaneous delivery of vascular endothelial growth factor on the function of a chronically implanted amperometric glucose sensor. Glucose 136-143 vascular endothelial growth factor A Rattus norvegicus 45-79 15117580-11 2004 Values for the functional measures for saline controls fell between near and distant VEGF values. Sodium Chloride 39-45 vascular endothelial growth factor A Rattus norvegicus 85-89 15019818-9 2004 CONCLUSION(S): It is speculated that GnRH-a treatment may prevent early OHSS by reducing vascular permeability through the decrease in VEGF and its receptors. gnrh-a 37-43 vascular endothelial growth factor A Rattus norvegicus 135-139 15047939-0 2004 Administration of low-dose LH induces ovulation and prevents vascular hyperpermeability and vascular endothelial growth factor expression in superovulated rats. Luteinizing Hormone 27-29 vascular endothelial growth factor A Rattus norvegicus 92-126 15066146-4 2004 Further, rats receiving a continuous infusion of VEGF into the striatum via encapsulated hVEGF-secreting cells (baby hamster kidney-VEGF) displayed a significant decrease in amphetamine-induced rotational behavior and a significant preservation of tyrosine hydroxylase-positive neurons and fibers compared with control animals. Amphetamine 174-185 vascular endothelial growth factor A Rattus norvegicus 49-53 15066146-4 2004 Further, rats receiving a continuous infusion of VEGF into the striatum via encapsulated hVEGF-secreting cells (baby hamster kidney-VEGF) displayed a significant decrease in amphetamine-induced rotational behavior and a significant preservation of tyrosine hydroxylase-positive neurons and fibers compared with control animals. Tyrosine 248-256 vascular endothelial growth factor A Rattus norvegicus 49-53 15060719-0 2004 Angiogenesis inhibition by the novel VEGF receptor tyrosine kinase inhibitor, PTK787/ZK222584, causes significant anti-arthritic effects in models of rheumatoid arthritis. vatalanib 78-84 vascular endothelial growth factor A Rattus norvegicus 37-41 15060719-0 2004 Angiogenesis inhibition by the novel VEGF receptor tyrosine kinase inhibitor, PTK787/ZK222584, causes significant anti-arthritic effects in models of rheumatoid arthritis. vatalanib 85-93 vascular endothelial growth factor A Rattus norvegicus 37-41 15040023-0 2004 Vascular endothelial growth factor antisense oligodeoxynucleotides with lipiodol in arterial embolization of liver cancer in rats. Ethiodized Oil 72-80 vascular endothelial growth factor A Rattus norvegicus 0-34 15040023-4 2004 This study was to explore the inhibitory effect of VEGF antisense oligodeoxynucleotides (ODNs) on VEGF expression in cultured Walker-256 cells and to observe the anti-tumor effect of intra-arterial infusion of antisense ODNs mixed with lipiodol on rat liver cancer. Oligodeoxyribonucleotides 66-87 vascular endothelial growth factor A Rattus norvegicus 98-102 15040023-4 2004 This study was to explore the inhibitory effect of VEGF antisense oligodeoxynucleotides (ODNs) on VEGF expression in cultured Walker-256 cells and to observe the anti-tumor effect of intra-arterial infusion of antisense ODNs mixed with lipiodol on rat liver cancer. Oligodeoxyribonucleotides 89-93 vascular endothelial growth factor A Rattus norvegicus 51-55 15040023-4 2004 This study was to explore the inhibitory effect of VEGF antisense oligodeoxynucleotides (ODNs) on VEGF expression in cultured Walker-256 cells and to observe the anti-tumor effect of intra-arterial infusion of antisense ODNs mixed with lipiodol on rat liver cancer. Oligodeoxyribonucleotides 89-93 vascular endothelial growth factor A Rattus norvegicus 98-102 15040023-4 2004 This study was to explore the inhibitory effect of VEGF antisense oligodeoxynucleotides (ODNs) on VEGF expression in cultured Walker-256 cells and to observe the anti-tumor effect of intra-arterial infusion of antisense ODNs mixed with lipiodol on rat liver cancer. Ethiodized Oil 236-244 vascular endothelial growth factor A Rattus norvegicus 51-55 15040023-21 2004 VEGF antisense ODNs mixed with lipiodol embolizing liver cancer is better in inhibiting liver cancer growth, VEGF expression and microvessel density than lipiodol alone. Ethiodized Oil 31-39 vascular endothelial growth factor A Rattus norvegicus 109-113 15040023-21 2004 VEGF antisense ODNs mixed with lipiodol embolizing liver cancer is better in inhibiting liver cancer growth, VEGF expression and microvessel density than lipiodol alone. Ethiodized Oil 154-162 vascular endothelial growth factor A Rattus norvegicus 0-4 15119632-14 2004 CONCLUSION: Using a chronic inflammatory infusion model of PD in the rat, we show that dialysis with GDP-containing PD fluid is associated with increased VEGF production and peritoneal vascularization. Guanosine Diphosphate 101-104 vascular endothelial growth factor A Rattus norvegicus 154-158 14981120-2 2004 We hypothesized that macroporous scaffolds of biomineralized 85:15 poly(lactide-co-glycolide), which locally release vascular endothelial growth factor-165 (VEGF), would direct simultaneous regeneration of bone and vascular tissue. Polyglactin 910 67-92 vascular endothelial growth factor A Rattus norvegicus 117-155 14981120-2 2004 We hypothesized that macroporous scaffolds of biomineralized 85:15 poly(lactide-co-glycolide), which locally release vascular endothelial growth factor-165 (VEGF), would direct simultaneous regeneration of bone and vascular tissue. Polyglactin 910 67-92 vascular endothelial growth factor A Rattus norvegicus 157-161 15086165-8 2004 The level of serum VEGF in the HAL group increased significantly compared with that of the control group (92.5+/-43.9 pg/mL vs. 54.9+/-19.3 pg/mL, P<0.05). hal 31-34 vascular endothelial growth factor A Rattus norvegicus 19-23 15086165-9 2004 The expression of VEGF and MMP-1 mRNA in the tumor tissue of the HAL group increased significantly compared with that of the control and the laparotomy control groups (P<0.05). hal 65-68 vascular endothelial growth factor A Rattus norvegicus 18-22 15086165-10 2004 The blood perfusion data of the tumor, represented by number of Hoechst 33342 labeled cells, showed an inverse correlation with the expression of VEGF mRNA in tumor tissue (P<0.05). bisbenzimide ethoxide trihydrochloride 64-77 vascular endothelial growth factor A Rattus norvegicus 146-150 15086165-11 2004 While 6 days after HAL, the blood perfusion of tumor in HAL group decreased and the expression of VEGF and MMP-1 increased only slightly, not significantly, compared with that in the control group. hal 19-22 vascular endothelial growth factor A Rattus norvegicus 98-102 14744780-5 2004 Capsaicin inhibited both VEGF-induced vessel sprouting in rat aortic ring assay and VEGF-induced vessel formation in the mouse Matrigel plug assay. Capsaicin 0-9 vascular endothelial growth factor A Rattus norvegicus 25-29 15071924-5 2004 CONCLUSION: Finasteride can inhibit the protein expression of VEGF and eNOS and thereby can suppress angiogenesis of capillary in the ventral prostate of rat. Finasteride 12-23 vascular endothelial growth factor A Rattus norvegicus 62-66 14751661-8 2004 Moreover, OZR that received perindopril showed higher: 1) myocyte density (2044 +/- 67 v 847 +/- 91 myocytes/mm(2), P <.01) and 2) capillary density (1348 +/- 118 v 436 +/- 78 capillaries/mm(2), P <.01); higher amount of: 1) vascular endothelial growth factor (VEGF) in the myocardium (P <.01) and higher percentage of capillaries with positive immunostaining for eNOS (P <.01), compared with untreated OZR. Perindopril 28-39 vascular endothelial growth factor A Rattus norvegicus 231-265 14751661-8 2004 Moreover, OZR that received perindopril showed higher: 1) myocyte density (2044 +/- 67 v 847 +/- 91 myocytes/mm(2), P <.01) and 2) capillary density (1348 +/- 118 v 436 +/- 78 capillaries/mm(2), P <.01); higher amount of: 1) vascular endothelial growth factor (VEGF) in the myocardium (P <.01) and higher percentage of capillaries with positive immunostaining for eNOS (P <.01), compared with untreated OZR. Perindopril 28-39 vascular endothelial growth factor A Rattus norvegicus 267-271 14751661-9 2004 There was a correlation between both the amount of VEGF in myocardium and the number of capillaries (r = 0.88; P <.01) and VEGF and eNOS expression in myocardial capillaries (r = 0.93; P <.01) in OZR treated with perindopril. Perindopril 219-230 vascular endothelial growth factor A Rattus norvegicus 51-55 15084346-4 2004 The maximum level of VEGF mRNA was observed at 1 h after raloxifene and 6 h after tamoxifen or ospemifene treatment. Raloxifene Hydrochloride 57-67 vascular endothelial growth factor A Rattus norvegicus 21-25 15084346-4 2004 The maximum level of VEGF mRNA was observed at 1 h after raloxifene and 6 h after tamoxifen or ospemifene treatment. Tamoxifen 82-91 vascular endothelial growth factor A Rattus norvegicus 21-25 15084346-4 2004 The maximum level of VEGF mRNA was observed at 1 h after raloxifene and 6 h after tamoxifen or ospemifene treatment. Ospemifene 95-105 vascular endothelial growth factor A Rattus norvegicus 21-25 15084346-5 2004 Maximum levels of the c-fos and VEGF mRNA after raloxifene treatment were higher than those seen after treatments with E2 or a corresponding dose of tamoxifen or ospemifene. Raloxifene Hydrochloride 48-58 vascular endothelial growth factor A Rattus norvegicus 32-36 14757151-7 2004 Supplementation with prostaglandin E(2) attenuated the inhibitory action of dexamethasone on VEGF expression and reversed the adverse effects of dexamethasone on angiogenesis and ulcer healing, without influencing bFGF expression. Dinoprostone 21-39 vascular endothelial growth factor A Rattus norvegicus 93-97 14757151-7 2004 Supplementation with prostaglandin E(2) attenuated the inhibitory action of dexamethasone on VEGF expression and reversed the adverse effects of dexamethasone on angiogenesis and ulcer healing, without influencing bFGF expression. Dexamethasone 76-89 vascular endothelial growth factor A Rattus norvegicus 93-97 14757151-8 2004 We concluded that dexamethasone given at non-ulcerogenic doses could decrease angiogenesis and delay acetic acid-induced ulcer healing; these actions were at least, in part, due to depletion of prostaglandin E(2) level followed by down-regulation of VEGF at the ulcer margin of the stomach. Dexamethasone 18-31 vascular endothelial growth factor A Rattus norvegicus 250-254 14561656-6 2004 However, if VEGF was given locally in the testes of animals pretreated with hCG 4 or 8 h earlier, VEGF acted in synergy with hCG to increase vascular carbon leakage by forming interendothelial cell gaps. Carbon 150-156 vascular endothelial growth factor A Rattus norvegicus 12-16 14561656-6 2004 However, if VEGF was given locally in the testes of animals pretreated with hCG 4 or 8 h earlier, VEGF acted in synergy with hCG to increase vascular carbon leakage by forming interendothelial cell gaps. Carbon 150-156 vascular endothelial growth factor A Rattus norvegicus 98-102 14718351-4 2004 The aim of the present study was to assess the effects of AT2 receptor blockade on VEGF expression in the retina, initially in experimental diabetic rats induced by injection of streptozotocin. Streptozocin 178-192 vascular endothelial growth factor A Rattus norvegicus 83-87 14718351-7 2004 Treatment with either valsartan or PD123319 attenuated retinal VEGF expression. Valsartan 22-31 vascular endothelial growth factor A Rattus norvegicus 63-67 14718351-7 2004 Treatment with either valsartan or PD123319 attenuated retinal VEGF expression. PD 123319 35-43 vascular endothelial growth factor A Rattus norvegicus 63-67 14718351-9 2004 VEGF expression was also increased in the retina from angiotensin II infused rats, and this was attenuated by valsartan and PD123319. Valsartan 110-119 vascular endothelial growth factor A Rattus norvegicus 0-4 14718351-9 2004 VEGF expression was also increased in the retina from angiotensin II infused rats, and this was attenuated by valsartan and PD123319. PD 123319 124-132 vascular endothelial growth factor A Rattus norvegicus 0-4 15027193-1 2004 OBJECTIVE: To investigate the effect of Qianlie Huichun on the expression of vascular endothelial growth factor(VEGF) in prostate tissues and expound its anti-prostatomegaly action in model rats with prostatic hypertrophy induced by injected testosterone. Testosterone 242-254 vascular endothelial growth factor A Rattus norvegicus 112-116 15027193-7 2004 RESULTS: The difference of VEGF expression between Qianlie Huichun groups and the model group was significant(P < 0.01), and so was it between the medium and large dosage middle, large amount of Qianlie Huichun groups and the estriol group(P < 0.01). Estriol 229-236 vascular endothelial growth factor A Rattus norvegicus 27-31 14744780-5 2004 Capsaicin inhibited both VEGF-induced vessel sprouting in rat aortic ring assay and VEGF-induced vessel formation in the mouse Matrigel plug assay. Capsaicin 0-9 vascular endothelial growth factor A Rattus norvegicus 84-88 15609080-1 2004 The role of muscle contraction, prostanoids, nitric oxide and adenosine in the regulation of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and endothelial cell proliferative compounds in skeletal muscle cell cultures was examined. Adenosine 62-71 vascular endothelial growth factor A Rattus norvegicus 93-127 15609080-1 2004 The role of muscle contraction, prostanoids, nitric oxide and adenosine in the regulation of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and endothelial cell proliferative compounds in skeletal muscle cell cultures was examined. Adenosine 62-71 vascular endothelial growth factor A Rattus norvegicus 129-133 15609080-9 2004 Adenosine enhanced the basal VEGF release from muscle cells by 75% compared to control. Adenosine 0-9 vascular endothelial growth factor A Rattus norvegicus 29-33 15609080-10 2004 The present data demonstrate that contractile activity, NO, adenosine and products of cyclooxygenase regulate the expression of VEGF and bFGF mRNA in skeletal muscle cells and that contractile activity and NO regulate endothelial cell proliferative compounds in muscle extracellular fluid. Adenosine 60-69 vascular endothelial growth factor A Rattus norvegicus 128-132 12943528-4 2004 An increased expression of both eNOS and VEGF in colonic tissue from azoxymethane-treated rats compared with that from control rats was found. Azoxymethane 69-81 vascular endothelial growth factor A Rattus norvegicus 41-45 15812146-8 2004 Physical binding of VEGF to the heparin may then prevent a rapid clearance from the implant, while the release rate may become coupled to the degradation of the collagen matrix. Heparin 32-39 vascular endothelial growth factor A Rattus norvegicus 20-24 12943528-7 2004 Expression of the VEGF receptor Flk-1, but not Flt-1, was increased in colonic tissue of azoxymethane-treated rats compared with control rats. Azoxymethane 89-101 vascular endothelial growth factor A Rattus norvegicus 18-22 12943528-12 2004 Overexpression of eNOS, VEGF and its receptor Flk-1 occurred early after azoxymethane administration in rat colonic tissue, even before morphological changes associated with tumour generation were observed, and aspirin prevented the overexpression of both eNOS and VEGF receptor Flk-1. Aspirin 211-218 vascular endothelial growth factor A Rattus norvegicus 265-269 12943528-12 2004 Overexpression of eNOS, VEGF and its receptor Flk-1 occurred early after azoxymethane administration in rat colonic tissue, even before morphological changes associated with tumour generation were observed, and aspirin prevented the overexpression of both eNOS and VEGF receptor Flk-1. Azoxymethane 73-85 vascular endothelial growth factor A Rattus norvegicus 24-28 12943528-12 2004 Overexpression of eNOS, VEGF and its receptor Flk-1 occurred early after azoxymethane administration in rat colonic tissue, even before morphological changes associated with tumour generation were observed, and aspirin prevented the overexpression of both eNOS and VEGF receptor Flk-1. Aspirin 211-218 vascular endothelial growth factor A Rattus norvegicus 24-28 14673953-1 2004 BACKGROUND: Recent studies show that testosterone-stimulated growth of the glandular tissue in the ventral prostate in adult castrated rats is preceded by increased epithelial VEGF synthesis, endothelial cell proliferation, vascular growth, and increased blood flow. Testosterone 37-49 vascular endothelial growth factor A Rattus norvegicus 176-180 15207361-6 2004 Vitamin E induced the expression of the alpha subunit of hypoxia-inducible factor-1 (HIF-1) and its target genes, including vascular endothelial growth factor (VEGF) and heme oxygenase-1. Vitamin E 0-9 vascular endothelial growth factor A Rattus norvegicus 124-158 15207361-6 2004 Vitamin E induced the expression of the alpha subunit of hypoxia-inducible factor-1 (HIF-1) and its target genes, including vascular endothelial growth factor (VEGF) and heme oxygenase-1. Vitamin E 0-9 vascular endothelial growth factor A Rattus norvegicus 160-164 15207361-7 2004 The hypoxia response element on the VEGF promoter was responsible for this vitamin E-induced transcriptional activation of VEGF gene. Vitamin E 75-84 vascular endothelial growth factor A Rattus norvegicus 36-40 15207361-7 2004 The hypoxia response element on the VEGF promoter was responsible for this vitamin E-induced transcriptional activation of VEGF gene. Vitamin E 75-84 vascular endothelial growth factor A Rattus norvegicus 123-127 15490972-6 2004 TAC-101 (8 mg/kg) was orally administered 5 days per week for 4 weeks and then hepatic tumors were immunohistochemically evaluated for microvessel density (MVD) and vascular endothelial growth factor (VEGF). TAC 101 0-7 vascular endothelial growth factor A Rattus norvegicus 201-205 15031602-2 2004 The effects of histamine and the H2 receptor antagonist ranitidine on renal VEGF and IL-6 synthesis were investigated in a well-established rat model of renal ischemia/reperfusion injury. Ranitidine 56-66 vascular endothelial growth factor A Rattus norvegicus 76-80 15031602-11 2004 The beneficial effects of ranitidine were partly mediated by decreased IL-6 and VEGF mRNA expression and significant early increase in renal VEGF abundance. Ranitidine 26-36 vascular endothelial growth factor A Rattus norvegicus 80-84 15031602-11 2004 The beneficial effects of ranitidine were partly mediated by decreased IL-6 and VEGF mRNA expression and significant early increase in renal VEGF abundance. Ranitidine 26-36 vascular endothelial growth factor A Rattus norvegicus 141-145 15490972-0 2004 4-[3,5-Bis(trimethylsilyl)benzamido] benzoic acid inhibits angiogenesis in colon cancer through reduced expression of vascular endothelial growth factor. TAC 101 0-49 vascular endothelial growth factor A Rattus norvegicus 118-152 15490972-6 2004 TAC-101 (8 mg/kg) was orally administered 5 days per week for 4 weeks and then hepatic tumors were immunohistochemically evaluated for microvessel density (MVD) and vascular endothelial growth factor (VEGF). TAC 101 0-7 vascular endothelial growth factor A Rattus norvegicus 165-199 15339503-0 2004 [Effect of tetromethylpyrazine and aminoguanidine on expression of vascular endothelial growth factor in kidney of diabetic rats]. tetromethylpyrazine 11-30 vascular endothelial growth factor A Rattus norvegicus 67-101 15339503-0 2004 [Effect of tetromethylpyrazine and aminoguanidine on expression of vascular endothelial growth factor in kidney of diabetic rats]. pimagedine 35-49 vascular endothelial growth factor A Rattus norvegicus 67-101 15339503-5 2004 RESULTS: The expression of VEGF in renal cortex of the rats in group TMP+AG and group C was alike. tmp+ag 69-75 vascular endothelial growth factor A Rattus norvegicus 27-31 15339503-6 2004 The expression of VEGF in renal cortex of group TMP and group AG decreased significantly as compared with that of group C, but was still above normal level. Thymidine Monophosphate 48-51 vascular endothelial growth factor A Rattus norvegicus 18-22 15339503-7 2004 CONCLUSION: The therapeutic mechanism of tetromethylpyrazine and aminoguanidine on diabetic nephropathy may be inhibiting the over-expression of VEGF in kidney of diabetic rats. tetromethylpyrazine 41-60 vascular endothelial growth factor A Rattus norvegicus 145-149 15339503-7 2004 CONCLUSION: The therapeutic mechanism of tetromethylpyrazine and aminoguanidine on diabetic nephropathy may be inhibiting the over-expression of VEGF in kidney of diabetic rats. pimagedine 65-79 vascular endothelial growth factor A Rattus norvegicus 145-149 14664702-10 2003 The VEGF signaling system would work less well in diabetic penile tIssues as a result of the reduced expression, leading to diminished endothelial production of nitric oxide and apoptosis-related erectile tIssue damage. Nitric Oxide 161-173 vascular endothelial growth factor A Rattus norvegicus 4-8 14638905-8 2003 Valsartan and PD123319 attenuated angiotensin II-associated increases in VEGF gene and protein expression. Valsartan 0-9 vascular endothelial growth factor A Rattus norvegicus 73-77 14638905-8 2003 Valsartan and PD123319 attenuated angiotensin II-associated increases in VEGF gene and protein expression. PD 123319 14-22 vascular endothelial growth factor A Rattus norvegicus 73-77 12881220-11 2003 Furthermore, staurosporine, a nonselective PKC inhibitor, prevented the induction of VEGF by hypoxia. Staurosporine 13-26 vascular endothelial growth factor A Rattus norvegicus 85-89 14598030-8 2003 Thalidomide, but not rosiglitazone, was associated with the inhibition of basement membrane thickening and the blockade of the increase of VEGF in ocular fluid, thus representing a potential therapeutic drug for the prevention of diabetic retinopathy. Thalidomide 0-11 vascular endothelial growth factor A Rattus norvegicus 139-143 14563693-2 2003 We present a new class of bioactive synthetic hydrogel matrices based on poly(ethylene glycol) (PEG) and synthetic peptides that exploits the activity of vascular endothelial growth factor (VEGF) alongside the base matrix functionality for cellular ingrowth, that is, induction of cell adhesion by pendant RGD-containing peptides and provision of cell-mediated remodeling by cross-linking matrix metalloproteinase substrate peptides. Polyethylene Glycols 73-94 vascular endothelial growth factor A Rattus norvegicus 154-188 14563693-2 2003 We present a new class of bioactive synthetic hydrogel matrices based on poly(ethylene glycol) (PEG) and synthetic peptides that exploits the activity of vascular endothelial growth factor (VEGF) alongside the base matrix functionality for cellular ingrowth, that is, induction of cell adhesion by pendant RGD-containing peptides and provision of cell-mediated remodeling by cross-linking matrix metalloproteinase substrate peptides. Polyethylene Glycols 73-94 vascular endothelial growth factor A Rattus norvegicus 190-194 14563693-2 2003 We present a new class of bioactive synthetic hydrogel matrices based on poly(ethylene glycol) (PEG) and synthetic peptides that exploits the activity of vascular endothelial growth factor (VEGF) alongside the base matrix functionality for cellular ingrowth, that is, induction of cell adhesion by pendant RGD-containing peptides and provision of cell-mediated remodeling by cross-linking matrix metalloproteinase substrate peptides. Polyethylene Glycols 96-99 vascular endothelial growth factor A Rattus norvegicus 154-188 14563693-2 2003 We present a new class of bioactive synthetic hydrogel matrices based on poly(ethylene glycol) (PEG) and synthetic peptides that exploits the activity of vascular endothelial growth factor (VEGF) alongside the base matrix functionality for cellular ingrowth, that is, induction of cell adhesion by pendant RGD-containing peptides and provision of cell-mediated remodeling by cross-linking matrix metalloproteinase substrate peptides. Polyethylene Glycols 96-99 vascular endothelial growth factor A Rattus norvegicus 190-194 14554226-0 2003 Effects of transcutaneous topical injection of oxygen on vascular endothelial growth factor gene into the healing ligament in rats. Oxygen 47-53 vascular endothelial growth factor A Rattus norvegicus 57-91 14611750-5 2003 In tissue located 1 mm away from the infusion site, capillary density in VEGF-treated animals was 200-300% higher than in saline controls. Sodium Chloride 122-128 vascular endothelial growth factor A Rattus norvegicus 73-77 12698263-4 2003 RESULTS: Tenocytes cultivated under normal oxygen pressure released measurable amounts of VEGF into their culture supernatants. Oxygen 43-49 vascular endothelial growth factor A Rattus norvegicus 90-94 12698263-6 2003 Hypoxic conditions alone (5% O(2)) raised VEGF secretion only 2-fold. Oxygen 29-34 vascular endothelial growth factor A Rattus norvegicus 42-46 14554226-5 2003 However, the expression of VEGF mRNA in the topical oxygen injection group (Group C) was lower than that in control group (p<0.05). Oxygen 52-58 vascular endothelial growth factor A Rattus norvegicus 27-31 14554226-6 2003 Our results suggest that oxygen is able to accelerate vessel formation in spite of its effect of decreasing VEGF mRNA. Oxygen 25-31 vascular endothelial growth factor A Rattus norvegicus 108-112 14619584-0 2003 [Effects of cilazapril on the expression of vascular endothelial growth factor and intercellular adhesion molecule-1 in diabetic rat glomeruli]. Cilazapril 12-22 vascular endothelial growth factor A Rattus norvegicus 44-78 14565159-1 2003 Depending on dose, dexamethasone has been shown to inhibit or stimulate growth of rat 9L gliosarcoma and decrease the expression of vascular endothelial growth factor (VEGF), an important mediator of tumor-associated angiogenesis. Dexamethasone 19-32 vascular endothelial growth factor A Rattus norvegicus 132-166 14565159-1 2003 Depending on dose, dexamethasone has been shown to inhibit or stimulate growth of rat 9L gliosarcoma and decrease the expression of vascular endothelial growth factor (VEGF), an important mediator of tumor-associated angiogenesis. Dexamethasone 19-32 vascular endothelial growth factor A Rattus norvegicus 168-172 14614207-8 2003 Addition of anti-progesterone RU486, which reduced the ovarian enlargement, attenuated VEGF production dose dependently whereas the VEGF gene expression was stable. Mifepristone 30-35 vascular endothelial growth factor A Rattus norvegicus 87-91 14619584-6 2003 Cilazapril could reduce KW/BW, CCr and 24 hours urine protein count and significantly suppress the overexpression of VEGF and ICAM-1 in cilazapril treatment group after 8 weeks, compared with the DM model group(P < 0.05). Cilazapril 0-10 vascular endothelial growth factor A Rattus norvegicus 117-121 14619584-6 2003 Cilazapril could reduce KW/BW, CCr and 24 hours urine protein count and significantly suppress the overexpression of VEGF and ICAM-1 in cilazapril treatment group after 8 weeks, compared with the DM model group(P < 0.05). Cilazapril 136-146 vascular endothelial growth factor A Rattus norvegicus 117-121 14619584-7 2003 CONCLUSION: Cilazapril can suppress the overproduction of two cytokines, VEGF and ICAM-1, thus preventing the progression of diabetic nephropathy. Cilazapril 12-22 vascular endothelial growth factor A Rattus norvegicus 73-77 12930443-5 2003 With an immediate injection with BDNF+VEGF the ICP was significantly higher than in the controls, at 67.8 (38.5) cmH2O. cmh2o 113-118 vascular endothelial growth factor A Rattus norvegicus 38-42 12963813-10 2003 In isolated rat arteries, VEGF pretreatment markedly potentiated S1P-mediated vasorelaxation and eNOS Ser-1179 phosphorylation. Serine 102-105 vascular endothelial growth factor A Rattus norvegicus 26-30 12930443-6 2003 Even delayed injection with BDNF+VEGF improved the ICP, to 78.0 (21.8) cmH2O. cmh2o 71-76 vascular endothelial growth factor A Rattus norvegicus 33-37 12949371-11 2003 Both VEGF and Flk-1 were restored in pancreatic endocrine cells of fetuses and pups given taurine. Taurine 90-97 vascular endothelial growth factor A Rattus norvegicus 5-9 12937991-1 2003 BACKGROUND: We investigated the role of the VEGF-VEGF receptor 2 (KDR) system in the development of choroidal neovascularization (CNV) and its possibility as a therapeutic target utilizing KDR selective receptor tyrosine kinase (RTK) inhibitor (SU5416) both in vitro and in an experimental CNV model. Semaxinib 245-251 vascular endothelial growth factor A Rattus norvegicus 44-48 12937991-7 2003 RESULTS: VEGF-induced KDR phosphorylation in cultured BCECs was inhibited by SU5416 in a dose-dependent manner (0-3 microM) with IC50 of 0.29 +/- 0.071 microM. Semaxinib 77-83 vascular endothelial growth factor A Rattus norvegicus 9-13 12937991-8 2003 SU5416 treatment also resulted in a dose-dependent prohibition of VEGF-induced p44/p42 MAPK phosphorylation, [3H]thymidine uptake and in vitro tube formation with corresponding concentrations that inhibited KDR phosphorylation. Semaxinib 0-6 vascular endothelial growth factor A Rattus norvegicus 66-70 12937991-8 2003 SU5416 treatment also resulted in a dose-dependent prohibition of VEGF-induced p44/p42 MAPK phosphorylation, [3H]thymidine uptake and in vitro tube formation with corresponding concentrations that inhibited KDR phosphorylation. Tritium 110-112 vascular endothelial growth factor A Rattus norvegicus 66-70 12947564-11 2003 CONCLUSIONS: BMI improved the acute ischemic cardiac function by both upregulating the expressions of VEGF and Flk-1 in transplanted BMCs and recipient endogenous cardiomyocytes that enhanced angiogenesis. S-benzyl-N-malonylcysteine 133-137 vascular endothelial growth factor A Rattus norvegicus 102-106 12885426-6 2003 Investigations were also performed to determine whether the administration of phosphoramidon, an endothelin-converting enzyme (ECE) inhibitor, and BQ-123, an endothelin receptor ET(A) antagonist, suppresses angiogenesis and VEGF expression. phosphoramidon 78-92 vascular endothelial growth factor A Rattus norvegicus 224-228 12885426-6 2003 Investigations were also performed to determine whether the administration of phosphoramidon, an endothelin-converting enzyme (ECE) inhibitor, and BQ-123, an endothelin receptor ET(A) antagonist, suppresses angiogenesis and VEGF expression. cyclo(Trp-Asp-Pro-Val-Leu) 147-153 vascular endothelial growth factor A Rattus norvegicus 224-228 12846751-12 2003 Overexpression of TGF beta 1 and VEGF was observed in the glomeruli of diabetic rats and was attenuated by losartan, simvastatin, or the combination of both to a similar level. Losartan 107-115 vascular endothelial growth factor A Rattus norvegicus 33-37 12895454-6 2003 Behavioral measurements indicate that VEGF pretreatment of the intrastriatal graft site accelerates recovery of amphetamine-induced rotational asymmetry in unilateral 6-OHDA lesioned rats. Amphetamine 112-123 vascular endothelial growth factor A Rattus norvegicus 38-42 12895454-6 2003 Behavioral measurements indicate that VEGF pretreatment of the intrastriatal graft site accelerates recovery of amphetamine-induced rotational asymmetry in unilateral 6-OHDA lesioned rats. Oxidopamine 167-173 vascular endothelial growth factor A Rattus norvegicus 38-42 12846751-12 2003 Overexpression of TGF beta 1 and VEGF was observed in the glomeruli of diabetic rats and was attenuated by losartan, simvastatin, or the combination of both to a similar level. Simvastatin 117-128 vascular endothelial growth factor A Rattus norvegicus 33-37 12626331-2 2003 Hyperoxia exposure (>95% O2 days 4-14) arrests lung alveolarization and may do so through suppression of the VEGF signaling system. Oxygen 28-30 vascular endothelial growth factor A Rattus norvegicus 112-116 12900614-7 2003 It was concluded that administration of exogenous VEGF could protect flaps from ischemia-reperfusion injury through the regulation of proinflammatory cytokines and the inhibition of cytotoxic nitric oxide production. Nitric Oxide 192-204 vascular endothelial growth factor A Rattus norvegicus 50-54 12947338-0 2003 Morphine inhibits VEGF expression in myocardial ischemia. Morphine 0-8 vascular endothelial growth factor A Rattus norvegicus 18-22 12947338-3 2003 We hypothesize that morphine inhibits myocardial VEGF expression by inhibiting hypoxia-induced factor 1alpha (HIF-1alpha) and the signal transduction mechanisms involving Erk-1,2 MAP kinase (p42/p44), and PI3 kinase activity (phospho-Akt). Morphine 20-28 vascular endothelial growth factor A Rattus norvegicus 49-53 12947338-6 2003 Using a rat coronary ligation model, we show that morphine treatment: (1) decreases myocardial VEGF protein expression (immunohistochemistry); (2) decreases HIF-1alpha protein expression (immunoblot); and (3) decreases phospho-Erk-1,2 and phospho-Akt expression. Morphine 50-58 vascular endothelial growth factor A Rattus norvegicus 95-99 12947338-7 2003 CONCLUSIONS: (1) Morphine inhibits hypoxia-induced VEGF transcription, in part, through an HIF-1alpha-mediated mechanism and (2) morphine inhibition of hypoxia-induced HIF-1alpha may be mediated by inhibition of ERK 1,2 MAP kinase activity and PI3 kinase activity. Morphine 17-25 vascular endothelial growth factor A Rattus norvegicus 51-55 12717136-0 2003 Midazolam stimulates vascular endothelial growth factor release in aortic smooth muscle cells: role of the mitogen-activated protein kinase superfamily. Midazolam 0-9 vascular endothelial growth factor A Rattus norvegicus 21-55 12819242-8 2003 In the kidney of rats treated with cobalt, mRNA levels of several genes that serve for tissue protection, such as HO-1, EPO, Glut-1, and VEGF, were increased before ischemic injury. Cobalt 35-41 vascular endothelial growth factor A Rattus norvegicus 137-141 12808163-7 2003 Perindopril treatment was associated with normalization of both capillary endothelial cell density and glomerular VEGF mRNA. Perindopril 0-11 vascular endothelial growth factor A Rattus norvegicus 114-118 12800090-0 2003 Increased vascular endothelial growth factor mRNA expression in the heart of streptozotocin-induced diabetic rats. Streptozocin 77-91 vascular endothelial growth factor A Rattus norvegicus 10-44 12800090-6 2003 Densitometric analysis of PCR products showed that VEGF mRNA levels were meanly 4.8-fold higher in STZ-induced diabetic rats than controls (VEGF/GAPDH densitometric ratio, 3.46 +/- 0.20 v 0.74 +/- 0.10, P <.001). Streptozocin 99-102 vascular endothelial growth factor A Rattus norvegicus 51-55 12800090-6 2003 Densitometric analysis of PCR products showed that VEGF mRNA levels were meanly 4.8-fold higher in STZ-induced diabetic rats than controls (VEGF/GAPDH densitometric ratio, 3.46 +/- 0.20 v 0.74 +/- 0.10, P <.001). Streptozocin 99-102 vascular endothelial growth factor A Rattus norvegicus 140-144 12521947-9 2003 These results place 20-HETE in the downstream signaling pathway for angiogenesis and show that both VEGF and 20-HETE are involved in the angiogenesis induced by electrical stimulation in skeletal muscle. 20-hydroxy-5,8,11,14-eicosatetraenoic acid 20-27 vascular endothelial growth factor A Rattus norvegicus 100-104 12717136-8 2003 RESULTS: Continuous infusion of midazolam, but not propofol, increased the VEGF concentration in rat plasma. Midazolam 32-41 vascular endothelial growth factor A Rattus norvegicus 75-79 12717136-9 2003 In cultured cells, midazolam stimulated VEGF release, but propofol and ketamine did not. Midazolam 19-28 vascular endothelial growth factor A Rattus norvegicus 40-44 12717136-11 2003 PD98059 and U0126, specific inhibitors of MAP kinase kinase, significantly reduced the midazolam-stimulated release of VEGF. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 0-7 vascular endothelial growth factor A Rattus norvegicus 119-123 12717136-11 2003 PD98059 and U0126, specific inhibitors of MAP kinase kinase, significantly reduced the midazolam-stimulated release of VEGF. U 0126 12-17 vascular endothelial growth factor A Rattus norvegicus 119-123 12717136-11 2003 PD98059 and U0126, specific inhibitors of MAP kinase kinase, significantly reduced the midazolam-stimulated release of VEGF. Midazolam 87-96 vascular endothelial growth factor A Rattus norvegicus 119-123 12717136-12 2003 SP600125, a specific inhibitor of SAPK/JNK, significantly reduced midazolam-stimulated VEGF release. pyrazolanthrone 0-8 vascular endothelial growth factor A Rattus norvegicus 87-91 12717136-12 2003 SP600125, a specific inhibitor of SAPK/JNK, significantly reduced midazolam-stimulated VEGF release. Midazolam 66-75 vascular endothelial growth factor A Rattus norvegicus 87-91 12717136-13 2003 Applied together, PD98059 and SP600125 produced an additive reduction in midazolam-stimulated VEGF release. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 18-25 vascular endothelial growth factor A Rattus norvegicus 94-98 12606430-4 2003 Immature (age, 21 days) Sprague-Dawley rats were injected with 500 ng of VEGF in saline or 50 microg of diethylstilbestrol (DES) in oil under the bursa of one ovary. Sodium Chloride 81-87 vascular endothelial growth factor A Rattus norvegicus 73-77 12717136-13 2003 Applied together, PD98059 and SP600125 produced an additive reduction in midazolam-stimulated VEGF release. pyrazolanthrone 30-38 vascular endothelial growth factor A Rattus norvegicus 94-98 12717136-13 2003 Applied together, PD98059 and SP600125 produced an additive reduction in midazolam-stimulated VEGF release. Midazolam 73-82 vascular endothelial growth factor A Rattus norvegicus 94-98 12717136-14 2003 Moreover, a bolus injection of PD98059 truly inhibited the midazolam-increased VEGF concentration in rat plasma in vivo. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 31-38 vascular endothelial growth factor A Rattus norvegicus 79-83 12717136-14 2003 Moreover, a bolus injection of PD98059 truly inhibited the midazolam-increased VEGF concentration in rat plasma in vivo. Midazolam 59-68 vascular endothelial growth factor A Rattus norvegicus 79-83 12717136-15 2003 CONCLUSIONS: Midazolam, but not propofol or ketamine, stimulates VEGF release in aortic smooth muscle cells. Midazolam 13-22 vascular endothelial growth factor A Rattus norvegicus 65-69 12770729-6 2003 The addition of potent synthetic progesterone antagonist RU486, which reduces the extension of OHSS, attenuates the ovarian kinin and VEGF production dose-dependently whereas the VEGF gene expression was stable. Mifepristone 57-62 vascular endothelial growth factor A Rattus norvegicus 134-138 12772586-1 2003 In an air pouch-type carrageenin-induced inflammation model in rats, the selective cyclooxygenase (COX)-2 inhibitor NS-398 dose dependently inhibited the granulation tissue formation, angiogenesis and the level of vascular endothelial growth factor (VEGF) in the granulation tissue. N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide 116-122 vascular endothelial growth factor A Rattus norvegicus 214-248 12772586-1 2003 In an air pouch-type carrageenin-induced inflammation model in rats, the selective cyclooxygenase (COX)-2 inhibitor NS-398 dose dependently inhibited the granulation tissue formation, angiogenesis and the level of vascular endothelial growth factor (VEGF) in the granulation tissue. N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide 116-122 vascular endothelial growth factor A Rattus norvegicus 250-254 12770729-6 2003 The addition of potent synthetic progesterone antagonist RU486, which reduces the extension of OHSS, attenuates the ovarian kinin and VEGF production dose-dependently whereas the VEGF gene expression was stable. Progesterone 33-45 vascular endothelial growth factor A Rattus norvegicus 134-138 12770729-6 2003 The addition of potent synthetic progesterone antagonist RU486, which reduces the extension of OHSS, attenuates the ovarian kinin and VEGF production dose-dependently whereas the VEGF gene expression was stable. Mifepristone 57-62 vascular endothelial growth factor A Rattus norvegicus 179-183 12778363-2 2003 White adipocytes are capable of producing vascular endothelial growth factor (VEGF) in response to insulin and catecholamines. Catecholamines 111-125 vascular endothelial growth factor A Rattus norvegicus 42-76 12590138-0 2003 Distinct protein kinase C isoforms mediate regulation of vascular endothelial growth factor expression by A2A adenosine receptor activation and phorbol esters in pheochromocytoma PC12 cells. Phorbol Esters 144-158 vascular endothelial growth factor A Rattus norvegicus 57-91 12590138-9 2003 Following prolonged PMA treatment to down-regulate susceptible PKC isoforms, CGS21680 but not PMA inhibited the cobalt chloride induction of VEGF mRNA. cobaltous chloride 112-127 vascular endothelial growth factor A Rattus norvegicus 141-145 12590138-11 2003 Phorbol 12,13-diacetate reduced VEGF mRNA levels while down-regulating PKCepsilon but not PKCalpha expression. phorbol-12,13-diacetate 0-23 vascular endothelial growth factor A Rattus norvegicus 32-36 12590138-13 2003 Together, the findings suggest that phorbol ester-induced down-regulation of VEGF mRNA occurs as a result of a reduction of PKCepsilon activity, whereas that mediated by the A(2A)AR occurs following deactivation of PKCzeta. Phorbol Esters 36-49 vascular endothelial growth factor A Rattus norvegicus 77-81 12609969-6 2003 ELISA measurements showed that treatment with hMSCs significantly (P<0.05) raised endogenous rat VEGF levels in the IBZ from 10.5+/-1.7 ng/mL in the control group to 17.5+/-1.6 ng/mL in the hMSC-treated group. ibz 119-122 vascular endothelial growth factor A Rattus norvegicus 100-104 12609969-6 2003 ELISA measurements showed that treatment with hMSCs significantly (P<0.05) raised endogenous rat VEGF levels in the IBZ from 10.5+/-1.7 ng/mL in the control group to 17.5+/-1.6 ng/mL in the hMSC-treated group. hmsc 46-50 vascular endothelial growth factor A Rattus norvegicus 100-104 12778363-2 2003 White adipocytes are capable of producing vascular endothelial growth factor (VEGF) in response to insulin and catecholamines. Catecholamines 111-125 vascular endothelial growth factor A Rattus norvegicus 78-82 12778363-10 2003 Multiple linear regression analyses uncovered statistically significant inverse correlations between plasma VEGF and blood beta-hydroxybutyrate or serum corticosterone. 3-Hydroxybutyric Acid 123-143 vascular endothelial growth factor A Rattus norvegicus 108-112 12778363-10 2003 Multiple linear regression analyses uncovered statistically significant inverse correlations between plasma VEGF and blood beta-hydroxybutyrate or serum corticosterone. Corticosterone 153-167 vascular endothelial growth factor A Rattus norvegicus 108-112 12778363-11 2003 Blood glucose, in contrast, correlated directly with plasma VEGF. Glucose 6-13 vascular endothelial growth factor A Rattus norvegicus 60-64 12595343-0 2003 Nitric oxide enhances angiogenesis via the synthesis of vascular endothelial growth factor and cGMP after stroke in the rat. Nitric Oxide 0-12 vascular endothelial growth factor A Rattus norvegicus 56-90 12657614-7 2003 An inhibitor of ERK, AG126, and an inhibitor of ERK kinase (MEK), PD98059, exhibited a dose-dependent reduction of ERK phosphorylation and EC proliferation, but not tube formation, in VEGF-stimulated BRMECs. AG 127 21-26 vascular endothelial growth factor A Rattus norvegicus 184-188 12657614-7 2003 An inhibitor of ERK, AG126, and an inhibitor of ERK kinase (MEK), PD98059, exhibited a dose-dependent reduction of ERK phosphorylation and EC proliferation, but not tube formation, in VEGF-stimulated BRMECs. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 66-73 vascular endothelial growth factor A Rattus norvegicus 184-188 12606532-0 2003 Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats. fidarestat 27-37 vascular endothelial growth factor A Rattus norvegicus 76-110 12639820-0 2003 Cyclosporine A up-regulates expression of matrix metalloproteinase 2 and vascular endothelial growth factor in rat heart. Cyclosporine 0-14 vascular endothelial growth factor A Rattus norvegicus 73-107 12639820-3 2003 Since the immunosuppressive therapy induces myocardial toxicity, the aim of this study was to evaluate in the myocardium of CsA-treated rats the expression variations of vascular endothelial growth factor (VEGF) and matrix metalloproteinase 2 (MMP2), to verify if: VEGF increased, VEGF increase was associated with MMP2 increase and they could be considered as repair proteins. Cyclosporine 124-127 vascular endothelial growth factor A Rattus norvegicus 170-204 12639820-3 2003 Since the immunosuppressive therapy induces myocardial toxicity, the aim of this study was to evaluate in the myocardium of CsA-treated rats the expression variations of vascular endothelial growth factor (VEGF) and matrix metalloproteinase 2 (MMP2), to verify if: VEGF increased, VEGF increase was associated with MMP2 increase and they could be considered as repair proteins. Cyclosporine 124-127 vascular endothelial growth factor A Rattus norvegicus 206-210 12639820-3 2003 Since the immunosuppressive therapy induces myocardial toxicity, the aim of this study was to evaluate in the myocardium of CsA-treated rats the expression variations of vascular endothelial growth factor (VEGF) and matrix metalloproteinase 2 (MMP2), to verify if: VEGF increased, VEGF increase was associated with MMP2 increase and they could be considered as repair proteins. Cyclosporine 124-127 vascular endothelial growth factor A Rattus norvegicus 265-269 12639820-3 2003 Since the immunosuppressive therapy induces myocardial toxicity, the aim of this study was to evaluate in the myocardium of CsA-treated rats the expression variations of vascular endothelial growth factor (VEGF) and matrix metalloproteinase 2 (MMP2), to verify if: VEGF increased, VEGF increase was associated with MMP2 increase and they could be considered as repair proteins. Cyclosporine 124-127 vascular endothelial growth factor A Rattus norvegicus 265-269 12639820-7 2003 The group II animals (CsA-treated) showed structural degenerative changes with myocardial fibrosis and a clear increase both in MMP2 and VEGF. Cyclosporine 22-25 vascular endothelial growth factor A Rattus norvegicus 137-141 12768069-12 2003 In the TMZ group, MDA and VEGF levels and neoangiogenesis were significantly less than those of the hypertonic dextrose group. Trimetazidine 7-10 vascular endothelial growth factor A Rattus norvegicus 26-30 12595343-3 2003 Treatment with DETANONOate significantly increased VEGF levels in the ischemic boundary regions as measured by ELISA. 2,2'-(hydroxynitrosohydrazono)bis-ethanamine 15-26 vascular endothelial growth factor A Rattus norvegicus 51-55 12595343-6 2003 Blocking VEGF activity by a neutralized antibody against VEGF receptor 2 significantly attenuated DETANONOate-induced capillary-like tube formation. 2,2'-(hydroxynitrosohydrazono)bis-ethanamine 98-109 vascular endothelial growth factor A Rattus norvegicus 9-13 12595343-6 2003 Blocking VEGF activity by a neutralized antibody against VEGF receptor 2 significantly attenuated DETANONOate-induced capillary-like tube formation. 2,2'-(hydroxynitrosohydrazono)bis-ethanamine 98-109 vascular endothelial growth factor A Rattus norvegicus 57-61 12631117-0 2003 Nitric oxide modulates vascular endothelial growth factor and receptors in chronic cyclosporine nephrotoxicity. Nitric Oxide 0-12 vascular endothelial growth factor A Rattus norvegicus 23-57 12554697-3 2003 These include vascular endothelial cell growth factor (VEGF), which stimulates the incorporation of bromodeoxyuridine (BrdU) into neuronal precursor cells in vitro and in the adult rat brain in vivo. Bromodeoxyuridine 100-117 vascular endothelial growth factor A Rattus norvegicus 55-59 12554697-3 2003 These include vascular endothelial cell growth factor (VEGF), which stimulates the incorporation of bromodeoxyuridine (BrdU) into neuronal precursor cells in vitro and in the adult rat brain in vivo. Bromodeoxyuridine 119-123 vascular endothelial growth factor A Rattus norvegicus 55-59 12554697-4 2003 Using BrdU labeling as an index of cell proliferation, we found that the in vitro neuroproliferative effect of VEGF was associated with up-regulation of E2F family transcription factors, cyclin D1, cyclin E, and cdc25. Bromodeoxyuridine 6-10 vascular endothelial growth factor A Rattus norvegicus 111-115 12554697-6 2003 The proliferative effect of VEGF was inhibited by the extracellular signal-regulated kinase kinase (MEK) inhibitor PD98059, the phospholipase C (PLC) inhibitor U73122, the protein kinase C (PKC) inhibitor GF102390X, and the phosphatidylinositol 3-kinase (PI3K) inhibitor wortmannin, indicating involvement of multiple signaling pathways. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 115-122 vascular endothelial growth factor A Rattus norvegicus 28-32 12554697-6 2003 The proliferative effect of VEGF was inhibited by the extracellular signal-regulated kinase kinase (MEK) inhibitor PD98059, the phospholipase C (PLC) inhibitor U73122, the protein kinase C (PKC) inhibitor GF102390X, and the phosphatidylinositol 3-kinase (PI3K) inhibitor wortmannin, indicating involvement of multiple signaling pathways. 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione 160-166 vascular endothelial growth factor A Rattus norvegicus 28-32 12554697-6 2003 The proliferative effect of VEGF was inhibited by the extracellular signal-regulated kinase kinase (MEK) inhibitor PD98059, the phospholipase C (PLC) inhibitor U73122, the protein kinase C (PKC) inhibitor GF102390X, and the phosphatidylinositol 3-kinase (PI3K) inhibitor wortmannin, indicating involvement of multiple signaling pathways. gf102390x 205-214 vascular endothelial growth factor A Rattus norvegicus 28-32 12554697-6 2003 The proliferative effect of VEGF was inhibited by the extracellular signal-regulated kinase kinase (MEK) inhibitor PD98059, the phospholipase C (PLC) inhibitor U73122, the protein kinase C (PKC) inhibitor GF102390X, and the phosphatidylinositol 3-kinase (PI3K) inhibitor wortmannin, indicating involvement of multiple signaling pathways. Wortmannin 271-281 vascular endothelial growth factor A Rattus norvegicus 28-32 12588602-2 2003 Subsequently, clotrimazole (CLT) was reported to exert an inhibitory effect on the in vitro proliferation of vascular endothelial cells stimulated by VEGF. Clotrimazole 14-26 vascular endothelial growth factor A Rattus norvegicus 150-154 12588602-2 2003 Subsequently, clotrimazole (CLT) was reported to exert an inhibitory effect on the in vitro proliferation of vascular endothelial cells stimulated by VEGF. Clotrimazole 28-31 vascular endothelial growth factor A Rattus norvegicus 150-154 12588602-9 2003 RESULTS: The ratio of VEGF-positive cells and the expression of VEGF mRNA were lower in the 20-CLT group than in the 10-BBN group. 10-bbn 117-123 vascular endothelial growth factor A Rattus norvegicus 64-68 12631117-0 2003 Nitric oxide modulates vascular endothelial growth factor and receptors in chronic cyclosporine nephrotoxicity. Cyclosporine 83-95 vascular endothelial growth factor A Rattus norvegicus 23-57 12631117-2 2003 We have previously shown that VEGF is up-regulated in a model of chronic cyclosporine (CsA) nephrotoxicity and that l-arginine (l-Arg) improved while N-nitro-l-arginine-methyl ester (L-NAME) worsened fibrosis. Cyclosporine 73-85 vascular endothelial growth factor A Rattus norvegicus 30-34 12631117-2 2003 We have previously shown that VEGF is up-regulated in a model of chronic cyclosporine (CsA) nephrotoxicity and that l-arginine (l-Arg) improved while N-nitro-l-arginine-methyl ester (L-NAME) worsened fibrosis. Cyclosporine 87-90 vascular endothelial growth factor A Rattus norvegicus 30-34 12631117-2 2003 We have previously shown that VEGF is up-regulated in a model of chronic cyclosporine (CsA) nephrotoxicity and that l-arginine (l-Arg) improved while N-nitro-l-arginine-methyl ester (L-NAME) worsened fibrosis. Arginine 116-126 vascular endothelial growth factor A Rattus norvegicus 30-34 12631117-2 2003 We have previously shown that VEGF is up-regulated in a model of chronic cyclosporine (CsA) nephrotoxicity and that l-arginine (l-Arg) improved while N-nitro-l-arginine-methyl ester (L-NAME) worsened fibrosis. NG-Nitroarginine Methyl Ester 183-189 vascular endothelial growth factor A Rattus norvegicus 30-34 12631117-7 2003 VEGF mRNA and protein expressions increased with CsA, further increased with L-NAME and became significantly reduced with L-Arg. Cyclosporine 49-52 vascular endothelial growth factor A Rattus norvegicus 0-4 12631117-7 2003 VEGF mRNA and protein expressions increased with CsA, further increased with L-NAME and became significantly reduced with L-Arg. NG-Nitroarginine Methyl Ester 77-83 vascular endothelial growth factor A Rattus norvegicus 0-4 12631117-7 2003 VEGF mRNA and protein expressions increased with CsA, further increased with L-NAME and became significantly reduced with L-Arg. Arginine 122-127 vascular endothelial growth factor A Rattus norvegicus 0-4 12631117-11 2003 CONCLUSIONS: VEGF expression in chronic CsA nephrotoxicity is increased by nitric oxide blockade and decreased by nitric oxide enhancement. Nitric Oxide 75-87 vascular endothelial growth factor A Rattus norvegicus 13-17 12631117-11 2003 CONCLUSIONS: VEGF expression in chronic CsA nephrotoxicity is increased by nitric oxide blockade and decreased by nitric oxide enhancement. Nitric Oxide 114-126 vascular endothelial growth factor A Rattus norvegicus 13-17 12631117-13 2003 The actions of VEGF in this model remain speculative, but it is probable that VEGF plays a role, either independently or through nitric oxide, in CsA-induced fibrosis. Nitric Oxide 129-141 vascular endothelial growth factor A Rattus norvegicus 78-82 12631117-13 2003 The actions of VEGF in this model remain speculative, but it is probable that VEGF plays a role, either independently or through nitric oxide, in CsA-induced fibrosis. Cyclosporine 146-149 vascular endothelial growth factor A Rattus norvegicus 78-82 12480545-0 2003 17alpha-estradiol-induced VEGF-A expression in rat pituitary tumor cells is mediated through ER independent but PI3K-Akt dependent signaling pathway. alfatradiol 0-17 vascular endothelial growth factor A Rattus norvegicus 26-32 12535662-9 2003 These results strongly suggest that p44/p42 MAP kinase plays a role at least partly in the simvastatin-stimulated VEGF release in vascular smooth muscle cells. Simvastatin 91-102 vascular endothelial growth factor A Rattus norvegicus 114-118 12535662-0 2003 Simvastatin stimulates VEGF release via p44/p42 MAP kinase in vascular smooth muscle cells. Simvastatin 0-11 vascular endothelial growth factor A Rattus norvegicus 23-27 12535662-2 2003 In the present study, we investigated the effect of simvastatin on vascular endothelial growth factor (VEGF) release, and the underlying mechanism, in a rat aortic smooth muscle cell line, A10 cells. Simvastatin 52-63 vascular endothelial growth factor A Rattus norvegicus 67-101 12535662-2 2003 In the present study, we investigated the effect of simvastatin on vascular endothelial growth factor (VEGF) release, and the underlying mechanism, in a rat aortic smooth muscle cell line, A10 cells. Simvastatin 52-63 vascular endothelial growth factor A Rattus norvegicus 103-107 12535662-3 2003 Administration of simvastatin increased the VEGF level in rat plasma in vivo. Simvastatin 18-29 vascular endothelial growth factor A Rattus norvegicus 44-48 12535662-4 2003 In cultured cells, simvastatin significantly stimulated VEGF release in a dose-dependent manner. Simvastatin 19-30 vascular endothelial growth factor A Rattus norvegicus 56-60 12535662-6 2003 PD98059 and U-0126, inhibitors of the upstream kinase that activates p44/p42 MAP kinase, significantly reduced the simvastatin-induced VEGF release in a dose-dependent manner. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 0-7 vascular endothelial growth factor A Rattus norvegicus 135-139 12535662-6 2003 PD98059 and U-0126, inhibitors of the upstream kinase that activates p44/p42 MAP kinase, significantly reduced the simvastatin-induced VEGF release in a dose-dependent manner. U 0126 12-18 vascular endothelial growth factor A Rattus norvegicus 135-139 12535662-6 2003 PD98059 and U-0126, inhibitors of the upstream kinase that activates p44/p42 MAP kinase, significantly reduced the simvastatin-induced VEGF release in a dose-dependent manner. Simvastatin 115-126 vascular endothelial growth factor A Rattus norvegicus 135-139 12535662-8 2003 Moreover, a bolus injection of PD98059 truly suppressed the simvastatin-increased VEGF level in rat plasma in vivo. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 31-38 vascular endothelial growth factor A Rattus norvegicus 82-86 12535662-8 2003 Moreover, a bolus injection of PD98059 truly suppressed the simvastatin-increased VEGF level in rat plasma in vivo. Simvastatin 60-71 vascular endothelial growth factor A Rattus norvegicus 82-86 12504784-0 2003 Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. Celecoxib 0-9 vascular endothelial growth factor A Rattus norvegicus 68-102 12480545-1 2003 17alpha-E(2), a weak estrogen exhibited both agonistic and antagonistic effects, and caused a time- and dose-dependent induction of VEGF-A mRNA expression in GH3 rat pituitary tumor cells. 17alpha-e 0-9 vascular endothelial growth factor A Rattus norvegicus 132-138 12504784-2 2003 The objective of this study was to determine whether celecoxib, a selective cyclooxygenase-2 enzyme inhibitor, reaches ocular tissues following oral administration and inhibits the retinal VEGF expression and vascular leakage in a streptozotocin-induced diabetic rat model. Celecoxib 53-62 vascular endothelial growth factor A Rattus norvegicus 189-193 12504784-7 2003 Celecoxib treatment inhibited VEGF mRNA expression without any significant reduction in cyclooxygenase-2 mRNA. Celecoxib 0-9 vascular endothelial growth factor A Rattus norvegicus 30-34 12504784-11 2003 Thus, celecoxib reaches the retina after oral administration and reduces diabetes-induced retinal VEGF mRNA expression and vascular leakage by inhibiting the activity of cyclooxygenase-2 enzyme. Celecoxib 6-15 vascular endothelial growth factor A Rattus norvegicus 98-102 12480545-3 2003 Inhibition of phosphatidylinositol-3 kinase (PI3K) activity by wortmannin decreased the effect of 17alpha-E(2) on VEGF-A mRNA expression. Wortmannin 63-73 vascular endothelial growth factor A Rattus norvegicus 114-120 15166499-0 2003 Norepinephrine upregulates vascular endothelial growth factor in rat cardiac myocytes by a paracrine mechanism. Norepinephrine 0-14 vascular endothelial growth factor A Rattus norvegicus 27-61 12507898-7 2003 In diabetic Ren-2, vascular endothelial growth factor (VEGF) and VEGFR-2 mRNA were increased in retinae and irides and reduced with LIS. Lisinopril 132-135 vascular endothelial growth factor A Rattus norvegicus 19-53 12507898-7 2003 In diabetic Ren-2, vascular endothelial growth factor (VEGF) and VEGFR-2 mRNA were increased in retinae and irides and reduced with LIS. Lisinopril 132-135 vascular endothelial growth factor A Rattus norvegicus 55-59 14753438-6 2003 VEGF expression as demonstrated immunohistochemically appeared to coincide with vasogenic edema, diagnosed as high intensity areas on apparent diffusion coefficient of water (ADCw) maps. Water 168-173 vascular endothelial growth factor A Rattus norvegicus 0-4 15166499-2 2003 The present study in cultured neonatal rat cardiac myocytes tested the hypothesis that norepinephrine also stimulates expression of vascular endothelial growth factor (VEGF), an important angiogenic factor. Norepinephrine 87-101 vascular endothelial growth factor A Rattus norvegicus 132-166 15166499-2 2003 The present study in cultured neonatal rat cardiac myocytes tested the hypothesis that norepinephrine also stimulates expression of vascular endothelial growth factor (VEGF), an important angiogenic factor. Norepinephrine 87-101 vascular endothelial growth factor A Rattus norvegicus 168-172 15166499-4 2003 When cardiac myocytes were stimulated with 1 micro M norepinephrine for 24 h in the presence or absence of the specific alpha - and beta -adrenoceptor antagonists prazosin and propranolol, respectively, VEGF mRNA levels and splice variant pattern did not change, whereas atrial natriuretic peptide mRNA levels increased 3 to 4-fold. Norepinephrine 53-67 vascular endothelial growth factor A Rattus norvegicus 203-207 15166499-4 2003 When cardiac myocytes were stimulated with 1 micro M norepinephrine for 24 h in the presence or absence of the specific alpha - and beta -adrenoceptor antagonists prazosin and propranolol, respectively, VEGF mRNA levels and splice variant pattern did not change, whereas atrial natriuretic peptide mRNA levels increased 3 to 4-fold. Prazosin 163-171 vascular endothelial growth factor A Rattus norvegicus 203-207 15166499-4 2003 When cardiac myocytes were stimulated with 1 micro M norepinephrine for 24 h in the presence or absence of the specific alpha - and beta -adrenoceptor antagonists prazosin and propranolol, respectively, VEGF mRNA levels and splice variant pattern did not change, whereas atrial natriuretic peptide mRNA levels increased 3 to 4-fold. Propranolol 176-187 vascular endothelial growth factor A Rattus norvegicus 203-207 15166499-5 2003 CoCl(2) increased VEGF mRNA levels in cardiac myocytes five-fold. cobaltous chloride 0-7 vascular endothelial growth factor A Rattus norvegicus 18-22 15166499-6 2003 When cardiac myocytes were cultured with conditioned medium from non-myocytes that had been stimulated with norepinephrine for 24 h VEGF mRNA increased 2-fold. Norepinephrine 108-122 vascular endothelial growth factor A Rattus norvegicus 132-136 12658918-1 2002 OBJECTIVE: To observe the effect of bizhongxiao (BZX) decoction on the expression of VEGF in the synovial membrane of C II-induced arthritis(CIA) in rats and to explore the mechanism of BZX decoction in the treatment of rheumatoid arthritis RA. sesamol 49-52 vascular endothelial growth factor A Rattus norvegicus 85-89 12507295-9 2003 The appearance of VEGF lagged and it existed around the pores of hydroxyapatite even on the 21st day of the implantation. Durapatite 65-79 vascular endothelial growth factor A Rattus norvegicus 18-22 12676137-0 2003 Vascular endothelial growth factor inhibits outward delayed-rectifier potassium currents in acutely isolated hippocampal neurons. Potassium 70-79 vascular endothelial growth factor A Rattus norvegicus 0-34 14696965-5 2003 Treatment of the cells with phorbolmyristate acetate (PMA), a protein kinase C (PKC) activator, enhanced expression of the 2 major VEGF isoforms in the cultured dental follicle cells, whereas adding a specific PKC inhibitor prevented this. Tetradecanoylphorbol Acetate 28-52 vascular endothelial growth factor A Rattus norvegicus 131-135 14696965-5 2003 Treatment of the cells with phorbolmyristate acetate (PMA), a protein kinase C (PKC) activator, enhanced expression of the 2 major VEGF isoforms in the cultured dental follicle cells, whereas adding a specific PKC inhibitor prevented this. Tetradecanoylphorbol Acetate 54-57 vascular endothelial growth factor A Rattus norvegicus 131-135 14696965-6 2003 Treatment with PMA also increased the protein level of VEGF. Tetradecanoylphorbol Acetate 15-18 vascular endothelial growth factor A Rattus norvegicus 55-59 12573617-0 2003 Adeno-associated viral vector-mediated gene transfer of VEGF normalizes skeletal muscle oxygen tension and induces arteriogenesis in ischemic rat hindlimb. Oxygen 88-94 vascular endothelial growth factor A Rattus norvegicus 56-60 12573617-6 2003 We asked whether an intra-arterial injection of AAV-VEGF(165) normalizes muscle oxygen tension by increasing skeletal muscle oxygen tension, and promotes arteriogenesis and angiogenesis in a rat model of severe hindlimb ischemia. Oxygen 80-86 vascular endothelial growth factor A Rattus norvegicus 52-56 12573617-6 2003 We asked whether an intra-arterial injection of AAV-VEGF(165) normalizes muscle oxygen tension by increasing skeletal muscle oxygen tension, and promotes arteriogenesis and angiogenesis in a rat model of severe hindlimb ischemia. Oxygen 125-131 vascular endothelial growth factor A Rattus norvegicus 52-56 12573617-7 2003 We found that AAV-VEGF treatment normalized muscle oxygen tension in the ischemic limb. Oxygen 51-57 vascular endothelial growth factor A Rattus norvegicus 18-22 12573617-10 2003 We conclude that intra-arterial AAV-mediated gene transfer of AAV-VEGF(165) normalizes muscle oxygen tension and leads to arteriogenesis in rats with severe hindlimb ischemia. Oxygen 94-100 vascular endothelial growth factor A Rattus norvegicus 66-70 12658918-8 2002 The expression of VEGF of the model group was notably higher than that of the BZX decoction group and the MTX group in different times (P < 0.01). sesamol 78-81 vascular endothelial growth factor A Rattus norvegicus 18-22 12658918-8 2002 The expression of VEGF of the model group was notably higher than that of the BZX decoction group and the MTX group in different times (P < 0.01). Methotrexate 106-109 vascular endothelial growth factor A Rattus norvegicus 18-22 12658918-9 2002 The expression of VEGF of the model group rose step by step, but that of the BZX decoction group and the MTX group decreased and was significantly lower than that of the model group (P < 0.01). sesamol 77-80 vascular endothelial growth factor A Rattus norvegicus 18-22 12658918-9 2002 The expression of VEGF of the model group rose step by step, but that of the BZX decoction group and the MTX group decreased and was significantly lower than that of the model group (P < 0.01). Methotrexate 105-108 vascular endothelial growth factor A Rattus norvegicus 18-22 12658918-10 2002 The expression of VEGF of the BZX decoction group was significantly lower than that of the MTX group(P < 0.05). sesamol 30-33 vascular endothelial growth factor A Rattus norvegicus 18-22 12658918-10 2002 The expression of VEGF of the BZX decoction group was significantly lower than that of the MTX group(P < 0.05). Methotrexate 91-94 vascular endothelial growth factor A Rattus norvegicus 18-22 12658918-12 2002 BZX decoction and MTX could decrease the expression of VEGF, but the curative effect of BZX decoction is significantly better than that of MTX. sesamol 0-3 vascular endothelial growth factor A Rattus norvegicus 55-59 12658918-12 2002 BZX decoction and MTX could decrease the expression of VEGF, but the curative effect of BZX decoction is significantly better than that of MTX. Methotrexate 18-21 vascular endothelial growth factor A Rattus norvegicus 55-59 12658918-13 2002 BZX decoction could inhibit the formation of the synovial pannus or bone in RA by decreasing the expression of VEGF. sesamol 0-3 vascular endothelial growth factor A Rattus norvegicus 111-115 12213286-5 2002 Vascular endothelial growth factor (VEGF) was administered in a sustained releasing formula to pubescent female COP rats 2 weeks after N-nitroso-N-methylurea (NMU) treatment. Methylnitrosourea 135-157 vascular endothelial growth factor A Rattus norvegicus 0-34 12213286-5 2002 Vascular endothelial growth factor (VEGF) was administered in a sustained releasing formula to pubescent female COP rats 2 weeks after N-nitroso-N-methylurea (NMU) treatment. Methylnitrosourea 159-162 vascular endothelial growth factor A Rattus norvegicus 0-34 12438525-7 2002 Furthermore, addition of VEGF-neutralizing antibody (2.5 microg/kg twice a week) or NOS inhibitor (N(G)-nitro-L-arginine methyl ester, 10 mg/kg/day) prevented the pro-angiogenic effect induced by the perindopril/indapamide combination. Perindopril 200-211 vascular endothelial growth factor A Rattus norvegicus 25-29 12444056-5 2002 The objective of this study was to determine to what degree immunoneutralization of VEGF would interfere with a) estradiol-induced uterine edema and b) pregnancy. Estradiol 113-122 vascular endothelial growth factor A Rattus norvegicus 84-88 12438525-7 2002 Furthermore, addition of VEGF-neutralizing antibody (2.5 microg/kg twice a week) or NOS inhibitor (N(G)-nitro-L-arginine methyl ester, 10 mg/kg/day) prevented the pro-angiogenic effect induced by the perindopril/indapamide combination. Indapamide 212-222 vascular endothelial growth factor A Rattus norvegicus 25-29 12437967-5 2002 High glucose modestly increased reactive oxygen species (ROS) generation, decreased DNA synthesis, and up-regulated vascular endothelial growth factor (VEGF) mRNA levels in cultured pericytes. Glucose 5-12 vascular endothelial growth factor A Rattus norvegicus 116-150 12437967-5 2002 High glucose modestly increased reactive oxygen species (ROS) generation, decreased DNA synthesis, and up-regulated vascular endothelial growth factor (VEGF) mRNA levels in cultured pericytes. Glucose 5-12 vascular endothelial growth factor A Rattus norvegicus 152-156 12376368-2 2002 In vitro, hypoxia increased VEGF mRNA and protein levels, with maximal stimulation at 0% O2 for 18 h. A similar upregulation of VEGF expression was found in alveolar epithelial type II (ATII) cells freshly isolated from rats exposed to 8% O2 for 24 h. In vitro, hypoxia-induced upregulation of VEGF mRNA was due to an increase in transcription, rather than an increase in RNA stability, inasmuch as the half-life of VEGF mRNA was unchanged. Oxygen 239-241 vascular endothelial growth factor A Rattus norvegicus 128-132 12153400-4 2002 VEGF augmented tyrosine phosphorylation of IRS-1 in kidney epithelial cells and rat heart endothelial cells in a time-dependent manner. Tyrosine 15-23 vascular endothelial growth factor A Rattus norvegicus 0-4 12153400-7 2002 Incubation of epithelial cells with antisense IRS-1 oligonucleotide, but not sense oligonucleotide, reduced expression of the protein and VEGF-induced PI 3-kinase activity in IRS-1 immunoprecipitates. Oligonucleotides 52-67 vascular endothelial growth factor A Rattus norvegicus 138-142 12376368-2 2002 In vitro, hypoxia increased VEGF mRNA and protein levels, with maximal stimulation at 0% O2 for 18 h. A similar upregulation of VEGF expression was found in alveolar epithelial type II (ATII) cells freshly isolated from rats exposed to 8% O2 for 24 h. In vitro, hypoxia-induced upregulation of VEGF mRNA was due to an increase in transcription, rather than an increase in RNA stability, inasmuch as the half-life of VEGF mRNA was unchanged. Oxygen 239-241 vascular endothelial growth factor A Rattus norvegicus 128-132 12376368-2 2002 In vitro, hypoxia increased VEGF mRNA and protein levels, with maximal stimulation at 0% O2 for 18 h. A similar upregulation of VEGF expression was found in alveolar epithelial type II (ATII) cells freshly isolated from rats exposed to 8% O2 for 24 h. In vitro, hypoxia-induced upregulation of VEGF mRNA was due to an increase in transcription, rather than an increase in RNA stability, inasmuch as the half-life of VEGF mRNA was unchanged. Oxygen 239-241 vascular endothelial growth factor A Rattus norvegicus 128-132 12376368-3 2002 Upregulation of VEGF mRNA by hypoxia was mimicked by CoCl2 and desferrioxamine in normoxic AEC and was not prevented by inhibitors of reactive oxygen species, suggesting that hypoxic VEGF regulation involved an O2-dependent protein that requires ferrous ions but is independent of reactive oxygen species generation. cobaltous chloride 53-58 vascular endothelial growth factor A Rattus norvegicus 16-20 12376368-3 2002 Upregulation of VEGF mRNA by hypoxia was mimicked by CoCl2 and desferrioxamine in normoxic AEC and was not prevented by inhibitors of reactive oxygen species, suggesting that hypoxic VEGF regulation involved an O2-dependent protein that requires ferrous ions but is independent of reactive oxygen species generation. Deferoxamine 63-78 vascular endothelial growth factor A Rattus norvegicus 16-20 12376368-3 2002 Upregulation of VEGF mRNA by hypoxia was mimicked by CoCl2 and desferrioxamine in normoxic AEC and was not prevented by inhibitors of reactive oxygen species, suggesting that hypoxic VEGF regulation involved an O2-dependent protein that requires ferrous ions but is independent of reactive oxygen species generation. Reactive Oxygen Species 281-304 vascular endothelial growth factor A Rattus norvegicus 16-20 12376368-3 2002 Upregulation of VEGF mRNA by hypoxia was mimicked by CoCl2 and desferrioxamine in normoxic AEC and was not prevented by inhibitors of reactive oxygen species, suggesting that hypoxic VEGF regulation involved an O2-dependent protein that requires ferrous ions but is independent of reactive oxygen species generation. Reactive Oxygen Species 281-304 vascular endothelial growth factor A Rattus norvegicus 183-187 12399430-10 2002 A specific VEGF receptor-2 inhibitor (SU5416) was administered in three different protocols: on a daily basis, every 48 h, or two injections after hCG. Semaxinib 38-44 vascular endothelial growth factor A Rattus norvegicus 11-15 12234789-6 2002 Treatment of OLETF rats with candesartan, an AT(1) receptor blocker, inhibited vascular expressions of VEGF, HIF-1alpha, and AGEs, and ameliorated the morphometric changes. oletf 13-18 vascular endothelial growth factor A Rattus norvegicus 103-107 12518248-8 2002 Dexamethasone and nerve growth factor (NGF) increased VEGF mRNA expression and accumulation of VEGF protein of PC12 subclones with established metastatic activity in vivo. Dexamethasone 0-13 vascular endothelial growth factor A Rattus norvegicus 54-58 12518248-8 2002 Dexamethasone and nerve growth factor (NGF) increased VEGF mRNA expression and accumulation of VEGF protein of PC12 subclones with established metastatic activity in vivo. Dexamethasone 0-13 vascular endothelial growth factor A Rattus norvegicus 95-99 12518248-11 2002 These results suggest that VEGF is a mediator of angiogenesis in the PC12 pheochromocytoma cell line, and that dexamethasone and NGF affect VEGF expression. Dexamethasone 111-124 vascular endothelial growth factor A Rattus norvegicus 140-144 12407161-2 2002 Because bucillamine inhibits the production of VEGF, it is possible that this drug may inhibit choroidal neovascularization (CNV). bucillamine 8-19 vascular endothelial growth factor A Rattus norvegicus 47-51 12271463-5 2002 VEGF antisense oligodeoxynucleotide infusion reduced VEGF induction and resulted in an enlargement of infarct volume of the brain caused by ischemia. Oligodeoxyribonucleotides 15-35 vascular endothelial growth factor A Rattus norvegicus 0-4 12271463-5 2002 VEGF antisense oligodeoxynucleotide infusion reduced VEGF induction and resulted in an enlargement of infarct volume of the brain caused by ischemia. Oligodeoxyribonucleotides 15-35 vascular endothelial growth factor A Rattus norvegicus 53-57 12368654-3 2002 The same magnitude of protection was observed in cultures treated with VEGF, which also reduced excitotoxic neuron death induced directly by an exposure to -methyl-d-aspartate. methyl-d-aspartate 157-175 vascular endothelial growth factor A Rattus norvegicus 71-75 12234789-6 2002 Treatment of OLETF rats with candesartan, an AT(1) receptor blocker, inhibited vascular expressions of VEGF, HIF-1alpha, and AGEs, and ameliorated the morphometric changes. candesartan 29-40 vascular endothelial growth factor A Rattus norvegicus 103-107 12397694-3 2002 Retinal VEGF mRNA expression was significantly higher and the latencies of oscillatory potentials were significantly elongated in STZ-treated SHRSP compared with a non-treated SHRSP group matched for age. Streptozocin 130-133 vascular endothelial growth factor A Rattus norvegicus 8-12 12218334-7 2002 In contrast, the number of VEGF-positive smooth muscle cells in the media was greater in the L-NAME group than in the control group. NG-Nitroarginine Methyl Ester 93-99 vascular endothelial growth factor A Rattus norvegicus 27-31 12397694-4 2002 Treatment with TCV-116(3 mg/kg) significantly diminished retinal VEGF mRNA expression and the latencies of oscillatory potentials, but had no effect on plasma glucose concentrations. candesartan cilexetil 15-22 vascular endothelial growth factor A Rattus norvegicus 65-69 12373001-9 2002 In addition, the PC of IgE was increased with the increase in the MC-derived vascular endothelial growth factor/permeability factor (VEGF). Methylcholanthrene 66-68 vascular endothelial growth factor A Rattus norvegicus 77-131 12181492-3 2002 VEGF (>10 ng/ml) stimulated 5-bromo-2"-deoxyuridine (BrdUrd) incorporation into cells that expressed immature neuronal marker proteins and increased cell number in cultures by 20-30%. Bromodeoxyuridine 31-54 vascular endothelial growth factor A Rattus norvegicus 0-4 12181492-5 2002 Intracerebroventricular administration of VEGF into rat brain increased BrdUrd labeling of cells in the subventricular zone (SVZ) and the subgranular zone (SGZ) of the hippocampal dentate gyrus (DG), where VEGFR2/Flk-1 was colocalized with the immature neuronal marker, doublecortin (Dcx). doublecortin 270-282 vascular endothelial growth factor A Rattus norvegicus 42-46 12205050-3 2002 Recently, it has been shown that the neurotransmitter dopamine is a potent inhibitor of VEGF-induced angiogenesis. Dopamine 54-62 vascular endothelial growth factor A Rattus norvegicus 88-92 12373001-9 2002 In addition, the PC of IgE was increased with the increase in the MC-derived vascular endothelial growth factor/permeability factor (VEGF). Methylcholanthrene 66-68 vascular endothelial growth factor A Rattus norvegicus 133-137 12373001-12 2002 Release of VEGF from the activated MC increases, and the VEGF enhances the permeability of IgE. Methylcholanthrene 35-37 vascular endothelial growth factor A Rattus norvegicus 11-15 12211063-7 2002 On the other hand, this PGF(2alpha) analog induced expression of luteal VEGF mRNA. Prostaglandins F 24-27 vascular endothelial growth factor A Rattus norvegicus 72-76 12216707-11 2002 Rats receiving EPA demonstrated decreased VEGF-alpha mRNA levels (0.023 +/- 0 0.001) compared with those receiving corn oil (0.129 +/- 0.047) or saline (0.150 +/- 0.026; p < .05). Eicosapentaenoic Acid 15-18 vascular endothelial growth factor A Rattus norvegicus 42-52 12216707-12 2002 CONCLUSIONS: These data demonstrate that EPA supplementation inhibits tumor growth, potentially through alterations in the expression of the pro-angiogenic VEGF-alpha. Eicosapentaenoic Acid 41-44 vascular endothelial growth factor A Rattus norvegicus 156-166 12183421-5 2002 Selective inhibition of VEGF signaling has been demonstrated in vivo in a growth factor-induced hypotension model in anesthetized rat: administration of ZD6474 (2.5 mg/kg, i.v.) vandetanib 153-159 vascular endothelial growth factor A Rattus norvegicus 24-28 12183421-7 2002 Once-daily oral administration of ZD6474 to growing rats for 14 days produced a dose-dependent increase in the femoro-tibial epiphyseal growth plate zone of hypertrophy, which is consistent with inhibition of VEGF signaling and angiogenesis in vivo. vandetanib 34-40 vascular endothelial growth factor A Rattus norvegicus 209-213 12087245-10 2002 Furthermore, by using actinomycin D and cycloheximide, the authors demonstrated that the rhPDGF-BB-induced VEGF mRNA expression was transcriptionally mediate and not dependent on de novo protein synthesis. Dactinomycin 22-35 vascular endothelial growth factor A Rattus norvegicus 107-111 12138133-6 2002 30 mM D-glucose, but not 30 mM L-glucose, resulted in the elevation of VEGF mRNA in RPTEC, but not in GEC, although both cell types showed a comparable modest increase in VEGF expression. Glucose 6-15 vascular endothelial growth factor A Rattus norvegicus 71-75 12138133-6 2002 30 mM D-glucose, but not 30 mM L-glucose, resulted in the elevation of VEGF mRNA in RPTEC, but not in GEC, although both cell types showed a comparable modest increase in VEGF expression. Glucose 6-15 vascular endothelial growth factor A Rattus norvegicus 171-175 12138133-7 2002 Combined treatment (hypoxia and 30 mM D-glucose) resulted in an increase of VEGF mRNA only in RPTEC; however, an enhanced protein expression was detectable in both cell types. Glucose 38-47 vascular endothelial growth factor A Rattus norvegicus 76-80 12138133-10 2002 In contrast, 30 mM D-glucose suppressed angiogenesis in co-cultures with both cell types despite increased mRNA for VEGF receptors 1 and 2. Glucose 19-28 vascular endothelial growth factor A Rattus norvegicus 116-120 12110003-0 2002 Angiotensin II regulation of vascular endothelial growth factor and receptors Flt-1 and KDR/Flk-1 in cyclosporine nephrotoxicity. Cyclosporine 101-113 vascular endothelial growth factor A Rattus norvegicus 29-63 12119253-7 2002 Nifedipine stimulated vascular endothelial growth factor (VEGF) production from VSMCs, and this stimulation of VEGF production was abolished by HOE-140, an antagonist of the bradykinin B(2) receptor. Nifedipine 0-10 vascular endothelial growth factor A Rattus norvegicus 22-56 12119253-7 2002 Nifedipine stimulated vascular endothelial growth factor (VEGF) production from VSMCs, and this stimulation of VEGF production was abolished by HOE-140, an antagonist of the bradykinin B(2) receptor. Nifedipine 0-10 vascular endothelial growth factor A Rattus norvegicus 58-62 12119253-7 2002 Nifedipine stimulated vascular endothelial growth factor (VEGF) production from VSMCs, and this stimulation of VEGF production was abolished by HOE-140, an antagonist of the bradykinin B(2) receptor. Nifedipine 0-10 vascular endothelial growth factor A Rattus norvegicus 111-115 12119253-8 2002 A neutralizing antibody against VEGF inhibited the upregulation of endothelial SOD by nifedipine. Nifedipine 86-96 vascular endothelial growth factor A Rattus norvegicus 32-36 12119253-9 2002 In addition, recombinant VEGF induced an increase in the levels of SOD expression in ECs, and supernatant derived from nifedipine-treated VSMCs enhanced NO production from ECs. Nifedipine 119-129 vascular endothelial growth factor A Rattus norvegicus 25-29 12119253-9 2002 In addition, recombinant VEGF induced an increase in the levels of SOD expression in ECs, and supernatant derived from nifedipine-treated VSMCs enhanced NO production from ECs. vsmcs 138-143 vascular endothelial growth factor A Rattus norvegicus 25-29 12119253-11 2002 CONCLUSIONS: The calcium antagonist nifedipine indirectly upregulates endothelial SOD expression by stimulating VEGF production from adjacent VSMCs. Calcium 17-24 vascular endothelial growth factor A Rattus norvegicus 112-116 12119253-11 2002 CONCLUSIONS: The calcium antagonist nifedipine indirectly upregulates endothelial SOD expression by stimulating VEGF production from adjacent VSMCs. Nifedipine 36-46 vascular endothelial growth factor A Rattus norvegicus 112-116 12094014-1 2002 Long-term (10-week) treatment of Fischer 344 (F344) rats with the synthetic estrogen diethylstilbestrol (DES) increases the level of vascular endothelial growth factor (VEGF) in the pituitary. Diethylstilbestrol 85-103 vascular endothelial growth factor A Rattus norvegicus 133-167 12094014-1 2002 Long-term (10-week) treatment of Fischer 344 (F344) rats with the synthetic estrogen diethylstilbestrol (DES) increases the level of vascular endothelial growth factor (VEGF) in the pituitary. Diethylstilbestrol 85-103 vascular endothelial growth factor A Rattus norvegicus 169-173 12094014-1 2002 Long-term (10-week) treatment of Fischer 344 (F344) rats with the synthetic estrogen diethylstilbestrol (DES) increases the level of vascular endothelial growth factor (VEGF) in the pituitary. Diethylstilbestrol 105-108 vascular endothelial growth factor A Rattus norvegicus 133-167 12094014-1 2002 Long-term (10-week) treatment of Fischer 344 (F344) rats with the synthetic estrogen diethylstilbestrol (DES) increases the level of vascular endothelial growth factor (VEGF) in the pituitary. Diethylstilbestrol 105-108 vascular endothelial growth factor A Rattus norvegicus 169-173 12089375-9 2002 Concomitantly, labeling of the VEGF receptor Flk-1 in PTC endothelial cells decreased and PTC lumina began to regress, demonstrating endothelial cell apoptosis (as detected in terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labeling and electron-microscopic studies). dutp-biotin 223-234 vascular endothelial growth factor A Rattus norvegicus 31-35 12154044-9 2002 Dietary CLA decreased serum levels of vascular endothelial growth factor (VEGF) and whole mammary gland levels of VEGF and its receptor Flk-1. Linoleic Acids, Conjugated 8-11 vascular endothelial growth factor A Rattus norvegicus 38-72 12154044-9 2002 Dietary CLA decreased serum levels of vascular endothelial growth factor (VEGF) and whole mammary gland levels of VEGF and its receptor Flk-1. Linoleic Acids, Conjugated 8-11 vascular endothelial growth factor A Rattus norvegicus 74-78 12154044-9 2002 Dietary CLA decreased serum levels of vascular endothelial growth factor (VEGF) and whole mammary gland levels of VEGF and its receptor Flk-1. Linoleic Acids, Conjugated 8-11 vascular endothelial growth factor A Rattus norvegicus 114-118 12110003-3 2002 We have previously shown that VEGF is up-regulated in a chronic cyclosporine (CsA) nephrotoxicity model. Cyclosporine 64-76 vascular endothelial growth factor A Rattus norvegicus 30-34 12110003-3 2002 We have previously shown that VEGF is up-regulated in a chronic cyclosporine (CsA) nephrotoxicity model. Cyclosporine 78-81 vascular endothelial growth factor A Rattus norvegicus 30-34 12110003-8 2002 VEGF mRNA and protein expressions increased with CsA and became significantly reduced with Ang II blockade. Cyclosporine 49-52 vascular endothelial growth factor A Rattus norvegicus 0-4 12162707-0 2002 Pharmacokinetic characterization of 14C-vascular endothelial growth factor controlled release microspheres using a rat model. Carbon-14 36-39 vascular endothelial growth factor A Rattus norvegicus 40-74 12162707-1 2002 The objectives of this study were to characterize the pharmacokinetics of vascular endothelial growth factor (VEGF) in poly(lactic-co-glycolic) acid (PLGA) microspheres using a rat model, and to develop a pharmacokinetic model for this controlled release formulation. Polylactic Acid-Polyglycolic Acid Copolymer 119-148 vascular endothelial growth factor A Rattus norvegicus 74-108 12162707-1 2002 The objectives of this study were to characterize the pharmacokinetics of vascular endothelial growth factor (VEGF) in poly(lactic-co-glycolic) acid (PLGA) microspheres using a rat model, and to develop a pharmacokinetic model for this controlled release formulation. Polylactic Acid-Polyglycolic Acid Copolymer 119-148 vascular endothelial growth factor A Rattus norvegicus 110-114 12162707-2 2002 14C-VEGF was encapsulated using a solid-in-oil-in-water emulsification method. Oils 43-46 vascular endothelial growth factor A Rattus norvegicus 4-8 12162707-2 2002 14C-VEGF was encapsulated using a solid-in-oil-in-water emulsification method. Water 50-55 vascular endothelial growth factor A Rattus norvegicus 4-8 12162707-10 2002 14C-Methylation via reductive alkylation of VEGF did not affect its mitogenic activity, however approximately 25% activity was lost following release from PLGA microspheres. Carbon-14 0-3 vascular endothelial growth factor A Rattus norvegicus 44-48 12087245-10 2002 Furthermore, by using actinomycin D and cycloheximide, the authors demonstrated that the rhPDGF-BB-induced VEGF mRNA expression was transcriptionally mediate and not dependent on de novo protein synthesis. Cycloheximide 40-53 vascular endothelial growth factor A Rattus norvegicus 107-111 11981751-5 2002 Our results show that in DEN-treated rats, although the progression of liver fibrosis is associated with hepatocellular hypoxia and angiogenesis, VEGF and Flt-1 expressions in the liver are increased and correlated with the density of microvessels. Diethylnitrosamine 25-28 vascular endothelial growth factor A Rattus norvegicus 146-150 12010247-3 2002 They were then treated by an intracavernosal injection with 4 microg of VEGF in phosphate-buffered saline (PBS) or PBS alone. Phosphate-Buffered Saline 80-105 vascular endothelial growth factor A Rattus norvegicus 72-76 12010247-3 2002 They were then treated by an intracavernosal injection with 4 microg of VEGF in phosphate-buffered saline (PBS) or PBS alone. pbs 107-110 vascular endothelial growth factor A Rattus norvegicus 72-76 12023386-5 2002 Raw cells also express Flt-1, and VEGF treatment stimulated chemotaxis, cell proliferation, the association of Flt-1 with focal adhesion kinase (FAK), and the tyrosine phosphorylation of FAK in Raw cells. Tyrosine 159-167 vascular endothelial growth factor A Rattus norvegicus 34-38 12069500-7 2002 The use of an inhibitor of VEGF receptors such as SU5416 is distinct and it is likely complementary to other agents in the treatment of such cancers. Semaxinib 50-56 vascular endothelial growth factor A Rattus norvegicus 27-31 12046073-6 2002 The serum VEGF level in the HAL group increased significantly as against that of the control group (93 ng.L(-1)+/-44 ng.L(-1) vs 55 ng.L(-1)+/-19 ng.L(-1), P<0.05). hal 28-31 vascular endothelial growth factor A Rattus norvegicus 10-14 12046073-7 2002 The expression of VEGF and MMP-1 mRNA in the tumor tissue of the HAL group increased significantly compared with that of the control and the laparotomy control groups (P<0.05). hal 65-68 vascular endothelial growth factor A Rattus norvegicus 18-22 12046073-8 2002 The blood perfusion data of the tumor, represented by the number of Hoechst 33342 labeled cells, showed a good linear inverse correlation with the serum VEGF level (r=-0.606, P<0.05) and the expression of VEGF mRNA in the tumor tissue ( r =-0.338, P<0.01). bisbenzimide ethoxide trihydrochloride 68-81 vascular endothelial growth factor A Rattus norvegicus 153-157 11979343-8 2002 Dexamethasone aggravated proteinuria (protein, 0.4 +/- 0.1 mg/mg creatinine in the NC group, 6.3 +/- 2.0 mg/mg creatinine in the DC group, and 21.1 +/- 1.9 mg/mg creatinine in the D-Dex group; P < 0.05) and diminished VEGF release (22 +/- 3 pg/mg total protein in the NC group, 292 +/- 26 pg/mg total protein in the DC group, and 198 +/- 23 pg/mg total protein in the D-Dex group; P < 0.05). Dexamethasone 0-13 vascular endothelial growth factor A Rattus norvegicus 221-225 11979343-8 2002 Dexamethasone aggravated proteinuria (protein, 0.4 +/- 0.1 mg/mg creatinine in the NC group, 6.3 +/- 2.0 mg/mg creatinine in the DC group, and 21.1 +/- 1.9 mg/mg creatinine in the D-Dex group; P < 0.05) and diminished VEGF release (22 +/- 3 pg/mg total protein in the NC group, 292 +/- 26 pg/mg total protein in the DC group, and 198 +/- 23 pg/mg total protein in the D-Dex group; P < 0.05). Deuterium 0-1 vascular endothelial growth factor A Rattus norvegicus 221-225 11979343-8 2002 Dexamethasone aggravated proteinuria (protein, 0.4 +/- 0.1 mg/mg creatinine in the NC group, 6.3 +/- 2.0 mg/mg creatinine in the DC group, and 21.1 +/- 1.9 mg/mg creatinine in the D-Dex group; P < 0.05) and diminished VEGF release (22 +/- 3 pg/mg total protein in the NC group, 292 +/- 26 pg/mg total protein in the DC group, and 198 +/- 23 pg/mg total protein in the D-Dex group; P < 0.05). Dextromethorphan 0-3 vascular endothelial growth factor A Rattus norvegicus 221-225 12227386-0 2002 By reducing production of vascular endothelial growth factor octreotide improves the peritoneal vascular alterations induced by hypertonic peritoneal dialysis solution. Octreotide 61-71 vascular endothelial growth factor A Rattus norvegicus 26-60 12021965-0 2002 Increased vascular endothelial growth factor peptide and gene expression in hypoplastic lung in nitrofen induced congenital diaphragmatic hernia in rats. nitrofen 96-104 vascular endothelial growth factor A Rattus norvegicus 10-44 12021965-5 2002 The aim of this study was to investigate mRNA and protein levels of VEGF in CDH lung and to determine whether antenatal Dex treatment has any effect on the production of VEGF. Dexamethasone 120-123 vascular endothelial growth factor A Rattus norvegicus 170-174 12021965-14 2002 VEGF immunoreactivity in pulmonary vessel walls was increased in the CDH and CDH-Dex groups compared to the NC group. cdh-dex 77-84 vascular endothelial growth factor A Rattus norvegicus 0-4 12227386-10 2002 Moreover, VEGF level and neoangiogenesis were significantly less in the octreotide group than in the group treated with hypertonic dextrose alone. Octreotide 72-82 vascular endothelial growth factor A Rattus norvegicus 10-14 12227386-11 2002 CONCLUSION: Our data document that, by increasing the production of VEGF, a high glucose concentration can cause vascular alterations within the peritoneal membrane. Glucose 81-88 vascular endothelial growth factor A Rattus norvegicus 68-72 12227386-12 2002 Octreotide can protect against the vascular alterations and preserve peritoneal function by inhibiting overexpression of VEGF and regulating the inflammatory response in the peritoneum. Octreotide 0-10 vascular endothelial growth factor A Rattus norvegicus 121-125 12006174-13 2002 As CO and iron, respectively the inducer and the inhibitor of VEGF synthesis, are concomitantly produced during the degradation of heme, these data indicate that HO by-products may differentially modulate VEGF production. Iron 10-14 vascular endothelial growth factor A Rattus norvegicus 205-209 12006174-13 2002 As CO and iron, respectively the inducer and the inhibitor of VEGF synthesis, are concomitantly produced during the degradation of heme, these data indicate that HO by-products may differentially modulate VEGF production. Heme 131-135 vascular endothelial growth factor A Rattus norvegicus 62-66 12006174-13 2002 As CO and iron, respectively the inducer and the inhibitor of VEGF synthesis, are concomitantly produced during the degradation of heme, these data indicate that HO by-products may differentially modulate VEGF production. Heme 131-135 vascular endothelial growth factor A Rattus norvegicus 205-209 12025960-2 2002 Treatment of rats with both the synthetic VEGF receptor-1/2 antagonist 3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-indolin-2-one (SU5416) (200 mg/kg, single s.c. injection) and hypoxia (3 weeks) causes irreversible severe PH characterized by marked elevation of pulmonary artery pressure (PAP), right ventricular hypertrophy, and obliteration of pulmonary arteries by proliferating endothelial cells (EC). Semaxinib 71-126 vascular endothelial growth factor A Rattus norvegicus 42-46 11948139-6 2002 Neovastat was shown to compete against the binding of VEGF to its receptor in endothelial cells and significantly inhibited the VEGF-dependent tyrosine phosphorylation of VEGF receptor-2, whereas it had no significant effect on VEGF receptor-1 activity. Tyrosine 143-151 vascular endothelial growth factor A Rattus norvegicus 128-132 11948139-6 2002 Neovastat was shown to compete against the binding of VEGF to its receptor in endothelial cells and significantly inhibited the VEGF-dependent tyrosine phosphorylation of VEGF receptor-2, whereas it had no significant effect on VEGF receptor-1 activity. Tyrosine 143-151 vascular endothelial growth factor A Rattus norvegicus 128-132 11948139-6 2002 Neovastat was shown to compete against the binding of VEGF to its receptor in endothelial cells and significantly inhibited the VEGF-dependent tyrosine phosphorylation of VEGF receptor-2, whereas it had no significant effect on VEGF receptor-1 activity. Tyrosine 143-151 vascular endothelial growth factor A Rattus norvegicus 128-132 12575192-0 2002 [Effects of testosterone on VEGF and FLK-1 protein expression in the ventral prostate of rat]. Testosterone 12-24 vascular endothelial growth factor A Rattus norvegicus 28-32 12575192-1 2002 OBJECTIVE: To investigate the effects of testosterone on VEGF and FLK-1 protein expression in the ventral prostate of Rat. Testosterone 41-53 vascular endothelial growth factor A Rattus norvegicus 57-61 12575192-8 2002 CONCLUSION: Testosterone can stimulate prostatic growth probably by upregulating the protein expression of VEGF and FLK-1. Testosterone 12-24 vascular endothelial growth factor A Rattus norvegicus 107-111 12006174-1 2002 Hypoxia, cytokines, and nitric oxide (NO) stimulate the generation of vascular endothelial growth factor (VEGF) and induce heme oxygenase-1 (HO-1) expression in vascular tissue. Nitric Oxide 24-36 vascular endothelial growth factor A Rattus norvegicus 70-104 12006174-1 2002 Hypoxia, cytokines, and nitric oxide (NO) stimulate the generation of vascular endothelial growth factor (VEGF) and induce heme oxygenase-1 (HO-1) expression in vascular tissue. Nitric Oxide 24-36 vascular endothelial growth factor A Rattus norvegicus 106-110 12006174-5 2002 In contrast, inhibition of HO activity by tin protoporphyrin IX (SnPPIX) totally prevented cytokine-induced increase in VEGF, despite an augmented synthesis of intracellular NO. tin protoporphyrin IX 42-63 vascular endothelial growth factor A Rattus norvegicus 120-124 12006174-5 2002 In contrast, inhibition of HO activity by tin protoporphyrin IX (SnPPIX) totally prevented cytokine-induced increase in VEGF, despite an augmented synthesis of intracellular NO. tin protoporphyrin IX 65-71 vascular endothelial growth factor A Rattus norvegicus 120-124 12006174-7 2002 Similarly, VEGF synthesis induced by hypoxia was down-regulated by SnPPIX, but not by inhibitors of NO synthase. tin protoporphyrin IX 67-73 vascular endothelial growth factor A Rattus norvegicus 11-15 12006174-10 2002 Among the products of HO-1, biliverdin and bilirubin showed no effect, whereas iron ions inhibited VEGF synthesis. Iron 79-83 vascular endothelial growth factor A Rattus norvegicus 99-103 12006174-13 2002 As CO and iron, respectively the inducer and the inhibitor of VEGF synthesis, are concomitantly produced during the degradation of heme, these data indicate that HO by-products may differentially modulate VEGF production. Carbon Monoxide 3-5 vascular endothelial growth factor A Rattus norvegicus 62-66 12006174-13 2002 As CO and iron, respectively the inducer and the inhibitor of VEGF synthesis, are concomitantly produced during the degradation of heme, these data indicate that HO by-products may differentially modulate VEGF production. Carbon Monoxide 3-5 vascular endothelial growth factor A Rattus norvegicus 205-209 12006174-13 2002 As CO and iron, respectively the inducer and the inhibitor of VEGF synthesis, are concomitantly produced during the degradation of heme, these data indicate that HO by-products may differentially modulate VEGF production. Iron 10-14 vascular endothelial growth factor A Rattus norvegicus 62-66 12025960-2 2002 Treatment of rats with both the synthetic VEGF receptor-1/2 antagonist 3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-indolin-2-one (SU5416) (200 mg/kg, single s.c. injection) and hypoxia (3 weeks) causes irreversible severe PH characterized by marked elevation of pulmonary artery pressure (PAP), right ventricular hypertrophy, and obliteration of pulmonary arteries by proliferating endothelial cells (EC). Semaxinib 128-134 vascular endothelial growth factor A Rattus norvegicus 42-46 12025960-8 2002 We conclude that EC death induced by VEGFR-2 blockade with SU5416 may trigger an EC selection process that allows for the expansion of apoptosis-resistant EC, possibly driven by mechanisms independent of VEGF and VEGFR-2. Semaxinib 59-65 vascular endothelial growth factor A Rattus norvegicus 37-41 11919334-9 2002 The VEGF response was reduced by cyclooxygenase inhibition (indomethacin) in both groups. Indomethacin 60-72 vascular endothelial growth factor A Rattus norvegicus 4-8 11919334-12 2002 These results show an attenuated uterine artery vasodilator response to VEGF produced by a low-protein diet in pregnancy, partly because of a reduction of the nitric oxide component of VEGF-mediated relaxation. Nitric Oxide 159-171 vascular endothelial growth factor A Rattus norvegicus 72-76 11919334-12 2002 These results show an attenuated uterine artery vasodilator response to VEGF produced by a low-protein diet in pregnancy, partly because of a reduction of the nitric oxide component of VEGF-mediated relaxation. Nitric Oxide 159-171 vascular endothelial growth factor A Rattus norvegicus 185-189 11861517-10 2002 An experimental mimic of hypoxia, CoCl(2), also increased adipocyte VEGF, and this effect was additive with 100 nM insulin. cobaltous chloride 34-41 vascular endothelial growth factor A Rattus norvegicus 68-72 11784722-6 2002 Moreover, PTEN-C/S increased the length of vascular sprouts in the rat aortic ring assay and modulated VEGF-mediated tube formation in an in vitro angiogenesis assay, whereas PTEN-wild type inhibited these effects. Sulfur 17-18 vascular endothelial growth factor A Rattus norvegicus 103-107 11890674-5 2002 They were then treated with intracavernous injection of 4 microg of VEGF in phosphate-buffered saline (PBS) or PBS alone. Phosphate-Buffered Saline 76-101 vascular endothelial growth factor A Rattus norvegicus 68-72 12126060-7 2002 VEGF induction was confirmed by the increased levels in the fluids in the sponge matrix after topical injection of 8-bromo-cAMP. 8-Bromo Cyclic Adenosine Monophosphate 115-127 vascular endothelial growth factor A Rattus norvegicus 0-4 12126060-8 2002 Immunohistochemical investigation further revealed the VEGF-expressed cells in the sponge granulation tissues to be fibroblasts, and the intensity of positive reactions was enhanced by bFGF, 8-bromo-cAMP, forskolin, and amrinone. 8-Bromo Cyclic Adenosine Monophosphate 191-203 vascular endothelial growth factor A Rattus norvegicus 55-59 12126060-8 2002 Immunohistochemical investigation further revealed the VEGF-expressed cells in the sponge granulation tissues to be fibroblasts, and the intensity of positive reactions was enhanced by bFGF, 8-bromo-cAMP, forskolin, and amrinone. Colforsin 205-214 vascular endothelial growth factor A Rattus norvegicus 55-59 12126060-8 2002 Immunohistochemical investigation further revealed the VEGF-expressed cells in the sponge granulation tissues to be fibroblasts, and the intensity of positive reactions was enhanced by bFGF, 8-bromo-cAMP, forskolin, and amrinone. Amrinone 220-228 vascular endothelial growth factor A Rattus norvegicus 55-59 12126060-12 2002 Daily topical injections of neutralizing antibody or anti-sense oligonucleotide against VEGF significantly suppressed angiogenesis. Oligonucleotides 64-79 vascular endothelial growth factor A Rattus norvegicus 88-92 11877364-0 2002 Vascular endothelial growth factor is necessary in the development of arteriosclerosis by recruiting/activating monocytes in a rat model of long-term inhibition of nitric oxide synthesis. Nitric Oxide 164-176 vascular endothelial growth factor A Rattus norvegicus 0-34 11877364-6 2002 We observed vascular inflammation associated with increased VEGF expression within 3 days of L-NAME administration, which was prevented by pretreatment with ACE inhibitor, angiotensin II receptor antagonist, or neutralizing monocyte chemoattractant protein-1 antibody. NG-Nitroarginine Methyl Ester 93-99 vascular endothelial growth factor A Rattus norvegicus 60-64 11842056-6 2002 Ethanol increased VEGF, TGF-beta(1), bFGF, and Flt-1 mRNA at rest and after acute exercise. Ethanol 0-7 vascular endothelial growth factor A Rattus norvegicus 18-22 11842056-9 2002 These findings suggest that 1) ethanol can increase skeletal muscle angiogenic growth factor gene expression and 2) the mechanisms responsible for the ethanol-induced increases in VEGF, TGF-beta(1), and Flt-1 mRNA appear to be different from those responsible for exercise-induced regulation. Ethanol 151-158 vascular endothelial growth factor A Rattus norvegicus 180-184 11901189-5 2002 The insulin-induced retinal HIF-1alpha and VEGF increases and the related blood-retinal barrier breakdown are suppressed by inhibitors of p38 mitogen-activated protein kinase (MAPK) and phosphatidylinositol (PI) 3-kinase, but not inhibitors of p42/p44 MAPK or protein kinase C. Taken together, these findings indicate that acute intensive insulin therapy produces a transient worsening of diabetic blood-retinal barrier breakdown via an HIF-1alpha-mediated increase in retinal VEGF expression. Phosphatidylinositols 186-206 vascular endothelial growth factor A Rattus norvegicus 43-47 11934234-2 2002 METHODS: The ability of BAPSG to inhibit aldose reductase activity and glucose-induced vascular endothelial growth factor (VEGF) expression was assessed in a retinal pigment epithelial cell line (ARPE-19). Glucose 71-78 vascular endothelial growth factor A Rattus norvegicus 123-127 11934234-9 2002 The implant reduced galactitol accumulation, glutathione depletion, cataract scores, and VEGF expression in galactose-fed rats. Galactose 108-117 vascular endothelial growth factor A Rattus norvegicus 89-93 11934234-10 2002 CONCLUSIONS: An injectable biodegradable implant of BAPSG sustained drug release in vitro and in vivo, and reduced galactitol accumulation, glutathione depletion, cataract scores, and VEGF expression in galactose-fed rats. N-(((4-benzoylamino)phenyl)sulfonyl)glycine 52-57 vascular endothelial growth factor A Rattus norvegicus 184-188 11850530-2 2002 In this study, a phosphorothioate oligonucleotide (PS-oligo) targeting both human and rat VEGF(165) genes upstream of the translation initiation code, named DS135 in this study, was evaluated for its uptake dynamics and retinal tolerance after intravitreal (IV) and subretinal (SR) injections in the rhesus monkey. Phosphorothioate Oligonucleotides 17-49 vascular endothelial growth factor A Rattus norvegicus 90-94 12192761-6 2002 The treatment groups received VEGF in 0.9% NaCl (treatment 1) and VEGF in PVA (treatment 2). Sodium Chloride 43-47 vascular endothelial growth factor A Rattus norvegicus 30-34 11834720-9 2002 Moreover, the stress-mediated induction of HIF-1alpha and VEGF was suppressed by gadolinium (a stretch-activated channel inhibitor), wortmannin, and rapamycin (a FRAP inhibitor). Gadolinium 81-91 vascular endothelial growth factor A Rattus norvegicus 58-62 11834720-9 2002 Moreover, the stress-mediated induction of HIF-1alpha and VEGF was suppressed by gadolinium (a stretch-activated channel inhibitor), wortmannin, and rapamycin (a FRAP inhibitor). Wortmannin 133-143 vascular endothelial growth factor A Rattus norvegicus 58-62 11834720-9 2002 Moreover, the stress-mediated induction of HIF-1alpha and VEGF was suppressed by gadolinium (a stretch-activated channel inhibitor), wortmannin, and rapamycin (a FRAP inhibitor). Sirolimus 149-158 vascular endothelial growth factor A Rattus norvegicus 58-62 11839570-10 2002 Further, VEGF TrapA(40) reduced the diabetes-related nitric oxide increases in the retinae of diabetic animals. Nitric Oxide 53-65 vascular endothelial growth factor A Rattus norvegicus 9-13 11850530-2 2002 In this study, a phosphorothioate oligonucleotide (PS-oligo) targeting both human and rat VEGF(165) genes upstream of the translation initiation code, named DS135 in this study, was evaluated for its uptake dynamics and retinal tolerance after intravitreal (IV) and subretinal (SR) injections in the rhesus monkey. Phosphorothioate Oligonucleotides 51-59 vascular endothelial growth factor A Rattus norvegicus 90-94 11855754-5 2002 When administered orally twice daily for 10 days, the compound 317615 x 2HCl markedly decreased the neoangiogenesis induced by VEGF or bFGF in the rat corneal micropocket assay. 2hcl 72-76 vascular endothelial growth factor A Rattus norvegicus 127-131 11730812-0 2001 Vascular endothelial growth factor synthesis in vascular smooth muscle cells is enhanced by 7-ketocholesterol and lysophosphatidylcholine independently of their effect on nitric oxide generation. 7-ketocholesterol 92-109 vascular endothelial growth factor A Rattus norvegicus 0-34 12428069-12 2002 CONCLUSION: The results provide strong evidence for the role of VEGF in the repair of tissue damage induced by ethanol. Ethanol 111-118 vascular endothelial growth factor A Rattus norvegicus 64-68 11744811-0 2002 Downregulation of vascular endothelial growth factor and its receptors in the kidney in rats with puromycin aminonucleoside nephrosis. Puromycin 98-107 vascular endothelial growth factor A Rattus norvegicus 18-52 11744811-1 2002 AIM: We aimed to examine the possible involvement of vascular endothelial growth factor (VEGF) in the pathogenesis of puromycin aminonucleoside nephrosis (PAN). Puromycin 118-127 vascular endothelial growth factor A Rattus norvegicus 53-87 11744811-1 2002 AIM: We aimed to examine the possible involvement of vascular endothelial growth factor (VEGF) in the pathogenesis of puromycin aminonucleoside nephrosis (PAN). Puromycin 118-127 vascular endothelial growth factor A Rattus norvegicus 89-93 11744811-2 2002 METHODS: The expression and localization of the mRNA of VEGF and its receptors, flt-1 and flk-1, were analyzed in the kidneys of puromycin aminonucleoside-injected rats by use of Northern blotting and in situ hybridization. Puromycin Aminonucleoside 129-154 vascular endothelial growth factor A Rattus norvegicus 56-60 11934468-3 2002 By 3 days, VEGF delivery caused significantly increased cerebral angiogenesis (25 ng/ml was most effective) in both experimental models when compared to saline controls; VEGF infusion resulted in a 100% increase in an index of vascular proliferation, and gelatin sponge delivery produced a 65% increase. Sodium Chloride 153-159 vascular endothelial growth factor A Rattus norvegicus 11-15 11934468-5 2002 Infusion of VEGF produced extensive protein leakage that persisted after saline-induced permeability was mostly resolved, while gelatin sponge administration caused milder barrier dysfunction. Sodium Chloride 73-79 vascular endothelial growth factor A Rattus norvegicus 12-16 11730812-9 2001 The results indicate that VEGF and NO synthesis in VSMC can be modulated by oxLDL. vsmc 51-55 vascular endothelial growth factor A Rattus norvegicus 26-30 11730812-0 2001 Vascular endothelial growth factor synthesis in vascular smooth muscle cells is enhanced by 7-ketocholesterol and lysophosphatidylcholine independently of their effect on nitric oxide generation. Lysophosphatidylcholines 114-137 vascular endothelial growth factor A Rattus norvegicus 0-34 11730812-1 2001 Nitric oxide (NO) generated by inducible NO synthase (iNOS) enhances vascular endothelial growth factor (VEGF) synthesis in vascular smooth muscle cells (VSMC) and both NO and modified low density lipoprotein (LDL) augment VEGF production in macrophages. Nitric Oxide 0-12 vascular endothelial growth factor A Rattus norvegicus 69-103 11730812-1 2001 Nitric oxide (NO) generated by inducible NO synthase (iNOS) enhances vascular endothelial growth factor (VEGF) synthesis in vascular smooth muscle cells (VSMC) and both NO and modified low density lipoprotein (LDL) augment VEGF production in macrophages. Nitric Oxide 0-12 vascular endothelial growth factor A Rattus norvegicus 105-109 11730812-1 2001 Nitric oxide (NO) generated by inducible NO synthase (iNOS) enhances vascular endothelial growth factor (VEGF) synthesis in vascular smooth muscle cells (VSMC) and both NO and modified low density lipoprotein (LDL) augment VEGF production in macrophages. Nitric Oxide 0-12 vascular endothelial growth factor A Rattus norvegicus 223-227 11730812-4 2001 Both LPC and 7-Kchol significantly augmented VEGF production in rat and human VSMC. Lysophosphatidylcholines 5-8 vascular endothelial growth factor A Rattus norvegicus 45-49 11730812-4 2001 Both LPC and 7-Kchol significantly augmented VEGF production in rat and human VSMC. 7-ketocholesterol 13-20 vascular endothelial growth factor A Rattus norvegicus 45-49 11730812-5 2001 Increase in VEGF generation was related to the activation of VEGF promoter by both 7-Kchol and LPC and enhancement of VEGF mRNA transcription. 7-ketocholesterol 83-90 vascular endothelial growth factor A Rattus norvegicus 12-16 11730812-5 2001 Increase in VEGF generation was related to the activation of VEGF promoter by both 7-Kchol and LPC and enhancement of VEGF mRNA transcription. 7-ketocholesterol 83-90 vascular endothelial growth factor A Rattus norvegicus 61-65 11730812-5 2001 Increase in VEGF generation was related to the activation of VEGF promoter by both 7-Kchol and LPC and enhancement of VEGF mRNA transcription. 7-ketocholesterol 83-90 vascular endothelial growth factor A Rattus norvegicus 61-65 11758829-11 2001 Since HIF-1alpha initiates transcription of VEGF mRNA, HIF-1alpha activation by ethanol-induced injury is likely responsible for activation of VEGF gene and induction of angiogenesis. Ethanol 80-87 vascular endothelial growth factor A Rattus norvegicus 44-48 11724747-0 2001 Enhancement by histamine of vascular endothelial growth factor production in granulation tissue via H(2) receptors. Histamine 15-24 vascular endothelial growth factor A Rattus norvegicus 28-62 11724747-2 2001 Roles of histamine in the production of vascular endothelial growth factor (VEGF) in the carrageenin-induced granulation tissue in rats were analysed in vitro and in vivo. Histamine 9-18 vascular endothelial growth factor A Rattus norvegicus 40-74 11724747-2 2001 Roles of histamine in the production of vascular endothelial growth factor (VEGF) in the carrageenin-induced granulation tissue in rats were analysed in vitro and in vivo. Histamine 9-18 vascular endothelial growth factor A Rattus norvegicus 76-80 11724747-2 2001 Roles of histamine in the production of vascular endothelial growth factor (VEGF) in the carrageenin-induced granulation tissue in rats were analysed in vitro and in vivo. Carrageenan 89-100 vascular endothelial growth factor A Rattus norvegicus 40-74 11724747-2 2001 Roles of histamine in the production of vascular endothelial growth factor (VEGF) in the carrageenin-induced granulation tissue in rats were analysed in vitro and in vivo. Carrageenan 89-100 vascular endothelial growth factor A Rattus norvegicus 76-80 11724747-4 2001 Incubation of the minced granulation tissue in the presence of histamine (1 and 10 microM) increased the content of VEGF protein in the conditioned medium in a time- and concentration-dependent manner. Histamine 63-72 vascular endothelial growth factor A Rattus norvegicus 116-120 11724747-5 2001 The levels of VEGF mRNA in the minced granulation tissue were also increased by histamine in a concentration-dependent manner. Histamine 80-89 vascular endothelial growth factor A Rattus norvegicus 14-18 11724747-7 2001 The increase in the content of VEGF protein in the conditioned medium by histamine (10 microM) was suppressed by the H(2) receptor antagonist cimetidine (IC(50) 0.37 microM), but not by the H(1) receptor antagonist pyrilamine maleate, the H(3) receptor antagonist thioperamide or the cyclo-oxygenase inhibitor indomethacin. Histamine 73-82 vascular endothelial growth factor A Rattus norvegicus 31-35 11724747-7 2001 The increase in the content of VEGF protein in the conditioned medium by histamine (10 microM) was suppressed by the H(2) receptor antagonist cimetidine (IC(50) 0.37 microM), but not by the H(1) receptor antagonist pyrilamine maleate, the H(3) receptor antagonist thioperamide or the cyclo-oxygenase inhibitor indomethacin. Cimetidine 142-152 vascular endothelial growth factor A Rattus norvegicus 31-35 11724747-7 2001 The increase in the content of VEGF protein in the conditioned medium by histamine (10 microM) was suppressed by the H(2) receptor antagonist cimetidine (IC(50) 0.37 microM), but not by the H(1) receptor antagonist pyrilamine maleate, the H(3) receptor antagonist thioperamide or the cyclo-oxygenase inhibitor indomethacin. Pyrilamine 215-233 vascular endothelial growth factor A Rattus norvegicus 31-35 11724747-7 2001 The increase in the content of VEGF protein in the conditioned medium by histamine (10 microM) was suppressed by the H(2) receptor antagonist cimetidine (IC(50) 0.37 microM), but not by the H(1) receptor antagonist pyrilamine maleate, the H(3) receptor antagonist thioperamide or the cyclo-oxygenase inhibitor indomethacin. thioperamide 264-276 vascular endothelial growth factor A Rattus norvegicus 31-35 11724747-7 2001 The increase in the content of VEGF protein in the conditioned medium by histamine (10 microM) was suppressed by the H(2) receptor antagonist cimetidine (IC(50) 0.37 microM), but not by the H(1) receptor antagonist pyrilamine maleate, the H(3) receptor antagonist thioperamide or the cyclo-oxygenase inhibitor indomethacin. Indomethacin 310-322 vascular endothelial growth factor A Rattus norvegicus 31-35 11724747-9 2001 The histamine-induced increase in the content of VEGF protein in the conditioned medium was inhibited by the cyclic AMP antagonist Rp-cAMP (IC(50) 6.8 microM), and the protein kinase A inhibitor H-89 (IC(50) 12.5 microM), but not by the protein kinase C inhibitors Ro 31-8425 and calphostin C or the tyrosine kinase inhibitor genistein. Histamine 4-13 vascular endothelial growth factor A Rattus norvegicus 49-53 11724747-9 2001 The histamine-induced increase in the content of VEGF protein in the conditioned medium was inhibited by the cyclic AMP antagonist Rp-cAMP (IC(50) 6.8 microM), and the protein kinase A inhibitor H-89 (IC(50) 12.5 microM), but not by the protein kinase C inhibitors Ro 31-8425 and calphostin C or the tyrosine kinase inhibitor genistein. Cyclic AMP 109-119 vascular endothelial growth factor A Rattus norvegicus 49-53 11724747-9 2001 The histamine-induced increase in the content of VEGF protein in the conditioned medium was inhibited by the cyclic AMP antagonist Rp-cAMP (IC(50) 6.8 microM), and the protein kinase A inhibitor H-89 (IC(50) 12.5 microM), but not by the protein kinase C inhibitors Ro 31-8425 and calphostin C or the tyrosine kinase inhibitor genistein. Cyclic AMP 134-138 vascular endothelial growth factor A Rattus norvegicus 49-53 11724747-9 2001 The histamine-induced increase in the content of VEGF protein in the conditioned medium was inhibited by the cyclic AMP antagonist Rp-cAMP (IC(50) 6.8 microM), and the protein kinase A inhibitor H-89 (IC(50) 12.5 microM), but not by the protein kinase C inhibitors Ro 31-8425 and calphostin C or the tyrosine kinase inhibitor genistein. N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide 195-199 vascular endothelial growth factor A Rattus norvegicus 49-53 11724747-9 2001 The histamine-induced increase in the content of VEGF protein in the conditioned medium was inhibited by the cyclic AMP antagonist Rp-cAMP (IC(50) 6.8 microM), and the protein kinase A inhibitor H-89 (IC(50) 12.5 microM), but not by the protein kinase C inhibitors Ro 31-8425 and calphostin C or the tyrosine kinase inhibitor genistein. Ro 31-8425 265-275 vascular endothelial growth factor A Rattus norvegicus 49-53 11724747-9 2001 The histamine-induced increase in the content of VEGF protein in the conditioned medium was inhibited by the cyclic AMP antagonist Rp-cAMP (IC(50) 6.8 microM), and the protein kinase A inhibitor H-89 (IC(50) 12.5 microM), but not by the protein kinase C inhibitors Ro 31-8425 and calphostin C or the tyrosine kinase inhibitor genistein. calphostin C 280-292 vascular endothelial growth factor A Rattus norvegicus 49-53 11724747-9 2001 The histamine-induced increase in the content of VEGF protein in the conditioned medium was inhibited by the cyclic AMP antagonist Rp-cAMP (IC(50) 6.8 microM), and the protein kinase A inhibitor H-89 (IC(50) 12.5 microM), but not by the protein kinase C inhibitors Ro 31-8425 and calphostin C or the tyrosine kinase inhibitor genistein. Genistein 326-335 vascular endothelial growth factor A Rattus norvegicus 49-53 11724747-11 2001 Simultaneous injection of cimetidine (400 microg) and indomethacin (100 microg) into the air pouch of rats additively reduced the carrageenin-induced increase in VEGF protein levels and angiogenesis in the granulation tissue as assessed by using carmine dye. Cimetidine 26-36 vascular endothelial growth factor A Rattus norvegicus 162-166 11724747-11 2001 Simultaneous injection of cimetidine (400 microg) and indomethacin (100 microg) into the air pouch of rats additively reduced the carrageenin-induced increase in VEGF protein levels and angiogenesis in the granulation tissue as assessed by using carmine dye. Indomethacin 54-66 vascular endothelial growth factor A Rattus norvegicus 162-166 11724747-11 2001 Simultaneous injection of cimetidine (400 microg) and indomethacin (100 microg) into the air pouch of rats additively reduced the carrageenin-induced increase in VEGF protein levels and angiogenesis in the granulation tissue as assessed by using carmine dye. Carrageenan 130-141 vascular endothelial growth factor A Rattus norvegicus 162-166 11724747-13 2001 These findings indicate that histamine has an activity to induce VEGF production in the granulation tissue via the H(2) receptor-cyclic AMP-protein kinase A pathway and augments angiogenesis in the granulation tissue. Histamine 29-38 vascular endothelial growth factor A Rattus norvegicus 65-69 11735166-0 2001 Tamoxifen inhibits endothelial cell proliferation and attenuates VEGF-mediated angiogenesis and migration in vivo. Tamoxifen 0-9 vascular endothelial growth factor A Rattus norvegicus 65-69 11735166-3 2001 We hypothesized that tamoxifen may attenuate the angiogenetic response to VEGF. Tamoxifen 21-30 vascular endothelial growth factor A Rattus norvegicus 74-78 11735166-6 2001 The effect of oral tamoxifen (20 mg/day) on VEGF-mediated angiogenesis in vivo was assessed using a Matrigel angiogenesis assay in the Sprague-Dawley rat. Tamoxifen 19-28 vascular endothelial growth factor A Rattus norvegicus 44-48 11735166-8 2001 Oral administration of tamoxifen in the rat (20 mg/day) significantly reduced endothelial cell proliferation and migration in response to VEGF. Tamoxifen 23-32 vascular endothelial growth factor A Rattus norvegicus 138-142 11735166-9 2001 CONCLUSION: Tamoxifen (5.0 microg/ml) reduces proliferation of a VEGF-dependent endothelial cell line in vitro. Tamoxifen 12-21 vascular endothelial growth factor A Rattus norvegicus 65-69 11735166-10 2001 In vivo, orally administered tamoxifen reduces VEGF-mediated angiogenesis in the rat. Tamoxifen 29-38 vascular endothelial growth factor A Rattus norvegicus 47-51 11735166-11 2001 These findings indicate that tamoxifen may directly inhibit the effect of VEGF on the endothelial cell, in addition to its previously described effect of reducing serum VEGF levels. Tamoxifen 29-38 vascular endothelial growth factor A Rattus norvegicus 74-78 11735166-11 2001 These findings indicate that tamoxifen may directly inhibit the effect of VEGF on the endothelial cell, in addition to its previously described effect of reducing serum VEGF levels. Tamoxifen 29-38 vascular endothelial growth factor A Rattus norvegicus 169-173 11735166-12 2001 This data supports a role for tamoxifen in modulation of the VEGF-dependent angiogenic response to surgical trauma, particularly as an adjuvant therapy for VEGF-dependent tumours. Tamoxifen 30-39 vascular endothelial growth factor A Rattus norvegicus 61-65 11735166-12 2001 This data supports a role for tamoxifen in modulation of the VEGF-dependent angiogenic response to surgical trauma, particularly as an adjuvant therapy for VEGF-dependent tumours. Tamoxifen 30-39 vascular endothelial growth factor A Rattus norvegicus 156-160 11732982-0 2001 Expression of vascular endothelial growth factor (VEGF) receptors in rat corpus luteum: regulation by oestradiol during mid-pregnancy. Estradiol 102-112 vascular endothelial growth factor A Rattus norvegicus 14-48 11732982-0 2001 Expression of vascular endothelial growth factor (VEGF) receptors in rat corpus luteum: regulation by oestradiol during mid-pregnancy. Estradiol 102-112 vascular endothelial growth factor A Rattus norvegicus 50-54 11758829-11 2001 Since HIF-1alpha initiates transcription of VEGF mRNA, HIF-1alpha activation by ethanol-induced injury is likely responsible for activation of VEGF gene and induction of angiogenesis. Ethanol 80-87 vascular endothelial growth factor A Rattus norvegicus 143-147 11885966-1 2001 We previously reported that endogenous prostaglandins (PGs) may increase cAMP facilitated angiogenesis through the induction of vascular endothelial growth factor (VEGF) in rat sponge implantation models. Prostaglandins 39-53 vascular endothelial growth factor A Rattus norvegicus 128-162 11885966-1 2001 We previously reported that endogenous prostaglandins (PGs) may increase cAMP facilitated angiogenesis through the induction of vascular endothelial growth factor (VEGF) in rat sponge implantation models. Prostaglandins 39-53 vascular endothelial growth factor A Rattus norvegicus 164-168 11885966-1 2001 We previously reported that endogenous prostaglandins (PGs) may increase cAMP facilitated angiogenesis through the induction of vascular endothelial growth factor (VEGF) in rat sponge implantation models. Prostaglandins 55-58 vascular endothelial growth factor A Rattus norvegicus 128-162 11885966-1 2001 We previously reported that endogenous prostaglandins (PGs) may increase cAMP facilitated angiogenesis through the induction of vascular endothelial growth factor (VEGF) in rat sponge implantation models. Prostaglandins 55-58 vascular endothelial growth factor A Rattus norvegicus 164-168 11885966-1 2001 We previously reported that endogenous prostaglandins (PGs) may increase cAMP facilitated angiogenesis through the induction of vascular endothelial growth factor (VEGF) in rat sponge implantation models. Cyclic AMP 73-77 vascular endothelial growth factor A Rattus norvegicus 128-162 11885966-1 2001 We previously reported that endogenous prostaglandins (PGs) may increase cAMP facilitated angiogenesis through the induction of vascular endothelial growth factor (VEGF) in rat sponge implantation models. Cyclic AMP 73-77 vascular endothelial growth factor A Rattus norvegicus 164-168 11885966-5 2001 VEGF induction was confirmed by the increased levels in the fluids in the sponge matrix after topical injection of 8-bromo-cAMP. 8-Bromo Cyclic Adenosine Monophosphate 115-127 vascular endothelial growth factor A Rattus norvegicus 0-4 11885966-6 2001 Immunohistochemical investigation further revealed the VEGF-expressed cells in the sponge granulation tissues to be fibroblasts, and the intensity of positive reactions was enhanced by 8-bromo-cAMP, forskolin and amrinone. 8-Bromo Cyclic Adenosine Monophosphate 185-197 vascular endothelial growth factor A Rattus norvegicus 55-59 11885966-6 2001 Immunohistochemical investigation further revealed the VEGF-expressed cells in the sponge granulation tissues to be fibroblasts, and the intensity of positive reactions was enhanced by 8-bromo-cAMP, forskolin and amrinone. Colforsin 199-208 vascular endothelial growth factor A Rattus norvegicus 55-59 11885966-6 2001 Immunohistochemical investigation further revealed the VEGF-expressed cells in the sponge granulation tissues to be fibroblasts, and the intensity of positive reactions was enhanced by 8-bromo-cAMP, forskolin and amrinone. Amrinone 213-221 vascular endothelial growth factor A Rattus norvegicus 55-59 11885966-7 2001 Angiogenesis without topical injections of the above compounds was suppressed by SQ22,536, an inhibitor for AC, or H-89, an inhibitor for PKA, with concomitant reductions in VEGF levels. N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide 115-119 vascular endothelial growth factor A Rattus norvegicus 174-178 11885966-8 2001 Daily topical injections of neutralizing antibody or anti-sense oligonucleotide against VEGF significantly suppressed angiogenesis. Oligonucleotides 64-79 vascular endothelial growth factor A Rattus norvegicus 88-92 11684638-7 2001 CONCLUSIONS: These results indicate that cell-based VEGF gene transfer is an effective method of preventing the development and progression of pulmonary hypertension in the monocrotaline model and suggest a potential therapeutic role for angiogenic factors in the therapy of this devastating disease. Monocrotaline 173-186 vascular endothelial growth factor A Rattus norvegicus 52-56 11514283-8 2001 Western blot analysis showed that VEGF expression was increased in the exercised control group, and both losartan and captopril blocked this increase. Captopril 118-127 vascular endothelial growth factor A Rattus norvegicus 34-38 11597932-8 2001 Conversely, bosentan induced a marked increase in vessel density at 3 and 28 days (1.4-fold and 1.7-fold, respectively, compared with no treatment; P<0.05), which was associated with an increase in VEGF and endothelial NO synthase levels in ischemic legs (by 31+/-8% and 45+/-23%, respectively, at 3 days and by 65+/-13% and 55+/-15%, respectively, at 28 days; P<0.05 versus nontreated rats). Bosentan 12-20 vascular endothelial growth factor A Rattus norvegicus 201-205 11557101-3 2001 Further, we demonstrate that: (4) The observed astrocyte-produced, VEGF-mediated protection from apoptosis (survival) is inhibitable with soluble recombinant VEGF receptor-1 (sFlt), and is associated with a robust induction of MAPK tyrosine phosphorylation. Tyrosine 232-240 vascular endothelial growth factor A Rattus norvegicus 67-71 11557101-3 2001 Further, we demonstrate that: (4) The observed astrocyte-produced, VEGF-mediated protection from apoptosis (survival) is inhibitable with soluble recombinant VEGF receptor-1 (sFlt), and is associated with a robust induction of MAPK tyrosine phosphorylation. Tyrosine 232-240 vascular endothelial growth factor A Rattus norvegicus 158-162 11527387-3 2001 We investigated whether prostaglandin E(2) (PGE(2)) can induce VEGF expression in rat gastric microvascular endothelial cells (RGMEC) and the signaling pathway(s) involved. Dinoprostone 44-50 vascular endothelial growth factor A Rattus norvegicus 63-67 11527387-4 2001 We demonstrated that PGE(2) significantly increased ERK2 and JNK1 activation and VEGF mRNA and protein expression. Prostaglandins E 21-24 vascular endothelial growth factor A Rattus norvegicus 81-85 11527387-5 2001 Incubation of RGMEC with PD 98059 (MEK kinase inhibitor) significantly reduced PGE(2)-induced ERK2 activity, VEGF mRNA and protein expression. Dinoprostone 79-85 vascular endothelial growth factor A Rattus norvegicus 109-113 11527387-7 2001 Our data suggest that PGE(2)-stimulates VEGF expression in RGMEC via transactivation of JNK1 by ERK2. Dinoprostone 22-28 vascular endothelial growth factor A Rattus norvegicus 40-44 11527387-8 2001 One potential implication of this finding is that increased PG levels in cancers could facilitate tumor growth by stimulating VEGF synthesis and angiogenesis. Prostaglandins 60-62 vascular endothelial growth factor A Rattus norvegicus 126-130 11527387-0 2001 PGE(2) stimulates VEGF expression in endothelial cells via ERK2/JNK1 signaling pathways. Dinoprostone 0-5 vascular endothelial growth factor A Rattus norvegicus 18-22 11527387-3 2001 We investigated whether prostaglandin E(2) (PGE(2)) can induce VEGF expression in rat gastric microvascular endothelial cells (RGMEC) and the signaling pathway(s) involved. Dinoprostone 24-42 vascular endothelial growth factor A Rattus norvegicus 63-67 11461947-4 2001 High glucose exposure upregulates VEGF expression in various cell types and tissues. Glucose 5-12 vascular endothelial growth factor A Rattus norvegicus 34-38 11485918-10 2001 Thereafter, damaged glomeruli gradually recovered after development of capillary network by week 8, and significant improvement of renal function was evident in the VEGF-treated group during week 8 (creatinine: VEGF(165), 0.3 +/- 0.1; control, 2.6 +/- 0.9 mg/dl, P < 0.001; proteinuria: VEGF(165), 54 +/- 15; control, 318 +/- 60 mg/day, P < 0.001). Creatinine 199-209 vascular endothelial growth factor A Rattus norvegicus 165-169 11530111-1 2001 OBJECTIVE: Vascular endothelial growth factor (VEGF) induces the release of nitric oxide (NO) from endothelial cells. Nitric Oxide 76-88 vascular endothelial growth factor A Rattus norvegicus 11-45 11530111-1 2001 OBJECTIVE: Vascular endothelial growth factor (VEGF) induces the release of nitric oxide (NO) from endothelial cells. Nitric Oxide 76-88 vascular endothelial growth factor A Rattus norvegicus 47-51 11530111-7 2001 In these cells, L-NAME significantly reduced NO synthesis and decreased VEGF generation. NG-Nitroarginine Methyl Ester 16-22 vascular endothelial growth factor A Rattus norvegicus 72-76 11461947-12 2001 The present results thus support an causative link among high glucose exposure, upregulation of VEGF, and peritoneal microvascular dysfunction. Glucose 62-69 vascular endothelial growth factor A Rattus norvegicus 96-100 11508274-5 2001 RESULTS: Retinal VEGF mRNA expression was significantly higher and the latencies of oscillatory potentials were significantly elongated in STZ-treated spontaneously hypertensive rats compared with a non-treated spontaneously hypertensive rat group matched for age. Streptozocin 139-142 vascular endothelial growth factor A Rattus norvegicus 17-21 11468554-0 2001 Expression of vascular endothelial growth factor and its receptors Flt-1 and KDR/Flk-1 in chronic cyclosporine nephrotoxicity. Cyclosporine 98-110 vascular endothelial growth factor A Rattus norvegicus 14-48 11468554-4 2001 RESULTS: CsA induced VEGF mRNA and protein expressions at 7 and 28 days in LSD rats. Cyclosporine 9-12 vascular endothelial growth factor A Rattus norvegicus 21-25 11493277-4 2001 The objective of this study was to determine the in vitro release behavior of VEGF from calcium alginate microspheres and the potency of this controlled release system in promoting localized neovascularization at the subcutaneous site of the rat model. Alginates 88-104 vascular endothelial growth factor A Rattus norvegicus 78-82 11528531-7 2001 With prazosin, VEGF-positive capillaries increased after 2 and 4 days, accompanied by a threefold increase in PCNA. Prazosin 5-13 vascular endothelial growth factor A Rattus norvegicus 15-19 11528531-10 2001 CONCLUSIONS: Higher capillary shear stress with prazosin than with stimulation may upregulate VEGF expression in the early stages of treatment. Prazosin 48-56 vascular endothelial growth factor A Rattus norvegicus 94-98 11528533-0 2001 Vascular dysfunction induced by AGE is mediated by VEGF via mechanisms involving reactive oxygen species, guanylate cyclase, and protein kinase C. OBJECTIVE: These experiments were designed to elucidate mechanisms mediating vascular dysfunction induced by advanced glycation end products (AGEs). Reactive Oxygen Species 81-104 vascular endothelial growth factor A Rattus norvegicus 51-55 11528533-6 2001 CONCLUSIONS: These observations indicate potentially important roles for oxygen free-radicals and nitric oxide in mediating permeability and blood flow changes induced by glycated proteins via mechanisms involving increased protein kinase C activity and VEGF production. oxygen free-radicals 73-93 vascular endothelial growth factor A Rattus norvegicus 254-258 11528533-6 2001 CONCLUSIONS: These observations indicate potentially important roles for oxygen free-radicals and nitric oxide in mediating permeability and blood flow changes induced by glycated proteins via mechanisms involving increased protein kinase C activity and VEGF production. Nitric Oxide 98-110 vascular endothelial growth factor A Rattus norvegicus 254-258 11718052-9 2001 Pinacidil may partly inhibit the development of HPH and pulmonary vascular remodelling by decreasing VEGF and ET-1. Pinacidil 0-9 vascular endothelial growth factor A Rattus norvegicus 101-105 11454697-4 2001 The current investigation evaluated a potential drug interaction between the angiogenesis inhibitor O-(N-chloroacetyl-carbamoyl)-fumagillol (TNP-470) and the alkylating agent temozolomide (TMZ), in xenograft models that differentially expressed vascular endothelial growth factor (VEGF), a driving force for angiogenesis. o-(n-chloroacetyl-carbamoyl)-fumagillol 100-139 vascular endothelial growth factor A Rattus norvegicus 245-279 11454697-4 2001 The current investigation evaluated a potential drug interaction between the angiogenesis inhibitor O-(N-chloroacetyl-carbamoyl)-fumagillol (TNP-470) and the alkylating agent temozolomide (TMZ), in xenograft models that differentially expressed vascular endothelial growth factor (VEGF), a driving force for angiogenesis. o-(n-chloroacetyl-carbamoyl)-fumagillol 100-139 vascular endothelial growth factor A Rattus norvegicus 281-285 11454697-4 2001 The current investigation evaluated a potential drug interaction between the angiogenesis inhibitor O-(N-chloroacetyl-carbamoyl)-fumagillol (TNP-470) and the alkylating agent temozolomide (TMZ), in xenograft models that differentially expressed vascular endothelial growth factor (VEGF), a driving force for angiogenesis. Temozolomide 175-187 vascular endothelial growth factor A Rattus norvegicus 245-279 11454697-4 2001 The current investigation evaluated a potential drug interaction between the angiogenesis inhibitor O-(N-chloroacetyl-carbamoyl)-fumagillol (TNP-470) and the alkylating agent temozolomide (TMZ), in xenograft models that differentially expressed vascular endothelial growth factor (VEGF), a driving force for angiogenesis. Temozolomide 175-187 vascular endothelial growth factor A Rattus norvegicus 281-285 11508274-7 2001 Treatment with TCV-116 (3 mg/kg) significantly diminished retinal VEGF mRNA expression and the latencies of oscillatory potential peaks, but had no effect on plasma glucose concentrations. candesartan cilexetil 15-22 vascular endothelial growth factor A Rattus norvegicus 66-70 11393178-0 2001 Effects of the xenoestrogen bisphenol A on expression of vascular endothelial growth factor (VEGF) in the rat. bisphenol A 28-39 vascular endothelial growth factor A Rattus norvegicus 57-91 11529667-3 2001 An oligonucleotide targeted to the VEGF sequence was examined for its effect on VEGF production in vitro and the development of choroidal neovascularisation in vivo in the eye. Oligonucleotides 3-18 vascular endothelial growth factor A Rattus norvegicus 80-84 11881112-10 2001 Four weeks of pretreatment with losartan decreased infarct size and VEGF, and improved endothelial dysfunction. Losartan 32-40 vascular endothelial growth factor A Rattus norvegicus 68-72 11442000-0 2001 Thyroid stimulating hormone downregulates vascular endothelial growth factor expression in FRTL-5 cells. Thyrotropin 0-27 vascular endothelial growth factor A Rattus norvegicus 42-76 11442000-1 2001 We studied the regulation of the expression of vascular endothelial growth factor (VEGF) by TSH in monolayer cultures of rat thyroid FRTL-5 cell lines. Thyrotropin 92-95 vascular endothelial growth factor A Rattus norvegicus 47-81 11442000-1 2001 We studied the regulation of the expression of vascular endothelial growth factor (VEGF) by TSH in monolayer cultures of rat thyroid FRTL-5 cell lines. Thyrotropin 92-95 vascular endothelial growth factor A Rattus norvegicus 83-87 11442000-2 2001 The VEGF mRNA synthesis was significantly inhibited by TSH as well as dibutyryl cyclic adenosine monophosphate (cAMP) in a dose-dependent manner in FRTL-5 cells. Bucladesine 70-110 vascular endothelial growth factor A Rattus norvegicus 4-8 11442000-2 2001 The VEGF mRNA synthesis was significantly inhibited by TSH as well as dibutyryl cyclic adenosine monophosphate (cAMP) in a dose-dependent manner in FRTL-5 cells. Cyclic AMP 112-116 vascular endothelial growth factor A Rattus norvegicus 4-8 11442000-4 2001 Our results suggest that the direct effect of TSH/cAMP is to inhibit the VEGF synthesis in monolayer cells. Thyrotropin 46-49 vascular endothelial growth factor A Rattus norvegicus 73-77 11442000-4 2001 Our results suggest that the direct effect of TSH/cAMP is to inhibit the VEGF synthesis in monolayer cells. Cyclic AMP 50-54 vascular endothelial growth factor A Rattus norvegicus 73-77 11353854-6 2001 Although both aspirin and ticlopidine markedly suppressed platelet aggregation, only ticlopidine impaired gastric ulcer healing and angiogenesis as well as reversing the ulcer-associated changes in serum levels of VEGF and endostatin. Ticlopidine 85-96 vascular endothelial growth factor A Rattus norvegicus 214-218 11316858-3 2001 VEGF expression is upregulated by high ambient glucose concentrations in several cell types in vitro and in glomeruli of diabetic rats. Glucose 47-54 vascular endothelial growth factor A Rattus norvegicus 0-4 11393178-0 2001 Effects of the xenoestrogen bisphenol A on expression of vascular endothelial growth factor (VEGF) in the rat. bisphenol A 28-39 vascular endothelial growth factor A Rattus norvegicus 93-97 11393178-4 2001 In the present study we investigated the effects of BPA on expression of another estrogen-target gene, vascular endothelial growth factor (VEGF), in the uterus, vagina, and pituitary of F344 and S-D rats. bisphenol A 52-55 vascular endothelial growth factor A Rattus norvegicus 103-137 11393178-4 2001 In the present study we investigated the effects of BPA on expression of another estrogen-target gene, vascular endothelial growth factor (VEGF), in the uterus, vagina, and pituitary of F344 and S-D rats. bisphenol A 52-55 vascular endothelial growth factor A Rattus norvegicus 139-143 11393178-7 2001 There was a significant effect of dose of BPA on the type of VEGF isoform expressed in the uterus, vagina, and pituitary. bisphenol A 42-45 vascular endothelial growth factor A Rattus norvegicus 61-65 11393178-8 2001 BPA induced greater (P < 0.01) levels of VEGF164 and VEGF120+188 than VEGF110 levels. bisphenol A 0-3 vascular endothelial growth factor A Rattus norvegicus 44-51 11393178-9 2001 The lowest BPA dose that had a significant (P< 0.05) effect on VEGF expression compared with vehicle treatment was 37.5 mg/kg body wt. bisphenol A 11-14 vascular endothelial growth factor A Rattus norvegicus 66-70 11393178-11 2001 This is the first report that the primary response of the uterus, vagina, and pituitary to BPA includes rapid induction of VEGF expression. bisphenol A 91-94 vascular endothelial growth factor A Rattus norvegicus 123-127 11304492-10 2001 Chelerythrine but not bisindolylmaleimide blocked all of the IP effects on the nuclear translocation of PKCepsilon, enhancement of VEGF mRNA expression and angiogenesis, and infarct size limitation. chelerythrine 0-13 vascular endothelial growth factor A Rattus norvegicus 131-135 11338378-9 2001 These results suggested that endogenous PGs generated through COX-2 may enhance the neovascularization in sponge granuloma by increased expression of VEGF and that a COX-2 inhibitor would facilitate the management of conditions involving angiogenesis. Prostaglandins 40-43 vascular endothelial growth factor A Rattus norvegicus 150-154 11401064-3 2001 The results showed that VEGF mRNA abundance was increased three-fold and that of bFGF 1.5-fold when 12% O2+5% CO2 were breathed, but TGF-beta1 did not change. Oxygen 104-106 vascular endothelial growth factor A Rattus norvegicus 24-28 11401064-3 2001 The results showed that VEGF mRNA abundance was increased three-fold and that of bFGF 1.5-fold when 12% O2+5% CO2 were breathed, but TGF-beta1 did not change. Carbon Dioxide 110-113 vascular endothelial growth factor A Rattus norvegicus 24-28 11160633-8 2001 In contrast, pretreatment with indomethacin alone enhanced VEGF- or ACh-induced relaxations and the effect was greater in the adult SHR than in WKY rats. Indomethacin 31-43 vascular endothelial growth factor A Rattus norvegicus 59-64 11272159-7 2001 Cyclic stretch increased basal thymidine uptake 60 +/- 10% (P < 0.001) and VEGF-stimulated thymidine uptake by 2.6 +/- 0.2-fold (P = 0.005). Thymidine 94-103 vascular endothelial growth factor A Rattus norvegicus 78-82 11272159-8 2001 VEGF-NAb reduced cyclic stretch-induced thymidine uptake by 65%. Thymidine 40-49 vascular endothelial growth factor A Rattus norvegicus 0-4 11230305-11 2001 In addition, increases in VEGF expression to electrical stimulation were observed only in the S/ren(RR) group fed a low salt diet. Salts 120-124 vascular endothelial growth factor A Rattus norvegicus 26-30 11179052-0 2001 VEGF(121)- and bFGF-induced increase in collateral blood flow requires normal nitric oxide production. Nitric Oxide 78-90 vascular endothelial growth factor A Rattus norvegicus 0-4 11160633-10 2001 The results demonstrate that VEGF induces endothelium- or nitric oxide-dependent relaxation, which is blunted in the adult SHR. Nitric Oxide 58-70 vascular endothelial growth factor A Rattus norvegicus 29-33 11296854-11 2001 Both lisinopril and losartan blocked elevation in VEGF expression and inhibited the angiogenesis induced by stimulation. Lisinopril 5-15 vascular endothelial growth factor A Rattus norvegicus 50-54 11296854-11 2001 Both lisinopril and losartan blocked elevation in VEGF expression and inhibited the angiogenesis induced by stimulation. Losartan 20-28 vascular endothelial growth factor A Rattus norvegicus 50-54 11121378-5 2001 Our results demonstrate that pH and lactate concentration do independently affect osteoblast VEGF mRNA and protein production. Lactic Acid 36-43 vascular endothelial growth factor A Rattus norvegicus 93-97 11162532-5 2001 Furthermore, PKCdelta-specific inhibitor, Rottrelin, significantly suppressed this VEGF-resistant apoptosis of cultured SE cells, whereas conventional PKC-specific inhibitor, Go6976 could not. rottrelin 42-51 vascular endothelial growth factor A Rattus norvegicus 83-87 11121378-8 2001 Similarly, an elevated lactate concentration (22 mM) also depressed osteoblast elaboration of VEGF at both neutral and acidic pH (P < 0.001). Lactic Acid 23-30 vascular endothelial growth factor A Rattus norvegicus 94-98 11163598-2 2001 VEGF was extracted efficiently and reproducibly from muscle homogenate with low concentrations of non-ionic detergents, such as Triton X-100, Nonidet P-40, and Tween 20. Octoxynol 128-140 vascular endothelial growth factor A Rattus norvegicus 0-4 11163598-2 2001 VEGF was extracted efficiently and reproducibly from muscle homogenate with low concentrations of non-ionic detergents, such as Triton X-100, Nonidet P-40, and Tween 20. Polysorbates 160-168 vascular endothelial growth factor A Rattus norvegicus 0-4 11163598-2 2001 VEGF was extracted efficiently and reproducibly from muscle homogenate with low concentrations of non-ionic detergents, such as Triton X-100, Nonidet P-40, and Tween 20. Nonidet P-40 142-154 vascular endothelial growth factor A Rattus norvegicus 0-4 11163598-5 2001 Immunoblotting revealed that the predominant molecular species of VEGF concentrated with heparin-sepharose beads was VEGF(188). Heparin 89-96 vascular endothelial growth factor A Rattus norvegicus 66-70 11133689-3 2001 To study whether estradiol is involved in VEGF expression between Day 12 and Day 15, rats undergoing hypophysectomy-hysterectomy on Day 12 were treated with estradiol until Day 15. Estradiol 17-26 vascular endothelial growth factor A Rattus norvegicus 42-46 11163598-5 2001 Immunoblotting revealed that the predominant molecular species of VEGF concentrated with heparin-sepharose beads was VEGF(188). Heparin 89-96 vascular endothelial growth factor A Rattus norvegicus 117-121 11163598-5 2001 Immunoblotting revealed that the predominant molecular species of VEGF concentrated with heparin-sepharose beads was VEGF(188). Sepharose 97-106 vascular endothelial growth factor A Rattus norvegicus 66-70 11163598-5 2001 Immunoblotting revealed that the predominant molecular species of VEGF concentrated with heparin-sepharose beads was VEGF(188). Sepharose 97-106 vascular endothelial growth factor A Rattus norvegicus 117-121 11133689-8 2001 In conclusion, the present study has demonstrated that VEGF contributes to luteal angiogenesis, CL development, and progesterone production during mid-pregnancy in rats and that luteal VEGF expression is increased by estradiol. Progesterone 116-128 vascular endothelial growth factor A Rattus norvegicus 55-59 11950149-3 2001 It is proposed that adenosine and NO are similarly responsible for causing the tonic vasodilation that gradually wanes in the first 7 days of chronic hypoxia and that concomitantly, adenosine and hypoxia stimulate VEGF expression, so increasing venular permeability and triggering angiogenesis. Adenosine 20-29 vascular endothelial growth factor A Rattus norvegicus 214-218 11950149-3 2001 It is proposed that adenosine and NO are similarly responsible for causing the tonic vasodilation that gradually wanes in the first 7 days of chronic hypoxia and that concomitantly, adenosine and hypoxia stimulate VEGF expression, so increasing venular permeability and triggering angiogenesis. Adenosine 182-191 vascular endothelial growth factor A Rattus norvegicus 214-218 11133689-4 2001 Protein concentrations and mRNA levels of VEGF in the CL were significantly decreased by hypophysectomy-hysterectomy, and this inhibitory effect was completely reversed by estradiol treatment. Estradiol 172-181 vascular endothelial growth factor A Rattus norvegicus 42-46 11133689-7 2001 The recovery in the vascular density, CL weight, and serum progesterone concentration caused by estradiol was significantly inhibited by the anti-VEGF antibody treatment. Progesterone 59-71 vascular endothelial growth factor A Rattus norvegicus 146-150 11133689-7 2001 The recovery in the vascular density, CL weight, and serum progesterone concentration caused by estradiol was significantly inhibited by the anti-VEGF antibody treatment. Estradiol 96-105 vascular endothelial growth factor A Rattus norvegicus 146-150 11928895-0 2001 Expression of vascular endothelial growth factor (VEGF) in rat brain after subarachnoid haemorrhage and endothelin receptor blockage with BQ-123. cyclo(Trp-Asp-Pro-Val-Leu) 138-144 vascular endothelial growth factor A Rattus norvegicus 14-48 11928895-0 2001 Expression of vascular endothelial growth factor (VEGF) in rat brain after subarachnoid haemorrhage and endothelin receptor blockage with BQ-123. cyclo(Trp-Asp-Pro-Val-Leu) 138-144 vascular endothelial growth factor A Rattus norvegicus 50-54 11928895-7 2001 After 48 hours the brain was removed and expression of VEGF studied immunohistochemically on paraffin sections. Paraffin 93-101 vascular endothelial growth factor A Rattus norvegicus 55-59 11104784-3 2000 Chronic treatment of rats with the VEGF receptor blocker SU5416 led to enlargement of the air spaces, indicative of emphysema. Semaxinib 57-63 vascular endothelial growth factor A Rattus norvegicus 35-39 12539553-0 2001 The study on the relationship between serum vascular endothelial growth factor and proteinuria in adriamycin-induced nephrotic rats. Doxorubicin 98-108 vascular endothelial growth factor A Rattus norvegicus 44-78 12539553-1 2001 To study the relationship between serum vascular endothelial growth factor (VEGF) and proteinuria in adriamycin-induced nephrotic rats, a rat model of adriamycin-induced nephrotitis was developed by injection of adriamycin into a tail vein in a rat. Doxorubicin 101-111 vascular endothelial growth factor A Rattus norvegicus 76-80 12539553-4 2001 The results showed that: (1) The adriamycin-induced nephrotic syndrome rat model was developed successfully; (2) Serum VEGF levels and proteinuria were significantly increased at 7th day after intravenous injection of adriamycin. Doxorubicin 33-43 vascular endothelial growth factor A Rattus norvegicus 119-123 12539553-4 2001 The results showed that: (1) The adriamycin-induced nephrotic syndrome rat model was developed successfully; (2) Serum VEGF levels and proteinuria were significantly increased at 7th day after intravenous injection of adriamycin. Doxorubicin 218-228 vascular endothelial growth factor A Rattus norvegicus 119-123 12539553-7 2001 It was concluded that VEGF might play an important role in the pathogenesis of proteinuria in adriamycin-induced nephrotic rats. Doxorubicin 94-104 vascular endothelial growth factor A Rattus norvegicus 22-26 11288154-6 2001 The data demonstrated that the VEGF plasmid- and lipofectamine-treated muscle flaps had significantly greater total survival and capillary count 7 days after reperfusion compared with the flaps treated only with lipofectamine. Lipofectamine 212-225 vascular endothelial growth factor A Rattus norvegicus 31-35 11104729-7 2000 In rats pretreated with Ad.VEGF (10(8) pfu) 2 d before a 2-wk exposure to hypoxia (10% O(2)), lower values versus Ad. ad 24-26 vascular endothelial growth factor A Rattus norvegicus 27-31 11104729-11 2000 Pretreatment with Ad.VEGF (10(8) pfu) increased endothelial nitric oxide synthase activity in lung tissue and partially restored endothelium-dependent vasodilation in isolated lungs from chronically hypoxic rats, as assessed by improvement of ionophore A23187-induced vasodilation and attenuation of endothelin-1 (300 pmol)-induced vasoconstriction, an effect abolished in the presence of nitro-L-arginine methylester. Calcimycin 253-259 vascular endothelial growth factor A Rattus norvegicus 21-25 11118051-0 2000 Suppression of ganglioside GD3 expression in a rat F-11 tumor cell line reduces tumor growth, angiogenesis, and vascular endothelial growth factor production. Gangliosides 15-26 vascular endothelial growth factor A Rattus norvegicus 112-146 11104784-4 2000 The VEGF receptor inhibitor SU5416 induced alveolar septal cell apoptosis but did not inhibit lung cell proliferation. Semaxinib 28-34 vascular endothelial growth factor A Rattus norvegicus 4-8 11236633-7 2000 RESULTS: The expression of VEGF in PAEC was increased under hypoxia condition (1% O2) (P < 0.01). Oxygen 82-84 vascular endothelial growth factor A Rattus norvegicus 27-31 11045944-1 2000 We tested whether increased endogenous adenosine produced by the adenosine kinase inhibitor GP-515 (Metabasis Therapeutics) can induce vascular endothelial growth factor (VEGF) expression in cultured rat myocardial myoblasts (RMMs). Adenosine 39-48 vascular endothelial growth factor A Rattus norvegicus 135-169 11045944-1 2000 We tested whether increased endogenous adenosine produced by the adenosine kinase inhibitor GP-515 (Metabasis Therapeutics) can induce vascular endothelial growth factor (VEGF) expression in cultured rat myocardial myoblasts (RMMs). Adenosine 39-48 vascular endothelial growth factor A Rattus norvegicus 171-175 11045944-1 2000 We tested whether increased endogenous adenosine produced by the adenosine kinase inhibitor GP-515 (Metabasis Therapeutics) can induce vascular endothelial growth factor (VEGF) expression in cultured rat myocardial myoblasts (RMMs). GP 515 92-98 vascular endothelial growth factor A Rattus norvegicus 135-169 11045944-1 2000 We tested whether increased endogenous adenosine produced by the adenosine kinase inhibitor GP-515 (Metabasis Therapeutics) can induce vascular endothelial growth factor (VEGF) expression in cultured rat myocardial myoblasts (RMMs). GP 515 92-98 vascular endothelial growth factor A Rattus norvegicus 171-175 11074883-1 2000 HYPOTHESIS: Hyperbaric oxygen (HBO) therapy increases vascular endothelial growth factor (VEGF) levels in wounds. Oxygen 23-29 vascular endothelial growth factor A Rattus norvegicus 54-88 11074883-1 2000 HYPOTHESIS: Hyperbaric oxygen (HBO) therapy increases vascular endothelial growth factor (VEGF) levels in wounds. Oxygen 23-29 vascular endothelial growth factor A Rattus norvegicus 90-94 11046121-6 2000 Protein levels of vascular endothelial growth factor (VEGF) in granulation tissue and in the pouch fluid were higher at day 6 than at day 3, and the levels were decreased by treatment with NS-398 (10-100 microg) in a dose-dependent manner. N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide 189-195 vascular endothelial growth factor A Rattus norvegicus 18-52 11197533-3 2000 The aim of this study was to assess whether vascular endothelial growth factor (VEGF), a highly specific endothelial cell mitogen, can enhance vascularisation and, indirectly, axonal regeneration within a silicone nerve regeneration chamber. Silicones 205-213 vascular endothelial growth factor A Rattus norvegicus 44-78 11197533-3 2000 The aim of this study was to assess whether vascular endothelial growth factor (VEGF), a highly specific endothelial cell mitogen, can enhance vascularisation and, indirectly, axonal regeneration within a silicone nerve regeneration chamber. Silicones 205-213 vascular endothelial growth factor A Rattus norvegicus 80-84 11046121-6 2000 Protein levels of vascular endothelial growth factor (VEGF) in granulation tissue and in the pouch fluid were higher at day 6 than at day 3, and the levels were decreased by treatment with NS-398 (10-100 microg) in a dose-dependent manner. N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide 189-195 vascular endothelial growth factor A Rattus norvegicus 54-58 11046121-8 2000 Dexamethasone (10 microg) also reduced VEGF protein levels in granulation tissue at day 6. Dexamethasone 0-13 vascular endothelial growth factor A Rattus norvegicus 39-43 11046121-10 2000 It was shown that VEGF mRNA and protein levels in the minced granulation tissue were increased by PGE(2) in a concentration-dependent manner. Dinoprostone 98-104 vascular endothelial growth factor A Rattus norvegicus 18-22 11046121-11 2000 These findings suggest that COX-2-derived PGE(2) plays a significant role in angiogenesis in the carrageenin-induced granulation tissue through VEGF formation. Prostaglandins E 42-45 vascular endothelial growth factor A Rattus norvegicus 144-148 11046121-11 2000 These findings suggest that COX-2-derived PGE(2) plays a significant role in angiogenesis in the carrageenin-induced granulation tissue through VEGF formation. Carrageenan 97-108 vascular endothelial growth factor A Rattus norvegicus 144-148 11029637-0 2000 Induction of VEGF and VEGF receptors in the spinal cord after mechanical spinal injury and prostaglandin administration. Prostaglandins 91-104 vascular endothelial growth factor A Rattus norvegicus 13-17 11029637-0 2000 Induction of VEGF and VEGF receptors in the spinal cord after mechanical spinal injury and prostaglandin administration. Prostaglandins 91-104 vascular endothelial growth factor A Rattus norvegicus 22-26 11029637-4 2000 To test the hypothesis that prostaglandins may be involved in the VEGF response after lesion we investigated whether intraspinal microinjections of prostaglandin F2alpha (PGF2alpha) alters VEGF expression in the spinal cord. Prostaglandins 28-42 vascular endothelial growth factor A Rattus norvegicus 66-70 11029637-4 2000 To test the hypothesis that prostaglandins may be involved in the VEGF response after lesion we investigated whether intraspinal microinjections of prostaglandin F2alpha (PGF2alpha) alters VEGF expression in the spinal cord. Dinoprost 148-169 vascular endothelial growth factor A Rattus norvegicus 189-193 11029637-4 2000 To test the hypothesis that prostaglandins may be involved in the VEGF response after lesion we investigated whether intraspinal microinjections of prostaglandin F2alpha (PGF2alpha) alters VEGF expression in the spinal cord. Dinoprost 171-180 vascular endothelial growth factor A Rattus norvegicus 189-193 11029637-6 2000 Finally, by use of an in vitro model with cell cultures of meningeal fibroblast and astrocyte origin, resembling the lesion area cellular content after spinal cord injury but devoid of inflammatory cells, we showed that VEGF is expressed in this in vitro model cell system after treatment with PGF2alpha and prostaglandin E2 (PGE2). Dinoprost 294-303 vascular endothelial growth factor A Rattus norvegicus 220-224 11029637-6 2000 Finally, by use of an in vitro model with cell cultures of meningeal fibroblast and astrocyte origin, resembling the lesion area cellular content after spinal cord injury but devoid of inflammatory cells, we showed that VEGF is expressed in this in vitro model cell system after treatment with PGF2alpha and prostaglandin E2 (PGE2). Dinoprostone 308-324 vascular endothelial growth factor A Rattus norvegicus 220-224 11029637-6 2000 Finally, by use of an in vitro model with cell cultures of meningeal fibroblast and astrocyte origin, resembling the lesion area cellular content after spinal cord injury but devoid of inflammatory cells, we showed that VEGF is expressed in this in vitro model cell system after treatment with PGF2alpha and prostaglandin E2 (PGE2). Dinoprostone 326-330 vascular endothelial growth factor A Rattus norvegicus 220-224 11029637-7 2000 These data suggest that cells within a lesion area in the spinal cord are capable of expressing VEGF and its receptors in response to mechanical injury and that prostaglandins may induce VEGF expression in such cells, even in the absence of inflammatory cells. Prostaglandins 161-175 vascular endothelial growth factor A Rattus norvegicus 187-191 10997699-2 2000 METHODS: This study investigates the effect of high glucose on the signaling and production of VEGF in rat mesangial cells in culture and measures the urinary VEGF level in patients with different stages of diabetic nephropathy. Glucose 52-59 vascular endothelial growth factor A Rattus norvegicus 95-99 11014986-1 2000 BACKGROUND: There is evidence from in vitro studies to suggest that the genes of platelet-derived growth factor (PDGF), and vascular endothelial growth factor (VEGF) are, like the erythropoietin gene, regulated by oxygen tension. Oxygen 214-220 vascular endothelial growth factor A Rattus norvegicus 124-158 11014986-1 2000 BACKGROUND: There is evidence from in vitro studies to suggest that the genes of platelet-derived growth factor (PDGF), and vascular endothelial growth factor (VEGF) are, like the erythropoietin gene, regulated by oxygen tension. Oxygen 214-220 vascular endothelial growth factor A Rattus norvegicus 160-164 11014986-7 2000 Chronic hypoxia did also not change VEGF gene expression; however, concomitant treatment with LU135252 increased all VEGF subtypes (188, 164, 120). darusentan 94-102 vascular endothelial growth factor A Rattus norvegicus 117-121 10995821-4 2000 Treatment with VEGF-2 induced a 250% increase in the number of syntaxin-immunopositive cells and a 67% increase in high-affinity GABA uptake, both markers for amacrine cells. gamma-Aminobutyric Acid 129-133 vascular endothelial growth factor A Rattus norvegicus 15-19 10995821-6 2000 VEGF-2 induced an approximately 300% increase in the number of bromodeoxyuridine-labeled (BrdU) retinal cells within 48 hr of treatment. Bromodeoxyuridine 63-80 vascular endothelial growth factor A Rattus norvegicus 0-4 10995821-8 2000 Furthermore, there was a developmentally dependent increase in the mitogenic response to VEGF-2, with retinal cultures derived from E15, E20, or P1 animals demonstrating a 50, 100, and 300% increase in thymidine incorporation, respectively. Thymidine 202-211 vascular endothelial growth factor A Rattus norvegicus 89-93 10960447-0 2000 Glycine prevents apoptosis of rat sinusoidal endothelial cells caused by deprivation of vascular endothelial growth factor. Glycine 0-7 vascular endothelial growth factor A Rattus norvegicus 88-122 10960447-3 2000 Here, we investigated the effect of glycine on apoptosis of primary cultured rat SECs induced by vascular endothelial growth factor (VEGF) deprivation. Glycine 36-43 vascular endothelial growth factor A Rattus norvegicus 97-131 10960447-3 2000 Here, we investigated the effect of glycine on apoptosis of primary cultured rat SECs induced by vascular endothelial growth factor (VEGF) deprivation. Glycine 36-43 vascular endothelial growth factor A Rattus norvegicus 133-137 10960447-8 2000 Interestingly, this increase in TUNEL-positive cells after VEGF deprivation was prevented significantly when glycine (1-10 mmol/L) was added to the medium, the levels being around 60% of VEGF deprivation without glycine. Glycine 109-116 vascular endothelial growth factor A Rattus norvegicus 59-63 10960447-8 2000 Interestingly, this increase in TUNEL-positive cells after VEGF deprivation was prevented significantly when glycine (1-10 mmol/L) was added to the medium, the levels being around 60% of VEGF deprivation without glycine. Glycine 109-116 vascular endothelial growth factor A Rattus norvegicus 187-191 10960447-10 2000 Moreover, Bcl-2 protein levels in SECs were decreased 8 hours after VEGF deprivation, which was prevented almost completely by glycine. Glycine 127-134 vascular endothelial growth factor A Rattus norvegicus 68-72 10960447-11 2000 It is concluded that glycine prevents apoptosis of primary cultured SECs under VEGF deprivation. Glycine 21-28 vascular endothelial growth factor A Rattus norvegicus 79-83 10963684-6 2000 Two phosphatidylinositol 3"-kinase inhibitors, wortmannin and LY294002, reversed the neuroprotective effect of VEGF, implicating the phosphatidylinositol 3"-kinase/Akt signal transduction system in VEGF-mediated neuroprotection. Wortmannin 47-57 vascular endothelial growth factor A Rattus norvegicus 111-115 10963684-6 2000 Two phosphatidylinositol 3"-kinase inhibitors, wortmannin and LY294002, reversed the neuroprotective effect of VEGF, implicating the phosphatidylinositol 3"-kinase/Akt signal transduction system in VEGF-mediated neuroprotection. Wortmannin 47-57 vascular endothelial growth factor A Rattus norvegicus 198-202 10963684-6 2000 Two phosphatidylinositol 3"-kinase inhibitors, wortmannin and LY294002, reversed the neuroprotective effect of VEGF, implicating the phosphatidylinositol 3"-kinase/Akt signal transduction system in VEGF-mediated neuroprotection. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 62-70 vascular endothelial growth factor A Rattus norvegicus 111-115 10963684-6 2000 Two phosphatidylinositol 3"-kinase inhibitors, wortmannin and LY294002, reversed the neuroprotective effect of VEGF, implicating the phosphatidylinositol 3"-kinase/Akt signal transduction system in VEGF-mediated neuroprotection. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 62-70 vascular endothelial growth factor A Rattus norvegicus 198-202 10821793-10 2000 Topical injections of PGE(2) and beraprost sodium, a PGI(2) analogue, increased the expression of VEGF mRNA, with angiogenesis enhancement. Prostaglandins E 22-25 vascular endothelial growth factor A Rattus norvegicus 98-102 10840165-0 2000 Induction of the angiogenic factor VEGF in the uterus by the antiprogestin onapristone. onapristone 75-86 vascular endothelial growth factor A Rattus norvegicus 35-39 10840165-2 2000 While investigating the actions of antiprogestins on steroid hormone induced gene expression of angiogenic factors such as vascular endothelial growth factor (VEGF), we noted that onapristone alone induces VEGF transcript levels in the immature, ovariectomized rat uterus. Steroids 53-68 vascular endothelial growth factor A Rattus norvegicus 123-157 10840165-2 2000 While investigating the actions of antiprogestins on steroid hormone induced gene expression of angiogenic factors such as vascular endothelial growth factor (VEGF), we noted that onapristone alone induces VEGF transcript levels in the immature, ovariectomized rat uterus. Steroids 53-68 vascular endothelial growth factor A Rattus norvegicus 159-163 10840165-2 2000 While investigating the actions of antiprogestins on steroid hormone induced gene expression of angiogenic factors such as vascular endothelial growth factor (VEGF), we noted that onapristone alone induces VEGF transcript levels in the immature, ovariectomized rat uterus. onapristone 180-191 vascular endothelial growth factor A Rattus norvegicus 206-210 10840165-4 2000 This induction of VEGF and c-fos by onapristone is inhibited by the antiestrogen ICI 182,780, but not by the antiprogestin RU-486. onapristone 36-47 vascular endothelial growth factor A Rattus norvegicus 18-22 10937597-2 2000 This study examined the antiangiogenic potential of an existing drug, pentoxifylline (PTX), which inhibits PKC-dependent activation of NFkappaB and is reported to prevent hypoxia-induced expression of VEGF. Pentoxifylline 70-84 vascular endothelial growth factor A Rattus norvegicus 201-205 10937597-2 2000 This study examined the antiangiogenic potential of an existing drug, pentoxifylline (PTX), which inhibits PKC-dependent activation of NFkappaB and is reported to prevent hypoxia-induced expression of VEGF. Pentoxifylline 86-89 vascular endothelial growth factor A Rattus norvegicus 201-205 10937597-9 2000 CONCLUSIONS: Systemic PTX significantly inhibited VEGF-mediated retinal vasculogenesis, but was not effective in reducing neovascularization in the oxygen-exposed neonatal rat. Pentoxifylline 22-25 vascular endothelial growth factor A Rattus norvegicus 50-54 10787417-0 2000 Vascular endothelial growth factor up-regulates ICAM-1 expression via the phosphatidylinositol 3 OH-kinase/AKT/Nitric oxide pathway and modulates migration of brain microvascular endothelial cells. Phosphatidylinositols 74-94 vascular endothelial growth factor A Rattus norvegicus 0-34 10787417-0 2000 Vascular endothelial growth factor up-regulates ICAM-1 expression via the phosphatidylinositol 3 OH-kinase/AKT/Nitric oxide pathway and modulates migration of brain microvascular endothelial cells. Nitric Oxide 111-123 vascular endothelial growth factor A Rattus norvegicus 0-34 10787417-2 2000 In this study, using rat primary brain microvascular endothelial cells (BMEC), we demonstrate that the vascular endothelial growth factor (VEGF), a potent promoter of angiogenesis, up-regulates the expression of the intracellular adhesion molecule-1 (ICAM-1) through a novel pathway that includes phosphatidylinositol 3 OH-kinase (PI3K), AKT, and nitric oxide (NO), resulting in the migration of BMEC. Nitric Oxide 347-359 vascular endothelial growth factor A Rattus norvegicus 103-137 10787417-2 2000 In this study, using rat primary brain microvascular endothelial cells (BMEC), we demonstrate that the vascular endothelial growth factor (VEGF), a potent promoter of angiogenesis, up-regulates the expression of the intracellular adhesion molecule-1 (ICAM-1) through a novel pathway that includes phosphatidylinositol 3 OH-kinase (PI3K), AKT, and nitric oxide (NO), resulting in the migration of BMEC. Nitric Oxide 347-359 vascular endothelial growth factor A Rattus norvegicus 139-143 10836978-4 2000 Serum-starved NRK52-E incubated with VEGF showed a significant increase in [(3)H]thymidine incorporation compared with control (2.3-fold at 1-10 ng/ml, P < 0. Thymidine 81-90 vascular endothelial growth factor A Rattus norvegicus 37-41 10836978-6 2000 VEGF also protected NRK52-E from hydrogen peroxide-induced apoptosis and necrosis compared with control (annexin-V-FITC-positive cells, 39 vs. 54%; viable cells, 50. Hydrogen Peroxide 33-50 vascular endothelial growth factor A Rattus norvegicus 0-4 10953337-0 2000 2-Methoxyestradiol blocks estrogen-induced rat pituitary tumor growth and tumor angiogenesis: possible role of vascular endothelial growth factor. 2-Methoxyestradiol 0-18 vascular endothelial growth factor A Rattus norvegicus 111-145 10953337-9 2000 These studies suggest that 2-ME may have therapeutic potential for hormone-induced cancer and that its angiostatic activity may be modulated through down-regulation of VEGF expression. 2-Methoxyestradiol 27-31 vascular endothelial growth factor A Rattus norvegicus 168-172 10821793-10 2000 Topical injections of PGE(2) and beraprost sodium, a PGI(2) analogue, increased the expression of VEGF mRNA, with angiogenesis enhancement. beraprost 33-49 vascular endothelial growth factor A Rattus norvegicus 98-102 10821793-10 2000 Topical injections of PGE(2) and beraprost sodium, a PGI(2) analogue, increased the expression of VEGF mRNA, with angiogenesis enhancement. Epoprostenol 53-59 vascular endothelial growth factor A Rattus norvegicus 98-102 10821793-11 2000 The enhanced angiogenesis by bFGF was significantly inhibited by topical injections of VEGF anti-sense oligonucleotide. Oligonucleotides 103-118 vascular endothelial growth factor A Rattus norvegicus 87-91 10828845-0 2000 Expression of vascular endothelial growth factor in response to high glucose in rat mesangial cells. Glucose 69-76 vascular endothelial growth factor A Rattus norvegicus 14-48 10821793-12 2000 These results suggested that COX-2 may enhance bFGF-induced neovascularization in sponge granuloma by PG-mediated expression of VEGF, and that a COX-2 inhibitor would facilitate the management of conditions involving angiogenesis. Prostaglandins 102-104 vascular endothelial growth factor A Rattus norvegicus 128-132 10828845-3 2000 The purpose of this study was to investigate VEGF expression in response to high glucose in rat cultured mesangial cells and to identify its signal pathway via protein kinase C (PKC). Glucose 81-88 vascular endothelial growth factor A Rattus norvegicus 45-49 10869376-3 2000 Treatment of cells with the AR agonist CGS21680 reduced the VEGF mRNA level to approximately 20% of that in control cells with an EC(50) value of 0.47 nM, indicative of mediation by the A(2A)AR. 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine 39-47 vascular endothelial growth factor A Rattus norvegicus 60-64 10828845-5 2000 Calphostin-C as a PKC inhibitor and phorbol myristate acetate (PMA) as a PKC downregulator were instillated into culture media to evaluate the role of PKC in mediating the glucose-induced increase in VEGF expression. Glucose 172-179 vascular endothelial growth factor A Rattus norvegicus 200-204 10828845-6 2000 High glucose increased expression of VEGF at the mRNA and protein levels, identified by semi-quantitative RT-PCR and western blotting, within 3 h and in a time- and glucose concentration-dependent manner. Glucose 5-12 vascular endothelial growth factor A Rattus norvegicus 37-41 10828845-6 2000 High glucose increased expression of VEGF at the mRNA and protein levels, identified by semi-quantitative RT-PCR and western blotting, within 3 h and in a time- and glucose concentration-dependent manner. Glucose 165-172 vascular endothelial growth factor A Rattus norvegicus 37-41 10828845-7 2000 Calphostin-C and PMA inhibited glucose-induced increases in VEGF expression at the mRNA and protein levels. Glucose 31-38 vascular endothelial growth factor A Rattus norvegicus 60-64 10828845-8 2000 In conclusion, high glucose can directly increase VEGF expression in rat mesangial cells via a PKC-dependent mechanism. Glucose 20-27 vascular endothelial growth factor A Rattus norvegicus 50-54 10869376-4 2000 Down-regulation of VEGF mRNA by CGS21680 was abolished by pretreatment of cells with the AR antagonist ZM241385. ZM 241385 103-111 vascular endothelial growth factor A Rattus norvegicus 19-23 10869376-11 2000 Thus, depending on the cell type, adenosine may have an inhibitory effect on VEGF production, which may have implications in blood vessel development. Adenosine 34-43 vascular endothelial growth factor A Rattus norvegicus 77-81 10859479-0 2000 The mitogenic effect of 17beta-estradiol on in vitro endothelial cell proliferation and on in vivo reendothelialization are both dependent on vascular endothelial growth factor. Estradiol 24-40 vascular endothelial growth factor A Rattus norvegicus 142-176 10872610-10 2000 CONCLUSIONS: The up-regulation of VEGF isoforms during the progression of uterine-peritoneal adhesion may be a compensatory mechanism regulating angiogenesis in order to provide nutrients and oxygen to the injured tissues. Oxygen 192-198 vascular endothelial growth factor A Rattus norvegicus 34-38 10807476-4 2000 METHODS: We used a rat model to test the ability of US and an ultrasonic contrast agent perflurocarbon exposed sonicated dextrose albumin (PESDA) to increase uptake of VEGF in the myocardium. perflurocarbon 88-102 vascular endothelial growth factor A Rattus norvegicus 168-172 10859479-13 2000 In conclusion, the present study demonstrates that E2 increases endothelial cell proliferation in vitro and reendothelialization in vivo by means of a mechanism dependent on endogenous VEGF. Estradiol 51-53 vascular endothelial growth factor A Rattus norvegicus 185-189 10688880-4 2000 It inhibits (125)I-VEGF(165) binding to endothelial and tumor cells and VEGF(165)-induced tyrosine phosphorylation of KDR in endothelial cells. Tyrosine 90-98 vascular endothelial growth factor A Rattus norvegicus 72-76 10807401-2 2000 Our experiments revealed accelerated healing, without decreased gastric acid secretion, of chronic cysteamine-induced duodenal ulcers in rats treated daily for 3 weeks with intragastric administration of bFGF, PDGF or VEGF. Cysteamine 99-109 vascular endothelial growth factor A Rattus norvegicus 218-222 10749807-8 2000 The exercise-induced increase in VEGF mRNA was attenuated approximately 50% by 30 and 300 mg/kg L-NAME; the TGF-beta(1) mRNA increase was unaffected by 300 mg/kg L-NAME. NG-Nitroarginine Methyl Ester 96-102 vascular endothelial growth factor A Rattus norvegicus 33-37 10712388-7 2000 In addition, we studied the effect of sodium nitroprusside (SNP; 10 and 100 micromol/L) and chemically related compounds, potassium ferrocyanide and ferricyanide, on VEGF generation. potassium ferrocyanide 122-144 vascular endothelial growth factor A Rattus norvegicus 166-170 10712388-0 2000 Nitric oxide induces the synthesis of vascular endothelial growth factor by rat vascular smooth muscle cells. Nitric Oxide 0-12 vascular endothelial growth factor A Rattus norvegicus 38-72 10712388-1 2000 Vascular endothelial growth factor (VEGF) is known to induce the release of nitric oxide (NO) from endothelial cells. Nitric Oxide 76-88 vascular endothelial growth factor A Rattus norvegicus 0-34 10712388-7 2000 In addition, we studied the effect of sodium nitroprusside (SNP; 10 and 100 micromol/L) and chemically related compounds, potassium ferrocyanide and ferricyanide, on VEGF generation. hexacyanoferrate III 149-161 vascular endothelial growth factor A Rattus norvegicus 166-170 10712388-1 2000 Vascular endothelial growth factor (VEGF) is known to induce the release of nitric oxide (NO) from endothelial cells. Nitric Oxide 76-88 vascular endothelial growth factor A Rattus norvegicus 36-40 10712388-9 2000 L-NAME and DAHP totally inhibited NO generation and decreased the IL-1beta-upregulated VEGF synthesis by 30% to 40%. NG-Nitroarginine Methyl Ester 0-6 vascular endothelial growth factor A Rattus norvegicus 87-91 10712388-9 2000 L-NAME and DAHP totally inhibited NO generation and decreased the IL-1beta-upregulated VEGF synthesis by 30% to 40%. 5-dehydro-3-deoxy-D-arabino-heptulosonic acid-7-phosphate 11-15 vascular endothelial growth factor A Rattus norvegicus 87-91 10712388-12 2000 Inhibition of NO generation by L-NAME decreased VEGF synthesis. NG-Nitroarginine Methyl Ester 31-37 vascular endothelial growth factor A Rattus norvegicus 48-52 10653393-13 2000 The scanning electron microscopic method and the hyaluronic acid uptake rate showed a protective effect of VEGF against SEC damage in the cold-preserved livers. Hyaluronic Acid 49-64 vascular endothelial growth factor A Rattus norvegicus 107-111 11263262-0 2000 Bilobalide promotes expression of glial cell line-derived neurotrophic factor and vascular endothelial growth factor in rat astrocytes. bilobalide 0-10 vascular endothelial growth factor A Rattus norvegicus 82-116 11263262-1 2000 AIM: To study the effects of bilobalide on the expression of glial cell line-derived neurotrophic factor (GDNF) and vascular endothelial growth factor (VEGF) in rat astrocytes in vitro. bilobalide 29-39 vascular endothelial growth factor A Rattus norvegicus 116-150 11263262-1 2000 AIM: To study the effects of bilobalide on the expression of glial cell line-derived neurotrophic factor (GDNF) and vascular endothelial growth factor (VEGF) in rat astrocytes in vitro. bilobalide 29-39 vascular endothelial growth factor A Rattus norvegicus 152-156 11263262-3 2000 Immunohistochemistry method was used to detect GDNF and VEGF protein expression in cells treated with bilobalide 50 mumol.L-1 for 24 h. RESULTS: GDNF and VEGF mRNA increased markedly after astrocytes were treated with bilobalide 50 mumol.L-1 for 12 h. GDNF and VEGF protein were detected in the cytoplasm of astrocytes after the cells were treated with bilobalide 50 mumol.L-1 for 24 h. CONCLUSION: Bilobalide induced GDNF and VEGF expression in the cultured astrocytes. bilobalide 102-112 vascular endothelial growth factor A Rattus norvegicus 56-60 11263262-3 2000 Immunohistochemistry method was used to detect GDNF and VEGF protein expression in cells treated with bilobalide 50 mumol.L-1 for 24 h. RESULTS: GDNF and VEGF mRNA increased markedly after astrocytes were treated with bilobalide 50 mumol.L-1 for 12 h. GDNF and VEGF protein were detected in the cytoplasm of astrocytes after the cells were treated with bilobalide 50 mumol.L-1 for 24 h. CONCLUSION: Bilobalide induced GDNF and VEGF expression in the cultured astrocytes. bilobalide 102-112 vascular endothelial growth factor A Rattus norvegicus 154-158 11263262-3 2000 Immunohistochemistry method was used to detect GDNF and VEGF protein expression in cells treated with bilobalide 50 mumol.L-1 for 24 h. RESULTS: GDNF and VEGF mRNA increased markedly after astrocytes were treated with bilobalide 50 mumol.L-1 for 12 h. GDNF and VEGF protein were detected in the cytoplasm of astrocytes after the cells were treated with bilobalide 50 mumol.L-1 for 24 h. CONCLUSION: Bilobalide induced GDNF and VEGF expression in the cultured astrocytes. bilobalide 102-112 vascular endothelial growth factor A Rattus norvegicus 154-158 11263262-3 2000 Immunohistochemistry method was used to detect GDNF and VEGF protein expression in cells treated with bilobalide 50 mumol.L-1 for 24 h. RESULTS: GDNF and VEGF mRNA increased markedly after astrocytes were treated with bilobalide 50 mumol.L-1 for 12 h. GDNF and VEGF protein were detected in the cytoplasm of astrocytes after the cells were treated with bilobalide 50 mumol.L-1 for 24 h. CONCLUSION: Bilobalide induced GDNF and VEGF expression in the cultured astrocytes. bilobalide 102-112 vascular endothelial growth factor A Rattus norvegicus 154-158 10706112-4 2000 Chronic once-daily oral dosing of ZD4190 to young rats produced a dose-dependent increase in the femoral epiphyseal growth plate area, which may be attributed to the inhibition of VEGF signaling in vivo because vascular invasion of cartilage is a prerequisite to the process of ossification. ZD 4190 34-40 vascular endothelial growth factor A Rattus norvegicus 180-184 10706112-8 2000 ZD4190 is one of a series of VEGF RTK inhibitors that may have utility in the treatment of a range of histologically diverse solid tumor types. ZD 4190 0-6 vascular endothelial growth factor A Rattus norvegicus 29-33 10694204-6 2000 VEGF also significantly preserved the endothelium-dependent relaxation to ACh indicating a preservation of endothelium-derived NO. Acetylcholine 74-77 vascular endothelial growth factor A Rattus norvegicus 0-4 10667605-4 2000 The expression of VEGF mRNA and protein by RAS-3 cells was strongly suppressed in the presence of LY294002, an inhibitor of phosphatidylinositol 3"-kinase, but remained largely unaffected in the same cells treated with an inhibitor (PD98059) of mitogen-activated protein/extracellular signal-regulated kinase kinase 1 (MKK/MEK-1). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 98-106 vascular endothelial growth factor A Rattus norvegicus 18-22 10667605-4 2000 The expression of VEGF mRNA and protein by RAS-3 cells was strongly suppressed in the presence of LY294002, an inhibitor of phosphatidylinositol 3"-kinase, but remained largely unaffected in the same cells treated with an inhibitor (PD98059) of mitogen-activated protein/extracellular signal-regulated kinase kinase 1 (MKK/MEK-1). 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 233-240 vascular endothelial growth factor A Rattus norvegicus 18-22 10667605-6 2000 The impact of mutant ras on VEGF expression was also significantly amplified at high cell density, conditions under which RAS-3 cells became less sensitive to LY294002-induced VEGF down-regulation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 159-167 vascular endothelial growth factor A Rattus norvegicus 28-32 10667605-6 2000 The impact of mutant ras on VEGF expression was also significantly amplified at high cell density, conditions under which RAS-3 cells became less sensitive to LY294002-induced VEGF down-regulation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 159-167 vascular endothelial growth factor A Rattus norvegicus 176-180 10801078-4 2000 Following subretinal injection into rat eyes, fluorescein angiography indicated that the in vivo delivery of Ad.RSV.VEGF was associated with vascular leakage. Fluorescein 46-57 vascular endothelial growth factor A Rattus norvegicus 116-120 10656295-9 2000 H2O2 levels correlated with increased VEGF (correlation coefficient = 0.82, p = .001) in this model of nonproliferative diabetic retinopathy. Hydrogen Peroxide 0-4 vascular endothelial growth factor A Rattus norvegicus 38-42 10608891-8 1999 Adenovirus-mediated overexpression of HCPTPA also inhibited VEGF-induced cellular responses (endothelial cell migration and proliferation) and inhibited angiogenesis in the rat aortic ring assay. hcptpa 38-44 vascular endothelial growth factor A Rattus norvegicus 60-64 10604929-0 2000 Carboxyamido-triazole inhibits angiogenesis by blocking the calcium-mediated nitric-oxide synthase-vascular endothelial growth factor pathway. carboxyamido-triazole 0-21 vascular endothelial growth factor A Rattus norvegicus 99-133 10604929-0 2000 Carboxyamido-triazole inhibits angiogenesis by blocking the calcium-mediated nitric-oxide synthase-vascular endothelial growth factor pathway. Calcium 60-67 vascular endothelial growth factor A Rattus norvegicus 99-133 10668753-6 2000 At the time of loop implantation the control group received 0.9 percent NaCl or a 16 percent vol/wet polyvinyl alcohol (PVA) solution: the treatment group received VEGF in 0.9 percent NaCl or VEGF in PVA. Sodium Chloride 184-188 vascular endothelial growth factor A Rattus norvegicus 164-168 10720919-10 2000 Retinas from timolol-treated animals expressed VEGF protein, though the level was inferior to that found in controls raised under room air conditions. Timolol 13-20 vascular endothelial growth factor A Rattus norvegicus 47-51 10613739-2 2000 Hepatic stellate cells are oxygen-sensing cells, capable of producing VEGF. Oxygen 27-33 vascular endothelial growth factor A Rattus norvegicus 70-74 10587525-3 1999 Reduced tissue oxygen tension triggers VEGF expression, and increased protein and mRNA levels for VEGF and its receptors (Flt-1, Flk-1/KDR) occur in the ischemic rat brain. Oxygen 15-21 vascular endothelial growth factor A Rattus norvegicus 39-43 10606733-3 1999 VEGF increased in cultured rat mesothelial and human endothelial cells exposed to methylglyoxal, but not to glyoxal or 3-deoxyglucosone. Pyruvaldehyde 82-95 vascular endothelial growth factor A Rattus norvegicus 0-4 10606733-3 1999 VEGF increased in cultured rat mesothelial and human endothelial cells exposed to methylglyoxal, but not to glyoxal or 3-deoxyglucosone. Glyoxal 88-95 vascular endothelial growth factor A Rattus norvegicus 0-4 10844408-3 1999 Here, we show that thrombn enhanced vascular endothelial growth factor (VEGF) production in a dose- and time-dependent manner in the supernatant of cultured PC-12 cells, as determined by enzyme-linked immunosorbent assay (ELISA). thrombn 19-26 vascular endothelial growth factor A Rattus norvegicus 36-70 10844408-3 1999 Here, we show that thrombn enhanced vascular endothelial growth factor (VEGF) production in a dose- and time-dependent manner in the supernatant of cultured PC-12 cells, as determined by enzyme-linked immunosorbent assay (ELISA). thrombn 19-26 vascular endothelial growth factor A Rattus norvegicus 72-76 10512636-14 1999 When incubated with HF and cycloheximide or HF and heparin, the cell growth was inhibited, suggesting that the mechanism of action of HF is similar to that of VEGF. Cycloheximide 27-40 vascular endothelial growth factor A Rattus norvegicus 159-163 10516092-6 1999 Actinomycin D inhibited the TGF-beta1-induced peak in VEGF mRNA, whereas cycloheximide did not. Dactinomycin 0-13 vascular endothelial growth factor A Rattus norvegicus 54-58 10516092-9 1999 Dexamethasone similarly inhibited VEGF protein expression. Dexamethasone 0-13 vascular endothelial growth factor A Rattus norvegicus 34-38 10510332-5 1999 In rats with mesangioproliferative nephritis, the VEGF(165) aptamer (but not a sequence-scrambled control RNA or PEG alone) led to a reduction of glomerular endothelial regeneration and an increase in endothelial cell death, provoking an 8-fold increase in the frequency of glomerular microaneurysms by day 6. Polyethylene Glycols 113-116 vascular endothelial growth factor A Rattus norvegicus 50-54 10512636-14 1999 When incubated with HF and cycloheximide or HF and heparin, the cell growth was inhibited, suggesting that the mechanism of action of HF is similar to that of VEGF. Heparin 51-58 vascular endothelial growth factor A Rattus norvegicus 159-163 10438525-10 1999 In addition, intra-ocular injection of VEGF also caused tyrosine phosphorylation of ZO-1 as early as 15 min and increased phosphorylation 4-fold after 90 min. Tyrosine 56-64 vascular endothelial growth factor A Rattus norvegicus 39-43 10423343-7 1999 In contrast, VEGF mRNA levels increased significantly in both groups of ramipril-treated animals v. placebo-treated SHR-SP. Ramipril 72-80 vascular endothelial growth factor A Rattus norvegicus 13-17 11601290-2 1999 METHODS: The expression of VEGF in control and study group in rats was performed with the Strept Avidin-Biotin-Peroxidase Complex (SABC) method. sabc 131-135 vascular endothelial growth factor A Rattus norvegicus 27-31 10423343-7 1999 In contrast, VEGF mRNA levels increased significantly in both groups of ramipril-treated animals v. placebo-treated SHR-SP. shr-sp 116-122 vascular endothelial growth factor A Rattus norvegicus 13-17 10417401-9 1999 VEGF protein was higher in alinidine-treated rats than in controls after 2 weeks and increased further after 3 weeks of treatment. alinidine 27-36 vascular endothelial growth factor A Rattus norvegicus 0-4 10417401-10 1999 Injection of VEGF-neutralizing antibodies over a 2-week period completely blocked alinidine-stimulated angiogenesis. alinidine 82-91 vascular endothelial growth factor A Rattus norvegicus 13-17 10431842-0 1999 Alterations in the immunohistochemical distribution patterns of vascular endothelial growth factor receptors Flk1 and Flt1 in bleomycin-induced rat lung fibrosis. Bleomycin 126-135 vascular endothelial growth factor A Rattus norvegicus 64-98 10459859-7 1999 Inhibition of VEGF synthesis and function by antisense oligonucleotide and by suramin, respectively arrested the OP-1-induced alkaline phosphatase activity and mineralized bone nodule formation. Oligonucleotides 55-70 vascular endothelial growth factor A Rattus norvegicus 14-18 10459859-7 1999 Inhibition of VEGF synthesis and function by antisense oligonucleotide and by suramin, respectively arrested the OP-1-induced alkaline phosphatase activity and mineralized bone nodule formation. Suramin 78-85 vascular endothelial growth factor A Rattus norvegicus 14-18 10347094-4 1999 We found that the 2 VEGF receptors, KDR/Flk-1 and Flt-1, were expressed in cardiac myocytes and that KDR/Flk-1 was significantly tyrosine phosphorylated on VEGF stimulation. Tyrosine 129-137 vascular endothelial growth factor A Rattus norvegicus 20-24 10431842-7 1999 Bleomycin-induced fibrogenesis was characterised by a decrease in Flk1 immunoreactivity of Clara cells, and an increase in VEGF-immunoreactive myofibroblasts and type 2 pneumocytes by day 5 p.t., followed by a progressive accumulation of Flk1-immunoreactive mast cells by day 24 p.t. Bleomycin 0-9 vascular endothelial growth factor A Rattus norvegicus 123-127 10431842-10 1999 Since mast cells are known to be chemotactically attracted by VEGF, we suggest that VEGF/Flk1 represents the molecular link between proliferation of myofibroblasts, accumulation of mast cells, and the burst of fibrosis at sites of initial lesions in bleomycin-induced fibrosis. Bleomycin 250-259 vascular endothelial growth factor A Rattus norvegicus 84-88 10336886-0 1999 Vascular endothelial growth factor attenuates leukocyte-endothelium interaction during acute endothelial dysfunction: essential role of endothelium-derived nitric oxide. Nitric Oxide 156-168 vascular endothelial growth factor A Rattus norvegicus 0-34 10336886-1 1999 Vascular endothelial growth factor (VEGF) is an endothelium-specific secreted protein that induces vasodilation and increases endothelial release of nitric oxide (NO). Nitric Oxide 149-161 vascular endothelial growth factor A Rattus norvegicus 0-34 10336886-1 1999 Vascular endothelial growth factor (VEGF) is an endothelium-specific secreted protein that induces vasodilation and increases endothelial release of nitric oxide (NO). Nitric Oxide 149-161 vascular endothelial growth factor A Rattus norvegicus 36-40 10336886-6 1999 At 4 and 24 h posttreatment, VEGF significantly attenuated thrombin-induced and L-NAME-induced leukocyte rolling, adherence, and transmigration in rat mesenteric venules. NG-Nitroarginine Methyl Ester 80-86 vascular endothelial growth factor A Rattus norvegicus 29-33 10336886-12 1999 Vascular endothelial growth factor attenuates leukocyte-endothelium interaction during acute endothelial dysfunction: essential role of endothelium-derived nitric oxide. Nitric Oxide 156-168 vascular endothelial growth factor A Rattus norvegicus 0-34 10347094-4 1999 We found that the 2 VEGF receptors, KDR/Flk-1 and Flt-1, were expressed in cardiac myocytes and that KDR/Flk-1 was significantly tyrosine phosphorylated on VEGF stimulation. Tyrosine 129-137 vascular endothelial growth factor A Rattus norvegicus 156-160 10347094-5 1999 VEGF induced tyrosine phosphorylation and activation of p125(FAK) as well as tyrosine phosphorylation of paxillin; this was accompanied by subcellular translocation of p125(FAK) from perinuclear sites to the focal adhesions. Tyrosine 13-21 vascular endothelial growth factor A Rattus norvegicus 0-4 10347094-5 1999 VEGF induced tyrosine phosphorylation and activation of p125(FAK) as well as tyrosine phosphorylation of paxillin; this was accompanied by subcellular translocation of p125(FAK) from perinuclear sites to the focal adhesions. Tyrosine 77-85 vascular endothelial growth factor A Rattus norvegicus 0-4 10347094-6 1999 This VEGF-induced activation of p125(FAK) was inhibited partially by the tyrosine kinase inhibitors genistein and tyrphostin. Genistein 100-109 vascular endothelial growth factor A Rattus norvegicus 5-9 10347094-6 1999 This VEGF-induced activation of p125(FAK) was inhibited partially by the tyrosine kinase inhibitors genistein and tyrphostin. Tyrphostins 114-124 vascular endothelial growth factor A Rattus norvegicus 5-9 10235544-1 1999 PURPOSE: To determine the temporal and spatial relationships between neovascularization and basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) mRNA and protein expression in the rat cornea after cautery with silver nitrate. Silver Nitrate 241-255 vascular endothelial growth factor A Rattus norvegicus 134-168 10329451-1 1999 Binding of vascular endothelial growth factor (VEGF) to its receptor, VEGFR-2 (Flk-1/KDR), induces dimerization and activation of the tyrosine kinase domain of the receptor, resulting in autophosphorylation of cytoplasmic tyrosine residues used as docking sites for signaling proteins that relay the signals for cell proliferation, migration, and permeability enhancement. Tyrosine 134-142 vascular endothelial growth factor A Rattus norvegicus 11-45 10329451-1 1999 Binding of vascular endothelial growth factor (VEGF) to its receptor, VEGFR-2 (Flk-1/KDR), induces dimerization and activation of the tyrosine kinase domain of the receptor, resulting in autophosphorylation of cytoplasmic tyrosine residues used as docking sites for signaling proteins that relay the signals for cell proliferation, migration, and permeability enhancement. Tyrosine 134-142 vascular endothelial growth factor A Rattus norvegicus 47-51 10329451-7 1999 Pretreatment of HUVEC with antisense oligodeoxyribonucleotide (ODN) for lipocortin V significantly inhibited VEGF-induced cell proliferation, which was accompanied by a decrease in protein synthesis and tyrosine phosphorylation of lipocortin V. Oligodeoxyribonucleotides 37-61 vascular endothelial growth factor A Rattus norvegicus 109-113 10329451-7 1999 Pretreatment of HUVEC with antisense oligodeoxyribonucleotide (ODN) for lipocortin V significantly inhibited VEGF-induced cell proliferation, which was accompanied by a decrease in protein synthesis and tyrosine phosphorylation of lipocortin V. Oligodeoxyribonucleotides 63-66 vascular endothelial growth factor A Rattus norvegicus 109-113 10329964-0 1999 VEGF increases permeability of the blood-brain barrier via a nitric oxide synthase/cGMP-dependent pathway. Cyclic GMP 83-87 vascular endothelial growth factor A Rattus norvegicus 0-4 10329964-8 1999 However, superfusion with VEGF (0.1 nM) produced a marked increase in clearance of FITC-dextran-10K and a modest dilatation of pial arterioles. fitc-dextran-10 83-98 vascular endothelial growth factor A Rattus norvegicus 26-30 10329964-10 1999 L-NMMA and ODQ inhibited VEGF-induced increases in permeability of the BBB and arteriolar dilatation. omega-N-Methylarginine 0-6 vascular endothelial growth factor A Rattus norvegicus 25-29 10329964-10 1999 L-NMMA and ODQ inhibited VEGF-induced increases in permeability of the BBB and arteriolar dilatation. 1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one 11-14 vascular endothelial growth factor A Rattus norvegicus 25-29 10329964-11 1999 The findings of the present study suggest that VEGF, which appears to be increased in brain tissue during cerebrovascular trauma, increases the permeability of the BBB via the synthesis/release of nitric oxide and subsequent activation of soluble guanylate cyclase. Nitric Oxide 197-209 vascular endothelial growth factor A Rattus norvegicus 47-51 10333051-0 1999 Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. opb 171-174 vascular endothelial growth factor A Rattus norvegicus 51-85 10333051-6 1999 We also examined OPB-9195"s effects on renal expression of VEGF mRNA and protein. opb 17-20 vascular endothelial growth factor A Rattus norvegicus 59-63 10333051-8 1999 In contrast, OPB-9195 treatment greatly suppressed the renal expression of TGF-beta, VEGF and type IV collagen mRNAs and proteins to that seen in non-diabetic rats. opb 13-16 vascular endothelial growth factor A Rattus norvegicus 85-89 10333051-9 1999 CONCLUSION/INTERPRETATION: Since OPB-9195, an AGE-inhibitor, prevented the progression of diabetic nephropathy by blocking type IV collagen production and suppressing overproduction of two growth factors, TGF-beta and VEGF, in diabetic rats, this compound warrants further investigation. OPB 9195 33-41 vascular endothelial growth factor A Rattus norvegicus 218-222 10235544-12 1999 Treatment with either dexamethasone or systemic hyperoxia inhibited both neovascularization and the increase in VEGF expression. Dexamethasone 22-35 vascular endothelial growth factor A Rattus norvegicus 112-116 10235544-13 1999 Dexamethasone inhibited 27% of cautery-induced VEGF upregulation at 24 hours and 23% at 48 hours, hyperoxia inhibited 32% at 24 hours and 43% at 48 hours, and combined treatment with both dexamethasone and hyperoxia had an additive effect (56% inhibition at 24 hours). Dexamethasone 0-13 vascular endothelial growth factor A Rattus norvegicus 47-51 10210429-9 1999 RESULTS: VEGF mRNA and protein levels were significantly decreased by castration and testosterone treatment induced VEGF synthesis in the rat ventral prostate epithelium. Testosterone 85-97 vascular endothelial growth factor A Rattus norvegicus 9-13 10233112-7 1999 Densitometric mRNA/18S levels for vascular endothelial growth factor (VEGF) were increased 50% by NP and acetylcholine, were unaffected by PGE1 and PGE2, and were reduced 40% by PGI2. Acetylcholine 105-118 vascular endothelial growth factor A Rattus norvegicus 34-68 10233112-7 1999 Densitometric mRNA/18S levels for vascular endothelial growth factor (VEGF) were increased 50% by NP and acetylcholine, were unaffected by PGE1 and PGE2, and were reduced 40% by PGI2. Acetylcholine 105-118 vascular endothelial growth factor A Rattus norvegicus 70-74 10233112-7 1999 Densitometric mRNA/18S levels for vascular endothelial growth factor (VEGF) were increased 50% by NP and acetylcholine, were unaffected by PGE1 and PGE2, and were reduced 40% by PGI2. Epoprostenol 178-182 vascular endothelial growth factor A Rattus norvegicus 34-68 10233112-7 1999 Densitometric mRNA/18S levels for vascular endothelial growth factor (VEGF) were increased 50% by NP and acetylcholine, were unaffected by PGE1 and PGE2, and were reduced 40% by PGI2. Epoprostenol 178-182 vascular endothelial growth factor A Rattus norvegicus 70-74 10233112-10 1999 For the principal putative angiogenic growth factor, VEGF, these data suggest that naturally secreted vasodilators in contracting skeletal muscle could be involved in regulation of gene expression, namely, nitric oxide in a positive and PGI2 in a negative direction. Nitric Oxide 206-218 vascular endothelial growth factor A Rattus norvegicus 53-57 10233112-10 1999 For the principal putative angiogenic growth factor, VEGF, these data suggest that naturally secreted vasodilators in contracting skeletal muscle could be involved in regulation of gene expression, namely, nitric oxide in a positive and PGI2 in a negative direction. Epoprostenol 237-241 vascular endothelial growth factor A Rattus norvegicus 53-57 10210429-0 1999 Testosterone induces vascular endothelial growth factor synthesis in the ventral prostate in castrated rats. Testosterone 0-12 vascular endothelial growth factor A Rattus norvegicus 21-55 10210429-9 1999 RESULTS: VEGF mRNA and protein levels were significantly decreased by castration and testosterone treatment induced VEGF synthesis in the rat ventral prostate epithelium. Testosterone 85-97 vascular endothelial growth factor A Rattus norvegicus 116-120 10210429-11 1999 CONCLUSIONS: Castration down regulates VEGF and testosterone induces VEGF synthesis in epithelial cells in the rat ventral prostate. Testosterone 48-60 vascular endothelial growth factor A Rattus norvegicus 69-73 10079260-6 1999 In situ hybridization revealed that VEGF was highly expressed in distal airway epithelial cells in controls but disappeared in the oxygen-exposed animals. Oxygen 131-137 vascular endothelial growth factor A Rattus norvegicus 36-40 10215998-3 1999 In this study we test the hypothesis that the antioedema effect of dexamethasone is mediated by downregulation of VEGF or VEGF receptor expression. Dexamethasone 67-80 vascular endothelial growth factor A Rattus norvegicus 114-118 10215998-3 1999 In this study we test the hypothesis that the antioedema effect of dexamethasone is mediated by downregulation of VEGF or VEGF receptor expression. Dexamethasone 67-80 vascular endothelial growth factor A Rattus norvegicus 122-126 10215998-4 1999 VEGF mRNA and protein levels of two rat glioma cells lines, C6 and GS-9L, were determined after incubation with dexamethasone under normoxic and hypoxic conditions. Dexamethasone 112-125 vascular endothelial growth factor A Rattus norvegicus 0-4 10215998-5 1999 In normoxic C6 and GS9L cells, we observed 50-60% downregulation of VEGF mRNA by dexamethasone (P=0.015 and P=0. Dexamethasone 81-94 vascular endothelial growth factor A Rattus norvegicus 68-72 10215998-8 1999 The inhibitory effect of dexamethasone on VEGF gene expression by tumour cells was markedly reduced by hypoxia which suggests that the upregulation of VEGF driven by hypoxia overcomes the effect of the dexamethasone. Dexamethasone 25-38 vascular endothelial growth factor A Rattus norvegicus 42-46 10215998-8 1999 The inhibitory effect of dexamethasone on VEGF gene expression by tumour cells was markedly reduced by hypoxia which suggests that the upregulation of VEGF driven by hypoxia overcomes the effect of the dexamethasone. Dexamethasone 25-38 vascular endothelial growth factor A Rattus norvegicus 151-155 10215998-8 1999 The inhibitory effect of dexamethasone on VEGF gene expression by tumour cells was markedly reduced by hypoxia which suggests that the upregulation of VEGF driven by hypoxia overcomes the effect of the dexamethasone. Dexamethasone 202-215 vascular endothelial growth factor A Rattus norvegicus 42-46 10215998-8 1999 The inhibitory effect of dexamethasone on VEGF gene expression by tumour cells was markedly reduced by hypoxia which suggests that the upregulation of VEGF driven by hypoxia overcomes the effect of the dexamethasone. Dexamethasone 202-215 vascular endothelial growth factor A Rattus norvegicus 151-155 10215998-10 1999 In a subcutaneous glioma tumour model, we observed only a 15% decrease in VEGF mRNA expression in dexamethasone treated animals (n = 12) compared with controls animals (P = 0.24). Dexamethasone 98-111 vascular endothelial growth factor A Rattus norvegicus 74-78 10215998-11 1999 We conclude that dexamethasone may decrease brain tumour-associated oedema by reduction of VEGF expression in tumour cells. Dexamethasone 17-30 vascular endothelial growth factor A Rattus norvegicus 91-95 10340756-11 1999 Because VEGF is stimulated by hypoxia, its preferential mRNA expression near the epicardium, that is, farthest from the ventricular lumen and the O2 source, fits with the hypothesis that a hypoxic gradient is a driving force in the transmural vascularization process. Oxygen 146-148 vascular endothelial growth factor A Rattus norvegicus 8-12 10326865-0 1999 Expression of vascular endothelial growth factor and its receptors during lung carcinogenesis by N-nitrosobis(2-hydroxypropyl)amine in rats. diisopropanolnitrosamine 97-131 vascular endothelial growth factor A Rattus norvegicus 14-48 10326865-1 1999 The expression of vascular endothelial growth factor (VEGF) and its receptors (VEGFRs), VEGFR-1/Flt-1 and VEGFR-2/Flk-1, was investigated by immunohistochemical and northern blot analysis during lung carcinogenesis by N-nitrosobis(2-hydroxypropyl)amine (BHP) in male Wistar rats. diisopropanolnitrosamine 218-252 vascular endothelial growth factor A Rattus norvegicus 18-52 10326865-1 1999 The expression of vascular endothelial growth factor (VEGF) and its receptors (VEGFRs), VEGFR-1/Flt-1 and VEGFR-2/Flk-1, was investigated by immunohistochemical and northern blot analysis during lung carcinogenesis by N-nitrosobis(2-hydroxypropyl)amine (BHP) in male Wistar rats. bhp 254-257 vascular endothelial growth factor A Rattus norvegicus 18-52 10079260-10 1999 We speculate that VEGF functions as a survival factor in the normal adult rat lung, and its loss during hyperoxia contributes to the pathophysiology of oxygen-induced lung damage. Oxygen 152-158 vascular endothelial growth factor A Rattus norvegicus 18-22 10435050-8 1999 Since eNOS mRNA levels remained elevated in VEGF-treated cells in the presence of actinomycin D. Dactinomycin 82-95 vascular endothelial growth factor A Rattus norvegicus 44-48 10024512-0 1999 Differential regulation of vascular endothelial growth factor and its receptor fms-like-tyrosine kinase is mediated by nitric oxide in rat renal mesangial cells. Nitric Oxide 119-131 vascular endothelial growth factor A Rattus norvegicus 27-61 10024512-4 1999 Using S-nitroso-glutathione (GSNO) as an NO-donating agent, VEGF expression was strongly induced, whereas expression of its FLT-1 receptor simultaneously decreased. S-Nitrosoglutathione 6-27 vascular endothelial growth factor A Rattus norvegicus 60-64 10024512-4 1999 Using S-nitroso-glutathione (GSNO) as an NO-donating agent, VEGF expression was strongly induced, whereas expression of its FLT-1 receptor simultaneously decreased. S-Nitrosoglutathione 29-33 vascular endothelial growth factor A Rattus norvegicus 60-64 10024512-5 1999 Expressional regulation of VEGF and FLT-1 mRNA was transient and occurred rapidly within 1-3 h after GSNO treatment. S-Nitrosoglutathione 101-105 vascular endothelial growth factor A Rattus norvegicus 27-31 10342375-3 1999 METHODS: Rat VEGF or KDR cDNA was inserted in PGEM or pBluescript to prepare antisense or sense riboprobes. 7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid 46-50 vascular endothelial growth factor A Rattus norvegicus 13-17 10342375-6 1999 The sections were subjected to in situ hybridization with digoxigenin (DIG)-labeled single-strand rat VEGF and KDR cDNA riboprobes. Digoxigenin 58-69 vascular endothelial growth factor A Rattus norvegicus 102-106 10342375-6 1999 The sections were subjected to in situ hybridization with digoxigenin (DIG)-labeled single-strand rat VEGF and KDR cDNA riboprobes. Digoxigenin 71-74 vascular endothelial growth factor A Rattus norvegicus 102-106 10098638-0 1999 Expression of vascular endothelial growth factor in N-butyl-N-(4-hydroxybutyl)nitrosamine-induced rat bladder carcinogenesis. Butylhydroxybutylnitrosamine 52-89 vascular endothelial growth factor A Rattus norvegicus 14-48 10098638-12 1999 The present study suggests that upregulation of epithelial VEGF may begin at a quite early stage in BBN-induced rat bladder carcinogenesis, but bFGF may not be involved. Butylhydroxybutylnitrosamine 100-103 vascular endothelial growth factor A Rattus norvegicus 59-63 9892418-5 1999 Immunohistochemistry (IH), double immunofluorescence microscopy (DIF), and immunoelectron microscopy (IEM) were used to study the differential distribution of VEGF in paraffin-embedded (IH, DIF) and in cryo-substituted, Lowicryl-embedded (IEM) specimens of normal rat and human lungs and fibrotic rat lungs. Paraffin 167-175 vascular endothelial growth factor A Rattus norvegicus 159-163 9928995-4 1999 It is concluded that sympathetic control of VEGF expression via noradrenaline acting on beta3-adrenoceptors plays a major role in developmental and adaptive angiogenesis, and defects in this contribute to the reduced thermogenic capacity of BAT in genetic obesity. Norepinephrine 64-77 vascular endothelial growth factor A Rattus norvegicus 44-48 9892418-8 1999 Fibrotic lesions in bleomycin-treated rat lungs were rich in VEGF-positive cells presenting with a heterogeneous phenotype (mainly SP-D-positive type II pneumocytes, alpha-SM actin-positive myofibroblasts). Bleomycin 20-29 vascular endothelial growth factor A Rattus norvegicus 61-65 9836521-3 1998 In this study, we examined the gene expression of VEGF mRNA in three tumor cell lines and in isolated whole and dispersed rat islets in vitro by Northern blot hybridization in normoxic (5% CO2, 95% humidified air) and hypoxic (1% O2, 5% CO2, 94% N2) culture conditions. Oxygen 190-192 vascular endothelial growth factor A Rattus norvegicus 50-54 10668485-11 1999 SC-236 was also effective in reducing angiogenesis driven by bFGF, vascular endothelium growth factor (VEGF), or carrageenan in the matrigel rat model. 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide 0-6 vascular endothelial growth factor A Rattus norvegicus 67-101 10668485-11 1999 SC-236 was also effective in reducing angiogenesis driven by bFGF, vascular endothelium growth factor (VEGF), or carrageenan in the matrigel rat model. 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide 0-6 vascular endothelial growth factor A Rattus norvegicus 103-107 9930879-9 1999 In contrast, connective tissue mast cells (CTMC), which were located in the submucosa of the digestive tract and in the connective tissues of the respiratory tract and other organs, were intensely immunopositive for histamine, whereas they showed no reactivity to anti-VEGF antibody. ctmc 43-47 vascular endothelial growth factor A Rattus norvegicus 269-273 9930879-10 1999 The specific occurrence of VEGF in GL/MMC suggests that this cell type is involved in paracrine regulation of the permeability of nearby microvessels, and that VEGF immunoreactivity can be used as a histochemical marker to distinguish GL/MMC from CTMC. gl 35-37 vascular endothelial growth factor A Rattus norvegicus 27-31 9930879-10 1999 The specific occurrence of VEGF in GL/MMC suggests that this cell type is involved in paracrine regulation of the permeability of nearby microvessels, and that VEGF immunoreactivity can be used as a histochemical marker to distinguish GL/MMC from CTMC. ctmc 247-251 vascular endothelial growth factor A Rattus norvegicus 27-31 9836521-3 1998 In this study, we examined the gene expression of VEGF mRNA in three tumor cell lines and in isolated whole and dispersed rat islets in vitro by Northern blot hybridization in normoxic (5% CO2, 95% humidified air) and hypoxic (1% O2, 5% CO2, 94% N2) culture conditions. N2,N6-bis(4-(2-aminoethoxy)quinolin-2-yl)-4-((4-fluorobenzyl)oxy)pyridine-2,6-dicarboxamide 189-192 vascular endothelial growth factor A Rattus norvegicus 50-54 9836521-3 1998 In this study, we examined the gene expression of VEGF mRNA in three tumor cell lines and in isolated whole and dispersed rat islets in vitro by Northern blot hybridization in normoxic (5% CO2, 95% humidified air) and hypoxic (1% O2, 5% CO2, 94% N2) culture conditions. N2,N6-bis(4-(2-aminoethoxy)quinolin-2-yl)-4-((4-fluorobenzyl)oxy)pyridine-2,6-dicarboxamide 237-240 vascular endothelial growth factor A Rattus norvegicus 50-54 9836521-3 1998 In this study, we examined the gene expression of VEGF mRNA in three tumor cell lines and in isolated whole and dispersed rat islets in vitro by Northern blot hybridization in normoxic (5% CO2, 95% humidified air) and hypoxic (1% O2, 5% CO2, 94% N2) culture conditions. Nitrogen 246-248 vascular endothelial growth factor A Rattus norvegicus 50-54 9792547-3 1998 We reported previously, using skin chambers mounted on backs of SD rats, that neutralizing antibodies directed against VEGF blocked vascular permeability and blood flow changes induced by elevated tissue glucose and sorbitol levels in a dosage-dependent manner. Glucose 204-211 vascular endothelial growth factor A Rattus norvegicus 119-123 9834466-7 1998 Results indicate that circulating levels of gonadal steroids and LH may be associated with the differential expression of VPF/VEGF mRNA and its translation activity in the endometrium during different stages of the estrous cycle. Steroids 52-60 vascular endothelial growth factor A Rattus norvegicus 122-125 9834466-7 1998 Results indicate that circulating levels of gonadal steroids and LH may be associated with the differential expression of VPF/VEGF mRNA and its translation activity in the endometrium during different stages of the estrous cycle. Steroids 52-60 vascular endothelial growth factor A Rattus norvegicus 126-130 9840733-0 1998 Upregulation of vascular endothelial growth factor by H2O2 in rat heart endothelial cells. Hydrogen Peroxide 54-58 vascular endothelial growth factor A Rattus norvegicus 16-50 9840733-4 1998 Using rat heart endothelial cell culture as a model system, we examined the effect of H2O2 on the gene expression of vascular endothelial growth factor (VEGF), a potent mitogen of endothelial cells and a vascular permeability factor. Hydrogen Peroxide 86-90 vascular endothelial growth factor A Rattus norvegicus 117-151 9840733-4 1998 Using rat heart endothelial cell culture as a model system, we examined the effect of H2O2 on the gene expression of vascular endothelial growth factor (VEGF), a potent mitogen of endothelial cells and a vascular permeability factor. Hydrogen Peroxide 86-90 vascular endothelial growth factor A Rattus norvegicus 153-157 9840733-5 1998 By Northern blot analysis we found that VEGF mRNA responded to H2O2 in a dose-and time-dependent manner. Hydrogen Peroxide 63-67 vascular endothelial growth factor A Rattus norvegicus 40-44 9840733-10 1998 Immunoblot analysis showed that the amount of secreted VEGF was elevated in the medium 4 h after H2O2 stimulation. Hydrogen Peroxide 97-101 vascular endothelial growth factor A Rattus norvegicus 55-59 9840733-11 1998 Our results demonstrate that VEGF gene expression is upregulated by H2O2 in these endothelial cells. Hydrogen Peroxide 68-72 vascular endothelial growth factor A Rattus norvegicus 29-33 9792547-3 1998 We reported previously, using skin chambers mounted on backs of SD rats, that neutralizing antibodies directed against VEGF blocked vascular permeability and blood flow changes induced by elevated tissue glucose and sorbitol levels in a dosage-dependent manner. Sorbitol 216-224 vascular endothelial growth factor A Rattus norvegicus 119-123 9792547-5 1998 In addition, we show that 1) TBC1635, a novel heparin-binding growth factor antagonist, blocks the vascular hyperpermeability and blood flow increases induced by elevated tissue levels of glucose and sorbitol and by topical application of VEGF and FGF-2 to granulation tissue in skin chambers, and 2) suramin, a commercially available growth factor antagonist, blocks glucose-induced vascular dysfunction. tbc1635 29-36 vascular endothelial growth factor A Rattus norvegicus 239-243 9811001-11 1998 Compared with the two control groups, flaps receiving VEGF cDNA had significantly greater tissue viability at the end of 7 days: 93.9 versus 28.1 percent for the control plasmid DNA group and 31.9 percent for the saline group (p < 0.05). Sodium Chloride 213-219 vascular endothelial growth factor A Rattus norvegicus 54-58 9811001-12 1998 Immunohistochemical staining documented increased deposition of VEGF protein in flaps that were infused with the VEGF cDNA versus saline alone (p < 0.05). Sodium Chloride 130-136 vascular endothelial growth factor A Rattus norvegicus 113-117 9790948-6 1998 Injection of testosterone in adult rats induced a transient increase of the ventral lobe weight and the specific activity of prostatic VEGF, leading to a 7-fold increase in the prostate content of VEGF. Testosterone 13-25 vascular endothelial growth factor A Rattus norvegicus 135-139 9849861-0 1998 Changes in VEGF expression and in the vasculature during the growth of early-stage ethylnitrosourea-induced malignant astrocytomas in rats. Ethylnitrosourea 83-99 vascular endothelial growth factor A Rattus norvegicus 11-15 9790948-6 1998 Injection of testosterone in adult rats induced a transient increase of the ventral lobe weight and the specific activity of prostatic VEGF, leading to a 7-fold increase in the prostate content of VEGF. Testosterone 13-25 vascular endothelial growth factor A Rattus norvegicus 197-201 9798977-8 1998 Pentoxifylline (PTX), a methylxanthine derivative, significantly inhibited the hypoxia-induced increase in PCA as well as VEGF release in all three cell lines tested. Pentoxifylline 16-19 vascular endothelial growth factor A Rattus norvegicus 122-126 10684080-4 1998 The VEGF cRNA was labeled with digoxigenin-UTP by in vitro transcription. digoxigenin-utp 31-46 vascular endothelial growth factor A Rattus norvegicus 4-8 9798977-8 1998 Pentoxifylline (PTX), a methylxanthine derivative, significantly inhibited the hypoxia-induced increase in PCA as well as VEGF release in all three cell lines tested. Pentoxifylline 0-14 vascular endothelial growth factor A Rattus norvegicus 122-126 9751672-8 1998 By contrast, profound dilation of collaterals was observed after acetylcholine in VEGF-treated animals. Acetylcholine 65-78 vascular endothelial growth factor A Rattus norvegicus 82-86 9751672-10 1998 The resulting blood flow in the ischemic limb after administration of acetylcholine in the control animals was only 64.6+/-17.0% of that of the contralateral normal limb, whereas blood flow was augmented to 106.1+/-8.4% in VEGF-treated animals (P<0.05). Acetylcholine 70-83 vascular endothelial growth factor A Rattus norvegicus 223-227 9746434-0 1998 Modulation of VEGF production by pH and glucose in retinal Muller cells. Glucose 40-47 vascular endothelial growth factor A Rattus norvegicus 14-18 9746434-1 1998 PURPOSE: To investigate the influence of pH and glucose concentration, both of which represent significant biochemical variables in tissue ischemia, on the production of VEGF protein by retinal Muller cells and C6 glioma cells, under normoxic and hypoxic conditions. Glucose 48-55 vascular endothelial growth factor A Rattus norvegicus 170-174 9746434-3 1998 The effect of pH (range 7.0-8.0) and glucose concentration (0.6-25 mmol/L) on VEGF protein production, under both normoxic and hypoxic conditions, were evaluated by ELISA analysis of the conditioned media. Glucose 37-44 vascular endothelial growth factor A Rattus norvegicus 78-82 9746434-5 1998 RESULTS: Hypoxia caused a 7.9-fold increase in VEGF production in C6 cells at 24 h, and a 3.4-fold increase in Muller cells after 48 h. Under hypoxic conditions, VEGF protein production was increased further by increasing pH and increasing glucose, and decreased by low pH and low glucose. Glucose 240-247 vascular endothelial growth factor A Rattus norvegicus 162-166 9746434-5 1998 RESULTS: Hypoxia caused a 7.9-fold increase in VEGF production in C6 cells at 24 h, and a 3.4-fold increase in Muller cells after 48 h. Under hypoxic conditions, VEGF protein production was increased further by increasing pH and increasing glucose, and decreased by low pH and low glucose. Glucose 281-288 vascular endothelial growth factor A Rattus norvegicus 162-166 9746434-7 1998 CONCLUSIONS: Both glucose and pH significantly affected VEGF production induced by low oxygen. Glucose 18-25 vascular endothelial growth factor A Rattus norvegicus 56-60 9746434-7 1998 CONCLUSIONS: Both glucose and pH significantly affected VEGF production induced by low oxygen. Oxygen 87-93 vascular endothelial growth factor A Rattus norvegicus 56-60 9726824-8 1998 In addition, in mice developing EAU, which does not have an abrupt onset as it does in rats and may involve neovascularization, a comparable upregulation of VEGF in the inner retina to that seen in rats developing EAU occurs with no increase in TGFbeta1 or TGFbeta2. Water 32-35 vascular endothelial growth factor A Rattus norvegicus 157-161 9726824-8 1998 In addition, in mice developing EAU, which does not have an abrupt onset as it does in rats and may involve neovascularization, a comparable upregulation of VEGF in the inner retina to that seen in rats developing EAU occurs with no increase in TGFbeta1 or TGFbeta2. Water 214-217 vascular endothelial growth factor A Rattus norvegicus 157-161 9701350-6 1998 Brain edema was significantly reduced in VEGF-treated animals (P = 0.01), and furthermore, extravasation of Evans blue was also decreased in those animals (P < 0.01). Evans Blue 108-118 vascular endothelial growth factor A Rattus norvegicus 41-45 9701350-7 1998 Terminal deoxynucleotidyl transferase-mediated dUTP-biotin in situ nick end labeling and immunohistochemical analysis for 70-kDa heat shock protein showed an amelioration of the stainings at 24 and 48 hours after reperfusion with VEGF treatment, which indicated reduction of neuronal damage. dutp-biotin 47-58 vascular endothelial growth factor A Rattus norvegicus 230-234 9701350-8 1998 These results indicate that treatment with topical VEGF application significantly reduces ischemic brain damage, such as infarct volume, edema formation, and extravasation of Evans blue, and that the reductions were associated with that of neuronal injury. Evans Blue 175-185 vascular endothelial growth factor A Rattus norvegicus 51-55 9674643-6 1998 ET-1-induced VEGF mRNA expression was abolished by a selective ET(A) receptor antagonist, BQ-485, but not by an ET(B)-selective blocker, BQ-788. BQ 485 90-96 vascular endothelial growth factor A Rattus norvegicus 13-17 9714188-2 1998 In the present study, the localization and magnitude of VEGF, VEGF receptor-1 (VEGFR-1), and VEGF receptor-2 (VEGFR-2) gene expression were examined in the eye of streptozotocin-induced diabetic rats using quantitative in situ hybridization. Streptozocin 163-177 vascular endothelial growth factor A Rattus norvegicus 56-60 9674643-9 1998 Coculture of BAECs and VSMCs enhanced both ET-1 and VEGF gene expression in these cells, and the conditioned media from BAECs and VSMCs reproduced the augmentation of each gene expression, which was partially inhibited by BQ-485 or an antibody specific to VEGF. BQ 485 222-228 vascular endothelial growth factor A Rattus norvegicus 52-56 9571172-0 1998 Effect of vascular endothelial growth factor on nitric oxide production by cultured rat mesangial cells. Nitric Oxide 48-60 vascular endothelial growth factor A Rattus norvegicus 10-44 9571172-1 1998 Vascular endothelial growth factor (VEGF) stimulates nitric oxide (NO) production by endothelial cells in vitro and in vivo. Nitric Oxide 53-65 vascular endothelial growth factor A Rattus norvegicus 0-34 9571172-1 1998 Vascular endothelial growth factor (VEGF) stimulates nitric oxide (NO) production by endothelial cells in vitro and in vivo. Nitric Oxide 53-65 vascular endothelial growth factor A Rattus norvegicus 36-40 9571172-3 1998 Therefore, we measured nitrite accumulation in cytokine-stimulated, rat mesangial cells (RMC) in response to graded concentrations of VEGF. Nitrites 23-30 vascular endothelial growth factor A Rattus norvegicus 134-138 9531974-3 1998 VEGF mRNA levels reached a plateau within 2 h after the addition of AII and decreased after 4 h. The induction was superinduced by cycloheximide and blocked by actinomycin D. Cycloheximide 131-144 vascular endothelial growth factor A Rattus norvegicus 0-4 9614352-3 1998 The purpose of this study was to determine the distribution of VEGF in thyroid tissues during goitre formation, and to study the actions of VEGF on the regulation of thymidine incorporation and iodine uptake by thyroid follicular cells. Thymidine 166-175 vascular endothelial growth factor A Rattus norvegicus 140-144 9614352-3 1998 The purpose of this study was to determine the distribution of VEGF in thyroid tissues during goitre formation, and to study the actions of VEGF on the regulation of thymidine incorporation and iodine uptake by thyroid follicular cells. Iodine 194-200 vascular endothelial growth factor A Rattus norvegicus 140-144 9614352-6 1998 Immunocytochemistry performed for VEGF using the avidin-biotin system showed that VEGF is present in normal thyroid and is located mainly in the vascular endothelium and interfollicular stromal tissue. avidin-biotin 49-62 vascular endothelial growth factor A Rattus norvegicus 34-38 9614352-6 1998 Immunocytochemistry performed for VEGF using the avidin-biotin system showed that VEGF is present in normal thyroid and is located mainly in the vascular endothelium and interfollicular stromal tissue. avidin-biotin 49-62 vascular endothelial growth factor A Rattus norvegicus 82-86 9614352-9 1998 In the absence of TSH, incubation with VEGF caused a significant reduction in [3H]thymidine incorporation, but did not significantly alter [125I] uptake. Tritium 79-81 vascular endothelial growth factor A Rattus norvegicus 39-43 9614352-9 1998 In the absence of TSH, incubation with VEGF caused a significant reduction in [3H]thymidine incorporation, but did not significantly alter [125I] uptake. Thymidine 82-91 vascular endothelial growth factor A Rattus norvegicus 39-43 9614352-10 1998 Incubation with TSH (1 mU/ml) caused a fourfold increase in [3H]thymidine incorporation that was diminished by co-incubation with 10 ng/ml or greater VEGF. Thyrotropin 16-19 vascular endothelial growth factor A Rattus norvegicus 150-154 9614352-10 1998 Incubation with TSH (1 mU/ml) caused a fourfold increase in [3H]thymidine incorporation that was diminished by co-incubation with 10 ng/ml or greater VEGF. Tritium 61-63 vascular endothelial growth factor A Rattus norvegicus 150-154 9614352-10 1998 Incubation with TSH (1 mU/ml) caused a fourfold increase in [3H]thymidine incorporation that was diminished by co-incubation with 10 ng/ml or greater VEGF. Thymidine 64-73 vascular endothelial growth factor A Rattus norvegicus 150-154 9614352-11 1998 Similarly, 10 ng/ml or greater VEGF significantly reduced the ability of TSH to increase [125I] uptake. Thyrotropin 73-76 vascular endothelial growth factor A Rattus norvegicus 31-35 9614352-12 1998 The antagonistic effects of VEGF on TSH-stimulated [3H]thymidine incorporation or [125I] uptake were significantly reduced in the presence of an anti-VEGF antiserum. Thyrotropin 36-39 vascular endothelial growth factor A Rattus norvegicus 28-32 9614352-12 1998 The antagonistic effects of VEGF on TSH-stimulated [3H]thymidine incorporation or [125I] uptake were significantly reduced in the presence of an anti-VEGF antiserum. Thyrotropin 36-39 vascular endothelial growth factor A Rattus norvegicus 150-154 9614352-12 1998 The antagonistic effects of VEGF on TSH-stimulated [3H]thymidine incorporation or [125I] uptake were significantly reduced in the presence of an anti-VEGF antiserum. Tritium 52-54 vascular endothelial growth factor A Rattus norvegicus 28-32 9614352-12 1998 The antagonistic effects of VEGF on TSH-stimulated [3H]thymidine incorporation or [125I] uptake were significantly reduced in the presence of an anti-VEGF antiserum. Thymidine 55-64 vascular endothelial growth factor A Rattus norvegicus 28-32 9568844-7 1998 RESULTS: In kidneys preconstricted by noradrenaline (NA 1.5 x 10(-7) mol/l) VEGF/VPF (155 pmol/l) caused an almost complete return of renal perfusion flow rate to pre-NA values (before NA 113 +/- 4%, after NA 100%, 15 min with VEGF/VPF 111 +/- 4%). Norepinephrine 38-51 vascular endothelial growth factor A Rattus norvegicus 76-84 9568844-9 1998 In the presence of the NO-synthase inhibitor N(W)-nitro-L-arginine (L-NNA; 5 x 10(-5) mol/l) VEGF/VPF caused only small, transient relaxations (before NNA 109 +/- 5%, after NNA 100%, 15 min with VEGF 95 +/- 2%). n(w)-nitro-l-arginine 45-66 vascular endothelial growth factor A Rattus norvegicus 93-97 9568844-9 1998 In the presence of the NO-synthase inhibitor N(W)-nitro-L-arginine (L-NNA; 5 x 10(-5) mol/l) VEGF/VPF caused only small, transient relaxations (before NNA 109 +/- 5%, after NNA 100%, 15 min with VEGF 95 +/- 2%). n(w)-nitro-l-arginine 45-66 vascular endothelial growth factor A Rattus norvegicus 98-101 9568844-9 1998 In the presence of the NO-synthase inhibitor N(W)-nitro-L-arginine (L-NNA; 5 x 10(-5) mol/l) VEGF/VPF caused only small, transient relaxations (before NNA 109 +/- 5%, after NNA 100%, 15 min with VEGF 95 +/- 2%). n(w)-nitro-l-arginine 45-66 vascular endothelial growth factor A Rattus norvegicus 195-199 9568844-9 1998 In the presence of the NO-synthase inhibitor N(W)-nitro-L-arginine (L-NNA; 5 x 10(-5) mol/l) VEGF/VPF caused only small, transient relaxations (before NNA 109 +/- 5%, after NNA 100%, 15 min with VEGF 95 +/- 2%). Nitroarginine 68-73 vascular endothelial growth factor A Rattus norvegicus 93-97 9568844-9 1998 In the presence of the NO-synthase inhibitor N(W)-nitro-L-arginine (L-NNA; 5 x 10(-5) mol/l) VEGF/VPF caused only small, transient relaxations (before NNA 109 +/- 5%, after NNA 100%, 15 min with VEGF 95 +/- 2%). Nitroarginine 68-73 vascular endothelial growth factor A Rattus norvegicus 98-101 9568844-9 1998 In the presence of the NO-synthase inhibitor N(W)-nitro-L-arginine (L-NNA; 5 x 10(-5) mol/l) VEGF/VPF caused only small, transient relaxations (before NNA 109 +/- 5%, after NNA 100%, 15 min with VEGF 95 +/- 2%). Nitroarginine 68-73 vascular endothelial growth factor A Rattus norvegicus 195-199 9568844-9 1998 In the presence of the NO-synthase inhibitor N(W)-nitro-L-arginine (L-NNA; 5 x 10(-5) mol/l) VEGF/VPF caused only small, transient relaxations (before NNA 109 +/- 5%, after NNA 100%, 15 min with VEGF 95 +/- 2%). H-Arg(NO2)-OH 70-73 vascular endothelial growth factor A Rattus norvegicus 93-97 9568844-9 1998 In the presence of the NO-synthase inhibitor N(W)-nitro-L-arginine (L-NNA; 5 x 10(-5) mol/l) VEGF/VPF caused only small, transient relaxations (before NNA 109 +/- 5%, after NNA 100%, 15 min with VEGF 95 +/- 2%). H-Arg(NO2)-OH 70-73 vascular endothelial growth factor A Rattus norvegicus 98-101 9501870-5 1998 RESULTS: PGE2 induced VEGF and bFGF mRNA expression in a dose- and time-dependent manner. Dinoprostone 9-13 vascular endothelial growth factor A Rattus norvegicus 22-26 9501870-6 1998 VEGF and bFGF mRNA reached peaks of 2- and 3.5-fold at 10 microM PGE2. Dinoprostone 65-69 vascular endothelial growth factor A Rattus norvegicus 0-4 9501870-8 1998 When treated with 10 microM PGE2, the increases in VEGF and bFGF mRNA reached maximum by 2 hours, then slowly declined toward the control level within 24 hours of PGE2 treatment. Dinoprostone 28-32 vascular endothelial growth factor A Rattus norvegicus 51-55 9501870-8 1998 When treated with 10 microM PGE2, the increases in VEGF and bFGF mRNA reached maximum by 2 hours, then slowly declined toward the control level within 24 hours of PGE2 treatment. Dinoprostone 163-167 vascular endothelial growth factor A Rattus norvegicus 51-55 9501870-9 1998 The inductions of VEGF and bFGF mRNA expression by PGE2 were blocked by the specific PKA inhibitors H-89 (30 microM) or SQ 22536 (500 microM, 1000 microM). Dinoprostone 51-55 vascular endothelial growth factor A Rattus norvegicus 18-22 9501870-9 1998 The inductions of VEGF and bFGF mRNA expression by PGE2 were blocked by the specific PKA inhibitors H-89 (30 microM) or SQ 22536 (500 microM, 1000 microM). N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide 100-104 vascular endothelial growth factor A Rattus norvegicus 18-22 9501870-10 1998 Forskolin (10 microM), a cyclic adenosine monophosphate activator, also stimulated VEGF and bFGF mRNA expression. Colforsin 0-9 vascular endothelial growth factor A Rattus norvegicus 83-87 9501870-11 1998 However, the effects of forskolin and PGE2 on VEGF gene expression were not additive, whereas forskolin enhanced the effect of PGE2 on bFGF mRNA expression. Colforsin 24-33 vascular endothelial growth factor A Rattus norvegicus 46-50 9501870-11 1998 However, the effects of forskolin and PGE2 on VEGF gene expression were not additive, whereas forskolin enhanced the effect of PGE2 on bFGF mRNA expression. Dinoprostone 38-42 vascular endothelial growth factor A Rattus norvegicus 46-50 9501870-14 1998 CONCLUSIONS: These results indicate that PGE2 stimulates VEGF and bFGF mRNA expression in cultured rat Muller cells. Dinoprostone 41-45 vascular endothelial growth factor A Rattus norvegicus 57-61 9501870-16 1998 These findings raise the possibility that endogenous PGE2 stimulates VEGF and bFGF mRNA expression in Muller cells in vivo under conditions in which PGE2 production is increased, such as in injury. Dinoprostone 53-57 vascular endothelial growth factor A Rattus norvegicus 69-73 9501870-0 1998 Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Muller cells. Dinoprostone 0-16 vascular endothelial growth factor A Rattus norvegicus 25-59 9501870-1 1998 PURPOSE: To investigate the induction of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) gene expression by prostaglandin E2 (PGE2) in cultured rat Muller cells and to study the mechanism of the induction. Dinoprostone 144-160 vascular endothelial growth factor A Rattus norvegicus 41-75 9501870-1 1998 PURPOSE: To investigate the induction of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) gene expression by prostaglandin E2 (PGE2) in cultured rat Muller cells and to study the mechanism of the induction. Dinoprostone 144-160 vascular endothelial growth factor A Rattus norvegicus 77-81 9501870-1 1998 PURPOSE: To investigate the induction of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) gene expression by prostaglandin E2 (PGE2) in cultured rat Muller cells and to study the mechanism of the induction. Dinoprostone 162-166 vascular endothelial growth factor A Rattus norvegicus 41-75 9501870-1 1998 PURPOSE: To investigate the induction of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) gene expression by prostaglandin E2 (PGE2) in cultured rat Muller cells and to study the mechanism of the induction. Dinoprostone 162-166 vascular endothelial growth factor A Rattus norvegicus 77-81 9531974-3 1998 VEGF mRNA levels reached a plateau within 2 h after the addition of AII and decreased after 4 h. The induction was superinduced by cycloheximide and blocked by actinomycin D. Dactinomycin 160-173 vascular endothelial growth factor A Rattus norvegicus 0-4 9531974-4 1998 Losartan, an AT1 receptor antagonist, abolished the induction of VEGF mRNA by AII, whereas PD 123319, an AT2 receptor antagonist, had no effect on VEGF mRNA induction. Losartan 0-8 vascular endothelial growth factor A Rattus norvegicus 65-69 9400995-0 1997 Upregulation of the angiogenic factors PlGF, VEGF and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization. Thyrotropin 92-95 vascular endothelial growth factor A Rattus norvegicus 45-49 9473343-0 1998 Regulation of vascular endothelial growth factor expression by cAMP in rat aortic smooth muscle cells. Cyclic AMP 63-67 vascular endothelial growth factor A Rattus norvegicus 14-48 9473343-2 1998 VEGF is regulated by multiple factors such as hypoxia, phorbol esters, and growth factors. Phorbol Esters 55-69 vascular endothelial growth factor A Rattus norvegicus 0-4 9473343-3 1998 However, data concerning the expression of VEGF in the different vascular cell types and its regulation by cAMP are not available. Cyclic AMP 107-111 vascular endothelial growth factor A Rattus norvegicus 43-47 9473343-6 1998 A 4-h treatment with forskolin (10(-5) M) induced a 2-fold stimulation of VEGF mRNA expression in smooth muscle cells and fibroblasts, but, in contrast, did not affect VEGF expression in endothelial cells. Colforsin 21-30 vascular endothelial growth factor A Rattus norvegicus 74-78 9473343-7 1998 In smooth muscle cells, a pharmacologically induced increase in intracellular cAMP levels using iloprost or isoprenaline led to a rise in VEGF mRNA expression comparable to that induced by forskolin. Cyclic AMP 78-82 vascular endothelial growth factor A Rattus norvegicus 138-142 9473343-7 1998 In smooth muscle cells, a pharmacologically induced increase in intracellular cAMP levels using iloprost or isoprenaline led to a rise in VEGF mRNA expression comparable to that induced by forskolin. Iloprost 96-104 vascular endothelial growth factor A Rattus norvegicus 138-142 9473343-7 1998 In smooth muscle cells, a pharmacologically induced increase in intracellular cAMP levels using iloprost or isoprenaline led to a rise in VEGF mRNA expression comparable to that induced by forskolin. Isoproterenol 108-120 vascular endothelial growth factor A Rattus norvegicus 138-142 9473343-8 1998 Adenosine, which increases cAMP levels in smooth muscle cells, also increases VEGF expression. Adenosine 0-9 vascular endothelial growth factor A Rattus norvegicus 78-82 9473343-9 1998 Moreover, the 2.2-fold stimulation of VEGF expression by adenosine was enhanced following a cotreatment with cobalt chloride (a hypoxia miming agent). Adenosine 57-66 vascular endothelial growth factor A Rattus norvegicus 38-42 9473343-9 1998 Moreover, the 2.2-fold stimulation of VEGF expression by adenosine was enhanced following a cotreatment with cobalt chloride (a hypoxia miming agent). cobaltous chloride 109-124 vascular endothelial growth factor A Rattus norvegicus 38-42 9473343-10 1998 The observed additive effect (4.3-fold increase) suggests that these two factors, hypoxia and adenosine, regulate VEGF mRNA expression in smooth muscle cells by independent mechanisms. Adenosine 94-103 vascular endothelial growth factor A Rattus norvegicus 114-118 9777366-0 1998 Evidence for upregulation and redistribution of vascular endothelial growth factor (VEGF) receptors flt-1 and flk-1 in the oxygen-injured rat retina. Oxygen 123-129 vascular endothelial growth factor A Rattus norvegicus 48-82 9777366-0 1998 Evidence for upregulation and redistribution of vascular endothelial growth factor (VEGF) receptors flt-1 and flk-1 in the oxygen-injured rat retina. Oxygen 123-129 vascular endothelial growth factor A Rattus norvegicus 84-88 9777366-10 1998 Comparison of VEGF protein immunolabel with both of the VEGFR immunolabels revealed overlap and strong similarity on day 20 in the oxygen-injured eyes. Oxygen 131-137 vascular endothelial growth factor A Rattus norvegicus 14-18 9409562-8 1997 In isolated perfused rat lungs, PGI2 and PGE2 increases VEGF mRNA abundance whereas Rp-cAMP inhibits the prostaglandin-induced VEGF gene activation. Epoprostenol 32-36 vascular endothelial growth factor A Rattus norvegicus 56-60 9409562-8 1997 In isolated perfused rat lungs, PGI2 and PGE2 increases VEGF mRNA abundance whereas Rp-cAMP inhibits the prostaglandin-induced VEGF gene activation. Dinoprostone 41-45 vascular endothelial growth factor A Rattus norvegicus 56-60 9409562-8 1997 In isolated perfused rat lungs, PGI2 and PGE2 increases VEGF mRNA abundance whereas Rp-cAMP inhibits the prostaglandin-induced VEGF gene activation. Cyclic AMP 87-91 vascular endothelial growth factor A Rattus norvegicus 127-131 9409562-8 1997 In isolated perfused rat lungs, PGI2 and PGE2 increases VEGF mRNA abundance whereas Rp-cAMP inhibits the prostaglandin-induced VEGF gene activation. Prostaglandins 105-118 vascular endothelial growth factor A Rattus norvegicus 127-131 9409562-9 1997 Thus, our data suggest that prostaglandins stimulate VEGF gene expression in monocytic cells and in rat lungs via a cAMP-dependent mechanism. Prostaglandins 28-42 vascular endothelial growth factor A Rattus norvegicus 53-57 9409562-9 1997 Thus, our data suggest that prostaglandins stimulate VEGF gene expression in monocytic cells and in rat lungs via a cAMP-dependent mechanism. Cyclic AMP 116-120 vascular endothelial growth factor A Rattus norvegicus 53-57 9438388-4 1998 A soluble VEGF receptor was constructed by fusing the entire extracellular domain of murine flk-1 to a six-histidine tag at the COOH terminus (ExFlk.6His). CHEMBL4070290 103-106 vascular endothelial growth factor A Rattus norvegicus 10-14 9438388-4 1998 A soluble VEGF receptor was constructed by fusing the entire extracellular domain of murine flk-1 to a six-histidine tag at the COOH terminus (ExFlk.6His). Histidine 107-116 vascular endothelial growth factor A Rattus norvegicus 10-14 9438388-4 1998 A soluble VEGF receptor was constructed by fusing the entire extracellular domain of murine flk-1 to a six-histidine tag at the COOH terminus (ExFlk.6His). Carbonic Acid 128-132 vascular endothelial growth factor A Rattus norvegicus 10-14 9438388-4 1998 A soluble VEGF receptor was constructed by fusing the entire extracellular domain of murine flk-1 to a six-histidine tag at the COOH terminus (ExFlk.6His). 6his 149-153 vascular endothelial growth factor A Rattus norvegicus 10-14 9438388-6 1998 ExFlk.6His bound to endothelial cells only in the presence of VEGF, and cell surface cross-linking yielded a high molecular weight complex consistent with the VEGF-mediated formation of a heterodimer between ExFlk.6His and the endogenous VEGF receptor. 6his 6-10 vascular endothelial growth factor A Rattus norvegicus 62-66 9438388-6 1998 ExFlk.6His bound to endothelial cells only in the presence of VEGF, and cell surface cross-linking yielded a high molecular weight complex consistent with the VEGF-mediated formation of a heterodimer between ExFlk.6His and the endogenous VEGF receptor. 6his 6-10 vascular endothelial growth factor A Rattus norvegicus 159-163 9438388-6 1998 ExFlk.6His bound to endothelial cells only in the presence of VEGF, and cell surface cross-linking yielded a high molecular weight complex consistent with the VEGF-mediated formation of a heterodimer between ExFlk.6His and the endogenous VEGF receptor. 6his 6-10 vascular endothelial growth factor A Rattus norvegicus 159-163 9438388-6 1998 ExFlk.6His bound to endothelial cells only in the presence of VEGF, and cell surface cross-linking yielded a high molecular weight complex consistent with the VEGF-mediated formation of a heterodimer between ExFlk.6His and the endogenous VEGF receptor. 6his 214-218 vascular endothelial growth factor A Rattus norvegicus 159-163 9438388-6 1998 ExFlk.6His bound to endothelial cells only in the presence of VEGF, and cell surface cross-linking yielded a high molecular weight complex consistent with the VEGF-mediated formation of a heterodimer between ExFlk.6His and the endogenous VEGF receptor. 6his 214-218 vascular endothelial growth factor A Rattus norvegicus 159-163 9438388-9 1998 These results demonstrate the potential of ExFlk.6His to inhibit VEGF action by a potent "dominant-negative" mechanism and suggest that targeting VEGF action using a soluble receptor may be an effective antiangiogenic therapy for cancer and other "angiogenic" diseases. 6his 49-53 vascular endothelial growth factor A Rattus norvegicus 65-69 9438388-9 1998 These results demonstrate the potential of ExFlk.6His to inhibit VEGF action by a potent "dominant-negative" mechanism and suggest that targeting VEGF action using a soluble receptor may be an effective antiangiogenic therapy for cancer and other "angiogenic" diseases. 6his 49-53 vascular endothelial growth factor A Rattus norvegicus 146-150 9461033-0 1997 Triphenylethylene antiestrogens induce uterine vascular endothelial growth factor expression via their partial estrogen agonist activity. triphenylethylene 0-17 vascular endothelial growth factor A Rattus norvegicus 47-81 9461033-1 1997 Estradiol induces vascular endothelial growth factor (VEGF) expression in the rat uterus and this may contribute to the hyperemia and increased vascularity produced by estrogens in this target tissue. Estradiol 0-9 vascular endothelial growth factor A Rattus norvegicus 18-52 9461033-1 1997 Estradiol induces vascular endothelial growth factor (VEGF) expression in the rat uterus and this may contribute to the hyperemia and increased vascularity produced by estrogens in this target tissue. Estradiol 0-9 vascular endothelial growth factor A Rattus norvegicus 54-58 9461033-7 1997 All four compounds increase uterine VEGF and c-fos mRNA levels indicating that the triphenylethylene class of antiestrogens are predominantly agonists for the induction of these genes in the uterus. triphenylethylene 83-100 vascular endothelial growth factor A Rattus norvegicus 36-40 9400995-0 1997 Upregulation of the angiogenic factors PlGF, VEGF and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization. Thiouracil 147-157 vascular endothelial growth factor A Rattus norvegicus 45-49 9400995-4 1997 In vivo studies demonstrated that in the thyroid gland of thiouracil-fed rats, increased mRNA and protein expression of PIGF, VEGF, Flt-1 and Flk-1/KDR occurred subsequent to the rise in the serum thyroid stimulating hormone (TSH) levels and in parallel with thyroid capillary proliferation. Thiouracil 58-68 vascular endothelial growth factor A Rattus norvegicus 126-130 9258227-0 1997 An aldose reductase inhibitor and aminoguanidine prevent vascular endothelial growth factor expression in rats with long-term galactosemia. pimagedine 34-48 vascular endothelial growth factor A Rattus norvegicus 57-91 9359850-4 1997 The cold-induced increase in VEGF mRNA was abolished by surgical sympathetic denervation, but mimicked by administration of noradrenaline or a beta3-adrenoceptor agonist CL316,243, indicating the critical role of the beta-adrenergic pathway in VEGF expression in BAT. Norepinephrine 124-137 vascular endothelial growth factor A Rattus norvegicus 29-33 9359850-4 1997 The cold-induced increase in VEGF mRNA was abolished by surgical sympathetic denervation, but mimicked by administration of noradrenaline or a beta3-adrenoceptor agonist CL316,243, indicating the critical role of the beta-adrenergic pathway in VEGF expression in BAT. cl316 170-175 vascular endothelial growth factor A Rattus norvegicus 29-33 9359850-5 1997 Among three isoforms of VEGF, the mRNA of a short form (VEGF120) lacking heparin-binding activity was preferentially increased after cold exposure and treatment with the adrenergic agonists. Heparin 73-80 vascular endothelial growth factor A Rattus norvegicus 24-28 9463639-10 1997 Nitric oxide synthesis inhibitor prevented, in a reversible fashion, the effect of VEGF. Nitric Oxide 0-12 vascular endothelial growth factor A Rattus norvegicus 83-87 9360099-0 1997 Vascular endothelial growth factor enhances vascularization in microporous small caliber polyurethane grafts. Polyurethanes 89-101 vascular endothelial growth factor A Rattus norvegicus 0-34 9415300-7 1997 At the microvascular level (diameter < 100 microns), however, papaverine induced significant vasodilation in the VEGF-treated animals, and almost no vasodilation in the controls. Papaverine 65-75 vascular endothelial growth factor A Rattus norvegicus 116-120 9277513-5 1997 VEGF mRNA levels increased 60% in MP and 80% in LP above those in NP (P < 0.05) in uterine tissues; VEGF mRNA levels were also detectable in placentas and elevated approximately fivefold in LP vs. MP tissues (P < 0.01). leucylproline 48-50 vascular endothelial growth factor A Rattus norvegicus 0-4 9277513-5 1997 VEGF mRNA levels increased 60% in MP and 80% in LP above those in NP (P < 0.05) in uterine tissues; VEGF mRNA levels were also detectable in placentas and elevated approximately fivefold in LP vs. MP tissues (P < 0.01). leucylproline 193-195 vascular endothelial growth factor A Rattus norvegicus 0-4 9277513-5 1997 VEGF mRNA levels increased 60% in MP and 80% in LP above those in NP (P < 0.05) in uterine tissues; VEGF mRNA levels were also detectable in placentas and elevated approximately fivefold in LP vs. MP tissues (P < 0.01). leucylproline 193-195 vascular endothelial growth factor A Rattus norvegicus 103-107 9378108-5 1997 VEGF up-regulation was also observed in ROS-17/2.8 and OHS-4 osteoblast-like cells but not in MCF-7 and MDA-MB231 breast carcinoma cells. ros 40-43 vascular endothelial growth factor A Rattus norvegicus 0-4 9378108-5 1997 VEGF up-regulation was also observed in ROS-17/2.8 and OHS-4 osteoblast-like cells but not in MCF-7 and MDA-MB231 breast carcinoma cells. hydroxide ion 55-58 vascular endothelial growth factor A Rattus norvegicus 0-4 9151791-0 1997 Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor. Glucose 41-48 vascular endothelial growth factor A Rattus norvegicus 79-113 9202052-7 1997 Staurosporine, a protein kinase C inhibitor, also blocked stretch-induced increase of VEGF expression. Staurosporine 0-13 vascular endothelial growth factor A Rattus norvegicus 86-90 9151791-1 1997 The purpose of these experiments was to investigate a potential role for vascular endothelial growth factor (VEGF) in mediating vascular dysfunction induced by increased glucose flux via the sorbitol pathway. Glucose 170-177 vascular endothelial growth factor A Rattus norvegicus 73-107 9151791-1 1997 The purpose of these experiments was to investigate a potential role for vascular endothelial growth factor (VEGF) in mediating vascular dysfunction induced by increased glucose flux via the sorbitol pathway. Glucose 170-177 vascular endothelial growth factor A Rattus norvegicus 109-113 9151791-1 1997 The purpose of these experiments was to investigate a potential role for vascular endothelial growth factor (VEGF) in mediating vascular dysfunction induced by increased glucose flux via the sorbitol pathway. Sorbitol 191-199 vascular endothelial growth factor A Rattus norvegicus 73-107 9151791-1 1997 The purpose of these experiments was to investigate a potential role for vascular endothelial growth factor (VEGF) in mediating vascular dysfunction induced by increased glucose flux via the sorbitol pathway. Sorbitol 191-199 vascular endothelial growth factor A Rattus norvegicus 109-113 9151791-3 1997 Albumin permeation and blood flow were increased two- to three-fold by 30 mM glucose and 1 mM sorbitol; these increases were prevented by coadministration of neutralizing VEGF antibodies. Glucose 77-84 vascular endothelial growth factor A Rattus norvegicus 171-175 9151791-3 1997 Albumin permeation and blood flow were increased two- to three-fold by 30 mM glucose and 1 mM sorbitol; these increases were prevented by coadministration of neutralizing VEGF antibodies. Sorbitol 94-102 vascular endothelial growth factor A Rattus norvegicus 171-175 9151791-5 1997 Topical application of a superoxide generating system increased albumin permeation and blood flow and these changes were markedly attenuated by VEGF antibody and NOS inhibitors. Superoxides 25-35 vascular endothelial growth factor A Rattus norvegicus 144-148 9151791-6 1997 Application of sodium nitroprusside for 7 d or the single application of a calcium ionophore, A23187, mimicked effects of glucose, sorbitol, and VEGF on vascular dysfunction and the ionophore effect was prevented by coadministration of aminoguanidine. Nitroprusside 15-35 vascular endothelial growth factor A Rattus norvegicus 145-149 9151791-6 1997 Application of sodium nitroprusside for 7 d or the single application of a calcium ionophore, A23187, mimicked effects of glucose, sorbitol, and VEGF on vascular dysfunction and the ionophore effect was prevented by coadministration of aminoguanidine. Calcium 75-82 vascular endothelial growth factor A Rattus norvegicus 145-149 9151791-6 1997 Application of sodium nitroprusside for 7 d or the single application of a calcium ionophore, A23187, mimicked effects of glucose, sorbitol, and VEGF on vascular dysfunction and the ionophore effect was prevented by coadministration of aminoguanidine. Calcimycin 94-100 vascular endothelial growth factor A Rattus norvegicus 145-149 9151791-6 1997 Application of sodium nitroprusside for 7 d or the single application of a calcium ionophore, A23187, mimicked effects of glucose, sorbitol, and VEGF on vascular dysfunction and the ionophore effect was prevented by coadministration of aminoguanidine. pimagedine 236-250 vascular endothelial growth factor A Rattus norvegicus 145-149 9151791-7 1997 These observations suggest a potentially important role for VEGF in mediating vascular dysfunction induced by "hypoxia-like" cytosolic metabolic imbalances (reductive stress, increased superoxide, and nitric oxide production) linked to increased flux of glucose via the sorbitol pathway. Superoxides 185-195 vascular endothelial growth factor A Rattus norvegicus 60-64 9151791-7 1997 These observations suggest a potentially important role for VEGF in mediating vascular dysfunction induced by "hypoxia-like" cytosolic metabolic imbalances (reductive stress, increased superoxide, and nitric oxide production) linked to increased flux of glucose via the sorbitol pathway. Nitric Oxide 201-213 vascular endothelial growth factor A Rattus norvegicus 60-64 9151791-7 1997 These observations suggest a potentially important role for VEGF in mediating vascular dysfunction induced by "hypoxia-like" cytosolic metabolic imbalances (reductive stress, increased superoxide, and nitric oxide production) linked to increased flux of glucose via the sorbitol pathway. Glucose 254-261 vascular endothelial growth factor A Rattus norvegicus 60-64 9151791-7 1997 These observations suggest a potentially important role for VEGF in mediating vascular dysfunction induced by "hypoxia-like" cytosolic metabolic imbalances (reductive stress, increased superoxide, and nitric oxide production) linked to increased flux of glucose via the sorbitol pathway. Sorbitol 270-278 vascular endothelial growth factor A Rattus norvegicus 60-64 9118206-0 1997 VEGF and bFGF mRNA are expressed in ethylnitrosourea-induced experimental rat gliomas. Ethylnitrosourea 36-52 vascular endothelial growth factor A Rattus norvegicus 0-4 9126290-7 1997 VEGF mRNA levels were 10-fold higher in 3% O2-treated explants than in 20% O2-treated explants. Oxygen 43-45 vascular endothelial growth factor A Rattus norvegicus 0-4 9126290-7 1997 VEGF mRNA levels were 10-fold higher in 3% O2-treated explants than in 20% O2-treated explants. Oxygen 75-77 vascular endothelial growth factor A Rattus norvegicus 0-4 9126290-8 1997 Addition of anti-VEGF antibodies to 3% O2-treated explants prevented low oxygen-induced growth and endothelial cell differentiation and proliferation. Oxygen 39-41 vascular endothelial growth factor A Rattus norvegicus 17-21 9126290-8 1997 Addition of anti-VEGF antibodies to 3% O2-treated explants prevented low oxygen-induced growth and endothelial cell differentiation and proliferation. Oxygen 73-79 vascular endothelial growth factor A Rattus norvegicus 17-21 9126290-10 1997 Upregulation of VEGF expression by low oxygen and prevention of low oxygen-induced tubulogenesis and vasculogenesis by anti-VEGF antibodies indicate that these changes were mediated by VEGF. Oxygen 39-45 vascular endothelial growth factor A Rattus norvegicus 16-20 9126290-10 1997 Upregulation of VEGF expression by low oxygen and prevention of low oxygen-induced tubulogenesis and vasculogenesis by anti-VEGF antibodies indicate that these changes were mediated by VEGF. Oxygen 68-74 vascular endothelial growth factor A Rattus norvegicus 124-128 9126290-10 1997 Upregulation of VEGF expression by low oxygen and prevention of low oxygen-induced tubulogenesis and vasculogenesis by anti-VEGF antibodies indicate that these changes were mediated by VEGF. Oxygen 68-74 vascular endothelial growth factor A Rattus norvegicus 124-128 9073561-9 1997 Additional studies with the transcription inhibitor actinomycin-D furthermore demonstrated that the VEGF gene was continuously transcribed in the rat omental adipocytes. Dactinomycin 52-65 vascular endothelial growth factor A Rattus norvegicus 100-104 9027719-1 1997 There is accumulating evidence from in vitro studies suggesting that the genes of endothelin-1, PDGF, and VEGF are, like the erythropoietin gene, regulated by oxygen tension and by divalent cations. Oxygen 159-165 vascular endothelial growth factor A Rattus norvegicus 106-110 9027719-4 1997 Carbon monoxide (0.1%) treatment for six hours stimulated renal erythropoietin gene expression 140-fold; however, endothelin-1, endothelin-3, PDGF-A, PDGF-B, and VEGF gene expression was not affected. Carbon Monoxide 0-15 vascular endothelial growth factor A Rattus norvegicus 162-166 9027720-1 1997 This study examined the expression of EPO, VEGF and VEGF receptor gene under conditions of reduced oxygen supply in primary cultures of rat hepatocytes, and compared it with the expression of these genes in hypoxic rat livers in vivo. Oxygen 99-105 vascular endothelial growth factor A Rattus norvegicus 52-56 9073561-10 1997 Incubation of the omental adipocytes under hypoxic conditions induced approximately a 1.7-fold increase in VEGF protein expression, which was abolished by actinomycin-D. Dactinomycin 155-168 vascular endothelial growth factor A Rattus norvegicus 107-111 8906225-2 1996 The gene encoding VEGF is abundantly present in lung tissue and is induced by short-term and long-term hypoxia, as well as by prostacyclin, prostaglandin E2, and cyclic AMP. Epoprostenol 126-138 vascular endothelial growth factor A Rattus norvegicus 18-22 9042159-5 1997 VEGF supplementation to a serum-free culture medium increased the 5-bromo-2"-deoxyuridine-pulse labeling index of ductal cells more than 2-fold. Bromodeoxyuridine 66-89 vascular endothelial growth factor A Rattus norvegicus 0-4 9386988-0 1997 Detection of vascular endothelial growth factor (VEGF) protein in vascular and non-vascular cells of the normal and oxygen-injured rat retina. Oxygen 116-122 vascular endothelial growth factor A Rattus norvegicus 13-47 9386988-0 1997 Detection of vascular endothelial growth factor (VEGF) protein in vascular and non-vascular cells of the normal and oxygen-injured rat retina. Oxygen 116-122 vascular endothelial growth factor A Rattus norvegicus 49-53 9386988-9 1997 There was also a pan-retinal distribution of non-endothelial cells that were VEGF-positive in both room air and oxygen-injured rats, with stronger immunostaining in day 16 oxygen-injured retinas. Oxygen 112-118 vascular endothelial growth factor A Rattus norvegicus 77-81 9386988-13 1997 The production of VEGF by these cells--in particular, Muller cells--may promote preretinal neovascularization in oxygen-injured eyes. Oxygen 113-119 vascular endothelial growth factor A Rattus norvegicus 18-22 9046048-4 1997 We found increased VEGF immunoreactivity in ganglion cells of rats with oxygen-induced ischemic retinopathy and in ganglion cells, the inner plexiform layer, and some cells in the inner nuclear layer of rats with experimental autoimmune uveoretinitis (EAU), in which there was no identifiable ischemia or NV. Oxygen 72-78 vascular endothelial growth factor A Rattus norvegicus 19-23 8906225-2 1996 The gene encoding VEGF is abundantly present in lung tissue and is induced by short-term and long-term hypoxia, as well as by prostacyclin, prostaglandin E2, and cyclic AMP. Dinoprostone 140-156 vascular endothelial growth factor A Rattus norvegicus 18-22 8906225-2 1996 The gene encoding VEGF is abundantly present in lung tissue and is induced by short-term and long-term hypoxia, as well as by prostacyclin, prostaglandin E2, and cyclic AMP. Cyclic AMP 162-172 vascular endothelial growth factor A Rattus norvegicus 18-22 8766002-1 1996 This study sought to investigate whether a common protein kinase activity is involved in the sequence of events by which oxygen controls the expression of the genes for erythropoietin (EPO) and for vascular endothelial growth factor (VEGF) in rat hepatocytes. Oxygen 121-127 vascular endothelial growth factor A Rattus norvegicus 198-232 8859080-5 1996 RESULTS: The inner nuclear layer of oxygen-exposed retinas exhibited a continuous intense band of VPF/VEGF messenger RNA expression across the peripheral avascular zone that dropped sharply in vascular retina. Oxygen 36-42 vascular endothelial growth factor A Rattus norvegicus 98-101 8859080-5 1996 RESULTS: The inner nuclear layer of oxygen-exposed retinas exhibited a continuous intense band of VPF/VEGF messenger RNA expression across the peripheral avascular zone that dropped sharply in vascular retina. Oxygen 36-42 vascular endothelial growth factor A Rattus norvegicus 102-106 8823305-4 1996 Our goals were to determine if suppression of permeability by dexamethasone might involve inhibition of VPF action or expression, and if dexamethasone effects in this setting are mediated by the glucocorticoid receptor (GR). Dexamethasone 62-75 vascular endothelial growth factor A Rattus norvegicus 104-107 8823305-6 1996 Since 80% of the permeability-inducing activity in 9L-conditioned medium was removed by anti-VPF antibodies, we examined dexamethasone effects of VPF expression in 9L cells. Dexamethasone 121-134 vascular endothelial growth factor A Rattus norvegicus 146-149 8823305-7 1996 Dexamethasone inhibited FCS- and PDGF-dependent induction of VPF expression. Dexamethasone 0-13 vascular endothelial growth factor A Rattus norvegicus 61-64 8823305-9 1996 Dexamethasone may decrease brain tumor-associated vascular permeability by two GR-dependent mechanisms: reduction of the response of the vasculature to tumor-derived permeability factors (including VPF), and reduction of VPF expression by tumor cells. Dexamethasone 0-13 vascular endothelial growth factor A Rattus norvegicus 198-201 8823305-9 1996 Dexamethasone may decrease brain tumor-associated vascular permeability by two GR-dependent mechanisms: reduction of the response of the vasculature to tumor-derived permeability factors (including VPF), and reduction of VPF expression by tumor cells. Dexamethasone 0-13 vascular endothelial growth factor A Rattus norvegicus 221-224 8752163-0 1996 Uterine expression of vascular endothelial growth factor is increased by estradiol and tamoxifen. Estradiol 73-82 vascular endothelial growth factor A Rattus norvegicus 22-56 8752163-0 1996 Uterine expression of vascular endothelial growth factor is increased by estradiol and tamoxifen. Tamoxifen 87-96 vascular endothelial growth factor A Rattus norvegicus 22-56 8752163-2 1996 Because vascular growth accompanies normal endometrial regeneration and may also be involved in uterine tumor growth, we studied VEGF regulation by 17 beta-estradiol (E2) and tamoxifen, two agents that can increase uterine cell proliferation and tumor incidence. Estradiol 148-165 vascular endothelial growth factor A Rattus norvegicus 129-133 8752163-2 1996 Because vascular growth accompanies normal endometrial regeneration and may also be involved in uterine tumor growth, we studied VEGF regulation by 17 beta-estradiol (E2) and tamoxifen, two agents that can increase uterine cell proliferation and tumor incidence. Tamoxifen 175-184 vascular endothelial growth factor A Rattus norvegicus 129-133 8752163-4 1996 E2-dependent VEGF induction is inhibited by actinomycin D but not puromycin, suggesting that the effect is due at least in part to direct estrogen receptor regulation of VEGF transcription. Dactinomycin 44-57 vascular endothelial growth factor A Rattus norvegicus 13-17 8752163-4 1996 E2-dependent VEGF induction is inhibited by actinomycin D but not puromycin, suggesting that the effect is due at least in part to direct estrogen receptor regulation of VEGF transcription. Dactinomycin 44-57 vascular endothelial growth factor A Rattus norvegicus 170-174 8752163-7 1996 The antiestrogens tamoxifen, 4-OH tamoxifen, and nafoxidine produce similar increases in uterine VEGF mRNA levels within 6 h, with 1 mg/kg tamoxifen producing a maximum response of 15-20-fold. Tamoxifen 18-27 vascular endothelial growth factor A Rattus norvegicus 97-101 8752163-7 1996 The antiestrogens tamoxifen, 4-OH tamoxifen, and nafoxidine produce similar increases in uterine VEGF mRNA levels within 6 h, with 1 mg/kg tamoxifen producing a maximum response of 15-20-fold. hydroxytamoxifen 29-43 vascular endothelial growth factor A Rattus norvegicus 97-101 8752163-7 1996 The antiestrogens tamoxifen, 4-OH tamoxifen, and nafoxidine produce similar increases in uterine VEGF mRNA levels within 6 h, with 1 mg/kg tamoxifen producing a maximum response of 15-20-fold. Nafoxidine 49-59 vascular endothelial growth factor A Rattus norvegicus 97-101 8752163-7 1996 The antiestrogens tamoxifen, 4-OH tamoxifen, and nafoxidine produce similar increases in uterine VEGF mRNA levels within 6 h, with 1 mg/kg tamoxifen producing a maximum response of 15-20-fold. Tamoxifen 34-43 vascular endothelial growth factor A Rattus norvegicus 97-101 8752163-8 1996 The tamoxifen response was also inhibited by actinomycin D but not by puromycin, again suggesting direct transcriptional regulation of VEGF expression by antiestrogens. Tamoxifen 4-13 vascular endothelial growth factor A Rattus norvegicus 135-139 8752163-8 1996 The tamoxifen response was also inhibited by actinomycin D but not by puromycin, again suggesting direct transcriptional regulation of VEGF expression by antiestrogens. Dactinomycin 45-58 vascular endothelial growth factor A Rattus norvegicus 135-139 8766002-1 1996 This study sought to investigate whether a common protein kinase activity is involved in the sequence of events by which oxygen controls the expression of the genes for erythropoietin (EPO) and for vascular endothelial growth factor (VEGF) in rat hepatocytes. Oxygen 121-127 vascular endothelial growth factor A Rattus norvegicus 234-238 8766002-4 1996 Staurosporine did not change EPO and VEGF mRNA levels at 20% O2, but in a concentration-dependent manner, decreased EPO and VEGF mRNA at 1% O2 with IC50 values of 30 nM and 1000 nM, respectively. Staurosporine 0-13 vascular endothelial growth factor A Rattus norvegicus 124-128 8605975-2 1996 This paper compares mRNA levels of two putative hypoxia, heavy metal and heat shock sensitive genes: heme oxygenase-1 (HO-1) and vascular endothelial growth factor (VEGF) in myocyte-enriched cultures of neonatal rat heart cells. Metals 63-68 vascular endothelial growth factor A Rattus norvegicus 165-169 9112668-7 1996 In normal rat retinas astrocytes located just beneath the inner limiting membrane revealed immunohistochemically the weak expression of VEGF, while in diabetic retinas six months after the streptozotocin treatment, the enhanced expression of VEGF mRNA and protein mainly by glial cells such as Muller cells and astrocytes, was confirmed by immunohistochemistry and in situ hybridization. Streptozocin 189-203 vascular endothelial growth factor A Rattus norvegicus 242-246 8761851-6 1996 VEGF (250 micrograms/kg) significantly decreased cardiac output and stroke volume without affecting the inotropic state of the left ventricle, as determined by dP/dt. dp 160-162 vascular endothelial growth factor A Rattus norvegicus 0-4 8761851-6 1996 VEGF (250 micrograms/kg) significantly decreased cardiac output and stroke volume without affecting the inotropic state of the left ventricle, as determined by dP/dt. Thymidine 163-165 vascular endothelial growth factor A Rattus norvegicus 0-4 8761851-10 1996 In addition, pretreatment with N omega-nitro-L-arginine methyl-ester (L-NAME), a nitric oxide (NO) synthase inhibitor, significantly attenuated the depressor and tachycardic responses to VEGF, suggesting that VEGF-induced hypotension may be mediated by NO. NG-Nitroarginine Methyl Ester 31-68 vascular endothelial growth factor A Rattus norvegicus 187-191 8761851-10 1996 In addition, pretreatment with N omega-nitro-L-arginine methyl-ester (L-NAME), a nitric oxide (NO) synthase inhibitor, significantly attenuated the depressor and tachycardic responses to VEGF, suggesting that VEGF-induced hypotension may be mediated by NO. NG-Nitroarginine Methyl Ester 31-68 vascular endothelial growth factor A Rattus norvegicus 209-213 8761851-10 1996 In addition, pretreatment with N omega-nitro-L-arginine methyl-ester (L-NAME), a nitric oxide (NO) synthase inhibitor, significantly attenuated the depressor and tachycardic responses to VEGF, suggesting that VEGF-induced hypotension may be mediated by NO. NG-Nitroarginine Methyl Ester 70-76 vascular endothelial growth factor A Rattus norvegicus 187-191 8761851-10 1996 In addition, pretreatment with N omega-nitro-L-arginine methyl-ester (L-NAME), a nitric oxide (NO) synthase inhibitor, significantly attenuated the depressor and tachycardic responses to VEGF, suggesting that VEGF-induced hypotension may be mediated by NO. NG-Nitroarginine Methyl Ester 70-76 vascular endothelial growth factor A Rattus norvegicus 209-213 8928889-4 1996 After an acute myocardial infarction, we observed an initial rapid (1h) rise in VEGF (275%), flk-1 (375%), and flt-1 (400%) mRNA expression throughout the entire heart. Hydrogen 68-70 vascular endothelial growth factor A Rattus norvegicus 80-84 8606491-1 1996 In the retinas of streptozotocin-induced diabetic rats, the relationship between the expression of vascular endothelial growth factor (VEGF) and the breakdown of the blood-retinal barrier (BRB) was investigated. Streptozocin 18-32 vascular endothelial growth factor A Rattus norvegicus 99-133 8606491-1 1996 In the retinas of streptozotocin-induced diabetic rats, the relationship between the expression of vascular endothelial growth factor (VEGF) and the breakdown of the blood-retinal barrier (BRB) was investigated. Streptozocin 18-32 vascular endothelial growth factor A Rattus norvegicus 135-139 8927508-1 1996 There is accumulating evidence from in vitro experiments that the gene expression of the vascular endothelial growth factor (VEGF) is, like that of the erythropoietin (EPO) gene, regulated by the oxygen tension and by divalent cations such as cobalt. Oxygen 196-202 vascular endothelial growth factor A Rattus norvegicus 89-123 8927508-1 1996 There is accumulating evidence from in vitro experiments that the gene expression of the vascular endothelial growth factor (VEGF) is, like that of the erythropoietin (EPO) gene, regulated by the oxygen tension and by divalent cations such as cobalt. Oxygen 196-202 vascular endothelial growth factor A Rattus norvegicus 125-129 8927508-1 1996 There is accumulating evidence from in vitro experiments that the gene expression of the vascular endothelial growth factor (VEGF) is, like that of the erythropoietin (EPO) gene, regulated by the oxygen tension and by divalent cations such as cobalt. Cobalt 243-249 vascular endothelial growth factor A Rattus norvegicus 89-123 8927508-1 1996 There is accumulating evidence from in vitro experiments that the gene expression of the vascular endothelial growth factor (VEGF) is, like that of the erythropoietin (EPO) gene, regulated by the oxygen tension and by divalent cations such as cobalt. Cobalt 243-249 vascular endothelial growth factor A Rattus norvegicus 125-129 8605975-5 1996 Conversely, VEGF mRNA expression is stimulated by short as well as long periods of anoxia, by Cd2+, Co2+, Ni2+ and Mn2+ but not by hemin or heat shocks. Cobalt(2+) 100-104 vascular endothelial growth factor A Rattus norvegicus 12-16 8605975-5 1996 Conversely, VEGF mRNA expression is stimulated by short as well as long periods of anoxia, by Cd2+, Co2+, Ni2+ and Mn2+ but not by hemin or heat shocks. Nickel(2+) 106-110 vascular endothelial growth factor A Rattus norvegicus 12-16 8605975-5 1996 Conversely, VEGF mRNA expression is stimulated by short as well as long periods of anoxia, by Cd2+, Co2+, Ni2+ and Mn2+ but not by hemin or heat shocks. Manganese(2+) 115-119 vascular endothelial growth factor A Rattus norvegicus 12-16 8605975-5 1996 Conversely, VEGF mRNA expression is stimulated by short as well as long periods of anoxia, by Cd2+, Co2+, Ni2+ and Mn2+ but not by hemin or heat shocks. Hemin 131-136 vascular endothelial growth factor A Rattus norvegicus 12-16 7497521-0 1995 Suppression of collagen-induced arthritis by an angiogenesis inhibitor, AGM-1470, in combination with cyclosporin: reduction of vascular endothelial growth factor (VEGF). O-(Chloroacetylcarbamoyl)fumagillol 72-80 vascular endothelial growth factor A Rattus norvegicus 128-162 7497521-0 1995 Suppression of collagen-induced arthritis by an angiogenesis inhibitor, AGM-1470, in combination with cyclosporin: reduction of vascular endothelial growth factor (VEGF). O-(Chloroacetylcarbamoyl)fumagillol 72-80 vascular endothelial growth factor A Rattus norvegicus 164-168 7497521-0 1995 Suppression of collagen-induced arthritis by an angiogenesis inhibitor, AGM-1470, in combination with cyclosporin: reduction of vascular endothelial growth factor (VEGF). Cyclosporine 102-113 vascular endothelial growth factor A Rattus norvegicus 128-162 7497521-13 1995 TNF-alpha levels remained elevated, even in treated rats, while vascular endothelial growth factor levels were reduced in rats receiving AGM-1470 compared to both arthritic controls and naive rats. O-(Chloroacetylcarbamoyl)fumagillol 137-145 vascular endothelial growth factor A Rattus norvegicus 64-98 7489357-3 1995 We show that regression of retinal capillaries in neonatal rats exposed to high oxygen, is preceded by a shut-off of vascular endothelial growth factor (VEGF) production by nearby neuroglial cells. Oxygen 80-86 vascular endothelial growth factor A Rattus norvegicus 117-151 7553632-7 1995 Furthermore, pharmacological disruption of mutant RAS protein function in H-ras transformed rat intestinal epithelial cells by treatment with L-739,749 (a protein farnesyltransferase inhibitor) caused a significant suppression of VEGF/VPF. l-739 142-147 vascular endothelial growth factor A Rattus norvegicus 230-234 7553632-7 1995 Furthermore, pharmacological disruption of mutant RAS protein function in H-ras transformed rat intestinal epithelial cells by treatment with L-739,749 (a protein farnesyltransferase inhibitor) caused a significant suppression of VEGF/VPF. l-739 142-147 vascular endothelial growth factor A Rattus norvegicus 235-238 7489357-3 1995 We show that regression of retinal capillaries in neonatal rats exposed to high oxygen, is preceded by a shut-off of vascular endothelial growth factor (VEGF) production by nearby neuroglial cells. Oxygen 80-86 vascular endothelial growth factor A Rattus norvegicus 153-157 7623107-11 1995 Hypoxic regulation of VEGF expression in the intact developing retina was demonstrated by showing that oxygen-enriched atmospheres that inhibit vessel formation also suppress endogenous VEGF production. Oxygen 103-109 vascular endothelial growth factor A Rattus norvegicus 22-26 7623107-11 1995 Hypoxic regulation of VEGF expression in the intact developing retina was demonstrated by showing that oxygen-enriched atmospheres that inhibit vessel formation also suppress endogenous VEGF production. Oxygen 103-109 vascular endothelial growth factor A Rattus norvegicus 186-190 7977826-5 1994 These results suggest that induction of VEGF mRNA is upregulated by oxygen deprivation in the heart and that not only infarction but also chronic ischemia in the clinical setting could induce VEGF as a potent angiogenesis factor to stimulate coronary collateral formation. Oxygen 68-74 vascular endothelial growth factor A Rattus norvegicus 40-44 7558244-4 1995 Under standard in vitro conditions (21% O2) VEGF expression in astrocytes in barely detectable by northern analysis. Oxygen 40-42 vascular endothelial growth factor A Rattus norvegicus 44-48 7558244-5 1995 However, after exposure to 0.2% O2 for as little as 3 h VEGF mRNA levels are markedly increased reaching a maximum by approximately 8 h of exposure. Oxygen 32-34 vascular endothelial growth factor A Rattus norvegicus 56-60 7558244-6 1995 Treatment of astrocytes with CoCl2 or desferrioxamine results in a similar induction of VEGF, suggesting that the oxygen sensor regulating VEGF expression in astrocytes is a heme-containing molecule. cobaltous chloride 29-34 vascular endothelial growth factor A Rattus norvegicus 88-92 7558244-6 1995 Treatment of astrocytes with CoCl2 or desferrioxamine results in a similar induction of VEGF, suggesting that the oxygen sensor regulating VEGF expression in astrocytes is a heme-containing molecule. cobaltous chloride 29-34 vascular endothelial growth factor A Rattus norvegicus 139-143 7558244-6 1995 Treatment of astrocytes with CoCl2 or desferrioxamine results in a similar induction of VEGF, suggesting that the oxygen sensor regulating VEGF expression in astrocytes is a heme-containing molecule. Deferoxamine 38-53 vascular endothelial growth factor A Rattus norvegicus 88-92 7558244-6 1995 Treatment of astrocytes with CoCl2 or desferrioxamine results in a similar induction of VEGF, suggesting that the oxygen sensor regulating VEGF expression in astrocytes is a heme-containing molecule. Deferoxamine 38-53 vascular endothelial growth factor A Rattus norvegicus 139-143 7558244-6 1995 Treatment of astrocytes with CoCl2 or desferrioxamine results in a similar induction of VEGF, suggesting that the oxygen sensor regulating VEGF expression in astrocytes is a heme-containing molecule. Oxygen 114-120 vascular endothelial growth factor A Rattus norvegicus 88-92 7558244-6 1995 Treatment of astrocytes with CoCl2 or desferrioxamine results in a similar induction of VEGF, suggesting that the oxygen sensor regulating VEGF expression in astrocytes is a heme-containing molecule. Oxygen 114-120 vascular endothelial growth factor A Rattus norvegicus 139-143 7558244-6 1995 Treatment of astrocytes with CoCl2 or desferrioxamine results in a similar induction of VEGF, suggesting that the oxygen sensor regulating VEGF expression in astrocytes is a heme-containing molecule. Heme 174-178 vascular endothelial growth factor A Rattus norvegicus 88-92 7558244-6 1995 Treatment of astrocytes with CoCl2 or desferrioxamine results in a similar induction of VEGF, suggesting that the oxygen sensor regulating VEGF expression in astrocytes is a heme-containing molecule. Heme 174-178 vascular endothelial growth factor A Rattus norvegicus 139-143 7558244-9 1995 Furthermore, chronic exposure to TPA or treatment with herbimycin A results in the enhancement of the hypoxia-mediated increase in VEGF mRNA levels. Tetradecanoylphorbol Acetate 33-36 vascular endothelial growth factor A Rattus norvegicus 131-135 7558244-9 1995 Furthermore, chronic exposure to TPA or treatment with herbimycin A results in the enhancement of the hypoxia-mediated increase in VEGF mRNA levels. herbimycin 55-67 vascular endothelial growth factor A Rattus norvegicus 131-135 7706486-7 1995 Since endotoxin treatment of rats decreased lung VEGF mRNA, we postulated that nitric oxide (NO) or an NO-related metabolite might be involved in lung VEGF gene expression. Nitric Oxide 79-91 vascular endothelial growth factor A Rattus norvegicus 49-53 7706486-7 1995 Since endotoxin treatment of rats decreased lung VEGF mRNA, we postulated that nitric oxide (NO) or an NO-related metabolite might be involved in lung VEGF gene expression. Nitric Oxide 79-91 vascular endothelial growth factor A Rattus norvegicus 151-155 7706486-8 1995 Indeed, sodium nitroprusside, a NO donor, decreased and L-NAME (N-nitro-L-arginine methyl ester), an inhibitor of NO-synthesis, increased both VEGF and VEGF receptor transcripts. Nitroprusside 8-28 vascular endothelial growth factor A Rattus norvegicus 152-156 7706486-8 1995 Indeed, sodium nitroprusside, a NO donor, decreased and L-NAME (N-nitro-L-arginine methyl ester), an inhibitor of NO-synthesis, increased both VEGF and VEGF receptor transcripts. NG-Nitroarginine Methyl Ester 56-62 vascular endothelial growth factor A Rattus norvegicus 152-156 7706486-8 1995 Indeed, sodium nitroprusside, a NO donor, decreased and L-NAME (N-nitro-L-arginine methyl ester), an inhibitor of NO-synthesis, increased both VEGF and VEGF receptor transcripts. n-nitro-l-arginine methyl ester 64-95 vascular endothelial growth factor A Rattus norvegicus 152-156 7728992-4 1995 In the present study, VPF/VEGF mRNA and protein were demonstrated to be markedly stimulated in primary rat cardiac myocytes in vitro in response to reduction of the oxygen tension to 1% or inhibition of the electron transport chain. Oxygen 165-171 vascular endothelial growth factor A Rattus norvegicus 22-25 7728992-4 1995 In the present study, VPF/VEGF mRNA and protein were demonstrated to be markedly stimulated in primary rat cardiac myocytes in vitro in response to reduction of the oxygen tension to 1% or inhibition of the electron transport chain. Oxygen 165-171 vascular endothelial growth factor A Rattus norvegicus 26-30 7728992-6 1995 Phorbol ester and the depolarizing agent veratridine, stimulators of protein kinase C and calcium influx, respectively, were found to markedly increase VPF/VEGF mRNA expression in cardiac myocytes. Phorbol Esters 0-13 vascular endothelial growth factor A Rattus norvegicus 152-155 7728992-6 1995 Phorbol ester and the depolarizing agent veratridine, stimulators of protein kinase C and calcium influx, respectively, were found to markedly increase VPF/VEGF mRNA expression in cardiac myocytes. Phorbol Esters 0-13 vascular endothelial growth factor A Rattus norvegicus 156-160 7728992-6 1995 Phorbol ester and the depolarizing agent veratridine, stimulators of protein kinase C and calcium influx, respectively, were found to markedly increase VPF/VEGF mRNA expression in cardiac myocytes. Veratridine 41-52 vascular endothelial growth factor A Rattus norvegicus 152-155 7728992-6 1995 Phorbol ester and the depolarizing agent veratridine, stimulators of protein kinase C and calcium influx, respectively, were found to markedly increase VPF/VEGF mRNA expression in cardiac myocytes. Veratridine 41-52 vascular endothelial growth factor A Rattus norvegicus 156-160 7728992-6 1995 Phorbol ester and the depolarizing agent veratridine, stimulators of protein kinase C and calcium influx, respectively, were found to markedly increase VPF/VEGF mRNA expression in cardiac myocytes. Calcium 90-97 vascular endothelial growth factor A Rattus norvegicus 152-155 7728992-6 1995 Phorbol ester and the depolarizing agent veratridine, stimulators of protein kinase C and calcium influx, respectively, were found to markedly increase VPF/VEGF mRNA expression in cardiac myocytes. Calcium 90-97 vascular endothelial growth factor A Rattus norvegicus 156-160 7728992-7 1995 Forskolin, a potent stimulator of adenylate cyclase, produced a small but significant increase in VPF/VEGF mRNA expression in the cardiac myocytes. Colforsin 0-9 vascular endothelial growth factor A Rattus norvegicus 98-101 7728992-7 1995 Forskolin, a potent stimulator of adenylate cyclase, produced a small but significant increase in VPF/VEGF mRNA expression in the cardiac myocytes. Colforsin 0-9 vascular endothelial growth factor A Rattus norvegicus 102-106 7533611-0 1995 Suppression of VEGF-induced angiogenesis by the protein tyrosine kinase inhibitor, lavendustin A. lavendustin A 83-96 vascular endothelial growth factor A Rattus norvegicus 15-19 7533611-16 1995 This VEGF/bFGF neovascular response was also blocked by daily co-administration of lavendustin A (10 jig),suramin (3 mg) or a monoclonal anti-bFGF antibody (DG2, I jig), but not lavendustin B (10 g).6 These results suggest that selective inhibition of PTK could have therapeutic potential in angiogenic diseases where VEGF plays a dominant role. lavendustin A 83-96 vascular endothelial growth factor A Rattus norvegicus 5-9 7533611-16 1995 This VEGF/bFGF neovascular response was also blocked by daily co-administration of lavendustin A (10 jig),suramin (3 mg) or a monoclonal anti-bFGF antibody (DG2, I jig), but not lavendustin B (10 g).6 These results suggest that selective inhibition of PTK could have therapeutic potential in angiogenic diseases where VEGF plays a dominant role. lavendustin A 83-96 vascular endothelial growth factor A Rattus norvegicus 318-322 7533611-16 1995 This VEGF/bFGF neovascular response was also blocked by daily co-administration of lavendustin A (10 jig),suramin (3 mg) or a monoclonal anti-bFGF antibody (DG2, I jig), but not lavendustin B (10 g).6 These results suggest that selective inhibition of PTK could have therapeutic potential in angiogenic diseases where VEGF plays a dominant role. Suramin 106-113 vascular endothelial growth factor A Rattus norvegicus 5-9 7533611-16 1995 This VEGF/bFGF neovascular response was also blocked by daily co-administration of lavendustin A (10 jig),suramin (3 mg) or a monoclonal anti-bFGF antibody (DG2, I jig), but not lavendustin B (10 g).6 These results suggest that selective inhibition of PTK could have therapeutic potential in angiogenic diseases where VEGF plays a dominant role. lavendustin B 178-191 vascular endothelial growth factor A Rattus norvegicus 5-9 7533611-17 1995 Furthermore, blockade of the angiogenic activity of VEGF and VEGF,/bFGF by suramin reveals an alternative strategy in angio suppression. Suramin 75-82 vascular endothelial growth factor A Rattus norvegicus 52-56 7980544-0 1994 Cobalt stimulates the expression of vascular endothelial growth factor mRNA in rat cardiac cells. Cobalt 0-6 vascular endothelial growth factor A Rattus norvegicus 36-70 7980544-4 1994 Experiments using actinomycin D and cycloheximide indicated that VEGF mRNA levels in cardiac cells are regulated both at transcriptional and post transcriptional levels. Dactinomycin 18-31 vascular endothelial growth factor A Rattus norvegicus 65-69 7980544-4 1994 Experiments using actinomycin D and cycloheximide indicated that VEGF mRNA levels in cardiac cells are regulated both at transcriptional and post transcriptional levels. Cycloheximide 36-49 vascular endothelial growth factor A Rattus norvegicus 65-69 7980544-5 1994 It is concluded that an oxygen sensing mechanism is present in cardiac cells and controls the expression of VEGF mRNAs. Oxygen 24-30 vascular endothelial growth factor A Rattus norvegicus 108-112 8200985-4 1994 The aim of this study was to examine the possible role of VEGF in PG stimulation of bone formation. pg 66-68 vascular endothelial growth factor A Rattus norvegicus 58-62 8200985-5 1994 We found that in rat calvaria-derived osteoblast-enriched cells and in the osteoblastic RCT-3 cell line PGE2 and E1 increased VEGF mRNA and protein levels. Dinoprostone 104-108 vascular endothelial growth factor A Rattus norvegicus 126-130 8200985-6 1994 The increased expression of VEGF mRNA produced by PGE2 was rapid (maximal at 1 h), transient (declined by 3 h), potentiated by cycloheximide, and abolished by actinomycin D. Dinoprostone 50-54 vascular endothelial growth factor A Rattus norvegicus 28-32 8200985-6 1994 The increased expression of VEGF mRNA produced by PGE2 was rapid (maximal at 1 h), transient (declined by 3 h), potentiated by cycloheximide, and abolished by actinomycin D. Cycloheximide 127-140 vascular endothelial growth factor A Rattus norvegicus 28-32 8200985-6 1994 The increased expression of VEGF mRNA produced by PGE2 was rapid (maximal at 1 h), transient (declined by 3 h), potentiated by cycloheximide, and abolished by actinomycin D. Dactinomycin 159-172 vascular endothelial growth factor A Rattus norvegicus 28-32 8200985-7 1994 PGE2 had no effect on VEGF mRNA stability, suggesting transcriptional regulation of VEGF expression by PGF2. Dinoprost 103-107 vascular endothelial growth factor A Rattus norvegicus 84-88 8200985-8 1994 Rp-cAMP, a cAMP antagonist, suppressed VEGF mRNA induced by PGE2, indicating cAMP mediation. Cyclic AMP 3-7 vascular endothelial growth factor A Rattus norvegicus 39-43 8200985-8 1994 Rp-cAMP, a cAMP antagonist, suppressed VEGF mRNA induced by PGE2, indicating cAMP mediation. Cyclic AMP 11-15 vascular endothelial growth factor A Rattus norvegicus 39-43 8200985-8 1994 Rp-cAMP, a cAMP antagonist, suppressed VEGF mRNA induced by PGE2, indicating cAMP mediation. Dinoprostone 60-64 vascular endothelial growth factor A Rattus norvegicus 39-43 8200985-8 1994 Rp-cAMP, a cAMP antagonist, suppressed VEGF mRNA induced by PGE2, indicating cAMP mediation. Cyclic AMP 11-15 vascular endothelial growth factor A Rattus norvegicus 39-43 8200985-9 1994 The upregulation of VEGF expression by PGE2 in the preosteoblastic RCT-1 cells was potentiated by treatment with retinoic acid, which induces the differentiation of these cells. Dinoprostone 39-43 vascular endothelial growth factor A Rattus norvegicus 20-24 8200985-9 1994 The upregulation of VEGF expression by PGE2 in the preosteoblastic RCT-1 cells was potentiated by treatment with retinoic acid, which induces the differentiation of these cells. Tretinoin 113-126 vascular endothelial growth factor A Rattus norvegicus 20-24 8200985-10 1994 The upregulation of VEGF mRNA by PGE2 was inhibited by dexamethasone treatment. Dinoprostone 33-37 vascular endothelial growth factor A Rattus norvegicus 20-24 8200985-10 1994 The upregulation of VEGF mRNA by PGE2 was inhibited by dexamethasone treatment. Dexamethasone 55-68 vascular endothelial growth factor A Rattus norvegicus 20-24 8200985-13 1994 Stimulation of VEGF expression by PGs and its suppression by glucocorticoids, which, respectively, stimulate and suppress bone formation, strongly implicate the involvement of VEGF in bone metabolism. Phosphatidylglycerols 34-37 vascular endothelial growth factor A Rattus norvegicus 15-19 33786174-5 2021 Furthermore, the role of cocaine in increasing the expression of hypoxia inducible factor-1 (HIF-1alpha) and vascular endothelial growth factor (VEGF) in cells was also determined. Cocaine 25-32 vascular endothelial growth factor A Rattus norvegicus 109-143 1729274-1 1992 Vascular endothelial growth factor (VEGF) is a secreted heparin-binding mitogen; its growth-promoting activity is limited to vascular endothelial cells in vitro and VEGF also stimulates angiogenesis in vivo. Heparin 56-63 vascular endothelial growth factor A Rattus norvegicus 0-34 1729274-1 1992 Vascular endothelial growth factor (VEGF) is a secreted heparin-binding mitogen; its growth-promoting activity is limited to vascular endothelial cells in vitro and VEGF also stimulates angiogenesis in vivo. Heparin 56-63 vascular endothelial growth factor A Rattus norvegicus 36-40 8373380-6 1993 The expression of VEGF mRNA in myocyte enriched cultures of new born rat ventricles was increased 2 fold by serum, 5 fold by phorbol myristate acetate and 7 fold by hypoxic conditions. Tetradecanoylphorbol Acetate 125-150 vascular endothelial growth factor A Rattus norvegicus 18-22 33786174-5 2021 Furthermore, the role of cocaine in increasing the expression of hypoxia inducible factor-1 (HIF-1alpha) and vascular endothelial growth factor (VEGF) in cells was also determined. Cocaine 25-32 vascular endothelial growth factor A Rattus norvegicus 145-149 33786174-9 2021 The HIF-1alpha and VEGF levels were significantly increased in the challenged cells at higher cocaine doses compared with the unchallenged cells. Cocaine 94-101 vascular endothelial growth factor A Rattus norvegicus 19-23 33771578-5 2021 Western blot analysis revealed a significant increase in hippocampal BDNF and VEGF protein levels in both EE and CET groups (P < 0.001), along with an increase in GR protein levels. cet 113-116 vascular endothelial growth factor A Rattus norvegicus 78-82 33762951-9 2021 In addition, BO significantly downregulated the serum level of TNF-alpha and significantly increased the serum levels of VEGF and TGF-beta1. borage oil 13-15 vascular endothelial growth factor A Rattus norvegicus 121-125 33800631-2 2021 We previously demonstrated that incorporation of VEGF into electrospun tubular scaffolds from poly(3-hydroxybutyrate-co-3-hydroxyvalerate)/poly(epsilon-caprolactone) enhances formation of an endothelial cell monolayer. poly(3-hydroxybutyrate)-co-(3-hydroxyvalerate) 94-138 vascular endothelial growth factor A Rattus norvegicus 49-53 33800631-2 2021 We previously demonstrated that incorporation of VEGF into electrospun tubular scaffolds from poly(3-hydroxybutyrate-co-3-hydroxyvalerate)/poly(epsilon-caprolactone) enhances formation of an endothelial cell monolayer. polycaprolactone 139-164 vascular endothelial growth factor A Rattus norvegicus 49-53 33814979-8 2021 In addition, rats treated with the AGN showed less inflammatory reaction and fibrosis, not only in the expression of NLRP3, inflammasome downstream factors IL-1beta and IL-18, and fibrosis markers TGF-beta, TIMP1, and VEGF but also in the observation of HE staining, anatomical characteristics, Sirius Red staining, and type I collagen immunohistochemistry. agnuside 35-38 vascular endothelial growth factor A Rattus norvegicus 218-222 33818692-7 2021 Our results illustrated a significant drop in VEGF (vascular endothelial growth factor) level in the tramadol group. Tramadol 101-109 vascular endothelial growth factor A Rattus norvegicus 46-50 33818692-7 2021 Our results illustrated a significant drop in VEGF (vascular endothelial growth factor) level in the tramadol group. Tramadol 101-109 vascular endothelial growth factor A Rattus norvegicus 52-86 32890875-6 2021 The anti-HER2 monoclonal antibody trastuzumab significantly decreased serum vascular endothelial-derived growth factor (VEGF) levels and that of proliferation-related proteins in the bladder tissues of DMAV-exposed rats. Dimethylarsinate 202-206 vascular endothelial growth factor A Rattus norvegicus 76-118 33236604-12 2020 Compared with the CON group, the survival rate of skin flaps, the number of microvessels in skin flaps and the levels of VEGF mRNA, bFGF mRNA, SOD, NO in skin flaps also increased with the dose of ATR, which reached a peak at 30 mg/kg ATR ( P<0.05). Atorvastatin 197-200 vascular endothelial growth factor A Rattus norvegicus 121-125 33237074-9 2020 Vitamin D deficiency also lowered the placental protein levels of pro-angiogenic proteins VEGF and Flt-1 (p < 0.05 and p < 0.01, respectively), while the levels of these proteins in the VDS-PE group were similar to those in the control group. Vitamin D 0-9 vascular endothelial growth factor A Rattus norvegicus 90-94 33237074-11 2020 CONCLUSION: A low dose vitamin D supplementation given from pre-pregnancy and throughout pregnancy was beneficial in reducing the blood pressure and normalizing the placental levels of VEGF and Flt-1. Vitamin D 23-32 vascular endothelial growth factor A Rattus norvegicus 185-189 34748867-8 2022 The pharmacological indicators, including expression of vascular endothelial growth factor (VEGF) and hypoxia-inducible factor-1alpha (HIF-1alpha) in the retina of Sprague Dawley (SD) rats induced by streptozotocin (STZ), were detected by enzyme-linked immunosorbent assay (ELISA). Streptozocin 200-214 vascular endothelial growth factor A Rattus norvegicus 56-90 20034820-3 2010 The aim of this study was to evaluate the effects of a poly (L,D-lactic-co-glycolic acid) (PLGA) membrane with VEGF encapsulated into PLGA microspheres on bone regeneration at bone defects in rat calvaria. poly (l,d-lactic-co-glycolic acid) 55-89 vascular endothelial growth factor A Rattus norvegicus 111-115 18773819-1 2008 OBJECTIVE: To observe the effects of cobalt chloride (CoCl2)-simulated hypoxia on VEGF and TGF-beta1 expression and to provide theoretical basis for deciphering the molecular mechanism of clinical distraction osteogenesis. cobaltous chloride 37-52 vascular endothelial growth factor A Rattus norvegicus 82-86 18773819-1 2008 OBJECTIVE: To observe the effects of cobalt chloride (CoCl2)-simulated hypoxia on VEGF and TGF-beta1 expression and to provide theoretical basis for deciphering the molecular mechanism of clinical distraction osteogenesis. cobaltous chloride 54-59 vascular endothelial growth factor A Rattus norvegicus 82-86 34953950-10 2022 On PND8, GBH-treated rats showed increased vascular endothelial growth factor (VEGF) expression and decreased Notch1, inducible nitric oxide synthase (iNOS) and Angiopoietin-2 (Ang2) mRNA levels. gbh 9-12 vascular endothelial growth factor A Rattus norvegicus 43-77 34953950-10 2022 On PND8, GBH-treated rats showed increased vascular endothelial growth factor (VEGF) expression and decreased Notch1, inducible nitric oxide synthase (iNOS) and Angiopoietin-2 (Ang2) mRNA levels. gbh 9-12 vascular endothelial growth factor A Rattus norvegicus 79-83 34878940-11 2022 In vitro studies showed that MEx treatment enhanced distal lung branching and increased VEGF and SPC gene expression. CHEMBL1802335 29-32 vascular endothelial growth factor A Rattus norvegicus 88-92 23337128-4 2013 The effect of VEGF on Na(+) channel steady-state inactivation was inhibited by the specific VEGF Flk-1 receptor antagonist SU1498, but was not affected by protein kinase C (PKC)-activator 1-oleoyl-2-acetyl-sn-glycerol (OAG). SU 1498 123-129 vascular endothelial growth factor A Rattus norvegicus 14-18 23337128-4 2013 The effect of VEGF on Na(+) channel steady-state inactivation was inhibited by the specific VEGF Flk-1 receptor antagonist SU1498, but was not affected by protein kinase C (PKC)-activator 1-oleoyl-2-acetyl-sn-glycerol (OAG). SU 1498 123-129 vascular endothelial growth factor A Rattus norvegicus 92-96 23337128-4 2013 The effect of VEGF on Na(+) channel steady-state inactivation was inhibited by the specific VEGF Flk-1 receptor antagonist SU1498, but was not affected by protein kinase C (PKC)-activator 1-oleoyl-2-acetyl-sn-glycerol (OAG). 1-oleoyl-2-acetylglycerol 219-222 vascular endothelial growth factor A Rattus norvegicus 14-18 19279317-7 2009 Cloricromene treatment significantly lowered retinal TNFalpha, ICAM-1, VEGF, and eNOS. cloricromen 0-12 vascular endothelial growth factor A Rattus norvegicus 71-75 19279317-8 2009 Furthermore, immunohistochemical analysis for VEGF, ICAM-1, nitrotyrosine (a marker of peroxynitrite), and tight junctions revealed positive staining in the retina from STZ-treated rats. Streptozocin 169-172 vascular endothelial growth factor A Rattus norvegicus 46-50 19279317-9 2009 The degree of staining for VEGF, ICAM-1, nitrotyrosine, and tight junctions was markedly reduced in tissue sections obtained from diabetic rats treated with cloricromene. cloricromen 157-169 vascular endothelial growth factor A Rattus norvegicus 27-31 34808298-10 2022 ZJP could dose-dependently decrease the serum IL-6, MCP-1, PGE2, TNF-alpha, and VEGF level and significantly improved gastric tissue inflammatory lesions. zjp 0-3 vascular endothelial growth factor A Rattus norvegicus 80-84 34748867-8 2022 The pharmacological indicators, including expression of vascular endothelial growth factor (VEGF) and hypoxia-inducible factor-1alpha (HIF-1alpha) in the retina of Sprague Dawley (SD) rats induced by streptozotocin (STZ), were detected by enzyme-linked immunosorbent assay (ELISA). Streptozocin 200-214 vascular endothelial growth factor A Rattus norvegicus 92-96 34748867-8 2022 The pharmacological indicators, including expression of vascular endothelial growth factor (VEGF) and hypoxia-inducible factor-1alpha (HIF-1alpha) in the retina of Sprague Dawley (SD) rats induced by streptozotocin (STZ), were detected by enzyme-linked immunosorbent assay (ELISA). Streptozocin 216-219 vascular endothelial growth factor A Rattus norvegicus 56-90 34748867-14 2022 The results of PLSR and CCA revealed that the contents of puerarin, daidzin, salvianolic acid B and ginsenoside Rb1 were inversely correlated with the expression of VEGF and HIF-1alpha. puerarin 58-66 vascular endothelial growth factor A Rattus norvegicus 165-169 34748867-14 2022 The results of PLSR and CCA revealed that the contents of puerarin, daidzin, salvianolic acid B and ginsenoside Rb1 were inversely correlated with the expression of VEGF and HIF-1alpha. daidzin 68-75 vascular endothelial growth factor A Rattus norvegicus 165-169 34748867-14 2022 The results of PLSR and CCA revealed that the contents of puerarin, daidzin, salvianolic acid B and ginsenoside Rb1 were inversely correlated with the expression of VEGF and HIF-1alpha. salvianolic acid B 77-95 vascular endothelial growth factor A Rattus norvegicus 165-169 34561804-12 2022 Taken together, experimental findings suggested that FFBR could accelerate the healing process of gastric ulcers in rats through mediating NF-kappaB and VEGF/PGE2 pathways. Dinoprostone 158-162 vascular endothelial growth factor A Rattus norvegicus 153-157 34748867-16 2022 The results of intervention on primary culture retinal Muller cells showed that puerarin, daidzin, salvianolic acid B, and ginsenoside Rb1 can significantly inhibit the expression of VEGF and HIF-1alpha. puerarin 80-88 vascular endothelial growth factor A Rattus norvegicus 183-187 34748867-16 2022 The results of intervention on primary culture retinal Muller cells showed that puerarin, daidzin, salvianolic acid B, and ginsenoside Rb1 can significantly inhibit the expression of VEGF and HIF-1alpha. daidzin 90-97 vascular endothelial growth factor A Rattus norvegicus 183-187 34748867-16 2022 The results of intervention on primary culture retinal Muller cells showed that puerarin, daidzin, salvianolic acid B, and ginsenoside Rb1 can significantly inhibit the expression of VEGF and HIF-1alpha. salvianolic acid B 99-117 vascular endothelial growth factor A Rattus norvegicus 183-187 34563688-4 2022 METHODS: Sprague-Dawley rats underwent left pneumonectomy (Pn) followed by injection of the VEGF inhibitor Sugen-5416 (Su/Pn). Semaxinib 107-117 vascular endothelial growth factor A Rattus norvegicus 92-96 34942190-11 2022 MiR-204-5p agomiR promoted the viability, migration, invasion, and tube formation of EPCs, the levels of VEGFA and Ang1 and the activation of PI3K/AKT pathway in EPCs, while miR-204-5p antagomiR and SPRED1 worked oppositely. mir-204-5p 0-10 vascular endothelial growth factor A Rattus norvegicus 105-110 34853408-6 2022 Norepinephrine further increased VEGF mRNA expression under hypoxia; this effect was abolished by doxazosin. Norepinephrine 0-14 vascular endothelial growth factor A Rattus norvegicus 33-37 34853408-6 2022 Norepinephrine further increased VEGF mRNA expression under hypoxia; this effect was abolished by doxazosin. Doxazosin 98-107 vascular endothelial growth factor A Rattus norvegicus 33-37 34853408-11 2022 In conclusion, doxazosin abolished the beneficial effects of ADSC sheets on rat MI hearts as well as the enhancing effect of norepinephrine on VEGF expression in ADSCs, indicating that ADSC sheets promote angiogenesis and prevent cardiac dysfunction and remodeling after MI via their alpha1-ARs. Doxazosin 15-24 vascular endothelial growth factor A Rattus norvegicus 143-147 34853408-11 2022 In conclusion, doxazosin abolished the beneficial effects of ADSC sheets on rat MI hearts as well as the enhancing effect of norepinephrine on VEGF expression in ADSCs, indicating that ADSC sheets promote angiogenesis and prevent cardiac dysfunction and remodeling after MI via their alpha1-ARs. Norepinephrine 125-139 vascular endothelial growth factor A Rattus norvegicus 143-147 34837757-9 2022 Meanwhile, Dl-NBP can significantly elevate levels of HIF-1alpha protein (p < 0.001) and VEGF mRNA (p = 0.001) / protein (p < 0.001) in NSCs in the hypoxic environment. dl-nbp 11-17 vascular endothelial growth factor A Rattus norvegicus 89-93 34837757-12 2022 The HIF-1alpha - VEGF pathway may be implicated in this protective effect of dl-NBP. 3-n-butylphthalide 77-83 vascular endothelial growth factor A Rattus norvegicus 17-21 34840942-3 2022 The objective of this study is to analyse the combination of ellagic acid and hydroxyapatite to promote FGF-2, VEGF and ALP expression as angiogenesis markers in a bone defect model. Ellagic Acid 61-73 vascular endothelial growth factor A Rattus norvegicus 111-115 34840942-3 2022 The objective of this study is to analyse the combination of ellagic acid and hydroxyapatite to promote FGF-2, VEGF and ALP expression as angiogenesis markers in a bone defect model. Durapatite 78-92 vascular endothelial growth factor A Rattus norvegicus 111-115 34840942-7 2022 The combination of ellagic acid and hydroxyapatite promoted FGF-2, VEGF and ALP expression as angiogenesis markers in the bone defect model. Ellagic Acid 19-31 vascular endothelial growth factor A Rattus norvegicus 67-71 34840942-7 2022 The combination of ellagic acid and hydroxyapatite promoted FGF-2, VEGF and ALP expression as angiogenesis markers in the bone defect model. Durapatite 36-50 vascular endothelial growth factor A Rattus norvegicus 67-71 34543634-0 2022 Curcumin improves angiogenesis in the heart of aged rats: Involvement of TSP1/NF-kappaB/VEGF-A signaling. Curcumin 0-8 vascular endothelial growth factor A Rattus norvegicus 88-94 34543634-6 2022 RESULTS: After 2 months, curcumin-age had significantly higher cardiac VEGF-A and NF-kappaB and lower cardiac TSP-1 expression levels in comparison with age and young. Curcumin 25-33 vascular endothelial growth factor A Rattus norvegicus 71-77 34932671-0 2021 Effects of ergosteroside combined risedronate on fracture healing and BMP-2, BMP-7 and VEGF expression in rats. ergosteroside 11-24 vascular endothelial growth factor A Rattus norvegicus 87-91 34781187-0 2022 Matrine inhibits synovial angiogenesis in collagen-induced arthritis rats by regulating HIF-VEGF-Ang and inhibiting the PI3K/Akt signaling pathway. matrine 0-7 vascular endothelial growth factor A Rattus norvegicus 92-96 34826534-9 2022 Animals receiving sovateltide demonstrated a significant (p<0.0001) upregulation of ETB receptor, VEGF, and NGF expression in the brain compared to vehicle-treated animals. SPI-1620 18-29 vascular endothelial growth factor A Rattus norvegicus 98-102 33904385-3 2021 And we found that positive expression of VEGF and VEGF receptor 2 (VEGFR2) was observed by Immunohistochemical staining in the epididymal tissues of arsenic-exposed rats. Arsenic 149-156 vascular endothelial growth factor A Rattus norvegicus 41-45 34987400-7 2021 AIA-caused increase in circulating transforming growth factor beta, interleukin 6, hypoxia inducible factor-1 alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) in blood and local HIF-1alpha/VEGF expression in joints was abrogated by MAN treatment, and pannus formation within matrigel plugs implanted in AIA rats was inhibited too. mangostin 248-251 vascular endothelial growth factor A Rattus norvegicus 133-167 34987400-7 2021 AIA-caused increase in circulating transforming growth factor beta, interleukin 6, hypoxia inducible factor-1 alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) in blood and local HIF-1alpha/VEGF expression in joints was abrogated by MAN treatment, and pannus formation within matrigel plugs implanted in AIA rats was inhibited too. mangostin 248-251 vascular endothelial growth factor A Rattus norvegicus 169-173 34987400-7 2021 AIA-caused increase in circulating transforming growth factor beta, interleukin 6, hypoxia inducible factor-1 alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) in blood and local HIF-1alpha/VEGF expression in joints was abrogated by MAN treatment, and pannus formation within matrigel plugs implanted in AIA rats was inhibited too. mangostin 248-251 vascular endothelial growth factor A Rattus norvegicus 205-209 34987400-12 2021 Consistently, MAN restored lipopolysaccharide-elicited changes on levels of glucose and LDH in HUVECs culture system, and exerted similar effects with LDH inhibitor stiripentol on glycometabolism and VEGF production as well as tubule formation capability of HUVECs. stiripentol 165-176 vascular endothelial growth factor A Rattus norvegicus 200-204 34775044-4 2021 The crosslinked particles, XDSCS NPs, are stable in NaCl solutions up to 3 M. XDSCS NPs were able to incorporate heparin-binding proteins (VEGF and SDF-1alpha) rapidly and efficiently, and maintain the full biological activity of the proteins. Heparin 113-120 vascular endothelial growth factor A Rattus norvegicus 139-143 34863047-4 2022 We fabricated a polyurethane conduit grafted with a vascular endothelial growth factor (VEGF)-loaded hydrogel (abbreviated as PU/Gel/VEGF conduit). Polyurethanes 16-28 vascular endothelial growth factor A Rattus norvegicus 133-137 34863047-5 2022 The leachate generated during the use of the PU/Gel/VEGF conduit could facilitate the proliferation, migration, and expression of the neural marker S100beta in RSC96 cells (in vitro). Polyurethanes 45-47 vascular endothelial growth factor A Rattus norvegicus 52-56 34863047-9 2022 Overall, the results indicated that PU/Gel/VEGF conduits could promote the process of peripheral nerve regeneration. Polyurethanes 36-38 vascular endothelial growth factor A Rattus norvegicus 43-47 34668398-0 2021 Melatonin ameliorates aging-related impaired angiogenesis in gastric endothelial cells via local actions on mitochondria & VEGF-survivin signaling. Melatonin 0-9 vascular endothelial growth factor A Rattus norvegicus 123-127 34688831-9 2021 PMF treatment also suppressed the VEGF levels and enhanced the bFGF levels in both neural tissues. Phenylmethylsulfonyl Fluoride 0-3 vascular endothelial growth factor A Rattus norvegicus 34-38 34334080-0 2021 Dexmedetomidine improves oxygen-glucose deprivation/reoxygenation (OGD/R) -induced neurological injury through regulating SNHG11/miR-324-3p/VEGFA axis. Dexmedetomidine 0-15 vascular endothelial growth factor A Rattus norvegicus 140-145 34334080-6 2021 Furthermore, we found that SNHG11 upregulated vascular endothelial growth factor A (VEGFA) expression by targeting miR-324-3p. mir-324-3p 115-125 vascular endothelial growth factor A Rattus norvegicus 46-82 34334080-6 2021 Furthermore, we found that SNHG11 upregulated vascular endothelial growth factor A (VEGFA) expression by targeting miR-324-3p. mir-324-3p 115-125 vascular endothelial growth factor A Rattus norvegicus 84-89 34334080-9 2021 In conclusion, our work demonstrated that Dex improved OGD/R-induced neurological injury via SNHG11/miR-324-3p/VEGFA axis. Dexmedetomidine 42-45 vascular endothelial growth factor A Rattus norvegicus 111-116 34707702-10 2021 Furthermore, VEGF expression and Ang-1 secretion decreased in the STZ + GM group compared with STZ rats. Streptozocin 66-69 vascular endothelial growth factor A Rattus norvegicus 13-17 33472443-2 2021 Resveratrol is a highly effective anti-VEGF agent against CNV. Resveratrol 0-11 vascular endothelial growth factor A Rattus norvegicus 39-43 34707702-3 2021 The present study aimed to investigate the potential vascular protective effect of gymnemic acid (GM) by assessing the morphological changes of microvasculature, along with VEGFA and angiopoietin-1 (Ang-1) protein expression in the brains of diabetic rats. gymnemic acid 83-96 vascular endothelial growth factor A Rattus norvegicus 173-178 34283928-0 2021 Angiogenesis effects of 4-methoxy benzyl alcohol on cerebral ischemia-reperfusion injury via regulation of VEGF-Ang/Tie2 balance. anisyl alcohol 24-48 vascular endothelial growth factor A Rattus norvegicus 107-111 34493133-8 2021 AITC increased the levels of Bax, caspase-3, HO-1, GAP43, and VEGF, while decreasing IL-1beta, IL-6, NF-kappaB, Bcl-2, GFAP, Grp78, activating ATF4 and ATF6 as compared to the LED group (p <0.05). allyl isothiocyanate 0-4 vascular endothelial growth factor A Rattus norvegicus 62-66 34765018-4 2021 Bioinformatics analysis and dual luciferase reporter assay were used to predict and validate the interaction between miRNA-23a and VEGF and cell proliferative ability was assessed with the MTT assay. monooxyethylene trimethylolpropane tristearate 189-192 vascular endothelial growth factor A Rattus norvegicus 131-135 34707702-10 2021 Furthermore, VEGF expression and Ang-1 secretion decreased in the STZ + GM group compared with STZ rats. gymnemic acid 72-74 vascular endothelial growth factor A Rattus norvegicus 13-17 34711116-13 2021 ZYPs treatment increased the expression of VEGF, ER, MMP-9, LIF, and HB-EGF, but decreased TGF-beta expression. zyps 0-4 vascular endothelial growth factor A Rattus norvegicus 43-47 34010584-9 2021 Myrtenol promoted angiogenesis in the brain tissues of MCAO rats, which was reflected by increased VEGF (0.86-fold) and FGF2 (0.51-fold). myrtenol 0-8 vascular endothelial growth factor A Rattus norvegicus 99-103 34363706-11 2021 The molecular analysis indicated higher expression of bone formation (ALP), remodeling (CatK), and vascularization (VEGF) genes in implant-adherent cells in the CAF group. Caffeine 161-164 vascular endothelial growth factor A Rattus norvegicus 116-120 34637793-10 2021 SIGNIFICANCE: In conclusion, vanillin enhanced liver regeneration in TAA induced liver damage model; targeting growth factors (HGF, VEGF) and cellular proliferation marker cyclin D1. vanillin 29-37 vascular endothelial growth factor A Rattus norvegicus 132-136 34836410-3 2021 The livers of ethanol-treated rats showed steatosis; necrosis and mononuclear infiltration; and significant upregulation of the mRNA expression of the prooxidant (Cyp2e1, iNos), lipogenic (Srebp1, Acc), proinflammatory (Tlr4, Nf-kappab, TnfA, Il-1B, and Il-6), and profibrogenic (TgfB, Col1, VegfA) genes. Ethanol 14-21 vascular endothelial growth factor A Rattus norvegicus 292-297 34592429-0 2021 Tetrandrine promotes angiogenesis via transcriptional regulation of VEGF-A. tetrandrine 0-11 vascular endothelial growth factor A Rattus norvegicus 68-74 34592429-3 2021 In this study, tetrandrine (Tet) was found from 23 herbal chemicals to increase VEGF-A mRNA expression in H9c2 cells and the effect was confirmed in freshly isolated neonatal rat cardiomyocytes. tetrandrine 15-26 vascular endothelial growth factor A Rattus norvegicus 80-86 34592429-3 2021 In this study, tetrandrine (Tet) was found from 23 herbal chemicals to increase VEGF-A mRNA expression in H9c2 cells and the effect was confirmed in freshly isolated neonatal rat cardiomyocytes. tetrandrine 28-31 vascular endothelial growth factor A Rattus norvegicus 80-86 34592429-4 2021 The effect of Tet on VEGF-A expression and the possible mechanism were investigated. tetrandrine 14-17 vascular endothelial growth factor A Rattus norvegicus 21-27 34592429-5 2021 Tet treatment increased de novo VEGF-A mRNA synthesis and did not affect VEGF-A mRNA stability. tetrandrine 0-3 vascular endothelial growth factor A Rattus norvegicus 32-38 34592429-6 2021 The circulating chromosome conformation capture (4C) experiments indicated that Tet enhanced VEGF-A transcription by targeting a regulatory element beyond the 2.6 kb region of the translation start site. tetrandrine 80-83 vascular endothelial growth factor A Rattus norvegicus 93-99 34592429-9 2021 Moreover, in myocardial infarction (MI) model Tet treatment elevated neovascularization, reduced infarction size, and improved heart function via upregulating VEGF-A levels. tetrandrine 46-49 vascular endothelial growth factor A Rattus norvegicus 159-165 34592429-10 2021 Our results suggested that Tet increased VEGF-A transcription through a novel mechanism that likely involves a distant regulatory element and may be useful for therapeutic angiogenesis for ischemic diseases. tetrandrine 27-30 vascular endothelial growth factor A Rattus norvegicus 41-47 34917429-9 2021 Furthermore, VEGF and TGF-beta were overexpressed, whereas HIF-1alpha, IL-1beta, and IL-6 were downregulated in the rats treated with CO2. Carbon Dioxide 134-137 vascular endothelial growth factor A Rattus norvegicus 13-17 34763682-12 2021 RESULTS: The results of PCR showed that the mRNA levels of VEGF and CD31 in the DFO group were significantly higher than those in the control group. Deferoxamine 80-83 vascular endothelial growth factor A Rattus norvegicus 59-63 34763682-13 2021 The immunohistochemistry results indicated that positive cell expression of HIF-1a, VEGF, and CD31 in the DFO group was also higher. Deferoxamine 106-109 vascular endothelial growth factor A Rattus norvegicus 84-88 34795412-10 2021 Moreover, catalpol treatment significantly increased the expression of vascular endothelial growth factor (VEGF) through up-regulating PI3K/AKT signaling, followed by increasing FAK and Paxillin and activating PI3K/AKT and MEK1/2/ERK1/2 pathways. catalpol 10-18 vascular endothelial growth factor A Rattus norvegicus 71-105 34795412-10 2021 Moreover, catalpol treatment significantly increased the expression of vascular endothelial growth factor (VEGF) through up-regulating PI3K/AKT signaling, followed by increasing FAK and Paxillin and activating PI3K/AKT and MEK1/2/ERK1/2 pathways. catalpol 10-18 vascular endothelial growth factor A Rattus norvegicus 107-111 34595851-1 2021 BACKGROUND: Bevacizumab-induced vascular endothelial growth factor (VEGF) inhibition may lead to a decrease in adenosine triphosphate (ATP) levels, an increase in intracellular Na+ and Ca2+ concentrations and an increase in reactive oxygen species (ROS) generation, as well as to cell damage. Adenosine 111-120 vascular endothelial growth factor A Rattus norvegicus 32-66 34755767-8 2021 This study showed an increase in the Vegf-a EL in the ASC group (2.3) vs. CG (0.93, p=0.0008). asc 54-57 vascular endothelial growth factor A Rattus norvegicus 37-43 34595851-1 2021 BACKGROUND: Bevacizumab-induced vascular endothelial growth factor (VEGF) inhibition may lead to a decrease in adenosine triphosphate (ATP) levels, an increase in intracellular Na+ and Ca2+ concentrations and an increase in reactive oxygen species (ROS) generation, as well as to cell damage. Adenosine 111-120 vascular endothelial growth factor A Rattus norvegicus 68-72 34595851-1 2021 BACKGROUND: Bevacizumab-induced vascular endothelial growth factor (VEGF) inhibition may lead to a decrease in adenosine triphosphate (ATP) levels, an increase in intracellular Na+ and Ca2+ concentrations and an increase in reactive oxygen species (ROS) generation, as well as to cell damage. Adenosine Triphosphate 135-138 vascular endothelial growth factor A Rattus norvegicus 32-66 34595851-1 2021 BACKGROUND: Bevacizumab-induced vascular endothelial growth factor (VEGF) inhibition may lead to a decrease in adenosine triphosphate (ATP) levels, an increase in intracellular Na+ and Ca2+ concentrations and an increase in reactive oxygen species (ROS) generation, as well as to cell damage. Adenosine Triphosphate 135-138 vascular endothelial growth factor A Rattus norvegicus 68-72 34595851-1 2021 BACKGROUND: Bevacizumab-induced vascular endothelial growth factor (VEGF) inhibition may lead to a decrease in adenosine triphosphate (ATP) levels, an increase in intracellular Na+ and Ca2+ concentrations and an increase in reactive oxygen species (ROS) generation, as well as to cell damage. Reactive Oxygen Species 224-247 vascular endothelial growth factor A Rattus norvegicus 32-66 34595851-1 2021 BACKGROUND: Bevacizumab-induced vascular endothelial growth factor (VEGF) inhibition may lead to a decrease in adenosine triphosphate (ATP) levels, an increase in intracellular Na+ and Ca2+ concentrations and an increase in reactive oxygen species (ROS) generation, as well as to cell damage. Reactive Oxygen Species 224-247 vascular endothelial growth factor A Rattus norvegicus 68-72 34595851-1 2021 BACKGROUND: Bevacizumab-induced vascular endothelial growth factor (VEGF) inhibition may lead to a decrease in adenosine triphosphate (ATP) levels, an increase in intracellular Na+ and Ca2+ concentrations and an increase in reactive oxygen species (ROS) generation, as well as to cell damage. Reactive Oxygen Species 249-252 vascular endothelial growth factor A Rattus norvegicus 32-66 34595851-1 2021 BACKGROUND: Bevacizumab-induced vascular endothelial growth factor (VEGF) inhibition may lead to a decrease in adenosine triphosphate (ATP) levels, an increase in intracellular Na+ and Ca2+ concentrations and an increase in reactive oxygen species (ROS) generation, as well as to cell damage. Reactive Oxygen Species 249-252 vascular endothelial growth factor A Rattus norvegicus 68-72 34517281-9 2021 RESULTS: Compared with the control group, the flap survival area of memantine group, especially the high-dose group, was larger, VEGF expression, microvascular density, angiogenesis, blood perfusion, and superoxide dismutase in the flap were higher in the Memantine-H group than in the Memantine-L and control groups (P < 0.01). Memantine 68-77 vascular endothelial growth factor A Rattus norvegicus 129-133 34507115-7 2021 Licorice extract supplementation accelerated wound healing by increasing angiogenesis and collagen deposition through up-regulation of bFGF, VEGF and TGF-beta gene expression levels compared with the control group. licorice extract 0-16 vascular endothelial growth factor A Rattus norvegicus 141-145 34517281-9 2021 RESULTS: Compared with the control group, the flap survival area of memantine group, especially the high-dose group, was larger, VEGF expression, microvascular density, angiogenesis, blood perfusion, and superoxide dismutase in the flap were higher in the Memantine-H group than in the Memantine-L and control groups (P < 0.01). Memantine 256-265 vascular endothelial growth factor A Rattus norvegicus 129-133 34480934-0 2021 Synergism effect of swimming exercise and genistein on the inflammation, oxidative stress, and VEGF expression in the retina of diabetic-ovariectomized rats. Genistein 42-51 vascular endothelial growth factor A Rattus norvegicus 95-99 34510666-3 2021 This study aimed to evaluate the changes in serum and liver tissue levels of VEGF, TGF-beta and MMP-2 in melatonin treated septic rats. Melatonin 105-114 vascular endothelial growth factor A Rattus norvegicus 77-81 34510666-12 2021 Melatonin treatment may have therapeutic effect against sepsis since it prevents the increase in serum VEGF level. Melatonin 0-9 vascular endothelial growth factor A Rattus norvegicus 103-107 34218375-9 2021 Furthermore, deltamethrin increased mRNA expression levels of PARP-1, VEGF, and immunohistochemical expressions of c-fos in the tissues. decamethrin 13-25 vascular endothelial growth factor A Rattus norvegicus 70-74 34647412-8 2021 The results showed that minocycline ameliorated portal hypertension, hemodynamic abnormalities, reduced collateral shunting, mesenteric vascular density, plasma VEGF level and alleviated liver fibrosis. Minocycline 24-35 vascular endothelial growth factor A Rattus norvegicus 161-165 34791626-0 2021 Vascular endothelial growth factor ameliorated palmitate-induced cardiomyocyte injury via JNK pathway. Palmitates 47-56 vascular endothelial growth factor A Rattus norvegicus 0-34 34829572-8 2021 Further biochemical assessment of the hind limb tissue showed decreased oxidative stress, increased levels of nitric oxide and endothelial nitric oxide synthase (eNOS), and enhancement of the levels of heme oxygenase-1 (HO-1) and vascular endothelial growth factor (VEGF) in the groups treated with methyl gallate and quercetin. methyl gallate 299-313 vascular endothelial growth factor A Rattus norvegicus 230-264 34829572-8 2021 Further biochemical assessment of the hind limb tissue showed decreased oxidative stress, increased levels of nitric oxide and endothelial nitric oxide synthase (eNOS), and enhancement of the levels of heme oxygenase-1 (HO-1) and vascular endothelial growth factor (VEGF) in the groups treated with methyl gallate and quercetin. methyl gallate 299-313 vascular endothelial growth factor A Rattus norvegicus 266-270 34829572-8 2021 Further biochemical assessment of the hind limb tissue showed decreased oxidative stress, increased levels of nitric oxide and endothelial nitric oxide synthase (eNOS), and enhancement of the levels of heme oxygenase-1 (HO-1) and vascular endothelial growth factor (VEGF) in the groups treated with methyl gallate and quercetin. Quercetin 318-327 vascular endothelial growth factor A Rattus norvegicus 230-264 34829572-8 2021 Further biochemical assessment of the hind limb tissue showed decreased oxidative stress, increased levels of nitric oxide and endothelial nitric oxide synthase (eNOS), and enhancement of the levels of heme oxygenase-1 (HO-1) and vascular endothelial growth factor (VEGF) in the groups treated with methyl gallate and quercetin. Quercetin 318-327 vascular endothelial growth factor A Rattus norvegicus 266-270 34829572-9 2021 Expression levels of hypoxia inducible factor-1 alpha (HIF-1alpha), VEGF, fibroblast growth factor-2 (FGF-2), and miR-146a were upregulated in the muscle tissue of methyl gallate- and quercetin-treated groups along with downregulation of nuclear factor kappa B (NF-kappaB). methyl gallate 164-178 vascular endothelial growth factor A Rattus norvegicus 68-72 34829572-9 2021 Expression levels of hypoxia inducible factor-1 alpha (HIF-1alpha), VEGF, fibroblast growth factor-2 (FGF-2), and miR-146a were upregulated in the muscle tissue of methyl gallate- and quercetin-treated groups along with downregulation of nuclear factor kappa B (NF-kappaB). Quercetin 184-193 vascular endothelial growth factor A Rattus norvegicus 68-72 34278923-8 2021 Effects of quercetin on repair and regenerations of diabetic wounds in terms of wound closure, inflammation, angiogenesis, fibroblast proliferation, collagen synthesis, epithelialization, axonal regeneration etc was studied.Results: Quercetin accelerated the wound closure and increased the expressions of IL-10, VEGF and TGF-beta1 in granulation/healing tissue of diabetic wound. Quercetin 11-20 vascular endothelial growth factor A Rattus norvegicus 313-317 34278923-8 2021 Effects of quercetin on repair and regenerations of diabetic wounds in terms of wound closure, inflammation, angiogenesis, fibroblast proliferation, collagen synthesis, epithelialization, axonal regeneration etc was studied.Results: Quercetin accelerated the wound closure and increased the expressions of IL-10, VEGF and TGF-beta1 in granulation/healing tissue of diabetic wound. Quercetin 233-242 vascular endothelial growth factor A Rattus norvegicus 313-317 34633271-14 2021 These findings were also improved by immunohistochemical analysis of GFAP, VEGF, caspase3, and histopathological examinations, in which pretreatment of rats with lycopene and chrysin reversed all clonidine-induced alterations. Lycopene 162-170 vascular endothelial growth factor A Rattus norvegicus 75-79 34633271-14 2021 These findings were also improved by immunohistochemical analysis of GFAP, VEGF, caspase3, and histopathological examinations, in which pretreatment of rats with lycopene and chrysin reversed all clonidine-induced alterations. chrysin 175-182 vascular endothelial growth factor A Rattus norvegicus 75-79 34661261-8 2021 MTX administration also resulted in downregulation of vascular endothelial growth factor (VEGF), while caused upregulation of interleukin 1 beta (IL-1B) and interleukin 6 (IL-6) in comparison to the control group. Methotrexate 0-3 vascular endothelial growth factor A Rattus norvegicus 54-88 34661261-8 2021 MTX administration also resulted in downregulation of vascular endothelial growth factor (VEGF), while caused upregulation of interleukin 1 beta (IL-1B) and interleukin 6 (IL-6) in comparison to the control group. Methotrexate 0-3 vascular endothelial growth factor A Rattus norvegicus 90-94 34661261-9 2021 Also, MTX group showed histological abnormalities besides negative VEGF and positive iNOS as detected by immunohistochemical staining compared to the control group. Methotrexate 6-9 vascular endothelial growth factor A Rattus norvegicus 67-71 34365555-0 2021 Acteoside isolated from Colebrookea oppositifolia attenuates I/R brain injury in Wistar rats via modulation of HIF-1alpha, NF-kappaB, and VEGF pathways. acteoside 0-9 vascular endothelial growth factor A Rattus norvegicus 138-142 34365555-9 2021 CONCLUSION: These findings suggest that acteoside possess potent anti-stroke activity through modulation of HIF-1alpha, NF-kappaB, and VEGF pathway along with its potent antioxidant activity. acteoside 40-49 vascular endothelial growth factor A Rattus norvegicus 135-139 34791626-10 2021 These findings indicated the protective effects of VEGF in confronting the ceramide-induced cardiomyocyte apoptosis, and would devote therapeutic targets for cardiovascular safeguard in dealing with fatty acid stress. Ceramides 75-83 vascular endothelial growth factor A Rattus norvegicus 51-55 34791626-10 2021 These findings indicated the protective effects of VEGF in confronting the ceramide-induced cardiomyocyte apoptosis, and would devote therapeutic targets for cardiovascular safeguard in dealing with fatty acid stress. Fatty Acids 199-209 vascular endothelial growth factor A Rattus norvegicus 51-55 34576081-9 2021 The expression of Fractalkine and VEGFalpha, but not CINC-1, TIMP-1, and sICAM was downregulated by butyrate. Butyrates 100-108 vascular endothelial growth factor A Rattus norvegicus 34-43 34545676-14 2021 MiR-423-5p knockdown in ADSCs ameliorated high glucose-mediated damage to HUVECs and improved erectile function in DM rats by inducing eNOS and VEGFa overexpression, indicating that miR-423-5p may be a potential target in the treatment of DMED. mir-423-5p 0-10 vascular endothelial growth factor A Rattus norvegicus 144-149 34320422-14 2021 It was found that DHE has a regulating effect on tumor angiogenesis and can inhibit the relative gene and protein expression of HIF-1alpha-mediated VEGF signaling pathway. dehydroevodiamine 18-21 vascular endothelial growth factor A Rattus norvegicus 148-152 34320422-15 2021 CONCLUSIONS: The present work highlighted the role of DHE ameliorated gastric injury in MNNG-induced CAG rats in vivo and GES-1 cell migration in vitro by inhibiting HIF-1alpha/VEGF angiogenesis pathway. dehydroevodiamine 54-57 vascular endothelial growth factor A Rattus norvegicus 177-181 34660198-0 2021 Immobilization of bioactive vascular endothelial growth factor onto Ca-deficient hydroxyapatite-coated Mg by covalent bonding using polydopamine. Magnesium 103-105 vascular endothelial growth factor A Rattus norvegicus 28-62 34660198-0 2021 Immobilization of bioactive vascular endothelial growth factor onto Ca-deficient hydroxyapatite-coated Mg by covalent bonding using polydopamine. polydopamine 132-144 vascular endothelial growth factor A Rattus norvegicus 28-62 34660198-4 2021 Methods: Mg was firstly coated with Ca-deficient hydroxyapatite (CDHA) via hydrothermal treatment, and polydopamine (DOPA) was then used as the connecting medium to immobilize vascular endothelial growth factor (VEGF) on the CDHA coating. polydopamine 103-115 vascular endothelial growth factor A Rattus norvegicus 176-210 34660198-4 2021 Methods: Mg was firstly coated with Ca-deficient hydroxyapatite (CDHA) via hydrothermal treatment, and polydopamine (DOPA) was then used as the connecting medium to immobilize vascular endothelial growth factor (VEGF) on the CDHA coating. polydopamine 103-115 vascular endothelial growth factor A Rattus norvegicus 212-216 34660198-4 2021 Methods: Mg was firstly coated with Ca-deficient hydroxyapatite (CDHA) via hydrothermal treatment, and polydopamine (DOPA) was then used as the connecting medium to immobilize vascular endothelial growth factor (VEGF) on the CDHA coating. Dihydroxyphenylalanine 117-121 vascular endothelial growth factor A Rattus norvegicus 176-210 34660198-4 2021 Methods: Mg was firstly coated with Ca-deficient hydroxyapatite (CDHA) via hydrothermal treatment, and polydopamine (DOPA) was then used as the connecting medium to immobilize vascular endothelial growth factor (VEGF) on the CDHA coating. Dihydroxyphenylalanine 117-121 vascular endothelial growth factor A Rattus norvegicus 212-216 34660198-4 2021 Methods: Mg was firstly coated with Ca-deficient hydroxyapatite (CDHA) via hydrothermal treatment, and polydopamine (DOPA) was then used as the connecting medium to immobilize vascular endothelial growth factor (VEGF) on the CDHA coating. cdha 225-229 vascular endothelial growth factor A Rattus norvegicus 176-210 34660198-4 2021 Methods: Mg was firstly coated with Ca-deficient hydroxyapatite (CDHA) via hydrothermal treatment, and polydopamine (DOPA) was then used as the connecting medium to immobilize vascular endothelial growth factor (VEGF) on the CDHA coating. cdha 225-229 vascular endothelial growth factor A Rattus norvegicus 212-216 34660198-8 2021 VEGF could be firmly immobilized on Mg via polydopamine. Magnesium 36-38 vascular endothelial growth factor A Rattus norvegicus 0-4 34660198-8 2021 VEGF could be firmly immobilized on Mg via polydopamine. polydopamine 43-55 vascular endothelial growth factor A Rattus norvegicus 0-4 34660198-9 2021 The CCK-8, live/dead staining and adhesion test results showed that the VEGF-DOPA-CDHA coating exhibited excellent biocompatibility and could significantly improve the adhesion and proliferation of MC3T3-E1 cells on Mg. Microtubule formation, immunofluorescence and Quantitative Real-Time PCR (qRT-PCR) experiments showed that VEGF immobilized on Mg still possessed bioactivity in promoting the differentiation of rat mesenchymal stem cells into endothelial cells. Dihydroxyphenylalanine 77-81 vascular endothelial growth factor A Rattus norvegicus 327-331 34660198-9 2021 The CCK-8, live/dead staining and adhesion test results showed that the VEGF-DOPA-CDHA coating exhibited excellent biocompatibility and could significantly improve the adhesion and proliferation of MC3T3-E1 cells on Mg. Microtubule formation, immunofluorescence and Quantitative Real-Time PCR (qRT-PCR) experiments showed that VEGF immobilized on Mg still possessed bioactivity in promoting the differentiation of rat mesenchymal stem cells into endothelial cells. cdha 82-86 vascular endothelial growth factor A Rattus norvegicus 327-331 34660198-9 2021 The CCK-8, live/dead staining and adhesion test results showed that the VEGF-DOPA-CDHA coating exhibited excellent biocompatibility and could significantly improve the adhesion and proliferation of MC3T3-E1 cells on Mg. Microtubule formation, immunofluorescence and Quantitative Real-Time PCR (qRT-PCR) experiments showed that VEGF immobilized on Mg still possessed bioactivity in promoting the differentiation of rat mesenchymal stem cells into endothelial cells. Magnesium 347-349 vascular endothelial growth factor A Rattus norvegicus 327-331 34660198-10 2021 Conclusion: In this study, we enabled the angiogenic biological activity of Mg by immobilizing VEGF on Mg. Mg was successfully coated with a functional VEGF-DOPA-CDHA composite coating. Magnesium 76-78 vascular endothelial growth factor A Rattus norvegicus 95-99 34660198-10 2021 Conclusion: In this study, we enabled the angiogenic biological activity of Mg by immobilizing VEGF on Mg. Mg was successfully coated with a functional VEGF-DOPA-CDHA composite coating. Magnesium 76-78 vascular endothelial growth factor A Rattus norvegicus 152-156 34660198-10 2021 Conclusion: In this study, we enabled the angiogenic biological activity of Mg by immobilizing VEGF on Mg. Mg was successfully coated with a functional VEGF-DOPA-CDHA composite coating. Dihydroxyphenylalanine 157-161 vascular endothelial growth factor A Rattus norvegicus 95-99 34660198-10 2021 Conclusion: In this study, we enabled the angiogenic biological activity of Mg by immobilizing VEGF on Mg. Mg was successfully coated with a functional VEGF-DOPA-CDHA composite coating. Dihydroxyphenylalanine 157-161 vascular endothelial growth factor A Rattus norvegicus 152-156 34660198-10 2021 Conclusion: In this study, we enabled the angiogenic biological activity of Mg by immobilizing VEGF on Mg. Mg was successfully coated with a functional VEGF-DOPA-CDHA composite coating. cdha 162-166 vascular endothelial growth factor A Rattus norvegicus 152-156 34660198-11 2021 The CDHA coating significantly increased the corrosion resistance of Mg and prohibited the negative effect of excessively high local alkalinity on the biological activity of VEGF. cdha 4-8 vascular endothelial growth factor A Rattus norvegicus 174-178 34660198-11 2021 The CDHA coating significantly increased the corrosion resistance of Mg and prohibited the negative effect of excessively high local alkalinity on the biological activity of VEGF. Magnesium 69-71 vascular endothelial growth factor A Rattus norvegicus 174-178 34660198-12 2021 As an intermediate layer, the DOPA coating protects Mg, and DOPA provides a binding site for VEGF so that VEGF can be firmly immobilized on Mg and give Mg angiogenic bioactivity during the initial period of implantation. Dihydroxyphenylalanine 30-34 vascular endothelial growth factor A Rattus norvegicus 93-97 34660198-12 2021 As an intermediate layer, the DOPA coating protects Mg, and DOPA provides a binding site for VEGF so that VEGF can be firmly immobilized on Mg and give Mg angiogenic bioactivity during the initial period of implantation. Dihydroxyphenylalanine 30-34 vascular endothelial growth factor A Rattus norvegicus 106-110 34660198-12 2021 As an intermediate layer, the DOPA coating protects Mg, and DOPA provides a binding site for VEGF so that VEGF can be firmly immobilized on Mg and give Mg angiogenic bioactivity during the initial period of implantation. Dihydroxyphenylalanine 60-64 vascular endothelial growth factor A Rattus norvegicus 93-97 34660198-12 2021 As an intermediate layer, the DOPA coating protects Mg, and DOPA provides a binding site for VEGF so that VEGF can be firmly immobilized on Mg and give Mg angiogenic bioactivity during the initial period of implantation. Dihydroxyphenylalanine 60-64 vascular endothelial growth factor A Rattus norvegicus 106-110 34660198-16 2021 In this study, VEGF was connected on the surface of degradable magnesium by covalent bonding. Magnesium 63-72 vascular endothelial growth factor A Rattus norvegicus 15-19 34494412-7 2021 Further, inhibiting miR-140-5p directly increased VEGFA expression, revealing a novel regulatory axis between H19, miR-140-5p, and VEGFA in modulating tenogenic differentiation. mir-140-5p 20-30 vascular endothelial growth factor A Rattus norvegicus 50-55 34572376-7 2021 RESULTS: VEGF, cluster of differentiation 31 (CD31), and von Willebrand factor (vWF) expressions increased after CCI in the ipsilateral lumbar spinal cord compared to that in the contralateral side of CCI and control rats from post-operative day (POD) 7 to 28, with a peak at POD 14. CCI 113-116 vascular endothelial growth factor A Rattus norvegicus 9-13 34572376-9 2021 Fumagillin and anti-VEGF-A reduced CCI-induced thermal hyperalgesia from POD 5 to 14 and mechanical allodynia from POD 3 to 14. CCI 35-38 vascular endothelial growth factor A Rattus norvegicus 20-26 34369537-5 2021 The in vitro study revealed that the osteogenic activity of rat bone marrow mesenchymal stem cells (rBMSCs) was affected by varying concentrations of Sr ions in coatings and the optimal osteogenic differentiation was observed in the 2SrHA-PET group, which significantly up-regulated the expression of BMP-2, OCN, Col-I and VEGF. Strontium 150-152 vascular endothelial growth factor A Rattus norvegicus 323-327 34494412-7 2021 Further, inhibiting miR-140-5p directly increased VEGFA expression, revealing a novel regulatory axis between H19, miR-140-5p, and VEGFA in modulating tenogenic differentiation. mir-140-5p 20-30 vascular endothelial growth factor A Rattus norvegicus 131-136 34532123-12 2021 Immunohistochemical analyses displayed that the levels of VEGF and Vimentin in the tumors of ATO plus VNP20009 group were obviously lower than those of other groups. Arsenic Trioxide 93-96 vascular endothelial growth factor A Rattus norvegicus 58-62 34118646-8 2021 KEY FINDINGS: Topiramate improved the body weight gain, decreased serum CEA, augmented the antioxidant defenses in the colonic tissues with significant amelioration of the inflammatory changes, decline in tissue VEGF and p-AKT/mTOR/MAP kinase signaling and increased Nrf2/HO-1 content in a dose-dependent manner when compared to rats treated with azoxymethane alone. Topiramate 14-24 vascular endothelial growth factor A Rattus norvegicus 212-216 34578859-8 2021 Higher doses of BC induced significantly higher relative mRNA expression of OPG, VEGFA, FGF2 and RANKL (p < 0.05). biochar 16-18 vascular endothelial growth factor A Rattus norvegicus 81-86 34186235-0 2021 Biodegradable magnesium combined with distraction osteogenesis synergistically stimulates bone tissue regeneration via CGRP-FAK-VEGF signaling axis. Magnesium 14-23 vascular endothelial growth factor A Rattus norvegicus 128-132 34186235-10 2021 We revealed, for the first time, a CGRP-FAK-VEGF signaling axis linking sensory nerve and endothelial cells, which may be the main mechanism underlying Mg-enhanced critical size bone defect repair when combined with DO, suggesting a great potential of Mg implants in reducing DO treatment time for clinical applications. Magnesium 152-154 vascular endothelial growth factor A Rattus norvegicus 44-48 34149894-5 2021 Pathological changes and positive expression of VEGF in the ankle joints were investigated using hematoxylin-eosin staining and immunohistochemical staining, respectively. Hematoxylin 97-108 vascular endothelial growth factor A Rattus norvegicus 48-52 34149894-5 2021 Pathological changes and positive expression of VEGF in the ankle joints were investigated using hematoxylin-eosin staining and immunohistochemical staining, respectively. Eosine Yellowish-(YS) 109-114 vascular endothelial growth factor A Rattus norvegicus 48-52 34147541-9 2021 Simvastatin increased levels of circulating EPCs and decreased iNOS, MMP-2, MMP-9 and VEGF mRNA levels, while increased eNOS mRNA in aneurysmal tissue. Simvastatin 0-11 vascular endothelial growth factor A Rattus norvegicus 86-90 34381142-6 2021 VEGF-A, VEGF receptor 2, and the co-receptor Neuropilin-1 were upregulated by Rapamycin within 7 days. Sirolimus 78-87 vascular endothelial growth factor A Rattus norvegicus 0-6 34354407-12 2021 The levels of pro-inflammatory mediators, cholesterol, TG, LDL, and HDL, MCP-1, VEGF, and MMP-9 was remarkably suppressed by the nimbolide treatment. nimbolide 129-138 vascular endothelial growth factor A Rattus norvegicus 80-84 34139652-12 2021 In conclusion; Etanercept and/or Cabergoline decreased volume, TNF-alpha, VEGF, and CD 146/PDGF-Rbeta staining of the ectopic endometrial implant. Cabergoline 33-44 vascular endothelial growth factor A Rattus norvegicus 74-78 34367293-8 2021 Celastrol-treated cells increased quantities of proangiogenic cytokines compared to vehicle-pretreated cells, with a significant 3.0-fold and 1.8-fold increase of VEGFa and SDF-1alpha, respectively (p < 0.05). celastrol 0-9 vascular endothelial growth factor A Rattus norvegicus 163-168 34314063-6 2022 Comparison of membrane formation around polycaprolactone (PCL), MMA-eluting PCL (high dose PCL-MMA and low dose PCL-MMA), and surgical PMMA revealed robust membranes enveloped all groups after 4 weeks in vivo, with elevated expression of osteogenic bone morphogenetic protein-2 (BMP2) and angiogenic vascular endothelial growth factor (VEGF) compared with the surrounding muscle and bone tissues. Methylmethacrylate 64-67 vascular endothelial growth factor A Rattus norvegicus 300-334 34314063-6 2022 Comparison of membrane formation around polycaprolactone (PCL), MMA-eluting PCL (high dose PCL-MMA and low dose PCL-MMA), and surgical PMMA revealed robust membranes enveloped all groups after 4 weeks in vivo, with elevated expression of osteogenic bone morphogenetic protein-2 (BMP2) and angiogenic vascular endothelial growth factor (VEGF) compared with the surrounding muscle and bone tissues. Methylmethacrylate 64-67 vascular endothelial growth factor A Rattus norvegicus 336-340 34287581-4 2021 Similarly, engeletin (100, 200, or 400 nM) markedly enhanced the migration, tube formation, and VEGF expression of HUVECs in an OGD/R model system, while the VEGF receptor (R) inhibitor axitinib reversed the observed changes in HUVEC tube formation activity and Vash-2, VEGF, and CD31 expression. Axitinib 186-194 vascular endothelial growth factor A Rattus norvegicus 270-274 34356178-1 2021 Defining the relationship between vascular development and the expression of hypoxia-inducible factors (Hifs) and vascular endothelial growth factor (Vegf) in the auditory brainstem is important to understand how tissue hypoxia caused by oxygen shortage contributes to sensory deficits in neonates. Oxygen 238-244 vascular endothelial growth factor A Rattus norvegicus 114-148 34356178-1 2021 Defining the relationship between vascular development and the expression of hypoxia-inducible factors (Hifs) and vascular endothelial growth factor (Vegf) in the auditory brainstem is important to understand how tissue hypoxia caused by oxygen shortage contributes to sensory deficits in neonates. Oxygen 238-244 vascular endothelial growth factor A Rattus norvegicus 150-154 34335280-7 2021 Moreover, tanshinol also attenuated GC-elicited the activation of TXNIP signaling pathway, and simultaneously reversed the down-regulation of Wnt and VEGF pathway as manifested by using Western-blot method in GIO rats, EA cells, and human osteoblast-like MG63 cells (MG cells). tanshinol 10-19 vascular endothelial growth factor A Rattus norvegicus 150-154 34269823-1 2022 PURPOSE: It is thought that orthodontic forces initially reduce periodontal blood flow during orthodontic tooth movement (OTM) via tissue compression with cells responding to concomitant oxygen deprivation with expression of vascular endothelial growth factor (VEGF) triggering angiogenesis via binding to its receptor VEGFR-2. Oxygen 187-193 vascular endothelial growth factor A Rattus norvegicus 225-259 34269823-1 2022 PURPOSE: It is thought that orthodontic forces initially reduce periodontal blood flow during orthodontic tooth movement (OTM) via tissue compression with cells responding to concomitant oxygen deprivation with expression of vascular endothelial growth factor (VEGF) triggering angiogenesis via binding to its receptor VEGFR-2. Oxygen 187-193 vascular endothelial growth factor A Rattus norvegicus 261-265 34238316-10 2021 Whereas plasma cytokine levels (IL1-beta, IL6, IL10, and TNFalpha) were not significantly affected, VEGF levels increased and IFABP levels decreased after ibuprofen. Ibuprofen 155-164 vascular endothelial growth factor A Rattus norvegicus 100-104 34162150-9 2021 Eighty-four potential target genes and mechanisms of rno-miR-140-5p were predicted, and the effect of miR-140-5p on the potential target genes VEGFA and JAG1 was experimentally validated. -mir-140-5p 56-67 vascular endothelial growth factor A Rattus norvegicus 143-148 34118146-13 2021 However, PD98059 obstructed the functions of FGF21 and VEGFA. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 9-16 vascular endothelial growth factor A Rattus norvegicus 55-60 34475701-11 2021 On day 28 in diabetic rats, a positive correlation (r=0.65, p=0.01) was detected between mean blood glucose level and the expression levels of HSP 90, iNOS, and VEGF. Glucose 100-107 vascular endothelial growth factor A Rattus norvegicus 161-165 34293080-10 2021 sCD146 induced upregulation of phospho-ERK1/2, NF-kappaB , VEGF and MMP-9 in Muller cells. scd146 0-6 vascular endothelial growth factor A Rattus norvegicus 59-63 34293080-11 2021 The hypoxia mimetic agent cobalt chloride, VEGF and TNF-alpha induced upregulation of sCD146 in HRMECs. scd146 86-92 vascular endothelial growth factor A Rattus norvegicus 43-47 34293080-13 2021 Intravitreal administration of sCD146 in normal rats significantly increased retinal vascular permeability and induced significant upregulation of phospho-ERK1/2, intercellular adhesion molecule-1 and VEGF in the retina. scd146 31-37 vascular endothelial growth factor A Rattus norvegicus 201-205 34248676-9 2021 As hypoxia time increased, the expression of VEGF increased gradually, but VEGF expression in group B (10% O2) was the highest. Oxygen 107-109 vascular endothelial growth factor A Rattus norvegicus 75-79 34183011-7 2021 Meanwhile, both the mRNA and protein expression levels of PI3K, mTOR, HIF-1alpha, and VEGF in the lung tissues were down-regulated with XCD treatment. 3-methyl-N-[(1R)-1-(5-methyl-1,2-oxazol-3-yl)ethyl]-4-[6-(trifluoromethyl)-1H-indol-3-yl]-1H-pyrrole-2-carboxamide 136-139 vascular endothelial growth factor A Rattus norvegicus 86-90 34183011-8 2021 Therefore, the regulations of XCD on PI3K/mTOR/HIF-1alpha/VEGF signaling pathway was probably a crucial mechanism involved in the protective mechanism of XCD on ALI treatment. 3-methyl-N-[(1R)-1-(5-methyl-1,2-oxazol-3-yl)ethyl]-4-[6-(trifluoromethyl)-1H-indol-3-yl]-1H-pyrrole-2-carboxamide 30-33 vascular endothelial growth factor A Rattus norvegicus 58-62 34183011-8 2021 Therefore, the regulations of XCD on PI3K/mTOR/HIF-1alpha/VEGF signaling pathway was probably a crucial mechanism involved in the protective mechanism of XCD on ALI treatment. 3-methyl-N-[(1R)-1-(5-methyl-1,2-oxazol-3-yl)ethyl]-4-[6-(trifluoromethyl)-1H-indol-3-yl]-1H-pyrrole-2-carboxamide 154-157 vascular endothelial growth factor A Rattus norvegicus 58-62 34174018-8 2021 Histological examination showed improved cerebral microangiopathy, increased expression of claudin-1 and -3, CD31, and VEGF in the cerebral cortical microvasculature and choroid plexus in PE rats treated with omega-3. omega-3 209-216 vascular endothelial growth factor A Rattus norvegicus 119-123 34070854-6 2021 Moreover, wortmannin treatment reduced basophil-mediated inflammatory response, improved bladder angiogenesis by increasing capillary density and VEGF expression, to reverse antiangiogenic effect to repair KIC. Wortmannin 10-20 vascular endothelial growth factor A Rattus norvegicus 146-150 34103198-4 2022 The enzyme-linked immunosorbent assay (ELISA) revealed that nifedipine inhibited release of inflammatory factors TNF-alpha, IL-6, IL-1beta and VEGF in serum. Nifedipine 60-70 vascular endothelial growth factor A Rattus norvegicus 143-147 34103198-5 2022 The RT-PCR analysis showed that nifedipine down regulated mRNA levels of TRPC-6 and VEGF in skin tissue. Nifedipine 32-42 vascular endothelial growth factor A Rattus norvegicus 84-88 34103198-6 2022 Furthermore, immunohistochemical examination showed nifedipine inhibited expression of IL-1beta, IL-6, and TNF-alpha inflammatory protein and further inhibited expression of TRP (transient receptor potential) family proteins TRPM-7, TRPC-1, TRPC-3 and TRPC-6 and reduced expression of VEGF in skin and relieved erythema and oedema. Nifedipine 52-62 vascular endothelial growth factor A Rattus norvegicus 285-289 34156775-5 2021 RESULTS: The intraperitoneal injections of melatonin and its analogs led to a significant decrease in the level of HIF-1alpha and VEGF-A in the retina of the rat pups of the experimental group until the beginning of pathological vasoproliferation. Melatonin 43-52 vascular endothelial growth factor A Rattus norvegicus 130-136 34064854-11 2021 Rapamycin was administered by activating autophagy and mitophagy, which increased apoptosis (assessed by Western blot analysis of Bcl-2, Bax, and Cleaved-caspase 3) and reduced angiogenesis (assessed by immunohistochemical analysis of vascular endothelial grow factor (VEGF) and CD34) in the lesions. Sirolimus 0-9 vascular endothelial growth factor A Rattus norvegicus 235-267 34064854-11 2021 Rapamycin was administered by activating autophagy and mitophagy, which increased apoptosis (assessed by Western blot analysis of Bcl-2, Bax, and Cleaved-caspase 3) and reduced angiogenesis (assessed by immunohistochemical analysis of vascular endothelial grow factor (VEGF) and CD34) in the lesions. Sirolimus 0-9 vascular endothelial growth factor A Rattus norvegicus 269-273 34104195-12 2021 The immunoreactive score showed that the BHA-GEL-GEN group had higher VEGF expression compared to two other groups. Butylated Hydroxyanisole 41-44 vascular endothelial growth factor A Rattus norvegicus 70-74 35447318-10 2022 We conclude that female chronic CAF diet consumption impairs feto-placental development and could be explained by an epigenetic disruption of Igf and Vegf systems. cafestol palmitate 32-35 vascular endothelial growth factor A Rattus norvegicus 150-154 34751117-0 2021 Hydroxysafflor yellow A promotes angiogenesis in rat brain microvascular endothelial cells injured by oxygen-glucose deprivation/reoxygenation(OGD/R) through SIRT1-HIF-1alpha-VEGFA signaling pathway. hydroxysafflor yellow A 0-23 vascular endothelial growth factor A Rattus norvegicus 175-180 34751117-2 2021 In this study, we investigated the effects of hydroxysafflor yellow A(HSYA) on angiogenesis of BMECs injured by OGD/R via SIRT1-HIF-1alpha-VEGFA signaling pathway. hydroxysafflor yellow A 46-69 vascular endothelial growth factor A Rattus norvegicus 139-144 34751117-2 2021 In this study, we investigated the effects of hydroxysafflor yellow A(HSYA) on angiogenesis of BMECs injured by OGD/R via SIRT1-HIF-1alpha-VEGFA signaling pathway. hydroxysafflor yellow A 70-74 vascular endothelial growth factor A Rattus norvegicus 139-144 35412389-5 2022 We hypothesize that high glucose conditions change the astrocytic expression of Cx43 and increase VEGF secretion leading to impairment of CMEC barrier properties in vitro and in vivo. Glucose 25-32 vascular endothelial growth factor A Rattus norvegicus 98-102 35236242-0 2022 Ellagic acid inhibits proinflammatory intermediary manufacture by suppressing NF-kappaB/Akt, VEGF and activating Nrf-2/Caspase-3 signaling pathways in rat testicular damage: a new way for testicular damage cure and in silico approach. Ellagic Acid 0-12 vascular endothelial growth factor A Rattus norvegicus 93-97 35092734-18 2022 Consequently, miR-376c-3p played an important role in renal IRI by promoting angiogenesis via targeting HIF-1alpha/VEGF pathway in male rats. mir-376c-3p 14-25 vascular endothelial growth factor A Rattus norvegicus 115-119 35412389-6 2022 Using co-culture of neonatal rat astrocytes and CMEC, we mimic hypoglycemic conditions using high glucose (HG) feeding media and show a significant decrease in Cx43 expression and the corresponding increase in secreted VEGF. Glucose 98-105 vascular endothelial growth factor A Rattus norvegicus 219-223 35412389-6 2022 Using co-culture of neonatal rat astrocytes and CMEC, we mimic hypoglycemic conditions using high glucose (HG) feeding media and show a significant decrease in Cx43 expression and the corresponding increase in secreted VEGF. Mercury 107-109 vascular endothelial growth factor A Rattus norvegicus 219-223 35596156-0 2022 Glabridin, a bioactive component of licorice, ameliorates diabetic nephropathy by regulating ferroptosis and the VEGF/Akt/ERK pathways. glabridin 0-9 vascular endothelial growth factor A Rattus norvegicus 113-117 35622274-13 2022 Bergenin significantly suppressed levels of pro-inflammatory cytokines, cholesterol, TG, LDL, AI, MMP-9, VEGF, and MCP-1 and increased the level of HDL and antioxidant enzymes in STZ-induced DR rats. bergenin 0-8 vascular endothelial growth factor A Rattus norvegicus 105-109 35294604-7 2022 The median TNF-alpha and VEGF levels were significantly lower in the ezetimibe group when compared to the control group (4 (3-4) vs 2 (1-3), p 0.029; 4 (3-4) vs 2 (2-3), p 0.002; respectively). Ezetimibe 69-78 vascular endothelial growth factor A Rattus norvegicus 25-29 35133684-11 2022 MTEP also attenuated MCT-induced elevations in the protein expressions of mGluR5, collagen types I & III, CILP1, Ang 2, and VEGF and decreased PI3K, AKT, and P38MAPK phosphorylations and inflammatory cytokine levels. 3-((2-methyl-1,3-thiazol-4-yl)ethynyl)piperidine 0-4 vascular endothelial growth factor A Rattus norvegicus 124-128 35588954-0 2022 Delta-9-tetrahydrocannabinol increases vascular endothelial growth factor (VEGF) secretion through a cyclooxygenase-dependent mechanism in rat granulosa cells. Dronabinol 0-28 vascular endothelial growth factor A Rattus norvegicus 39-73 35588954-0 2022 Delta-9-tetrahydrocannabinol increases vascular endothelial growth factor (VEGF) secretion through a cyclooxygenase-dependent mechanism in rat granulosa cells. Dronabinol 0-28 vascular endothelial growth factor A Rattus norvegicus 75-79 35588954-2 2022 The aim of this study was to assess the effect of THC on the expression and secretion of the angiogenic factor vascular endothelial growth factor (VEGF) in the ovary, and to determine if these effects were mediated by prostaglandins. Dronabinol 50-53 vascular endothelial growth factor A Rattus norvegicus 111-145 35588954-2 2022 The aim of this study was to assess the effect of THC on the expression and secretion of the angiogenic factor vascular endothelial growth factor (VEGF) in the ovary, and to determine if these effects were mediated by prostaglandins. Dronabinol 50-53 vascular endothelial growth factor A Rattus norvegicus 147-151 35588954-6 2022 THC-exposed SIGCs had a significant increase in VEGF and PGE2 secretion, along with an increase in proliferation and cell survival when challenged with an apoptosis-inducing factor. Dronabinol 0-3 vascular endothelial growth factor A Rattus norvegicus 48-52 35588954-7 2022 Pre-treatment with COX inhibitors reversed the THC-induced increase in both PGE2 and VEGF secretion. Dronabinol 47-50 vascular endothelial growth factor A Rattus norvegicus 85-89 35628328-10 2022 H2S treatment also reduced apoptotic and inflammatory markers, such as caspase-3, intracellular adhesion molecule 1 (ICAM-1), vascular endothelial growth factor (VEGF), and inducible nitric oxide synthase (iNOS). Deuterium 0-3 vascular endothelial growth factor A Rattus norvegicus 126-160 35628328-10 2022 H2S treatment also reduced apoptotic and inflammatory markers, such as caspase-3, intracellular adhesion molecule 1 (ICAM-1), vascular endothelial growth factor (VEGF), and inducible nitric oxide synthase (iNOS). Deuterium 0-3 vascular endothelial growth factor A Rattus norvegicus 162-166 35510332-5 2022 We found puerarin inhibited hypoxia-induced upregulation of VEGF at both the mRNA and protein level via decreasing HIF-1alpha expression in RPE cells. puerarin 9-17 vascular endothelial growth factor A Rattus norvegicus 60-64 35554780-8 2022 In a word, USCs-EVs-miR-26a-5p is a promising therapy for DOP by activating HIF-1alpha/VEGFA pathway through HDAC4 inhibition. Diethylhexyl Phthalate 58-61 vascular endothelial growth factor A Rattus norvegicus 87-92 35554780-16 2022 USCs-EVs-miR-26a-5p could prevent the pathogenesis of DOP via HIF-1alpha/VEGFA aix. Diethylhexyl Phthalate 54-57 vascular endothelial growth factor A Rattus norvegicus 73-78 35568201-9 2022 The immunoreactivity of glutamine synthetase and vascular endothelial growth factor (VEGF) decreased in the retinas of neonatal and adult rats injected intravitreally with ouabain. Ouabain 172-179 vascular endothelial growth factor A Rattus norvegicus 49-83 35568201-9 2022 The immunoreactivity of glutamine synthetase and vascular endothelial growth factor (VEGF) decreased in the retinas of neonatal and adult rats injected intravitreally with ouabain. Ouabain 172-179 vascular endothelial growth factor A Rattus norvegicus 85-89 35537702-0 2022 Trilobatin promotes angiogenesis after cerebral ischemia-reperfusion injury via SIRT7/VEGFA signaling pathway in rats. trilobatin 0-10 vascular endothelial growth factor A Rattus norvegicus 86-91 35522621-10 2022 Gene expression of fibronectin, FSP-1, VEGF, TGF-beta, and SMAD3 were reduced by LDE-PTX. lde-ptx 81-88 vascular endothelial growth factor A Rattus norvegicus 39-43 35620404-0 2022 Mechanism of Fructus Mume Pills Underlying Their Protective Effects in Rats with Acetic Acid-Inducedulcerative Colitis via the Regulation of Inflammatory Cytokines and the VEGF-PI3K/Akt-eNOS Signaling Pathway. Acetic Acid 81-92 vascular endothelial growth factor A Rattus norvegicus 172-176 35620404-13 2022 FMPs also significantly decreased the VEGFA, VEGFR2, Src, and eNOS protein expressions in colon tissue through the VEGF-PI3K/Akt-eNOS signaling pathway. fmps 0-4 vascular endothelial growth factor A Rattus norvegicus 38-43 35620404-13 2022 FMPs also significantly decreased the VEGFA, VEGFR2, Src, and eNOS protein expressions in colon tissue through the VEGF-PI3K/Akt-eNOS signaling pathway. fmps 0-4 vascular endothelial growth factor A Rattus norvegicus 115-119 35620404-15 2022 FMPs alleviate AA-induced UC by regulating microvascular permeability through the VEGF-PI3K/Akt-eNOS signaling pathway. fmps 0-4 vascular endothelial growth factor A Rattus norvegicus 82-86 35245677-13 2022 Adult rats with a history of AIE showed significantly fewer total cells expressing VEGFa in the AMG and dHPC following the acute ethanol challenge in adulthood. Ethanol 129-136 vascular endothelial growth factor A Rattus norvegicus 83-88 35133684-11 2022 MTEP also attenuated MCT-induced elevations in the protein expressions of mGluR5, collagen types I & III, CILP1, Ang 2, and VEGF and decreased PI3K, AKT, and P38MAPK phosphorylations and inflammatory cytokine levels. Monocrotaline 21-24 vascular endothelial growth factor A Rattus norvegicus 124-128 35133684-12 2022 mGluR5 blockade using MTEP ameliorates PAH-induced pathological right cardiac remodeling via inhibiting the signaling cascade involving PI3K/AKT, P38MAPK, Ang 2, and VEGF. 3-((2-methyl-1,3-thiazol-4-yl)ethynyl)piperidine 22-26 vascular endothelial growth factor A Rattus norvegicus 166-170 35558877-12 2022 To further determine the mechanism of this protective effect, we found that 2-ME inhibited the expression of HIF-1alpha, MMP-9, and VEGF, which was associated with the inflammatory response to EBI and BBB disruption after SAH. 2-Methoxyestradiol 76-80 vascular endothelial growth factor A Rattus norvegicus 132-136 35446751-0 2022 Physico-mechanical and Biological Evaluation of Heparin/VEGF-loaded Electrospun Polycaprolactone/ Decellularized Rat Aorta Extracellular Matrix for Small-Diameter Vascular Grafts. Heparin 48-55 vascular endothelial growth factor A Rattus norvegicus 56-60 35446751-0 2022 Physico-mechanical and Biological Evaluation of Heparin/VEGF-loaded Electrospun Polycaprolactone/ Decellularized Rat Aorta Extracellular Matrix for Small-Diameter Vascular Grafts. polycaprolactone 80-96 vascular endothelial growth factor A Rattus norvegicus 56-60 34995553-7 2022 Nevertheless, the VEGFR2 agonist, vascular endothelial growth factor 164 (VEGF164), induced a concentration-dependent relaxation of CBA, which is similar to the effect of NaHS. cba 132-135 vascular endothelial growth factor A Rattus norvegicus 34-72 34995553-7 2022 Nevertheless, the VEGFR2 agonist, vascular endothelial growth factor 164 (VEGF164), induced a concentration-dependent relaxation of CBA, which is similar to the effect of NaHS. cba 132-135 vascular endothelial growth factor A Rattus norvegicus 74-81 35078262-8 2022 Furthermore, sulpiride decreased retinal haemorrhages in response to the intravitreal administration of vascular endothelial growth factor (VEGF). Sulpiride 13-22 vascular endothelial growth factor A Rattus norvegicus 104-138 35485156-15 2022 Protein chip showed that THSWD promoted the upregulation of CINC-1(x2.91), CINC-3(x1.59), LIX(x1.5), Thymus Chemokine (x2.55), VEGF (x1.22) and the down-regulation of TIMP-1 (x2.98). thswd 25-30 vascular endothelial growth factor A Rattus norvegicus 127-131 35450343-6 2022 Coadministration of melatonin and stem cells enhanced the number of transplanted stem cells in the retinal tissue and significantly reduced retinal BDEF, VEGF, APOA1, and RBP4 levels as compared to melatonin and/or stem alone. Melatonin 20-29 vascular endothelial growth factor A Rattus norvegicus 154-158 35366690-9 2022 RESULTS: The autophagy agonist rapamycin reduced the lesion size, the microvessel density, and VEGF expression, and promoted the production of autophagosomes and the expression of autophagy-related proteins, while the autophagy inhibitor chloroquine had the opposite effects. Sirolimus 31-40 vascular endothelial growth factor A Rattus norvegicus 95-99 35093690-10 2022 Immunohistochemistry revealed that paeoniflorin was associated with significantly increased VEGF expression, and decreased level of HMGB1, TLR4, TNF-alpha, NF-kappaB, IL-6, IL-1beta, caspase-1, NLPR3, and IL-18. peoniflorin 35-47 vascular endothelial growth factor A Rattus norvegicus 92-96 35304259-8 2022 Further studies demonstrate that AE-18 exerts the effects in the prevention, treatment, and prolongation of the time window of cerebral ischemic injury mainly through inhibiting excitotoxicity and improving BBB permeability, VEGF and BDNF. ae-18 33-38 vascular endothelial growth factor A Rattus norvegicus 225-229 35467082-10 2022 AMD3100 reduced the TACE induced MVD in HCC tissues with the reduction of HIF-1alpha and VEGF expression. plerixafor 0-7 vascular endothelial growth factor A Rattus norvegicus 89-93 35467082-10 2022 AMD3100 reduced the TACE induced MVD in HCC tissues with the reduction of HIF-1alpha and VEGF expression. Chlorotrianisene 20-24 vascular endothelial growth factor A Rattus norvegicus 89-93 35467177-7 2022 Bladders from omega-3-treated rats showed lower expression ofKI-67 (p < 0.05), VEGF (p < 0.001) and IL-6 (p < 0.001) and significant higher expression of mi-RNA (p < 0.001). omega-3 14-21 vascular endothelial growth factor A Rattus norvegicus 79-83 35484974-6 2022 Correlation analysis showed that S24-7 abundance was negatively correlated with the level of VEGF, and metabolites associated with S24-7-including 3-aminobutanoic acid, dacarbazine, L-leucine, 3-ketosphinganine, 1-methylnicotinamide, and N-acetyl-L-glutamate-were also significantly correlated with VEGF levels. Leucine 184-191 vascular endothelial growth factor A Rattus norvegicus 93-97 35484974-7 2022 The findings suggest that antibiotic exposure during pregnancy, specifically ceftriaxone sodium, will adversely affects the behavior of offspring rats due to the imbalance of gut microbiota, especially S24-7, via VEGF and various metabolic pathways. Ceftriaxone 77-95 vascular endothelial growth factor A Rattus norvegicus 213-217 35167880-0 2022 Hyperbaric oxygen therapy mitigates left ventricular remodeling, upregulates MMP-2 and VEGF, and inhibits the induction of MMP-9, TGF-beta1, and TNF-alpha in streptozotocin-induced diabetic rat heart. Oxygen 11-17 vascular endothelial growth factor A Rattus norvegicus 87-91 35113004-9 2022 MCM3AP-AS1 silencing or miR-24-3p elevation improved cardiac function and myocardial pathological injury, suppressed malondialdehyde content, and also enhanced VEGF expression and superoxide dismutase activity in MI rats. mir-24-3p 24-33 vascular endothelial growth factor A Rattus norvegicus 160-164 35078262-8 2022 Furthermore, sulpiride decreased retinal haemorrhages in response to the intravitreal administration of vascular endothelial growth factor (VEGF). Sulpiride 13-22 vascular endothelial growth factor A Rattus norvegicus 140-144 35355803-0 2022 Study of Alveolar Bone Remodeling Using Deciduous Tooth Stem Cells and Hydroxyapatite by Vascular Endothelial Growth Factor Enhancement and Inhibition of Matrix Metalloproteinase-8 Expression in vivo. Durapatite 71-85 vascular endothelial growth factor A Rattus norvegicus 89-123 35415073-5 2022 Results: Eight weeks after surgery, the BP + Mg group had significantly reduced occurrence of MRONJ-like lesion and histological osteonecrosis, increased bone microstructural parameters, and increased expressions of VEGFA and CGRP, than the BP + Ti group. Diphosphonates 40-42 vascular endothelial growth factor A Rattus norvegicus 216-221 35415073-7 2022 Conclusion: Biodegradable Mg implant could alleviate the development of MRONJ-like lesion, possibly via upregulating VEGF- and CGRP-mediated angiogenesis. Magnesium 26-28 vascular endothelial growth factor A Rattus norvegicus 117-121 35368529-12 2022 The results revealed that the expression of LGALS3, VEGF and CAV1 genes was highly significantly increased in only Cisp treated group when compared with other treated groups. Cisplatin 115-119 vascular endothelial growth factor A Rattus norvegicus 52-56 35355803-4 2022 Purpose: The aim of this study was to determine the effect of hydroxyapatite incorporated with stem cells from exfoliated deciduous teeth (SHED) in Wistar rats" initial alveolar bone remodeling based on the findings of MMP-8 and VEGF expressions. Durapatite 62-76 vascular endothelial growth factor A Rattus norvegicus 229-233 35256585-4 2022 By targeting the MT1 receptor, melatonin reversed OA-induced pathology and effectively reduced levels of TNF-alpha, IL-8, and VEGF expression in OA synovial fibroblasts and synovium from rats with severe OA. Melatonin 31-40 vascular endothelial growth factor A Rattus norvegicus 126-130 35220281-0 2022 Human Umbilical Cord-Derived Mesenchymal Stem Cells Repair SU5416-Injured Emphysema by Inhibiting Apoptosis via Rescuing VEGF-VEGFR2-AKT Pathway in Rats. Semaxinib 59-65 vascular endothelial growth factor A Rattus norvegicus 121-125 35198633-10 2022 5-FU treatment also decreased body weight, TAC (total antioxidant capacity) values, VEGF (vascular endothelial growth factor) expression, blood cells, and hemoglobin (Hb) levels. Fluorouracil 0-4 vascular endothelial growth factor A Rattus norvegicus 84-88 35172410-15 2022 At 3, 5, and 7 days after operation, HIF-1alpha and VEGF expressions in ChokeIIzone of DMOG group were significantly higher than those in YC-1 group and control group ( P<0.05). chokeiizone 72-83 vascular endothelial growth factor A Rattus norvegicus 52-56 35172410-15 2022 At 3, 5, and 7 days after operation, HIF-1alpha and VEGF expressions in ChokeIIzone of DMOG group were significantly higher than those in YC-1 group and control group ( P<0.05). oxalylglycine 87-91 vascular endothelial growth factor A Rattus norvegicus 52-56 35444350-0 2022 Histomorphological Changes in a Rat Model of Polycystic Ovary Syndrome and the Contribution of Stevia Leaf Extract in Modulating the Ovarian Fibrosis, VEGF, and TGF-beta Immunoexpressions: Comparison with Metformin. stevia leaf extract 95-114 vascular endothelial growth factor A Rattus norvegicus 151-155 35221674-7 2022 Molecular docking analysis found that the active components beta-amyrin, cajanin, eleutheroside A have high affinity for TNF-alpha, VEGFA, IL-2, AKT, and PI3K, etc. beta-amyrin 60-71 vascular endothelial growth factor A Rattus norvegicus 132-137 35221674-7 2022 Molecular docking analysis found that the active components beta-amyrin, cajanin, eleutheroside A have high affinity for TNF-alpha, VEGFA, IL-2, AKT, and PI3K, etc. Cajanin 73-80 vascular endothelial growth factor A Rattus norvegicus 132-137 35221674-7 2022 Molecular docking analysis found that the active components beta-amyrin, cajanin, eleutheroside A have high affinity for TNF-alpha, VEGFA, IL-2, AKT, and PI3K, etc. lyoniside 82-97 vascular endothelial growth factor A Rattus norvegicus 132-137 35273950-5 2022 A proper dose of strontium ions (0.2-1 mM) could enhance the secretion of VEGFA and Ang-1 in HUVECs as well as in the co-culture system with BMSCs, exhibiting potential to create an angiogenic microenvironment in the early stage that would be beneficial to osteogenesis. Strontium 17-26 vascular endothelial growth factor A Rattus norvegicus 74-79 34982963-7 2022 In in silico analysis, the binding affinities of the fullerene C60 nanoparticle to transcription factors such as caspase-3, Bcl-2, Nrf-2, NF-kappaB, TNF-alpha, COX-2, VEGF and Akt were demonstrated by molecular docking. Fullerenes 53-62 vascular endothelial growth factor A Rattus norvegicus 167-171 35198633-10 2022 5-FU treatment also decreased body weight, TAC (total antioxidant capacity) values, VEGF (vascular endothelial growth factor) expression, blood cells, and hemoglobin (Hb) levels. Fluorouracil 0-4 vascular endothelial growth factor A Rattus norvegicus 90-124 35138531-4 2022 DMBA-induced mammary gland carcinoma as marked by an elevation of mRNA level of cancer promoter genes (Serpin and MIF, LOX-1, and COL1A1) and serum level of VEGF, TNF-alpha, TGF-beta, CA15-3, and caspase-3 with the reduction in mRNA level of suppressor gene (FST and ADRP). 6,11-dimethylbenzo(b)naphtho(2,3-d)thiophene 0-4 vascular endothelial growth factor A Rattus norvegicus 157-161 35022915-14 2022 Transforming growth factor-beta (TGFbeta) significantly increased in a time-dependent manner and platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) significantly increased in a time- and dose-dependent manner in phenytoin 1% and 3% in the 6- and 12-day protocols. Phenytoin 245-254 vascular endothelial growth factor A Rattus norvegicus 139-173 35211013-5 2022 Also, PGG significantly declined the elevations in gastric mucosal MDA, TNF-alpha, IL-6, PECAM-1, VEGF, and iNOS expression. pentagalloylglucose 6-9 vascular endothelial growth factor A Rattus norvegicus 98-102 35112334-9 2022 What"s more, ERK1/2 signaling pathway inhibitor U0126 also could inhibit the expression of VEGF. U 0126 48-53 vascular endothelial growth factor A Rattus norvegicus 91-95 35022915-14 2022 Transforming growth factor-beta (TGFbeta) significantly increased in a time-dependent manner and platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) significantly increased in a time- and dose-dependent manner in phenytoin 1% and 3% in the 6- and 12-day protocols. Phenytoin 245-254 vascular endothelial growth factor A Rattus norvegicus 175-179 35153110-10 2022 Furthermore, carboxymethyl chitosan/plantamajoside hydrogel significantly promoted the expression levels of VEGF, CD31, alpha-SMA (alpha-smooth muscle actin) and collagen III, and reduced the expression level of collagen I (P < 0.05). carboxymethyl-chitosan 13-35 vascular endothelial growth factor A Rattus norvegicus 108-112 34994065-1 2022 In the present study, we demonstrate the regulatory effects and mechanism of broussonin A and B, diphenylpropane derivatives isolated from Broussonetia kazinoki, on vascular endothelial growth factor-A (VEGF-A)-stimulated endothelial cell responses in vitro and microvessel sprouting ex vivo. broussonin a and b 77-95 vascular endothelial growth factor A Rattus norvegicus 203-209 34994065-1 2022 In the present study, we demonstrate the regulatory effects and mechanism of broussonin A and B, diphenylpropane derivatives isolated from Broussonetia kazinoki, on vascular endothelial growth factor-A (VEGF-A)-stimulated endothelial cell responses in vitro and microvessel sprouting ex vivo. 1,1-DIPHENYLPROPANE 97-112 vascular endothelial growth factor A Rattus norvegicus 203-209 34994065-2 2022 Treatment with broussonin A or B suppressed VEGF-A-stimulated endothelial cell proliferation by regulating the expression of cell cycle-related proteins and the phosphorylation status of retinoblastoma protein. broussonin a or b 15-32 vascular endothelial growth factor A Rattus norvegicus 44-50 34994065-3 2022 In addition, treatment with broussonin A or B abrogated VEGF-A-stimulated angiogenic responses including endothelial cell migration, invasion, tube formation and microvessel formation from rat aortic rings. broussonin a or b 28-45 vascular endothelial growth factor A Rattus norvegicus 56-62 35197751-0 2022 Impact of preconditioning stem cells with all-trans retinoic acid signaling pathway on cisplatin-induced nephrotoxicity by down-regulation of TGFbeta1, IL-6, and caspase-3 and up-regulation of HIF1alpha and VEGF. Tretinoin 52-65 vascular endothelial growth factor A Rattus norvegicus 207-211 35197751-6 2022 ATRA also supported ADMSCs by a significant down-regulation of caspase-3, il-6 and TGFbeta1, and a significant up-regulation of HIF1, VEGF and CD31 compared to group of cisplatin which reversed the cisplatin effect. Tretinoin 0-4 vascular endothelial growth factor A Rattus norvegicus 134-138 35153110-10 2022 Furthermore, carboxymethyl chitosan/plantamajoside hydrogel significantly promoted the expression levels of VEGF, CD31, alpha-SMA (alpha-smooth muscle actin) and collagen III, and reduced the expression level of collagen I (P < 0.05). plantamajoside 36-50 vascular endothelial growth factor A Rattus norvegicus 108-112 35081014-4 2022 RESULTS: Lactucaxanthin administration was found to lower oxidative stress markers (protein carbonylation and lipid peroxidation) by augmenting antioxidant activity expression and ameliorated VEGF-A levels in diabetic group. Lactucaxanthin 9-23 vascular endothelial growth factor A Rattus norvegicus 192-198 35527148-6 2022 Western blotting assay analysis showed that ZnO-EGCG@H downregulated trauma inflammatory factors (TNF-alpha, IL-6) by 46.9% and 57%, respectively, while upregulating 1.7-fold VEGF and 2-fold EGF, accelerating wound healing by reducing inflammatory response and promoting proliferation of vascular endothelial cells and skin epidermal cells. Zinc Oxide 44-47 vascular endothelial growth factor A Rattus norvegicus 175-185 35527148-6 2022 Western blotting assay analysis showed that ZnO-EGCG@H downregulated trauma inflammatory factors (TNF-alpha, IL-6) by 46.9% and 57%, respectively, while upregulating 1.7-fold VEGF and 2-fold EGF, accelerating wound healing by reducing inflammatory response and promoting proliferation of vascular endothelial cells and skin epidermal cells. epigallocatechin gallate 48-52 vascular endothelial growth factor A Rattus norvegicus 175-185 35081125-0 2022 1,8 Cineole and Ellagic acid inhibit hepatocarcinogenesis via upregulation of MiR-122 and suppression of TGF-beta1, FSCN1, Vimentin, VEGF, and MMP-9. Eucalyptol 0-11 vascular endothelial growth factor A Rattus norvegicus 133-137 35081125-0 2022 1,8 Cineole and Ellagic acid inhibit hepatocarcinogenesis via upregulation of MiR-122 and suppression of TGF-beta1, FSCN1, Vimentin, VEGF, and MMP-9. Ellagic Acid 16-28 vascular endothelial growth factor A Rattus norvegicus 133-137 35081125-8 2022 Moreover, Cin and EA treatment exhibited significant downregulation in transforming growth factor beta-1 (TGF-beta1), Fascin-1 (FSCN1), vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), and epithelial-mesenchymal transition (EMT) key marker, vimentin, along with a restoration of histopathological findings compared to HCC group. Ellagic Acid 18-20 vascular endothelial growth factor A Rattus norvegicus 136-170 35081125-8 2022 Moreover, Cin and EA treatment exhibited significant downregulation in transforming growth factor beta-1 (TGF-beta1), Fascin-1 (FSCN1), vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), and epithelial-mesenchymal transition (EMT) key marker, vimentin, along with a restoration of histopathological findings compared to HCC group. Ellagic Acid 18-20 vascular endothelial growth factor A Rattus norvegicus 172-176 35126151-0 2021 Rivastigmine Regulates the HIF-1alpha/VEGF Signaling Pathway to Induce Angiogenesis and Improves the Survival of Random Flaps in Rats. Rivastigmine 0-12 vascular endothelial growth factor A Rattus norvegicus 38-42 34988929-7 2022 Moderate VEGF positivity was observed in the vessels of the CNV group, a decrease in vessel proliferation, and weak VEGF positivity in the CNV + BA group. boric acid 145-147 vascular endothelial growth factor A Rattus norvegicus 116-120